

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 30, 2006, 14:01:44 ; Search time 33 Seconds
(without alignments)
3.446 Million cell updates/sec

Title: US-10-798-090A-305
Perfect score: 1773
Sequence: 1 augaccugcacaauacag.....cacccgagcagccuugag 1773

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 0.5

Searched: 1605 seqs, 32073 residues

Total number of hits satisfying chosen parameters: 3210

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1607 summaries

Database : rnpbm.subdb:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	32.2	1.8	37	1	US-09-826-509-279 Sequence 279, App
2	32.2	1.8	37	1	US-09-826-509-280 Sequence 280, App
3	32.2	1.8	37	1	US-10-925-095-279 Sequence 279, App
4	32.2	1.8	37	1	US-10-925-095-280 Sequence 280, App
5	26	1.5	32	1	US-09-826-509-79 Sequence 79, Appl
6	26	1.5	32	1	US-10-925-095-79 Sequence 79, Appl
7	25	1.4	25	1	US-10-719-956-108327 Sequence 108327, A
8	25	1.4	25	1	US-11-060-756-32251 Sequence 32251, A
9	25	1.4	25	1	US-11-060-756-32252 Sequence 32252, A
10	25	1.4	25	1	US-11-060-756-32253 Sequence 32253, A
11	25	1.4	25	1	US-11-060-756-32254 Sequence 32254, A
12	25	1.4	25	1	US-11-060-756-32255 Sequence 32255, A
13	25	1.4	25	1	US-11-060-756-32256 Sequence 32256, A
14	25	1.4	25	1	US-11-060-756-32257 Sequence 32257, A
15	25	1.4	25	1	US-11-060-756-32258 Sequence 32258, A
16	25	1.4	25	1	US-11-060-756-32259 Sequence 32259, A
17	25	1.4	25	1	US-11-060-756-32260 Sequence 32260, A
18	25	1.4	25	1	US-11-060-756-32261 Sequence 32261, A
19	25	1.4	25	1	US-11-060-756-32262 Sequence 32262, A
20	25	1.4	25	1	US-11-060-756-32263 Sequence 32263, A
21	25	1.4	25	1	US-11-060-756-32264 Sequence 32264, A
22	25	1.4	25	1	US-11-060-756-32265 Sequence 32265, A
23	25	1.4	25	1	US-11-060-756-32266 Sequence 32266, A
24	25	1.4	25	1	US-11-060-756-32267 Sequence 32267, A
25	25	1.4	25	1	US-11-060-756-32268 Sequence 32268, A
26	25	1.4	25	1	US-11-060-756-32269 Sequence 32269, A
27	25	1.4	25	1	US-11-060-756-32270 Sequence 32270, A
28	25	1.4	25	1	US-11-060-756-32271 Sequence 32271, A
29	25	1.4	25	1	US-11-060-756-32272 Sequence 32272, A
30	25	1.4	25	1	US-11-060-756-32273 Sequence 32273, A
31	25	1.4	25	1	US-11-060-756-32274 Sequence 32274, A
32	25	1.4	25	1	US-11-060-756-32275 Sequence 32275, A
33	25	1.4	25	1	US-11-060-756-32276 Sequence 32276, A

34	25	1.4	25	1	US-11-060-756-32277 Sequence 32277, A
35	25	1.4	25	1	US-11-060-756-32278 Sequence 32278, A
36	25	1.4	25	1	US-11-060-756-32279 Sequence 32279, A
37	25	1.4	25	1	US-11-060-756-32280 Sequence 32280, A
38	25	1.4	25	1	US-11-060-756-32281 Sequence 32281, A
39	25	1.4	25	1	US-11-060-756-32282 Sequence 32282, A
40	25	1.4	25	1	US-11-060-756-32283 Sequence 32283, A
41	25	1.4	25	1	US-11-060-756-32284 Sequence 32284, A
42	25	1.4	25	1	US-11-060-756-32285 Sequence 32285, A
43	25	1.4	25	1	US-11-060-756-32286 Sequence 32286, A
44	25	1.4	25	1	US-11-060-756-32287 Sequence 32287, A
45	25	1.4	25	1	US-11-060-756-32288 Sequence 32288, A
46	25	1.4	25	1	US-11-060-756-32289 Sequence 32289, A
47	25	1.4	25	1	US-11-060-756-32290 Sequence 32290, A
48	25	1.4	25	1	US-11-060-756-32291 Sequence 32291, A
49	25	1.4	25	1	US-11-060-756-32292 Sequence 32292, A
50	25	1.4	25	1	US-11-060-756-32293 Sequence 32293, A
51	25	1.4	25	1	US-11-060-756-32294 Sequence 32294, A
52	25	1.4	25	1	US-11-060-756-128746 Sequence 128746, A
53	25	1.4	25	1	US-11-060-756-132080 Sequence 132080, A
54	25	1.4	25	1	US-11-060-756-132080 Sequence 132080, A
55	25	1.4	25	1	US-11-060-756-134169 Sequence 134169, A
56	25	1.4	25	1	US-11-060-756-137147 Sequence 137147, A
57	25	1.4	25	1	US-11-060-756-151173 Sequence 151173, A
58	25	1.4	25	1	US-11-060-756-151519 Sequence 151519, A
59	25	1.4	25	1	US-11-060-756-164907 Sequence 164907, A
60	25	1.4	25	1	US-11-060-756-167980 Sequence 167980, A
61	25	1.4	25	1	US-11-060-756-169202 Sequence 169202, A
62	25	1.4	25	1	US-11-060-756-171665 Sequence 171665, A
63	25	1.4	25	1	US-11-060-756-175922 Sequence 175922, A
64	25	1.4	25	1	US-11-060-756-177330 Sequence 177330, A
65	25	1.4	25	1	US-11-060-756-180404 Sequence 180404, A
66	25	1.4	25	1	US-11-060-756-180430 Sequence 180430, A
67	25	1.4	25	1	US-11-060-756-187203 Sequence 187203, A
68	25	1.4	25	1	US-11-060-756-192377 Sequence 192377, A
69	25	1.4	25	1	US-11-060-756-195459 Sequence 195459, A
70	25	1.4	25	1	US-11-060-756-195924 Sequence 195924, A
71	25	1.4	25	1	US-11-060-756-204803 Sequence 204803, A
72	25	1.4	25	1	US-11-060-756-208188 Sequence 208188, A
73	25	1.4	25	1	US-11-060-756-212969 Sequence 212969, A
74	25	1.4	25	1	US-11-060-756-215815 Sequence 215815, A
75	25	1.4	25	1	US-11-060-756-217281 Sequence 217281, A
76	25	1.4	25	1	US-11-060-756-222249 Sequence 222249, A
77	25	1.4	25	1	US-11-060-756-222779 Sequence 222779, A
78	25	1.4	25	1	US-11-060-756-225356 Sequence 225356, A
79	25	1.4	25	1	US-11-060-756-225840 Sequence 225840, A
80	25	1.4	25	1	US-11-060-756-227514 Sequence 227514, A
81	25	1.4	25	1	US-11-060-756-236709 Sequence 236709, A
82	25	1.4	25	1	US-11-060-756-238898 Sequence 238898, A
83	25	1.4	25	1	US-11-060-756-243420 Sequence 243420, A
84	25	1.4	25	1	US-11-060-756-247277 Sequence 247277, A
85	25	1.4	25	1	US-11-060-756-254556 Sequence 254556, A
86	25	1.4	25	1	US-11-060-756-257044 Sequence 257044, A
87	25	1.4	25	1	US-11-060-756-260956 Sequence 260956, A
88	25	1.4	25	1	US-11-060-756-262560 Sequence 262560, A
89	25	1.4	25	1	US-11-060-756-265948 Sequence 265948, A
90	25	1.4	25	1	US-11-060-756-279400 Sequence 279400, A
91	25	1.4	25	1	US-11-060-756-279716 Sequence 279716, A
92	25	1.4	25	1	US-11-060-756-281261 Sequence 281261, A
93	25	1.4	25	1	US-11-060-756-283013 Sequence 283013, A
94	25	1.4	25	1	US-11-060-756-285037 Sequence 285037, A
95	25	1.4	25	1	US-11-060-756-286908 Sequence 286908, A
96	25	1.4	25	1	US-11-060-756-286908 Sequence 286908, A
97	25	1.4	25	1	US-11-060-756-287021 Sequence 287021, A
98	25	1.4	25	1	US-11-121-849-668384 Sequence 668384, A
99	25	1.4	25	1	US-11-121-849-668385 Sequence 668385, A
100	25	1.4	25	1	US-11-121-849-668386 Sequence 668386, A
101	25	1.4	25	1	US-11-121-849-668387 Sequence 668387, A
102	25	1.4	25	1	US-11-121-849-668388 Sequence 668388, A
103	25	1.4	25	1	US-11-121-849-668389 Sequence 668389, A
104	25	1.4	25	1	US-11-121-849-668390 Sequence 668390, A
105	25	1.4	25	1	US-11-121-849-668391 Sequence 668391, A
106	25	1.4	25	1	US-11-121-849-668392 Sequence 668392, A

107	25	1.4	25	1	US-11-121-849-668393	Sequence 668393,	180	20.2	1.1	25	1	US-11-060-756-128205	Sequence 128205,
108	24.8	1.4	31	1	US-09-801-274-1145	Sequence 1145, Ap	181	20.2	1.1	25	1	US-11-060-756-137566	Sequence 137566,
109	24.8	1.3	31	1	US-09-801-274-1338	Sequence 1328, Ap	182	20.2	1.1	25	1	US-11-060-756-139454	Sequence 139454,
110	23.4	1.4	25	1	US-10-719-956-108328	Sequence 108328,	183	20.2	1.1	25	1	US-11-060-756-146298	Sequence 146298,
111	23.4	1.3	25	1	US-10-719-900-371517	Sequence 371517,	184	20.2	1.1	25	1	US-11-060-756-163148	Sequence 163148,
112	23.4	1.3	25	1	US-10-719-900-452393	Sequence 452393,	185	20.2	1.1	25	1	US-11-060-756-164983	Sequence 164983,
113	23.4	1.3	25	1	US-10-719-900-563311	Sequence 563311,	186	20.2	1.1	25	1	US-11-060-756-168817	Sequence 168817,
114	23.4	1.3	25	1	US-10-719-900-650683	Sequence 650683,	187	20.2	1.1	25	1	US-11-060-756-168590	Sequence 168590,
115	23.4	1.3	25	1	US-10-719-900-650685	Sequence 650685,	188	20.2	1.1	25	1	US-11-060-756-192519	Sequence 192519,
116	23.4	1.3	25	1	US-10-719-900-847289	Sequence 847289,	189	20.2	1.1	25	1	US-11-060-756-218631	Sequence 218631,
117	23.4	1.3	25	1	US-11-036-317-407684	Sequence 407684,	190	20.2	1.1	25	1	US-11-060-756-218632	Sequence 218632,
118	23.4	1.3	25	1	US-11-036-317-413596	Sequence 413596,	191	20.2	1.1	25	1	US-11-060-756-256967	Sequence 256967,
119	23.4	1.3	25	1	US-11-036-317-443561	Sequence 443561,	192	20.2	1.1	25	1	US-11-060-756-263670	Sequence 263670,
120	23.4	1.3	25	1	US-11-036-317-455937	Sequence 455937,	193	20.2	1.1	25	1	US-11-060-756-273444	Sequence 273444,
121	23.4	1.3	25	1	US-11-060-756-175673	Sequence 175673,	194	20.2	1.1	25	1	US-11-060-756-282661	Sequence 282661,
122	23.4	1.3	25	1	US-11-060-756-183239	Sequence 183239,	195	20.2	1.1	25	1	US-11-060-756-282662	Sequence 282662,
123	23.4	1.3	25	1	US-11-136-527-158535	Sequence 158535,	196	20.2	1.1	25	1	US-11-121-849-48862	Sequence 48862, A
124	23.4	1.3	25	1	US-11-136-527-158536	Sequence 158536,	197	20.2	1.1	25	1	US-11-121-849-125376	Sequence 125376,
125	23.4	1.3	25	1	US-11-136-527-158538	Sequence 158538,	198	20.2	1.1	25	1	US-11-121-849-125380	Sequence 125380,
126	23.4	1.3	25	1	US-11-136-527-158539	Sequence 158539,	199	20.2	1.1	25	1	US-11-121-849-184585	Sequence 184585,
127	23	1.3	23	1	US-10-798-090-199	Sequence 199, App	200	20.2	1.1	25	1	US-11-121-849-184586	Sequence 184586,
128	23	1.3	23	1	US-10-798-090-200	Sequence 200, App	201	20.2	1.1	25	1	US-11-136-527-134960	Sequence 134960,
129	23	1.3	23	1	US-10-798-090-201	Sequence 201, App	202	20.2	1.1	25	1	US-11-136-527-134972	Sequence 134972,
130	23	1.3	23	1	US-10-798-090-202	Sequence 202, App	203	19	1.1	19	1	US-10-798-090-1	Sequence 1, Appl1
131	23	1.3	23	1	US-10-798-090-203	Sequence 203, App	204	19	1.1	19	1	US-10-798-090-2	Sequence 2, Appl1
132	23	1.3	23	1	US-10-798-090-204	Sequence 204, App	205	19	1.1	19	1	US-10-798-090-3	Sequence 3, Appl1
133	23	1.3	23	1	US-10-798-090-205	Sequence 205, App	206	19	1.1	19	1	US-10-798-090-4	Sequence 4, Appl1
134	23	1.3	23	1	US-10-798-090-206	Sequence 206, App	207	19	1.1	19	1	US-10-798-090-5	Sequence 5, Appl1
135	23	1.3	23	1	US-10-919-866-199	Sequence 199, App	208	19	1.1	19	1	US-10-798-090-6	Sequence 6, Appl1
136	23	1.3	23	1	US-10-919-866-200	Sequence 200, App	209	19	1.1	19	1	US-10-798-090-7	Sequence 7, Appl1
137	23	1.3	23	1	US-10-919-866-201	Sequence 201, App	210	19	1.1	19	1	US-10-798-090-8	Sequence 8, Appl1
138	23	1.3	23	1	US-10-919-866-202	Sequence 202, App	211	19	1.1	19	1	US-10-798-090-9	Sequence 9, Appl1
139	23	1.3	23	1	US-10-919-866-203	Sequence 203, App	212	19	1.1	19	1	US-10-798-090-10	Sequence 10, Appl
140	23	1.3	23	1	US-10-919-866-204	Sequence 204, App	213	19	1.1	19	1	US-10-798-090-11	Sequence 11, Appl
141	23	1.3	23	1	US-10-919-866-205	Sequence 205, App	214	19	1.1	19	1	US-10-798-090-12	Sequence 12, Appl
142	23	1.3	23	1	US-10-919-866-206	Sequence 206, App	215	19	1.1	19	1	US-10-798-090-13	Sequence 13, Appl
143	23	1.3	23	1	US-10-719-900-451173	Sequence 451173,	216	19	1.1	19	1	US-10-798-090-15	Sequence 15, Appl
144	22.4	1.3	25	1	US-11-136-527-158537	Sequence 158537,	217	19	1.1	19	1	US-10-798-090-16	Sequence 16, Appl
145	21.8	1.2	25	1	US-10-719-956-274609	Sequence 274609,	218	19	1.1	19	1	US-10-798-090-17	Sequence 17, Appl
146	21.8	1.2	25	1	US-10-719-900-371516	Sequence 371516,	219	19	1.1	19	1	US-10-798-090-18	Sequence 18, Appl
147	21.8	1.2	25	1	US-10-719-900-387771	Sequence 387771,	220	19	1.1	19	1	US-10-798-090-19	Sequence 19, Appl
148	21.8	1.2	25	1	US-10-719-900-452392	Sequence 452392,	221	19	1.1	19	1	US-10-798-090-20	Sequence 20, Appl
149	21.8	1.2	25	1	US-10-719-900-562103	Sequence 562103,	222	19	1.1	19	1	US-10-798-090-21	Sequence 21, Appl
150	21.8	1.2	25	1	US-10-719-900-563310	Sequence 563310,	223	19	1.1	19	1	US-10-798-090-22	Sequence 22, Appl
151	21.8	1.2	25	1	US-10-719-900-847290	Sequence 847290,	224	19	1.1	19	1	US-10-798-090-23	Sequence 23, Appl
152	21.8	1.2	25	1	US-11-036-317-485535	Sequence 485535,	225	19	1.1	19	1	US-10-798-090-24	Sequence 24, Appl
153	21.8	1.2	25	1	US-11-060-756-141921	Sequence 141921,	226	19	1.1	19	1	US-10-798-090-25	Sequence 25, Appl
154	21.8	1.2	25	1	US-11-060-756-146660	Sequence 146660,	227	19	1.1	19	1	US-10-798-090-26	Sequence 26, Appl
155	21.8	1.2	25	1	US-11-060-756-152117	Sequence 152117,	228	19	1.1	19	1	US-10-798-090-27	Sequence 27, Appl
156	21.8	1.2	25	1	US-11-136-527-158540	Sequence 158540,	229	19	1.1	19	1	US-10-798-090-28	Sequence 28, Appl
157	21.4	1.2	25	1	US-10-809-189-58455	Sequence 58455, A	230	19	1.1	19	1	US-10-798-090-29	Sequence 29, Appl
158	20.8	1.2	25	1	US-10-719-900-451174	Sequence 451174,	231	19	1.1	19	1	US-10-798-090-30	Sequence 30, Appl
159	20.8	1.2	25	1	US-11-060-756-140215	Sequence 140215,	232	19	1.1	19	1	US-10-798-090-31	Sequence 31, Appl
160	20.8	1.2	25	1	US-11-060-756-140215	Sequence 140215,	233	19	1.1	19	1	US-10-798-090-33	Sequence 32, Appl
161	20.8	1.2	25	1	US-11-060-756-176156	Sequence 176156,	234	19	1.1	19	1	US-10-798-090-32	Sequence 33, Appl
162	20.8	1.2	25	1	US-11-060-756-202713	Sequence 202713,	235	19	1.1	19	1	US-10-798-090-34	Sequence 34, Appl
163	20.8	1.2	25	1	US-11-060-756-239676	Sequence 239676,	236	19	1.1	19	1	US-10-798-090-35	Sequence 35, Appl
164	20.8	1.2	25	1	US-11-121-849-124288	Sequence 124288,	237	19	1.1	19	1	US-10-798-090-36	Sequence 36, Appl
165	20.8	1.2	25	1	US-11-136-527-158541	Sequence 158541,	238	19	1.1	19	1	US-10-798-090-37	Sequence 37, Appl
166	20.2	1.1	25	1	US-10-719-956-274610	Sequence 274610,	239	19	1.1	19	1	US-10-798-090-38	Sequence 38, Appl
167	20.2	1.1	25	1	US-10-719-956-580106	Sequence 580106,	240	19	1.1	19	1	US-10-798-090-39	Sequence 39, Appl
168	20.2	1.1	25	1	US-10-719-956-664015	Sequence 664015,	241	19	1.1	19	1	US-10-798-090-40	Sequence 40, Appl
169	20.2	1.1	25	1	US-10-719-900-43769	Sequence 43769, A	242	19	1.1	19	1	US-10-798-090-41	Sequence 41, Appl
170	20.2	1.1	25	1	US-10-719-900-55769	Sequence 55769, A	243	19	1.1	19	1	US-10-798-090-42	Sequence 42, Appl
171	20.2	1.1	25	1	US-10-719-900-387772	Sequence 387772,	244	19	1.1	19	1	US-10-798-090-43	Sequence 43, Appl
172	20.2	1.1	25	1	US-10-719-900-562102	Sequence 562102,	245	19	1.1	19	1	US-10-798-090-44	Sequence 44, Appl
173	20.2	1.1	25	1	US-10-719-900-795977	Sequence 795977,	246	19	1.1	19	1	US-10-798-090-45	Sequence 45, Appl
174	20.2	1.1	25	1	US-10-719-900-953129	Sequence 953129,	247	19	1.1	19	1	US-10-798-090-46	Sequence 46, Appl
175	20.2	1.1	25	1	US-10-809-189-99629	Sequence 99629, A	248	19	1.1	19	1	US-10-798-090-47	Sequence 47, Appl
176	20.2	1.1	25	1	US-10-809-189-115275	Sequence 115275,	249	19	1.1	19	1	US-10-798-090-48	Sequence 48, Appl
177	20.2	1.1	25	1	US-11-060-756-121819	Sequence 121819,	250	19	1.1	19	1	US-10-798-090-49	Sequence 49, Appl
178	20.2	1.1	25	1	US-11-060-756-121820	Sequence 121820,	251	19	1.1	19	1	US-10-798-090-50	Sequence 50, Appl
179	20.2	1.1	25	1	US-11-060-756-122169	Sequence 122169,	252	19	1.1	19	1	US-10-798-090-50	Sequence 50, Appl

253	19	1.1	19	1	US-10-798-090-51	Sequence 51, App1	C 326	19	1.1	19	1	US-10-798-090-124	Sequence 124, App1
254	19	1.1	19	1	US-10-798-090-52	Sequence 52, App1	C 327	19	1.1	19	1	US-10-798-090-125	Sequence 125, App1
255	19	1.1	19	1	US-10-798-090-53	Sequence 53, App1	C 328	19	1.1	19	1	US-10-798-090-126	Sequence 126, App1
256	19	1.1	19	1	US-10-798-090-54	Sequence 54, App1	C 329	19	1.1	19	1	US-10-798-090-127	Sequence 127, App1
257	19	1.1	19	1	US-10-798-090-55	Sequence 55, App1	C 330	19	1.1	19	1	US-10-798-090-128	Sequence 128, App1
258	19	1.1	19	1	US-10-798-090-56	Sequence 56, App1	C 331	19	1.1	19	1	US-10-798-090-129	Sequence 129, App1
259	19	1.1	19	1	US-10-798-090-57	Sequence 57, App1	C 332	19	1.1	19	1	US-10-798-090-130	Sequence 130, App1
260	19	1.1	19	1	US-10-798-090-58	Sequence 58, App1	C 333	19	1.1	19	1	US-10-798-090-131	Sequence 131, App1
261	19	1.1	19	1	US-10-798-090-59	Sequence 59, App1	C 334	19	1.1	19	1	US-10-798-090-132	Sequence 132, App1
262	19	1.1	19	1	US-10-798-090-60	Sequence 60, App1	C 335	19	1.1	19	1	US-10-798-090-133	Sequence 133, App1
263	19	1.1	19	1	US-10-798-090-61	Sequence 61, App1	C 336	19	1.1	19	1	US-10-798-090-134	Sequence 134, App1
264	19	1.1	19	1	US-10-798-090-62	Sequence 62, App1	C 337	19	1.1	19	1	US-10-798-090-135	Sequence 135, App1
265	19	1.1	19	1	US-10-798-090-63	Sequence 63, App1	C 338	19	1.1	19	1	US-10-798-090-136	Sequence 136, App1
266	19	1.1	19	1	US-10-798-090-64	Sequence 64, App1	C 339	19	1.1	19	1	US-10-798-090-137	Sequence 137, App1
267	19	1.1	19	1	US-10-798-090-65	Sequence 65, App1	C 340	19	1.1	19	1	US-10-798-090-138	Sequence 138, App1
268	19	1.1	19	1	US-10-798-090-66	Sequence 66, App1	C 341	19	1.1	19	1	US-10-798-090-139	Sequence 139, App1
269	19	1.1	19	1	US-10-798-090-67	Sequence 67, App1	C 342	19	1.1	19	1	US-10-798-090-140	Sequence 140, App1
270	19	1.1	19	1	US-10-798-090-68	Sequence 68, App1	C 343	19	1.1	19	1	US-10-798-090-141	Sequence 141, App1
271	19	1.1	19	1	US-10-798-090-69	Sequence 69, App1	C 344	19	1.1	19	1	US-10-798-090-142	Sequence 142, App1
272	19	1.1	19	1	US-10-798-090-70	Sequence 70, App1	C 345	19	1.1	19	1	US-10-798-090-143	Sequence 143, App1
273	19	1.1	19	1	US-10-798-090-71	Sequence 71, App1	C 346	19	1.1	19	1	US-10-798-090-144	Sequence 144, App1
274	19	1.1	19	1	US-10-798-090-72	Sequence 72, App1	C 347	19	1.1	19	1	US-10-798-090-145	Sequence 145, App1
275	19	1.1	19	1	US-10-798-090-73	Sequence 73, App1	C 348	19	1.1	19	1	US-10-798-090-146	Sequence 146, App1
276	19	1.1	19	1	US-10-798-090-74	Sequence 74, App1	C 349	19	1.1	19	1	US-10-798-090-147	Sequence 147, App1
277	19	1.1	19	1	US-10-798-090-75	Sequence 75, App1	C 350	19	1.1	19	1	US-10-798-090-148	Sequence 148, App1
278	19	1.1	19	1	US-10-798-090-76	Sequence 76, App1	C 351	19	1.1	19	1	US-10-798-090-149	Sequence 149, App1
279	19	1.1	19	1	US-10-798-090-77	Sequence 77, App1	C 352	19	1.1	19	1	US-10-798-090-150	Sequence 150, App1
280	19	1.1	19	1	US-10-798-090-78	Sequence 78, App1	C 353	19	1.1	19	1	US-10-798-090-151	Sequence 151, App1
281	19	1.1	19	1	US-10-798-090-79	Sequence 79, App1	C 354	19	1.				

c	399	19	1.1	19	1	US-10-798-090-197	Sequence 197, App
	400	19	1.1	19	1	US-10-798-090-198	Sequence 198, App
	401	19	1.1	19	1	US-10-919-866-1	Sequence 1, Appl
	402	19	1.1	19	1	US-10-919-866-2	Sequence 2, Appl
	403	19	1.1	19	1	US-10-919-866-3	Sequence 3, Appl
	404	19	1.1	19	1	US-10-919-866-4	Sequence 4, Appl
	405	19	1.1	19	1	US-10-919-866-5	Sequence 5, Appl
	406	19	1.1	19	1	US-10-919-866-6	Sequence 6, Appl
	407	19	1.1	19	1	US-10-919-866-7	Sequence 7, Appl
	408	19	1.1	19	1	US-10-919-866-8	Sequence 8, Appl
	409	19	1.1	19	1	US-10-919-866-9	Sequence 9, Appl
	410	19	1.1	19	1	US-10-919-866-10	Sequence 10, Appl
	411	19	1.1	19	1	US-10-919-866-11	Sequence 11, Appl
	412	19	1.1	19	1	US-10-919-866-12	Sequence 12, Appl
	413	19	1.1	19	1	US-10-919-866-13	Sequence 13, Appl
	414	19	1.1	19	1	US-10-919-866-14	Sequence 14, Appl
	415	19	1.1	19	1	US-10-919-866-15	Sequence 15, Appl
	416	19	1.1	19	1	US-10-919-866-16	Sequence 16, Appl
	417	19	1.1	19	1	US-10-919-866-17	Sequence 17, Appl
	418	19	1.1	19	1	US-10-919-866-18	Sequence 18, Appl
	419	19	1.1	19	1	US-10-919-866-19	Sequence 19, Appl
	420	19	1.1	19	1	US-10-919-866-20	Sequence 20, Appl
	421	19	1.1	19	1	US-10-919-866-21	Sequence 21, Appl
	422	19	1.1	19	1	US-10-919-866-22	Sequence 22, Appl
	423	19	1.1	19	1	US-10-919-866-23	Sequence 23, Appl
	424	19	1.1	19	1	US-10-919-866-24	Sequence 24, Appl
	425	19	1.1	19	1	US-10-919-866-25	Sequence 25, Appl
	426	19	1.1	19	1	US-10-919-866-26	Sequence 26, Appl
	427	19	1.1	19	1	US-10-919-866-27	Sequence 27, Appl
	428	19	1.1	19	1	US-10-919-866-28	Sequence 28, Appl
	429	19	1.1	19	1	US-10-919-866-29	Sequence 29, Appl
	430	19	1.1	19	1	US-10-919-866-30	Sequence 30, Appl
	431	19	1.1	19	1	US-10-919-866-31	Sequence 31, Appl
	432	19	1.1	19	1	US-10-919-866-32	Sequence 32, Appl
	433	19	1.1	19	1	US-10-919-866-33	Sequence 33, Appl
	434	19	1.1	19	1	US-10-919-866-34	Sequence 34, Appl
	435	19	1.1	19	1	US-10-919-866-35	Sequence 35, Appl
	436	19	1.1	19	1	US-10-919-866-36	Sequence 36, Appl
	437	19	1.1	19	1	US-10-919-866-37	Sequence 37, Appl
	438	19	1.1	19	1	US-10-919-866-38	Sequence 38, Appl
	439	19	1.1	19	1	US-10-919-866-39	Sequence 39, Appl
	440	19	1.1	19	1	US-10-919-866-40	Sequence 40, Appl
	441	19	1.1	19	1	US-10-919-866-41	Sequence 41, Appl
	442	19	1.1	19	1	US-10-919-866-42	Sequence 42, Appl
	443	19	1.1	19	1	US-10-919-866-43	Sequence 43, Appl
	444	19	1.1	19	1	US-10-919-866-44	Sequence 44, Appl
	445	19	1.1	19	1	US-10-919-866-45	Sequence 45, Appl
	446	19	1.1	19	1	US-10-919-866-46	Sequence 46, Appl
	447	19	1.1	19	1	US-10-919-866-47	Sequence 47, Appl
	448	19	1.1	19	1	US-10-919-866-48	Sequence 48, Appl
	449	19	1.1	19	1	US-10-919-866-49	Sequence 49, Appl
	450	19	1.1	19	1	US-10-919-866-50	Sequence 50, Appl
	451	19	1.1	19	1	US-10-919-866-51	Sequence 51, Appl
	452	19	1.1	19	1	US-10-919-866-52	Sequence 52, Appl
	453	19	1.1	19	1	US-10-919-866-53	Sequence 53, Appl
	454	19	1.1	19	1	US-10-919-866-54	Sequence 54, Appl
	455	19	1.1	19	1	US-10-919-866-55	Sequence 55, Appl
	456	19	1.1	19	1	US-10-919-866-56	Sequence 56, Appl
	457	19	1.1	19	1	US-10-919-866-57	Sequence 57, Appl
	458	19	1.1	19	1	US-10-919-866-58	Sequence 58, Appl
	459	19	1.1	19	1	US-10-919-866-59	Sequence 59, Appl
	460	19	1.1	19	1	US-10-919-866-60	Sequence 60, Appl
	461	19	1.1	19	1	US-10-919-866-61	Sequence 61, Appl
	462	19	1.1	19	1	US-10-919-866-62	Sequence 62, Appl
	463	19	1.1	19	1	US-10-919-866-63	Sequence 63, Appl
	464	19	1.1	19	1	US-10-919-866-64	Sequence 64, Appl
	465	19	1.1	19	1	US-10-919-866-65	Sequence 65, Appl
	466	19	1.1	19	1	US-10-919-866-66	Sequence 66, Appl
	467	19	1.1	19	1	US-10-919-866-67	Sequence 67, Appl
	468	19	1.1	19	1	US-10-919-866-68	Sequence 68, Appl
	469	19	1.1	19	1	US-10-919-866-69	Sequence 69, Appl
	470	19	1.1	19	1	US-10-919-866-70	Sequence 70, Appl
	471	19	1.1	19	1	US-10-919-866-71	Sequence 71, Appl

C 545	19	1.1	19	US-10-919-866-145	Sequence 145, App	618	19	1.1	19	1	US-11-083-784-97018	Sequence 97018, A
C 546	19	1.1	19	US-10-919-866-146	Sequence 146, App	619	19	1.1	19	1	US-11-083-784-97019	Sequence 97019, A
C 547	19	1.1	19	US-10-919-866-147	Sequence 147, App	620	19	1.1	19	1	US-11-083-784-97020	Sequence 97020, A
C 548	19	1.1	19	US-10-919-866-148	Sequence 148, App	621	19	1.1	19	1	US-11-083-784-97021	Sequence 97021, A
C 549	19	1.1	19	US-10-919-866-149	Sequence 149, App	622	19	1.1	19	1	US-11-083-784-97022	Sequence 97022, A
C 550	19	1.1	19	US-10-919-866-150	Sequence 150, App	623	19	1.1	19	1	US-11-083-784-97023	Sequence 97023, A
C 551	19	1.1	19	US-10-919-866-151	Sequence 151, App	624	19	1.1	19	1	US-11-083-784-97024	Sequence 97024, A
C 552	19	1.1	19	US-10-919-866-152	Sequence 152, App	625	19	1.1	19	1	US-11-083-784-97025	Sequence 97025, A
C 553	19	1.1	19	US-10-919-866-153	Sequence 153, App	626	19	1.1	19	1	US-11-083-784-97026	Sequence 97026, A
C 554	19	1.1	19	US-10-919-866-154	Sequence 154, App	627	19	1.1	19	1	US-11-083-784-97027	Sequence 97027, A
C 555	19	1.1	19	US-10-919-866-155	Sequence 155, App	628	19	1.1	19	1	US-11-083-784-97028	Sequence 97028, A
C 556	19	1.1	19	US-10-919-866-156	Sequence 156, App	629	19	1.1	19	1	US-11-083-784-97029	Sequence 97029, A
C 557	19	1.1	19	US-10-919-866-157	Sequence 157, App	630	19	1.1	19	1	US-11-083-784-97030	Sequence 97030, A
C 558	19	1.1	19	US-10-919-866-158	Sequence 158, App	631	19	1.1	19	1	US-11-083-784-97031	Sequence 97031, A
C 559	19	1.1	19	US-10-919-866-159	Sequence 159, App	632	19	1.1	19	1	US-11-083-784-97032	Sequence 97032, A
C 560	19	1.1	19	US-10-919-866-160	Sequence 160, App	633	19	1.1	19	1	US-11-083-784-97033	Sequence 97033, A
C 561	19	1.1	19	US-10-919-866-161	Sequence 161, App	634	19	1.1	19	1	US-11-083-784-97034	Sequence 97034, A
C 562	19	1.1	19	US-10-919-866-162	Sequence 162, App	635	19	1.1	19	1	US-11-083-784-97035	Sequence 97035, A
C 563	19	1.1	19	US-10-919-866-163	Sequence 163, App	636	19	1.1	19	1	US-11-083-784-97036	Sequence 97036, A
C 564	19	1.1	19	US-10-919-866-164	Sequence 164, App	637	19	1.1	19	1	US-11-083-784-97037	Sequence 97037, A
C 565	19	1.1	19	US-10-919-866-165	Sequence 165, App	638	19	1.1	19	1	US-11-083-784-97038	Sequence 97038, A
C 566	19	1.1	19	US-10-919-866-166	Sequence 166, App	639	19	1.1	19	1	US-11-083-784-97039	Sequence 97039, A
C 567	19	1.1	19	US-10-919-866-167	Sequence 167, App	640	19	1.1	19	1	US-11-083-784-97040	Sequence 97040, A
C 568	19	1.1	19	US-10-919-866-168	Sequence 168, App	641	19	1.1	19	1	US-11-083-784-97041	Sequence 97041, A
C 569	19	1.1	19	US-10-919-866-169	Sequence 169, App	642	19	1.1	19	1	US-11-083-784-97042	Sequence 97042, A
C 570	19	1.1	19	US-10-919-866-170	Sequence 170, App	643	19	1.1	19	1	US-11-083-784-97043	Sequence 97043, A
C 571	19	1.1	19	US-10-919-866-171	Sequence 171, App	644	19	1.1	19	1	US-11-083-784-97044	Sequence 97044, A
C 572	19	1.1	19	US-10-919-866-172	Sequence 172, App	645	19	1.1	19	1	US-11-083-784-97045	Sequence 97045, A
C 573	19	1.1	19	US-10-919-866-173	Sequence 173, App	646	19	1.1	19	1	US-11-083-784-97046	Sequence 97046, A
C												

651	19	1.1	19	1	US-11-083-784-97091	Sequence 97091, A	764	19	1.1	19	1	US-11-101-244-97064	Sequence 97064, A
652	19	1.1	19	1	US-11-083-784-97092	Sequence 97092, A	765	19	1.1	19	1	US-11-101-244-97065	Sequence 97065, A
653	19	1.1	19	1	US-11-083-784-97093	Sequence 97093, A	766	19	1.1	19	1	US-11-101-244-97066	Sequence 97066, A
654	19	1.1	19	1	US-11-083-784-97094	Sequence 97094, A	767	19	1.1	19	1	US-11-101-244-97067	Sequence 97067, A
655	19	1.1	19	1	US-11-083-784-97095	Sequence 97095, A	768	19	1.1	19	1	US-11-101-244-97068	Sequence 97068, A
656	19	1.1	19	1	US-11-083-784-97096	Sequence 97096, A	769	19	1.1	19	1	US-11-101-244-97069	Sequence 97069, A
657	19	1.1	19	1	US-11-083-784-97097	Sequence 97097, A	770	19	1.1	19	1	US-11-101-244-97070	Sequence 97070, A
658	19	1.1	19	1	US-11-083-784-97098	Sequence 97098, A	771	19	1.1	19	1	US-11-101-244-97071	Sequence 97071, A
659	19	1.1	19	1	US-11-101-244-96999	Sequence 96999, A	772	19	1.1	19	1	US-11-101-244-97072	Sequence 97072, A
700	19	1.1	19	1	US-11-101-244-97000	Sequence 97000, A	773	19	1.1	19	1	US-11-101-244-97073	Sequence 97073, A
701	19	1.1	19	1	US-11-101-244-97001	Sequence 97001, A	774	19	1.1	19	1	US-11-101-244-97074	Sequence 97074, A
702	19	1.1	19	1	US-11-101-244-97002	Sequence 97002, A	775	19	1.1	19	1	US-11-101-244-97075	Sequence 97075, A
703	19	1.1	19	1	US-11-101-244-97003	Sequence 97003, A	776	19	1.1	19	1	US-11-101-244-97076	Sequence 97076, A
704	19	1.1	19	1	US-11-101-244-97004	Sequence 97004, A	777	19	1.1	19	1	US-11-101-244-97077	Sequence 97077, A
705	19	1.1	19	1	US-11-101-244-97005	Sequence 97005, A	778	19	1.1	19	1	US-11-101-244-97078	Sequence 97078, A
706	19	1.1	19	1	US-11-101-244-97006	Sequence 97006, A	779	19	1.1	19	1	US-11-101-244-97079	Sequence 97079, A
707	19	1.1	19	1	US-11-101-244-97007	Sequence 97007, A	780	19	1.1	19	1	US-11-101-244-97080	Sequence 97080, A
708	19	1.1	19	1	US-11-101-244-97008	Sequence 97008, A	781	19	1.1	19	1	US-11-101-244-97081	Sequence 97081, A
709	19	1.1	19	1	US-11-101-244-97009	Sequence 97009, A	782	19	1.1	19	1	US-11-101-244-97082	Sequence 97082, A
710	19	1.1	19	1	US-11-101-244-97010	Sequence 97010, A	783	19	1.1	19	1	US-11-101-244-97083	Sequence 97083, A
711	19	1.1	19	1	US-11-101-244-97011	Sequence 97011, A	784	19	1.1	19	1	US-11-101-244-97084	Sequence 97084, A
712	19	1.1	19	1	US-11-101-244-97012	Sequence 97012, A	785	19	1.1	19	1	US-11-101-244-97085	Sequence 97085, A
713	19	1.1	19	1	US-11-101-244-97013	Sequence 97013, A	786	19	1.1	19	1	US-11-101-244-97086	Sequence 97086, A
714	19	1.1	19	1	US-11-101-244-97014	Sequence 97014, A	787	19	1.1	19	1	US-11-101-244-97087	Sequence 97087, A
715	19	1.1	19	1	US-11-101-244-97015	Sequence 97015, A	788	19	1.1	19	1	US-11-101-244-97088	Sequence 97088, A
716	19	1.1	19	1	US-11-101-244-97016	Sequence 97016, A	789	19	1.1	19	1	US-11-101-244-97089	Sequence 97089, A
717	19	1.1	19	1	US-11-101-244-97017	Sequence 97017, A	790	19	1.1	19	1	US-11-101-244-97090	Sequence 97090, A
718	19	1.1	19	1	US-11								

C 983	19	1.1	21	1	US-10-919-866-298	Sequence 298, App	1056	16.8	0.9	21	1	US-10-310-914A-146083	Sequence 146083,
C 984	19	1.1	21	1	US-10-919-866-299	Sequence 299, App	1057	16.8	0.9	21	1	US-10-310-914A-152663	Sequence 152663,
C 985	19	1.1	21	1	US-10-919-866-300	Sequence 300, App	1058	16.8	0.9	21	1	US-10-310-914A-886986	Sequence 886986,
C 986	19	1.1	21	1	US-10-919-866-301	Sequence 301, App	C1059	16.8	0.9	21	1	US-11-183-485-2	Sequence 2, Appl1
C 987	19	1.1	21	1	US-10-919-866-302	Sequence 302, App	C1060	16.8	0.9	21	1	US-11-183-486-2	Sequence 2, Appl1
C 988	19	1.1	21	1	US-10-919-866-312	Sequence 312, App	C1061	16.4	0.9	18	1	US-10-310-914A-59413	Sequence 85413, A
C 989	19	1.1	21	1	US-10-919-866-313	Sequence 313, App	C1062	16.4	0.9	18	1	US-10-310-914A-598921	Sequence 598921,
C 990	19	1.1	21	1	US-10-919-866-314	Sequence 314, App	C1063	16.4	0.9	18	1	US-10-310-914A-886257	Sequence 886257,
C 991	19	1.1	21	1	US-10-919-866-315	Sequence 315, App	C1064	16.4	0.9	18	1	US-10-310-914A-1202840	Sequence 1202840,
C 992	19	1.1	21	1	US-10-919-866-316	Sequence 316, App	C1065	16.4	0.9	19	1	US-10-310-914A-886252	Sequence 886252,
C 993	19	1.1	21	1	US-10-919-866-317	Sequence 317, App	C1067	16.4	0.9	19	1	US-10-310-914A-991339	Sequence 991339,
C 994	19	1.1	21	1	US-10-919-866-318	Sequence 318, App	C1068	16.4	0.9	19	1	US-10-310-914A-983423	Sequence 983423,
C 995	19	1.1	21	1	US-10-919-866-319	Sequence 319, App	C1069	16.4	0.9	19	1	US-11-083-784-14345	Sequence 14345, A
C 996	19	1.1	21	1	US-10-919-866-320	Sequence 320, App	C1070	16.4	0.9	19	1	US-11-083-784-14512	Sequence 14512, A
C 997	18.8	1.1	22	1	US-10-310-914A-446812	Sequence 446812,	C1071	16.4	0.9	19	1	US-11-083-784-14599	Sequence 14599, A
C 998	18	1.0	19	1	US-10-871-137-2	Sequence 2, Appl1	C1072	16.4	0.9	19	1	US-11-083-784-14678	Sequence 14678, A
C 999	18	1.0	19	1	US-11-083-784-97104	Sequence 97104, A	C1073	16.4	0.9	19	1	US-11-083-784-14753	Sequence 14753, A
C 1000	18	1.0	19	1	US-11-101-244-97104	Sequence 97104, A	C1074	16.4	0.9	19	1	US-11-083-784-82206	Sequence 82206, A
C 1001	18	1.0	20	1	US-10-280-183A-364	Sequence 364, App	C1075	16.4	0.9	19	1	US-11-083-784-82258	Sequence 82258, A
C1002	17.8	1.0	21	1	US-10-310-914A-1189557	Sequence 1189557,	C1076	16.4	0.9	19	1	US-11-083-784-246660	Sequence 246660,
C1003	17.8	1.0	21	1	US-10-310-914A-1352943	Sequence 1352943,	C1077	16.4	0.9	19	1	US-11-083-784-498676	Sequence 498676,
C1004	17.8	1.0	22	1	US-10-942-865-234	Sequence 234, App	C1078	16.4	0.9	19	1	US-11-083-784-498775	Sequence 498775,
C1005	17.8	1.0	22	1	US-10-310-914A-1189555	Sequence 1189555,	C1079	16.4	0.9	19	1	US-11-083-784-588102	Sequence 588102,
C1006	17.4	1.0	22	1	US-10-310-914A-1352927	Sequence 1352927,	C1080	16.4	0.9	19	1	US-11-083-784-668861	Sequence 668861,
C1007	17.4	1.0	19	1	US-11-083-784-14354	Sequence 14354, A	C1081	16.4	0.9	19	1	US-11-083-784-738023	Sequence 738023,
C1008	17.4	1.0	19	1	US-11-083-784-96787	Sequence 96787, A	C1082	16.4	0.9	19	1	US-11-083-784-829653	Sequence 829653,
C1009	17.4	1.0	19	1	US-11-083-784-96842	Sequence 96842, A	C1083	16.4	0.9	19	1	US-11-083-784-875701	Sequence 875701,
C1010	17.4	1.0	19	1	US-11-083-784-96860	Sequence 96860, A	C1084	16.4	0.9	19	1	US-11-083-784-923326	Sequence 923326,
C1011	17.4	1.0	19	1	US-11-083-784-96866	Sequence 96866, A	C1085	16.4	0.9	19	1	US-11-083-784-982420	Sequence 982420,
C1012	17.4	1.0	19	1	US-11-083-784-96897	Sequence 96897, A	C1086	16.4	0.9	19	1	US-11-083-784-1083345	Sequence 1083345,
C1013	17.4	1.0	19	1	US-11-083-784-97147	Sequence 97147, A	C1087	16.4	0.9	19	1	US-11-083-784-1216237	Sequence 1216237,
C1014	17.4	1.0	19	1	US-11-083-784-574415	Sequence 574415,	C1088	16.4	0.9	19	1	US-11-083-784-1308145	Sequence 1308145,
C1015	17.4	1.0	19	1	US-11-083-784-738029	Sequence 738029,	C1089	16.4	0.9	19	1	US-11-083-784-1422064	Sequence 1422064,
C1016	17.4	1.0	19	1	US-11-083-784-819276	Sequence 819276,	C1090	16.4	0.9	19	1	US-11-083-784-1422087	Sequence 1422087,
C1017	17.4	1.0	19	1	US-11-101-244-14354	Sequence 14354, A	C1091	16.4	0.9	19	1	US-11-101-244-14345	Sequence 14345, A
C1018	17.4	1.0	19	1	US-11-101-244-96787	Sequence 96787, A	C1092	16.4	0.9	19	1	US-11-101-244-14512	Sequence 14512, A
C1019	17.4	1.0	19	1	US-11-101-244-96842	Sequence 96842, A	C1093	16.4	0.9	19	1	US-11-101-244-14599	Sequence 14599, A
C1020	17.4	1.0	19	1	US-11-101-244-96860	Sequence 96860, A	C1094	16.4	0.9	19	1	US-11-101-244-14659	Sequence 14659, A
C1021	17.4	1.0	19	1	US-11-101-244-96866	Sequence 96866, A	C1095	16.4	0.9	19	1	US-11-101-244-14753	Sequence 14753, A
C1022	17.4	1.0	19	1	US-11-101-244-96897	Sequence 96897, A	C1096	16.4	0.9	19	1	US-11-101-244-82206	Sequence 82206, A
C1023	17.4	1.0	19	1	US-11-101-244-97416	Sequence 97416, A	C1097	16.4	0.9	19	1	US-11-101-244-82258	Sequence 82258, A
C1024	17.4	1.0	19	1	US-11-101-244-574416	Sequence 574416,	C1098	16.4	0.9	19	1	US-11-101-244-498576	Sequence 498576,
C1025	17.4	1.0	19	1	US-11-101-244-738029	Sequence 738029,	C1099	16.4	0.9	19	1	US-11-101-244-498676	Sequence 498676,
C1026	17.4	1.0	20	1	US-10-310-914A-886273	Sequence 886273,	C1100	16.4	0.9	19	1	US-11-101-244-498775	Sequence 498775,
C1027	17.4	1.0	20	1	US-10-310-914A-1387018	Sequence 1387018,	C1101	16.4	0.9	19	1	US-11-101-244-586102	Sequence 586102,
C1028	17.4	1.0	20	1	US-11-041-456-14	Sequence 14, App1	C1102	16.4	0.9	19	1	US-11-101-244-688861	Sequence 688861,
C1029	17.4	1.0	20	1	US-10-770-726-20980	Sequence 20980, A	C1103	16.4	0.9	19	1	US-11-101-244-738023	Sequence 738023,
C1030	17.4	1.0	21	1	US-10-676-154-105	Sequence 105, App1	C1104	16.4	0.9	19	1	US-11-101-244-829653	Sequence 829653,
C1031	17	1.0	17	1	US-10-310-914A-1156690	Sequence 1156690,	C1105	16.4	0.9	19	1	US-11-101-244-829653	Sequence 829653,
C1032	17	1.0	20	1	US-09-922-146-21	Sequence 21, App1	C1106	16.4	0.9	19	1	US-11-101-244-923326	Sequence 923326,
C1033	16.8	0.9	20	1	US-10-310-914A-34916	Sequence 34916, A	C1107	16.4	0.9	19	1	US-11-101-244-982420	Sequence 982420,
C1034	16.8	0.9	20	1	US-10-310-914A-44757	Sequence 44757, A	C1108	16.4	0.9	19	1	US-11-101-244-1083345	Sequence 1083345,
C1035	16.8	0.9	20	1	US-10-310-914A-85996	Sequence 85996, A	C1109	16.4	0.9	19	1	US-11-101-244-1216237	Sequence 1216237,
C1036	16.8	0.9	20	1	US-10-310-914A-205405	Sequence 205405,	C1110	16.4	0.9	19	1	US-11-101-244-1308145	Sequence 1308145,
C1037	16.8	0.9	20	1	US-10-310-914A-706110	Sequence 706110,	C1111	16.4	0.9	19	1	US-11-101-244-1422064	Sequence 1422064,
C1038	16.8	0.9	20	1	US-10-310-914A-740270	Sequence 740270,	C1112	16.4	0.9	19	1	US-11-101-244-1422087	Sequence 1422087,
C1039	16.8	0.9	20	1	US-10-310-914A-886771,	Sequence 886771,	C1113	16.4	0.9	19	1	US-11-110-271-540	Sequence 540, App
C1040	16.8	0.9	20	1	US-10-310-914A-1225898	Sequence 1225898,	C1114	16.4	0.9	19	1	US-11-176-026A-33	Sequence 33, App1
C1041	16.8	0.9	21	1	US-09-947-326-2	Sequence 2, Appl1	C1115	16.4	0.9	19	1	US-10-310-914A-471659	Sequence 471659,
C1042	16.8	0.9	21	1	US-09-967-726A-2	Sequence 2, Appl1	C1116	16.4	0.9	20	1	US-10-310-914A-698822	Sequence 698822,
C1043	16.8	0.9	21	1	US-10-080-794-2	Sequence 2, Appl1	C1117	16.4	0.9	20	1	US-10-310-914A-698823	Sequence 698823,
C1044	16.8	0.9	21	1	US-10-786-720-8032	Sequence 8032, App	C1118	16.4	0.9	20	1	US-10-310-914A-698823	Sequence 698823,
C1045	16.8	0.9	21	1	US-10-786-720-8034	Sequence 8034, App	C1119	16	0.9	18	1	US-10-310-914A-1371239	Sequence 1371239,
C1046	16.8	0.9	21	1	US-10-786-720-8036	Sequence 10266, A	C1120	16	0.9	19	1	US-11-083-784-456075	Sequence 456075,
C1047	16.8	0.9	21	1	US-10-786-720-10264	Sequence 10266, A	C1121	16	0.9	19	1	US-11-083-784-1024070	Sequence 1024070,
C1048	16.8	0.9	21	1	US-10-786-720-10266	Sequence 3, Appl1	C1122	16	0.9	19	1	US-11-083-784-1258463	Sequence 1258463,
C1049	16.8	0.9	21	1	US-10-828-394-3	Sequence 3, Appl1	C1123	16	0.9	19	1	US-11-083-784-1537374	Sequence 1537374,
C1050	16.8	0.9	21	1	US-10-828-395-3	Sequence 3, Appl1	C1124	16	0.9	19	1	US-11-101-244-456075	Sequence 456075,
C1051	16.8	0.9	21	1	US-10-770-726-373	Sequence 373, App	C1125	16	0.9	19	1	US-11-101-244-1024070	Sequence 1024070,
C1052	16.8	0.9	21	1	US-10-770-726-2392	Sequence 2392, App	C1126	16	0.9	19	1	US-11-101-244-1258463	Sequence 1258463,
C1053	16.8	0.9	21	1	US-10-770-726-23694	Sequence 23694, A	C1127	16	0.9	19	1	US-11-101-244-1537374	Sequence 1537374,
C1054	16.8	0.9	21	1	US-10-310-914A-70833	Sequence 70833, A	C1128	16	0.9	19	1	US-09-922-146-22	Sequence 22, App1
C1055	16.8	0.9	21	1	US-10-310-914A-146082	Sequence 146082,							

1129	16	0.9	20	1	US-10-310-914A-593301	Sequence 593301,	C1202	15.8	0.9	19	1	US-11-083-784-661229	Sequence 661229,
C1130	16	0.9	20	1	US-10-310-914A-1148207	Sequence 1148207,	C1203	15.8	0.9	19	1	US-11-083-784-691453	Sequence 691453,
C1131	15.8	0.9	19	1	US-09-817-014-154	Sequence 154, App	C1204	15.8	0.9	19	1	US-11-083-784-691532	Sequence 691532,
C1132	15.8	0.9	19	1	US-10-056-229-155	Sequence 155,	C1205	15.8	0.9	19	1	US-11-083-784-770039	Sequence 770039,
C1133	15.8	0.9	19	1	US-10-444-925-126	Sequence 126, App	C1206	15.8	0.9	19	1	US-11-083-784-771283	Sequence 771283,
C1134	15.8	0.9	19	1	US-10-750-185-18826	Sequence 18826, A	C1207	15.8	0.9	19	1	US-11-083-784-819337	Sequence 819337,
C1135	15.8	0.9	19	1	US-10-750-623-18826	Sequence 18826, A	C1208	15.8	0.9	19	1	US-11-083-784-845076	Sequence 845076,
C1136	15.8	0.9	19	1	US-10-310-914A-151740	Sequence 151740,	C1209	15.8	0.9	19	1	US-11-083-784-860780	Sequence 860780,
C1137	15.8	0.9	19	1	US-10-310-914A-213659	Sequence 213659,	C1210	15.8	0.9	19	1	US-11-083-784-878444	Sequence 878444,
C1138	15.8	0.9	19	1	US-10-310-914A-302114	Sequence 302114,	C1211	15.8	0.9	19	1	US-11-083-784-891418	Sequence 891418,
C1139	15.8	0.9	19	1	US-10-310-914A-302115	Sequence 302115,	C1212	15.8	0.9	19	1	US-11-083-784-909309	Sequence 909309,
C1140	15.8	0.9	19	1	US-10-310-914A-396511	Sequence 396511,	C1213	15.8	0.9	19	1	US-11-083-784-910002	Sequence 910002,
C1141	15.8	0.9	19	1	US-10-310-914A-520464	Sequence 520464,	C1214	15.8	0.9	19	1	US-11-083-784-910052	Sequence 910052,
C1142	15.8	0.9	19	1	US-10-310-914A-605977	Sequence 605977,	C1215	15.8	0.9	19	1	US-11-083-784-941970	Sequence 941970,
C1143	15.8	0.9	19	1	US-10-310-914A-608678	Sequence 608678,	C1216	15.8	0.9	19	1	US-11-083-784-941980	Sequence 941980,
C1144	15.8	0.9	19	1	US-10-310-914A-629308	Sequence 629308,	C1217	15.8	0.9	19	1	US-11-083-784-102579	Sequence 102579,
C1145	15.8	0.9	19	1	US-10-310-914A-647404	Sequence 647404,	C1218	15.8	0.9	19	1	US-11-083-784-102579	Sequence 102579,
C1146	15.8	0.9	19	1	US-10-310-914A-647405	Sequence 647405,	C1219	15.8	0.9	19	1	US-11-083-784-1052031	Sequence 1052031,
C1147	15.8	0.9	19	1	US-10-310-914A-670737	Sequence 670737,	C1220	15.8	0.9	19	1	US-11-083-784-1052035	Sequence 1052035,
C1148	15.8	0.9	19	1	US-10-310-914A-1016294	Sequence 1016294,	C1221	15.8	0.9	19	1	US-11-083-784-1082966	Sequence 1082966,
C1149	15.8	0.9	19	1	US-10-310-914A-1251060	Sequence 1251060,	C1222	15.8	0.9	19	1	US-11-083-784-1095950	Sequence 1095950,
C1150	15.8	0.9	19	1	US-10-310-914A-1252140	Sequence 1252140,	C1223	15.8	0.9	19	1	US-11-083-784-1143713	Sequence 1143713,
C1151	15.8	0.9	19	1	US-10-310-914A-1287594	Sequence 1287594,	C1224	15.8	0.9	19	1	US-11-083-784-1202196	Sequence 1202196,
C1152	15.8	0.9	19	1	US-11-014-373-239	Sequence 239, App	C1225	15.8	0.9	19	1	US-11-083-784-1237713	Sequence 1237713,
C1153	15.8	0.9	19	1	US-11-014-373-516	Sequence 516, App	C1226	15.8	0.9	19	1	US-11-083-784-1267843	Sequence 1267843,
C1154	15.8	0.9	19	1	US-11-071-864-72	Sequence 72, App1	C1227	15.8	0.9	19	1	US-11-083-784-1267942	Sequence 1267942,
C1155	15.8	0.9	19	1	US-11-083-784-14368	Sequence 14368, A	C1228	15.8	0.9	19	1	US-11-083-784-1302272	Sequence 1302272,
C1156	15.8	0.9	19	1	US-11-083-784-14415	Sequence 14415, A	C1229	15.8	0.9	19	1	US-11-083-784-1314576	Sequence 1314576,
C1157	15.8	0.9	19	1	US-11-083-784-15086	Sequence 15086, A	C1230	15.8	0.9	19	1	US-11-083-784-1348446	Sequence 1348446,
C1158	15.8	0.9	19	1	US-11-083-784-15128	Sequence 15128, A	C1231	15.8	0.9	19	1	US-11-083-784-1365309	Sequence 1365309,
C1159	15.8	0.9	19	1	US-11-083-784-15214	Sequence 15214, A	C1232	15.8	0.9	19	1	US-11-083-784-1372117	Sequence 1372117,
C1160	15.8	0.9	19	1	US-11-083-784-152249	Sequence 22249, A	C1233	15.8	0.9	19	1	US-11-083-784-1393220	Sequence 1393220,
C1161	15.8	0.9	19	1	US-11-083-784-152349	Sequence 22349, A	C1234	15.8	0.9	19	1	US-11-083-784-1432908	Sequence 1432908,
C1162	15.8	0.9	19	1	US-11-083-784-155869	Sequence 45869, A	C1235	15.8	0.9	19	1	US-11-083-784-1450263	Sequence 1450263,
C1163	15.8	0.9	19	1	US-11-083-784-152416	Sequence 55246, A	C1236	15.8	0.9	19	1	US-11-083-784-1462725	Sequence 1462725,
C1164	15.8	0.9	19	1	US-11-083-784-152520	Sequence 55250, A	C1237	15.8	0.9	19	1	US-11-083-784-1462771	Sequence 1462771,
C1165	15.8	0.9	19	1	US-11-083-784-152639	Sequence 55639, A	C1238	15.8	0.9	19	1	US-11-083-784-1466198	Sequence 1466198,
C1166	15.8	0.9	19	1	US-11-083-784-152708	Sequence 55708, A	C1239	15.8	0.9	19	1	US-11-083-784-1496063	Sequence 1496063,
C1167	15.8	0.9	19	1	US-11-083-784-152803	Sequence 55803, A	C1240	15.8	0.9	19	1	US-11-083-784-1526168	Sequence 1526168,
C1168	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1241	15.8	0.9	19	1	US-11-083-784-1540139	Sequence 1540139,
C1169	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1242	15.8	0.9	19	1	US-11-083-784-1555890	Sequence 1555890,
C1170	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1243	15.8	0.9	19	1	US-11-083-784-1567851	Sequence 1567851,
C1171	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1244	15.8	0.9	19	1	US-11-083-784-1571114	Sequence 1571114,
C1172	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1245	15.8	0.9	19	1	US-11-083-784-1586104	Sequence 1586104,
C1173	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1246	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1174	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1247	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1175	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1248	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1176	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1249	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1177	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1250	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1178	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1251	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1179	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1252	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1180	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1253	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1181	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1254	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1182	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1255	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1183	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1256	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1184	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1257	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1185	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1258	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1186	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1259	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1187	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1260	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1188	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1261	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1189	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1262	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1190	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1263	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1191	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1264	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1192	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1265	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1193	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1266	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1194	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1267	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1195	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1268	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1196	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1269	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1197	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1270	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1198	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1271	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1199	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1272	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1200	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1273	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,
C1201	15.8	0.9	19	1	US-11-083-784-152901	Sequence 55901, A	C1274	15.8	0.9	19	1	US-11-083-784-1586107	Sequence 1586107,

c1275	15.8	0.9	19	1	US-11-101-244-155844	Sequence 155844,	1348	15.4	0.9	18	1	US-10-740-926-187	Sequence 187, App
c1276	15.8	0.9	19	1	US-11-101-244-193107	Sequence 193107,	1349	15.4	0.9	18	1	US-10-310-914A-14756	Sequence 44756, A
c1277	15.8	0.9	19	1	US-11-101-244-214402	Sequence 214402,	1350	15.4	0.9	18	1	US-10-310-914A-101513	Sequence 101513,
1278	15.8	0.9	19	1	US-11-101-244-22230	Sequence 22230,	1351	15.4	0.9	18	1	US-10-310-914A-114172	Sequence 114172,
1279	15.8	0.9	19	1	US-11-101-244-222321	Sequence 222321,	1352	15.4	0.9	18	1	US-10-310-914A-114173	Sequence 114173,
1280	15.8	0.9	19	1	US-11-101-244-34052	Sequence 34052,	1353	15.4	0.9	18	1	US-10-310-914A-159541	Sequence 159541,
c1281	15.8	0.9	19	1	US-11-101-244-391588	Sequence 391588,	c1354	15.4	0.9	18	1	US-10-310-914A-172099	Sequence 172099,
1282	15.8	0.9	19	1	US-11-101-244-409997	Sequence 409997,	1355	15.4	0.9	18	1	US-10-310-914A-254139	Sequence 254139,
1283	15.8	0.9	19	1	US-11-101-244-417946	Sequence 417946,	1356	15.4	0.9	18	1	US-10-310-914A-284580	Sequence 284580,
c1284	15.8	0.9	19	1	US-11-101-244-462391	Sequence 462391,	c1357	15.4	0.9	18	1	US-10-310-914A-530021	Sequence 630021,
1285	15.8	0.9	19	1	US-11-101-244-482025	Sequence 482025,	c1358	15.4	0.9	18	1	US-10-310-914A-738321	Sequence 738321,
c1286	15.8	0.9	19	1	US-11-101-244-514801	Sequence 514801,	1359	15.4	0.9	18	1	US-10-310-914A-793976	Sequence 793976,
1287	15.8	0.9	19	1	US-11-101-244-535685	Sequence 535685,	c1360	15.4	0.9	18	1	US-10-310-914A-907246	Sequence 907246,
c1288	15.8	0.9	19	1	US-11-101-244-574664	Sequence 574664,	c1361	15.4	0.9	18	1	US-10-310-914A-93182	Sequence 93182,
c1289	15.8	0.9	19	1	US-11-101-244-581851	Sequence 581851,	c1362	15.4	0.9	18	1	US-10-310-914A-958139	Sequence 958139,
c1290	15.8	0.9	19	1	US-11-101-244-581953	Sequence 581953,	c1363	15.4	0.9	18	1	US-10-310-914A-1087769	Sequence 1087769,
1291	15.8	0.9	19	1	US-11-101-244-640147	Sequence 640147,	c1364	15.4	0.9	18	1	US-10-310-914A-1267042	Sequence 1267042,
c1292	15.8	0.9	19	1	US-11-101-244-645531	Sequence 645531,	1365	15.4	0.9	18	1	US-10-349-143-6934	Sequence 6934, Ap
c1293	15.8	0.9	19	1	US-11-101-244-653396	Sequence 653396,	1366	15.4	0.9	19	1	US-10-349-143-7458	Sequence 7458, Ap
c1294	15.8	0.9	19	1	US-11-101-244-653423	Sequence 653423,	1367	15.4	0.9	19	1	US-10-310-914A-313799	Sequence 313799,
c1295	15.8	0.9	19	1	US-11-101-244-661229	Sequence 661229,	1368	15.4	0.9	19	1	US-10-310-914A-344052	Sequence 344052,
c1296	15.8	0.9	19	1	US-11-101-244-691453	Sequence 691453,	c1369	15.4	0.9	19	1	US-10-310-914A-484813	Sequence 448813,
c1297	15.8	0.9	19	1	US-11-101-244-691532	Sequence 691532,	c1370	15.4	0.9	19	1	US-10-310-914A-598899	Sequence 598899,
1298	15.8	0.9	19	1	US-11-101-244-770039	Sequence 770039,	1371	15.4	0.9	19	1	US-10-310-914A-1061923	Sequence 1061923,
c1299	15.8	0.9	19	1	US-11-101-244-771283	Sequence 771283,	c1372	15.4	0.9	19	1	US-10-310-914A-1157469	Sequence 1157469,
1300	15.8	0.9	19	1	US-11-101-244-819337	Sequence 819337,	1373	15.4	0.9	19	1	US-11-083-784-96831	Sequence 96831, A
1301	15.8	0.9	19	1	US-11-101-244-845076	Sequence 845076,	1374	15.4	0.9	19	1	US-11-083-784-97156	Sequence 97156, A
1302	15.8	0.9	19	1	US-11-101-244-860780	Sequence 860780,	1375	15.4	0.9	19	1	US-11-083-784-97216	Sequence 97216, A
c1303	15.8	0.9	19	1	US-11-101-244-878444	Sequence 878444,	c1376	15.4	0.9	19	1	US-11-083-784-103182	Sequence 103182,
1304	15.8	0.9	19	1	US-11-101-244-878448	Sequence 878448,	c1377	15.4	0.9	19	1	US-11-083-784-103189	Sequence 103189,
c1305	15.8	0.9	19	1	US-11-101-244-891418	Sequence 891418,	c1378	15.4	0.9	19	1	US-11-083-784-131581	Sequence 131581,
c1306	15.8	0.9	19	1	US-11-101-244-909909	Sequence 909909,	c1379	15.4	0.9	19	1	US-11-083-784-164314	Sequence 164314,
c1307	15.8	0.9	19	1	US-11-101-244-910052	Sequence 910052,	1380	15.4	0.9	19	1	US-11-083-784-220921	Sequence 220921,
1308	15.8	0.9	19	1	US-11-101-244-941780	Sequence 941780,	c1381	15.4	0.9	19	1	US-11-083-784-234743	Sequence 234743,
1309	15.8	0.9	19	1	US-11-101-244-941970	Sequence 941970,	c1382	15.4	0.9	19	1	US-11-083-784-234762	Sequence 234762,
c1310	15.8	0.9	19	1	US-11-101-244-1025790	Sequence 1025790,	c1383	15.4	0.9	19	1	US-11-083-784-240931	Sequence 240931,
c1311	15.8	0.9	19	1	US-11-101-244-1038110	Sequence 1038110,	c1384	15.4	0.9	19	1	US-11-083-784-259725	Sequence 259725,
c1312	15.8	0.9	19	1	US-11-101-244-1052031	Sequence 1052031,	c1385	15.4	0.9	19	1	US-11-083-784-289369	Sequence 289369,
c1313	15.8	0.9	19	1	US-11-101-244-1052055	Sequence 1052055,	1386	15.4	0.9	19	1	US-11-083-784-345636	Sequence 345636,
1314	15.8	0.9	19	1	US-11-101-244-1082966	Sequence 1082966,	1387	15.4	0.9	19	1	US-11-083-784-354636	Sequence 354636,
1315	15.8	0.9	19	1	US-11-101-244-1095950	Sequence 1095950,	c1388	15.4	0.9	19	1	US-11-083-784-394748	Sequence 394748,
c1316	15.8	0.9	19	1	US-11-101-244-113713	Sequence 113713,	c1389	15.4	0.9	19	1	US-11-083-784-430047	Sequence 430047,
1317	15.8	0.9	19	1	US-11-101-244-1202136	Sequence 1202136,	c1390	15.4	0.9	19	1	US-11-083-784-430081	Sequence 430081,
c1318	15.8	0.9	19	1	US-11-101-244-1237713	Sequence 1237713,	c1391	15.4	0.9	19	1	US-11-083-784-430146	Sequence 430146,
1319	15.8	0.9	19	1	US-11-101-244-1267843	Sequence 1267843,	c1392	15.4	0.9	19	1	US-11-083-784-440174	Sequence 440174,
c1320	15.8	0.9	19	1	US-11-101-244-1267942	Sequence 1267942,	c1393	15.4	0.9	19	1	US-11-083-784-440609	Sequence 440609,
1321	15.8	0.9	19	1	US-11-101-244-1312578	Sequence 1312578,	1394	15.4	0.9	19	1	US-11-083-784-496109	Sequence 496109,
1322	15.8	0.9	19	1	US-11-101-244-1348446	Sequence 1348446,	1395	15.4	0.9	19	1	US-11-083-784-496206	Sequence 496206,
c1323	15.8	0.9	19	1	US-11-101-244-1365309	Sequence 1365309,	1396	15.4	0.9	19	1	US-11-083-784-498533	Sequence 498533,
1324	15.8	0.9	19	1	US-11-101-244-1372117	Sequence 1372117,	1397	15.4	0.9	19	1	US-11-083-784-498633	Sequence 498633,
1325	15.8	0.9	19	1	US-11-101-244-1393220	Sequence 1393220,	1398	15.4	0.9	19	1	US-11-083-784-498723	Sequence 498723,
1326	15.8	0.9	19	1	US-11-101-244-1450263	Sequence 1450263,	1399	15.4	0.9	19	1	US-11-083-784-5252568	Sequence 5252568,
1327	15.8	0.9	19	1	US-11-101-244-1453908	Sequence 1453908,	c1400	15.4	0.9	19	1	US-11-083-784-525148	Sequence 525148,
c1328	15.8	0.9	19	1	US-11-101-244-1450263	Sequence 1450263,	1401	15.4	0.9	19	1	US-11-083-784-535148	Sequence 535148,
c1329	15.8	0.9	19	1	US-11-101-244-1462725	Sequence 1462725,	1402	15.4	0.9	19	1	US-11-083-784-552201	Sequence 552201,
c1330	15.8	0.9	19	1	US-11-101-244-1462771	Sequence 1462771,	1403	15.4	0.9	19	1	US-11-083-784-552292	Sequence 552292,
c1331	15.8	0.9	19	1	US-11-101-244-1465138	Sequence 1465138,	1404	15.4	0.9	19	1	US-11-083-784-574443	Sequence 574443,
1332	15.8	0.9	19	1	US-11-101-244-1496063	Sequence 1496063,	c1405	15.4	0.9	19	1	US-11-083-784-581822	Sequence 581822,
c1333	15.8	0.9	19	1	US-11-101-244-1526168	Sequence 1526168,	c1406	15.4	0.9	19	1	US-11-083-784-581875	Sequence 581875,
c1334	15.8	0.9	19	1	US-11-101-244-1540139	Sequence 1540139,	c1407	15.4	0.9	19	1	US-11-083-784-581922	Sequence 581922,
c1335	15.8	0.9	19	1	US-11-101-244-1555839	Sequence 1555839,	c1408	15.4	0.9	19	1	US-11-083-784-581978	Sequence 581978,
c1336	15.8	0.9	19	1	US-11-101-244-1567851	Sequence 1567851,	c1409	15.4	0.9	19	1	US-11-083-784-588110	Sequence 588110,
c1337	15.8	0.9	19	1	US-11-101-244-1571143	Sequence 1571143,	c1410	15.4	0.9	19	1	US-11-083-784-596511	Sequence 596511,
c1338	15.8	0.9	19	1	US-11-101-244-1586104	Sequence 1586104,	1411	15.4	0.9	19	1	US-11-083-784-621759	Sequence 621759,
c1339	15.8	0.9	19	1	US-11-101-244-1586107	Sequence 1586107,	c1412	15.4	0.9	19	1	US-11-083-784-653624	Sequence 653624,
c1340	15.8	0.9	19	1	US-11-101-244-1586108	Sequence 1586108,	c1413	15.4	0.9	19	1	US-11-083-784-653627	Sequence 653627,
c1341	15.4	0.9	17	1	US-09-877-478-1123	Sequence 1123, Ap	1414	15.4	0.9	19	1	US-11-083-784-702236	Sequence 702236,
c1342	15.4	0.9	17	1	US-09-877-478-1124	Sequence 1123, Ap	1415	15.4	0.9	19	1	US-11-083-784-812530	Sequence 812530,
c1343	15.4	0.9	17	1	US-10-342-902-1123	Sequence 1123, Ap	1416	15.4	0.9	19	1	US-11-083-784-826194	Sequence 826194,
c1344	15.4	0.9	17	1	US-10-342-902-1124	Sequence 1123, Ap	c1417	15.4	0.9	19	1	US-11-083-784-913509	Sequence 913509,
c1345	15.4	0.9	17	1	US-10-669-841-1123	Sequence 1124, Ap	c1418	15.4	0.9	19	1	US-11-083-784-923681	Sequence 923681,
c1346	15.4	0.9	17	1	US-10-669-841-1124	Sequence 1124, Ap	c1419	15.4	0.9	19	1	US-11-083-784-946340	Sequence 946340,
c1347	15.4	0.9	18	1	US-10-449-801A-2	Sequence 2, Appl	1420	15.4	0.9	19	1	US-11-083-784-963463	Sequence 963463,

c1421	15.4	0.9	19	1	US-11-083-784-968672	Sequence 968672,
c1422	15.4	0.9	19	1	US-11-083-784-968744	Sequence 968744,
1423	15.4	0.9	19	1	US-11-083-784-1062866	Sequence 1062866,
1424	15.4	0.9	19	1	US-11-083-784-1085933	Sequence 1085933,
1425	15.4	0.9	19	1	US-11-083-784-1092663	Sequence 1092663,
1426	15.4	0.9	19	1	US-11-083-784-1092769	Sequence 1092769,
1427	15.4	0.9	19	1	US-11-083-784-1136074	Sequence 1136074,
1428	15.4	0.9	19	1	US-11-083-784-1153902	Sequence 1153902,
1429	15.4	0.9	19	1	US-11-083-784-1232377	Sequence 1232377,
1430	15.4	0.9	19	1	US-11-083-784-1237707	Sequence 1237707,
1431	15.4	0.9	19	1	US-11-083-784-1287587	Sequence 1287587,
1432	15.4	0.9	19	1	US-11-083-784-1287626	Sequence 1287626,
c1433	15.4	0.9	19	1	US-11-083-784-1297887	Sequence 1297887,
1434	15.4	0.9	19	1	US-11-083-784-133743	Sequence 133743,
1435	15.4	0.9	19	1	US-11-083-784-1398560	Sequence 1398560,
1436	15.4	0.9	19	1	US-11-083-784-1397050	Sequence 1397050,
1437	15.4	0.9	19	1	US-11-083-784-1307134	Sequence 1307134,
1438	15.4	0.9	19	1	US-11-083-784-1324599	Sequence 1324599,
c1439	15.4	0.9	19	1	US-11-083-784-133793	Sequence 133793,
c1440	15.4	0.9	19	1	US-11-083-784-1384793	Sequence 1384793,
c1441	15.4	0.9	19	1	US-11-083-784-1412484	Sequence 1412484,
c1442	15.4	0.9	19	1	US-11-083-784-1412508	Sequence 1412508,
c1443	15.4	0.9	19	1	US-11-083-784-1479942	Sequence 1479942,
c1444	15.4	0.9	19	1	US-11-083-784-1563128	Sequence 1563128,
1445	15.4	0.9	19	1	US-11-101-244-96831	Sequence 96831, A
1446	15.4	0.9	19	1	US-11-101-244-97216	Sequence 97216, A
1447	15.4	0.9	19	1	US-11-101-244-97216	Sequence 97216, A
c1448	15.4	0.9	19	1	US-11-101-244-103182	Sequence 103182,
c1449	15.4	0.9	19	1	US-11-101-244-103190	Sequence 103190,
1450	15.4	0.9	19	1	US-11-101-244-131581	Sequence 131581,
c1451	15.4	0.9	19	1	US-11-101-244-164314	Sequence 164314,
1452	15.4	0.9	19	1	US-11-101-244-202921	Sequence 220921,
c1453	15.4	0.9	19	1	US-11-101-244-234743	Sequence 234743,
c1454	15.4	0.9	19	1	US-11-101-244-234762	Sequence 234762,
c1455	15.4	0.9	19	1	US-11-101-244-246931	Sequence 240931,
c1456	15.4	0.9	19	1	US-11-101-244-259725	Sequence 259725,
c1457	15.4	0.9	19	1	US-11-101-244-259762	Sequence 259762,
1458	15.4	0.9	19	1	US-11-101-244-289336	Sequence 289336,
1459	15.4	0.9	19	1	US-11-101-244-345636	Sequence 345636,
c1460	15.4	0.9	19	1	US-11-101-244-394748	Sequence 394748,
c1461	15.4	0.9	19	1	US-11-101-244-430047	Sequence 430047,
c1462	15.4	0.9	19	1	US-11-101-244-430081	Sequence 430081,
c1463	15.4	0.9	19	1	US-11-101-244-430146	Sequence 430146,
c1464	15.4	0.9	19	1	US-11-101-244-430174	Sequence 430174,
c1465	15.4	0.9	19	1	US-11-101-244-440481	Sequence 440481,
1466	15.4	0.9	19	1	US-11-101-244-496009	Sequence 496009,
1467	15.4	0.9	19	1	US-11-101-244-496109	Sequence 496109,
1468	15.4	0.9	19	1	US-11-101-244-496206	Sequence 496206,
1469	15.4	0.9	19	1	US-11-101-244-498533	Sequence 498533,
1470	15.4	0.9	19	1	US-11-101-244-498633	Sequence 498633,
1471	15.4	0.9	19	1	US-11-101-244-498733	Sequence 498733,
c1472	15.4	0.9	19	1	US-11-101-244-525568	Sequence 525568,
1473	15.4	0.9	19	1	US-11-101-244-535148	Sequence 535148,
1474	15.4	0.9	19	1	US-11-101-244-552201	Sequence 552201,
1475	15.4	0.9	19	1	US-11-101-244-552292	Sequence 552292,
1476	15.4	0.9	19	1	US-11-101-244-574443	Sequence 574443,
c1477	15.4	0.9	19	1	US-11-101-244-581822	Sequence 581822,
c1478	15.4	0.9	19	1	US-11-101-244-581875	Sequence 581875,
c1479	15.4	0.9	19	1	US-11-101-244-581922	Sequence 581922,
c1480	15.4	0.9	19	1	US-11-101-244-581978	Sequence 581978,
c1481	15.4	0.9	19	1	US-11-101-244-588110	Sequence 588110,
c1482	15.4	0.9	19	1	US-11-101-244-596511	Sequence 596511,
1483	15.4	0.9	19	1	US-11-101-244-621759	Sequence 621759,
c1484	15.4	0.9	19	1	US-11-101-244-653624	Sequence 653624,
c1485	15.4	0.9	19	1	US-11-101-244-653627	Sequence 653627,
1486	15.4	0.9	19	1	US-11-101-244-702336	Sequence 702336,
1487	15.4	0.9	19	1	US-11-101-244-812530	Sequence 812530,
1488	15.4	0.9	19	1	US-11-101-244-826194	Sequence 826194,
c1490	15.4	0.9	19	1	US-11-101-244-913509	Sequence 913509,
c1491	15.4	0.9	19	1	US-11-101-244-946340	Sequence 946340,
1492	15.4	0.9	19	1	US-11-101-244-963463	Sequence 963463,
c1493	15.4	0.9	19	1	US-11-101-244-968672	Sequence 968672,
c1494	15.4	0.9	19	1	US-11-101-244-968744	Sequence 968744,
1495	15.4	0.9	19	1	US-11-101-244-1062866	Sequence 1062866,
1496	15.4	0.9	19	1	US-11-101-244-1085933	Sequence 1085933,
1497	15.4	0.9	19	1	US-11-101-244-1092663	Sequence 1092663,
1498	15.4	0.9	19	1	US-11-101-244-1092769	Sequence 1092769,
1499	15.4	0.9	19	1	US-11-101-244-1136074	Sequence 1136074,
1500	15.4	0.9	19	1	US-11-101-244-1153902	Sequence 1153902,
1501	15.4	0.9	19	1	US-11-101-244-1232377	Sequence 1232377,
1502	15.4	0.9	19	1	US-11-101-244-1237707	Sequence 1237707,
1503	15.4	0.9	19	1	US-11-101-244-1287587	Sequence 1287587,
1504	15.4	0.9	19	1	US-11-101-244-1287626	Sequence 1287626,
c1505	15.4	0.9	19	1	US-11-101-244-1297887	Sequence 1297887,
1506	15.4	0.9	19	1	US-11-101-244-133743	Sequence 133743,
1507	15.4	0.9	19	1	US-11-101-244-1398560	Sequence 1398560,
1508	15.4	0.9	19	1	US-11-101-244-1397050	Sequence 1397050,
1509	15.4	0.9	19	1	US-11-101-244-1307134	Sequence 1307134,
c1510	15.4	0.9	19	1	US-11-101-244-1324599	Sequence 1324599,
1511	15.4	0.9	19	1	US-11-101-244-133793	Sequence 133793,
1512	15.4	0.9	19	1	US-11-101-244-1384793	Sequence 1384793,
c1513	15.4	0.9	19	1	US-11-101-244-1412484	Sequence 1412484,
c1514	15.4	0.9	19	1	US-11-101-244-1412508	Sequence 1412508,
c1515	15.4	0.9	19	1	US-11-101-244-1479942	Sequence 1479942,
c1516	15.4	0.9	19	1	US-11-101-244-1563128	Sequence 1563128,
1517	15	0.8	18	1	US-10-310-914A-188750	Sequence 188750,
c1518	15	0.8	18	1	US-10-310-914A-188750	Sequence 188750,
c1519	15	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
1520	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
1521	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
1522	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
1523	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
1524	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1525	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
1526	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1527	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1528	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1529	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1530	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1531	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1532	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
1533	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1534	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1535	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1536	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1537	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
1538	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1539	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1540	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1541	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1542	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1543	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1544	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1545	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1546	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
1547	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1548	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1549	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1550	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1551	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
1552	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
1553	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
1554	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
1555	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1556	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
1557	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
1558	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1559	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
1560	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1561	14.8	0.8	18	1	US-10-310-914A-253464	Sequence 253464,
c1562	14.4	0.8	17	1	US-09-877-478-1752	Sequence 1752, Ap
1563	14.4	0.8	17	1	US-09-877-478-1752	Sequence 1752, Ap
c1564	14.4	0.8	17	1	US-10-342-902-1752	Sequence 1752, Ap
1565	14.4	0.8	17	1	US-10-342-902-1752	Sequence 1752, Ap
c1566	14.4	0.8	17	1	US-10-669-841-1752	Sequence 1752, Ap

```
1567 14.4 0.8 17 1 US-10-669-841-1806 Sequence 1806, Ap
c1568 14.4 0.8 17 1 US-10-310-914A-35633 Sequence 35633, A
1569 14.4 0.8 18 1 US-10-109-349A-43 Sequence 43, Appl
c1570 14.4 0.8 18 1 US-10-310-914A-87407 Sequence 87407, A
1571 14.4 0.8 18 1 US-10-310-914A-96132 Sequence 96132, A
c1572 14.4 0.8 18 1 US-10-310-914A-15781 Sequence 15781, A
1573 14.4 0.8 18 1 US-10-310-914A-17689 Sequence 17689, A
c1574 14.4 0.8 18 1 US-10-310-914A-18412 Sequence 18412, A
c1575 14.4 0.8 18 1 US-10-310-914A-193360 Sequence 193360, A
1576 14.4 0.8 18 1 US-10-310-914A-298526 Sequence 298526, A
c1577 14.4 0.8 18 1 US-10-310-914A-412825 Sequence 412825, A
c1578 14.4 0.8 18 1 US-10-310-914A-438320 Sequence 438320, A
1579 14.4 0.8 18 1 US-10-310-914A-481091 Sequence 481091, A
c1580 14.4 0.8 18 1 US-10-310-914A-504610 Sequence 504610, A
1581 14.4 0.8 18 1 US-10-310-914A-517275 Sequence 517275, A
c1582 14.4 0.8 18 1 US-10-310-914A-518000 Sequence 518000, A
c1583 14.4 0.8 18 1 US-10-310-914A-537429 Sequence 537429, A
1584 14.4 0.8 18 1 US-10-310-914A-600496 Sequence 600496, A
c1585 14.4 0.8 18 1 US-10-310-914A-689772 Sequence 689772, A
c1586 14.4 0.8 18 1 US-10-310-914A-703052 Sequence 703052, A
1587 14.4 0.8 18 1 US-10-310-914A-724939 Sequence 724939, A
c1588 14.4 0.8 18 1 US-10-310-914A-743634 Sequence 743634, A
c1589 14.4 0.8 18 1 US-10-310-914A-750829 Sequence 750829, A
c1590 14.4 0.8 18 1 US-10-310-914A-864924 Sequence 864924, A
c1591 14.4 0.8 18 1 US-10-310-914A-866395 Sequence 866395, A
c1592 14.4 0.8 18 1 US-10-310-914A-923103 Sequence 923103, A
c1593 14.4 0.8 18 1 US-10-310-914A-1115480 Sequence 1115480, A
c1594 14.4 0.8 18 1 US-10-310-914A-1192870 Sequence 1192870, A
1595 14.4 0.8 18 1 US-10-310-914A-1225415 Sequence 1225415, A
c1596 14.4 0.8 18 1 US-10-310-914A-1258988 Sequence 1258988, A
1597 14.4 0.8 18 1 US-10-310-914A-1364456 Sequence 1364456, A
c1598 14.4 0.8 18 1 US-10-310-914A-1385854 Sequence 1385854, A
c1599 14.4 0.8 18 1 US-11-085-775-60 Sequence 60, Appl
1600 14.2 0.8 19 1 US-10-310-914A-605977 Sequence 605977, A
c1601 14 0.8 17 1 US-09-864-636A-1705 Sequence 1705, Ap
c1602 14 0.8 17 1 US-09-864-426A-1705 Sequence 1705, Ap
c1603 14 0.8 17 1 US-10-084-839-1705 Sequence 1705, Ap
c1604 14 0.8 17 1 US-10-084-839-3966 Sequence 3966, Ap
c1605 14 0.8 17 1 US-10-084-839-3981 Sequence 3981, Ap
1606 14 0.8 17 1 US-10-374-466-84 Sequence 84, Appl
c1607 14 0.8 31 1 US-09-801-274-1145 Sequence 1145, Ap
```

ALIGNMENTS

```
RESULT 1
US-09-826-509-279
; Sequence 279, Application US/09826509
; Publication No. US20030204073A1
; GENERAL INFORMATION:
; APPLICANT: Lehmann-Brünsma, Karin
; APPLICANT: Liaw, Chen W.
; APPLICANT: Lin, I-Lin
; TITLE OF INVENTION: No. US20030204073A1-Endogenous, Constitutively Activated Known G
; FILE REFERENCE: AREN-207
; CURRENT APPLICATION NUMBER: US/09/826, 509
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 60/195, 747
; PRIOR FILING DATE: 2000-04-07
; PRIOR APPLICATION NUMBER: 09/170, 496
; PRIOR FILING DATE: 1998-10-13
; NUMBER OF SEQ ID NOS: 589
; SOFTWARE: PatentIn Version 2.1
; SEQ ID NO 279
; LENGTH: 37
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-826-509-279
```

Query Match 1.8%; Score 32.2; DB 1; Length 37;
Best Local Similarity 83.8%; Pred. No. 91;

```
Matches 31; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
QY 1449 GGUCAAGAGAGAAAGCGCCAGACCCUCAGUGCG 1485
||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 GGTCAAGAGAGAAAGCGAAACAGACCCCTCAGTGG 37

RESULT 2
US-09-826-509-280/c
; Sequence 280, Application US/09826509
; Publication No. US20030204073A1
; GENERAL INFORMATION:
; APPLICANT: Lehmann-Brünsma, Karin
; APPLICANT: Liaw, Chen W.
; APPLICANT: Lin, I-Lin
; TITLE OF INVENTION: No. US20030204073A1-Endogenous, Constitutively Activated Known G
; FILE REFERENCE: AREN-207
; CURRENT APPLICATION NUMBER: US/09/826, 509
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 60/195, 747
; PRIOR FILING DATE: 2000-04-07
; PRIOR APPLICATION NUMBER: 09/170, 496
; PRIOR FILING DATE: 1998-10-13
; NUMBER OF SEQ ID NOS: 589
; SOFTWARE: PatentIn Version 2.1
; SEQ ID NO 280
; LENGTH: 37
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-826-509-280
```

Query Match 1.8%; Score 32.2; DB 1; Length 37;

Best Local Similarity 83.8%; Pred. No. 91;

Matches 31; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1449 GGUCAAGAGAGAAAGCGCCAGACCCUCAGUGCG 1485

Db 37 GGTCAAGAGAGAAAGCGAAACAGACCCCTCAGTGG 1

```
RESULT 3
US-10-925-095-279
; Sequence 279, Application US/10925095
; Publication No. US20050019840A1
; GENERAL INFORMATION:
; APPLICANT: Lehmann-Brünsma, Karin
; APPLICANT: Liaw, Chen W.
; APPLICANT: Lin, I-Lin
; TITLE OF INVENTION: Non-Endogenous, Constitutively Activated Known G
; FILE REFERENCE: AREN-207
; CURRENT APPLICATION NUMBER: US/10/925, 095
; CURRENT FILING DATE: 2004-08-24
; PRIOR APPLICATION NUMBER: US/09/826, 509
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 60/195, 747
; PRIOR FILING DATE: 2000-04-07
; PRIOR APPLICATION NUMBER: 09/170, 496
; PRIOR FILING DATE: 1998-10-13
; NUMBER OF SEQ ID NOS: 589
; SOFTWARE: PatentIn Version 2.1
; SEQ ID NO 279
; LENGTH: 37
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-925-095-279
```

Query Match 1.8%; Score 32.2; DB 1; Length 37;

Best Local Similarity 83.8%; Pred. No. 91;

Matches 31; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1449 GGUCAAGAGAGAAAGCGCCAGACCCUCAGUGCG 1485


```

; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32251
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32251

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      1407 GAAGACGAGAGUCAGUACUAG 1431
DB      1 GAAGACGAGAGTCAGATCACTAAG 25

RESULT 9
US-11-060-756-32252
; Sequence 32252, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32252
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32252

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 2e+02;
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1406 UGAAGACGAGAGUCAGUACUAA 1430
DB      1 TGAAGACGAGAGTCAATCACTAA 25

RESULT 10
US-11-060-756-32253
; Sequence 32253, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32253
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32253

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 2e+02;

; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32254
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32254

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 76.0%; Pred. No. 2e+02;
Matches 19; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1647 AACATTCAGACACCTTCATCAAGT 1671
DB      1 AACATTCAGACACCTTCACAGATG 25

RESULT 12
US-11-060-756-32255
; Sequence 32255, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32255
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32255

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 56.0%; Pred. No. 2e+02;
Matches 14; Conservative 11; Mismatches 0; Indels 0; Gaps 0;

QY      1486 AUCUUCGUGCCUUCAGUACUCU 1510
DB      1 ACTTCTGCTCCTTCAATCACTACTT 25

RESULT 13
US-11-060-756-32256
; Sequence 32256, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
```

```
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32256
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32256
```

```
Query Match          1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 76.0%; Pred. No. 2e+02;
Matches 19; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1646 AAACAUCGAGAACCCUUCUACAGAU 1670
DB      1 AAACATTCAGAACCACTTCAAGAT 25
```

```
RESULT 14
US-11-060-756-32257
```

```
; Sequence 32257, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32257
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32257
```

```
Query Match          1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1408 AAGACCAAGAGTCAGATCACTAAGC 1432
DB      1 AAGACCAAGAGTCAGATCACTAAGC 25
```

```
RESULT 15
US-11-060-756-32258
```

```
; Sequence 32258, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32258
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32258
```

```
Query Match          1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 2e+02;
Matches 18; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1649 CAUUCAGAACCAACCUUCACAGUCCU 1673
DB      1 CATTGAGAACCACTTCAAGATGCT 25
```

```
RESULT 16
US-11-060-756-32259
; Sequence 32259, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32259
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32259
```

```
Query Match          1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 76.0%; Pred. No. 2e+02;
Matches 19; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1648 ACAUUCAGAACCAACCUUCACAGUCC 1672
DB      1 ACATTCAGAACCACTTCAAGATGC 25
```

```
RESULT 17
US-11-060-756-32260
```

```
; Sequence 32260, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32260
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32260
```

```
Query Match          1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 56.0%; Pred. No. 2e+02;
Matches 14; Conservative 11; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1487 UCUUGCUCGCCUUCACUACUCCUG 1511
DB      1 TCTTGCTGCTTCATCATCACTTG 25
```

```
RESULT 18
US-11-060-756-32261
```

```
; Sequence 32261, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32261
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32261
```

```
Query Match          1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 2e+02;
Matches 18; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
```

```

: FILE REFERENCE: AM01083 (031896-042000)
: CURRENT APPLICATION NUMBER: US/11/060,756
: CURRENT FILING DATE: 2005-02-18
: NUMBER OF SEQ ID NOS: 303284
: SOFTWARE: PatentIn version 3.2
: SEQ ID NO 32261
: LENGTH: 25
: TYPE: DNA
: ORGANISM: probe
US-11-060-756-32261

```

Query Match	1.4%	Score 25	DB 1	Length 25
Best Local Similarity	60.0%	Pred. No. 2e+02		
Matches 15; Conservative	10;	Mismatches 0;	Indels 0;	Gaps 0;

```

Oy      1485 GAUCUUGCUGGCCUUCAUCAUCCACU 1509
          ||::||::||::||::||:
Db      1 GATCTTGCTTGCCCTTCATCATCACT 25

```

RESULT 19
US-11-060-756-32262
; Sequence 32262, Application US/11060756
; Publication No. US20050221354A1

TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
TITLE OF INVENTION: Target Genes
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2

```

; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32262

```

RESULT 20
US-11-060-756-32263
; Sequence 32263, Application US/11060756
; Publication No. US20050221354A1

Query Match	1.4%	Score 25;	DB 1;	Length 25;
Best Local Similarity	72.0%	Pred. No. 2e+02;		
Matches 18; Conservative	7;	Mismatches 0;	Indels 0;	Gaps 0

QY 1518 AUAACAUCAUCAUGGUTUCUGUGAAC 1542
 | : ||||| : : : : : : : :
Db 1 ATACACATCATGTCTTCTGTGAAC 25

```

RESULT 21
US-11-060-756-32264
; Sequence 32264, Application US/11060756
; Publication NO. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32264
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32264

```

Query Match	1.4%	Score 25;	DB 1;	Length 25;
Best Local Similarity	88.0%	Pred. No. 2e+02;		
Matches	22;	Conservative	3;	Mismatches 0;
				Indels 0;
				Gaps 0

Oy	1413	CAGAAGUCAGAUCCUAAGCGGAAA	1437
		: :	
Db	1	CAGAAGTCAGATCACTAAGCGGAAA	25

```

RESULT 22
US-11-0660-756-32265
; Sequence 32265, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; PTL REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32265
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32265

```

Query Match	1.4%	Score 25;	DB 1;	Length 25;
Best Local Similarity	80.0%	Pred. No. 2e+02;		
Matches	20;	Conservative	5;	Mismatches 0;
				Indels 0;
				Gaps 0

```

OY      1643  ACATAACATUCAGAACCACTUUCAA 1667
          |||||:::|||||:::|||
Db       1    ACATAACATTCAGAACCACTTCAA 25

```

```

RESULT 23
US-11-060-756-32266
; Sequence 32266, Application US/11060756
; Publication No. US2005022154A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)

```

```

; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32266
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32266

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 80.0%; Pred. No. 2e+02;
Matches 20; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1642 AACAAACAUUCGAGAACCAUUCU 1666
      |||||:::|||||:::|||||
Db      1 AACAAACATTCTGAGAACCACTTCA 25

RESULT 24
US-11-060-756-32267
; Sequence 32267, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Mounts, William Martin
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32267
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32267

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 80.0%; Pred. No. 2e+02;
Matches 20; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1641 CAACAAACAUUCGAGAACCAUUC 1665
      |||||:::|||||:::|||||
Db      1 CAACAAACATTCTGAGAACCACTTTC 25

RESULT 25
US-11-060-756-32268
; Sequence 32268, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Mounts, William Martin
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32268
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32268

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 80.0%; Pred. No. 2e+02;
Matches 20; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1645 AAAACAUUCGAGAACCAUUCU 1669
```

```

      |||||:::|||||:::|||||
Db      1 AAAACATTCTGAGAACCACTTCA 25

RESULT 26
US-11-060-756-32269
; Sequence 32269, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Mounts, William Martin
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32269
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32269

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 80.0%; Pred. No. 2e+02;
Matches 20; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1644 CAACAAUCGAGAACCAUUCU 1668
      |||||:::|||||:::|||||
Db      1 CAACAACTTCTGAGAACCACTTCA 25

RESULT 27
US-11-060-756-32270
; Sequence 32270, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Mounts, William Martin
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32270
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32270

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 2e+02;
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1405 CUGAAGACGAGAACGAGUACUA 1429
      |:|||||:::|||||:::|||||
Db      1 CTGAAGACGAGAGTCAGATCACTA 25

RESULT 28
US-11-060-756-32271
; Sequence 32271, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Mounts, William Martin
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
```

```
/ CURRENT FILING DATE: 2005-02-18
/ NUMBER OF SEQ ID NOS: 303284
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 32271
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: probe
US-11-060-756-32271

Query Match
Best Local Similarity 60.0%; Pred. No. 2e+02;
Matches 15; Conservative 10; Mismatches 0; Indels 0; Gaps 0;

QY 1488 CUUGCUUGCCUUCAUCAUACUUGG 1512
1 CTTGCTGTCCTTCATCATCATCTGG 25
DB

RESULT 29
US-11-060-756-32272
/ Sequence 32272, Application US/11060756
/ Publication No. US20050221354A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Mounts, William Martin
/ TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
/ FILE OF INVENTION: Target Genes
/ FILE REFERENCE: AM101083 (031896-042000)
/ CURRENT APPLICATION NUMBER: US/11/060,756
/ CURRENT FILING DATE: 2005-02-18
/ NUMBER OF SEQ ID NOS: 303284
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 32272
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: probe
US-11-060-756-32272

Query Match
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1412 CCAAGAGUCAGCAUACUAGCGGA 1436
1 CCAAGAGTCAGATCACTAAGCGGA 25
DB

RESULT 30
US-11-060-756-32273
/ Sequence 32273, Application US/11060756
/ Publication No. US20050221354A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Mounts, William Martin
/ TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
/ FILE OF INVENTION: Target Genes
/ FILE REFERENCE: AM101083 (031896-042000)
/ CURRENT APPLICATION NUMBER: US/11/060,756
/ CURRENT FILING DATE: 2005-02-18
/ NUMBER OF SEQ ID NOS: 303284
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 32273
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: probe
US-11-060-756-32273

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1409 AGACGAGAGUCAGUACUACGCG 1433
1 AGACGAGAGTCAGATCACTAAGCG 1433
DB

RESULT 31
US-11-060-756-32274
/ Sequence 32274, Application US/11060756
/ Publication No. US20050221354A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Mounts, William Martin
/ TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
/ FILE OF INVENTION: Target Genes
/ FILE REFERENCE: AM101083 (031896-042000)
/ CURRENT APPLICATION NUMBER: US/11/060,756
/ CURRENT FILING DATE: 2005-02-18
/ NUMBER OF SEQ ID NOS: 303284
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 32274
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: probe
US-11-060-756-32274

Query Match
Best Local Similarity 80.0%; Pred. No. 2e+02;
Matches 20; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1640 GCAACAAAACUUCAGAACCCU 1664
1 GCAACAAAACATTCAGAACCACTT 25
DB

RESULT 32
US-11-060-756-32275
/ Sequence 32275, Application US/11060756
/ Publication No. US20050221354A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Mounts, William Martin
/ TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
/ FILE OF INVENTION: Target Genes
/ FILE REFERENCE: AM101083 (031896-042000)
/ CURRENT APPLICATION NUMBER: US/11/060,756
/ CURRENT FILING DATE: 2005-02-18
/ NUMBER OF SEQ ID NOS: 303284
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 32275
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: probe
US-11-060-756-32275

Query Match
Best Local Similarity 72.0%; Pred. No. 2e+02;
Matches 18; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1519 UGACAGUACUUGUCUGGAA 1543
1 TACAACATCATGCTCTGATGAACA 25
DB

RESULT 33
US-11-060-756-32276
/ Sequence 32276, Application US/11060756
/ Publication No. US20050221354A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Mounts, William Martin
/ TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
/ FILE OF INVENTION: Target Genes
/ FILE REFERENCE: AM101083 (031896-042000)
/ CURRENT APPLICATION NUMBER: US/11/060,756
/ CURRENT FILING DATE: 2005-02-18
```



```

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32281
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32281

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1410 GACCGAAGUCAGAUCAUAGCGG 1434
DB 1 GACCGAAGUCAGAUCAUAGCGG 25

RESULT 39
US-11-060-756-32282
; Sequence 32282, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32282
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32282

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 18; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1651 UUCAGAACCAUCUUCAGAUAGCUC 1675
DB 1 TTCAGAACCACTTTCAGATGCGC 25

RESULT 40
US-11-060-756-32283
; Sequence 32283, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32283
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32283

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 18; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1516 CCAUACAACAUCAUGGUCUGUGCA 1540
DB 1 CCATACACATCATGCTCTGGTGA 25

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32284
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32284

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1421 AGAUCACUAGCGGAAAGAGAUUC 1445
DB 1 AGATCACTAAGCGGAAAGAGATGC 25

RESULT 42
US-11-060-756-32285
; Sequence 32285, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32285
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-32285

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1419 UCAUACAUCUAGCGGAAAGAGAU 1443
DB 1 TCAGATCACTAAGCGGAAAGAGATG 25

RESULT 43
US-11-060-756-32286
; Sequence 32286, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
```

SEQ ID NO 32286
LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-11-060-756-32286

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 2e+02;
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1418 GUCAGAUCAUCUAGCGGAAAGCAU 1442
DB 1 GTCAGATCACTAGCGGAAAGCAT 25

RESULT 44
US-11-060-756-32287
Sequence 32287, Application US/11060756
Publication No. US20050221354A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 32287
LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-11-060-756-32287

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1411 ACCAGAGUCAGUACUAGCGGA 1435
DB 1 ACCAGAGTCAGATCACTAGCGGA 25

RESULT 45
US-11-060-756-32288
Sequence 32288, Application US/11060756
Publication No. US20050221354A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 32288
LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-11-060-756-32288

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 68.0%; Pred. No. 2e+02;
Matches 17; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1568 AAACUUUGAUAUCUGGCGUACUG 1592
DB 1 AAACCTTTGGAATCTGGGCTACTG 25

RESULT 46
US-11-060-756-32289
Sequence 32289, Application US/11060756
Publication No. US20050221354A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 32289
LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-11-060-756-32289

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 2e+02;
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1441 AUGUCCUUGUCAGAGGAAGAAG 1465
DB 1 ATGCTCCTGCTCAAGAGGAAGAAG 25

RESULT 47
US-11-060-756-32290
Sequence 32290, Application US/11060756
Publication No. US20050221354A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 32290
LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-11-060-756-32290

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 2e+02;
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1440 GAUGUCCUUGUCAGAGGAAGA 1464
DB 1 GATGCTCCTGCTCAAGAGGAAGA 25

RESULT 48
US-11-060-756-32291
Sequence 32291, Application US/11060756
Publication No. US20050221354A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 32291

LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-11-060-756-32291

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 2e+02;
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1420 CAGATCAGTAAAGCGGAAAAGATGT 1444
|||||:|||||:|||||:|||||:|||||:
DB 1 CAGATCAGTAAAGCGGAAAAGATGT 25

RESULT 49
US-11-060-756-32292
Sequence 32292, Application US/11060756
Publication No. US20050221354A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 32292
LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-11-060-756-32292

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 76.0%; Pred. No. 2e+02;
Matches 19; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1520 ACAACATCATGCTTCTGTGTAACAC 1544
|||||:|||||:|||||:|||||:|||||:
DB 1 ACAACATCATGCTTCTGTGTAACAC 25

RESULT 50
US-11-060-756-32293
Sequence 32293, Application US/11060756
Publication No. US20050221354A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 32293
LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-11-060-756-32293

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1416 AAGUCAGATCACTAAGCGGAAAAGG 1440
|||||:|||||:|||||:|||||:|||||:
DB 1 AAGTCAGATCACTAAGCGGAAAAGG 25

RESULT 51

US-11-060-756-32294
Sequence 32294, Application US/11060756
Publication No. US20050221354A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 32294
LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-11-060-756-32294

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 80.0%; Pred. No. 2e+02;
Matches 20; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1639 UCCACAAAACAUCAGAACCACTU 1663
|||||:|||||:|||||:|||||:|||||:
DB 1 TCCACAAAACACTCAGAACCACTT 25

RESULT 52
US-11-060-756-128746
Sequence 128746, Application US/11060756
Publication No. US20050221354A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 128746
LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-11-060-756-128746

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 80.0%; Pred. No. 2e+02;
Matches 20; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1181 AGGAGCTGGGATGCTGGA 1205
|||||:|||||:|||||:|||||:|||||:
DB 1 AGGAGCTGGGATGCTGGA 25

RESULT 53
US-11-060-756-131616
Sequence 131616, Application US/11060756
Publication No. US20050221354A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 131616
LENGTH: 25

```
/ TYPE: DNA
/ ORGANISM: probe
US-11-060-756-131616

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 17; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1568 AACCCUUUGAUCUGGCUACUG 1592
DB 1 AACCTTTGAACTCGGCTACTG 25

RESULT 54
US-11-060-756-132080
/ Sequence 132080, Application US/11060756
/ Publication No. US20050221354A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Mounts, William Martin
/ TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
/ FILE REFERENCE: AM101083 (031896-042000)
/ CURRENT APPLICATION NUMBER: US/11/060,756
/ CURRENT FILING DATE: 2005-02-18
/ NUMBER OF SEQ ID NOS: 303284
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 132080
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: probe
US-11-060-756-132080

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 19; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1311 AGCUAAGCUCGACGUCACUCC 1335
DB 1 AGCTAAGACTTCTGACGTCACTCC 25

RESULT 55
US-11-060-756-134169
/ Sequence 134169, Application US/11060756
/ Publication No. US20050221354A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Mounts, William Martin
/ TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
/ FILE REFERENCE: AM101083 (031896-042000)
/ CURRENT APPLICATION NUMBER: US/11/060,756
/ CURRENT FILING DATE: 2005-02-18
/ NUMBER OF SEQ ID NOS: 303284
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 134169
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: probe
US-11-060-756-134169

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 18; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1726 AGACAGUCGUCACUUUUCACAAGC 1750
DB 1 AGACAGTCGTCATTTTCACAAGC 25

RESULT 56
US-11-060-756-137147

/ Sequence 137147, Application US/11060756
/ Publication No. US20050221354A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Mounts, William Martin
/ TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
/ FILE REFERENCE: AM101083 (031896-042000)
/ CURRENT APPLICATION NUMBER: US/11/060,756
/ CURRENT FILING DATE: 2005-02-18
/ NUMBER OF SEQ ID NOS: 303284
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 137147
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: probe
US-11-060-756-137147

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1430 AGCGAAAAGAGUCCUGUCUA 1454
DB 1 AGCGAAAAGAGTCTCTGTCA 25

RESULT 57
US-11-060-756-151173
/ Sequence 151173, Application US/11060756
/ Publication No. US20050221354A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Mounts, William Martin
/ TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
/ FILE REFERENCE: AM101083 (031896-042000)
/ CURRENT APPLICATION NUMBER: US/11/060,756
/ CURRENT FILING DATE: 2005-02-18
/ NUMBER OF SEQ ID NOS: 303284
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 151173
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: probe
US-11-060-756-151173

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 18; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1540 AACACCCUUUGACAGCUGCAUAC 1564
DB 1 AACACCTTTGTGACAGTCGATAC 25

RESULT 58
US-11-060-756-151519
/ Sequence 151519, Application US/11060756
/ Publication No. US20050221354A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Mounts, William Martin
/ TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
/ FILE REFERENCE: AM101083 (031896-042000)
/ CURRENT APPLICATION NUMBER: US/11/060,756
/ CURRENT FILING DATE: 2005-02-18
/ NUMBER OF SEQ ID NOS: 303284
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 151519
/ LENGTH: 25
/ TYPE: DNA
```

```
; ORGANISM: probe
US-11-060-756-151519

Query Match
Best Local Similarity 76.0%; Pred. No. 2e+02;
Matches 19; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1647 AACAUUCAGAACCACTUUCAGAGUG 1671
||||:|||||:|||||:|||||:
Db 1 AACATTCAGAACCACTTTCAGAGATG 25

RESULT 59
US-11-060-756-164907
; Sequence 164907, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 164907
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-164907

Query Match
Best Local Similarity 76.0%; Pred. No. 2e+02;
Matches 19; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1554 CAGCGCAUACCCCAACCCUUGG 1578
||||:|||||:|||||:|||||:
Db 1 CAGCTGATACCCCAAAACCTTTGG 25

RESULT 60
US-11-060-756-167980
; Sequence 167980, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 167980
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-167980

Query Match
Best Local Similarity 72.0%; Pred. No. 2e+02;
Matches 18; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 1729 CAGCGGCAUUCUUCACGCGCG 1753
||||:|||||:|||||:|||||:
Db 1 CAGTCGTCATTTTTCACAGCGCG 25

RESULT 61
US-11-060-756-169202
; Sequence 169202, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 169202
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-169202

Query Match
Best Local Similarity 92.0%; Pred. No. 2e+02;
Matches 23; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1225 CAGGCCGAGAGCGUGAGCAUG 1249
|||||:|||||:|||||:|||||:
Db 1 CAGGCCGAGAGCGGTGAGCATG 25

RESULT 62
US-11-060-756-171665
; Sequence 171665, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 171665
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-171665

Query Match
Best Local Similarity 76.0%; Pred. No. 2e+02;
Matches 19; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1508 CUGGACCCCAUACCAACAGCGU 1532
|||||:|||||:|||||:|||||:
Db 1 CTTGACCCCAUACACATCATGT 25

RESULT 63
US-11-060-756-175922
; Sequence 175922, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 175922
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
```

US-11-060-756-175922

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1599 CUCACUACAAGACCGUGAACCC 1623

Db 1 CTACATCAACAGACCGTGAACCC 25

RESULT 64

US-11-060-756-177330
; Sequence 177330, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

APPLICANT: Wyeth
APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 177330
LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-11-060-756-177330

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 2e+02;
Matches 18; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 1358 CUCUACUCUCUCUACAAGAAC 1382

Db 1 CTCCTACTCTCTCTCTCAAGAAC 25

RESULT 65

US-11-060-756-180404
; Sequence 180404, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

APPLICANT: Wyeth
APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 180404
LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-11-060-756-180404

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 76.0%; Pred. No. 2e+02;
Matches 19; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1322 CUGAGCUCACUCCUACGUGGUA 1346

Db 1 CTGACGTCAACTCTCAGTGGTAA 25

RESULT 66

US-11-060-756-180430
; Sequence 180430, Application US/11060756
; Publication No. US20050221354A1

; GENERAL INFORMATION:

APPLICANT: Wyeth
APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 180430
LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-11-060-756-180430

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2e+02;
Matches 23; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1222 CUGAGCCCAAGAGCGUGAGC 1246

Db 1 CTGCAAGCCCAAGAGCGTGAACG 25

RESULT 67

US-11-060-756-187203
; Sequence 187203, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

APPLICANT: Wyeth
APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 187203
LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-11-060-756-187203

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 2e+02;
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1282 CCCAUCAGCUCAGCAGCGUG 1306

Db 1 CCCATCAGCTAGAGTCAAGCGTGG 25

RESULT 68

US-11-060-756-192377
; Sequence 192377, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

APPLICANT: Wyeth
APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2
SEQ ID NO 192377
LENGTH: 25
TYPE: DNA
ORGANISM: probe
US-11-060-756-192377

```
Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 64.0%; Pred. No. 2e+02;
Matches 16; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

Qy      1571 CCUUUGGAUCCUGGCUACUGGCU 1595
Db      1 CTTTGAAATCTGGGCTACTGGCT 25

RESULT 69
US-11-060-756-195459
; Sequence 195459, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 195459
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-195459

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy      1287 CCAGCTAGAGTCAAGCGGTGACACA 1311
Db      1 CCAGCTAGAGTCAAGCGGTGACACA 25

RESULT 70
US-11-060-756-199924
; Sequence 199924, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 199924
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-199924

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 80.0%; Pred. No. 2e+02;
Matches 20; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy      1300 GCCGUGACACAGCUAAGACUUCUG 1324
Db      1 GCCGTGACACAGCTAAGACTTCTG 25

RESULT 71
US-11-060-756-204803
; Sequence 204803, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 204803
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-204803

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 2e+02;
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      1290 GCUAGGUCAGCCGUGGACACAGCU 1314
Db      1 GCTTAGAGTCAAGCGGTGACACAGCT 25

RESULT 72
US-11-060-756-208188
; Sequence 208188, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 208188
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-208188

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 2e+02;
Matches 18; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy      1722 GCAGAGACAGUCGUCAUUUUACAC 1746
Db      1 GCAGAGACAGTCGTCATTTTTCAC 25

RESULT 73
US-11-060-756-212969
; Sequence 212969, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 212969
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-212969
```

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1415 GAGUCAGATCACTAAGCGGAAAG 1439
Db 1 GAGTCAGATCACTAAGCGGAAAG 25

RESULT 74
US-11-060-756-215815

; Sequence 215815, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug

; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756

; NUMBER OF SEQ ID NOS: 2005-02-18
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 215815
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-215815

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 2e+02;
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1434 GAAAGAGUCGCCUGUCAAGAG 1458
Db 1 GAAAGAGATGCCCTGCTCAAGAG 25

RESULT 75
US-11-060-756-217281

; Sequence 217281, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug

; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756

; NUMBER OF SEQ ID NOS: 2005-02-18
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 217281
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-217281

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1690 GACAAAAAAGAGCGCAAGCAGC 1714
Db 1 GACAAAAAAGAGCGCAAGCAGC 25

RESULT 76
US-11-060-756-222249

; Sequence 222249, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug

; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756

; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 222249
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-222249

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1410 GACCAGAGUCAGACUACGCG 1434
Db 1 GACCAGAGTCAGATCACTAAGCGG 25

RESULT 77
US-11-060-756-222779

; Sequence 222779, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug

; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756

; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 222779
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-222779

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 76.0%; Pred. No. 2e+02;
Matches 19; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1236 GAGCGTGACGATGAGCGAGTUTU 1260
Db 1 GAGCGTGACGATGAGCGAGTUTT 25

RESULT 78
US-11-060-756-224536

; Sequence 224536, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug

; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756

; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 224536
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-224536

Query Match 1.4%; Score 25; DB 1; Length 25;

Best Local Similarity 76.0%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 19; Conservative 6; Mismatches 0;

QY 1395 GAGUUGUCUGACAGCCAGAGU 1419
|||||:|||||:|||||:|||||:

Db 1 GAGGTTTGCTGTGAAGACCAAGT 25

RESULT 79
US-11-060-756-225840
; Sequence 225840, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 225840
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-225840

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 80.0%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 22; Conservative 3; Mismatches 0;

QY 1294 GAGUCAGCCGUGACACAGCUAGA 1318
|||||:|||||:|||||:|||||:

Db 1 GAGTCAGCCGTGACACAGCTAAGA 25

RESULT 80
US-11-060-756-227514
; Sequence 227514, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 227514
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-227514

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 24; Conservative 1; Mismatches 0;

QY 1206 GAGGAAGCCGACACAGTCAGGCC 1230
|||||:|||||:|||||:|||||:

Db 1 GAGGAAGCCGACACAGTCAGGCC 25

RESULT 81
US-11-060-756-236709
; Sequence 236709, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin

; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 236709
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-236709

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 80.0%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 20; Conservative 5; Mismatches 0;

QY 1327 GUCACUCCUGAGUGGUAAGCA 1351
|||:|||||:|||||:|||||:

Db 1 GTCACTCTCTAGTGGTAAAGCA 25

RESULT 82
US-11-060-756-238898
; Sequence 238898, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 238898
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-238898

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 21; Conservative 4; Mismatches 0;

QY 1296 GUCAGCCGUGACACAGCTAAGCU 1320
|||:|||||:|||||:|||||:

Db 1 GTCAGCCGTGACACAGCTAAGCT 25

RESULT 83
US-11-060-756-243420
; Sequence 243420, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 243420
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-243420

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 2e+02; Indels 0; Gaps 0;

Matches	18;	Conservative	7;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	1537	GUGAACACUUUUUGACACGUCGA	1561						
		: : : : : : : : : : : : : : :							
Db	1	GTGAACACCTTTTGTGACAGCTGCA	25						

```

RESULT 84
US-11-060-756-244727
; Sequence 244727, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

```

```

: APPLICANT: Mounts, William Martin
: TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drugs
: TITLE OF INVENTION: Target Genes
: FILE REFERENCE: AM101083 (031896-042000)
: CURRENT APPLICATION NUMBER: US/11/060,756
: CURRENT FILING DATE: 2005-02-18
: NUMBER OF SEQ ID NOS: 303284
: SOFTWARE: PatentIn version 3.2
: SEQ ID NO 244727

```

```

; SEQ ID NO 244727
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-244727

```

Query Match	1.4%	Score 25	DB 1	Length 25
Best Local Similarity	84.0%	Pred. No.	2e+02	
Matches	21	Conservative	4	Mismatches 0; Indels 0; Gaps 0;

```

QY      1339  GUGGCUAAGACACGGCCACUCUAC  1363
          |||:|||||:|:|:|
Db      1     GTGGTAAGACACGGCCACTTAC  25

```

RESULT 85
US-11-060-756-256456
; Sequence 256456, Application US/11060756
; Publication No. US20050221354A1

```

APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
TITLE OF INVENTION: Target Genes
FILE REFERENCE: AM101083 (031896-042000)
CURRENT APPLICATION NUMBER: US/11/060,756
CURRENT FILING DATE: 2005-02-18
NUMBER OF SEQ ID NOS: 303284
SOFTWARE: PatentIn version 3.2

```

```

; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-256456

```

Query Match	1.4%	Score 25	DB 1	Length 25
Best Local Similarity	80.0%	Pred. No.	2e+02	
Matches 20	Conservative 5	Mismatches 0	Indels 0	Gaps 0

```

Oy      1242  GGACGATGCGAGCGAGTUUUCCAAAA 1266
          |||||:|||||:::|||
Db      1    GGACGATGCGAGCGAGTUUUCCAAAA 25

```

RESULT 86
US-11-060-756-257044
; Sequence 257044, Application US/11060756
; Publication No. US20050221354A1

APPLICANT: Mounts, William Martin
TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug

```

? TITLE OF INVENTION: Target Genes
? FILE REFERENCE: AM101063 (031896-042000)
? CURRENT APPLICATION NUMBER: US/11/060,756
? CURRENT FILING DATE: 2005-02-18
? NUMBER OF SEQ ID NOS: 303384
? SOFTWARE: PatentIn version 3.2
? SEQ ID NO: 257044
? LENGTH: 25
? TYPE: DNA
? ORGANISM: probe
US-11-060-756-257044

```

ORGANISM: probe
US-11-060-756-257044

Query Match	1.4%	Score 25;	DB 1;	Length 25;
Best Local Similarity	80.0%	Pred. NC. 2e+02;		
Matches 20;	Conservative 5;	Mismatches 0;	Indels 0;	Gaps 0;

```

QY      1305  GGACACAGCTUAGACTUCGACGUC  1329
          |||||:|||||:
Db      1    GGACACAGCTAAGACTTCTGACGTC  25

```

RESULT 87
US-11-060-756-260956
; Sequence 260956, Application US/11060756
; Publication No. US20050221354A1

```

1  APPLICANT: Mounse, William Martin
2  TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
3  TITLE OF INVENTION: Target Genes
4  FILE REFERENCE: AM101083 (031896-042000)
5  CURRENT APPLICATION NUMBER: US/11/060,756
6  CURRENT FILING DATE: 2005-02-18
7  NUMBER OF SEQ ID NOS: 303284
8  SOFTWARE: PatentIn version 3.2

```

```

; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-260956

```

Query Match	1.4%	Score 25;	DB 1;	length 25;
Best Local Similarity	80.0%	Pred. NO. 2e+02;		
Matches 20; Conservative	5;	Mismatches	0;	Indels 0; Gaps 0;

```

Oy      1592  GCGUGUGCUACAUCAACGACCGU  1616
          |||::|||:|||||:
Db      1      GCGTGTGCTACATCAACGACCGT  25

```

RESULT 88
US-11-060-756-262560
; Sequence 262560, Application US/11060756
; Publication No. US20050221354A1

```

?
? APPLICANT: Mounts, William Martin
? TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
? TITLE OF INVENTION: Target Genes
? FILE REFERENCE: AM101083 (031896-042000)
? CURRENT APPLICATION NUMBER: US11/060,756
? CURRENT FILING DATE: 2005-02-18
? NUMBER OF SEQ ID NOS: 303284
?
? SOFTWARE: PatentIn version 3.2
?
? SEQ ID NO 262560

```

```

; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-262560

```

Query Match	1.4%	Score 25;	DB 1;	Length 25;
Best Local Similarity	80.0%	Pred. No. 2e+02;		
Matches 20; Conservative	5;	Mismatches	0;	Gaps 0;

Oy 1389 GGCCTAAGAGGTTTUGCTCTGAAAGACC 1413
 |||||::|::|
 Db 1 GGCCTAAGAGGTTTUGCTCTGAAAGACC 25

```

RESULT 89
US-11-060-756-265948
; Sequence 265948, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

```

Query Match	1.4%	Score 25;	DB 1;	Length 25;
Best Local Similarity	80.0%;	Pred. No. 2e+02;		
Matches 20; Conservative	5;	Mismatches	0;	Gaps 0;

```

RESULT 90
US-11-0660-756-279400
; Sequence 279400, Application US/11060756
; Publication No. US2005022354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drugs
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO: 279400
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-0660-756-279400

```

```

RESULT 91
US-11-0660-756-279716
; Sequence 279716, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: William Martin
; TITLE OF INVENTION: Mounts, Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes

```

```

: FILE REFERENCE: AM101093 (0318966-042000)
: CURRENT APPLICATION NUMBER: US/11/060,756
: CURRENT FILING DATE: 2005-02-18
: NUMBER OF SEQ ID NOS: 303284
: SOFTWARE: PatentIn version 3.2
: SEQ ID NO 279716
: LENGTH: 25
: TYPE: DNA
: ORGANISM: probe
: US-11-060-756-279716

```

Query Match	1.4%	Score 25;	DB 1;	Length 25;
Best Local Similarity	80.0%	Pred. No. 2e+02;		
Matches 20;	Conservative 5;	Mismatches 0;	Indels 0;	Gaps 0

```

RESULT 92
US-11-060-756-281261
; Sequence 281261, Application US//11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031895-042000)
; CURRENT APPLICATION NUMBER: US//11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 281261
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-281261

```

```

RESULT 93
US-11-060-756-283013
; Sequence 283013, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Wyeth
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 283013
;
; LENGTH: 25
;
; TYPE: DNA
;
; ORGANISM: probe
US-11-060-756-283013

```

Query Match	1.4%	Score 25;	DB 1;	length 25;
Best Local Similarity	76.0%	Pred. No. 28+02;		
Matches 19;	Conservative	6;	Mismatches 0;	Indels 0;
			Gaps	0.

Qy 1502 UCAUACUUGAGCCCAUACAACAU 1526
:||||:||||:||||:||||:||||:||||:
Db 1 TCATGACTTGACCCCATACACATCAT 25

RESULT 94
US-11-060-756-285037
; Sequence 285037, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 285037
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-285037

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 76.0%; Pred. No. 2e+02;
Matches 19; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1505 UCAUCUGAGCCCAUACAACAU 1529
:||||:||||:||||:||||:||||:||||:
Db 1 TCATGAGACCCCATACACATCAT 25

RESULT 95
US-11-060-756-286908
; Sequence 286908, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 286908
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-286908

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 2e+02;
Matches 18; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 1519 UCAACAUCUUGGUCUGGUAACA 1543
:||||:||||:||||:||||:||||:||||:
Db 1 TACAACATCATGTTCTGTGTAACA 25

RESULT 96
US-11-060-756-287021
; Sequence 287021, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)

; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 287021
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-287021

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 2e+02;
Matches 18; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 1314 UAAGACUUCUGAGCUACUCUCA 1338
:||||:||||:||||:||||:||||:||||:
Db 1 TAAAGCTTTCGACGTCACTCTCA 25

RESULT 97
US-11-121-849-668383
; Sequence 668383, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; TITLE OF INVENTION: Microarrays
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 668383
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-668383

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 2e+02;
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 850 ACGGAGUUCUGAGCUCGACGA 874
:||||:||||:||||:||||:||||:||||:
Db 1 ACGGAGTTCTCGAAGCTGCACGA 25

RESULT 98
US-11-121-849-668384
; Sequence 668384, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; TITLE OF INVENTION: Microarrays
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 668384
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-668384

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 80.0%; Pred. No. 2e+02;
Matches 20; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 866 GTGCGACGAGUACGACUCCACCA 890
||:|||||:|||||:|||||
Db 1 GCTGCGACGAGTTCGAACTTCACCA 25

RESULT 99
US-11-121-849-668385
; Sequence 668385, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma

; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; TITLE OF INVENTION: Microarrays
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 668385
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-668385

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2e+02;
Matches 23; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 894 AAGCAUGAAGCGUCCACAGAGG 918
|||:|||||:|||||:|||||
Db 1 AAGCATGAACGCTCCACAGAGG 25

RESULT 100
US-11-121-849-668386
; Sequence 668386, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma

; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; TITLE OF INVENTION: Microarrays
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 668386
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-668386

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 912 CAGGAGAGUAVGCCGCGCCAC 936
|||:|||||:|||||:|||||
Db 1 CAGGAGAGATATGGCGCTGCCAC 25

RESULT 101
US-11-121-849-668387
; Sequence 668387, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma

; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S

; TITLE OF INVENTION: Microarrays
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 668387
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-668387

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 76.0%; Pred. No. 2e+02;
Matches 19; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 931 UGCACUUCUGGUCCAAACAGA 955
:|||||:|||||:|||||
Db 1 TCCCACTCTGCTTCACACAGA 25

RESULT 102
US-11-121-849-668388
; Sequence 668388, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma

; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; TITLE OF INVENTION: Microarrays
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 668388
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-668388

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2e+02;
Matches 23; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 978 GAUGACCAAGACCAAGCAGCAGU 1002
||:|||||:|||||:|||||
Db 1 GATGACCAAGACCAAGCAGCAGT 25

RESULT 103
US-11-121-849-668389
; Sequence 668389, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma

; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; TITLE OF INVENTION: Microarrays
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 668389
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-668389

```
Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy      995 GAGCAGGAGCAGUUGGAGCAACAA 1019
Db      1 GCAGCAGTGACAGTTGGAACAA 25

RESULT 104
US-11-121-849-668390
; Sequence 668390, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 668390
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-668390

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 80.0%; Pred. No. 2e+02;
Matches 20; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy      1010 GGAACAACAUGAUGGUGGUGCCUC 1034
Db      1 GGAACAACAATGATGCTGCTGCCTC 25

RESULT 105
US-11-121-849-668391
; Sequence 668391, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 668391
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-668391

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 81.0%; Pred. No. 2e+02;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy      1058 ACGAGAGAGACAUGGCTCCGAGAC 1082
Db      1 ACGAGAGAGACAATTGGCTCCGAGAC 25

RESULT 106
US-11-121-849-668392
; Sequence 668392, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 668392
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-668392

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 2e+02;
Matches 21; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      1078 GAGACGAGAGCCAUUCUACUCCAUCC 1102
Db      1 GAGACGAGAGCCATCTACTCCATCC 25

RESULT 107
US-11-121-849-668393
; Sequence 668393, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 668393
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-668393

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 76.0%; Pred. No. 2e+02;
Matches 19; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy      1086 AGCCAUCUACUCCAUCCGUGGUCUAG 1110
Db      1 AGCCATCTACTCATGCTGCTCAAG 25

RESULT 108
US-09-801-274-1145
; Sequence 1145, Application US/09801274
; Patent No. US20020032319A1
; GENERAL INFORMATION:
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Lander, Eric S.
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: 2825.2009-001
; CURRENT APPLICATION NUMBER: US/09/801,274
; CURRENT FILING DATE: 2001-03-07
; PRIOR APPLICATION NUMBER: US 60/187,510
; PRIOR FILING DATE: 2000-03-07
; PRIOR APPLICATION NUMBER: US 60/206,129
; PRIOR FILING DATE: 2000-05-22
```

```
;; NUMBER OF SEQ ID NOS: 1802
;; SOFTWARE: fastseq for windows Version 4.0
;; SEQ ID NO 1145
;; LENGTH: 31
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-801-274-1145
```

```
Query Match 1.4%; Score 24.8; DB 1; Length 31;
Best Local Similarity 63.3%; Pred. No. 3.1e+02;
Matches 19; Conservative 8; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 687 CACCAUACUUNUGGACAGCAGCCAUCCGUCG 716
Db 1 CACCATCACTTTGGGACATGCCATTCCTGC 30
```

```
RESULT 109
US-09-801-274-1328
; Sequence 1328, Application US/09801274
; Patent No. US20020032319A1
; GENERAL INFORMATION:
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Lander, Eric S.
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: 2825.2009-001
; CURRENT APPLICATION NUMBER: US/09/801,274
; CURRENT FILING DATE: 2001-03-07
; PRIOR APPLICATION NUMBER: US 60/187,510
; PRIOR FILING DATE: 2000-03-07
; PRIOR APPLICATION NUMBER: US 60/206,129
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 1802
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1328
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-801-274-1328
```

```
Query Match 1.4%; Score 24.8; DB 1; Length 31;
Best Local Similarity 63.3%; Pred. No. 3.1e+02;
Matches 19; Conservative 8; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 1587 CUACUGGCGUGUCUACAUCAACGACCGU 1616
Db 1 CTACTGGCTCTGCTAGTCACAGCACCAT 30
```

```
RESULT 110
US-10-719-956-108328
; Sequence 108328, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 108328
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-108328
```

```
Query Match 1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 68.0%; Pred. No. 2.8e+02;
Matches 17; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 1726 AGACAGUCGCGUACUUNUUCACAAGC 1750
Db 1 AGACAGTCGGTCTTTTTCACAAGC 25
```

```
RESULT 111
US-10-719-900-371517
; Sequence 371517, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 371517
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-371517
```

```
Query Match 1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 64.0%; Pred. No. 2.8e+02;
Matches 16; Conservative 8; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 1572 CUUUGGAUUCUGGCGUACUGGCGU 1596
Db 1 CTAITGGAAITCGGCTACTGCGCTG 25
```

```
RESULT 112
US-10-719-900-452393
; Sequence 452393, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 452393
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-452393
```

```
Query Match 1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2.8e+02;
Matches 22; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 1410 GACCAAGUCAGUACUACUAGCGG 1434
Db 1 GACCAAGTCAGATCACCACAGCGG 25
```

```
RESULT 113
US-10-719-900-563311
; Sequence 563311, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
```

;; CURRENT FILING DATE: 2003-11-20
;; PRIOR APPLICATION NUMBER: 60/427,808
;; PRIOR FILING DATE: 2002-11-20
;; NUMBER OF SEQ ID NOS: 982914
;; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
;; SEQ ID NO 563311
;; LENGTH: 25
;; TYPE: DNA
;; ORGANISM: Mus musculus
US-10-719-900-563311

Query Match 1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 1586 GCUACUGGUGGUCUACAACACAG 1610
Db 1 GCTACTGGCTGTCTATATCAACAG 25

RESULT 114
US-10-719-900-650683
; Sequence 650683, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Method of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 650683
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-650683

Query Match 1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 1536 GGUGAACCCUUGUGACAGCUGC 1560
Db 1 GGTGAACACCTTCTGTGACAGCTGC 25

RESULT 115
US-10-719-900-650685
; Sequence 650685, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 650685
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-650685

Query Match 1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 1536 GGUGAACCCUUGUGACAGCUGC 1560
Db 1 GGTGAACACCTTCTGTGACAGCTGC 25

RESULT 116
US-10-719-900-847289
; Sequence 847289, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 847289
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-847289

Query Match 1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 76.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1551 UGACAGCUGCAUACCCAAACCCUU 1575
Db 1 TGACAGCTGCATACCCAAACCTAT 25

RESULT 117
US-11-036-317-407684
; Sequence 407684, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; PRIOR FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 407684
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-407684

Query Match 1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 1566 CAAACCCUUGGAUUGGCGUAC 1590
Db 1 CAAACCTATTGGAATCTGGCTAC 25

RESULT 118
US-11-036-317-413596
; Sequence 413596, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1

```
;; CURRENT APPLICATION NUMBER: US/11/036,317
;; CURRENT FILING DATE: 2005-01-13
;; PRIOR APPLICATION NUMBER: US 60/536,639
;; PRIOR FILING DATE: 2004-01-13
;; NUMBER OF SEQ ID NOS: 991174
;; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
;; SEQ ID NO 413596
;; LENGTH: 25
;; TYPE: DNA
;; ORGANISM: Mus musculus
US-11-036-317-413596
```

```
Query Match          1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2.8e+02;
Matches 22; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      1413 CAGAAGUCAGAUCAUACGCGGAAA 1437
Db      1 CAGAACTCAGATCACCACGCGGAAA 25
```

RESULT 119

```
US-11-036-317-442156
; Sequence 442156, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; APPLICANT: Blume, John
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; PRIOR FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 442156
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-442156
```

```
Query Match          1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2.8e+02;
Matches 22; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      978 GAUGACCAAGACCAAGCAGCAGU 1002
Db      1 GATGACCAAGACCAAGTAGCAGT 25
```

RESULT 120

```
US-11-036-317-455937
; Sequence 455937, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; APPLICANT: Blume, John
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; PRIOR FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 455937
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-455937
```

```
Query Match          1.3%; Score 23.4; DB 1; Length 25;
```

```
Best Local Similarity 68.0%; Pred. No. 2.8e+02;
Matches 17; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      1615 GUGAACCCCGUGUGUCUAGUCUCU 1639
Db      1 GTGAACCCCGTGTGCTATGCCCTGT 25
```

RESULT 121

```
US-11-060-756-175673
; Sequence 175673, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 175673
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-175673
```

```
Query Match          1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      1587 CUACUGGCUUGUCUACUACACAC 1611
Db      1 CTACTGCTGTGTCTAGTCACACAC 25
```

RESULT 122

```
US-11-060-756-183239
; Sequence 183239, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 183239
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-183239
```

```
Query Match          1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 76.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      1590 CUGGCUUGUCUACUACACACAC 1614
Db      1 CTGGCTGTGTCTAGTCACACACAC 25
```

RESULT 123

```
US-11-136-527-158535
; Sequence 158535, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
```

```
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 158535
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
US-11-136-527-158535

Query Match
Best Local Similarity 1.3%; Score 23.4; DB 1; Length 25;
Matches 19; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Db
1 AACATTCAGAACCACTTCAGATG 25

RESULT 124
US-11-136-527-158536
; Sequence 158536, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 158536
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
US-11-136-527-158536

Query Match
Best Local Similarity 1.3%; Score 23.4; DB 1; Length 25;
Matches 19; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Db
1 AACATTCAGAACCACTTCAGATG 25

RESULT 125
US-11-136-527-158538
; Sequence 158538, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 158538
```

```
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
US-11-136-527-158538

Query Match
Best Local Similarity 1.3%; Score 23.4; DB 1; Length 25;
Matches 18; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Db
1 CAATTCAGAACCACTTCAGATGCT 25

RESULT 126
US-11-136-527-158539
; Sequence 158539, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 158539
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
US-11-136-527-158539

Query Match
Best Local Similarity 1.3%; Score 23.4; DB 1; Length 25;
Matches 19; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Db
1 ACATTCAGAACCACTTCAGATGC 25

RESULT 127
US-10-798-090-199
; Sequence 199, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Stina Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Cholinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (b1A)
; FILE REFERENCE: 400/147 (MEH804-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
```

```
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 199
/ LENGTH: 23
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-199

Query Match          1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      15 UAACGUAACACCCGCGCCUUGU 37
Db      1 UAACGUAACACCCGCGCCUUGU 23

RESULT 128
US-10-798-090-200
/ Sequence 200, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Collinergic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ FILE REFERENCE: 400/147 (MEHB04-183)
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ CURRENT FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 200
/ LENGTH: 23
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-200
```

```
Query Match          1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      19 AGUACAACCCGCGCCUUGUCC 41
Db      1 AGUACAACCCGCGCCUUGUCC 23

RESULT 129
US-10-798-090-201
/ Sequence 201, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Collinergic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ FILE REFERENCE: 400/147 (MEHB04-183)
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ CURRENT FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 201
/ LENGTH: 23
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-201

Query Match          1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      313 UACUCCUCCUUAAGCCGCGCCUG 335
Db      1 UACUCCUCCUUAAGCCGCGCCUG 23

RESULT 130
US-10-798-090-202
/ Sequence 202, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Collinergic
```

```
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sina)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US 10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 202
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-798-090-202

Query Match      1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Oy      315 CUUCCUUAAGCCUGCCUGG 337
Db      1 CUUCCUUAAGCCUGCCUGG 23
```

```
RESULT 131
US-10-798-090-203
; Sequence 203, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US 10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
```

```
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 203
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-798-090-203

Query Match      1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Oy      973 GAGCAGAUAGACCAAGCCACAG 995
Db      1 GAGCAGAUAGACCAAGCCACAG 23
```

```
RESULT 132
US-10-798-090-204
; Sequence 204, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US 10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 204
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-798-090-204

Query Match      1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
```

```
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1710 GCAGCAGUACGACAGACAGU 1732
    |||||
    1 GCAGCAGUACGACAGACAGU 23

RESULT 133
US-10-798-090-205
; Sequence 205, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 205
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/s1NA sense r
US-10-798-090-205

Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1712 AGCAGUACGACAGACAGU 1734
    |||||
    1 AGCAGUACGACAGACAGU 23

RESULT 134
US-10-798-090-206
; Sequence 206, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 206
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/s1NA sense r
US-10-798-090-206

Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1713 GCAGUACGACAGACAGU 1735
    |||||
    1 GCAGUACGACAGACAGU 23

RESULT 135
US-10-919-866-199
; Sequence 199, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
```

```

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 199
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-199

Query Match
Best Local Similarity 1.3%; Score 23; DB 1; Length 23;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 15 UACAGUACAACCCGCUUUGU 37
Db 1 UACAGUACAACCCGCUUUGU 23

RESULT 136
US-10-919-866-200
; Sequence 200, Application US/10919866
; Publication No. US2005017664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 200
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-200

Query Match
Best Local Similarity 1.3%; Score 23; DB 1; Length 23;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 19 AGUACAACCCGCUUUGUUC 41
```

```

Db 1 AGUACAACCCGCUUUGUUC 23

RESULT 137
US-10-919-866-201
; Sequence 201, Application US/10919866
; Publication No. US2005017664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 201
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-201

Query Match
Best Local Similarity 1.3%; Score 23; DB 1; Length 23;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 313 UACUUCUUCUUAAGCCGCGUG 335
Db 1 UACUUCUUCUUAAGCCGCGUG 23

RESULT 138
US-10-919-866-202
; Sequence 202, Application US/10919866
; Publication No. US2005017664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 202
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-202
```

```

; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 202
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-202

Query Match          1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      315 CUUCCUCUUAAGCCUGCCUGUG 337
Db      1 CUUCCUCUUAAGCCUGCCUGUG 23

RESULT 139
US-10-919-866-203
; Sequence 203, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 204
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-204
```

```

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 203
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-203

Query Match          1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      973 GAGCAGUAGACCAAGACCAAG 995
Db      1 GAGCAGUAGACCAAGACCAAG 23

RESULT 140
US-10-919-866-204
; Sequence 204, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 204
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-204

Query Match          1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1710 GCAGCAGUACCAAGACCAAGU 1732
Db      1 GCAGCAGUACCAAGACCAAGU 23
```

```
RESULT 141
US-10-919-866-205
; Sequence 205, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 205
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-205

Query Match          1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1712 AGCAGUACGACGACGACGACGUCG 1734
DB      1 AGCAGUACGACGACGACGACGUCG 23

RESULT 142
US-10-919-866-206
; Sequence 206, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
```

```
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 206
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-206

Query Match          1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1713 GCAGUACGACGACGACGACGUCG 1735
DB      1 GCAGUACGACGACGACGACGUCG 23

RESULT 143
US-10-719-900-451173
; Sequence 451173, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Wei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 451173
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-451173

Query Match          1.3%; Score 22.4; DB 1; Length 25;
Best Local Similarity 75.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY      1648 ACAUUCAGAACCAUCUUCAGAGUG 1671
DB      2 ACATTGAGAACCACTTCAAGATG 25

RESULT 144
US-11-136-527-158537
; Sequence 158537, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
```

```
FILE REFERENCE: 031996-041000 (AM101086)
CURRENT APPLICATION NUMBER: US/11/136,527
CURRENT FILING DATE: 2005-05-25
PRIOR APPLICATION NUMBER: US 60/574,294
PRIOR FILING DATE: 2005-05-26
NUMBER OF SEQ ID NOS: 362830
SOFTWARE: Patent version 3.2
SEQ ID NO 158537
LENGTH: 25
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Probe
US-11-136-527-158537
```

```
Query Match      1.3%; Score 22.4; DB 1; Length 25;
Best Local Similarity 70.8%; Pred. No. 3.5e+02;
Matches 17; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1650 AATGAGAACCACTTTCAGAGGCU 1673
DB      1 ATTCAGAACCACTTCAGAGGCT 24
```

```
RESULT 145
US-10-719-956-274609
Sequence 274609, Application US/10719956
Publication No. US20040146910A1
GENERAL INFORMATION:
APPLICANT: Xue Mei Zhou
TITLE OF INVENTION: Methods of Genetic Analysis of Rat
FILE REFERENCE: 3527.1
CURRENT APPLICATION NUMBER: US/10/719,956
PRIOR FILING DATE: 2003-11-20
PRIOR APPLICATION NUMBER: 60/427,836
PRIOR FILING DATE: 2002 11 20
NUMBER OF SEQ ID NOS: 699466
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 274609
LENGTH: 25
TYPE: DNA
ORGANISM: Rattus norvegicus
US-10-719-956-274609
```

```
Query Match      1.2%; Score 21.8; DB 1; Length 25;
Best Local Similarity 64.0%; Pred. No. 3.9e+02;
Matches 16; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1582 CUGGCUACUGGCUAGCAUCA 1606
DB      1 CTGGGCTACTGCTATGCTACGCA 25
```

```
RESULT 146
US-10-719-900-371516
Sequence 371516, Application US/10719900
Publication No. US20050026164A1
GENERAL INFORMATION:
APPLICANT: Xue Mei Zhou
TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
FILE REFERENCE: 3528.1
CURRENT APPLICATION NUMBER: US/10/719,900
PRIOR FILING DATE: 2003-11-20
PRIOR APPLICATION NUMBER: 60/427,808
PRIOR FILING DATE: 2002 11 20
NUMBER OF SEQ ID NOS: 982914
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 371516
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-10-719-900-371516
```

```
Query Match      1.2%; Score 21.8; DB 1; Length 25;
Best Local Similarity 60.0%; Pred. No. 3.9e+02;
Matches 15; Conservative 8; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1572 CUUUGGAUUCUGGCUACUGGCU 1596
DB      1 CTATTGGAATCTCGGCTACTGCGCTG 25
```

```
RESULT 147
US-10-719-900-387771
Sequence 387771, Application US/10719900
Publication No. US20050026164A1
GENERAL INFORMATION:
APPLICANT: Xue Mei Zhou
TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
FILE REFERENCE: 3528.1
CURRENT APPLICATION NUMBER: US/10/719,900
PRIOR FILING DATE: 2003-11-20
PRIOR APPLICATION NUMBER: 60/427,808
PRIOR FILING DATE: 2002 11 20
NUMBER OF SEQ ID NOS: 982914
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 387771
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-10-719-900-387771
```

```
Query Match      1.2%; Score 21.8; DB 1; Length 25;
Best Local Similarity 64.0%; Pred. No. 3.9e+02;
Matches 16; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1582 CUGGCUACUGGCUAGCAUCA 1606
DB      1 CTGGGCTACTGCTTGTCTACGCA 25
```

```
RESULT 148
US-10-719-900-452392
Sequence 452392, Application US/10719900
Publication No. US20050026164A1
GENERAL INFORMATION:
APPLICANT: Xue Mei Zhou
TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
FILE REFERENCE: 3528.1
CURRENT APPLICATION NUMBER: US/10/719,900
PRIOR FILING DATE: 2003-11-20
PRIOR APPLICATION NUMBER: 60/427,808
PRIOR FILING DATE: 2002 11 20
NUMBER OF SEQ ID NOS: 982914
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 452392
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-10-719-900-452392
```

```
Query Match      1.2%; Score 21.8; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 3.9e+02;
Matches 21; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1410 GACCGAGAGCAGCAUCAGGCG 1434
DB      1 GACCGAGAGCAGCATCAGGCG 25
```

```
RESULT 149
US-10-719-900-562103
Sequence 562103, Application US/10719900
Publication No. US20050026164A1
GENERAL INFORMATION:
APPLICANT: Xue Mei Zhou
```

```

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 562103
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-562103

Query Match
Best Local Similarity 72.0%; Score 21.8; DB 1; Length 25;
Matches 18; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1390 GCCAAGAGGUGUCUCUGAAGACCA 1414
DB 1 GCTAAGAGGTTGCTCTCAAGACCA 25

RESULT 150
US-10-719-900-563310
; Sequence 563310, Application US/107199900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 563310
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-563310

Query Match
Best Local Similarity 68.0%; Score 21.8; DB 1; Length 25;
Matches 17; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1586 GCUACUGGCGUGCUACUACACAG 1610
DB 1 GCTACTGGCTGTCTATCAACAG 25

RESULT 151
US-10-719-900-847290
; Sequence 847290, Application US/107199900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 847290
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-847290

Query Match
1.2%; Score 21.8; DB 1; Length 25;
Score 21.8; DB 1; Length 25;
```

```

Best Local Similarity 72.0%; Pred. No. 3.9e+02;
Matches 18; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1551 UGACAGCUGAUNCCCAAAACCTUU 1575
DB 1 TGACAGCTGATTCACAAACCTAT 25

RESULT 152
US-11-036-317-485535
; Sequence 485535, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; APPLICANT: Blume, John
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; CURRENT FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; PRIOR FILING DATE: 2004-01-13
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 485535
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-485535

Query Match
Best Local Similarity 72.0%; Score 21.8; DB 1; Length 25;
Matches 18; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1009 UGGAACAACAUNAGUCUGCCU 1033
DB 1 TGAATTAACAACGATGCTGCTCT 25

RESULT 153
US-11-060-756-141921
; Sequence 141921, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 141921
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-141921

Query Match
Best Local Similarity 72.0%; Score 21.8; DB 1; Length 25;
Matches 18; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1589 ACUGGCGUGCUACUACACAGCAGC 1613
DB 1 ACTGGCTTGTTCATCAACAGCAC 25

RESULT 154
US-11-060-756-146660
; Sequence 146660, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

```

; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 146660
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-146660

Query Match
Best Local Similarity 72.0%; Score 21.8; DB 1; Length 25;
Matches 18; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1520 ACAACUAGUGUUGUGAAGACAC 1544
DB 1 ACAAGTCATGCTCTGTGAACAC 25

RESULT 155
US-11-060-756-152117
; Sequence 152117, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 152117
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-152117

Query Match
Best Local Similarity 68.0%; Score 21.8; DB 1; Length 25;
Matches 17; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1522 AACAUCAUGUUGUGAAGACCU 1546
DB 1 AACGTCATGCTCTGTGAACACT 25

RESULT 156
US-11-136-527-158540
; Sequence 158540, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 158540
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
```

```

US-11-136-527-158540

Query Match
Best Local Similarity 68.0%; Score 21.8; DB 1; Length 25;
Matches 17; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1651 UUCAGAACCACTTCAAGATGCTCC 1675
DB 1 TTCAGAACCACTTCAAGATGCTCC 25

RESULT 157
US-10-809-189-58455
; Sequence 58455, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Miltmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 58455
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-58455

Query Match
Best Local Similarity 60.9%; Score 21.4; DB 1; Length 25;
Matches 14; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 1526 UCAUGGUGUGUGAAGACCTTU 1548
DB 3 TCATGCTCTGTGAACACTTT 25

RESULT 158
US-10-719-900-451174
; Sequence 451174, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 451174
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-451174

Query Match
Best Local Similarity 70.8%; Score 20.8; DB 1; Length 25;
Matches 17; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1648 ACAUUGAAGCACTTUCAAGAU 1671
DB 2 ACATTCAGAACGACCTTCAAGATG 25
```

```
RESULT 159
US-11-060-756-140214
; Sequence 140214, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 140214
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-140214

Query Match
Best Local Similarity 1.2%; Score 20.8; DB 1; Length 25;
Matches 16; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1516 CCAUACAACAUCAUGGUCUGUG 1539
||:|||||:||||:||||:|
Db 2 CCGTACACATCATGTCGTGCTG 25

RESULT 160
US-11-060-756-140215
; Sequence 140215, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 140215
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-140215

Query Match
Best Local Similarity 1.2%; Score 20.8; DB 1; Length 25;
Matches 16; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1516 CCAUACAACAUCAUGGUCUGUG 1539
||:|||||:||||:||||:|
Db 2 CCGTACACATCATGTCGTGCTG 25

RESULT 161
US-11-060-756-176156
; Sequence 176156, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 176156
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-176156

Query Match
Best Local Similarity 1.2%; Score 20.8; DB 1; Length 25;
Matches 16; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1516 CCAUACAACAUCAUGGUCUGUG 1539
||:|||||:||||:||||:|
Db 2 CCGTACACATCATGTCGTGCTG 25

RESULT 162
US-11-060-756-202713
; Sequence 202713, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 202713
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-202713

Query Match
Best Local Similarity 1.2%; Score 20.8; DB 1; Length 25;
Matches 17; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1593 GCUUGUCUACUACAGACACCGU 1616
||:|||||:|||||:|
Db 1 GCTGTCTACGTCAACAGACACCAT 24

RESULT 163
US-11-060-756-239676
; Sequence 239676, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 239676
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-239676

Query Match
Best Local Similarity 1.2%; Score 20.8; DB 1; Length 25;
Matches 14; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 1526 UCAUGGUCUGUGAAGACACCUU 1549
.:|:|:|:|:|:|:|:|:|
Db 2 TCATGGTCTGCTGTAACACCTTCT 25
```

```
RESULT 164
US-11-121-849-124288
; Sequence 124288, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 124288
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-124288

Query Match
Best Local Similarity 1.2%; Score 20.8; DB 1; Length 25;
Matches 14; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 1526 UCAUGGUCUGUGACACCUUUU 1549
DB 2 TCATGCTCTGTTGACACCTTCT 25

RESULT 165
US-11-136-527-158541
; Sequence 158541, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 158541
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
US-11-136-527-158541

Query Match
Best Local Similarity 1.2%; Score 20.8; DB 1; Length 25;
Matches 17; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1653 CAGAACCACTUUCAGAGUCUGCU 1676
DB 1 CAGAACCACTTCAAGATGCTCTCT 24

RESULT 166
US-10-719-956-274610
; Sequence 274610, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
```

```
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 274610
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-274610

Query Match
Best Local Similarity 1.1%; Score 20.2; DB 1; Length 25;
Matches 15; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

QY 1582 CUGGCTACGCTGCTATGCTACGCA 1606
DB 1 CTGGCTCTGCTGCTATGCTACGCA 25

RESULT 167
US-10-719-956-580106
; Sequence 580106, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 580106
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-580106

Query Match
Best Local Similarity 1.1%; Score 20.2; DB 1; Length 25;
Matches 17; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1499 UCAUCAUACGUGACCCCAUCAA 1523
DB 1 TCATCATCATGATGACCCCTTATTA 25

RESULT 168
US-10-719-956-664015
; Sequence 664015, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 664015
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-664015

Query Match
Best Local Similarity 1.1%; Score 20.2; DB 1; Length 25;
Matches 19; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1372 UUCAAGAACCAUCUGGCCAAGA 1396
DB 1 UUCAAGAACCAUCUGGCCAAGA 1396
```

Db 1 TTCAGGAATCCACTGGCCAGGA 25

RESULT 169

US-10-719-900-43769

Sequence 43769, Application US/10719900

Publication No. US20050026164A1

GENERAL INFORMATION:

APPLICANT: Xue Mei Zhou

TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

FILE REFERENCE: 3528.1

CURRENT APPLICATION NUMBER: US/10/719,900

PRIOR FILING DATE: 2003-11-20

PRIOR APPLICATION NUMBER: 60/427,808

PRIOR FILING DATE: 2002 11 20

NUMBER OF SEQ ID NOS: 982914

SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

SEQ ID NO 43769

LENGTH: 25

TYPE: DNA

ORGANISM: Mus musculus

US-10-719-900-43769

Query Match

Best Local Similarity 1.1%; Score 20.2; DB 1; Length 25;

Best Local Similarity 80.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1459 AAGAAAGCGGCCGACCCGACG 1483

Db 1 AAGAAAGCGGCCGACCCGACG 25

RESULT 170

US-10-719-900-55769

Sequence 55769, Application US/10719900

Publication No. US20050026164A1

GENERAL INFORMATION:

APPLICANT: Xue Mei Zhou

TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

FILE REFERENCE: 3528.1

CURRENT APPLICATION NUMBER: US/10/719,900

PRIOR FILING DATE: 2003-11-20

PRIOR APPLICATION NUMBER: 60/427,808

PRIOR FILING DATE: 2002 11 20

NUMBER OF SEQ ID NOS: 982914

SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

SEQ ID NO 55769

LENGTH: 25

TYPE: DNA

ORGANISM: Mus musculus

US-10-719-900-55769

Query Match

Best Local Similarity 1.1%; Score 20.2; DB 1; Length 25;

Best Local Similarity 72.0%; Pred. No. 5.4e+02;

Matches 18; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1276 AAGCUCCCAUCCAGCAGUAGUCAG 1300

Db 1 AAGCTCCCATCCAGTTAAGTCTG 25

RESULT 171

US-10-719-900-387772

Sequence 387772, Application US/10719900

Publication No. US20050026164A1

GENERAL INFORMATION:

APPLICANT: Xue Mei Zhou

TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

FILE REFERENCE: 3528.1

CURRENT APPLICATION NUMBER: US/10/719,900

PRIOR FILING DATE: 2003-11-20

PRIOR APPLICATION NUMBER: 60/427,808

PRIOR FILING DATE: 2002 11 20

NUMBER OF SEQ ID NOS: 982914

SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

SEQ ID NO 387772

LENGTH: 25

TYPE: DNA

ORGANISM: Mus musculus

US-10-719-900-387772

Query Match

Best Local Similarity 1.1%; Score 20.2; DB 1; Length 25;

Best Local Similarity 60.0%; Pred. No. 5.4e+02;

Matches 15; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

QY 1582 CUGAGCUCAGGCGUGUCUACUCA 1606

Db 1 CTGGGCTACTGGGTTTGCTACGTCA 25

RESULT 172

US-10-719-900-562102

Sequence 562102, Application US/10719900

Publication No. US20050026164A1

GENERAL INFORMATION:

APPLICANT: Xue Mei Zhou

TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

FILE REFERENCE: 3528.1

CURRENT APPLICATION NUMBER: US/10/719,900

PRIOR FILING DATE: 2003-11-20

PRIOR APPLICATION NUMBER: 60/427,808

PRIOR FILING DATE: 2002 11 20

NUMBER OF SEQ ID NOS: 982914

SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

SEQ ID NO 562102

LENGTH: 25

TYPE: DNA

ORGANISM: Mus musculus

US-10-719-900-562102

Query Match

Best Local Similarity 1.1%; Score 20.2; DB 1; Length 25;

Best Local Similarity 68.0%; Pred. No. 5.4e+02;

Matches 17; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1390 GCCAAGAGGUGUCUCUGAGACCA 1414

Db 1 GCTAAGAGGTTCTCTCAAGACCA 25

RESULT 173

US-10-719-900-795977

Sequence 795977, Application US/10719900

Publication No. US20050026164A1

GENERAL INFORMATION:

APPLICANT: Xue Mei Zhou

TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

FILE REFERENCE: 3528.1

CURRENT APPLICATION NUMBER: US/10/719,900

PRIOR FILING DATE: 2003-11-20

PRIOR APPLICATION NUMBER: 60/427,808

PRIOR FILING DATE: 2002 11 20

NUMBER OF SEQ ID NOS: 982914

SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

SEQ ID NO 795977

LENGTH: 25

TYPE: DNA

ORGANISM: Mus musculus

US-10-719-900-795977

Query Match

Best Local Similarity 1.1%; Score 20.2; DB 1; Length 25;

Best Local Similarity 72.0%; Pred. No. 5.4e+02;

Matches 18; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1604 UCAACAGCACCGUAGAACCCCGUG 1628

Db 1 TCAACAGCACTGTCAACCCCATGTG 25

```
RESULT 174
US-10-719-900-953129
; Sequence 953129, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO: 953129
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-953129

Query Match          1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 56.0%; Pred. No. 5.4e+02;
Matches 14; Conservative 8; Mismatches 3; Indels 0; Gaps 0;

QY      1489 UUGCUUGCCUUGCAUCAUCGCUUGA 1513
DB      1 TTGCTGGCTTTCATCATCATCACTGCGA 25

RESULT 175
US-10-809-189-99629
; Sequence 99629, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Miltmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO: 99629
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-99629

Query Match          1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 5.4e+02;
Matches 18; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY      1507 ACUUGACCCCAUACAACAUCG 1531
DB      1 ACCTGACACCAATATAACATCATG 25

RESULT 176
US-10-809-189-115275
; Sequence 115275, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Miltmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
```

```
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO: 115275
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-115275

Query Match          1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 52.0%; Pred. No. 5.4e+02;
Matches 13; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

QY      469 AUGAAUUCUUGGUGCAUCAGCUUG 493
DB      1 ATGAACCTTCTGTGATATGCTTGG 25

RESULT 177
US-11-060-756-121819
; Sequence 121819, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO: 121819
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-121819

Query Match          1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 5.4e+02;
Matches 18; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY      1504 AUCACUUGACCCCAUACAACAUCA 1528
DB      1 ATCACATGACCCCGTATAACATCA 25

RESULT 178
US-11-060-756-121820
; Sequence 121820, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO: 121820
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
```

US-11-060-756-121820

Query Match 1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 5.4e+02;
Matches 18; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1504 AUCACUGAGCCCAUACAACAUCA 1558
|||:|||||:|||||:|||||:|||||:
DB 1 ATCACATGAGCCCGGTATACATCA 25

RESULT 179

US-11-060-756-122169
; Sequence 122169, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 122169
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-122169

Query Match 1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 5.4e+02;
Matches 18; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1501 AUCACUGAGCCCAUACAACAUCA 1555
|||:|||||:|||||:|||||:|||||:
DB 1 ATCATCACATGAGCCCGGTATACCA 25

RESULT 180

US-11-060-756-128205
; Sequence 128205, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 128205
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-128205

Query Match 1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 84.0%; Pred. No. 5.4e+02;
Matches 21; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1454 AGGAGAAAGAGCGCCGACGACCCU 1478
|||||:|||||:|||||:|||||:|||||:
DB 1 AGGAGAAAGAGCGGCTCGGACCT 25

RESULT 181
US-11-060-756-137566
; Sequence 137566, Application US/11060756
; Publication No. US20050221354A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 137566
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-137566

Query Match 1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 68.0%; Pred. No. 5.4e+02;
Matches 17; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1513 ACCCAUACAACAUCAUGGUGUGG 1537
|||||:|||||:|||||:|||||:|||||:
DB 1 ACCCGTATACATCATGTGCTCTGG 25

RESULT 182

US-11-060-756-139454
; Sequence 139454, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 139454
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-139454

Query Match 1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 5.4e+02;
Matches 18; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1507 ACUGAGCCCAUACAACAUCAUGG 1531
|||:|||||:|||||:|||||:|||||:
DB 1 ACCTGACACCGTACACATCATGG 25

RESULT 183

US-11-060-756-146298
; Sequence 146298, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 146298
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-146298

```
Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 68.0%; Pred. No. 5.4e+02;
Matches 17; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY      1513 ACCCCGACACATCATGCTGCTGG 1537
DB      1 ACACCGTACACATCATGCTGCTGG 25

RESULT 184
US-11-060-756-163148
; Sequence 163148, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 163148
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-163148

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 68.0%; Pred. No. 5.4e+02;
Matches 17; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY      1506 CACUUGACCCCAUACACAUCAUG 1530
DB      1 CACTTGCGCCCAUACATGTCATG 25

RESULT 185
US-11-060-756-164983
; Sequence 164983, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 164983
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-164983

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 64.0%; Pred. No. 5.4e+02;
Matches 16; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

QY      1514 CCCCAUACAACAUCAUGUUCUGU 1538
DB      1 CACCGTACACATCATGCTGCTGGT 25

RESULT 186
US-11-060-756-168817
; Sequence 168817, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 168817
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-168817

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 68.0%; Pred. No. 5.4e+02;
Matches 17; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY      1508 CUUGACCCCAUACAACAUCAUGU 1532
DB      1 CATGGACCCCGTATACATCATGCT 25

RESULT 187
US-11-060-756-188590
; Sequence 188590, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 188590
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-188590

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 64.0%; Pred. No. 5.4e+02;
Matches 16; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

QY      1514 CCCCAUACAACAUCAUGUUCUGU 1538
DB      1 CCCGTTATACATCATGCTGCTGGT 25

RESULT 188
US-11-060-756-192519
; Sequence 192519, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 192519
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-192519

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 68.0%; Pred. No. 5.4e+02;
Matches 17; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY      1508 CUUGACCCCAUACAACAUCAUGU 1532
DB      1 CATGGACCCCGTATACATCATGCT 25

RESULT 187
US-11-060-756-188590
; Sequence 188590, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 188590
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-188590

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 64.0%; Pred. No. 5.4e+02;
Matches 16; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

QY      1514 CCCCAUACAACAUCAUGUUCUGU 1538
DB      1 CCCGTTATACATCATGCTGCTGGT 25

RESULT 188
US-11-060-756-192519
; Sequence 192519, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 192519
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-192519
```

Query Match 1.1%; Score 20.2; DB 1; Length 25;
 Best Local Similarity 64.0%; Pred. No. 5.4e+02;
 Matches 16; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

QY 1517 CAACCAACCAUCGUCUGUGAA 1541
 |||||:||||:||||:||||:
 DB 1 CCAACACGTCATCATGTGCTGAA 25

RESULT 189

US-11-060-756-218631
 ; Sequence 218631, Application US/11060756
 ; Publication No. US20050221354A1
 ; GENERAL INFORMATION:

; APPLICANT: Wyeth
 ; APPLICANT: Mounts, William Martin
 ; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
 ; FILE REFERENCE: AM101083 (031896-042000)
 ; CURRENT APPLICATION NUMBER: US/11/060,756
 ; CURRENT FILING DATE: 2005-02-18
 ; NUMBER OF SEQ ID NOS: 303284
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 218631
 ; LENGTH: 25
 ; TYPE: DNA
 ; ORGANISM: probe
 ; US-11-060-756-218631

Query Match 1.1%; Score 20.2; DB 1; Length 25;
 Best Local Similarity 68.0%; Pred. No. 5.4e+02;
 Matches 17; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1512 GACCCCAUACAUCGUCUGUG 1536
 |||||:||||:||||:||||:
 DB 1 GACACCGTACATCATGTGCTG 25

RESULT 190

US-11-060-756-218632
 ; Sequence 218632, Application US/11060756
 ; Publication No. US20050221354A1
 ; GENERAL INFORMATION:

; APPLICANT: Wyeth
 ; APPLICANT: Mounts, William Martin
 ; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
 ; FILE REFERENCE: AM101083 (031896-042000)
 ; CURRENT APPLICATION NUMBER: US/11/060,756
 ; CURRENT FILING DATE: 2005-02-18
 ; NUMBER OF SEQ ID NOS: 303284
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 218632
 ; LENGTH: 25
 ; TYPE: DNA
 ; ORGANISM: probe
 ; US-11-060-756-218632

Query Match 1.1%; Score 20.2; DB 1; Length 25;
 Best Local Similarity 68.0%; Pred. No. 5.4e+02;
 Matches 17; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1512 GACCCCAUACAUCGUCUGUG 1536
 |||||:||||:||||:||||:
 DB 1 GACACCGTACATCATGTGCTG 25

RESULT 191

US-11-060-756-256967
 ; Sequence 256967, Application US/11060756
 ; Publication No. US20050221354A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Wyeth

; APPLICANT: Mounts, William Martin
 ; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
 ; FILE REFERENCE: AM101083 (031896-042000)
 ; CURRENT APPLICATION NUMBER: US/11/060,756
 ; CURRENT FILING DATE: 2005-02-18
 ; NUMBER OF SEQ ID NOS: 303284
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 256967
 ; LENGTH: 25
 ; TYPE: DNA
 ; ORGANISM: probe
 ; US-11-060-756-256967

Query Match 1.1%; Score 20.2; DB 1; Length 25;
 Best Local Similarity 68.0%; Pred. No. 5.4e+02;
 Matches 17; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1511 GACCCCAUACAUCGUCUGU 1535
 |||||:||||:||||:||||:
 DB 1 GACACCGTACATCATGTGCTG 25

RESULT 192

US-11-060-756-263670
 ; Sequence 263670, Application US/11060756
 ; Publication No. US20050221354A1
 ; GENERAL INFORMATION:

; APPLICANT: Wyeth
 ; APPLICANT: Mounts, William Martin
 ; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
 ; FILE REFERENCE: AM101083 (031896-042000)
 ; CURRENT APPLICATION NUMBER: US/11/060,756
 ; CURRENT FILING DATE: 2005-02-18
 ; NUMBER OF SEQ ID NOS: 303284
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 263670
 ; LENGTH: 25
 ; TYPE: DNA
 ; ORGANISM: probe
 ; US-11-060-756-263670

Query Match 1.1%; Score 20.2; DB 1; Length 25;
 Best Local Similarity 68.0%; Pred. No. 5.4e+02;
 Matches 17; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1510 UGACCCCAUACAUCGUCUG 1534
 |||||:||||:||||:||||:
 DB 1 TGGACACCGTACATCATGTGCTG 25

RESULT 193

US-11-060-756-273444
 ; Sequence 273444, Application US/11060756
 ; Publication No. US20050221354A1
 ; GENERAL INFORMATION:

; APPLICANT: Wyeth
 ; APPLICANT: Mounts, William Martin
 ; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
 ; FILE REFERENCE: AM101083 (031896-042000)
 ; CURRENT APPLICATION NUMBER: US/11/060,756
 ; CURRENT FILING DATE: 2005-02-18
 ; NUMBER OF SEQ ID NOS: 303284
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 273444
 ; LENGTH: 25
 ; TYPE: DNA
 ; ORGANISM: probe
 ; US-11-060-756-273444

Query Match 1.1%; Score 20.2; DB 1; Length 25;

Best Local Similarity 72.0%; Pred. No. 5.4e+02;
Matches 18; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

```

OY      1597 UGCUACAUCACAGCACCGUGAAC 1621
          |||:|||||:|||||
DB      1 TGCTACGTCAACAGCACCATCAACC 25

```

RESULT 194
US-11-060-756-282661

Query Match	1.1%	Score 20.2;	DB 1;	length 25;
Best Local Similarity	68.0%	Pred. No. 5.4e+02;		
Matches 17; Conservative	5;	Mismatches 3;	Indels 0;	Gaps 0;

```
QY      1499  UCAUCAUCACUTUGGACCCCAUACAA  1523
      :||:||||:||||||:|
Db      1    TCATCATTCACATGACCCCGTATAA  25
```

RESULT 195
US-11-060-756-282662
; Sequence 282662, Application US/11060756
; Publication No. US20050221354A1

```
Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 68.0%; Pred. No. 5.4e+02;
Matches 17; Conservative 5; Mismatches 3; Indels 0; Gaps 0;
```

```
OY      1499 UCAUCAUACACTUTGGACCCCAUAACA   1523  
          :||:|||:|||:|||:|||:|||:  
Db       1 TCATCATCATGACGCCCGTATAA    25
```

```

RESULT 196
US-11-121-849-48862
; Sequence 48862, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S

```

```

: TITLE OF INVENTION: Microarrays
: FILE REFERENCE: 3684.1
: CURRENT APPLICATION NUMBER: US/11/121,849
: CURRENT FILING DATE: 2005-05-03
: PRIOR APPLICATION NUMBER: 60/567,949
: PRIOR FILING DATE: 2004-05-03
: NUMBER OF SEQ ID NOS: 673904
: SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
: SEQ ID NO 48862
: LENGTH: 25
: TYPE: DNA
: ORGANISM: Homo sapien
US-11-121-849-48862

```

Query Match	1.1%	Score 20.2;	DB 1;	Length 25;
Best Local Similarity	52.0%	Pred. No. 5.4e+02;		
Matches 13; Conservative	9;	Mismatches 3;	Indels 0;	Gaps 0;

```
QY      1525 AUCAUUGUUCUGUGAACACCUUUU 1549
      ||::||: |:|:| | |:::
Db      1 AUCATGGTCTGCTGAGCTCTTT 25
```

RESULT 197
US-11-121-849-125376
; Sequence 125376, Application US/11121849
; Publication No. US20050272080A1

Query Match	1.1%	Score 20.2;	DB 1;	length 25;
Best Local Similarity	68.0%;	Pred. No. 5.4e+02;		
Matches 17;	Conservative 5;	Mismatches 3;	Indels 0;	Gaps 0;

```

Oy      1507  ACUTGGACCCCAUACAACAUC AUGG 1531
          ||::||| |||::|||::|||
Db      1     ACTTGGGCCCATATCATGT CATGG 25

```

```

RESULT 198
US-11-121-849-125380
; Sequence 125380, Application US//11121849
; Publication NO. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; TITLE OF INVENTION: Microarrays
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US//11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 125380
;
; LENGTH: 25
;
; TYPE: DNA
;
; ORGANISM: Homo sapien
US-11-121-849-125380

```

```
Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 64.0%; Pred. No. 5.4e+02;
Matches 16; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

Qy      1585 GGCUCAGCGGUGGUCACAUCAACA 1609
Db      1 GGTACTGCGCTTGTATCATCAACA 25

RESULT 199
US-11-121-849-184585
; Sequence 184585, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 184585
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-184585

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 5.4e+02;
Matches 18; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy      1501 AUCACUCCUGAGCCCAUACAACA 1525
Db      1 ATCATCATGACGACCCGATATACA 25

RESULT 200
US-11-121-849-184586
; Sequence 184586, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 184586
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-184586

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 68.0%; Pred. No. 5.4e+02;
Matches 17; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

Qy      1513 ACCCCAUACAUCAGUGGUCUG 1537
Db      1 ACCCGTATACATCATGATCGCTCG 25

RESULT 201
US-11-136-527-134960
; Sequence 134960, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 134960
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
US-11-136-527-134960

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 68.0%; Pred. No. 5.4e+02;
Matches 17; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

Qy      1505 UCACUGAGCCCAUACAACAU 1529
Db      1 TCACCTGACACCATATATCATCAT 25

RESULT 202
US-11-136-527-134972
; Sequence 134972, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Mounts, William M
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 134972
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
US-11-136-527-134972

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 5.4e+02;
Matches 18; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy      1506 CACUGAGCCCAUACAACAU 1530
Db      1 CACCTGACACCATATATCATCATG 25

RESULT 203
US-10-798-090-1
; Sequence 1, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBHB04-183)
```

```

; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-1

```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      3 GACCUUGCACAUAACAGU 21
DB      1 GACCUUGCACAUAACAGU 19

```

```

RESULT 204
US-10-798-090-2
; Sequence 2, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782

```

```

; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-2

```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      21 UACAAUCCUGCCUUGUUU 39
DB      1 UACAAUCCUGCCUUGUUU 19

```

```

RESULT 205
US-10-798-090-3
; Sequence 3, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-3

```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      39 UCCAAACUACGCUCCUCC 57

```

```
Db      1 UCCAAACAGCAGCCUCC 19
|||||
RESULT 206
US-10-798-090-4
; Sequence 4, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinegic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 4
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-4
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      57 CUGAUAACAAGCCUCC 75
|||||
Db      1 CUGAUAACAAGCCUCC 19
|||||
RESULT 207
US-10-798-090-5
; Sequence 5, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinegic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
```

```
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 5
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-5
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      75 CGAUGCAGGCGUCCCCG 93
|||||
Db      1 CGAUGCAGGCGUCCCCG 19
|||||
RESULT 208
US-10-798-090-6
; Sequence 6, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinegic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 6
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-6
```

```

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 6
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-6

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      93 GGGACCGCAGCAGUUC 111
DB      1 GGGACCGCAGCAGUUC 19

RESULT 209
US-10-798-090-7
; Sequence 7, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 7
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-7

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      111 CGGACGACAGCAGUUC 129
DB      1 CGGACGACAGCAGUUC 19
```

```

RESULT 210
US-10-798-090-8
; Sequence 8, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 8
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-8

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      129 UCGACGACGCGCAUUC 147
DB      1 UCGACGACGCGCAUUC 19

RESULT 211
US-10-798-090-9
; Sequence 9, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
```

```

; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23.
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 9
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-9

```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      147 CUCCUCCAGACGGUACC 165
Db      1 CUCCUCCAGACGGUACC 19

```

```

RESULT 212
US-10-798-090-10
; Sequence 10, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3

```

```

; SEQ ID NO 10
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-10

```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      165 CACCGAUACCCUUGCGGA 183
Db      1 CACCGAUACCCUUGCGGA 19

```

```

RESULT 213
US-10-798-090-11
; Sequence 11, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 11
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-11

```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      183 AGGUCAUACCGUUGCGCAA 201
Db      1 AGGUCAUACCGUUGCGCAA 19

```

```

RESULT 214
US-10-798-090-12

```

```
; Sequence 12, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1nA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/593,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 12
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/s1nA sense r
US-10-798-090-12

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      201 AGUGGUCUUCGCGCUCUUC 219
Db      1 AGUGGUCUUCGCGCUCUUC 19

RESULT 215
; Sequence 13, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1nA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/593,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
```

```
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 13
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/s1nA sense r
US-10-798-090-13

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      219 CUUACGGGCAUCCUGGCC 237
Db      1 CUUACGGGCAUCCUGGCC 19

RESULT 216
; Sequence 14, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1nA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/593,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 14
; LENGTH: 19
; TYPE: RNA
```

```

US-10-798-090-14
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
FEATURE:
ORGANISM: Artificial Sequence
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 237 CUUGUGACCAUCCAUUGGC 255
DB 1 CUUGUGACCAUCCAUUGGC 19

RESULT 217
US-10-798-090-15
Sequence 15, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Cholinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (sina)
FILE REFERENCE: 400/147 (MEHE04-183)
CURRENT APPLICATION NUMBER: US/10/798, 090
CURRENT FILING DATE: 2004-03-11
PRIORITY APPLICATION NUMBER: US 10/757, 803
PRIORITY FILING DATE: 2004-01-14
PRIORITY APPLICATION NUMBER: US 10/720, 448
PRIORITY FILING DATE: 2003-11-24
PRIORITY APPLICATION NUMBER: US 10/693, 059
PRIORITY FILING DATE: 2003-10-23
PRIORITY APPLICATION NUMBER: US 10/444, 853
PRIORITY FILING DATE: 2003-05-23
PRIORITY APPLICATION NUMBER: PCT/US03/05346
PRIORITY FILING DATE: 2003-02-20
PRIORITY APPLICATION NUMBER: PCT/US03/05028
PRIORITY FILING DATE: 2003-02-20
PRIORITY APPLICATION NUMBER: US 60/358, 580
PRIORITY FILING DATE: 2002-02-20
PRIORITY APPLICATION NUMBER: US 60/363, 124
PRIORITY FILING DATE: 2002-03-11
PRIORITY APPLICATION NUMBER: US 60/386, 782
PRIORITY FILING DATE: 2002-06-06
PRIORITY APPLICATION NUMBER: US 60/406, 784
PRIORITY FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 15
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-798-090-15

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 255 CAACAUCCUGUAUUGUG 273
DB 1 CAACAUCCUGUAUUGUG 19

RESULT 218
US-10-798-090-16
Sequence 16, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:

```

```

APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwiggen, Ivan
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MBHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
PRIORITY FILING DATE: 2004-03-11
PRIORITY APPLICATION NUMBER: US 10/757,803
PRIORITY FILING DATE: 2004-01-14
PRIORITY APPLICATION NUMBER: US 10/720,448
PRIORITY FILING DATE: 2003-11-24
PRIORITY APPLICATION NUMBER: US 10/693,059
PRIORITY FILING DATE: 2003-10-23
PRIORITY APPLICATION NUMBER: US 10/444,853
PRIORITY FILING DATE: 2003-05-23
PRIORITY APPLICATION NUMBER: PCT/US03/05346
PRIORITY FILING DATE: 2003-02-20
PRIORITY APPLICATION NUMBER: PCT/US03/05028
PRIORITY FILING DATE: 2003-02-20
PRIORITY APPLICATION NUMBER: US 60/356,580
PRIORITY FILING DATE: 2002-02-20
PRIORITY APPLICATION NUMBER: US 60/363,124
PRIORITY FILING DATE: 2002-03-11
PRIORITY APPLICATION NUMBER: US 60/386,782
PRIORITY FILING DATE: 2002-06-06
PRIORITY APPLICATION NUMBER: US 60/406,784
PRIORITY FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 16
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/sirna sense r
US-10-798-090-16

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches    19; Conservative   0; Mismatches    0; Indels    0; Gaps    0;

QY      273 GUCAUUUAGGUCAACAG 291
        |||||
Db       1 GUCAUUUAGGUCAACAG 19

RESULT 219
US-10-798-090-17
Sequence 17, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MBHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
PRIORITY FILING DATE: 2004-03-11
PRIORITY APPLICATION NUMBER: US 10/757,803
PRIORITY FILING DATE: 2004-01-14
PRIORITY APPLICATION NUMBER: US 10/720,448
PRIORITY FILING DATE: 2003-11-24
PRIORITY APPLICATION NUMBER: US 10/693,059
PRIORITY FILING DATE: 2003-10-23
PRIORITY APPLICATION NUMBER: US 10/444,853
PRIORITY FILING DATE: 2003-05-23
PRIORITY APPLICATION NUMBER: PCT/US03/05346
PRIORITY FILING DATE: 2003-02-20

```

```

; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 17
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-17

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      291 GCAGCTGAGACGCGUCAC 309
        |||
        1 GCAGCTGAGACGCGUCAC 19

RESULT 220
US-10-798-090-18
; Sequence 18, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 18
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-18
```

```

US-10-798-090-18

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      309 CACUCUCCUCCUCCUAGC 327
        |||
        1 CACUCUCCUCCUCCUAGC 19

RESULT 221
US-10-798-090-19
; Sequence 19, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 19
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-19

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      327 CCUGCCUGGCGGCAUCUG 345
        |||
        1 CCUGCCUGGCGGCAUCUG 19

RESULT 222
US-10-798-090-20
; Sequence 20, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
```

```
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ FILE REFERENCE: 400/147 (MEHB04-183)
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 20
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-20

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      345 GAUUAUCCGGGUCUAUUTCA 363
Db      1 GAUUAUCCGGGUCUAUUTCA 19

RESULT 223
US-10-798-090-21
/ Sequence 21, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ FILE REFERENCE: 400/147 (MEHB04-183)
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
```

```
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 21
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-21

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      363 AAUGAAUUCUGUUAACGACC 381
Db      1 AAUGAAUUCUGUUAACGACC 19

RESULT 224
US-10-798-090-22
/ Sequence 22, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ FILE REFERENCE: 400/147 (MEHB04-183)
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 22
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-22

Query Match          1.1%; Score 19; DB 1; Length 19;
```

Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 381 CUACAUCACUACAUGCA 399
|||||
Db 1 CUACAUCACUACAUGCA 19

RESULT 225

US-10-798-090-23
; Sequence 23, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/s1NA sense r
US-10-798-090-23

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 399 AUGGGCCUAGGGAACUG 417
|||||
Db 1 AUGGGCCUAGGGAACUG 19

RESULT 226

US-10-798-090-24
; Sequence 24, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)

FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 24
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/s1NA sense r
US-10-798-090-24

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 417 GGCCTUGACCTUGGCTU 435
|||||
Db 1 GGCCTUGACCTUGGCTU 19

RESULT 227

US-10-798-090-25
; Sequence 25, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11

;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 25
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-25

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 435 UGCCAUGACUACGUAGCC 453
Db 1 UGCCAUGACUACGUAGCC 19

RESULT 228
US-10-798-090-26
;; Sequence 26, Application US/10798090
;; Publication No. US20050014172A1
;; GENERAL INFORMATION:
;; APPLICANT: Sigma Therapeutics, Inc.
;; APPLICANT: Richards, Ivan
;; APPLICANT: MCSwigen, James
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
;; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
;; TITLE OF INVENTION: (siNA)
;; FILE REFERENCE: 400/147 (MEHB04-183)
;; CURRENT APPLICATION NUMBER: US/10/798,090
;; PRIOR FILING DATE: 2004-03-11
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 26
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-26

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 453 CAGCAUUGCCUCUGUUAUG 471
Db 1 CAGCAUUGCCUCUGUUAUG 19

RESULT 229
US-10-798-090-27
;; Sequence 27, Application US/10798090
;; Publication No. US20050014172A1
;; GENERAL INFORMATION:
;; APPLICANT: Sigma Therapeutics, Inc.
;; APPLICANT: Richards, Ivan
;; APPLICANT: MCSwigen, James
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
;; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
;; TITLE OF INVENTION: (siNA)
;; FILE REFERENCE: 400/147 (MEHB04-183)
;; CURRENT APPLICATION NUMBER: US/10/798,090
;; PRIOR FILING DATE: 2004-03-11
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 27
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-27

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 471 GAUUCUUCUGGUCUACG 489
Db 1 GAUUCUUCUGGUCUACG 19

RESULT 230
US-10-798-090-28
;; Sequence 28, Application US/10798090
;; Publication No. US20050014172A1
;; GENERAL INFORMATION:
;; APPLICANT: Sigma Therapeutics, Inc.
;; APPLICANT: Richards, Ivan
;; APPLICANT: MCSwigen, James
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
;; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
;; TITLE OF INVENTION: (siNA)
;; FILE REFERENCE: 400/147 (MEHB04-183)
;; CURRENT APPLICATION NUMBER: US/10/798,090
;; PRIOR FILING DATE: 2004-03-11


```
RESULT 233
US-10-798-090-31
; Sequence 31, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 31
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-31
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 543 AACAAAGAGCCGCGUGG 561
Db 1 AACAAAGAGCCGCGUGG 19

RESULT 234
US-10-798-090-32
; Sequence 32, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
```

```
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 32
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-32
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 561 GAUAUCGGUCUGCGUGG 579
Db 1 GAUAUCGGUCUGCGUGG 19

RESULT 235
US-10-798-090-33
; Sequence 33, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
```



```
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 36
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 37
; LENGTH: 19
```

```
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-37
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 651 UCCGGAGAGUCCUCACU 669
DB 1 UCCGGAGAGUCCUCACU 19

RESULT 240
US-10-798-090-38
; Sequence 38, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 38
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-38
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 UCCAGUCCUCAGAGAGCC 687
DB 1 UCCAGUCCUCAGAGAGCC 19

RESULT 241
US-10-798-090-39
; Sequence 39, Application US/10798090
; Publication No. US20050014172A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 39
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/sRNA sense r
US-10-798-090-39

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      687 CACCAUACUUUGGCACA 705
DB      1 CACCAUACUUUGGCACA 19

RESULT 242
US-10-798-090-40
; Sequence 40, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 40
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/sRNA sense r
US-10-798-090-40

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      705 AGCCAUCCGUCUUUUU 723
DB      1 AGCCAUCCGUCUUUUU 19

RESULT 243
US-10-798-090-41
; Sequence 41, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 41
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-41

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      723 UAUGCCUGUACCAUUAUG 741
      |||||
Db      1 UAUGCCUGUACCAUUAUG 19

RESULT 244
US-10-798-090-42
; Sequence 42, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: MCSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Collinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 42
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: MCSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Collinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      741 GACUUAUUUAUCUGAGG 759
      |||||
Db      1 GACUUAUUUAUCUGAGG 19

RESULT 245
US-10-798-090-43
; Sequence 43, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Collinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      759 GAUCUUAAGAAACUGAA 777
      |||||
Db      1 GAUCUUAAGAAACUGAA 19

RESULT 246
US-10-798-090-44
; Sequence 44, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: MCSwigen, James
; APPLICANT: Richards, Ivan
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Collinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
```

```

; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 44
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-44

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      777 AAAGCGUACCAAGAGCCUU 795
Db      1 AAAGCGUACCAAGAGCCUU 19

RESULT 247
US-10-798-090-45
; Sequence 45, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 45
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-45
```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      795 UCGUGCCUGCAAGCCUU 813
Db      1 UCGUGCCUGCAAGCCUU 19

RESULT 248
US-10-798-090-46
; Sequence 46, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 46
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-46

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      813 UCGGACAGAGCGAGAGACA 831
Db      1 UGGACAGAGCGAGAGACA 19

RESULT 249
US-10-798-090-47
; Sequence 47, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
US-10-798-090-47
```

;; TITLE OF INVENTION: (sina)
;; FILE REFERENCE: 400/147 (MBHB04-183)
;; CURRENT APPLICATION NUMBER: US/10/798,090
;; CURRENT FILING DATE: 2004-03-11
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 47
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-47

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 831 AGAAAACUUGUCCACCCC 849
DB 1 AGAAAACUUGUCCACCCC 19

RESULT 250
US-10-798-090-48
;; Sequence 48, Application US/10798090
;; Publication No. US20050014172A1
;; GENERAL INFORMATION:
;; APPLICANT: Sina Therapeutics, Inc.
;; APPLICANT: Richards, Ivan
;; APPLICANT: McSwiggen, James
;; TITLE OF INVENTION: RNA interference Mediated Inhibition of Muscarinic Colinergic
;; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
;; FILE REFERENCE: 400/147 (MBHB04-183)
;; CURRENT APPLICATION NUMBER: US/10/798,090
;; CURRENT FILING DATE: 2004-03-11
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124

;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 48
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-48

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 849 CACGGGAGUUCGAGAC 867
DB 1 CACGGGAGUUCGAGAC 19

RESULT 251
US-10-798-090-49
;; Sequence 49, Application US/10798090
;; Publication No. US20050014172A1
;; GENERAL INFORMATION:
;; APPLICANT: Sina Therapeutics, Inc.
;; APPLICANT: Richards, Ivan
;; APPLICANT: McSwiggen, James
;; TITLE OF INVENTION: RNA interference Mediated Inhibition of Muscarinic Colinergic
;; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
;; FILE REFERENCE: 400/147 (MBHB04-183)
;; CURRENT APPLICATION NUMBER: US/10/798,090
;; CURRENT FILING DATE: 2004-03-11
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 49
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-49

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
OY      867 CUGCAGCAGUUAAGAACU 885
      |||||
      1 CUGCAGCAGUUAAGAACU 19

RESULT 252
US-10-798-090-50
; Sequence 50, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 50
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/s1NA sense r
US-10-798-090-50

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      885 UCAACGCAAGCAUGCAA 903
      |||||
      1 UCAACGCAAGCAUGCAA 19

RESULT 253
US-10-798-090-51
; Sequence 51, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090

; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 51
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/s1NA sense r
US-10-798-090-51

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      903 ACGCUCCAAGAGGAG 921
      |||||
      1 ACGCUCCAAGAGGAG 19

RESULT 254
US-10-798-090-52
; Sequence 52, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
```

```

; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 52
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-52

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 921 GUAUGCGCGCUCACUUC 939
Db 1 GUAUGCGCGCUCACUUC 19

RESULT 255
US-10-798-090-53
; Sequence 53, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 53
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-53

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 939 CUGGUCACCAACCAAGAGC 957
Db 1 CUGGUCACCAACCAAGAGC 19
```

```

Db 1 CUGGUCACCAACCAAGAGC 19

RESULT 256
US-10-798-090-54
; Sequence 54, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 54
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-54

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 957 CUGGAACCCAGCUCGAG 975
Db 1 CUGGAACCCAGCUCGAG 19

RESULT 257
US-10-798-090-55
; Sequence 55, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
```

```
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEH04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No.4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 975 GCAGUGACGACGACGAC 993
Db 1 GCAGUGACGACGACGAC 19

RESULT 258
US-10-798-090-56
; Sequence 56, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEH04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 56
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEH04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No.4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 993 CAGCAGCAGCAGCAGUGG 1011
Db 1 CAGCAGCAGCAGCAGUGG 19
```

```
RESULT 259
US-10-798-090-57
; Sequence 57, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEH04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 57
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEH04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No.4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1011 GAACAACAAGCAGCAGC 1029
Db 1 GAACAACAAGCAGCAGC 19
```

RESULT 260
US-10-798-090-58
; Sequence 58, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 58
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-58

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1029 UGCUCCUCCUGAGACUCC 1047
Db 1 UGCUCCUCCUGAGACUCC 19

RESULT 261
US-10-798-090-59
; Sequence 59, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 59
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-59

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1047 CGCUCCUCCGACGAGAG 1065
Db 1 CGCUCCUCCGACGAGAG 19

RESULT 262
US-10-798-090-60
; Sequence 60, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 60

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-60

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1065 GGACAUUGGCUCCGAGAGC 1083
Db      1 GGACAUUGGCUCCGAGAGC 19

RESULT 263
US-10-798-090-61
; Sequence 61, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 61
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-61

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1083 GAGAGCAUCUACUCCAUCC 1101
Db      1 GAGAGCAUCUACUCCAUCC 19

RESULT 264
US-10-798-090-62
; Sequence 62, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 62
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-62

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1101 CGUGCUCAAGCUCCGGGU 1119
Db      1 CGUGCUCAAGCUCCGGGU 19

RESULT 265
US-10-798-090-63
; Sequence 63, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 63
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-63
```

```
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 63
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-63

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1119 UCACGACCAUCCUCCAC 1137
DB      1 UCACGACCAUCCUCCAC 19

RESULT 266
US-10-798-090-64
; Sequence 64, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 64
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-64

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1137 CUCCACCAAGUACCCUCA 1155
DB      1 CUCCACCAAGUACCCUCA 19

RESULT 267
US-10-798-090-65
; Sequence 65, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 65
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-65

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1155 AUCCGACCAUCCUCCAGUG 1173
DB      1 AUCCGACCAUCCUCCAGUG 19

RESULT 268
US-10-798-090-66
; Sequence 66, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
```

```

; APPLICANT: Richards, Ivan
; APPLICANT: MCSwiggan, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEH04-183)
; CURRENT APPLICATION NUMBER: US10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 66
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-66

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1173 GCCUGAGAGAGCUCGGG 1191
DB      1 GCCUGAGAGAGCUCGGG 19

RESULT 269
US-10-798-090-67
; Sequence 67, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwiggan, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEH04-183)
; CURRENT APPLICATION NUMBER: US10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
```

```

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 67
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-67

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1191 GAUGGUGACUCUGAGAGG 1209
DB      1 GAUGGUGACUCUGAGAGG 19

RESULT 270
US-10-798-090-68
; Sequence 68, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: MCSwiggan, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEH04-183)
; CURRENT APPLICATION NUMBER: US10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 68
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-68
```

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1209 GAAAGCCGACAAGCUCAG 1227
|||||

DB 1 GAAAGCCGACAAGCUCAG 19

RESULT 271

US-10-798-090-69

; Sequence 69, Application US/10798090
; Publication No. US20050014172A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwigen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic

; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid

; FILE REFERENCE: 400/147 (MEHB04-183)

; CURRENT APPLICATION NUMBER: US/10/798,090

; PRIOR FILING DATE: 2004-03-11

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-14

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 60/406,784

; PRIOR FILING DATE: 2002-08-29

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 304

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 69

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1227 GGGCCGAGAAGCGUGAC 1245
|||||

DB 1 GGGCCGAGAAGCGUGAC 19

RESULT 272

US-10-798-090-70

; Sequence 70, Application US/10798090
; Publication No. US20050014172A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwigen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic

; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid

; FILE OF INVENTION: (siNA)

; FILE REFERENCE: 400/147 (MEHB04-183)

; CURRENT APPLICATION NUMBER: US/10/798,090

; PRIOR FILING DATE: 2004-03-11

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-14

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 60/406,784

; PRIOR FILING DATE: 2002-08-29

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 304

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 70

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1245 CGAUGAGCGAGUUTUCA 1263
|||||

DB 1 CGAUGAGCGAGUUTUCA 19

RESULT 273

US-10-798-090-71

; Sequence 71, Application US/10798090
; Publication No. US20050014172A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwigen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic

; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid

; FILE REFERENCE: 400/147 (MEHB04-183)

; CURRENT APPLICATION NUMBER: US/10/798,090

; PRIOR FILING DATE: 2004-03-11

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-14

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

```

; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 71
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-71

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1263 AAAAGCUCUCCAGCCTU 1281
      |||||
      1 AAAAGCUCUCCAGCCTU 19

RESULT 274
US-10-798-090-72
; Sequence 72, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 72
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-72

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
```

```

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1281 UCCCAUCGAGGAGUCA 1299
      |||||
      1 UCCCAUCGAGGAGUCA 19

RESULT 275
US-10-798-090-73
; Sequence 73, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 73
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-73

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1299 AGCCGUGACAGCUAG 1317
      |||||
      1 AGCCGUGACAGCUAG 19

RESULT 276
US-10-798-090-74
; Sequence 74, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MHB04-183)
```

```
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ CURRENT FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 74
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-74
```

```
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1317 GACUUCUGAGUCUACUCC 1335
Db 1 GACUUCUGAGUCUACUCC 19
```

```
RESULT 277
US-10-798-090-75
/ Sequence 75, Application US/10798090
/ Publication No. US2005004172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sitna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: MCSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ TITLE OF INVENTION: (siNA)
/ FILE REFERENCE: 400/147 (MEHB04-183)
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ CURRENT FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
```

```
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 75
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-75
```

```
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1335 CUCAUGUGGUAGAGCAGC 1353
Db 1 CUCAUGUGGUAGAGCAGC 19
```

```
RESULT 278
US-10-798-090-76
/ Sequence 76, Application US/10798090
/ Publication No. US2005004172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sitna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: MCSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ TITLE OF INVENTION: (siNA)
/ FILE REFERENCE: 400/147 (MEHB04-183)
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ CURRENT FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 76
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-76
```

```
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1353 GGCACUCCUACUCCUCC 1371
```

```
Db          1 GGCACUCUACCCUGUCC 19
|||||
RESULT 279
US-10-798-090-77
; Sequence 77, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1nA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 77
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/s1nA sense r
US-10-798-090-77

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1371 CUUCAAGAGCCACUCUG 1389
|||||
Db          1 CUUCAAGAGCCACUCUG 19
|||||

RESULT 280
US-10-798-090-78
; Sequence 78, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1nA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29

; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 78
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/s1nA sense r
US-10-798-090-78

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1389 GGCACAGAGUUGCUCUG 1407
|||||
Db          1 GGCACAGAGUUGCUCUG 19
|||||

RESULT 281
US-10-798-090-79
; Sequence 79, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1nA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
```

```

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 79
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-79

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1407 GAAGACCGAAGUCAGAU 1425
Db      1 GAAGACCGAAGUCAGAU 19
|||||
```

```

RESULT 282
US-10-798-090-80
; Sequence 80, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT FILING DATE: 2004-03-11
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 80
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-80

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1425 CACUAGGCGAAGAGAU 1443
Db      1 CACUAGGCGAAGAGAU 19
|||||
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1425 CACUAGGCGAAGAGAU 1443
Db      1 CACUAGGCGAAGAGAU 19
|||||
```

```

RESULT 283
US-10-798-090-81
; Sequence 81, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT FILING DATE: 2004-03-11
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 81
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-81

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1443 GUCCCGUGUACAGAGAG 1461
Db      1 GUCCCGUGUACAGAGAG 19
|||||
```

```

RESULT 284
US-10-798-090-82
; Sequence 82, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT FILING DATE: 2004-03-11
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
```



```
; Sequence 85, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 85
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-85

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1515 CCCAUAACAACAUCAUGGU 1533
DB      1 CCCAUAACAACAUCAUGGU 19

RESULT 288
US-10-798-090-86
; Sequence 86, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
```

```
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 86
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-86

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1533 UCUUGUAAACACCUUUUGU 1551
DB      1 UCUUGUAAACACCUUUUGU 19

RESULT 289
US-10-798-090-87
; Sequence 87, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 87
; LENGTH: 19
; TYPE: RNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-87

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1551 UGACGACUCGCAUACCCCAA 1569
      |||||
      1 UGACGACUCGCAUACCCCAA 19

RESULT 290
US-10-798-090-88
; Sequence 88, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 88
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-88

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1569 AACCUUUUGAAUUCUGGCG 1587
      |||||
      1 AACCUUUUGAAUUCUGGCG 19

RESULT 291
US-10-798-090-89
; Sequence 89, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 89
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-89

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1587 CUACUGGUCUGUCUACUAC 1605
      |||||
      1 CUACUGGUCUGUCUACUAC 19

RESULT 292
US-10-798-090-90
; Sequence 90, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 90
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-90
```

```

; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
FEATURES
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/sRNA sense 1

```

```

; APPLICANT:  RICHARDS, Ivan
; APPLICANT:  McSwiggen, James

```

```

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 93
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-93

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1659 CACUUCAGAGUGCGUG 1677
DB      1 CACUUCAGAGUGCGUG 19

RESULT 296
US-10-798-090-94
; Sequence 94, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: MCSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
```

```

; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 94
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-94

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1677 GCUGGCGAGUGGACAAA 1695
DB      1 GCUGGCGAGUGGACAAA 19

RESULT 297
US-10-798-090-95
; Sequence 95, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: MCSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 95
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-798-090-95

Query Match          1.1%; Score 19; DB 1; Length 19;
```

Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1695 AAAAAGAGCGCAGAGAG 1713
|||||

DB 1 AAAAAGAGCGCAGAGAG 19

RESULT 298

US-10-798-090-96
; Sequence 96, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 96
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-96

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1713 GCAGUACGACGAGAGAG 1731
|||||

DB 1 GCAGUACGACGAGAGAG 19

RESULT 299

US-10-798-090-97
; Sequence 97, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11

FILE REFERENCE: 400/147 (MBHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 97
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-97

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1731 GUCGUCAUUUUUCACAG 1749
|||||

DB 1 GUCGUCAUUUUUCACAG 19

RESULT 300

US-10-798-090-98
; Sequence 98, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11

```

; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 98
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-99

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 GGGCGACCCGAGCAGGCC 1767
DB      1 GGGCGACCCGAGCAGGCC 19

RESULT 301
US-10-798-090-99
; Sequence 99, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 99
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-798-090-99

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      1753 GGACCGAGCAGCCUUGU 1771
DB      1 GGACCGAGCAGCCUUGU 19

RESULT 302
US-10-798-090-100/c
; Sequence 100, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 100
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-100

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      3 GACCUUGACAAUACAGU 21
DB      19 GACCTTGACATTAACAGT 1

RESULT 303
US-10-798-090-101/c
; Sequence 101, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
```

```

? PRIOR APPLICATION NUMBER: US 10/757,803
? PRIOR FILING DATE: 2004-01-14
? PRIOR APPLICATION NUMBER: US 10/720,448
? PRIOR FILING DATE: 2003-11-24
? PRIOR APPLICATION NUMBER: US 10/693,059
? PRIOR FILING DATE: 2003-10-23
? PRIOR APPLICATION NUMBER: US 10/444,853
? PRIOR FILING DATE: 2003-05-23
? PRIOR APPLICATION NUMBER: PCT/US03/05346
? PRIOR FILING DATE: 2003-02-20
? PRIOR APPLICATION NUMBER: PCT/US03/05028
? PRIOR FILING DATE: 2003-02-20
? PRIOR APPLICATION NUMBER: US 60/358,580
? PRIOR FILING DATE: 2002-02-20
? PRIOR APPLICATION NUMBER: US 60/363,124
? PRIOR FILING DATE: 2002-03-11
? PRIOR APPLICATION NUMBER: US 60/386,782
? PRIOR FILING DATE: 2002-06-06
? PRIOR APPLICATION NUMBER: US 60/406,784
? PRIOR FILING DATE: 2002-08-29
? Remaining Prior Application data removed - See File Wrapper or PALM.
? NUMBER OF SEQ ID NOS: 304
? SOFTWARE: PatentIn version 3.3
? SEQ ID NO 101
? LENGTH: 19
? TYPE: RNA
? ORGANISM: Artificial Sequence
? FEATURE:
? OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-101

```

Query Match	1.1%	Score 19	DB 1	Length 19
Best Local Similarity	57.9%	Pred. No.	4.3e-02	
Matches 11	Conservative 8	Mismatches 0	Indels 0	Gaps 0
QY	21	UACAACCTCGCCCTTGGGTTT	39	
db	19	TACAACCTCGCCCTTGGTTT	1	

```

RESULT 304
US-10-798-090-102/C
; Sequence 102, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA interference Mediated Inhibition of Muscarinic Cholinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid

```

```

1 FILE REFERENCE: 400/147 (MEHBD04-183)
2
3 CURRENT APPLICATION NUMBER: US 10/798,090
4
5 CURRENT FILING DATE: 2004-03-11
6
7 PRIOR APPLICATION NUMBER: US 10/757,803
8
9 PRIOR FILING DATE: 2004-01-14
10
11 PRIOR APPLICATION NUMBER: US 10/720,448
12
13 PRIOR FILING DATE: 2003-11-24
14
15 PRIOR APPLICATION NUMBER: US 10/593,059
16
17 PRIOR FILING DATE: 2003-10-23
18
19 PRIOR APPLICATION NUMBER: US 10/444,853
20
21 PRIOR FILING DATE: 2003-05-23
22
23 PRIOR APPLICATION NUMBER: PCT/US03/05346
24
25 PRIOR FILING DATE: 2003-02-20
26
27 PRIOR APPLICATION NUMBER: PCT/US03/05028
28
29 PRIOR FILING DATE: 2003-02-20
30
31 PRIOR APPLICATION NUMBER: US 60/358,580
32
33 PRIOR FILING DATE: 2002-02-20
34
35 PRIOR APPLICATION NUMBER: US 60/363,124
36
37 PRIOR FILING DATE: 2002-03-11
38
39 PRIOR APPLICATION NUMBER: US 60/386,782
40
41 PRIOR FILING DATE: 2002-06-06
42
43 PRIOR APPLICATION NUMBER: US 60/406,784

```

```

; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 102
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-798-050-102

```

Query Match	1.1%;	Score 19;	DB 1;	Length 19;
Best Local Similarity	78.9%;	Pred. No. 4.3e+02;		
Matches 15;	Conservative 4;	Mismatches 0;	Indels 0;	Gaps 0;

```
QY      39  UCCAACAUCAGCUCUCC 57
          :|||||:||||:|:|
Db      19  TCCAACATCAGCTCTCC 1
```

```

RESULT 305
US-10-798-090-103/C
; Sequence 103, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA interference Mediated Inhibition of Muscarinic Cholinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid

```

```

FILE REFERENCE: 400/147 (MHB004-183)
CURRENT APPLICATION NUMBER: US 10/798, 090
CURRENT FILING DATE: 2004-03-11
PRIORITY APPLICATION NUMBER: US 10/757, 803
PRIORITY FILING DATE: 2004-01-14
PRIORITY APPLICATION NUMBER: US 10/720, 448
PRIORITY FILING DATE: 2003-11-24
PRIORITY APPLICATION NUMBER: US 10/693, 059
PRIORITY FILING DATE: 2003-10-23
PRIORITY APPLICATION NUMBER: US 10/444, 853
PRIORITY FILING DATE: 2003-05-23
PRIORITY APPLICATION NUMBER: PCT/US03/05346
PRIORITY FILING DATE: 2003-02-20
PRIORITY APPLICATION NUMBER: PCT/US03/05028
PRIORITY FILING DATE: 2003-02-20
PRIORITY APPLICATION NUMBER: US 60/358, 580
PRIORITY FILING DATE: 2002-02-20
PRIORITY APPLICATION NUMBER: US 60/363, 124
PRIORITY FILING DATE: 2002-03-11
PRIORITY APPLICATION NUMBER: US 60/386, 782
PRIORITY FILING DATE: 2002-06-06
PRIORITY APPLICATION NUMBER: US 60/406, 784
PRIORITY FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 103

```

OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-103

Query Match	1.1%	Score 19;	DB 1;	length 19;
Best Local Similarity	84.2%	Pred. No. 4.3e+02;		
Matches 16;	Conservative 3;	Mismatches 0;	Indels 0;	Gaps 0;

Qy	57	CUGAUAACAGGCCCTCC	75
		: : : : : : :	
Db	19	CTGATACACAGCCCTCC	1

```
RESULT 306
US-10-798-090-104/c
; Sequence 104, Application US/10798090
; Publication No. US20050014172A1
GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 104
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: Richards, Ivan
; OTHER INFORMATION: Description of Artificial Sequence: sirna antisense region
US-10-798-090-104

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      75 CGAUGCAGGCGUGGCCCCG 93
DB      19 CGATGACGAGCTGCCCCCG 1

RESULT 307
US-10-798-090-105/c
; Sequence 105, Application US/10798090
; Publication No. US20050014172A1
GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
```

```
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 105
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: Richards, Ivan
; OTHER INFORMATION: Description of Artificial Sequence: sirna antisense region
US-10-798-090-105

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      93 GGAACCGCACCACUUC 111
DB      19 GGAACCGTCACCTATTC 1

RESULT 308
US-10-798-090-106/c
; Sequence 106, Application US/10798090
; Publication No. US20050014172A1
GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
```

```
SOFTWARE: PatentIn version 3.3
; SEQ ID NO 106
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: s1NA antisense region
US-10-798-090-106
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      111 CGGACGACUACAUGUUUCU 129
      |||||:||||:||||:
Db      19 CGGACGCTGCATGTTCT 1
```

RESULT 309

US-10-798-090-107/c

; Sequence 107, Application US/10798090

; Publication No. US20050014172A1

; GENERAL INFORMATION:

; APPLICANT: Sirta Therapeutics, Inc.

; APPLICANT: Richards, Ivan

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic

; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid

; TITLE OF INVENTION: (s1NA)

; FILE REFERENCE: 400/147 (MEHB04-183)

; CURRENT APPLICATION NUMBER: US/10/798,090

; CURRENT FILING DATE: 2004-03-11

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-14

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 60/406,784

; PRIOR FILING DATE: 2002-08-29

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 304

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 107

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; APPLICANT: Sirta Therapeutics, Inc.

; APPLICANT: Richards, Ivan

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic

; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid

; TITLE OF INVENTION: (s1NA)

; FILE REFERENCE: 400/147 (MEHB04-183)

; CURRENT APPLICATION NUMBER: US/10/798,090

; CURRENT FILING DATE: 2004-03-11

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-14

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

RESULT 310

```
US-10-798-090-108/c
; Sequence 108, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
```

; APPLICANT: Sirta Therapeutics, Inc.

; APPLICANT: Richards, Ivan

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic

; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid

; TITLE OF INVENTION: (s1NA)

; FILE REFERENCE: 400/147 (MEHB04-183)

; CURRENT APPLICATION NUMBER: US/10/798,090

; CURRENT FILING DATE: 2004-03-11

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-14

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 60/406,784

; PRIOR FILING DATE: 2002-08-29

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 304

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 108

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; APPLICANT: Sirta Therapeutics, Inc.

; APPLICANT: Richards, Ivan

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic

; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid

; TITLE OF INVENTION: (s1NA)

; FILE REFERENCE: 400/147 (MEHB04-183)

; CURRENT APPLICATION NUMBER: US/10/798,090

; CURRENT FILING DATE: 2004-03-11

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-14

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

RESULT 311

US-10-798-090-109/c

; Sequence 109, Application US/10798090

; Publication No. US20050014172A1

; GENERAL INFORMATION:

; APPLICANT: Sirta Therapeutics, Inc.

; APPLICANT: Richards, Ivan

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic

; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid

; TITLE OF INVENTION: (s1NA)

; FILE REFERENCE: 400/147 (MEHB04-183)

; CURRENT APPLICATION NUMBER: US/10/798,090

; CURRENT FILING DATE: 2004-03-11

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-14

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR FILING DATE: 2003-10-23

```

; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 109
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-109

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 165 CACCGAUGACCCGUCGGA 183
Db 19 CACCGATGACCTCTGGGA 1

RESULT 312
US-10-798-090-110/c
; Sequence 110, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitma Therapeutics, Inc.
; APPLICANT: MCSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 110
; LENGTH: 19
```

```

; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-110

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 183 AGGUCANACCGUCGCAA 201
Db 19 AGGTGATGACCTCTGGGA 1

RESULT 313
US-10-798-090-111/c
; Sequence 111, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitma Therapeutics, Inc.
; APPLICANT: MCSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 111
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-111

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 201 AGGUCGUCGUCGCUUC 219
Db 19 AGGTGATGACCTCTGGGA 1

RESULT 314
US-10-798-090-112/c
; Sequence 112, Application US/10798090
; Publication No. US20050014172A1
```

GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: MCSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (sRNA)
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 112
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
US-10-798-090-112

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 237 CUUACGGGCAUCCUGGCC 237
Db 19 CTTACGGGCAUCCUGGCC 1

RESULT 315
US-10-798-090-113/c
Sequence 113, Application US/10798090
Publication No. US2005004172A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: MCSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (sRNA)
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346

PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 113
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
US-10-798-090-113

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 237 CUUAGUGACCAUCCUGGCC 255
Db 19 CTTGGTGACCAUCCUGGCC 1

RESULT 316
US-10-798-090-114/c
Sequence 114, Application US/10798090
Publication No. US2005004172A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: MCSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (sRNA)
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 114
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:

```
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-114

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      255 CAACAUCCUGGUAUUGUG 273
      |||||:|:|:|:|:|:|:|
      19 CAACATCTGTGTAATGTG 1

RESULT 317
US-10-798-090-115/c
; Sequence 115, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBH04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 115
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-115

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      273 GUCAUUAGGUCACACAG 291
      |||||:|:|:|:|:|:|:|
      19 GTCATTAGTCAACACAG 1

RESULT 318
US-10-798-090-116/c
; Sequence 116, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan

; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBH04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 116
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-116

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      291 GGAGCTGAAGCGGUCAC 309
      |||||:|:|:|:|:|:|:|
      19 GGAGCTGAAGCGGTCAC 1

RESULT 319
US-10-798-090-117/c
; Sequence 117, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBH04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
```

```

; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 117
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-117

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      309 CAACUACUUCUCCUUAAGC 327
DB      19 CAACUACUUCUCCUUAAGC 1

RESULT 320
US-10-798-090-118/c
; Sequence 118, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 118
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-118
```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      327 CCUGGCCUUGCCGAUCUG 345
DB      19 CCUGGCCUUGCCGAUCUG 1

RESULT 321
US-10-798-090-119/c
; Sequence 119, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 119
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-119

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.3e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY      345 GAUUAUCGGGCGUACUUAUCA 363
DB      19 GAUUAUCGGGCGUACUUAUCA 1

RESULT 322
US-10-798-090-120/c
; Sequence 120, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
```

```

; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 120
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: s1NA antisense region
US-10-798-090-120

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy      363 AUAUAUCUGUUAUACGACC 381
Db      19 AATGAATCTGTTACGACC 1

RESULT 323
US-10-798-090-121/c
; Sequence 121, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: S1ma Therapeutics, Inc.
; APPLICANT: McSw1gen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
```

```

; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 121
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: s1NA antisense region
US-10-798-090-121

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy      381 CTACACUACGAAUACA 399
Db      19 CTACATCATCATGAATCGA 1

RESULT 324
US-10-798-090-122/c
; Sequence 122, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: S1ma Therapeutics, Inc.
; APPLICANT: McSw1gen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 122
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: s1NA antisense region
US-10-798-090-122

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

QY 399 AUGGCCUUGAGGACUG 417
|:||||:||||:|
Db 19 ATGGGCTTAGGGAAGTTG 1

RESULT 325

US-10-798-090-123/c
; Sequence 123, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 123
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090

Query Match 1.1%; Score 19; DB 1; Length 19;

Best Local Similarity 68.4%; Pred. No. 4.3e+02; Mismatches 0; Indels 0; Gaps 0;

QY 417 GACCUGAGCCUUGCCUU 435
|:||||:||||:|
Db 19 GGCGTGACCTGCTGCTT 1

RESULT 326

US-10-798-090-124/c
; Sequence 124, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090

; CURRENT FILING DATE: 2004-03-11

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-14

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 60/406,784

; PRIOR FILING DATE: 2002-08-29

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 304

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 124

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region

US-10-798-090-124

QY 435 UGCCAUGAGCUGAGCC 453
|:||||:||||:|
Db 19 TGCGATTGACTAGTAGCC 1

RESULT 327

US-10-798-090-125/c
; Sequence 125, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06

PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO: 125
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-125

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 453 CAGCAUUGCUCUGUUAUG 471
DB 19 CAGCAATGCTCTGTATG 1

RESULT 328
US-10-798-090-126/c
Sequence 126, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sitna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO: 126
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-126

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 471 GAUUCUUGUCUUAUCAGC 489
DB 19 GAUUCUUGUCUUAUCAGC 1

DB 19 GAATCTTCGTGATCAGC 1

RESULT 329
US-10-798-090-127/c
Sequence 127, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sitna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO: 127
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-127

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 4.3e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 489 CUUGACAGAUACUUUCC 507
DB 19 CTTGACAGATCTTCC 1

RESULT 330
US-10-798-090-128/c
Sequence 128, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sitna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14

;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: Patent version 3.3
;; SEQ ID NO: 128
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-128

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 507 CAUACGAGCGCGCTCAGC 525
DB 19 CATCAGAGCGCGCTCAGC 1

RESULT 331
US-10-798-090-129/c
;; Sequence 129, Application US/10798090
;; Publication No. US20050014172A1
;; GENERAL INFORMATION:
;; APPLICANT: Sigma Therapeutics, Inc.
;; APPLICANT: McSwiggen, James
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
;; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
;; FILE REFERENCE: 400/147 (MBHB04-183)
;; CURRENT APPLICATION NUMBER: US/10/798,090
;; CURRENT FILING DATE: 2004-03-11
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
US-10-798-090-130

;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: Patent version 3.3
;; SEQ ID NO: 129
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-129

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 525 GUACGAGCGCAAGACGA 543
DB 19 GTACGAGCGCAAGACGA 1

RESULT 332
US-10-798-090-130/c
;; Sequence 130, Application US/10798090
;; Publication No. US20050014172A1
;; GENERAL INFORMATION:
;; APPLICANT: Sigma Therapeutics, Inc.
;; APPLICANT: McSwiggen, James
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
;; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
;; FILE REFERENCE: 400/147 (MBHB04-183)
;; CURRENT APPLICATION NUMBER: US/10/798,090
;; CURRENT FILING DATE: 2004-03-11
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: Patent version 3.3
;; SEQ ID NO: 130
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-130

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 543 AACCAAGAGCGCGGTG 561
DB 19 AACCAAGAGCGCGGTG 1

```
RESULT 333
US-10-798-090-131/C
; Sequence 131, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 131
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-131
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 561 GAUGAUCGUCUGGUCUGG 579
DB 19 GATGATCGGCTGCGCTTGG 1

RESULT 334
US-10-798-090-132/C
; Sequence 132, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
```

```
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 132

QY 579 GGUCAUCCUUCUUGUCCUU 597
DB 19 GGTATCTCTCTTGTCTT 1

RESULT 335
US-10-798-090-133/C
; Sequence 133, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 133
```

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-133

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.3e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy      597 UGGGCGUCCGCGCAUCUG 615
      ::|||::|||::|||::|||
Db      19 TTGGGCTCCTCGCATCTTG 1

RESULT 336
US-10-798-090-134/c
; Sequence 134, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 134
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-134

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 4.3e+02;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

Qy      615 GUUCUGCAUACUUGGU 633
      ||::|||::|||::|||::|||
Db      19 GTTCTGCAATACCTTGTT 1

RESULT 337
US-10-798-090-135/c
; Sequence 135, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 135
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-135

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      633 UGAAAGAGAACTGUGCCU 651
      :|||||::|||::|||::|||
Db      19 TGGAAAGAGAACTGTCCT 1

RESULT 338
US-10-798-090-136/c
; Sequence 136, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 136
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-136
```

```
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 136
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-136

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      651 UCCGGAGAGUGGCUCAUU 669
Db      19 TCCGGAGAGTGGCTTCATT 1

RESULT 339
US-10-798-090-137/c
; Sequence 137, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 137
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-138/c

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      687 CACCAUAGUUUGGACCA 705
Db      19 CACCAUAGUUUGGACCA 1

RESULT 341
US-10-798-090-139/c
; Sequence 139, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 138
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-138
```

```

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 140
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
US-10-798-090-140

Query Match      1.1%; Score 19; DB 1, Length 19;
Best Local Similarity 63.2%; Pred. No. 4.3e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Cy          723 UAUGCUGUACCAUNUAG 741
              :|::||::|::||::|::|:
Db          19 TATGCTGTGCACCATYATG 1

RESULT 343
US-10-798-090-141/C
; Sequence 141, Application US/10798090
; Publication No. US20050014172A1
GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA interference Mediated Inhibition of Muscarinic Colinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MBHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 141
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
US-10-798-090-141

```


PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 144
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-144

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 795 UGCGGCGGCAAGCCUCU 813
Db 19 TCGTGCGCTGCAAGCCTCT 1

RESULT 347
US-10-798-090-145/c
Sequence 145, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 145
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-145

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4.3e+02;

Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 813 UGGAGCAGAGCAGAGACA 831
Db 19 TGGGACAGAGCAGAGACA 1

RESULT 348
US-10-798-090-146/c
Sequence 146, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 146
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-146

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 831 AGAAACUUGUCCACCCC 849
Db 19 AGAAACTTGTCCACCCC 1

RESULT 349
US-10-798-090-147/c
Sequence 147, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)

```
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ CURRENT FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 147
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-147
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      849 CACGGGACGUCUCGAGC 867
DB      19 CACGGGACGTCCTCGAAGC 1

RESULT 350
US-10-798-090-148/c
/ Sequence 148, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Richards, Ivan
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ TITLE OF INVENTION: (siNA)
/ FILE REFERENCE: 400/147 (MEHB04-183)
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ CURRENT FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
```

```
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 148
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-148
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      867 CUCGACGACUUCGAACTU 885
DB      19 CTCGACGACTTACGAACCT 1

RESULT 351
US-10-798-090-149/c
/ Sequence 149, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Richards, Ivan
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ TITLE OF INVENTION: (siNA)
/ FILE REFERENCE: 400/147 (MEHB04-183)
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ CURRENT FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 149
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-149
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      885 UCAACAGCAAGCAUGAAA 903
```

Db 19 TCAACGACGACGATGAAA 1

RESULT 352

US-10-798-090-150/c

Sequence 150, Application US/10798090

Publication No. US20050014172A1

GENERAL INFORMATION:

APPLICANT: Sirna Therapeutics, Inc.

APPLICANT: Richards, Ivan

APPLICANT: MCSwigen, James

TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic

TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid

FILE REFERENCE: 400/147 (MBH04-183)

CURRENT APPLICATION NUMBER: US/10/798,090

PRIOR FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: US 10/757,803

PRIOR FILING DATE: 2004-01-14

PRIOR APPLICATION NUMBER: US 10/720,448

PRIOR FILING DATE: 2003-11-24

PRIOR APPLICATION NUMBER: US 10/693,059

PRIOR FILING DATE: 2003-10-23

PRIOR APPLICATION NUMBER: US 10/444,853

PRIOR FILING DATE: 2003-05-23

PRIOR APPLICATION NUMBER: PCT/US03/05346

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: PCT/US03/05028

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: US 60/358,580

PRIOR FILING DATE: 2002-02-20

PRIOR APPLICATION NUMBER: US 60/363,124

PRIOR FILING DATE: 2002-03-11

PRIOR APPLICATION NUMBER: US 60/386,782

PRIOR FILING DATE: 2002-06-06

PRIOR APPLICATION NUMBER: US 60/406,784

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 304

SOFTWARE: PatentIn version 3.3

SEQ ID NO 150

LENGTH: 19

TYPE: RNA

ORGANISM: Artificial Sequence

FEATURE:

APPLICANT: Richards, Ivan

OTHER INFORMATION: Description of Artificial Sequence: sirna antisense region

US-10-798-090-150

Query Match 1.1%; Score 19; DB 1; Length 19;

Best Local Similarity 94.7%; Pred.No. 4.3e+02;

Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 903 ACGCTCAACGACGAGAG 921

Db 19 ACGCTCAACGACGAGAG 1

RESULT 353

US-10-798-090-151/c

Sequence 151, Application US/10798090

Publication No. US20050014172A1

GENERAL INFORMATION:

APPLICANT: Sirna Therapeutics, Inc.

APPLICANT: Richards, Ivan

APPLICANT: MCSwigen, James

TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic

TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid

FILE REFERENCE: 400/147 (MBH04-183)

CURRENT APPLICATION NUMBER: US/10/798,090

PRIOR FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: US 10/757,803

PRIOR FILING DATE: 2004-01-14

PRIOR APPLICATION NUMBER: US 10/720,448

PRIOR FILING DATE: 2003-11-24

PRIOR APPLICATION NUMBER: US 10/693,059

PRIOR FILING DATE: 2003-10-23

PRIOR APPLICATION NUMBER: US 10/444,853

PRIOR FILING DATE: 2003-05-23

PRIOR APPLICATION NUMBER: PCT/US03/05346

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: PCT/US03/05028

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: US 60/358,580

PRIOR FILING DATE: 2002-02-20

PRIOR APPLICATION NUMBER: US 60/363,124

PRIOR FILING DATE: 2002-03-11

PRIOR APPLICATION NUMBER: US 60/386,782

PRIOR FILING DATE: 2002-06-06

PRIOR APPLICATION NUMBER: US 60/406,784

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 304

SOFTWARE: PatentIn version 3.3

SEQ ID NO 151

LENGTH: 19

TYPE: RNA

ORGANISM: Artificial Sequence

FEATURE:

APPLICANT: Richards, Ivan

OTHER INFORMATION: Description of Artificial Sequence: sirna antisense region

US-10-798-090-151

Query Match 1.1%; Score 19; DB 1; Length 19;

Best Local Similarity 73.7%; Pred.No. 4.3e+02;

Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 921 GUAUGCCGCGGACGACUUC 939

Db 19 GUAUGCCGCGGACGACUUC 1

RESULT 354

US-10-798-090-152/c

Sequence 152, Application US/10798090

Publication No. US20050014172A1

GENERAL INFORMATION:

APPLICANT: Sirna Therapeutics, Inc.

APPLICANT: Richards, Ivan

APPLICANT: MCSwigen, James

TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic

TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid

FILE REFERENCE: 400/147 (MBH04-183)

CURRENT APPLICATION NUMBER: US/10/798,090

PRIOR FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: US 10/757,803

PRIOR FILING DATE: 2004-01-14

PRIOR APPLICATION NUMBER: US 10/720,448

PRIOR FILING DATE: 2003-11-24

PRIOR APPLICATION NUMBER: US 10/693,059

PRIOR FILING DATE: 2003-10-23

PRIOR APPLICATION NUMBER: US 10/444,853

PRIOR FILING DATE: 2003-05-23

PRIOR APPLICATION NUMBER: PCT/US03/05346

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: PCT/US03/05028

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: US 60/358,580

PRIOR FILING DATE: 2002-02-20

PRIOR APPLICATION NUMBER: US 60/363,124

PRIOR FILING DATE: 2002-03-11

PRIOR APPLICATION NUMBER: US 60/386,782

PRIOR FILING DATE: 2002-06-06

PRIOR APPLICATION NUMBER: US 60/406,784

PRIOR FILING DATE: 2002-08-29

```
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 152
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-152

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      939 CUGGUCACCAACCAAGAGC 957
DB      19 CTGGTTCCACACCAAGAGC 1

RESULT 355
US-10-798-090-153/c
; Sequence 153, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-153

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      957 CUGGAACCCAGCUCGAG 975
DB      19 CTGGAACCCAGCTCCGAG 1
```

```
RESULT 356
US-10-798-090-154/c
; Sequence 154, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 154
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-154

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      975 GCAGAGGACCAAGACCAC 993
DB      19 GCAGATGACCAAGACCAC 1

RESULT 357
US-10-798-090-155/c
; Sequence 155, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
```



```
/ Sequence 158, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sitna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: MCSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinicrgic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ TITLE OF INVENTION: (sRNA)
/ FILE REFERENCE: 400/147 (MEHB04-183)
/ CURRENT FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US/10/798,090
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO: 158
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-158

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1047 CGCCUCCGACGAGAG 1065
DB      19  CGCCTCTCCGACGAG 1

RESULT 361
US-10-798-090-159/c
/ Sequence 159, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sitna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: MCSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinicrgic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ TITLE OF INVENTION: (sRNA)
/ FILE REFERENCE: 400/147 (MEHB04-183)
/ CURRENT FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US/10/798,090
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
```

```
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO: 159
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-159

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      1065 GGCATUUGGCTCCGACG 1083
DB      19  GGCATTGGCTCCGACG 1

RESULT 362
US-10-798-090-160/c
/ Sequence 160, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sitna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: MCSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinicrgic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ TITLE OF INVENTION: (sRNA)
/ FILE REFERENCE: 400/147 (MEHB04-183)
/ CURRENT FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US/10/798,090
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO: 160
/ LENGTH: 19
/ TYPE: RNA
```

```
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-160

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1083 GAGAGCCATCUCUCCAUCC 1101
      |||||:||||:||||:||||:
Db      19 GAGAGCCATCTACTCCTC 1

RESULT 363
US-10-798-090-161/c
/ Sequence 161, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirta Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: MCSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ FILE REFERENCE: 400/147 (MBHB04-183)
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ CURRENT FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 161
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-161

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1101 CGUGUCACGUCUCCGGU 1119
      ||:||||:||||:||||:
Db      19 CGUGCTCAGCTTCGGGT 1

RESULT 364
US-10-798-090-162/c
/ Sequence 162, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirta Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: MCSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ FILE REFERENCE: 400/147 (MBHB04-183)
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ CURRENT FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 162
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-162

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      1119 UCAGCAGCACUCCUCCAC 1137
      :|||||:||||:||||:
Db      19 TCAGCAGCATCTCTCAC 1

RESULT 365
US-10-798-090-163/c
/ Sequence 163, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirta Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: MCSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ FILE REFERENCE: 400/147 (MBHB04-183)
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ CURRENT FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 163
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-163
```

```

; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 163
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-163

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1137 CUCCACGAGUACCCUCA 1155
Db      19 CTCGACGAGTACCTCTCA 1

RESULT 366
US-10-798-090-164/c
; Sequence 164, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 164
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
```

```

US-10-798-090-164

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      1155 AUCCGACACGUCGUGG 1173
Db      19 ATCGACGACCTGCGGTG 1

RESULT 367
US-10-798-090-165/c
; Sequence 165, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 165
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-165

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1173 GCCUGAGAGAGUCGCGG 1191
Db      19 GCCTGAGAGAGCTCGGG 1

RESULT 368
US-10-798-090-166/c
; Sequence 166, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
```


Best Local Similarity 94.7%; Pred. No. 4.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1227 GGCCTGAGAGCGTGGAC 1245

Db 19 GGCCTGAGAGCGTGGAC 1

RESULT 371

US-10-798-090-169/c

; Sequence 169, Application US/10798090

; Publication No. US20050014172A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: Richards, Ivan

; APPLICANT: MCSwigen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic

; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid

; TITLE OF INVENTION: (s1NA)

; FILE REFERENCE: 400/147 (MEHB04-183)

; CURRENT APPLICATION NUMBER: US/10/798,090

; CURRENT FILING DATE: 2004-03-11

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-14

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 60/406,784

; PRIOR FILING DATE: 2002-08-29

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 304

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 169

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: s1NA antisense region

US-10-798-090-169

Query Match 1.1%; Score 19; DB 1; Length 19;

Best Local Similarity 73.7%; Pred. No. 4.3e+02;

Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1245 CGAUGAGCGAGUUUCCA 1263

Db 19 CGATGAGCGAGTTTCCA 1

RESULT 372

US-10-798-090-170/c

; Sequence 170, Application US/10798090

; Publication No. US20050014172A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: Richards, Ivan

; APPLICANT: MCSwigen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic

; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid

; TITLE OF INVENTION: (s1NA)

; FILE REFERENCE: 400/147 (MEHB04-183)

; CURRENT APPLICATION NUMBER: US/10/798,090

; CURRENT FILING DATE: 2004-03-11

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-14

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 60/406,784

; PRIOR FILING DATE: 2002-08-29

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 304

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 170

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: s1NA antisense region

US-10-798-090-170

Query Match 1.1%; Score 19; DB 1; Length 19;

Best Local Similarity 73.7%; Pred. No. 4.3e+02;

Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1263 AAAAGCTUCCAGCTU 1281

Db 19 AAAAGCTTCCAGCTT 1

RESULT 373

US-10-798-090-171/c

; Sequence 171, Application US/10798090

; Publication No. US20050014172A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: Richards, Ivan

; APPLICANT: MCSwigen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic

; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid

; TITLE OF INVENTION: (s1NA)

; FILE REFERENCE: 400/147 (MEHB04-183)

; CURRENT APPLICATION NUMBER: US/10/798,090

; CURRENT FILING DATE: 2004-03-11

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-14

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

```

; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 171
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-171

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      1281 UCCCAUCCAGCUAGUCA 1299
Db      19  TCCCATCCAGCTAGACTCA 1
```

```

RESULT 374
US-10-798-090-172/c
; Sequence 172, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 172
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-172
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```

Qy      1299 AGCCGUGACACAGCUAG 1317
Db      19  AGCCGTGACACGACTAG 1
```

```

RESULT 375
US-10-798-090-173/c
; Sequence 173, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 173
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-173
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```

Qy      1317 GACUUCGACGCUACUCC 1335
Db      19  GACTTGTGACGTCACTCC 1
```

```

RESULT 376
US-10-798-090-174/c
; Sequence 174, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
```

```

; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 174
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-174
```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1335 CUCAGUGGUAAGACAGC 1353
DB      19 CTCAGTGGGTAAAGACAGC 1
```

```

RESULT 377
US-10-798-090-175/c
; Sequence 175, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
```

```

; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 175
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-175
```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1353 GGCACUCUACCCUCCUCC 1371
DB      19 GGCACCTCTACTCTCTCTC 1
```

```

RESULT 378
US-10-798-090-176/c
; Sequence 176, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (siNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 176
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-176
```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1371 CUUCAAGAGCCACUCUG 1389
DB      19 CTTCAAGAGGCCACTCTG 1
```

RESULT 379
US-10-798-090-177/c
Sequence 177, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirta Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (sRNA)
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 177
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
US-10-798-090-177
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
CY 1389 GGCCAGAGGUGUCUCUG 1407
DB 19 GGCCAGAGGTTGCTCTG 1
RESULT 380
US-10-798-090-178/c
Sequence 178, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirta Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (sRNA)
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448

PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 178
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
US-10-798-090-178
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
CY 1407 GAAGACCAAGAGGACAGC 1425
DB 19 GAAGACCAAGATCAGATC 1
RESULT 381
US-10-798-090-179/c
Sequence 179, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirta Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (sRNA)
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304

```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 179
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-179
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1425 CACUAAAGCGAAGGAUG 1443
DB      19  CACTAAGCGAAGGATG 1
```

```
RESULT 382
US-10-798-090-180/c
; Sequence 180, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 180
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-180
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1443 GUCCUGGUCAGAGAGAG 1461
DB      19  GTCCCTGTCAAGAGAG 1
```

RESULT 383

```
US-10-798-090-181/c
; Sequence 181, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 181
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-181
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1461 GAAGCGGCCAGACCCUC 1479
DB      19  GAAGCGGCCAGACCCCTC 1
```

```
RESULT 384
US-10-798-090-182/c
; Sequence 182, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
```

```
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 182
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-798-090-182

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1479 CAGGCGAUCUUCGUCGACC 1497
DB      19  CAGTGCATCTTCTTGACC 1

RESULT 385
US-10-798-090-183/c
; Sequence 183, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 183
; LENGTH: 19
```

```
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-798-090-183

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1515 CCCAUCACACUACUAGCC 1515
DB      19  CCAATCAATCACTTGACC 1

RESULT 386
US-10-798-090-184/c
; Sequence 184, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 184
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-798-090-184

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1515 CCCAUCACACUACUAGCC 1515
DB      19  CCAATCAATCACTTGACC 1

RESULT 387
US-10-798-090-185/c
; Sequence 185, Application US/10798090
; Publication No. US20050014172A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 185
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-185

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 4.3e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      1533 UCUGUGAACACCCUUUGU 1551
      :|||:|||:|||:|||:
Db      19 TCUGTGACACCTTTGT 1

RESULT 388
US-10-798-090-186/c
; Sequence 186, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 186
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-798-090-186

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      1551 UGACGUCGACCAACCCAA 1569
      :|||:|||:|||:|||:
Db      19 TGACGCTGCATACCCAAA 1

RESULT 389
US-10-798-090-187/c
; Sequence 187, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 187
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
```



```

; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 190
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-798-090-190

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.3e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY      1623 CGUGGCUAUGCUGUCG 1641
DB      19 CCGTCTGCTGCTCTGTC 1

RESULT 393
US-10-798-090-191/c
; Sequence 191, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sinn)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 191
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-798-090-191
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1641 CACAAACAAUUCAGACACC 1659
DB      19 CACCAAAACATTCAGACACC 1

RESULT 394
US-10-798-090-192/c
; Sequence 192, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sinn)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 192
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-798-090-192

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1659 CACUUUCAAAGUCUGUCG 1677
DB      19 CACTTCAAGATGCTGCTG 1

RESULT 395
US-10-798-090-193/c
; Sequence 193, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
US-10-798-090-193
```

```

; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 193
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: s1NA antisense region
US-10-798-090-193

```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1677 GCGUGCCAGUGGACAA 1695
Db      19 GCGTGCAGGTGACAA 1

```

```

RESULT 396
; Sequence 194, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sina Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124

```

```

; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 194
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: s1NA antisense region
US-10-798-090-194

```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1695 AAAAAGAGCGCAGCAG 1713
Db      19 AAAAAGAGCGCAGCAG 1

```

```

RESULT 397
; Sequence 195, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sina Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 195
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: s1NA antisense region
US-10-798-090-195

```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```

QY 1713 GCGGACCCGAGCAGCAG 1731
||||:|||||
Db 19 GCGGACCCGAGCAGCAG 1

RESULT 398
US-10-798-090-196/c
; Sequence 196, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 196
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: s1NA antisense region
US-10-798-090-196

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.3e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1731 GUGGUCATUUUCCACAG 1749
|:|:|:|:|:|:|:|:|:|
Db 19 GTGGCATTTTCACAG 1

RESULT 399
US-10-798-090-197/c
; Sequence 197, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090

; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 197
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: s1NA antisense region
US-10-798-090-197

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 GCGGACCCGAGCAGGCC 1767
|||||
Db 19 GCGGACCCGAGCAGGCC 1

RESULT 400
US-10-798-090-198/c
; Sequence 198, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06


```

; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-3

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      39 UCCAAACAUCAAGCUCUCC 57
      |||||
Db      1 UCCAAACAUCAAGCUCUCC 19

RESULT 404
US-10-919-866-4
; Sequence 4, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```

; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 4
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-4

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      57 CUGAUAACACAGCCUCC 75
      |||||
Db      1 CUGAUAACACAGCCUCC 19

RESULT 405
US-10-919-866-5
; Sequence 5, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 5
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-5

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      75 CGAUGAGGAGGCGCCCG 93
      |||||
Db      1 CGAUGAGGAGGCGCCCG 19
```

```
RESULT 406
US-10-919-866-6
; Sequence 6, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 6
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-919-866-6

Query Match          1.1% Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY          93 GGAACCGUCACUUC 111
Db          1 GGAACCGUCACUUC 19

RESULT 407
US-10-919-866-7
; Sequence 7, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
```

```
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 7
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-919-866-7

Query Match          1.1% Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY          111 CGGACGUCACUUCU 129
Db          1 CGGACGUCACUUCU 19

RESULT 408
US-10-919-866-8
; Sequence 8, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 8
```

```

; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-8

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      129 UCGAGCGGCGCAUUGC 147
      |||||
Db      1 UCGAGCGGCGCAUUGC 19

RESULT 409
US-10-919-866-9
; Sequence 9, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 9
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-9

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      147 CUCGUCUCCGAGCGUACC 165
      |||||
Db      1 CUCGUCUCCGAGCGUACC 19

RESULT 410
US-10-919-866-10
; Sequence 10, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 10
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-10

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      165 CACCGAUGACCCUCUGGA 183
      |||||
Db      1 CACCGAUGACCCUCUGGA 19

RESULT 411
US-10-919-866-11
; Sequence 11, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 11
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-11
```

```

; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 11
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-11

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      183 AGGUCAUACCGUCGCGCA 201
DB      1 AGGUCAUACCGUCGCGCA 19

RESULT 412
US-10-919-866-12
; Sequence 12, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sitma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 12
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
```

```

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-12

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      201 AGUGUCUUCACUGCCUUC 219
DB      1 AGUGUCUUCACUGCCUUC 19

RESULT 413
US-10-919-866-13
; Sequence 13, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sitma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 13
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-13

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      219 CUUACGGGCAUCCUGGCC 237
DB      1 CUUACGGGCAUCCUGGCC 19

RESULT 414
US-10-919-866-14
; Sequence 14, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sitma Therapeutics, Inc.
```

```

; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 14
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-14

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      237 CUUGUGACCAUCCAUCCGC 255
Db      1 CUUGUGACCAUCCAUCCGC 19

RESULT 415
US-10-919-866-15
; Sequence 15, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
```

```

; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 15
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-15

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      255 CAACAUCCUGUAUUGUG 273
Db      1 CAACAUCCUGUAUUGUG 19

RESULT 416
US-10-919-866-16
; Sequence 16, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 16
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-16
```



```

; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 19
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-19

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      327 CCUGGCCUGGCCGCAUCUG 345
Db      1 CCUGGCCUGGCCGCAUCUG 19

RESULT 420
US-10-919-866-20
; Sequence 20, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MBH04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 20
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-20

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      363 AAUGAUCUGGUTUACGACC 381
Db      1 AAUGAUCUGGUTUACGACC 19

RESULT 422
US-10-919-866-22
; Sequence 22, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MBH04-183-A)
```

```

; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 22
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-22

```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      381 CUACAUCACUAGCAUACA 399
DB      1 CUACAUCACUAGCAUACA 19

```

```

RESULT 423
; Sequence 23, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028

```

```

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-23

```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      399 AUGGCGCCUAGGCAACUG 417
DB      1 AUGGCGCCUAGGCAACUG 19

```

```

RESULT 424
; Sequence 24, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 24
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-24

```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      417 GCGCUGUAGCCUUGGCUU 435

```



```

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 27
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-27

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      471 GAUUCUUCGAGUACAGC 489
DB      1 GAUUCUUCGAGUACAGC 19

RESULT 428
US-10-919-866-28
; Sequence 28, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 28
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-28

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      489 CUUUGACAGUACUUUCC 507
DB      1 CUUUGACAGUACUUUCC 19
```

```

RESULT 429
US-10-919-866-29
; Sequence 29, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 29
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-29

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      507 CAUACAGAGCGCGCUCACG 525
DB      1 CAUACAGAGCGCGCUCACG 19

RESULT 430
US-10-919-866-30
; Sequence 30, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
```

```

; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 30
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-30

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 525 GUACGAGCGCAACGACA 543
DB 1 GUACGAGCGCAACGACA 19

RESULT 431
US-10-919-866-31
; Sequence 31, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
```

```

; SEQ ID NO 31
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-31

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 543 AACAAAGAGCGCGUGUG 561
DB 1 AACAAAGAGCGCGUGUG 19

RESULT 432
US-10-919-866-32
; Sequence 32, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 32
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-32

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 561 GAUGAUCGUCUGGUCUGG 579
DB 1 GAUGAUCGUCUGGUCUGG 19

RESULT 433
US-10-919-866-33
```

```
; Sequence 33, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sitma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 33
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-33
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 579 GGUCAUCCUCCUUGUCCU 597
DB 1 GGUCAUCCUCCUUGUCCU 19

RESULT 434
US-10-919-866-34
; Sequence 34, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sitma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
```

```
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 34
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-34
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 597 UUGGGUCCUCCGCAUCCUG 615
DB 1 UUGGGUCCUCCGCAUCCUG 19

RESULT 435
US-10-919-866-35
; Sequence 35, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sitma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 35
; LENGTH: 19
; TYPE: RNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-35

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 615 UCCGGGAGAGUGCUCUCCAU 669
|||||
Db 1 UCCGGGAGAGUGCUCUCCAU 19

RESULT 436
US-10-919-866-36
; Sequence 36, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 36
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-36

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 633 UCGAAGAGAACTGUGCCU 651
|||||
Db 1 UCGAAGAGAACTGUGCCU 19

RESULT 437
US-10-919-866-37
; Sequence 37, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 37
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-37

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 651 UCCGGGAGAGUGCUCUCCAU 669
|||||
Db 1 UCCGGGAGAGUGCUCUCCAU 19

RESULT 438
US-10-919-866-38
; Sequence 38, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 38
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-38
```

```

; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 38
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-38

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 UCAGUCCUACGAGACCC 687
DB 1 UCAGUCCUACGAGACCC 19

RESULT 439
US-10-919-866-39
; Sequence 39, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEH04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 39
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense

```

```

US-10-919-866-39
Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 687 CACCAUACUUCUGGACCA 705
DB 1 CACCAUACUUCUGGACCA 19

RESULT 440
US-10-919-866-40
; Sequence 40, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEH04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 40
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-40

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 705 AGCCAUCCGUCGUUUUUAU 723
DB 1 AGCCAUCCGUCGUUUUUAU 19

RESULT 441
US-10-919-866-41
; Sequence 41, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James

```

```

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US 10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 41
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-41

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      723 UAUGCCUGGACCAUAUG 741
Db      1 UAUGCCUGGACCAUAUG 19

RESULT 442
US-10-919-866-42
; Sequence 42, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: MCSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US 10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
```

```

; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 42
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-42

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      741 GACUAAUUUAACUGAGG 759
Db      1 GACUAAUUUAACUGAGG 19

RESULT 443
US-10-919-866-43
; Sequence 43, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: MCSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US 10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 43
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-43

Query Match          1.1%; Score 19; DB 1; Length 19;
```

Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 759 GAUCGUAAGCAAGACUAA 777
Db 1 GAUCGUAAGCAAGACUAA 19

RESULT 444

US-10-919-866-44

; Sequence 44, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 44
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sRNA)

; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 45
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20

QY 795 UGUGGCUAGCAAGCCUCU 813
Db 1 UGUGGCUAGCAAGCCUCU 19

RESULT 446

US-10-919-866-46

; Sequence 46, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20

```

; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 46
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-46

Query Match
Best Local Similarity 100.0%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      813 UGGACAGAGCGACAGACA 831
Db      1 UGGACAGAGCGACAGACA 19

RESULT 447
US-10-919-866-47
; Sequence 47, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 47
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-47

Query Match
Best Local Similarity 100.0%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      831 AGAAAACTUUCGCCACCC 849
Db      1 AGAAAACTUUCGCCACCC 19

RESULT 448
US-10-919-866-48
; Sequence 48, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 48
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-48

Query Match
Best Local Similarity 100.0%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      849 CACGGCAGUUCGCAAGC 867
Db      1 CACGGCAGUUCGCAAGC 19

RESULT 449
US-10-919-866-49
; Sequence 49, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
```

```

; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 49
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-49

```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      867 CUGCAGCAGUACGAACTU 885
      |||
      1 CUGCAGCAGUACGAACTU 19
DB

```

```

RESULT 450
US-10-919-866-50
; Sequence 50, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: Mesiwigen, James
; TITLE OF INVENTION: RNA interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 51
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-51

```

```

; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 50
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-50

```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      885 UCACGACGAAAGCAGAAA 903
      |||
      1 UCACGACGAAAGCAGAAA 19
DB

```

```

RESULT 451
US-10-919-866-51
; Sequence 51, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: Mesiwigen, James
; TITLE OF INVENTION: RNA interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 51
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-51

```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      903 ACGCUCACACGAGGAG 921
      |||
      1 ACGCUCACACGAGGAG 19
DB

```

```
RESULT 452
US-10-919-866-52
; Sequence 52, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 52
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURe:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-52
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 921 GUAGGCGCGCCGACACUUC 939
DB 1 GUAGGCGCGCCGACACUUC 19

RESULT 453
US-10-919-866-53
; Sequence 53, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
```

```
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 53
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURe:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-53
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 939 CUGGUCACACCAAGAGC 957
DB 1 CUGGUCACACCAAGAGC 19

RESULT 454
US-10-919-866-54
; Sequence 54, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
```

```

; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 54
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-54

Query Match
Best Local Similarity 100.0%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 957 CUGAAACCCAGCUCGAG 975
Db 1 CUGAAACCCAGCUCGAG 19

RESULT 455
US-10-919-866-55
; Sequence 55, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 55
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-55

Query Match
Best Local Similarity 100.0%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 975 GCAGAGGACCAAGCCAC 993
Db 1 GCAGAGGACCAAGCCAC 19

RESULT 456
US-10-919-866-56
; Sequence 56, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 56
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-56

Query Match
Best Local Similarity 100.0%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 993 CAGCAGCAGGACAGUGG 1011
Db 1 CAGCAGCAGGACAGUGG 19

RESULT 457
US-10-919-866-57
; Sequence 57, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
```

```

; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 57
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-57

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1011 GAACACAUGAUGCUCGU 1029
Db      1 GAACACAUGAUGCUCGU 19

RESULT 458
US-10-919-866-58
; Sequence 58, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/919,866
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 58
; LENGTH: 19
```

```

; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-58

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1029 UGCUCUCCUGAGAACUCC 1047
Db      1 UGCUCUCCUGAGAACUCC 19

RESULT 459
US-10-919-866-59
; Sequence 59, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-B)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/919,866
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 59
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-59

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1047 CGCUCUCCUGAGAGAGAG 1065
Db      1 CGCUCUCCUGAGAGAG 19

RESULT 460
US-10-919-866-60
; Sequence 60, Application US/10919866
; Publication No. US20050176664A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 60
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-60

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy      1065 GGACAUUGGCUCCGAGACG 1083
Db      1 GGACAUUGGCUCCGAGACG 19

RESULT 461
US-10-919-866-61
; Sequence 61, Application US/10919866
; Publication No. US2005017664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 61
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-61
```

```

; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 61
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-61

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy      1083 GAGGCCAUCGACUCCGAC 1101
Db      1 GAGGCCAUCGACUCCGAC 19

RESULT 462
US-10-919-866-62
; Sequence 62, Application US/10919866
; Publication No. US2005017664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 62
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-62
```

```
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-62
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1101 CGUGCCACGACUCCGGGU 1119
      |||||
DB       1  CGUGCCACGACUCCGGGU 19

RESULT 463
US-10-919-866-63
; Sequence 63, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 63
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: Sigma Therapeutics
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-63
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1119 UCACGACGACUCCUAC 1137
      |||||
DB       1  UCACGACGACUCCUAC 19

RESULT 464
US-10-919-866-64
; Sequence 64, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
```

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-64
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1137 CUCCACGAGUACCUCA 1155
      |||||
DB       1  CUCCACGAGUACCUCA 19

RESULT 465
US-10-919-866-65
; Sequence 65, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
```

PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 65
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-65

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1155 AUCGAGCAACUCGACGUG 1173
DB 1 AUCGAGCAACUCGACGUG 19

RESULT 466
US-10-919-866-66
Sequence 66, Application US/10919866
Publication No. US2005017664A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MBH04-183-A)
CURRENT FILING DATE: US/10/919,866
PRIOR FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 66
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-66

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1173 GCCUGAGGAGGACUGGGG 1191
DB 1 GCCUGAGGAGGACUGGGG 19

RESULT 467
US-10-919-866-67
Sequence 67, Application US/10919866
Publication No. US2005017664A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MBH04-183-A)
CURRENT FILING DATE: US/10/919,866
PRIOR FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 67
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-67

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1191 GAUGUGGACUCUGAGAGG 1209
DB 1 GAUGUGGACUCUGAGAGG 19

RESULT 468
US-10-919-866-68
Sequence 68, Application US/10919866
Publication No. US2005017664A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic

```

; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO: 68
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-68

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1209 GAAAGCCGACGAGCTGCGAG 1227
Db      1 GAAAGCCGACGAGCTGCGAG 19

RESULT 469
US-10-919-866-69
; Sequence 69, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO: 69
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-69

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1227 GGCCTGAAAGCGGCGAC 1245
Db      1 GGCCTGAAAGCGGCGAC 19

RESULT 470
US-10-919-866-70
; Sequence 70, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO: 70
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-70

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1245 CGAUGAGGACAGUUUCCA 1263
|||||
Db 1 CGAUGAGGACAGUUUCCA 19

RESULT 471

US-10-919-866-71
; Sequence 71, Application US/10919866
; Publication No. US20050176664A1

GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James

TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)

FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14

PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23

PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20

Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 71
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence

FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-71

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1263 AAAAGCUCUCCAGACUU 1281
|||||
Db 1 AAAAGCUCUCCAGACUU 19

RESULT 472
US-10-919-866-72
; Sequence 72, Application US/10919866
; Publication No. US20050176664A1

GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James

TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)

FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866

Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 71
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence

FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-71

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1281 UCCCAUCCAGCUAGAGUCA 1299
|||||
Db 1 UCCCAUCCAGCUAGAGUCA 19

RESULT 473
US-10-919-866-73
; Sequence 73, Application US/10919866
; Publication No. US20050176664A1

GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James

TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)

FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14

PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23

PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20

Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 72
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence

FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-72

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

PRIOR APPLICATION NUMBER: US 60/358,580
 PRIOR FILING DATE: 2002-02-20
 Remaining Prior Application data removed - See File Wrapper or PALM.
 NUMBER OF SEQ ID NOS: 324
 SOFTWARE: PatentIn version 3.3
 SEQ ID NO 73
 LENGTH: 19
 TYPE: RNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
 US-10-919-866-73

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 4.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1299 AGCCGUGACAGACUAG 1317
 DB 1 AGCCGUGACAGACUAG 19

RESULT 474
 US-10-919-866-74
 Sequence 74, Application US/10919866
 Publication No. US20050176664A1
 GENERAL INFORMATION:
 APPLICANT: Sitma Therapeutics, Inc.
 APPLICANT: Richards, Ivan
 APPLICANT: MCSwigen, James

TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
 TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
 FILE REFERENCE: 400/205 (MEHB04-183-A)
 CURRENT FILING DATE: 2004-08-17
 PRIOR FILING DATE: 2004-03-11
 PRIOR APPLICATION NUMBER: US 10/798,090
 PRIOR FILING DATE: 2004-05-24
 PRIOR APPLICATION NUMBER: PCT/US04/16390
 PRIOR FILING DATE: 2004-04-16
 PRIOR APPLICATION NUMBER: US 10/826,966
 PRIOR FILING DATE: 2004-01-14
 PRIOR APPLICATION NUMBER: US 10/757,803
 PRIOR FILING DATE: 2003-11-24
 PRIOR APPLICATION NUMBER: US 10/693,059
 PRIOR FILING DATE: 2003-11-23
 PRIOR APPLICATION NUMBER: US 10/444,853
 PRIOR FILING DATE: 2003-05-23
 PRIOR APPLICATION NUMBER: PCT/US03/05346
 PRIOR FILING DATE: 2003-02-20
 PRIOR APPLICATION NUMBER: PCT/US03/05028
 PRIOR FILING DATE: 2003-02-20
 PRIOR APPLICATION NUMBER: US 60/358,580
 PRIOR FILING DATE: 2002-02-20
 Remaining Prior Application data removed - See File Wrapper or PALM.
 NUMBER OF SEQ ID NOS: 324
 SOFTWARE: PatentIn version 3.3
 SEQ ID NO 74
 LENGTH: 19
 TYPE: RNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
 US-10-919-866-74

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 4.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1317 GACUUCGACGUAACUCC 1335
 |||||

DB 1 GACUUCGACGUAACUCC 19

RESULT 475
 US-10-919-866-75
 Sequence 75, Application US/10919866
 Publication No. US20050176664A1
 GENERAL INFORMATION:
 APPLICANT: Sitma Therapeutics, Inc.
 APPLICANT: Richards, Ivan
 APPLICANT: MCSwigen, James

TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
 TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
 FILE REFERENCE: 400/205 (MEHB04-183-A)
 CURRENT FILING DATE: 2004-08-17
 PRIOR FILING DATE: 2004-03-11
 PRIOR APPLICATION NUMBER: US 10/798,090
 PRIOR FILING DATE: 2004-05-24
 PRIOR APPLICATION NUMBER: PCT/US04/16390
 PRIOR FILING DATE: 2004-04-16
 PRIOR APPLICATION NUMBER: US 10/826,966
 PRIOR FILING DATE: 2004-01-14
 PRIOR APPLICATION NUMBER: US 10/757,803
 PRIOR FILING DATE: 2003-11-24
 PRIOR APPLICATION NUMBER: US 10/693,059
 PRIOR FILING DATE: 2003-11-23
 PRIOR APPLICATION NUMBER: US 10/444,853
 PRIOR FILING DATE: 2003-05-23
 PRIOR APPLICATION NUMBER: PCT/US03/05346
 PRIOR FILING DATE: 2003-02-20
 PRIOR APPLICATION NUMBER: PCT/US03/05028
 PRIOR FILING DATE: 2003-02-20
 PRIOR APPLICATION NUMBER: US 60/358,580
 PRIOR FILING DATE: 2002-02-20
 Remaining Prior Application data removed - See File Wrapper or PALM.
 NUMBER OF SEQ ID NOS: 324
 SOFTWARE: PatentIn version 3.3
 SEQ ID NO 75
 LENGTH: 19
 TYPE: RNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
 US-10-919-866-75

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 4.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1335 CUCAUGGGUAGAAGACG 1353
 DB 1 CUCAUGGGUAGAAGACG 19

RESULT 476
 US-10-919-866-76
 Sequence 76, Application US/10919866
 Publication No. US20050176664A1
 GENERAL INFORMATION:
 APPLICANT: Sitma Therapeutics, Inc.
 APPLICANT: Richards, Ivan
 APPLICANT: MCSwigen, James

TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
 TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
 FILE REFERENCE: 400/205 (MEHB04-183-A)
 CURRENT FILING DATE: 2004-08-17
 PRIOR FILING DATE: 2004-03-11

```

; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 76
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Description of Artificial Sequence: Target Sequence/siNA sense 1
; OTHER INFORMATION:
US-10-919-866-76
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1353 GGGCAGUACUCCUGUCC 1371
Db      1 GGGCAGUACUCCUGUCC 19
```

```

RESULT 477
US-10-919-866-77
; Sequence 77, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```

; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 77
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Description of Artificial Sequence: Target Sequence/siNA sense 1
; OTHER INFORMATION:
US-10-919-866-77
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1371 CUUCAAGAGAGCCACUCUG 1389
Db      1 CUUCAAGAGAGCCACUCUG 19
```

```

RESULT 478
US-10-919-866-78
; Sequence 78, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 78
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Description of Artificial Sequence: Target Sequence/siNA sense 1
; OTHER INFORMATION:
US-10-919-866-78
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1389 GGCAGAGAGUUGUCUCUG 1407
Db      1 GGCAGAGAGUUGUCUCUG 19
```

RESULT 479
US-10-919-866-79
; Sequence 79, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MBH04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 79
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-79
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1407 GAAAGCCGAGAGUCAGAU 1425
DB 1 GAAAGCCGAGAGUCAGAU 19
RESULT 480
US-10-919-866-80
; Sequence 80, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MBH04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 79
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r

; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 80
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-80
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1425 CACUAGCGGAAAAGAU 1443
DB 1 CACUAGCGGAAAAGAU 19
RESULT 481
US-10-919-866-81
; Sequence 81, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MBH04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 81

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-81

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1443 GUCCUGGUCAGAGGAG 1461
Db      1 GUCCUGGUCAGAGGAG 19

RESULT 482
US-10-919-866-82
; Sequence 82, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 82
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-82

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1461 GAAAGCGGCCGAGACCC 1479
Db      1 GAAAGCGGCCGAGACCC 19

RESULT 483
US-10-919-866-83
; Sequence 83, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 83
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-83

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1479 CAGUGGAGUCUGGCGCC 1497
Db      1 CAGUGGAGUCUGGCGCC 19

RESULT 484
US-10-919-866-84
; Sequence 84, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 84
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-84
```



```
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
TITLE OF INVENTION: Acid (siRNA)
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/919,866
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 87
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-87

Query Match          1.1% Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No: 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy      1551 UCACAGCUGCAUACCCCAA 1569
Db      1 UCACAGCUGCAUACCCCAA 19

RESULT 488
US-10-919-866-88
Sequence 88, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
TITLE OF INVENTION: Acid (siRNA)
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/919,866
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 87
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-89
```

```
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 88
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-88

Query Match          1.1% Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No: 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy      1569 AACCUUUGAAUUCUGGC 1587
Db      1 AACCUUUGAAUUCUGGC 19

RESULT 489
US-10-919-866-89
Sequence 89, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
TITLE OF INVENTION: Acid (siRNA)
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/919,866
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 89
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-89
```

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1587 CUACUGGCUUGGCUACAUCC 1605
CUACUGGCUUGGCUACAUCC 19

Db 1 CAACGACACCGUACACCC 19

RESULT 490
US-10-919-866-90
; Sequence 90, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 90
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-90

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1605 CAACGACACCGUACACCC 1623
CAACGACACCGUACACCC 19

Db 1 CAACGACACCGUACACCC 19

RESULT 491
US-10-919-866-91
; Sequence 91, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic

; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 91
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-91

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1623 CGUGGCUAUGGCUUGGC 1641
CGUGGCUAUGGCUUGGC 19

Db 1 CGUGGCUAUGGCUUGGC 19

RESULT 492
US-10-919-866-92
; Sequence 92, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 92
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-92

PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 92
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-92

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1641 CACAAACAUCCAGAAC 1659
Db 1 CACAAACAUCCAGAAC 19

RESULT 493
US-10-919-866-93
Sequence 93, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sitma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 93
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-93

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1659 CACUUCAGAGUGUGUG 1677
Db 1 CACUUCAGAGUGUGUG 19

RESULT 494
US-10-919-866-94
Sequence 94, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sitma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 94
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-919-866-94

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1677 GCUGGCCAGUGUGACAA 1695
Db 1 GCUGGCCAGUGUGACAA 19

RESULT 495
US-10-919-866-95
Sequence 95, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sitma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)

```

; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 95
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-95

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1695 AAAAAAGAGCCGACAGCAG 1713
Db      1 AAAAAAGAGCGCAGACAG 19
```

```

RESULT 496
US-10-919-866-96
; Sequence 96, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
```

```

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 96
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-96

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1713 GCAGUACGACAGACAGCAG 1731
Db      1 GCAGUACGACAGACAGCAG 19
```

```

RESULT 497
US-10-919-866-97
; Sequence 97, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 97
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-97
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1731 GUCGUCAUUUUUCACAG 1749
```

DB 1 GCGCGCAUUUUCACAG 19
|||||
RESULT 498
US-10-919-866-98.
; Sequence 98, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 98
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090

; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 99
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-919-866-99
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1753 GCACCCGACGAGCCTUUGU 1771
|||||
DB 1 GCACCCGACGAGCCTUUGU 19
|||||
RESULT 500
US-10-919-866-100/c
; Sequence 100, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 99
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r

```

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 100
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-100

Query Match
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 3 GACCTTGACCAATTAACAGT 21
DB 19 GACCTTGACCAATTAACAGT 1

RESULT 501
US-10-919-866-101/c
; Sequence 101, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 101
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-101

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 21 UACACCTGCGCCUUGGUTU 39
DB 19 TACACCTGCGCCCTTGT 1
```

```

RESULT 502
US-10-919-866-102/c
; Sequence 102, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 102
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-102

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 39 UCCAAACATCAGCTCCTCC 57
DB 19 TCCAACATCAGCTCCTCC 1

RESULT 503
US-10-919-866-103/c
; Sequence 103, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
```

```
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 103
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-103
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      57 CUGAUAACACAGCCGCCUCC 75
Db      19 CTGGAATACACAGCCCTCC 1
```

```
RESULT 504
US-10-919-866-104/c
; Sequence 104, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
```

```
; SEQ ID NO 104
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-104
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      75 CGAUGCAGGCGUCCGCCCG 93
Db      19 CGAATCAGGCGCTCCCGG 1
```

```
RESULT 505
US-10-919-866-105/c
; Sequence 105, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 105
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-105
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      93 GGAACCGGACUACUUAUUC 111
Db      19 GGAACCGGACUACUATTC 1
```

```
RESULT 506
US-10-919-866-106/c
```

```
; Sequence 106, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sRNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 106
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-106
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```
Oy 111 CGGAGCUCGCAUUCU 129
Db 19 CGGAGCCTGCATGTTTC 1
```

```
RESULT 507
US-10-919-866-107/c
; Sequence 107, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sRNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
```

```
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 107
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-107
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
Oy 129 UCGAGCAGCGCAUUC 147
Db 19 TCGAGCAGCTGCATGTTTC 1
```

```
RESULT 508
US-10-919-866-108/c
; Sequence 108, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sRNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 108
; LENGTH: 19
; TYPE: RNA
```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-108

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 147 CUCCUCCGACGAGGACC 165
DB 19 CTCCTCTCCAGACGTAAC 1

RESULT 509
US-10-919-866-109/c
; Sequence 109, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 109
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-109

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 165 CACCGAUGACCCUUGGGA 183
DB 19 CACCGATGACCTCTGGGA 1

RESULT 510
US-10-919-866-110/c
; Sequence 110, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 110
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-110

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 183 AGGCAUACCCGUGGCAA 201
DB 19 AGGTCATACCGTGGCAA 1

RESULT 511
US-10-919-866-111/c
; Sequence 111, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 111
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-111
```

```

; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 111
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-111

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 4.3e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      201 AGUGUCUUAUCCUUC 219
Db      19 AGTGGCTTCATCGCTTC 1

RESULT 512
US-10-919-866-112/c
; Sequence 112, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 112
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
```

```

US-10-919-866-112

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      219 CUUACGGGCAUCUGCC 237
Db      19 CTTACGGGCAUCTCGCC 1

RESULT 513
US-10-919-866-113/c
; Sequence 113, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 113
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-113

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      237 CUUGGACCAUCCGCG 255
Db      19 CTTGGACCAUCCGCG 1

RESULT 514
US-10-919-866-114/c
; Sequence 114, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
```

```

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US 10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 114
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-114

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      255 CACAUCCUGGUAUUGUG 273
Db      19 CACATCCTGTAATGTG 1

RESULT 515
US-10-919-866-115/C
; Sequence 115, Application US/10919866
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US 10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
```

```

; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 115
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-115

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      273 GCUAUTUAGGCAACAG 291
Db      19 GTCATTAAAGTCAACAG 1

RESULT 516
US-10-919-866-116/C
; Sequence 116, Application US/10919866
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US 10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 116
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-116

Query Match      1.1%; Score 19; DB 1; Length 19;
```

Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```

QY      291 GCAGCUGAAGACGGUCAAC 309
          ||||:|||||||:||||
Db      19  GCAGCTGAAGACGGTCAAC 1

```

RESULT 517
US-10-919-

US-10-919-866-117/c

; Sequence 117, Application US/10919866

Publication No. US20050176664A1

GENERAL INFORMATION:

APPLICANT: Sirna Therapeutics, Inc.

APPLICANT: Richards, Ivan

APPLICANT: McSwiggen, James

1. TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic

1. TITLE OF INVENTION: Receptor (C

```

; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 119
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-119

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.3e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY      345 GAUUAUGGGGUGUUAUUA 363
DB      19 GATTATCGGGCTATTCTCA 1

RESULT 520
US-10-919-866-120/c
; Sequence 120, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sitma Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/919,866
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 120
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-120

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      363 AAUGAAUUGUUAUACGACC 381
DB      19 AATGAATCTGTTCACGACC 1

RESULT 521
US-10-919-866-121/c
; Sequence 121, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sitma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/919,866
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 121
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-121

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      381 CUACAUCACUAGAUAUGCA 399
DB      19 CTACATCATCATGAATGCA 1

RESULT 522
US-10-919-866-122/c
; Sequence 122, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sitma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
```



```
RESULT 525
US-10-919-866-125/c
; Sequence 125, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 125
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-125

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      453 CAGCAUUGCUCUUGUANG 471
DB      19 CAGCAATGCTCTGTATG 1

RESULT 526
US-10-919-866-126/c
; Sequence 126, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
```

```
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 126
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324

RESULT 527
US-10-919-866-127/c
; Sequence 127, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324

QY      471 GAUUCUUGGUCAGC 489
DB      19 GAUUCUUGGUCAGC 1
```

```
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 127
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-127

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 4.3e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      489 CUUUGACAGUACUUUCC 507
DB      19 CTTGACAGATCTTTTC 1

RESULT 528
US-10-919-866-128/c
; Sequence 128, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 128
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-128

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      507 CAUACGAGGCGGCUACG 525
DB      19 CATCAGAGGCGGCTCAG 1

RESULT 529
US-10-919-866-129/c
; Sequence 129, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 129
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-129

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      525 GUACGAGCGCAACGACA 543
DB      19 GTACCGAGCGCAACGACA 1

RESULT 530
US-10-919-866-130/c
; Sequence 130, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
```

```
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-131

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      543 AACAAAGAGACCGCGUG 561
DB      19 AACAAAGAGACCGGTGTG 1

RESULT 531
US-10-919-866-131/c
/ Sequence 131, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Richard, Ivan
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/205 (MEHB04-183-A)
/ CURRENT APPLICATION NUMBER: US/10/919,866
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 131
/ LENGTH: 19
```

```
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-132

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 4.3e+02;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY      579 GAUCAUCCGUCGUGGUCG 597
DB      19 GGCATCTCTCTTGTCTT 1

RESULT 533
US-10-919-866-133/c
/ Sequence 133, Application US/10919866
/ Publication No. US20050176664A1
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Sigma Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: MCSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/205 (MEHB04-183-A)
/ CURRENT APPLICATION NUMBER: US/10/919,866
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 133
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
/ US-10-919-866-133

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.3e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY      597 UUGGCTCCUGCCAUCCUG 615
      ::|||:|||:|||:|||:
Db      19 TTGGGCTCCTGCCATCTTG 1

RESULT 534
US-10-919-866-134/C
/ Sequence 134, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sigma Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: MCSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/205 (MEHB04-183-A)
/ CURRENT APPLICATION NUMBER: US/10/919,866
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448

PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 135
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
```

```
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-135

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      633 UGGAAGAGACUGGCGCCU 651
      :|||||:|||||:|||||:
Db      19 TCGAAGAGACTGTCCT 1

RESULT 536
US-10-919-866-136/c
; Sequence 136, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 136
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-136

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      651 UCCGGAGAGUGGCUCAUU 669
      :|||||:|||||:|||||:
Db      19 TCCGGAGAGTCTTCATT 1

RESULT 537
US-10-919-866-137/c
; Sequence 137, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 137
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-137

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      669 UCAGUCCUCAGUGAGCCC 687
      :|||||:|||||:|||||:
Db      19 TCAATTCTCAGTGAAGCCC 1

RESULT 538
US-10-919-866-138/c
; Sequence 138, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 138
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-138
```

PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 138
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: s1NA antisense region
US-10-919-866-138

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 687 CACCAUACUUUGGACCA 705
DB 19 CACCACTTCTTTCGACCA 1

RESULT 539

US-10-919-866-139/c
Sequence 139, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirta Therapeutics, Inc.
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT FILING DATE: 2004-08-17
PRIOR FILING DATE: US 10/919,866
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 139
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: s1NA antisense region
US-10-919-866-139

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 4.3e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 705 ACCCAUCCGUCUUUUUUAU 723
DB 19 AGCCATCGCTGCTTTTAT 1

RESULT 540

US-10-919-866-140/c
Sequence 140, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirta Therapeutics, Inc.
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT FILING DATE: 2004-08-17
PRIOR FILING DATE: US 10/919,866
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 140
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: s1NA antisense region
US-10-919-866-140

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.3e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 723 UAUCCUGUACCAUUAUG 741
DB 19 TATGCTGTACCAATTATG 1

RESULT 541

US-10-919-866-141/c
Sequence 141, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirta Therapeutics, Inc.
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic

;; TITLE OF INVENTION: Acid (siNA)
;; FILE REFERENCE: 400/205 (MBHB04-183-A)
;; CURRENT APPLICATION NUMBER: US/10/919,866
;; CURRENT FILING DATE: 2004-08-17
;; PRIOR APPLICATION NUMBER: US 10/798,090
;; PRIOR FILING DATE: 2004-03-11
;; PRIOR APPLICATION NUMBER: PCT/US04/16390
;; PRIOR FILING DATE: 2004-05-24
;; PRIOR APPLICATION NUMBER: US 10/826,966
;; PRIOR FILING DATE: 2004-04-16
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-11-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 324
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 141
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-141

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.3e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 741 GACUUAUUUAACUGAGG 759
DB 19 GACTTATTACTGAGG 1

RESULT 542
US-10-919-866-142/c
;; Sequence 142, Application US/10919866
;; Publication No. US20050176664A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirta Therapeutics, Inc.
;; APPLICANT: Richards, Ivan
;; APPLICANT: McSwiggen, James
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
;; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
;; FILE REFERENCE: 400/205 (MBHB04-183-A)
;; CURRENT APPLICATION NUMBER: US/10/919,866
;; CURRENT FILING DATE: 2004-08-17
;; PRIOR APPLICATION NUMBER: US 10/798,090
;; PRIOR FILING DATE: 2004-03-11
;; PRIOR APPLICATION NUMBER: PCT/US04/16390
;; PRIOR FILING DATE: 2004-05-24
;; PRIOR APPLICATION NUMBER: US 10/826,966
;; PRIOR FILING DATE: 2004-04-16
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-11-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346

;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 324
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 142
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-142

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 759 GAUCUUAAGAAACUGAA 777
DB 19 GATCTATTAGAAACTGAA 1

RESULT 543
US-10-919-866-143/c
;; Sequence 143, Application US/10919866
;; Publication No. US20050176664A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirta Therapeutics, Inc.
;; APPLICANT: Richards, Ivan
;; APPLICANT: McSwiggen, James
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
;; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
;; FILE REFERENCE: 400/205 (MBHB04-183-A)
;; CURRENT APPLICATION NUMBER: US/10/919,866
;; CURRENT FILING DATE: 2004-08-17
;; PRIOR APPLICATION NUMBER: US 10/798,090
;; PRIOR FILING DATE: 2004-03-11
;; PRIOR APPLICATION NUMBER: PCT/US04/16390
;; PRIOR FILING DATE: 2004-05-24
;; PRIOR APPLICATION NUMBER: US 10/826,966
;; PRIOR FILING DATE: 2004-04-16
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-11-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 324
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 143
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-143

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 146
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-146

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 831 AGAAAACUUGUCACCCC 849
|||||:|||||
Db 19 AGAAAACUUGUCACCCC 1

RESULT 547
US-10-919-866-147/C
Sequence 147, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McGaughey, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MBHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
PRIOR FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 147
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-147

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 849 CACGGCAGUUCGAGAC 867
|||||:|||||

Db 19 CACGGCAGUUCGAGAC 1

RESULT 548
US-10-919-866-148/C
Sequence 148, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McGaughey, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MBHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
PRIOR FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 148
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-148

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 867 CUGCAGAGUACGAACTU 885
||:|||||:|||||
Db 19 CTGCAGAGTTCGAACTT 1

RESULT 549
US-10-919-866-149/C
Sequence 149, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McGaughey, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MBHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
PRIOR FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11

```

; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO: 149
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-149

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      885 UCAACAGCAAGCAUGAAA 903
DB      19 TCAACAGCAAGCAATGAAA 1

RESULT 550
US-10-919-866-150/c
; Sequence 150, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```

; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO: 150
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-151

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      903 ACGTCCACAGAGAGAG 921
DB      19 ACGTCCACAGAGAGAG 1

RESULT 551
US-10-919-866-151/c
; Sequence 151, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO: 151
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-151

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      921 GUAUGCCGCGCCACATTC 939
DB      19 GUAUGCCGCGCCACATTC 1
```

```

RESULT 552
US-10-919-866-152/c
; Sequence 152, Application US/10919866
; Publication No. US2005017664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 152
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-152
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 939 CUGGUCACACCAGAGC 957
DB 19 CTGGTTCACACCAGAGC 1
:::|||||
RESULT 553
US-10-919-866-153/c
; Sequence 153, Application US/10919866
; Publication No. US2005017664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966

```

```

PRIORITY: FILIN DATE: 2004-04-16
PRIORITY: APPLICATION NUMBER: US 10/757,803
PRIORITY: FILING DATE: 2004-01-14
PRIORITY: APPLICATION NUMBER: US 10/720,448
PRIORITY: FILING DATE: 2003-11-24
PRIORITY: APPLICATION NUMBER: US 10/693,059
PRIORITY: FILING DATE: 2003-11-23
PRIORITY: APPLICATION NUMBER: US 10/444,853
PRIORITY: FILING DATE: 2003-05-23
PRIORITY: APPLICATION NUMBER: PCT/US03/05346
PRIORITY: FILING DATE: 2003-02-20
PRIORITY: APPLICATION NUMBER: PCT/US03/05028
PRIORITY: FILING DATE: 2003-02-20
PRIORITY: APPLICATION NUMBER: US 60/358,580
PRIORITY: FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
SOFTWARE: PatentIn version 3.3
SEQ ID NO: 153
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-153

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      957 CTGGAACCCAGCTCCGAG 975
       1:|||||:|||||
Db      19 CTGGAACCCAGCTCCGAG 1

RESULT 554
US-10-919-866-154/c
Sequence 154, Application US/10919866
Publication No. US2005017666A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPlicant: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
SOFTWARE: PatentIn version 3.3
SEQ ID NO: 154
```

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-154

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      975 GCAGAGGACCAAGACCAC 993
Db      19 GCAGATGACCAAGACCAC 1

RESULT 555
US-10-919-866-155/c
; Sequence 155, Application US/10919866
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: MCSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 155
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-155

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      993 CAGCAGCAGGACGAGUGG 1011
Db      19 CAGCAGCAGTGAAGTTGG 1

RESULT 556
US-10-919-866-156/c
; Sequence 156, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: MCSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 156
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-156

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1011 GAACACCAUAGUGUGCU 1029
Db      19 GAACACCAATGATGCTGCT 1

RESULT 557
US-10-919-866-157/c
; Sequence 157, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: MCSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 157
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-157
```

```

; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 157
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-157

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1029 UGCGUCCUGGAGACUCC 1047
Db      19 TGCCTCTCGAGAACTCC 1

RESULT 558
US-10-919-866-158/c
; Sequence 158, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHBO4-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 158
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
```

```

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-158

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1047 CGCGUCCUGGAGAGAG 1065
Db      19 CGCCTCTCGAGAGAG 1

RESULT 559
US-10-919-866-159/c
; Sequence 159, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHBO4-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 159
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-159

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      1065 GGACAUUGGCGAGAGC 1083
Db      19 GGACATTGGCTCGAGAGC 1

RESULT 560
US-10-919-866-160/c
; Sequence 160, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
```

```

; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 160
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-160

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1083 GAGAGCCATCAGCUCGCAUC 1101
Db      19 GAGAGCCATCTCTCCATC 1

RESULT 561
US-10-919-866-161/c
; Sequence 161, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 162
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-162
```

```

; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-161

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1101 CGUGCUCAGCUCUCCGCGU 1119
Db      19 CGGCTCAAGCTTCCGGGT 1

RESULT 562
US-10-919-866-162/c
; Sequence 162, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 162
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-162
```

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1119 UGACGACCAUCCUCCUAC 1137
:|||||:|||||:
DB 19 TCACGACACCATCCTCAAC 1

RESULT 563
US-10-919-866-163/c
; Sequence 163, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 163
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-919-866-163

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1137 CUCCACCAAGUUAUCCUCA 1155
:|||||:|||||:
DB 19 CTCACCAAGTACCTCA 1

RESULT 564
US-10-919-866-164/c
; Sequence 164, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic

; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 164
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region.
US-10-919-866-164

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1155 AUGGACACUCCAGGUG 1173
:|||||:|||||:
DB 19 ATCGACACCTCAGTGTG 1

RESULT 565
US-10-919-866-165/c
; Sequence 165, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23

```

; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 165
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURES:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-165

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1173 GCCUGAGGAGAGCTUGGAGG 1191
DB      19  GCCTGAGGAGAGCTGCGG 1

RESULT 566
US-10-919-866-166/c
; Sequence 166, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEH804-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 166
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURES:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-166

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```

Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1191 GAUGUGGACUUGAGAGG 1209
DB      19  GATGGGAGAGCTGAGAGG 1

RESULT 567
US-10-919-866-167/c
; Sequence 167, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEH804-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 167
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURES:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-167

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1209 GAAGCGGACAGCTGCGAG 1227
DB      19  GAAGCGGAGAGCTGCGAG 1

RESULT 568
US-10-919-866-168/c
; Sequence 168, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEH804-183-A)
```

```
/ CURRENT APPLICATION NUMBER: US/10/919,866
/ PRIOR FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO: 168
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-168
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1227 GGCCCGAGAGCGUGGAC 1245
DB      19 GGCCCGAGAGCGGTGAC 1
```

```
RESULT 569
US-10-919-866-169/c
/ Sequence 169, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sitna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: MCSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/205 (MHB04-183-A)
/ CURRENT APPLICATION NUMBER: US/10/919,866
/ PRIOR FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
```

```
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO: 169
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-169
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1245 CGAUGAGGCGAGUUUCCA 1263
DB      19 CGATGAGGCGAGTTTCCA 1
```

```
RESULT 570
US-10-919-866-170/c
/ Sequence 170, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sitna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: MCSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/205 (MHB04-183-A)
/ CURRENT APPLICATION NUMBER: US/10/919,866
/ PRIOR FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO: 170
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-170
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1263 AAAAGCTUCUCCAGCTU 1281
```

Db 19 AAAAGCTTCTCAGCTT 1

RESULT 571
US-10-919-866-171/c
Sequence 171, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirta Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: MCSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT FILING DATE: 2004-08-17
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 171
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sirta antisense region
US-10-919-866-171

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1281 UCCCAUCCAGCUAGUCA 1299
Db 19 TCCCAATCCAGCTAGACTCA 1

RESULT 572
US-10-919-866-172/c
Sequence 172, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirta Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: MCSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT FILING DATE: 2004-08-17
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 172
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sirta antisense region
US-10-919-866-172

PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 172
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sirta antisense region
US-10-919-866-172

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1299 AGCCGUGACACAGCUAG 1317
Db 19 AGCCGTGACACAGCTAAG 1

RESULT 573
US-10-919-866-173/c
Sequence 173, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirta Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: MCSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT FILING DATE: 2004-08-17
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 173
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sirta antisense region
US-10-919-866-173

```

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 173
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-173

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1317 GACUUCUGACUGCACTCC 1335
DB      19 GACTCTGAGCTCACTCC 1
```

```

RESULT 574
US-10-919-866-174/c
; Sequence 174, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 174
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-174
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      1335 CUCAGUGGUAGACACG 1353
DB      19 CTCAGTGGGTAGACACG 1
```

```

RESULT 575
US-10-919-866-175/c
; Sequence 175, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 175
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-175

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1353 GGCACUCUACUCUUGUC 1371
DB      19 GGCACCTCACTCTGTC 1
```

```

RESULT 576
US-10-919-866-176/c
; Sequence 176, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
```

```
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 176
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-176
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1371 CUUCAAGAACCCATCTCUG 1389
DB      19 CTTCAAGAAAGCCACTCTG 1
```

```
RESULT 577
US-10-919-866-177/c
; Sequence 177, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 177
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-178/c
```

```
; SEQ ID NO 177
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-177
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1389 GGCACAGAGUUGUCUCUG 1407
DB      19 GGCACAGAGGTTGCTCTG 1
```

```
RESULT 578
US-10-919-866-178/c
; Sequence 178, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 178
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-179/c
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1407 GAAGACCAAGUCAGAUUC 1425
DB      19 GAAGACCAAGATCAGATC 1
```

```
RESULT 579
US-10-919-866-179/c
```

```
Sequence 179, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
PRIOR FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 179
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sirna antisense region
US-10-919-866-179
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1425 CACUAGCGGAAAGAGUG 1443
Db 19 CACTAAGCGGAAAGAGATG 1
RESULT 580
US-10-919-866-180/c
Sequence 180, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
PRIOR FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
```

```
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 180
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sirna antisense region
US-10-919-866-180
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 1443 GUCCUGGUCAGAGAGAG 1461
Db 19 GTCCUGGUCAGAGAGAG 1
RESULT 581
US-10-919-866-181/c
Sequence 181, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
PRIOR FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 181
LENGTH: 19
TYPE: RNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-181
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1461 GAAAGCGCCGACCCGAC 1479
Db      19 GAAAGCGCCGACCCGACCTC 1

RESULT 582
US-10-919-866-182/c
; Sequence 182, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 182
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-182
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy      1479 CAGUGCAUCUUGCUGGCC 1497
Db      19 CAGTGCATCTTGCTTGCC 1

RESULT 583
US-10-919-866-183/c
; Sequence 183, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 183
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-183
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy      1497 CUUCAUACUACUUGGACC 1515
Db      19 CTTGCATCATCTTGACCC 1

RESULT 584
US-10-919-866-184/c
; Sequence 184, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
```

```
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 184
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
US-10-919-866-184

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1515 CCCAACAACAUCCUGGU 1533
DB      19 CCCATCAACATCATGTT 1

RESULT 585
US-10-919-866-185/c
/ Sequence 185, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirta Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siRNA)
/ FILE REFERENCE: 400/205 (MEHBO4-183-A)
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 185
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
```

```
US-10-919-866-185

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 4.3e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      1533 UCUGUGAACACCCUUVGU 1551
DB      19 TCTGTCATCACTTTGT 1

RESULT 586
US-10-919-866-186/c
/ Sequence 186, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirta Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siRNA)
/ FILE REFERENCE: 400/205 (MEHBO4-183-A)
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 186
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
US-10-919-866-186

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      1551 UGACAGTGCACUACCCAAA 1569
DB      19 TGACAGCTGCATACCCAAA 1

RESULT 587
US-10-919-866-187/c
/ Sequence 187, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirta Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siRNA)
/ FILE REFERENCE: 400/205 (MEHBO4-183-A)
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 187
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
```

```

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 187
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-187

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy      1569 AACCUUGGAUUGCGGC 1587
Db      19 AACCTTTGGAATCTGGCC 1

RESULT 588
US-10-919-866-188/c
; Sequence 188, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853

```

```

; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 188
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-189

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy      1587 CUACUGGCUUGGCUACAU 1605
Db      19 CTAAGGCTGTGCTACATC 1

RESULT 589
US-10-919-866-189/c
; Sequence 189, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 189
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-189

```

Best Local Similarity 94.7%; Pred. No. 4.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1605 CAACGACCGUGAACCC 1623

Db 19 CAACGACCGUGAACCC 1

RESULT 590

US-10-919-866-190/c

Sequence 190, Application US/10919866

Publication No. US20050176664A1

GENERAL INFORMATION:

APPLICANT: Sigma Therapeutics, Inc.

APPLICANT: Richards, Ivan

APPLICANT: MCSwigen, James

TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic

TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic

FILE REFERENCE: 400/205 (MEHB04-183-A)

CURRENT FILING DATE: 2004-08-17

PRIOR FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: US 10/798,090

PRIOR FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: PCT/US04/16390

PRIOR FILING DATE: 2004-05-24

PRIOR APPLICATION NUMBER: US 10/826,966

PRIOR FILING DATE: 2004-04-16

PRIOR APPLICATION NUMBER: US 10/757,803

PRIOR FILING DATE: 2004-01-14

PRIOR APPLICATION NUMBER: US 10/720,448

PRIOR FILING DATE: 2003-11-24

PRIOR APPLICATION NUMBER: US 10/693,059

PRIOR FILING DATE: 2003-11-23

PRIOR APPLICATION NUMBER: US 10/444,853

PRIOR FILING DATE: 2003-05-23

PRIOR APPLICATION NUMBER: PCT/US03/05346

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: PCT/US03/05028

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: US 60/358,580

PRIOR FILING DATE: 2002-02-20

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 324

SOFTWARE: PatentIn version 3.3

SEQ ID NO 190

LENGTH: 19

TYPE: RNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region

US-10-919-866-190

Query Match 1.1%; Score 19; DB 1; Length 19;

Best Local Similarity 63.2%; Pred. No. 4.3e+02;

Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 1623 CGUGGCUAUGCUCUGGC 1641

Db 19 CGUGGCUAUGCUCUGGC 1

RESULT 591

US-10-919-866-191/c

Sequence 191, Application US/10919866

Publication No. US20050176664A1

GENERAL INFORMATION:

APPLICANT: Sigma Therapeutics, Inc.

APPLICANT: Richards, Ivan

APPLICANT: MCSwigen, James

TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic

TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic

FILE REFERENCE: 400/205 (MEHB04-183-A)

CURRENT FILING DATE: 2004-08-17

PRIOR FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: US 10/798,090

PRIOR FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: PCT/US04/16390

PRIOR FILING DATE: 2004-05-24

PRIOR APPLICATION NUMBER: US 10/826,966

PRIOR FILING DATE: 2004-04-16

PRIOR APPLICATION NUMBER: US 10/757,803

PRIOR FILING DATE: 2004-01-14

PRIOR APPLICATION NUMBER: US 10/720,448

PRIOR FILING DATE: 2003-11-24

PRIOR APPLICATION NUMBER: US 10/693,059

PRIOR FILING DATE: 2003-11-23

PRIOR APPLICATION NUMBER: US 10/444,853

PRIOR FILING DATE: 2003-05-23

PRIOR APPLICATION NUMBER: PCT/US03/05346

PRIOR FILING DATE: 2003-02-20

FILE REFERENCE: 400/205 (MEHB04-183-A)

CURRENT FILING DATE: 2004-08-17

PRIOR FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: US 10/798,090

PRIOR FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: PCT/US04/16390

PRIOR FILING DATE: 2004-05-24

PRIOR APPLICATION NUMBER: US 10/826,966

PRIOR FILING DATE: 2004-04-16

PRIOR APPLICATION NUMBER: US 10/757,803

PRIOR FILING DATE: 2004-01-14

PRIOR APPLICATION NUMBER: US 10/720,448

PRIOR FILING DATE: 2003-11-24

PRIOR APPLICATION NUMBER: US 10/693,059

PRIOR FILING DATE: 2003-11-23

PRIOR APPLICATION NUMBER: US 10/444,853

PRIOR FILING DATE: 2003-05-23

PRIOR APPLICATION NUMBER: PCT/US03/05346

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: PCT/US03/05028

PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: US 60/358,580

PRIOR FILING DATE: 2002-02-20

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 324

SOFTWARE: PatentIn version 3.3

SEQ ID NO 191

LENGTH: 19

TYPE: RNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region

US-10-919-866-191

Query Match 1.1%; Score 19; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 4.3e+02;

Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1641 CAACAAACATTCAGAAC 1659

Db 19 CAACAAACATTCAGAAC 1

RESULT 592

US-10-919-866-192/c

Sequence 192, Application US/10919866

Publication No. US20050176664A1

GENERAL INFORMATION:

APPLICANT: Sigma Therapeutics, Inc.

APPLICANT: Richards, Ivan

APPLICANT: MCSwigen, James

TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic

TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic

FILE REFERENCE: 400/205 (MEHB04-183-A)

CURRENT FILING DATE: 2004-08-17

PRIOR FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: US 10/798,090

PRIOR FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: PCT/US04/16390

PRIOR FILING DATE: 2004-05-24

PRIOR APPLICATION NUMBER: US 10/826,966

PRIOR FILING DATE: 2004-04-16

PRIOR APPLICATION NUMBER: US 10/757,803

PRIOR FILING DATE: 2004-01-14

PRIOR APPLICATION NUMBER: US 10/720,448

PRIOR FILING DATE: 2003-11-24

PRIOR APPLICATION NUMBER: US 10/693,059

PRIOR FILING DATE: 2003-11-23

PRIOR APPLICATION NUMBER: US 10/444,853

PRIOR FILING DATE: 2003-05-23

PRIOR APPLICATION NUMBER: PCT/US03/05346

PRIOR FILING DATE: 2003-02-20

```

; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 192
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-192

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1659 CACUUCAGAGUCUGCUG 1677
Db      19 CACTTCAGATGCTGCTG 1

RESULT 593
US-10-919-866-193/c
; Sequence 193, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 193
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-193

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      1677 GCGUGCCAGUGACAA 1695
Db      19 GCTGCGCAGTGTGACAAA 1

RESULT 594
US-10-919-866-194/c
; Sequence 194, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 194
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-194

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1695 AAAAAGAGCGCCAGCAG 1713
Db      19 AAAAAGAGCGCCAGCAG 1

RESULT 595
US-10-919-866-195/c
; Sequence 195, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
```

```

; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 195
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-195

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1731 GCAGUACGACGAGACAG 1731
DB      19 GCAGTACGACGAGACAG 1

RESULT 596
US-10-919-866-196/c
; Sequence 196, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 197
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-197
```

```

; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 196
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-196

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.3e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY      1731 GUCGUCAUUUUUCACAG 1749
DB      19 GUCGTCATTTTCACAG 1

RESULT 597
US-10-919-866-197/c
; Sequence 197, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 197
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-919-866-197
```

RESULT 598
US-10-919-866-198/c
; Sequence 198, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 198
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna antisense region
US-10-919-866-198

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1753 GCACCCGACGAGCCCTTGT 1771
DB 19 GCACCCGACGAGCCCTTGT 1

RESULT 599
US-11-083-784-96999
; Sequence 96999, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 96999
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-96999

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 306 CAACACUACUCCUCCUUA 324
DB 1 CAACACUACUCCUCCUUA 19

RESULT 600
US-11-083-784-97000
; Sequence 97000, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97000
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97000

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 296 UGAAGACGUCUACAACUA 314
DB 1 UGAAGACGUCUACAACUA 19

RESULT 601
US-11-083-784-97001
; Sequence 97001, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784

```
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 97001
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97001

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 655 GGAGAGGCGCCUUCAGU 673
Db 1 GGAGAGGCGCCUUCAGU 19

```
RESULT 602
US-11-083-784-97002
/ Sequence 97002, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 97002
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97002

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 815 GGACAGAGCGCAGACGA 833
Db 1 GGACAGAGCGCAGACGA 19

```
RESULT 603
US-11-083-784-97003
/ Sequence 97003, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
```

```
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 97003
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97003

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1439 GGAUGUCCUGGUGAAGA 1457
Db 1 GGAUGUCCUGGUGAAGA 19

```
RESULT 604
US-11-083-784-97004
/ Sequence 97004, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 97004
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97004

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 620 GGCAGUACUUGUGGAAA 638
Db 1 GGCAGUACUUGUGGAAA 19

```
RESULT 605
US-11-083-784-97005
/ Sequence 97005, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
```

```

; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97005
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97005
```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      546 AAAGAGACCGCGUGAUG 564
Db      1 AAAGAGACCGCGUGAUG 19
```

RESULT 606

```
US-11-083-784-97006
; Sequence 97006, Application US/11083784
; Publication No. US20050245475A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97006
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97006
```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      265 GUAAUUGUGUCAUUUAAGG 283
Db      1 GUAAUUGUGUCAUUUAAGG 19
```

RESULT 607

```
US-11-083-784-97007
; Sequence 97007, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
```

```

; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97007
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97007
```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      254 GCAACAUCCUGGUAUUGU 272
Db      1 GCAACAUCCUGGUAUUGU 19
```

RESULT 608

```
US-11-083-784-97008
; Sequence 97008, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97008
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97008
```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1653 CAGAACCAUUCUACAAGU 1671
Db      1 CAGAACCAUUCUACAAGU 19
```

RESULT 609

```
US-11-083-784-97009
```

```
; Sequence 97009, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97009
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97009

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1412 CCAGAAGUCAGUACUAA 1430
Db      1 CCAGAAGUCAGUACUAA 19

RESULT 610
US-11-083-784-97010
; Sequence 97010, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97010
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97010

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1305 GGACACAGUAGUACUUCU 1323
Db      1 GGACACAGUAGUACUUCU 19
```

```
RESULT 611
US-11-083-784-97011
; Sequence 97011, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97011
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97011

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      656 GAGAGUCUUCUACUACAGU 674
Db      1 GAGAGUCUUCUACUACAGU 19

RESULT 612
US-11-083-784-97012
; Sequence 97012, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97012
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97012

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      45 CAUCAGUCUUCUUCGAGUA 63
```

Db 1 CAUCCAGCUCUCCUGGAAUA 19

RESULT 613

US-11-083-784-97013
; Sequence 97013, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97013
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97013

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 509 UCACGAGCGCCUCACGUA 527

Db 1 UCACGAGCGCCUCACGUA 19

RESULT 614

US-11-083-784-97014
; Sequence 97014, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97014
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97014

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 204 GGUUCUUCAGCGCUUUCUA 222

Db 1 GGUUCUUCAGCGCUUUCUA 19

RESULT 615

US-11-083-784-97015
; Sequence 97015, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97015
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97015

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1628 GCUAGCUCUGUGCAACAA 1646

Db 1 GCUAGCUCUGUGCAACAA 19

RESULT 616

US-11-083-784-97016
; Sequence 97016, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97016
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97016

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 754 UGAGAGUCUUAUAGGAA 772
|||||
DB 1 UGAGAGUCUUAUAGGAA 19

RESULT 617
US-11-083-784-97017

; Sequence 97017, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:

; APPLICANT: Dharmoon, Inc.
; APPLICANT: Reynolds, Angela
; APPLICANT: Marshall, William
; APPLICANT: Leake, Devin
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97017
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-11-083-784-97017

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 456 CAUGCCUCUGUUAUGAAU 474
|||||
DB 1 CAUGCCUCUGUUAUGAAU 19

RESULT 618
US-11-083-784-97018

; Sequence 97018, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:

; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97018
; LENGTH: 19

; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97018

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 92 CGGAAACGUCACUCAAUU 110
|||||
DB 1 CGGAAACGUCACUCAAUU 19

RESULT 619
US-11-083-784-97019

; Sequence 97019, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:

; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97019
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97019

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 129 UGAGGACUCUGGCAAUUC 147
|||||
DB 1 UGAGGACUCUGGCAAUUC 19

RESULT 620
US-11-083-784-97020

; Sequence 97020, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:

; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911

```
; SOFTWARE: Proprietary
; SEQ ID NO 97020
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97020

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      579 GGUCAUCUCUUGCCU 597
DB      1 GGUCAUCUCUUGCCU 19

RESULT 621
US-11-083-784-97021
; Sequence 97021, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97021
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97021

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      455 GCAUCCUCUUGUUGAA 473
DB      1 GCAUCCUCUUGUUGAA 19

RESULT 622
US-11-083-784-97022
; Sequence 97022, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
```

```
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97022
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97022

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1723 CAGAGACAGUCGUCAUUU 1741
DB      1 CAGAGACAGUCGUCAUUU 19

RESULT 623
US-11-083-784-97023
; Sequence 97023, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97023
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97023

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1485 GAUCUCUCUUGCCUACUC 1503
DB      1 GAUCUCUCUUGCCUACUC 19

RESULT 624
US-11-083-784-97024
; Sequence 97024, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
```

```
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO: 97024
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97024
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      880 GAACUUCACACGCAAGCA 898
Db      1 GAACUUCACACGCAAGCA 19
```

RESULT 625

```
US-11-083-784-97025
/ Sequence 97025, Application US/11083784
/ Publication No. US20050245475A1
```

GENERAL INFORMATION:

```
/ APPLICANT: Dharmoon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO: 97025
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97025
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      720 UUAUAGCUCGUCACCAU 738
Db      1 UUAUAGCUCGUCACCAU 19
```

RESULT 626

```
US-11-083-784-97026
/ Sequence 97026, Application US/11083784
/ Publication No. US20050245475A1
```

GENERAL INFORMATION:

```
/ APPLICANT: Dharmoon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
```

```
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO: 97026
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97026
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      530 GAGCAACGACACACAA 548
Db      1 GAGCAACGACACACAA 19
```

RESULT 627

```
US-11-083-784-97027
/ Sequence 97027, Application US/11083784
/ Publication No. US20050245475A1
```

GENERAL INFORMATION:

```
/ APPLICANT: Dharmoon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO: 97027
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97027
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      275 CAUUAAGCUCACACGCA 293
Db      1 CAUUAAGCUCACACGCA 19
```

RESULT 628

```
US-11-083-784-97028
/ Sequence 97028, Application US/11083784
/ Publication No. US20050245475A1
```

GENERAL INFORMATION:

```
/ APPLICANT: Dharmoon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
```

```

; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97028
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97028

Query Match
Best Local Similarity 100.0%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 534 CAACGACACACACAGAGA 552
Db 1 CAACGACACACACAGAGA 19

RESULT 629
US-11-083-784-97029
; Sequence 97029, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97029
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97029

Query Match
Best Local Similarity 100.0%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1722 GCGAGACAGUGCGUCUAU 1740
Db 1 GCGAGACAGUGCGUCUAU 19

RESULT 630
US-11-083-784-97030
; Sequence 97030, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
```

```

; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97030
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97030

Query Match
Best Local Similarity 100.0%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 971 CCGAGCAGUAGCACCAGA 989
Db 1 CCGAGCAGUAGCACCAGA 19

RESULT 631
US-11-083-784-97031
; Sequence 97031, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97031
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97031

Query Match
Best Local Similarity 100.0%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 665 UCACUACAGUCCUCAGUGA 683
Db 1 UCACUACAGUCCUCAGUGA 19

RESULT 632
US-11-083-784-97032
; Sequence 97032, Application US/11083784
; Publication No. US20050245475A1
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacom, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 97032
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97032

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 532 GCGAAGCAACAAACAAGA 550
DB 1 GCGAAGCAACAAACAAGA 19

RESULT 633
US-11-083-784-97033
/ Sequence 97033, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacom, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 97033
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97033

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 453 CAGCAUAGCCUUGUUAUG 471
DB 1 CAGCAUAGCCUUGUUAUG 19

RESULT 634
```

```
US-11-083-784-97034
/ Sequence 97034, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacom, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 97034
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97034

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 253 GGCACAUCCUGUAUUG 271
DB 1 GGCACAUCCUGUAUUG 19

RESULT 635
US-11-083-784-97035
/ Sequence 97035, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacom, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 97035
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97035

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1419 UCAGAUCAUACCGGAAA 1437
DB 1 UCAGAUCAUACCGGAAA 19
```

```
RESULT 636
US-11-083-784-97036
; Sequence 97036, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97036
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97036

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1233 GAAGAGCGUGAGCAUGGA 1251
Db      1 GAAGAGCGUGAGCAUGGA 19

RESULT 637
US-11-083-784-97037
; Sequence 97037, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97037
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97037

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1233 GAAGAGCGUGAGCAUGGA 1251
Db      1 GAAGAGCGUGAGCAUGGA 19
```

```
QY      525 GUACGAGCCAAACGACA 543
Db      1 GUACGAGCCAAACGACA 19

RESULT 638
US-11-083-784-97038
; Sequence 97038, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97038
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97038

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      876 UUAAGAACTUCACACGCAA 894
Db      1 UUAAGAACTUCACACGCAA 19

RESULT 639
US-11-083-784-97039
; Sequence 97039, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97039
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97039

Query Match      1.1%; Score 19; DB 1; Length 19;
```

Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 758 GGATCUUAGGAAACTGA 776
|||||
Db 1 GGATCUUAGGAACTGA 19

RESULT 640

US-11-083-784-97040
; Sequence 97040, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97040
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97040

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 207 CUUCAUCCGCUUUCUUAACG 225
|||||
Db 1 CUUCAUCCGCUUUCUUAACG 19

RESULT 641

US-11-083-784-97041
; Sequence 97041, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97041
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-11-083-784-97041

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 677 UCAGUGAGCCACCAUUAAC 695
|||||
Db 1 UCAGUGAGCCACCAUUAAC 19

RESULT 642

US-11-083-784-97042
; Sequence 97042, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97042
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97042

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 483 CAUCAGCUCUUGACAGAUAC 501
|||||
Db 1 CAUCAGCUCUUGACAGAUAC 19

RESULT 643

US-11-083-784-97043
; Sequence 97043, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97043

```
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97043

Query Match
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1655 GAACACUUCUUAAGUGCU 1673
DB 1 GAACACUUCUUAAGUGCU 19

RESULT 644
US-11-083-784-97044
/ Sequence 97044, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmcon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 97044
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97044

Query Match
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 988 GACCAAGCAGCAGUGACA 1006
DB 1 GACCAAGCAGCAGUGACA 19

RESULT 645
US-11-083-784-97045
/ Sequence 97045, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmcon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
```

```
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 97045
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97045

Query Match
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 454 AGCAAGCCUCUGUUAUGA 472
DB 1 AGCAAGCCUCUGUUAUGA 19

RESULT 646
US-11-083-784-97046
/ Sequence 97046, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmcon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 97046
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97046

Query Match
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 UAGGAACTUGGCTGUGA 425
DB 1 UAGGAACTUGGCTGUGA 19

RESULT 647
US-11-083-784-97047
/ Sequence 97047, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmcon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
```

```
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97047
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97047
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      365 UGAACUGUUNUGACGACCUA 383
Db      1 UGAACUGUUNUGACGACCUA 19
```

RESULT 648

```
US-11-083-784-97048
; Sequence 97048, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97048
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97048
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1410 GACGAGAAGUCAGUACACU 1428
Db      1 GACGAGAAGUCAGUACACU 19
```

RESULT 649

```
US-11-083-784-97049
; Sequence 97049, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
```

```
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97049
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97049
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1139 CCACCAAGUACCCUCCAU 1157
Db      1 CCACCAAGUACCCUCCAU 19
```

RESULT 650

```
US-11-083-784-97050
; Sequence 97050, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97050
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97050
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1082 CGAGAGCAUCCUCCAU 1100
Db      1 CGAGAGCAUCCUCCAU 19
```

RESULT 651

```
US-11-083-784-97051
; Sequence 97051, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97051
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97051

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      307 AACACUACUCCUCCUUA 325
      |||
      1 AACACUACUCCUCCUUA 19

RESULT 652
US-11-083-784-97052
; Sequence 97052, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97052
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97052

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      261 CCUGGUAUUGUGUCAU 279
      |||
      1 CCUGGUAUUGUGUCAU 19

RESULT 653
US-11-083-784-97053
; Sequence 97053, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
```

```
APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97053
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97053

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1586 GCUACUGGCGUGUCACAU 1604
      |||
      1 GCUACUGGCGUGUCACAU 19

RESULT 654
US-11-083-784-97054
; Sequence 97054, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97054
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97054

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      482 UCAUCAGCUGUGACGAUA 500
      |||
      1 UCAUCAGCUGUGACGAUA 19

RESULT 655
US-11-083-784-97055
; Sequence 97055, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
```

```

; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97055
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97055
```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1307 ACACAGCUNAGACUUCUGA 1325

Db 1 ACACAGCUNAGACUUCUGA 19

RESULT 656
US-11-083-784-97056

```

; Sequence 97056, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97056
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97056
```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 544 ACAAGAGAGCCGGUGUGA 562

Db 1 ACAAGAGAGCCGGUGUGA 19

RESULT 657
US-11-083-784-97057
; Sequence 97057, Application US/11083784

```

; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97057
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97057
```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 361 UCAUGAUCUGUUUACGA 379

Db 1 UCAUGAUCUGUUUACGA 19

RESULT 658
US-11-083-784-97058

```

; Sequence 97058, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97058
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97058
```

```

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1517 CAUACAUCUAGUUUCU 1535

Db 1 CAUACAUCUAGUUUCU 19

RESULT 659
US-11-083-784-97059
; Sequence 97059, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97059
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97059

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1489 UUGCUCGCGUUGCAUCA 1507
|||||
DB 1 UUGCUCGCGUUGCAUCA 19

RESULT 660
US-11-083-784-97060
; Sequence 97060, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97060
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97060

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 UUAUGCCUGUACCAUUA 729
|||||

DB 1 UUAUGCCUGUACCAUUA 19

RESULT 661
US-11-083-784-97061
; Sequence 97061, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97061
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97061

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 549 GAGAGCCGGUGAUGAUC 567
|||||
DB 1 GAGAGCCGGUGAUGAUC 19

RESULT 662
US-11-083-784-97062
; Sequence 97062, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97062
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97062

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 486 CAGCUUUGACAGAUACUU 504
|||
Db 1 CAGCUUUGACAGAUACUU 19

RESULT 663
US-11-083-784-97063

; Sequence 97063, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97063
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97063

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1652 UCAGAACCCACUUCAGAU 1670
|||
Db 1 UCAGAACCCACUUCAGAU 19

RESULT 664
US-11-083-784-97064

; Sequence 97064, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97064
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97064

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1646 AACCAUUCAGAACCAUUCU 1664
|||
Db 1 AACCAUUCAGAACCAUUCU 19

RESULT 665
US-11-083-784-97065

; Sequence 97065, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97065
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97065

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1314 UAAGACUUCGACGUCAC 1332
|||
Db 1 UAAGACUUCGACGUCAC 19

RESULT 666
US-11-083-784-97066

; Sequence 97066, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97066
; LENGTH: 19
; TYPE: RNA
US-11-083-784-97066

```
; ORGANISM: Homo sapiens
US-11-083-784-97066

Query Match
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 998 GCAGUGACAGUGGACAA 1016
Db 1 GCAGUGACAGUGGACAA 19

RESULT 667
US-11-083-784-97067
; Sequence 97067, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97067
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97067

Query Match
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 255 CAACAUCCTGUGAUAUUG 273
Db 1 CAACAUCCTGUGAUAUUG 19

RESULT 668
US-11-083-784-97068
; Sequence 97068, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
```

```
; SEQ ID NO 97068
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97068

Query Match
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 330 GGCCTUGGCCGACUGAUU 348
Db 1 GGCCTUGGCCGACUGAUU 19

RESULT 669
US-11-083-784-97069
; Sequence 97069, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97069
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97069

Query Match
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 619 UGCGAUAUCUUGUGGA 637
Db 1 UGCGAUAUCUUGUGGA 19

RESULT 670
US-11-083-784-97070
; Sequence 97070, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
```

;; PRIOR FILING DATE: 2002-11-14
;; NUMBER OF SEQ ID NOS: 1591911
;; SOFTWARE: Proprietary
;; SEQ ID NO 97070
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-11-083-784-97070

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 101 UCACUCUUCUGCGCAGCUA 119
DB 1 UCACUCUUCUGCGCAGCUA 19

RESULT 671
US-11-083-784-97071

;; Sequence 97071, Application US/11083784
;; Publication No. US20050245475A1
;; GENERAL INFORMATION:

;; APPLICANT: Dharmacom, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin
;; APPLICANT: Marshall, William
;; APPLICANT: Scaringe, Stephen
;; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;; FILE REFERENCE: 13499US
;; CURRENT APPLICATION NUMBER: US/11/083,784
;; PRIOR FILING DATE: 2005-03-18
;; PRIOR APPLICATION NUMBER: US/10/714,333
;; PRIOR FILING DATE: 2003-11-14
;; PRIOR APPLICATION NUMBER: 60/502,050
;; PRIOR FILING DATE: 2003-09-10
;; PRIOR APPLICATION NUMBER: 60/426,137
;; PRIOR FILING DATE: 2002-11-14
;; NUMBER OF SEQ ID NOS: 1591911
;; SOFTWARE: Proprietary
;; SEQ ID NO 97071
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-11-083-784-97071

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 886 CAACGCAAGCAUGGAAC 904
DB 1 CAACGCAAGCAUGGAAC 19

RESULT 672
US-11-083-784-97072

;; Sequence 97072, Application US/11083784
;; Publication No. US20050245475A1
;; GENERAL INFORMATION:

;; APPLICANT: Dharmacom, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin
;; APPLICANT: Marshall, William
;; APPLICANT: Scaringe, Stephen
;; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;; FILE REFERENCE: 13499US
;; CURRENT APPLICATION NUMBER: US/11/083,784
;; PRIOR FILING DATE: 2005-03-18
;; PRIOR APPLICATION NUMBER: US/10/714,333
;; PRIOR FILING DATE: 2003-11-14

;; PRIOR APPLICATION NUMBER: 60/502,050
;; PRIOR FILING DATE: 2003-09-10
;; PRIOR APPLICATION NUMBER: 60/426,137
;; PRIOR FILING DATE: 2002-11-14
;; NUMBER OF SEQ ID NOS: 1591911
;; SOFTWARE: Proprietary
;; SEQ ID NO 97072
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-11-083-784-97072

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 756 GAGAUUCUUAAGGAACU 774
DB 1 GAGAUUCUUAAGGAACU 19

RESULT 673
US-11-083-784-97073

;; Sequence 97073, Application US/11083784
;; Publication No. US20050245475A1
;; GENERAL INFORMATION:

;; APPLICANT: Dharmacom, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin
;; APPLICANT: Marshall, William
;; APPLICANT: Scaringe, Stephen
;; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;; FILE REFERENCE: 13499US
;; CURRENT APPLICATION NUMBER: US/11/083,784
;; CURRENT FILING DATE: 2005-03-18
;; PRIOR APPLICATION NUMBER: US/10/714,333
;; PRIOR FILING DATE: 2003-11-14
;; PRIOR APPLICATION NUMBER: 60/502,050
;; PRIOR FILING DATE: 2003-09-10
;; PRIOR APPLICATION NUMBER: 60/426,137
;; PRIOR FILING DATE: 2002-11-14
;; NUMBER OF SEQ ID NOS: 1591911
;; SOFTWARE: Proprietary
;; SEQ ID NO 97073
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-11-083-784-97073

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 752 ACUGAGAUUCUUAAGGA 770
DB 1 ACUGAGAUUCUUAAGGA 19

RESULT 674
US-11-083-784-97074

;; Sequence 97074, Application US/11083784
;; Publication No. US20050245475A1
;; GENERAL INFORMATION:

;; APPLICANT: Dharmacom, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin
;; APPLICANT: Marshall, William
;; APPLICANT: Scaringe, Stephen
;; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;; FILE REFERENCE: 13499US
;; CURRENT APPLICATION NUMBER: US/11/083,784

```
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97074
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97074
```

```
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 572 UGGCTUGGGUCAUCCUCCU 590
Db 1 UGGCTUGGGUCAUCCUCCU 19
```

```
RESULT 675
US-11-083-784-97075
; Sequence 97075, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97075
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97075
```

```
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 297 GAAGACGGUCAAACUAC 315
Db 1 GAAGACGGUCAAACUAC 19
```

```
RESULT 676
US-11-083-784-97076
; Sequence 97076, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
```

```
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97076
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97076
```

```
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1754 CACCGAGCGGCGCCUGUA 1772
Db 1 CACCGAGCGGCGCCUGUA 19
```

```
RESULT 677
US-11-083-784-97077
; Sequence 97077, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97077
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97077
```

```
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1551 UGACGCGUCCAUCCCAA 1569
Db 1 UGACGCGUCCAUCCCAA 19
```

```
RESULT 678
US-11-083-784-97078
; Sequence 97078, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
```

```
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 97078
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97078

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      308 ACAACUACUCCUUAAG 326
      |||||
Db      1 ACACTACUCCUUAAG 19

RESULT 679
US-11-083-784-97079
/ Sequence 97079, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmoon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 97079
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97079

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      109 UUCGCGACUACAUGUU 127
      |||||
Db      1 UUCGGCAGCUACAUGUU 19

RESULT 680
US-11-083-784-97080
/ Sequence 97080, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Dharmoon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 97080
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97080

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1473 GACCCUACUGGCAUCUG 1491
      |||||
Db      1 GACCCUACUGGCAUCUG 19

RESULT 681
US-11-083-784-97081
/ Sequence 97081, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmoon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 97081
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97081

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      451 GCCAGCAUGCCUUGUA 469
      |||||
Db      1 GCCAGCAUGCCUUGUA 19

RESULT 682
US-11-083-784-97082
```

```
; Sequence 97082, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97082
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97082
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1203 GGAGGAAAGCCGACAG 1221
DB      1   GGAGGAAAGCCGACAG 19
```

```
RESULT 683
US-11-083-784-97083
; Sequence 97083, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97083
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97083
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      896 GCAUGAAGCUCGACAG 914
DB      1   GCAUGAAGCUCGACAG 19
```

```
RESULT 684
US-11-083-784-97084
; Sequence 97084, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97084
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97084
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      816 GACAGAGCGACAGAGAA 834
DB      1   GACAGAGCGACAGAGAA 19
```

```
RESULT 685
US-11-083-784-97085
; Sequence 97085, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97085
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97085
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      432 GCUUGCAUUGACGUA 450
```

Db 1 GCUUGCCAUUGACUACGUA 19

RESULT 686

US-11-083-784-97086
; Sequence 97086, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97086
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97086

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 23 CAACUUGCCUUGUUC 41
Db 1 CAACUUGCCUUGUUC 19

RESULT 687

US-11-083-784-97087
; Sequence 97087, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97087
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97087

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1537 GUGACACCUUUGUACA 1555
Db 1 GUGACACCUUUGUACA 19

RESULT 688

US-11-083-784-97088
; Sequence 97088, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97088
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97088

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1271 UCUCACGCUUCCAUCCA 1289
Db 1 UCUCACGCUUCCAUCCA 19

RESULT 689

US-11-083-784-97089
; Sequence 97089, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97089
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97089

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      680 GUGAGCCGACCAUUCUU 698
      |||||
Db      1 GUGAGCCGACCAUUCUU 19

RESULT 690
US-11-083-784-97090
; Sequence 97090, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97090
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97090

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      373 UUUACGACCUCAUCAUCA 391
      |||||
Db      1 UUUACGACCUCAUCAUCA 19

RESULT 691
US-11-083-784-97091
; Sequence 97091, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97091
; LENGTH: 19
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97091

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      759 GAUCUUAUAGAAACUGAA 777
      |||||
Db      1 GAUCUUAUAGAAACUGAA 19

RESULT 692
US-11-083-784-97092
; Sequence 97092, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97092
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97092

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      262 CUGGUAUUGUGUCAUUA 280
      |||||
Db      1 CUGGUAUUGUGUCAUUA 19

RESULT 693
US-11-083-784-97093
; Sequence 97093, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
```

```
 ; SOFTWARE: Proprietary
 ; SEQ ID NO 97093
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-11-083-784-97093
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      249 CAUCGGCAACAUCCUGGUA 267
Db      1 CAUCGGCAACAUCCUGGUA 19
```

```
RESULT 694
US-11-083-784-97094
 ; Sequence 97094, Application US/11083784
 ; Publication No. US20050245475A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Dharmacon, Inc.
 ; APPLICANT: Khvorova, Anastasia
 ; APPLICANT: Reynolds, Angela
 ; APPLICANT: Leake, Devin
 ; APPLICANT: Marshall, William
 ; APPLICANT: Scaringe, Stephen
 ; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
 ; FILE REFERENCE: 13499US
 ; CURRENT APPLICATION NUMBER: US/11/083,784
 ; PRIOR FILING DATE: 2005-03-18
 ; PRIOR APPLICATION NUMBER: US/10/714,333
 ; PRIOR FILING DATE: 2003-11-14
 ; PRIOR FILING DATE: 2003-09-10
 ; PRIOR FILING DATE: 2003-09-10
 ; PRIOR FILING DATE: 2002-11-14
 ; PRIOR FILING DATE: 2002-11-14
 ; NUMBER OF SEQ ID NOS: 1591911
 ; SOFTWARE: Proprietary
 ; SEQ ID NO 97094
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-11-083-784-97094
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      493 GACAGAACUUUCCAUCA 511
Db      1 GACAGAACUUUCCAUCA 19
```

```
RESULT 695
US-11-083-784-97095
 ; Sequence 97095, Application US/11083784
 ; Publication No. US20050245475A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Dharmacon, Inc.
 ; APPLICANT: Khvorova, Anastasia
 ; APPLICANT: Reynolds, Angela
 ; APPLICANT: Leake, Devin
 ; APPLICANT: Marshall, William
 ; APPLICANT: Scaringe, Stephen
 ; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
 ; FILE REFERENCE: 13499US
 ; CURRENT APPLICATION NUMBER: US/11/083,784
 ; PRIOR FILING DATE: 2005-03-18
 ; PRIOR FILING DATE: US/10/714,333
 ; PRIOR FILING DATE: 2003-11-14
 ; PRIOR APPLICATION NUMBER: 60/502,050
 ; PRIOR FILING DATE: 2003-09-10
```

```
 ; PRIOR APPLICATION NUMBER: 60/426,137
 ; PRIOR FILING DATE: 2002-11-14
 ; NUMBER OF SEQ ID NOS: 1591911
 ; SOFTWARE: Proprietary
 ; SEQ ID NO 97095
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-11-083-784-97095
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      452 CCAGCAUGCCUCUGUUAU 470
Db      1 CCAGCAUGCCUCUGUUAU 19
```

```
RESULT 696
US-11-083-784-97096
 ; Sequence 97096, Application US/11083784
 ; Publication No. US20050245475A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Dharmacon, Inc.
 ; APPLICANT: Khvorova, Anastasia
 ; APPLICANT: Reynolds, Angela
 ; APPLICANT: Leake, Devin
 ; APPLICANT: Marshall, William
 ; APPLICANT: Scaringe, Stephen
 ; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
 ; FILE REFERENCE: 13499US
 ; CURRENT APPLICATION NUMBER: US/11/083,784
 ; PRIOR FILING DATE: 2005-03-18
 ; PRIOR FILING DATE: US/10/714,333
 ; PRIOR FILING DATE: 2003-11-14
 ; PRIOR FILING DATE: 2003-09-10
 ; PRIOR FILING DATE: 2003-09-10
 ; PRIOR FILING DATE: 2002-11-14
 ; PRIOR FILING DATE: 2002-11-14
 ; NUMBER OF SEQ ID NOS: 1591911
 ; SOFTWARE: Proprietary
 ; SEQ ID NO 97096
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-11-083-784-97096
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1407 GAAGACCAGAGUCAGAU 1425
Db      1 GAAGACCAGAGUCAGAU 19
```

```
RESULT 697
US-11-083-784-97097
 ; Sequence 97097, Application US/11083784
 ; Publication No. US20050245475A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Dharmacon, Inc.
 ; APPLICANT: Khvorova, Anastasia
 ; APPLICANT: Reynolds, Angela
 ; APPLICANT: Leake, Devin
 ; APPLICANT: Marshall, William
 ; APPLICANT: Scaringe, Stephen
 ; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
 ; FILE REFERENCE: 13499US
 ; CURRENT APPLICATION NUMBER: US/11/083,784
 ; PRIOR FILING DATE: 2005-03-18
 ; PRIOR APPLICATION NUMBER: US/10/714,333
```

```

; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 97097
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97097
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

Qy      91 CCGGGAACCGUCACUCU 109
Db      1 CCGGGAACCGUCACUCU 19
```

RESULT 698

```

US-11-083-784-97098
; Sequence 97098, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 97098
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97098
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

Qy      284 UCAACAAGCAGCUGAAGAC 302
Db      1 UCAACAAGCAGCUGAAGAC 19
```

RESULT 699

```

US-11-101-244-96999
; Sequence 96999, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
```

```

; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 96999
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-96999
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

Qy      306 CAACAACUACUCCUCUUA 324
Db      1 CAACAACUACUCCUCUUA 19
```

RESULT 700

```

US-11-101-244-97000
; Sequence 97000, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 97000
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97000
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

Qy      296 UGAAGACGUCACAACTUA 314
Db      1 UGAAGACGUCACAACTUA 19
```

RESULT 701

```

US-11-101-244-97001
; Sequence 97001, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
```

```

; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97001
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97001
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      655 GGAGAGUGGCUCAUUCAGU 673
      |||
Db      1 GGAGAGUGGCUCAUUCAGU 19
```

```

RESULT 702
US-11-101-244-97002
; Sequence 97002, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97002
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97002
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      815 GGACAGAGCGCAGACAGA 833
      |||
Db      1 GGACAGAGCGCAGACAGA 19
```

```

RESULT 703
US-11-101-244-97003
; Sequence 97003, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: US/11/101,244
```

```

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97003
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97003
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1439 GGAUGUCCUGGUCAGGA 1457
      |||
Db      1 GGAUGUCCUGGUCAGGA 19
```

```

RESULT 704
US-11-101-244-97004
; Sequence 97004, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97004
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97004
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      620 GGCATACUUGUGGAAA 638
      |||
Db      1 GGCATACUUGUGGAAA 19
```

```

RESULT 705
US-11-101-244-97005
; Sequence 97005, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
```

```
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97005
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97005

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 546 AAAGAGAGCCGGUGUGAUG 564
DB 1 AAAGAGAGCCGGUGUGAUG 19

RESULT 706
US-11-101-244-97006
; Sequence 97006, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97006
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97006

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 265 GUAAUUGUGUCAUUUUAAGG 283
DB 1 GUAAUUGUGUCAUUUUAAGG 19

RESULT 707
US-11-101-244-97007
; Sequence 97007, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137
```

```
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97007
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97007

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 254 GCAACAUCCUGGUAAUUGU 272
DB 1 GCAACAUCCUGGUAAUUGU 19

RESULT 708
US-11-101-244-97008
; Sequence 97008, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97008
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97008

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1653 CAGAACCAUUCUACAAGU 1671
DB 1 CAGAACCAUUCUACAAGU 19

RESULT 709
US-11-101-244-97009
; Sequence 97009, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
```

```
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97009
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97009
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy          1412 CCAGAGUCGACUACUAA 1430
Db          1 CCAGAGUCGACUACUAA 19
```

RESULT 710

```
US-11-101-244-97010
; Sequence 97010, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97010
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97010
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy          1305 GGACACAGCUGAUCUUCU 1323
Db          1 GGACACAGCUGAUCUUCU 19
```

RESULT 711

```
US-11-101-244-97011
; Sequence 97011, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
```

```
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97011
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97011
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy          656 GAGAGUGUCUACUACUGU 674
Db          1 GAGAGUGUCUACUACUGU 19
```

RESULT 712

```
US-11-101-244-97012
; Sequence 97012, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97012
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97012
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy          45 CAUCAGCUCUCCUGGUA 63
Db          1 CAUCAGCUCUCCUGGUA 19
```

RESULT 713

```
US-11-101-244-97013
; Sequence 97013, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
```

```
; SOFTWARE: Proprietary
; SEQ ID NO 97013
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97013
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY          509 UCACGAGCGCGCUCACGUA 527
Db          1 UCACGAGCGCGCUCACGUA 19
```

```
RESULT 714
US-11-101-244-97014
; Sequence 97014, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97014
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97014
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY          204 GGUUCUUCATGCGCUUCUUA 222
Db          1 GGUUCUUCATGCGCUUCUUA 19
```

```
RESULT 715
US-11-101-244-97015
; Sequence 97015, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
```

```
; SEQ ID NO 97015
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97015
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY          1628 GCUAUGCUCUGGCAACAA 1646
Db          1 GCUAUGCUCUGGCAACAA 19
```

```
RESULT 716
US-11-101-244-97016
; Sequence 97016, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97016
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97016
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY          754 UGGAGAGUCCUAUAGGAAA 772
Db          1 UGGAGAGUCCUAUAGGAAA 19
```

```
RESULT 717
US-11-101-244-97017
; Sequence 97017, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97017
```

LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-97017

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
456 CAUGCCUCGUGAUAU 474
1 CAUGCCUCGUGAUAU 19

RESULT 718
US-11-101-244-97018
Sequence 97018, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 97018
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-97018

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
92 GCGAACGCGACUCACUUU 110
1 GCGAACGCGACUCACUUU 19

RESULT 719
US-11-101-244-97019
Sequence 97019, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 97019
LENGTH: 19

TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-97019

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
129 UCGAGCAGCUGGCAUUTC 147
1 UCGAGCAGCUGGCAUUTC 19

RESULT 720
US-11-101-244-97020
Sequence 97020, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 97020
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-97020

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
579 GGUCATCUCGCUUUGUCCUU 597
1 GGUCATCUCGCUUUGUCCUU 19

RESULT 721
US-11-101-244-97021
Sequence 97021, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 97021
LENGTH: 19
TYPE: RNA

ORGANISM: Homo sapiens
US-11-101-244-97021

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 455 GCAUGCCUCUGUAVGAA 473
|||||
Db 1 GCAUGCCUCUGUAVGAA 19

RESULT 722
US-11-101-244-97022

Sequence 97022, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:

APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US

CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 97022

LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-97022

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1723 CAGAGCAGUCGUCUUAUU 1741
|||||
Db 1 CAGAGCAGUCGUCUUAUU 19

RESULT 723
US-11-101-244-97023

Sequence 97023, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:

APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US

CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 97023

LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens

US-11-101-244-97023

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1485 GAUCUCUGCCUUCUAC 1503
|||||
Db 1 GAUCUCUGCCUUCUAC 19

RESULT 724
US-11-101-244-97024

Sequence 97024, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:

APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US

CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 97024

LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-97024

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 880 GAUCUCACAGCAAGCA 898
|||||
Db 1 GAUCUCACAGCAAGCA 19

RESULT 725
US-11-101-244-97025

Sequence 97025, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:

APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US

CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 97025

LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-97025

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 720 UUAUAGCCUGUACCAU 738
|||||
DB 1 UUAUAGCCUGUACCAU 19

RESULT 726

US-11-101-244-97026
; Sequence 97026, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:

; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97026
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-11-101-244-97026

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 530 GAGCCAAACGAACAACAA 548
|||||
DB 1 GAGCCAAACGAACAACAA 19

RESULT 727

US-11-101-244-97027
; Sequence 97027, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:

; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97027
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-11-101-244-97027

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 275 CAUUAAGGUCACAAAGCA 293
|||||
DB 1 CAUUAAGGUCACAAAGCA 19

RESULT 728

US-11-101-244-97028
; Sequence 97028, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:

; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97028
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-11-101-244-97028

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 534 CAACGACACAAAGACA 552
|||||
DB 1 CAACGACACAAAGACA 19

RESULT 729

US-11-101-244-97029
; Sequence 97029, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:

; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97029
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-11-101-244-97029

Query Match 1.1%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1722 GCAGAGACAGCGGUCAUU 1740
Db 1 GCAGAGACAGCGGUCAUU 19

RESULT 730

US-11-101-244-97030
; Sequence 97030, Application US/11101244
; Publication No. US20050246794A1

GENERAL INFORMATION:

APPLICANT: Dharmcon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 97030
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-97030

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 971 CCGAGCAGAUAGCACAAGA 989
Db 1 CCGAGCAGAUAGCACAAGA 19

RESULT 731

US-11-101-244-97031
; Sequence 97031, Application US/11101244
; Publication No. US20050246794A1

GENERAL INFORMATION:

APPLICANT: Dharmcon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 97031
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-97031

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 665 UCAUUCAGUUCUCCAGUGA 683
Db 1 UCAUUCAGUUCUCCAGUGA 19

RESULT 732

US-11-101-244-97032
; Sequence 97032, Application US/11101244
; Publication No. US20050246794A1

GENERAL INFORMATION:

APPLICANT: Dharmcon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 97032
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-97032

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 532 GCCAAACGAAACAACAAGA 550
Db 1 GCCAAACGAAACAACAAGA 19

RESULT 733

US-11-101-244-97033
; Sequence 97033, Application US/11101244
; Publication No. US20050246794A1

GENERAL INFORMATION:

APPLICANT: Dharmcon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 97033
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-97033

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 453 CAGCAUGCCUCUGUAUG 471
|||
Db 1 CAGCAUGCCUCUGUAUG 19

RESULT 734
US-11-101-244-97034
; Sequence 97034, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97034
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97034

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0;
Qy 253 GCGAACAUCCUGUAUUG 271
|||
Db 1 GCGAACAUCCUGUAUUG 19

RESULT 735
US-11-101-244-97035
; Sequence 97035, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97035
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97035

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0;

Qy 1419 UCAGAUCAUCUAGCGGAAA 1437
|||
Db 1 UCAGAUCAUCUAGCGGAAA 19

RESULT 736
US-11-101-244-97036
; Sequence 97036, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97036
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97036

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0;
Qy 1233 GAAAGCGUGGACGAUGGA 1251
|||
Db 1 GAAAGCGUGGACGAUGGA 19

RESULT 737
US-11-101-244-97037
; Sequence 97037, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97037
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97037

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0;
Qy 525 GUACGAGCCAAAGACA 543

Db 1 GUBCCGAGCCAAACGACA 19

```
RESULT 738
US-11-101-244-97038
; Sequence 97038, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97038
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97038
```

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 876 UUACGACUUCACAGCAA 894
Db 1 UURCGACUUCACAGCAA 19

```
RESULT 739
US-11-101-244-97039
; Sequence 97039, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97039
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97039
```

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 758 GGAUCUUAAGAAACUGA 776
Db 1 GGAUCUUAAGAAACUGA 776

Db 1 GGAUCUUAAGAAACUGA 19

```
RESULT 740
US-11-101-244-97040
; Sequence 97040, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97040
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97040
```

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 207 CUUCAGUCGCUUCUUAACG 225
Db 1 CUUCAGUCGCUUCUUAACG 19

```
RESULT 741
US-11-101-244-97041
; Sequence 97041, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97041
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97041
```

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 677 UCAGUGAGCCCAACUUAAC 695
Db 1 UCAGUGAGCCCAACUUAAC 19

RESULT 742

```
US-11-101-244-97042
; Sequence 97042, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97042
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97042
```

Query Match

Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 483 CAUCAGCTUUGACAGUAC 501
|||||

Db 1 CAUCAGCTUUGACAGUAC 19

RESULT 743

```
US-11-101-244-97043
; Sequence 97043, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97043
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97043
```

Query Match

Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1655 GAACCACTUUGAAGUCU 1673
|||||

Db 1 GAACCACTUUGAAGUCU 19

RESULT 744

```
US-11-101-244-97044
; Sequence 97044, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97044
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97044
```

Query Match

Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 988 GACCAAGCAGCAGUGACA 1006
|||||

Db 1 GACCAAGCAGCAGUGACA 19

RESULT 745

```
US-11-101-244-97045
; Sequence 97045, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97045
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97045
```

Query Match

Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 454 AGCAAGCCTCUGUAUGA 472
|||||

Db 1 AGCAAGCCTCUGUAUGA 19

RESULT 746

```
US-11-101-244-97046
; Sequence 97046, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97046
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97046
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 407 UAGGAACTUGGCTCUGCA 425

Db 1 UAGGAACTUGGCTCUGCA 19

RESULT 747

```
US-11-101-244-97047
; Sequence 97047, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97047
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97047
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 365 UGAUCUUTUUGACACUA 383

Db 1 UGAUCUUTUUGACACUA 19

RESULT 748

US-11-101-244-97048

```
; Sequence 97048, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97048
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97048
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1410 GACCAAGUACAUCAU 1428

Db 1 GACCAAGUACAUCAU 19

RESULT 749

```
US-11-101-244-97049
; Sequence 97049, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97049
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97049
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1139 CCACCAAGUACCAUCC 1157

Db 1 CCACCAAGUACCAUCC 19

RESULT 750

US-11-101-244-97050

```
; Sequence 97050, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97050
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97050
```

```
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1082 CGAGAGCCCAUCCUCCAU 1100
Db 1 CGAGAGCCCAUCCUCCAU 19
```

```
RESULT 751
US-11-101-244-97051
; Sequence 97051, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97051
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97051
```

```
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 307 AACACUACUCCUCCUUA 325
Db 1 AACACUACUCCUCCUUA 19
```

```
RESULT 752
US-11-101-244-97052
; Sequence 97052, Application US/11101244
```

```
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97052
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97052
```

```
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 261 CCUGGUAUUGUGUCAUU 279
Db 1 CCUGGUAUUGUGUCAUU 19
```

```
RESULT 753
US-11-101-244-97053
; Sequence 97053, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97053
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97053
```

```
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1586 GCUACUGGUGGUCUACAU 1604
Db 1 GCUACUGGUGGUCUACAU 19
```

```
RESULT 754
US-11-101-244-97054
; Sequence 97054, Application US/11101244
; Publication No. US20050246794A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97054
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97054

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      482 UCAUCAGCUCUUGACAGAU 500
DB      1 UCAUCAGCUCUUGACAGAU 19

RESULT 755
US-11-101-244-97055
; Sequence 97055, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97055
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97055

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1307 ACACAGCUGAAGACUCUCGA 1325
DB      1 ACACAGCUGAAGACUCUCGA 19

RESULT 756
US-11-101-244-97056
; Sequence 97056, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
```

```

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97056
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97056

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      544 ACAAGAGAGCCGCGUCUGA 562
DB      1 ACAAGAGAGCCGCGUCUGA 19

RESULT 757
US-11-101-244-97057
; Sequence 97057, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97057
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97057

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      361 UCAUGAUAUCUGUUGCGA 379
DB      1 UCAUGAUAUCUGUUGCGA 19

RESULT 758
US-11-101-244-97058
; Sequence 97058, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
```

```
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97058
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97058
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1517 CAUACAACUACUGGUCU 1535
      |||||
Db      1 CAUACAACUACUGGUCU 19
```

```
RESULT 759
US-11-101-244-97059
; Sequence 97059, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97059
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97059
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1489 UUGCUGCCUUCACUACUCA 1507
      |||||
Db      1 UUGCUGCCUUCACUACUCA 19
```

```
RESULT 760
US-11-101-244-97060
; Sequence 97060, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
```

```
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97060
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97060
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      721 UAUAGCCUGUCACCAUUA 739
      |||||
Db      1 UAUAGCCUGUCACCAUUA 19
```

```
RESULT 761
US-11-101-244-97061
; Sequence 97061, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97061
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97061
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      549 GAGAGCCGGUGUGAUGAUC 567
      |||||
Db      1 GAGAGCCGGUGUGAUGAUC 19
```

```
RESULT 762
US-11-101-244-97062
; Sequence 97062, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
```

```

; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97062
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97062
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      486 CAGCUUUGACAGUACUU 504
DB      1 CAGCUUUGACAGUACUU 19
```

RESULT 763

```
US-11-101-244-97063
; Sequence 97063, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97063
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97063
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1652 UCAGAACGACUUCAGAU 1670
DB      1 UCAGAACGACUUCAGAU 19
```

RESULT 764

```
US-11-101-244-97064
; Sequence 97064, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
```

```

; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97064
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97064
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1646 AAACAUCUAGAACCAUCUU 1664
DB      1 AAACAUCUAGAACCAUCUU 19
```

RESULT 765

```
US-11-101-244-97065
; Sequence 97065, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97065
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97065
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1314 UAAGACUUCUAGCGUAC 1332
DB      1 UAAGACUUCUAGCGUAC 19
```

RESULT 766

```
US-11-101-244-97066
; Sequence 97066, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
```

```

; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97066
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97066

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      998 GCAGUGACAGUGGACAA 1016
Db      1 GCAGUGACAGUGGACAA 19
```

```

RESULT 767
US-11-101-244-97067
; Sequence 97067, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97067
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97067
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      255 CAACAUCCTUGGUAUUGUG 273
Db      1 CAACAUCCTUGGUAUUGUG 19
```

```

RESULT 768
US-11-101-244-97068
; Sequence 97068, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
```

```

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97068
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97068

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      330 GGCCUGGCGGATCUGAUU 348
Db      1 GGCCUGGCGGATCUGAUU 19
```

```

RESULT 769
US-11-101-244-97069
; Sequence 97069, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97069
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97069
```

```

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      619 UGGCAUACUUGUGGAA 637
Db      1 UGGCAUACUUGUGGAA 19
```

```

RESULT 770
US-11-101-244-97070
; Sequence 97070, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97070
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97070

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      101 UCACUCACUUCGCGCAGCTA 119
Db      1 UCACUCACUUCGCGCAGCTA 19

RESULT 771
US-11-101-244-97071
; Sequence 97071, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97071
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97071

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      886 CAACGCAAAAGCAUGAAAC 904
Db      1 CAACGCAAAAGCAUGAAAC 19

RESULT 772
US-11-101-244-97072
; Sequence 97072, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
```

```
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97072
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97072

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      756 GAGGAUCUUAAGGAACU 774
Db      1 GAGGAUCUUAAGGAACU 19

RESULT 773
US-11-101-244-97073
; Sequence 97073, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97073
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97073

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      752 ACUGAGAUUUAAGGA 770
Db      1 ACUGAGAUUUAAGGA 19

RESULT 774
US-11-101-244-97074
; Sequence 97074, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
```

```
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97074
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97074
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      572 UGGCTUGGUCACUCCCU 590
DB      1 UGGCTUGGUCACUCCCU 19
```

```
RESULT 775
US-11-101-244-97075
; Sequence 97075, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97075
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97075
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      297 GAAGACGUCACACUAC 315
DB      1 GAAGACGUCACACUAC 19
```

```
RESULT 776
US-11-101-244-97076
; Sequence 97076, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
```

```
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97076
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97076
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1754 CACCCGAGCAGCCUUGUA 1772
DB      1 CACCCGAGCAGCCUUGUA 19
```

```
RESULT 777
US-11-101-244-97077
; Sequence 97077, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97077
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97077
```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1551 UGACAGCUCACUACCCAA 1569
DB      1 UGACAGCUCACUACCCAA 19
```

```
RESULT 778
US-11-101-244-97078
; Sequence 97078, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
```

```
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97078
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97078
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0;
```

```
QY      308 ACAACUACUCCUCCUUAAG 326
      |||||
Db      1 ACAACUACUCCUCCUUAAG 19
```

RESULT 779

```
US-11-101-244-97079
; Sequence 97079, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97079
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97079
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0;
```

```
QY      109 UUCGGCAGCUACAUUGUU 127
      |||||
Db      1 UUCGGCAGCUACAUUGUU 19
```

RESULT 780

```
US-11-101-244-97080
; Sequence 97080, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
```

```
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97080
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97080
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0;
```

```
QY      1473 GACCCUACAGGCGAUCUG 1491
      |||||
Db      1 GACCCUACAGGCGAUCUG 19
```

RESULT 781

```
US-11-101-244-97081
; Sequence 97081, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97081
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97081
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0;
```

```
QY      451 GCCAGCAUAGCCUCUGUA 469
      |||||
Db      1 GCCAGCAUAGCCUCUGUA 19
```

RESULT 782

```
US-11-101-244-97082
; Sequence 97082, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
```

```
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 97082
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97082
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1203 GGAGAGAAAGCCGACAAG 1221
Db      1 GGAGAGAAAGCCGACAAG 19
```

RESULT 783

```
US-11-101-244-97083
; Sequence 97083, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 97083
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97083
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      896 GCAUGAAGCGUCGACAG 914
Db      1 GCAUGAAGCGUCGACAG 19
```

RESULT 784

```
US-11-101-244-97084
; Sequence 97084, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
```

```
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 97084
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97084
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      816 GACAGAGCGAGACAGAA 834
Db      1 GACAGAGCGAGACAGAA 19
```

RESULT 785

```
US-11-101-244-97085
; Sequence 97085, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 97085
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97085
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      432 GCUUGCAUUGACUACGUA 450
Db      1 GCUUGCAUUGACUACGUA 19
```

RESULT 786

```
US-11-101-244-97086
; Sequence 97086, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
```

```
; SOFTWARE: Proprietary
; SEQ ID NO 97086
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97086
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      23 CAACCCGCGCCUUGUCC 41
      |||
Db      1 CAACCCGCGCCUUGUCC 19
```

RESULT 787

```
US-11-101-244-97087
; Sequence 97087, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97087
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97087
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1537 GUGAACCCUUGUGACA 1555
      |||
Db      1 GUGAACCCUUGUGACA 19
```

RESULT 788

```
US-11-101-244-97088
; Sequence 97088, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
```

```
; SEQ ID NO 97088
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97088
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1271 UCUCCAAGCUCUCCAUCCA 1289
      |||
Db      1 UCUCCAAGCUCUCCAUCCA 19
```

RESULT 789

```
US-11-101-244-97089
; Sequence 97089, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97089
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97089
```

```
Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      680 GUGAGCCCAUCAUACUUU 698
      |||
Db      1 GUGAGCCCAUCAUACUUU 19
```

RESULT 790

```
US-11-101-244-97090
; Sequence 97090, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
```

LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-97090

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 373 UUUAGACCCACUACUCA 391
Db 1 UUUAGACCCACUACUCA 19

RESULT 791
US-11-101-244-97091

Sequence 97091, Application US/11101244
Publication No. US20050246794A1

GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 97091
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-97091

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 759 GAUCUUAAGGAACUGAA 777
Db 1 GAUCUUAAGGAACUGAA 19

RESULT 792
US-11-101-244-97092

Sequence 97092, Application US/11101244
Publication No. US20050246794A1

GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 97092
LENGTH: 19

TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-97092

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 262 CUGGUAUUGUGCAUUUA 280
Db 1 CUGGUAUUGUGCAUUUA 19

RESULT 793
US-11-101-244-97093

Sequence 97093, Application US/11101244
Publication No. US20050246794A1

GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 97093
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-97093

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 249 CAUCGGCAACUCCUGUA 267
Db 1 CAUCGGCAACUCCUGUA 19

RESULT 794
US-11-101-244-97094

Sequence 97094, Application US/11101244
Publication No. US20050246794A1

GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 97094
LENGTH: 19
TYPE: RNA

; ORGANISM: Homo sapiens
US-11-101-244-97094

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 493 GACGAGUACUUUCCAUCA 511
|||||
DB 1 GACGAGUACUUUCCAUCA 19

RESULT 795

US-11-101-244-97095
; Sequence 97095, Application US/11101244
; Publication No. US20050246794A1

; GENERAL INFORMATION:

; APPLICANT: Dharmoon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/101,244

; PRIOR FILING DATE: 2005-04-07

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 97095

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-97095

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 452 CCAGCAATGCCUCUGUUAU 470
|||||
DB 1 CCAGCAATGCCUCUGUUAU 19

RESULT 796

US-11-101-244-97096
; Sequence 97096, Application US/11101244
; Publication No. US20050246794A1

; GENERAL INFORMATION:

; APPLICANT: Dharmoon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/101,244

; PRIOR FILING DATE: 2005-04-07

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 97096

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-97096

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1407 GAGAGCCGAGAGUCAGAU 1425
|||||
DB 1 GAGAGCCGAGAGUCAGAU 19

RESULT 797

US-11-101-244-97097
; Sequence 97097, Application US/11101244
; Publication No. US20050246794A1

; GENERAL INFORMATION:

; APPLICANT: Dharmoon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/101,244

; PRIOR FILING DATE: 2005-04-07

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 97097

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-97097

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 91 CCGGAGACCGUCACUCUAU 109
|||||
DB 1 CCGGAGACCGUCACUCUAU 19

RESULT 798

US-11-101-244-97098
; Sequence 97098, Application US/11101244
; Publication No. US20050246794A1

; GENERAL INFORMATION:

; APPLICANT: Dharmoon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/101,244

; PRIOR FILING DATE: 2005-04-07

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 97098

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-97098

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 284 UCACACGACGCGUAGAC 302

DB 1 UCACACGACGCGUAGAC 19

RESULT 799

US-11-127-877-144

; Sequence 144, Application US/11127877
; Publication No. US20050287565A1

; GENERAL INFORMATION:

; APPLICANT: Merchiers, Pascal G.

; APPLICANT: Hoffmann, Marcel G.

; APPLICANT: Spittaels, Koentraad F. F.

; TITLE OF INVENTION: Methods, Compositions and Compound Assays For Inhibiting
; FILE REFERENCE: P27, 800-B USA

; CURRENT APPLICATION NUMBER: US/11/127,877

; PRIOR FILING DATE: 2005-05-12

; PRIOR APPLICATION NUMBER: 60/570,352

; PRIOR FILING DATE: 2004-05-12

; PRIOR APPLICATION NUMBER: 60/603,948

; NUMBER OF SEQ ID NOS: 590

; SOFTWARE: Patentin version 3.3

; SEQ ID NO 144

; LENGTH: 19

; TYPE: DNA

; ORGANISM: Homo sapiens

US-11-127-877-144

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 291 GCAGCTGAAGACGCGUAC 309

DB 1 GCAGCTGAAGACGCGUAC 19

RESULT 800

US-11-127-877-145

; Sequence 145, Application US/11127877
; Publication No. US20050287565A1

; GENERAL INFORMATION:

; APPLICANT: Merchiers, Pascal G.

; APPLICANT: Hoffmann, Marcel G.

; APPLICANT: Spittaels, Koentraad F. F.

; TITLE OF INVENTION: Methods, Compositions and Compound Assays For Inhibiting
; FILE REFERENCE: P27, 800-B USA

; CURRENT APPLICATION NUMBER: US/11/127,877

; PRIOR FILING DATE: 2005-05-12

; PRIOR APPLICATION NUMBER: 60/570,352

; PRIOR FILING DATE: 2004-05-12

; PRIOR APPLICATION NUMBER: 60/603,948

; NUMBER OF SEQ ID NOS: 590

; SOFTWARE: Patentin version 3.3

; SEQ ID NO 145

; LENGTH: 19

; TYPE: DNA

; ORGANISM: Homo sapiens

US-11-127-877-145

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;

Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 549 GAGAGCGGUGUGAUGAUC 567

DB 1 GAGAGCGGUGUGAUGAUC 19

RESULT 801

US-11-127-877-146

; Sequence 146, Application US/11127877
; Publication No. US20050287565A1

; GENERAL INFORMATION:

; APPLICANT: Merchiers, Pascal G.

; APPLICANT: Hoffmann, Marcel G.

; APPLICANT: Spittaels, Koentraad F. F.

; TITLE OF INVENTION: Methods, Compositions and Compound Assays For Inhibiting
; FILE REFERENCE: P27, 800-B USA

; CURRENT APPLICATION NUMBER: US/11/127,877

; PRIOR FILING DATE: 2005-05-12

; PRIOR APPLICATION NUMBER: 60/570,352

; PRIOR FILING DATE: 2004-05-12

; PRIOR APPLICATION NUMBER: 60/603,948

; NUMBER OF SEQ ID NOS: 590

; SOFTWARE: Patentin version 3.3

; SEQ ID NO 146

; LENGTH: 19

; TYPE: DNA

; ORGANISM: Homo sapiens

US-11-127-877-146

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1014 CAACAUGAUGCGUGGCC 1032

DB 1 CAACAUGAUGCGUGGCC 19

RESULT 802

US-11-127-877-147

; Sequence 147, Application US/11127877
; Publication No. US20050287565A1

; GENERAL INFORMATION:

; APPLICANT: Merchiers, Pascal G.

; APPLICANT: Hoffmann, Marcel G.

; APPLICANT: Spittaels, Koentraad F. F.

; TITLE OF INVENTION: Methods, Compositions and Compound Assays For Inhibiting
; FILE REFERENCE: P27, 800-B USA

; CURRENT APPLICATION NUMBER: US/11/127,877

; PRIOR FILING DATE: 2005-05-12

; PRIOR APPLICATION NUMBER: 60/570,352

; PRIOR FILING DATE: 2004-05-12

; PRIOR APPLICATION NUMBER: 60/603,948

; NUMBER OF SEQ ID NOS: 590

; SOFTWARE: Patentin version 3.3

; SEQ ID NO 147

; LENGTH: 19

; TYPE: DNA

; ORGANISM: Homo sapiens

US-11-127-877-147

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1581 UCUGGCGUACUGCGUGC 1599

```
Db          1 TCTGGGCTACTGGCTGTGC 19
          :|:||||:|:||||:|:|
RESULT 803
US-10-798-090-207
; Sequence 207, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 207
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sRNA sense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-798-090-207

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY          17 ACAGUNCAACUCCUCCUU 35
          |||
Db          1 ACAGUNCAACUCCUCCUU 19

RESULT 804
US-10-798-090-208
; Sequence 208, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)

; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 208
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sRNA sense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-798-090-208

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY          21 UACACCCUCCUCCUCCUU 39
          |||
Db          1 UACACCCUCCUCCUCCUU 19

RESULT 805
US-10-798-090-209
; Sequence 209, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
```

```

; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 209
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc.feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-798-090-209

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      315 CUCCUCUUAAGCCUGGCC 333
DB      1 CUCCUCUUAAGCCUGGCC 19

RESULT 806
US-10-798-090-210
; Sequence 210, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 210
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
```

```

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc.feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-798-090-210

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      317 UCCUCUUAAGCCUGGCCUG 335
DB      1 UCCUCUUAAGCCUGGCCUG 19

RESULT 807
US-10-798-090-211
; Sequence 211, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sitma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 211
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc.feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-798-090-211

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      975 GCAGATGACCAAGACCCAC 993
DB      1 GCAGATGACCAAGACCCAC 19
```

RESULT 808
US-10-798-090-212
; Sequence 212, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 212
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sRNA sense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-798-090-212

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1712 AGCAGUACGACGACGACA 1730
Db 1 AGCAGUACGACGACGACA 19
|||||

RESULT 809
US-10-798-090-213
; Sequence 213, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090

; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 213
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sRNA sense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-798-090-213

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1714 CAGUACGACGACGACGU 1732
Db 1 CAGUACGACGACGACGU 19
|||||

RESULT 810
US-10-798-090-214
; Sequence 214, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20

PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 214
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
US-10-798-090-214

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02; Mismatches 0; Indels 0; Gaps 0;

Qy 1715 AGUACGACGAGACGACGUC 1733
DB 1 AGUACGACGAGACGAGUC 19

RESULT 811

US-10-798-090-215/c
Sequence 215, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (siNA)
FILE REFERENCE: 400/147 (MHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 215
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region

FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
US-10-798-090-215

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.1e+02; Mismatches 5; Indels 0; Gaps 0;

Qy 17 ACAGUACACCTGCGCTTU 35
DB 19 ACAGTACACCTGCGCTT 1

RESULT 812

US-10-798-090-216/c
Sequence 216, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (siNA)
FILE REFERENCE: 400/147 (MHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 216
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region

FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
US-10-798-090-216

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 5.1e+02; Mismatches 8; Indels 0; Gaps 0;

Qy 21 UACACCGCGCCUUGUU 39
DB 19 TACACCTGCGCTTGT 1

```
RESULT 813
US-10-798-090-217/C
; Sequence 217, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 217
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-798-090-217

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred.No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      315 CUUCUCUUAAGCCUGGCC 333
DB      19 CTCCTCTTAAGCCTGGCC 1

RESULT 814
US-10-798-090-218/C
; Sequence 218, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
```

```
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 218
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-798-090-218

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred.No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      317 UCCUCUUAAGCCUGGCCUG 335
DB      19 TCCTCTTAAGCCTGGCCTG 1

RESULT 815
US-10-798-090-219/C
; Sequence 219, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
```

```

; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See file Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 219
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n is a, c, g, or u
US-10-798-090-219

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      975 GCAGAUAGACCAAGACCAC 993
      |||||:|||||
Db      19 GCAGATGACCAAGACCAC 1

RESULT 816
US-10-798-090-220/c
; Sequence 220, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See file Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 220
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
```

```

; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-798-090-220

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1712 AGAGUACGACGAGAGACA 1730
      |||||:|||||
Db      19 AGAGTACGACGAGAGACA 1

RESULT 817
US-10-798-090-221/c
; Sequence 221, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See file Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 221
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-798-090-221

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1714 CAGUACGACGACGAGAGU 1732
      |||||:|||||
Db      19 CAGTACGACGACGAGAGT 1

RESULT 818
US-10-798-090-222/c
```

```
; Sequence 222, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: MCSwigen, Ivan
; APPLICANT: Richards, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1nA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 222
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-798-090-222

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1715 AGUACCAGACGACGACGUC 1733
DB      19  AGTACCAGACGACGACGTC 1

RESULT 819
US-10-798-090-223
; Sequence 223, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, James
; APPLICANT: MCSwigen, Ivan
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1nA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
```

```
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 223
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; NAME/KEY: misc feature
; LOCATION: (2)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (7)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (10)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-223

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      17  ACAGUCACACUCCGCCUUU 35
DB      1  ACAGUCACACUCCGCCUUU 19

RESULT 820
US-10-798-090-224
; Sequence 224, Application US/10798090
; Publication No. US20050014172A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MSB04-183)
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 224
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(3)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety
; US-10-798-090-224

```

```

Query Match          1.1%; Score 19; DB 1; Length 21;
Best local Similarity 100.0%; Pred. No. 5,1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      21 UGACACCGCCGCUUUGUU 39
      |||||
Db       1 UGACACCGCCGCUUUGUU 19

RESULT 821
US-10-798-090-225
; Sequence 225, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MSB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 225
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(9)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(1)
; OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(15)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:

```

```
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-225
```

```
Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      315 CUCCUCUUAAGCCUGGCC 333
DB      1 CUCCUCUUAAGCCUGGCC 19
```

```
RESULT 822
US-10-798-090-226
; Sequence 226, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1nA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 226
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; NAME/KEY: misc_feature
; LOCATION: (11)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(18)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
```

```
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-226
```

```
Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      317 UCCUCUUAAGCCUGGCCUG 335
DB      1 UCCUCUUAAGCCUGGCCUG 19
```

```
RESULT 823
US-10-798-090-227
; Sequence 227, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1nA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 227
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; NAME/KEY: misc_feature
; LOCATION: (2)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
```

```
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (10)..(11)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (16)..(17)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-227
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 975 GCAGAGCAGCAGACAC 993

Db 1 GCAGAGCAGCAGACAC 19

RESULT 824

US-10-798-090-228

```
Sequence 228, Application US/10798090
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See file wrapper or PALM.
SOFTWARE: Patent version 3.3
SEQ ID NO 228
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
```

```
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc feature
LOCATION: (3)..(3)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (6)..(6)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (8)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (12)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (18)..(18)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-228
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1712 AGCAGUACGACGAGACA 1730

Db 1 AGCAGUACGACGAGACA 19

RESULT 825

US-10-798-090-229

```
Sequence 229, Application US/10798090
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
```

```
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO: 229
;; LENGTH: 21
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (1)..(1)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (1)..(1)
;; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (4)..(4)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (6)..(7)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (10)..(10)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (16)..(16)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (19)..(19)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (20)..(21)
;; OTHER INFORMATION: n stands for thymidine
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (21)..(21)
;; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-229

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1714 CAGUACGACGACGACAGU 1732
Db      1 CAGUACGACGACGACAGU 19

RESULT 826
US-10-798-090-230
;; Sequence 230, Application US/10798090
;; Publication No. US20050014172A1
;; GENERAL INFORMATION:
;; APPLICANT: Sigma Therapeutics, Inc.
;; APPLICANT: Richards, Ivan
;; APPLICANT: MCSwigen, James
;; TITLE OF INVENTION: RNA interference Mediated Inhibition of Muscarinic Colinergic
;; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
;; TITLE OF INVENTION: (siNA)
```

```
;; FILE REFERENCE: 400/147 (MBH04-183)
;; CURRENT APPLICATION NUMBER: US/10798,090
;; CURRENT FILING DATE: 2004-03-11
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO: 230
;; LENGTH: 21
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (1)..(1)
;; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (3)..(3)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (5)..(6)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (9)..(9)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (15)..(15)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (18)..(19)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (20)..(21)
;; OTHER INFORMATION: n stands for thymidine
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (21)..(21)
;; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-230

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1715 AGUACGACGACGACGUC 1733
Db      1 AGUACGACGACGACGUC 19
```

RESULT 827
US-10-798-090-231/c
Sequence 231, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (sRNA)
FILE REFERENCE: 400/147 (MHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 231
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(6)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(14)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(17)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage

US-10-798-090-231
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 17 ACAGUACAACCCUGCCUUU 35
|||||:|||||:|||||:
Db 19 ACAGTACAACCTGCCTT 1
RESULT 828
US-10-798-090-232/c
Sequence 232, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (sRNA)
FILE REFERENCE: 400/147 (MHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 232
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(16)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(18)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)

```

; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-798-090-232

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 5.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy      21  UGACACCGCCGCGGCGGCGG 39
Db      19  TACAACCTGCGCTTGTGT 1

RESULT 829
US-10-798-090-233/c
; Sequence 233, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 233
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature

; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-798-090-233

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy      315  CUUCCUUAUAGCCGCGCC 333
Db      19  CTTCCCTTAACCTGCGCC 1

RESULT 830
US-10-798-090-234/c
; Sequence 234, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 234
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
```

LOCATION: (20)..(21)
OTHER INFORMATION: n strands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-798-090-234

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 317 UCCUCUUAAGCCUGGCTG 335
Db 19 TCCTTTAGCCTGCGCTG 1

RESULT 831
US-10-798-090-235/c
Sequence 235, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Cholinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (sRNA)
FILE REFERENCE: 400/147 (MEH04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: Patent version 3.3
SEQ ID NO 235
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (2)..(2)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(8)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:

NAME/KEY: misc_feature
LOCATION: (15)..(17)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n strands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-798-090-235

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 975 GCAGUGACCAAGACCAC 993
Db 19 GCAGATGACCAAGACCAC 1

RESULT 832
US-10-798-090-236/c
Sequence 236, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Cholinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (sRNA)
FILE REFERENCE: 400/147 (MEH04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: Patent version 3.3
SEQ ID NO 236
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:

```
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(7)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (9)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(16)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-798-090-236
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred.No.5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
Oy 1712 AGCAGUACGACGACAGACA 1730
Db 19 AGCAGTACGACGACAGACA 1
```

```
RESULT 833
US-10-798-090-237/c
Sequence 237, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (s1nA)
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-06-29
```

```
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 237
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: s1nA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (2)..(3)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(18)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION:
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-798-090-237
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred.No.5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
Oy 1714 CAGUACGACGACGACAGU 1732
Db 19 CAGTACGACGACGACAGT 1
```

```
RESULT 834
US-10-798-090-238/c
Sequence 238, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (s1nA)
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
```

;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 238
;; LENGTH: 21
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
;; NAME/KEY: misc_feature
;; LOCATION: (3)..(4)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (6)..(10)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (12)..(13)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (16)..(16)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (18)..(19)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (20)..(20)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; NAME/KEY: misc_feature
;; LOCATION: (20)..(21)
;; OTHER INFORMATION: n stands for thymidine
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (20)..(20)
;; OTHER INFORMATION: Phosphorothioate 3'-internucleotide linkage
US-10-798-090-238
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1715 AGUACGACGACGACGUC 1733
DB 19 AGTACCAGCAGACGACGTC 1
RESULT 835
US-10-798-090-239
;; Sequence 239, Application US/10798090
;; Publication No. US20050014172A1
;; GENERAL INFORMATION:
;; APPLICANT: Sigma Therapeutics, Inc.
;; APPLICANT: Richards, Ivan
;; APPLICANT: McSwigen, James
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinegic
;; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
;; FILE REFERENCE: 400/147 (MBH04-183)
;; CURRENT APPLICATION NUMBER: US/10/798,090
;; CURRENT FILING DATE: 2004-03-11
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14

;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 239
;; LENGTH: 21
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
;; NAME/KEY: misc_feature
;; LOCATION: (1)..(1)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (1)..(1)
;; OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
;; NAME/KEY: misc_feature
;; LOCATION: (2)..(2)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (3)..(4)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (5)..(5)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (6)..(6)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (7)..(7)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (8)..(9)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (10)..(13)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (14)..(14)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (15)..(19)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature

LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-239

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 17 ACAGUACAACCTGCGCTUU 35
DB 1 ACAGUACAACCTGCGCTUU 19

RESULT 836
US-10-798-090-240
Sequence 240, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/593,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 240
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc_feature
LOCATION: (2)..(2)
OTHER INFORMATION: 2'-deoxy
FEATURE:

NAME/KEY: misc_feature
LOCATION: (3)..(3)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (4)..(5)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-240

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 UACAACCTGCGCTUUUUU 39
DB 1 UACAACCTGCGCTUUUUU 19

RESULT 837
US-10-798-090-241
Sequence 241, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580

PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 241
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sinA sense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(12)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(17)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-241

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 315 CUUCCUUAAGCCUGGCC 333
|||||
Db 1 CUUCCUUAAGCCUGGCC 19

RESULT 838
US-10-798-090-242
Sequence 242, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: SinA Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 242
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sinA sense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(7)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8)..(10)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(15)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(18)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-242

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 317 UCCUUAAGCCUGGCC 335
|||||

Db 1 UCCUCUUAAGCCUGGCCUG 19

```
RESULT 839
US-10-798-090-243
; Sequence 243, Application US/10798090
; Publication No. US20050014172A1
GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 243
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sigma sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(5)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(9)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(11)
```

```
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(15)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety
US-10-798-090-243
```

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 975 GCAGATGACCAAGACCAC 993
Db 1 GCAGATGACCAAGACCAC 19

```
RESULT 840
US-10-798-090-244
; Sequence 244, Application US/10798090
; Publication No. US20050014172A1
GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
```

```
/ SEQ ID NO 244
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: sinA sense region
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (1)-(2)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (1)-(1)
/ OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (3)-(3)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (4)-(5)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (6)-(6)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (7)-(7)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (8)-(9)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (10)-(11)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (12)-(12)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (13)-(17)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (18)-(18)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (19)-(19)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (20)-(21)
/ OTHER INFORMATION: n stands for thymidine
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (21)-(21)
/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
/ US-10-798-090-244
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1712 AGCAGUACGACGAGACA 1730
Db 1 AGCAGUACGACGAGACA 19
```

```
RESULT 841
US-10-798-090-245
/ Sequence 245. Application US/10798090
/ Publication No. US2005004172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: MCSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Cholinergic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ TITLE OF INVENTION: (SINA)
/ FILE REFERENCE: 400/147 (MBHB04-183)
/ CURRENT FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 245
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: sinA sense region
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (1)-(1)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (1)-(1)
/ OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (2)-(3)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (4)-(4)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (5)-(5)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (6)-(7)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (8)-(9)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc feature
```

```
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(15)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(18)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-245
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1714 CAGUACGACGACGACGUC 1732
Db 1 AGUACGACGACGACGACGUC 19
```

```
RESULT 842
US-10-798-090-246
Sequence 246, Application US/10798090
GENERAL INFORMATION:
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MBH04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
```

```
SOFTWARE: PatentIn version 3.3
SEQ ID NO 246
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)-(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(3)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)-(6)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (7)..(8)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (9)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(14)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(17)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-246
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1715 AGUACGACGACGACGUC 1733
Db 1 AGUACGACGACGACGUC 19
```

```
RESULT 843
US-10-798-090-247/c
Sequence 247, Application US/10798090
```

```
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 247
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(5)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(6)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (7)..(10)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(13)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(14)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(17)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
```

```
NAME/KEY: misc_feature
LOCATION: (18)..(18)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n strands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-internucleotide linkage
US-10-798-090-247

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 17 ACAGUACAACCTGCGCCUU 35
DB 19 ACAGTACAACCTGCGCTT 1

RESULT 844
US-10-798-090-248/C
Sequence 248, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 248
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(3)
OTHER INFORMATION: 2'-deoxy
```

```
FEATURE:
NAME/KEY: misc_feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(9)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(14)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(16)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(17)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(18)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-798-090-248

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 5.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy      21 UACACUCUGCCUUGUU 39
Db      19 TACAACCTGCCTTTGTTT 1

RESULT 845
US-10-798-090-249/c
; Sequence 249, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1nA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
```

```
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: Patencin version 3.3
SEQ ID NO 249
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: s1nA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(4)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(7)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(19)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-798-090-249

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy      315 CUUCUCUAGCCUGCC 333
Db      19 CTTCCTTAGCCTGACC 1

RESULT 846
US-10-798-090-250/c
; Sequence 250, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1nA)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
```

;; CURRENT FILING DATE: 2004-03-11
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 250
;; LENGTH: 21
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE: OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
;; FEATURE: NAME/KEY: misc_feature
;; LOCATION: (1)..(1)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE: NAME/KEY: misc_feature
;; LOCATION: (2)..(4)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE: NAME/KEY: misc_feature
;; LOCATION: (5)..(6)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE: NAME/KEY: misc_feature
;; LOCATION: (7)..(9)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE: NAME/KEY: misc_feature
;; LOCATION: (10)..(12)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE: NAME/KEY: misc_feature
;; LOCATION: (13)..(19)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE: NAME/KEY: misc_feature
;; LOCATION: (20)..(21)
;; OTHER INFORMATION: n stands for thymidine
;; FEATURE: NAME/KEY: misc_feature
;; LOCATION: (20)..(20)
;; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-798-090-250

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
317 UCCUCUUAAGCCUGGCG 335
19 TCCTCTTAGCCTGGCTG 1

RESULT 847
US-10-798-090-251/c
;; Sequence 251, Application US/10798090
;; Publication No. US20050014172A1
;; GENERAL INFORMATION:
;; APPLICANT: siRNA Therapeutics, Inc.
;; APPLICANT: Richards, Ivan
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Cholinergic
;; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
;; TITLE OF INVENTION: (siRNA)
;; FILE REFERENCE: 400/147 (MHR04-183)
;; CURRENT FILING DATE: 2004-03-11
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 251
;; LENGTH: 21
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE: OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
;; FEATURE: NAME/KEY: misc_feature
;; LOCATION: (1)..(1)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE: NAME/KEY: misc_feature
;; LOCATION: (2)..(2)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE: NAME/KEY: misc_feature
;; LOCATION: (3)..(4)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE: NAME/KEY: misc_feature
;; LOCATION: (5)..(8)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE: NAME/KEY: misc_feature
;; LOCATION: (9)..(10)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE: NAME/KEY: misc_feature
;; LOCATION: (11)..(13)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE: NAME/KEY: misc_feature
;; LOCATION: (14)..(14)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE: NAME/KEY: misc_feature

```
LOCATION: (15)..(17)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(18)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-798-090-251
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 975 GCAGGACGACCAAGCCAC 993
DB 19 GCAGATGACCAAGCCAC 1
```

```
RESULT 848
US-10-798-090-252/C
Sequence 252, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 252
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
FEATURE:
```

```
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (2)..(2)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(7)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(8)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (9)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(12)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(14)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(16)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(17)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-798-090-252
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1712 AGCAGTACGACGACGACA 1730
DB 19 AGCAGTACGACGACGACA 1
```

```
RESULT 849
US-10-798-090-253/C
Sequence 253, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FEATURE:
```

FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 253
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (2)..(3)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(14)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(18)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:

NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n strands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-internucleotide linkage
US-10-798-090-253
Query Match 1.14; Score 19; DB 1; Length 21;
Best Local Similarity 89.54; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 1714 CAGUACCGACGACGACGU 1732
Db 19 CAGTACCGACGACGACGT 1
RESULT 850
US-10-798-090-254/C
Sequence 254, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Richarde, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Cholinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 254
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(4)
OTHER INFORMATION: 2'-deoxy-2'-fluoro

```
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(5)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(11)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (12)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(15)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(17)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-798-090-254

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1715 AGUACGACGACGACGACGUC 1733
Db 19 ACTACCAGCAGACGACGAC 1

RESULT 851
US-10-798-090-255
Sequence 255, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Stima Therapeutics, Inc.
APPLICANT: McSwiggen, James
APPLICANT: Richards, Ivan
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Cholinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (sinn)
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23

PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 255
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sinn sense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc_feature
LOCATION: (2)..(2)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(4)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(5)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(6)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (7)..(7)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8)..(9)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(14)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
```

US-10-798-090-255

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 17 ACAGUACAACCCUCCUU 35
|||||
DB 1 ACAGUACAACCCUCCUU 19

RESULT 852

US-10-798-090-256
; Sequence 256, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 256
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(2)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(3)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (4)..(5)

; OTHER INFORMATION: 2'-O-methyl

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (6)..(9)

; OTHER INFORMATION: 2'-deoxy-2'-fluoro

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (10)..(10)

; OTHER INFORMATION: 2'-O-methyl

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (11)..(15)

; OTHER INFORMATION: 2'-deoxy-2'-fluoro

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (16)..(16)

; OTHER INFORMATION: 2'-O-methyl

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (17)..(19)

; OTHER INFORMATION: 2'-deoxy-2'-fluoro

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (20)..(21)

; OTHER INFORMATION: n stands for thymidine

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (21)..(21)

; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety

US-10-798-090-256

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 21 UACAACCCUCCUUGUU 39
|||||
DB 1 UACAACCCUCCUUGUU 19

RESULT 853

US-10-798-090-257
; Sequence 257, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784

```
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 257
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(11)
; OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(12)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(17)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety
US-10-798-090-257

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      315 CUUCCUUAAGCCUGGCC 333
Db      1 CUUCCUUAAGCCUGGCC 19

RESULT 854
US-10-798-090-258
; Sequence 258, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (SINA)
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT FILING DATE: 2004-03-11
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
```

```
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 258
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(10)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(15)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(18)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety
US-10-798-090-258

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      317 UCCUCUUAAGCCUGGCC 335
Db      1 UCCUCUUAAGCCUGGCC 19

RESULT 855
US-10-798-090-259
; Sequence 259, Application US/10798090
```

Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: MCSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 259
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
NAME/KEY: misc_feature
LOCATION: (2)..(2)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(5)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(6)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (7)..(9)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(11)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (12)..(15)
OTHER INFORMATION: 2'-O-methyl
FEATURE:

NAME/KEY: misc_feature
LOCATION: (16)..(17)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(18)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n strands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety
US-10-798-090-259
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 975 GCAGUGACCAAGACCAC 993
Db 1 GCAGUGACCAAGACCAC 19
RESULT 856
US-10-798-090-260
Sequence 260, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: MCSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 260
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sirna sense region

```
FEATURE:
NAME/KEY: misc.feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc.feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyribose moiety
FEATURE:
NAME/KEY: misc.feature
LOCATION: (3)..(3)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc.feature
LOCATION: (4)..(5)
OTHER INFORMATION: 2'-O-methyl
NAME/KEY: misc.feature
LOCATION: (6)..(6)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc.feature
LOCATION: (7)..(7)
OTHER INFORMATION: 2'-O-methyl
NAME/KEY: misc.feature
LOCATION: (8)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc.feature
LOCATION: (10)..(11)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc.feature
LOCATION: (12)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc.feature
LOCATION: (13)..(17)
OTHER INFORMATION: 2'-O-methyl
NAME/KEY: misc.feature
LOCATION: (18)..(18)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc.feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-O-methyl
NAME/KEY: misc.feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc.feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyribose moiety
US-10-798-090-260

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1712 AGCAGUACGACGACAGACA 1730
DB      1 AGCAGUACGACGACAGACA 19

RESULT 857
US-10-798-090-261
Sequence 261, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Silma Therapeutics, Inc.
```

```
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MBH04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 261
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
FEATURE:
NAME/KEY: misc.feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc.feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyribose moiety
FEATURE:
NAME/KEY: misc.feature
LOCATION: (2)..(3)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc.feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc.feature
LOCATION: (5)..(5)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc.feature
LOCATION: (6)..(7)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc.feature
LOCATION: (8)..(9)
OTHER INFORMATION: 2'-O-methyl
NAME/KEY: misc.feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc.feature
LOCATION: (11)..(15)
OTHER INFORMATION: 2'-O-methyl
```

```
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (16)..(16)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (17)..(18)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (19)..(19)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-261
```

```
Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1714 CAGUACGACGACGACGU 1732

Db 1 CAGUACGACGACGACGU 19

```
RESULT 858
US-10-798-090-262
/ Sequence 262, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sigma Therapeutics, Inc.
/ APPLICANT: McSwigen, James
/ APPLICANT: Richards, Ivan
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ TITLE OF INVENTION: (s1nA)
/ FILE REFERENCE: 400/147 (MBHB04-183)
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ CURRENT FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 262
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
```

```
/ OTHER INFORMATION: Description of Artificial Sequence: s1nA sense region
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(2)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(1)
/ OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (3)..(3)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (4)..(4)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (5)..(6)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (7)..(8)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (9)..(9)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (10)..(14)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (15)..(15)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (16)..(17)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (18)..(19)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-262
```

```
Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1715 AGUACGACGACGACGUC 1733

Db 1 AGUACGACGACGACGUC 19

```
RESULT 859
US-10-798-090-263/c
/ Sequence 263, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sigma Therapeutics, Inc.
/ APPLICANT: McSwigen, James
/ APPLICANT: Richards, Ivan
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
```

TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 263
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
NAME/KEY: misc_feature
LOCATION: (1)..(5)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (7)..(10)
OTHER INFORMATION: 2'-O-methyl
NAME/KEY: misc_feature
LOCATION: (6)..(6)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (7)..(10)
OTHER INFORMATION: 2'-O-methyl
NAME/KEY: misc_feature
LOCATION: (11)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(13)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(14)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(17)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(18)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)

OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-798-090-263
Query Match 1.1%; Score 19; DB 1; Length 21;
Best local Similarity 73.7%; Pred. No. 5.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 17 ACAGUACAACUCCUCCUU 35
Db 19 ACAGTACAACCTGCCTT 1
|||||:|||||:|||||:
US-10-798-090-264/c
; Sequence 264, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 264
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(3)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature

```
/ LOCATION: (5)..(9)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (10)..(10)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (11)..(14)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (15)..(16)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (17)..(17)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (18)..(18)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (19)..(19)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-798-090-264
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 5.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 21 UGAAACCTGCGCCUUGUUT 39
      |||||:|||||:|||||:
Db 19 TACAACCTGCGCTTGT 1
```

```
RESULT 861
US-10-798-090-265/c
; Sequence 265, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
```

```
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 265
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
```

```
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(2)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (3)..(4)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (5)..(7)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (8)..(10)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (11)..(19)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-798-090-265
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 315 CUUCUUAAGCCUGGCC 333
      |||||:|||||:|||||:
Db 19 CTTCCTTAAGCCTGGCC 1
```

```
RESULT 862
US-10-798-090-266/c
; Sequence 266, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
```

```

; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 266
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(4)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(9)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(19)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; US-10-798-090-266

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 317 UCCUCUUAAGCCUGGCTUG 335
Db 19 TCCTCTTAAGCTGGGCTG 1

RESULT 863
US-10-798-090-267/C
; Sequence 267, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
```

```

; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 267
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(4)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)..(10)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: 2'-O-methyl
```

```
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (19)..(19)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-798-090-267

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      975 GCAGATGACCAAGACCAC 993
      |||||:|||||
Db      19 GCAGATGACCAAGACCAC 1

RESULT 864
US-10-798-090-268/c
/ Sequence 268, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirta Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: MCSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ TITLE OF INVENTION: (s1nA)
/ FILE REFERENCE: 400/147 (MBH04-183)
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ PRIOR APPLICATION NUMBER: US 60/406,784
/ PRIOR FILING DATE: 2002-08-29
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 304
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 268
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: s1nA antisense region
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(1)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (2)..(2)
```

```
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (3)..(7)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (8)..(8)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (9)..(10)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (11)..(12)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (13)..(13)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (14)..(14)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (15)..(16)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (17)..(17)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (18)..(19)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-798-090-268

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1712 AGCAGTACGACGAGAGACA 1730
      |||||:|||||
Db      19 AGCAGTACGACGAGAGACA 1

RESULT 865
US-10-798-090-269/c
/ Sequence 269, Application US/10798090
/ Publication No. US20050014172A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirta Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: MCSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
/ TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
/ TITLE OF INVENTION: (s1nA)
/ FILE REFERENCE: 400/147 (MBH04-183)
/ CURRENT APPLICATION NUMBER: US/10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
```

PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 269
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (2)..(3)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(14)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(18)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)

OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-internucleotide linkage
US-10-798-090-269
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
DB 19 CAGTACGACGACGACGT 1
QY 1714 CAGUACGACGACGACGU 1732
RESULT 866
US-10-798-090-270/c
Sequence 270, Application US/10798090
GENERAL INFORMATION:
APPLICANT: Sirta Therapeutics, Inc.
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT FILING DATE: 2004-03-11
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 270
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(4)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(5)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature

```
LOCATION: (6)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(11)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (12)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(15)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(17)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-internucleotide linkage
US-10-798-090-270
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1715 AGUACGACGACGACGACGUC 1733
DB 19 AGTACCAGACGACGACGTC 1
```

```
RESULT 867
US-10-798-090-271
Sequence 271, Application US/10798090
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
```

```
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 271
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety
US-10-798-090-271
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 17 ACAGUACAACCCGCGCCUU 35
DB 1 ACAGUACAACCCGCGCCUU 19
```

```
RESULT 868
US-10-798-090-272
Sequence 272, Application US/10798090
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colineergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
```

```

; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 272
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(21)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-272
```

```

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      21 UACAACTTCGCGCCUUGUU 39
          |||||
Db       1 UACAACTTCGCGCCUUGUU 19
```

RESULT 869

```

US-10-798-090-273
; Sequence 273, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 273
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```

; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-273
```

```

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      315 CUUCCUUAAGCCUUGCC 333
          |||||
Db       1 CUUCCUUAAGCCUUGCC 19
```

RESULT 870

```

US-10-798-090-274
; Sequence 274, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 274
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
```

LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-274

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 317 UCCUCUUAAGCCUGGCCUG 335
Db 1 UCCUCUUAAGCCUGGCCUG 19

RESULT 871
US-10-798-090-275
Sequence 275, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 275
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-275

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 975 GCAGAUAGACCAAGACCAC 993
Db 1 GCAGAUAGACCAAGACCAC 19

RESULT 872
US-10-798-090-276
Sequence 276, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 276
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-276

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1712 ACAGUACCAAGACAGACA 1730
|||||

DB 1 AGUACGACGACGACGACA 19

RESULT 873
US-10-798-090-277
; Sequence 277, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sina)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT FILING DATE: 2004-03-11
; PRIOR FILING DATE: 2004-01-14
; PRIOR FILING DATE: 2004-01-14
; PRIOR FILING DATE: 2003-11-24
; PRIOR FILING DATE: 2003-11-24
; PRIOR FILING DATE: 2003-11-24
; PRIOR FILING DATE: 2003-10-23
; PRIOR FILING DATE: 2003-10-23
; PRIOR FILING DATE: 2003-05-23
; PRIOR FILING DATE: 2003-05-23
; PRIOR FILING DATE: 2003-02-20
; PRIOR FILING DATE: 2003-02-20
; PRIOR FILING DATE: 2003-02-20
; PRIOR FILING DATE: 2003-02-20
; PRIOR FILING DATE: 2002-03-11
; PRIOR FILING DATE: 2002-03-11
; PRIOR FILING DATE: 2002-06-06
; PRIOR FILING DATE: 2002-06-06
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 277
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sina sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-277

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1714 CAGUACGACGACGACGACG 1732
|||||
1 CAGUACGACGACGACGACG 19

RESULT 874
US-10-798-090-278
; Sequence 278, Application US/10798090
; Publication No. US20050014172A1

; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sina)
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT FILING DATE: 2004-03-11
; PRIOR FILING DATE: 2004-01-14
; PRIOR FILING DATE: 2004-01-14
; PRIOR FILING DATE: 2003-11-24
; PRIOR FILING DATE: 2003-11-24
; PRIOR FILING DATE: 2003-11-24
; PRIOR FILING DATE: 2003-10-23
; PRIOR FILING DATE: 2003-10-23
; PRIOR FILING DATE: 2003-05-23
; PRIOR FILING DATE: 2003-05-23
; PRIOR FILING DATE: 2003-02-20
; PRIOR FILING DATE: 2003-02-20
; PRIOR FILING DATE: 2003-02-20
; PRIOR FILING DATE: 2003-02-20
; PRIOR FILING DATE: 2002-03-11
; PRIOR FILING DATE: 2002-03-11
; PRIOR FILING DATE: 2002-06-06
; PRIOR FILING DATE: 2002-06-06
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 278
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sina sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-798-090-278

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1715 AGUACGACGACGACGACGUC 1733
|||||
1 AGUACGACGACGACGACGUC 19

DB 1 AGUACGACGACGACGACGUC 19

RESULT 875
US-10-798-090-279/C
; Sequence 279, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sina)

```
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 279
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
NAME/KEY: misc feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-798-090-279

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      17 ACAGUACAACUCCGCUUU 35
Db      19 ACAGUACAACCTCGCCTTT 1

RESULT 876
US-10-798-090-280/c
Sequence 280, Application US/10798090
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
```

```
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 280
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
NAME/KEY: misc feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-798-090-280

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 5.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      21 UACACCTCCGCUUUGUU 39
Db      19 TACAACCTCGCCTTGT 1

RESULT 877
US-10-798-090-281/c
Sequence 281, Application US/10798090
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
```

```

; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 281
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-798-090-281
```

```

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      315 CUUCUCUUAAGCCUGGCC 333
          |||:|:|:|:|:|:|:|:|:|
Db      19 CTTCTTTAAGCCTGCTG 1
```

```

RESULT 878
US-10-798-090-282/c
; Sequence 282, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 282
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
```

```

; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-798-090-282
```

```

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      317 UCUCUUAAGCCUGGCCUG 335
          |||:|:|:|:|:|:|:|:|:|
Db      19 TCTCTTAAGCCTGCTG 1
```

```

RESULT 879
US-10-798-090-283/c
; Sequence 283, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1NA)
; FILE REFERENCE: 400/147 (MBHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 283
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-798-090-283

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
```

```
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 975 GCAGAGGACCAAGACCAC 993
Db 19 GCAGATGACCAAGACCAC 1

RESULT 880
US-10-798-090-284/c
; Sequence 284, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 284
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-798-090-284

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5,1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1712 AGCAGUACCAAGACAGA 1730
Db 19 AGCAGTACCAGACAGACA 1

RESULT 881
US-10-798-090-285/c
; Sequence 285, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 285
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-798-090-285

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5,1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 1714 CAGUACCAAGACAGU 1732
Db 19 CAGTACCAGACAGACAGT 1

RESULT 882
US-10-798-090-286/c
; Sequence 286, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
```

```

; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 286
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-798-090-286
```

```
Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1715 AGUACAGCAGACAGCAGUC 1733
Db      19 AGTACCAGCAGACAGCAGTC 1
```

```

RESULT 883
US-10-798-090-296
; Sequence 296, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
```

```

; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 296
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)-(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-798-090-296
```

```
Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1011 GAACAACAUGAUGCUGCU 1029
Db      1 GAACAACAUGAUGCUGCU 19
```

```

RESULT 884
US-10-798-090-297/c
; Sequence 297, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (sRNA)
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2002-06-06
```

```

; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 297
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal glyceryl moiety
; US-10-798-090-297

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 5.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1011 GAACACAUAUGAUGCUGCU 1029
Db      19  GAACACAUAUGAUGCUGCT 1

RESULT 885
US-10-798-090-298
; Sequence 298, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Richard, Ivan
; APPLICANT: Sigma Therapeutics, Inc.
; TITLE OF INVENTION: RNA interference Mediated Inhibition of Muscarinic Colineergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MEH04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 298
; LENGTH: 21
; TYPE: RNA
```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(3)
; OTHER INFORMATION: 2'-O-Methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(6)
; OTHER INFORMATION: 2'-O-Methyl
; NAME/KEY: misc_feature
; LOCATION: (8)..(9)
; OTHER INFORMATION: 2'-O-Methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(12)
; OTHER INFORMATION: 2'-O-Methyl
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-O-Methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(17)
; OTHER INFORMATION: 2'-O-Methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; NAME/KEY: misc_feature
; LOCATION: (7)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; NAME/KEY: misc_feature
; LOCATION: (10)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; NAME/KEY: misc_feature
; LOCATION: (13)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; NAME/KEY: misc_feature
; LOCATION: (15)..(16)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide Linkage
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; US-10-798-090-298

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1011 GAACACAUAUGAUGCUGCU 1029
Db      1  GAACACAUAUGAUGCUGCU 19

RESULT 886
US-10-798-090-299/c
; Sequence 299, Application US/10798090
```

Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirta Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (s1nA)
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 304
SOFTWARE: PatentIn version 3.3
SEQ ID NO 299
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: s1nA antisense region
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)-(2)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc feature
LOCATION: (4)-(5)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc feature
LOCATION: (7)-(7)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc feature
LOCATION: (10)-(10)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc feature
LOCATION: (13)-(13)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc feature
LOCATION: (16)-(16)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc feature
LOCATION: (3)-(3)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (6)-(6)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:

NAME/KEY: misc feature
LOCATION: (8)-(9)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (11)-(12)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (14)-(15)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (17)-(19)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)-(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)-(21)
OTHER INFORMATION: 3'-3 attached terminal glyceryl moiety
US-10-798-090-299
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 5.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1011 GAACAACAAUGAUGGUCU 1029
DB 19 GAACAACATGATGCTGCT 1
RESULT 887
US-10-798-090-300
Sequence 300, Application US/10798090
Publication No. US20050014172A1
GENERAL INFORMATION:
APPLICANT: Sirta Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
TITLE OF INVENTION: (s1nA)
FILE REFERENCE: 400/147 (MEHB04-183)
CURRENT APPLICATION NUMBER: US/10/798,090
CURRENT FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 60/406,784
PRIOR FILING DATE: 2002-08-29
Remaining Prior Application data removed - See File Wrapper or PALM.

```

; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 300
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(4)
; OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(7)
; OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(10)
; OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(13)
; OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(16)
; OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyribose moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-798-090-300

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAACAACAUGAUGUGUCU 1029
DB 1 GAACAACAUGAUGUGUCU 19

RESULT 889
US-10-798-090-301/c
; Sequence 301, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; FILE REFERENCE: 400/147 (MBH04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
```

```

; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/366,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 301
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(3)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide Linkage
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal glyceryl moiety
US-10-798-090-301

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 5.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAACAACAUGAUGUGUCU 1029
DB 19 GAACAACAUGAUGUGUCU 1

RESULT 889
```

```
US-10-798-090-302
; Sequence 302, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1nA)
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 304
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 302
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: s1nA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(3)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(6)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(9)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(12)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(17)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (4)..(4)
```

```
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(16)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; US-10-798-090-302

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAACACAAUGAGUGCGUCU 1029
Db 1 GAACACAAUGAGUGCGUCU 19

RESULT 890
US-10-798-090-303
; Sequence 303, Application US/10798090
; Publication No. US20050014172A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colinergic
; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
; TITLE OF INVENTION: (s1nA)
; FILE REFERENCE: 400/147 (MHB04-183)
; CURRENT APPLICATION NUMBER: US/10/798,090
; CURRENT FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
```

;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 303
;; LENGTH: 21
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE: OTHER INFORMATION: Description of Artificial Sequence: s1nA sense region
;; NAME/KEY: misc_feature
;; LOCATION: (4)..(4)
;; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (7)..(7)
;; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (10)..(10)
;; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (13)..(13)
;; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (15)..(16)
;; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (18)..(19)
;; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (1)..(1)
;; OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (21)..(21)
;; OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (20)..(21)
;; OTHER INFORMATION: n stands for thymidine
;; US-10-798-090-303

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1011 GAACAACAUGAGCUCGU 1029
Db 1 GAACAACAUGAGCUCGU 19

RESULT 891
US-10-798-090-304/c
;; Sequence 304, Application US/10798090
;; Publication No. US20050014172A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirta Therapeutics, Inc.
;; APPLICANT: Richards, Ivan
;; APPLICANT: McSwiggen, James
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Muscarinic Colnergic
;; TITLE OF INVENTION: Receptor Gene Expression Using Short Interfering Nucleic Acid
;; TITLE OF INVENTION: (s1nA)
;; FILE REFERENCE: 400/147 (MEHB04-183)

;; CURRENT APPLICATION NUMBER: US/10/798,090
;; CURRENT FILING DATE: 2004-03-11
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; PRIOR APPLICATION NUMBER: US 60/406,784
;; PRIOR FILING DATE: 2002-08-29
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 304
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 304
;; LENGTH: 21
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE: OTHER INFORMATION: Description of Artificial Sequence: s1nA antisense region
;; NAME/KEY: misc_feature
;; LOCATION: (1)..(2)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (4)..(5)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (7)..(7)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (10)..(10)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (13)..(13)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (16)..(16)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (3)..(3)
;; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (6)..(6)
;; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (8)..(9)
;; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (11)..(12)
;; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;; FEATURE:
;; NAME/KEY: misc_feature

```
; LOCATION: (14)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal glyceryl moiety
US-10-798-090-304

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 5.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1011 GAACAACAUGAUGCUCU 1029
DB      19 GAACAACAATGATGCTGCT 1

RESULT 892
US-10-919-866-207
; Sequence 207, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT FILING DATE: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 207
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
; FEATURE:
```

```
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-919-866-207

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      17 ACAGUACAACUUGCCUUU 35
DB      1 ACAGUACAACUUGCCUUU 19

RESULT 893
US-10-919-866-208
; Sequence 208, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT FILING DATE: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 208
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-919-866-208

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      21 UACAACUUGCCUUUGUUU 39
DB      1 UACAACUUGCCUUUGUUU 19

RESULT 894
```

US-10-919-866-209
; Sequence 209, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 209
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-919-866-209

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 315 CUCCUCUUAAGCCUGGCC 333
DB 1 CUCCUCUUAAGCCUGGCC 19

RESULT 895
US-10-919-866-210
; Sequence 210, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11

; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 210
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-919-866-210

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 317 UCCUCUUAAGCCUGGCCUG 335
DB 1 UCCUCUUAAGCCUGGCCUG 19

RESULT 896
US-10-919-866-211
; Sequence 211, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028

```

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 211
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-919-866-211

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      975 GCAGUAGACCAAGACCAC 993
DB      1 GCAGUAGACCAAGACCAC 19

RESULT 897
US-10-919-866-212
; Sequence 212, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 212
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
```

```

; OTHER INFORMATION: n stands for thymidine
US-10-919-866-212

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1712 AGCAGUACCAAGACGACA 1730
DB      1 AGCAGUACCAAGACGACA 19

RESULT 898
US-10-919-866-213
; Sequence 213, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 213
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-919-866-213

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1714 CAGUACCAAGACGACAGU 1732
DB      1 CAGUACCAAGACGACAGU 19

RESULT 899
US-10-919-866-214
; Sequence 214, Application US/10919866
```

```
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sigma Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/205 (MEHB04-183-A)
/ CURRENT APPLICATION NUMBER: US10/919,866
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 214
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
US-10-919-866-214

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1715 AGUACGACGAGACAGUC 1733
DB 1 AGUACGACGAGACAGUC 19

RESULT 900
US-10-919-866-215/C
/ Sequence 215, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sigma Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/205 (MEHB04-183-A)
/ CURRENT APPLICATION NUMBER: US10/919,866
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
```

```
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 215
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
US-10-919-866-215

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 17 ACAGUACAACCTCGCCUTU 35
DB 19 ACAGUACAACCTCGCCTT 1

RESULT 901
US-10-919-866-216/C
/ Sequence 216, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sigma Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/205 (MEHB04-183-A)
/ CURRENT APPLICATION NUMBER: US10/919,866
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 216
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
US-10-919-866-216
```

```

; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 216
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc.feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-919-866-216

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 5.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      21 UGCAACGCGCCUUGGCUU 39
Db      19 TACAACCTGCGCTTGTCTT 1

RESULT 902
US-10-919-866-217/C
; Sequence 217, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McGwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 217
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc.feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-919-866-217
```

```

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      315 CUUCUCUUAAGCCUGGCC 333
Db      19 CTTCCTTAAGCCTGCGC 1

RESULT 903
US-10-919-866-218/C
; Sequence 218, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McGwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 218
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc.feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-919-866-218

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      317 UCCUCUUAAGCCUGGCCUG 335
Db      19 TCCTCTTAAGCCTGCGCTG 1

RESULT 904
US-10-919-866-219/C
; Sequence 219, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
```

```

; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US 10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 219
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirta sense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n is a, c, g, or u
US-10-919-866-219

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Cy      975 GCAGUAGCAACCAAGCCAC 993
Db      19 GCAGATGCACCAAGCCAC 1

RESULT 905
US-10-919-866-220/c
; Sequence 220, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US 10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16

```

```

; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 220
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sirta antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-919-866-220

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Cy      1712 AGCAGUACCAAGCCAGACA 1730
Db      19 AGCAGTACCAAGCCAGACA 1

RESULT 906
US-10-919-866-221/c
; Sequence 221, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US 10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.

```

NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO: 221
LENGTH: 21

TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
US-10-919-866-221

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1714 CAGUACGACGACGACG 1732
DB 19 CAGTCCAGCAGACGACGT 1

RESULT 907
US-10-919-866-222/c
Sequence 222, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirta Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT FILING DATE: 2004-08-17
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO: 222
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
US-10-919-866-222

Query Match 1.1%; Score 19; DB 1; Length 21;

Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1715 AGUACGACGACGACGUC 1733
DB 19 AGTACCAGCAGACGACGTC 1

RESULT 908
US-10-919-866-223
Sequence 223, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirta Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO: 223
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
NAME/KEY: misc_feature
LOCATION: (2)..(2)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
NAME/KEY: misc_feature
LOCATION: (5)..(5)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
NAME/KEY: misc_feature
LOCATION: (7)..(7)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
NAME/KEY: misc_feature
LOCATION: (10)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
NAME/KEY: misc_feature

```
/ LOCATION: (15)..(19)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n strands for thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-223

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      17 ACAGUACAACCTCGCCUUTU 35
Db      1 ACAGUACAACCTCGCCUUTU 19

RESULT 909
US-10-919-866-224
/ Sequence 224, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: McGwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/205 (MEH04-183-A)
/ CURRENT APPLICATION NUMBER: US/10/919,866
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 224
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(1)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(1)
/ OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
/ FEATURE:
```

```
/ NAME/KEY: misc_feature
/ LOCATION: (3)..(3)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (6)..(9)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (11)..(15)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (17)..(19)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n strands for thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-224

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      21 UACACCTCGCCCTUUGUUU 39
Db      1 UACACCTCGCCCTUUGUUU 19

RESULT 910
US-10-919-866-225
/ Sequence 225, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: McGwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/205 (MEH04-183-A)
/ CURRENT APPLICATION NUMBER: US/10/919,866
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 225
/ LENGTH: 21
```

```

; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(9)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (13)..(15)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-225
```

```

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      315 CUCCUCUUAAGCCUGGCC 333
Db      1 CUCCUCUUAAGCCUGGCC 19
```

```

RESULT 911
US-10-919-866-226
; Sequence 226, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEH804-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
```

```

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 226
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (11)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (16)..(18)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-226
```

```

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      317 UCCUCUUAAGCCUGGCCUG 335
Db      1 UCCUCUUAAGCCUGGCCUG 19
```

```

RESULT 912
US-10-919-866-227
; Sequence 227, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEH804-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-05-23
```

```

: PRIOR APPLICATION NUMBER: PCT/US04/16390
: PRIOR FILING DATE: 2004-05-24
: PRIOR APPLICATION NUMBER: US 10/826,966
: PRIOR FILING DATE: 2004-04-16
: PRIOR APPLICATION NUMBER: US 10/757,803
: PRIOR FILING DATE: 2004-01-14
: PRIOR APPLICATION NUMBER: US 10/720,448
: PRIOR FILING DATE: 2003-11-24
: PRIOR APPLICATION NUMBER: US 10/693,059
: PRIOR FILING DATE: 2003-11-23
: PRIOR APPLICATION NUMBER: US 10/444,853
: PRIOR FILING DATE: 2003-05-23
: PRIOR APPLICATION NUMBER: PCT/US03/05346
: PRIOR FILING DATE: 2003-02-20
: PRIOR APPLICATION NUMBER: PCT/US03/05028
: PRIOR FILING DATE: 2003-02-20
: PRIOR APPLICATION NUMBER: US 60/358,580
: PRIOR FILING DATE: 2002-02-20
: Remaining Prior Application data removed - See File Wrapper or PALM.
: NUMBER OF SEQ ID NOS: 324
: SOFTWARE: PatentIn version 3.3
: SEQ ID NO: 228
: LENGTH: 21
: TYPE: RNA
: ORGANISM: Artificial Sequence
: FEATURE:
: OTHER INFORMATION: Description of Artificial Sequence: sRNA sense region
: FEATURE:
: NAME/KEY: misc feature
: LOCATION: (1)..(1)
: OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
: FEATURE:
: NAME/KEY: misc feature
: LOCATION: (3)..(3)
: OTHER INFORMATION: 2'-deoxy-2'-fluoro
: FEATURE:
: NAME/KEY: misc feature
: LOCATION: (6)..(6)
: OTHER INFORMATION: 2'-deoxy-2'-fluoro
: FEATURE:
: NAME/KEY: misc feature
: LOCATION: (8)..(9)
: OTHER INFORMATION: 2'-deoxy-2'-fluoro
: FEATURE:
: NAME/KEY: misc feature
: LOCATION: (12)..(12)
: OTHER INFORMATION: 2'-deoxy-2'-fluoro
: FEATURE:
: NAME/KEY: misc feature
: LOCATION: (18)..(18)
: OTHER INFORMATION: 2'-deoxy-2'-fluoro
: FEATURE:
: NAME/KEY: misc feature
: LOCATION: (20)..(21)
: OTHER INFORMATION: n stands for thymidine
: FEATURE:
: NAME/KEY: misc feature
: LOCATION: (21)..(21)
: OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety
: US-10-919-866-228

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1712 AGCAGUACGACGACAGACA 1730
|||||
DB 1 AGCAGUACGACGACAGACA 19

```



```
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-231

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1715 AGUACGAGAGAGAGAGC 1733
DB      1 AGUACGAGAGAGAGAGC 19

RESULT 916
US-10-919-866-231/C
; Sequence 231, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 231
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
```

```
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(14)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(17)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-919-866-231

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      17 ACAGUACAACCCGCCUUU 35
DB      19 ACAGTACAACCTGCCTT 1

RESULT 917
US-10-919-866-232/C
; Sequence 232, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
```

```
; SEQ ID NO 232
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(16)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorochioate 3'-Internucleotide Linkage
US-10-919-866-232
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 5.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 21 UGACACCTGCGCCUUGUU 39
Db 19 TACCACTTCGCTTGT 1
```

```
RESULT 918
US-10-919-866-233/c
; Sequence 233, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
```

```
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 233
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorochioate 3'-Internucleotide Linkage
US-10-919-866-233
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 315 CUUCUCUUAAGCCUGCC 333
Db 19 CTTCCCTTAGCCTGCC 1
```

```
RESULT 919
US-10-919-866-234/c
; Sequence 234, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 218.
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX
XX 24-NOV-2003; 2003US-00720448.
XX
XX 03-DEC-2003; 2003US-00727780.
XX
XX 14-JAN-2004; 2004US-00757803.
XX
XX 10-FEB-2004; 2004US-0543480P.
XX
XX 13-FEB-2004; 2004US-00780447.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 16-APR-2004; 2004US-00826966.
XX
XX 30-APR-2004; 2004WO-US013456.
XX
XX 24-MAY-2004; 2004WO-US016390.
XX
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX PI Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX PS Claim 33; SEQ ID NO 218; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SO Sequence 21 BP; 6 A; 4 C; 7 G; 2 T; 2 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 21;
XX Best Local Similarity 68.4%; Pred. No. 1.9e+02;
XX Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 317 UCCUCUUAAGCCUGGCCUG 335
XX :||:|||||:|||||:
XX Db 19 TCCTCTTAAGCCCGGCTG 1

RESULT 598
AEA02372
ID AEA02372 standard; RNA; 21 BP.
XX
XX AEA02372;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 256.

XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX
XX 24-NOV-2003; 2003US-00720448.
XX
XX 03-DEC-2003; 2003US-00727780.
XX
XX 14-JAN-2004; 2004US-00757803.
XX
XX 10-FEB-2004; 2004US-0543480P.
XX
XX 13-FEB-2004; 2004US-00780447.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 16-APR-2004; 2004US-00826966.
XX
XX 30-APR-2004; 2004WO-US013456.
XX
XX 24-MAY-2004; 2004WO-US016390.
XX
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX PI Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX PS Claim 33; SEQ ID NO 256; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SO Sequence 21 BP; 3 A; 6 C; 2 G; 2 T; 8 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 1.9e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 21 UACCACTCGCCUUGUUU 39
XX |||||
XX Db 1 UACCACTCGCCUUGUUU 19

RESULT 599
AEA02410/C
ID AEA02410 standard; RNA; 21 BP.
XX
XX AEA02410;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 294.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM

XX		AEA02370;	
AC			
XX			
DT	28-JUL-2005	(first entry)	
XX			
DE		Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 254.	
XX			
KM		Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory; Neuroprotective; Nootropic; Uropathic; chronic obstructive pulmonary disease; asthma; allergic rhinitis; sinusitis; inflammation; allergy; cystic fibrosis; alzhemiers disease; microtubule disorder; cholinegenic receptor muscarinic 3; CHRM3; ss; siRNA; RNA interference; gene silencing; short interfering RNA.	
KW			
XX		Synthetic.	
OS			
NN		WO2005045040-A2.	
PJ			
PD	19-MAY--2005.		
PF	20-AUG--2004; 2004WO-US027367.		
PR	23-OCT--2003; 2003US-00693059. 24-NOV--2003; 2003US-00720448. 03-DEC--2003; 2003US-00727780. 14-Jan--2004; 2004US-00757803. 10-FEB--2004; 2004US-0543480P. 13-FEB--2004; 2004US-00780447. 11-MAR--2004; 2004US-00798090. 16-APR--2004; 2004US-00826966. 30-APR--2004; 2004MO-US01345E. 24-May--2004; 2004WO-US016390. 17-Aug--2004; 2004US-00919866.		
PA	(SIRN-) SIRNA THERAPEUTICS INC.		
PI			
XI	Richards I, Macswigen J;		
DR	WPI; 2005-356237/36.		
XX			
PT	New short interfering nucleic acid molecule that directs cleavage of a cholinergic receptor muscarinic 3 RNA, useful for treating or preventing respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary disease.		
PS			
XX	Claim 33; SEQ ID NO 254; 164pp; English.		
CC	The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siRNA) molecule that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference (RNAi). The siRNA molecule, compounds, compositions, and methods are useful for treating or preventing respiratory and pulmonary diseases, disorders, and/or conditions, including chronic obstructive pulmonary disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies, cystic fibrosis, Alzheimers's disease, and/or urinary incontinence. The present sequence represents a cholinergic receptor muscarinic 3 siRNA.		
SO	Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;		
QY	Query Match 1.1%; Score 19; DB 1; Length 21; Best Local Similarity 89.5%; Pred. No. 1.9e+02; Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;		
DB	1715 AGUACCAGCAGGACAGUC 1733 : - 19 AGTACCAAGCAGGACAGTC 1		
RESULT 596			
ID	AEA02384/C		
XX	AEA02384 standard; RNA; 21 BP.		
NC	AEA02384;		

XX	28-JUL-2005	(first entry)	
DE	Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 268.		
XX			
KM	Respiratory-Gen; Antiasthmatic; Antiallergic; Antiinflammatory;		
KM	Neuroprotective; Nootropic; Uropahic; asthma; allergic rhinitis;		
KM	chronic obstructive pulmonary disease; asthma; allergic rhinitis;		
KM	sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;		
KM	micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;		
XX	siRNA; RNA interference; gene silencing; short interfering RNA.		
OS	Synthetic.		
XX			
PN	WO2005045040-A2.		
XX			
PD	19-MAY-2005.		
XX			
PF	20-AUG-2004; 2004WO-US027357.		
XX			
PR	23-OCT-2003; 2003US-00693059.		
PR	24-NOV-2003; 2003US-00720448.		
PR	03-DEC-2003; 2003US-00727780.		
PR	14-JAN-2004; 2004US-00757803.		
PR	10-FEB-2004; 2004US-0543480P.		
PR	13-FEB-2004; 2004US-00780447.		
PR	11-MAR-2004; 2004US-00798090.		
PR	16-APR-2004; 2004US-00826966.		
PR	30-APR-2004; 2004WO-US013456.		
PR	24-MAY-2004; 2004WO-US016390.		
PR	17-AUG-2004; 2004US-00919866.		
XX			
PA	(SIRM-) siRNA THERAPEUTICS INC.		
XX			
PI	Richards I, Macswiggen J;		
XX			
XX	WPI; 2005-356237/36.		
PT			
PR	New short interfering nucleic acid molecule that directs cleavage of a		
PT	cholinergic receptor muscarinic 3 RNA, useful for treating or preventing		
PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary		
PI	disease.		
XX			
PS	Claim 33; SEQ ID NO 268; 184pp; English.		
XX			
CC	The invention relates to a chemically synthesized double stranded short		
CC	interfering nucleic acid (siNA) molecule that directs cleavage of a		
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference		
CC	(RNAi). The siNA molecule, compounds, compositions, and methods are		
CC	useful for treating or preventing respiratory and pulmonary diseases,		
CC	disorders, and/or conditions, including chronic obstructive pulmonary		
CC	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,		
CC	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The		
CC	present sequence represents a cholinergic receptor muscarinic 3 siRNA.		
XX			
SO	Sequence 21 BP; 1 A; 5 C; 5 G; 2 T; 8 U; 0 Other;		
XX			
Query Match	1.1%; Score 19; DB 1; Length 21;		
Best Local Similarity	94.7%; Pred. No. 1.9e+02;		
Matches 18; Conservative	1; Mismatches 0; Indels 0; Gaps 0;		
OY	1712 AGCAGUACGACGACAGACA 1730		
DB	19 AGCAGTACGACGACAGACA 1		
XX			
RESULT 597			
ID	AEA02334/C		
XX	AEA02334 standard; RNA; 21 BP.		
AC	AEA02334;		
XX			
DT	28-JUL-2005 (first entry)		

RESULT 593
 ID AEA02382/c
 AC AEA02382 standard; RNA; 21 BP.
 XX
 AC AEA02382;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 266.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX
 PN WO2005045040-A2.
 XX
 PD 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 XX
 PR 24-NOV-2003; 2003US-00720448.
 XX
 PR 03-DEC-2003; 2003US-0072780.
 XX
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PR 10-FEB-2004; 2004US-0543480P.
 XX
 PR 13-FEB-2004; 2004US-00780447.
 XX
 PR 11-MAR-2004; 2004US-00798090.
 XX
 PR 16-APR-2004; 2004US-00826986.
 XX
 PR 30-APR-2004; 2004WO-US013456.
 XX
 PR 24-MAY-2004; 2004WO-US016390.
 XX
 PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Richards I, Macswiggen J;
 XX
 DR WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 266; 184bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 21 BP; 6 A; 4 C; 7 G; 2 T; 2 U; 0 Other;
 XX
 Query Match 1.1%; Score 19; DB 1; Length 21;
 Best Local Similarity 68.4%; Pred. No. 1.9e+02;
 Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
 QY 317 UCCUCUAGCCGCGCCUG 335
 Db 19 TCCTCTTAGCCCTGCGCTG 1

RESULT 594

AEA02408/c
 ID AEA02408 standard; RNA; 21 BP.
 XX
 AC AEA02408;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 292.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX
 PN WO2005045040-A2.
 XX
 PD 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 XX
 PR 24-NOV-2003; 2003US-00720448.
 XX
 PR 03-DEC-2003; 2003US-0072780.
 XX
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PR 10-FEB-2004; 2004US-0543480P.
 XX
 PR 13-FEB-2004; 2004US-00780447.
 XX
 PR 11-MAR-2004; 2004US-00798090.
 XX
 PR 16-APR-2004; 2004US-00826986.
 XX
 PR 30-APR-2004; 2004WO-US013456.
 XX
 PR 24-MAY-2004; 2004WO-US016390.
 XX
 PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Richards I, Macswiggen J;
 XX
 DR WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 292; 184bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 21 BP; 1 A; 5 C; 5 G; 2 T; 8 U; 0 Other;
 XX
 Query Match 1.1%; Score 19; DB 1; Length 21;
 Best Local Similarity 94.7%; Pred. No. 1.9e+02;
 Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1712 AGCAGUACCGACGACAGACA 1730
 Db 19 AGCAGTACCGACGACAGACA 1

RESULT 595
 AEA02370/c
 ID AEA02370 standard; RNA; 21 BP.

QY 317 UCCUUAAGCCUGCCUG 335
:|:|:|:|:|:|:|:|:|
Db 19 TCCTCTTAGCCGCGCTG 1

RESULT 591
AEA02425
ID AEA02425 standard; RNA; 21 BP.
XX
AC AEA02425;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 318.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 11-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 318; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 7 A; 4 C; 4 G; 2 T; 4 U; 0 Other;
XX

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAACAACAUGAUGCGUCU 1029
|||||

Db 1 GAACAACAUGAUGCGUCU 19

RESULT 592
AEA02327
ID AEA02327 standard; RNA; 21 BP.
XX
AC AEA02327;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 211.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 211; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 7 A; 6 C; 5 G; 2 T; 1 U; 0 Other;
XX

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 975 GCAGATGACCAAGACCAC 993
|||||

Db 1 GCAGATGACCAAGACCAC 19

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 1715 AGUACGACGAGACAGUC 1733
|||:|||||:|||||:
19 AGTACCAGCAGACAGCAGTC 1

Db

RESULT 589
AEA02362
ID AEA02362 standard; RNA; 21 BP.
XX
AC AEA02362;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 246.
XX
KW Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW micurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 246; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 7 A; 5 C; 5 G; 2 T; 2 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1715 AGUACGACGAGACAGUC 1733
|||||:|||||:|||||:
1 AGUACGACGAGACAGUC 19

Db

RESULT 590
AEA02366/C
ID AEA02366 standard; RNA; 21 BP.
XX
AC AEA02366;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 250.
XX
KW Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW micurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 250; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 6 A; 4 C; 7 G; 2 T; 2 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.9e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

CC Present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1715 AGUACGACGACGACGAGUC 1733
DB 19 AGTACGACGACGACGAGTC 1
RESULT 587
AEA02352/c
ID AEA02352 standard; RNA; 21 BP.
XX
AC AEA02352;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 236.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN MO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 236; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.

SQ Sequence 21 BP; 1 A; 5 C; 5 G; 2 T; 8 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.9e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1712 AGCAGUACGACGACGAGACA 1730
DB 19 AGCGATGCCAGCAGACACA 1
RESULT 588
AEA02354/c
ID AEA02354 standard; RNA; 21 BP.
XX
AC AEA02354;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 238.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN MO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 238; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;

CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX SQ Sequence 21 BP; 3 A; 6 C; 2 G; 2 T; 8 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred.No.1.9e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 21 UACAACCCGCGCCUUGUUU 39
 |||||
 1 UACAACCCGCGCCUUGUUU 19

RESULT 585
 AEA02398/c
 ID AEA02398 standard; RNA; 21 BP.

XX AEA02398;

DT 28-JUL-2005 (first entry)

XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 282.

KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neutroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 KW microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.

XX Synthetic.

OS WO2005045040-A2.

XX WO2005045040-A2.

XX 19-MAY-2005.

PF 20-AUG-2004; 2004WO-US027367.

XX 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 03-DEC-2003; 2003US-00727780.

PR 14-JAN-2004; 2004US-00757803.

PR 10-FEB-2004; 2004US-0543480P.

PR 13-FEB-2004; 2004US-00780447.

PR 11-MAR-2004; 2004US-00798090.

PR 16-APR-2004; 2004US-00826966.

PR 30-APR-2004; 2004WO-US013456.

PR 24-MAY-2004; 2004WO-US013390.

PR 17-AUG-2004; 2004US-00919866.

XX (SIRN-) SIRNA THERAPEUTICS INC.

XX Richards I, Macswiggen J;

XX WPI; 2005-356237/36.

PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.

XX Claim 33; SEQ ID NO 282; 184pp; English.

CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary

CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX SQ Sequence 21 BP; 6 A; 4 C; 7 G; 2 T; 2 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 21;
 Best Local Similarity 68.4%; Pred.No.1.9e+02;
 Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

OY 317 UCCUCCUAGCCUGGCCUG 335
 :||:|||||
 19 TCCTTTAGCCTGCGCTG 1

RESULT 586
 AEA02418/c
 ID AEA02418 standard; RNA; 21 BP.

XX AEA02418;

DT 28-JUL-2005 (first entry)

XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 302.

KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neutroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 KW microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.

XX Synthetic.

OS WO2005045040-A2.

XX WO2005045040-A2.

XX 19-MAY-2005.

PF 20-AUG-2004; 2004WO-US027367.

XX 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 03-DEC-2003; 2003US-00727780.

PR 14-JAN-2004; 2004US-00757803.

PR 10-FEB-2004; 2004US-0543480P.

PR 13-FEB-2004; 2004US-00780447.

PR 11-MAR-2004; 2004US-00798090.

PR 16-APR-2004; 2004US-00826966.

PR 30-APR-2004; 2004WO-US013456.

PR 24-MAY-2004; 2004WO-US013390.

PR 17-AUG-2004; 2004US-00919866.

XX (SIRN-) SIRNA THERAPEUTICS INC.

XX Richards I, Macswiggen J;

XX WPI; 2005-356237/36.

PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.

XX Claim 33; SEQ ID NO 302; 184pp; English.

CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The

CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP, 7 A; 5 C; 5 G; 2 T; 2 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1714 CAGUACGACGACGACGACG 1732
DB 1 CAGUACGACGACGACGACG 19
XX
RESULT 583
AEA02340
ID AEA02340 standard; RNA; 21 BP.
XX
AC AEA02340;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 224.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzhemiers disease;
KW micurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macewiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 224; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a

CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP, 3 A; 6 C; 2 G; 2 T; 8 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 21 UACACCTCCGCCUUCUUU 39
DB 1 UACACCTCCGCCUUCUUU 19
XX
RESULT 584
AEA02388
ID AEA02388 standard; RNA; 21 BP.
XX
AC AEA02388;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 272.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzhemiers disease;
KW micurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macewiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 272; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are

PT disease.
XX
XX Claim 33; SEQ ID NO 298; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 6 A; 4 C; 7 G; 2 T; 2 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.9e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 317 UCCUCUUAAGCCUGGCGCUG 335
DB 19 TCCTCTTAAGCCTGGCCTG 1
XX
RESULT 581
AEA02426
ID AEA02426 standard; RNA; 21 BP.
XX
AC AEA02426;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 319.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
XX mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-0072780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.

PS Claim 33; SEQ ID NO 319; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 7 A; 4 C; 4 G; 2 T; 4 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1011 GAACACACAUAGUAGCUGCU 1029
DB 1 GAACACACAUAGUAGCUGCU 19
XX
RESULT 582
AEA02329
ID AEA02329 standard; RNA; 21 BP.
XX
AC AEA02329;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 213.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
XX mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-0072780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 213; 184pp; English.
XX

PT	cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT	disease.
PS	Claim 33; SEQ ID NO 229; 184pp; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siNA) molecule that directs cleavage of a
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC	(RNAi). The siNA molecule, compounds, compositions, and methods are
CC	useful for treating or preventing respiratory and pulmonary diseases,
CC	disorders, and/or conditions, including chronic obstructive pulmonary
CC	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC	present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX	
SO	Sequence 21 BP; 7 A; 5 C; 5 G; 2 T; 2 U; 0 Other;
Qy	
Db	1714 CAGUACGACGACGACAGU 1732 1 CAGUACGACGACGACAGU 19
RESULT 580	
AEO2414/c	
ID	AEO2414 standard; RNA; 21 BP.
AC	
XX	AEO2414;
DT	28-JUL-2005 (first entry)
DB	
KW	Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 298.
XX	
XX	Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW	Neuroprotective; Nootropic; Uropathic;
KW	chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW	sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW	micturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW	siRNA; RNA interference; gene silencing; short interfering RNA.
XX	
OS	Synthetic.
XX	
WO	WO2005045040-A2.
PN	
PD	
PD	19-MAY-2005.
PF	
PF	20-AUG-2004; 2004WO-US027367.
XX	
XX	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00720448.
PR	03-DEC-2003; 2003US-00727780.
PR	14-JAN-2004; 2004US-00757803.
PR	10-FEB-2004; 2004US-0543480P.
PR	13-FEB-2004; 2004US-00780447.
PR	11-MAR-2004; 2004US-00798090.
PR	16-APR-2004; 2004US-00826966.
PR	30-APR-2004; 2004WO-US013456.
PR	24-MAY-2004; 2004WO-US016390.
PR	17-AUG-2004; 2004US-00919866.
XX	
PA	(SIRN-) SIRNA THERAPEUTICS INC.
PI	
PI	Richards I, Macswigen J;
DR	WPI; 2005-356237/36.
XX	
XX	New short interfering nucleic acid molecule that directs cleavage of a
XX	cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary

Pt		New short interfering nucleic acid molecule that directs cleavage of a
Pt		cholestergic receptor muscarinic 3 RNA, useful for treating or preventing
Pt		respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
Pt		disease.
Ps	Claim 33; SEQ ID NO 243; 184pp; English.	
Cc	The invention relates to a chemically synthesized double stranded short	
Cc	interfering nucleic acid (siRNA) molecule that directs cleavage of a	
Cc	cholestergic receptor muscarinic 3 (CHRM3) RNA via RNA interference	
Cc	(RNAi). The siNA molecule, compounds, compositions, and methods are	
Cc	useful for treating or preventing respiratory and pulmonary diseases,	
Cc	disorders, and/or conditions, including chronic obstructive pulmonary	
Cc	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,	
Cc	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The	
Cc	present sequence represents a cholinergic receptor muscarinic 3 siRNA.	
Sx		
Sx	Sequence 21 BP; 7 A; 6 C; 5 G; 2 T; 1 U; 0 Other;	
Oy		
Db	975 GCAGUGGACCAAGCCAC 993 1 GCAGUGGACCAAGCCAC 19	
AEA02377		
ID	AEA02377 standard; RNA; 21 BP.	
XX AC	AEA02377;	
Dt	28-Jul-2005 (first entry)	
Xx DE	Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 261.	
Kw XX	Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory; Neuroprotective; Nootropic; Utopathic; chronic obstructive pulmonary disease; asthma; allergic rhinitis; sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease; micrution disorder; cholinegeric receptor muscarinic 3; CHRM3; ss; siRNA; RNA interference; gene silencing; short interfering RNA. Synthetic.	
XX OS		
PN WO	WO2005045040-A2.	
PD XX	19-MAY-2005.	
PF XX	20-AUG-2004; 2004MO-USO27367.	
PR XX	23-OCT-2003; 2003US-00693059.	
PR XX	24-NOV-2003; 2003US-00720448.	
PR XX	03-DEC-2003; 2003US-00727780.	
PR XX	14-JAN-2004; 2004US-00757803.	
PR XX	10-FEB-2004; 2004US-0543480P.	
PR XX	13-FEB-2004; 2004US-00780447.	
PR XX	11-MAR-2004; 2004US-00798090.	
PR XX	16-APR-2004; 2004US-00826966.	
PR XX	30-APR-2004; 2004MO-USO13456.	
PR XX	24-MAY-2004; 2004MO-USO16390.	
PR XX	17-AUG-2004; 2004US-00919866.	
PA XX	(SIRN-) SIRNA THERAPEUTICS INC.	
PI XX	Richards I; Macewiggen J;	
DR WP:	2005-35637/36.	

XX	WPI; 2005-356237/36.
-DR	
XX	New short interfering nucleic acid molecule that directs cleavage of a
PT	cholenergic receptor muscarinic 3 RNA, useful for treating or preventing
PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT	disease.
PS	Claim 33; SEQ ID NO 261; 184bp; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC	cholenergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC	(RNAi). The siRNA molecule, compounds, compositions, and methods are
CC	useful for treating or preventing respiratory and pulmonary diseases,
CC	disorders, and/or conditions, including chronic obstructive pulmonary
CC	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC	present sequence represents a cholenergic receptor muscarinic 3 siRNA.
SQ	
XX	Sequence 21 BP; 7 A; 5 C; 5 G; 2 T; 2 U; 0 Other;
OY	
Query Match	1.1%; Score 19; DB 1; Length 21;
Best Local Similarity	100.0%; Pred. No. 1.9e+02; Mismatches 0; Gaps 0;
Matches	19; Conservative 0; Indels 0;
DB	
1714	CAGUACGACGACGACGACGU 1732
1	CAGUACGACGACGACGACGU 19
RESULT 578	
AEA02378	
ID	AEA02378 standard; RNA; 21 BP.
XX	
AC	AEA02378;
XX	
DT	28-JUL-2005 (first entry)
DE	
Cholinergic receptor muscarinic 3 siRNA	SEQ ID NO 262.
KX	Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
KM	Neuroprotective; Nootropic; Utopathic;
KW	chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW	sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW	mucrition disorder; cholenergic receptor muscarinic 3; CHRM3; ss;
KW	siRNA; RNA interference; gene silencing; short interfering RNA.
OS	Synthetic.
XX	
PN	WO2005045040-A2.
XX	
PD	19-MAY-2005.
PF	
20-AUG-2004;	2004WO-US027367.
XX	
XX	
PR	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00720448.
PR	03-DEC-2003; 2003US-00727780.
PR	14-JAN-2004; 2004US-00757803.
PR	10-FEB-2004; 2004US-0545480P.
PR	13-FEB-2004; 2004US-00780447.
PR	11-MAR-2004; 2004US-00798090.
PR	16-APR-2004; 2004US-00826966.
PR	30-APR-2004; 2004WO-US013456.
PR	24-MAY-2004; 2004WO-US016330.
PR	17-AUG-2004; 2004US-00919866.
XX	
PA	(SIRN-) SIRNA THERAPEUTICS INC.
XX	
PI	Richards I, Macswigen J;
XX	
DR	WPI; 2005-356237/36.

PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 259; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 7 A; 6 C; 5 G; 2 T; 1 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 975 GCAGUGAGCCAGACCCAC 993
DB 1 GCAGUGAGCCAGACCCAC 19
|||||
RESULT 575
AEA02346
ID AEA02346 standard; RNA; 21 BP.
XX
AC AEA02346;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 230.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
PR

XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 230; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 7 A; 5 C; 5 G; 2 T; 2 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1715 AGUACCGAGAGACAGUC 1733
DB 1 AGUACCGAGAGACAGUC 19
|||||
RESULT 576
AEA02359
ID AEA02359 standard; RNA; 21 BP.
XX
AC AEA02359;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 243.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
PR
PA (SIRN-) SIRNA THERAPEUTICS INC.

```

PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) siRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 240; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SQ Sequence 21 BP; 3 A; 6 C; 2 G; 2 T; 8 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 1.9e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 21 UACACCCUGCCGCUUGUUU 39
Db 1 UACACCCUGCCGCUUGUUU 19

RESULT 573
AEA02368/c
ID AEA02368 standard; RNA; 21 BP.
XX
XX AEA02368;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 252.
XX
XX Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.

```

```

PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) siRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 252; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SQ Sequence 21 BP; 1 A; 5 C; 5 G; 2 T; 8 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 21;
XX Best Local Similarity 94.7%; Pred. No. 1.9e+02;
XX Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 1712 AGCAGUACGACGACAGACA 1730
Db 19 AGCAGTACGACGACAGACA 1

RESULT 574
AEA02375
ID AEA02375 standard; RNA; 21 BP.
XX
XX AEA02375;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 259.
XX
XX Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.

```

[illegible]

```

XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX
XX 24-NOV-2003; 2003US-00720448.
XX
XX 03-DEC-2003; 2003US-00727780.
XX
XX 14-JAN-2004; 2004US-00757803.
XX
XX 10-FEB-2004; 2004US-0543480P.
XX
XX 13-FEB-2004; 2004US-00780447.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 16-APR-2004; 2004US-00826966.
XX
XX 30-APR-2004; 2004WO-US013456.
XX
XX 24-MAY-2004; 2004WO-US016390.
XX
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macewiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 270; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1715 AGUACGACGACGACGACGUC 1733
DB 19 AGTACCAGCAGACGACGATC 1
RESULT 569
AEA02423
ID AEA02423 standard; RNA; 21 BP.
XX
XX AEA02423;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 316.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX

```

```

XX 23-OCT-2003; 2003US-00693059.
XX
XX 24-NOV-2003; 2003US-00720448.
XX
XX 03-DEC-2003; 2003US-00727780.
XX
XX 14-JAN-2004; 2004US-00757803.
XX
XX 10-FEB-2004; 2004US-0543480P.
XX
XX 13-FEB-2004; 2004US-00780447.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 16-APR-2004; 2004US-00826966.
XX
XX 30-APR-2004; 2004WO-US013456.
XX
XX 24-MAY-2004; 2004WO-US016390.
XX
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macewiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 316; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 21 BP; 7 A; 4 C; 4 G; 2 T; 4 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1011 GAACACAAUGAUGGUGCU 1029
DB 1 GAACACAAUGAUGGUGCU 19
RESULT 570
AEA02394
ID AEA02394 standard; RNA; 21 BP.
XX
XX AEA02394;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 278.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX

```


KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
OS Synthetic.
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richarde I, Macswiggen J;
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 220; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 21 BP; 1 A; 5 C; 5 G; 2 T; 8 U; 0 Other;
XX
XX
XX Query Match 1.1%; Score 19; DB 1; Length 21;
XX Best Local Similarity 94.7%; Pred. No. 1.9e+02;
XX Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1712 AGCAGUACCGACGAGACA 1730
XX |||:|||||
XX DB 19 AGCAGTACCGACGAGACA 1
XX
XX
XX RESULT 565
XX AEA02402/C
XX ID AEA02402 standard; RNA; 21 BP.
XX
XX AEA02402;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 286.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.

XX
XX OS Synthetic.
XX
XX PN WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richarde I, Macswiggen J;
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 286; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
XX
XX
XX Query Match 1.1%; Score 19; DB 1; Length 21;
XX Best Local Similarity 89.5%; Pred. No. 1.9e+02;
XX Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1715 AGUACCGACGAGACAGUC 1733
XX |||:|||||
XX DB 19 AGTACCGACGAGACAGTC 1
XX
XX
XX RESULT 566
XX AEA02416/C
XX ID AEA02416 standard; RNA; 21 BP.
XX
XX AEA02416;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 300.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS

PS Disclosure; SEQ ID NO 222; 84pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
SQ Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1715 AGUACGACGACGACGACGUC 1733
DB 19 AGTACCAGCAGACGACGATC 1
RESULT 561
ADM27957/C
ID ADM27957 standard; RNA; 21 BP.
AC ADM27957;
XX
XX 07-APR-2005 (first entry)
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #254.
XX
XX gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nontropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /tag= a
FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX

PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX PI Richards I, Mcswiggen J;
XX
XX MPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
PS Disclosure; SEQ ID NO 254; 84pp; English.
XX
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
SQ Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1715 AGUACGACGACGACGACGUC 1733
DB 19 AGTACCAGCAGACGACGATC 1
RESULT 562
ADM27985/C
ID ADM27985 standard; RNA; 21 BP.
AC ADM27985;
XX
XX 07-APR-2005 (first entry)
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #282.
XX
XX
XX gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nontropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /tag= a
FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX

Db 19 AGTACCAGACAGACAGATC 1
||:|||||:|||||:|
RESULT 559
ADM27973/c
ID ADM27973 standard; RNA; 21 BP.
XX
AC ADM27973;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #270.
XX
KW gene expression; antispasmodic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; utropanic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /*tag= a
FT /note= "deoxythymidine nucleotide"
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGEN J.
XX
PI Richards I, Mcswigen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 270; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance

CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1715 AGUACCAGACAGACAGATC 1733
Db 19 AGTACCAGACAGACAGATC 1
||:|||||:|||||:|
RESULT 560
ADM27925/c
ID ADM27925 standard; RNA; 21 BP.
XX
AC ADM27925;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #222.
XX
KW gene expression; antispasmodic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; utropanic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /*tag= a
FT /note= "deoxythymidine nucleotide"
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGEN J.
XX
PI Richards I, Mcswigen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.

[illegible]

XX	Cholinergic receptor muscarinic 3 gene targeted siRNA #238.
XX	gene expression; antistomatitic; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW	respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM	nootropic; uteroblastic; short interfering RNA; RNA interference; siRNA;
KM	cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM	inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM	hyperextension; emphysema; irritable bowel syndrome; Alzheimer's disease;
KV	incontinence; ss.
XX	Synthetic.
OS	
XX	
FH	Key Location/Qualifiers
FT	misc_difference 20..21
FT	/tag= a
FT	/note= "deoxythymidine nucleotide"
XX	
NB	US2005014172-A1.
XX	
PD	20-JAN-2005.
XX	
P	11-MAR-2004; 2004US-00798090.
XX	
PR	20-FEB-2002; 2002US-0358580P.
PR	11-MAR-2002; 2002US-0363124P.
PR	20-MAY-2002; 2002WO-US015876.
PR	06-JUN-2002; 2002US-036782P.
PR	29-AUG-2002; 2002US-0406784P.
PR	05-SEP-2002; 2002US-0408378P.
PR	09-SEP-2002; 2002US-0409293P.
PR	15-JAN-2003; 2003US-0440129P.
PR	20-FEB-2003; 2003WO-US005028.
PR	20-FEB-2003; 2003US-05005346.
PR	30-APR-2003; 2003US-00427160.
PR	23-MAY-2003; 2003US-00444853.
PR	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00720448.
PR	14-JAN-2004; 2004US-00757803.
PA	(RICH/) RICHARDS I.
PA	(MCSW/) MCSWIGGEN J.
X1	Richards I, Mcswiggen J;
P1	WPI; 2005-090672/10.
DR	
XX	
PT	Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.
XX	
PS	Disclosure; SEQ ID NO 238; 84bp; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hyperextension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.
XX	
SQ	Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
XX	
Query Match	1.1%; Score 19; DB 1; Length 21;
Best Local Similarity	89.5%; Pred.No. 1.9e+02;
Matches 17; Conservative	2; Mismatches 0; Indels 0; Gaps 0;

PR 20-FEB-2003; 2003WO-US005346-
PR 30-APR-2003; 2003US-00427160-
PR 23-MAY-2003; 2003US-00444853-
PR 23-OCT-2003; 2003US-00693059-
PR 24-NOV-2003; 2003US-00720448-
PR 14-JAN-2004; 2004US-00757803-
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswigen J;
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 286; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1715 AGUACCAGACAGACAGUC 1733
Db ||:|||||:|||||:1
19 AGTACCAGACAGACAGACGTC 1
XX
RESULT 556
ADW27916 ID ADW27916 standard; RNA; 21 BP.
XX
AC ADW27916;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #213.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /*tag= a
FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX

PF 11-MAR-2004; 2004US-00798090-
XX
XX 20-FEB-2002; 2002US-0356580P-
PR 11-MAR-2002; 2002US-0363124P-
PR 20-MAY-2002; 2002WO-US015876-
PR 06-JUN-2002; 2002US-0386782P-
PR 29-AUG-2002; 2002US-0406784P-
PR 05-SEP-2002; 2002US-0408378P-
PR 09-SEP-2002; 2002US-0409293P-
PR 15-JAN-2003; 2003US-0440129P-
PR 20-FEB-2003; 2003WO-US005346-
PR 30-APR-2003; 2003US-00427160-
PR 23-MAY-2003; 2003US-00444853-
PR 23-OCT-2003; 2003US-00693059-
PR 24-NOV-2003; 2003US-00720448-
PR 14-JAN-2004; 2004US-00757803-
XX
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswigen J;
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 213; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 21 BP; 7 A; 5 C; 5 G; 2 T; 2 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1714 CAGUACCAGACAGACAGU 1732
Db |||||||:|||||:1
1 CAGUACCAGACAGACAGU 19
XX
RESULT 557
ADW27939/C ID ADW27939 standard; RNA; 21 BP.
XX
AC ADW27939;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #236.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
XX


```
RESULT 552
ID ADW27914
AC ADW27914;
XX
XX 07-APR-2005 (first entry)
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #211.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uteropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX misc_difference 20..21
XX /*tag= a
XX /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 211; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
```

```
SO Sequence 21 BP; 7 A; 6 C; 5 G; 2 T; 1 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 975 GCAGAUAGACCAAGACCAC 993
DB 1 GCAGAUAGACCAAGACCAC 19
RESULT 553
ID ADW27969/c
AC ADW27969;
XX
XX 07-APR-2005 (first entry)
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #266.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uteropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX misc_difference 20..21
XX /*tag= a
XX /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 266; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
```

```
FT      /*tag= a
PT      /note= "deoxythymidine nucleotide"
PN      US2005014172-A1.
XX
XX      20-JAN-2005.
XX
XX      11-MAR-2004; 2004US-00798090.
XX
XX      20-FEB-2002; 2002US-0358580P.
XX      11-MAR-2002; 2002US-0363124P.
XX      20-MAY-2002; 2002WO-US015876.
XX      06-JUN-2002; 2002US-0386782P.
XX      29-AUG-2002; 2002US-0406784P.
XX      05-SEP-2002; 2002US-0408378P.
XX      09-SEP-2002; 2002US-0409293P.
XX      15-JAN-2003; 2003US-0440129P.
XX      20-FEB-2003; 2003WO-US005028.
XX      30-APR-2003; 2003US-00427160.
XX      23-MAY-2003; 2003US-00444853.
XX      23-OCT-2003; 2003US-00693059.
XX      24-NOV-2003; 2003US-00720448.
XX      14-JAN-2004; 2004US-00757803.
XX
XX      (RICH/) RICHARDS I.
XX      (MCSW/) MCSWIGGEN J.
XX
XX      Richarde I, Mcswiggen J;
XX
XX      WPI; 2005-090672/10.
XX
XX      Novel chemically synthesized double stranded short interfering nucleic
XX      acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX      RNA through RNA interference, useful for treating asthma.
XX
XX      Disclosure; SEQ ID NO 208; 84bp; English.
XX
XX      The invention relates to a chemically synthesized double stranded short
XX      interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX      cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX      where each strand of (I) has 19-23 nucleotides, and does not require the
XX      presence of nucleotides having a 2-hydroxy group for mediating RNA
XX      interference. (I) is useful for treating diseases e.g., asthma, allergic
XX      rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX      vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX      Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX      towards nuclease. Double stranded short interfering nucleic acid molecule
XX      was produced by solid phase oligonucleotide synthesis method. This
XX      sequence represents an example of a siRNA molecule of the invention.
XX
XX      Sequence 21 BP; 3 A; 6 C; 2 G; 2 T; 8 U; 0 Other;
XX
XX      Query Match      1.1%; Score 19; DB 1; Length 21;
XX      Best Local Similarity 100.0%; Pred. No. 1.9e+02;
XX      Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX      21 UACACCTUCGCCUUCUUU 39
XX      |||||
XX      1 UACACCTUCGCCUUCUUU 19
XX
XX      RESULT 551
XX      ADM27998/c
XX      ID      ADM27998 standard; RNA; 21 BP.
XX      AC      ADM27998;
XX      XX
XX      DT      07-APR-2005 (first entry)
XX      XX      Cholinergic receptor muscarinic 3 gene targeted siRNA #295.
XX      DE      gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
XX      XX
```

```
KW      respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW      nontropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW      cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW      inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW      hypertension; emphysema; irritable bowel syndrome; Alzheimer disease;
KW      incontinence; ss.
XX
XX      Synthetic.
XX
XX      Key      Location/Qualifiers
XX      FT      misc_difference 20..21
XX      FT      /*tag= a
XX      FT      /note= "deoxythymidine nucleotide"
XX
XX      US2005014172-A1.
XX
XX      20-JAN-2005.
XX
XX      11-MAR-2004; 2004US-00798090.
XX
XX      20-FEB-2002; 2002US-0358580P.
XX      11-MAR-2002; 2002US-0363124P.
XX      20-MAY-2002; 2002WO-US015876.
XX      06-JUN-2002; 2002US-0386782P.
XX      29-AUG-2002; 2002US-0406784P.
XX      05-SEP-2002; 2002US-0408378P.
XX      09-SEP-2002; 2002US-0409293P.
XX      15-JAN-2003; 2003US-0440129P.
XX      20-FEB-2003; 2003WO-US005028.
XX      20-FEB-2003; 2003WO-US005346.
XX      30-APR-2003; 2003US-00427160.
XX      23-MAY-2003; 2003US-00444853.
XX      23-OCT-2003; 2003US-00693059.
XX      24-NOV-2003; 2003US-00720448.
XX      14-JAN-2004; 2004US-00757803.
XX
XX      (RICH/) RICHARDS I.
XX      (MCSW/) MCSWIGGEN J.
XX
XX      Richarde I, Mcswiggen J;
XX
XX      WPI; 2005-090672/10.
XX
XX      Novel chemically synthesized double stranded short interfering nucleic
XX      acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX      RNA through RNA interference, useful for treating asthma.
XX
XX      Disclosure; SEQ ID NO 304; 84bp; English.
XX
XX      The invention relates to a chemically synthesized double stranded short
XX      interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX      cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX      where each strand of (I) has 19-23 nucleotides, and does not require the
XX      presence of nucleotides having a 2-hydroxy group for mediating RNA
XX      interference. (I) is useful for treating diseases e.g., asthma, allergic
XX      rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX      vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX      Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX      towards nuclease. Double stranded short interfering nucleic acid molecule
XX      was produced by solid phase oligonucleotide synthesis method. This
XX      sequence represents an example of a siRNA molecule of the invention.
XX
XX      Sequence 21 BP; 4 A; 4 C; 4 G; 2 T; 7 U; 0 Other;
XX
XX      Query Match      1.1%; Score 19; DB 1; Length 21;
XX      Best Local Similarity 78.9%; Pred. No. 1.9e+02;
XX      Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
XX
XX      1011 GAACACAUGAUGUGUCU 1029
XX      |||||
XX      19 GAACACAUGAUGUGUCU 1
XX
XX      Db
```

PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswiggen J;
XX WPI, 2005-090672/10.
DR
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 299; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 21 BP; 4 A; 4 C; 4 G; 2 T; 7 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 21;
XX Best Local Similarity 78.9%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 1011 GAACAACAUGAUGCGUCU 1029
Db 19 GAACAACATGATGCTGCT 1
XX
XX RESULT 549
XX ADM27955/C
XX ID ADM27955 standard; RNA; 21 BP.
XX
XX ADM27955;
XX
XX 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #252.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX FT misc_difference 20..21 a
XX FT /*tag="a
XX FT /note="deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX PR

PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005346.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI, 2005-090672/10.
XX
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 252; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 21 BP; 1 A; 5 C; 5 G; 2 T; 8 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 21;
XX Best Local Similarity 94.7%; Pred. No. 1.9e+02;
XX Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 1712 AGCAGUACCGACGAGACA 1730
Db 19 AGCAGTACCAGCAGAGACA 1
XX
XX RESULT 550
XX ADM27911
XX ID ADM27911 standard; RNA; 21 BP.
XX
XX ADM27911;
XX
XX 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #208.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX FT misc_difference 20..21
XX FT

CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.

XX Sequence 21 BP; 4 A; 4 C; 4 G; 2 T; 7 U; 0 Other;

SO Query Match 1.1%; Score 19; DB 1; Length 21;
 Best Local Similarity 78.9%; Pred. No. 1.9e+02;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAACACCAATGAGTCTGCT 1
 DB 19 GAACACCAATGAGTCTGCT 1

RESULT 547
 ADM27917
 ID ADM27917 standard; RNA; 21 BP.
 XX
 AC ADM27917;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #214.

XX gene expression; antiaesthetic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neurotropic; uteropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 KW incontinence; ss.

XX Synthetic.

XX Key Location/Qualifiers
 FT misc_difference 20..21
 FT /tag= a
 FT /note= "deoxythymidine nucleotide"

XX US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 XX (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 PI Richards I, Mcswiggen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic

PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.

XX disclosure, SEQ ID NO 214; 84bp; English.

XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.

XX Sequence 21 BP; 7 A; 5 C; 5 G; 2 T; 2 U; 0 Other;

SO Query Match 1.1%; Score 19; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1715 AGUACGACGACGACGACGUC 1733
 DB 1 AGUACGACGACGACGACGUC 19

RESULT 548
 ADM27993/c
 ID ADM27993 standard; RNA; 21 BP.
 XX
 AC ADM27993;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #290.

XX gene expression; antiaesthetic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neurotropic; uteropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 KW incontinence; ss.

XX Synthetic.

XX Key Location/Qualifiers
 FT misc_difference 20..21
 FT /tag= a
 FT /note= "deoxythymidine nucleotide"

XX US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR


```
XX 20-JAN-2005.
PD
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswigen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 218; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 21 BP; 6 A; 4 C; 7 G; 2 T; 2 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.9e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
OY 317 UCCUCUUAAGCCUGGCCUG 335
:||||:||||:||||:
DB 19 TCCTCTTAGCCTGCGCCTG 1
XX
RESULT 544
ADM27923/C
ID ADM27923 standard; RNA; 21 BP.
XX
AC ADM27923;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #220.
XX
KW gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uterapathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
```

```
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /tag= a
FT /note= "deoxythymidine nucleotide".
XX
EN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswigen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 220; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 21 BP; 1 A; 5 C; 5 G; 2 T; 8 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.9e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 1712 AGCAGUACGACGACGACA 1730
:||||:||||:||||:
DB 19 AGCAGTACGACGACGACA 1
XX
RESULT 545
ADM27991/C
ID ADM27991 standard; RNA; 21 BP.
XX
```

PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 250; 84pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
SQ Sequence 21 BP; 6 A; 4 C; 7 G; 2 T; 2 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.9e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 317 UCCUCUAGCCGCGCUG 335
Db :|||:|||||:|||||:
19 TCCTCTTAGCCCTGCGCTG 1

RESULT 542
ADW27971/C
ID ADW27971 standard; RNA; 21 BP.
XX
AC ADW27971;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #268.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /*tag= a
FT /note="deoxythymidine nucleotide"
XX
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0359580P.
XX
PR 11-MAR-2002; 2002US-0363124P.
XX
PR 20-MAY-2002; 2002WO-US015876.
XX
PR 06-JUN-2002; 2002US-0386782P.
XX
PR 29-AUG-2002; 2002US-0406784P.
XX
PR 05-SEP-2002; 2002US-0408378P.
XX
PN

PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 268; 84pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
SQ Sequence 21 BP; 1 A; 5 C; 5 G; 2 T; 8 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.9e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1712 AGCAGUACGACGAGACA 1730
Db :||||:|||||:|||||:
19 AGCAGTACGACGAGACA 1

RESULT 543
ADW27921/C
ID ADW27921 standard; RNA; 21 BP.
XX
AC ADW27921;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #218.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /*tag= a
FT /note="deoxythymidine nucleotide"
XX
XX
PN US2005014172-A1.
XX
PD

CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
SQ Sequence 19 BP, 2 A, 11 C, 3 G, 0 T, 3 U, 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1173 GCCUGAGGAGGAGCTCGGG 1191
DB 19 GCCTGAGGAGAGCTCGGG 1
RESULT 540
ADM27937/c
ID ADM27937 standard; RNA; 21 BP.
AC ADM27937;
XX
XX
DT 07-APR-2005 (first entry)
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #234.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
incontinence; ss.
XX
XX Synthetic.
OS
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /tag= a
FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 234; 84pp; English.
XX
XX

XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
SQ Sequence 21 BP, 6 A, 4 C, 7 G, 2 T, 2 U, 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.9e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 317 UCCUCUUAAGCCUGGCCUG 335
DB 19 TCCTCTTAGCCCTGCGCTG 1
RESULT 541
ADM27953/c
ID ADM27953 standard; RNA; 21 BP.
AC ADM27953;
XX
XX
DT 07-APR-2005 (first entry)
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #250.
XX
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
incontinence; ss.
XX
XX Synthetic.
OS
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /tag= a
FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX
XX

CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 5 A; 4 C; 6 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1677 GCGUGCCAGUGGACAA 1695
DB 1 GCGUGCCAGUGGACAA 19
RESULT 538
AEA02213
ID AEA02213 standard; RNA; 19 BP.
XX
AC AEA02213;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 97.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHR3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 97; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHR3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,

CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 4 C; 4 G; 0 T; 7 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1731 GCGGUCAUUUUUCACAAG 1749
DB 1 GCGGUCAUUUUUCACAAG 19
RESULT 539
AEA02281/c
ID AEA02281 standard; RNA; 19 BP.
XX
AC AEA02281;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 165.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHR3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 165; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHR3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,

PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
PS Claim 33; SEQ ID NO 39; 184bp; English.
CC
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 5 A; 6 C; 2 G; 0 T; 6 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 687 CACCAUACUUCUGGACCA 705
Db 1 CACCAUACUUCUGGACCA 19
|||||
RESULT 534
AEA02167
ID AEA02167 standard; RNA; 19 BP.
XX
AC AEA02167;
XX
XX 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 51.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
DR
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.

XX
PS Claim 33; SEQ ID NO 51; 184bp; English.
XX
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 7 A; 5 C; 6 G; 0 T; 1 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 903 ACGCUCACACAGAGAGAG 921
Db 1 ACGCUCACACAGAGAGAG 19
|||||
RESULT 535
AEA02179
ID AEA02179 standard; RNA; 19 BP.
XX
AC AEA02179;
XX
XX 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 63.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
DR
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
PS Claim 33; SEQ ID NO 63; 184bp; English.

DR WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 29; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 8 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 507 CAUCACGAGCGCCGUCACG 525
Db 1 CAUCACGAGCGCCGUCACG 19
RESULT 532
AEA02150
ID AEA02150 standard; RNA; 19 BP.
AC AEA02150;
XX
XX 28-JUL-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 34.
DE
XX
XX Respiratory-Gen.; Antiaesthetic; Anti-allergic; Anti-inflammatory;
XX Neutropoietic; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
XX mucritution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
PD
XX
XX 20-AUG-2004; 2004WO-US027367.
PF
XX
XX 23-OCT-2003; 2003US-00693059.
PR
XX 24-NOV-2003; 2003US-00720448.
PR
XX 03-DEC-2003; 2003US-00727780.
PR
XX 14-JAN-2004; 2004US-00757803.
PR
XX 10-FEB-2004; 2004US-0543480P.
PR
XX 13-FEB-2004; 2004US-00780447.
PR
XX 11-MAR-2004; 2004US-00798090.
PR
XX 16-APR-2004; 2004US-00826966.
PR
XX 30-APR-2004; 2004WO-US013456.
PR
XX 24-MAY-2004; 2004WO-US016390.
PR
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macewiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX

PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 34; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 1 A; 6 C; 5 G; 0 T; 7 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 597 UUGGCGUCCUGCCAUUCUG 615
Db 1 UUGGCGUCCUGCCAUUCUG 19
RESULT 533
AEA02155
ID AEA02155 standard; RNA; 19 BP.
AC AEA02155;
XX
XX 28-JUL-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 39.
DE
XX
XX Respiratory-Gen.; Antiaesthetic; Anti-allergic; Anti-inflammatory;
XX Neutropoietic; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
XX mucritution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
PD
XX
XX 20-AUG-2004; 2004WO-US027367.
PF
XX
XX 23-OCT-2003; 2003US-00693059.
PR
XX 24-NOV-2003; 2003US-00720448.
PR
XX 03-DEC-2003; 2003US-00727780.
PR
XX 14-JAN-2004; 2004US-00757803.
PR
XX 10-FEB-2004; 2004US-0543480P.
PR
XX 13-FEB-2004; 2004US-00780447.
PR
XX 11-MAR-2004; 2004US-00798090.
PR
XX 16-APR-2004; 2004US-00826966.
PR
XX 30-APR-2004; 2004WO-US013456.
PR
XX 24-MAY-2004; 2004WO-US016390.
PR
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macewiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing

PI	Richards I, Macswiggen J;
XX	
DR	WPI, 2005-356237/36.
XX	
PT	New short interfering nucleic acid molecule that directs cleavage of a
PT	cholelnergic receptor muscarinic 3 RNA, useful for treating or preventing
PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX	disease.
PS	Claim 33; SEQ ID NO 173; 184pp; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siNA) molecule that directs cleavage of a
CC	cholelnergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC	(RNAi). The siNA molecule, compounds, compositions, and methods are
CC	useful for treating or preventing respiratory and pulmonary diseases,
CC	disorders, and/or conditions, including chronic obstructive pulmonary
CC	diseases, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX	present sequence represents a cholelnergic receptor muscarinic 3 siRNA.
XX	
SEQ	Sequence 19 BP; 5 A; 3 C; 7 G; 0 T; 4 U; 0 Other;
Query Match	1.1%; Score 19; DB 1; Length 19;
Best Local Similarity	73.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;	
OY	1317 GACUUCGACGUCGACCTCC 1335
	: : :
Db	19 GACCTTCGACGCTCACTCC 1
RESULT 531	
AEA02145	
ID	AEA02145 standard; RNA; 19 BP.
XX	
AC	AEA02145;
XX	
DT	28-JUN-2005 (first entry)
XX	
DE	Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 29.
XX	
XX	Respiratory; Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW	Nootropic; Nootropic; Utopathic;
KW	chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW	sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW	multitrition disorder; cholelnergic receptor muscarinic 3; CHRM3; ss;
KW	siRNA; RNA interference; gene silencing; short interfering RNA.
XX	
OS	Synthetic.
XX	
WO	WO2005045040-A2.
XX	
PD	19-MAY-2005.
XX	
PF	20-AUG-2004; 2004WO-US027367.
XX	
XX	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00720448.
PR	03-DEC-2003; 2003US-00727780.
PR	14-JAN-2004; 2004US-00757803.
PR	10-FEB-2004; 2004US-0543480P.
PR	13-FEB-2004; 2004US-00780447.
PR	11-MAR-2004; 2004US-00798090.
PR	16-APR-2004; 2004US-00826966.
PR	30-APR-2004; 2004WO-US013456.
PR	24-MAY-2004; 2004WO-US016390.
PR	17-AUG-2004; 2004US-00919866.
XX	
XX	(SIRN-) SIRNA THERAPEUTICS INC.
XX	
XX	Richards I, Macswiggen J;
XX	
PI	

PR 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US015390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PI Richards I, Macswiggen J;
XX WPI; 2005-356237/36.
XX
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 137; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 5 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 669 UCAGUUCCTCAGAGAGCCC 687
DB 19 TCAGTTCCTCAGAGAGCCC 1
RESULT 528
AEA02279/c
ID AEA02279 standard; RNA; 19 BP.
XX
XX AEA02279;
AC
XX
XX 28-JUL-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 163.
DE
XX
XX Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
KW microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX
XX WO2005045040-A2.
PN
XX
XX 19-MAY-2005.
PD
XX
XX 20-AUG-2004; 2004WO-US027367.
PF
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
XX

PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA Richards I, Macswiggen J;
XX WPI; 2005-356237/36.
XX
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 163; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 4 A; 1 C; 9 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1137 CUCACCAAGUAGCCUCA 1155
DB 19 CTCACCAAGTTACCTCA 1
RESULT 529
AEA02280/c
ID AEA02280 standard; RNA; 19 BP.
XX
XX AEA02280;
AC
XX
XX 28-JUL-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 164.
DE
XX
XX Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
KW microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX
XX WO2005045040-A2.
PN
XX
XX 19-MAY-2005.
PD
XX
XX 20-AUG-2004; 2004WO-US027367.
PF
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX

PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX PI Richards I, Macswigen J;
XX DR WPI; 2005-356237/36.
XX
XX PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX PS Claim 33; SEQ ID NO 56; 184pp; English.
XX
XX CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SQ Sequence 19 BP; 5 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 993 CAGCAGCAGGACGACGUGG 1011
DB 1 CAGCAGCAGGACGACGUGG 19
RESULT 526
AEA02223/c
ID AEA02223 standard; RNA; 19 BP.
XX
XX AC AEA02223;
XX
XX DT 28-JUL-2005 (first entry)
XX
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 107.
XX
XX KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX OS Synthetic.
XX
XX PN WO2005045040-A2.
XX
XX PD 19-MAY-2005.
XX
XX PF 20-AUG-2004; 2004WO-US027367.
XX
XX PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.

PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX PI Richards I, Macswigen J;
XX XX DR WPI; 2005-356237/36.
XX
XX PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX PS Claim 33; SEQ ID NO 107; 184pp; English.
XX
XX CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SQ Sequence 19 BP; 5 A; 5 C; 5 G; 0 T; 4 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 129 UCGAGCAGCGGCAUUC 147
DB 19 TCGAGCAGCTCGCAATTTC 1
RESULT 527
AEA02253/c
ID AEA02253 standard; RNA; 19 BP.
XX
XX AC AEA02253;
XX
XX DT 28-JUL-2005 (first entry)
XX
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 137.
XX
XX KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX OS Synthetic.
XX
XX PN WO2005045040-A2.
XX
XX PD 19-MAY-2005.
XX
XX PF 20-AUG-2004; 2004WO-US027367.
XX
XX PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.

PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-054380P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 XX (SIRN-) SIRNA THERAPEUTICS INC.
 PA Richards I, Macswiggen J;
 PI WPI; 2005-356237/36.
 DR
 XX New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 PS Claim 33; SEQ ID NO 40; 184bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 19 BP; 3 A; 5 C; 3 G; 0 T; 8 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 705 AGCCAUCCGCGCUUUUUU 723
 Db 1 AGCCAUCCGCGCUUUUUU 19
 RESULT 524
 AEA02161
 ID AEA02161 standard; RNA; 19 BP.
 AC AEA02161;
 XX
 DT 28-JUL-2005 (first entry)
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 45.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
 KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX
 PN WO2005045040-A2.
 PD 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-054380P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 XX (SIRN-) SIRNA THERAPEUTICS INC.
 PA Richards I, Macswiggen J;
 PI WPI; 2005-356237/36.
 DR
 XX New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 PS Claim 33; SEQ ID NO 45; 184bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 19 BP; 2 A; 7 C; 5 G; 0 T; 5 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 795 UGCGGCGCGCAAGCCUCU 813
 Db 1 UGCGGCGCGCAAGCCUCU 19

PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-054380P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 XX (SIRN-) SIRNA THERAPEUTICS INC.
 PA Richards I, Macswiggen J;
 PI WPI; 2005-356237/36.
 DR
 XX New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 PS Claim 33; SEQ ID NO 45; 184bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 19 BP; 2 A; 7 C; 5 G; 0 T; 5 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 795 UGCGGCGCGCAAGCCUCU 813
 Db 1 UGCGGCGCGCAAGCCUCU 19
 RESULT 525
 AEA02172
 ID AEA02172 standard; RNA; 19 BP.
 AC AEA02172;
 XX
 DT 28-JUL-2005 (first entry)
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 56.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
 KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX
 PN WO2005045040-A2.
 PD 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.

PD 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 XX (SIRN-) SIRNA THERAPEUTICS INC.
 PA
 PI Richards I, Macswigen J;
 XX
 DR WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 16; 184pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 19 BP; 7 A; 3 C; 4 G; 0 T; 5 U; 0 Other;
 XX
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 273 GUCAUUUAAGGUCACACAG 291
 Db 1 GUCAUUUAAGGUCACACAG 19
 RESULT 522
 AEA02141
 ID AEA02141 standard; RNA; 19 BP.
 XX
 AC AEA02141;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 25.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
 KW micturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX
 XX WO2005045040-A2.
 PN
 XX 19-MAY-2005.
 PD
 XX 19-MAY-2005.
 XX

PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 XX (SIRN-) SIRNA THERAPEUTICS INC.
 PA
 PI Richards I, Macswigen J;
 XX
 DR WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 25; 184pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 19 BP; 4 A; 6 C; 4 G; 0 T; 5 U; 0 Other;
 XX
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 435 UGCGAUUGACUACGUGGCC 453
 Db 1 UGCGAUUGACUACGUGGCC 19
 RESULT 523
 AEA02156
 ID AEA02156 standard; RNA; 19 BP.
 XX
 AC AEA02156;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 40.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
 KW micturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX
 XX WO2005045040-A2.
 PN
 XX 19-MAY-2005.
 PD
 XX 20-AUG-2004; 2004WO-US027367.
 XX

OS Synthetic.
 XX
 PN WO2005045040-A2.
 XX
 PD 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Richards I, Macewiggen J;
 DR WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 178; 184bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 19 BP; 2 A; 5 C; 4 G; 0 T; 8 U; 0 Other;
 XX
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.6e+02;
 Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 OY 1407 GAAGACCGAGAGUCAGAU 1425
 DB 19 GAAGACCGAGAGTCATC 1
 XX
 RESULT 520
 AEA02309/c
 ID AEA02309 standard; RNA; 19 BP.
 XX
 AC AEA02309;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 193.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX

PN WO2005045040-A2.
 XX
 PD 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Richards I, Macewiggen J;
 DR WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 193; 184bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 19 BP; 4 A; 6 C; 4 G; 0 T; 5 U; 0 Other;
 XX
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 78.9%; Pred. No. 1.6e+02;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 OY 1677 GCTGTCCTCAGTGTGACAAA 1695
 DB 19 GCTGTCCTCAGTGTGACAAA 1
 XX
 RESULT 521
 AEA02132
 ID AEA02132 standard; RNA; 19 BP.
 XX
 AC AEA02132;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 16.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX
 PN WO2005045040-A2.
 XX

KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004MO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004MO-US013456.
PR 24-MAY-2004; 2004MO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
PS Claim 33; SEQ ID NO 147; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 3 A; 6 C; 6 G; 0 T; 4 U; 0 Other;
XX
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.6e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 849 CACGGGACAGUUCUGAGGC 867
DB |||||:|||||
19 CACGGGACAGTCTCGAGC 1

RESULT 518
AEA02283/C
ID AEA02283 standard; RNA; 19 BP.
XX
AC AEA02283;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 167.
XX
KW Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;

KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004MO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004MO-US013456.
PR 24-MAY-2004; 2004MO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
PS Claim 33; SEQ ID NO 167; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 1 A; 6 C; 5 G; 0 T; 7 U; 0 Other;
XX
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.6e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1209 GAAGCCGACAGCUCGAG 1227
DB |||||:|||||
19 GAAGCCGACAGCTGCAG 1

RESULT 519
AEA02294/C
ID AEA02294 standard; RNA; 19 BP.
XX
AC AEA02294;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 178.
XX
KW Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.

XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 KW microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 PN WO2005045040-A2.
 XX
 PD 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 XX PR 24-NOV-2003; 2003US-00720448.
 XX PR 03-DEC-2003; 2003US-00727780.
 XX PR 14-JAN-2004; 2004US-00757803.
 XX PR 10-FEB-2004; 2004US-0543480P.
 XX PR 13-FEB-2004; 2004US-00780447.
 XX PR 11-MAR-2004; 2004US-00798090.
 XX PR 16-APR-2004; 2004US-00826966.
 XX PR 30-APR-2004; 2004WO-US013456.
 XX PR 24-MAY-2004; 2004WO-US016390.
 XX PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Richards I, Macawiggen J;
 XX
 DR WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 109; 184pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 19 BP; 3 A; 5 C; 7 G; 0 T; 4 U; 0 Other;
 QY Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 1.6e+02;
 Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 165 CACCGAUGACCCUUCGGA 183
 Db 19 CACCGATGACCTCTGGGA 1
 RESULT 516
 AEA02231/C
 ID AEA02231 standard; RNA; 19 BP.
 XX
 AC AEA02231;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 115.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;

KW Neuroprotective; Nootropic; Uropathic;
 KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 KW microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 PN WO2005045040-A2.
 XX
 PD 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 XX PR 24-NOV-2003; 2003US-00720448.
 XX PR 03-DEC-2003; 2003US-00727780.
 XX PR 14-JAN-2004; 2004US-00757803.
 XX PR 10-FEB-2004; 2004US-0543480P.
 XX PR 13-FEB-2004; 2004US-00780447.
 XX PR 11-MAR-2004; 2004US-00798090.
 XX PR 16-APR-2004; 2004US-00826966.
 XX PR 30-APR-2004; 2004WO-US013456.
 XX PR 24-MAY-2004; 2004WO-US016390.
 XX PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Richards I, Macawiggen J;
 XX
 DR WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 115; 184pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 19 BP; 5 A; 4 C; 3 G; 0 T; 7 U; 0 Other;
 QY Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 73.7%; Pred. No. 1.6e+02;
 Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 273 GUCATUUAAGUCACAAAG 291
 Db 19 GTCATTTAAGTCACAAAG 1
 RESULT 517
 AEA02263/C
 ID AEA02263 standard; RNA; 19 BP.
 XX
 AC AEA02263;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 147.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;

```
XX 28-JUL-2005 (first entry)
DT
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 60.
DE
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX micturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
OS
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX
XX 24-NOV-2003; 2003US-00720448.
XX
XX 03-DEC-2003; 2003US-00727780.
XX
XX 14-JAN-2004; 2004US-00757803.
XX
XX 10-FEB-2004; 2004US-0543480P.
XX
XX 13-FEB-2004; 2004US-00780447.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 16-APR-2004; 2004US-00826966.
XX
XX 30-APR-2004; 2004WO-US013456.
XX
XX 24-MAY-2004; 2004WO-US016390.
XX
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswigen J;
XX
XX MPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 60; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 4 A; 5 C; 7 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1065 GGACAUUGGCGUCGAGCG 1083
DB 1 GGACAUUGGCGUCGAGACG 19
RESULT 514
ID AEA02185 standard; RNA; 19 BP.
XX
XX AEA02185;
XX
XX 28-JUL-2005 (first entry)
DT
```

```
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 69.
DE
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX micturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
OS
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX
XX 24-NOV-2003; 2003US-00720448.
XX
XX 03-DEC-2003; 2003US-00727780.
XX
XX 14-JAN-2004; 2004US-00757803.
XX
XX 10-FEB-2004; 2004US-0543480P.
XX
XX 13-FEB-2004; 2004US-00780447.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 16-APR-2004; 2004US-00826966.
XX
XX 30-APR-2004; 2004WO-US013456.
XX
XX 24-MAY-2004; 2004WO-US016390.
XX
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswigen J;
XX
XX MPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 69; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 5 A; 5 C; 8 G; 0 T; 1 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1227 GGCCGAGAGCGGUGAC 1245
DB 1 GGCCGAGAGCGGUGAC 19
RESULT 515
ID AEA02225/c
XX
XX AEA02225 standard; RNA; 19 BP.
XX
XX AEA02225;
XX
XX 28-JUL-2005 (first entry)
DT Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 109.
DE
```

ID	AEAO2168
AC	AEAO2163; standard; RNA; 19 BP.
AD	
AE	AEAO2163;
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	
AO	
AP	
AQ	
AR	
AS	
AT	
AV	
AW	
AX	
AY	
AZ	
BA	
BB	
BC	
BD	
BE	
BF	
BG	
BH	
BI	
BJ	
BK	
BL	
BM	
BN	
BO	
BP	
BQ	
BR	
BS	
BT	
BU	
BV	
BW	
BX	
BY	
BZ	
CA	
CB	
CC	
CD	
CE	
CF	
CG	
CH	
CI	
CJ	
CK	
CL	
CM	
CN	
CO	
CP	
CQ	
CR	
CS	
CT	
CU	
CV	
CW	
CX	
CY	
CA	
CB	
CC	
CD	
CE	
CF	
CG	
CH	
CI	
CJ	
CK	
CL	
CM	
CN	
CO	
CP	
CQ	
CR	
CS	
CT	
CU	
CV	
CW	
CX	
CY	
CA	
CB	
CC	
CD	
CE	
CF	
CG	
CH	
CI	
CJ	
CK	
CL	
CM	
CN	
CO	
CP	
CQ	
CR	
CS	
CT	
CU	
CV	
CW	
CX	
CY	
CA	
CB	
CC	
CD	
CE	
CF	
CG	
CH	
CI	
CJ	
CK	
CL	
CM	
CN	
CO	
CP	
CQ	
CR	
CS	
CT	
CU	
CV	
CW	
CX	
CY	
CA	
CB	
CC	
CD	
CE	
CF	
CG	
CH	
CI	
CJ	
CK	
CL	
CM	
CN	
CO	
CP	
CQ	
CR	
CS	
CT	
CU	
CV	
CW	
CX	
CY	
CA	
CB	
CC	
CD	
CE	
CF	
CG	
CH	
CI	
CJ	
CK	
CL	
CM	
CN	
CO	
CP	
CQ	
CR	
CS	
CT	
CU	
CV	
CW	
CX	
CY	
CA	
CB	
CC	
CD	
CE	
CF	
CG	
CH	
CI	
CJ	
CK	
CL	
CM	
CN	
CO	
CP	
CQ	
CR	
CS	
CT	
CU	
CV	
CW	
CX	
CY	
CA	
CB	
CC	
CD	
CE	
CF	
CG	
CH	
CI	
CJ	
CK	
CL	
CM	
CN	
CO	
CP	
CQ	
CR	
CS	
CT	
CU	
CV	
CW	
CX	
CY	
CA	
CB	
CC	
CD	
CE	
CF	
CG	
CH	
CI	
CJ	
CK	
CL	
CM	
CN	
CO	
CP	
CQ	
CR	
CS	
CT	
CU	

[illegible]

Db 19 CCGGCGCTGNGCGATCTG 1

RESULT 509
AEA02275/C
ID AEA02275 standard; RNA; 19 BP.
XX
AC AEA02275;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 159.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mucritution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 159; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 3 A; 7 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.6e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1065 GAGCAUUGGCTCCGAGACG 1083
|||:|||||
Db 19 GAGCAUUGGCTCCGAGACG 1

RESULT 510
AEA02159
ID AEA02159 standard; RNA; 19 BP.
XX
AC AEA02159;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 43.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mctritution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 43; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 9 A; 2 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 759 GAUCUUAAGGAACUGAA 777
|||||
Db 1 GAUCUUAAGGAACUGAA 19

RESULT 511

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1749 GCGCGACCCGAGCAGGCC 1767
 |||||
 DB 1 GCGCGACCCGAGCAGGCC 19

RESULT 507
 AEA02219/C
 ID AEA02219 standard; RNA; 19 BP.
 AC AEA02219;
 XX
 XX
 DT 28-JUL-2005 (first entry)

Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 103.
 XX
 XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 XX Neutropoietic; Nootropic; Uropathic;
 XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 XX microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 XX siRNA; RNA interference; gene silencing; short interfering RNA.
 OS Synthetic.
 XX
 XX WO2005045040-A2.
 XX
 XX PD 19-MAY-2005.
 XX
 XX PF 20-AUG-2004; 2004WO-US027367.
 XX
 XX PR 23-OCT-2003; 2003US-00693059.
 XX PR 24-NOV-2003; 2003US-00720448.
 XX PR 03-DEC-2003; 2003US-00727780.
 XX PR 14-JAN-2004; 2004US-00757803.
 XX PR 10-FEB-2004; 2004US-0543480P.
 XX PR 13-FEB-2004; 2004US-007980447.
 XX PR 11-MAR-2004; 2004US-00798090.
 XX PR 16-APR-2004; 2004US-00826966.
 XX PR 30-APR-2004; 2004WO-US013456.
 XX PR 24-MAY-2004; 2004WO-US016390.
 XX PR 17-AUG-2004; 2004US-00919866.
 XX
 XX PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 XX PI Richards I, Macswiggen J;
 XX
 XX DR WPI; 2005-356237/36.
 XX
 XX PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 XX PS Claim 33; SEQ ID NO 103; 184pp; English.
 XX
 XX CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 XX SQ Sequence 19 BP; 3 A; 3 C; 9 G; 0 T; 4 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 1.6e+02;
 Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 57 CUGGAUACAGCCGCCUC 75
 |||||
 DB 19 CTGATACAGCCCTCC 1

RESULT 508
 AEA02234/C
 ID AEA02234 standard; RNA; 19 BP.
 AC AEA02234;
 XX
 XX
 DT 28-JUL-2005 (first entry)

Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 118.
 XX
 XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 XX Neutropoietic; Nootropic; Uropathic;
 XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 XX microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 XX siRNA; RNA interference; gene silencing; short interfering RNA.
 OS Synthetic.
 XX
 XX WO2005045040-A2.
 XX
 XX PD 19-MAY-2005.
 XX
 XX PF 20-AUG-2004; 2004WO-US027367.
 XX
 XX PR 23-OCT-2003; 2003US-00693059.
 XX PR 24-NOV-2003; 2003US-00720448.
 XX PR 03-DEC-2003; 2003US-00727780.
 XX PR 14-JAN-2004; 2004US-00757803.
 XX PR 10-FEB-2004; 2004US-0543480P.
 XX PR 13-FEB-2004; 2004US-00780447.
 XX PR 11-MAR-2004; 2004US-00798090.
 XX PR 16-APR-2004; 2004US-00826966.
 XX PR 30-APR-2004; 2004WO-US013456.
 XX PR 24-MAY-2004; 2004WO-US016390.
 XX PR 17-AUG-2004; 2004US-00919866.
 XX
 XX PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 XX PI Richards I, Macswiggen J;
 XX
 XX DR WPI; 2005-356237/36.
 XX
 XX PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 XX PS Claim 33; SEQ ID NO 118; 184pp; English.
 XX
 XX CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 XX SQ Sequence 19 BP; 5 A; 6 C; 7 G; 0 T; 1 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 73.7%; Pred. No. 1.6e+02;
 Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Sequence 19 BP; 3 A; 4 C; 4 G; 0 T; 8 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1533 UCUGUGAACACCCUUGU 1551
|||||
Db 1 UCUGUGAACACCCUUGU 19

RESULT 505
AEA02212
ID AEA02212 standard; RNA; 19 BP.
AC AEA02212;
DT 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 96.
DE
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neutroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswigen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 96; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimers disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 7 A; 5 C; 6 G; 0 T; 1 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1713 GCAGUACGACGACAGCAG 1731
|||||
Db 1 GCAGUACGACGACAGCAG 19

RESULT 506
AEA02214
ID AEA02214 standard; RNA; 19 BP.
AC AEA02214;
DT 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 98.
DE
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neutroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswigen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 98; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimers disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 3 A; 9 C; 7 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;

CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 5 A; 7 C; 3 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1083 GAGAGCCCAUCUACUCCAUCC 1101
DB 1 GAGAGCCCAUCUACUCCAUCC 19
RESULT 503
AEA02191
ID AEA02191 standard; RNA; 19 BP.
XX
AC AEA02191;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 75.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 75; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAI). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The

CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 5 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1335 CUACUGCGGUAGAGCAGC 1353
DB 1 CUACUGCGGUAGAGCAGC 19
RESULT 504
AEA02202
ID AEA02202 standard; RNA; 19 BP.
XX
AC AEA02202;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 86.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 86; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAI). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.

CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 5 A; 7 C; 1 G; 0 T; 6 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 309 CACUACUUCUCUUAAGC 327
Db 1 CACUACUUCUCUUAAGC 19
RESULT 501
AEA02169
ID AEA02169 standard; RNA; 19 BP.
AC AEA02169;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 53.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 53; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are

CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 6 A; 6 C; 4 G; 0 T; 3 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 939 CUGGUCACACCAAGAGC 957
Db 1 CUGGUCACACCAAGAGC 19
RESULT 502
AEA02177
ID AEA02177 standard; RNA; 19 BP.
AC AEA02177;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 61.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 61; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary

PS Claim 33; SEQ ID NO 180; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 3 A; 7 C; 4 G; 0 T; 5 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.6e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 1443 GUCCUCGUCACGAGAG 1461
Db 19 GTCCTGTCTCAGAGAG 1
RESULT 499
AEA02124
ID AEA02124 standard; RNA; 19 BP.
AC AEA02124;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 8.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW mucrition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00826966.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 8; 184pp; English.
XX

CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 5 C; 5 G; 0 T; 5 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 129 UCGAGCAGCUGGCAUUC 147
Db 1 UCGAGCAGCUGGCAUUC 19
RESULT 500
AEA02134
ID AEA02134 standard; RNA; 19 BP.
AC AEA02134;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 18.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW mucrition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 18; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC

PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 146; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 2 C; 7 G; 0 T; 6 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 831 AGAAAACUUUGUCCACCCC 849
DB 19 AGAAACTTGTGCACCCC 1
RESULT 497
AEA02276/c
ID AEA02276 standard; RNA; 19 BP.
XX
AC AEA02276;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 160.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM mucritution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macewiggen J;
XX
XX MPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary

PT disease.
XX
PS Claim 33; SEQ ID NO 160; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 3 C; 7 G; 0 T; 5 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1083 GAGAGCCAUUCUCCCAUC 1101
DB 19 GAGAGCCATCTACTCCATC 1
RESULT 498
AEA02296/c
ID AEA02296 standard; RNA; 19 BP.
XX
AC AEA02296;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 160.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM mucritution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macewiggen J;
XX
XX MPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX

XX WPI; 2005-356237/36.
DR
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 125; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 6 A; 4 C; 5 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 453 CAGCAUAGCCTCUGUUAUG 471
DB 19 CAGCAATGCTCTGTATG 1
RESULT 495
AEA02254/c
ID AEA02254 standard; RNA; 19 BP.
XX
AC AEA02254;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 138.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW mucurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) siRNA THERAPEUTICS INC.
XX
PA Richards I, Macswigen J;
XX
PI WPI; 2005-356237/36.
XX
DR

XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 138; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 6 A; 2 C; 6 G; 0 T; 5 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 687 CACCAUACUUVUGGCACA 705
DB 19 CACCATCTCTTTGGCACA 1
RESULT 496
AEA02262/c
ID AEA02262 standard; RNA; 19 BP.
XX
AC AEA02262;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 146.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW mucurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) siRNA THERAPEUTICS INC.
XX
PA Richards I, Macswigen J;
XX
PI WPI; 2005-356237/36.
XX
DR New short interfering nucleic acid molecule that directs cleavage of a
XX
PT

```
XX (SIRM-) SIRM THERAPEUTICS INC.
PA
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 102; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 1 C; 9 G; 0 T; 5 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 39 UCCAAACAUACGCUCC 57
Db :|||||:|||||:|||||
19 TCCAAACATCAGCTCCTCC 1
RESULT 493
AEA02228/C
ID AEA02228 standard; RNA; 19 BP.
XX
AC AEA02228;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 112.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM micrution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRM-) SIRM THERAPEUTICS INC.
```

```
XX Richards I, Macswigen J;
PI
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 112; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 5 C; 7 G; 0 T; 3 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 219 CUUACGGGCAUCCUGGCC 237
Db :|||||:|||||:|||||
19 CTTAACGGGCACTCCTGACC 1
RESULT 494
AEA02241/C
ID AEA02241 standard; RNA; 19 BP.
XX
AC AEA02241;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 125.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM micrution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRM-) SIRM THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
```

PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richard I, Macswiggen J;
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 24; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 1 A; 6 C; 6 G; 0 T; 6 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 417 GGCCTUGAACCTCUGGCTU 435
DB 1 GGCCTUGAACCTCUGGCTU 19
RESULT 491
AEA02188
ID AEA02188 standard; RNA; 19 BP.
XX
XX AEA02188;
AC
XX 28-JUL-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 72.
DE
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX
XX WO2005045040-A2.
PN
XX
XX 19-MAY-2005.
PD
XX
XX 20-AUG-2004; 2004WO-US027367.
PF
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.

PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richard I, Macswiggen J;
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 72; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 5 A; 7 C; 3 G; 0 T; 4 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1281 UCCCAUCCAGCUGAGUCA 1299
DB 1 UCCCAUCCAGCUGAGUCA 19
RESULT 492
AEA02218/c
ID AEA02218 standard; RNA; 19 BP.
XX
XX AEA02218;
AC
XX 28-JUL-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 102.
DE
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX
XX WO2005045040-A2.
PN
XX
XX 19-MAY-2005.
PD
XX
XX 20-AUG-2004; 2004WO-US027367.
PF
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.

PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
PA (SIRN-) SIRNA THERAPEUTICS INC.
PI Richards I, Macswigen J;
XX WPI; 2005-356237/36.
DR
XX
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
PS Claim 33; SEQ ID NO 1; 184pp; English.
XX
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 7 A; 5 C; 3 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3 GACCTUGCACAUAACAGU 21
Db 1 GACCTUGCACAUAACAGU 19
RESULT 489
AEA02122
ID AEA02122 standard; RNA; 19 BP.
XX
XX
AC AEA02122;
XX
XX
DT 28-JUL-2005 (first entry)
XX
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 6.
XX
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR

PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
PA (SIRN-) SIRNA THERAPEUTICS INC.
PI Richards I, Macswigen J;
XX WPI; 2005-356237/36.
DR
XX
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
PS Claim 33; SEQ ID NO 6; 184pp; English.
XX
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 6 C; 4 G; 0 T; 5 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 93 GGGACCGUCACUUAUUC 111
Db 1 GGGACCGUCACUUAUUC 19
RESULT 490
AEA02140
ID AEA02140 standard; RNA; 19 BP.
XX
XX
AC AEA02140;
XX
XX
DT 28-JUL-2005 (first entry)
XX
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 24.
XX
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR

XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00727780.
PR 10-FEB-2004; 2004US-00757803.
PR 13-FEB-2004; 2004US-0543480P.
PR 11-MAR-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00798090.
PR 30-APR-2004; 2004US-00826966.
PR 24-MAY-2004; 2004WO-US013456.
PR 17-AUG-2004; 2004US-00919866.
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA Richards I, Macswiggen J;
XX WPI; 2005-356237/36.
DR New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
PS Claim 33; SEQ ID NO 144; 184bp; English.
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 5 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 795 UGCGGCGGCAAGCCUCU 813
DB 19 TCGTGGCTGCGAAGCCTCT 1
RESULT 487
AEA02292/c
-ID AEA02292 standard; RNA; 19 BP.
XX AEA02292;
AC
XX
XX 28-JUL-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 176.
DE
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neutroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX
XX WO2005045040-A2.
PN
XX
XX 19-MAY-2005.
PD
XX
XX 20-AUG-2004; 2004WO-US027367.
PF
XX
XX 23-OCT-2003; 2003US-00693059.
PR

PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US013456.
PR 17-AUG-2004; 2004US-00919866.
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA Richards I, Macswiggen J;
XX WPI; 2005-356237/36.
DR New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
PS Claim 33; SEQ ID NO 176; 184bp; English.
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 4 C; 6 G; 0 T; 5 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1371 CUTCAGGAAGCCACUCUG 1389
DB 19 CTTCAAGGAAGCCACTCTG 1
RESULT 488
AEA02117
ID AEA02117 standard; RNA; 19 BP.
XX AEA02117;
AC
XX
XX 28-JUL-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 1.
DE
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neutroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX
XX WO2005045040-A2.
PN
XX
XX 19-MAY-2005.
PD
XX
XX 20-AUG-2004; 2004WO-US027367.
PF
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR

```
XX 19-MAY-2005.
PD 20-AUG-2004; 2004MO-US027367.
XX
PF 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004MO-US013456.
PR 24-MAY-2004; 2004MO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
PI WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 134; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 9 A; 4 C; 3 G; 0 T; 3 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 1.6e+02;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;
QY 615 GUUCUGGCAUAUCUUGU 633
DB 19 GTTCTGGCAATCTTGT 1
RESULT 485
AEA02257/c
ID AEA02257 standard; RNA; 19 BP.
XX
XX AEA02257;
AC
XX
XX 28-JUL-2005 (first entry)
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 141.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mucritution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
```

```
XX 20-AUG-2004; 2004MO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004MO-US013456.
XX 24-MAY-2004; 2004MO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
PI WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 141; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 7 A; 5 C; 2 G; 0 T; 5 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 1.6e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
QY 741 GACUUAUUUUAUCUGAGG 759
DB 19 GACTATTATTACTGGAGG 1
RESULT 486
AEA02260/c
ID AEA02260 standard; RNA; 19 BP.
XX
XX AEA02260;
AC
XX
XX 28-JUL-2005 (first entry)
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 144.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mucritution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004MO-US027367.
```

XX OS Synthetic.
XX PN WO2005045040-A2.
XX PD 19-MAY-2005.
XX PF 20-AUG-2004; 2004WO-US027367.
XX PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004WO-US013456.
XX PR 24-MAY-2004; 2004WO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX PA (SIRN-) SIRNA THERAPEUTICS INC.
XX PI Richards I, Macswigen J;
XX DR WPI; 2005-356237/36.
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX PS Claim 33; SEQ ID NO 123; 184pp; English.
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, and/or conditions, including chronic obstructive pulmonary
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX SQ Sequence 19 BP; 6 A; 6 C; 6 G; 0 T; 1 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 68.4%; Pred. No. 1.6e+02;
XX Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
OY 417 GGCCTGUGACCTCCTGCTT 435
DB 19 GGCCTGTGACCTCTGCTT 1
XX
XX RESULT 483
XX AEA02246/c
XX ID AEA02246 standard; RNA; 19 BP.
XX AC AEA02246;
XX XX
XX DT 28-JUL-2005 (first entry)
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 130.
XX XX
XX KW Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
XX KW Neuroprotective; Nootropic; Uropathic;
XX KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX KW sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
XX KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX OS Synthetic.
XX PN

XX OS WO2005045040-A2.
XX PN 19-MAY-2005.
XX PD 20-AUG-2004; 2004WO-US027367.
XX PF 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004WO-US013456.
XX PR 24-MAY-2004; 2004WO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX PA (SIRN-) SIRNA THERAPEUTICS INC.
XX PI Richards I, Macswigen J;
XX DR WPI; 2005-356237/36.
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX PS Claim 33; SEQ ID NO 130; 184pp; English.
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, and/or conditions, including chronic obstructive pulmonary
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX SQ Sequence 19 BP; 2 A; 7 C; 3 G; 0 T; 7 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 89.5%; Pred. No. 1.6e+02;
XX Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY 543 AACAAAGAGCGCGUGUG 561
DB 19 AACAAAGAGCGCGGTG 1
XX
XX RESULT 484
XX AEA02250/c
XX ID AEA02250 standard; RNA; 19 BP.
XX AC AEA02250;
XX XX
XX DT 28-JUL-2005 (first entry)
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 134.
XX XX
XX KW Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
XX KW Neuroprotective; Nootropic; Uropathic;
XX KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX KW sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
XX KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX OS Synthetic.
XX PN WO2005045040-A2.

KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
OS Synthetic.
XX WO2005045040-A2.
XX PN
XX PD 19-MAY-2005.
XX PF 20-AUG-2004; 2004MO-US027367.
XX PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004MO-US013456.
XX PR 24-MAY-2004; 2004MO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX PA (SIRN-) SIRNA THERAPEUTICS INC.
XX PI Richards I, Macswigen J;
XX DR WPI; 2005-356237/36.
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX PS Claim 33; SEQ ID NO 88; 184pp; English.
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, and/or conditions, including chronic obstructive pulmonary
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX SQ Sequence 19 BP; 4 A; 4 C; 5 G; 0 T; 6 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1569 AACCUUUGCAUUCUGGC 1587
DB 1 AACCUUUGCAUUCUGGC 19
RESULT 481
AEA02208
ID AEA02208 standard; RNA; 19 BP.
XX
XX AC AEA02208;
XX DT 28-JUL-2005 (first entry)
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 92.
XX KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX KM Neuroprotective; Nootropic; Uropathic;
XX KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;

KM microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
OS Synthetic.
XX WO2005045040-A2.
XX PN
XX PD 19-MAY-2005.
XX PF 20-AUG-2004; 2004MO-US027367.
XX PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004MO-US013456.
XX PR 24-MAY-2004; 2004MO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX PA (SIRN-) SIRNA THERAPEUTICS INC.
XX PI Richards I, Macswigen J;
XX DR WPI; 2005-356237/36.
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX PS Claim 33; SEQ ID NO 92; 184pp; English.
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, and/or conditions, including chronic obstructive pulmonary
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX SQ Sequence 19 BP; 10 A; 6 C; 1 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1641 CAACAAACAUUCAGAAC 1659
DB 1 CAACAAACAUUCAGAAC 19
RESULT 482
AEA02239/C
ID AEA02239 standard; RNA; 19 BP.
XX
XX AC AEA02239;
XX DT 28-JUL-2005 (first entry)
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 123.
XX KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX KM Neuroprotective; Nootropic; Uropathic;
XX KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX KM microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX KM siRNA; RNA interference; gene silencing; short interfering RNA.

DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 65.
XX Respiratory-Gen.; Antiasthmatic; Anti allergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX
XX PD 19-MAY-2005.
XX
XX PF 20-AUG-2004; 2004WO-US027367.
XX
XX PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004WO-US013456.
XX PR 24-MAY-2004; 2004WO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX PI Richards I, Macswigen J;
XX
XX DR WPI; 2005-356237/36.
XX
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX PS Claim 33; SEQ ID NO 65; 184pp; English.
XX
XX CC The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SQ Sequence 19 BP; 5 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1155 AUCGACACACUCGACGUG 1173
XX |||||
XX 1 AUCGACACACUCGACGUG 19
XX
XX DB
XX
XX RESULT 479
XX AEA02201
XX ID AEA02201 standard; RNA; 19 BP.
XX
XX AC AEA02201;
XX
XX XX 28-JUL-2005 (first entry)
XX
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 85.
XX

KW Respiratory-Gen.; Antiasthmatic; Anti allergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX
XX PD 19-MAY-2005.
XX
XX PF 20-AUG-2004; 2004WO-US027367.
XX
XX PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004WO-US013456.
XX PR 24-MAY-2004; 2004WO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX PI Richards I, Macswigen J;
XX
XX DR WPI; 2005-356237/36.
XX
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX PS Claim 33; SEQ ID NO 85; 184pp; English.
XX
XX CC The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SQ Sequence 19 BP; 6 A; 6 C; 2 G; 0 T; 5 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1515 CCCAUCACACUACUGGU 1533
XX |||||
XX 1 CCCAUCACACUACUGGU 19
XX
XX DB
XX
XX RESULT 480
XX AEA02204
XX ID AEA02204 standard; RNA; 19 BP.
XX
XX AC AEA02204;
XX
XX XX 28-JUL-2005 (first entry)
XX
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 88.
XX
XX KW Respiratory-Gen.; Antiasthmatic; Anti allergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;

AC AEA02119;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 3.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 3; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 5 A; 9 C; 1 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 39 UCCAAACUACGUCUCC 57
Db 1 UCCAAACUACGUCUCC 19
RESULT 477
AEA02130
ID AEA02130 standard; RNA; 19 BP.
XX
AC AEA02130;
XX

DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 14.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 14; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 3 A; 6 C; 5 G; 0 T; 5 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 237 CUUGUGACCAUCAUCGC 255
Db 1 CUUGUGACCAUCAUCGC 19
RESULT 478
AEA02181
ID AEA02181 standard; RNA; 19 BP.
XX
AC AEA02181;
XX
DT 28-JUL-2005 (first entry)
XX

RESULT 474
AEA02305/C
ID AEA02305 standard; RNA; 19 BP.
XX
XX
AC AEA02305;
XX
XX
DT 28-JUL-2005 (first entry)
XX
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 189.
XX
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neutroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW micurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX
OS Synthetic.
XX
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richard I, Macswiggen J;
XX
XX
DR WPI; 2005-356237/36.
XX
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
PS Claim 33; SEQ ID NO 189; 184bp; English.
XX
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX
SQ Sequence 19 BP; 1 A; 3 C; 9 G; 0 T; 6 U; 0 Other;
XX
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.6e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1605 CAACAGCACCUGAACCCC 1623
|||
DB 19 CAACAGCACCUGAACCCC 1

RESULT 475
AEA02118

ID AEA02118 standard; RNA; 19 BP.
XX
XX
AC AEA02118;
XX
XX
DT 28-JUL-2005 (first entry)
XX
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 2.
XX
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neutroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW micurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX
OS Synthetic.
XX
XX
PN WO2005045040-A2.
XX
XX
PD 19-MAY-2005.
XX
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richard I, Macswiggen J;
XX
XX
DR WPI; 2005-356237/36.
XX
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
PS Claim 33; SEQ ID NO 2; 184bp; English.
XX
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX
SQ Sequence 19 BP; 3 A; 6 C; 2 G; 0 T; 8 U; 0 Other;
XX
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 UACACCTUCGCCUUGUUU 39
|||
DB 1 UACACCTUCGCCUUGUUU 19

RESULT 476
AEA02119
ID AEA02119 standard; RNA; 19 BP.
XX

Db 19 TGGCATTGACTAGTACC 1

RESULT 472
AEA02255/c
ID AEA02255 standard; RNA; 19 BP.
XX
AC AEA02255;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 139.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM mucritation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004WO-US013456.
XX PR 24-MAY-2004; 2004WO-US013390.
XX PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX
PS Claim 33; SEQ ID NO 139; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary,
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 8 A; 3 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 1.6e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 705 AGCCAUCGCGCUCUUUUU 723
DB 19 AGCCATCGCTGCTTTTAT 1

RESULT 473
AEA02268/c
ID AEA02268 standard; RNA; 19 BP.
XX
AC AEA02268;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 152.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM mucritation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004WO-US013456.
XX PR 24-MAY-2004; 2004WO-US013390.
XX PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX
PS Claim 33; SEQ ID NO 152; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary,
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 3 A; 4 C; 6 G; 0 T; 6 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.6e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 939 CUGGUCACACCAACGAGC 957
DB 19 CTGGTCACACCAAGAGC 1

Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 111 CGGCGACUACGAGUUCU 129

DB 19 CGGCGACTACAAATGTTCT 1

RESULT 470

AE02232/c
ID AEA02232 standard; RNA; 19 BP.

AC AEA02232;

DT 28-JUL-2005 (first entry)

DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 116.

KW Respiratory-Gen.; Antiaschmatic; Antiallergic; Antiinflammatory;

KW Neuroprotective; Nootropic; Uropathic;

KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;

KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;

KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;

KW siRNA; RNA interference; gene silencing; short interfering RNA.

OS Synthetic.

PN WO2005045040-A2.

PD 19-MAY-2005.

PF 20-AUG-2004; 2004WO-US027367.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 03-DEC-2003; 2003US-00727803.

PR 14-JAN-2004; 2004US-00757803.

PR 10-FEB-2004; 2004US-0543480P.

PR 13-FEB-2004; 2004US-00780447.

PR 11-MAR-2004; 2004US-00798090.

PR 16-APR-2004; 2004US-00826966.

PR 30-APR-2004; 2004WO-US013456.

PR 24-MAY-2004; 2004WO-US016390.

PR 17-AUG-2004; 2004US-00919866.

PA (SIRN-) SIRNA THERAPEUTICS INC.

PI Richards I, Macswigen J;

DR WPI; 2005-356237/36.

PT New short interfering nucleic acid molecule that directs cleavage of a

PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing

PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary

PT disease.

PS Claim 33; SEQ ID NO 116; 184pp; English.

XX The invention relates to a chemically synthesized double stranded short

XX interfering nucleic acid (siNA) molecule that directs cleavage of a

XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference

XX (RNAi). The siNA molecule, compounds, compositions, and methods are

XX useful for treating or preventing respiratory and pulmonary diseases,

XX disorders, and/or conditions, including chronic obstructive pulmonary

XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,

XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The

XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX Sequence 19 BP; 2 A; 6 C; 5 G; 0 T; 6 U; 0 Other;

XX Query Match 1.1%; Score 19; DB 1; Length 19;

XX Best Local Similarity 89.5%; Pred. No. 1.6e+02;

XX Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 291 GCACGUGAGACGCGUAC 309

DB 19 GCACGUGAGACGCGUAC 1

RESULT 471

AE02240/c
ID AEA02240 standard; RNA; 19 BP.

AC AEA02240;

DT 28-JUL-2005 (first entry)

DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 124.

KW Respiratory-Gen.; Antiaschmatic; Antiallergic; Antiinflammatory;

KW Neuroprotective; Nootropic; Uropathic;

KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;

KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;

KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;

KW siRNA; RNA interference; gene silencing; short interfering RNA.

OS Synthetic.

PN WO2005045040-A2.

PD 19-MAY-2005.

PF 20-AUG-2004; 2004WO-US027367.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 03-DEC-2003; 2003US-00727803.

PR 14-JAN-2004; 2004US-00757803.

PR 10-FEB-2004; 2004US-0543480P.

PR 13-FEB-2004; 2004US-00780447.

PR 11-MAR-2004; 2004US-00798090.

PR 16-APR-2004; 2004US-00826966.

PR 30-APR-2004; 2004WO-US013456.

PR 24-MAY-2004; 2004WO-US016390.

PR 17-AUG-2004; 2004US-00919866.

PA (SIRN-) SIRNA THERAPEUTICS INC.

PI Richards I, Macswigen J;

DR WPI; 2005-356237/36.

PT New short interfering nucleic acid molecule that directs cleavage of a

PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing

PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary

PT disease.

PS Claim 33; SEQ ID NO 124; 184pp; English.

XX The invention relates to a chemically synthesized double stranded short

XX interfering nucleic acid (siNA) molecule that directs cleavage of a

XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference

XX (RNAi). The siNA molecule, compounds, compositions, and methods are

XX useful for treating or preventing respiratory and pulmonary diseases,

XX disorders, and/or conditions, including chronic obstructive pulmonary

XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,

XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The

XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX Sequence 19 BP; 5 A; 4 C; 6 G; 0 T; 4 U; 0 Other;

XX Query Match 1.1%; Score 19; DB 1; Length 19;

XX Best Local Similarity 73.7%; Pred. No. 1.6e+02;

XX Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

XX QY 435 UGCCAUUGACGUGACC 453

XX SQ Sequence 19 BP; 4 A; 1 C; 10 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1191 GAUGGUGACUUGAGAGG 1209
Db 1 GAUGGUGACUUGAGAGG 19
RESULT 468
AEA02203
ID AEA02203 standard; RNA; 19 BP.
XX AC AEA02203;
XX DT 28-JUL-2005 (first entry)
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 87.
XX KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX KM Neuroprotective; Nootropic; Uropathic;
XX KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX KM Sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX KM Micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX OS Synthetic.
XX PN WO2005045040-A2.
XX PD 19-MAY-2005.
XX PF 20-AUG-2004; 2004WO-US027367.
XX PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004WO-US013456.
XX PR 24-MAY-2004; 2004WO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX PA (SIRN-) SIRNA THERAPEUTICS INC.
XX PI Richards I, Macswiggen J;
XX DR WPI; 2005-356237/36.
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX PS Claim 33; SEQ ID NO 87; 184pp; English.
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, and/or conditions, including chronic obstructive pulmonary
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX SQ Sequence 19 BP; 7 A; 6 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1551 UGACAGCUGCAUACCCCAA 1569
Db 1 UGACAGCUGCAUACCCCAA 19
RESULT 469
AEA02222/c
ID AEA02222 standard; RNA; 19 BP.
XX AC AEA02222;
XX DT 28-JUL-2005 (first entry)
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 106.
XX KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX KM Neuroprotective; Nootropic; Uropathic;
XX KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX KM Sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX KM Micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX OS Synthetic.
XX PN WO2005045040-A2.
XX PD 19-MAY-2005.
XX PF 20-AUG-2004; 2004WO-US027367.
XX PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004WO-US013456.
XX PR 24-MAY-2004; 2004WO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX PA (SIRN-) SIRNA THERAPEUTICS INC.
XX PI Richards I, Macswiggen J;
XX DR WPI; 2005-356237/36.
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX PS Claim 33; SEQ ID NO 106; 184pp; English.
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, and/or conditions, including chronic obstructive pulmonary
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX SQ Sequence 19 BP; 6 A; 4 C; 5 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;

CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX SEQ Sequence 19 BP; 6 A; 3 C; 6 G; 0 T; 4 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 633 UGGAAGAGACUGCCU 651

Db 1 UGGAAGAGACUGCCU 19

RESULT 466

AEAO2170

ID AEAO2170 standard; RNA; 19 BP.

XX AC AEAO2170;

DT 28-JUL-2005 (first entry)

DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 54.

XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neutroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
XX microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.

OS Synthetic.

XX PN WO2005045040-A2.

XX PD 19-MAY-2005.

XX PF 20-AUG-2004; 2004WO-US027367.

XX PR 23-OCT-2003; 2003US-00693059.

XX PR 24-NOV-2003; 2003US-00720448.

XX PR 03-DEC-2003; 2003US-00727780.

XX PR 14-JAN-2004; 2004US-00757803.

XX PR 10-FEB-2004; 2004US-0543480P.

XX PR 13-FEB-2004; 2004US-00780447.

XX PR 11-MAR-2004; 2004US-00798090.

XX PR 16-APR-2004; 2004US-00826966.

XX PR 30-APR-2004; 2004WO-US013456.

XX PR 24-MAY-2004; 2004WO-US016390.

XX PR 17-AUG-2004; 2004US-00919866.

XX PA (SIRN-) SIRNA THERAPEUTICS INC.

XX PI Richards I, Macswiggen J;

XX DR WPI; 2005-356237/36.

XX PT New short interfering nucleic acid molecule that directs cleavage of a

XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing

XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary

XX PS disease.

XX PS Claim 33; SEQ ID NO 54; 184pp; English.

CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX SEQ Sequence 19 BP; 5 A; 7 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 957 CUGAACCACGUCGAG 975

Db 1 CUGAACCACGUCGAG 19

RESULT 467

AEAO2183

ID AEAO2183 standard; RNA; 19 BP.

XX AC AEAO2183;

DT 28-JUL-2005 (first entry)

DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 67.

XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neutroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
XX microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.

OS Synthetic.

XX PN WO2005045040-A2.

XX PD 19-MAY-2005.

XX PF 20-AUG-2004; 2004WO-US027367.

XX PR 23-OCT-2003; 2003US-00693059.

XX PR 24-NOV-2003; 2003US-00720448.

XX PR 03-DEC-2003; 2003US-00727780.

XX PR 14-JAN-2004; 2004US-00757803.

XX PR 10-FEB-2004; 2004US-0543480P.

XX PR 13-FEB-2004; 2004US-00780447.

XX PR 11-MAR-2004; 2004US-00798090.

XX PR 16-APR-2004; 2004US-00826966.

XX PR 30-APR-2004; 2004WO-US013456.

XX PR 24-MAY-2004; 2004WO-US016390.

XX PR 17-AUG-2004; 2004US-00919866.

XX PA (SIRN-) SIRNA THERAPEUTICS INC.

XX PI Richards I, Macswiggen J;

XX DR WPI; 2005-356237/36.

XX PT New short interfering nucleic acid molecule that directs cleavage of a

XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing

XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary

XX PS disease.

XX PS Claim 33; SEQ ID NO 67; 184pp; English.

CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP, 1 A; 7 C; 6 G; 0 T; 5 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 327 CCUGGCCUGGCCGCAUCUG 345
DB 1 CCUGGCCUGGCCGCAUCUG 19
RESULT 464
AEA02147
ID AEA02147 standard; RNA; 19 BP.
XX
AC AEA02147;
XX
DT 28-JUL-2005 (first entry)
XX
DB Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 31.
XX
KW Respiratory-Gen.; Antihistaminic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 31; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference

CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 7 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 543 AACAAAGAGAGCCGUGUG 561
DB 1 AACAAAGAGAGCCGUGUG 19
RESULT 465
AEA02152
ID AEA02152 standard; RNA; 19 BP.
XX
AC AEA02152;
XX
DT 28-JUL-2005 (first entry)
XX
DB Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 36.
XX
KW Respiratory-Gen.; Antihistaminic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 36; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,

Pt	New short interfering nucleic acid molecule that directs cleavage of a cholinergic receptor muscarinic 3 RNA, useful for treating or preventing respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary disease.
Xx	
Xx	
Ps	Claim 33; SEQ ID NO 169; 184pp; English.
Cc	The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siRNA) molecule that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference (RNAI). The siNA molecule, compounds, compositions, and methods are useful for treating or preventing respiratory and pulmonary diseases, disorders, and/or conditions, including chronic obstructive pulmonary disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies, cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The present sequence represents a cholinergic receptor muscarinic 3 siRNA.
Sq	Sequence 19 BP; 5 A; 6 C; 4 G; 0 T; 4 U; 0 Other;
Gy	
Dn	Query Match Blast Local Similarity 1.1%; Score 19; DB 1; Length 19; Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
	CGAUGAGGCGACGUUUCCA 1263 : ::: 19 CGATGGAGCAGATTTCCA 1
Ae	RESULT 460 AEA02293/C ID AEA02293 standard; RNA; 19 BP. Ac AEA02293; Xx Xx Xx Dt 28-JUL-2005 (first entry) Dd Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 177. Kw Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory; Xx Neuroprotective; Nootropic; Uropathic; Km Chronic obstructive pulmonary disease; asthma; allergic rhinitis; Kv sinusitis; inflammation; allergy; cystic fibrosis; alzhemiers disease; Rm mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss; Sina; RNA interference; gene silencing; short interfering RNA. Oo Synthetic. Xx Syntheic. Xk W02005040-A2. Pn Pn Pn Pn Pd Pf Pt Ps Px Py Pz Pd 19-MAY-2005. Pf 20-AUG-2004; 2004WO-US027367. Pt 23-OCT-2003; 2003US-00693059. Px 24-NOV-2003; 2003US-00720448. Py 03-DEC-2003; 2003US-00720448. Pz 14-JAN-2004; 2004US-00757803. Pa 10-FEB-2004; 2004US-053480P. Pr 13-FEB-2004; 2004US-00780447. Rs 11-MAR-2004; 2004US-00798090. Sc 16-APR-2004; 2004US-00826966. Td 30-APR-2004; 2004WO-US013456. Te 24-MAY-2004; 2004WO-US016390. Tf 17-AUG-2004; 2004US-00919866. Tp (SIRN-) SIRNA THERAPEUTICS INC. Tr Richards I, Macswigen J; Ts WPI: 2005-356237/36. Tx New short interfering nucleic acid molecule that directs cleavage of a cholinergic receptor muscarinic 3 RNA, useful for treating or preventing

```
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 177, 184pp; English.
PS
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAI). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 5 A; 7 C; 4 G; 0 T; 3 U; 0 Other;

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity   73.7%; Pred. No. 1.6e+02;
Matches    14; Conservative     5; Mismatches    0; Indels    0; Gaps    0;

QY          1389 GGCCAAGAGGUGUCUUGCUG 1407
Db           ||||| |:::||:| :|
              19 GGCCAAGAGGTTCCTCG 1

RESULT 461
AEA02301/C
ID AEA02301 standard; RNA; 19 BP.
XX
AC AEA02301;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 185.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Trophathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micronutrient disorder; cholinergic receptor muscarinic 3; CHRM3; ssr;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
PD 19-MAY-2005.
PF 20-AUG-2004; 2004WO-US027367.
PX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826366.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
X1 Richards I, Macswiggen J,
PI WPI; 2005-356237/36.
DR New short interfering nucleic acid molecule that directs cleavage of a
XT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
```

PI Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 158; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX
SQ Sequence 19 BP; 2 A; 6 C; 8 G; 0 T; 3 U; 0 Other;
XX
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02; Indels 0; Gaps 0;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
OY 1047 CGCCUCCUCCGACGAGAG 1065
DB 19 CGCCTCTCCGACGAGAG 1
XX
XX
RESULT 458
AEA02282/C
ID AEA02282 standard; RNA; 19 BP.
XX
XX
AC AEA02282;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 166.
XX
XX Respiratory-Gen.; Antiaesthetic; Antiallergic; Antiinflammatory;
XX Neutroprotective; Nootropic; Uropathic;
XX chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX microtution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX
OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX
PD 19-MAY-2005.
XX
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
XX
XX 23-OCT-2003; 2003US-00693059.
XX
XX 24-NOV-2003; 2003US-00720448.
XX
XX 03-DEC-2003; 2003US-00727780.
XX
XX 14-JAN-2004; 2004US-00757803.
XX
XX 10-FEB-2004; 2004US-0543480P.
XX
XX 13-FEB-2004; 2004US-00780447.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 16-APR-2004; 2004US-00826966.
XX
XX 30-APR-2004; 2004WO-US013456.
XX
XX 24-MAY-2004; 2004WO-US016390.
XX
XX 17-AUG-2004; 2004US-00919866.
XX
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX
XX Richards I, Macswiggen J;
XX
XX
XX

DR WPI; 2005-356237/36.
XX
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
XX Claim 33; SEQ ID NO 166; 184pp; English.
XX
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX
SQ Sequence 19 BP; 4 A; 10 C; 1 G; 0 T; 4 U; 0 Other;
XX
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02; Indels 0; Gaps 0;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
XX
OY 1191 GAUGUGGACUUGAGAGG 1209
DB 19 GATGGTGACCTGGAGAGG 1
XX
XX
RESULT 459
AEA02285/C
ID AEA02285 standard; RNA; 19 BP.
XX
XX
AC AEA02285;
XX
XX 28-JUL-2005 (first entry)
XX
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 169.
XX
XX Respiratory-Gen.; Antiaesthetic; Antiallergic; Antiinflammatory;
XX Neutroprotective; Nootropic; Uropathic;
XX chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX microtution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX
OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX
PD 19-MAY-2005.
XX
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
XX
XX 23-OCT-2003; 2003US-00693059.
XX
XX 24-NOV-2003; 2003US-00720448.
XX
XX 03-DEC-2003; 2003US-00727780.
XX
XX 14-JAN-2004; 2004US-00757803.
XX
XX 10-FEB-2004; 2004US-0543480P.
XX
XX 13-FEB-2004; 2004US-00780447.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 16-APR-2004; 2004US-00826966.
XX
XX 30-APR-2004; 2004WO-US013456.
XX
XX 24-MAY-2004; 2004WO-US016390.
XX
XX 17-AUG-2004; 2004US-00919866.
XX
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX
XX Richards I, Macswiggen J;
XX
XX
XX WPI; 2005-356237/36.
XX
XX
XX

PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 155; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 3 A; 7 C; 4 G; 0 T; 5 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.6e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
OY 993 GAGCAGCAGUGACAGUUG 1011
Db 19 CAGCAGCAGTGAAGATTGG 1
RESULT 456
AEA02272/C
ID AEA02272 standard; RNA; 19 BP.
XX
AC AEA02272;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 156.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00780090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX

PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 156; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 4 C; 4 G; 0 T; 7 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
OY 1011 GAACACAUGAUGUGUGU 1029
Db 19 GAACACAATGATGCTGCT 1
RESULT 457
AEA02274/C
ID AEA02274 standard; RNA; 19 BP.
XX
AC AEA02274;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 158.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00780090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX

PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00825966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX PI Richards I, Macswigen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 148; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 5 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
XX
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
OY 867 CUGCAGCAGUACGACU 885
DB 19 CTGCAGCAGTTACGACTT 1
XX
XX
XX RESULT 454
AEO2269/c
ID AEO2269 standard; RNA; 19 BP.
XX
XX AEO2269;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 153.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
XX microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00825966.
XX 30-APR-2004; 2004US-00919866.
XX 17-AUG-2004; 2004US-00919866.

PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX PI Richards I, Macswigen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 153; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 2 A; 5 C; 7 G; 0 T; 5 U; 0 Other;
XX
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY 957 CUGAAACCCAGCTCCGAG 975
DB 19 CTGGAACCCAGCTCCGAG 1
XX
XX
XX RESULT 455
AEO2271/c
ID AEO2271 standard; RNA; 19 BP.
XX
XX AEO2271;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 155.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
XX microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00825966.
XX 30-APR-2004; 2004US-00919866.
XX 17-AUG-2004; 2004US-00919866.

PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-0078090.
PR 16-APR-2004; 2004US-0082696.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswigen J;
XX
XX WPI; 2005-356237/36.
XX
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
XX Claim 33; SEQ ID NO 114; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 6 A; 4 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 255 CACCAUCCUGGUAUUGUG 273

DB 19 CACATCTCTGTATTGTG 1

RESULT 452

AEA02252/c

ID AEA02252 standard; RNA; 19 BP.

AC AEA02252;

DT 28-JUL-2005 (first entry)

DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 136.

KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;

KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;

KW micronutrient disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.

XX Synthetic.

OS WO2005045040-A2.

PN 19-MAY-2005.

PD 20-AUG-2004; 2004WO-US027367.

PF 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.

PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-0078090.
PR 16-APR-2004; 2004US-0082696.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswigen J;
XX
XX WPI; 2005-356237/36.
XX
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
XX Claim 33; SEQ ID NO 136; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 6 A; 6 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 651 UCCGGGAGAGGUCUUCANU 669

DB 19 TCCGGGAGAGGCTTCACTT 1

RESULT 453

AEA02264/c

ID AEA02264 standard; RNA; 19 BP.

AC AEA02264;

DT 28-JUL-2005 (first entry)

DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 148.

KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;

KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;

KW micronutrient disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.

XX Synthetic.

OS WO2005045040-A2.

PN 19-MAY-2005.

PD 20-AUG-2004; 2004WO-US027367.

PF 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 03-DEC-2003; 2003US-00727780.

PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.

PF 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-0072780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX PS Claim 33; SEQ ID NO 105; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SQ Sequence 19 BP; 5 A; 4 C; 6 G; 0 T; 4 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 93 GGAACCGACGACUUC 111
Db |||||:||||:||||
19 GGAACCGACGACATTTTC 1
XX
XX RESULT 450
AEA02226/c
ID AEA02226 standard; RNA; 19 BP.
XX
XX AEA02226;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 110.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX

PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-0072780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX PS Claim 33; SEQ ID NO 110; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SQ Sequence 19 BP; 4 A; 5 C; 5 G; 0 T; 5 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 183 AGGUCACGACGUCGCAA 201
Db |||||:||||:||||
19 AGGTCATACCGTGTGCAA 1
XX
XX RESULT 451
AEA02230/c
ID AEA02230 standard; RNA; 19 BP.
XX
XX AEA02230;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 114.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX
XX 24-NOV-2003; 2003US-00720448.
XX
XX

PN WO2005045040-A2.
XX
XX
PD 19-MAY-2005.
XX
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX
PI Richards I, Macswiggen J;
XX
XX
DR WPI; 2005-356237/36.
XX
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
PS Claim 33; SEQ ID NO 59; 184pp; English.
XX
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX
SQ Sequence 19 BP; 3 A; 8 C; 6 G; 0 T; 2 U; 0 Other;
XX
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1047 CGCCUCUCCGACGAGAG 1065
DB 1 CGCCUCUCCGACGAGAG 19
XX
XX
RESULT 448
AEA02220/C
ID AEA02220 standard; RNA; 19 BP.
XX
XX
AC AEA02220;
XX
XX
DT 28-JUL-2005 (first entry)
XX
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 104.
XX
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX
OS Synthetic.
XX
XX
PN WO2005045040-A2.
XX

PD 19-MAY-2005.
XX
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX
PI Richards I, Macswiggen J;
XX
XX
DR WPI; 2005-356237/36.
XX
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
PS Claim 33; SEQ ID NO 104; 184pp; English.
XX
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX
SQ Sequence 19 BP; 2 A; 7 C; 8 G; 0 T; 2 U; 0 Other;
XX
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
QY 75 CGAUGCAGGCGUCCCCG 93
DB 19 CGATGCAAGGCGTCCCCG 1
XX
XX
RESULT 449
AEA02221/C
ID AEA02221 standard; RNA; 19 BP.
XX
XX
AC AEA02221;
XX
XX
DT 28-JUL-2005 (first entry)
XX
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 105.
XX
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX
OS Synthetic.
XX
XX
PN WO2005045040-A2.
XX
XX
PD 19-MAY-2005.
XX

KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX Synthetic.
 OS
 XX WO2005045040-A2.
 PN
 XX 19-MAY-2005.
 PD
 XX 20-AUG-2004; 2004WO-US027367.
 PF
 XX 23-OCT-2003; 2003US-00693059.
 PR
 XX 24-NOV-2003; 2003US-00720448.
 PR
 XX 03-DEC-2003; 2003US-00727780.
 PR
 XX 14-JAN-2004; 2004US-00757803.
 PR
 XX 10-FEB-2004; 2004US-0543480P.
 PR
 XX 13-FEB-2004; 2004US-00780447.
 PR
 XX 11-MAR-2004; 2004US-00798090.
 PR
 XX 16-APR-2004; 2004US-00826966.
 PR
 XX 30-APR-2004; 2004WO-US013456.
 PR
 XX 24-MAY-2004; 2004WO-US016390.
 PR
 XX 17-AUG-2004; 2004US-00919866.
 PA
 XX (SIRN-) SIRNA THERAPEUTICS INC.
 PI
 XX Richard I, Macewiggen J;
 DR
 XX WPI; 2005-356237/36.
 PT
 XX New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 PS
 XX Claim 33; SEQ ID NO 38; 184bp; English.
 CC
 XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 19 BP; 3 A; 7 C; 4 G; 0 T; 5 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 669 UCAGUCCUCAGUGAGCCC 687
 DB 1 UCAGUCCUCAGUGAGCCC 19
 RESULT 446
 AEA02165
 ID AEA02165 standard; RNA; 19 BP.
 AC AEA02165;
 XX
 XX 28-JUL-2005 (first entry)
 DT
 XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 49.
 DE
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer disease;
 KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX

OS Synthetic.
 XX
 XX WO2005045040-A2.
 PN
 XX 19-MAY-2005.
 PD
 XX 20-AUG-2004; 2004WO-US027367.
 PF
 XX 23-OCT-2003; 2003US-00693059.
 PR
 XX 24-NOV-2003; 2003US-00720448.
 PR
 XX 03-DEC-2003; 2003US-00727780.
 PR
 XX 14-JAN-2004; 2004US-00757803.
 PR
 XX 10-FEB-2004; 2004US-0543480P.
 PR
 XX 13-FEB-2004; 2004US-00780447.
 PR
 XX 11-MAR-2004; 2004US-00798090.
 PR
 XX 16-APR-2004; 2004US-00826966.
 PR
 XX 30-APR-2004; 2004WO-US013456.
 PR
 XX 24-MAY-2004; 2004WO-US016390.
 PR
 XX 17-AUG-2004; 2004US-00919866.
 PA
 XX (SIRN-) SIRNA THERAPEUTICS INC.
 PI
 XX Richard I, Macewiggen J;
 DR
 XX WPI; 2005-356237/36.
 PT
 XX New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 PS
 XX Claim 33; SEQ ID NO 49; 184bp; English.
 CC
 XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 19 BP; 5 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 867 CUGCAGCAGUACGAACUU 885
 DB 1 CUGCAGCAGUACGAACUU 19
 RESULT 447
 AEA02175
 ID AEA02175 standard; RNA; 19 BP.
 AC AEA02175;
 XX
 XX 28-JUL-2005 (first entry)
 DT
 XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 59.
 DE
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer disease;
 KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX

KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-0072780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) siRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 20; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases.
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 3 C; 5 G; 0 T; 7 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 345 GAUUAUCCGGGUGCAUUCUCA 363
DB 1 GAUUAUCCGGGUGCAUUCUCA 19
RESULT 444
AEA02143
ID AEA02143 standard; RNA; 19 BP.
XX
AC AEA02143;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 27.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;

KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-0072780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) siRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 27; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases.
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 5 C; 4 G; 0 T; 6 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 471 GAUUCUUCUGUGCAUCAGC 489
DB 1 GAUUCUUCUGUGCAUCAGC 19
RESULT 445
AEA02154
ID AEA02154 standard; RNA; 19 BP.
XX
AC AEA02154;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 38.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;

```
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 15.
DE Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neutropoietic; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX micriturion disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX Synthetic.
OS WO2005045040-A2.
XX PN 19-MAY-2005.
XX PD
XX PF 20-AUG-2004; 2004WO-US027367.
XX PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004WO-US013456.
XX PR 24-MAY-2004; 2004WO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX PA (SIRN-) SIRNA THERAPEUTICS INC.
XX PI Richards I, Macswiggen J;
XX DR WPI; 2005-356237/36.
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX PS Claim 33; SEQ ID NO 15; 184pp; English.
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, and/or conditions, including chronic obstructive pulmonary
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX SQ Sequence 19 BP; 5 A; 4 C; 4 G; 0 T; 6 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 255 CAACAUCUCUGUAUUGUG 273
DB 1 CAACAUCUCUGUAUUGUG 19
RESULT 442
AEA02133
ID AEA02133 standard; RNA; 19 BP.
XX
XX AEA02133;
AC
XX
XX 28-JUL-2005 (first entry)
DT
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 17.
DE
```

```
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neutropoietic; Nootropic; Uropathic; asthma; allergic rhinitis;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX micriturion disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX Synthetic.
OS WO2005045040-A2.
XX PN 19-MAY-2005.
XX PD
XX PF 20-AUG-2004; 2004WO-US027367.
XX PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004WO-US013456.
XX PR 24-MAY-2004; 2004WO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX PA (SIRN-) SIRNA THERAPEUTICS INC.
XX PI Richards I, Macswiggen J;
XX DR WPI; 2005-356237/36.
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX PS Claim 33; SEQ ID NO 17; 184pp; English.
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, and/or conditions, including chronic obstructive pulmonary
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX SQ Sequence 19 BP; 6 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 291 GAGCUGAAGACGCGCAAC 309
DB 1 GAGCUGAAGACGCGCAAC 19
RESULT 443
AEA02136
ID AEA02136 standard; RNA; 19 BP.
XX
XX AEA02136;
AC
XX
XX 28-JUL-2005 (first entry)
DT
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 20.
DE Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
```

XX	AEA02123;
AC	28-JUL-2005 (first entry)
DT	Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 7.
XX	
DE	Respiratory-Gen.; Antiaesthetic; Antiinflammatory;
XX	Neuroprotective; Nootropic; Uropathic;
KW	Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW	sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
KM	micritium disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM	siRNA; RNA interference; gene silencing; short interfering RNA.
OS	Synthetic.
XX	
PN	WO2005045040-A2.
XX	
PD	19-MAY-2005.
XX	
PF	20-AUG-2004; 2004WO-US027367.
XX	
PR	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00720448.
PR	03-DEC-2003; 2003US-00727780.
PR	14-JAN-2004; 2004US-00757803.
PR	10-FEB-2004; 2004US-0543480P.
PR	13-FEB-2004; 2004US-00780447.
PR	11-MAR-2004; 2004US-00798090.
PR	16-APR-2004; 2004US-00826966.
PR	30-APR-2004; 2004WO-US013456.
PR	24-MAY-2004; 2004WO-US016390.
PR	17-AUG-2004; 2004US-00919866.
XX	
PA	(SIRN-) SIRNA THERAPEUTICS INC.
XX	
PI	Richards I, Macswigen J;
XX	
DR	WPI; 2005-356237/36.
XX	
PT	New short interfering nucleic acid molecule that directs cleavage of a
PT	cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT	disease.
XX	
PS	Claim 33; SEQ ID NO 7; 184pp; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siNA) molecule that directs cleavage of a
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC	(RNAi). The siNA molecule, compounds, compositions, and methods are
CC	useful for treating or preventing respiratory and pulmonary diseases,
CC	disorders, and/or conditions, including chronic obstructive pulmonary
CC	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC	present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX	
SO	Sequence 19 BP; 4 A; 5 C; 4 G; 0 T; 6 U; 0 Other;
XX	
QY	Query Match 1.1%; Score 19; DB 1; Length 19;
XX	Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX	Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
DB	111 CGGCGCAACAAGUUCU 129
XX	
XX	1 CGGCGCAACAAGUUCU 19
XX	
XX	RESULT 440
XX	AEA02127
XX	ID AEA02127 standard; RNA; 19 BP.
XX	
XX	AEA02127;

XX	DT	28-JUL-2005	(first entry)
XX	DE	Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 11.	
XX	KM	Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;	
XX	KM	Neuroprotective; Nootropic; Utopathic;	
XX	KM	chronic obstructive pulmonary disease; asthma; allergic rhinitis;	
XX	KM	sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;	
XX	KM	micrutiion disorder; cholinergic receptor muscarinic 3; CHRM3; ss;	
XX	KM	siRNA; RNA interference; gene silencing; short interfering RNA.	
XX	OS	Synthetic.	
XX	PN	WO2005045040-A2.	
XX	XX		
XX	PD	19-MAY-2005.	
XX	XX		
XX	XX	20-AUG-2004; 2004WO-US027367.	
XX	PF		
XX	PR	23-OCT-2003; 2003US-00693059.	
XX	PR	24-NOV-2003; 2003US-00720448.	
XX	PR	03-DEC-2003; 2003US-00727780.	
XX	PR	14-JAN-2004; 2004US-00757803.	
XX	PR	10-FEB-2004; 2004US-0543480P.	
XX	PR	13-FEB-2004; 2004US-00780447.	
XX	PR	11-MAR-2004; 2004US-00798090.	
XX	PR	16-APR-2004; 2004US-00826966.	
XX	PR	30-APR-2004; 2004WO-US013456.	
XX	PR	24-MAY-2004; 2004WO-US016390.	
XX	PR	17-AUG-2004; 2004US-00919866.	
XX	PA	(SIRN-) SIRNA THERAPEUTICS INC.	
XX	PI	Richards I, Macswigen J;	
XX	XX		
XX	DR	WPI; 2005-356237/36.	
XX	PT	New short interfering nucleic acid molecule that directs cleavage of a	
XX	PT	cholinergic receptor muscarinic 3 RNA, useful for treating or preventing	
XX	PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary	
XX	PT	disease.	
XX	PS	Claim 33; SEQ ID NO 11, 184pp; English.	
XX	CC	The invention relates to a chemically synthesized double stranded short	
XX	CC	interfering nucleic acid (siRNA) molecule that directs cleavage of a	
XX	CC	cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference	
XX	CC	(RNAi). The siRNA molecule, compounds, compositions, and methods are	
XX	CC	useful for treating or preventing respiratory and pulmonary diseases,	
XX	CC	disorders, and/or conditions, including chronic obstructive pulmonary	
XX	CC	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,	
XX	CC	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The	
XX	CC	present sequence represents a cholinergic receptor muscarinic 3 siRNA.	
XX	SQ		
XX	XX	Sequence 19 BP; 5 A; 5 C; 5 G; 0 T; 4 U; 0 Other;	
XX	XX		
XX	XX	Query Match 1.1%; Score 19; DB 1; Length 19;	
XX	XX	Best Local Similarity 100.0%; Pred. No. 1.6e+02;	
XX	XX	Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
XX	OY	183 AGGCAUACCGGUGGCAA 201	
XX	DB	1 AGGCAUACCGGUGGCAA 19	
XX	XX		
XX	XX	RESULT 441	
XX	XX	AEA02131	
XX	XX	ID AEA02131 standard; RNA; 19 BP.	
XX	XX	AEA02131;	
XX	XX	28-JUL-2005 (first entry)	

RESULT 437
ID AEA02313/c
AC AEA02313 standard; RNA; 19 BP.
XX
XX AEA02313;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 197.
XX
XX Respiratory-Gen.; Antiaesthetic; Anti-allergic; Anti-inflammatory;
XX Neutropenic; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX OS
XX WO2005045040-A2.
XX PN
XX 19-MAY-2005.
XX PD
XX 20-AUG-2004; 2004WO-US027367.
XX PF
XX 23-OCT-2003; 2003US-00693059.
XX PR
XX 24-NOV-2003; 2003US-00720448.
XX PR
XX 03-DEC-2003; 2003US-00727780.
XX PR
XX 14-JAN-2004; 2004US-00757803.
XX PR
XX 10-FEB-2004; 2004US-0543480P.
XX PR
XX 13-FEB-2004; 2004US-00780447.
XX PR
XX 11-MAR-2004; 2004US-00798090.
XX PR
XX 16-APR-2004; 2004US-00826966.
XX PR
XX 30-APR-2004; 2004WO-US013456.
XX PR
XX 24-MAY-2004; 2004WO-US016390.
XX PR
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX PA
XX
XX PI Richards I, Macswiggen J;
XX
XX DR WPI; 2005-356237/36.
XX
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX
XX PS Claim 33; SEQ ID NO 197; 184bp; English.
XX
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, and/or conditions, including chronic obstructive pulmonary
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SQ Sequence 19 BP; 0 A; 7 C; 9 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred.No. 1.6e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1749 GCGGCAACCGAGAGAGCC 1767
XX ||||||||||||||||||||
XX DB 19 GCGGCAACCGAGAGAGCC 1
XX
XX RESULT 438

AEA02120
ID AEA02120 standard; RNA; 19 BP.
XX
XX AC AEA02120;
XX
XX DT 28-JUL-2005 (first entry)
XX
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 4.
XX
XX Respiratory-Gen.; Antiaesthetic; Anti-allergic; Anti-inflammatory;
XX Neutropenic; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX OS
XX WO2005045040-A2.
XX PN
XX 19-MAY-2005.
XX PD
XX 20-AUG-2004; 2004WO-US027367.
XX PF
XX 23-OCT-2003; 2003US-00693059.
XX PR
XX 24-NOV-2003; 2003US-00720448.
XX PR
XX 03-DEC-2003; 2003US-00727780.
XX PR
XX 14-JAN-2004; 2004US-00757803.
XX PR
XX 10-FEB-2004; 2004US-0543480P.
XX PR
XX 13-FEB-2004; 2004US-00780447.
XX PR
XX 11-MAR-2004; 2004US-00798090.
XX PR
XX 16-APR-2004; 2004US-00826966.
XX PR
XX 30-APR-2004; 2004WO-US013456.
XX PR
XX 24-MAY-2004; 2004WO-US016390.
XX PR
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX PA
XX
XX PI Richards I, Macswiggen J;
XX
XX DR WPI; 2005-356237/36.
XX
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX
XX PS Claim 33; SEQ ID NO 4; 184bp; English.
XX
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, and/or conditions, including chronic obstructive pulmonary
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SQ Sequence 19 BP; 4 A; 9 C; 3 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred.No. 1.6e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 57 CUGGAUACACAGCCCTCUC 75
XX ||||||||||||||||||||
XX DB 1 CUGGAUACACAGCCCTCUC 19
XX
XX RESULT 439
XX AEA02123
XX ID AEA02123 standard; RNA; 19 BP.

OY 1353 GGCGACUACUACUUGUCC 1371
|||||:||||:||||
DB 19 GGCGACTTACTCTGTGCC 1

RESULT 435
AEA02295/c
ID AEA02295 standard; RNA; 19 BP.
XX
AC AEA02295;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 179.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neutroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micronutrition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 11-MAR-2004; 2004US-00780447.
PR 13-FEB-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 179; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 2 A; 6 C; 3 G; 0 T; 8 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 1425 CACUAGCGGAAAGAGU 1443
|||||:|||||:|||||:|

DB 19 CACTAAGCGGAAAGATG 1

RESULT 436
AEA02303/c
ID AEA02303 standard; RNA; 19 BP.
XX
AC AEA02303;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 187.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neutroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micronutrition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 187; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 6 A; 5 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

OY 1569 AACCUUUGAUAUCUGGC 1587
|||||:|||||:|||||:|

DB 19 AACCTTTTGAAATCGGC 1

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 507 CAUACAGAGCGCCGUCACG 525
||:|||||:|||||:|||||
Db 19 CATCAGAGCGCCGCTCAG 1

RESULT 433
AEA02288/c
ID AEA02288 standard; RNA; 19 BP.
AC AEA02288;
DT 28-JUL-2005 (first entry)
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 172.
XX
XX Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
XX Neutroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mucrition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 172; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 2 A; 6 C; 5 G; 0 T; 6 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 89.5%; Pred. No. 1.6e+02;

Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 1299 AGCCGTGACACAGCTAAG 1317
|||||:|||||:|||||
Db 19 AGCCGTGACACAGCTAAG 1

RESULT 434
AEA02291/c
ID AEA02291 standard; RNA; 19 BP.
AC AEA02291;
DT 28-JUL-2005 (first entry)
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 175.
XX
XX Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
XX Neutroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mucrition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 175; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 5 A; 3 C; 9 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 73.7%; Pred. No. 1.6e+02;
XX Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

CC Present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 3 C; 9 G; 0 T; 3 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
OY 147 CUCCUCCGACGAGGUAAC 165
|:|||||:|||||:|||||
DB 19 CTCCTCTCCAGACGTACC 1
RESULT 431
AEA02243/c
ID AEA02243 standard; RNA; 19 BP.
AC AEA02243;
XX
XX 28-JUL-2005 (first entry)
DT
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 127.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX microtubion disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
OS
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
PD
XX
XX 20-AUG-2004; 2004WO-US027367.
PF
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX
XX Richards I, Macswiggen J;
PI
XX
XX WPI; 2005-356237/36.
DR
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
XX Claim 33; SEQ ID NO 127; 184dp; English.
PS
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAI). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX

SQ Sequence 19 BP; 8 A; 2 C; 5 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 1.6e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
OY 489 CUUGACGAGUACUUC 507
|:|||||:|||||:|||||
DB 19 CTTGACGAGTACTTTC 1
RESULT 432
AEA02244/c
ID AEA02244 standard; RNA; 19 BP.
XX
XX AEA02244;
AC
XX
XX 28-JUL-2005 (first entry)
DT
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 128.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX microtubion disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
OS
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
PD
XX
XX 20-AUG-2004; 2004WO-US027367.
PF
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX
XX Richards I, Macswiggen J;
PI
XX
XX WPI; 2005-356237/36.
DR
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
XX Claim 33; SEQ ID NO 128; 184dp; English.
PS
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAI). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 2 A; 5 C; 8 G; 0 T; 4 U; 0 Other;

CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 3 A; 4 C; 6 G; 0 T; 6 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 651 UCCGGAGAGUGUCUACAUU 669
Db 1 UCCGGAGAGUGUCUACAUU 19
RESULT 429
AEA02160
ID AEA02160 standard; RNA; 19 BP.
XX
AC AEA02160;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 44.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 44; 184dp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC diseases, and/or conditions, including chronic obstructive pulmonary

CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 8 A; 4 C; 4 G; 0 T; 3 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 777 AAAGCGUACCAAGAGCUU 795
Db 1 AAAGCGUACCAAGAGCUU 19
RESULT 430
AEA02224/C
ID AEA02224 standard; RNA; 19 BP.
XX
AC AEA02224;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 108.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 108; 184dp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The

CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 165 CACCGAUGACCCUCUGGA 183
Db 1 CACCGAUGACCCUCUGGA 19
RESULT 427
AEA02146
ID AEA02146 standard; RNA; 19 BP.
XX
AC AEA02146;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 30.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PE 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
DR New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
PS Claim 33; SEQ ID NO 30; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a

CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 8 A; 6 C; 4 G; 0 T; 1 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 525 GUACCGAGCCAAAGCA 543
Db 1 GUACCGAGCCAAAGCA 19
RESULT 428
AEA02153
ID AEA02153 standard; RNA; 19 BP.
XX
AC AEA02153;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 37.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PE 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
DR New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
PS Claim 33; SEQ ID NO 37; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are

PT disease.
XX
PS Claim 33; SEQ ID NO 182; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 6 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 1479 CAGUGCGAUCUGCUGCC 1497
Db 19 CAGTGGATCTTGCTTGCC 1
RESULT 425
AEA02311/c
ID AEA02311 standard; RNA; 19 BP.
XX
AC AEA02311;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 195.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX

PS Claim 33; SEQ ID NO 195; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 1 A; 6 C; 5 G; 0 T; 7 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.6e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1713 GCAGUACAGCAGAGCAG 1731
Db 19 GCAGTCCAGCAGAGCAG 1
RESULT 426
AEA02126
ID AEA02126 standard; RNA; 19 BP.
XX
AC AEA02126;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 10.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
PS Claim 33; SEQ ID NO 10; 184pp; English.
XX

[illegible]

```

XX  Richards I, Macswiggen J;
PI  WPI; 2005-356237/36.
XX
XX  New short interfering nucleic acid molecule that directs cleavage of a
PT  cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT  respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT  disease.
XX
PS  Claim 33; SEQ ID NO 119; 184bp; English.
XX
XX  The invention relates to a chemically synthesized double stranded short
CC  interfering nucleic acid (siNA) molecule that directs cleavage of a
CC  cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC  (RNAi). The siNA molecule, compounds, compositions, and methods are
CC  useful for treating or preventing respiratory and pulmonary diseases,
CC  disorders, and/or conditions, including chronic obstructive pulmonary
CC  disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC  cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC  present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ  Sequence 19 BP; 7 A; 5 C; 3 G; 0 T; 4 U; 0 Other;
XX
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 1.6e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
XX
QY  345 GAUUAUCGGGAGUCAUUUA 363
    ||:|||||:|||||:|
Db  19 GATTATCGGGTCATTTC 1
XX
RESULT 421
AEA02237/C
ID  AEA02237 standard; RNA; 19 BP.
XX
AC  AEA02237;
XX
DT  28-JUL-2005 (first entry)
XX
DE  Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 121.
XX
KW  Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW  Neuroprotective; Nootropic; Uropathic;
KW  chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW  sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
KW  micurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW  siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS  Synthetic.
XX
PN  WO2005045040-A2.
XX
PD  19-MAY-2005.
XX
PF  20-AUG-2004; 2004WO-US027367.
XX
PR  23-OCT-2003; 2003US-00693059.
XX  24-NOV-2003; 2003US-00720448.
XX  03-DEC-2003; 2003US-00727780.
XX  14-JAN-2004; 2004US-00757803.
XX  10-FEB-2004; 2004US-0543480P.
XX  13-FEB-2004; 2004US-00780447.
XX  11-MAR-2004; 2004US-00798090.
XX  16-APR-2004; 2004US-00826966.
XX  30-APR-2004; 2004WO-US013456.
XX  24-MAY-2004; 2004WO-US016390.
XX  17-AUG-2004; 2004US-00919866.
XX
PA  (SIRN-) SIRNA THERAPEUTICS INC.
XX  Richards I, Macswiggen J;
PI

```

```

XX  Richards I, Macswiggen J;
PI  WPI; 2005-356237/36.
XX
XX  New short interfering nucleic acid molecule that directs cleavage of a
PT  cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT  respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT  disease.
XX
PS  Claim 33; SEQ ID NO 121; 184bp; English.
XX
XX  The invention relates to a chemically synthesized double stranded short
CC  interfering nucleic acid (siNA) molecule that directs cleavage of a
CC  cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC  (RNAi). The siNA molecule, compounds, compositions, and methods are
CC  useful for treating or preventing respiratory and pulmonary diseases,
CC  disorders, and/or conditions, including chronic obstructive pulmonary
CC  disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC  cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC  present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ  Sequence 19 BP; 5 A; 2 C; 5 G; 0 T; 7 U; 0 Other;
XX
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
XX
QY  381 CUACATCAUCAGCAUACA 399
    |:|:|:|:|:|:|:|:|:|
Db  19 CTRACATCATCATGATCGA 1
XX
RESULT 422
AEA02259/C
ID  AEA02259 standard; RNA; 19 BP.
XX
AC  AEA02259;
XX
DT  28-JUL-2005 (first entry)
XX
DE  Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 143.
XX
KW  Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW  Neuroprotective; Nootropic; Uropathic;
KW  chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW  sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
KW  micurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW  siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS  Synthetic.
XX
PN  WO2005045040-A2.
XX
PD  19-MAY-2005.
XX
PF  20-AUG-2004; 2004WO-US027367.
XX
PR  23-OCT-2003; 2003US-00693059.
XX  24-NOV-2003; 2003US-00720448.
XX  03-DEC-2003; 2003US-00727780.
XX  14-JAN-2004; 2004US-00757803.
XX  10-FEB-2004; 2004US-0543480P.
XX  13-FEB-2004; 2004US-00780447.
XX  11-MAR-2004; 2004US-00798090.
XX  16-APR-2004; 2004US-00826966.
XX  30-APR-2004; 2004WO-US013456.
XX  24-MAY-2004; 2004WO-US016390.
XX  17-AUG-2004; 2004US-00919866.
XX
PA  (SIRN-) SIRNA THERAPEUTICS INC.
XX  Richards I, Macswiggen J;
PI

```

PR 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswigen J;
XX
XX WPI; 2005-356237/36.
XX
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
XX Claim 33; SEQ ID NO 198; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 3 A; 6 C; 7 G; 0 T; 3 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.6e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 1753 GCACCCGAGCAGCCCTTGT 1771
DB 19 GCACCCGAGCAGCCCTTGT 1
RESULT 419
ID AEA02129 standard; RNA; 19 BP.
XX
XX AEA02129;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 13.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-0780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.

XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswigen J;
XX
XX WPI; 2005-356237/36.
XX
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
XX Claim 33; SEQ ID NO 13; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 3 A; 7 C; 5 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 219 CUUACGGGCAUCCUGGCC 237
DB 1 CUUACGGGCAUCCUGGCC 19
RESULT 420
ID AEA02235/c
XX
XX AEA02235 standard; RNA; 19 BP.
XX
XX AEA02235;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 119.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.

PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004US-0016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macewiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 162; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 3 A; 1 C; 9 G; 0 T; 6 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.6e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
OY 1119 UCACAGCACCAUCCUAC 1137
Db 19 TCACAGCACCATCTCTAC 1
RESULT 417
AEA02284/C
ID AEA02284 standard; RNA; 19 BP.
AC AEA02284;
XX
XX 28-JUL-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 168.
DE
XX Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX WO2005045040-A2.
PN
XX 19-MAY-2005.
PD
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR

PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macewiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 168; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 1 A; 8 C; 5 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.6e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 1227 GGGCCGAGAGAGCGGAGC 1245
Db 19 GGGCCGAGAGAGCGGAGC 1
RESULT 418
AEA02314/C
ID AEA02314 standard; RNA; 19 BP.
AC AEA02314;
XX
XX 28-JUL-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 198.
DE
XX Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX WO2005045040-A2.
PN
XX 19-MAY-2005.
PD
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR

PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004US-00826966.
PR 24-MAY-2004; 2004US-00919866.
PR 17-AUG-2004; 2004US-00919866.
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX PA
XX PI
XX Richards I, Macswiggen J;
XX WPI; 2005-356237/36.
XX DR
XX XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX PS Claim 33; SEQ ID NO 133; 184pp; English.
XX CC
XX CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SQ Sequence 19 BP; 7 A; 5 C; 6 G; 0 T; 1 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 1.6e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
QY 597 UUGAGGCUCCUGCAUCUG 615
Db 19 TTGGGCTCTCGTCACATCTTG 1
:::|||||:::|||||:::|||||
:::|||||:::|||||:::|||||
RESULT 415
AEA02251/C
ID AEA02251 standard; RNA; 19 BP.
XX
XX AC AEA02251;
XX DT 28-JUL-2005 (first entry)
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 135.
XX XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzhemiers disease;
XX mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX OS
XX Synthetic.
XX PN WO2005045040-A2.
XX PD 19-MAY-2005.
XX PF 20-AUG-2004; 2004WO-US027367.
XX XX
XX 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.

PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004US-00826966.
PR 24-MAY-2004; 2004US-00919866.
PR 17-AUG-2004; 2004US-00919866.
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX PA
XX PI
XX Richards I, Macswiggen J;
XX WPI; 2005-356237/36.
XX DR
XX XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX PS Claim 33; SEQ ID NO 135; 184pp; English.
XX CC
XX CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SQ Sequence 19 BP; 4 A; 6 C; 3 G; 0 T; 6 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 633 UGGAAGAGAACUGGCCU 651
Db 19 TGGAAAGAGAACTGTCCT 1
:::|||||:::|||||:::|||||
:::|||||:::|||||:::|||||
RESULT 416
AEA02278/C
ID AEA02278 standard; RNA; 19 BP.
XX
XX AC AEA02278;
XX DT 28-JUL-2005 (first entry)
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 162.
XX XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzhemiers disease;
XX mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX OS
XX Synthetic.
XX PN WO2005045040-A2.
XX PD 19-MAY-2005.
XX PF 20-AUG-2004; 2004WO-US027367.
XX XX
XX 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.

[illegible][illegible]

```
XX XX WO2005045040-A2.
XX XX
XX PD 19-MAY-2005.
XX PF 20-AUG-2004; 2004MO-US027367.
XX PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004MO-US013456.
XX PR 24-MAY-2004; 2004MO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX PA (SIRM-) SIRM THERAPEUTICS INC.
XX PI Richards I, Macswigen J;
XX DR WPI; 2005-356237/36.
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX PS Claim 33; SEQ ID NO 95; 184pp; English.
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX SQ Sequence 19 BP; 10 A; 3 C; 6 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1695 AAAAAAGAGCGCAGCAG 1713
XX DB 1 AAAAAAGAGCGCAGCAG 19
XX
XX RESULT 411
XX AEA02216/C
XX ID AEA02216 standard; RNA; 19 BP.
XX AC AEA02216;
XX XX
XX DT 28-JUL-2005 (first entry)
XX XX
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 100.
XX KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX KW Neutroprotective; Nootropic; Uropathic;
XX KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX KW microtition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX OS Synthetic.
XX PN WO2005045040-A2.
XX PD
```

```
XX XX 19-MAY-2005.
XX PD 20-AUG-2004; 2004MO-US027367.
XX PF 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004MO-US013456.
XX PR 24-MAY-2004; 2004MO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX PA (SIRM-) SIRM THERAPEUTICS INC.
XX PI Richards I, Macswigen J;
XX DR WPI; 2005-356237/36.
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX PS Claim 33; SEQ ID NO 100; 184pp; English.
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX SQ Sequence 19 BP; 4 A; 3 C; 5 G; 0 T; 7 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 78.9%; Pred. No. 1.6e+02;
XX Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 3 GACCTUGCACAUAACAGU 21
XX DB 19 GACCTTGACAAATTAACAGT 1
XX
XX RESULT 412
XX AEA02233/C
XX ID AEA02233 standard; RNA; 19 BP.
XX AC AEA02233;
XX XX
XX DT 28-JUL-2005 (first entry)
XX XX
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 117.
XX KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX KW Neutroprotective; Nootropic; Uropathic;
XX KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX KW microtition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX OS Synthetic.
XX PN WO2005045040-A2.
XX PD 19-MAY-2005.
XX
```

KW	micriturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW	siRNA; RNA interference; gene silencing; short interfering RNA.
XX	Synthetic.
XX	WO2005045040-A2.
XX	19-MAY-2005.
XX	20-AUG-2004; 2004WO-US027357.
XX	23-OCT-2003; 2003US-00693059.
XX	PR 24-NOV-2003; 2003US-00720448.
XX	PR 03-DEC-2003; 2003US-00727780.
XX	PR 14-JAN-2004; 2004US-00757803.
XX	PR 10-FEB-2004; 2004US-0543480P.
XX	PR 13-FEB-2004; 2004US-00780447.
XX	PR 11-MAR-2004; 2004US-00798090.
XX	PR 16-APR-2004; 2004US-00826956.
XX	PR 30-APR-2004; 2004WO-US013456.
XX	PR 24-MAY-2004; 2004WO-US016390.
XX	PR 17-AUG-2004; 2004US-00919866.
XX	(SIRN-) SIRNA THERAPEUTICS INC.
XX	Richards I, Macewigsen J;
XX	WPI; 2005-356237/36.
XX	New short interfering nucleic acid molecule that directs cleavage of a
XX	cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX	disease.
XX	Claim 33; SEQ ID NO 81; 184pp; English.
XX	The invention relates to a chemically synthesized double stranded short
XX	interfering nucleic acid (siRNA) molecule that directs cleavage of a
XX	cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX	(RNAi). The siRNA molecule, compounds, compositions, and methods are
XX	useful for treating or preventing respiratory and pulmonary diseases,
XX	disorders, and/or conditions, including chronic obstructive pulmonary
XX	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX	present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX	Sequence 19 BP; 5 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
XX	Query Match 1.1%; Score 19; DB 1; Length 19;
XX	Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX	Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1443 GUCCUGUCUACAAGAGAAG 1461
DB	1 GUCCUGUCUACAAGAGAAG 19
RESULT 409	
AEAO2199	
ID	AEAO2199 standard; RNA; 19 BP.
XX	
AC	AEAO2199;
XX	
DT	28-JUL-2005 (first entry)
XX	
DE	Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 83.
XX	
XX	Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW	Neuroprotective; Nootropic; Uropathic;
KW	Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW	sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
KW	micriturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW	siRNA; RNA interference; gene silencing; short interfering RNA.

OS	Synthetic.
XX	
XX	WO2005045040-A2.
PN	
PD	19-MAY-2005.
XX	
XX	
PF	20-AUG-2004; 2004WO-US027367.
XX	
PR	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00726048.
PR	03-DEC-2003; 2003US-00727780.
PR	14-JAN-2004; 2004US-00757803.
PR	10-FEB-2004; 2004US-053480P.
PR	13-FEB-2004; 2004US-00780447.
PR	11-MAR-2004; 2004US-00798090.
PR	16-APR-2004; 2004US-00826966.
PR	30-APR-2004; 2004WO-US013456.
PR	24-MAY-2004; 2004WO-US016390.
PR	17-AUG-2004; 2004US-00919866.
XX	
PA	(SIRM-) SIRMNA THERAPEUTICS INC.
XX	
PI	Richards I, Macswiggen J;
XX	
XX	WPI; 2005-356237/36.
XX	
PT	New short interfering nucleic acid molecule that directs cleavage of a
PT	cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT	disease.
XX	
PS	Claim 33; SEQ ID NO 83; 184pp; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC	(RNAi). The siRNA molecule, compounds, compositions, and methods are
CC	useful for treating or preventing respiratory and pulmonary diseases,
CC	disorders, and/or conditions, including chronic obstructive pulmonary
CC	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC	present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX	
SEQ	Sequence 19 BP; 2 A; 6 C; 5 G; 0 T; 6 U; 0 Other;
XX	
Query Match	1.1%; Score 19; DB 1; Length 19;
Best Local Similarity	100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
XX	
QY	1479 CAGUGCCAGUCUGGCGCC 1497
DB	1 CAGUGCCAGUCUGGCGCC 19
XX	
RESULT 410	
ID	AEA02211
ID	AEA02211 standard; RNA; 19 BP.
XX	
AC	AEA02211;
XX	
DT	28-JUN-2005 (first entry)
XX	
DE	Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 95.
XX	
KM	Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM	Neuroprotective; Nootropic; Utopathic;
KM	chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM	sinusitis; inflammation; allergy; cystic fibrosis; alzhemiers disease;
KM	micriturition disorder; cholinergic receptor muscarinic 3; CHRM3; si;
XX	siRNA; RNA interference; gene silencing; short interfering RNA.
XX	
OS	Synthetic.

KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 57; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 7 A; 4 C; 4 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1011 GAACAACAUGAUGUGUCU 1029
Db 1 GAACAACAUGAUGUGUCU 19
RESULT 407
AEA02190
ID AEA02190 standard; RNA; 19 BP.
XX
AC AEA02190;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 74.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;

KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 74; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1317 GACUUCGACGUCACUCC 1335
Db 1 GACUUCGACGUCACUCC 19
RESULT 408
AEA02197
ID AEA02197 standard; RNA; 19 BP.
XX
AC AEA02197;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 81.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;

[illegible]

DE	Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 28.
XX	
KM	Respiratory; Gen.; Antisthmatic; Antiasthma; Antiinflammatory;
KM	Neuroprotective; Neurotropic; Otopathic;
KW	Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW	sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KV	mucronation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX	siRNA; RNA interference; gene silencing; short interfering RNA.
OS	Synthetic.
XX	
PN	WO2005045040-A2.
XX	
PD	19-MAY-2005.
XX	
PF	20-AUG-2004; 2004WO-US027367.
XX	
PR	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00720448.
PR	03-DEC-2003; 2003US-00727780.
PR	14-JAN-2004; 2004US-00757803.
PR	10-FEB-2004; 2004US-0543480P.
PR	13-FEB-2004; 2004US-00780447.
PR	11-MAR-2004; 2004US-00798090.
PR	16-APR-2004; 2004US-00826366.
PR	30-APR-2004; 2004WO-US013456.
PR	24-MAY-2004; 2004WO-US016390.
PR	17-AUG-2004; 2004US-00919866.
XX	
PA	(SIRN-) SIRNA THERAPEUTICS INC.
XX	
PI	Richards I, Macewigen J,
XX	
DR	WP1; 2005-356237/36.
XX	
PT	New short interfering nucleic acid molecule that directs cleavage of a
PT	cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT	disease.
XX	
PS	Claim 33; SEQ ID NO 28; 18app; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siNA) molecule that directs cleavage of a
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC	(RNAi). The siNA molecule, compounds, compositions, and methods are
CC	useful for treating or preventing respiratory and pulmonary diseases,
CC	disorders, and/or conditions, including chronic obstructive pulmonary
CC	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC	present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX	
SQ	Sequence 19 BP; 4 A; 5 C; 2 G; 0 T; 8 U; 0 Other;
XX	
Query Match	1.1%; Score 19; DB 1; Length 19;
Best Local Similarity	100.0%; Pred.No. 1.6e+02;
Matches	19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	489 CUUUGACGAGUACUUUCC 507
DB	1 CUUUGACGAGUACUUUCC 19
XX	
RESULT 406	
AEA02173	
ID	AEA02173 standard; RNA; 19 BP.
XX	
AEAO2173;	
XX	
DT	28-JUL-2005 (first entry)
XX	
DE	Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 57.
XX	

ID AEA02306 standard; RNA; 19 BP.
XX
AC AEA02306;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 190.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neutroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richard I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 190; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 7 A; 6 C; 5 G; 0 T; 1 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 1.6e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
QY 1623 CGUGGCUAUGCUCUGGC 1641
||:|:|:|:|:|:|:|:|:|
Db 19 CGTGTCTATGCTCTGTGC 1
||:|:|:|:|:|:|:|:|:|
RESULT 403
AEA02137
ID AEA02137 standard; RNA; 19 BP.
XX

AC AEA02137;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 21.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neutroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richard I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 21; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 6 A; 4 C; 3 G; 0 T; 6 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 363 AAUGAUCUGUUGACGC 381
|||||:|:|:|:|:|:|:|:|:|
Db 1 AAUGAUCUGUUGACGC 19
|||||:|:|:|:|:|:|:|:|:|
RESULT 404
AEA02138
ID AEA02138 standard; RNA; 19 BP.
XX
AC AEA02138;
XX

RESULT 400
ID AEA02302/c
AEA02302 standard; RNA; 19 BP.
XX
AC AEA02302;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 186.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neutroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00788447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macewiggen J;
XX
PI WPI; 2005-356237/36.
XX
DR New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
PS Claim 33; SEQ ID NO 186; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 3 A; 3 C; 6 G; 0 T; 7 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.6e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 1551 UGACGCTGCAUACCCAAA 1569
DB 19 TGACAGCTGCATACCCAAA 1

RESULT 401
ID AEA02304/c
AEA02304 standard; RNA; 19 BP.
XX
AC AEA02304;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 188.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neutroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00788447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macewiggen J;
XX
PI WPI; 2005-356237/36.
XX
DR New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
PS Claim 33; SEQ ID NO 188; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 6 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 1587 CUACUGCTGUGCUAUC 1605
DB 19 CTAAGCTGTGTCTATATC 1

RESULT 402
AEA02306/c

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No.1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1371 CUUCAAGGAAGCCACUCUG 1389
|||||
1 CUUCAAGGAAGCCACUCUG 19

Db 1 CUUCAAGGAAGCCACUCUG 19

RESULT 396

AEAO2198
ID AEAO2198 standard; RNA; 19 BP.

AC AEA02198;

DT 28-JUL-2005 (first entry)

DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 82.

KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM mucritium disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.

OS Synthetic.

PN WO2005045040-A2.

PD 19-MAY-2005.

PF 20-AUG-2004; 2004WO-US027367.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 03-DEC-2003; 2003US-0072780.

PR 14-JAN-2004; 2004US-00757803.

PR 10-FEB-2004; 2004US-0543480P.

PR 13-FEB-2004; 2004US-00780447.

PR 11-MAR-2004; 2004US-00798090.

PR 16-APR-2004; 2004US-00826966.

PR 30-APR-2004; 2004WO-US013456.

PR 24-MAY-2004; 2004WO-US016390.

PR 17-AUG-2004; 2004US-00919866.

PA (SIRN-) SIRNA THERAPEUTICS INC.

PI Richard I, Macswigen J;

DR WPI; 2005-356237/36.

PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.

PS Claim 33; SEQ ID NO 82; 184pp; English.

CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX Sequence 19 BP; 5 A; 8 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred.No.1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1461 GAAAGCGGCCGACCCUC 1479
|||||
1 GAAAGCGGCCGACCCUC 19

Db 1 GAAAGCGGCCGACCCUC 19

RESULT 397

AEAO2242/C
ID AEAO2242 standard; RNA; 19 BP.

AC AEA02242;

DT 28-JUL-2005 (first entry)

DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 126.

KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM mucritium disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.

OS Synthetic.

PN WO2005045040-A2.

PD 19-MAY-2005.

PF 20-AUG-2004; 2004WO-US027367.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 03-DEC-2003; 2003US-0072780.

PR 14-JAN-2004; 2004US-00757803.

PR 10-FEB-2004; 2004US-0543480P.

PR 13-FEB-2004; 2004US-00780447.

PR 11-MAR-2004; 2004US-00798090.

PR 16-APR-2004; 2004US-00826966.

PR 30-APR-2004; 2004WO-US013456.

PR 24-MAY-2004; 2004WO-US016390.

PR 17-AUG-2004; 2004US-00919866.

PA (SIRN-) SIRNA THERAPEUTICS INC.

PI Richard I, Macswigen J;

DR WPI; 2005-356237/36.

PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.

PS Claim 33; SEQ ID NO 126; 184pp; English.

CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX Sequence 19 BP; 6 A; 4 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;

Best Local Similarity 68.4%; Pred.No.1.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 5 A; 2 C; 6 G; 0 T; 6 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 1515 CCCAUNCAACAUCAUGGU 1533
|||:|||||:|:|:|:
DB 19 CCCATACACATCATGTT 1
RESULT 394
AEA02186
ID AEA02186 standard; RNA; 19 BP.
AC AEA02186;
XX
XX 28-JUL-2005 (first entry)
DT
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 70.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX microtubion disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
DR
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
PS
XX Claim 33; SEQ ID NO 70; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX
SQ Sequence 19 BP; 4 A; 4 C; 6 G; 0 T; 5 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1245 CGAUGGAGGCGAGUUCGA 1263
|||||:|||||:|:|:|:
DB 1 CGAUGGAGGCGAGUUCGA 19
RESULT 395
AEA02193
ID AEA02193 standard; RNA; 19 BP.
AC AEA02193;
XX
XX 28-JUL-2005 (first entry)
DT
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 77.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX microtubion disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
DR
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
PS
XX Claim 33; SEQ ID NO 77; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 5 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 5 A; 2 C; 5 G; 0 T; 7 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 1263 AAAAGCUCUCCAGCCTT 1281
DB 19 AAAAGCTTCTCCAGCCTT 1
RESULT 392
AEA02287/c
ID AEA02287 standard; RNA; 19 BP.
XX
AC AEA02287;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 171.
XX
KW Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 171; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,

CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 3 C; 7 G; 0 T; 5 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1281 UCCCAUCCAGUAGAGUCA 1299
DB 19 TCCCATCCAGCTAGAGTCA 1
RESULT 393
AEA02300/c
ID AEA02300 standard; RNA; 19 BP.
XX
AC AEA02300;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 184.
XX
KW Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 184; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,

XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 2 A; 3 C; 4 G; 0 T; 10 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 885 UCACAGCAAGCAUGAAA 903
Db :|||||:|||||:
19 TCACAGCAAGCATGAAA 1
RESULT 390
AEA02273/c
ID AEA02273 standard; RNA; 19 BP.
XX
AC AEA02273;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 157.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 157; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short

CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 4 C; 8 G; 0 T; 3 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1029 UGCGUCCUGAGACUCC 1047
Db :|||||:|||||:
19 TGCCTCCTGAGAACTCC 1
RESULT 391
AEA02286/c
ID AEA02286 standard; RNA; 19 BP.
XX
AC AEA02286;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 170.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 170; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference

XX	Claim 33; SEQ ID NO 142; 184pp; English.
PS	
XX	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siNA) molecule that directs cleavage of a
CC	cholelergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC	(RNAi). The siNA molecule, compounds, compositions, and methods are
CC	useful for treating or preventing respiratory and pulmonary diseases,
CC	disorders, and/or conditions, including chronic obstructive pulmonary
CC	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC	present sequence represents a cholelergic receptor muscarinic 3 siRNA.
XX	
XX	Sequence 19 BP; 4 A; 4 C; 2 G; 0 T; 9 U; 0 Other;
SO	
Query Match	1.1%; Score 19; DB 1; Length 19;
Best Local Similarity	78.9%; Pred. No. 1.6e+02;
Matches	15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
OY	759 GAUCUADUAGGAACUGAA 777
DB	19 GATCTATPAGGAAACTGAA 1
RESULT 389	
ID	AEA02265/c
XX	AEA02265 standard; RNA; 19 BP.
AC	AEA02265;
XX	
XX	28-JUL-2005 (first entry)
DE	
XX	Cholelergic receptor muscarinic 3 siRNA SEQ ID NO 149.
KW	
KW	Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW	Neuroprotective; Nootropic; Utophatic;
KW	chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW	sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
KW	micrutiution disorder; cholelergic receptor muscarinic 3; CHRM3; ss;
KW	siRNA; RNA interference; gene silencing; short interfering RNA.
XX	
OS	Synthetic.
XX	
PN	WO2005045040-A2.
XX	
PD	19-MAY-2005.
XX	
PF	20-AUG-2004; 2004WO-US027367.
XX	
PR	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00720448.
PR	03-DEC-2003; 2003US-00727780.
PR	14-JAN-2004; 2004US-00757803.
PR	10-FEB-2004; 2004US-0543480P.
PR	13-FEB-2004; 2004US-00780447.
PR	11-MAR-2004; 2004US-00798090.
PR	16-APR-2004; 2004US-00826966.
PR	30-APR-2004; 2004WO-US013456.
PR	24-MAY-2004; 2004WO-US016390.
PR	17-AUG-2004; 2004US-00919866.
XX	
PA	(SIRN-) SIRNA THERAPEUTICS INC.
XX	
PI	Richards I, Macewigsen J;
XX	
DR	WPI; 2005-356237/36.
XX	
PT	New short interfering nucleic acid molecule that directs cleavage of a
PT	cholelergic receptor muscarinic 3 RNA, useful for treating or preventing
PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX	disease.
XX	
PS	Claim 33; SEQ ID NO 149; 184pp; English.

DR WPI; 2005-356237/36.
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
PS Claim 33; SEQ ID NO 76; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 2 A; 9 C; 3 G; 0 T; 5 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1353 GGCACUCUACCCUGUCC 1371
DB 1 GGCACUCUACCCUGUCC 19
RESULT 386
AEA02200
ID AEA02200 standard; RNA; 19 BP.
XX
XX AEA02200;
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 84.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
PD
XX
XX 20-AUG-2004; 2004WO-US027367.
PF
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX
XX Richards I, Macswiggen J;
PI
XX
XX WPI; 2005-356237/36.
DR
XX

PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
PS Claim 33; SEQ ID NO 84; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 4 A; 7 C; 2 G; 0 T; 6 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1497 CUUCACUACUACUUGACC 1515
DB 1 CUUCACUACUACUUGACC 19
RESULT 387
AEA02238/c
ID AEA02238 standard; RNA; 19 BP.
XX
XX AEA02238;
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 122.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
PD
XX
XX 20-AUG-2004; 2004WO-US027367.
PF
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX
XX Richards I, Macswiggen J;
PI
XX
XX WPI; 2005-356237/36.
DR
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing

PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 55; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 7 A; 6 C; 5 G; 0 T; 1 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 975 GCAGAGGACCAAGACCAC 993
DB: |||||
1 GCAGAGGACCAAGACCAC 19
XX
RESULT 384
AEA02178
ID AEA02178 standard; RNA; 19 BP.
XX
AC AEA02178;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 62.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
PA
XX

PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 62; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 2 A; 6 C; 6 G; 0 T; 5 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1101 CGGCTCAGAGCTCCGCGG 1119
DB: |||||
1 CGGCTCAGAGCTCCGCGG 19
XX
RESULT 385
AEA02192
ID AEA02192 standard; RNA; 19 BP.
XX
AC AEA02192;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 76.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
PA
XX
PI Richards I, Macswiggen J;
XX

PR 17-AUG-2004; 2004US-00919866.

Claim 33, SEQ ID NO 33, 184pp, English.
New short interfering nucleic acid molecule that directs cleavage of a cholinergic receptor muscarinic 3 RNA, useful for treating or preventing respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary disease.

The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siRNA) molecule that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference (RNAi). The siRNA molecule, compounds, compositions, and methods are useful for treating or preventing respiratory and pulmonary diseases, disorders, and/or conditions, including chronic obstructive pulmonary disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies, cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The present sequence represents a cholinergic receptor muscarinic 3 siRNA.

Query Match	1.1%;	Score 19;	DB 1;	Length 19;
Best Local Similarity	100.0%;	Pred. No. 1.6e+02;		
Matches	19;	Conservative	0;	Mismatches 0;
				Indels

QY 579 GGUCAUCCUCCUUUGUCCUU 597
|||||
Db 1 GGUCAUCCUCCUUUGUCCUU 19

RESULT 383

ID AEA02171 standard; RNA; 19 BP.

AC AEA02171;

DT 28-JUL-2005 (first entry)

DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 55.

KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KM Neuroprotective; Nootropic; Uropathic;
 KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KM sinusitis; inflammation; allergy; cystic fibrosis; alchemers disease;
 KM mitochondrial disorder; cholinergic receptor muscarinic 3 / CHRM3; ss;
 siRNA; RNA interference; gene silencing; short interfering RNA.
 XS Synthetic.

OS Synthetic.

PN WO2005045040

PD 19-MAY-2005.

PF 20-AUG-2004; 2004WO-US027367.

PR 23-OCT-2003; 2003US-00693059.

PR 03-DEC-2003; 2003US-00727780.

PR 10-FEB-2004; 2004US-0543480P.

PR 11-MAR-2004; 2004US-00798090.

PR 30-APR-2004; 2004WO-US013456.

PR 17-AUG-2004; 2004US-00919866.

PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 145; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 1 A; 8 C; 3 G; 0 T; 7 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.6e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 813 UGGGACAGAGCGACAGACA 831
DB 19 TGGGACAGAGCGACAGACA 1
RESULT 380
AEA02267/C
ID AEA02267 standard; RNA; 19 BP.
XX
XX AEA02267;
AC
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 151.
XX
XX Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
XX Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mucritation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.

PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 151; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 5 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 921 GUUAGCCGCGCCACACUC 939
DB 19 GUAUGCCGCGCTGCACCTTC 1
RESULT 381
AEA02139
ID AEA02139 standard; RNA; 19 BP.
XX
XX AEA02139;
AC
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 23.
XX
XX Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
XX Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mucritation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.

PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00722780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX
PI Richards I, Macswigen J;
XX WPI, 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 101; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 8 A; 2 C; 6 G; 0 T; 3 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 1.6e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
QY 21 UACACCCUGCCCUUUGUU 39
:|||||:|||||:|:
Db 19 TACACCTCGCCTTGTGT 1
RESULT 378
AEA02256/c
ID AEA02256 standard; RNA; 19 BP.
XX
XX AEA02256;
AC
XX
XX 28-JUL-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 140.
DE
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neutropoietic; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW metcurtion disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX
OS Synthetic.
XX
XX WO2005045040-A2.
PN
XX
XX 19-MAY-2005.
PD
XX
XX 20-AUG-2004; 2004WO-US027367.
PF
XX
XX 23-OCT-2003; 2003US-00693059.
PR
XX
XX 24-NOV-2003; 2003US-00720448.
PR
XX
XX 24-NOV-2003; 2003US-00720448.

PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX
PI Richards I, Macswigen J;
XX WPI, 2005-356237/36.
XX
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 140; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 7 A; 3 C; 5 G; 0 T; 4 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 1.6e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
QY 723 UAGCCGUCACCAUUAUG 741
:|||||:|||||:|:
Db 19 TATGCCGTGCACCATATG 1
RESULT 379
AEA02261/c
ID AEA02261 standard; RNA; 19 BP.
XX
XX AEA02261;
AC
XX
XX 28-JUL-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 145.
DE
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neutropoietic; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW metcurtion disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX
OS Synthetic.
XX
XX WO2005045040-A2.
PN
XX
XX 19-MAY-2005.
PD
XX
XX 20-AUG-2004; 2004WO-US027367.
PF
XX
XX 23-OCT-2003; 2003US-00693059.
PR
XX
XX 24-NOV-2003; 2003US-00720448.
PR
XX
XX 03-DEC-2003; 2003US-00727780.
PR
XX
XX 14-JAN-2004; 2004US-00757803.

PD 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Richards I, Macewiggen J;
 XX
 DR WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 90; 184pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 19 BP; 6 A; 9 C; 3 G; 0 T; 1 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1605 CAACGACCCGUGAACCC 1623
 DB 1 CAACGACCCGUGAACCC 19
 RESULT 376
 AEA02209
 ID AEA02209 standard; RNA; 19 BP.
 XX
 AC AEA02209;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DB Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 93.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzhemiers disease;
 KW micrurtion disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX
 PN WO2005045040-A2.
 XX
 PD 19-MAY-2005.
 XX

PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Richards I, Macewiggen J;
 XX
 DR WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 93; 184pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 19 BP; 4 A; 5 C; 4 G; 0 T; 6 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1659 CACUUCAGAAGUCGUG 1677
 DB 1 CACUUCAGAAGUCGUG 19
 RESULT 377
 AEA02217/C
 ID AEA02217 standard; RNA; 19 BP.
 XX
 AC AEA02217;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DB Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 101.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzhemiers disease;
 KW micrurtion disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX
 PN WO2005045040-A2.
 XX
 PD 19-MAY-2005.
 XX
 PD 20-AUG-2004; 2004WO-US027367.
 XX

OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004US-00826966.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 79; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 8 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1407 GAAGACCGAAGCAGCAGC 1425
DB 1 GAAGACCGAAGCAGCAGC 19
RESULT 374
AEA02196
ID AEA02196 standard; RNA; 19 BP.
XX
AC AEA02196;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 80.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzhemiers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX

PN WO2005045040-A2.
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004US-00826966.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 80; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 8 A; 3 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1425 CACUAGCGGAAAGGAGC 1443
DB 1 CACUAGCGGAAAGGAGC 19
RESULT 375
AEA02206
ID AEA02206 standard; RNA; 19 BP.
XX
AC AEA02206;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 90.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzhemiers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX

KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX PD 19-MAY-2005.
XX
XX PF 20-AUG-2004; 2004WO-US027367.
XX
XX PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004WO-US013456.
XX PR 24-MAY-2004; 2004WO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX
XX PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX PI Richards I, Macswiggen J;
XX
XX DR WPI; 2005-356237/36.
XX
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX
XX PS Claim 33; SEQ ID NO 46; 184pp; English.
XX
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, and/or conditions, including chronic obstructive pulmonary
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SQ Sequence 19 BP; 7 A; 3 C; 8 G; 0 T; 1 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 813 UGAGACAGAGCGCAGACGA 831
XX |||||
XX 1 UGAGACAGAGCGCAGACGA 19
XX
XX DB
XX
XX RESULT 372
XX AEA02182
XX ID AEA02182 standard; RNA; 19 BP.
XX AC AEA02182;
XX XX
XX DT 28-JUL-2005 (first entry)
XX
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 66.
XX
XX KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX KW Neuroprotective; Nootropic; Uropathic;
XX KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;

KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX
XX PN WO2005045040-A2.
XX
XX PD 19-MAY-2005.
XX
XX PF 20-AUG-2004; 2004WO-US027367.
XX
XX PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004WO-US013456.
XX PR 24-MAY-2004; 2004WO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX
XX PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX PI Richards I, Macswiggen J;
XX
XX DR WPI; 2005-356237/36.
XX
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX
XX PS Claim 33; SEQ ID NO 66; 184pp; English.
XX
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, and/or conditions, including chronic obstructive pulmonary
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SQ Sequence 19 BP; 3 A; 3 C; 11 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1173 GCCUGAGAGAGCGCGG 1191
XX |||||
XX 1 GCCUGAGAGAGCGCGG 19
XX
XX DB
XX
XX RESULT 373
XX AEA02195
XX ID AEA02195 standard; RNA; 19 BP.
XX AC AEA02195;
XX XX
XX DT 28-JUL-2005 (first entry)
XX
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 79.
XX
XX KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX KW Neuroprotective; Nootropic; Uropathic;
XX KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.

XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic; ashma; allergic rhinitis;
KW chronic obstructive pulmonary disease; ashma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mucutition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004WO-US013456.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 183; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 6 A; 2 C; 7 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 1497 CUUCAUCGCAUCGCGC 1515
Db ||:||||:||||:||||
19 CTTCACTCATCTTGAC 1
RESULT 370
AEA02128
ID AEA02128 standard; RNA; 19 BP.
XX
XX AEA02128;
XX
XX
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 12.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;

KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; ashma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mucutition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 12; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 2 A; 5 C; 4 G; 0 T; 8 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 201 AGUGGUCUUCGCGCUC 219
Db |||||||||
1 AGUGGUCUUCGCGCUC 19
RESULT 371
AEA02162
ID AEA02162 standard; RNA; 19 BP.
XX
XX AEA02162;
XX
XX
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 46.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; ashma; allergic rhinitis;

XX 28-JUL-2005 (first entry)
DT
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 113.
DE
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neutroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
OS
XX Synthetic.
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 113; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 5 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
SQ
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 73.7%; Pred. No. 1.6e+02;
XX Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 237 CUUGGUGACCAUUGCGC 255
DB 19 CTTGGTACCATCATCGGC 1
RESULT 368
ID AEA02245/C
AC AEA02245 standard; RNA; 19 BP.
XX AEA02245;
XX 28-JUL-2005 (first entry)
DT

XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 129.
DE
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neutroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
OS
XX Synthetic.
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 129; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 1 A; 4 C; 6 G; 0 T; 8 U; 0 Other;
SQ
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 94.7%; Pred. No. 1.6e+02;
XX Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 525 GUACGAGCCAAACGACA 543
DB 19 GTACCGAGCCAAACGACA 1
RESULT 369
ID AEA02299/C
AC AEA02299 standard; RNA; 19 BP.
XX AEA02299;
XX 28-JUL-2005 (first entry)
DT Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 183.
XX

AEA02205
ID AEA02205 standard; RNA; 19 BP.
XX
AC AEA02205;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 89.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neutropoietic; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 89; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 3 A; 6 C; 4 G; 0 T; 6 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1587 CUACUGGCGUGGCUACUC 1605
DB 1 CUACUGGCGUGGCUACUC 19

XX
AC AEA02227;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 111.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neutropoietic; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 111; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 8 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 1.6e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
QY 201 AGUGGUCUACGCGUUC 219
DB 19 AGUGGUCUACGCGUUC 19

RESULT 367
AEA02229/c
ID AEA02229 standard; RNA; 19 BP.
XX
AC AEA02229;

DB 1 CUCCACCAAGUACCCUCA 19

RESULT 363
AEA02184
ID AEA02184 standard; RNA; 19 BP.
XX
AC AEA02184;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 68.
XX
KM Respiratory-Gen.; Antiaesthetic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
KM mucrition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richard I. Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 68; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 7 A; 5 C; 6 G; 0 T; 1 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1209 GAAAGCCGACAGCUCAG 1227
DB 1 GAAAGCCGACAGCUCAG 19

RESULT 364
AEA02189
ID AEA02189 standard; RNA; 19 BP.
XX
AC AEA02189;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 73.
XX
KM Respiratory-Gen.; Antiaesthetic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
KM mucrition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richard I. Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 73; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 6 A; 5 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1299 AGCCGUGACACAGCUAG 1317
DB 1 AGCCGUGACACAGCUAG 19

RESULT 365

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 885 UCACAGCAAGCAUGAAA 903
|||||
Db 1 UCACAGCAAGCAUGAAA 19

RESULT 361
AEA02174
ID AEA02174 standard; RNA; 19 BP.
XX
AC AEA02174;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 58.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 58; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 3 A; 8 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1029 UGCCUCCUGAGACUCC 1047
|||||
Db 1 UGCCUCCUGAGACUCC 19

RESULT 362
AEA02180
ID AEA02180 standard; RNA; 19 BP.
XX
AC AEA02180;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 64.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 64; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 5 A; 9 C; 1 G; 0 T; 4 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1137 CUCACCAAGUACCUCA 1155
|||||

SEQ Sequence 19 BP; 4 A; 5 C; 3 G; 0 T; 7 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 723 UAUCCUUCACCAUUAUG 741
|||||
DB 1 UAUCCUUCACCAUUAUG 19
RESULT 359
AEA02164
ID AEA02164 standard; RNA; 19 BP.
AC AEA02164;
XX
XX
XX 28-JUL-2005 (first entry)
DT
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 48.
XX
XX Respiratory-Gen.; Antiasthmatic; Anti allergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mucritution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX WO2005045040-A2.
PN
XX 19-MAY-2005.
PD
XX 20-AUG-2004; 2004WO-US027367.
PF
XX 23-OCT-2003; 2003US-00693059.
PR
XX 24-NOV-2003; 2003US-00720448.
PR
XX 03-DEC-2003; 2003US-00727780.
PR
XX 14-JAN-2004; 2004US-00757803.
PR
XX 10-FEB-2004; 2004US-0543480P.
PR
XX 13-FEB-2004; 2004US-00780447.
PR
XX 11-MAR-2004; 2004US-00798090.
PR
XX 16-APR-2004; 2004US-0082966.
PR
XX 30-APR-2004; 2004WO-US013456.
PR
XX 24-MAY-2004; 2004WO-US016390.
PR
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX Richards I, Macswiggen J;
PI
XX WPI; 2005-356237/36.
DR
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
PT
PS Claim 33; SEQ ID NO 48; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 4 A; 6 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 849 CACGGCAGUUCUGAAGC 867
|||||
DB 1 CACGGCAGUUCUGAAGC 19
RESULT 360
AEA02166
ID AEA02166 standard; RNA; 19 BP.
AC AEA02166;
XX
XX
XX 28-JUL-2005 (first entry)
DT
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 50.
XX
XX Respiratory-Gen.; Antiasthmatic; Anti allergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mucritution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX WO2005045040-A2.
PN
XX 19-MAY-2005.
PD
XX 20-AUG-2004; 2004WO-US027367.
PF
XX 23-OCT-2003; 2003US-00693059.
PR
XX 24-NOV-2003; 2003US-00720448.
PR
XX 03-DEC-2003; 2003US-00727780.
PR
XX 14-JAN-2004; 2004US-00757803.
PR
XX 10-FEB-2004; 2004US-0543480P.
PR
XX 13-FEB-2004; 2004US-00780447.
PR
XX 11-MAR-2004; 2004US-00798090.
PR
XX 16-APR-2004; 2004US-0082966.
PR
XX 30-APR-2004; 2004WO-US013456.
PR
XX 24-MAY-2004; 2004WO-US016390.
PR
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX Richards I, Macswiggen J;
PI
XX WPI; 2005-356237/36.
DR
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
PT
PS Claim 33; SEQ ID NO 50; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 19 BP; 10 A; 4 C; 3 G; 0 T; 2 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;

CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP, 3 A; 9 C; 3 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 147 CUCCUCCGACGAGUACC 165
Db 1 CUCCUCCGACGAGUACC 19
RESULT 357
AEA02151
ID AEA02151 standard; RNA; 19 BP.
XX
AC AEA02151;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 35.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
WPI; 2005-356237/36.
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 35; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The

CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP, 3 A; 3 C; 4 G; 0 T; 9 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 615 GUUCUGCAUACUUGGU 633
Db 1 GUUCUGCAUACUUGGU 19
RESULT 358
AEA02157
ID AEA02157 standard; RNA; 19 BP.
XX
AC AEA02157;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 41.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
WPI; 2005-356237/36.
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 41; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.

CC	Cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC	(RNAi). The siNA molecule, compounds, compositions, and methods are
CC	useful for treating or preventing respiratory and pulmonary diseases,
CC	disorders, and/or conditions, including chronic obstructive pulmonary
CC	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC	present sequence represents a cholinergic receptor muscarinic 3 siNA.
XX	Sequence 19 BP; 6 A; 4 C; 5 G; 0 T; 4 U; 0 Other;
SO	
Query Match	1.1%; Score 19; DB 1; Length 19;
Best Local Similarity	68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative	6; Mismatches 0; Indels 0; Gaps 0;
Oy	1659 CACUUCAGAGCUGCUG 1677
Db	19 CACUUCAGAGCUGCUG 1
RESULT 355	
.AEA02312/c	
ID	AEA02312 standard; RNA; 19 BP.
XX	AEA02312;
AC	
XX	28-JUL-2005 (first entry)
DT	
XX	Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 196.
DE	
XX	Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
XX	Neuroprotective; Nootropic; Utopachic;
KW	chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW	sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW	micurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW	siRNA; RNA interference; gene silencing; short interfering RNA.
XX	
OS	Synthetic.
XX	
PN	WO2005045040-A2.
XX	
PD	19-MAY-2005.
XX	
PF	20-AUG-2004; 2004WO-US027367.
XX	
XX	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00720448.
PR	03-DEC-2003; 2003US-00727780.
PR	14-JAN-2004; 2004US-0057803.
PR	10-FEB-2004; 2004US-0543800P.
PR	13-FEB-2004; 2004US-00780447.
PR	11-MAR-2004; 2004US-00798090.
PR	16-APR-2004; 2004US-00826966.
PR	30-APR-2004; 2004WO-US013456.
PR	24-MAY-2004; 2004WO-US016390.
PR	17-AUG-2004; 2004US-00919866.
XX	
PA	(SIRN-) SIRNA THERAPEUTICS INC.
XX	
PI	Richards I; Macewiggen J;
XX	
DR	WPI; 2005-356237/36.
XX	
PT	New short interfering nucleic acid molecule that directs cleavage of a
PT	cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX	disease.
XX	
PS	Claim 33; SEQ ID NO 196; 184bp; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siNA) molecule that directs cleavage of a
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC	(RNAi). The siNA molecule, compounds, compositions, and methods are

CC		useful for treating or preventing respiratory and pulmonary diseases,
CC		diseases, and/or conditions, including chronic obstructive pulmonary
CC		disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC		cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC		present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX		
SQ	Sequence 19 BP; 7 A; 4 C; 4 G; 0 T; 4 U; 0 Other;	
Query Match	1.1%; Score 19; DB 1; Length 19;	
Best Local Similarity	63.2%; Pred. No. 1.6e+02;	
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;		
OY	1731 GUUCGUCAUUUUUCACAAG 1749 :: :: :: 19 GTCCGTACTTTTCACAAG 1	
DB		
RESULT 356		
AEA02125		
ID	AEA02125 standard; RNA; 19 BP.	
AC		
AEAO2125;		
XX		
DT	28-JUL-2005 (first entry)	
DE		
XX	Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 9.	
XX		
KW	Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;	
KW	Neuroprotective; Nootropic; Uropathic;	
KW	Chronic obstructive pulmonary disease; asthma; allergic rhinitis;	
KW	sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;	
KW	mucurcution disorder; cholinergic receptor muscarinic 3; CHRM3. ss;	
OS	siRNA; RNA interference; gene silencing; short interfering RNA.	
XX		
SYN	Synthetic.	
XX		
PX	WO2005045040-A2.	
PD		
XX	19-MAY-2005.	
PF		
XX	20-AUG-2004; 2004WO-US027367.	
PR	23-OCT-2003; 2003US-00693059.	
PR	24-NOV-2003; 2003US-00720448.	
PR	03-DEC-2003; 2003US-00727780.	
PR	14-JAN-2004; 2004US-00757803.	
PR	10-FEB-2004; 2004US-0543480P.	
PR	13-FEB-2004; 2004US-00780447.	
PR	11-MAR-2004; 2004US-00798090.	
PR	16-APR-2004; 2004US-00826966.	
PR	30-APR-2004; 2004WO-US013456.	
PR	24-MAY-2004; 2004WO-US016390.	
PR	17-AUG-2004; 2004US-00919866.	
XX		
PA	(SIRN-) SIRNA THERAPEUTICS INC.	
PI		
XX	Richards I, Macawiggen J;	
DR	WPI; 2005-356237/36.	
XX		
PT	New short interfering nucleic acid molecule that directs cleavage of a	
PT	cholinergic receptor muscarinic 3 RNA, useful for treating or preventing	
PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary	
PT	disease.	
XX		
PS	Claim 33; SEQ ID NO 9; 184pp; English.	
XX		
CC	The invention relates to a chemically synthesized double stranded short	
CC	interfering nucleic acid (sirna) molecule that directs cleavage of a	
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference	
CC	(RNAi). The sirna molecule, compounds, compositions, and methods are	
CC	useful for treating or preventing respiratory and pulmonary diseases,	
CC	diseases, and/or conditions, including chronic obstructive pulmonary	

PS Claim 33; SEQ ID NO 181; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 1 A; 5 C; 8 G; 0 T; 5 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.6e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1461 GAAGCGGCCGAGCCGUC 1479
Db 19 GAAGCGGCCGAGCCCTC 1
RESULT 353
AEA02307/c
ID AEA02307 standard; RNA; 19 BP.
XX
XX AEA02307;
AC
XX
DT 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 191.
DE
XX
XX Respiratory-Gen.; Antiasmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
PD
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX
XX Richards I, Macswigen J;
PI
XX
XX WPI, 2005-356237/36.
DR
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 191; 184pp; English.
PS
XX

CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 2 A; 1 C; 6 G; 0 T; 10 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1641 CAACAAACAUUCAGAAC 1659
Db 19 CAACAAACAUUCAGAAC 1
RESULT 354
AEA02308/c
ID AEA02308 standard; RNA; 19 BP.
XX
XX AEA02308;
AC
XX
DT 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 192.
DE
XX
XX Respiratory-Gen.; Antiasmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
PD
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX
XX Richards I, Macswigen J;
PI
XX
XX WPI, 2005-356237/36.
DR
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 192; 184pp; English.
PS
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC

PT Cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 161; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 5 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 1101 CGUGCUCAAGCUCGCGGU 1119
DB 19 CGTGCTCAAGCTTCGGGT 1
XX
RESULT 351
AEA02290/C
ID AEA02290 standard; RNA; 19 BP.
XX
AC AEA02290;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 174.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM micronutrition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary

PT disease.
XX
XX Claim 33; SEQ ID NO 174; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 3 A; 7 C; 4 G; 0 T; 5 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.6e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 1335 CUCAGUGGUAAGACACG 1353
DB 19 CTCAGTGGGTAAAGACACG 1
XX
RESULT 352
AEA02297/C
ID AEA02297 standard; RNA; 19 BP.
XX
AC AEA02297;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 181.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM micronutrition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX

XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 99; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 3 A; 7 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1753 GCACCCGACGAGCCUUGU 1771
DB 1 GCACCCGACGAGCCUUGU 19
RESULT 349
AEA02236/c
ID AEA02236 standard; RNA; 19 BP.
XX
AC AEA02236;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 120.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826986.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.

XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 120; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 19 BP; 6 A; 3 C; 4 G; 0 T; 6 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 363 AAUGAUCUGUACGACC 381
DB 19 AATGAATCTTTACGACC 1
RESULT 350
AEA02277/c
ID AEA02277 standard; RNA; 19 BP.
XX
AC AEA02277;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 161.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826986.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a

XX (SIRN-) SIRNA THERAPEUTICS INC.
 XX PI Richards I, Macswiggen J;
 XX DR WPI, 2005-356237/36.
 XX PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX PS Claim 33; SEQ ID NO 71, 184pp; English.
 XX CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX SQ Sequence 19 BP; 7 A; 5 C; 2 G; 0 T; 5 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred.No.1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1263 AAAAAGCUCUCCACGCU 1281
 DB 1 AAAAAGCUCUCCACGCU 19
 RESULT 347
 ID AEA02194 standard; RNA; 19 BP.
 XX AC AEA02194;
 XX DT 28-JUL-2005 (first entry)
 XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 78.
 XX KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX OS Synthetic.
 XX PN WO2005045040-A2.
 XX PD 19-MAY-2005.
 XX PF 20-AUG-2004; 2004WO-US027367.
 XX PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX PA (SIRN-) SIRNA THERAPEUTICS INC.

XX PI Richards I, Macswiggen J;
 XX DR WPI, 2005-356237/36.
 XX PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX PS Claim 33; SEQ ID NO 78; 184pp; English.
 XX CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX SQ Sequence 19 BP; 3 A; 4 C; 7 G; 0 T; 5 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred.No.1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1389 GGCAGAGAGGUGUCUCUG 1407
 DB 1 GGCAGAGAGGUGUCUCUG 19
 RESULT 348
 ID AEA02215 standard; RNA; 19 BP.
 XX AC AEA02215;
 XX DT 28-JUL-2005 (first entry)
 XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 99.
 XX KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX OS Synthetic.
 XX PN WO2005045040-A2.
 XX PD 19-MAY-2005.
 XX PF 20-AUG-2004; 2004WO-US027367.
 XX PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX PI Richards I, Macswiggen J;

PR	24-MAY-2004; 2004WO-US016390.
PR	17-AUG-2004; 2004US-00919866.
XX	
XX	
PA	(SIRN-) SIRNA THERAPEUTICS INC.
PI	Richards I, Macswiggen J;
XX	
DR	WPI; 2005-356237/36.
XX	
PT	New short interfering nucleic acid molecule that directs cleavage of a
PT	cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT	disease.
XX	
PS	Claim 33; SEQ ID NO 42; 184bp; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siNA) molecule that directs cleavage of a
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC	(RNAi). The siNA molecule, compounds, compositions, and methods are
CC	useful for treating or preventing respiratory and pulmonary diseases,
CC	disorders, and/or conditions, including chronic obstructive pulmonary
CC	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC	present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX	
SO	Sequence 19 BP; 5 A; 2 C; 5 G; 0 T; 7 U; 0 Other;

Query Match 1.14; Score 19; DB 1; Length 19;

	Query Match	1.1%	Score 19;	DB 1;	Length 19;
	Best Local Similarity	100.0%;	Pred. NO.	1.6e+02;	
	Matches	19;	Conservative	0;	Mismatches 0; Indels 0; Gaps
Oy	741	GACUAAUUUAATCUGAGG	759		
Dd	1	GACTAUUUUAATCUGAGG	19		

ID	AEA02187	standard; RNA; 19 BP.
XX		
XX	AEA02187;	
XX		
DT	28-JUL-2005	(first entry)
XX		
DE		Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 71.
XX		
KW		Respiratory-Gen.; Antisclerotic; Antiallergic; Antiinflammatory;
KW		Neuroprotective; Nootropic; Uropathic;
KW		chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW		sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW		metastatic disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW		siRNA; RNA interference; gene silencing; short interfering RNA.
XX		
SS		Synthetic.

PN	MO2005045040-A2.
XX	
PD	19-MAY-2005.
XX	
XX	
PF	20-AUG-2004; 2004MO-US027367.
XX	
PR	23-OCT-2003; 2003US-00693059
PR	24-NOV-2003; 2003US-00720448
PR	14-JAN-2004; 2003US-00727780
PR	13-DEC-2003; 2004US-00572803
PR	10-FEB-2004; 2004US-0543480P
PR	13-FEB-2004; 2004US-00780447
PR	11-MAR-2004; 2004US-00798990
PR	16-APR-2004; 2004US-00826866
PR	30-APR-2004; 2004MO-US013456
PR	14-MAY-2004; 2004MO-US016390
PR	17-AUG-2004; 2004US-00919866

PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00780490.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004US-00757803.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
XX Claim 33; SEQ ID NO 5; 184bp; English.
XX
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX
SQ Sequence 19 BP; 2 A; 8 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 75 CGAUGCAGGCGUGCCCCCG 93
Db 1 CGAUGCAGGCGUGCCCCCG 19
RESULT 343
AEA02142
ID AEA02142 standard; RNA; 19 BP.
XX
XX AEA02142;
AC
XX
XX
XX 28-JUL-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 26.
DE
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX PD 19-MAY-2005.
XX
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX PF
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 10-FEB-2004; 2004US-0543480P.

PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004US-00757803.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX
XX Claim 33; SEQ ID NO 26; 184bp; English.
XX
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX
SQ Sequence 19 BP; 4 A; 5 C; 4 G; 0 T; 6 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 453 CAGCAUGCCUCUGUUAUG 471
Db 1 CAGCAUGCCUCUGUUAUG 19
RESULT 344
AEA02148
ID AEA02148 standard; RNA; 19 BP.
XX
XX AEA02148;
AC
XX
XX
XX 28-JUL-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 32.
DE
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX PD 19-MAY-2005.
XX
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX PF
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.

PR	14-JAN-2004;	2004US-00757803.
XX	(RICH//) RICHARDS I.	
PA	(MCSW/) MCSWIGGEN J.	
XX		
PI	Richards I, Mcswiggen J;	
XX		
DR	WPI; 2005-090672/10.	
XX		
PT	Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.	
XX		
PS	Disclosure; SEQ ID NO 168; 84pp; English.	
XX		
CC	The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,	
CC	where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (II) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome,	
CC	Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.	
XX		
SQ	Sequence 19 BP; 1 A; 8 C; 5 G; 0 T; 5 U; 0 Other;	
	Query Match	1.1%; Score 19; DB 1; Length 19;
	Best Local Similarity	94.7%; Pred. No. 1.6e+02;
	Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;	
OY	1227 GGCCGAGAAAGCGCUGAC 1245	
DB	19 GGCCGAGAAAGCGCUGAC 1	
RESULT 341		
ADWJ27889/C		
ID	ADWJ27889 standard; RNA; 19 BP.	
XX		
AC	ADWJ27889;	
XX		
DT	07-APR-2005 (first entry)	
DE		
XX	Cholinergic receptor muscarinic 3 gene targeted siRNA #186.	
KW	gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.; respiratory-gen.; hypoesnastic; gastrointestinal-gen.; neuroprotective; nootropic; uteropathic; short interfering RNA; RNA interference; siRNA; cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis; inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction; hyperextension; emphysema; irritable bowel syndrome; Alzheimers disease; incontinence; ss.	
OS	Synthetic.	
XX		
PN	US2005014172-A1.	
XX		
PD	20-JAN-2005.	
XX		
PF	11-MAR-2004; 2004US-00798090.	
XX		
PR	20-FEB-2002; 2002US-0358580P.	
PR	11-MAR-2002; 2002US-0363124P.	
PR	20-MAY-2002; 2002WO-US015876.	
PR	06-JUN-2002; 2002US-0386782P.	
PR	29-AUG-2002; 2002US-0406784P.	
PR	05-SEP-2002; 2002US-0408378P.	
PR	09-SEP-2002; 2002US-0409293P.	
PR	15-JAN-2003; 2003US-0440129P.	

PR	20-FEB-2003; 2003WO-US0005028.
PR	20-FEB-2003; 2003WO-US0005346.
PR	30-APR-2003; 2003US-00427160.
PR	23-MAY-2003; 2003US-00444853.
PR	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00720448.
PR	14-JAN-2004; 2004US-00757803.
XX	
PA	(RICH/) RICHARDS I.
PA	(MCSW/) MCSWIGEN J.
XX	
PI	Richards I, Mcswigen J;
XX	
DR	WPI; 2005-090672/10.
XX	
PT	Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT	RNA through RNA interference, useful for treating asthma.
PT	
PS	Disclosure; SEQ ID NO 186; 84pp; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC	where each strand of (I) has 19-23 nucleotides, and does not require the
CC	presence of nucleotides having a 2-hydroxy group for mediating RNA
CC	interference. (I) is useful for treating diseases e.g., asthma, allergic
CC	rinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC	vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC	Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC	towards nuclease. Double stranded short interfering nucleic acid molecule
CC	was produced by solid phase oligonucleotide synthesis method. This
CC	sequence represents an example of a siRNA molecule of the invention.
XX	
SO	Sequence 19 BP; 3 A; 3 C; 6 G; 0 T; 7 U; 0 Other;
	Query Match 1.1%; Score 19; DB 1; Length 19;
	Best Local Similarity 84.2%; Pred.No. 1.6e+02;
	Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
OY	1551 UGACGAGCUCGACUACCCCAA 1569
	: :
DB	19 TGACAGCGCATACCCTCAA 1
RESULT 342	
AEA02121	
ID	AEA02121 standard; RNA; 19 BP.
XX	
XX	AEA02121;
XX	
DT	28-JUL-2005 (first entry)
XX	
DE	Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 5.
XX	
KW	Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW	Neuroprotective; Nootropic; Utopathic;
KW	chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW	sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW	mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX	siRNA; RNA interference; gene silencing; short interfering RNA.
XX	
OS	Synthetic.
XX	
PN	WO2005045040-A2.
XX	
PD	19-MAY-2005.
XX	
PF	20-AUG-2004; 2004WO-US027367.
XX	
XX	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00720448.
PR	03-DEC-2003; 2003US-00727780.
PR	

XX		Disclosure; SEQ ID NO 145; 84bp; English.
PS		
XX		The invention relates to a chemically synthesized double stranded short
CC		interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC		cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC		where each strand of (I) has 19-23 nucleotides, and does not require the
CC		presence of nucleotides having a 2-hydroxy group for mediating RNA
CC		interference. (I) is useful for treating diseases e.g., asthma, allergic
CC		rinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC		vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC		Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC		towards nuclease. Double stranded short interfering nucleic acid molecule
CC		was produced by solid phase oligonucleotide synthesis method. This
CC		sequence represents an example of a siRNA molecule of the invention.
XX		
SO		Sequence 19 BP; 1 A; 8 C; 3 G; 0 T; 7 U; 0 Other;
	Query Match	1.1%; Score 19; DB 1; Length 19;
	Best Local Similarity	94.7%; Pred. No. 1.6e+02;
	Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;	
OY		
	813 UGCGACAGAGCAGACAGA 831	
	:	
Db	19 TGCGACAGAGCGCAGACGA 1	
RESULT 339		
ADMW27852/C		
ID	ADMW27852 standard; RNA; 19 BP.	
AD	ADMW27852;	
XX		
DT	07-APR-2005 (first entry)	
XX		
DE	Cholinergic receptor muscarinic 3 gene targeted siRNA #149.	
XX		
KM	gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;	
KM	respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;	
KM	nootropic; uropachic; short interfering RNA; RNA interference; siRNA;	
KM	cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;	
KM	inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;	
KM	hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;	
KX	incontinence; ss.	
XX		
OS	Synthetic.	
XX		
PN	US2005014172-A1.	
XX		
PD	20-JAN-2005.	
XX		
PF	11-MAR-2004; 2004US-00798090.	
XX		
PR	20-FEB-2002; 2002US-0358580P-	
PR	11-MAR-2002; 2002US-0363124P-	
PR	20-MAY-2002; 2002WO-US015876-	
PR	06-JUN-2002; 2002US-0386782P-	
PR	29-AUG-2002; 2002US-0406784P-	
PR	05-SEP-2002; 2002US-0408378P-	
PR	09-SEP-2002; 2002US-0409293P-	
PR	15-JAN-2003; 2003US-0440129P-	
PR	20-FEB-2003; 2003WO-US005028-	
PR	20-FEB-2003; 2003WO-US005346-	
PR	30-APR-2003; 2003US-0042716O-	
PR	23-MAY-2003; 2003US-0044485J-	
PR	23-OCT-2003; 2003US-0069305S-	
PR	24-NOV-2003; 2003US-00720448-	
PR	14-JAN-2004; 2004US-00757803.	
XX		
PA	(RICH/) RICHARDS I.	
PA	(MCSW/) MCSWIGEN J.	
PI	Richards I, Mcswigen J;	

XX		
DR	WPI; 2005-090672/10.	
PT	Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.	
PS	Disclosure; SEQ ID NO 149; 84pp; English.	
CC	The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (II) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.	
SQ	Sequence 19 BP; 2 A; 3 C; 4 G; 0 T; 10 U; 0 Other;	
	Query Match 1.1%; Score 19; DB 1; Length 19;	
	Best Local Similarity 89.5%; Pred. No. 1.6e+02;	
	Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;	
OY	885 UCAACAGCAAGAUGAAA 903 : 19 TCACGCGAAAGCATGAAA 1	
Dd		
RESULT 340		
ID	ADW27871/C	
AD	ADW27871 standard; RNA; 19 BP.	
XX	ADW27871;	
DT	07-APR-2005 (first entry)	
DE	Cholinergic receptor muscarinic 3 gene targeted siRNA #168.	
XX		
KM	gene expression; antiasthmatic; anti-allergic; anti-inflammatory; CNS-Gen.; respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective; nootropic; uteraphnic; short interfering RNA; RNA interference; siRNA; cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis; inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction; hyperextension; emphysema; irritable bowel syndrome; Alzheimers disease; incontinence; ss.	
KV		
XX		
OS	Synthetic.	
PX	US2005014172-A1.	
PN		
XX		
PD	20-JAN-2005.	
PF	11-MAR-2004; 2004US-00798090.	
XX		
PR	20-FEB-2002; 2002US-0358580P.	
PR	11-MAR-2002; 2002US-0363124P.	
PR	20-MAY-2002; 2002WO-US015876.	
PR	06-JUN-2002; 2002US-0386782P.	
PR	29-AUG-2002; 2002US-0406784P.	
PR	05-SEP-2002; 2002US-0408378P.	
PR	09-SEP-2002; 2002US-0409293P.	
PR	15-OAN-2003; 2003US-0440122P.	
PR	20-FEB-2003; 2003WO-US005028.	
PR	30-APR-2003; 2003US-00505346.	
PR	23-MAY-2003; 2003US-0042716O.	
PR	23-OCT-2003; 2003US-00693059.	
PR	24-NOV-2003; 2003US-00720448.	

CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 6 A; 6 C; 6 G; 0 T; 1 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 417 GGCGTGGACCTGCGCTT 435
Db 19 GGCGTGGACCTGCGCTT 1
RESULT 337
ID ADM27845/c
XX ADM27845 standard; RNA; 19 BP.
AC ADM27845;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #142.
XX
KM gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; utroptic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-0044853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswigen J;
XX WPI; 2005-090672/10.
XX
DR Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 142; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,

CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 4 A; 4 C; 2 G; 0 T; 9 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 759 GAUCUUAAGGAAACUGAA 777
Db 19 GATCTATAAGGAAACUGAA 1
RESULT 338
ID ADM27848/c
XX ADM27848 standard; RNA; 19 BP.
XX
AC ADM27848;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #145.
XX
KM gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; utroptic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-0044853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswigen J;
XX WPI; 2005-090672/10.
XX
DR Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.

Db 1 CUUCAUCAUCACUUGACC 19

RESULT 335
ADM27801
ID ADM27801 standard; RNA; 19 BP.
XX
AC ADM27801;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #98.
XX
KM gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM neotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
KM incontinence; ss.
XX
KM Synthetic.
XX
OS US2005014172-A1.
XX
PN 20-JAN-2005.
XX
PD 11-MAR-2004; 2004US-00798090.
XX
PE 20-FEB-2002; 2002US-0358580P.
XX
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-036782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-0042716P.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
XX
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 98; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 19 BP; 3 A; 9 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 GCGCGACCCGAGAGGCC 1767
|||||
Db 1 GCGCGACCCGAGAGGCC 19

RESULT 336
ADM27826/c
ID ADM27826 standard; RNA; 19 BP.
XX
AC ADM27826;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #123.
XX
KM gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM neotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
KM incontinence; ss.
XX
XX Synthetic.
XX
OS US2005014172-A1.
XX
PN 20-JAN-2005.
XX
PD 11-MAR-2004; 2004US-00798090.
XX
PE 20-FEB-2002; 2002US-0358580P.
XX
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-036782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-0042716P.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
XX
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 123; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance

XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003US-00427160.
PR 30-APR-2003; 2003US-00444853.
PR 23-MAY-2003; 2003US-00693059.
PR 23-OCT-2003; 2003US-00720448.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswigen J;
XX WPI; 2005-090672/10.
XX
DR Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 31; 84pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX
SQ Sequence 19 BP; 7 A; 3 C; 7 G; 0 T; 2 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 543 AACAAAGAGAGCCGUGUG 561
|||||
Db 1 AACAAAGAGAGCCGUGUG 19
|||||
RESULT 334
ADM27787
ID ADM27787 standard; RNA; 19 BP.

XX
AC ADM27787;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #84.
XX
KM gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003US-00427160.
PR 30-APR-2003; 2003US-00444853.
PR 23-MAY-2003; 2003US-00693059.
PR 23-OCT-2003; 2003US-00720448.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswigen J;
XX WPI; 2005-090672/10.
XX
DR Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 84; 84pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX
SQ Sequence 19 BP; 4 A; 7 C; 2 G; 0 T; 6 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1497 CUUCAUACACUUGACC 1515
|||||

PR	11-MAR-2002;	2002US-0363124P.
PR	20-MAY-2002;	2002WO-US015876.
PR	06-JUN-2002;	2002US-0386782P.
PR	29-AUG-2002;	2002US-0406784P.
PR	05-SEP-2002;	2002US-0408378P.
PR	09-SEP-2002;	2002US-0409293P.
PR	15-JAN-2003;	2003US-0440129P.
PR	20-FEB-2003;	2003WO-US005028.
PR	20-FEB-2003;	2003WO-US005346.
PR	30-APR-2003;	2003US-0042716O.
PR	23-MAY-2003;	2003US-00444853.
PR	23-OCT-2003;	2003US-00693059.
PR	24-NOV-2003;	2003US-00720448.
PR	14-JAN-2004;	2004US-00757803.
XX		
PA	(RICH/) RICHARDS I.	
PA	(MCSW/) MCSWIGGEN J.	
XX		
PI	Richards I,	Mcswiggen J;
XX		
XX	WPI:	2005-090672/10.
DR		
XX		
PT	Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.	
PT		
XX		
PS	Disclosure; SEQ ID NO 166; 84bp; English.	
CC	The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (II) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.	
CC		
CC		
CC		
CC		
CC		
CC		
CC		
SQ	Sequence 19 BP; 4 A; 10 C; 1 G; 0 T; 4 U; 0 Other;	
XX		
Query Match	1.1%; Score 19; DB 1; Length 19;	
Best Local Similarity	78.9%; Pred. No. 1.6e+02;	
Matches	15; Conservative	4; Mismatches
		0; Indels
		0; Gaps
OY	1191 GAUGGUGACUUGAGAGC	1209
	: :	
	: :	
DB	19 GATGGTGACTTGGAGAGG	1
RESULT 331		
ID	ADM27896/c	
XX	ADM27896 standard; RNA; 19 BP.	
XX		
AC	ADM27896;	
DT	07-APR-2005 (first entry)	
XX		
DE	Cholinergic receptor muscarinic 3 gene targeted siRNA #193.	
XX		
KW	gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-gen.; respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective; nocotropic; uterathic; short interfering RNA; RNA interference; siRNA; cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis; inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction; hyperextension; emphysema; irritable bowel syndrome; Alzheimers disease; incontinence; ss.	
KW		
XX		
OS	Synthetic.	
NN	US2005014172-A1.	

CC	cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC	where each strand of (I) has 19-23 nucleotides, and does not require the
CC	presence of nucleotides having a 2-hydroxy group for mediating RNA
CC	interference. (I) is useful for treating diseases e.g., asthma, allergic
CC	rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC	vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC	Alzheimer's disease or urinary incontinence. (II) has increased resistance
CC	towards nuclease. Double stranded short interfering nucleic acid molecule
CC	was produced by solid phase oligonucleotide synthesis method. This
CC	sequence represents an example of a siRNA molecule of the invention.
XX	
SQ	Sequence 19 BP; 2 A; 9 C; 3 G; 0 T; 5 U; 0 Other;
Qy	Query Match 1.1%; Score 19; DB 1; Length 19;
Db	Best Local Similarity 100.0%; Pred. No. 1.6e+02;
	Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
	1353 GGCGCACUCUACCUUGGCC 1371
	1 GGCGCACUCUACCUUGGCC 19
RESULT 326	
ADW27793	
ID	ADW27793 standard; RNA; 19 BP.
XX	
AC	ADW27793;
XX	
DT	07-APR-2005 (first entry)
DE	
XX	Cholinergic receptor muscarinic 3 gene targeted siRNA #90.
KW	gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW	respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW	nootropic; urapahic; short interfering RNA; RNA interference; siRNA;
KW	cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW	inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW	hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX	incontinence; ss.
OS	Synthetic.
PN	US2005014172-A1.
PD	
XX	
PD	20-JAN-2005.
XX	
PE	11-MAR-2004; 2004US-00798090.
XX	
PR	20-FEB-2002; 2002US-035680P.
PR	11-MAR-2002; 2002US-0363124P.
PR	20-MAY-2002; 2002WO-US015876.
PR	06-JUN-2002; 2002US-0366782P.
PR	29-AUG-2002; 2002US-0406784P.
PR	05-SEP-2002; 2002US-0408378P.
PR	09-SEP-2002; 2002US-0409293P.
PR	15-JAN-2003; 2003US-0440129P.
PR	20-FEB-2003; 2003WO-US005028.
PR	20-FEB-2003; 2003WO-US005346.
PR	30-APR-2003; 2003US-0042716O.
PR	23-MAY-2003; 2003US-00444853.
PR	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00720448.
PR	14-JAN-2004; 2004US-00757803.
PA	(RICHA I.) RICHARDS I.
PA	(MCSW J.) MCSWIGGEN J.
XX	
PI	Richards I, Mcswigen J;
DR	WPI: 2005-090672/10.
TX	
Pt	Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3

PT	RNA through RNA interference, useful for treating asthma.
XX	
PS	Disclosure; SEQ ID NO 90; 84pp; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siRNA) molecule (1) that directs cleavage of a
CC	cholelnergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC	where each strand of (1) has 19-23 nucleotides, and does not require the
CC	presence of nucleotides having a 2-hydroxy group for mediating RNA
CC	interference. (1) is useful for treating diseases e.g., asthma, allergic
CC	rinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC	vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC	Alzheimer's disease or urinary incontinence. (1) has increased resistance
CC	towards nuclease. Double stranded short interfering nucleic acid molecule
CC	was produced by solid phase oligonucleotide synthesis method. This
CC	sequence represents an example of a siRNA molecule of the invention.
XX	
CC	Sequence 19 BP; 6 A; 9 C; 3 G; 0 T; 1 U; 0 Other;
XX	
Query Match	1.1%; Score 19; DB 1; Length 19;
Best Local Similarity	100.0%; Pred. No. 1.6e+02;
Matches	19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1605 CAACAGCACCGUAAACCC 1623
DB	1 CAACGACGACCGUAAACCC 19
RESULT 327	
ADM27803/C	
ID	ADM27803 standard; RNA; 19 BP.
XX	
XX	ADM27803;
AC	
XX	
DT	07-APR-2005 (first entry)
XX	
DE	Cholinergic receptor muscarinic 3 gene targeted siRNA #100.
XX	
KW	gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW	respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW	nootropic; uteraphalic; short interfering RNA; RNA interference; siRNA;
KW	cholelnergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW	inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW	hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW	incontinence; se.
XX	
OS	Synthetic.
XX	
PN	US2005014172-A1.
XX	
PD	20-JAN-2005.
XX	
XX	
PF	11-MAR-2004; 2004US-00798090.
XX	
PR	20-FEB-2002; 2002US-0358580P.
PR	11-MAR-2002; 2002US-0363124P.
PR	20-MAY-2002; 2002WO-US015876.
PR	06-JUN-2002; 2002US-0386782P.
PR	29-AUG-2002; 2002US-0406784P.
PR	05-SEP-2002; 2002US-0408378P.
PR	09-SEP-2002; 2002US-0409233P.
PR	15-JAN-2003; 2003US-0440129P.
PR	20-FEB-2003; 2003WO-US005028.
PR	20-FEB-2003; 2003WO-US005346.
PR	30-APR-2003; 2003US-00427160.
PR	23-MAY-2003; 2003US-00444853.
PR	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00720448.
PR	14-JAN-2004; 2004US-00757803.
XX	
XX	(RICH/) RICHARDS I.
PA	PA
XX	(MCSW/) MCSWIGEN J.
XX	

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 507 CAUACAGAGGCGCCUACG 525
|||||
DB 1 CAUACAGAGGCGCCUACG 19

RESULT 324
ADM27773
ID ADM27773 strand; RNA; 19 BP.
AC ADM27773;
DT 07-APR-2005 (first entry)
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #70.
XX
XX gene expression; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nocrotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX Synthetic.
XX OS
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 70; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,

CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 19 BP; 4 A; 4 C; 6 G; 0 T; 5 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1245 CGAUGAGGCGAGUUUCCA 1263
|||||
DB 1 CGAUGAGGCGAGUUUCCA 19

RESULT 325
ADM27779
ID ADM27779 strand; RNA; 19 BP.
AC ADM27779;
DT 07-APR-2005 (first entry)
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #76.
XX
XX gene expression; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nocrotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX Synthetic.
XX OS
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 76; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a

ID ADW27730 standard; RNA; 19 BP.
XX
AC ADW27730;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #27.
XX
KM gene expression; antisthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM neurotropic; utropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003US-05005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX WPI; 2005-090672/10.
XX
DR
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 27; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX
SQ Sequence 19 BP; 4 A; 5 C; 4 G; 0 T; 6 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

471 GAADCUUCUGUCAUCAGC 489

Db |||||
1 GAADCUUCUGUCAUCAGC 19
RESULT 323
ADW27732
ID ADW27732 standard; RNA; 19 BP.
XX
AC ADW27732;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #29.
XX
KM gene expression; antisthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM neurotropic; utropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003US-05005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX
PA (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX WPI; 2005-090672/10.
XX
DR
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 29; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX
SQ Sequence 19 BP; 4 A; 8 C; 5 G; 0 T; 2 U; 0 Other;

KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 KW incontinence; ss.
 XX Synthetic.
 XX OS
 XX PN US2005014172-A1.
 XX PD 20-JAN-2005.
 XX PF 11-MAR-2004; 2004US-00798090.
 XX PR 20-FEB-2002; 2002US-0358580P.
 XX PR 11-MAR-2002; 2002US-0363124P.
 XX PR 20-MAY-2002; 2002WO-US015876.
 XX PR 06-JUN-2002; 2002US-0386782P.
 XX PR 29-AUG-2002; 2002US-0406784P.
 XX PR 05-SEP-2002; 2002US-0408378P.
 XX PR 09-SEP-2002; 2002US-0409293P.
 XX PR 15-JAN-2003; 2003US-0440129P.
 XX PR 20-FEB-2003; 2003WO-US005028.
 XX PR 20-FEB-2003; 2003WO-US005346.
 XX PR 30-APR-2003; 2003US-00427160.
 XX PR 23-MAY-2003; 2003US-00444853.
 XX PR 23-OCT-2003; 2003US-00693059.
 XX PR 24-NOV-2003; 2003US-00720448.
 XX PR 14-JAN-2004; 2004US-00757803.
 XX PA (RICH/) RICHARDS I.
 XX PA (MCSW/) MCSWIGGEN J.
 XX PI Richard I, Mcswigen J;
 XX DR WPI; 2005-090672/10.
 XX PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX PS Disclosure; SEQ ID NO 162; 84pp; English.
 XX CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX SQ Sequence 19 BP; 3 A; 1 C; 9 G; 0 T; 6 U; 0 Other;
 XX QY Query Match 1.1%; Score 19; DB 1; Length 19;
 XX DB Best Local Similarity 84.2%; Pred. No. 1.6e+02;
 XX Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 XX 1119 UCACGACCAUCCUCCAC 1137
 XX :|||||:|||||:
 XX 19 TCACGACCACTCTCTCAC 1
 XX
 XX RESULT 321
 XX ADM27888/c
 XX ID ADM27888 standard; RNA; 19 BP.
 XX XX
 XX AC ADM27888;
 XX XX
 XX DT 07-APR-2005 (first entry)
 XX XX

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #185.
 XX XX
 XX gene expression; antispasmodic; anti-allergic; anti-inflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uterapathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 KW incontinence; ss.
 XX Synthetic.
 XX OS
 XX PN US2005014172-A1.
 XX PD 20-JAN-2005.
 XX PF 11-MAR-2004; 2004US-00798090.
 XX PR 20-FEB-2002; 2002US-0358580P.
 XX PR 11-MAR-2002; 2002US-0363124P.
 XX PR 20-MAY-2002; 2002WO-US015876.
 XX PR 06-JUN-2002; 2002US-0386782P.
 XX PR 29-AUG-2002; 2002US-0406784P.
 XX PR 05-SEP-2002; 2002US-0408378P.
 XX PR 09-SEP-2002; 2002US-0409293P.
 XX PR 15-JAN-2003; 2003US-0440129P.
 XX PR 20-FEB-2003; 2003WO-US005028.
 XX PR 20-FEB-2003; 2003WO-US005346.
 XX PR 30-APR-2003; 2003US-00427160.
 XX PR 23-MAY-2003; 2003US-00444853.
 XX PR 23-OCT-2003; 2003US-00693059.
 XX PR 24-NOV-2003; 2003US-00720448.
 XX PR 14-JAN-2004; 2004US-00757803.
 XX PA (RICH/) RICHARDS I.
 XX PA (MCSW/) MCSWIGGEN J.
 XX PI Richard I, Mcswigen J;
 XX DR WPI; 2005-090672/10.
 XX PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX PS Disclosure; SEQ ID NO 185; 84pp; English.
 XX CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX SQ Sequence 19 BP; 8 A; 4 C; 4 G; 0 T; 3 U; 0 Other;
 XX QY Query Match 1.1%; Score 19; DB 1; Length 19;
 XX DB Best Local Similarity 57.9%; Pred. No. 1.6e+02;
 XX Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
 XX 1533 UCUGUGAACAACCCUUUGU 1551
 XX :|||:|||||:|||||:
 XX 19 TCTGTGAACACCTTTGT 1
 XX
 XX RESULT 322
 XX ADM27730

PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 PI Richards I, Mcswigen J;
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 155; 84bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 19 BP; 3 A; 7 C; 4 G; 0 T; 5 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 1.6e+02;
 Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 Oy 993 CAGCAGCAGUGACAGUGG 1011
 Db 19 CAGCAGCAGTGCAGCTTGG 1
 RESULT 319
 ADMW27864/c
 ID ADMW27864 standard; RNA; 19 BP.
 XX
 AC ADMW27864;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #161.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX

PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 PI Richards I, Mcswigen J;
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 161; 84bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 19 BP; 5 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 73.7%; Pred. No. 1.6e+02;
 Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 Oy 1101 CGUGCUCAGCUCUCCGGGU 1119
 Db 19 CGGCTCAGAGCTTCCGGGT 1
 RESULT 320
 ADMW27865/c
 ID ADMW27865 standard; RNA; 19 BP.
 XX
 AC ADMW27865;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #162.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW

PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 PI Richards I, Mcswiggen J;
 XX
 XX WPI; 2005-090672/10.
 DR
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 PS Disclosure; SEQ ID NO 89; 84pp; English.
 XX
 XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 19 BP; 3 A; 6 C; 4 G; 0 T; 6 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1587 CUACUGCGUGGCUACUAC 1605
 Db 1 CUACUGCGUGGCUACUAC 19
 RESULT 317
 ADM27825/C
 ID ADM27825 standard; RNA; 19 BP.
 XX
 AC ADM27825;
 XX
 DT 07-APR-2005 (first entry)
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #122.
 XX
 XX gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 XX
 XX Synthetic.
 OS
 XX US2005014172-A1.
 PN
 XX 20-JAN-2005.
 PD
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 XX (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 XX Richards I, Mcswiggen J;
 PI
 XX WPI; 2005-090672/10.
 DR
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 PS Disclosure; SEQ ID NO 122; 84pp; English.
 XX
 XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 19 BP; 5 A; 7 C; 3 G; 0 T; 4 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 73.7%; Pred. No. 1.6e+02;
 Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 399 AUGGCGCUUAGGACUUG 417
 Db 19 AUGGCGCTTAGGGAACCTTG 1
 RESULT 318
 ADM27858/C
 ID ADM27858 standard; RNA; 19 BP.
 XX
 AC ADM27858;
 XX
 DT 07-APR-2005 (first entry)
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #155.
 XX
 XX gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 XX
 XX Synthetic.
 OS
 XX US2005014172-A1.
 PN
 XX 20-JAN-2005.
 PD
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX

PT	acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT	RNA through RNA interference, useful for treating asthma.
XX	
XX	
PS	Disclosure; SEQ ID NO 48; 84pp; English.
CC	
CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC	where each strand of (I) has 19-23 nucleotides, and does not require the
CC	presence of nucleotides having a 2-hydroxy group for mediating RNA
CC	interference. (I) is useful for treating diseases e.g., asthma, allergic
CC	rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC	vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC	Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC	towards nuclease. Double stranded short interfering nucleic acid molecule
CC	was produced by solid phase oligonucleotide synthesis method. This
CC	sequence represents an example of a siRNA molecule of the invention.
XX	
XX	Sequence 19 BP; 4 A; 6 C; 6 G; 0 T; 3 U; 0 Other;
QY	
QY	849 CACGGGCGAGTUCGAGC 867
DB	1 CACGGGCGAGTUCGAGC 19
DB	
RESULT 315	
ID	ADW27782 standard; RNA; 19 BP.
ADW27782	
XX	
XX	ADW27782;
XX	
DT	07-APR-2005 (first entry)
XX	
DE	Cholinergic receptor muscarinic 3 gene targeted siRNA #79.
XX	
KW	gene expression; antiaesthetic; antiallergic; antiinflammatory; CNS-Gen.;
KW	respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW	nociceptic; utopachic; short interfering RNA; RNA interference; siRNA;
KW	cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW	inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW	hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW	incontinence; ss.
XX	
OS	Synthetic.
XX	
PN	US2005014172-A1.
XX	
PD	20-JAN-2005.
XX	
XX	
XX	11-MAR-2004; 2004US-00798090.
XX	
XX	
PR	20-FEB-2002; 2002US-0358580P.
PR	11-MAR-2002; 2002US-0361124P.
PR	20-MAY-2002; 2002WO-US015876.
PR	06-JUN-2002; 2002US-0386782P.
PR	25-AUG-2002; 2002US-0406784P.
PR	05-SEP-2002; 2002US-0408378P.
PR	09-SEP-2002; 2002US-0409293P.
PR	15-JAN-2003; 2003US-0440129P.
PR	20-FEB-2003; 2003WO-US005028.
PR	20-FEB-2003; 2003US-00505346.
PR	30-APR-2003; 2003WO-00427160.
PR	23-MAY-2003; 2003US-00444853.
PR	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00720448.
PR	14-JAN-2004; 2004US-00757803.
XX	
XX	
XX	(RICH/) RICHARDS I.
XX	(MCSW/) MCSWIGEN J.

Pt	Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.
Pt	Disclosure; SEQ ID NO 79; 84pp; English.
Pt	The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary hypertension or hyperextension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.
SQ	Sequence 19 BP; 8 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
Query Match	1.1%; Score 19; DB 1; Length 19;
Best Local Similarity	100.0%; Pred. No. 1.6e+02;
Matches	19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy	1407 GAAGACCGAAGUCAGAUGC 1425 1 GAAGACCGAAGUCAGAUGC 19
Db	
RESULT 316	
ID	ADW27792
ID	ADW27792 standard; RNA; 19 BP.
XX	
AC	ADM27792;
XX	
DT	07-APR-2005 (first entry)
XX	
DE	Cholinergic receptor muscarinic 3 gene targeted siRNA #89.
XX	
KM	gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.; respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective; nootropic; uteroblastic; short interfering RNA; RNA interference; siRNA;
KM	cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis; inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM	hyperextension; emphysema; irritable bowel syndrome; Alzheimers disease; incontinence; sr.
KM	
XX	
DS	Synthetic.
XX	
PN	US2005014172-A1.
XX	
PD	20-JAN-2005.
XX	
PP	11-MAR-2004; 2004US-00798090.
XX	
PR	20-FEB-2002; 2002US-0358580P.
PR	11-MAR-2002; 2002US-0363124P.
PR	20-MAY-2002; 2002WO-US015876.
PR	06-JUN-2002; 2002US-0386782P.
PR	29-AUG-2002; 2002US-0406784P.
PR	05-SEP-2002; 2002US-0408378P.
PR	09-SEP-2002; 2002US-0409293P.
PR	15-JAN-2003; 2003US-0440139P.
PR	20-FEB-2003; 2003WO-US005028.
PR	20-FEB-2003; 2003WO-US005346.
PR	30-APR-2003; 2003US-00427160.
PR	23-MAY-2003; 2003US-00444853.
PR	

OY 687 CACCAUACUUGGACCA 705
|||||:|||||
Db 19 CACCACTACTTTCGACCA 1

RESULT 311
ADM27850/c
XX ADM27850 standard; RNA; 19 BP.
XX
XX ADM27850;
AC
XX 07-APR-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #147.
DB
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM neotropic; utropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
XX Synthetic.
OS
XX US2005014172-A1.
PN
XX 20-JAN-2005.
PD
XX
XX 11-MAR-2004; 2004US-00798090.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
DR
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX
XX Disclosure; SEQ ID NO 147; 84bp; English.

SO Sequence 19 BP; 3 A; 6 C; 6 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.6e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 849 CACGGCAGUUCGAGC 867
|||||:|||||
Db 19 CACGGCAGTTCGAGC 1

RESULT 312
ADM27892/c
XX ADM27892 standard; RNA; 19 BP.
ID
XX
XX ADM27892;
AC
XX 07-APR-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #189.
DB
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM neotropic; utropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
XX Synthetic.
OS
XX US2005014172-A1.
PN
XX 20-JAN-2005.
PD
XX
XX 11-MAR-2004; 2004US-00798090.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
DR
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX
XX Disclosure; SEQ ID NO 189; 84bp; English.

The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimers disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.

XX Cholinergic receptor muscarinic 3 gene targeted siRNA #119.
DE
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
XX incontinence; ss.
XX
XX Synthetic.
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richard I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX
XX Disclosure; SEQ ID NO 119; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 19 BP; 7 A; 5 C; 3 G; 0 T; 4 U; 0 Other;
XX
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 63.2%; Pred. No. 1.6e+02;
XX Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
XX
XX 345 GAUUAUCGGGCAUUAUCA 363
XX ||::|||::|||::|||::|||
XX Db 19 GATTATCGGAGTCATTCA 1
XX
XX RESULT 310

ADW27841/C
ID ADW27841 standard; RNA; 19 BP.
XX
XX
XX ADW27841;
XX
XX 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #138.
DE
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
XX incontinence; ss.
XX
XX Synthetic.
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richard I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX
XX Disclosure; SEQ ID NO 138; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 19 BP; 6 A; 2 C; 6 G; 0 T; 5 U; 0 Other;
XX
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 68.4%; Pred. No. 1.6e+02;
XX Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
XX

PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720446.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 PI Richards I, Mcswiggen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 52; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 CC
 SQ Sequence 19 BP; 2 A; 7 C; 5 G; 0 T; 5 U; 0 Other;
 XX
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 921 GUAGGCGCGUGCCACUUC 939
 DB 1 GUAGGCGCGUGCCACUUC 19
 XX
 RESULT 306
 ADW27756
 ID ADW27756 standard; RNA; 19 BP.
 XX
 AC ADW27756;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #53.
 XX
 KW gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 KW
 OS Synthetic.
 XX
 PN US200504172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.

XX
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 PI Richards I, Mcswiggen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 53; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 CC
 SQ Sequence 19 BP; 6 A; 6 C; 4 G; 0 T; 3 U; 0 Other;
 XX
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 939 CUGGUCACCAACCAAGAGC 957
 DB 1 CUGGUCACCAACCAAGAGC 19
 XX
 RESULT 307
 ADW27758
 ID ADW27758 standard; RNA; 19 BP.
 XX
 AC ADW27758;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #55.
 XX
 KW gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 KW
 OS Synthetic.

CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.

SO Sequence 19 BP; 6 A; 3 C; 4 G; 0 T; 6 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 363 AATGAAUCUGUUUACGACC 361

Db 19 AATGAACTGTTACGACC 1

RESULT 302

ADMW27830/C

ID ADMW27830 standard; RNA; 19 BP.

AC ADMW27830;

DT 07-APR-2005 (first entry)

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #127.

XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uteropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
XX incontinence; ss.

OS Synthetic.

PN US2005014172-A1.

XX 20-JAN-2005.

PD 11-MAR-2004; 2004US-00798090.

PF 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2003US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

PR 20-FEB-2003; 2003WO-US005028.

PR 30-APR-2003; 2003US-00427160.

PR 23-MAY-2003; 2003US-00444853.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 14-JAN-2004; 2004US-00757803.

XX (RICH/) RICHARDS I.
XX (MCSM/) MCSWIGGEN J.
XX Richards I, Mcswiggen J;
XX PI
XX DR
XX WIPI; 2005-090672/10.

PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.

PS Disclosure; SEQ ID NO 127; 84pp; English.

XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.

SO Sequence 19 BP; 8 A; 2 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 1.6e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 489 CUUGACAGAUACUUUCC 507

Db 19 CUUGACAGACTTTTCC 1

RESULT 303

ADMW27836/C

ID ADMW27836 standard; RNA; 19 BP.

AC ADMW27836;

DT 07-APR-2005 (first entry)

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #133.

XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uteropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
XX incontinence; ss.

OS Synthetic.

PN US2005014172-A1.

XX 20-JAN-2005.

PD 11-MAR-2004; 2004US-00798090.

PF 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

PR 20-FEB-2003; 2003WO-US005028.

PR 30-APR-2003; 2003US-00427160.

PR 23-MAY-2003; 2003US-00444853.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 14-JAN-2004; 2004US-00757803.

XX (RICH/) RICHARDS I.
XX

XX SQ Sequence 19 BP; 4 A; 1 C; 10 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1191 GAUGGUGACUUGGAGAGG 1209
DB 1 GAUGGUGACUUGGAGAGG 19
RESULT 300
ADM27814/C
ID ADM27814 standard; RNA; 19 BP.
XX ADM27814;
AC ADM27814;
XX 07-APR-2005 (first entry)
DT
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #111.
DE
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
KM incontinence; ss.
XX Synthetic.
OS
XX US2005014172-A1.
PN
XX 20-JAN-2005.
PD
XX 11-MAR-2004; 2004US-00798090.
PF
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 30-APR-2003; 2003WO-US005346.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
DR
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 111; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic

CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nucleases. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 8 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 1.6e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
QY 201 AGUGGUCUACUGGCUUUC 219
DB 19 AGUGGUCUACUGGCUUUC 1
RESULT 301
ADM27823/C
ID ADM27823 standard; RNA; 19 BP.
XX ADM27823;
AC ADM27823;
XX 07-APR-2005 (first entry)
DT
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #120.
DE
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
KM incontinence; ss.
XX Synthetic.
OS
XX US2005014172-A1.
PN
XX 20-JAN-2005.
PD
XX 11-MAR-2004; 2004US-00798090.
PF
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 30-APR-2003; 2003WO-US005346.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
DR
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 120; 84pp; English.
XX

RESULT 298
 ID ADW27754 standard; RNA; 19 BP.
 XX ADW27754;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #51.
 XX
 AC gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406782P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 30-FEB-2003; 2003WO-US005346.
 PR 20-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-0044853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGEN J.
 XX
 PI Richards I, Mcswigen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 51; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 19 BP; 7 A; 5 C; 6 G; 0 T; 1 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 903 ACGCUCCAACAGAGAG 921
 |||||
 DB 1 ACGCUCCAACAGAGAG 19
 XX
 RESULT 299
 ID ADW27770 standard; RNA; 19 BP.
 XX ADW27770;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #67.
 XX
 AC gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406782P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 30-FEB-2003; 2003WO-US005346.
 PR 20-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-0044853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGEN J.
 XX
 PI Richards I, Mcswigen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 67; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.

KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
KM incontinence; ss.
XX Synthetic.
XX OS
XX PN US2005014172-A1.
XX PD 20-JAN-2005.
XX PF 11-MAR-2004; 2004US-00798090.
XX PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX PA (RICH/) RICHARDS I.
XX PA (MCSM/) MCSWIGGEN J.
XX PI Richards I, Mcswiggen J;
XX DR WPI; 2005-090672/10.
XX PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX PS Disclosure; SEQ ID NO 23; 84bp; English.
XX CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX SC Sequence 19 BP; 4 A; 3 C; 7 G; 0 T; 5 U; 0 Other;
QY Query Match 1.1%; Score 19; DB 1; Length 19;
Db Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 399 AUGGGCCUAGGAACTUG 417
Db 1 AUGGGCCUAGGAACTUG 19
|||||
RESULT 297
ADM27748
ID ADM27748 standard; RNA; 19 BP.
XX AC ADM27748;
XX

DT 07-APR-2005 (first entry)
XX DE Cholinergic receptor muscarinic 3 gene targeted siRNA #45.
XX KM gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
KM incontinence; ss.
XX Synthetic.
XX OS
XX PN US2005014172-A1.
XX PD 20-JAN-2005.
XX PF 11-MAR-2004; 2004US-00798090.
XX PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX PA (RICH/) RICHARDS I.
XX PA (MCSM/) MCSWIGGEN J.
XX PI Richards I, Mcswiggen J;
XX DR WPI; 2005-090672/10.
XX PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX PS Disclosure; SEQ ID NO 45; 84bp; English.
XX CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX SC Sequence 19 BP; 2 A; 7 C; 5 G; 0 T; 5 U; 0 Other;
QY Query Match 1.1%; Score 19; DB 1; Length 19;
Db Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 795 UCGUGCCUGCAAGCCUCU 813
Db 1 UCGUGCCUGCAAGCCUCU 19
|||||

PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US050528.
 PR 20-FEB-2003; 2003WO-US05346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 PI Richards I, Mcswiggen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 PT
 PS Disclosure; SEQ ID NO 174; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 CC
 SO Sequence 19 BP; 3 A; 7 C; 4 G; 0 T; 5 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 1.6e+02;
 Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 1335 CUCAGUGCGUAGAGCAGC 1353
 DB 19 CTCAGTGGTAAAGACAGC 1
 RESULT 295
 ID ADW27713 standard; RNA; 19 BP.
 XX
 AC ADW27713;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #10.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 KW incontinence; ss.
 XX

OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US050528.
 PR 20-FEB-2003; 2003WO-US05346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 PI Richards I, Mcswiggen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 PT
 PS Disclosure; SEQ ID NO 10; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 CC
 SO Sequence 19 BP; 4 A; 7 C; 5 G; 0 T; 3 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 165 CACCGAUGACCCUCUGGA 183
 DB 1 CACCGAUGACCCUCUGGA 19
 RESULT 296
 ID ADW27726 standard; RNA; 19 BP.
 XX
 AC ADW27726;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #23.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW

PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 PA (RICH/) RICHARDS I.
 PA (MCSM/) MCSWIGGEN J.
 PI Richards I, Mcswiggen J;
 DR WPI; 2005-090672/10.
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 PS Disclosure; SEQ ID NO 170; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 19 BP; 5 A; 2 C; 5 G; 0 T; 7 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 73.7%; Pred. No. 1.6e+02;
 Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1263 AAAAAGCTUCCAGGCTU 1281
 DB 19 AAAAAGCTTCTCCAGCTT 1

RESULT 293
 ADW27874/C
 ID ADW27874 standard; RNA; 19 BP.
 XX
 AC ADW27874;
 XX
 DT 07-APR-2005 (first entry)

Cholinergic receptor muscarinic 3 gene targeted siRNA #171.

gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
 respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KM incontinence; ss.

XX OS Synthetic.

XX PN US2005014172-A1.

XX PD 20-JAN-2005.

XX PE 11-MAR-2004; 2004US-00798090.

XX PR 20-FEB-2002; 2002US-0358580P.

XX PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSM/) MCSWIGGEN J.
 PI Richards I, Mcswiggen J;
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 171; 84pp; English.

CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 19 BP; 4 A; 3 C; 7 G; 0 T; 5 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 78.9%; Pred. No. 1.6e+02;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1281 UCCCAUCCAGCTGAGUCA 1299
 DB 19 TCCCATCCAGCTAGAGTCA 1

RESULT 294
 ADW27877/C
 ID ADW27877 standard; RNA; 19 BP.
 XX
 AC ADW27877;
 XX
 DT 07-APR-2005 (first entry)

Cholinergic receptor muscarinic 3 gene targeted siRNA #174.

gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
 KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KM incontinence; ss.

XX OS Synthetic.

XX PN US2005014172-A1.

XX PD 20-JAN-2005.

XX Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.

PS Disclosure; SEQ ID NO 141; 84pp; English.

XX The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule CC was produced by solid phase oligonucleotide synthesis method. This CC sequence represents an example of a siRNA molecule of the invention.

XX Sequence 19 BP; 7 A; 5 C; 2 G; 0 T; 5 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 1.6e+02; Mismatches 0; Gaps 0; Matches 12; Conservative 7; Indels 0;

QY 741 GACUATUUUACUGAGC 759
DB 19 GACTATTATCTGAGG 1
|||||:|||||

RESULT 291
ADW27846/C
ID ADW27846 standard; RNA; 19 BP.
XX ADW27846;
AC
XX
XX
DT 07-APR-2005 (first entry)

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #143.

XX gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.

XX Synthetic.

PN US2005014172-A1.

XX 20-JAN-2005.

PD 11-MAR-2004; 2004US-00798090.

XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 29-AUG-2002; 2002US-0406784P.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX

PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mswiggen J;
XX WPI; 2005-090672/10.

XX Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.

PS Disclosure; SEQ ID NO 143; 84pp; English.

XX The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule CC was produced by solid phase oligonucleotide synthesis method. This CC sequence represents an example of a siRNA molecule of the invention.

XX Sequence 19 BP; 3 A; 4 C; 4 G; 0 T; 8 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.6e+02; Mismatches 16; Conservative 3; Indels 0; Gaps 0; Matches 16;

QY 777 AAGCGUACCAAGAGCTU 795
DB 19 AAGCGTACCAAGAGCTT 1
|||||:|||||

RESULT 292
ADW27873/C
ID ADW27873 standard; RNA; 19 BP.
XX ADW27873;
AC
XX
XX
DT 07-APR-2005 (first entry)

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #170.

XX gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.

XX Synthetic.

PN US2005014172-A1.

XX 20-JAN-2005.

PD 11-MAR-2004; 2004US-00798090.

XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
XX

CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome.
CC Alzheimer's disease or urinary incontinence. (II) has increased resistance
CC towards nucleases. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
SQ Sequence 19 BP; 2 A; 7 C; 3 G; 0 T; 7 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 543 AACAAAGAGCGCGGUG 561
Db 19 AACAAAGAGCGCGGTG 1
|||||
RESULT 289
ADW27834/C
ID ADW27834 standard; RNA; 19 BP.
AC ADW27834;
XX
XX 07-APR-2005 (first entry)
DT
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #131.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
XX OS
XX US2005014172-A1.
PN
XX 20-JAN-2005.
PD
XX
XX 11-MAR-2004; 2004US-00798090.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGEN J.
XX
XX Richards I, Mcswigen J;
PI
XX MPI; 2005-090672/10.
DR
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 131; 84pp; English.
XX
XX

XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (II) has increased resistance
XX towards nucleases. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
SQ Sequence 19 BP; 6 A; 8 C; 3 G; 0 T; 2 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 561 GAUGAUGGUGGUGGUGG 579
Db 19 GATGATCGGTCGCTTGG 1
|||||
RESULT 290
ADW27844/C
ID ADW27844 standard; RNA; 19 BP.
AC ADW27844;
XX
XX 07-APR-2005 (first entry)
DT
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #141.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
XX OS
XX US2005014172-A1.
PN
XX 20-JAN-2005.
PD
XX
XX 11-MAR-2004; 2004US-00798090.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGEN J.
XX
XX Richards I, Mcswigen J;
PI
XX MPI; 2005-090672/10.
DR
XX
XX

Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 129 UCGAGCAGCUGGCAUUC 147
 :|||||:|||||:
 Db 19 TCGAGCAGCUGGCAATTTC 1

RESULT 287
 ADM27817/c
 ID ADM27817 standard; RNA; 19 BP.
 XX
 AC ADM27817;
 XX
 DT 07-APR-2005 (first entry)
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #114.
 XX
 XX gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 PI Richards I, Mcswiggen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 114; 84bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This

CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 19 BP; 6 A; 4 C; 4 G; 0 T; 5 U; 0 Other;
 XX
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 68.4%; Pred. No. 1.6e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 255 CACACUCCUGGUAUUGUG 273
 :|||||:|||||:
 Db 19 CAACATCCTGTAAATTGTG 1

RESULT 288
 ADM27833/c
 ID ADM27833 standard; RNA; 19 BP.
 XX
 AC ADM27833;
 XX
 DT 07-APR-2005 (first entry)
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #130.
 XX
 XX gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 PI Richards I, Mcswiggen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 130; 84bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA

XX 07-APR-2005 (first entry)
DT Cholinergic receptor muscarinic 3 gene targeted siRNA #104.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neotropic; uropathic, short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX Synthetic.
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003US-00427160.
XX 30-APR-2003; 2003US-00444853.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSM/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 104; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (II) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 19 BP; 2 A; 7 C; 8 G; 0 T; 2 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

RESULT 286
ADM27810/c
ID ADM27810 standard; RNA; 19 BP.
XX
XX ADM27810;
XX
XX 07-APR-2005 (first entry)
DT Cholinergic receptor muscarinic 3 gene targeted siRNA #107.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neotropic; uropathic, short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX Synthetic.
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003US-00427160.
XX 30-APR-2003; 2003US-00444853.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSM/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 107; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (II) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 19 BP; 5 A; 5 C; 5 G; 0 T; 4 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02;

XX Synthetic.
OS
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX MPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 85; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 19 BP; 6 A; 6 C; 2 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1515 CCCAUAACAUCACUGGCU 1533
DB 1 CCCAUAACAUCACUGGCU 19
RESULT 284
ADW27798
ID ADW27798 standard; RNA; 19 BP.
XX
XX ADW27798;
XX
XX 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #95.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;

KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimer disease;
KW incontinence; ss.
XX
XX Synthetic.
OS
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005346.
XX 20-FEB-2003; 2003WO-US005028.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX MPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 95; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 19 BP; 10 A; 3 C; 6 G; 0 T; 0 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1695 AAAAAGAGCGCAGCAG 1713
DB 1 AAAAAGAGCGCAGCAG 19
RESULT 285
ADW27807/c
ID ADW27807 standard; RNA; 19 BP.
XX
XX ADW27807;
XX

PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX WPI; 2005-090672/10.
XX
XX
XX
XX
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 57; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX
XX Sequence 19 BP; 7 A; 4 C; 4 G; 0 T; 4 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1011 GAACACACAUAGUCUGCU 1029
DB 1 GAACACACAUAGUCUGCU 19
RESULT 282
ADW27777
ID ADW27777 standard; RNA; 19 BP.
XX
XX ADW27777;
XX
XX 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #74.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX
XX Synthetic.
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX PD

XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 10-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX WPI; 2005-090672/10.
XX
XX
XX
XX
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 74; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX
XX Sequence 19 BP; 4 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1317 GACUUCUGACGUCACUCC 1335
DB 1 GACUUCUGACGUCACUCC 19
RESULT 283
ADW27788
ID ADW27788 standard; RNA; 19 BP.
XX
XX ADW27788;
XX
XX 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #85.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX
XX
XX
XX
XX

PS Disclosure; SEQ ID NO 37; 84pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nucleases. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siNA molecule of the invention.
XX
SQ Sequence 19 BP; 3 A; 4 C; 6 G; 0 T; 6 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 651 UCCGGGAGAGUGCUCUCCAUU 669
DB 1 UCCGGGAGAGUGCUCUCCAUU 19
RESULT 278
ADM27742
XX ADM27742 standard; RNA; 19 BP.
XX
AC ADM27742;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #39.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uterapathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-0042716P.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGEN J.
XX Richards I, Mcswigen J;
XX

DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 39; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nucleases. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 5 A; 6 C; 2 G; 0 T; 6 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 687 CACCAUACUUCUGGCACA 705
DB 1 CACCAUACUUCUGGCACA 19
RESULT 279
ADM27744
XX ADM27744 standard; RNA; 19 BP.
XX
AC ADM27744;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #41.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uterapathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-0042716P.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX

CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.

XX Sequence 19 BP; 6 A; 5 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 291 GCAGCTGAGACGGUCCAC 309

DB 1 GCAGCTGAGACGGUCCAC 19

RESULT 276

ADM27728 ADM27728 standard; RNA; 19 BP.

AC ADM27728;

DT 07-APR-2005 (first entry)

DB Cholinergic receptor muscarinic 3 gene targeted siRNA #25.

XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.

OS Synthetic.

PN US2005014172-A1.

PD 20-JAN-2005.

PF 11-MAR-2004; 2004US-00798090.

XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003US-00427160.
XX 30-APR-2003; 2003US-00444853.
XX 23-MAY-2003; 2003US-00693059.
XX 23-OCT-2003; 2003US-00720448.
XX 24-NOV-2003; 2003US-00757803.
XX 14-JAN-2004; 2004US-00757803.

PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGEN J.

PI Richards I, Mcswigen J;

DR WPI; 2005-090672/10.

PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.

PS Disclosure; SEQ ID NO 25; 84pp; English.

XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the

CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.

XX Sequence 19 BP; 4 A; 6 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 435 UGCGAUVGACUACGUGACC 453

DB 1 UGCGAUVGACUACGUGACC 19

RESULT 277

ADM27740 ADM27740 standard; RNA; 19 BP.

AC ADM27740;

DT 07-APR-2005 (first entry)

DB Cholinergic receptor muscarinic 3 gene targeted siRNA #37.

XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.

OS Synthetic.

PN US2005014172-A1.

PD 20-JAN-2005.

PF 11-MAR-2004; 2004US-00798090.

XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003US-00427160.
XX 30-APR-2003; 2003US-00444853.
XX 23-MAY-2003; 2003US-00693059.
XX 23-OCT-2003; 2003US-00720448.
XX 24-NOV-2003; 2003US-00757803.
XX 14-JAN-2004; 2004US-00757803.

PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGEN J.

PI Richards I, Mcswigen J;

DR WPI; 2005-090672/10.

PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.

XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the

RESULT 274

ADW27707

ID ADW27707 standard; RNA; 19 BP.

AC ADW27707;

DT 07-APR-2005 (first entry)

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #4.

XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uropathic, short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.

OS Synthetic.

PN US2005014172-A1.

PD 20-JAN-2005.

PF 11-MAR-2004; 2004US-00798090.

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

PR 20-FEB-2003; 2003WO-US005028.

PR 30-APR-2003; 2003US-00427160.

PR 23-MAY-2003; 2003US-00444853.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 14-JAN-2004; 2004US-00757803.

XX (RICH/) RICHARDS I.

PA (MCSW/) MCSWIGGEN J.

XX Richards I, Mcswigen J;

PI Richards I, Mcswigen J;

XX Richards I, Mcswigen J;

XX Richards I, Mcswigen J;

XX Richards I, Mcswigen J;

XX Richards I, Mcswigen J;

XX Richards I, Mcswigen J;

XX Richards I, Mcswigen J;

XX Richards I, Mcswigen J;

Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 57 CUGGAUACACAGCCCUCC 75
Db 1 CUGGAUACACAGCCCUCC 19

RESULT 275

ADW27720

ID ADW27720 standard; RNA; 19 BP.

AC ADW27720;

DT 07-APR-2005 (first entry)

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #17.

XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uropathic, short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.

OS Synthetic.

PN US2005014172-A1.

PD 20-JAN-2005.

PF 11-MAR-2004; 2004US-00798090.

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

PR 20-FEB-2003; 2003WO-US005028.

PR 30-APR-2003; 2003US-00427160.

PR 23-MAY-2003; 2003US-00444853.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 14-JAN-2004; 2004US-00757803.

XX (RICH/) RICHARDS I.

PA (MCSW/) MCSWIGGEN J.

XX Richards I, Mcswigen J;

PI Richards I, Mcswigen J;

XX Richards I, Mcswigen J;

XX Richards I, Mcswigen J;

XX Richards I, Mcswigen J;

XX Richards I, Mcswigen J;

Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 57 CUGGAUACACAGCCCUCC 75
Db 1 CUGGAUACACAGCCCUCC 19

Disclosure; SEQ ID NO 17; 84bp; English.

The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule

KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003US-00427160.
PR 30-APR-2003; 2003US-00444853.
PR 23-MAY-2003; 2003US-00693059.
PR 23-OCT-2003; 2003US-00720448.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
PI
XX
XX WPI; 2005-090672/10.
DR
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX
PS Disclosure; SEQ ID NO 188; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX
SQ Sequence 19 BP; 6 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 1587 CUACUGGCUUGUCUACAU 1605
DB 19 CTACTGGCTGTGCTACATC 1
RESULT 273
ADM27897/c
ID ADM27897 standard; RNA; 19 BP.
XX

AC ADM27897;
XX
DT 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #194.
DE
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003US-00427160.
PR 30-APR-2003; 2003US-00444853.
PR 23-MAY-2003; 2003US-00693059.
PR 23-OCT-2003; 2003US-00720448.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
PI
XX
XX WPI; 2005-090672/10.
DR
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX
PS Disclosure; SEQ ID NO 194; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX
SQ Sequence 19 BP; 0 A; 6 C; 3 G; 0 T; 10 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1695 AAAAAAGAGCGCCGACAG 1713
DB 19 AAAAAAGAGCGCCGACAG 1

PD 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002MO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003MO-US005028.
PR 20-FEB-2003; 2003MO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-0044853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
PI
PI WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX
PS Disclosure; SEQ ID NO 183; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 19 BP; 6 A; 2 C; 7 G; 0 T; 4 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02; Indels 0; Gaps 0;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 1497 CUUCAUACUACUUGAGCC 1515
DB 19 CTTGATCATCATCTTGAGCC 1
RESULT 271
ADM27890/c
XX ADM27890 standard; RNA; 19 BP.
XX
XX ADM27890;
XX
XX 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #187.
XX
XX gene expression; antispasmodic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uterapathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;

KM incontinence; ss.
XX
XX Synthetic.
OS
XX US2005014172-A1.
PN
XX 20-JAN-2005.
PD
XX
XX 11-MAR-2004; 2004US-00798090.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002MO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003MO-US005028.
PR 20-FEB-2003; 2003MO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-0044853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
PI
PI WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX
PS Disclosure; SEQ ID NO 187; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 19 BP; 6 A; 5 C; 4 G; 0 T; 4 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02; Indels 0; Gaps 0;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 1569 AACCUUUGAUAUUGAGCC 1587
DB 19 AACCTTTTGGAAATCTGGCC 1
RESULT 272
ADM27891/c
XX ADM27891 standard; RNA; 19 BP.
XX
XX ADM27891;
XX
XX 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #188.

PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-0044853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX
PI Richards I, Mcswiggen J;
DR WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 154; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 1 A; 5 C; 6 G; 0 T; 7 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.6e+02; Indels 0; Gaps 0;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 975 GCAGUAGACCAAGCCAC 993
DB 19 GCAGATGACCAAGACAC 1
RESULT 269
ADM27859/C
ID ADM27859 standard; RNA; 19 BP.
XX
AC ADM27859;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #156.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM neotropic; uteropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-0044853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX
PI Richards I, Mcswiggen J;
DR WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 156; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 4 A; 4 C; 4 G; 0 T; 7 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02; Indels 0; Gaps 0;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1011 GAACACCAUAGUCUGCU 1029
DB 19 GAACACCAATGATGCTGCT 1
RESULT 270
ADM27886/C
ID ADM27886 standard; RNA; 19 BP.
XX
AC ADM27886;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #183.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM neotropic; uteropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX

```

XX DR WPI; 2005-090672/10.
XX
XX PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of Cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX PS Disclosure; SEQ ID NO 150; 84bp; English.
XX
XX CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siNA molecule of the invention.
XX
XX SQ Sequence 19 BP; 1 A; 6 C; 5 G; 0 T; 7 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 94.7%; Pred. No. 1.6e+02;
XX Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
OY 903 ACGCTCCACAGAGGAG 921
Db |||:|||||:|||||:
19 ACGCTCCACAGAGGAG 1

RESULT 267
ADW27854/c
ID ADW27854 standard; RNA; 19 BP.
XX
AC ADW27854;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #151.
XX
XX gene expression; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neotropic; utropanic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX OS Synthetic.
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.

```

```

PR 14-JAN-2004; 2004US-00757803.
XX
XX PA (RICH/) RICHARDS I.
XX PA (MCSW/) MCSWIGEN J.
XX
XX PI Richards I, Mcswigen J;
XX
XX DR WPI; 2005-090672/10.
XX
XX PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of Cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX PS Disclosure; SEQ ID NO 151; 84bp; English.
XX
XX CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siNA molecule of the invention.
XX
XX SQ Sequence 19 BP; 5 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 73.7%; Pred. No. 1.6e+02;
XX Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
XX
OY 921 GUAUGGCCGCGCCACUUC 939
Db ||:|||||:|||||:
19 GTATGCCGCGCCACUUC 1

RESULT 268
ADW27857/c
ID ADW27857 standard; RNA; 19 BP.
XX
AC ADW27857;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #154.
XX
XX gene expression; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neotropic; utropanic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX OS Synthetic.
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.

```

CC Where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (II) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 10 A; 4 C; 3 G; 0 T; 2 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 885 UCACAGCAGAACGAGAAA 903
DB 1 UCACAGCAGAACGAGAAA 19
RESULT 265
ADM27839/C
ID ADM27839 standard; RNA; 19 BP.
XX
AC ADM27839;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #136.
XX
KM gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; utropanic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGEN J.
XX
PI Richards I, Mcswigen J;
XX
DR WPI, 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.

XX
PS Disclosure; SEQ ID NO 136; 84pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (II) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 6 A; 6 C; 4 G; 0 T; 3 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 651 UCCGGAGAGUGGCUCAU 669
DB 19 TCCGGAGAGTGTCTCAT 1
RESULT 266
ADM27853/C
ID ADM27853 standard; RNA; 19 BP.
XX
AC ADM27853;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #150.
XX
KM gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; utropanic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGEN J.
XX
PI Richards I, Mcswigen J;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No.1.6e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 183 AGGCUAACCUGCUGCAA 201
|||||
1 AGGCUAACCUGCUGCAA 19

Db

RESULT 263
ADW27746
ID ADW27746 standard; RNA; 19 BP.
XX
XX ADW27746;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #43.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-gen.;
respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-0044853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswigen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 43; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance

CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siNA molecule of the invention.
XX
SQ Sequence 19 BP; 9 A; 2 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No.1.6e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 759 GAUCUAUAGGAAACUGAA 777
|||||
1 GAUCUAUAGGAAACUGAA 19

Db

RESULT 264
ADW27753
ID ADW27753 standard; RNA; 19 BP.
XX
XX ADW27753;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #50.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-gen.;
respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-0044853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswigen J;
XX
DR WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 50; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance

XX AC ADW27862;
 XX DT 07-APR-2005 (first entry)
 XX DE Cholinergic receptor muscarinic 3 gene targeted siRNA #159.
 XX XX
 XX gene expression; antiallergic; antiinflammatory; CNS-Gen.;
 XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 XX incontinence; ss.
 XX Synthetic.
 XX OS
 XX PN US2005014172-A1.
 XX PD 20-JAN-2005.
 XX PF 11-MAR-2004; 2004US-00798090.
 XX XX
 XX 20-FEB-2002; 2002US-0358580P.
 XX PR 11-MAR-2002; 2002US-0363124P.
 XX PR 20-MAY-2002; 2002WO-US015876.
 XX PR 06-JUN-2002; 2002US-0386782P.
 XX PR 29-AUG-2002; 2002US-0406784P.
 XX PR 05-SEP-2002; 2002US-0408378P.
 XX PR 09-SEP-2002; 2002US-0409293P.
 XX PR 15-JAN-2003; 2003US-0440129P.
 XX PR 20-FEB-2003; 2003WO-US005028.
 XX PR 20-FEB-2003; 2003WO-US005346.
 XX PR 30-APR-2003; 2003US-00427160.
 XX PR 23-MAY-2003; 2003US-00444853.
 XX PR 23-OCT-2003; 2003US-00693059.
 XX PR 24-NOV-2003; 2003US-00720448.
 XX PR 14-JAN-2004; 2004US-00757803.
 XX XX
 XX (RICH/) RICHARDS I.
 XX PA (MCSW/) MCSWIGGEN J.
 XX XX
 XX PI Richards I, Mcswiggen J;
 XX DR WPI; 2005-090672/10.
 XX XX
 XX Novel chemically synthesized double stranded short interfering nucleic
 XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 XX RNA through RNA interference, useful for treating asthma.
 XX PS Disclosure; SEQ ID NO 159; 84pp; English.
 XX XX
 XX The invention relates to a chemically synthesized double stranded short
 XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 XX where each strand of (I) has 19-23 nucleotides, and does not require the
 XX presence of nucleotides having a 2-hydroxy group for mediating RNA
 XX interference. (I) is useful for treating diseases e.g., asthma, allergic
 XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
 XX towards nuclease. Double stranded short interfering nucleic acid molecule
 XX was produced by solid phase oligonucleotide synthesis method. This
 XX sequence represents an example of a siRNA molecule of the invention.
 XX CC
 XX Sequence 19 BP; 3 A; 7 C; 5 G; 0 T; 4 U; 0 Other;
 XX SQ
 XX Query Match 1.1%; Score 19; DB 1; Length 19;
 XX Best Local Similarity 84.2%; Pred. No. 1.6e+02;
 XX Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 XX 1065 GGACATUGGCTCCGAGACG 1083
 XX |||||:||||:|||||

Db 19 GGACATTGCTCCGAGACG 1
 RESULT 262
 ADW27714
 ID ADW27714 standard; RNA; 19 BP.
 XX XX
 XX ADW27714;
 XX DT 07-APR-2005 (first entry)
 XX DE Cholinergic receptor muscarinic 3 gene targeted siRNA #11.
 XX XX
 XX gene expression; antiallergic; antiinflammatory; CNS-Gen.;
 XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 XX incontinence; ss.
 XX Synthetic.
 XX OS
 XX PN US2005014172-A1.
 XX PD 20-JAN-2005.
 XX PF 11-MAR-2004; 2004US-00798090.
 XX XX
 XX 20-FEB-2002; 2002US-0358580P.
 XX PR 11-MAR-2002; 2002US-0363124P.
 XX PR 20-MAY-2002; 2002WO-US015876.
 XX PR 06-JUN-2002; 2002US-0386782P.
 XX PR 29-AUG-2002; 2002US-0406784P.
 XX PR 05-SEP-2002; 2002US-0408378P.
 XX PR 09-SEP-2002; 2002US-0409293P.
 XX PR 15-JAN-2003; 2003US-0440129P.
 XX PR 20-FEB-2003; 2003WO-US005028.
 XX PR 20-FEB-2003; 2003WO-US005346.
 XX PR 30-APR-2003; 2003US-00427160.
 XX PR 23-MAY-2003; 2003US-00444853.
 XX PR 23-OCT-2003; 2003US-00693059.
 XX PR 24-NOV-2003; 2003US-00720448.
 XX PR 14-JAN-2004; 2004US-00757803.
 XX XX
 XX (RICH/) RICHARDS I.
 XX PA (MCSW/) MCSWIGGEN J.
 XX XX
 XX PI Richards I, Mcswiggen J;
 XX DR WPI; 2005-090672/10.
 XX XX
 XX Novel chemically synthesized double stranded short interfering nucleic
 XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 XX RNA through RNA interference, useful for treating asthma.
 XX PS Disclosure; SEQ ID NO 11; 84pp; English.
 XX XX
 XX The invention relates to a chemically synthesized double stranded short
 XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 XX where each strand of (I) has 19-23 nucleotides, and does not require the
 XX presence of nucleotides having a 2-hydroxy group for mediating RNA
 XX interference. (I) is useful for treating diseases e.g., asthma, allergic
 XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
 XX towards nuclease. Double stranded short interfering nucleic acid molecule
 XX was produced by solid phase oligonucleotide synthesis method. This
 XX sequence represents an example of a siRNA molecule of the invention.
 XX CC
 XX Sequence 19 BP; 5 A; 5 C; 5 G; 0 T; 4 U; 0 Other;
 XX SQ

KW	hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX	incontinence; ss.
XX	
OS	Synthetic.
PV	US2005014172-A1.
XX	
PD	
XX	
PF	20-JAN-2005.
XX	
PR	11-MAR-2004; 2004US-00798090.
XX	
PR	20-FEB-2002; 2002US-0358580P.
PR	11-MAY-2002; 2002US-0363124P.
PR	20-MAY-2002; 2002WO-US015876.
PR	06-JUN-2002; 2002US-0386782P.
PR	29-AUG-2002; 2002US-0406784P.
PR	05-SEP-2002; 2002US-0408378P.
PR	09-SEP-2002; 2002US-0409293P.
PR	15-JAN-2003; 2003US-0440129P.
PR	20-FEB-2003; 2003WO-US005028.
PR	20-FEB-2003; 2003WO-US005346.
PR	30-APR-2003; 2003US-0042716P.
PR	23-MAY-2003; 2003US-00444853.
PR	23-OCT-2003; 2003US-00683059.
PR	24-NOV-2003; 2003US-00720448.
PR	14-JAN-2004; 2004US-00757803.
PA	(RICH/) RICHARDS I.
PA	(MCSW/) MCSWIGEN J.
XX	
PL	Richards I, Mcswigen J;
DR	WPI; 2005-090672/10.
XX	
PT	Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.
PS	Disclosure; SEQ ID NO 144; 84bp; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.
XX	
SEQ	Sequence 19 BP; 5 A; 5 C; 7 G; 0 T; 2 U; 0 Other;
QY	Query Match 1.1%; Score 19; DB 1; Length 19; Best Local Similarity 73.7%; Pred.No. 1.6e+02; Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
DB	795 UGUCUGGCCUCCAGACCUUCU 813 :: :: :: :: : 19 TGCTGCCTGCACGCTCT 1
ADW	RESULT 260 ADW27860/C
AC	ADW27860 standard; RNA; 19 BP.
XX	ADW27860;
DT	07-APR-2005 (first entry)
XX	
DE	Cholinergic receptor muscarinic 3 gene targeted siRNA #157.

XX gene expression; antiasthmatic; anti-allergic; anti-inflammatory; CNS-Gen.;
 XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 XX nootropic; uteroplacental short interfering RNA; RNA interference; siRNA;
 XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 XX incontinence; ss.
 XX
 XX Synthetic.
 XX
 XX US2005014172-A1.
 XX
 XX 20-JAN-2005.
 XX
 XX 11-MAR-2004; 2004US-00798090.
 XX
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 XX 11-MAR-2002; 2002US-0363124P.
 XX 20-MAY-2002; 2002WO-US015876.
 XX 06-JUN-2002; 2002US-036782P.
 XX 29-AUG-2002; 2002US-0406784P.
 XX 05-SEP-2002; 2002US-0408378P.
 XX 09-SEP-2002; 2002US-0409293P.
 XX 15-JAN-2003; 2003US-0440129P.
 XX 20-FEB-2003; 2003WO-US005028.
 XX 20-FEB-2003; 2003WO-US005346.
 XX 30-APR-2003; 2003US-00427160.
 XX 23-MAY-2003; 2003US-00444853.
 XX 23-OCT-2003; 2003US-00693059.
 XX 24-NOV-2003; 2003US-00720448.
 XX 14-JAN-2004; 2004US-00757803.
 XX
 XX
 XX (RICH/) RICHARDS I.
 XX (MCSW/) MCSWIGGEN J.
 XX
 XX Richards I, Mcswiggen J;
 XX
 XX WPI; 2005-090672/10.
 XX
 XX
 XX Novel chemically synthesized double stranded short interfering nucleic
 XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 XX RNA through RNA interference, useful for treating asthma.
 XX
 XX Disclosure; SEQ ID NO 157; 84pp; English.
 XX
 XX
 XX The invention relates to a chemically synthesized double stranded short
 XX interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
 XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 XX where each strand of (I) has 19-23 nucleotides, and does not require the
 XX presence of nucleotides having a 2-hydroxy group for mediating RNA
 XX interference. (I) is useful for treating diseases e.g., asthma, allergic
 XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
 XX to RNase H. Double stranded short interfering nucleic acid molecule
 XX was produced by solid phase oligonucleotide synthesis method. This
 XX sequence represents an example of a siRNA molecule of the invention.
 XX
 XX
 XX Sequence 19 BP; 4 A; 4 C; 8 G; 0 T; 3 U; 0 Other;
 XX
 XX
 XX Query Match 1.1%; Score 19; DB 1; Length 19;
 XX Best Local Similarity 78.9%; Pred. No. 1.6e+02;
 XX Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 XX
 XX 1029 UGCCUCCUGAGAUCUC 1047
 XX :|||:|||:|||:|||
 XX 19 TGCCCTCCCTGGAGAACTCC 1
 XX
 XX RESULT 261
 XX ADMW27862/C
 XX ID ADMW27862 standard; RNA; 19 BP.

PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 132; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 9 A; 3 C; 6 G; 0 T; 1 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 1.6e+02;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;
QY 579 GGUCAUCCUCCUUGUCCU 597
DB 19 GGTGATCTCCTTGTCTCT 1
RESULT 258
ADM27840/C
XX ADM27840 standard; RNA; 19 BP.
AC ADM27840;
XX
DT 07-APR-2005 (first entry)
XX
DB Cholinergic receptor muscarinic 3 gene targeted siRNA #137.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.

XX
PD 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
PF
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
PR 11-MAR-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 137; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 5 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 669 UCAGUUCUCCAGGAGCCC 687
DB 19 TCAGTCTCCTCAGGAGCCC 1
RESULT 259
ADM27847/C
XX ADM27847 standard; RNA; 19 BP.
AC ADM27847;
XX
DT 07-APR-2005 (first entry)
XX
DB Cholinergic receptor muscarinic 3 gene targeted siRNA #144.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM

PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswiggen J;
XX WPI; 2005-090672/10.
DR
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 97; 84pp; English.
PS
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
SQ Sequence 19 BP; 4 A; 4 C; 4 G; 0 T; 7 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No.1.6e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1731 GUCCGUCAUUUUUCACAG 1749
DB 1 GUCCGUCAUUUUUCACAG 19
RESULT 256
ADM27802
ID ADM27802 standard; RNA; 19 BP.
XX
AC ADM27802;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #99.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; sg.
XX
XX Synthetic.
OS
XX US2005014172-A1.
PN
XX 20-JAN-2005.
PD
XX
XX 11-MAR-2004; 2004US-00798090.
PF
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA
PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
PI
XX WPI; 2005-090672/10.
DR
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 99; 84pp; English.
PS
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
SQ Sequence 19 BP; 3 A; 7 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No.1.6e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1753 GCACCCGAGCAGCCUUGU 1771
DB 1 GCACCCGAGCAGCCUUGU 19
RESULT 257
ADM27835/C
ID ADM27835 standard; RNA; 19 BP.
XX
AC ADM27835;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #132.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; sg.
XX
XX Synthetic.
OS
XX US2005014172-A1.
PN
XX 20-JAN-2005.
PD
XX 11-MAR-2004; 2004US-00798090.
PF
XX 20-FEB-2002; 2002US-0358580P.
XX

PT RNA through RNA interference, useful for treating asthma.
 XX
 XX Disclosure; SEQ ID NO 81; 84pp; English.
 PS
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 CC
 XX
 SQ Sequence 19 BP; 5 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1443 GUCCUGGUCAGAGAGAAAG 1461
 DB 1 GUCCUGGUCAGAGAGAGAG 19
 RESULT 254
 ADW27789
 ID ADW27789 standard; RNA; 19 BP.
 XX
 AC ADW27789;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #86.
 XX
 XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 XX nootropic; uteropathic; short interfering RNA; RNA interference; siRNA;
 XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 XX incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 XX 11-MAR-2004; 2004US-00798090.
 PF
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 XX (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 PA
 XX

PI Richards I, Mcswigen J;
 XX
 XX WPI; 2005-090672/10.
 DR
 XX
 XX Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 86; 84pp; English.
 CC
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 CC
 XX
 SQ Sequence 19 BP; 3 A; 4 C; 4 G; 0 T; 8 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1533 UCUGUGGAACACCUUUUGU 1551
 DB 1 UCUGUGGAACACCUUUUGU 19
 RESULT 255
 ADW27800
 ID ADW27800 standard; RNA; 19 BP.
 XX
 AC ADW27800;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #97.
 XX
 XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 XX nootropic; uteropathic; short interfering RNA; RNA interference; siRNA;
 XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 XX incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 XX 11-MAR-2004; 2004US-00798090.
 PF
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR

CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.

XX Sequence 19 BP; 2 A; 6 C; 6 G; 0 T; 5 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No.1.6e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1101 CGUGCUCACAGCUCUGCGGU 1119
|||

Db 1 CGUGCUCACAGCUCUGCGGU 19

RESULT 252

ADW27769
ID ADW27769 standard; RNA; 19 BP.

AC ADW27769;

XX 07-APR-2005 (first entry)

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #66.

XX gene expression; antispasmodic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.

XX Synthetic.

XX US2005014172-A1.

XX 20-JAN-2005.

XX 11-MAR-2004; 2004US-00798090.

XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-0042716P.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.

PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.

PI Richards I, Mcswigen J;

XX WPI; 2005-090672/10.

XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.

PS Disclosure: SEQ ID NO 66; 84pp; English.

XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a

CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.

XX Sequence 19 BP; 3 A; 3 C; 11 G; 0 T; 2 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No.1.6e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1173 GCCUGAGAGAGACUGCGG 1191
|||

Db 1 GCCUGAGAGAGACUGCGG 19

RESULT 253

ADW27784
ID ADW27784 standard; RNA; 19 BP.

AC ADW27784;

XX 07-APR-2005 (first entry)

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #81.

XX gene expression; antispasmodic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.

XX Synthetic.

XX US2005014172-A1.

XX 20-JAN-2005.

XX 11-MAR-2004; 2004US-00798090.

XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-0042716P.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.

PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.

PI Richards I, Mcswigen J;

XX WPI; 2005-090672/10.

XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3

Db 1 GACUADUUUADACUGAGG 19
 |||||
 RESULT 250
 ADM27749
 ID ADM27749 standard; RNA; 19 BP.
 XX
 AC ADM27749;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #46.
 XX
 KM gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KM nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
 KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KM incontinence; ss.
 KM
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-036782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-0042716P.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 PI Richards I, Mcswigen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 46; 84dp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siNA molecule of the invention.
 CC
 CC Sequence 19 BP; 7 A; 3 C; 8 G; 0 T; 1 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 813 UGGGACAGAGCAGAGACA 831
 |||||
 Db 1 UGGGACAGAGCAGAGACA 19
 RESULT 251
 ADM27765
 ID ADM27765 standard; RNA; 19 BP.
 XX
 AC ADM27765;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #62.
 XX
 KM gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KM nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
 KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KM incontinence; ss.
 KM
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-036782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-0042716P.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 PI Richards I, Mcswigen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 62; 84dp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #20.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM neotropic; utropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
XX Synthetic.
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002MO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003MO-US005028.
XX 20-FEB-2003; 2003MO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 20; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX
SQ Sequence 19 BP; 4 A; 3 C; 5 G; 0 T; 7 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 345 GAUUAUCCGGGCAUUAUCA 363
Db ||||||||||||||||
1 GAUUAUCCGGGCAUUAUCA 19
RESULT 249
ADM27745

ID ADM27745 standard; RNA; 19 BP.
XX
XX
AC ADM27745;
XX
DT 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #42.
DE
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM neotropic; utropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
XX Synthetic.
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002MO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003MO-US005028.
XX 20-FEB-2003; 2003MO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 42; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX
SQ Sequence 19 BP; 5 A; 2 C; 5 G; 0 T; 7 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 741 GACUUAUUUAUACUGAGG 759

PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 PI Richards I, Mcswiggen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 16; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 CC
 SQ Sequence 19 BP; 7 A; 3 C; 4 G; 0 T; 5 U; 0 Other;
 QY
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 273 GUCAUUUAGGUCACACAG 291
 1 GUCAUUUAGGUCACACAG 19
 RESULT 247
 ADM27721
 ID ADM27721 standard; RNA; 19 BP.
 XX
 AC ADM27721;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #18.
 XX
 KW gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;

KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 PI Richards I, Mcswiggen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 18; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 CC
 SQ Sequence 19 BP; 5 A; 7 C; 1 G; 0 T; 6 U; 0 Other;
 QY
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 309 CAAUCUACUCUCUCUUAAGC 327
 1 CAAUCUACUCUCUCUUAAGC 19
 RESULT 248
 ADM27723
 ID ADM27723 standard; RNA; 19 BP.
 XX
 AC ADM27723;
 XX
 DT 07-APR-2005 (first entry)
 XX

```

PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-0044853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 148; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 19 BP; 5 A; 4 C; 5 G; 0 T; 5 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 73.7%; Pred. No. 1.6e+02;
XX Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
OY 867 CUGCAGAGUUGAAGACU 885
DB 19 CTGCAGCACTTACGAACCT 1

```

RESULT 245

ADM27881/C

ID ADM27881 standard; RNA; 19 BP.

XX ADM27881;

XX 07-APR-2005 (first entry)

XX Cholinergic receptor muscarinic 3 gene targeted siRNA #178.

XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;

XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;

XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;

XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;

XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;

XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;

XX incontinence; ss.

XX Synthetic.

XX US2005014172-A1.

XX 20-JAN-2005.

XX 11-MAR-2004; 2004US-00798090.

```

PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-036782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-0044853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 178; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 19 BP; 2 A; 5 C; 4 G; 0 T; 8 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 89.5%; Pred. No. 1.6e+02;
XX Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY 1407 GAAGACCGAAGUCAGAU 1425
DB 19 GAAGACCGAAGTCAGATC 1

```

RESULT 246

ADM27719

ID ADM27719 standard; RNA; 19 BP.

XX ADM27719;

XX 07-APR-2005 (first entry)

XX Cholinergic receptor muscarinic 3 gene targeted siRNA #16.

XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;

XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;

XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;

XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;

XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;

XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;

XX incontinence; ss.

XX Synthetic.

XX Richards I, Mcswigen J;
 XX WPI, 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 109; 84bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 19 BP; 3 A; 5 C; 7 G; 0 T; 4 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 1.6e+02;
 Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 QY 165 CACCGAUGACCCUUGGA 163
 Db |||||:||||:|||||
 19 CACCGATGACCTCTGGGA 1
 RESULT 243
 ID ADW27813/C
 XX ADW27813 standard; RNA; 19 BP.
 AC
 XX ADW27813;
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #110.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 KW
 OS Synthetic.
 XX
 XX US2005014172-A1.
 PN
 XX
 PD 20-JAN-2005.
 XX
 PD 11-MAR-2004; 2004US-00798090.
 XX
 PF 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.

PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 XX
 PA (RICH/) RICHARDS I.
 XX (MCSW/) MCSWIGEN J.
 PI Richards I, Mcswigen J;
 XX
 XX WPI, 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 110; 84bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 19 BP; 4 A; 5 C; 5 G; 0 T; 5 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 78.9%; Pred. No. 1.6e+02;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 183 AGGUCAUACCGUCGCAA 201
 Db |||||:||||:|||||
 19 AGGCTATACCTCTGGCA 1
 RESULT 244
 ID ADW27851/C
 XX ADW27851 standard; RNA; 19 BP.
 AC
 XX ADW27851;
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #148.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 KW
 OS Synthetic.
 XX
 XX US2005014172-A1.
 PN
 XX
 PD 20-JAN-2005.
 XX
 PD 11-MAR-2004; 2004US-00798090.
 XX
 PF 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.

CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.

SQ Sequence 19 BP; 5 A; 9 C; 1 G; 0 T; 4 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1137 CUCGACCAAGUUNACCCUCA 1155
1 CUCGACCAAGUUNACCCUCA 19

RESULT 241
ADW27799
ID ADW27799 standard; RNA; 19 BP.
XX
AC ADW27799;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #96.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
PD 20-JAN-2005.
XX
XX
PF 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-0042716P.
XX 23-MAY-2003; 2003US-0044853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic

PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
PS Disclosure; SEQ ID NO 96; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.

SQ Sequence 19 BP; 7 A; 5 C; 6 G; 0 T; 1 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1713 GCAGUACGACGACGACAG 1731
1 GCAGUACGACGACGACAG 19

RESULT 242
ADW27812/C
ID ADW27812 standard; RNA; 19 BP.
XX
AC ADW27812;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #109.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
PD 20-JAN-2005.
XX
XX
PF 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-0042716P.
XX 23-MAY-2003; 2003US-0044853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX PA (MCSW/) MCSWIGGEN J.
XX

SEQ Sequence 19 BP; 4 A; 5 C; 7 G; 0 T; 3 U; 0 Other:
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1065 GGACAUUGGCUCCGAGACG 1083
DB 1 GGACAUUGGCUCCGAGACG 19
RESULT 239
ADM27766
ID ADM27766 standard; RNA; 19 BP.
XX ADM27766;
DT 07-APR-2005 (first entry)
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #63:
DE gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
KM incontinence; ss.
XX Synthetic.
OS US2005014172-A1.
XX 20-JAN-2005.
PD 11-MAR-2004; 2004US-00798090.
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGEN J.
XX Richards I, Mcswigen J;
PI WPI; 2005-090672/10.
DR Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 63; 84pp; English.
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary

CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nucleases. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SEQ Sequence 19 BP; 6 A; 9 C; 1 G; 0 T; 3 U; 0 Other:
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1119 UCACAGACCAUCCUCCAAC 1137
DB 1 UCACAGACCAUCCUCCAAC 19
RESULT 240
ADM27767.
ID ADM27767 standard; RNA; 19 BP.
XX ADM27767;
DT 07-APR-2005 (first entry)
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #64.
DE gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
KM incontinence; ss.
XX Synthetic.
OS US2005014172-A1.
XX 20-JAN-2005.
PD 11-MAR-2004; 2004US-00798090.
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGEN J.
XX Richards I, Mcswigen J;
PI WPI; 2005-090672/10.
DR Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 64; 84pp; English.
XX The invention relates to a chemically synthesized double stranded short

ADW27722
 ID ADW27722 standard; RNA; 19 BP.
 AC ADW27722;
 XX
 XX 07-APR-2005 (first entry)
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #19.
 XX
 XX Gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neotropic; utropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 XX Synthetic.
 XX
 XX US2005014172-A1.
 PN 20-JAN-2005.
 XX
 XX 11-MAR-2004; 2004US-00798090.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-0044853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 XX (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 XX
 PI Richards I, Mcswiggen J;
 DR WPI; 2005-090672/10.
 XX
 XX Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 XX Disclosure; SEQ ID NO 19; 84bp; English.
 XX
 XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 XX Sequence 19 BP; 1 A; 7 C; 6 G; 0 T; 5 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 327 CCUGGCCUGGCCAUCUG 345
 Db 1 CCUGGCCUGGCCAUCUG 19
 RESULT 238
 ADW27763
 ID ADW27763 standard; RNA; 19 BP.
 XX
 XX AC ADW27763;
 XX
 XX 07-APR-2005 (first entry)
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #60.
 XX
 XX Gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neotropic; utropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 XX Synthetic.
 XX
 XX US2005014172-A1.
 PN 20-JAN-2005.
 XX
 XX 11-MAR-2004; 2004US-00798090.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-0044853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 XX (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 XX
 PI Richards I, Mcswiggen J;
 DR WPI; 2005-090672/10.
 XX
 XX Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 XX Disclosure; SEQ ID NO 60; 84bp; English.
 XX
 XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX

KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
KW incontinence; ss.
KM Synthetic.
OS
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-036782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX
XX Disclosure; SEQ ID NO 167; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nucleases. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 19 BP; 1 A; 6 C; 5 G; 0 T; 7 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 94.7%; Pred. No. 1.6e+02;
XX Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1209 GAAAGCCGACAGGUCGAG 1227
XX DB 19 GAAAGCCGACAGGUCGAG 1
XX
XX RESULT 236
XX ADW27898/c
XX ID ADW27898 standard; RNA; 19 BP.
XX XX
XX AC ADW27898;
XX XX
XX DT 07-APR-2005 (first entry)

XX
XX DE Cholinergic receptor muscarinic 3 gene targeted siRNA #195.
XX
XX gene expression; antiasthmatic; anti-allergic; anti-inflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
XX incontinence; ss.
XX
XX Synthetic.
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-036782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX
XX Disclosure; SEQ ID NO 195; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nucleases. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 19 BP; 1 A; 6 C; 5 G; 0 T; 7 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 94.7%; Pred. No. 1.6e+02;
XX Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1713 GCGAGUACGACAGAGACAG 1731
XX DB 19 GCGAGUACGACAGAGACAG 1
XX
XX RESULT 237

XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-0044853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
PA (RICH/) RICHARDS I.
PA (MCSM/) MCSWIGGEN J.
PI Richards I, Mcswiggen J;
XX WPI; 2005-090672/10.
DR Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 125; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 6 A; 4 C; 5 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 453 CAGCAUUGCCUCGUUAUG 471
DB 19 CAGCAUUGCCUCGUUAUG 1
RESULT 234
ADM27831/C
ID ADM27831 standard; RNA; 19 BP.
XX
XX ADM27831;
AC
XX
XX 07-APR-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #128.
DE
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimer disease;
XX hyperintense; ss.
XX
XX Synthetic.

XX PN US2005014172-A1.
XX PD 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-0044853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSM/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 126; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 2 A; 5 C; 8 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 507 CAUACGAGCGCGCUCACG 525
DB 19 CAUACGAGCGCGCUCACG 1
RESULT 235
ADM27870/C
ID ADM27870 standard; RNA; 19 BP.
XX
XX ADM27870;
AC
XX
XX 07-APR-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #167.
DE
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX
XX Synthetic.

PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JUN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 PI Richards I, Mcswiggen J;
 XX MPI; 2005-090672/10.
 DR
 XX Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 88; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 SQ Sequence 19 BP; 4 A; 4 C; 5 G; 0 T; 6 U; 0 Other;
 QY
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1569 AACUUUGAUAUCUGGCG 1587
 1 AACUUUGAUAUCUGGCG 19
 RESULT 232
 ADW27795
 ID ADW27795 standard; RNA; 19 BP.
 XX
 AC ADW27795;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #92.
 XX
 KW gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JUN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JUN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 PI Richards I, Mcswiggen J;
 XX MPI; 2005-090672/10.
 DR
 XX Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 92; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 SQ Sequence 19 BP; 10 A; 6 C; 1 G; 0 T; 2 U; 0 Other;
 QY
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1641 CAACAAACAUUCAGAAC 1659
 1 CAACAAACAUUCAGAAC 19
 RESULT 233
 ADW27828/c
 ID ADW27828 standard; RNA; 19 BP.
 XX
 AC ADW27828;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #125.
 XX
 KW gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.

PT Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.

PS Disclosure; SEQ ID NO 47; 84pp; English.

XX

CC The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (II) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule CC was produced by solid phase oligonucleotide synthesis method. This CC sequence represents an example of a siRNA molecule of the invention.

XX

SQ Sequence 19 BP; 6 A; 7 C; 2 G; 0 T; 4 U; 0 Other;

QY Query Match 1.1%; Score 19; DB 1; Length 19; Best Local Similarity 100.0%; Pred. No. 1.6e+02; Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 831 AGAAACUUGUCACCCC 849
1 AGAAACUUGUCACCCC 19

RESULT 230
ADM27780
ID ADM27780 standard; RNA; 19 BP.

XX

AC ADM27780;

XX

DT 07-APR-2005 (first entry)

XX

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #77.

XX

KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.; respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective; KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA; KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis; KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction; KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease; KM incontinence; ss.

XX

OS Synthetic.

XX

PN US2005014172-A1.

XX

PD 20-JAN-2005.

XX

PF 11-MAR-2004; 2004US-00798090.

XX

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

PR 20-FEB-2003; 2003WO-US005028.

PR 20-FEB-2003; 2003WO-US005346.

PR 30-APR-2003; 2003US-00427160.

PR 23-MAY-2003; 2003US-00444853.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 14-JAN-2004; 2004US-00757803.

XX

PA (RICH/) RICHARDS I.

PA (MCSW/) MCSWIGGEN J.

XX

PI Richards I, Mcswigen J;

XX

DR WPI; 2005-090672/10.

XX

PT Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.

PS Disclosure; SEQ ID NO 77; 84pp; English.

XX

CC The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (II) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule CC was produced by solid phase oligonucleotide synthesis method. This CC sequence represents an example of a siRNA molecule of the invention.

XX

SQ Sequence 19 BP; 5 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

QY Query Match 1.1%; Score 19; DB 1; Length 19; Best Local Similarity 100.0%; Pred. No. 1.6e+02; Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 1371 CUCACGAGACCAUCUCG 1389
1 CUCACGAGACCAUCUCG 19

RESULT 231
ADM27791
ID ADM27791 standard; RNA; 19 BP.

XX

AC ADM27791;

XX

DT 07-APR-2005 (first entry)

XX

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #88.

XX

KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.; KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective; KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA; KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis; KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction; KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease; KM incontinence; ss.

XX

OS Synthetic.

XX

PN US2005014172-A1.

XX

PD 20-JAN-2005.

XX

PF 11-MAR-2004; 2004US-00798090.

XX

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

PR 20-FEB-2003; 2003WO-US005028.

PR 20-FEB-2003; 2003WO-US005346.

PR 30-APR-2003; 2003US-00427160.

CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nucleic acid. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.

XX Sequence 19 BP; 3 A; 6 C; 5 G; 0 T; 5 U; 0 Other;

SO Query Match 1.1%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 1.6e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 237 CUUGUGACCAUCCGCGC 255

DB 1 CUUGUGACCAUCCGCGC 19

RESULT 228

ID ADM27733 standard; RNA; 19 BP.

AC ADM27733;

DT 07-APR-2005 (first entry)

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #30.

XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
XX incontinence; ss.

OS Synthetic.

PN US2005014172-A1.

PD 20-JAN-2005.

PF 11-MAR-2004; 2004US-00798090.

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

PR 20-FEB-2003; 2003WO-US005028.

PR 20-FEB-2003; 2003WO-US005346.

PR 30-APR-2003; 2003US-00427160.

PR 23-MAY-2003; 2003US-00444853.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 14-JAN-2004; 2004US-00757803.

PA (RICH/) RICHARDS I.

PA (MCSW/) MCSWIGGEN J.

PI Richards I, Mcswiggen J;

DR WPI; 2005-090672/10.

XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.

XX Disclosure; SEQ ID NO 30; 84pp; English.

CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nucleic acid. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.

XX Sequence 19 BP; 8 A; 6 C; 4 G; 0 T; 1 U; 0 Other;

SO Query Match 1.1%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 1.6e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 525 GUACGAGCGCAACGACA 543

DB 1 GUACGAGCGCAACGACA 19

RESULT 229

ID ADM27750 standard; RNA; 19 BP.

AC ADM27750;

DT 07-APR-2005 (first entry)

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #47.

XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
XX incontinence; ss.

OS Synthetic.

PN US2005014172-A1.

PD 20-JAN-2005.

PF 11-MAR-2004; 2004US-00798090.

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

PR 20-FEB-2003; 2003WO-US005028.

PR 20-FEB-2003; 2003WO-US005346.

PR 30-APR-2003; 2003US-00427160.

PR 23-MAY-2003; 2003US-00444853.

PA (RICH/) RICHARDS I.

PA (MCSW/) MCSWIGGEN J.

PI Richards I, Mcswiggen J;

DR WPI; 2005-090672/10.

XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.

XX Disclosure; SEQ ID NO 30; 84pp; English.

QY 93 GGGAAACCGUACUACUUC 111
|||||
Db 1 GGGAAACCGUACUACUUC 19

RESULT 226
ADW27710
ID ADW27710 standard; RNA; 19 BP.
XX
AC ADW27710;
XX
DT 07-APR-2005 (first entry)
XX

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #7.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX

PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-0042716P.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX
PA (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
XX

PT Novel chemically synthesized double stranded short interfering nucleic
acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX
PS Disclosure; SEQ ID NO 7; 84pp; English.
XX

CC The invention relates to a chemically synthesized double stranded short
interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nucleases. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.

XX
SQ Sequence 19 BP; 4 A; 5 C; 4 G; 0 T; 6 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 111 CGGACGCUACAUGUUCU 129
|||||
Db 1 CGGACGCUACAUGUUCU 19

RESULT 227
ADW27717
ID ADW27717 standard; RNA; 19 BP.
XX
AC ADW27717;
XX
DT 07-APR-2005 (first entry)
XX

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #14.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX

PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-0042716P.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX
PA (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
XX

PT Novel chemically synthesized double stranded short interfering nucleic
acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX
PS Disclosure; SEQ ID NO 14; 84pp; English.
XX

CC The invention relates to a chemically synthesized double stranded short
interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic

DT 07-APR-2005 (first entry)
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #198.
XX
XX gene expression; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
XX incontinence; ss.
XX Synthetic.
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 198; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nucleases. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 19 BP; 3 A; 6 C; 7 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 84.2%; Pred. No. 1.6e+02;
XX Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1753 GCACCGAGAGCCUUGU 1771
XX |||||
XX 19 GCACCGAGAGCCCTTGT 1

RESULT 225
ADW27709
ID ADW27709 standard; RNA; 19 BP.
XX
XX ADW27709;
XX
XX 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #6.
XX
XX gene expression; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
XX incontinence; ss.
XX Synthetic.
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 6; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nucleases. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 19 BP; 4 A; 6 C; 4 G; 0 T; 5 U; 0 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OS Synthetic.
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PP 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 184; 84pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 5 A; 2 C; 6 G; 0 T; 6 U; 0 Other;
QY
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
Db 1515 CCCAUAACAACUACUGUU 1533
19 CCCATACACATCATCGTGT 1
RESULT 223
ADM27894/C
ID ADM27894 standard; RNA; 19 BP.
XX ADM27894;
XX
XX 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #191.
XX
XX gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM

KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PP 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 191; 84pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 2 A; 1 C; 6 G; 0 T; 10 U; 0 Other;
QY
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Db 1641 CAAACAACAACUACGAACC 1659
19 CAACAACAACATTCAGAAC 1
RESULT 224
ADM27901/C
ID ADM27901 standard; RNA; 19 BP.
XX ADM27901;
XX
XX

PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 PI Richards I, Mcswigen J;
 XX WPI; 2005-090672/10.
 DR Novel chemically synthesized double stranded short interfering nucleic
 XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 PS Disclosure; SEQ ID NO 173; 84pp; English.
 XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX Sequence 19 BP; 5 A; 3 C; 7 G; 0 T; 4 U; 0 Other;
 SQ
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 73.7%; Pred. No. 1.6e+02;
 Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
 QY 1317 GACUUCUAGCGUACACUCC 1335
 DB 19 GACUUCUAGCGUACACUCC 1
 RESULT 221
 ADM27879/C
 ID ADM27879 standard; RNA; 19 BP.
 XX ADM27879;
 AC
 XX 07-APR-2005 (first entry)
 DT
 XX Cholinergic receptor muscarinic 3 gene targeted siRNA #176.
 DE
 XX gene expression; antiasthmatic; anti-allergic; anti-inflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 KW incontinence; ss.
 XX
 XX OS Synthetic.
 XX US2005014172-A1.
 XX 20-JAN-2005.
 XX

PF 11-MAR-2004; 2004US-00798090.
 XX 20-FEB-2002; 2002US-0358580P.
 XX 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 PI Richards I, Mcswigen J;
 XX WPI; 2005-090672/10.
 DR Novel chemically synthesized double stranded short interfering nucleic
 XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 PS Disclosure; SEQ ID NO 176; 84pp; English.
 XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX Sequence 19 BP; 4 A; 4 C; 6 G; 0 T; 5 U; 0 Other;
 SQ
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 78.9%; Pred. No. 1.6e+02;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 1371 CUUCAGGAGGACUUCUG 1389
 DB 19 CUUCAGGAGGACUUCUG 1
 RESULT 222
 ADM27887/C
 ID ADM27887 standard; RNA; 19 BP.
 XX ADM27887;
 AC
 XX 07-APR-2005 (first entry)
 DT
 XX Cholinergic receptor muscarinic 3 gene targeted siRNA #184.
 DE
 XX gene expression; antiasthmatic; anti-allergic; anti-inflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 KW incontinence; ss.
 XX

PA	(RICH//) RICHARDS I.
PA	(MCSW/) MCSWIGGEN J.
XX	
XX	Richards I, Mcswigen J;
XX	WPI, 2005-090672/10.
DR	
PT	Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.
XX	
PS	Disclosure; SEQ ID NO 126; 84bp; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC	where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.
CC	
CC	
SQ	Sequence 19 BP; 6 A; 4 C; 5 G; 0 T; 4 U; 0 Other;
Query Match	1.1%; Score 19; DB 1; Length 19;
Best Local Similarity	68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative	6; Mismatches 0; Indels 0; Gaps 0;
Oy	471 GAUUCUGGUGCAUACAGC 489 ::: ::: :: Db 19 GAATCTTGTCGCATCACG 1
RESULT 219	
ADM27867/c	
ID	ADM27867 standard; RNA; 19 BP.
XX	
AC	ADM27867;
XX	
DT	07-APR-2005 (first entry)
XX	
XX	Cholinergic receptor muscarinic 3 gene targeted siRNA #164.
XX	
KW	gene expression; antiaesthetic; antiasthmatic; antiinflammatory; CNS-Gen.; respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective; nootropic; uteroplacental; short interfering RNA; RNA interference; siRNA; cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis; inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction; hyperextension; emphysema; irritable bowel syndrome; Alzheimers disease; incontinence; ss.
KW	
KM	
XX	
OS	Synthetic.
PN	US2005014172-A1.
XX	
PD	20-JAN-2005.
XX	
PF	11-MAR-2004; 2004US-00798090.
XX	
PR	20-FEB-2002; 2002US-0358580P.
PR	11-MAR-2002; 2002US-0353124P.
PR	20-MAY-2002; 2002WO-US015876.
PR	06-JUN-2002; 2002US-036782P.
PR	29-AUG-2002; 2002US-0406784P.
PR	05-SEP-2002; 2002US-0408378P.
PR	09-SEP-2002; 2002US-0409293P.
PR	15-JAN-2003; 2003US-0440129P.
PR	20-FEB-2003; 2003WO-US005028.
PR	20-FEB-2003; 2003WO-US005346.

PR	30-APR-2003;	2003US-004277160.
PR	23-MAY-2003;	2003US-00444853.
PR	23-OCT-2003;	2003US-00693059.
PR	24-NOV-2003;	2003US-00720448.
PR	14-JAN-2004;	2004US-00757803.
XX		
XX	(RICH/) RICHARDS I.	
PA	(MCSW/) MCSWIGGEN J.	
PI	Richards I, Mcswiggen J;	
XX		
XX	WPI; 2005-090672/10.	
DR		
PT	Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.	
PT		
PS	Disclosure; SEQ ID NO 164; 84pp; English.	
XX		
XX	The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (1) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (1) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (1) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (1) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.	
XX		
XX	Sequence 19 BP; 3 A; 6 C; 5 G; 0 T; 5 U; 0 Other;	
XX		
Query Match	1.1%; Score 19; DB 1; Length 19;	
Best Local Similarity	84.2%; Pred. No. 1.6e+02;	
Matches	16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;	
Qy	1155 AUGGACACACCGGAGG 1173	
Db	19 ATCGGACACCTGCGAGG 1	
	: : :	
RESULT 220		
ADM27876/C		
ID	ADM27876 standard; RNA; 19 BP.	
XX		
AC	ADM27876;	
XX		
DT	07-APR-2005 (first entry)	
XX		
DB	Cholinergic receptor muscarinic 3 gene targeted siRNA #173.	
XX		
XX	gene expression; antiaesthetic; antiallergic; antiinflammatory; CNS-Gen.; respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective; nootropic; uterobatic; short interfering RNA; RNA interference; siRNA;	
KW	cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis; inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;	
KW	hyperextension; emphysema; irritable bowel syndrome; Alzheimers disease; incontinence; ss.	
XX		
XX		
OS	Synthetic.	
XX		
PN	US2005014172-A1.	
XX		
PD	20-JAN-2005.	
XX		
PF	11-MAR-2004; 2004US-00798090.	
XX		
FR	20-FEB-2002; 2002US-0358580P.	
FR	11-MAR-2002; 2002US-0363124P.	
FR	20-MAY-2002; 2002MO-US015876.	
FR	06-JUN-2002; 2002US-0386782P.	

XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, emphysema, irritable bowel syndrome,
 CC vasoconstriction or hypertension, irritable bowel syndrome, pulmonary
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.

XX Sequence 19 BP; 5 A; 4 C; 6 G; 0 T; 4 U; 0 Other;
 SQ
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1677 GCGUGCCAGUGGACAA 1695
 DB 1 GCGUGCCAGUGGACAA 19

RESULT 217
 ADW27819/C
 ID ADW27819 standard; RNA; 19 BP.
 AC ADW27819;
 XX
 DT 07-APR-2005 (first entry)

XX Cholinergic receptor muscarinic 3 gene targeted siRNA #116.
 DE
 XX

XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.

OS Synthetic.

PN US2005014172-A1.

XX 20-JAN-2005.

PF 11-MAR-2004; 2004US-00798090.

XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 20-FEB-2003; 2003US-00427160.
 PR 30-APR-2003; 2003US-00444853.
 PR 23-MAY-2003; 2003US-00693059.
 PR 23-OCT-2003; 2003US-00720448.
 PR 14-NOV-2003; 2003US-00757803.
 PR 14-JAN-2004; 2004US-00757803.

PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.

XX Richards I, Mcswiggen J;

XX WPI; 2005-090672/10.
 DR

XX Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX Disclosure; SEQ ID NO 116; 84bp; English.

XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, emphysema, irritable bowel syndrome,
 CC vasoconstriction or hypertension, irritable bowel syndrome, pulmonary
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.

XX Sequence 19 BP; 2 A; 6 C; 5 G; 0 T; 6 U; 0 Other;
 SQ
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.6e+02;
 Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 291 GCGCTGAGACGGTCAAC 309
 DB 19 GCGCTGAGACGGTCAAC 1

RESULT 218
 ADW27829/C
 ID ADW27829 standard; RNA; 19 BP.
 AC ADW27829;
 XX
 DT 07-APR-2005 (first entry)

XX Cholinergic receptor muscarinic 3 gene targeted siRNA #126.
 DE
 XX

XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.

OS Synthetic.

PN US2005014172-A1.

XX 20-JAN-2005.

PF 11-MAR-2004; 2004US-00798090.

XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 20-FEB-2003; 2003US-00427160.
 PR 30-APR-2003; 2003US-00444853.
 PR 23-MAY-2003; 2003US-00693059.
 PR 23-OCT-2003; 2003US-00720448.
 PR 14-NOV-2003; 2003US-00757803.
 PR 14-JAN-2004; 2004US-00757803.

XX

CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 3 A; 4 C; 7 G; 0 T; 5 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1389 GGCCAGAGGUGGUCUG 1407
DB 1 GGCCAGAGGUGGUCUG 19
RESULT 215
ADM27783
ID ADM27783 standard; RNA; 19 BP.
XX
XX ADM27783;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #80.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
KW incontinence; ss.
XX
XX Synthetic.
OS
PN US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005346.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGEN J.
XX
PI Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 80; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA

CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 8 A; 3 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1425 CACUAGCCGAAAGGAGUG 1443
DB 1 CACUAGCCGAAAGGAGUG 19
RESULT 216
ADM27797
ID ADM27797 standard; RNA; 19 BP.
XX
XX ADM27797;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #94.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
KW incontinence; ss.
XX
XX Synthetic.
OS
PN US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005346.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGEN J.
XX
PI Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 94; 84pp; English.
XX

RESULT 213
 ID ADW27747 standard; RNA; 19 BP.
 XX
 AC ADW27747;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #44.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW inconitence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 PI Richards I, Mcswiggen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 44; 84bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SO Sequence 19 BP; 8 A; 4 C; 4 G; 0 T; 3 U; 0 Other:
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 777 AAAGCGUACCAAGACCU 795
 DB 1 AAAGCGUACCAAGACCU 19
 RESULT 214
 ID ADW27781 standard; RNA; 19 BP.
 XX
 AC ADW27781;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #78.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW inconitence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 PI Richards I, Mcswiggen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 78; 84bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This

PR 20-FEB-2003; 2003MO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswiggen J;
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 182; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (II) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 6 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 1479 CAGUGCGAUCUUGCUGCC 1497
DB 19 CAGTGGCATCTTGGCTTGCC 1
RESULT 208
ADM27900/C
ID ADM27900 standard; RNA; 19 BP.
XX
AC ADM27900;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #197.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.

PR 06-JUN-2002; 2002US-0386782P.
PR 29-SEP-2002; 2002US-0406784P.
PR 06-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003MO-US005028.
PR 20-FEB-2003; 2003MO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswiggen J;
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 197; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (II) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 0 A; 7 C; 9 G; 0 T; 3 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1749 GCGCGACCCGAGCAGGCC 1767
DB 19 GCGCGACCCGAGCAGGCC 1
RESULT 209
ADM27706
ID ADM27706 standard; RNA; 19 BP.
XX
AC ADM27706;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #3.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.

DR WPI: 2005-090672/10.
 XX
 XX Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 XX Disclosure; SEQ ID NO 175; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 XX Sequence 19 BP; 5 A; 3 C; 9 G; 0 T; 2 U; 0 Other:
 QY
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 73.7%; Pred. No. 1.6e+02; Mismatches 0; Gaps 0;
 Matches 14; Conservative 5; Indels 0; Gaps 0;
 DB 1353 GGCACUCUACCCUGUCC 1371
 |||||:||||:||||:
 19 GGCACCTCTACCTGTCTC 1
 RESULT 206
 ID ADW27882/c
 XX ADW27882 standard; RNA; 19 BP.
 AC
 XX ADW27882;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #179.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.

XX
 XX (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 XX Richards I, Mcswiggen J;
 PT
 XX WPI: 2005-090672/10.
 XX
 CC Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 XX Disclosure; SEQ ID NO 179; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 XX Sequence 19 BP; 2 A; 6 C; 3 G; 0 T; 8 U; 0 Other:
 QY
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.6e+02; Mismatches 0; Gaps 0;
 Matches 17; Conservative 2; Indels 0; Gaps 0;
 DB 1425 CACTAAGCGGAAAGGATG 1443
 |||||:|||||:||||:
 19 CACTAAGCGGAAAGGATG 1
 RESULT 207
 ID ADW27885/c
 XX ADW27885 standard; RNA; 19 BP.
 AC
 XX ADW27885;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #182.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.

CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.

XX
SQ Sequence 19 BP, 4 A, 3 C, 7 G, 0 T, 5 U, 0 Other;

QY Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Db 1083 GAGAGCCAUACUCCAUCC 1101
|||||:|:|:|:|:|:|:|:|:|
19 GAGAGCCATCTACTCCATC 1

RESULT 204
ADW27875/c
XX ADW27875 standard; RNA, 19 BP.
XX
AC ADW27875;
XX
DT 07-APR-2005 (first entry)
XX
DB Cholinergic receptor muscarinic 3 gene targeted siRNA #172.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
OS Synthetic.
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX
XX 11-MAR-2002; 2002US-0363124P.
XX
XX 20-MAY-2002; 2002WO-US015876.
XX
XX 06-JUN-2002; 2002US-0386782P.
XX
XX 29-AUG-2002; 2002US-0406784P.
XX
XX 05-SEP-2002; 2002US-0408378P.
XX
XX 09-SEP-2002; 2002US-0409293P.
XX
XX 15-JAN-2003; 2003US-0440129P.
XX
XX 20-FEB-2003; 2003WO-US005028.
XX
XX 20-FEB-2003; 2003WO-US005346.
XX
XX 30-APR-2003; 2003US-00427160.
XX
XX 23-MAY-2003; 2003US-0044853.
XX
XX 23-OCT-2003; 2003US-00693059.
XX
XX 24-NOV-2003; 2003US-00720448.
XX
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX
XX (MCSW/) MCSWIGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX WPI: 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.

PS Disclosure; SEQ ID NO 172; 84bp; English.

XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.

XX
SQ Sequence 19 BP, 2 A, 6 C, 5 G, 0 T, 6 U, 0 Other;

QY Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Db 1299 AGCCGUGACACAGCUAAG 1317
|||||:|:|:|:|:|:|:|:|:|
19 AGCCGUGACACAGCTAAG 1

RESULT 205
ADW27878/c
XX ADW27878 standard; RNA, 19 BP.
XX
XX
AC ADW27878;
XX
DT 07-APR-2005 (first entry)
XX
DB Cholinergic receptor muscarinic 3 gene targeted siRNA #175.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
OS Synthetic.
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX
XX 11-MAR-2002; 2002US-0363124P.
XX
XX 20-MAY-2002; 2002WO-US015876.
XX
XX 06-JUN-2002; 2002US-0386782P.
XX
XX 29-AUG-2002; 2002US-0406784P.
XX
XX 05-SEP-2002; 2002US-0408378P.
XX
XX 09-SEP-2002; 2002US-0409293P.
XX
XX 15-JAN-2003; 2003US-0440129P.
XX
XX 20-FEB-2003; 2003WO-US005028.
XX
XX 20-FEB-2003; 2003WO-US005346.
XX
XX 30-APR-2003; 2003US-00427160.
XX
XX 23-MAY-2003; 2003US-0044853.
XX
XX 23-OCT-2003; 2003US-00693059.
XX
XX 24-NOV-2003; 2003US-00720448.
XX
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX
XX (MCSW/) MCSWIGEN J.
XX
XX Richards I, Mcswigen J;
XX

AC ADW27824;
XX
XX 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #121.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nontropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003US-00505346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
XX
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX
XX Disclosure; SEQ ID NO 121; 84pp; English.
XX
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX CC was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX
XX Sequence 19 BP; 5 A; 2 C; 5 G; 0 T; 7 U; 0 Other;
XX
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
XX Best Local Similarity 73.7%; Pred. No. 1.6e+02;
XX Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
XX
XX 381 CUCACUACUACUACUACGA 399
XX :||:||||:||||:||||:
XX 19 CTACATCATCATCATGATCGA 1

RESULT: 201
ADW27827/C
ID ADW27827 standard; RNA; 19 BP.
XX
XX
XX ADW27827;
XX
XX 07-APR-2005 (first entry)
XX
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #124.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nontropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX
XX Synthetic.
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003US-00505346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
XX
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX
XX Disclosure; SEQ ID NO 124; 84pp; English.
XX
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX CC was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX
XX Sequence 19 BP; 5 A; 4 C; 6 G; 0 T; 4 U; 0 Other;
XX
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;

P	D		20-JAN-2005.
X	X		
P	F	XX	11-MAR-2004; 2004US-00798090.
X	X		
P	R	20-FEB-2002;	200ZUS-0356580P.
P	R	11-MAR-2002;	200ZUS-0363124P.
P	R	20-MAY-2002;	200ZMO-USO15876.
P	R	06-JUN-2002;	2002US-0386782P.
P	R	29-AUG-2002;	200ZUS-0406784P.
P	R	05-SEP-2002;	200ZUS-0408378P.
P	R	09-SEP-2002;	200ZUS-0409293P.
P	R	15-JAN-2003;	2003US-0440129P.
P	R	20-FEB-2003;	2003WO-USO05028.
P	R	30-APR-2003;	2003US-0402716P.
P	R	23-MAY-2003;	2003US-00444853.
P	R	23-OCT-2003;	2003US-00693059.
P	R	24-NOV-2003;	2003US-00720448.
P	R	14-JAN-2004;	2004US-00757803.
X	X		
P	A	(RICH/) RICHARDS I.	
P	A	(MCSW) MCSWIGEN J.	
X	X		
P	I	Richards I,	Mcswigen J;
X	X		
D	R		WPI; 2005-090672/10.
X	X		
P	T		Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.
X	X		
P	S		Disclosure; SEQ ID NO 91; 84pp; English.
X	X		
C	C		The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.
C	C		
S	Q		Sequence 19 BP; 1 A; 5 C; 6 G; 0 T; 7 U; 0 Other;
Query Match		1.1%; Score 19; DB 1; Length 19;	
Best Local Similarity		100.0%; Pred. No. 1.6e+02;	
Matches	19;	Conservative	0; Mismatches 0; Indels 0; Gaps 0;
Oy		1623 CGUGUGCUAUCCUCGUGC 1641 	
Db		1 CGUGUGCUAUCCUCGUGC 19	
RESULT 198			
ADW27816/c	ID		
ADW27816;	AC		
DT	07-APR-2005	(first entry)	
Cholinergic receptor muscarinic 3 gene targeted siRNA #113.			
KX		gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-gen.; respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective; nootropic; uterohetic; short interfering RNA; RNA interference; siRNA; inflammatory receptor muscarinic 3; asthma; allergic rhinitis; sinusitis; inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction; hyperextension; emphysema; irritable bowel syndrome; Alzheimers disease;	

XX
PS Disclosure; SEQ ID NO 21; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (II) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (II) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 6 A; 4 C; 3 G; 0 T; 6 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02; Mismatches 0; Gaps 0;
Matches 19; Conservative 0; Indels 0; Gaps 0;
QY 363 AAUGAUCUGUUACGACC 381
Db 1 AAUGAUCUGUUACGACC 19
|||||
RESULT 193
ADM27727 1.1%; Score 19; DB 1; Length 19;
ID ADM27727 standard; RNA; 19 BP.
XX
AC ADM27727;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #24.
XX
KW gene expression; antispasmodic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003US-0042716P.
PR 30-APR-2003; 2003US-0044853.
PR 23-MAY-2003; 2003US-00693059.
PR 23-OCT-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
RA (RICH) RICHARDS I.
PA (MCSW) MCSWIGEN J.
XX
PI Richards I, Mcswigen J;

XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 24; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (II) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (II) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 1 A; 6 C; 6 G; 0 T; 6 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02; Mismatches 0; Gaps 0;
Matches 19; Conservative 0; Indels 0; Gaps 0;
QY 417 GGCCTUGACCCUUGGCUU 435
Db 1 GGCCTUGACCCUUGGCUU 19
|||||
RESULT 194
ADM27736 1.1%; Score 19; DB 1; Length 19;
ID ADM27736 standard; RNA; 19 BP.
XX
AC ADM27736;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #33.
XX
KW gene expression; antispasmodic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003US-0042716P.
PR 30-APR-2003; 2003US-0044853.
PR 23-MAY-2003; 2003US-00693059.
PR 23-OCT-2003; 2003US-00720448.
PR 24-NOV-2003; 2003US-00757803.

CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.

XX SQ Sequence 19 BP; 4 A; 5 C; 5 G; 0 T; 5 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No.1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 129 UCGAGCAGCUGGCAUUC 147

Db 1 UCGAGCAGCUGGCAUUC 19

RESULT 191

ID ADM27712

XX ADM27712 standard; RNA; 19 BP.

AC ADM27712;

XX 07-APR-2005 (first entry)

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #9.
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; utroptatic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.

OS Synthetic.

XX US2005014172-A1.

XX PD 20-JAN-2005.

XX PF 11-MAR-2004; 2004US-00798090.

XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-0044853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.

PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.

PI Richards I, Mcswiggen J;

XX WPI; 2005-090672/10.

DR Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PI RNA through RNA interference, useful for treating asthma.

XX Disclosure; SEQ ID NO 9; 84pp; English.

CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,

CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.

XX SQ Sequence 19 BP; 3 A; 9 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No.1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 147 CUCCUCUCCAGACGUACC 165

Db 1 CUCCUCUCCAGACGUACC 19

RESULT 192

ID ADM27724

XX ADM27724 standard; RNA; 19 BP.

AC ADM27724;

XX 07-APR-2005 (first entry)

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #21.
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; utroptatic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.

OS Synthetic.

XX US2005014172-A1.

XX PD 20-JAN-2005.

XX PF 11-MAR-2004; 2004US-00798090.

XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-0044853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.

PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.

PI Richards I, Mcswiggen J;

XX WPI; 2005-090672/10.

DR Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PI RNA through RNA interference, useful for treating asthma.

Db 19 CAACTACTTCCTCTAAGC 1

RESULT 189

ADW27855/c

ID ADW27855 standard; RNA; 19 BP.

XX

AC ADW27855;

XX

DT 07-APR-2005 (first entry)

XX

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #152.

XX

KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-gen.;

KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;

KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;

KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;

KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;

KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;

KW incontinence; ss.

XX

OS Synthetic.

XX

PN US2005014172-A1.

XX

PD 20-JAN-2005.

XX

PF 11-MAR-2004; 2004US-00798090.

XX

PR 20-FEB-2002; 2002US-0358580P.

XX

PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

PR 20-FEB-2003; 2003WO-US005028.

PR 20-FEB-2003; 2003WO-US005346.

PR 30-APR-2003; 2003US-00427160.

PR 23-MAY-2003; 2003US-00444853.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 14-JAN-2004; 2004US-00757803.

XX

PA (RICH/) RICHARDS I.

PA (MCSW/) MCSWIGGEN J.

XX

PI Richards I, Mcswiggen J;

XX

DR WPI; 2005-090672/10.

XX

PT Novel chemically synthesized double stranded short interfering nucleic

PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3

PT RNA through RNA interference, useful for treating asthma.

XX

PS Disclosure; SEQ ID NO 152; 84pp; English.

XX

CC The invention relates to a chemically synthesized double stranded short

CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a

CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,

CC where each strand of (I) has 19-23 nucleotides, and does not require the

CC presence of nucleotides having a 2-hydroxy group for mediating RNA

CC interference. (I) is useful for treating diseases e.g., asthma, allergic

CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary

CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,

CC Alzheimer's disease or urinary incontinence. (I) has increased resistance

CC towards nuclease. Double stranded short interfering nucleic acid molecule

CC was produced by solid phase oligonucleotide synthesis method. This

CC sequence represents an example of a siRNA molecule of the invention.

XX

XX Sequence 19 BP; 3 A; 4 C; 6 G; 0 T; 6 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;

Best Local Similarity 84.2%; Pred. No. 1.6e+02;

Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 939 CUGGUDCAACCAAGAGC 957

||:|||||

Db 19 CTGGTTCAACCAAGAGC 1

RESULT 190

ADW27711

ID ADW27711 standard; RNA; 19 BP.

XX

AC ADW27711;

XX

DT 07-APR-2005 (first entry)

XX

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #8.

XX

KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-gen.;

KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;

KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;

KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;

KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;

KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;

KW incontinence; ss.

XX

OS Synthetic.

XX

PN US2005014172-A1.

XX

PD 20-JAN-2005.

XX

PF 11-MAR-2004; 2004US-00798090.

XX

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

PR 20-FEB-2003; 2003WO-US005028.

PR 20-FEB-2003; 2003WO-US005346.

PR 30-APR-2003; 2003US-00427160.

PR 23-MAY-2003; 2003US-00444853.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 14-JAN-2004; 2004US-00757803.

XX

PA (RICH/) RICHARDS I.

PA (MCSW/) MCSWIGGEN J.

XX

PI Richards I, Mcswiggen J;

XX

DR WPI; 2005-090672/10.

XX

PT Novel chemically synthesized double stranded short interfering nucleic

PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3

PT RNA through RNA interference, useful for treating asthma.

XX

PS Disclosure; SEQ ID NO 8; 84pp; English.

XX

CC The invention relates to a chemically synthesized double stranded short

CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a

CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,

CC where each strand of (I) has 19-23 nucleotides, and does not require the

CC presence of nucleotides having a 2-hydroxy group for mediating RNA

CC interference. (I) is useful for treating diseases e.g., asthma, allergic

CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary

CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,

CC Alzheimer's disease or urinary incontinence. (I) has increased resistance

XX gene expression; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uteropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX Synthetic.
XX US2005014172-A1.
XX 20-JAN-2005.
XX 11-MAR-2004; 2004US-00798090.
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2003US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX Richards I, Mcswigen J;
XX MPI; 2005-090672/10.
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX Disclosure; SEQ ID NO 115; 84pp; English.
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX Sequence 19 BP; 5 A; 4 C; 3 G; 0 T; 7 U; 0 Other;
SQ Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 273 GUCAUUAAGUCACACAG 291
|:|||||:|||||
Db 19 GTCATTTAAGTCAACAAG 1
RESULT 188
ADM27820/c
ID ADM27820 standard; RNA; 19 BP.

XX ADM27820;
AC 07-APR-2005 (first entry)
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #117.
XX gene expression; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uteropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX Synthetic.
XX US2005014172-A1.
XX 20-JAN-2005.
XX 11-MAR-2004; 2004US-00798090.
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX Richards I, Mcswigen J;
XX MPI; 2005-090672/10.
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX Disclosure; SEQ ID NO 117; 84pp; English.
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX Sequence 19 BP; 6 A; 1 C; 7 G; 0 T; 5 U; 0 Other;
SQ Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 309 CAACUACUUCUCUUAAC 327
|:|||||:|||||

PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX Richards I, Mcswigen J;
 XX WPI; 2005-090672/10.
 DR Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 13; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 19 BP; 3 A; 7 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 219 CTTAAGCGGCAUCCUGGCC 237
 |||||
 1 CTTAAGCGGCAUCCUGGCC 19
 Db
 RESULT 184
 ADM27735
 ID ADM27735 standard; RNA; 19 BP.
 XX
 AC ADM27735;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #32.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;-
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neotropic; uteropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX Richards I, Mcswigen J;
 XX WPI; 2005-090672/10.
 DR Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 32; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 19 BP; 2 A; 3 C; 8 G; 0 T; 6 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 561 GAUGAUGGUCUUGG 579
 |||||
 1 GAUGAUGGUCUUGG 19
 Db
 RESULT 185
 ADM27762
 ID ADM27762 standard; RNA; 19 BP.
 XX
 AC ADM27762;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #59.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neotropic; uteropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.

Query Match	1.1%	Score 19;	DB 1;	Length 19;
Best Local Similarity	68.4%	Pred. No. 1.6e+02;		
Matches 13;	Conservative 6;	Mismatches 0;	Indels 0;	Gaps 0;
OY	1659 CACUUCAGAUUCUGUCUG 1677			
DB	19 CACUUCAGAUUCUGUCUG 1			
RESULT 182				
ADW27704				
ID	ADW27704 standard; RNA; 19 BP.			
XX				
AC	ADW27704;			
XX				
DT	07-APR-2005 (first entry)			
XX				
DE	Cholinergic receptor muscarinic 3 gene targeted siRNA #1.			
XX				
KW	gene expression; antiaesthetic; antiallergic; antiinflammatory; CNS-Gen.;			
KW	respiratory-gen.; hypocoelusive; gastrointestinal-gen.; neuroprotective;			
KW	neotropic; uteroplacental; short interfering RNA; RNA interference; siRNA;			
KW	cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;			
KW	inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;			
KW	hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;			
XX	incontinence; ss.			
XX				
OS	Synthetic.			
XX				
UN	US2005014172-A1.			
XX				
PD	20-JAN-2005.			
XX				
PF	11-MAR-2004; 2004US-00798090.			
XX				
PR	20-FEB-2002; 2002US-0358580P.			
PR	11-MAR-2002; 2002US-0363124P.			
PR	20-MAY-2002; 2002WO-US015876.			
PR	06-JUN-2002; 2002US-0386782P.			
PR	29-AUG-2002; 2002US-0406784P.			
PR	05-SEP-2002; 2002US-0408378P.			
PR	09-SEP-2002; 2002US-0409233P.			
PR	15-JAN-2003; 2003US-0440129P.			
PR	20-FEB-2003; 2003WO-US005028.			
PR	20-FEB-2003; 2003WO-US005346.			
PR	30-APR-2003; 2003US-00427160.			
PR	23-MAY-2003; 2003US-00444853.			
PR	23-OCT-2003; 2003US-00693059.			
PR				
PI	Richards I, McSwiggen J;			
XX				
DR	WPI, 2005-090672/10.			
XX				
PT	Novel chemically synthesized double stranded short interfering nucleic			
PT	acid molecule that directs cleavage of cholinergic receptor muscarinic 3			
PT	RNA through RNA interference, useful for treating asthma.			
XX				
PS	Disclosure; SEQ ID NO 192; 84bp; English.			
XX				
CC	The invention relates to a chemically synthesized double stranded short			
CC	interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a			
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,			
CC	where each strand of (I) has 19-23 nucleotides, and does not require the			
CC	presence of nucleotides having a 2-hydroxy group for mediating RNA			
CC	interference. (I) is useful for treating diseases e.g., asthma, allergic			
CC	rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary			
CC	vasoconstriction or hypertension, emphysema, irritable bowel syndrome,			
CC	Alzheimer's disease or urinary incontinence. (I) has increased resistance			
CC	towards nuclease. Double stranded short interfering nucleic acid molecule			
CC	was produced by solid phase oligonucleotide synthesis method. This			
CC	sequence represents an example of a siRNA molecule of the invention.			
XX				
SQ	Sequence 19 BP; 6 A; 4 C; 5 G; 0 T; 4 U; 0 Other;			

PR	24-NOV-2003; 2003US-00720448.
PR	14-JAN-2004; 2004US-00757803.
XX	(RICH/) RICHARDS I.
PA	(MCSW/) MCSWIGEN J.
XX	
PI	Richards I, Mcswigen J;
XX	
XX	WPI; 2005-090672/10.
DR	
XX	
PT	Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.
PT	
PS	Disclosure; SEQ ID NO 1; 84pp; English.
CC	
XX	The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC	where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasooconstruction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.
CC	
XX	Sequence 19 BP; 7 A; 5 C; 3 G; 0 T; 4 U; 0 Other;
SQ	
Query Match	1.1%; Score 19; DB 1; Length 19;
Best Local Similarity	100.0%; Pred. No. 1.6e+02;
Matches	19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy	3 GACCTUGCACAUAACAGU 21 1 GACCTUGCACAUAACAGU 19
Db	
RESULT 183	
ID	ADM27716 standard; RNA; 19 BP.
XX	
AC	ADM27716;
XX	
DT	07-APR-2005 (first entry)
XX	
DE	Cholinergic receptor muscarinic 3 gene targeted siRNA #13.
XX	
KW	gene expression; antiaesthetic; antiasthmatic; antiinflammatory; CNS-Gen.; respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective; nootropic; uterapathic; short interfering RNA; RNA interference; siRNA; cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis; inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction; hyperextension; emphysema; irritable bowel syndrome; Alzheimers disease; incontinence; ss.
KW	
KM	
XX	Synthetic.
OS	
PX	US2005014172-A1.
PN	
FD	20-JAN-2005.
XX	
PF	11-MAR-2004; 2004US-00798090.
XX	
PR	20-FEB-2002; 2002US-0358580P.
PR	11-MAR-2002; 2002US-0363124P.
PR	20-MAY-2002; 2002WO-US015876.
PR	06-JUN-2002; 2002US-0386782P.
PR	29-AUG-2002; 2002US-0406784P.
PR	05-SEP-2002; 2002US-0408378P.
PR	09-SEP-2002; 2002US-0409293P.
PR	

CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 5 A; 6 C; 4 G; 0 T; 4 U; 0 Other;
QY Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
DB 1245 CGAUGAGGCGAGUUNUCCA 1263
19 CGATGAGGCGAGTTTCCA 1
RESULT 180
ADM27883/C
ID ADM27883 standard; RNA; 19 BP.
AC ADM27883;
DT 07-APR-2005 (first entry)
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #180.
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #180.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM neotropic; utroplastic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
XX Synthetic.
OS
XX
XX US2005014172-A1.
PN 20-JAN-2005.
PD
XX
XX 11-MAR-2004; 2004US-00798090.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
PI
XX
XX WPI; 2005-090672/10.
DR
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3

PT RNA through RNA interference, useful for treating asthma.
XX
XX disclosure; SEQ ID NO 180; 84bp; English.
PS
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 3 A; 7 C; 4 G; 0 T; 5 U; 0 Other;
QY Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.6e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
DB 1443 GUCCUGGUGAAGAGAGAG 1461
19 GTCCCTGCTCAAGAGAGAG 1
RESULT 181
ADM27895/C
ID ADM27895 standard; RNA; 19 BP.
AC ADM27895;
DT 07-APR-2005 (first entry)
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #192.
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #192.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM neotropic; utroplastic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
XX Synthetic.
OS
XX
XX US2005014172-A1.
PN 20-JAN-2005.
PD
XX
XX 11-MAR-2004; 2004US-00798090.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 93 GGGAAACCGCACUACUUC 111
|||||:||||:||||:
DB 19 GGGAAACCGTCACCTCATTTTC 1

RESULT 178
ADM27811/c
ID ADM27811 standard; RNA; 19 BP.
XX
AC ADM27811;
XX
XX 07-APR-2005 (first entry)
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #108.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
XX 20-JAN-2005.
PD
XX
PF 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-0042716P.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
DR
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 108; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,

CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 4 A; 3 C; 9 G; 0 T; 3 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 147 CUCCUCUCGACGUAAC 165
|||:|||||:||||:
DB 19 CTCCTCTCCGACGCTACC 1

RESULT 179
ADM27872/c
ID ADM27872 standard; RNA; 19 BP.
XX
AC ADM27872;
XX
XX 07-APR-2005 (first entry)
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #169.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
XX 20-JAN-2005.
PD
XX
PF 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-0042716P.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
DR
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 169; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a

ID ADW27805 standard; RNA; 19 BP.
XX
AC ADW27805;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #102.
XX
KM gene expression; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nocotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 30-FEB-2003; 2003WO-US005346.
PR 20-APR-2003; 2003US-00427160.
PR 30-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 102; 84pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 4 A; 1 C; 9 G; 0 T; 5 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 39 UCCAAACUACGUCUCC 57

DB
19 TCCTAACATCAGCTCTCC 1
|||||:|||||:
RESULT 177
ADW27808/c
ID ADW27808 standard; RNA; 19 BP.
XX
AC ADW27808;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #105.
XX
KM gene expression; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nocotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 30-FEB-2003; 2003WO-US005346.
PR 20-APR-2003; 2003US-00427160.
PR 30-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 105; 84pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 5 A; 4 C; 6 G; 0 T; 4 U; 0 Other;

DE Cholineergic receptor muscarinic 3 gene targeted siRNA #73.

XX gene expression; antiasthmatic; anti-allergic; anti-inflammatory; CNS-Gen.;

XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;

KW nootropic; uteroplacental short interfering RNA; RNA interference; siRNA;

KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;

KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;

KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;

KW incontinence; ss.

OS Synthetic.

XX

XX US2005014172-A1.

PN

PN 20-JAN-2005.

PD

PD 20-JAN-2005.

PF

PF 11-MAR-2004; 2004US-00798090.

XX

XX

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

PR 20-FEB-2003; 2003WO-US0050528.

PR 20-FEB-2003; 2003WO-US005346.

PR 30-APR-2003; 2003US-00427160.

PR 23-MAY-2003; 2003US-00444853.

PR 23-OCT-2003; 2003US-00693059.

PR 14-NOV-2003; 2003US-00720448.

PR 14-JAN-2004; 2004US-00757803.

XX

PA (RICH/) RICHARDS I.

PA (MCSW/) MCSWIGEN J.

XX

XX Richards I., Mcswigen J;

PI WPI; 2005-090672/10.

XX

XX Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholineergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.

PT

PS Disclosure; SEQ ID NO 73; 84pp; English.

CC The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.

CC

CC Sequence 19 BP; 6 A, 5 C; 6 G; 0 T; 2 U; 0 Other;

SQ

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Gy 1299 AGCGUGACACAGCUNAAG 1317
|||||
Db 1 AGCGUGACACAGCUNAAG 19

RESULT 176
ADM27805/c

PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX PA (MCSW/) MCSWIGGEN J.
XX PI Richarde I, Mcswigen J;
XX WPI, 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 165; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 2 A; 11 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 1173 GCCUGAGGAGGAGCGGG 1191
Db 19 GCTTAGAGAGAGCTGGGG 1
|||:|||||||:||||
ADW27880/C
ID ADW27880 standard; RNA; 19 BP.
XX
XX ADW27880;
AC
XX
XX 07-APR-2005 (first entry)
DT
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #177.
XX
XX gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
XX Synthetic.
OS
XX
XX US2005014172-A1.
PN
XX
XX 20-JAN-2005.
PD
XX
XX 11-MAR-2004; 2004US-00798090.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2003US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
XX

PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
XX WPI, 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 177; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 5 A; 7 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 1389 GGCCAGAGGUGUCUCUG 1407
Db 19 GGCCAGAGGTTTCTCTG 1
|||||||:|||||
ADW27884/C
ID ADW27884 standard; RNA; 19 BP.
XX
XX ADW27884;
AC
XX
XX 07-APR-2005 (first entry)
DT
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #181.
XX
XX gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
XX Synthetic.
OS
XX
XX US2005014172-A1.
PN
XX
XX 20-JAN-2005.
PD
XX
XX 11-MAR-2004; 2004US-00798090.
PF
XX

PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 PS Disclosure; SEQ ID NO 135; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 SQ Sequence 19 BP; 4 A; 6 C; 3 G; 0 T; 6 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 78.9%; Pred. No. 1.6e+02;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 633 UGGAAGAGAACUGGCGCU 651
 Db 19 TGGAAAGAGAACTGTGCTT 1
 RESULT 169
 ID ADM27856/c
 XX ADM27856 standard; RNA; 19 BP.
 AC ADM27856;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #153.
 XX
 AC gene expression; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 XX
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00448553.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 XX
 PA (Rich/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.

XX
 PI Richards I, Mcswiggen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 135; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 SQ Sequence 19 BP; 2 A; 5 C; 7 G; 0 T; 5 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.6e+02;
 Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 957 CUGAAACCCAGCUCGAG 975
 Db 19 CTGGAACCCAGCTCCGAG 1
 RESULT 170
 ID ADM27868/c
 XX ADM27868 standard; RNA; 19 BP.
 AC ADM27868;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #165.
 XX
 AC gene expression; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00448553.

CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nucleases. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 6 A; 4 C; 5 G; 0 T; 4 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.6e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 111 CCGCAGCUNACAAUGUUCU 129
Db 19 CCGCAGCTACATCTTCT 1
RESULT 167
ADW27815/c
ID ADW27815 standard; RNA; 19 BP.
XX
AC ADW27815;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #112.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
XX
OS Synthetic.
XX
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-0044853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX
PI Richards I, Mcswigen J;
XX
XX
DR WPI; 2005-090672/10.
XX
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
PS Disclosure; SEQ ID NO 112; 84bp; English.
XX
XX
CT The invention relates to a chemically synthesized double stranded short

CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (II) has increased resistance
CC towards nucleases. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 4 A; 5 C; 7 G; 0 T; 3 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.6e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 219 CUUACGGCAUCCUGCC 237
Db 19 CTTACGGGCACTCTGACC 1
RESULT 168
ADW27838/c
ID ADW27838 standard; RNA; 19 BP.
XX
AC ADW27838;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #135.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
XX
OS Synthetic.
XX
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-0044853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX
PI Richards I, Mcswigen J;
XX
XX
DR WPI; 2005-090672/10.
XX
XX
PT Novel chemically synthesized double stranded short interfering nucleic

OY 1551 UGACAGCUGCAUACCCAAA 1569
 |||||
 DB 1 UGACAGCUGCAUACCCAAA 19

RESULT 165
 ADM27804/C
 ID ADM27804 standard; RNA; 19 BP.
 XX ADM27804;
 AC
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #101.
 XX
 XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KM neotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KM incontinence; ss.
 XX
 XX Synthetic.
 OS
 XX US2005014172-A1.
 XX PN
 PD 20-JAN-2005.
 XX
 XX 11-MAR-2004; 2004US-00798090.
 PF
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 30-APR-2003; 2003WO-US005346.
 PR 20-MAY-2003; 2003US-0042716P.
 PR 23-MAY-2003; 2003US-0044853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 XX (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 XX Richards I, Mcswigen J;
 XX
 XX WPI; 2005-090672/10.
 DR
 XX
 XX Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 101; 84pp; English.
 XX
 XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX

SQ Sequence 19 BP; 8 A; 2 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 57.9%; Pred. No. 1.6e+02;
 Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

OY 21 UACAACCCUGCCUUGUUU 39
 |||||
 DB 19 TACAACCTCGCCTTGT 1

RESULT 166
 ADM27809/C
 ID ADM27809 standard; RNA; 19 BP.
 XX ADM27809;
 AC
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #106.
 XX
 XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KM neotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KM incontinence; ss.
 XX
 XX Synthetic.
 OS
 XX US2005014172-A1.
 XX PN
 PD 20-JAN-2005.
 XX
 XX 11-MAR-2004; 2004US-00798090.
 PF
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 30-APR-2003; 2003WO-US005346.
 PR 20-MAY-2003; 2003US-0042716P.
 PR 23-MAY-2003; 2003US-0044853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 XX (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 XX Richards I, Mcswigen J;
 XX
 XX WPI; 2005-090672/10.
 DR
 XX
 XX Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 106; 84pp; English.
 XX
 XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary

XX Cholinergic receptor muscarinic 3 gene targeted siRNA #75.
DE gene expression; antisthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX Synthetic.
XX OS
XX PN US2005014172-A1.
XX PD 20-JAN-2005.
XX PF 11-MAR-2004; 2004US-00798090.
XX PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 30-FEB-2003; 2003WO-US005346.
PR 20-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-0044853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX PI Richards I, Mcswiggen J;
XX DR WPI; 2005-090672/10.
XX PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX PS Disclosure; SEQ ID NO 75; 84pp; English.
XX CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX SQ Sequence 19 BP; 5 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1335 CUACUGGUGUAGACAGC 1353
DB 1 CUACUGGUGUAGACAGC 19
RESULT 164

ADW27790
ID ADW27790 standard; RNA; 19 BP.
XX AC ADW27790;
XX DT 07-APR-2005 (first entry)
XX DE Cholinergic receptor muscarinic 3 gene targeted siRNA #87.
XX KW gene expression; antisthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX Synthetic.
XX OS
XX PN US2005014172-A1.
XX PD 20-JAN-2005.
XX PF 11-MAR-2004; 2004US-00798090.
XX PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 30-FEB-2003; 2003WO-US005346.
PR 20-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-0044853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX PI Richards I, Mcswiggen J;
XX DR WPI; 2005-090672/10.
XX PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX PS Disclosure; SEQ ID NO 87; 84pp; English.
XX CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX SQ Sequence 19 BP; 7 A; 6 C; 3 G; 0 T; 3 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX US2005014172-A1.
 XX
 XX 20-JAN-2005.
 XX
 XX 11-MAR-2004; 2004US-00798090.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 XX 11-MAR-2002; 2002US-0363124P.
 XX 20-MAY-2002; 2002WO-US015876.
 XX 06-JUN-2002; 2002US-0386782P.
 XX 29-AUG-2002; 2002US-0406784P.
 XX 05-SEP-2002; 2002US-0408378P.
 XX 09-SEP-2002; 2002US-0409293P.
 XX 15-JAN-2003; 2003US-0440129P.
 XX 20-FEB-2003; 2003WO-US005028.
 XX 20-FEB-2003; 2003WO-US005346.
 XX 30-APR-2003; 2003US-00427160.
 XX 23-MAY-2003; 2003US-00444853.
 XX 23-OCT-2003; 2003US-00693059.
 XX 24-NOV-2003; 2003US-00720448.
 XX 14-JAN-2004; 2004US-00757803.
 XX
 XX (RICH/) RICHARDS I.
 XX (MCSW/) MCSWIGGEN J.
 XX
 XX Richards I, Mcswigen J;
 XX
 XX WPI; 2005-090672/10.
 XX
 XX Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.
 XX
 XX Disclosure; SEQ ID NO 56; 84bp; English.
 XX
 XX The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.
 XX
 XX Sequence 19 BP; 5 A; 4 C; 7 G; 0 T; 3 U; 0 Other;
 XX
 XX Query Match 1.1%; Score 19; DB 1; Length 19;
 XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 XX QY 993 CAGCAGCAGUGACAGUGG 1011
 XX ||||||||||||||||
 XX 1 CAGCAGCAGUGACAGUGG 19
 XX
 XX RESULT 162
 XX ADM27771
 XX ID ADM27771 standard; RNA; 19 BP.
 XX
 XX ADM27771;
 XX
 XX 07-APR-2005 (first entry)
 XX
 XX Cholinergic receptor muscarinic 3 gene targeted siRNA #68.
 XX
 XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;

KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 KW incontinence; ss.
 XX
 XX Synthetic.
 XX
 XX OS
 XX
 XX PN US2005014172-A1.
 XX
 XX PD 20-JAN-2005.
 XX
 XX 11-MAR-2004; 2004US-00798090.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 XX 11-MAR-2002; 2002US-0363124P.
 XX 20-MAY-2002; 2002WO-US015876.
 XX 06-JUN-2002; 2002US-0386782P.
 XX 29-AUG-2002; 2002US-0406784P.
 XX 05-SEP-2002; 2002US-0408378P.
 XX 09-SEP-2002; 2002US-0409293P.
 XX 15-JAN-2003; 2003US-0440129P.
 XX 20-FEB-2003; 2003WO-US005028.
 XX 20-FEB-2003; 2003WO-US005346.
 XX 30-APR-2003; 2003US-00427160.
 XX 23-MAY-2003; 2003US-00444853.
 XX 23-OCT-2003; 2003US-00693059.
 XX 24-NOV-2003; 2003US-00720448.
 XX 14-JAN-2004; 2004US-00757803.
 XX
 XX (RICH/) RICHARDS I.
 XX (MCSW/) MCSWIGGEN J.
 XX
 XX Richards I, Mcswigen J;
 XX
 XX WPI; 2005-090672/10.
 XX
 XX Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.
 XX
 XX Disclosure; SEQ ID NO 68; 84bp; English.
 XX
 XX The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.
 XX
 XX Sequence 19 BP; 7 A; 5 C; 6 G; 0 T; 1 U; 0 Other;
 XX
 XX Query Match 1.1%; Score 19; DB 1; Length 19;
 XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 XX QY 1209 GAAAGCCGACAGCUCAG 1227
 XX ||||||||||||||||
 XX 1 GAAAGCCGACAGCUCAG 19
 XX
 XX RESULT 163
 XX ADM27778
 XX ID ADM27778 standard; RNA; 19 BP.
 XX
 XX ADM27778;
 XX
 XX 07-APR-2005 (first entry)

PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX WPI; 2005-090672/10.
XX
DR Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 35; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 3 A; 3 C; 4 G; 0 T; 9 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 615 GUUCUGGCAUACUUGU 633
DB 1 GUUCUGGCAUACUUGU 19
XX
RESULT 160
ID ADM27752 standard; RNA; 19 BP.
XX
AC ADM27752;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #49.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
XX OS
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX

XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX WPI; 2005-090672/10.
XX
DR Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 49; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP; 5 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 867 CUGCAGCAGUACGAACTU 885
DB 1 CUGCAGCAGUACGAACTU 19
XX
RESULT 161
ID ADM27759 standard; RNA; 19 BP.
XX
AC ADM27759;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #56.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
XX OS
XX

PA (MCSW/) MCSWIGGEN J.
 XX
 XX Richards I, Mcswigen J;
 PI
 XX WPI; 2005-090672/10.
 DR
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 PS
 XX Disclosure; SEQ ID NO 2; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC is produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 CC
 SQ Sequence 19 BP; 3 A; 6 C; 2 G; 0 T; 8 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 21 UACAACTCCGCGCCUUCUU 39
 Db 1 UACAACTCCGCGCCUUCUU 19
 RESULT 158
 ADM27708
 ID ADM27708 standard; RNA; 19 BP.
 XX
 AC ADM27708;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DS Cholinergic receptor muscarinic 3 gene targeted siRNA #5.
 XX
 XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 XX neurotropic; uteropathic; short interfering RNA; RNA interference; siRNA;
 XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 XX hypertension; emphysema; irritable bowel syndrome; Alzheimer disease;
 XX incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.

PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 XX (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 XX Richards I, Mcswigen J;
 PI
 XX WPI; 2005-090672/10.
 DR
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 PS
 XX Disclosure; SEQ ID NO 5; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC is produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 CC
 SQ Sequence 19 BP; 2 A; 8 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 75 CGAUGCAGGCGCGCCCCG 93
 Db 1 CGAUGCAGGCGCGCCCCG 19
 RESULT 159
 ADM27738
 ID ADM27738 standard; RNA; 19 BP.
 XX
 AC ADM27738;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DS Cholinergic receptor muscarinic 3 gene targeted siRNA #35.
 XX
 XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 XX neurotropic; uteropathic; short interfering RNA; RNA interference; siRNA;
 XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 XX hypertension; emphysema; irritable bowel syndrome; Alzheimer disease;
 XX incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.

CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.

SO Sequence 19 BP; 7 A; 3 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 1.6e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 723 UAUCCUGUACCAUUAUG 741

Db 19 TAGCCTGTACCACTTATG 1

RESULT 156
ADW27893/C
ID ADW27893 standard; RNA; 19 BP.

XX ADW27893;

DT 07-APR-2005 (first entry)

XX Cholinergic receptor muscarinic 3 gene targeted siRNA #190.

KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.

XX Synthetic.

OS US2005014172-A1.

PN 20-JAN-2005.

PD 11-MAR-2004; 2004US-00798090.

PF 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

PR 20-FEB-2003; 2003WO-US005028.

PR 30-APR-2003; 2003US-00427160.

PR 23-MAY-2003; 2003US-00444853.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 14-JAN-2004; 2004US-00757803.

XX (RICH/) RICHARDS I.

PA (MCSW/) MCSWIGEN J.

XX Richards I, Mcswigen J;

PI WPI, 2005-090672/10.

DR XX

PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.

PS Disclosure; SEQ ID NO 190; 84pp; English.

XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.

SO Sequence 19 BP; 7 A; 6 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 1.6e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1623 CGUGUGUANGCUGUGGC 1641

Db 19 CGUGUGUANGCUGUGGC 1

RESULT 157
ADW27705
ID ADW27705 standard; RNA; 19 BP.

XX ADW27705;

DT 07-APR-2005 (first entry)

XX Cholinergic receptor muscarinic 3 gene targeted siRNA #2.

KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.

XX Synthetic.

OS US2005014172-A1.

PN 20-JAN-2005.

PD 11-MAR-2004; 2004US-00798090.

PF 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

PR 20-FEB-2003; 2003WO-US005028.

PR 30-APR-2003; 2003US-00427160.

PR 23-MAY-2003; 2003US-00444853.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 14-JAN-2004; 2004US-00757803.

XX (RICH/) RICHARDS I.

XX Sequence 19 BP, 9 A, 4 C, 3 G, 0 T, 3 U, 0 Other;
SQ Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 1.6e+02;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;
QY 615 GUUCUGGCAUACUUCUU 633
|:::|||||:|:::|
DB 19 GTTCTGGCAATCTTGT 1

RESULT 154
ADM27842/C
ID ADM27842 standard; RNA; 19 BP.
XX ADM27842;
AC
XX
DT 07-APR-2005 (first entry)
XX

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #139.
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
XX incontinence; ss.
XX
XX Synthetic.
XX OS
XX PN US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 30-APR-2003; 2003US-0042716P.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-0069305P.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 139; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic

XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nucleases. Double stranded short interfering nucleic acid molecule
XX CC was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 19 BP, 8 A, 3 C, 5 G, 0 T, 3 U, 0 Other;
QY Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 1.6e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
QY 705 AGCCAUUGCGUUCUUUUAU 723
|:::|||||:|:::|
DB 19 AGCCATCGCTGCTTTTAT 1

RESULT 155
ADM27843/C
ID ADM27843 standard; RNA; 19 BP.
XX ADM27843;
AC
XX
DT 07-APR-2005 (first entry)
XX

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #140.
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
XX incontinence; ss.
XX
XX Synthetic.
XX OS
XX PN US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 30-APR-2003; 2003US-0042716P.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-0069305P.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 140; 84pp; English.
XX

[illegible]

PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 PI Richards I, Mcswiggen J;
 DR WPI; 2005-090672/10.
 PT Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 PS Disclosure; SEQ ID NO 61; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 19 BP; 5 A; 7 C; 3 G; 0 T; 4 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1083 GAGAGCCAUCCUACCAUC 1101
 DB 1 GAGAGCCAUCCUACCAUC 19
 RESULT 147
 ADM27768
 ID ADM27768 standard; RNA; 19 BP.
 AC ADM27768;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #65.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 KW incontinence; ss.
 KW
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 30-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 PI Richards I, Mcswiggen J;
 DR WPI; 2005-090672/10.
 PT Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 PS Disclosure; SEQ ID NO 65; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 19 BP; 5 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1155 AUCGACACCCUGCAGGUG 1173
 DB 1 AUCGACACCCUGCAGGUG 19
 RESULT 148
 ADM27775
 ID ADM27775 standard; RNA; 19 BP.
 AC ADM27775;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #72.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
 KW incontinence; ss.
 KW
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.

XX

PR 20-FEB-2003; 2003WO-US005346.

CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
SQ Sequence 23 BP, 5 A; 7 C; 2 G; 2 T; 5 U; 2 Other;

Query Match 1.1%; Score 19.4; DB 1; Length 23;
Best Local Similarity 90.5%; Pred. No. 2.1e+02;
Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 17 ACAGUACACCCUCCUUGU 37
|||||
DB 2 ACAGUACACCCUCCUUT 22

RESULT 143

ADM27931
ID ADM27931 standard; RNA; 23 BP.

AC ADM27931;

DT 07-APR-2005 (first entry)

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #228.

XX gene expression; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nontropic; uteropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
XX incontinence; ss.

OS Synthetic.

XX Key Location/Qualifiers
XX misc_difference 22.23
XX FT /tag= a
XX FT /note= "deoxythymidine nucleotide"

XX PN US2005014172-A1.

XX PD 20-JAN-2005.

XX PF 11-MAR-2004; 2004US-00798090.

XX PR 20-FEB-2002; 2002US-0358580P.

XX PR 11-MAR-2002; 2002US-0363124P.

XX PR 20-MAY-2002; 2002WO-US015876.

XX PR 06-JUN-2002; 2002US-0386782P.

XX PR 29-AUG-2002; 2002US-0406784P.

XX PR 05-SEP-2002; 2002US-0408378P.

XX PR 09-SEP-2002; 2002US-0409293P.

XX PR 15-JAN-2003; 2003US-0440129P.

XX PR 20-FEB-2003; 2003WO-US005028.

XX PR 20-FEB-2003; 2003WO-US005346.

XX PR 30-APR-2003; 2003US-00427160.

XX PR 23-MAY-2003; 2003US-00444853.

XX PR 23-OCT-2003; 2003US-00693059.

XX PR 24-NOV-2003; 2003US-00720448.

XX PR 14-JAN-2004; 2004US-00757803.

XX PA (RICH/) RICHARDS I.
XX PA (MCSW/) MCSWIGGEN J.
XX PI Richards I, Mcswiggen J;
XX DR MPI; 2005-090672/10.

PT Novel, chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX Disclosure; SEQ ID NO 228; 84pp; English.

XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference.
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.

SQ Sequence 23 BP, 8 A; 5 C; 5 G; 2 T; 1 U; 2 Other;
Query Match 1.1%; Score 19.4; DB 1; Length 23;
Best Local Similarity 90.5%; Pred. No. 2.1e+02;
Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1712 ACAGUACACGAGAGACAGU 1732
|||||
DB 2 ACAGUACACGAGAGACATT 22

RESULT 144

ADM27718
ID ADM27718 standard; RNA; 19 BP.

AC ADM27718;

DT 07-APR-2005 (first entry)

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #15.

XX gene expression; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nontropic; uteropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
XX incontinence; ss.

OS Synthetic.

XX PN US2005014172-A1.

XX PD 20-JAN-2005.

XX PF 11-MAR-2004; 2004US-00798090.

XX PR 20-FEB-2002; 2002US-0358580P.

XX PR 11-MAR-2002; 2002WO-US015876.

XX PR 06-JUN-2002; 2002US-0386782P.

XX PR 29-AUG-2002; 2002US-0406784P.

XX PR 05-SEP-2002; 2002US-0408378P.

XX PR 09-SEP-2002; 2002US-0409293P.

XX PR 15-JAN-2003; 2003US-0440129P.

XX PR 20-FEB-2003; 2003WO-US005028.

XX PR 20-FEB-2003; 2003WO-US005346.

XX PR 30-APR-2003; 2003US-00427160.

XX PR 23-MAY-2003; 2003US-00444853.

XX PR 23-OCT-2003; 2003US-00693059.

XX PR 24-NOV-2003; 2003US-00720448.

XX PA (RICH/) RICHARDS I.
XX PA (MCSW/) MCSWIGGEN J.
XX PI Richards I, Mcswiggen J;
XX DR MPI; 2005-090672/10.

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #271.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
OS
XX
XX
XX Key Location/Qualifiers
FH misc_difference 22..23
FT /tag= a
FT /note= "deoxythymidine nucleotide"
PN US2005014172-A1.
XX
XX 20-JAN-2005.
PD
XX
XX 11-MAR-2004; 2004US-00798090.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX
XX Richards I, Mcswigen J;
PI WPI; 2005-090672/10.
XX
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX
XX Disclosure; SEQ ID NO 271; 84bp; English.
PS
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX
XX Sequence 23 BP; 5 A; 7 C; 2 G; 2 T; 5 U; 2 Other;
SQ
Query Match 1.1%; Score 19.4; DB 1; Length 23;
Best Local Similarity 90.5%; Pred. No. 2.1e+02;
Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

17 ACAGUACAACUCCUUGU 37
|||||||

DB 2 ACAGUACAACUCCUUGU 22
RESULT 142
ADW27958
ID ADW27958 standard; RNA; 23 BP.
XX
XX ADW27958;
AC
XX
XX 07-APR-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #255.
DE
XX
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
OS
XX
XX
XX Key Location/Qualifiers
FH misc_difference 22..23
FT /tag= a
FT /note= "deoxythymidine nucleotide"
PN US2005014172-A1.
XX
XX 20-JAN-2005.
PD
XX
XX 11-MAR-2004; 2004US-00798090.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX
XX Richards I, Mcswigen J;
PI WPI; 2005-090672/10.
XX
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX
XX Disclosure; SEQ ID NO 255; 84bp; English.
PS
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule

XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswigen J;
XX WPI; 2005-090672/10.
DR
XX
XX
PT Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.
PT
XX
XX
PS Disclosure; SEQ ID NO 244; 84pp; English.
XX
XX
CC The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule CC was produced by solid phase oligonucleotide synthesis method. This CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 23 BP; 8 A; 5 C; 5 G; 2 T; 1 U; 2 Other;
XX
Query Match 1.1%; Score 19.4; DB 1; Length 23;
Best Local Similarity 90.5%; Pred. No. 2.1e+02;
Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1712 AGCAGUACCGACGACGACAGU 1732
DB 2 AGCAGUACCGACGACGACATT 22
RESULT 140
ADM27979
ID ADM27979 standard; RNA; 23 BP.
XX
XX ADM27979;
AC
XX
DT 07-APR-2005 (first entry)
XX
DB Cholinergic receptor muscarinic 3 gene targeted siRNA #276.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.; respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective; KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA; KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis; KM inflammation; allergy; cystic fibrosis; pulmonary vasconstriction; KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease; KM incontinence; ss.
XX
OS Synthetic.

XX
FH Key Location/Qualifiers
FT msc_difference 22.23
FT /tag=a
FT /note="deoxythymidine nucleotide"
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
DR
XX
XX
XX Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.
XX
XX
XX
PS Disclosure; SEQ ID NO 276; 84pp; English.
XX
XX
XX The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule CC was produced by solid phase oligonucleotide synthesis method. This CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 23 BP; 8 A; 5 C; 5 G; 2 T; 1 U; 2 Other;
XX
Query Match 1.1%; Score 19.4; DB 1; Length 23;
Best Local Similarity 90.5%; Pred. No. 2.1e+02;
Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1712 AGCAGUACCGACGACGACAGU 1732
DB 2 AGCAGUACCGACGACGACATT 22
RESULT 141
ADM27974
ID ADM27974 standard; RNA; 23 BP.
XX
XX ADM27974;
AC
XX
DT 07-APR-2005 (first entry)
XX

DR WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 239; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (II) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (II) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 23 BP; 5 A; 7 C; 2 G; 2 T; 5 U; 2 Other;
XX
Query Match 1.1%; Score 19.4; DB 1; Length 23;
Best Local Similarity 90.5%; Pred. No. 2.1e+02;
Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 17 ACAGUACAACUCCGCUUUGU 37
Db 2 ACAGUACAACUCCGCUUUT 22
RESULT 138
ADM27963
XX ADM27963 standard; RNA; 23 BP.
XX
AC ADM27963;
XX
DT 07-APR-2005 (first entry)
XX
DB Cholinergic receptor muscarinic 3 gene targeted siRNA #260.
XX
KM gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
XX Synthetic.
OS
XX
FH Key Location/Qualifiers
FT misc_difference 22..23
FT /*tag= a
FT /note= "deoxythymidine nucleotide"
FT
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX
XX 11-MAR-2002; 2002US-0363124P.
XX
XX 20-MAY-2002; 2002US-0361587P.
XX
XX 06-JUN-2002; 2002US-0386782P.
XX
XX 29-AUG-2002; 2002US-0406784P.
XX
XX 05-SEP-2002; 2002US-0408378P.
XX
XX 09-SEP-2002; 2002US-0409293P.
XX
XX 15-JAN-2003; 2003US-0440129P.
XX
XX 20-FEB-2003; 2003US-0500502P.
XX
XX 20-FEB-2003; 2003US-0500534P.
XX
XX

PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSM/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 260; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (II) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (II) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 23 BP; 8 A; 5 C; 5 G; 2 T; 1 U; 2 Other;
XX
Query Match 1.1%; Score 19.4; DB 1; Length 23;
Best Local Similarity 90.5%; Pred. No. 2.1e+02;
Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1712 AGCAGUACGACGAGACAGU 1732
Db 2 AGCAGUACGACGAGACACTT 22
RESULT 139
ADM27947
XX ADM27947 standard; RNA; 23 BP.
XX
AC ADM27947;
XX
DT 07-APR-2005 (first entry)
XX
DB Cholinergic receptor muscarinic 3 gene targeted siRNA #244.
XX
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
OS
XX
FH Key Location/Qualifiers
FT misc_difference 22..23
FT /*tag= a
FT /note= "deoxythymidine nucleotide"
FT
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX

Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.7e+02;
Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
1712 AGCAGUACGACGAGACAGU 1732
1 AGCAGUACGACGAGACATT 21
Db

RESULT 136
ADM27926
ID ADM27926 strand; RNA; 23 BP.
AC ADM27926;
XX
XX 07-APR-2005 (first entry)
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #223.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nocotropic; uteropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH misc_difference 22..23
FT /*tag= a
FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
PD
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
PI
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure, SEQ ID NO 223; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,

CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 23 BP; 5 A; 7 C; 2 G; 2 T; 5 U; 2 Other;
SQ

Query Match 1.1%; Score 19.4; DB 1; Length 23;
Best Local Similarity 90.5%; Pred. No. 2.1e+02;
Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
17 ACAGUACAACUCCUCCUUGU 37
2 ACAGUACAACUCCUCCUUT 22
Db

RESULT 137
ADM27942
ID ADM27942 strand; RNA; 23 BP.
XX
XX ADM27942;
AC
XX
XX 07-APR-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #239.
DE
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nocotropic; uteropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH misc_difference 22..23
FT /*tag= a
FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
PD
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
PI
XX

CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 5 A; 7 C; 2 G; 2 T; 5 U; 0 Other;
Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.7e+02;
Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 17 ACAGUACAACCTCGCCUUTU 37
DB 1 ACAGUACAACCTCGCCUUTT 21
RESULT 134
AEA02332/c
ID AEA02332 standard; RNA; 21 BP.
XX
AC AEA02332;
XX
DT 28-JUL-2005 (first entry)
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 216.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 216; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX
SQ Sequence 21 BP; 8 A; 2 C; 6 G; 2 T; 3 U; 0 Other;
Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 1.7e+02;
Matches 12; Conservative 8; Mismatches 1; Indels 0; Gaps 0;
QY 19 AGUACAACCTCGCCUUTUU 39
DB 21 AATACACCTCGCCTTGT 1
RESULT 135
AEA02392
ID AEA02392 standard; RNA; 21 BP.
XX
AC AEA02392;
XX
DT 28-JUL-2005 (first entry)
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 276.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 276; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 8 A; 5 C; 5 G; 2 T; 1 U; 0 Other;

(RNAi). The siNA molecule, compounds, compositions, and methods are useful for treating or preventing respiratory and pulmonary diseases, disorders, and/or conditions, including chronic obstructive pulmonary disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies, cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX Sequence 21 BP; 8 A; 2 C; 6 G; 2 T; 3 U; 0 Other;

Query Match 1.1%; Score 19.4; DB 1; Length 21;

Best Local Similarity 57.1%; Pred. No. 1.7e+02;

Matches 12; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

OY 19 AGUACACCCUCCGCUUUGUU 39

DB 21 AATACACCTCGCCTTGT 1

RESULT 132

AE02385/C ID AE02385 standard; RNA; 21 BP.

XX AE02385;

XX 28-JUL-2005 (first entry)

XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 269.

XX Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;

XX Neuroprotective; Nootropic; Uropathic;

XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;

XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;

XX mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;

XX siRNA; RNA interference; gene silencing; short interfering RNA.

XX Synthetic.

XX WO2005045040-A2.

XX 19-MAY-2005.

XX 20-AUG-2004; 2004WO-US027367.

XX 23-OCT-2003; 2003US-00693059.

XX 24-NOV-2003; 2003US-00720448.

XX 03-DEC-2003; 2003US-00727780.

XX 14-JAN-2004; 2004US-00757803.

XX 10-FEB-2004; 2004US-0543480P.

XX 13-FEB-2004; 2004US-00780447.

XX 11-MAR-2004; 2004US-00798090.

XX 16-APR-2004; 2004US-00826966.

XX 30-APR-2004; 2004WO-US013456.

XX 24-MAY-2004; 2004WO-US016390.

XX 17-AUG-2004; 2004US-00919866.

XX (SIRN-) SIRNA THERAPEUTICS INC.

XX Richards I, Macswigen J;

XX WPI; 2005-356237/36.

XX New short interfering nucleic acid molecule that directs cleavage of a

XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing

XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary

XX disease.

XX Claim 33; SEQ ID NO 269; 184pp; English.

XX The invention relates to a chemically synthesized double stranded short

XX interfering nucleic acid (siNA) molecule that directs cleavage of a

XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference

XX (RNAi). The siNA molecule, compounds, compositions, and methods are

XX useful for treating or preventing respiratory and pulmonary diseases,

CC disorders, and/or conditions, including chronic obstructive pulmonary

CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,

CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The

CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;

Query Match 1.1%; Score 19.4; DB 1; Length 21;

Best Local Similarity 85.7%; Pred. No. 1.7e+02;

Matches 18; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 1712 AGCAGUACCGAGAGACAGU 1732

DB 21 AACGTACCGACGAGACAGT 1

RESULT 133

AE02323 ID AE02323 standard; RNA; 21 BP.

XX AE02323;

XX 28-JUL-2005 (first entry)

XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 207.

XX Respiratory-Gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;

XX Neuroprotective; Nootropic; Uropathic;

XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;

XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;

XX mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;

XX siRNA; RNA interference; gene silencing; short interfering RNA.

XX Synthetic.

XX WO2005045040-A2.

XX 19-MAY-2005.

XX 20-AUG-2004; 2004WO-US027367.

XX 23-OCT-2003; 2003US-00693059.

XX 24-NOV-2003; 2003US-00720448.

XX 03-DEC-2003; 2003US-00727780.

XX 14-JAN-2004; 2004US-00757803.

XX 10-FEB-2004; 2004US-0543480P.

XX 13-FEB-2004; 2004US-00780447.

XX 11-MAR-2004; 2004US-00798090.

XX 16-APR-2004; 2004US-00826966.

XX 30-APR-2004; 2004WO-US013456.

XX 24-MAY-2004; 2004WO-US016390.

XX 17-AUG-2004; 2004US-00919866.

XX (SIRN-) SIRNA THERAPEUTICS INC.

XX Richards I, Macswigen J;

XX WPI; 2005-356237/36.

XX New short interfering nucleic acid molecule that directs cleavage of a

XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing

XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary

XX disease.

XX Claim 33; SEQ ID NO 207; 184pp; English.

XX The invention relates to a chemically synthesized double stranded short

XX interfering nucleic acid (siNA) molecule that directs cleavage of a

XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference

XX (RNAi). The siNA molecule, compounds, compositions, and methods are

XX useful for treating or preventing respiratory and pulmonary diseases,

XX asthma, allergic rhinitis, sinusitis, inflammation, allergies,

XX disease, and/or conditions, including chronic obstructive pulmonary

XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,

XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorder, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 8 A; 5 C; 5 G; 2 T; 1 U; 0 Other;
Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.7e+02;
Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1712 AGCAGUACGACGACAGACAGU 1732
DB 1 AGCAGUACGACGACAGACATT 21
RESULT 130
ID AEA02364/c
XX AEA02364 standard; RNA; 21 BP.
AC
XX AEA02364;
DT 28-JUL-2005 (first entry)
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 248.
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 248.
XX
XX Respiratory-Gen.; Antihistaminic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mucritution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
XX WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswigen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 248; 184pp, English.
XX
XX The invention relates to a chemically synthesized double stranded short

CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorder, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 8 A; 2 C; 6 G; 2 T; 3 U; 0 Other;
Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 1.7e+02;
Matches 12; Conservative 8; Mismatches 1; Indels 0; Gaps 0;
QY 19 AGUACACUCCUCCUUGUUU 39
DB 21 AATACAACTCGCCTTGT 1
RESULT 131
ID AEA02404/c
XX AEA02404 standard; RNA; 21 BP.
AC
XX AEA02404;
DT 28-JUL-2005 (first entry)
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 288.
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 288.
XX
XX Respiratory-Gen.; Antihistaminic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mucritution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
XX WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswigen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 288; 184pp, English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference

Query Match	1.1%	Score 19.4	DB 1	Length 21
Best Local Similarity	85.7%	Pred. No. 1.7e+02		
Matches 18	Conservative 2	Mismatches 1	Indels 0	Gaps 0
Db	1712 AGCAGUACCGACGACGACGU 1732			
	21 AACAGTACGACGACGACGACGT 1			
RESULT 128				
AEA02353/c				
ID	AEA02353 standard; RNA; 21 BP.			
XX	AEA02353;			
AC				
DT	28-JUL-2005 (first entry)			
XX				
DE	Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 237.			
KW	Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;			
KW	Neuroprotective; Nootropic; Uropathic;			
KW	chronic obstructive pulmonary disease; asthma; allergic rhinitis;			
KW	sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;			
KW	micturition disorder; cholinergic receptor muscarinic 3; CHRM3; se;			
KW	siRNA; RNA interference; gene silencing; short interfering RNA.			
OS	Synthetic.			
XX				
PN	WO2005045040-A2.			
XX				
PD	19-MAY-2005.			
XX				
PF	20-AUG-2004; 2004WO-US027367.			
XX				
PR	23-OCT-2003; 2003US-00693059.			
PR	24-NOV-2003; 2003US-00720448.			
PR	03-DEC-2003; 2003US-00727780.			
PR	14-JAN-2004; 2004US-00757803.			
PR	10-FEB-2004; 2004US-0543480P.			
PR	13-FEB-2004; 2004US-00780447.			
PR	11-MAR-2004; 2004US-00798090.			
PR	16-APR-2004; 2004US-00826966.			
PR	30-APR-2004; 2004WO-US013456.			
PR	24-MAY-2004; 2004WO-US016390.			
PR	17-AUG-2004; 2004US-00919866.			
PA	(SIRN-) SIRNA THERAPEUTICS INC.			
XX				
PI	Richards I, Macawigsen J;			
XX				
DR	WPI, 2005-356237/36.			
XX				
XX				
PT	New short interfering nucleic acid molecule that directs cleavage of a			
PT	cholinergic receptor muscarinic 3 RNA, useful for treating or preventing			
PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary			
PT	disease.			

PS	Claim 33; SEQ ID NO 237; 184pp; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siNA) molecule that directs cleavage of a
CC	cholenergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC	(RNAi). The siNA molecule, compounds, compositions, and methods are
CC	useful for treating or preventing respiratory and pulmonary diseases,
CC	disorders, and/or conditions, including chronic obstructive pulmonary
CC	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC	present sequence represents a cholenergic receptor muscarinic 3 siRNA.
XX	
SQ	Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
OY	
Dd	1712 AGCAGUACGACGACAGACAGU 1732 : 21 AACGTATCGACGACGACAGT 1
RESULT 129	
AEA02376	
ID	AEA02376 standard; RNA; 21 BP.
XX	
AC	AEA02376;
DX	
DT	28-JUN-2005 (first entry)
DE	Cholenergic receptor muscarinic 3 siRNA SEQ ID NO 260.
XX	
KW	Respiratory-gen.; Antiasthmatic; Anti-allergic; Anti-inflammatory;
KM	Neuroprotective; Nootropic; Uropeptic;
KM	chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW	sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW	mucritution disorder; cholenergic receptor muscarinic 3; CHRM3; ss;
KW	siRNA; RNA interference; gene silencing; short interfering RNA.
XX	
OS	Synthetic.
XX	
FN	WO2005045040-A2.
XX	
PD	19-MAY-2005.
XX	
PF	20-AUG-2004; 2004WO-US027367.
XX	
PR	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00720448.
PR	03-DEC-2003; 2003US-00727780.
PR	14-JAN-2004; 2004US-00757803.
PR	10-FEB-2004; 2004US-0543480P.
PR	13-FEB-2004; 2004US-00780447.
PR	11-MAR-2004; 2004US-00798090.
PR	16-APR-2004; 2004US-00826966.
PR	30-APR-2004; 2004WO-US013456.
PR	24-MAY-2004; 2004WO-US016390.
PR	17-AUG-2004; 2004US-00919866.
XX	
PA	(SIRN-) SIRNA THERAPEUTICS INC.
XX	
PI	Richards I, Macswiggen J;
XX	
WP	WI; 2005-356237/36.
XX	
PT	New short interfering nucleic acid molecule that directs cleavage of a
PT	cholenergic receptor muscarinic 3 RNA, useful for treating or preventing
PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX	disease.
XX	
PS	Claim 33; SEQ ID NO 260; 184pp; English.

DR WPI; 2005-356237/36.
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 271; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 5 A; 7 C; 2 G; 2 T; 5 U; 0 Other;
Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.7e+02;
Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 17 ACAGUACAACCCUGCCUUGU 37
DB 1 ACAGUACAACCCUGCCUUTTT 21
RESULT 126
AEA02412/c
ID AEA02412 standard; RNA; 21 BP.
AC AEA02412;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 296.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
PI Richards I, Macswiggen J;
XX WPI; 2005-356237/36.
XX
DR

PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 296; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 8 A; 2 C; 6 G; 2 T; 3 U; 0 Other;
Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 1.7e+02;
Matches 12; Conservative 8; Mismatches 1; Indels 0; Gaps 0;
QY 19 AGUACAACCCUGCCUUGUU 39
DB 21 AATACAACCTCGCTTGTTT 1
RESULT 127
AEA02337/c
ID AEA02337 standard; RNA; 21 BP.
AC AEA02337;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 221.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
PI Richards I, Macswiggen J;
XX WPI; 2005-356237/36.
XX
DR New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing

PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Richards I, Macswigen J;
 XX WPI; 2005-356237/36.
 DR
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 255; 184bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 CC
 SQ Sequence 21 BP; 5 A; 7 C; 2 G; 2 T; 5 U; 0 Other;
 XX
 QY Query Match 1.1%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 1.7e+02;
 Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 XX
 Db 17 ACAGUACAACCCUCCUUGU 37
 1 ACAGUACAACCCUCCUUTT 21
 |||||
 AEA02417/c
 ID AEA02417 standard; RNA; 21 BP.
 XX
 AC AEA02417;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 301.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
 KW micturition disorder; cholinergic receptor muscarinic 3; CHRM3; 88;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX
 PN WO2005045040-A2.
 XX
 PD 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX

PI Richards I, Macswigen J;
 XX
 XX WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 301; 184bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 CC
 SQ Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
 XX
 QY Query Match 1.1%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.7e+02;
 Matches 18; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 XX
 Db 1712 ACAGUACGACGACGACAGU 1732
 21 AACGTACGACGACGACAGT 1
 |||||
 AEA02387
 ID AEA02387 standard; RNA; 21 BP.
 XX
 AC AEA02387;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 271.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neuroprotective; Nootropic; Uropathic;
 KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
 KW micturition disorder; cholinergic receptor muscarinic 3; CHRM3; 88;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX
 PN WO2005045040-A2.
 XX
 PD 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Richards I, Macswigen J;
 XX

PR	17-AUG-2004; 2004US-00919866.
XX	
PA	(SIRN-) SIRNA THERAPEUTICS INC.
XX	
PI	Richards I, Macawiggen J;
XX	
XX	WPI; 2005-356237/36.
DR	
XX	
PT	New short interfering nucleic acid molecule that directs cleavage of a
PT	cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT	disease.
XX	
XX	
PS	Claim 33; SEQ ID NO 244; 184bp; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (sina) molecule that directs cleavage of a
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC	(RNAi). The sina molecule, compounds, compositions, and methods are
CC	useful for treating or preventing respiratory and pulmonary diseases,
CC	disorders, and/or conditions, including chronic obstructive pulmonary
CC	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC	present sequence represents a cholinergic receptor muscarinic 3 sina.
XX	
SO	Sequence 21 BP; 8 A; 5 C; 5 G; 2 T; 1 U; 0 Other;

Query Match 1.1%, Score 19.4; DB 1; Length 21;

Query Match	1.1%	Score 19.4;	DB 1;	length 21;
Best Local Similarity	90.5%;	Pred. No. 1.7e+02;		
Matches 19; Conservative	1;	Mismatches	1;	Indels 0; Gaps 0;
0y	1712	AGCAGUACCGACAGACAGU	1732	

```

QY      1712 AGCAGUACCGACGAGACAGU 1732
          |||||
Db      1   AGCAGUACCGACGAGACATT 21

```

```
RESULT 123
AEA02371
ID AEA02371 standard, RNA, 21 BP
XX
AC AEA02371;
```

DT	28-JUL-2005	(first entry)
XX		
DE		Cholinergic receptor musca

KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antinf

KM Respiratory-Gen., Antiaesthetic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Utopahic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KM mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA, RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX

PN WO20050450

PD 19-MAY-2005.

20-AUG-2004; 2004WO-US027367.

23-OCT-2003; 2003US-00693059.

PR 03-DEC-2003; 2003US-00727780.

PR 10-FBB-2004; 2004US-0543480P.

11-MAR-2004; 2004US-00798090. PR

PR 30-APR-2004; 2004WO-US013456.

PR 17-AUG-2004; 2004US-00919866.

PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Richards I, Macswiggen J;
 XX
 DR WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 228; 184pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 21 BP; 8 A; 5 C; 5 G; 2 T; 1 U; 0 Other;
 XX
 Query Match 1.1%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 1.7e+02;
 Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1712 AGCAGUACGACGACGACGACG 1732
 Db 1 AGCAGUACGACGACGACGACGACTT 21
 RESULT 118
 ID AEA02401/c
 XX AEA02401 standard; RNA; 21 BP.
 AC
 XX AEA02401;
 DT 28-JUL-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 285.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neutroprotective; Nootropic; Uropathic;
 KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
 KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX
 PN WO2005045040-A2.
 XX
 PD 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Richards I, Macswiggen J;
 XX
 DR WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 285; 184pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
 XX
 Query Match 1.1%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.7e+02;
 Matches 18; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 1712 AGCAGUACGACGACGACGACG 1732
 Db 21 AACAGTACGACGACGACGACGT 1

PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Richards I, Macswiggen J;
 XX
 DR WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 285; 184pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
 XX
 Query Match 1.1%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.7e+02;
 Matches 18; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 1712 AGCAGUACGACGACGACGACG 1732
 Db 21 AACAGTACGACGACGACGACGT 1
 RESULT 119
 ID AEA02409/c
 XX AEA02409 standard; RNA; 21 BP.
 AC
 XX AEA02409;
 DT 28-JUL-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 293.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KW Neutroprotective; Nootropic; Uropathic;
 KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
 KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX
 PN WO2005045040-A2.
 XX
 PD 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Richards I, Macswiggen J;
 XX
 DR WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 285; 184pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
 XX
 Query Match 1.1%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.7e+02;
 Matches 18; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 1712 AGCAGUACGACGACGACGACG 1732
 Db 21 AACAGTACGACGACGACGACGT 1

PD 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Richards I, Macswigen J;
 XX
 DR WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 232; 184bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 21 BP; 8 A; 2 C; 6 G; 2 T; 3 U; 0 Other;
 XX
 Query Match 1.1%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 57.1%; Pred. No. 1.7e+02;
 Matches 12; Conservative 8; Mismatches 1; Indels 0; Gaps 0;
 OY 19 AGUACACCCUGCCUUGUUU 39
 DB 21 AATACACCTCGCCTTGT 1
 RESULT 116
 AEA02355
 ID AEA02355 standard; RNA; 21 BP.
 XX
 AC AEA02355;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 239.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 XX Neuroprotective; Nootropic; Uropathic;
 KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX
 PN WO2005045040-A2.
 XX
 PD 19-MAY-2005.
 XX

PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Richards I, Macswigen J;
 XX
 DR WPI; 2005-356237/36.
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 239; 184bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 21 BP; 5 A; 7 C; 2 G; 2 T; 5 U; 0 Other;
 XX
 Query Match 1.1%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 1.7e+02;
 Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 OY 17 ACAGUACACCCUGCCUUGU 37
 DB 1 ACAGUACACCCUGCCUUT 21
 RESULT 117
 AEA02344
 ID AEA02344 standard; RNA; 21 BP.
 XX
 AC AEA02344;
 XX
 DT 28-JUL-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 228.
 XX
 KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 XX Neuroprotective; Nootropic; Uropathic;
 KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KW siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 OS Synthetic.
 XX
 PN WO2005045040-A2.
 XX
 PD 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX

OS Synthetic.
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswigen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 223; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 21 BP; 5 A; 7 C; 2 G; 2 T; 5 U; 0 Other;
SQ
Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.7e+02;
Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 17 ACAGUACACUCGCGCCUUGU 37
DB 1 ACAGUACACUCGCGCCUUTT 21
RESULT 114
AEA02369/C
ID AEA02369 standard; RNA; 21 BP.
XX
XX AEA02369;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 253.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
KW mucrition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX

PN WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 11-MAR-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswigen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 253; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
SQ
Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1712 AGCAGUACGACGACAGACAGU 1732
DB 21 AACGATACGACGACAGACAGT 1
RESULT 115
AEA02348/C
ID AEA02348 standard; RNA; 21 BP.
XX
XX AEA02348;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 232.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzhemers disease;
KW mucrition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX
XX WO2005045040-A2.
XX
XX

XX 20-JAN-2005.
 PD
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-0044853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 PI
 XX
 PI Richarde I, Mcswigen J;
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 221; 84bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2'-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
 Query Match 1.1%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 1.7e+02;
 Matches 18; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 1712 AGCAGUACCGACGACAGACAGU 1732
 Db | |||:|||||:|||||:
 21 AACGATCCACGACGACAGACGAT 1
 RESULT 112
 AEA02380/c
 ID AEA02380 standard; RNA; 21 BP.
 AC
 XX AEA02380;
 DT 28-JUL-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 264.
 XX
 KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KM Neuroprotective; Nootropic; Uropathic;
 KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 KM mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 XX

KM siRNA; RNA interference; gene silencing; short interfering RNA.
 XX
 XX Synthetic.
 XX
 PN WO2005045040-A2.
 PD
 XX 19-MAY-2005.
 XX
 PF 20-AUG-2004; 2004WO-US027367.
 XX
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 11-MAR-2004; 2004US-00798090.
 PR 16-APR-2004; 2004US-00826966.
 PR 30-APR-2004; 2004WO-US013456.
 PR 24-MAY-2004; 2004WO-US016390.
 PR 17-AUG-2004; 2004US-00919866.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 PA
 PI
 XX
 PI Richarde I, Macswigen J;
 DR WPI; 2005-356237/36.
 XX
 XX
 PT New short interfering nucleic acid molecule that directs cleavage of a
 PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 PT disease.
 XX
 PS Claim 33; SEQ ID NO 264; 184bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
 CC useful for treating or preventing respiratory and pulmonary diseases,
 CC disorders, and/or conditions, including chronic obstructive pulmonary
 CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 XX
 SQ Sequence 21 BP; 8 A; 2 C; 6 G; 2 T; 3 U; 0 Other;
 Query Match 1.1%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 57.1%; Pred. No. 1.7e+02;
 Matches 12; Conservative 8; Mismatches 1; Indels 0; Gaps 0;
 QY 19 AGUACAACCGCCGCUUUGUU 39
 Db | |||:|||||:|||||:
 21 AATACAACCTCGCTTGTGT 1
 RESULT 113
 AEA02339
 ID AEA02339 standard; RNA; 21 BP.
 AC
 XX AEA02339;
 DT 28-JUL-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 223.
 XX
 KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
 KM Neuroprotective; Nootropic; Uropathic;
 KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 KM mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 KM siRNA; RNA interference; gene silencing; short interfering RNA.
 XX

	Pt	PR	09-SEP-2002; 2002US-0409293P.
	Pt	PR	15-JAN-2003; 2003US-0440139P.
	Pt	PR	20-FEB-2003; 2003US-0440128P.
	Pt	PR	20-FEB-2003; 2003WO-US005028P.
	Pt	PR	30-APR-2003; 2003WO-US005346P.
	Pt	PR	23-MAY-2003; 2003US-00427160P.
	Pt	PR	23-OCT-2003; 2003US-00444853P.
	Pt	PR	23-OCT-2003; 2003US-00693059P.
	Pt	PR	24-NOV-2003; 2003US-00720448P.
	Pt	PR	14-JAN-2004; 2004US-00757803P.
	PA	(RICH/) RICHARDS I.	
	PA	(MCSW/) MCSWIGGEN J.	
	PI	Richards I,	Mcswiggen J;
	XX		
	XX		
	XX		
	XX		
	XX		
	XX		
	PS	Disclosure; SEQ ID NO 253; 84bp; English.	
	CC	The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2'-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance toward nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.	
	CC	Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;	
	SQ		
	Query Match	1.1%; Score 19.4; DB 1; Length 21;	
	Best Local Similarity	85.7%; Pred. No. 1.7e+02;	
	Matches 18; Conservative 2; Mismatches 1;	Indels 0; Gaps 0;	
Oy	1712 AGCAGUACGACGACAGCU 1732	:	
Dd	21 AACGGTACCAGACGACT 1		
	RESULT 111		
	ADMW27924/C		
ID	ADMW27924 standard; RNA; 21 BP.		
AC	ADMW27924;		
XX			
XX	07-APR-2005 (first entry)		
DE	Cholinergic receptor muscarinic 3 gene targeted siRNA #221.		
Kw	gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.; respiratory.gen.; hypotensive; gastrointestinal.gen.; neuroprotective; nootropic; uteroblastic; short interfering RNA; RNA interference; siRNA;		
Kw	cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;		
Kw	inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;		
Kw	hyperextension; emphysema; irritable bowel syndrome; Alzheimers disease;		
Kw	incontinence; ss.		
XX			
XX	Synthetic.		
OS			
FH	Key Location/Qualifiers		
FT	misc_difference 20..21		
FT	/tag= a		
FT	/note= "deoxythymidine nucleotide"		
XX			
PN	US2005014172-A1.		

[illegible]

XX	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC	where each strand of (I) has 19-23 nucleotides, and does not require the
CC	presence of nucleotides having a 2-hydroxy group for mediating RNA
CC	interference. (I) is useful for treating diseases e.g., asthma, allergic
CC	rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC	vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC	Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC	towards nuclease. Double stranded short interfering nucleic acid molecule
CC	was produced by solid phase oligonucleotide synthesis method. This
CC	sequence represents an example of a siRNA molecule of the invention.
SQ	Sequence 21 BP; 8 A; 2 C; 6 G; 2 T; 3 U; 0 Other;
Query Match	1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity	57.1%; Pred. No. 1.7e+02;
Matches 12; Conservative 8; Mismatches 1; Indels 0; Gaps 0;	
Gy	19 AGUACAACUCGCGCCUGUGUUU 39
	: : : :::: :
Db	21 AATACAACTCGCCTTGTTT 1
RESULT 109	
ID	ADW27935/C
XX	ADW27935 standard; RNA; 21 BP.
AC	ADW27935;
XX	
DT	07-APR-2005 (first entry)
XX	
DE	Cholinergic receptor muscarinic 3 gene targeted siRNA #32.
XX	
KW	gene expression; antiaesthetic; antiasthmatic; neuroprotective;
KW	respiratory-gen.; hypocoelomic; gastrointestinal-gen.; neuroprotective;
KW	nootropic; uteropathic; short interfering RNA; RNA interference; siRNA;
KW	cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW	inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW	hyperextension; emphysema; irritable bowel syndrome; Alzheimers disease;
KV	incontinence; ss.
XX	
OS	Synthetic.
XX	
FH	Key Location/Qualifiers
FT	misc_difference 20..21
FT	/tag= a
FT	/*tag= "deoxythymidine nucleotide"
XX	
PN	US2005014172-A1.
XX	
PD	20-JAN-2005.
XX	
PF	11-MAR-2004; 2004US-00798090.
PR	20-FEB-2002; 2002US-0358580P.
PR	11-MAR-2002; 2002US-0363124P.
PR	20-MAY-2002; 2002WO-US015876.
PR	06-JUN-2002; 2002US-0386782P.
PR	29-AUG-2002; 2002US-0406784P.
PR	05-SEP-2002; 2002US-0408378P.
PR	09-SEP-2002; 2002US-0409293P.
PR	15-JAN-2003; 2003US-0440129P.
PR	20-FEB-2003; 2003WO-US005028.
PR	20-FEB-2003; 2003WO-US005346.
PR	30-APR-2003; 2003US-00427160.
PR	23-OCT-2003; 2003US-00444853.
PR	24-NOV-2003; 2003US-00693059.
PR	14-JAN-2004; 2004US-00757803.
XX	
PA	(RICH/) RICHARDS I.

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #269.
XX
KM gene expression; antispasmodic; antiallergic; antiinflammatory; CNS-gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uteroplacental; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21 a
FT /tag= "a
FT /note= "deoxythymidine nucleotide"
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richard I, Mcswigen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 269; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
XX
Query Match 1.1%; Score 19.4; DB 1; Length 21;
Beet Local Similarity 85.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1712 AGCAGUACGACGAGACAGU 1732
| |||:|||||||:|||||:
| |||:|||||||:|||||:

Db 21 AACGATACGACGAGACACT 1
RESULT 107
ADM27988/c
ID ADM27988 standard; RNA; 21 BP.
XX
AC ADM27988;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #285.
XX
KM gene expression; antispasmodic; antiallergic; antiinflammatory; CNS-gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uteroplacental; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21 a
FT /tag= "a
FT /note= "deoxythymidine nucleotide"
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswigen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 285; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule

XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswiggen J;
XX WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 207; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule CC was produced by solid phase oligonucleotide synthesis method. This CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 21 BP; 5 A; 7 C; 2 G; 2 T; 5 U; 0 Other;
XX
XX Query Match 1.1%; Score 19.4; DB 1; Length 21;
XX Best Local Similarity 90.5%; Pred. No. 1.7e+02;
XX Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 17 ACAGUACACUCCGCUUUGU 37
Db 1 ACAGUACACUCCGCUUUT 21
XX
XX RESULT 105
XX ID ADW27915 standard; RNA; 21 BP.
XX
XX ADW27915;
XX
XX 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #212.
XX
XX gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.

XX Key Location/Qualifiers
XX FH msc_difference 20. 21
XX FT /*tag = a
XX FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JUN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005346.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX
XX Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX
XX Disclosure; SEQ ID NO 212; 84pp; English.
XX
XX
XX The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule CC was produced by solid phase oligonucleotide synthesis method. This CC sequence represents an example of a siRNA molecule of the invention.
XX
XX
SQ Sequence 21 BP; 8 A; 5 C; 5 G; 2 T; 1 U; 0 Other;
XX
XX Query Match 1.1%; Score 19.4; DB 1; Length 21;
XX Best Local Similarity 90.5%; Pred. No. 1.7e+02;
XX Matches 19; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1712 AGCAGUACGACGAGACAGU 1732
Db 1 AGCAGUACGACGAGACATT 21
XX
XX RESULT 106
XX ID ADW27972/c
XX ID ADW27972 standard; RNA; 21 BP.
XX
XX ADW27972;
XX
XX 07-APR-2005 (first entry)
XX
XX

PR	30-APR-2003;	2003US-00427160.
PR	23-MAY-2003;	2003US-00444853.
PR	23-OCT-2003;	2003US-00693059.
PR	24-NOV-2003;	2003US-00720448.
PR	14-JAN-2004;	2004US-00757803.
XX		
PA	(RICH/) RICHARDS I.	
PA	(MCSW/) MCSWIGGEN J.	
PI	Richards I, Mcswiggen J;	
XX		
DR	WPI, 2005-090672/10.	
XX		
PT	Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3	
PT	RNA through RNA interference, useful for treating asthma.	
XX		
PS	Disclosure; SEQ ID NO 237, 84pp; English.	
XX		
CC	The invention relates to a chemically synthesized double stranded short	
CC	interfering nucleic acid (siNA) molecule (I) that directs cleavage of a	
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,	
CC	where each strand of (I) has 19-23 nucleotides, and does not require the	
CC	presence of nucleotides having a 2-hydroxy group for mediating RNA	
CC	interference. (I) is useful for treating diseases e.g., asthma, allergic	
CC	rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary	
CC	vasoconstriction or hypertension, emphysema, irritable bowel syndrome,	
CC	Alzheimer's disease or urinary incontinence. (I) has increased resistance	
CC	toward nuclease. Double stranded short interfering nucleic acid molecule	
CC	was produced by solid phase oligonucleotide synthesis method. This	
CC	sequence represents an example of a siNA molecule of the invention.	
XX		
SO	Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;	
Query Match	1.1%; Score 19.4; DB 1; Length 21;	
Best Local Similarity	85.7%; Pred. No. 1.7e+02;	
Matches 18; Conservative 2; Mismatches 1; Indels 0; Gaps 0;		
Oy	1712 AGCAGUACGACGACAGACAGU 1732	
	: : :	
Db	21 AACGATCACGACGACGACGT 1	
RESULT 104		
ID	ADM27910 standard; RNA; 21 BP.	
AC	ADM27910;	
XX		
DT	07-APR-2005 (first entry)	
XX		
DE	Cholinergic receptor muscarinic 3 gene targeted siRNA #207.	
XX		
XX	gene expression; antisthmatic; antiallergic; antiinflammatory; CNS-Gen.;	
XX	respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;	
KW	nootropic; uteroblastic; short interfering RNA; RNA interference; siRNA;	
KW	cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;	
KW	inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;	
KW	hypertension; emphysema; irritable bowel syndrome; Alzheimer disease;	
KW	incontinence; ss.	
XX		
OS	Synthetic.	
XX		
PH	Key Location/Qualifiers	
FT	misc_difference 20..21	
FT	/*tag= a	
XX	/note= "deoxythymidine nucleotide"	
XX		
PN	US2005014172-A1.	
XX		
PD	20-JAN-2005.	
XX		
XX	11-MAR-2004; 2004US-00798090.	
XX		

Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 1.7e+02;
Matches 12; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

OY 19 AGUACAACCCGCGCCUUGUUU 39
|:|||||:|||||:|||||:|
21 AATACAACTCGCCTTGT 1

Db

RESULT 101
ADM27951/C
ID ADM27951 standard; RNA; 21 BP.
AC ADM27951;
XX
XX
XX 07-APR-2005 (first entry)
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #248.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX misc_difference 20..21 a
XX FT /*tag= a
XX FT /note="deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX PA (MCSW/) MCSWIGGEN J.
XX PI
XX Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
XX
XX DR Novel chemically synthesized double stranded short interfering nucleic
XX PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX PT RNA through RNA interference, useful for treating asthma.
XX
XX PS Disclosure; SEQ ID NO 248; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,

CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.

XX Sequence 21 BP; 8 A; 2 C; 6 G; 2 T; 3 U; 0 Other;
XX SQ

Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 1.7e+02;
Matches 12; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

OY 19 AGUACAACCCGCGCCUUGUUU 39
|:|||||:|||||:|||||:|
21 AATACAACTCGCCTTGT 1

Db

RESULT 102
ADM27967/C
ID ADM27967 standard; RNA; 21 BP.
XX
XX ADM27967;
XX
XX 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #264.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX misc_difference 20..21 a
XX FT /*tag= a
XX FT /note="deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX PA (MCSW/) MCSWIGGEN J.
XX PI
XX Richards I, Mcswigen J;
XX

PT protein production in cells used in drug development process.
XX
PS Claim 11; SEQ ID NO 6656; 402pp; English.
XX
CC The invention relates to a polynucleotide comprising an RNA sequence. The
CC polynucleotides, vector, libraries, and method are useful in lowering the
CC amount of RNA and/or protein production in cells used in drug development
CC process. The present sequence represents a knock-down target sequence.
XX
SQ Sequence 21 BP; 7 A; 6 C; 7 G; 6 T; 0 U; 0 Other;
Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 1.7e+02;
Matches 14; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
Oy 1579 AAUUCUGGCUACUGCUGUC 1599
Db 1 ACTCTGGCTACTGCTGTC 21
RESULT 99
ID ADU41441 standard; DNA; 21 BP.
XX
AC ADU41441;
XX
DT 27-JAN-2005 (first entry)
XX
DE Knock-down target sequence #6620.
XX
KW ds; RNA production; protein production; drug development;
XX knock-down target.
XX
OS Unidentified.
XX
PN WO2004094636-A1.
XX
PD 04-NOV-2004.
XX
PF 24-APR-2003; 2003WO-EP004362.
XX
PR 24-APR-2003; 2003WO-EP004362.
XX
PA (GALA-) GALAPAGOS GENOMICS NV.
XX (VSCH/) VAN DER SCHUEREN J.
XX
PI Artes GUF, Lambrecht MJY, Djokic K, Clasen RJ, Mesic B;
PI Griffioen S, Bergs CJL;
XX
DR MPI; 2004-775940/76.
XX
PT New knockdown sequences, useful in lowering the amount of RNA and/or
PT protein production in cells used in drug development process.
XX
PS Claim 11; SEQ ID NO 6657; 402pp; English.
XX
CC The invention relates to a polynucleotide comprising an RNA sequence. The
CC polynucleotides, vector, libraries, and method are useful in lowering the
CC amount of RNA and/or protein production in cells used in drug development
CC process. The present sequence represents a knock-down target sequence.
XX
SQ Sequence 21 BP; 7 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.7e+02;
Matches 18; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
Oy 289 AAGCAGCUGAGACGUCUAC 309
Db 1 ACGCAGCTGACACGCTAAC 21
RESULT 100

ADW27983/C
ID ADW27983 standard; RNA; 21 BP.
XX
AC ADW27983;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #280.
XX
KW gene expression; anticholinergic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uteropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hyperextension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /*tag= a
FT /note= "deoxythymidine nucleotide"
XX
PN US2005014172-A1.
XX
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR MPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 280; 84pp; English.
XX
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hyperextension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 21 BP; 8 A; 2 C; 6 G; 2 T; 3 U; 0 Other;

Query Match 1.1%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 81.0%; Pred. No. 1.7e+02;
 Matches 17; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

158 ACGGUNCACCAUGAGCCUC 178
 |||||:|||||:|||||:|
 1 ACGGTACCACTGATGACCTC 21

Db

RESULT 96
 ADU41439
 ID ADU41439 standard; DNA; 21 BP.
 XX
 AC ADU41439;
 XX
 DT 27-JAN-2005 (first entry)
 XX
 DE Knock-down target sequence #6618.
 XX
 KM ds; RNA production; protein production; drug development;
 KW Knock-down target.
 XX
 OS Unidentified.
 XX
 PN MO2004094636-A1.
 XX
 PD 04-NOV-2004.
 XX
 PF 24-APR-2003; 2003WO-EP004362.
 XX
 PR 24-APR-2003; 2003WO-EP004362.
 XX
 PA (GALA-) GALAPAGOS GENOMICS NV.
 PA (VSCH/) VAN DER SCHUEREN J.
 XX
 PI Arts GJF, Lambrecht MJY, Djokic K, Claesen RJ, Mesic E;
 PI Griffioen S, Bergs CJL;
 XX
 DR WPI; 2004-775940/76.
 XX
 PT New knockdown sequences, useful in lowering the amount of RNA and/or
 PT protein production in cells used in drug development process.
 XX
 PS Claim 11; SEQ ID NO 6655; 402bp; English.
 XX
 CC The invention relates to a polynucleotide comprising an RNA sequence. The
 CC polynucleotides, vector, libraries, and method are useful in lowering the
 CC amount of RNA and/or protein production in cells used in drug development
 CC process. The present sequence represents a knock-down target sequence.
 XX
 SQ Sequence 21 BP; 6 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 1.1%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 76.2%; Pred. No. 1.7e+02;
 Matches 16; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

1012 AACACCAUGAUGCUGCGCC 1032
 |||||:|||||:|||||:|
 1 ACCACATGATGCTGCTGCC 21

Db

RESULT 97
 ADU41542
 ID ADU41542 standard; DNA; 21 BP.
 XX
 AC ADU41542;
 XX
 DT 27-JAN-2005 (first entry)
 XX
 DE Knock-down target sequence #6721.
 XX
 KM ds; RNA production; protein production; drug development;
 KW

KW knock-down target.
 XX
 OS Unidentified.
 XX
 PN MO2004094636-A1.
 XX
 PD 04-NOV-2004.
 XX
 PF 24-APR-2003; 2003WO-EP004362.
 XX
 PR 24-APR-2003; 2003WO-EP004362.
 XX
 PA (GALA-) GALAPAGOS GENOMICS NV.
 PA (VSCH/) VAN DER SCHUEREN J.
 XX
 PI Arts GJF, Lambrecht MJY, Djokic K, Claesen RJ, Mesic E;
 PI Griffioen S, Bergs CJL;
 XX
 DR WPI; 2004-775940/76.
 XX
 PT New knockdown sequences, useful in lowering the amount of RNA and/or
 PT protein production in cells used in drug development process.
 XX
 PS Claim 11; SEQ ID NO 6765; 402bp; English.
 XX
 CC The invention relates to a polynucleotide comprising an RNA sequence. The
 CC polynucleotides, vector, libraries, and method are useful in lowering the
 CC amount of RNA and/or protein production in cells used in drug development
 CC process. The present sequence represents a knock-down target sequence.
 XX
 SQ Sequence 21 BP; 5 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 1.1%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 76.2%; Pred. No. 1.7e+02;
 Matches 16; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

547 AAGAGAGCCGUGUGAUGC 567
 |||||:|||||:|||||:|
 1 ACGAGAGCCGCTGTGATGATC 21

Db

RESULT 98
 ADU41440
 ID ADU41440 standard; DNA; 21 BP.
 XX
 AC ADU41440;
 XX
 DT 27-JAN-2005 (first entry)
 XX
 DE Knock-down target sequence #6619.
 XX
 KM ds; RNA production; protein production; drug development;
 KW Knock-down target.
 XX
 OS Unidentified.
 XX
 PN MO2004094636-A1.
 XX
 PD 04-NOV-2004.
 XX
 PF 24-APR-2003; 2003WO-EP004362.
 XX
 PR 24-APR-2003; 2003WO-EP004362.
 XX
 PA (GALA-) GALAPAGOS GENOMICS NV.
 PA (VSCH/) VAN DER SCHUEREN J.
 XX
 PI Arts GJF, Lambrecht MJY, Djokic K, Claesen RJ, Mesic E;
 PI Griffioen S, Bergs CJL;
 XX
 DR WPI; 2004-775940/76.
 XX
 PT New knockdown sequences, useful in lowering the amount of RNA and/or

XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580B.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 30-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-0042716O.
PR 23-MAY-2003; 2003US-0044485S.
PR 23-OCT-2003; 2003US-0069305Y.
PR 24-NOV-2003; 2003US-0072044B.
XX 14-JAN-2004; 2004US-0075780J.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswigen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 205; 84bp; English.

CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siNA) molecule (1) that directs cleavage of a
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC	where each strand of (1) has 19-23 nucleotides, and does not require the
CC	presence of nucleotides having a 2-hydroxy group for mediating RNA
CC	interference. (1) is useful for treating diseases e.g., asthma, allergic
CC	rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC	vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC	Alzheimer's disease or urinary incontinence. (1) has increased resistance
CC	towards nuclease. Double stranded short interfering nucleic acid molecule
CC	was produced by solid phase oligonucleotide synthesis method. This
CC	sequence represents an example of the invention.
XX	
XX	Sequence 23 BP; 8 A; 4 C; 9 G; 0 T; 2 U; 0 Other;
QY	
Db	1712 AGCAGUACCGACGAGACAGUCG 1734
	1 AGCAGUACCGACGAGACAGUCG 23
RESULT 95	
ID	ABS98536
XX	ABS98536 standard; DNA; 21 BP.
XX	
XX	ABS98536;
XX	
XX	23-DEC-2002 (first entry)
DE	
XX	Human acetyl choline muscarinic receptor 3 polymorphic sequence #2.
XX	
KM	Human; ds; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1;
KM	cytochrome P450 A2; CYP4501A2; cytochrome P450 02B; CYP45002B1; ITP;
KM	adrenergic receptor beta1; ADERB1; aryl hydrocarbon; AHR; MRE3; NR112;
KM	aryl hydrocarbon receptor nuclear translocator; AHR1; catepsin S; CTSS;
KM	cytochrome 2; C0X2; diazepam binding inhibitor; DBI; haematological;
KM	epoxide hydrolase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
KM	glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;

KM HMMT; kallikrein 2; KLR2; nicotinamide-N-methyl transferase; NNMT;
 KM MDPH quinone oxidoreductase 2; NQO2; sulfoxidoreductase thermolabile; STM;
 KM UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
 KM UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; UPA;
 KM multidrug resistance 1; lactoferrin; orphan nuclear receptor;
 KM acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
 KM altered drug metabolism; cardiovascular function; colorectal tumour;
 KM central nervous system; pulmonary; immunological; SNP;
 KM single nucleotide polymorphism.
 OS Homo sapiens.
 XX
 XX Wo0200257410-A2.
 XX
 PD 25-JUL-2002.
 XX
 XX 28-NOV-2001; 2001WO-US044838.
 XX
 PR 28-NOV-2000; 2000US-00724389.
 XX
 PA (DNAS-) DNA SCI LAB INC.
 PI Guida M, Hall J;
 PT WPI; 2002-696522/75.
 DR
 XX
 XX Isolated nucleic acid molecules having polymorphisms in known human genes
 PT e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
 PT for locating, identifying and characterizing the genes responsible for
 PT disorder-related traits.
 PS Example 28; Page 159; 714pp; English.
 XX
 XX This invention relates to the sequence of an isolated nucleic acid
 CC molecule comprising at least one base variation from that of a known
 CC human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2),
 CC cyclochole P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1),
 CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
 CC (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
 CC inhibitor (DBI), epoxide hydrolase 2 (EPHX2), 5-lipoxygenase activating
 CC protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
 CC transferase (HMMT), (kallikrein 2) KLR2, nicotinamide -N-methyl
 CC sulfoxidoreductase thermolabile (STM), UDP-glucuronosyl transferase 2B4
 CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
 CC transferase (UGT2B15), urokinase receptor (UPA), multidrug resistance 1
 CC (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
 CC (MRP3), orphan nuclear receptor (NR112), or acetylcholine muscarinic
 CC receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
 CC The polymorphisms in the human genes cited in the invention are useful as
 CC genetic linkage markers for locating and characterising the genes that
 CC are responsible for specific traits within the genome and eventually
 CC identifying the genes responsible for a variety of disorder-related
 CC traits as a result of their e.g. overexpression, constitutive
 CC expression, mutation or underexpression, which may be used in diagnosing
 CC and/or treating the disorders. The nucleic acid molecules comprising the
 CC polymorphic sequences contained in CYP450A1, CYP450A2, CYP4502E1,
 CC ARNT, EPHX2, GST12, NNMT, NQO2, NR112, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
 CC MDR1 and/or MDR3 are useful for screening individuals for altered drug
 CC metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2,
 CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for
 CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
 CC used to screen for altered cardiovascular function. In COX2 for altered
 CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
 CC nervous system function, in FLAP and HMMT for altered pulmonary,
 CC immunological or haematological function, in KLR2 for altered serine
 CC protease activity in the prostate, in LTF for altered immunological or
 CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
 CC peripheral nervous system function. The present sequence represents a
 CC polymorphic DNA sequence of the invention
 XX
 XX Sequence 21 BP; 5 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

```

OS Synthetic.
XX Key Location/Qualifiers
XX misc_difference 22..23
XX /tag=a
XX /note="deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 274; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 23 BP; 2 A; 7 C; 4 G; 2 T; 6 U; 2 Other;
XX
XX Query Match 1.1%; Score 20; DB 1; Length 23;
XX Best Local Similarity 95.0%; Pred. No. 1.8e+02;
XX Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX 317 UCCUCUAAAGCCGCGCUGU 336
XX |||||
XX 2 UCCUCUAAAGCCGCGCUGU 21
XX
XX RESULT 93
XX ID AAF30781 standard; DNA; 23 BP.
XX AC AAF30781;
XX XX
XX DT 21-JUN-2001 (first entry)

```

```

XX DE CHRM2 gene fragment 2 forward PCR primer.
XX KM Cholinergic receptor muscarinic 2; CHRM2 gene; human; drug screening;
XX genotyping; haplotyping; PCR primer; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200127313-A2.
XX
XX 19-APR-2001.
XX
XX 12-OCT-2000; 2000WO-US028212.
XX
XX 14-OCT-1999; 99US-0159314P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Choi JY, Denton RR, Nandabalan K, Stephens JC;
XX
XX WPI; 2001-290729/30.
XX
XX New polymorphic polypeptide encoding cholinergic receptor, muscarinic 2,
XX (CHRM2), useful for in drug screening assays, comprises serine at amino
XX acid position 331.
XX
XX Example 1; Page 28; 45pp; English.
XX
XX The present sequence is that of a primer corresponding to nucleotides 298
XX -320 of the human cholinergic receptor, muscarinic acid 2 (CHRM2) cDNA
XX sequence given in AAF30770. It was used as forward primer, with the
XX reverse primer given in AAF30782, for the PCR amplification of a 492 bp
XX fragment of the CHRM2 gene. The gene was amplified in 5 fragments and
XX these were sequenced to detect polymorphisms. A novel A/T polymorphism
XX was identified at nucleotide 1185. CHRM2 polymorphic variant
XX polynucleotides are used in claimed genotyping and haplotyping methods,
XX and the variant polypeptide (see AAB20483) is used in a claimed method
XX for drug screening
XX
XX Sequence 23 BP; 6 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 1.1%; Score 19.8; DB 1; Length 23;
XX Best Local Similarity 69.6%; Pred. No. 1.9e+02;
XX Matches 16; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
XX
XX 239 UGGUGACCAUCCGCAACAU 261
XX |||||
XX 1 TGGTGACATATCGGAAACATC 23
XX
XX RESULT 94
XX ID ADW27908 standard; RNA; 23 BP.
XX AC ADW27908;
XX
XX 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #205.
XX
XX gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uteropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
XX incontinence; ss.
XX
XX OS Synthetic.
XX
XX PN US2005014172-A1.
XX XX
XX DT 20-JAN-2005.

```

PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 273; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 23 BP; 2 A; 8 C; 3 G; 2 T; 6 U; 2 Other;
XX
Query Match 1.1%; Score 20; DB 1; Length 23;
Best Local Similarity 95.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 315 CUUCCUCUUAAGCGGCCU 334
DB 2 CUUCCUCUUAAGCGGCCCT 21
XX
RESULT 91
ADM27944
ID ADM27944 standard; RNA; 23 BP.
XX
AC ADM27944;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #241.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimer disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 22..23
FT /tag= a
FT /note= "deoxythymidine nucleotide"
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX

PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 241; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 23 BP; 2 A; 8 C; 3 G; 2 T; 6 U; 2 Other;
XX
Query Match 1.1%; Score 20; DB 1; Length 23;
Best Local Similarity 95.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 315 CUUCCUCUUAAGCGGCCU 334
DB 2 CUUCCUCUUAAGCGGCCCT 21
XX
RESULT 92
ADM27977
ID ADM27977 standard; RNA; 23 BP.
XX
AC ADM27977;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #274.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimer disease;
KW incontinence; ss.
XX

CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2'-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance toward nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.

XX Sequence 23 BP; 2 A; 7 C; 4 G; 2 T; 6 U; 2 Other;

```

Query Match          1.1%   Score 20 : DB 1; Length 23;
Best Local Similarity 95.0%   Pred No. 1,8e+02;
Matches      19; Conservative    1; Mismatches     0; Indels     0; Gaps     0;

QY              317 UCCUCUUAAGCCUGGCGCUGU 336
                   |||||
ob              2   UCCUCUUAAGCCUGGCGCUGU 21

```

RESULT 89	
ADW27928	
ID	ADW27928 standard, RNA; 23 BP.
XX	
AC	ADW27928;
XX	
DT	07-APR-2005 (first entry)
XX	
EE	Cholinergic receptor muscarinic 3 gene targeted siRNA #225

KM gene expression; anaphylactic; antiinflammatory; CNS-gen.
 KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KM neurotropic; uteroplacental; short interfering RNA; RNA interference; siRNA;
 KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KM hypertension; epiphyseal; irritable bowel syndrome; Alzheimer disease;
 KM incontinence; ss.

na		
OS	Synthetic.	
XX		
FH	Key	Location/Qualifiers
FT	misc_difference	22..23
FT		/tag= a
FT		/note= "deoxythymidine nucleotide"

PN US2005014172-A1.

PD 20-JAN-2005.

PF 11-MAR-2004; 2004US-00798090.

PR	20-FEB-2002	2002US-0358560P
PR	11-MAR-2002	2002US-0363124P
PR	10-MAY-2002	2002MO-US015876
PR	06-JUN-2002	2002US-0386782P
PR	29-AUG-2002	2002US-0406784P
PR	05-SEP-2002	2002US-0408378P
PR	09-SEP-2002	2002US-0409233P
PR	15-JAN-2003	2003US-0440129P
PR	20-FEB-2003	2003MO-US005028
PR	20-FEB-2003	2003MO-US005346
PR	30-MAY-2003	2003US-00427160
PR	23-MAY-2003	2003US-00444853
PR	23-OCT-2003	2003US-00693059
PR	24-NOV-2003	2003US-00720448
PR	14-JAN-2004	2004US-00757803

PA	(RICH/) RICHARDS I.
PA	(MCSW/) MCSWIGGEN J.
XX	
PI	Richards I, Mcswiggen J;

XX
DR WPI; 2005-090672/10.

PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.

PS Disclosure; SEQ ID NO 225; 84pp; English.

The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siNA molecule of the invention.

SQ Sequence 23 BP, 2 A, 8 C, 3 G, 2 T, 6 U, 2 Other;
 Query Match 1.1%; Score 20; DB 1; Length 23;
 Best Local Similarity 95.0%; Pred. No. 1.8e+02;
 Matches 19; Conservative 1; Mismatches 0; Gaps 0

QY 315 CUUCUCUUAAGCCUGGCCU 334
|||||:|||||
Db 2 CUUCUCUUAAGCCUGGCCU 21

RESULT 90	
ADW27976	
ID	ADW27976 standard; RNA; 23 BP.

XX	ADW27976;	
AC		
XX		
DT	07-APR-2005	(first entry)
XX		
DE	Cholinergic receptor muscarinic 3 gene targeted siRNA #273	

KM gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-gen
 KM respiratory-gen.; hypotensive; gastroenteroal-gen.; neuroprotective;
 KM nootropic; uterapathic; short interfering RNA; RNA interference; siRNA;
 KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KM inflammatory; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KM hyperreflexia; emphysema; irritable bowel syndrome; Alzheimers disease;
 KM incontinence; ss.

OS	Synthetic.	Location/Qualifiers
XX		
FH	Key	
FT	misc_difference 22.23	
FT		/*tag= a
FT		/note= "deoxythymidine nucleotide"

PN US2005014172-A1.

PD 20-JAN-2005.

PF 11-MAR-2004; 2004US-00798090.

PR 20-FEB-2002; 2002USO-0358580P
PR 11-MAR-2002; 2002USO-0363124P
PR 20-MAY-2002; 2002WCO-USO15876
PR 06-JUN-2002; 2002USO-0365782P
PR 29-AUG-2002; 2002USO-0406784P
PR 05-SEP-2002; 2002USO-0408378P
PR 09-SEP-2002; 2002USO-0409293P
PR 15-JUN-2003; 2003USO-0440129P
PR 20-FEB-2003; 2003WCO-USO05028

RESULT 87
ADM27960
ID ADM27960 standard; RNA; 23 BP.
XX
AC ADM27960;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #257.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 22..23
FT /*tag= a
FT /note= "deoxythymidine nucleotide"
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 30-FEB-2003; 2003WO-US005346.
PR 20-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 257; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.

SO Sequence 23 BP; 2 A; 8 C; 3 G; 2 T; 6 U; 2 Other;
Query Match 1.1%; Score 20; DB 1; Length 23;
Best Local Similarity 95.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Oy 315 CUUCCUCUUAAGCCUGCCU 334
|||||
Db 2 CUUCCUCUUAAGCCUGCCCT 21
RESULT 88
ADM27961
ID ADM27961 standard; RNA; 23 BP.
XX
AC ADM27961;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #258.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 22..23
FT /*tag= a
FT /note= "deoxythymidine nucleotide"
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 30-FEB-2003; 2003WO-US005346.
PR 20-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 258; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a

```

FT      /*tag= a
PT      /note= "deoxythymidine nucleotide"
PN      US2005014172-A1.
XX
XX      20-JAN-2005.
XX
XX      11-MAR-2004; 2004US-00798090.
XX
XX      20-FEB-2002; 2002US-0358580P.
XX      11-MAR-2002; 2002US-0363124P.
XX      20-MAY-2002; 2002WO-US015876.
XX      06-JUN-2002; 2002US-0386782P.
XX      29-AUG-2002; 2002US-0406784P.
XX      05-SEP-2002; 2002US-0408378P.
XX      09-SEP-2002; 2002US-0409293P.
XX      15-JAN-2003; 2003US-0440129P.
XX      20-FEB-2003; 2003WO-US005028.
XX      30-APR-2003; 2003US-00427160.
XX      23-MAY-2003; 2003US-00444853.
XX      23-OCT-2003; 2003US-00693059.
XX      24-NOV-2003; 2003US-00720448.
XX      14-JAN-2004; 2004US-00757803.
XX
XX      (RICH/) RICHARDS I.
XX      (MCSW/) MCSWIGGEN J.
XX
XX      Richards I, Mcswiggen J;
XX
XX      WPI; 2005-090672/10.
XX
XX      Novel chemically synthesized double stranded short interfering nucleic
XX      acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX      RNA through RNA interference, useful for treating asthma.
XX
XX      Disclosure; SEQ ID NO 226; 84pp; English.
XX
XX      The invention relates to a chemically synthesized double stranded short
XX      interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX      cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX      where each strand of (I) has 19-23 nucleotides, and does not require the
XX      presence of nucleotides having a 2-hydroxy group for mediating RNA
XX      interference. (I) is useful for treating diseases e.g., asthma, allergic
XX      rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX      vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX      Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX      towards nucleases. Double stranded short interfering nucleic acid molecule
XX      was produced by solid phase oligonucleotide synthesis method. This
XX      sequence represents an example of a siRNA molecule of the invention.
XX
XX      Sequence 23 BP; 2 A; 7 C; 4 G; 2 T; 6 U; 2 Other;
XX
XX      Query Match      1.1%; Score 20; DB 1; Length 23;
XX      Best Local Similarity 95.0%; Pred. No. 1.8e+02;
XX      Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX      317 UCCUCUUAAGCCUGGCCUGU 336
XX      |||||||||||||||||||:
XX      2 UCCUCUUAAGCCUGGCCUGU 21
XX
XX      RESULT 86
XX      ADM27945
XX      ID      ADM27945 standard; RNA; 23 BP.
XX
XX      AC      ADM27945;
XX
XX      DT      07-APR-2005 (first entry)
XX
XX      Cholinergic receptor muscarinic 3 gene targeted siRNA #242.
XX
XX      gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;

```

```

XX      respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX      nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX      cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX      inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX      hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX      incontinence; ss.
XX
XX      Synthetic.
XX
XX      Key      Location/Qualifiers
XX      FT      misc_difference 22..23
XX      FT      /*tag= a
XX      FT      /note= "deoxythymidine nucleotide"
XX
XX      US2005014172-A1.
XX
XX      20-JAN-2005.
XX
XX      11-MAR-2004; 2004US-00798090.
XX
XX      20-FEB-2002; 2002US-0358580P.
XX      11-MAR-2002; 2002US-0363124P.
XX      20-MAY-2002; 2002WO-US015876.
XX      06-JUN-2002; 2002US-0386782P.
XX      29-AUG-2002; 2002US-0406784P.
XX      05-SEP-2002; 2002US-0408378P.
XX      09-SEP-2002; 2002US-0409293P.
XX      15-JAN-2003; 2003US-0440129P.
XX      20-FEB-2003; 2003WO-US005028.
XX      30-APR-2003; 2003US-00427160.
XX      23-MAY-2003; 2003US-00444853.
XX      23-OCT-2003; 2003US-00693059.
XX      24-NOV-2003; 2003US-00720448.
XX      14-JAN-2004; 2004US-00757803.
XX
XX      (RICH/) RICHARDS I.
XX      (MCSW/) MCSWIGGEN J.
XX
XX      Richards I, Mcswiggen J;
XX
XX      WPI; 2005-090672/10.
XX
XX      Novel chemically synthesized double stranded short interfering nucleic
XX      acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX      RNA through RNA interference, useful for treating asthma.
XX
XX      Disclosure; SEQ ID NO 242; 84pp; English.
XX
XX      The invention relates to a chemically synthesized double stranded short
XX      interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX      cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX      where each strand of (I) has 19-23 nucleotides, and does not require the
XX      presence of nucleotides having a 2-hydroxy group for mediating RNA
XX      interference. (I) is useful for treating diseases e.g., asthma, allergic
XX      rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX      vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX      Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX      towards nucleases. Double stranded short interfering nucleic acid molecule
XX      was produced by solid phase oligonucleotide synthesis method. This
XX      sequence represents an example of a siRNA molecule of the invention.
XX
XX      Sequence 23 BP; 2 A; 7 C; 4 G; 2 T; 6 U; 2 Other;
XX
XX      Query Match      1.1%; Score 20; DB 1; Length 23;
XX      Best Local Similarity 95.0%; Pred. No. 1.8e+02;
XX      Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX      317 UCCUCUUAAGCCUGGCCUGU 336
XX      |||||||||||||||||||:
XX      2 UCCUCUUAAGCCUGGCCUGU 21
XX
XX      Db

```

XX WO2005045040-A2.
XX
XX
XX PD 19-MAY-2005.
XX PF 20-AUG-2004; 2004WO-US027367.
XX PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004WO-US013456.
XX PR 24-MAY-2004; 2004WO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX PA
XX PI Richards I, Macswiggen J;
XX DR WPI; 2005-356237/36.
XX
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX PS Claim 33; SEQ ID NO 233; 184bp; English.
XX
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, and/or conditions, including chronic obstructive pulmonary
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SQ Sequence 21 BP; 6 A; 3 C; 8 G; 2 T; 2 U; 0 Other;
XX
XX Query Match 1.1%; Score 20; DB 1; Length 21;
XX Best Local Similarity 70.0%; Pred. No. 1.5e+02;
XX Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 314 ACUUCUCUUAAGCCUGGCC 333
XX ||:||||:||||:||||
XX Db 20 ACTTCTCTTAAGCCGCGCC 1
XX
XX RESULT 84
XX ID AEA02367/c
XX ID AEA02367 standard; RNA; 21 BP.
XX
XX AC AEA02367;
XX
XX DT 28-JUN-2005 (first entry)
XX
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 251.
XX
XX KW Respiratory-Gen.; Antiaesthetic; Antiallergic; Antiinflammatory;
XX KW Neutroprotective; Nootropic; Uropathic;
XX KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX OS Synthetic.
XX
XX PN WO2005045040-A2.

XX 19-MAY-2005.
XX PD
XX PF 20-AUG-2004; 2004WO-US027367.
XX PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004WO-US013456.
XX PR 24-MAY-2004; 2004WO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX PA
XX PI Richards I, Macswiggen J;
XX DR WPI; 2005-356237/36.
XX
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX PS Claim 33; SEQ ID NO 251; 184bp; English.
XX
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, and/or conditions, including chronic obstructive pulmonary
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX SQ Sequence 21 BP; 1 A; 5 C; 6 G; 2 T; 7 U; 0 Other;
XX
XX Query Match 1.1%; Score 20; DB 1; Length 21;
XX Best Local Similarity 95.0%; Pred. No. 1.5e+02;
XX Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 974 AGCAGUAGACCAAGACAC 993
XX ||||||:||||:||||:||||
XX Db 20 AGCAGATGACCAAGACAC 1
XX
XX RESULT 85
XX ID ADW27929
XX ID ADW27929 standard; RNA; 23 BP.
XX
XX AC ADW27929;
XX
XX DT 07-APR-2005 (first entry)
XX
XX DE Cholinergic receptor muscarinic 3 gene targeted siRNA #226.
XX
XX KW Gene expression; antiaesthetic; antiallergic; antiinflammatory; CNS-Gen.;
XX KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neutroprotective;
XX KW neotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX KW Cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX KW incontinence; ss.
XX
XX OS Synthetic.
XX
XX PN Key Location/Qualifiers
XX FT misc_difference 22..23

micrurion disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 siRNA; RNA interference; gene silencing; short interfering RNA.
 Synthetic.
 WO2005045040-A2.
 19-MAY-2005.
 20-AUG-2004; 2004WO-US027367.
 23-OCT-2003; 2003US-00693059.
 24-NOV-2003; 2003US-00720448.
 03-DEC-2003; 2003US-00727780.
 14-JAN-2004; 2004US-00757803.
 10-FEB-2004; 2004US-0543480P.
 13-FEB-2004; 2004US-00780447.
 11-MAR-2004; 2004US-00798090.
 16-APR-2004; 2004US-00826966.
 30-APR-2004; 2004WO-US013456.
 24-MAY-2004; 2004WO-US016390.
 17-AUG-2004; 2004US-00919866.
 (SIRN-) SIRNA THERAPEUTICS INC.
 Richards I, Macswiggen J;
 WPI; 2005-356237/36.
 New short interfering nucleic acid molecule that directs cleavage of a
 cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 disease.
 Claim 33; SEQ ID NO 267; 184pp; English.
 The invention relates to a chemically synthesized double stranded short
 interfering nucleic acid (siNA) molecule that directs cleavage of a
 cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 (RNAi). The siNA molecule, compounds, compositions, and methods are
 useful for treating or preventing respiratory and pulmonary diseases,
 disorders, and/or conditions, including chronic obstructive pulmonary
 disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 Sequence 21 BP; 1 A; 5 C; 6 G; 2 T; 7 U; 0 Other;
 Query Match 1.1%; Score 20; DB 1; Length 21;
 Best Local Similarity 95.0%; Pred. No. 1.5e+02;
 Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 974 AGCAGUGAGCCAGACGAC 993
 |||||:|||||
 DB 20 AGCAGATGAGCCAGACGAC 1
 RESULT 82
 AEA02407/c
 ID AEA02407 standard; RNA; 21 BP.
 AC AEA02407;
 AC
 DT 28-JUL-2005 (first entry)
 DT
 XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 291.
 XX
 DE Respiratory-Gen.; Antiaesthetic; Antiallergic; Antiinflammatory;
 XX Neuroprotective; Nootropic; Uropathic;
 XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 XX microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 XX siRNA; RNA interference; gene silencing; short interfering RNA.

Synthetic.
 WO2005045040-A2.
 19-MAY-2005.
 20-AUG-2004; 2004WO-US027367.
 23-OCT-2003; 2003US-00693059.
 24-NOV-2003; 2003US-00720448.
 03-DEC-2003; 2003US-00727780.
 14-JAN-2004; 2004US-00757803.
 10-FEB-2004; 2004US-0543480P.
 13-FEB-2004; 2004US-00780447.
 11-MAR-2004; 2004US-00798090.
 16-APR-2004; 2004US-00826966.
 30-APR-2004; 2004WO-US013456.
 24-MAY-2004; 2004WO-US016390.
 17-AUG-2004; 2004US-00919866.
 (SIRN-) SIRNA THERAPEUTICS INC.
 Richards I, Macswiggen J;
 WPI; 2005-356237/36.
 New short interfering nucleic acid molecule that directs cleavage of a
 cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
 respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
 disease.
 Claim 33; SEQ ID NO 291; 184pp; English.
 The invention relates to a chemically synthesized double stranded short
 interfering nucleic acid (siNA) molecule that directs cleavage of a
 cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
 (RNAi). The siNA molecule, compounds, compositions, and methods are
 useful for treating or preventing respiratory and pulmonary diseases,
 disorders, and/or conditions, including chronic obstructive pulmonary
 disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
 cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
 present sequence represents a cholinergic receptor muscarinic 3 siRNA.
 Sequence 21 BP; 1 A; 5 C; 6 G; 2 T; 7 U; 0 Other;
 Query Match 1.1%; Score 20; DB 1; Length 21;
 Best Local Similarity 95.0%; Pred. No. 1.5e+02;
 Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 974 AGCAGUGAGCCAGACGAC 993
 |||||:|||||
 DB 20 AGCAGATGAGCCAGACGAC 1
 RESULT 83
 AEA02349/c
 ID AEA02349 standard; RNA; 21 BP.
 AC AEA02349;
 AC
 DT 28-JUL-2005 (first entry)
 DT
 XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 233.
 XX
 DE Respiratory-Gen.; Antiaesthetic; Antiallergic; Antiinflammatory;
 XX Neuroprotective; Nootropic; Uropathic;
 XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
 XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
 XX microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
 XX siRNA; RNA interference; gene silencing; short interfering RNA.
 OS Synthetic.

KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 247; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 5 A; 2 C; 7 G; 2 T; 5 U; 0 Other;
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 16 AACAGUACAACCGCCUUU 35
DB 20 AACGTAACAACCTCGCCTTT 1

RESULT 80
AEA02381/c
ID AEA02381 standard; RNA; 21 BP.
XX
AC AEA02381;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 265.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;

KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 265; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 6 A; 3 C; 8 G; 2 T; 2 U; 0 Other;
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 314 ACUUCUUAACCGGCC 333
DB 20 ACTTCTCTTAACCTGACC 1

RESULT 81
AEA02383/c
ID AEA02383 standard; RNA; 21 BP.
XX
AC AEA02383;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 267.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;

ID AEA02333 standard; RNA; 21 BP.
XX
AC AEA02333;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 217.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 11-FEB-2004; 2004US-00780447.
XX
PR 13-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 217; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 6 A; 3 C; 8 G; 2 T; 2 U; 0 Other;
XX
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 314 ACUUCUUAAGCCGCC 333
DB 20 ACTTCCTTAAGCGGCC 1
RESULT 76
AEA02403/C
ID AEA02403 standard; RNA; 21 BP.
XX

AC AEA02403;
XX
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 287.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 287; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 5 A; 2 C; 7 G; 2 T; 5 U; 0 Other;
XX
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 16 AACGUAACACCGCCUUU 35
DB 20 AACGUAACACCGCCU 1
RESULT 77
AEA02335/C
ID AEA02335 standard; RNA; 21 BP.
XX
XX
AC AEA02335;
XX

RESULT 73

AEA02347/c

ID AEA02347 standard; RNA; 21 BP.

AC AEA02347;

XX 28-JUL-2005 (first entry)

DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 231.

XX Respiratory-Gen.; Antiaschmatic; Antiasthmatic; Antiinflammatory;

XX Neutropenic; Nootropic; Uropathic;

XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;

XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;

XX microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;

XX siRNA; RNA interference; gene silencing; short interfering RNA.

XX Synthetic.

XX WO2005045040-A2.

XX 19-MAY-2005.

XX 20-AUG-2004; 2004WO-US027367.

XX 23-OCT-2003; 2003US-00693059.

XX 24-NOV-2003; 2003US-00720448.

XX 03-DEC-2003; 2003US-00727780.

XX 14-JAN-2004; 2004US-00757803.

XX 10-FEB-2004; 2004US-0543480P.

XX 13-FEB-2004; 2004US-00780447.

XX 11-MAR-2004; 2004US-00798090.

XX 16-APR-2004; 2004US-00826966.

XX 30-APR-2004; 2004WO-US013456.

XX 24-MAY-2004; 2004WO-US016390.

XX 17-AUG-2004; 2004US-00919866.

XX (SIRN-) SIRNA THERAPEUTICS INC.

XX Richards I, Macswigen J;

XX WPI; 2005-356237/36.

XX New short interfering nucleic acid molecule that directs cleavage of a

XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing

XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary

XX disease.

XX Claim 33; SEQ ID NO 231; 184pp; English.

XX The invention relates to a chemically synthesized double stranded short

XX interfering nucleic acid (siNA) molecule that directs cleavage of a

XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference

XX (RNAi). The siNA molecule, compounds, compositions, and methods are

XX useful for treating or preventing respiratory and pulmonary diseases,

XX disorders, and/or conditions, including chronic obstructive pulmonary

XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,

XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The

XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX Sequence 21 BP; 5 A; 2 C; 7 G; 2 T; 5 U; 0 Other;

XX Query Match 1.1%; Score 20; DB 1; Length 21;

XX Best Local Similarity 75.0%; Pred. No. 1.5e+02;

XX Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 16 AACAGUACAACGCGCCUUU 35

DB 20 AACGTAACAACCTGCGCTTT 1

RESULT 74

AEA02365/c

ID AEA02365 standard; RNA; 21 BP.

AC AEA02365;

XX 28-JUL-2005 (first entry)

DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 249.

XX Respiratory-Gen.; Antiaschmatic; Antiasthmatic; Antiinflammatory;

XX Neutropenic; Nootropic; Uropathic;

XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;

XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;

XX microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;

XX siRNA; RNA interference; gene silencing; short interfering RNA.

XX Synthetic.

XX WO2005045040-A2.

XX 19-MAY-2005.

XX 20-AUG-2004; 2004WO-US027367.

XX 23-OCT-2003; 2003US-00693059.

XX 24-NOV-2003; 2003US-00720448.

XX 03-DEC-2003; 2003US-00727780.

XX 14-JAN-2004; 2004US-00757803.

XX 10-FEB-2004; 2004US-0543480P.

XX 13-FEB-2004; 2004US-00780447.

XX 11-MAR-2004; 2004US-00798090.

XX 16-APR-2004; 2004US-00826966.

XX 30-APR-2004; 2004WO-US013456.

XX 24-MAY-2004; 2004WO-US016390.

XX 17-AUG-2004; 2004US-00919866.

XX (SIRN-) SIRNA THERAPEUTICS INC.

XX Richards I, Macswigen J;

XX WPI; 2005-356237/36.

XX New short interfering nucleic acid molecule that directs cleavage of a

XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing

XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary

XX disease.

XX Claim 33; SEQ ID NO 249; 184pp; English.

XX The invention relates to a chemically synthesized double stranded short

XX interfering nucleic acid (siNA) molecule that directs cleavage of a

XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference

XX (RNAi). The siNA molecule, compounds, compositions, and methods are

XX useful for treating or preventing respiratory and pulmonary diseases,

XX disorders, and/or conditions, including chronic obstructive pulmonary

XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,

XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The

XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX Sequence 21 BP; 6 A; 3 C; 8 G; 2 T; 2 U; 0 Other;

XX Query Match 1.1%; Score 20; DB 1; Length 21;

XX Best Local Similarity 70.0%; Pred. No. 1.5e+02;

XX Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

OY 314 ACUUCUUAACGCGCC 333

DB 20 ACTTCTTAAGCTGACC 1

RESULT 75

AEA02333/c

OY 317 UCCUCUUAAGCCUGGCCU 336
|||||
1 UCCUCUUAAGCCUGGCCUGT 20

Db

RESULT 71
AEA02397/c
ID AEA02397 standard; RNA; 21 BP.

AC AEA02397;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholineergic receptor muscarinic 3 siRNA SEQ ID NO 281.

DE Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neutropoietic; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX micrurition disorder; cholineergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.

OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX PI Richards I, Macswigen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholineergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 281; 184bp; English.

PS The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholineergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholineergic receptor muscarinic 3 siRNA.

XX Sequence 21 BP; 6 A; 3 C; 8 G; 2 T; 2 U; 0 Other;

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

OY 314 ACUCCUUAAGCCUGGCC 333

Db 20 ACTTCCTTAAGCCTGCC 1
||::||::||::||::||::||
1 UCCUCUUAAGCCUGGCC 20

RESULT 72
AEA02341
ID AEA02341 standard; RNA; 21 BP.

AC AEA02341;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholineergic receptor muscarinic 3 siRNA SEQ ID NO 225.

DE Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neutropoietic; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX micrurition disorder; cholineergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.

OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX PI Richards I, Macswigen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholineergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 225; 184bp; English.

PS The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholineergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholineergic receptor muscarinic 3 siRNA.

XX Sequence 21 BP; 2 A; 8 C; 3 G; 2 T; 6 U; 0 Other;

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 315 CUUCUCUUAAGCCUGGCCU 334
|||||
1 CUUCUCUUAAGCCUGGCCCT 20

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 317 UCCUCUUAAGCCUGCCUGU 336
Db 1 UCCUCUUAAGCCUGCCUGU 20

RESULT 69
AEA02358
ID AEA02358 standard; RNA; 21 BP.
XX
AC AEA02358;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 242.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neutropoietic; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US013390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 242; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAI). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 2 A; 7 C; 4 G; 2 T; 6 U; 0 Other;
XX
Query Match 1.1%; Score 20; DB 1; Length 21;

Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 317 UCCUCUUAAGCCUGCCUGU 336
Db 1 UCCUCUUAAGCCUGCCUGU 20

RESULT 70
AEA02390
ID AEA02390 standard; RNA; 21 BP.
XX
AC AEA02390;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 274.
XX
KM Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neutropoietic; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KM mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US013390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 274; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAI). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 2 A; 7 C; 4 G; 2 T; 6 U; 0 Other;
XX
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 1 A; 5 C; 6 G; 2 T; 7 U; 0 Other;
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 974 AGCAGATGACCAAGACCAC 993
DB 20 AGCAGATGACCAAGACCAC 1
RESULT 67
AEA02351/c
ID AEA02351 standard; RNA; 21 BP.
XX
AC AEA02351;
XX
DT 28-JUL-2005 (first entry)
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 235.
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neutropoietic; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 235; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX
SQ Sequence 21 BP; 1 A; 5 C; 6 G; 2 T; 7 U; 0 Other;
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 974 AGCAGATGACCAAGACCAC 993
DB 20 AGCAGATGACCAAGACCAC 1
RESULT 68
AEA02326
ID AEA02326 standard; RNA; 21 BP.
XX
AC AEA02326;
XX
DT 28-JUL-2005 (first entry)
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 210.
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neutropoietic; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 210; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 2 A; 7 C; 4 G; 2 T; 6 U; 0 Other;

CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX

Sequence 21 BP; 5 A; 2 C; 7 G; 2 T; 5 U; 0 Other;

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 16 AACAGUACACCCUGCCUUU 35
|||:|||||:|||||:
Db 20 AACAGTACAACTCGCCTTT 1

RESULT 65
ID AEA02373 standard; RNA; 21 BP.
XX
AC AEA02373;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 257.
XX
KM Respiratory-Gen.; Antiaesthetic; Anti-allergic; Anti-inflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; Alzheimer's disease;
XX microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 257; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,

CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX

Sequence 21 BP; 2 A; 8 C; 3 G; 2 T; 6 U; 0 Other;

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 315 CUUCCUUAAGCCUGCCU 334
|||||:|||||:|||||:
Db 1 CUUCCUUAAGCCUGCCU 20

RESULT 66
ID AEA02415/c
XX
AC AEA02415; standard; RNA; 21 BP.
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 299.
XX
KM Respiratory-Gen.; Antiaesthetic; Anti-allergic; Anti-inflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; Alzheimer's disease;
XX microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 299; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,

XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 6 A; 3 C; 8 G; 2 T; 2 U; 0 Other;
XX
QY Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
XX
Db 314 ACTUCCCUAAGCCUGGCC 333
||::||::||::||::||::||
20 ACTTCTTAAGCTTGCC 1
XX
RESULT 63
AEA02374 ID AEA02374 standard; RNA; 21 BP.
XX
AC AEA02374;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 258.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtubition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 258; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short

CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 2 A; 7 C; 4 G; 2 T; 6 U; 0 Other;
XX
QY Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
Db 317 UCCUCUUAAGCCUGCCUGU 336
|||||||
1 UCCUCUUAAGCCUGCCUGU 20
XX
RESULT 64
AEA02331/c ID AEA02331 standard; RNA; 21 BP.
XX
AC AEA02331;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 215.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtubition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 215; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference

PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 209; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 2 A; 8 C; 3 G; 2 T; 6 U; 0 Other;
XX
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 315 CUUCCUUAAGCCUGGCU 334
1 CUUCCUUAAGCCUGGCU 20
Db
RESULT 61
AEA02399/c
ID AEA02399 standard; RNA; 21 BP.
XX
AC AEA02399;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 283.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neutroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.

XX
PS Claim 33; SEQ ID NO 283; 184pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 1 A; 5 C; 6 G; 2 T; 7 U; 0 Other;
XX
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 974 AGCAGUGGACCAAGCCAC 993
20 AGCAGUGGACCAAGCCAC 1
Db
RESULT 62
AEA02405/c
ID AEA02405 standard; RNA; 21 BP.
XX
AC AEA02405;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 289.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neutroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswigen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 289; 184pp; English.

DR WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 241; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 2 A; 8 C; 3 G; 2 T; 6 U; 0 Other;
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 315 CUUCCUCUUAAGCCUGGCUU 334
1 CUUCCUCUUAAGCCUGGCUU 20
DB
RESULT 59
AEA02379/c
ID AEA02379 standard; RNA; 21 BP.
XX
AC AEA02379;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 263.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micritution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX

PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 263; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 5 A; 2 C; 7 G; 2 T; 5 U; 0 Other;
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
OY 16 AACAGUACAACUCCGCUU 35
20 AACAGTACAACCTCGCCTT 1
DB
RESULT 60
AEA02325
ID AEA02325 standard; RNA; 21 BP.
XX
AC AEA02325;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 209.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT

PR	17-AUG-2004; 2004US-00919866.
XX	
PA	(SIRN-) SIRNA THERAPEUTICS INC.
XX	
PI	Richards I, Macswigen J;
XX	
DR	WPI; 2005-356237/36.
XX	
PT	New short interfering nucleic acid molecule that directs cleavage of a
PT	cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT	disease.
PI	
XX	
PX	Claim 33; SEQ ID NO 279; 184bp; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siNA) molecule that directs cleavage of a
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC	(RNAi). The siNA molecule, compounds, compositions, and methods are
CC	useful for treating or preventing respiratory and pulmonary diseases,
CC	disorders, and/or conditions, including chronic obstructive pulmonary
CC	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC	present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX	
XX	
SEQ	Sequence 21 BP; 5 A; 2 C; 7 G; 2 T; 5 U; 0 Other;
Query March	1.1%; Score 20; DB 1; Length 21;
Best Local Similarity	75.0%; Pred. No. 1.5e+02;
Matches 15; Conservative	5; Mismatches 0; Indels 0; Gaps 0;
OY	16 AACAGUACAACCCUGCCUUU 35
	: : :
Db	20 AACAGTCAACCTCGCCTT 1
RESULT 56	
AEA02411/c	
ID	AEA02411 standard; RNA; 21 BP.
AC	AEA02411;
XX	
DT	28-JUN-2005 (first entry)
XX	
DE	Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 295.
XX	
KW	Respiratory-Gen.; Antiasthmatic; Antiinflammatory;
KW	Neuroprotective; Nootropic; Uropathic;
KW	Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW	sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW	mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW	siRNA; RNA interference; gene silencing; short interfering RNA.
XX	
XX	Synthetic.
XX	
PN	WO2005045040-A2.
XX	
PD	19-MAY-2005.
XX	
XX	20-AUG-2004; 2004WO-US027367.
XX	
PX	23-OCT-2003; 2003US-00693059.
XX	
PR	24-NOV-2003; 2003US-00726448.
PR	03-DEC-2003; 2003US-00727780.
PR	14-JAN-2004; 2004US-00757803.
PR	10-FEB-2004; 2004US-0543480P.
PR	13-FEB-2004; 2004US-00780447.
PR	11-MAR-2004; 2004US-00798090.
PR	16-APR-2004; 2004US-00826966.
PR	30-APR-2004; 2004WO-US013456.
PR	24-MAY-2004; 2004WO-US016390.
PR	17-AUG-2004; 2004US-00919866.
XX	

PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
PS Disclosure; SEQ ID NO 251; 84pp; English.
XX
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 21 BP; 1 A; 5 C; 6 G; 2 T; 7 U; 0 Other;
XX
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 974 AGCAGAGGACCCAGACAC 993
|||:|||||:|||||
Db 20 AGCAGATGACCCAGACAC 1
XX
RESULT 53
ADW27984/c
ID ADW27984 standard; RNA; 21 BP.
XX
AC ADW27984;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #281.
XX
KM gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
XX Synthetic.
OS
XX
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /*tag= a
FT /note="deoxythymidine nucleotide"
XX
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswigen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 281; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 21 BP; 6 A; 3 C; 8 G; 2 T; 2 U; 0 Other;
XX
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
OY 314 ACUUCUCUUAAGCCUGGCC 333
||:||||:|||||
Db 20 ACTTCCTTAAAGCCTGCCC 1
XX
RESULT 54
AEA02389
ID AEA02389 standard; RNA; 21 BP.
XX
AC AEA02389;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 273.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00798090.
XX 16-APR-2004; 2004US-00826966.

Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 314 ACUCCUCUUAAGCCUGGCC 333
||::||::||::||::||
Db 20 ACTTCCCTTAAAGCTGAGCC 1

RESULT 51
ADW27952/C
ID ADW27952 standard; RNA; 21 BP.
XX
AC ADW27952;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #249.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /*tag= a
FT /note="deoxythymidine nucleotide"
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswiggen J;
XX
FI WPI; 2005-090672/10.
XX
DR Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 249; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic

CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimers disease or urinary incontinence. (I) has increased resistance
CC towards nucleic acid degrading enzymes. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 21 BP; 6 A; 3 C; 8 G; 2 T; 2 U; 0 Other;

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 314 ACUCCUCUUAAGCCUGGCC 333
||::||::||::||::||
Db 20 ACTTCCCTTAAAGCTGAGCC 1

RESULT 52
ADW27954/C
ID ADW27954 standard; RNA; 21 BP.
XX
AC ADW27954;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #251.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /*tag= a
FT /note="deoxythymidine nucleotide"
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswiggen J;
XX
FI WPI; 2005-090672/10.
XX
DR Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.

KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
OS Synthetic.
XX
XX
XX
FH Key Location/Qualifiers
FT misc_difference 20. 21 a
FT /tag= "a
FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003US-00427160.
XX 30-APR-2003; 2003US-00447160.
XX 23-MAY-2003; 2003US-0044853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX MPI; 2005-090672/10.
XX
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX
XX Disclosure; SEQ ID NO 217; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 21 BP; 6 A; 3 C; 8 G; 2 T; 2 U; 0 Other;
XX
XX
XX Query Match 1.1%; Score 20; DB 1; Length 21;
XX Best Local Similarity 70.0%; Pred. No. 1.5e+02;
XX Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
XX
XX 314 ACUCCUCUUAAGCCUGGCC 333
XX |||::|||::|||::|||::|||
XX 20 ACTTCTCTTAAGCCCTGGCC 1

AC ADW27936;
XX 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #233.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM neutropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
XX Synthetic.
XX
XX
XX Key Location/Qualifiers
FH misc_difference 20. 21
FT /tag= "a
FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003US-00447160.
XX 30-APR-2003; 2003US-0044853.
XX 23-MAY-2003; 2003US-00693059.
XX 23-OCT-2003; 2003US-00720448.
XX 24-NOV-2003; 2003US-00757803.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX MPI; 2005-090672/10.
XX
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX
XX Disclosure; SEQ ID NO 233; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 21 BP; 6 A; 3 C; 8 G; 2 T; 2 U; 0 Other;
XX
XX
XX Query Match 1.1%; Score 20; DB 1; Length 21;
XX Best Local Similarity 70.0%; Pred. No. 1.5e+02;
XX

PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX
PI Richards I, Mcswigen J;
XX WPI, 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.
PT
XX
XX Disclosure; SEQ ID NO 267; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 21 BP; 1 A; 5 C; 6 G; 2 T; 7 U; 0 Other;
SQ
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 974 AGCAGUGACCAAGACAC 993
DB 20 AGCAGTGGACCAAGACAC 1
RESULT 48
ADM27982/C
ID ADM27982 standard; RNA; 21 BP.
XX
AC ADM27982;
XX
XX 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #279.
DE
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.; respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective; nootropic; uropathic; short interfering RNA; RNA interference; siRNA; cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis; inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction; hypertension; emphysema; irritable bowel syndrome; Alzheimer disease; incontinence; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH misc_difference 20.21
FT /tag= a
FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.

XX
XX 20-JAN-2005.
XX
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX
PI Richards I, Mcswigen J;
XX
XX WPI, 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.
PT
XX
XX Disclosure; SEQ ID NO 279; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 21 BP; 5 A; 2 C; 7 G; 2 T; 5 U; 0 Other;
SQ
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 16 AACAGUACAACCCGCGCUU 35
DB 20 AACAGTGAACCTCGCCTT 1
RESULT 49
ADM27920/C
ID ADM27920 standard; RNA; 21 BP.
XX
AC ADM27920;
XX
XX 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #217.
DE
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.; respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective; nootropic; uropathic; short interfering RNA; RNA interference; siRNA; cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis; inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX
XX

XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, emphysema, irritable bowel syndrome,
 CC vasoconstriction or hypertension, allergic cystic fibrosis, pulmonary
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.

CC Sequence 21 BP, 5 A, 2 C, 7 G, 2 T, 5 U, 0 Other;
 SQ

Query Match 1.1%; Score 20; DB 1; Length 21;
 Best Local Similarity 75.0%; Pred. No. 1.5e+02;
 Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 16 AACAGUACAACCCGCTTU 35
 ||||:||||:||||:|
 20 AACAGTACAACCTCGCTTT 1

Db

RESULT 46
 ADW27950/C
 ID ADW27950 standard; RNA; 21 BP.
 XX
 AC ADW27950;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #247.
 XX
 KW gene expression; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT misc_difference 20..21
 FT /*tag= a
 FT /note= "deoxythymidine nucleotide"
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.

PA (MCSW/) MCSWIGGEN J.
 XX Richards I, Mcswiggen J;
 XX WPI; 2005-090672/10.
 DR

XX Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 XX Disclosure; SEQ ID NO 247; 84bp; English.
 XX

CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.

CC Sequence 21 BP, 5 A, 2 C, 7 G, 2 T, 5 U, 0 Other;
 SQ

Query Match 1.1%; Score 20; DB 1; Length 21;
 Best Local Similarity 75.0%; Pred. No. 1.5e+02;
 Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 16 AACAGUACAACCCGCTTU 35
 ||||:||||:||||:|
 20 AACAGTACAACCTCGCTTT 1

Db

RESULT 47
 ADW27970/C
 ID ADW27970 standard; RNA; 21 BP.
 XX
 AC ADW27970;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #267.
 XX
 KW gene expression; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW neotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT misc_difference 20..21
 FT /*tag= a
 FT /note= "deoxythymidine nucleotide"
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR

Db 1 UCCUCUUAAGCCUGGCCUGT 20

RESULT 44
ID ADM27986/c
ADW27986 standard; RNA; 21 BP.

AC ADM27986;
XX
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #283.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH misc_difference 20..21
FT /*tag= a
FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003US-00693059.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX PS Disclosure; SEQ ID NO 283; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimers disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule

CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siNA molecule of the invention.
XX
XX SO Sequence 21 BP; 1 A; 5 C; 6 G; 2 T; 7 U; 0 Other;
XX
XX Query Match 1.1%; Score 20; DB 1; Length 21;
XX Best Local Similarity 95.0%; Pred. No. 1.5e+02;
XX Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 974 AGCAGAGGACCAAGCCAC 993
XX |||||:|||||
XX DB 20 AGCAGATGACCAAGCCAC 1
XX
XX RESULT 45
XX ADM27918/c
XX ID ADM27918 standard; RNA; 21 BP.
XX
XX AC ADM27918;
XX
XX DT 07-APR-2005 (first entry)
XX
XX DE Cholinergic receptor muscarinic 3 gene targeted siRNA #215.
XX
XX KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX KW incontinence; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH misc_difference 20..21
FT /*tag= a
FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003US-00693059.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGEN J.
XX
XX Richards I, Mcswigen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX PS Disclosure; SEQ ID NO 215; 84pp; English.

XX Key Location/Qualifiers
FH misc_difference 20..21
FT /*tag= a
FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 231; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 21 BP; 5 A; 2 C; 7 G; 2 T; 5 U; 0 Other;
XX
XX Query Match 1.1%; Score 20; DB 1; Length 21;
XX Best Local Similarity 75.0%; Pred. No. 1.5e+02;
XX Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
XX
XX 16 AACAGUACAACCCGCUUU 35
XX |||||:|||||:|||||:|||||:
XX Db 20 AACAGTACAACTCCGCTTT 1

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #210.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimer disease;
XX incontinence; ss.
XX
XX Synthetic.
XX
XX
XX FH Key Location/Qualifiers
XX misc_difference 20..21
XX FT /*tag= a
XX FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 210; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 21 BP; 2 A; 7 C; 4 G; 2 T; 6 U; 0 Other;
XX
XX Query Match 1.1%; Score 20; DB 1; Length 21;
XX Best Local Similarity 95.0%; Pred. No. 1.5e+02;
XX Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX 317 UCCUCUUAAGCCUGGCUUG 336
XX |||||:|||||:|||||:|||||:

PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
PI Richards I, Mcswiggen J;
XX WPI; 2005-090672/10.
DR
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 219; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 21 BP; 1 A; 5 C; 6 G; 2 T; 7 U; 0 Other;
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 974 AGCAGUAGGACCAAGCCAC 993
Db 20 AGCAGATGACCAAGCCAC 1
RESULT 41
ADM27966/C
ID ADM27966 standard; RNA; 21 BP.
XX
AC ADM27966;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #263.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /*tag=a
FT /note="deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX

XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0361124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX WPI; 2005-090672/10.
DR
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 263; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 21 BP; 5 A; 2 C; 7 G; 2 T; 5 U; 0 Other;
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 16 AACAGUACAACGCGCCUUU 35
Db 20 AACAGTCAACCTCGCCTTT 1
RESULT 42
ADM27934/C
ID ADM27934 standard; RNA; 21 BP.
XX
AC ADM27934;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #231.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX

CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 21 BP; 6 A; 3 C; 8 G; 2 T; 2 U; 0 Other;
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
OY 314 ACUCCUCUUAAGCCUGGCC 333
DB 20 ACTCTCTTAAGCCCGGCC 1
RESULT 39
ADM27912
ID ADM27912 standard; RNA; 21 BP.
XX
AC ADM27912;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #209.
XX
KM gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /tag= a
FT /note= "deoxythymidine nucleotide"
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-0042716P.
XX 23-MAY-2003; 2003US-0044853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGEN J.
XX
PI Richarde I, Mcswigen J;
XX

DR WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 209; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 21 BP; 2 A; 8 C; 3 G; 2 T; 6 U; 0 Other;
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 315 CUUCCUCUUAAGCCUGGCCU 334
DB 1 CUUCCUCUUAAGCCUGGCCU 20
RESULT 40
ADM27922/C
ID ADM27922 standard; RNA; 21 BP.
XX
AC ADM27922;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #219.
XX
KM gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21
FT /tag= a
FT /note= "deoxythymidine nucleotide"
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.

ADW27938/c
ID ADW27938 standard; RNA; 21 BP.
XX
AC ADW27938;
XX
DT 07-APR-2005 (first entry)
XX
DB Cholinergic receptor muscarinic 3 gene targeted siRNA #235.
XX
KM gene expression; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uteropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21 a
FT /*tag= /note= "deoxythymidine nucleotide"
FT
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-0042716P.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 235; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 21 BP; 1 A; 5 C; 6 G; 2 T; 7 U; 0 Other;

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.5e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
CY 974 AGCAGATGACCAAGACCAC 993
DB 20 AGCAGATGACCAAGACCAC 1
RESULT 38
ADW27968/c
ID ADW27968 standard; RNA; 21 BP.
XX
AC ADW27968;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #265.
XX
KM gene expression; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uteropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 20..21 a
FT /*tag= /note= "deoxythymidine nucleotide"
FT
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-0042716P.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 265; 84bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,

KW altered drug metabolism; cardiovascular function; colorectal tumour;
KW central nervous system; pulmonary; immunological; SNP;
KW single nucleotide polymorphism.
XX
XX Homo sapiens.
XX
XX MO200257410-A2.
XX
XX 25-JUL-2002.
XX
XX 28-NOV-2001; 2001WO-US044838.
XX
XX 28-NOV-2000; 2000US-00724389.
XX
XX (DNAS-) DNA SCI LAB INC.
XX
XX Guida M, Hall J;
XX
XX WPI; 2002-698522/75.
XX
XX
XX Isolated nucleic acid molecules having polymorphisms in known human genes
XX e.g. cytochrome P450 and catepsin S useful as genetic linkage markers
XX for locating, identifying and characterizing the genes responsible for
XX disorder-related traits.
XX
XX
XX Example 28; Page 159; 714pp; English.
XX
XX This invention relates to the sequence of an isolated nucleic acid
XX molecule comprising at least one base variation from that of a known
XX human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),
XX cytochrome P450 02B1 (CYP45002B1), adrenergic receptor beta1 (ADBR1),
XX aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
XX (ARNT), catepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
XX inhibitor (DBI), epoxide hydrolase 2 (EPHX2), 5-lipoxygenase activating
XX protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
XX transferase (HNMT), (kallikrein 2) KLK2, nicotinamide -N-methyl
XX transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
XX sulfoltransferase thermostable (STM), UDP-glucuronosyl transferase 2B4
XX (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
XX transferase (UGT2B15), uridine kinase receptor (URK), multidrug resistance 1
XX (MDR1), lactoferrin (LTF), multidrug resistance associated protein 3
XX (MRP3), orphan nuclear receptor (NR112), or acetylcholine muscarinic
XX receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
XX The polymorphisms in the human genes cited in the invention are useful as
XX genetic linkage markers for locating and characterizing the genes that
XX are responsible for specific traits within the genome and eventually
XX identifying the genes responsible for a variety of disorder-related
XX traits as a result of their e.g., overexpression, constitutive
XX expression, mutation or underexpression, which may be used in diagnosing
XX and/or treating the disorders. The nucleic acid molecules comprising the
XX polymorphic sequences contained in CYP4501A1, CYP4501A2, CYP4502B1,
XX ARNT, EPHX2, GST12, NNMT, NQO2, NR112, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
XX MDR1 and/or MRP3 are useful for screening individuals for altered drug
XX metabolism. The polymorphic sequences contained in CYP4501A1, CYP4501A2,
XX AHR, MRP1 and/or MRP3 may also be used to screen individuals for
XX susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
XX used to screen for altered cardiovascular function. In COX2 for altered
XX susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
XX nervous system function, in FLAP and HNMT for altered pulmonary,
XX immunological or haematological function, in KLK2 for altered serine
XX protease activity in the prostate, in LTF for altered immunological or
XX haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
XX peripheral nervous system function. The present sequence represents a
XX polymorphic DNA sequence of the invention
XX
XX Sequence 21 BP; 5 A; 9 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX
XX Query Match 1.2%; Score 21; DB 1; Length 21;
XX Best Local Similarity 85.7%; Pred. No. 1.1e+02;
XX Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
XX
XX 158 ACGGACACGACGACCCCTC 178
XX
XX ||||:|||||||:||||:|

DB 1 ACGTACACGATGACCTC 21
XX
XX RESULT 36
XX AAD05887
XX ID AAD05887 standard; DNA; 20 BP.
XX
XX AAD05887;
XX
XX 31-JUL-2001 (first entry)
XX
XX
XX Human CHRM3 gene amplifying forward primer #4.
XX
XX Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
XX single nucleotide polymorphism; forensic application; gene therapy;
XX Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
XX sudden infant death syndrome; genotyping; haplotyping;
XX chromosome 1q41-q44; PCR primer; ss.
XX
XX Homo sapiens.
XX
XX MO200129176-A2.
XX
XX 26-APR-2001.
XX
XX 12-OCT-2000; 2000WO-US028247.
XX
XX 15-OCT-1999; 99US-0159860P.
XX
XX (GENA-) GENA1SSANCE PHARM INC.
XX
XX Choi JY, Denton RR, Nandabalan K, Stephens JC;
XX WPI; 2001-300326/31.
XX
XX Novel polymorphic variant of reference sequence for human cholinergic
XX receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
XX purposes.
XX
XX Example 1; Page 29; 54pp; English.
XX
XX The patent relates to polymorphic variants of human cholinergic receptor,
XX muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
XX single nucleotide polymorphism selected from cytosine at PS1, adenine at
XX PS2 or PS3, and cytosine at PS4. The invention also relates to a method
XX for genotyping and haplotyping the CHRM3 gene for identification of
XX variants. The polymorphic variant is useful for therapeutic purposes, for
XX studying the expression and biological function of CHRM3, as well as for
XX developing drugs targeting the CHRM3 protein. The variant is also useful
XX in diagnostics and forensic applications. The recombinant nonhuman
XX organism transfected with the polymorphic variant is useful for studying
XX expression of CHRM3 isogenes in vivo, for in vivo screening and testing
XX of drugs targeted against CHRM3 protein, and for testing the efficacy of
XX therapeutic agents and compounds for Alzheimer's disease, Sjogren's
XX syndrome, disorders associated with smooth muscle contractility and
XX sudden infant death syndrome. The CHRM3 protein variant is useful in drug
XX screening assays and its antibodies are useful in immunoassays to detect
XX CHRM3 protein variants in biological samples. The present sequence is a
XX PCR primer used for amplifying a fragment of human CHRM3 gene for
XX detecting polymorphic sites
XX
XX Sequence 20 BP; 7 A; 6 C; 5 G; 2 T; 0 U; 0 Other;
XX
XX
XX Query Match 1.1%; Score 20; DB 1; Length 20;
XX Best Local Similarity 90.0%; Pred. No. 1.3e+02;
XX Matches 18; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
XX 896 GCAUGAACGCUCAACAG 915
XX
XX ||||:|||||||:|||||||
XX DB 1 GCATGAAACGCTCCAAACAG 20
XX
XX ||||:|||||||:|||||||

RESULT 37

```
XX OS Homo sapiens.
XX FN WO200129176-A2.
XX PD 26-APR-2001.
XX PF 12-OCT-2000; 2000WO-US028247.
XX PR 15-OCT-1999; 99US-0159860P.
XX PA (GENA-) GENAISSANCE PHARM INC.
XX PI Choi JY, Denton RR, Nandabalan K, Stephens JC;
XX DR WPI; 2001-300326/31.
XX PT Novel polymorphic variant of reference sequence for human cholinergic
XX PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
XX PT purposes.
XX PS Example 1; Page 29; 54pp; English.
XX CC The patent relates to polymorphic variants of human cholinergic receptor,
XX CC muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
XX CC single nucleotide polymorphism selected from cytosine at P81, adenine at
XX CC P82 or P83, and cytosine at P84. The invention also relates to a method
XX CC for genotyping and haplotyping the CHRM3 gene for identification of
XX CC variants. The polymorphic variant is useful for therapeutic purposes, for
XX CC studying the expression and biological function of CHRM3, as well as for
XX CC developing drugs targeting the CHRM3 protein. The variant is also useful
XX CC in diagnostics and forensic applications. The recombinant nonhuman
XX CC organism transfected with the polymorphic variant is useful for studying
XX CC expression of CHRM3 isogenes in vivo, for in vivo screening and testing
XX CC of drugs targeted against CHRM3 protein, and for testing the efficacy of
XX CC therapeutic agents and compounds for Alzheimer's disease, Sjogren's
XX CC syndrome, disorders associated with smooth muscle contractility and
XX CC sudden infant death syndrome. The CHRM3 protein variant is useful in drug
XX CC screening assays and its antibodies are useful in immunoassays to detect
XX CC CHRM3 protein variants in biological samples. The present sequence is a
XX CC PCR primer used for amplifying a fragment of human CHRM3 gene for
XX CC detecting polymorphic sites
XX SQ Sequence 22 BP; 4 A; 8 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 1.2%; Score 22; DB 1; Length 22;
XX Best Local Similarity 72.7%; Pred. No. 92;
XX Matches 16; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 99 CGUCACUACUUUGGAGGACUAC 120
DB 1 CGTCACTCATTTTCGGCAGCTAC 22
RESULT 34
AAH62586
ID AAH62586 standard; DNA; 21 BP.
XX
XX AAH62586;
XX AC
XX DT 09-SEP-2004 (revised)
XX DT 12-SEP-2001 (first entry)
XX DE CHRM1 polymorphism containing DNA fragment #487.
XX KW Single nucleotide polymorphism; SNP; human; cancer; inflammation;
XX KW heart disease; paternity testing; forensic science; ds.
XX OS Homo sapiens.
XX OS Unidentified.
XX FT Key Location/Qualifiers
XX FT variation 11
```

```
FT FT /*tag= a
FT FT /standard_name= "single nucleotide polymorphism"
XX PN WO200138576-A2.
XX PD 31-MAY-2001.
XX PF 17-NOV-2000; 2000WO-US031639.
XX PR 24-NOV-1999; 99US-0167334P.
XX PA (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX PI Cargill M, Ireland JS, Lander ES;
XX DR WPI; 2001-367705/38.
XX PT New nucleic acid segments of the human genome, particularly from genes
XX PT including polymorphic sites, for phenotype correlation, forensics,
XX PT paternity testing, medicine and genetic analysis.
XX PS Claim 1; Page 68; 80pp; English.
XX CC DNA sequences AAH62100 - AAH62688 represent segments of human genes which
XX CC contain single nucleotide polymorphisms (SNPs). A method is included in
XX CC the invention for analysing a nucleic acid sample, which consists of
XX CC determining the base occupying any one of the polymorphic sites given in
XX CC the SNP containing sequences. The nucleotide sequences can be used in the
XX CC diagnosis or monitoring of diseases, such as cancer, inflammation, heart
XX CC diseases, diseases of the cardiovascular system, and infection by
XX CC microorganisms. The oligonucleotides are also useful in the manufacture
XX CC of a medicament for the treatment or prophylaxis of the diseases, and as
XX CC a pharmaceutical. SNP containing oligonucleotides are useful in
XX CC applications such as phenotype correlation, forensics, paternity testing,
XX CC medicine and genetic analysis
XX SQ Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
XX
XX Query Match 1.2%; Score 21; DB 1; Length 21;
XX Best Local Similarity 71.4%; Pred. No. 1.1e+02;
XX Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 228 CAUCCUGGCCUUGAGCAGCAU 248
DB 1 CACCTCGGCGCTTGATGACCAT 21
RESULT 35
ABS98535
ID ABS98535 standard; DNA; 21 BP.
XX
XX ABS98535;
XX AC
XX DT 23-DEC-2002 (first entry)
XX DE Human acetyl choline muscarinic receptor 3 polymorphic sequence #1.
XX KW Human; ds; cytochrome P450 A1; CYP4501A1; UGT2B4; MDRI;
XX KW cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
XX KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR112;
XX KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
XX KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
XX KW epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
XX KW glutathione-S-transferase 12; GSTI2; histamine-N-methyl transferase;
XX KW HMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
XX KW NADPH quinone oxidoreductase 2; NQO2; sulfortransferase; thioredoxin; STM;
XX KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
XX KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; uridine kinase receptor; UPA;
XX KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
XX KW acetylcholine muscarinic receptor; CHRM1; CHMR2; CHMR3; CHMR4; CHMR5;
```

XX DE Human CHR3 gene amplifying forward primer #3.
 XX KM Human; cholinergic receptor muscarinic 3; CHR3; drug screening;
 XX KM single nucleotide polymorphism; forensic application; gene therapy;
 XX KM Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
 XX KM sudden infant death syndrome; genotyping; haplotyping;
 XX KM chromosome 1q41-q44; PCR primer; ss.
 XX OS Homo sapiens.
 XX PN WO200129176-A2.
 XX PD 26-APR-2001.
 XX PR 12-OCT-2000; 2000MO-US028247.
 XX PR 15-OCT-1999; 99US-0159860P.
 XX PA (GENA-) GENA159860P.
 XX PI Choi JY, Denton RR, Nandabalan K, Stephens JC;
 XX DR WPI; 2001-300326/31.
 XX PT Novel polymorphic variant of reference sequence for human cholinergic
 XX PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
 XX PT purposes.
 XX PS Example 1; Page 29; 54pp; English.
 XX CC The patent relates to polymorphic variants of human cholinergic receptor,
 XX CC muscarinic 3 (CHR3) gene. The polymorphic variant comprises at least one
 XX CC single nucleotide polymorphism selected from cytosine at P51, adenine at
 XX CC P52 or P53, and cytosine at P54. The invention also relates to a method
 XX CC for genotyping and haplotyping the CHR3 gene for identification of
 XX CC variants. The polymorphic variant is useful for therapeutic purposes, for
 XX CC studying the expression and biological function of CHR3, as well as for
 XX CC developing drugs targeting the CHR3 protein. The variant is also useful
 XX CC in diagnostics and forensic applications. The recombinant nonhuman
 XX CC organism transfected with the polymorphic variant is useful for studying
 XX CC expression of CHR3 isogenes in vivo, for in vivo screening and testing
 XX CC of drugs targeted against CHR3 protein, and for testing the efficacy of
 XX CC therapeutic agents and compounds for Alzheimer's disease, Sjogren's
 XX CC syndrome, disorders associated with smooth muscle contractility and
 XX CC sudden infant death syndrome. The CHR3 protein variant is useful in drug
 XX CC screening assays and its antibodies are useful in immunoassays to detect
 XX CC CHR3 protein variants in biological samples. The present sequence is a
 XX CC PCR primer used for amplifying a fragment of human CHR3 gene for
 XX CC detecting polymorphic sites
 XX SQ Sequence 22 BP; 12 A; 5 C; 5 G; 0 T; 0 U; 0 Other;
 QY Query Match 1.2%; Score 22; DB 1; Length 22;
 Db Best Local Similarity 100.0%; Pred. No. 92;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 535 AAACGAACAACAAGAGACCG 556
 Db 1 AAACGAACAACAAGAGACCG 22
 RESULT 32
 AAD05886/c
 ID AAD05886 standard; DNA; 22 BP.
 XX AC AAD05886;
 XX DE Human CHR3 gene amplifying forward primer #3.
 XX DT 31-JUL-2001 (first entry)
 XX KM Human; cholinergic receptor muscarinic 3; CHR3; drug screening;

KM single nucleotide polymorphism; forensic application; gene therapy;
 KM Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
 KM sudden infant death syndrome; genotyping; haplotyping;
 KM chromosome 1q41-q44; PCR primer; ss.
 OS Homo sapiens.
 PN WO200129176-A2.
 PD 26-APR-2001.
 PR 12-OCT-2000; 2000MO-US028247.
 PR 15-OCT-1999; 99US-0159860P.
 PA (GENA-) GENA159860P.
 PI Choi JY, Denton RR, Nandabalan K, Stephens JC;
 DR WPI; 2001-300326/31.
 PT Novel polymorphic variant of reference sequence for human cholinergic
 PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
 PT purposes.
 PS Example 1; Page 29; 54pp; English.
 CC The patent relates to polymorphic variants of human cholinergic receptor,
 CC muscarinic 3 (CHR3) gene. The polymorphic variant comprises at least one
 CC single nucleotide polymorphism selected from cytosine at P51, adenine at
 CC P52 or P53, and cytosine at P54. The invention also relates to a method
 CC for genotyping and haplotyping the CHR3 gene for identification of
 CC variants. The polymorphic variant is useful for therapeutic purposes, for
 CC studying the expression and biological function of CHR3, as well as for
 CC developing drugs targeting the CHR3 protein. The variant is also useful
 CC in diagnostics and forensic applications. The recombinant nonhuman
 CC organism transfected with the polymorphic variant is useful for studying
 CC expression of CHR3 isogenes in vivo, for in vivo screening and testing
 CC of drugs targeted against CHR3 protein, and for testing the efficacy of
 CC therapeutic agents and compounds for Alzheimer's disease, Sjogren's
 CC syndrome, disorders associated with smooth muscle contractility and
 CC sudden infant death syndrome. The CHR3 protein variant is useful in drug
 CC screening assays and its antibodies are useful in immunoassays to detect
 CC CHR3 protein variants in biological samples. The present sequence is a
 CC PCR primer used for amplifying a fragment of human CHR3 gene for
 CC detecting polymorphic sites
 SQ Sequence 22 BP; 1 A; 6 C; 6 G; 9 T; 0 U; 0 Other;
 QY Query Match 1.2%; Score 22; DB 1; Length 22;
 Db Best Local Similarity 95.5%; Pred. No. 92;
 Matches 21; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 973 GAGCAGATGACCAAGACCA 994
 Db 22 GAGCAGATGACCAAGACCA 1
 RESULT 33
 AAD05883
 ID AAD05883 standard; DNA; 22 BP.
 XX AC AAD05883;
 XX DE Human CHR3 gene amplifying forward primer #2.
 XX DT 31-JUL-2001 (first entry)
 XX KM Human; cholinergic receptor muscarinic 3; CHR3; drug screening;
 XX KM single nucleotide polymorphism; forensic application; gene therapy;
 XX KM Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
 XX KM sudden infant death syndrome; genotyping; haplotyping;
 XX KM chromosome 1q41-q44; PCR primer; ss.

```

AEA02316
ID AEA02316 standard; RNA; 23 BP.
XX
AC AEA02316;
XX
DT 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 200.
XX
KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neutroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KW micrition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX
PN WO2005045040-A2.
XX
PD 19-MAY-2005.
XX
PF 20-AUG-2004; 2004WO-US027367.
XX
PR 23-OCT-2003; 2003US-00693059.
XX
PR 24-NOV-2003; 2003US-00720448.
XX
PR 03-DEC-2003; 2003US-00727780.
XX
PR 14-JAN-2004; 2004US-00757803.
XX
PR 10-FEB-2004; 2004US-0543480P.
XX
PR 13-FEB-2004; 2004US-00780447.
XX
PR 11-MAR-2004; 2004US-00798090.
XX
PR 16-APR-2004; 2004US-00826966.
XX
PR 30-APR-2004; 2004WO-US013456.
XX
PR 24-MAY-2004; 2004WO-US016390.
XX
PR 17-AUG-2004; 2004US-00919866.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Richards I, Macswiggen J;
XX
DR WPI; 2005-356237/36.
XX
PT New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
PS Claim 33; SEQ ID NO 200; 184bp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 23 BP; 4 A; 8 C; 3 G; 0 T; 8 U; 0 Other;
XX
Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

OY 19 AGUACACCCGCUUUGUUC 41
    |||||
DB 1 AGUACACCCGCUUUGUUC 23

```

```

RESULT 30
AAD05882/C
ID AAD05882 standard; DNA; 22 BP.

```

```

XX
AC AAD05882;
XX
DT 31-JUL-2001 (first entry)
XX
DE Human CHRM3 gene amplifying reverse primer #1.
XX
KW Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
KW single nucleotide polymorphism; forensic application; gene therapy;
KW Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
KW sudden infant death syndrome; genotyping; haplotyping;
KW chromosome 1q41-q44; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200129176-A2.
XX
PD 26-APR-2001.
XX
PF 12-OCT-2000; 2000WO-US028247.
XX
PR 15-OCT-1999; 99US-0159860P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Choi YJ, Denton RR, Nandabalan K, Stephens JC;
XX
DR WPI; 2001-300326/31.
XX
PT Novel polymorphic variant of reference sequence for human cholinergic
PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
PT purposes.
XX
PS Example 1; Page 29; 54pp; English.
XX
CC The patent relates to polymorphic variants of human cholinergic receptor,
CC muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
CC single nucleotide polymorphism selected from cytosine at P81, adenine at
CC P82 or P83, and cytosine at P84. The invention also relates to a method
CC for genotyping and haplotyping the CHRM3 gene for identification of
CC variants. The polymorphic variant is useful for therapeutic purposes, for
CC studying the expression and biological function of CHRM3, as well as for
CC developing drugs targeting the CHRM3 protein. The variant is also useful
CC in diagnostics and forensic applications. The recombinant nonhuman
CC organism transfected with the polymorphic variant is useful for studying
CC expression of CHRM3 isogenes in vivo, for in vivo screening and testing
CC of drugs targeted against CHRM3 protein, and for testing the efficacy of
CC therapeutic agents and compounds for Alzheimer's disease, Sjogren's
CC syndrome, disorders associated with smooth muscle contractility and
CC sudden infant death syndrome. The CHRM3 protein variant is useful in drug
CC screening assays and its antibodies are useful in immunoassays to detect
CC CHRM3 protein variants in biological samples. The present sequence is a
CC PCR primer used for amplifying a fragment of human CHRM3 gene for
XX detecting polymorphic sites
XX
SQ Sequence 22 BP; 6 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
XX
Query Match 1.2%; Score 22; DB 1; Length 22;
Best Local Similarity 72.7%; Pred. No. 92;
Matches 16; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

```

```

OY 252 CGGCACATCCGUAUUGUG 273
    |||||
DB 22 CGGCACATCCGUAUUGUG 1

```

```

RESULT 31
AAD05885
ID AAD05885 standard; DNA; 22 BP.
XX
AC AAD05885;
XX
DT 31-JUL-2001 (first entry)

```

Db 1 AGCAGUACGACGAGACAGUCG 23

RESULT 27

AEA02322
ID AEA02322 standard; RNA; 23 BP.

AC AEA02322;

DT 28-JUL-2005 (first entry)

DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 206.

Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
Neuroprotective; Nootropic; Uropathic;
Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
micturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
siRNA; RNA interference; gene silencing; short interfering RNA.

OS Synthetic.

PN WO2005045040-A2.

PD 19-MAY-2005.

PF 20-AUG-2004; 2004WO-US027367.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 03-DEC-2003; 2003US-00727780.

PR 14-JAN-2004; 2004US-00757803.

PR 10-FEB-2004; 2004US-0543480P.

PR 13-FEB-2004; 2004US-00780447.

PR 11-MAR-2004; 2004US-00798090.

PR 16-APR-2004; 2004US-00826966.

PR 30-APR-2004; 2004WO-US013456.

PR 24-MAY-2004; 2004WO-US016390.

PR 17-AUG-2004; 2004US-00919866.

(SIRN-) SIRNA THERAPEUTICS INC.

Richard I, Macswiggen J;

WPI; 2005-356237/36.

New short interfering nucleic acid molecule that directs cleavage of a
cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
disease.

Claim 33; SEQ ID NO 206; 184pp; English.

The invention relates to a chemically synthesized double stranded short
interfering nucleic acid (siNA) molecule that directs cleavage of a
cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
(RNAi). The siNA molecule, compounds, compositions, and methods are
useful for treating or preventing respiratory and pulmonary diseases,
disorders, and/or conditions, including chronic obstructive pulmonary
disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
cystic fibrosis, alzheimer's disease, and/or urinary incontinence. The
present sequence represents a cholinergic receptor muscarinic 3 siRNA.

SQ Sequence 23 BP; 7 A; 6 C; 8 G; 0 T; 2 U; 0 Other;

Query Match 1.3%; Score 23; DB 1; Length 23;

Best Local Similarity 100.0%; Pred. No. 76;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1713 GCAGUACGACGACGAGUCG 1735

Db 1 GCAGUACGACGACGAGUCG 23

RESULT 28

AEA02320
ID AEA02320 standard; RNA; 23 BP.

AC AEA02320;

DT 28-JUL-2005 (first entry)

DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 204.

Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
Neuroprotective; Nootropic; Uropathic;
Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
micturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
siRNA; RNA interference; gene silencing; short interfering RNA.

OS Synthetic.

PN WO2005045040-A2.

PD 19-MAY-2005.

PF 20-AUG-2004; 2004WO-US027367.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 03-DEC-2003; 2003US-00727780.

PR 14-JAN-2004; 2004US-00757803.

PR 10-FEB-2004; 2004US-0543480P.

PR 13-FEB-2004; 2004US-00780447.

PR 11-MAR-2004; 2004US-00798090.

PR 16-APR-2004; 2004US-00826966.

PR 30-APR-2004; 2004WO-US013456.

PR 24-MAY-2004; 2004WO-US016390.

PR 17-AUG-2004; 2004US-00919866.

(SIRN-) SIRNA THERAPEUTICS INC.

Richard I, Macswiggen J;

WPI; 2005-356237/36.

New short interfering nucleic acid molecule that directs cleavage of a
cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
disease.

Claim 33; SEQ ID NO 204; 184pp; English.

The invention relates to a chemically synthesized double stranded short
interfering nucleic acid (siNA) molecule that directs cleavage of a
cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
(RNAi). The siNA molecule, compounds, compositions, and methods are
useful for treating or preventing respiratory and pulmonary diseases,
disorders, and/or conditions, including chronic obstructive pulmonary
disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
cystic fibrosis, alzheimer's disease, and/or urinary incontinence. The
present sequence represents a cholinergic receptor muscarinic 3 siRNA.

SQ Sequence 23 BP; 8 A; 6 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 1.3%; Score 23; DB 1; Length 23;

Best Local Similarity 100.0%; Pred. No. 76;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1710 GCAGUACGACGACGAGACGU 1732

Db 1 GCAGUACGACGACGAGACGU 23

RESULT 29

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 15 UACAGUACACUCCGCUUGU 37
 |||||
Db 1 UACAGUACACUCCGCUUGU 23

RESULT 25

AEA02319
ID AEA02319 standard; RNA; 23 BP.

AC AEA02319;
XX

DT 28-JUL-2005 (first entry)
XX

DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 203.

KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;

KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;

KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.

XX Synthetic.
XX

OS WO2005045040-A2.
XX

PN 19-MAY-2005.
XX

PD 20-AUG-2004; 2004WO-US027367.
XX

PF 23-OCT-2003; 2003US-00693059.
XX

PR 24-NOV-2003; 2003US-00720448.
XX

PR 03-DEC-2003; 2003US-00727780.
XX

PR 14-JAN-2004; 2004US-00757803.
XX

PR 10-FEB-2004; 2004US-0543480P.
XX

PR 13-FEB-2004; 2004US-00780447.
XX

PR 11-MAR-2004; 2004US-00798090.
XX

PR 16-APR-2004; 2004US-00826966.
XX

PR 30-APR-2004; 2004WO-US013456.
XX

PR 24-MAY-2004; 2004WO-US016390.
XX

PR 17-AUG-2004; 2004US-00919866.
XX

PA (SIRN-) SIRNA THERAPEUTICS INC.
XX

PI Richards I, Macswigen J;
XX

DR WPI; 2005-356237/36.
XX

XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.

PT disease.
XX

PS Claim 33; SEQ ID NO 203; 184bp; English.
XX

XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX Sequence 23 BP; 9 A; 6 C; 7 G; 0 T; 1 U; 0 Other;
XX

Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 76;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 973 GAGCAGUGGACCAAGCAG 995
 |||||
Db 1 GAGCAGUGGACCAAGCAG 23

RESULT 26

AEA02321
ID AEA02321 standard; RNA; 23 BP.

AC AEA02321;
XX

DT 28-JUL-2005 (first entry)
XX

DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 205.

KW Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;

KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;

KW microtubule disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.

XX Synthetic.
XX

OS WO2005045040-A2.
XX

PN 19-MAY-2005.
XX

PD 20-AUG-2004; 2004WO-US027367.
XX

PF 23-OCT-2003; 2003US-00693059.
XX

PR 24-NOV-2003; 2003US-00720448.
XX

PR 03-DEC-2003; 2003US-00727780.
XX

PR 14-JAN-2004; 2004US-00757803.
XX

PR 10-FEB-2004; 2004US-0543480P.
XX

PR 13-FEB-2004; 2004US-00780447.
XX

PR 11-MAR-2004; 2004US-00798090.
XX

PR 16-APR-2004; 2004US-00826966.
XX

PR 30-APR-2004; 2004WO-US013456.
XX

PR 24-MAY-2004; 2004WO-US016390.
XX

PR 17-AUG-2004; 2004US-00919866.
XX

PA (SIRN-) SIRNA THERAPEUTICS INC.
XX

PI Richards I, Macswigen J;
XX

DR WPI; 2005-356237/36.
XX

XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.

PT disease.
XX

PS Claim 33; SEQ ID NO 205; 184bp; English.
XX

XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.

XX Sequence 23 BP; 8 A; 6 C; 7 G; 0 T; 2 U; 0 Other;
XX

Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 76;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1712 AGCAGUACGACGACAGUCG 1734
 |||||

SQ Sequence 23 BP; 2 A; 8 C; 5 G; 0 T; 8 U; 0 Other;
Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 315 CUUCCUUAAGCCUGCCUG 337
|||||
DB 1 CUUCCUUAAGCCUGCCUG 23

RESULT 23
AEA02317
ID AEA02317 standard; RNA; 23 BP.
AC AEA02317;
XX 28-JUL-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 201.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mucritulion disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
PD 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00826966.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 201; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 23 BP; 3 A; 8 C; 4 G; 0 T; 8 U; 0 Other;

Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 313 UACUCCUUAAGCCUGCCUG 335
|||||
DB 1 UACUCCUUAAGCCUGCCUG 23

RESULT 24
AEA02315
ID AEA02315 standard; RNA; 23 BP.
XX
XX AEA02315;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 199.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neuroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mucritulion disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
OS Synthetic.
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 03-DEC-2003; 2003US-00727780.
XX 14-JAN-2004; 2004US-00757803.
XX 10-FEB-2004; 2004US-0543480P.
XX 13-FEB-2004; 2004US-00780447.
XX 11-MAR-2004; 2004US-00780447.
XX 16-APR-2004; 2004US-00826966.
XX 30-APR-2004; 2004WO-US013456.
XX 24-MAY-2004; 2004WO-US016390.
XX 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX disease.
XX
XX Claim 33; SEQ ID NO 199; 184bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX (RNAi). The siNA molecule, compounds, compositions, and methods are
XX useful for treating or preventing respiratory and pulmonary diseases,
XX disorders, and/or conditions, including chronic obstructive pulmonary
XX disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 23 BP; 6 A; 7 C; 3 G; 0 T; 7 U; 0 Other;
XX
XX Query Match 1.3%; Score 23; DB 1; Length 23;
XX Best Local Similarity 100.0%; Pred. No. 76;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1713 GCAGUACGACGACAGUCCG 1735
|||||
Db 1 GCAGUACGACGACAGUCCG 23

RESULT 21
ADM27907
ID ADM27907 standard; RNA; 23 BP.
XX
XX ADM27907;
XX
XX 07-APR-2005 (first entry)
XX
XX Cholineergic receptor muscarinic 3 gene targeted siRNA #204.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholineergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
XX Synthetic.
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003US-0440129P.
PR 30-APR-2003; 2003US-0442716P.
PR 23-MAY-2003; 2003US-0444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholineergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 204; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholineergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This

CC sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 23 BP, 8 A; 6 C; 7 G; 0 T; 2 U; 0 Other;
SQ

Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1710 GCAGUACGACGACAGU 1732
|||||
Db 1 GCAGUACGACGACAGU 23

RESULT 22
AEA02318
ID AEA02318 standard; RNA; 23 BP.
XX
XX AEA02318;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholineergic receptor muscarinic 3 siRNA SEQ ID NO 202.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mutation disorder; cholineergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholineergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 202; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholineergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAI). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimers disease, and/or urinary incontinence. The
CC present sequence represents a cholineergic receptor muscarinic 3 siRNA.

XX 07-APR-2005 (first entry)
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #203.
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX Synthetic.
XX US2005014172-A1.
XX 20-JAN-2005.
XX 11-MAR-2004; 2004US-00798090.
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-0044853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX Richards I, Mcswiggen J;
XX MPI; 2005-090672/10.
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX Disclosure; SEQ ID NO 203; 84bp; English.
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX Sequence 23 BP; 9 A; 6 C; 7 G; 0 T; 1 U; 0 Other;
SQ Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 973 GAGCAGUGAGCCAGACACAG 995
DB 1 GAGCAGUGAGCCAGACACAG 23

RESULT 20
ADW27909.1
ID ADW27909 standard; RNA; 23 BP.
XX
XX ADW27909;
AC
XX 07-APR-2005 (first entry)
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #206.
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX Synthetic.
XX US2005014172-A1.
XX 20-JAN-2005.
XX 11-MAR-2004; 2004US-00798090.
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003US-00427160.
XX 30-APR-2003; 2003US-0044853.
XX 23-MAY-2003; 2003US-0044853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX Richards I, Mcswiggen J;
XX MPI; 2005-090672/10.
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX Disclosure; SEQ ID NO 206; 84bp; English.
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX Sequence 23 BP; 7 A; 6 C; 8 G; 0 T; 2 U; 0 Other;
SQ Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 76;

XX Synthetic.
OS
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
PI
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 200; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 23 BP; 4 A; 8 C; 3 G; 0 T; 8 U; 0 Other;
SQ
Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 19 AGUACACCCUCCGUUUTUCC 41
Db 1 AGUACACCCUCCGUUUTUCC 23
RESULT 18
ADW27904
ID ADW27904 standard; RNA; 23 BP.
XX
XX ADW27904;
AC
XX
XX 07-APR-2005 (first entry)
DT
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #201.
DE
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;

KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
XX Synthetic.
OS
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
PI
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 201; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 23 BP; 3 A; 8 C; 4 G; 0 T; 8 U; 0 Other;
SQ
Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 313 UACUUCUCUUAAGCCGCGCUG 335
Db 1 UACUUCUCUUAAGCCGCGCUG 23
RESULT 19
ADW27906
ID ADW27906 standard; RNA; 23 BP.
XX
XX ADW27906;

PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409338P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 PI Richards I, Mcswiggen J;
 XX
 DR MPI; 2005-090672/10.
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 PS Disclosure; SEQ ID NO 199; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 23 BP; 6 A; 7 C; 3 G; 0 T; 7 U; 0 Other;
 Query Match 1.3%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 76;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 15 UAAAGUACAACCCGCUUUGU 37
 DB 1 UAAAGUACAACCCGCUUUGU 23
 RESULT 16
 ADW27905
 ID ADW27905 standard; RNA; 23 BP.
 XX
 AC ADW27905;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #202.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 XX
 OS Synthetic.
 XX
 PN US2005014172-A1.
 XX
 PD 20-JAN-2005.

XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409338P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 PI Richards I, Mcswiggen J;
 XX
 DR MPI; 2005-090672/10.
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 PS Disclosure; SEQ ID NO 202; 84pp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 23 BP; 2 A; 8 C; 5 G; 0 T; 8 U; 0 Other;
 Query Match 1.3%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 76;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 315 CUUCCUUAAGCCUGCCUGG 337
 DB 1 CUUCCUUAAGCCUGCCUGG 23
 RESULT 17
 ADW27903
 ID ADW27903 standard; RNA; 23 BP.
 XX
 AC ADW27903;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #200.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.

XX	12-OCT-2000; 2000WO-US028247.
PX	15-OCT-1999; 99US-0159860P.
XX	(GENA-) GENAISSANCE PHARM INC.
PA	
XX	Choi JY, Denton RR, Nandabalan K, Stephens JC;
P1	WPI; 2001-300326/31.
DR	
XX	
PT	Novel polymorphic variant of reference sequence for human cholinergic
PT	receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
PT	purposes.
XX	
PS	Example 1; Page 29; 54pp; English.
XX	
CC	The patent relates to polymorphic variants of human cholinergic receptor,
CC	muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
CC	single nucleotide polymorphism selected from cytosine at PS1, adenine at
CC	PS2 or PS3, and cytosine at PS4. The invention also relates to a method
CC	for genotyping and haplotyping the CHRM3 gene for identification of
CC	variants. The polymorphic variant is useful for therapeutic purposes, for
CC	studying the expression and biological function of CHRM3, as well as for
CC	developing drugs targeting the CHRM3 protein. The variant is also useful
CC	in diagnostics and forensic applications. The recombinant nonhuman
CC	organism transfected with the polymorphic variant is useful for studying
CC	expression of CHRM3 isoforms in vivo, for in vivo screening and testing of
CC	drugs targeted against CHRM3 protein, and for testing the efficacy of
CC	therapeutic agents and compounds for Alzheimer's disease, Sjogren's
CC	sndrome, disorders associated with smooth muscle contractility and
CC	sudden infant death syndrome. The CHRM3 protein variant is useful in drug
CC	screening assays and its antibodies are useful in immunoassays to detect
CC	CHRM3 protein variants in biological samples. The present sequence is a
CC	PCR primer used for amplifying a fragment of human CHRM3 gene for
CC	detecting polymorphic sites
SQ	
Sequence	24 BP; 7 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
Query Match	1.4%; Score 24; DB 1; Length 24;
Best Local Similarity	79.2%; Pred. No. 63;
Matches	19; Conservative 5; Mismatches 0; Indels 0; Gaps 0.
OY	1304 UGACACAGCUNAAGACUUCUGACG 1327
DB	1 TGACACAGCTAAAGACTTGTGCG 24
RESULT 14	
ID	AAD05884/C
AC	AAD05884 standard; DNA; 23 BP.
XX	AAD05884;
DT	
XX	31-JUN-2001 (first entry)
DE	
XX	Human CHRM3 gene amplifying reverse primer #2.
KM	Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
KV	single nucleotide polymorphism; forensic application; gene therapy;
KW	Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
KW	sudden infant death syndrome; genotyping; haplotyping;
XX	chromosome 1q41-q44; PCR primer; ss.
OS	Homo sapiens.
XX	
PN	MO200129176-A2.
PD	
XX	26-APR-2001.
PF	
XX	12-OCT-2000; 2000WO-US028247.
PR	15-OCT-1999; 99US-0159860P.

XX	(GENA-)	GENAISSANCE PHARM INC.
PA		
XX		
PI	Choi JY,	Denton RR, Nandabalan K, Stephens JC;
XX		
DR	WPI,	2001-300326/31.
XX		
PT	Novel polymorphic variant of reference sequence for human cholinergic	
PT	receptor, muscarinic 3 gene, useful for diagnostic and therapeutic	
PT	purposes.	
XX		
PS	Example 1;	Page 29; 54pp; English.
XX		
CC	The patent relates to polymorphic variants of human cholinergic receptor,	
CC	muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one	
CC	single nucleotide polymorphism selected from cytosine at PS1, adenine at	
CC	PS2 or PS3, and cytosine at PS4. The invention also relates to a method	
CC	for genotyping and haplotyping the CHRM3 gene for identification of	
CC	variants. The polymorphic variant is useful for therapeutic purposes, for	
CC	studying the expression and biological function of CHRM3, as well as for	
CC	developing drugs targeting the CHRM3 protein. The variant is also useful	
CC	in diagnostics and forensic applications. The recombinant nonhuman	
CC	organism transfected with the polymorphic variant is useful for studying	
CC	expression of CHRM3 isogenes in vivo, for in vivo screening and testing	
CC	of drugs targeted against CHRM3 protein, and for testing the efficacy of	
CC	therapeutic agents and compounds for Alzheimer's disease, Sjogren's	
CC	syndrome, disorders associated with smooth muscle contractility and	
CC	sudden infant death syndrome. The CHRM3 protein variant is useful in drug	
CC	screening assays and its antibodies are useful in immunoassays to detect	
CC	CHRM3 protein variants in biological samples. The present sequence is a	
CC	PCR primer used for amplifying a fragment of human CHRM3 gene for	
CC	detecting polymorphic sites	
XX		
QO	Sequence 23 BP; 5 A; 7 C; 5 G; 6 T; 0 U; 0 Other;	
XX		
Query Match	1.3%;	Score 23; DB 1; Length 23;
Best Local Similarity	78.3%;	Pred. No. 76;
Matches 18;	Conservative 5;	Mismatches 0; Indels 0; Gaps 0;
QY	631	GUUGAAAGAGAACTGUCCTCC 653
DB	23	GTTGGAAAGAGAACTGTCCTCC 1
: : : :		
RESULT 15		
ADW27902		
ID	ADW27902	standard; RNA; 23 BP.
XX		
AC	ADW27902;	
XX		
DT	07-APR-2005	(first entry)
XX		
DB	Cholinergic receptor muscarinic 3 gene targeted siRNA #199.	
XX		
KW	gene expression; antiasthmatic; anti-allergic; anti-inflammatory; CNS-Gen.;	
KW	respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;	
KW	neurotic; uropathic; short interfering RNA; RNA interference; siRNA;	
KW	cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;	
KW	inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;	
KW	hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;	
KW	incontinence; ss.	
XX		
OS	Synthetic.	
XX		
XX	US2005014172-A1.	
XX		
XX	20-JAN-2005.	
XX		
PD		
PF	11-MAR-2004;	2004US-00798090.
XX		
XX	20-FEB-2002;	2002US-0358580P.
XX		
XX	11-MAR-2002;	2002US-0363124P.
XX		
XX	20-MAY-2002;	2002WO-US015876.
XX		

XX Human; resequence; genotype; disease; forensic; paternity testing;
KM single nucleotide polymorphism; SNP; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT variation 16
FT /tag= a
FT /standard_name= "single nucleotide polymorphism"
XX
XX WO200166800-A2.
XX
XX 13-SEP-2001.
XX
XX 07-MAR-2001; 2001WO-US007268.
XX
XX 07-MAR-2000; 2000US-0187510P.
XX
XX 22-MAY-2000; 2000US-0206129P.
XX
XX (WHD) WHITEHEAD INST BIOMEDICAL RES.
XX
XX Cargill M, Ireland JS, Lander ES;
XX
XX WPI; 2001-522952/57.
XX
XX Nucleic acid molecules from the human genome which include polymorphic
PT sites, useful in methods for predicting the presence, absence or severity
PT of a particular phenotype or disorder (e.g. diabetes) associated with a
PT particular genotype.
XX
XX Claim 1; Page 98; 145pp; English.
XX
XX The invention relates to the identification of nucleic acid molecules
CC (AA129513-AA131314) from the human genome which include polymorphic sites
CC which can predispose individuals to disease. Various genes from a number
CC of individuals were resequenced and single nucleotide polymorphisms
CC (SNPs) in these genes discovered. The method is useful for predicting the
CC presence, absence or severity of a particular phenotype or disorder (e.g.
CC diabetes) associated with a particular genotype. The nucleic acids
CC containing the polymorphic sites may be useful in forensics and paternity
CC testing
CC
CC Revised record issued on 04-NOV-2004 : Correction to Feature Table Key
XX
XX Sequence 31 BP, 5 A; 12 C; 5 G; 9 T; 0 U; 0 Other;
SQ
Query Match 1.4%; Score 25.2; DB 1; Length 31;
Best Local Similarity 66.7%; Pred. No. 79;
Matches 20; Conservative 7; Mismatches 3; Indels 0; Gaps 0;
QY 687 CACCAUACUUUUGGACAGCCGACUCCGCTGC 716
DB 1 CACCATCACTTTTGCGACATGCGCATGCTGC 30
RESULT 12
AAD05888/c
ID AAD05888 standard; DNA; 25 BP.
XX
XX AAD05888;
XX
XX 31-JUL-2001 (first entry)
XX
XX Human CHRM3 gene amplifying reverse primer #4.
XX
XX Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
KM single nucleotide polymorphism; forensic application; gene therapy;
KM Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
KM sudden infant death syndrome; genotyping; haployping;
KM chromosome 1q41-q44; PCR primer; ss.
XX
XX Homo sapiens.
OS

XX
XX WO200129176-A2.
XX
XX 26-APR-2001.
XX
XX 12-OCT-2000; 2000WO-US028247.
XX
XX 15-OCT-1999; 99US-0159860P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Chai JY, Denton RR, Nandabalan K, Stephens JC;
XX
XX WPI; 2001-300326/31.
XX
XX Novel polymorphic variant of reference sequence for human cholinergic
PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
PT purposes.
XX
XX Example 1; Page 29; 54pp; English.
XX
XX The patent relates to polymorphic variants of human cholinergic receptor,
CC muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
CC single nucleotide polymorphism selected from cytosine at PS1, adenine at
CC PS2 or PS3, and cytosine at PS4. The invention also relates to a method
CC for genotyping and haployping the CHRM3 gene for identification of
CC variants. The polymorphic variant is useful for therapeutic purposes, for
CC studying the expression and biological function of CHRM3, as well as for
CC developing drugs targeting the CHRM3 protein. The variant is also useful
CC in diagnostics and forensic applications. The recombinant nonhuman
CC organism transfected with the polymorphic variant is useful for studying
CC expression of CHRM3 isogenes in vivo, for in vivo screening and testing
CC of drugs targeted against CHRM3 protein, and for testing the efficacy of
CC therapeutic agents and compounds for Alzheimer's disease, Sjogren's
CC syndrome, disorders associated with smooth muscle contractility and
CC sudden infant death syndrome. The CHRM3 protein variant is useful in drug
CC screening assays and its antibodies are useful in immunoassays to detect
CC CHRM3 protein variants in biological samples. The present sequence is a
CC PCR primer used for amplifying a fragment of human CHRM3 gene for
CC detecting polymorphic sites
XX
XX Sequence 25 BP, 3 A; 7 C; 6 G; 9 T; 0 U; 0 Other;
SQ
Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 52;
Matches 22; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 1410 GACCGAGAGUCAGAUCAUACCGG 1434
DB 25 GACCGAGAGTCAATCATCAATACCGG 1
RESULT 13
AAD05889
ID AAD05889 standard; DNA; 24 BP.
XX
XX AAD05889;
XX
XX 31-JUL-2001 (first entry)
XX
XX Human CHRM3 gene amplifying forward primer #5.
XX
XX Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
KM single nucleotide polymorphism; forensic application; gene therapy;
KM Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
KM sudden infant death syndrome; genotyping; haployping;
KM chromosome 1q41-q44; PCR primer; ss.
XX
XX Homo sapiens.
XX
XX WO200129176-A2.
XX
XX 26-APR-2001.
PD

```

QY      1495 GCCUUCAUCAUCGACCCCAUACAAC 1524
      |||::|||::|||::|||::|||::|||::|||
Db      1  GCCTCATCATCAAGTGACCCCTTACACC 30

RESULT 9
AAZ94358
ID      AAZ94358 standard; DNA; 30 BP.
XX
AC      AAZ94358;
XX
DT      03-JUL-2000 (first entry)
XX
DE      Drosophila muscarinic acetylcholine receptor PCR primer.
XX
KW      G protein coupled receptor; GPCR; insect; MAR;
XX      muscarinic acetylcholine receptor; drug screening; PCR primer; ss.
XX
OS      Drosophila melanogaster.
XX
PN      WO200012705-A2.
XX
PD      09-MAR-2000.
XX
PF      01-SEP-1999; 99WO-US020013.
XX
PR      01-SEP-1998; 98US-0098704P.
XX
PA      (PAUS/) PAUSCH M H.
XX      (WESS/) WESS J.
XX
PI      Pausch MH, Wess J;
XX
DR      WPI; 2000-246754/21.
XX
PT      New G protein-coupled receptors with a mutation in an intracellular
PT      domain, useful for high throughput screening assays for e.g. drugs,
PT      insecticides or nematocides.
XX
PS      Example 2; Page 12; 37pp; English.
XX
CC      This is the DNA sequence of a primer that was used in the PCR
CC      amplification of a DNA fragment consisting of the C-terminal coding
CC      portion of Drosophila melanogaster muscarinic acetylcholine receptor
CC      (MAR) from a Pml site in the 6th transmembrane domain. MAR is a G
CC      protein coupled receptor (GPCR). The PCR product was ligated into
CC      expression plasmid p426GPD. Yeast cells containing an intracellular loop
CC      3 (IC3) deleted Drosophila MAR produced an agonist-dependent growth
CC      response. The invention provides modified GPCRs having a mutation in IC3
CC      that results in an improved functional response in cell-based assays. The
CC      modification promotes growth stimulation by a GPCR agonist, especially by
CC      improving coupling between the receptor and a heterotrimeric G protein.
CC      Polynucleotides encoding the mutated GPCR, chimeric GPCR, vectors and
CC      host cells are also claimed. The modified GPCRs can be used in improved
CC      high throughput screening assays (especially in yeast cells) for
CC      therapeutic drugs, insecticides, nematocides etc. Agonists of G protein-
CC      coupled insect MARs possess substantial insecticide and miticide activity
XX
SQ      Sequence 30 BP; 8 A; 10 C; 4 G; 8 T; 0 U; 0 Other;

Query Match      1.4%; Score 25.2; DB 1; Length 30;
Best Local Similarity 66.7%; Pred. No. 73;
Matches 20; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

QY      1498 UUCAUCAUCACUUGACCCCAUACAAC 1527
      ::|||::|||::|||::|||::|||::|||
Db      1  TTCATCATCAACGCGACCTCCGTAACAACATC 30

RESULT 10
AAI30840
ID      AAI30840 standard; DNA; 31 BP.

```

```

XX
AC      AAI30840;
XX
DT      04-NOV-2004 (revised)
DT      18-OCT-2001 (first entry)
XX
DE      Human single nucleotide polymorphism (SNP) CHRM4 2.
XX
KW      Human; resequence; genotype; disease; forensic; paternity testing;
XX      single nucleotide polymorphism; SNP; ss.
XX
OS      Homo sapiens.
XX
FH      Key      location/Qualifiers
FT      variation 16
FT      /*tag= a
FT      /standard_name= "single nucleotide polymorphism"
XX
PN      WO200166800-A2.
XX
PD      13-SEP-2001.
XX
PF      07-MAR-2001; 2001WO-US007268.
XX
PR      07-MAR-2000; 2000US-0187510P.
XX
PR      22-MAY-2000; 2000US-0206129P.
XX
PA      (WHEB ) WHITEHEAD INST BIOMEDICAL RES.
XX
PI      Cargill M, Ireland JS, Lander ES;
XX
DR      WPI; 2001-522952/57.
XX
PT      Nucleic acid molecules from the human genome which include polymorphic
PT      sites, useful in methods for predicting the presence, absence or severity
PT      of a particular phenotype or disorder (e.g. diabetes) associated with a
PT      particular genotype.
XX
PS      Claim 1; Page 11; 145pp; English.
XX
CC      The invention relates to the identification of nucleic acid molecules
CC      (AAI29513-AAI31314) from the human genome which include polymorphic sites
CC      which can predispose individuals to disease. Various genes from a number
CC      of individuals were resequenced and single nucleotide polymorphisms
CC      (SNPs) in these genes discovered. The method is useful for predicting the
CC      presence, absence or severity of a particular phenotype or disorder (e.g.
CC      diabetes) associated with a particular genotype. The nucleic acids
CC      containing the polymorphic sites may be useful in forensics and paternity
CC      testing
XX
CC      Revised record issued on 04-NOV-2004 : Correction to Feature Table Key
XX
SQ      Sequence 31 BP; 7 A; 12 C; 5 G; 7 T; 0 U; 0 Other;

Query Match      1.4%; Score 25.2; DB 1; Length 31;
Best Local Similarity 66.7%; Pred. No. 79;
Matches 20; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

QY      1587 CUACUGGCUUGGCUACAUCAACGACCGU 1616
      |::|||::|||::|||::|||::|||::|||
Db      1  CTACTGGCTCTGCTACGACAGCACCAT 30

RESULT 11
AAI30657
ID      AAI30657 standard; DNA; 31 BP.
XX
AC      AAI30657;
XX
DT      04-NOV-2004 (revised)
DT      18-OCT-2001 (first entry)
XX
DE      Human single nucleotide polymorphism (SNP) 166.

```

CC therapeutic drugs, insecticides, nematocides etc., and are especially
 CC useful for assays using orphan receptors; Agonists of G protein-coupled
 CC insect MARs possess substantial insecticide and miticide activity

XX SQ Sequence 30 BP; 8 A; 10 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 1.4%; Score 25.2; DB 1; Length 30;
 Best Local Similarity 66.7%; Pred. No. 73;
 Matches 20; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

OY 1498 TPCCAUACACUUGACCCCAUACAACAU 1527
 :||:|||||:|||||:|||||:|||||:
 Db 1 TTCATCATCATCGGACTCCGTACAACATC 30

RESULT 7
 AA294302
 ID AA294302 standard; DNA; 30 BP.

XX AC AA294302;

XX DT 03-JUL-2000 (first entry)

XX DE Rat M3 muscarinic acetylcholine receptor PCR primer.

XX KM G protein coupled receptor; muscarinic acetylcholine receptor; MAR; rat;
 XX screening; PCR primer; ss.

XX OS Rattus sp.

XX PN WO200012704-A2.

XX PD 09-MAR-2000.

XX PF 01-SEP-1999; 99WO-US020011.

XX PR 01-SEP-1998; 98US-0098704P.

XX PA (PAUSCH M H.

XX PA (LATIN) LAI M.

XX PA (SILV) SILVERMAN S.

XX PA (BIRS) BIRSAN C.

XX PA (BAUM) BAUMBAUCH W.

XX PA (TSEN) TSENG B.

XX PA (KAJK) KAJKOWSKI B A.

XX PA (OZEN) OZENBERGER B A.

XX PI Pausch MH, Lai M, Silverman S, Birsan C, Baumbauch W, Tseng E;

XX PI Kajkowski EM, Ozenberger BA;

XX DR WPI; 2000-246753/21.

XX PT Novel host cells comprising heterologous G protein-coupled receptor

XX PT modified to be constitutively active, useful for high throughput

XX PT screening assays for e.g. drugs, insecticides or nematocides.

XX PS Example 1; Page 20; 75pp; English.

CC This primer sequence, which includes a 5' PmlI site, was used in the PCR
 CC amplification of a C-terminal coding fragment of rat M3 muscarinic
 CC acetylcholine receptor (MAR). MAR is a G protein coupled receptor (GPCR).
 CC The PCR product was ligated into yeast expression plasmid p426GP.
 CC Comparison of the expression of wild-type MAR and intracellular loop 3
 CC (IC3) deleted MAR showed that deletion of a portion of the IC3 produced a
 CC functional GPCR in yeast. Modification of internal domains was therefore
 CC suggested to be a generalizable method for improving the function of
 CC heterologous GPCRs expressed in yeast. The invention relates to mutant
 CC GPCRs with constitutively activating mutations that permit the detection
 CC of the receptors' functional activity in the absence of activating
 CC ligands, host cells that contain mutations that promote the functional
 CC activity of the GPCRs, host cells expressing such receptors, and vectors
 CC useful for making such cells. The host cells are useful in high
 CC throughput screening assays for therapeutic drugs, insecticides,

CC nematocides etc., and are especially useful for assays using orphan
 CC receptors

XX SQ Sequence 30 BP; 6 A; 14 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 1.4%; Score 25.2; DB 1; Length 30;
 Best Local Similarity 70.0%; Pred. No. 73;
 Matches 21; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

OY 1495 GCCUUCACUACUUGACCCCAUACAAC 1524
 ||||:|||||:|||||:|||||:|||||:
 Db 1 GCGTCATCATCATCGGACCCCTCAAC 30

RESULT 8
 AA294353
 ID AA294353 standard; DNA; 30 BP.

XX AC AA294353;

XX DT 03-JUL-2000 (first entry)

XX DE Rat muscarinic acetylcholine receptor PCR primer.

XX KM G protein coupled receptor; GPCR; rat; MAR;
 XX muscarinic acetylcholine receptor; drug screening; PCR primer; ss.

XX OS Rattus sp.

XX PN WO200012705-A2.

XX PD 09-MAR-2000.

XX PF 01-SEP-1999; 99WO-US020013.

XX PR 01-SEP-1998; 98US-0098704P.

XX PA (PAUSCH M H.

XX PA (MESS) MESS J.

XX PI Pausch MH, Mess J;

XX DR WPI; 2000-246754/21.

XX PT New G protein-coupled receptors with a mutation in an intracellular

XX PT domain, useful for high throughput screening assays for e.g. drugs,
 XX insecticides or nematocides.

XX PS Example 1; Page 8; 37pp; English.

CC This primer sequence, which includes a 5' PmlI site, was used in the PCR
 CC amplification of an C-terminal coding fragment of rat M3 muscarinic
 CC acetylcholine receptor (MAR). MAR is a G protein coupled receptor (GPCR).
 CC The PCR product was ligated into yeast expression plasmid p426GP.
 CC Comparison of the expression of wild-type MAR and intracellular loop 3
 CC (IC3) deleted MAR showed that deletion of a portion of the IC3 produced a
 CC functional GPCR in yeast. Modification of internal domains was therefore
 CC suggested to be a generalizable method for improving the function of
 CC heterologous GPCRs expressed in yeast. The invention provides modified
 CC GPCRs having a mutation in IC3 that results in an improved functional
 CC response in cell-based assays. The modification promotes growth
 CC stimulation by a GPCR agonist, especially by improving coupling between
 CC the receptor and a heterotrimeric G protein. Polynucleotides encoding the
 CC mutated GPCR, chimeric GPCR, vectors and host cells are also claimed. The
 CC modified GPCRs can be used in improved high throughput screening assays
 CC (especially in yeast cells) for therapeutic drugs, insecticides,
 CC nematocides etc

XX SQ Sequence 30 BP; 6 A; 14 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 1.4%; Score 25.2; DB 1; Length 30;
 Best Local Similarity 70.0%; Pred. No. 73;
 Matches 21; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

XX New G protein-coupled receptors with a mutation in an intracellular
PT domain, useful for high throughput screening assays for e.g. drugs,
PT insecticides or nematocides.
XX
PS Example 1; Page 8; 37pp; English.
XX
CC This primer sequence, which includes a 3' PmlI site, was used in the PCR
CC amplification of DNA encoding intracellular loops (IC3) of rat M3
CC muscarinic acetylcholine receptor (MAR). MAR is a G protein coupled
CC receptor (GPCR). Comparison of the expression of wild-type MAR and IC3
CC deleted MAR showed that deletion of a portion of the IC3 produced a
CC functional GPCR in yeast. Modification of internal domains was therefore
CC suggested to be a generalizable method for improving the function of
CC heterologous GPCRs expressed in yeast. The invention provides modified
CC GPCRs having a mutation in IC3 that results in an improved functional
CC response in cell-based assays. The modification promotes growth
CC stimulation by a GPCR agonist, especially by improving coupling between
CC the receptor and a heterotrimeric G protein. Polynucleotides encoding the
CC mutated GPCR, chimeric GPCR, vectors and host cells are also claimed. The
CC modified GPCRs can be used in improved high throughput screening assays
CC (especially in yeast cells) for therapeutic drugs, insecticides,
CC nematocides etc
XX
SQ Sequence 30 BP; 6 A; 4 C; 13 G; 7 T; 0 U; 0 Other;
XX
Query Match 1.5%; Score 26.8; DB 1; Length 30;
Best Local Similarity 73.3%; Pred. No. 46;
Matches 22; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
XX
OY 1495 GCCUUCAGUACACUGAGACCCCAUACAAC 1524
Db 30 GCCTTCATCATCTACGTGAGACCCCTACAAAC 1
XX
RESULT 5
ABI97627
ID ABI97627 standard; DNA; 32 BP.
XX
AC ABI97627;
XX
DT 18-FEB-2002 (first entry)
XX
DE Endogenous human GPCR 5' primer SEQ ID NO: 79.
XX
KW Human; G protein-coupled receptor; GPCR; non-endogenous; mutant;
KW constitutively activated GPCR; agonist; disease; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO20017172-A2.
XX
PD 18-OCT-2001.
XX
PF 05-APR-2001; 2001WO-US011098.
XX
PR 07-APR-2000; 2000US-0195747P.
XX
PA (AREN-) ARENA PHARM INC.
XX
PI Lehmann-Bruinsma K, Liaw CW, Lin I;
XX
DR WPI; 2001-648759/74.
XX
PT Identifying agonists of G protein-coupled receptors (GPCRs) for use in
PT disease treatment, comprises contacting candidate compounds with versions
PT of GPCRs.
XX
PS Example 1; Page 31; 394pp; English.
XX
CC The invention relates to G protein-coupled receptors (GPCRs) for which
CC the endogenous ligand has been identified. Non-endogenous constitutively
CC activated versions of known GPCRs are used in the invention for the

CC direct identification of candidate compounds as receptor agonists,
CC inverse agonists or partial agonists. Such agonists are useful as
CC therapeutic agents for diseases or disorders associated with GPCRs. The
CC present sequence is a primer used to prepare an endogenous version of a
CC known GPCR in an example illustrating the invention
XX
SQ Sequence 32 BP; 13 A; 10 C; 3 G; 6 T; 0 U; 0 Other;
XX
Query Match 1.5%; Score 26; DB 1; Length 32;
Best Local Similarity 80.8%; Pred. No. 67;
Matches 21; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
XX
OY 1 AUGACCCUUGCAUAUACAGUACAAC 26
Db 7 ATGACCTTGCAATATACGTACAC 32
XX
RESULT 6
AA294307
ID AA294307 standard; DNA; 30 BP.
XX
AC AA294307;
XX
DT 03-JUL-2000 (first entry)
XX
DE Drosophila muscarinic acetylcholine receptor PCR primer.
XX
KW G protein coupled receptor; muscarinic acetylcholine receptor; MAR;
KW insect; insecticide; miticide; screening; PCR primer; ss.
XX
OS Drosophila melanogaster.
XX
PN WO200012704-A2.
XX
PD 03-MAR-2000.
XX
PF 01-SEP-1999; 99WO-US020011.
XX
PR 01-SEP-1998; 98US-0098704P.
XX
PA (PAUS/) PAUSCH M H.
PA (LAIM/) LAI M.
PA (SILV/) SILVERMAN S.
PA (BIRS/) BIRSAN C.
PA (BAUM/) BAUMBACH W.
PA (TSEN/) TSENG B.
PA (KAJK/) KAJKOWSKI E M.
PA (OZEN/) OZENBERGER B A.
XX
PI Pausch MH, Lai M, Silverman S, Birsan C, Baumbauch W, Tseng B;
PI Kajokowski EM, Ozenberger BA;
XX
DR WPI; 2000-246753/21.
XX
PT Novel host cells comprising heterologous G protein-coupled receptor
PT modified to be constitutively active, useful for high throughput
PT screening assays for e.g. drugs, insecticides or nematocides.
XX
PS Example 2; Page 23; 75pp; English.
XX
CC This is the DNA sequence of a primer that was used in the PCR
CC amplification of a DNA fragment consisting of the C-terminal coding
CC portion of Drosophila melanogaster muscarinic acetylcholine receptor
CC (MAR) starting from a PmlI site in the 6th transmembrane domain. MAR is a
CC G protein coupled receptor (GPCR). The PCR product was ligated into
CC expression plasmid p426GPD. Yeast cells containing an intracellular loop
CC 3 (IC3) deleted Drosophila MAR produced an agonist-dependent growth
CC response. The invention relates to mutant GPCRs with constitutively
CC activating mutations that permit the detection of the receptors'
CC functional activity in the absence of activating ligands, host cells that
CC contain mutations that promote the functional activity of the GPCRs, host
CC cells expressing such receptors, and vectors useful for making such
CC cells. The host cells are useful in high throughput screening assays for

KM constitutively activated GPCR; agonist; disease; PCR primer; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200177172-A2.
 XX 18-OCT-2001.
 XX PF 05-APR-2001; 2001WO-US011098.
 XX PR 07-APR-2000; 2000US-0195747P.
 XX (AREN-) ARENA PHARM INC.
 XX PI Lehmann-Brunisma K, Liaw CW, Lin I;
 XX WPI; 2001-648759/74.
 DR WPI; 2001-648759/74.
 XX PT Identifying agonists of G protein-coupled receptors (GPCRs) for use in
 PT disease treatment, comprises contacting candidate compounds with versions
 PT of GPCRs.
 XX PS Example 2; Page 52; 394pp; English.
 CC The invention relates to G protein-coupled receptors (GPCRs) for which
 CC the endogenous ligand has been identified. Non-endogenous constitutively
 CC activated versions of known GPCRs are used in the invention for the
 CC direct identification of candidate compounds as receptor agonists,
 CC inverse agonists or partial agonists. Such agonists are useful as
 CC therapeutic agents for diseases or disorders associated with GPCRs. The
 CC present sequence is a primer used to prepare a non-endogenous version of
 CC a known GPCR in an example illustrating the invention
 XX SQ Sequence 37 BP; 14 A; 8 C; 12 G; 3 T; 0 U; 0 Other;
 Query Match 1.8%; Score 32.2; DB 1; Length 37;
 Best Local Similarity 83.8%; Pred. No. 15;
 Matches 31; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
 QY 1449 GCGUAGAAGAGAAAGCGCCGACCCUACUGCG 1485
 DB 1 GGTCAAGAGAGAAAGCGAAACAGACCTCAGTGGC 37
 RESULT 3
 AA294304/C
 ID AA294304 standard; DNA; 30 BP.
 XX AC AA294304;
 XX DT 03-JUL-2000 (first entry)
 XX DE Rat M3 muscarinic acetylcholine receptor IC3 PCR primer.
 XX KW G protein coupled receptor; muscarinic acetylcholine receptor; MAR; rat;
 XX screening; PCR primer; ss.
 XX OS Rattus sp.
 XX PN WO200012704-A2.
 XX PD 09-MAR-2000.
 XX PF 01-SEP-1999; 99WO-US020011.
 XX PR 01-SEP-1998; 98US-0098704P.
 XX (PAUS/) PAUSCH M H.
 XX (LAIW/) LAI M.
 XX (SILV/) SILVERMAN S.
 XX (BIRS/) BIRSAN C.
 XX (BAUM/) BAUMBAUCH W.

PA (TSEN/) TSENG E.
 PA (KAJK/) KAJKOWSKI E M.
 PA (OZEN/) OZENBERGER B A.
 XX PI Pausch MH, Lai M, Silverman S, Birsan C, Baumbauch W, Tseng E;
 XX PI Kajokowski EM, Ozenberger BA;
 XX WPI; 2000-246753/21.
 DR WPI; 2000-246753/21.
 XX PT Novel host cells comprising heterologous G protein-coupled receptor
 PT modified to be constitutively active, useful for high throughput
 PT screening assays for e.g. drugs, insecticides or nematocides.
 XX PS Example 1; Page 20; 75pp; English.
 CC This primer sequence, which includes a 3' PmlI site, was used in the PCR
 CC amplification of DNA encoding intracellular loop 3 (IC3) of rat M3
 CC muscarinic acetylcholine receptor (MAR). MAR is a G protein coupled
 CC receptor (GPCR). The PCR product was ligated into yeast expression
 CC plasmid p426GPD. Comparison of the expression of wild-type MAR and IC3-
 CC deleted MAR showed that deletion of a portion of the IC3 produced a
 CC functional GPCR in yeast. Modification of internal domains was therefore
 CC suggested to be a generalizable method for improving the function of
 CC heterologous GPCRs expressed in yeast. The invention relates to mutant
 CC GPCRs with constitutively activating mutations that permit the detection
 CC of the receptors' functional activity in the absence of activating
 CC ligands, host cells that contain mutations that promote the functional
 CC activity of the GPCRs, host cells expressing such receptors, and vectors
 CC useful for making such cells. The host cells are useful in high
 CC throughput screening assays for therapeutic drugs, insecticides,
 CC nematocides etc., and are especially useful for assays using orphan
 CC receptors
 XX SQ Sequence 30 BP; 6 A; 4 C; 13 G; 7 T; 0 U; 0 Other;
 Query Match 1.5%; Score 26.8; DB 1; Length 30;
 Best Local Similarity 73.3%; Pred. No. 46;
 Matches 22; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
 QY 1495 GCGUACAUCAUCGACCCCAUACAAC 1524
 DB 30 GCGTTCATCATCAGCGACCCCTTCAAC 1
 RESULT 4
 AA294355/C
 ID AA294355 standard; DNA; 30 BP.
 XX AC AA294355;
 XX DT 03-JUL-2000 (first entry)
 XX DE Rat muscarinic acetylcholine receptor IC3 PCR primer.
 XX KW G protein coupled receptor; GPCR; rat; MAR;
 XX muscarinic acetylcholine receptor; drug screening; PCR primer; ss.
 XX OS Rattus sp.
 XX PN WO200012705-A2.
 XX PD 09-MAR-2000.
 XX PF 01-SEP-1999; 99WO-US020013.
 XX PR 01-SEP-1998; 98US-0098704P.
 XX (PAUS/) PAUSCH M H.
 XX (WESS/) WESS J.
 XX PI Pausch MH, Wess J;
 XX WPI; 2000-246754/21.

837	13.4	0.8	15	1	ABBS0501	Human myosin heavy
C 838	13.4	0.8	15	1	AED62264	DNA encoding dendi
C 839	13.4	0.8	16	1	AAK57943	PCR primer for G.
C 840	13.4	0.8	16	1	ADU85273	Human MetAP-2 G-cl
C 841	13.4	0.8	16	1	ABL31167	Human HLA genocyp1
C 842	13.4	0.8	16	1	ABX79735	EST polymorphic DN
C 843	13.4	0.8	16	1	ACC78169	Human GCP-2 SNPs a
C 844	13.4	0.8	18	1	AA066362	PCR primer used me
C 845	13.4	0.8	21	1	ADG77919	Canine disease mar
C 846	13.2	0.7	37	1	ABI97828	Non-endogenous hum
C 847	13.2	0.7	37	1	ABI97827	Non-endogenous hum
C 848	13.3	0.7	15	1	AAT52257	Mouse ICM hammer
C 849	13.3	0.7	15	1	AAT56190	Mouse TNF-a hamme
C 850	13.3	0.7	15	1	AAT52188	Human ICM hammer
C 851	13.3	0.7	15	1	AAT56673	Human TNF-alpha ha
C 852	13.3	0.7	15	1	AA167297	Human FBP8 allele
C 853	13.3	0.7	15	1	AAFA8814	IGFBP3 oligonucleo
C 854	13.3	0.7	15	1	AAFA8813	IGFBP3 oligonucleo
C 855	13.3	0.7	15	1	AAFA8812	IGFBP3 oligonucleo
C 856	13.3	0.7	15	1	ADV35610	Human anti-HER2 NC
C 857	13.3	0.7	15	1	ADV37407	Human anti-HER2 NC
C 858	13.3	0.7	15	1	ADV63338	Human Her2 class I
C 859	13.3	0.7	15	1	AAD25418	Human GNRH2 gene p
C 860	13.3	0.7	15	1	ABL39489	Human ETPB allele-
C 861	13.3	0.7	15	1	ABK34185	Human interleukin
C 862	13.3	0.7	15	1	AA142977	Human cerberus 1 (
C 863	13.3	0.7	15	1	ABBS59475	RNA sequence #1, f
C 864	13.3	0.7	15	1	ABK81771	Human CHRM5 gene p
C 865	13.3	0.7	15	1	ABK81787	Human CHRM5 gene p
C 866	13.3	0.7	15	1	ABK81790	Human CHRM5 gene p
C 867	13.3	0.7	15	1	AA053513	Human GNRH2 gene p
C 868	13.3	0.7	15	1	ACN37146	Human peridontal
C 869	13.3	0.7	16	1	AAV43494	HIV-1 co-receptor
C 870	12.8	0.7	16	1	AAQ92112	p53 detection prob
C 871	12.8	0.7	16	1	AAQ99941	Human MTS2 PCR hem
C 872	12.8	0.7	16	1	AAT00733	Multiple tumor su
C 873	12.8	0.7	16	1	AAT91218	Hairpin ribozyme r
C 874	12.8	0.7	16	1	AA069786	Human multiple tum
C 875	12.8	0.7	16	1	AAT60188	Synthetic cyclin B
C 876	12.8	0.7	16	1	AAV53836	Nucleotide sequenc
C 877	12.8	0.7	16	1	AAV11255	Human MTS2 PCR pri
C 878	12.8	0.7	16	1	AAV10600	PCR primer E1F for
C 879	12.8	0.7	16	1	AAA95660	Human MTS2 mRNA ex
C 880	12.8	0.7	16	1	AA297624	HIV-1 protease gen
C 881	12.8	0.7	16	1	AAZ48799	PCR primer for hum
C 882	12.8	0.7	16	1	AAZ39998	PCR primer for hum
C 883	12.8	0.7	16	1	AAA86546	Cyclin B1 hairpin
C 884	12.8	0.7	16	1	AAA86776	PCNA hammerhead ri
C 885	12.8	0.7	16	1	AAA39370	Human MTS2 PCR pri
C 886	12.8	0.7	16	1	AAA13059	Antisense oligonuc
C 887	12.8	0.7	16	1	AAAI1192	Human multiple tum
C 888	12.8	0.7	16	1	AAAG6959	Human leukocyte an
C 889	12.8	0.7	16	1	AAAF8188	Primer #19. Homo
C 890	12.8	0.7	16	1	AAAS02581	PCR primer E1F use
C 891	12.8	0.7	16	1	AAAD04709	Human MTS2 CDNA am
C 892	12.8	0.7	16	1	AAAC93088	Primer E1F used to
C 893	12.8	0.7	16	1	AAHE1712	Cyclin B1 hairpin/
C 894	12.8	0.7	16	1	AAHE1942	Cyclin B1 hammethe
C 895	12.8	0.7	16	1	ABK28877	HPV blocker probe
C 896	12.8	0.7	16	1	ABBS5965	Human DNA represen
C 897	12.8	0.7	16	1	ACCS9079	Mouse gadd45beta c
C 898	12.8	0.7	16	1	ADBI3992	Optineurin promote
C 899	12.8	0.7	16	1	AAU56944	Human hypoxia-indu
C 900	12.8	0.7	16	1	ADRE9964	Human survivin gen
C 901	12.8	0.7	16	1	ADW09715	Human survivin ant
C 902	12.8	0.7	16	1	ADW09475	Human survivin ant
C 903	12.8	0.7	16	1	ADW09716	Human survivin ant
C 904	12.8	0.7	16	1	ADW09717	Human survivin ant
C 905	12.8	0.7	16	1	ADW09714	Human survivin ant
C 906	12.8	0.7	16	1	ADK85197	Mouse gadd45 DNA f
C 907	12.8	0.7	16	1	AEA52090	Prostate cancer ge
C 908	12.8	0.7	16	1	AEF09334	Human PFS8 TP6 pr
C 909	12.8	0.7	16	1	AEF56675	Human genomic DNA

910 12.4 0.7 19 1 ADW27878 Cholinergic recepc

ALIGNMENTS

RESULT 1
ID ABI97828/c
ABI97828 standard; DNA; 37 BP.

AC ABI97828;
XX

DT 18-FEB-2002 (first entry)

DE Non-endogenous human GPCR 3' primer SEQ ID NO: 280.

XX Human; G protein-coupled receptor; GPCR; non-endogenous; mutant;

KM constitutively activated GPCR; agonist; disease; PCR primer; ss.

XX Homo sapiens.

OS Synthetic.

PN WO200177172-A2.

PD 18-OCT-2001.

PF 05-APR-2001; 2001WO-US011098.

PR 07-APR-2000; 2000US-0195747P.

PA (AREN-) ARENA PHARM INC.

XX Lehmann-Bruinsma K, Liaw CM, Lin I;

XX WPI; 2001-648759/74.

PT Identifying agonists of G protein-coupled receptors (GPCRs) for use in

PT disease treatment, comprises contacting candidate compounds with versions

PT of GPCRs.

XX Example 2; Page 52; 394pp; English.

XX The invention relates to G protein-coupled receptors (GPCRs) for which

CC the endogenous ligand has been identified. Non-endogenous constitutively

CC activated versions of known GPCRs are used in the invention for the

CC direct identification of candidate compounds as receptor agonists,

CC inverse agonists or partial agonists. Such agonists are useful as

CC therapeutic agents for diseases or disorders associated with GPCRs. The

CC present sequence is a primer used to prepare a non-endogenous version of

CC a known GPCR in an example illustrating the invention

XX Sequence 37 BP; 3 A; 12 C; 8 G; 14 T; 0 U; 0 Other;

XX Query Match 1.8%; Score 32.2; DB 1; Length 37;

XX Best local Similarity 83.8%; Pred. No. 15;

XX Matches 31; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1449 GGUCAAGAGAAAGACCGCCAGACCTCAGUGCG 1485

Db 37 GGTCAAGAGAAAGAAAGCGAAACAGACCTCAGTGG 1

RESULT 2
ABI97827
ID ABI97827 standard; DNA; 37 BP.

AC ABI97827;
XX

DT 18-FEB-2002 (first entry)

DE Non-endogenous human GPCR 5' primer SEQ ID NO: 279.

XX Human; G protein-coupled receptor; GPCR; non-endogenous; mutant;

C 691	15.4	0.9	18	1	AED88402	Human leukocyte an
C 692	15.4	0.9	19	1	AAZ72578	Human biallelic ma
C 693	15.4	0.9	19	1	AAZ73102	Human biallelic ma
C 694	15.4	0.9	19	1	ADP79744	Hepatitis B virus
C 695	15	0.8	15	1	AAD05870	Human cholinergic
C 696	15	0.8	15	1	AAD05851	Human cholinergic
C 697	15	0.8	15	1	AAD05855	Human cholinergic
C 698	15	0.8	15	1	AAD05853	Human cholinergic
C 699	15	0.8	15	1	AAD05866	Human cholinergic
C 700	15	0.8	15	1	AAD05869	Human cholinergic
C 701	15	0.8	15	1	AAD05865	Human cholinergic
C 702	15	0.8	15	1	AAD05862	Human cholinergic
C 703	15	0.8	15	1	AAD05861	Human cholinergic
C 704	15	0.8	17	1	AAA27491	Oestrogen receptor
C 705	15	0.8	17	1	AAA27262	Human MEX1 antisen
C 706	14.8	0.8	18	1	AAZ57686	Human G-alpha-12 a
C 707	14.6	0.8	17	1	ABX34294	PCR primer #1 for
C 708	14.6	0.8	18	1	ADK58092	Primer Gamma 15 fo
C 709	14.6	0.8	18	1	AA792041	Sense primer deriv
C 710	14.6	0.8	18	1	AA792017	Capture probe deri
C 711	14.4	0.8	17	1	AAV07214	Calcium-integrin b
C 712	14.4	0.8	17	1	ADV49564	HBV DNAzyme substr
C 713	14.4	0.8	17	1	ADV61822	HBV DNAzyme substr
C 714	14.4	0.8	17	1	ADV48881	HBV zinzyme riboz
C 715	14.4	0.8	17	1	ADV48759	HBV zinzyme riboz
C 716	14.4	0.8	17	1	ADV49459	HBV DNAzyme substr
C 717	14.4	0.8	17	1	ADV61734	HBV ambertzyme ribo
C 718	14.4	0.8	17	1	ACD54032	HBV zinzyme substr
C 719	14.4	0.8	17	1	ACD53927	HBV zinzyme substr
C 720	14.4	0.8	17	1	ACD63215	Murine oligonucleo
C 721	14.4	0.8	17	1	ACD64380	Murine oligonucleo
C 722	14.4	0.8	17	1	ADMS6672	Hepatitis B virus
C 723	14.4	0.8	17	1	ADMS9618	Hepatitis B virus
C 724	14.4	0.8	18	1	AAA95979	TPA-F3 exon 2 5' s
C 725	14.4	0.8	18	1	AAAC6362	PCR primer used me
C 726	14.4	0.8	18	1	AAH91930	Human inflammatory
C 727	14.4	0.8	18	1	ABX79924	EST polymorphic DN
C 728	14.4	0.8	18	1	ADDS6552	Human gene express
C 729	14.4	0.8	18	1	ADK82758	Mediterranean anem
C 730	14.4	0.8	18	1	ABE19149	Primer B021PB for
C 731	14.4	0.8	18	1	ABE16016	Probe for blood ce
C 732	14.4	0.8	18	1	ABE16009	Probe for blood ce
C 733	14	0.8	16	1	AAZ44479	Tomato restriction
C 734	14	0.8	17	1	AAK89373	DNA sequence of GP
C 735	14	0.8	17	1	AD194395	Human VCAW-associa
C 736	14	0.8	17	1	ABT35752	Tumour suppression
C 737	14	0.8	17	1	ABT39960	Tumour suppression
C 738	14	0.8	17	1	ACC53382	Human tumour suppr
C 739	14	0.8	31	1	AAI30657	Human single nucle
C 740	13.8	0.8	17	1	ADG76483	Human leukocyte an
C 741	13.8	0.8	17	1	AAK71350	Human KDR VEGF rec
C 742	13.8	0.8	17	1	AAK72924	Mouse flk-1 VEGF r
C 743	13.8	0.8	17	1	AAV97482	Human EGF-R target
C 744	13.8	0.8	17	1	AAV36047	Human genomic SNP
C 745	13.8	0.8	17	1	AAA36049	Human genomic SNP
C 746	13.8	0.8	17	1	ADMB9934	Human PTP-1B NCH r
C 747	13.8	0.8	17	1	ADV38943	HBV hammerhead rib
C 748	13.8	0.8	17	1	ADV64213	Human HER2 class I
C 749	13.8	0.8	17	1	ADMB1480	Human PTP-1B hamme
C 750	13.8	0.8	17	1	ADV64685	Human Her2 class I
C 751	13.8	0.8	17	1	ADN08955	Human PTP-1B DNAzy
C 752	13.8	0.8	17	1	ADN09139	Human PTP-1B DNAzy
C 753	13.8	0.8	17	1	ABN02309	Human GMP-1, 17-m
C 754	13.8	0.8	17	1	ABO64199	Human KROMA portl
C 755	13.8	0.8	17	1	ABV75110	Human PVP-Ba asso
C 756	13.8	0.8	17	1	ABV90085	Human POSH1 scan
C 757	13.8	0.8	17	1	ABK56975	Human CICAL gene e
C 758	13.8	0.8	17	1	ABK57457	Human CICAL gene e
C 759	13.8	0.8	17	1	ACN08066	WNV minus strand H
C 760	13.8	0.8	17	1	ACN14064	WNV minus strand D
C 761	13.8	0.8	17	1	ACN06766	WNV ambertzyme subs
C 762	13.8	0.8	17	1	ACN00273	WNV Hammerhead Rib
C 763	13.8	0.8	17	1	ACN04254	WNV zinzyme substr
C 764	13.8	0.8	17	1	ACN12490	WNV minus strand Z
C 765	13.8	0.8	17	1	ACN01779	WNV DNAzyme substr
C 766	13.8	0.8	17	1	ACN05337	WNV DNAzyme substr
C 767	13.8	0.8	17	1	ACN15104	WNV minus strand A
C 768	13.8	0.8	17	1	ABT35871	Tumour suppression
C 769	13.8	0.8	17	1	ACA06558	NFKB sub-unit modu
C 770	13.8	0.8	17	1	ACA06557	NFKB sub-unit modu
C 771	13.8	0.8	17	1	ACA06556	NFKB sub-unit modu
C 772	13.8	0.8	17	1	ADB05992	Human MD212b scan
C 773	13.8	0.8	17	1	ADB03586	Human MD27 scanin
C 774	13.8	0.8	17	1	ADB03585	Human MD27 scanin
C 775	13.8	0.8	17	1	ABZ64829	Human HER2 DNAzyme
C 776	13.8	0.8	17	1	ABZ65495	Human HER2 DNAzyme
C 777	13.8	0.8	17	1	ACD63055	HCV minus strand D
C 778	13.8	0.8	17	1	ACD59641	HCV DNAzyme substr
C 779	13.8	0.8	17	1	ACD60608	HCV DNAzyme substr
C 780	13.8	0.8	17	1	ACD51564	HBV hammerhead rib
C 781	13.8	0.8	17	1	ACD64713	HCV minus strand D
C 782	13.8	0.8	17	1	ACD67984	Murine oligonucleo
C 783	13.8	0.8	17	1	ACC67516	Murine oligonucleo
C 784	13.8	0.8	17	1	ACC64254	Murine oligonucleo
C 785	13.8	0.8	17	1	ADB41161	Tumour suppression
C 786	13.8	0.8	17	1	ADB44177	Tumour suppression
C 787	13.8	0.8	17	1	ADB43561	Tumour suppression
C 788	13.8	0.8	17	1	ADC04113	Human Na/H exchang
C 789	13.8	0.8	17	1	ADC37820	Human AMLPia scan
C 790	13.8	0.8	17	1	ADB45399	Tumour suppression
C 791	13.8	0.8	17	1	AD148646	Human tumour suppr
C 792	13.8	0.8	17	1	AD150810	Human tumour suppr
C 793	13.8	0.8	17	1	AD149697	Human tumour suppr
C 794	13.8	0.8	17	1	ABX94795	Beta-actin PCR pri
C 795	13.8	0.8	17	1	ADL50113	Human PKR substrat
C 796	13.8	0.8	17	1	ADL49742	Human PKR substrat
C 797	13.8	0.8	17	1	ABE58314	Human VEGF recepto
C 798	13.8	0.8	17	1	ADP92104	Human cytolestin
C 799	13.8	0.8	17	1	ADMS8521	Hepatitis B virus
C 800	13.8	0.8	17	1	AD184170	HCV DNAzyme substr
C 801	13.8	0.8	17	1	AD184660	HCV DNAzyme substr
C 802	13.8	0.8	17	1	AD185893	HCV DNAzyme substr
C 803	13.8	0.8	17	1	AD186711	HCV DNAzyme substr
C 804	13.8	0.8	17	1	ADP46073	Extend primer 45 u
C 805	13.8	0.8	17	1	ACN65399	Human GDMPL-1 prob
C 806	13.8	0.8	17	1	ADMS12595	Forward RT-PCR pri
C 807	13.8	0.8	17	1	ADV62279	Human beta-actin c
C 808	13.8	0.8	17	1	ADK99460	Extend primer 33 u
C 809	13.8	0.8	17	1	ADZ33903	Human HER2 substra
C 810	13.8	0.8	17	1	ADZ34569	Human HER2 substra
C 811	13.8	0.8	17	1	ABE35378	Human leukocyte an
C 812	13.8	0.8	17	1	ABE35374	Human leukocyte an
C 813	13.8	0.8	17	1	ABE52637	Human leukocyte an
C 814	13.8	0.8	17	1	ABE16022	Probe for blood ce
C 815	13.8	0.8	17	1	ABE16029	Probe for blood ce
C 816	13.6	0.8	15	1	ABE52248	Human PKG2 allele
C 817	13.4	0.8	15	1	AAK46463	Human B7-1 hammet
C 818	13.4	0.8	15	1	AAZ64090	Substrate for ham
C 819	13.4	0.8	15	1	AAD05872	Human cholinergic
C 820	13.4	0.8	15	1	AAD05871	Human cholinergic
C 821	13.4	0.8	15	1	AAD05864	Human cholinergic
C 822	13.4	0.8	15	1	AAD05867	Human cholinergic
C 823	13.4	0.8	15	1	AAD05854	Human cholinergic
C 824	13.4	0.8	15	1	AAD05856	Human cholinergic
C 825	13.4	0.8	15	1	AAD05863	Human cholinergic
C 826	13.4	0.8	15	1	AAD05868	Human cholinergic
C 827	13.4	0.8	15	1	AAD05852	Human cholinergic
C 828	13.4	0.8	15	1	AAK46730	ICGFP3 oligonucleo
C 829	13.4	0.8	15	1	AAK46731	ICGFP3 oligonucleo
C 830	13.4	0.8	15	1	AAA91436	Human CHRM5 gene,
C 831	13.4	0.8	15	1	AAA91451	Human CHRM5 gene,
C 832	13.4	0.8	15	1	AAA91454	Human anti-Her2 ha
C 833	13.4	0.8	15	1	ADV20569	Human anti-Her2 NC
C 834	13.4	0.8	15	1	ADV35913	Hepatitis C virus
C 835	13.4	0.8	15	1	ABX01143	Hepatitis C virus
C 836	13.4	0.8	15	1	ABE75851	Hepatitis C virus

C 545	19	1.1	21	1	ADM27991	Cholinergic recept
C 546	19	1.1	21	1	ADM27995	Cholinergic recept
C 547	19	1.1	21	1	ADM27917	Cholinergic recept
C 548	19	1.1	21	1	ADM27993	Cholinergic recept
C 549	19	1.1	21	1	ADM27955	Cholinergic recept
C 550	19	1.1	21	1	ADM27911	Cholinergic recept
C 551	19	1.1	21	1	ADM27998	Cholinergic recept
C 552	19	1.1	21	1	ADM27914	Cholinergic recept
C 553	19	1.1	21	1	ADM27969	Cholinergic recept
C 554	19	1.1	21	1	ADM27987	Cholinergic recept
C 555	19	1.1	21	1	ADM27989	Cholinergic recept
C 556	19	1.1	21	1	ADM27916	Cholinergic recept
C 557	19	1.1	21	1	ADM27939	Cholinergic recept
C 558	19	1.1	21	1	ADM27941	Cholinergic recept
C 559	19	1.1	21	1	ADM27973	Cholinergic recept
C 560	19	1.1	21	1	ADM27925	Cholinergic recept
C 561	19	1.1	21	1	ADM27957	Cholinergic recept
C 562	19	1.1	21	1	ADM27985	Cholinergic recept
C 563	19	1.1	21	1	ADM27992	Cholinergic recept
C 564	19	1.1	21	1	ABAO2336	Cholinergic recept
C 565	19	1.1	21	1	ABAO2402	Cholinergic recept
C 566	19	1.1	21	1	ABAO2416	Cholinergic recept
C 567	19	1.1	21	1	ABAO2324	Cholinergic recept
C 568	19	1.1	21	1	ABAO2386	Cholinergic recept
C 569	19	1.1	21	1	ABAO2423	Cholinergic recept
C 570	19	1.1	21	1	ABAO2394	Cholinergic recept
C 571	19	1.1	21	1	ABAO2421	Cholinergic recept
C 572	19	1.1	21	1	ABAO2356	Cholinergic recept
C 573	19	1.1	21	1	ABAO2368	Cholinergic recept
C 574	19	1.1	21	1	ABAO2375	Cholinergic recept
C 575	19	1.1	21	1	ABAO2346	Cholinergic recept
C 576	19	1.1	21	1	ABAO2359	Cholinergic recept
C 577	19	1.1	21	1	ABAO2377	Cholinergic recept
C 578	19	1.1	21	1	ABAO2378	Cholinergic recept
C 579	19	1.1	21	1	ABAO2345	Cholinergic recept
C 580	19	1.1	21	1	ABAO2414	Cholinergic recept
C 581	19	1.1	21	1	ABAO2426	Cholinergic recept
C 582	19	1.1	21	1	ABAO2339	Cholinergic recept
C 583	19	1.1	21	1	ABAO2340	Cholinergic recept
C 584	19	1.1	21	1	ABAO2368	Cholinergic recept
C 585	19	1.1	21	1	ABAO2398	Cholinergic recept
C 586	19	1.1	21	1	ABAO2418	Cholinergic recept
C 587	19	1.1	21	1	ABAO2352	Cholinergic recept
C 588	19	1.1	21	1	ABAO2354	Cholinergic recept
C 589	19	1.1	21	1	ABAO2362	Cholinergic recept
C 590	19	1.1	21	1	ABAO2366	Cholinergic recept
C 591	19	1.1	21	1	ABAO2345	Cholinergic recept
C 592	19	1.1	21	1	ABAO2382	Cholinergic recept
C 593	19	1.1	21	1	ABAO2382	Cholinergic recept
C 594	19	1.1	21	1	ABAO2408	Cholinergic recept
C 595	19	1.1	21	1	ABAO2370	Cholinergic recept
C 596	19	1.1	21	1	ABAO2384	Cholinergic recept
C 597	19	1.1	21	1	ABAO2334	Cholinergic recept
C 598	19	1.1	21	1	ABAO2372	Cholinergic recept
C 599	19	1.1	21	1	ABAO2410	Cholinergic recept
C 600	19	1.1	21	1	ABAO2350	Cholinergic recept
C 601	19	1.1	21	1	ABAO2351	Cholinergic recept
C 602	19	1.1	21	1	ABAO2381	Cholinergic recept
C 603	19	1.1	21	1	ABAO2400	Cholinergic recept
C 604	19	1.1	21	1	ABAO2419	Cholinergic recept
C 605	19	1.1	21	1	ABAO2330	Cholinergic recept
C 606	19	1.1	21	1	ABAO2338	Cholinergic recept
C 607	19	1.1	21	1	ABAO2343	Cholinergic recept
C 608	19	1.1	21	1	ABAO2393	Cholinergic recept
C 609	19	1.1	21	1	ABAO2406	Cholinergic recept
C 610	19	1.1	23	1	ADM27981	Cholinergic recept
C 611	19	1.1	23	1	ADM27930	Cholinergic recept
C 612	19	1.1	23	1	ADM27990	Cholinergic recept
C 613	19	1.1	23	1	ADM27927	Cholinergic recept
C 614	19	1.1	23	1	ADM27993	Cholinergic recept
C 615	19	1.1	23	1	ADM27980	Cholinergic recept
C 616	19	1.1	23	1	ADM27932	Cholinergic recept
C 617	19	1.1	23	1	ADM27964	Cholinergic recept
<hr/>						
618	19	1.1	23	1	ADM27975	Cholinergic recept
619	19	1.1	23	1	ADM27959	Cholinergic recept
620	19	1.1	23	1	ADM27978	Cholinergic recept
621	19	1.1	23	1	ADM27946	Cholinergic recept
622	19	1.1	23	1	ADM27962	Cholinergic recept
623	19	1.1	23	1	ADM27948	Cholinergic recept
624	19	1.1	23	1	ADM27997	Cholinergic recept
625	19	1.1	23	1	ADM27943	Cholinergic recept
626	19	1.1	23	1	ADM27965	Cholinergic recept
627	19	1.1	23	1	ADM27996	Cholinergic recept
628	19	1.1	23	1	ADM27949	Cholinergic recept
629	19	1.1	23	1	ADM27994	Cholinergic recept
630	18.4	1.0	20	1	AA172996	M3 Muscarinic rece
631	18.4	1.0	20	1	AE877801	Human dopamine rec
632	18.4	1.0	21	1	ADG77919	Canine disease mar
633	18	1.0	18	1	ADM97793	Reverse primer for
634	18	1.0	20	1	AA597754	Murine SAC1 gene-s
635	18	1.0	20	1	ADM16094	Murine SAC1 DNA PC
636	17.8	1.0	22	1	AAAC8007	Human CLASP probe/
637	17.8	1.0	22	1	ABK84929	Cadherin-like asyn
638	17.8	1.0	22	1	ABQ94025	NOV11 reverse PCR
639	17.4	1.0	20	1	ABE77800	Human dopamine rec
640	17.4	1.0	20	1	ABE77802	Human dopamine rec
641	17.4	1.0	20	1	ABE87549	Human gene 7 ampli
642	17.4	1.0	21	1	ADU29901	Knock-down target
643	17	1.0	17	1	AAA36048	Human genomic SNP
644	17	1.0	18	1	AB977720	Human kelleikrin 2
645	16.8	0.9	20	1	AAA66616	Dog genomic marker
646	16.8	0.9	20	1	AAA66540	Dog genomic marker
647	16.8	0.9	20	1	ABZ81123	Dual specific phos
648	16.8	0.9	20	1	ADP10779	Set 1 left PCR pri
649	16.8	0.9	20	1	ABE77803	Human dopamine rec
650	16.8	0.9	21	1	AAA84224	Murine testosterone
651	16.8	0.9	21	1	ACF96336	DNA sequence of a
652	16.8	0.9	21	1	AAU52773	FRAXF PCR primer
653	16.8	0.9	21	1	ADM83067	Human TRPM-2 antis
654	16.8	0.9	21	1	ADT92407	Antisense oligo th
655	16.8	0.9	21	1	ADT92430	Antisense oligo th
656	16.8	0.9	21	1	ADU80647	RecQ1 directed sir
657	16.8	0.9	21	1	AEA84953	Human lupus-relate
658	16.8	0.9	21	1	AEA82719	Human lupus-relate
659	16.8	0.9	21	1	AEA84951	Human lupus-relate
660	16.8	0.9	21	1	AEA82721	Human lupus-relate
661	16.8	0.9	21	1	AE017042	Human anti-cluster
662	16.8	0.9	21	1	AEF52902	Human PLOD2 gene s
663	16.8	0.9	21	1	AEF42813	Human PLOD2 antis
664	16.4	0.9	19	1	AEF34701	B2AR gene polymorp
665	16.4	0.9	20	1	AAZ01770	PCR primer used to
666	16.4	0.9	20	1	AAZ01506	Herpesvirus entry
667	16.4	0.9	20	1	AE877799	Human dopamine rec
668	16	0.9	20	1	ABZ81124	Dual specific phos
669	15.8	0.9	19	1	ABA81947	Rat G-protein sero
670	15.8	0.9	19	1	ADH01514	Protein tyrosine p
671	15.8	0.9	19	1	ADK98261	Primer of the inve
672	15.8	0.9	19	1	ADR27216	Human single nucle
673	15.8	0.9	19	1	AEC82252	Human marker rever
674	15.8	0.9	19	1	AEC90641	STAR-3 siRNA targe
675	15.8	0.9	19	1	AEC90918	STAR-3 siRNA targe
676	15.4	0.9	17	1	AAFO7204	Hammerhead ribozym
677	15.4	0.9	17	1	ADVA77176	HBV inozyme subutr
678	15.4	0.9	17	1	ADVA77175	HBV inozyme subutr
679	15.4	0.9	17	1	ACDS2496	HBV inozyme subutr
680	15.4	0.9	17	1	ACDS2497	HBV inozyme subutr
681	15.4	0.9	17	1	ADM58989	Hepatitis B virus
682	15.4	0.9	17	1	ADM58990	Hepatitis B virus
683	15.4	0.9	18	1	AA735438	Non-Hodgkin's B ce
684	15.4	0.9	18	1	AA735454	Immunoglobulin hea
685	15.4	0.9	18	1	AAK23093	Primer #16. Synth
686	15.4	0.9	18	1	ADE14992	Beer spoilage-asso
687	15.4	0.9	18	1	ADM16801	Hepatitis B virus
688	15.4	0.9	18	1	AEA04773	Indian hedgehog (i
689	15.4	0.9	18	1	AED16008	Probe for blood ce
690	15.4	0.9	18	1	AED16015	Probe for blood ce

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 30, 2006, 13:52:05 ; Search time 18 Seconds
(without alignments)
3.418 Million cell updates/sec

Title: US-10-798-090A-305

Perfect score: 1773

Sequence: 1 augaccuugcacaauaacag.....cacccgagcagccuugag 1773

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 904 seqs, 17348 residues

Total number of hits satisfying chosen parameters: 1808

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 910 summaries

Database : rng.subdb:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	32.2	1.8	37	1	AB197828 Non-endogenous hum
C 2	32.2	1.8	37	1	AB197827 Non-endogenous hum
C 3	26.8	1.5	30	1	AA294304 Rat M3 muscarinic
C 4	26.8	1.5	30	1	AA294355 Rat muscarinic ace
C 5	26.8	1.5	30	1	AB197627 Endogenous human G
C 6	25.2	1.4	30	1	AA294307 Drosophila muscar
C 7	25.2	1.4	30	1	AA294302 Rat M3 muscarinic
C 8	25.2	1.4	30	1	AA294353 Rat muscarinic ace
C 9	25.2	1.4	30	1	AA294358 Drosophila muscar
C 10	25.2	1.4	31	1	AA130840 Human single nucle
C 11	25.2	1.4	31	1	AA130657 Human single nucle
C 12	25.2	1.4	25	1	AD05888 Human CHRM3 gene a
C 13	24	1.4	24	1	AD05889 Human CHRM3 gene a
C 14	23	1.3	23	1	AD05884 Human CHRM3 gene a
C 15	23	1.3	23	1	ADW27902 Cholinergic recept
C 16	23	1.3	23	1	ADW27905 Cholinergic recept
C 17	23	1.3	23	1	ADW27903 Cholinergic recept
C 18	23	1.3	23	1	ADW27904 Cholinergic recept
C 19	23	1.3	23	1	ADW27906 Cholinergic recept
C 20	23	1.3	23	1	ADW27909 Cholinergic recept
C 21	23	1.3	23	1	ADW27907 Cholinergic recept
C 22	23	1.3	23	1	AEA02318 Cholinergic recept
C 23	23	1.3	23	1	AEA02317 Cholinergic recept
C 24	23	1.3	23	1	AEA02315 Cholinergic recept
C 25	23	1.3	23	1	AEA02319 Cholinergic recept
C 26	23	1.3	23	1	AEA02322 Cholinergic recept
C 27	23	1.3	23	1	AEA02320 Cholinergic recept
C 28	23	1.3	23	1	AEA02320 Cholinergic recept
C 29	23	1.3	23	1	AEA02316 Cholinergic recept
C 30	22	1.2	22	1	AD05882 Human CHRM3 gene a
C 31	22	1.2	22	1	AD05885 Human CHRM3 gene a
C 32	22	1.2	22	1	AD05886 Human CHRM3 gene a
C 33	22	1.2	22	1	AD05883 Human CHRM3 gene a

C 34	21	1.2	21	1	AAH62586 CHRM1 polymorphism
C 35	21	1.2	21	1	ABS98535 Human acetyl choli
C 36	20	1.1	20	1	AD05887 Human CHRM3 gene a
C 37	20	1.1	20	1	ADW27938 Cholinergic recept
C 38	20	1.1	21	1	ADW27968 Cholinergic recept
C 39	20	1.1	21	1	ADW27912 Cholinergic recept
C 40	20	1.1	21	1	ADW27922 Cholinergic recept
C 41	20	1.1	21	1	ADW27966 Cholinergic recept
C 42	20	1.1	21	1	ADW27934 Cholinergic recept
C 43	20	1.1	21	1	ADW27913 Cholinergic recept
C 44	20	1.1	21	1	ADW27986 Cholinergic recept
C 45	20	1.1	21	1	ADW27918 Cholinergic recept
C 46	20	1.1	21	1	ADW27950 Cholinergic recept
C 47	20	1.1	21	1	ADW27970 Cholinergic recept
C 48	20	1.1	21	1	ADW27982 Cholinergic recept
C 49	20	1.1	21	1	ADW27920 Cholinergic recept
C 50	20	1.1	21	1	ADW27952 Cholinergic recept
C 51	20	1.1	21	1	ADW27954 Cholinergic recept
C 52	20	1.1	21	1	ADW27984 Cholinergic recept
C 53	20	1.1	21	1	AEA02389 Cholinergic recept
C 54	20	1.1	21	1	AEA02395 Cholinergic recept
C 55	20	1.1	21	1	AEA02411 Cholinergic recept
C 56	20	1.1	21	1	AEA02413 Cholinergic recept
C 57	20	1.1	21	1	AEA02413 Cholinergic recept
C 58	20	1.1	21	1	AEA02357 Cholinergic recept
C 59	20	1.1	21	1	AEA02379 Cholinergic recept
C 60	20	1.1	21	1	AEA02325 Cholinergic recept
C 61	20	1.1	21	1	AEA02399 Cholinergic recept
C 62	20	1.1	21	1	AEA02405 Cholinergic recept
C 63	20	1.1	21	1	AEA02374 Cholinergic recept
C 64	20	1.1	21	1	AEA02331 Cholinergic recept
C 65	20	1.1	21	1	AEA02373 Cholinergic recept
C 66	20	1.1	21	1	AEA02415 Cholinergic recept
C 67	20	1.1	21	1	AEA02351 Cholinergic recept
C 68	20	1.1	21	1	AEA02326 Cholinergic recept
C 69	20	1.1	21	1	AEA02358 Cholinergic recept
C 70	20	1.1	21	1	AEA02390 Cholinergic recept
C 71	20	1.1	21	1	AEA02397 Cholinergic recept
C 72	20	1.1	21	1	AEA02341 Cholinergic recept
C 73	20	1.1	21	1	AEA02347 Cholinergic recept
C 74	20	1.1	21	1	AEA02365 Cholinergic recept
C 75	20	1.1	21	1	AEA02333 Cholinergic recept
C 76	20	1.1	21	1	AEA02403 Cholinergic recept
C 77	20	1.1	21	1	AEA02335 Cholinergic recept
C 78	20	1.1	21	1	AEA02342 Cholinergic recept
C 79	20	1.1	21	1	AEA02363 Cholinergic recept
C 80	20	1.1	21	1	AEA02381 Cholinergic recept
C 81	20	1.1	21	1	AEA02383 Cholinergic recept
C 82	20	1.1	21	1	AEA02407 Cholinergic recept
C 83	20	1.1	21	1	AEA02349 Cholinergic recept
C 84	20	1.1	21	1	AEA02367 Cholinergic recept
C 85	20	1.1	23	1	ADW27929 Cholinergic recept
C 86	20	1.1	23	1	ADW27945 Cholinergic recept
C 87	20	1.1	23	1	ADW27960 Cholinergic recept
C 88	20	1.1	23	1	ADW27961 Cholinergic recept
C 89	20	1.1	23	1	ADW27961 Cholinergic recept
C 90	20	1.1	23	1	ADW27966 Cholinergic recept
C 91	20	1.1	23	1	ADW27944 Cholinergic recept
C 92	20	1.1	23	1	ADW27977 Cholinergic recept
C 93	19.8	1.1	23	1	AAF30781 CHRM2 gene fragmen
C 94	19.8	1.1	23	1	ADW27908 Human acetyl choli
C 95	19.4	1.1	21	1	ABS98536 Knock-down target
C 96	19.4	1.1	21	1	ADU41439 Knock-down target
C 97	19.4	1.1	21	1	ADU41432 Knock-down target
C 98	19.4	1.1	21	1	ADU41440 Knock-down target
C 99	19.4	1.1	21	1	ADU41441 Knock-down target
C 100	19.4	1.1	21	1	ADW27983 Cholinergic recept
C 101	19.4	1.1	21	1	ADW27951 Cholinergic recept
C 102	19.4	1.1	21	1	ADW27967 Cholinergic recept
C 103	19.4	1.1	21	1	ADW27940 Cholinergic recept
C 104	19.4	1.1	21	1	ADW27910 Cholinergic recept
C 105	19.4	1.1	21	1	ADW27915 Cholinergic recept
C 106	19.4	1.1	21	1	ADW27972 Cholinergic recept

THIS PAGE BLANK (u870)

Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1405 CUGAGAGCCGAG 1418

Db 18 CTGATGACCGAG 5

Search completed: June 30, 2006, 13:47:25
Job time : 13 secs

```

source
1. .15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 71.4%; Score 12.4; DB 1; Length 15;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 1355 CCACUACUACUUG 1368
1 |||||:||||:|
Db 1 CCACGCTACCTCTG 14

RESULT 526
AX633609 15 bp RNA linear PAT 21-FEB-2003
AX633609
DEFINITION Sequence 748 from Patent EP1260586.
ACCESSION AX633609
VERSION AX633609.1 GI:28469223
KEYWORDS
SOURCE
ORGANISM
REFERENCE
unidentified
AUTHORS unclassified sequences.
1
Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A.,
Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McWiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Ueman,N., Wincott,F.E. and
Wolf,T.
Method and reagent for inhibiting the expression of disease related
genes
Patent: EP 1260586-A 748 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
LOCATION/Qualifiers
1. .15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

FEATURES
source

TITLE
JOURNAL
RIBOZYME PHARMACEUTICALS, INC. (US)
LOCATION/Qualifiers
1. .15

FEATURES
source

Query Match
Best Local Similarity 71.4%; Score 12.4; DB 1; Length 15;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 1355 CCACUACUACUUG 1368
1 |||||:||||:|
Db 1 CCACGCTACCTCTG 14

RESULT 527
AX636211/c 15 bp RNA linear PAT 21-FEB-2003
AX636211
DEFINITION Sequence 3350 from Patent EP1260586.
ACCESSION AX636211
VERSION AX636211.1 GI:28471825
KEYWORDS
SOURCE
ORGANISM
REFERENCE
unidentified
AUTHORS unclassified sequences.
1
Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A.,
Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McWiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Ueman,N., Wincott,F.E. and
Wolf,T.
Method and reagent for inhibiting the expression of disease related
genes
Patent: EP 1260586-A 3350 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
LOCATION/Qualifiers
1. .15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

FEATURES
source

```

										/db_xref="taxon:32644"	
Query Match	0.7%	Score 12.4;	DB 1;	Length 15;							
Best Local Similarity	85.7%	Pred. No. 3.1e+02;									
Matches 12;	Conservative 1;	Mismatches 1;	Indels 0;	Gaps 0;							
Oy	1177	GAGAGAGAGCGGG	1190								
Db	14	GAGCAGAGCTGGG	1								
RESULT 528											
LOCUS	AX636885	15 bp	RNA	linear	PAT 21-FEB-2003						
DEFINITION	Sequence 4024 from Patent EP1260586.										
ACCESSION	AX636885										
VERSION	AX636885.1	GI:28472499									
KEYWORDS											
SOURCE	unidentified										
ORGANISM	unclassified										
REFERENCE	unclassified sequences.										
AUTHORS	1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A., Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., Mcgwiner,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweeney,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.										
TITLE	Method and reagent for inhibiting the expression of disease related genes										
JOURNAL	Patent: EP 1260586-A 4024 27-NOV-2002;										
FEATURES	RIBOZYME PHARMACEUTICALS, INC. (US)										
SOURCE	location/Qualifiers										
	1..15										
	/organism="unidentified"										
	/mol_type="unassigned RNA"										
	/db_xref="taxon:32644"										
Query Match	0.7%	Score 12.4;	DB 1;	Length 15;							
Best Local Similarity	64.3%	Pred. No. 3.1e+02;									
Matches 9;	Conservative 4;	Mismatches 1;	Indels 0;	Gaps 0;							
Oy	96	AACGCCACUCACU	109								
Db	2	AACCTGCACTCAT	15								
RESULT 529											
LOCUS	CS096202	19 bp	RNA	linear	PAT 03-JUN-2005						
DEFINITION	Sequence 27 from Patent WO2005045040.										
ACCESSION	CS096202										
VERSION	CS096202.1	GI:66952675									
KEYWORDS											
SOURCE	synthetic construct										
ORGANISM	synthetic construct										
REFERENCE	other sequences; artificial sequences.										
AUTHORS	1 Richards,I. and Macswiggen,J.										
TITLE	RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)										
JOURNAL	Patent: WO 2005045040-A 27 19-MAY-2005;										
FEATURES	Sigma Therapeutics, Inc. (US)										
SOURCE	Location/Qualifiers										
	1..19										
	/organism="synthetic construct"										
	/mol_type="unassigned RNA"										
	/db_xref="taxon:32630"										
	/note="Description of Artificial Sequence: Target Sequence/siNA sense region"										
Query Match	0.7%	Score 12.4;	DB 1;	Length 19;							
Best Local Similarity	85.7%	Pred. No. 4.7e+02;									

Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1158 GGACACTCAGG 1171
|||||:|||||
Db 14 GGACACTCAGG 1

RESULT 521
AR226465 AR226465 15 bp mRNA linear PAT 20-DEC-2002
LOCUS Sequence 11 from patent US 6444789.
DEFINITION AR226465
ACCESSION AR226465.1 GI:27265002
VERSION
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Luo, S.
TITLE CD16-II variants
JOURNAL Patent: US 6444789-A 11 03-SEP-2002;
Applied Research Systems ARS Holding N.V.;
WOX;

FEATURES
source 1. .15
/organism="unknown"
/mol_type="mRNA"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1712 AGCAGUACGAGG 1725
|||||:|||||
Db 2 AGCAGTAGCAGG 15

RESULT 522
AR226474/c AR226474 15 bp mRNA linear PAT 20-DEC-2002
LOCUS Sequence 22 from patent US 6444789.
DEFINITION AR226474
ACCESSION AR226474
VERSION AR226474.1 GI:27265011
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Luo, S.
TITLE CD16-II variants
JOURNAL Patent: US 6444789-A 22 03-SEP-2002;
Applied Research Systems ARS Holding N.V.;
WOX;

FEATURES
source 1. .15
Location/Qualifiers
/organism="unknown"
/mol_type="mRNA"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1712 AGCAGUACGAGG 1725
|||||:|||||
Db 14 AGCAGTAGCAGG 1

RESULT 523
161824/c 161824 15 bp DNA linear PAT 07-OCT-1997
LOCUS Sequence 378 from patent US 5658780.
DEFINITION 161824
ACCESSION 161824.1 GI:2479772
VERSION

KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb, D.T., Draper, K.G. and McSwiggen, J.
JOURNAL Rel a targeted ribozymes
TITLE Patent: US 5658780-A 378 19-AUG-1997;
JOURNAL Location/Qualifiers
FEATURES 1. .15
source /organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1177 GAGCAGAGCUGG 1190
|||||:|||||
Db 14 GAGCAGAGCUGG 1

RESULT 524
AR708719 AR708719 15 bp DNA linear PAT 21-SEP-2005
LOCUS Sequence 19 from patent US 6936259.
DEFINITION AR708719
ACCESSION AR708719
VERSION AR708719.1 GI:75998630
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Potter, A.A., Perez-Casal, J., Fontaine, M. and Song, X.
TITLE CAMP factor of Streptococcus uberis
JOURNAL Patent: US 6936259-A 19 30-AUG-2005;
University of Saskatchewan; Saskatchewan;
CAK;

FEATURES
source 1. .15
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 816 GACGAGGACGAGA 829
|||||:|||||
Db 15 GACGAGGACGAGA 2

RESULT 525
AX633376 AX633376 15 bp RNA linear PAT 21-FEB-2003
LOCUS Sequence 515 from Patent EP1260586.
DEFINITION AX633376
ACCESSION AX633376
VERSION AX633376.1 GI:28468990
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE unclassified sequences.
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Dizenzo, A.,
Karpelisky, A., Draper, K.G., Kistich, K., Matulic-Adamic, J.,
Mcswiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M.,
Swedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and
Woolf, T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 515 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES Location/Qualifiers

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 64.3%; Pred. No. 3.1e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 96 AACCGCACCAU 109
|||:||||:
2 AACTGCTACTCAT 15

Db

RESULT 516
CS104321 15 bp DNA linear PAT 10-JUN-2005
DEFINITION Sequence 41 from Patent WO2005047318.
ACCESSION CS104321
VERSION CS104321.1 GI:67512538
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Bostwick,R.J., Corradi,J., Defay,T., Furlong,S., Hirata,L.T.,
Rayn,V., and Robbins,A.
TITLE Gnal splice variant and uses thereof
JOURNAL Patent: WO 2005047318-A 41 26-MAY-2005;
Astrazeneca AB (SE)
FEATURES
source location/Qualifiers
1..15
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 965 CCAGCUCGAGCAG 978
|||||
1 CCGCCCCGAGCAG 14

Db

RESULT 517
AR179938 15 bp DNA linear PAT 20-APR-2002
LOCUS AR179938
DEFINITION Sequence 6 from patent US 6333152.
ACCESSION AR179938
VERSION AR179938.1 GI:20221971
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 6 25-DEC-2001;
FEATURES
source location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 399 AUGGCGCTTAGGGA 412
|-:|||||:
2 ATGGGCTTAGGGA 15

Db

RESULT 518
AR179958 15 bp DNA linear PAT 20-APR-2002
LOCUS AR179958/c
DEFINITION Sequence 26 from patent US 6333152.

ACCESSION AR179958
VERSION AR179958.1 GI:20221991
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 26 25-DEC-2001;
FEATURES
source location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 64.3%; Pred. No. 3.1e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 602 CUCGCGCAUCUG 615
|-:|||||:
14 CTCCTGCCATCATG 1

Db

RESULT 519
AR180430 15 bp DNA linear PAT 20-APR-2002
LOCUS AR180430
DEFINITION Sequence 498 from patent US 6333152.
ACCESSION AR180430
VERSION AR180430.1 GI:20222463
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 498 25-DEC-2001;
FEATURES
source location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 399 AUGGCGCTTAGGGA 412
|-:|||||:
2 ATGGGCTTAGGGA 15

Db

RESULT 520
AR180530 15 bp DNA linear PAT 20-APR-2002
LOCUS AR180530/c
DEFINITION Sequence 598 from patent US 6333152.
ACCESSION AR180530
VERSION AR180530.1 GI:20222563
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 598 25-DEC-2001;
FEATURES
source location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;

	FT	Key	location/Qualifiers
	FT	source	1..15 /organism='Hepatitis virus (hepatitis C FT
FEATURES	source	virus)'. location/Qualifiers 1..15 /organism="unidentified" /mol_type="genomic RNA" /db_xref="taxon:32644"	
Query Match		0.7%; Score 12.4; DB 1; Length 15;	
Best Local Similarity	64.3%; Pred. No. 3.1e+02;		
Matches	9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;		
OY	383 ACATCAUCAUGAAU 396		
Db	1 ACATCATCATGTAT 14		
:: :: :			
RESULT 512			
LOCUS	CS002487	15 bp DNA	linear PAT 07-FEB-2005
DEFINITION	Sequence 515 from Patent EP1502950.		
ACCESSION	CS002487		
VERSION	CS002487.1 GI:58737842		
KEYWORDS	.		
SOURCE	unidentified		
ORGANISM	unclassified		
REFERENCE	unclassified sequences.		
AUTHORS	1		
TITLE	Stinchcomb,D.T., Chowrira,B., Dierenzo,A., Draper,K.G., Dudycz,L.W., Grim,M.S., Karpelesky,A., Kisich,K., Matulich-Adamic,J., McSwiggan,J.A., Modak,A., Pavco,P., Belgelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T. Method for purifying chemically modified RNA Patent: EP 1502950-A 515 02-FEB-2005; Ribozyme Pharmaceuticals, Inc. (US)		
JOURNAL	Location/Qualifiers		
FEATURES	1..15 /organism="unidentified" /mol_type="unassigned DNA" /db_xref="taxon:32644"		
source			
Query Match		0.7%; Score 12.4; DB 1; Length 15;	
Best Local Similarity	71.4%; Pred. No. 3.1e+02;		
Matches	10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;		
OY	1355 CCACUCUACCUCUCG 1368		
Db	1 CCAGCTACTACTCTG 14		
:: :: :			
RESULT 513			
LOCUS	CS002720	15 bp DNA	linear PAT 07-FEB-2005
DEFINITION	Sequence 748 from Patent EP1502950.		
ACCESSION	CS002720		
VERSION	CS002720.1 GI:58738075		
KEYWORDS	.		
SOURCE	unidentified		
ORGANISM	unclassified		
REFERENCE	unclassified sequences.		
AUTHORS	1		
TITLE	Stinchcomb,D.T., Chowrira,B., Dierenzo,A., Draper,K.G., Dudycz,L.W., Grim,M.S., Karpelesky,A., Kisich,K., Matulich-Adamic,J., McSwiggan,J.A., Modak,A., Pavco,P., Belgelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T. Method for purifying chemically modified RNA Patent: EP 1502950-A 748 02-FEB-2005; Ribozyme Pharmaceuticals, Inc. (US)		
JOURNAL	Location/Qualifiers		
FEATURES			

```

source
1. .15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.7%; Score 12.4; DB 1; Length 15;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 1355 CCACUCUACCCUCUG 1368
|||||:|||||:|
1 CCACGCTACCTCTG 14

RESULT 514
LOCUS CS005322/C 15 bp DNA linear PAT 07-FEB-2005
DEFINITION Sequence 3350 from Patent EP1502950.
ACCESSION CS005322
VERSION CS005322.1 GI:58740677
KEYWORDS
' unidentified
unidentified
unclassified sequences.

ORGANISM
REFERENCE
AUTHORS
1 Stinchcomb,D.T., Chowrira,B., Drenzo,A., Draper,K.G., Dudycz,L.W.,
Grimm,S., Kapelsky,A., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Wolf,T.
Method for purifying chemically modified RNA
Patent: EP 1502950-A 3350 02-FEB-2005;
Ribozyne Pharmaceuticals, Inc. (US)
Location/Qualifiers
1. .15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

FEATURES
source

Query Match
Best Local Similarity 0.7%; Score 12.4; DB 1; Length 15;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 1177 GAGGAGAGCCUGGG 1190
|||||:|||||:|
14 GAGCAGAGGCTGG 1

RESULT 515
LOCUS CS005996 15 bp DNA linear PAT 07-FEB-2005
DEFINITION Sequence 4024 from Patent EP1502950.
ACCESSION CS005996
VERSION CS005996.1 GI:58741351
KEYWORDS
' unidentified
unidentified
unclassified sequences.

ORGANISM
REFERENCE
AUTHORS
1 Stinchcomb,D.T., Chowrira,B., Drenzo,A., Draper,K.G., Dudycz,L.W.,
Grimm,S., Kapelsky,A., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Wolf,T.
Method for purifying chemically modified RNA
Patent: EP 1502950-A 4024 02-FEB-2005;
Ribozyne Pharmaceuticals, Inc. (US)
Location/Qualifiers
1. .15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

FEATURES
source

```

/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 57.1%; Pred. No. 3.1e+02;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 264 GGAAATGCTCAT 277
DB 14 GGAAATGCTCAT 1

RESULT 509
BD208892
LOCUS BD208892 15 bp RNA linear PAT 17-JUL-2003
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection.
ACCESSION BD208892
VERSION BD208892.1 GI:33018662
KEYWORDS JP 2002512791-A/2482.
SOURCE unidentified
ORGANISM unclassified sequences.
REFERENCE 1 (bases 1 to 15)
AUTHORS Blatt,L., Mcswigen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
JOURNAL Patent: JP 2002512791-A 2482 08-MAY-2002;
RIBOZYME PHARMACEUTICALS INC
OS Hepatitis virus (hepatitis C virus)
PN JP 2002512791-A/2482
PD 08-MAY-2002
PF 26-APR-1999 JP 2000545591
PR 27-APR-1998 US 60/083217,18-SEP-1998 US 60/100842 PR
25-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PI
LAWRENCE BLATT, JAMES A MCSWIGEN, ELISABETH ROBERTS, PAMELA A PI
PAVCO,
PI DENNIS MACEJAK
PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection.
FH Key Location/Qualifiers
FT source 1..15
FT virus)'/organism='Hepatitis virus (hepatitis C virus)'
FEATURES
source 1..15
location/Qualifiers
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 64.3%; Pred. No. 3.1e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 485 UCAGCUUUGACAGA 498
DB 2 TCACCTTGACAGA 15

RESULT 510
BD208893
LOCUS BD208893 15 bp RNA linear PAT 17-JUL-2003
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection.
ACCESSION BD208893
VERSION BD208893.1 GI:33018663
KEYWORDS JP 2002512791-A/2483.
SOURCE unidentified
ORGANISM unidentified

unclassified sequences.
1 (bases 1 to 15)
AUTHORS Blatt,L., Mcswigen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
JOURNAL Patent: JP 2002512791-A 2483 08-MAY-2002;
RIBOZYME PHARMACEUTICALS INC
OS Hepatitis virus (hepatitis C virus)
PN JP 2002512791-A/2483
PD 08-MAY-2002
PF 26-APR-1999 JP 2000545591
PR 27-APR-1998 US 60/083217,18-SEP-1998 US 60/100842 PR
25-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PI
LAWRENCE BLATT, JAMES A MCSWIGEN, ELISABETH ROBERTS, PAMELA A PI
PAVCO,
PI DENNIS MACEJAK
PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection.
FH Key Location/Qualifiers
FT source 1..15
FT virus)'/organism='Hepatitis virus (hepatitis C virus)'
FEATURES
source 1..15
location/Qualifiers
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 64.3%; Pred. No. 3.1e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 485 UCAGCUUUGACAGA 498
DB 1 TCACCTTGACAGA 14

RESULT 511
BD208983
LOCUS BD208983 15 bp RNA linear PAT 17-JUL-2003
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection.
ACCESSION BD208983
VERSION BD208983.1 GI:33018753
KEYWORDS JP 2002512791-A/2573.
SOURCE unidentified
ORGANISM unclassified sequences.
REFERENCE 1 (bases 1 to 15)
AUTHORS Blatt,L., Mcswigen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
JOURNAL Patent: JP 2002512791-A 2573 08-MAY-2002;
RIBOZYME PHARMACEUTICALS INC
OS Hepatitis virus (hepatitis C virus)
PN JP 2002512791-A/2573
PD 08-MAY-2002
PF 26-APR-1999 JP 2000545591
PR 27-APR-1998 US 60/083217,18-SEP-1998 US 60/100842 PR
25-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PI
LAWRENCE BLATT, JAMES A MCSWIGEN, ELISABETH ROBERTS, PAMELA A PI
PAVCO,
PI DENNIS MACEJAK
PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection.
FH Key Location/Qualifiers
FT source 1..15
FT virus)'/organism='Hepatitis virus (hepatitis C virus)'
FEATURES
source 1..15
location/Qualifiers
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

JOURNAL Inter cellular adhesion molecule-1 (ICAM-1)
Patent: US 6132967-A 571 17-OCT-2000;
Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1355 CCACUCUACCCUG 1368
|||||
1 CCACGCTACTCTG 14

RESULT 505
AR133631/c AR133631 15 bp DNA linear PAT 16-MAY-2001
LOCUS Sequence 2056 from patent US 6194150.
DEFINITION AR133631
ACCESSION AR133631
VERSION AR133631.1 GI:14122536
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE Unclassified.
1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 2056 27-FEB-2001;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 282 GGUCAACAAGCAGC 295
|||:|||||
15 GGTCAGCAAGCAGC 2

RESULT 506
AR133905/c AR133905 15 bp DNA linear PAT 16-MAY-2001
LOCUS Sequence 2330 from patent US 6194150.
DEFINITION AR133905
ACCESSION AR133905
VERSION AR133905.1 GI:14122810
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 2330 27-FEB-2001;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 3.1e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 282 GGUCAACAAGCAGC 295
|||:|||||
15 GGTCAGCAAGCAGC 2

RESULT 507

AX937516/c AX937516 15 bp DNA linear PAT 06-JAN-2004
LOCUS Sequence 19 from Patent WO03091437.
DEFINITION AX937516
ACCESSION AX937516
VERSION AX937516.1 GI:40713556
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Potter,A.A., Perez-Casal,J., Fontaine,M. and Song,X.
TITLE Chimeric camp factors for vaccination against streptococcus
infection
JOURNAL Patent: WO 03091437-A 19 06-NOV-2003;
University of Saskatchewan (CA)
Location/Qualifiers
source 1. .15
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: 556-2"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 816 GACAGAGCGCAGACA 829
|||||
15 GACAGAGCGCAGACA 2

RESULT 508
BD074150/c BD074150 15 bp DNA linear PAT 27-AUG-2002
LOCUS Composition binding specifically to colorectal cancer and
DEFINITION utilization thereof.
ACCESSION BD074150
VERSION JP 2001512666-A/41.
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unidentified sequences.
REFERENCE 1 (bases 1 to 15)
AUTHORS Waldman,S.A., Pearlman,J.M., Barber,M.T., Schultz,S. and
Parkinson,S.J.
TITLE Composition binding specifically to colorectal cancer and
JOURNAL utilization thereof
PATENT: JP 2001512666-A 41 28-AUG-2001;
THOMAS JEFFERSON UNIVERSITY
COMMENT OS Unidentified
PN JP 2001512666-A/41
PD 28-AUG-2001
PF 07-AUG-1998 JP 2000506228
PR 07-AUG-1997 US 08/908643
PI SCOTT A WALDMAN, JOSHUA M PEARLMAN, MICHAEL T BARBER, STEPHANIE
SCHULTZ,
PI SCOTT J PARKINSON
PC C12N15/09,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12O1/68,G01N33/
PC 574//
PC A61K31/7088,A61K39/00,A61K39/395,A61K39/395,A61K48/00,A61P35/
PC 00,A61P35/04,
PC C12N15/00,C12N5/00
CC Strandedness: Double;
CC Topology: Linear;
CC Composition binding specifically to colorectal cancer and CC
utilization
CC thereof
FH Key location/Qualifiers
FT source 1. .15
/organism='unidentified'.
FT Location/Qualifiers
source 1. .15
/organism="unidentified"

FEATURES
source
1. .15
/organism="unidentified"

TITLE Ribozyme treatment of diseases or conditions related to levels of

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 3.2e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 685 CCCACCAUACUUCUUG 700
Db 16 CCCACTATATATTTTG 1

RESULT 495
AX132918 16 bp DNA linear PAT 15-MAY-2001
LOCUS Sequence 4136 from Patent WO0130362.
DEFINITION AX132918
ACCESSION AX132918
VERSION AX132918.1 GI:14139228
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Homnidae; Homo.

REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 4136 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
source Location/Qualifiers
1.16
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Hairpin ribozyme recognition site for cyclin B1"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 3.2e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 725 UGCCUGUACACCAUUAU 740
Db 1 TGACTGTCTCCATTAT 16

RESULT 496
AX133148 16 bp DNA linear PAT 15-MAY-2001
LOCUS Sequence 4366 from Patent WO0130362.
DEFINITION AX133148
ACCESSION AX133148
VERSION AX133148.1 GI:14139458
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Homnidae; Homo.

REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 4366 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
source Location/Qualifiers
1.16
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Hammerhead ribozyme recognition site for cyclin B1"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 3.2e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 725 UGCCUGUACACCAUUAU 740
Db 1 TGACTGTCTCCATTAT 16

RESULT 497
AR041461 15 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 251 from patent US 581300.
DEFINITION AR041461
ACCESSION AR041461
VERSION AR041461.1 GI:5961957
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF- α ribozymes
JOURNAL Patent: US 581300-A 251 22-SEP-1998;
FEATURES
source Location/Qualifiers
1.15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 64.3%; Pred. No. 3.1e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 96 AACGUCACUACUUAU 109
Db 2 AACGTGCTACTCATTT 15

RESULT 498
AR056273 15 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 477 from patent US 5837542.
DEFINITION AR056273
ACCESSION AR056273
VERSION AR056273.1 GI:5981850
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 477 17-NOV-1998;
FEATURES
source Location/Qualifiers
1.15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 3.1e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1355 CCACUCUACUUCUG 1368
Db 1 CCACGCTACTCTTG 14

RESULT 499
AR056367 15 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 571 from patent US 5837542.
DEFINITION AR056367
ACCESSION AR056367
VERSION AR056367.1 GI:5981944
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 15)

Db 1 CACGAGCCCTCTCTG 16

RESULT 490
LOCUS AR574808 16 bp DNA
DEFINITION Sequence 4136 from patent US 6770633.
ACCESSION AR574808
VERSION AR574808.1 GI:56575700
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 16)
TITLE Robbins,J.M. and Triltz,R.
JOURNAL Ribozyme therapy for the treatment of proliferative skin and eye diseases
Patent: US 6770633-A 4136 03-AUG-2004;
Immunosol, Inc.; San Diego, CA
FEATURES
source
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 3.2e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 725 UGCCGUCACCAUUAU 740
Db 1 TGACGTCTCCATTAT 16

RESULT 491
LOCUS AR575038 16 bp DNA
DEFINITION Sequence 4366 from patent US 6770633.
ACCESSION AR575038
VERSION AR575038.1 GI:56575930
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 16)
TITLE Robbins,J.M. and Triltz,R.
JOURNAL Ribozyme therapy for the treatment of proliferative skin and eye diseases
Patent: US 6770633-A 4366 03-AUG-2004;
Immunosol, Inc.; San Diego, CA
FEATURES
source
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 3.2e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 725 UGCCGUCACCAUUAU 740
Db 1 TGACGTCTCCATTAT 16

RESULT 492
LOCUS AR580871 16 bp DNA
DEFINITION Sequence 17 from patent US 6790616.
ACCESSION AR580871
VERSION AR580871.1 GI:56611541
KEYWORDS
SOURCE
ORGANISM Unknown.

Unclassified.
1 (bases 1 to 16)
AUTHORS Moribe,T. and Kaneshige,T.
TITLE Method for typing of HLA class I alleles
JOURNAL Patent: US 6790616-A 17 14-SEP-2004;
Shionogi & Co., Ltd.; Osaka;
MOX;
FEATURES
source
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 3.2e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 915 GAGGAGUAGGCCGC 930
Db 1 GAGGATGTATGGCTGC 16

RESULT 493
LOCUS AR589528 16 bp DNA
DEFINITION Sequence 114 from patent US 6803187.
ACCESSION AR589528
VERSION AR589528.1 GI:56636836
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 16)
TITLE Stuyver,L.
JOURNAL Method for detection of drug-selected mutations in the HIV protease gene
Patent: US 6803187-A 114 12-OCT-2004;
Imogenetics N.V.; Ghent;
EPX;
FEATURES
source
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 3.2e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 685 CCCACCAUACUUG 700
Db 16 CCCACTATATTTTG 1

RESULT 494
LOCUS AX007572 16 bp DNA
DEFINITION Sequence 114 from Patent W0967428.
ACCESSION AX007572
VERSION AX007572.1 GI:9995269
KEYWORDS
SOURCE
ORGANISM Aids-associated retrovirus
Aids-associated retrovirus
Viruses; Retro-transcribing viruses; Retroviridae.
REFERENCE 1
AUTHORS Stuyver,L.
TITLE Method for detection of drug-selected mutations in the hiv protease gene
JOURNAL Patent: WO 967428-A 114 29-DEC-1999;
INNOGENETICS NV (BE); STUYVER LIEVEN (BE)
FEATURES
source
1..16
/organism="Aids-associated retrovirus"
/mol_type="unassigned DNA"
/db_xref="taxon:11966"

Db 16 TCATATACCAAAACAT 1

RESULT 485

LOCUS CS228123 16 bp DNA linear PAT 15-DEC-2005

DEFINITION Sequence 15 from Patent EP1602732.

ACCESSION CS228123

VERSION CS228123.1 GI:83695716

KEYWORDS

SOURCE .

ORGANISM synthetic construct

synthetic construct

other sequences; artificial sequences.

REFERENCE 1

AUTHORS Sidransky,D.

TITLE Nucleic acid mutation detection by analysis of sputum

JOURNAL Patent: EP 1602732-A 15 07-DEC-2005;

THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US)

FEATURES

Location/Qualifiers

1..16

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Primer"

Query Match 0.7%; Score 12.8; DB 1; Length 16;

Best Local Similarity 75.0%; Pred. No. 3.2e+02;

Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Oy 45 CAUCAGCUCUCCUGG 60

Db 1 CACCGAGCCCTCTCG 16

RESULT 486

LOCUS CS251086 16 bp DNA linear PAT 18-JAN-2006

DEFINITION Sequence 630 from Patent WO2005123945.

ACCESSION CS251086

VERSION CS251086.1 GI:85360898

KEYWORDS

SOURCE .

ORGANISM synthetic construct

synthetic construct

other sequences; artificial sequences.

REFERENCE 1

AUTHORS Lesche,R.

TITLE Epigenetic markers for the treatment of breast cancer

JOURNAL Patent: WO 2005123945-A 630 29-DEC-2005;

Epigenomics AG (DE)

FEATURES

Location/Qualifiers

1..16

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="DETECTION OLIGONUCLEOTIDE"

Query Match 0.7%; Score 12.8; DB 1; Length 16;

Best Local Similarity 68.8%; Pred. No. 3.2e+02;

Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Oy 1132 CUCAACUCCACCAAGU 1147

Db 16 CTAACCTCACCACACT 1

RESULT 487

LOCUS 126792 16 bp DNA linear PAT 07-OCT-1996

DEFINITION Sequence 15 from patent US 5561041.

ACCESSION 126792

VERSION 126792.1 GI:1606662

KEYWORDS

SOURCE .

Unknown.

ORGANISM Unknown.

Unclassified.

REFERENCE 1 (bases 1 to 16)

AUTHORS Sidransky,D.

TITLE Nucleic acid mutation detection by analysis of sputum

JOURNAL Patent: US 5561041-A 15 01-OCT-1996;

Location/Qualifiers

1..16

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;

Best Local Similarity 75.0%; Pred. No. 3.2e+02;

Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Oy 45 CAUCAGCUCUCCUGG 60

Db 1 CACCGAGCCCTCTCG 16

RESULT 488

LOCUS 141165 16 bp DNA linear PAT 13-MAY-1997

DEFINITION Sequence 21 from patent US 5624819.

ACCESSION 141165

VERSION 141165.1 GI:2081755

KEYWORDS

SOURCE .

ORGANISM Unknown.

Unclassified.

REFERENCE 1 (bases 1 to 16)

AUTHORS Skolnick,M.H., Cannon-Albright,L.A. and Kamb,A.

TITLE Germline mutations in the MTS gene

JOURNAL Patent: US 5624819-A 21 29-APR-1997;

Location/Qualifiers

1..16

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;

Best Local Similarity 81.2%; Pred. No. 3.2e+02;

Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Oy 1465 GCGGCCAGACCCUCA 1480

Db 16 GCTGGCGAGACCTCA 1

RESULT 489

LOCUS 191533 16 bp DNA linear PAT 01-DEC-1998

DEFINITION Sequence 15 from patent US 5726019.

ACCESSION 191533

VERSION 191533.1 GI:3936003

KEYWORDS

SOURCE .

ORGANISM Unknown.

Unclassified.

REFERENCE 1 (bases 1 to 16)

AUTHORS Sidransky,D.

TITLE Analysis of sputum by amplification and detection of mutant nucleic acid sequences

JOURNAL Patent: US 5726019-A 15 10-MAR-1998;

Location/Qualifiers

1..16

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;

Best Local Similarity 75.0%; Pred. No. 3.2e+02;

Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Oy 45 CAUCAGCUCUCCUGG 60

QY 1208 GGAAGCCGACAGCU 1223
 DB 16 GGAAGACGACAACT 1

RESULT 481
 BD233018/c 16 bp DNA linear PAT 17-JUL-2003

LOCUS BD233018
 DEFINITION Method of detecting mutation selected by drug in HIV protease gene.
 ACCESSION BD233018
 VERSION BD233018.1 GI:33042788
 KEYWORDS JP 2002518065-A/114.
 Aids-associated retrovirus
 SOURCE Aids-associated retrovirus
 ORGANISM Aids-associated retrovirus
 Viruses; Retro-transcribing viruses; Retroviridae.
 1 (bases 1 to 16)

REFERENCE
 AUTHORS Stuyver, L.
 TITLE Method of detecting mutation selected by drug in HIV protease gene
 JOURNAL Patent: JP 2002518065-A 114 25-JUN-2002;
 INNOCENTICS NV

COMMENT
 OS Aids-associated retrovirus
 PN JP 2002518065-A/114
 PD 25-JUN-2002
 PF 22-JUN-1999 JP 2000556068
 PR 24-JUN-1998 EP 98870143.9
 PI LIEVEN STUYVER
 PC C12N15/09,C12Q1/68,C12Q1/70,C12N15/00
 CC Method of detecting mutation selected by drug in HIV protease
 CC gene
 FH Key Location/Qualifiers
 FT source 1..16
 FEATURES
 source Location/Qualifiers
 1..16
 /organism="Aids-associated retrovirus"
 /mol_type="genomic DNA"
 /db_xref="taxon:11966"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 50.0%; Pred. No. 3.2e+02;
 Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 685 CCCACCAUUAUUUG 700
 DB 16 CCCACTATTATTTTG 1

RESULT 482
 CO858571 16 bp DNA linear PAT 31-AUG-2004

LOCUS CO858571
 DEFINITION Sequence 33 from Patent WO2004069991.
 ACCESSION CO858571
 VERSION CO858571.1 GI:51852538
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
 Homnidae; Homo.

REFERENCE
 1 Hansen, B., Thru, C.A., Petersen, K.D., Westergaard, M. and Wiesenbach, M.
 TITLE Oligometric compounds for the modulation of survivin expression
 JOURNAL Patent: WO 2004069991-A 33 19-AUG-2004;
 Santaris Pharma A/S (DK)
 Location/Qualifiers
 1..16
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 31.2%; Pred. No. 3.2e+02;

Matches 5; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

QY 714 UGCUUUUUNAUCCU 729
 DB 1 TGCCTTTATGTTCT 16

RESULT 483
 CS020466 16 bp DNA linear PAT 23-FEB-2005

LOCUS CS020466
 DEFINITION Sequence 41 from Patent EP1506784.
 ACCESSION CS020466
 VERSION CS020466.1 GI:60221088
 KEYWORDS Mus musculus (house mouse)
 SOURCE Mus musculus
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
 Sciurognathi; Murioidea; Muridae; Murinae; Mus.

REFERENCE
 1 Franzoso, G., Desmarte, E., Zazzeroni, F., Papa, S. and Bubici, C.
 TITLE Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
 JOURNAL Patent: EP 1506784-A 41 16-FEB-2005;
 University of Chicago (US)
 Location/Qualifiers
 1..16
 /organism="Mus musculus"
 /mol_type="unassigned DNA"
 /db_xref="taxon:10090"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 81.2%; Pred. No. 3.2e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 956 GCUGAAACCCAGCUC 971
 DB 1 GCTGAAACCCCGCGC 16

RESULT 484
 CS113935/c 16 bp DNA linear PAT 24-JUN-2005

LOCUS CS113935
 DEFINITION Sequence 693 from Patent WO2005054517.
 ACCESSION CS113935
 VERSION CS113935.1 GI:68225480
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.

REFERENCE
 1 Day, K.J., Cottrell, S., Distler, J., Morotli, A., Yamamura, S., Dekker, S., Ocamp, Y. and Devos, T.
 TITLE Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders
 JOURNAL Patent: WO 2005054517-A 693 16-JUN-2005;
 Epigenomics AG (DE)
 Location/Qualifiers
 1..16
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Detection oligonucleotide for PEROXISOMAL MEMBRANE PROTEIN PEX14 (PEROXIN-14) (PEROXISOMAL MEMBRANE ANCHOR PROTEIN PEX14) (PTS1 RECEPTOR DOCKING PROTEIN)"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 68.8%; Pred. No. 3.2e+02;
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1558 UGCAUACCCAAACCU 1573

ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Kamb,A.
TITLE MTS2 gene
JOURNAL Patent: US 6180776-A 21 30-JAN-2001;
FEATURES
source
1.16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No.3.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1465 GCGGCCGACGCCUCA 1480
DB 16 GCTGGCCAGACCTCA 1

RESULT 477
ARI44931/c 16 bp DNA PAT 08-AUG-2001
LOCUS ARI44931
DEFINITION Sequence 21 from patent US 6210949.
ACCESSION ARI44931
VERSION ARI44931.1 GI:15106798
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Stone,S., Jiang,P. and Kamb,A.
TITLE Mouse MTS2 gene
JOURNAL Patent: US 6210949-A 21 03-APR-2001;
FEATURES
source
1.16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No.3.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1465 GCGGCCGACGCCUCA 1480
DB 16 GCTGGCCAGACCTCA 1

RESULT 478
ARI45932/c 16 bp DNA PAT 08-AUG-2001
LOCUS ARI45932
DEFINITION Sequence 21 from patent US 6218146.
ACCESSION ARI45932
VERSION ARI45932.1 GI:15109121
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Kamb,A.
TITLE MTS2 gene
JOURNAL Patent: US 6218146-A 21 17-APR-2001;
FEATURES
source
1.16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No.3.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1465 GCGGCCGACGCCUCA 1480
DB 16 GCTGGCCAGACCTCA 1

DB 16 GCTGGCCAGACCTCA 1

RESULT 479
AX927955 16 bp DNA PAT 19-DEC-2003
LOCUS AX927955
DEFINITION Sequence 41 from Patent WO03085110.
ACCESSION AX927955
VERSION AX927955.1 GI:40250840
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Thirne,C.A., h G.A.M. and Kristjansen,P.E.
TITLE Oligomeric compounds for the modulation hlf-1alpha expression
JOURNAL Patent: WO 03085110-A 41 16-OCT-2003;
Cureon A/S (DK)
FEATURES
source
1.16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence:antisense oligonucleotide to human HIF-1a"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No.3.2e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1016 ACAUGAUGCUGCUGC 1031
DB 1 AAAATGATGCTACTGC 16

RESULT 480
BD009273/c 16 bp DNA PAT 31-JAN-2002
LOCUS BD009273
DEFINITION Hepatitis B inhibitors.
ACCESSION BD009273
VERSION BD009273.1 GI:18637646
KEYWORDS JP 2001503750-A/1.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Hominiidae; Homo.
REFERENCE 1 (bases 1 to 16)
AUTHORS Murray,K. and Dyson,M.R.
TITLE Hepatitis B inhibitors
JOURNAL Patent: JP 2001503750-A 1 21-MAR-2001;
BIOGEN INC
COMMENT OS Homo sapiens (human)
PN JP 2001503750-A/1
PD 21-MAR-2001
PF 31-OCT-1997 JP 1998520812
PR 31-OCT-1996 US 60/030534
PI KENNETH MORRAY,MICHAEL RICHARD DYSON
PC C07K14/02,C07K7/04
CC
FH Key Location/Qualifiers
FT source 1.16
/organism='Homo sapiens (human)'.
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No.3.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

LOCUS AR062791 16 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 21 from patent US 5843756.
ACCESSION AR062791
VERSION AR062791.1 GI:5990482
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Stone,S., Jiang,P. and Kamb,A.
TITLE Mouse MTS1 gene
JOURNAL Patent: US 5843756-A 21 01-DEC-1998;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 3.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1465 GCGGCCGAGACCCCTCA 1480
Db 16 GCTGGCCAGACCCCTCA 1

RESULT 472
LOCUS AR087869 16 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 21 from patent US 5989815.
ACCESSION AR087869
VERSION AR087869.1 GI:10014632
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Skolnick,M.H., Cannon-Albright,L.A. and Kamb,A.
TITLE Methods for detecting predisposition to cancer at the MTS gene
JOURNAL Patent: US 5989815-A 21 23-NOV-1999;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 3.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1465 GCGGCCGAGACCCCTCA 1480
Db 16 GCTGGCCAGACCCCTCA 1

RESULT 473
LOCUS AR091339 16 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 21 from patent US 5994095.
ACCESSION AR091339
VERSION AR091339.1 GI:10018094
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Kamb,A.
TITLE MTS2 gene
JOURNAL Patent: US 5994095-A 21 30-NOV-1999;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 3.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1465 GCGGCCGAGACCCCTCA 1480
Db 16 GCTGGCCAGACCCCTCA 1

RESULT 474
LOCUS AR118045 16 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 21 from patent US 6140473.
ACCESSION AR118045
VERSION AR118045.1 GI:14098951
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Kamb,A.
TITLE Antibodies specific for MTS2 Polypeptide
JOURNAL Patent: US 6140473-A 21 31-OCT-2000;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 3.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1465 GCGGCCGAGACCCCTCA 1480
Db 16 GCTGGCCAGACCCCTCA 1

RESULT 475
LOCUS AR119026 16 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 152 from patent US 6150092.
ACCESSION AR119026
VERSION AR119026.1 GI:14100936
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Uchida,K., Uchida,T., Tanaka,Y., Matsuda,Y. and Kondo,S.
TITLE Antisense nucleic acid compound targeted to VEGF
JOURNAL Patent: US 6150092-A 152 21-NOV-2000;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 3.2e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 674 UCCUCAGAGAGCCAC 689
Db 1 TCCTCAGTGGCCACAC 16

RESULT 476
LOCUS AR127764 16 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 21 from patent US 6180776.
ACCESSION AR127764
VERSION AR127764.1 GI:14114359
KEYWORDS
SOURCE Unknown.

KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE unclassified sequences.
AUTHORS 1
Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Dizenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.B., and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 4390 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source Location/Qualifiers
1.16
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1231 CAGAAGCGGUG 1243
Db 13 CAGAAGCGCTGG 1

RESULT 467
LOCUS AR435971/c 16 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 230 from patent US 6656731.
ACCESSION AR435971 GI:40199055
VERSION AR435971.1
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Eckstein,F., Ludwig,J. and Beigelman,L.
TITLE Nucleic acid catalysts with endonuclease activity
JOURNAL Patent: US 6656731-A 230 02-DEC-2003;
Max Planck Gesellschaft zur Forderung der Wissenschaften E.V. and
Sima Therapeutics; Munich;
DEX;
FEATURES
source Location/Qualifiers
1.16
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.7%; Score 13; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 3e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CCACGACGACG 1002
Db 14 CCACGACGACG 2

RESULT 468
LOCUS AR001331/c 16 bp DNA linear PAT 04-DEC-1998
DEFINITION Sequence 21 from patent US 5739027.
ACCESSION AR001331
VERSION AR001331.1 GI:3963398
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 16)
TITLE MTS1L beta. gene

JOURNAL Patent: US 5739027-A 21 14-APR-1998;
FEATURES Location/Qualifiers
source 1.16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 3.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1465 GCGGCCAGACCCUCA 1480
Db 16 GCTGGCCAGACCTCA 1

RESULT 469
LOCUS AR037511/c 16 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 21 from patent US 5801236.
ACCESSION AR037511
VERSION AR037511.1 GI:5955367
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Kamb,A.
TITLE Probes for MTS1 gene and polynucleotides encoding mutant MTS1 genes
JOURNAL Patent: US 5801236-A 21 01-SEP-1998;
FEATURES Location/Qualifiers
source 1.16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 3.2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1465 GCGGCCAGACCCUCA 1480
Db 16 GCTGGCCAGACCTCA 1

RESULT 470
LOCUS AR054083 16 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 10 from patent US 5834440.
ACCESSION AR054083
VERSION AR054083.1 GI:5978945
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 16)
TITLE Goldenberg,T. and Tritz,R.
JOURNAL Ribozyme therapy for the inhibition of restenosis
Patent: US 5834440-A 10 10-NOV-1998;
FEATURES Location/Qualifiers
source 1.16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 3.2e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 725 UGCCUGACACUAU 740
Db 1 TGACTGTCTCATTA 16

RESULT 471
LOCUS AR062791/c

QY 861 UCGAGCUCGAGC 873
Db 14 TCGAAGCTCGAGC 2

RESULT 462
AR397716/c
LOCUS AR397716 15 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 97 from patent US 6617438.
ACCESSION AR397716
VERSION AR397716.1 GI:40134919
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Beigelman,L., Burgin,A.B., Beaudry,A., Karpetsky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE Oligoribonucleotides with enzymatic activity
JOURNAL Patent: US 6617438-A 97 09-SEP-2003;
Sirma Therapeutics, Inc.; Boulder, CO
FEATURES
source
1.15
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 2.6e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 861 UCGAGCUCGAGC 873
Db 14 TCGAAGCTCGAGC 2

RESULT 463
AX633249/c
LOCUS AX633249 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 388 from Patent EP1260586.
ACCESSION AX633249
VERSION AX633249.1 GI:28468863
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 unclassified sequences.
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpetsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 388 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1.15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 506 CCAUCAAGAGGCC 518
Db 15 CCATCAGAGGCC 3

RESULT 464
AX633318/c
LOCUS AX633318 15 bp RNA linear PAT 21-FEB-2003

DEFINITION Sequence 457 from Patent EP1260586.
ACCESSION AX633318
VERSION AX633318.1 GI:28468932
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 unclassified sequences.
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpetsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 457 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1.15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 506 CCAUCAAGAGGCC 518
Db 15 CCATCAGAGGCC 3

RESULT 465
AX636734/c
LOCUS AX636734 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 3873 from Patent EP1260586.
ACCESSION AX636734
VERSION AX636734.1 GI:28472348
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 unclassified sequences.
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpetsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 3873 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1.15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1231 CAGAAGAGCGUGA 1243
Db 13 CAGAAGAGCGTGG 1

RESULT 466
AX637251/c
LOCUS AX637251 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 4390 from Patent EP1260586.
ACCESSION AX637251
VERSION AX637251.1 GI:28472865

TITLE Woolf,T.
JOURNAL Method for purifying chemically modified RNA
Patent: EP 1502950-A 388 02-FEB-2005;
Ribozyme Pharmaceuticals, Inc. (US)

FEATURES

source 1. .15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 506 CCAUACGAGGCC 518
|||:|||||
15 CCATCAGAGGCC 3

Db 15 CCATCAGAGGCC 3

RESULT 458
LOCUS CS002429/c 15 bp DNA linear PAT 07-FEB-2005

DEFINITION Sequence 457 from Patent EP1502950.

ACCESSION CS002429

VERSION CS002429.1 GI:58737784

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

1
Stinchcomb,D.T., Chowrira,B., Drenzo,A., Draper,K.G., Dudycz,L.W.,
Grimm,S., Karpelsky,A., Kisch,K., Matulic-Adamic,J.,
McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
Method for purifying chemically modified RNA
Patent: EP 1502950-A 457 02-FEB-2005;
Ribozyme Pharmaceuticals, Inc. (US)

TITLE Method for purifying chemically modified RNA

JOURNAL Ribozyme Pharmaceuticals, Inc. (US)

FEATURES

source 1. .15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 506 CCAUACGAGGCC 518
|||:|||||
15 CCATCAGAGGCC 3

Db 15 CCATCAGAGGCC 3

RESULT 459
LOCUS CS005845/c 15 bp DNA linear PAT 07-FEB-2005

DEFINITION Sequence 3873 from Patent EP1502950.

ACCESSION CS005845

VERSION CS005845.1 GI:58741200

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

1
Stinchcomb,D.T., Chowrira,B., Drenzo,A., Draper,K.G., Dudycz,L.W.,
Grimm,S., Karpelsky,A., Kisch,K., Matulic-Adamic,J.,
McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
Method for purifying chemically modified RNA
Patent: EP 1502950-A 3873 02-FEB-2005;
Ribozyme Pharmaceuticals, Inc. (US)

TITLE Method for purifying chemically modified RNA

JOURNAL Ribozyme Pharmaceuticals, Inc. (US)

FEATURES

source

1. .15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1231 CAGAGAGCGTGG 1243
|||||:|||||
13 CAGAGAGCGTGG 1

Db 13 CAGAGAGCGTGG 1

RESULT 460
LOCUS CS006362/c 15 bp DNA linear PAT 07-FEB-2005

DEFINITION Sequence 4390 from Patent EP1502950.

ACCESSION CS006362

VERSION CS006362.1 GI:58741717

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

1
Stinchcomb,D.T., Chowrira,B., Drenzo,A., Draper,K.G., Dudycz,L.W.,
Grimm,S., Karpelsky,A., Kisch,K., Matulic-Adamic,J.,
McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
Method for purifying chemically modified RNA
Patent: EP 1502950-A 4390 02-FEB-2005;
Ribozyme Pharmaceuticals, Inc. (US)

TITLE Method for purifying chemically modified RNA

JOURNAL Ribozyme Pharmaceuticals, Inc. (US)

FEATURES

source 1. .15
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1231 CAGAGAGCGTGG 1243
|||||:|||||
13 CAGAGAGCGTGG 1

Db 13 CAGAGAGCGTGG 1

RESULT 461
LOCUS AR285725/c 15 bp RNA linear PAT 10-APR-2003

DEFINITION Sequence 97 from patent US 6528640.

ACCESSION AR285725

VERSION AR285725.1 GI:29723319

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

1 (bases 1 to 15)
Beigelman,L., Burgin,A., Beaudry,A., Karpelsky,A.,
Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
Synthetic ribonucleic acids with RNase activity
Patent: US 6528640-A 97 04-MAR-2003;
Ribozyme Pharmaceuticals, Incorporated; Boulder, CO

TITLE Synthetic ribonucleic acids with RNase activity

JOURNAL Ribozyme Pharmaceuticals, Incorporated; Boulder, CO

FEATURES

source 1. .15
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 2.6e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1231 CAGAGAGCGTGG 1243
DB 13 CAGAGAGCGTGG 1
RESULT 453
AR056190/c 15 bp DNA PAT 29-SEP-1999
LOCUS AR056190
DEFINITION Sequence 394 from patent US 5837542.
ACCESSION AR056190
VERSION AR056190.1 GI:5981767
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwigen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 394 17-NOV-1998;
FEATURES
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 506 CCAUCCAGAGGCC 518
DB 15 CCATCAGAGGCC 3
RESULT 454
AR056412/c 15 bp DNA PAT 29-SEP-1999
LOCUS AR056412
DEFINITION Sequence 616 from patent US 5837542.
ACCESSION AR056412
VERSION AR056412.1 GI:5981989
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwigen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 616 17-NOV-1998;
FEATURES
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 506 CCAUCCAGAGGCC 518
DB 15 CCATCAGAGGCC 3
RESULT 455
AR113948/c

LOCUS AR113948 15 bp DNA PAT 16-MAY-2001
DEFINITION Sequence 394 from patent US 6132967.
ACCESSION AR113948
VERSION AR113948.1 GI:14094270
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwigen,J., Sullivan,S. and Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 394 17-OCT-2000;
FEATURES
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 506 CCAUCCAGAGGCC 518
DB 15 CCATCAGAGGCC 3
RESULT 456
AR114170/c 15 bp DNA PAT 16-MAY-2001
LOCUS AR114170
DEFINITION Sequence 616 from patent US 6132967.
ACCESSION AR114170
VERSION AR114170.1 GI:14094492
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwigen,J., Sullivan,S. and Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 616 17-OCT-2000;
FEATURES
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 506 CCAUCCAGAGGCC 518
DB 15 CCATCAGAGGCC 3
RESULT 457
CS002360/c 15 bp DNA PAT 07-FEB-2005
LOCUS CS002360
DEFINITION Sequence 388 from Patent EP1502950.
ACCESSION CS002360
VERSION CS002360.1 GI:58737715
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Chowrira,B., Dizenzo,A., Draper,K.G., Dudycz,L.W., Grimm,S., Karpelisky,A., Kisich,K., Matulic-Adamic,J., McSwigen,J.A., Modak,A., Payco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.B. and

Matches 7; Conservative 8; Mismatches 3; Indels 0; Gaps 0;

QY 204 GGUUCUACGCUUCU 221
 Db 28 GGTCGTTCGCTTCTT 11

RESULT 448
 AR591149

LOCUS AR591149 37 bp DNA linear PAT 15-DEC-2004
 DEFINITION Sequence 280 from patent US 6806054.
 ACCESSION AR591149
 VERSION AR591149.1 GI:56638958
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 37)
 AUTHORS Lehmann-Brinisma,K., Liaw,C.W. and Lin,I.-L.
 TITLE Non-endogenous, constitutively activated known G protein-coupled receptors
 JOURNAL Patent: US 6806054-A 280 19-OCT-2004;
 ARENA Pharmaceuticals, Inc.; San Diego, CA
 FEATURES
 source 1..37
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.7%; Score 13.2; DB 1; Length 37;
 Best Local Similarity 38.9%; Pred. No. 5.3e+02;
 Matches 7; Conservative 8; Mismatches 3; Indels 0; Gaps 0;

QY 204 GGUUCUACGCUUCU 221
 Db 10 GGTCGTTCGCTTCTT 27

RESULT 449
 AX280656/c

LOCUS AX280656 37 bp DNA linear PAT 02-NOV-2001
 DEFINITION Sequence 279 from Patent WO0177172.
 ACCESSION AX280656
 VERSION AX280656.1 GI:16608031
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE 1
 AUTHORS Lehmann-Brinisma,K., Liaw,C.W. and Lin,I.-L.
 TITLE Non-endogenous, constitutively activated known G protein-coupled receptors
 JOURNAL Patent: WO 0177172-A 279 18-OCT-2001;
 ARENA Pharmaceuticals, Inc. (US)
 FEATURES
 source 1..37
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.7%; Score 13.2; DB 1; Length 37;
 Best Local Similarity 38.9%; Pred. No. 5.3e+02;
 Matches 7; Conservative 8; Mismatches 3; Indels 0; Gaps 0;

QY 204 GGUUCUACGCUUCU 221
 Db 28 GGTCGTTCGCTTCTT 11

RESULT 450
 AX280657

LOCUS AX280657 37 bp DNA linear PAT 02-NOV-2001

DEFINITION Sequence 280 from Patent WO0177172.
 ACCESSION AX280657
 VERSION AX280657.1 GI:16608032
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE 1
 AUTHORS Lehmann-Brinisma,K., Liaw,C.W. and Lin,I.-L.
 TITLE Non-endogenous, constitutively activated known G protein-coupled receptors
 JOURNAL Patent: WO 0177172-A 280 18-OCT-2001;
 ARENA Pharmaceuticals, Inc. (US)
 FEATURES
 source 1..37
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.7%; Score 13.2; DB 1; Length 37;
 Best Local Similarity 38.9%; Pred. No. 5.3e+02;
 Matches 7; Conservative 8; Mismatches 3; Indels 0; Gaps 0;

QY 204 GGUUCUACGCUUCU 221
 Db 10 GGTCGTTCGCTTCTT 27

RESULT 451
 AR041251/c

LOCUS AR041251 15 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 41 from patent US 5811300.
 ACCESSION AR041251
 VERSION AR041251.1 GI:5961747
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)
 AUTHORS Sullivan,S., Draper,K., Kisch,K., Stinchcomb,D.T. and McSwiggen,J.
 TITLE TNF- α ribozymes
 JOURNAL Patent: US 5811300-A 41 22-SEP-1998;
 FEATURES
 source 1..15
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 2.6e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1231 CAGAGAGCGUGG 1243
 Db 13 CAGAGAGCGTGG 1

RESULT 452
 AR041763/c

LOCUS AR041763 15 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 553 from patent US 5811300.
 ACCESSION AR041763
 VERSION AR041763.1 GI:5962259
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)
 AUTHORS Sullivan,S., Draper,K., Kisch,K., Stinchcomb,D.T. and McSwiggen,J.
 TITLE TNF- α ribozymes
 JOURNAL Patent: US 5811300-A 553 22-SEP-1998;
 FEATURES
 Location/Qualifiers

FEATURES
source
location/Qualifiers
1..15
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 2.4e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 645 UGUGCCUGCGGAGA 659
1 TGTGACTCGGAGA 15

Db 1 TGTGACTCGGAGA 15

RESULT 444
BD104552/c 16 bp DNA linear PAT 27-AUG-2002

LOCUS BD104552
DEFINITION Kit and method for determining HLA type.
ACCESSION BD104552.1 GI:22650126
VERSION BD104552.1 GI:22650126
KEYWORDS WO 0192572-A/656.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 16)
AUTHORS Inoko,H., Kagiyama,T., Ichihara,T., Matsumura,Y., Moriya,S. and Nishida,M.
TITLE Kit and method for determining HLA type
JOURNAL Patient: WO 0192572-A 656 06-DEC-2001;
NISHIMBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO NISHIDA
COMMENT OS Artificial Sequence
PN WO 0192572-A/656
PD 06-DEC-2001
PR 01-JUN-2001 WO 2001JP004662
PI 01-JUN-2000 JP 00P 164798
PI HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO NISHIDA
PI SHOGO MORIYA,MICHIO NISHIDA
PC C12Q1/68,C12M1/00,C12N15/09,G01N3/53
CC Description of Artificial Sequence:capture
FH Key Location/Qualifiers
FT source 1..16
FT Location/Qualifiers
1..16
/organism="Artificial Sequence".
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 66.7%; Pred. No. 2.7e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 49 AGCUCUCCUGGAUA 63
16 AGCTCCTCGGTGA 2

Db 16 AGCTCCTCGGTGA 2

RESULT 445
AR241772 16 bp DNA linear PAT 20-DEC-2002

LOCUS AR241772
DEFINITION Sequence 60 from patent US 6472154.
ACCESSION AR241772
VERSION AR241772.1 GI:27287584
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)

AUTHORS Garner,H.R., Wren,J.D., Minna,J.D. and Fondon,J.W. III.
TITLE Polymorphic repeats in human genes
JOURNAL Patent: US 6472154-A 60 29-OCT-2002;
Board of Regents, The University of Texas System, Austin, TX
FEATURES
source
location/Qualifiers
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 815 GGACAGAGGACAGA 829
1 GGAGAGAGGACAGA 15

Db 1 GGAGAGAGGACAGA 15

RESULT 446
AX756484/c 16 bp DNA linear PAT 25-JUN-2003

LOCUS AX756484
DEFINITION Sequence 7 from Patent EP1312614.
ACCESSION AX756484
VERSION AX756484.1 GI:32251105
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Escary,J.L.
TITLE Polynucleotides and polypeptides of the gcp-2 gene
JOURNAL Patent: EP 1312614-A 7 21-MAY-2003;
Genodyssee (FR)
FEATURES
source
location/Qualifiers
1..16
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 60.0%; Pred. No. 2.7e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 592 GUCCUUGGCUCCU 606
16 GTCCTTCGGGCTCCT 2

Db 16 GTCCTTCGGGCTCCT 2

RESULT 447
AR591148/c 37 bp DNA linear PAT 15-DEC-2004

LOCUS AR591148
DEFINITION Sequence 279 from patent US 6806054.
ACCESSION AR591148
VERSION AR591148.1 GI:56638957
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 37)
AUTHORS Lehmann-Brinuma,K., Liaw,C.W. and Lin,I.-L.
TITLE Non-endogenous, constitutively activated known G protein-coupled receptors
JOURNAL Patent: US 6806054-A 279 19-OCT-2004;
Arena Pharmaceutical, Inc.; San Diego, CA
FEATURES
source
location/Qualifiers
1..37
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13.2; DB 1; Length 37;
Best Local Similarity 38.9%; Pred. No. 5.3e+02;

```

Db      17 TCAGTACTACGTGATC 1
      :|||::|:||||:|
RESULT 440
AX762401      17 bp      DNA      linear      PAT 25-JUN-2003
LOCUS      Sequence 5722 from Patent WO03040369.
ACCESSION      AX762401
VERSION      AX762401.1 GI:32257017
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Homiidae; Homo.
REFERENCE
AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE      Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
JOURNAL      Patent: WO 03040369-A 5722 15-MAY-2003;
FEATURES
SOURCE      Molecular Engines Laboratories (FR)
            Location/Qualifiers
            1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.8e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      1449 GGUCAAGGAGAGGAAG 1465
            |:|||||:|||||
Db      1 GATCAAGAGAGAGATAG 17

RESULT 441
HS13BE11      17 bp      DNA      linear      PRI 07-MAY-1996
LOCUS      HS13BE11
DEFINITION      H.sapiens primer 1 of STS to left arm of ICI YAC 13BE1.
ACCESSION      X87702
VERSION      X87702.1 GI:971423
KEYWORDS      primer.
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Homiidae; Homo.
REFERENCE
AUTHORS      Hoggar,N., Hey,Y., Brintnell,B., James,L., Jones,D., Mitchell,E.,
            Weissenbach,J. and Varley,J.M.
TITLE      Identification and cloning in yeast artificial chromosomes of a
            region of elevated loss of heterozygosity on chromosome 1p31.1 in
            human breast cancer
JOURNAL      Genomics 30 (2), 233-243 (1995)
REFERENCE
PUBMED      8586422
2 (bases 1 to 17)
Hoggar,N.
Direct Submision
Submitted (31-MAY-1995) N. Hoggar, Paterson Institute for Cancer
Research, Cancer Genetics, Wilmslow Road, Manchester, England., M20
9BX, UK
FEATURES
SOURCE      Location/Qualifiers
            1. .17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            /chromosome="1"
            /map="1p31"
            1. .17
            /note="primer 1 of STS to left arm of ICI YAC 13BE1"
misc_feature

```

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      129 UCGAGCAGCUGGCAU 145
            :|:|||||:|||||
Db      1 TGGTGCAGCTGGCAAT 17

RESULT 442
ARI31712/c      15 bp      DNA      linear      PAT 16-MAY-2001
LOCUS      ARI31712
DEFINITION      Sequence 137 from patent US 6194150.
ACCESSION      ARI31712
VERSION      ARI31712.1 GI:14120615
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
            Unclassified.
REFERENCE
AUTHORS      1 (bases 1 to 15)
            Scinchcomb,D.T., Jarvis,T. and McSwigen,J.
TITLE      Nucleic acid based inhibition of CD40
JOURNAL      Patent: US 6194150-A 137 27-FEB-2001;
FEATURES
SOURCE      Location/Qualifiers
            1. .15
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 2.4e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      486 CAGCTTUGACAGAU 500
            |||||:|||||:|
Db      15 CAGCTTGCAGCTGATA 1

RESULT 443
BD208668      15 bp      RNA      linear      PAT 17-JUN-2003
LOCUS      BD208668
DEFINITION      Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection.
ACCESSION      BD208668
VERSION      BD208668.1 GI:33018438
KEYWORDS      JP 2002512791-A/2258.
SOURCE      unidentified
            unidentified
            unclassified sequences.
ORGANISM      1 (bases 1 to 15)
            Blatt,L., Mcswigen,J.A., Roberts,F., Pavco,P.A. and Macejak,D.
            Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection
            Patent: JP 2002512791-A 2258 08-MAY-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT      OS Hepatitis virus (hepatitis C virus)
            PN JP 2002512791-A/2258
            PD 08-MAY-2002
            PF 26-APR-1999 JP 2000545991
            PR 27-APR-1998 US 60/083217,18-SEP-1998 US 60/100842 PR
            25-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PI
            LAWRENCE BLATT,JAMES A MCSWIGEN,ELISABETH ROBERTS,PAMELA A PI
            PAVCO,
            PI DENNIS MACEJAK
            PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
            PC A61K37/66,
            PC C12N15/00
            CC Enzymatic nucleic acid treatment of diseases or conditions
            related to
            CC hepatitis C virus infection.
            FH Key Location/Qualifiers
            FT 1. .15
            /organism='Hepatitis virus (hepatitis C FT

```

Molecular Engines Laboratories (FR)
FEATURES
source
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.8e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

OY 1589 ACUGCUGUCUACUC 1605
17 ACTGATGTCCTGATC 1

RESULT 436
AX753822 17 bp DNA linear PAT 23-JUN-2003
LOCUS AX753822
DEFINITION Sequence 169 from Patent WO03037931.
ACCESSION AX753822
VERSION AX753822.1 GI:3216519
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Homnidae; Homo.

REFERENCE
AUTHORS Shannon,M. and Phan,T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 169 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES
source
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1709 AGCAGCAGUACGACGAG 1725
1 AGCAGCAGCAGCAGCAG 17

RESULT 437
AX758163 17 bp DNA linear PAT 25-JUN-2003
LOCUS AX758163
DEFINITION Sequence 1484 from Patent WO03040369.
ACCESSION AX758163
VERSION AX758163.1 GI:32252779
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Homnidae; Homo.

REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 1484 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.8e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 1449 GGUCAAGAGAGAAAG 1465
1 GATCAAGTAGAAGAAAG 17

RESULT 438
AX760563 17 bp DNA linear PAT 25-JUN-2003
LOCUS AX760563
DEFINITION Sequence 3884 from Patent WO03040369.
ACCESSION AX760563
VERSION AX760563.1 GI:32255179
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Homnidae; Homo.

REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 3884 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.8e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 1449 GGUCAAGAGAGAAAG 1465
1 GATCAAGTAGAAGAAAG 17

RESULT 439
AX761179 17 bp DNA linear PAT 25-JUN-2003
LOCUS AX761179
DEFINITION Sequence 4500 from Patent WO03040369.
ACCESSION AX761179
VERSION AX761179.1 GI:32255795
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Homnidae; Homo.

REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 4500 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.8e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

OY 669 UCAGUCCUACGAGAC 685

ORGANISM Mus musculus
Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
Sciurognathi; Muroidae; Muridae; Mus.

REFERENCE 1
Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025176-A 5231 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers

FEATURES
source 1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.8e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1060 GAGGAGGACAUUGGCTC 1076
||| ||||| :||| :|||
17 GAAGAGGACATTCGATC 1

RESULT 432
AX729874/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX729874
DEFINITION Sequence 1508 from Patent WO03025175.
ACCESSION AX729874
VERSION AX729874.1 GI:30509217
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Hominidae; Homo.

REFERENCE 1
Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025175-A 1508 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

JOURNAL
Patent: WO 03025175-A 1508 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.8e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 955 AGCTUGAACCAGC 971
||| :||| :||| :|||
17 AGCTGAAAACCCAGATC 1

RESULT 433
AX735559 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX735559
DEFINITION Sequence 1149 from Patent WO03025177.
ACCESSION AX735559
VERSION AX735559.1 GI:30514836
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Hominidae; Homo.

REFERENCE 1
Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
Patent: WO 03025177-A 1149 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

JOURNAL
Patent: WO 03025177-A 1149 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers

AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 1149 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.8e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1449 GGUCAAGAGAGAGAAAG 1465
|: ||| ||||| |||||
1 GATCAAGTAGAGAGAAAG 17

RESULT 434
AX736610 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX736610/c
DEFINITION Sequence 2200 from Patent WO03025177.
ACCESSION AX736610
VERSION AX736610.1 GI:30515898
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Hominidae; Homo.

REFERENCE 1
Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
Patent: WO 03025177-A 2200 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers

FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

JOURNAL
Patent: WO 03025177-A 2200 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 2.8e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 32 CUUGUUUCCAAACATC 48
|::|::|::|::|::|
17 CTTGTGTTCCGAGATC 1

RESULT 435
AX737723 17 bp DNA linear PAT 08-MAY-2003
LOCUS AX737723
DEFINITION Sequence 3313 from Patent WO03025177.
ACCESSION AX737723
VERSION AX737723.1 GI:30517011
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Hominidae; Homo.

REFERENCE 1
Telerman, A., Amson, R. and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
Patent: WO 03025177-A 3313 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers


```

REFERENCE      1 Homidae; Homo.
AUTHORS       1 Gu,Y. and Nguyen,C.T.
TITLE         Human lcc1-domain containing protein
JOURNAL       Patent: EP 1262488-A 857 04-DEC-2002;
              Aeomica, Inc. (US)
FEATURES
source        1.17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match   0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.8e+02;
Matches       9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy            1661 CUUCAGAGUCGUCG 1677
Db            1 CTTGAGAGATGATGCTG 17

RESULT 423
LOCUS         AX616051 17 bp DNA linear PAT 20-FEB-2003
DEFINITION   Sequence 858 from Patent EP1262488.
ACCESSION    AX616051
VERSION      AX616051.1 GI:28447097
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
              Homidae; Homo.
REFERENCE     1
AUTHORS      Gu,Y. and Nguyen,C.T.
TITLE        Human lcc1-domain containing protein
JOURNAL      Patent: BP 1262488-A 858 04-DEC-2002;
              Aeomica, Inc. (US)
FEATURES
source        1.17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match   0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.8e+02;
Matches       9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy            1662 UUUCAAGATGCGUCG 1678
Db            1 TTGAGAGATGATGCTGC 17

RESULT 424
LOCUS         AX616052 17 bp DNA linear PAT 20-FEB-2003
DEFINITION   Sequence 859 from Patent EP1262488.
ACCESSION    AX616052
VERSION      AX616052.1 GI:28447098
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
              Homidae; Homo.
REFERENCE     1
AUTHORS      Gu,Y. and Nguyen,C.T.
TITLE        Human lcc1-domain containing protein
JOURNAL      Patent: EP 1262488-A 859 04-DEC-2002;
              Aeomica, Inc. (US)
FEATURES
source        1.17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

```

```

              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match   0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.8e+02;
Matches       9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy            1663 UUCAGAGUCGUCGCU 1679
Db            1 TTGAGAGATGATGCTGCT 17

RESULT 425
LOCUS         AX648760 17 bp DNA linear PAT 22-MAR-2003
DEFINITION   Sequence 600 from Patent EP1273660.
ACCESSION    AX648760
VERSION      AX648760.1 GI:29151578
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
              Homidae; Homo.
REFERENCE     1
AUTHORS      Gu,Y.
TITLE        Human sodium-hydrogen exchanger like protein 1
JOURNAL      Patent: EP 1273660-A 600 08-JAN-2003;
              Aeomica, Inc. (US)
FEATURES
source        1.17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match   0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.8e+02;
Matches      10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy            1087 GCCAUCUACUCCAUCCU 1103
Db            1 GCCATCTCCGCAATCGT 17

RESULT 426
LOCUS         AX691839 17 bp DNA linear PAT 31-MAR-2003
DEFINITION   Sequence 4571 from Patent EP1281758.
ACCESSION    AX691839
VERSION      AX691839.1 GI:29414780
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
              Homidae; Homo.
REFERENCE     1
AUTHORS      Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE        Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
              mdz12
JOURNAL      Patent: BP 1281758-A 4571 05-FEB-2003;
              Aeomica, Inc. (US)
FEATURES
source        1.17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match   0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.8e+02;
Matches      10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy            1313 CUAAGACUUCGACGUC 1329

```

RESULT 418
LOCUS AX475754 17 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 975 from Patent WO0224750.
ACCESSION AX475754
VERSION AX475754.1 GI:22215039
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Homnidae; Homo.
REFERENCE
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 975 28-MAR-2002;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
Qy 1280 UUCCCAUCCAGCUGAG 1296
Db 17 TTCCCTCCAGGAGAG 1
RESULT 419
LOCUS AX531289 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 798 from Patent EP1239051.
ACCESSION AX531289
VERSION AX531289.1 GI:25254364
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Homnidae; Homo.
REFERENCE
AUTHORS Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 798 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.8e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
Qy 281 AGGCAACAAGCAGCUG 297
Db 1 AAGTCATCAAGCAGCTG 17
RESULT 420
LOCUS AX579508 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 1346 from Patent WO0211674.
ACCESSION AX579508
VERSION AX579508.1 GI:27648710
KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Homnidae; Homo.
REFERENCE
AUTHORS Thompson, J., Mcswigen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (Clca-1)
JOURNAL Patent: WO 0211674-A 1346 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 2.8e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
Qy 358 AUUCAUGAUCUGU 374
Db 1 AGTTCATGATCTCTTCA 17
RESULT 421
LOCUS AX579990 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 1828 from Patent WO0211674.
ACCESSION AX579990
VERSION AX579990.1 GI:27649192
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Homnidae; Homo.
REFERENCE
AUTHORS Thompson, J., Mcswigen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (Clca-1)
JOURNAL Patent: WO 0211674-A 1828 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 2.8e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
Qy 360 UUCAUGAUCUGUUA 376
Db 1 TTCATGATCTCTTCA 17
RESULT 422
LOCUS AX616050 17 bp DNA linear PAT 20-FEB-2003
DEFINITION Sequence 857 from Patent EP1262488.
ACCESSION AX616050
VERSION AX616050.1 GI:28447096
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;

DEFINITION Sequence 636 from patent US 6656700.
ACCESSION AR434213
VERSION AR434213.1 GI:40197056
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Gu,Y. and Shannon,M.E.
JOURNAL Isoforms of human pregnancy-associated protein-E
Patent: US 6656700-A 636 02-DEC-2003;
Amersham PLC; Buckinghamshire;
GBX;
FEATURES
source 1..17
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
QY 1674 GCUCGUGGCCAGUG 1690
Db 17 GCCGCTCTGCCAGTGTG 1
RESULT 414
LOCUS AR458624 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2301 from patent US 6686188.
ACCESSION AR458624
VERSION AR458624.1 GI:42693681
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
JOURNAL Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
Patent: US 6686188-A 2301 03-FEB-2004;
Amersham PLC; Buckinghamshire;
GBX;
FEATURES
source 1..17
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.8e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 990 CCACGACGACGACGA 1006
Db 1 CCACGACGACGACGCA 17
RESULT 415
LOCUS AR482658 17 bp DNA linear PAT 14-MAY-2004
DEFINITION Sequence 104 from patent US 6703228.
ACCESSION AR482658
VERSION AR482658.1 GI:47245181
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Landers,J., Jordan,B., Housman,D.E. and Charest,A.
JOURNAL Methods and products related to genotyping and DNA analysis
Patent: US 6703228-A 104 09-MAR-2004;

Massachusetts Institute of Technology; Cambridge, MA
FEATURES
source 1..17
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.8e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 1567 AAAACCUUGUGAUCU 1583
Db 17 AAAACCTTTGAATCT 1
RESULT 416
LOCUS AR482660 17 bp DNA linear PAT 14-MAY-2004
DEFINITION Sequence 106 from patent US 6703228.
ACCESSION AR482660
VERSION AR482660.1 GI:47245183
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Landers,J., Jordan,B., Housman,D.E. and Charest,A.
JOURNAL Methods and products related to genotyping and DNA analysis
Patent: US 6703228-A 106 09-MAR-2004;
Massachusetts Institute of Technology; Cambridge, MA
FEATURES
source 1..17
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.8e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 1567 AAAACCUUGUGAUCU 1583
Db 17 AAAACCTTTGAATCT 1
RESULT 417
LOCUS AR597925 17 bp RNA linear PAT 15-DEC-2004
DEFINITION Sequence 1867 from patent US 6818447.
ACCESSION AR597925
VERSION AR597925.1 GI:56648939
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 17)
TITLE Payco,P., McSwigen,J., Stinchcomb,D. and Escobedo,J.
JOURNAL Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
Patent: US 6818447-A 1867 16-NOV-2004;
Sirma Therapeutics, Inc.; Boulder, CO
FEATURES
source 1..17
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 2.8e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
QY 606 UGCCAUCUGUUCUGGC 622
Db 1 TGCAGTCTCTCTGCG 17

```

VERSION      AR324465.1  GI:33710273
KEYWORDS
SOURCE       Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Payco P., McSwiggen,J.A., Stinchcomb,D.T. and Bascobedo,J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 656127-A 1867 20-MAY-2003;
              Ribozyme Pharmaceuticals, Inc. and Chiron Corporation; Boulder, CO
FEATURES
source       1..17
              /organism="unknown"
              /mol_type="unassigned RNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 2.8e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY      606 UCCCAUCUUCUGCGC 622
Db      1 TCCCATGTTCTTCTGCGC 17

RESULT 409
LOCUS      157076          17 bp      DNA          linear      PAT 07-OCT-1997
DEFINITION Sequence 15 from patent US 5650554.
ACCESSION  157076
VERSION    157076.1  GI:2477499
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Moloney,M.
TITLE      Oil-body proteins as carriers of high-value peptides in plants
JOURNAL    Patent: US 5650554-A 15 22-JUL-1997;
FEATURES
source     1..17
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.8e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      1343 GUAGAGCAGCGCCACU 1359
Db      1 GTTAAAGCAGCGCCACT 17

RESULT 410
LOCUS      AR398265          17 bp      RNA          linear      PAT 18-DEC-2003
DEFINITION Sequence 646 from patent US 6617438.
ACCESSION  AR398265
VERSION    AR398265.1  GI:40135936
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Beigelman,L., Burgin,A.B., Beaudry,A., Karpetsky,A.,
              Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE      Oligoribonucleotides with enzymatic activity
JOURNAL    Patent: US 6617438-A 646 09-SEP-2003;
              Sirna Therapeutics, Inc.; Boulder, CO
FEATURES
source     1..17
              /organism="unknown"
              /mol_type="unassigned RNA"

```

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.8e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY      1626 GUGCUAUGCUCUGUCA 1642
Db      1 GTGCTATGCTCTGGGCA 17

RESULT 411
LOCUS      AR398502          17 bp      RNA          linear      PAT 18-DEC-2003
DEFINITION Sequence 883 from patent US 6617438.
ACCESSION  AR398502
VERSION    AR398502.1  GI:40136378
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Beigelman,L., Burgin,A.B., Beaudry,A., Karpetsky,A.,
              Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE      Oligoribonucleotides with enzymatic activity
JOURNAL    Patent: US 6617438-A 883 09-SEP-2003;
              Sirna Therapeutics, Inc.; Boulder, CO
FEATURES
source     1..17
              /organism="unknown"
              /mol_type="unassigned RNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      406 UUAGGGAACUGGCGCC 422
Db      1 TTAGGGAAGCTGCGCCTG 17

RESULT 412
LOCUS      AR401922          17 bp      DNA          linear      PAT 18-DEC-2003
DEFINITION Sequence 262 from patent US 6623962.
ACCESSION  AR401922
VERSION    AR401922.1  GI:40149372
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Akhtar,S., Fell,P. and McSwiggen,J.A.
TITLE      Enzymatic nucleic acid treatment of diseases of conditions related
              to levels of epidermal growth factor receptors
JOURNAL    Patent: US 6623962-A 262 23-SEP-2003;
              Sirna Therapeutics, Inc. and Aetion University; Boulder, CO
FEATURES
source     1..17
              /organism="unknown"
              /mol_type="genomic DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.8e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      756 GAGGATCUAUAAGGAAA 772
Db      1 GAGGATCTTGAAGGAAA 17

RESULT 413
LOCUS      AR434213          17 bp      DNA          linear      PAT 18-DEC-2003

```

VERSION 114562.1 GI:997045
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Apple,R.J., Bugawan,T.L. and Erlich,H.A.
TITLE Methods and reagents for HLA class I A locus DNA typing
JOURNAL Patent: US 5451512-A 39 19-SEP-1995;
FEATURES
source Location/Qualifiers
1. 17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.8e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1420 CAGAUCAUAGGGGAA 1436
Db 1 CAGATCACCAAGCCAA 17

RESULT 404
LOCUS AR188612 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4100 from patent US 6346398.
ACCESSION AR188612
VERSION AR188612.1 GI:20234577
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 4100 12-FEB-2002;
FEATURES
source Location/Qualifiers
1. 17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 2.8e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 606 UGCCAUCUUGUCGAC 622
Db 1 TGCATGTTCTCTGCGC 17

RESULT 405
LOCUS AR190186 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 5674 from patent US 6346398.
ACCESSION AR190186
VERSION AR190186.1 GI:20236151
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5674 12-FEB-2002;
FEATURES
source Location/Qualifiers
1. 17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 47.1%; Pred. No. 2.8e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 606 UGCCAUCUUGUCGAC 622
Db 1 TGCATGTTCTCTGCGC 17

RESULT 406
LOCUS AR286275 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 647 from patent US 6528640.
ACCESSION AR286275
VERSION AR286275.1 GI:29723871
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A., Matulic-Adamic,J., Svedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 647 04-MAR-2003;
FEATURES
source Location/Qualifiers
1. 17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.8e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1626 GUGCUAUGCUCUGGCA 1642
Db 1 GTGCTATGCTCTGCGCA 17

RESULT 407
LOCUS AR286512 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 884 from patent US 6528640.
ACCESSION AR286512
VERSION AR286512.1 GI:29724108
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A., Matulic-Adamic,J., Svedler,D. and Zinnen,S.
TITLE Synthetic ribonucleic acids with RNase activity
JOURNAL Patent: US 6528640-A 884 04-MAR-2003;
FEATURES
source Location/Qualifiers
1. 17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.8e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 406 UUNGGAAUUGGCTUG 422
Db 1 TTAGGAACTGCGCTG 17

RESULT 408
LOCUS AR324465 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 1867 from patent US 6566127.
ACCESSION AR324465

```
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1709 AGCAGCAGUACGACGAG 1725
    |||||
    17 AGCAGCAGCAGCAGCAG 1

RESULT 400
LOCUS DD187816 17 bp DNA linear PAT 19-JAN-2006
DEFINITION Probe set and method for identification of allele of HLA.
ACCESSION DD187816
VERSION DD187816.1 GI:85644994
KEYWORDS WO 2005063985-A/257.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Chordata; Craniata; Vertebrata; Euteleostomi;
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
          Homiidae; Homo.
REFERENCE 1 (bases 1 to 17)
AUTHORS Tsukada,M.
TITLE Probe set and method for identification of allele of HLA
JOURNAL Patent: WO 2005063985-A 257 14-JUL-2005;

COMMENT
OS Homo sapiens
PN WO 2005063985-A/257
PD 14-JUL-2005 WO 2004JP019763
PR 24-DEC-2004 WO 2004JP019763
PR 25-DEC-2003 JP 03P 430556,25-DEC-2003 JP 03P 430555, PR
25-DEC-2003 JP 03P 430559,25-DEC-2003 JP 03P 430553, PR
25-DEC-2003 JP 03P 430558,25-DEC-2003 JP 03P 430557, PR
25-DEC-2003 JP 03P 430554
PI mamoru tsukada
CC FH
FEATURES
    source          Location/Qualifiers.
                    1..17
                    /organism="Homo sapiens"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.8e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 152 CUCCAGACGUGACACC 168
    |||||
    17 CTCGACGACGACACC 1

Db 17 CTCGACGACGACACC 1

RESULT 401
LOCUS DD190912 17 bp DNA linear PAT 19-JAN-2006
DEFINITION Probe set and method for identification of allele of HLA.
ACCESSION DD190912
VERSION DD190912.1 GI:85653118
KEYWORDS WO 2005063985-A/3353.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Chordata; Craniata; Vertebrata; Euteleostomi;
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
          Homiidae; Homo.
REFERENCE 1 (bases 1 to 17)
AUTHORS Tsukada,M.
TITLE Probe set and method for identification of allele of HLA
JOURNAL Patent: WO 2005063985-A 3353 14-JUL-2005;

COMMENT
OS Homo sapiens
```

```
PN WO 2005063985-A/3353
PD 14-JUL-2005
PR 24-DEC-2004 WO 2004JP019763
PR 25-DEC-2003 JP 03P 430556,25-DEC-2003 JP 03P 430555, PR
25-DEC-2003 JP 03P 430559,25-DEC-2003 JP 03P 430553, PR
25-DEC-2003 JP 03P 430558,25-DEC-2003 JP 03P 430557, PR
25-DEC-2003 JP 03P 430554
PI mamoru tsukada
CC FH
FEATURES
    source          Location/Qualifiers.
                    1..17
                    /organism="Homo sapiens"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1709 AGCAGCAGUACGACGAG 1725
    |||||
    17 AGCAGCAGCAGCAGCAG 1

Db 17 AGCAGCAGCAGCAGCAG 1

RESULT 402
LOCUS DD190916 17 bp DNA linear PAT 19-JAN-2006
DEFINITION Probe set and method for identification of allele of HLA.
ACCESSION DD190916
VERSION DD190916.1 GI:85653122
KEYWORDS WO 2005063985-A/3357.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Chordata; Craniata; Vertebrata; Euteleostomi;
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
          Homiidae; Homo.
REFERENCE 1 (bases 1 to 17)
AUTHORS Tsukada,M.
TITLE Probe set and method for identification of allele of HLA
JOURNAL Patent: WO 2005063985-A 3357 14-JUL-2005;

COMMENT
OS Homo sapiens
PN WO 2005063985-A/3357
PD 14-JUL-2005 WO 2004JP019763
PR 24-DEC-2004 WO 2004JP019763
PR 25-DEC-2003 JP 03P 430556,25-DEC-2003 JP 03P 430555, PR
25-DEC-2003 JP 03P 430559,25-DEC-2003 JP 03P 430553, PR
25-DEC-2003 JP 03P 430558,25-DEC-2003 JP 03P 430557, PR
25-DEC-2003 JP 03P 430554
PI mamoru tsukada
CC FH
FEATURES
    source          Location/Qualifiers.
                    1..17
                    /organism="Homo sapiens"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1709 AGCAGCAGUACGACGAG 1725
    |||||
    17 AGCAGCAGCAGCAGCAG 1

Db 17 AGCAGCAGCAGCAGCAG 1

RESULT 403
LOCUS I14562 17 bp DNA linear PAT 26-SEP-1995
DEFINITION Sequence 39 from patent US 5451512.
ACCESSION I14562
```

/note="probe HPA-3ba"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.8e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1179 GGAGGAGCTGGGAGCG 1195
Db 17 GGAGGGGCTGGGGCTGG 1

RESULT 396
LOCUS CS185409 17 bp DNA linear PAT 04-NOV-2005
DEFINITION Sequence 102 from Patent EP1591534.
ACCESSION CS185409
VERSION CS185409.1 GI:80747482
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS Belboer,S.H.
TITLE A method of genotyping blood cell antigens and a kit suitable for genotyping blood cell antigens
JOURNAL Patent: EP 1591534-A 102 02-NOV-2005;
Stichting Sangin Bioedvoorziening (NL)
LOCATION/Qualifiers

FEATURES
source 1. .17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="probe HPA-3ba CR"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.8e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1179 GGAGGAGCTGGGAGCG 1195
Db 1 GGAGGGGCTGGGGCTGG 17

RESULT 397
LOCUS DD185857/c 17 bp DNA linear PAT 19-JAN-2006
DEFINITION Probe sets for detection of HLA-A allele and methods thereof.
ACCESSION DD185857
VERSION DD185857.1 GI:85640490
KEYWORDS JP 2005185176-A/257.
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS Tsukada,M.
TITLE Probe sets for detection of HLA-A allele and methods thereof
JOURNAL Patent: JP 2005185176-A 257 14-JUL-2005;

COMMENT
OS artificial sequence
PN JP 2005185176-A/257
PD 14-JUL-2005
PF 25-DEC-2003 JP 2003430558
PI mamoru tsukada
CC probe for detection
FH Key Location/Qualifiers

FEATURES
source 1. .17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.8e+02;

Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 152 CUCCAGACGGUACCACC 168
Db 17 CTCGAGAGGACACC 1

RESULT 398
LOCUS DD186271/c 17 bp DNA linear PAT 19-JAN-2006
DEFINITION Probe sets and methods for identifying HLA-MICA allele.
ACCESSION DD186271
VERSION DD186271.1 GI:85641388
KEYWORDS JP 2005185177-A/34.
SOURCE
ORGANISM Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Homidae; Homo.
REFERENCE
AUTHORS Tsukada,M.
TITLE Probe sets and methods for identifying HLA-MICA allele
JOURNAL Patent: JP 2005185177-A 34 14-JUL-2005;
CANON INC

COMMENT
OS Homo sapiens
PN JP 2005185177-A/34
PD 14-JUL-2005
PF 25-DEC-2003 JP 2003430559
PI mamoru tsukada
CC
FH Key Location/Qualifiers

FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1709 AGCAGCAGUACGACGAG 1725
Db 17 AGCAGCAGCAGCAGCAG 1

RESULT 399
LOCUS DD186275/c 17 bp DNA linear PAT 19-JAN-2006
DEFINITION Probe sets and methods for identifying HLA-MICA allele.
ACCESSION DD186275
VERSION DD186275.1 GI:85641392
KEYWORDS JP 2005185177-A/38.
SOURCE
ORGANISM Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Homidae; Homo.
REFERENCE
AUTHORS Tsukada,M.
TITLE Probe sets and methods for identifying HLA-MICA allele
JOURNAL Patent: JP 2005185177-A 38 14-JUL-2005;
CANON INC

COMMENT
OS Homo sapiens
PN JP 2005185177-A/38
PD 14-JUL-2005
PF 25-DEC-2003 JP 2003430559
PI mamoru tsukada
CC
FH Key Location/Qualifiers

FEATURES
source 1. .17
/organism="Homo sapiens"

TITLE Methods and products related to genotyping and DNA analysis
JOURNAL Patent: JP 2002525127-A 106 13-AUG-2002;
COMMENT MASSACHUSETTS INSTITUTE OF TECHNOLOGY
OS Homo sapiens (human)
PN JP 2002525127-A/106
PD 13-AUG-2002
PF 24-SEP-1999 JP 2000572407
PR 25-SEP-1998 US 60/101757
PI JOHN E LANDERS, BARBARA JORDAN, DAVID E HOUSMAN, ALAIN CHAREST PC
C12N15/09, C12Q1/68, G01N33/53, G01N33/56, G01N33/58, G01N37/00, PC
G01N37/00,
PC C12N15/00
CC Methods and products related to genotyping and DNA analysis FH
Key Location/Qualifiers
FT source 1.17
/organism='Homo sapiens (human)'.
Location/Qualifiers
1.17
/organism='Homo sapiens'
/mol_type='genomic DNA'
/db_xref='taxon:9606'

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.8e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1567 AAAACCUUUGAUAUCU 1583
DB 17 AAAACCTTTTGAATCT 1

RESULT 392
CQ617561 17 bp DNA linear PAT 02-FEB-2004
LOCUS Sequence 2301 from Patent WO0192524.
DEFINITION CQ617561
ACCESSION CQ617561
VERSION CQ617561.1 GI:41667779
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Homnidae; Homo.

REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2301 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1.17
/organism='Homo sapiens'
/mol_type='unassigned DNA'
/db_xref='taxon:9606'

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.8e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 990 CCACGACGACGACGACA 1006
DB 1 CCACGACGACGACGACA 17

RESULT 393
CQ875811 17 bp DNA linear PAT 04-OCT-2004
LOCUS Sequence 5 from Patent EP1462527.
DEFINITION CQ875811
ACCESSION CQ875811
VERSION CQ875811.1 GI:53789556
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct

other sequences; artificial sequences.

REFERENCE
AUTHORS Costello,C., Ma,N., Schreiber,S. and Seeger,D.
TITLE Novel markers for inflammatory bowel disease
JOURNAL Patent: EP 1462527-A 5 29-SEP-2004;
CONARIS research institute AG (DE)
FEATURES
source Location/Qualifiers
1.17
/organism='synthetic construct'
/mol_type='unassigned DNA'
/db_xref='taxon:32630'

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.8e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 325 AGCCUGGCCUGGCCGA 341
DB 1 AGCCTGCGCTTTGCCGA 17

RESULT 394
CQ889694 17 bp DNA linear PAT 19-OCT-2004
LOCUS Sequence 5 from Patent WO2004085677.
DEFINITION CQ889694
ACCESSION CQ889694
VERSION CQ889694.1 GI:54305543
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS Costello,C., Ma,N., Schreiber,S. and Seeger,D.
TITLE Novel markers for inflammatory bowel disease
JOURNAL Patent: WO 2004085677-A 5 07-OCT-2004;
CONARIS research institute AG (DE)
FEATURES
source Location/Qualifiers
1.17
/organism='synthetic construct'
/mol_type='unassigned DNA'
/db_xref='taxon:32630'
/note='Primer'

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.8e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 325 AGCCUGGCCUGGCCGA 341
DB 1 AGCCTGCGCTTTGCCGA 17

RESULT 395
CS185402/c 17 bp DNA linear PAT 04-NOV-2005
LOCUS Sequence 95 from Patent EP1591534.
DEFINITION CS185402
ACCESSION CS185402
VERSION CS185402.1 GI:80747475
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS Beiboer,S.H.
TITLE A method of genotyping blood cell antigens and a kit suitable for
JOURNAL genotyping blood cell antigens
Patent: EP 1591534-A 95 02-NOV-2005;
Stichting Sanguin Bloedvoorziening (NL)
FEATURES
source Location/Qualifiers
1.17
/organism='synthetic construct'
/mol_type='unassigned DNA'
/db_xref='taxon:32630'

Matches	13;	Conservative	1;	Mismatches	0;	Indels	0;	Gaps	0;
Oy	1710	GCAGCAGTACACGC	1723						
Db	3	GCAGCAGTACACGC	16						
RESULT 384									
LOCUS	BD128459								
DEFINITION	BD128459	17 bp	DNA	linear	PAT 18-SEP-2002				
ACCESSION	BD128459	Isolation of target homologous gene in gene family and utilization of common sequence for recombination.							
VERSION	BD128459.1	GI:23223404							
KEYWORDS	JP 2002500882-A/6.								
SOURCE	synthetic construct								
ORGANISM	other sequences; artificial sequences.								
REFERENCE	1 (bases 1 to 17)								
AUTHORS	Patl,S., Zarling,D., Lehmann,C.W. and Zeng,H.								
TITLE	Isolation of target homologous gene in gene family and utilization of common sequence for recombination								
JOURNAL	Patent: JP 2002500882-A 6 15-JAN-2002;								
COMMENT	PANGENE CORP								
OS	Artificial Sequence								
PN	JP 2002500882-A/6								
PD	15-JAN-2002								
PF	11-DEC-1998 JP 2000528663								
PR	11-DEC-1997 US 60/070734								
PI	SUSHMA PARTI, DAVID ZARLING, CHRISTOPHER W LEHMANN, HONG ZENG PC								
CI2N15/09, CI2N1/15, CI2N1/19, CI2N1/21, CI2N5/10, CI2N9/00, CI2Q1/ PC									
68, CI2N15/00,									
PC	CI2N5/00								
CC	Description of Artificial Sequence: synthetic FH								
Location/Qualifiers									
FT	source	1.. 17							
FEATURES		Location/Qualifiers	/organism='Artificial Sequence'.						
source		1.. 17							
		/organism="synthetic construct"							
		/mol_type="genomic DNA"							
		/db_xref="taxon:32630"							
Query Match		0.8%;	Score 14;	DB 1;	length 17;				
Best Local Similarity		35.3%;	Pred. No. 2.6e+02;						
Matches	6;	Conservative	10;	Mismatches	1;	Indels	0;	Gaps	0;
Oy	304	GUACACACUACUCCU	320						
Db	1	GTMAATATATATTTT	17						
RESULT 385									
LOCUS	AX673704/C								
DEFINITION	Sequence 2149 from Patent WO03004526.								
ACCESSION	AX673704								
VERSION	AX673704.1	GI:29332052							
KEYWORDS									
SOURCE	Homo sapiens (human)								
ORGANISM	Homo sapiens								
	Eumetazoa; Chordata; Craniata; Vertebrata; Euteleostomi;								
	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;								
	Hominidae; Homo.								
REFERENCE	1								
AUTHORS	Teleman,A., Amsou,R. and Tuijinder,M.								
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines								
JOURNAL	Patent: WO 03004526-A 2149 16-JAN-2003;								
FEATURES	Molecular Engines Laboratories (FR)								
source	Location/Qualifiers								
	1.. 17								

```

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.6e+02;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      1045 UCCGCCUUCUGCGA 1058
Db       16 TCCGCCTCTCCGA 3

RESULT 386
LOCUS    AX729755/c              17 bp   DNA           linear   PAT 08-MAY-2003
DEFINITION Sequence 1389 from Patent WO03025175.
ACCESSION AX729755
VERSION   AX729755.1 GI:30509098
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Eueleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Homnidae; Homo.
REFERENCE 1 Telerman,A., Amson,R. and Tuijinder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE     reversion, apoptosis and/or virus resistance and their use as
          medicines
JOURNAL   Patent: WO 03025175-A 1389 27-MAR-2003;
FEATURES
source    Molecular Engines Laboratories (FR)
            Location/Qualifiers
            1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 2.6e+02;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      1045 UCCGCCUUCUGCGA 1058
Db       16 TCCGCCTCTCCGA 3

RESULT 387
LOCUS    AX733963/c              17 bp   DNA           linear   PAT 08-MAY-2003
DEFINITION Sequence 5597 from Patent WO03025175.
ACCESSION AX733963
VERSION   AX733963.1 GI:30513306
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Eueleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
            Homnidae; Homo.
REFERENCE 1 Telerman,A., Amson,R. and Tuijinder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE     reversion, apoptosis and/or virus resistance and their use as
          medicines
JOURNAL   Patent: WO 03025175-A 5597 27-MAR-2003;
FEATURES
source    Molecular Engines Laboratories (FR)
            Location/Qualifiers
            1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match          0.8%; Score 14; DB 1; Length 17;

```

ACCESSION CS185389
VERSION CS185389.1 GI:80747462
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Beiboer, S.H.
TITLE A method of genotyping blood cell antigens and a kit suitable for
JOURNAL genotyping blood cell antigens
Stichting Sanguin Bloedvoorziening (NLI)
location/Qualifiers
FEATURES
source 1. 18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="probe HPA-3ab"

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 2.6e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1180 GAGGAGCTGGGGAUGG 1195
Db 18 GAGGGGCTGGGGAUGG 3

RESULT 380
LOCUS CS185396 18 bp DNA linear PAT 04-NOV-2005
DEFINITION Sequence 89 from Patent EP1591534.
ACCESSION CS185396
VERSION CS185396.1 GI:80747469
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Beiboer, S.H.
TITLE A method of genotyping blood cell antigens and a kit suitable for
JOURNAL genotyping blood cell antigens
Patent: EP 1591534-A 89 02-NOV-2005;
Stichting Sanguin Bloedvoorziening (NLI)
location/Qualifiers
FEATURES
source 1. 18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="probe HPA-3ab CR"

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 2.6e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1180 GAGGAGCTGGGGAUGG 1195
Db 1 GAGGGGCTGGGGAUGG 16

RESULT 381
LOCUS AR216239 18 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 25 from patent US 6410710.
ACCESSION AR216239
VERSION AR216239.1 GI:23314693
KEYWORDS
SOURCE unknown.
ORGANISM unknown.
REFERENCE 1
AUTHORS Lederman, S., and Van Eynhoven, W.
TITLE Nucleic acid encoding a TRAF-3 deletion isoform

JOURNAL Patent: US 6410710-A 25 25-JUN-2002;
NY; The Trustees of the University in the City of New York; New York,
MOX;
FEATURES
source 1. 18
location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 62.5%; Pred. No. 2.6e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1393 AAGAGGCTGCTGCA 1408
Db 2 AAGAGGCTGCTGCTCA 17

RESULT 382
LOCUS AR241961 18 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 249 from patent US 6472154.
ACCESSION AR241961
VERSION AR241961.1 GI:27287773
KEYWORDS
SOURCE unknown.
ORGANISM unknown.
REFERENCE 1
AUTHORS Garner, H.R., Wren, J.D., Minna, J.D. and Fondon, J.W. III.
TITLE Polymorphic repeats in human genes
JOURNAL Patent: US 6472154-A 249 29-OCT-2002;
Board of Regents, The University of Texas System; Austin, TX
location/Qualifiers
FEATURES
source 1. 18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1701 GAGCGCAAGCAGCAG 1716
Db 1 GAGCGCGAGCAGCAG 16

RESULT 383
LOCUS A24597 16 bp DNA linear PAT 02-OCT-1995
DEFINITION Tomato genomic Pct1 fragment.
ACCESSION A24597
VERSION A24597.1 GI:1247303
KEYWORDS
SOURCE Lycopersicon esculentum (Solanum Lycopersicum)
ORGANISM Lycopersicon esculentum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
asterids; lamiales; Solanales; Solanaceae; Solanum; Lycopersicon.
REFERENCE 1
AUTHORS Zabeau, M., and Vos, P.
TITLE Selective restriction fragment amplification : a general method for
JOURNAL DNA fingerprinting
Patent: EP 0534858-A 7 31-MAR-1993;
KEYGENE N.V.
location/Qualifiers
FEATURES
source 1. 16
/organism="Lycopersicon esculentum"
/mol_type="unassigned DNA"
/db_xref="taxon:4081"

Query Match 0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.3e+02;

JOURNAL Patent: US 6083685-A 41 04-JUL-2000;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 14.6; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 2.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1113 UCCGGGUCACAGCACCA 1129
Db 17 TCGAGTCCACGACCA 1

RESULT 375
LOCUS AR157062 17 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 7 from patent US 6242587.
ACCESSION AR157062
VERSION AR157062.1 GI:15125766
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Naik,U.P. and Parise,L.V.
TITLE DNA molecules encoding a calcium-integrin binding protein
JOURNAL Patent: US 6242587-A 7 05-JUN-2001;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.4e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 248 UCAUCCGCAACAUCCU 263
Db 16 TCATCGCAACATCCT 1

RESULT 376
LOCUS AX722775 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 462 from Patent WO03025176.
ACCESSION AX722775
VERSION AX722775.1 GI:30423276
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 462 27-MAR-2003;
FEATURES Location/Qualifiers
source
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 2.4e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 473 AUCUUCUGAUCAG 488

Db 2 ATCTGCTGTCATCAG 17

RESULT 377
LOCUS AX723940 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1627 from Patent WO03025176.
ACCESSION AX723940
VERSION AX723940.1 GI:30503283
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 1627 27-MAR-2003;
FEATURES Location/Qualifiers
source
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.4e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1178 AGGAGAGCTGGGGAU 1193
Db 17 AGTAGAGCTGGGAGAT 2

RESULT 378
LOCUS CS173519 18 bp DNA linear PAT 05-OCT-2005
DEFINITION Sequence 5 from Patent WO2005060345.
ACCESSION CS173519
VERSION CS173519.1 GI:77153733
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Tooke,N.
TITLE New method for sequencing-by-synthesis
JOURNAL Patent: WO 2005060345-A 5 07-JUL-2005;
FEATURES Location/Qualifiers
source
1. .18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="chemically synthesized"

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 2.6e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1604 UCAACGCAACCGGAA 1619
Db 3 TCAACGCGCCCGTGA 18

RESULT 379
LOCUS CS185389 18 bp DNA linear PAT 04-NOV-2005
DEFINITION Sequence 82 from Patent EP1591534.

RESULT 370
DD174035
LOCUS DD174035 18 bp DNA linear PAT 19-DEC-2005
DEFINITION LEINAMYCIN BIOSYNTHESIS GENE CLUSTER AND ITS COMPONENTS AND THEIR USES.
ACCESSION DD174035
VERSION DD174035.1 GI:83971412
KEYWORDS JP 2005512504-A/6.
SOURCE unclassified
ORGANISM unclassified sequences.
REFERENCE 1 (bases 1 to 18)
AUTHORS Shen,B.,Chen,Y. and Tang,G.
TITLE LEINAMYCIN BIOSYNTHESIS GENE CLUSTER AND ITS COMPONENTS AND THEIR JOURNAL Patent: JP 2005512504-A 6 12-MAY-2005;
COMMENT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
OS Artificial
PN JP 2005512504-A/6
PD 12-MAY-2005
PF 22-MAR-2002 JP 2002576622
PR 26-MAR-2001 US 60/278935
PI ben shen,yi-qiang chen,gou-li tang
CC Synthetic oligonucleotide PCR primer.
FH Key Location/Qualifiers
FEATURES
source 1..18
/organism="unclassified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.8%; Score 14.6; DB 1; Length 18;
Best Local Similarity 61.1%; Pred. No. 2.4e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1270 UUCUCCAGCUCUCCCAUC 1287
Db 1 TTGCCCAAGCTTCCCATC 18

RESULT 371
A61305
LOCUS A61305 18 bp DNA linear PAT 09-MAR-1998
DEFINITION Sequence 17 from Patent WO9709452.
ACCESSION A61305
VERSION A61305.1 GI:3715719
KEYWORDS
SOURCE unclassified
ORGANISM unclassified sequences.
REFERENCE 1
AUTHORS Petrlik,J.
TITLE SYSTEMATIC EXTRACTION, AMPLIFICATION AND DETECTION OF RETROVIRAL SEQUENCES, AND OLIGONUCLEOTIDES FOR USE THEREIN
JOURNAL Patent: WO 9709452-A 17 13-MAR-1997;
UNIV CAMBRIDGE TECH (GB)
FEATURES
source 1..18
Location/Qualifiers
/organism="unclassified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.8%; Score 14.6; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 2.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 1113 UCCGGGUCACAGCACCA 1129
Db 2 TCTGAGTCAACGACCA 18

RESULT 372

A61329/c
LOCUS A61329 18 bp DNA linear PAT 09-MAR-1998
DEFINITION Sequence 41 from Patent WO9709452.
ACCESSION A61329
VERSION A61329.1 GI:3715743
KEYWORDS
SOURCE unclassified
ORGANISM unclassified sequences.
REFERENCE 1
AUTHORS Petrlik,J.
TITLE SYSTEMATIC EXTRACTION, AMPLIFICATION AND DETECTION OF RETROVIRAL SEQUENCES, AND OLIGONUCLEOTIDES FOR USE THEREIN
JOURNAL Patent: WO 9709452-A 41 13-MAR-1997;
UNIV CAMBRIDGE TECH (GB)
FEATURES
source 1..18
Location/Qualifiers
/organism="unclassified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.8%; Score 14.6; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 2.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 1113 UCCGGGUCACAGCACCA 1129
Db 17 TCTGAGTCAACGACCA 1

RESULT 373
AR100814
LOCUS AR100814 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 17 from patent US 6083685.
ACCESSION AR100814
VERSION AR100814.1 GI:12811612
KEYWORDS
SOURCE unknown.
ORGANISM unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Petrlik,J.
TITLE Systematic extraction, amplification and detection of retroviral sequences, and oligonucleotides for use therein
JOURNAL Patent: US 6083685-A 17 04-JUL-2000;
UNIV CAMBRIDGE TECH (GB)
FEATURES
source 1..18
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 14.6; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 2.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 1113 UCCGGGUCACAGCACCA 1129
Db 2 TCTGAGTCAACGACCA 18

RESULT 374
AR100838/c
LOCUS AR100838 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 41 from patent US 6083685.
ACCESSION AR100838
VERSION AR100838.1 GI:12811636
KEYWORDS
SOURCE unknown.
ORGANISM unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Petrlik,J.
TITLE Systematic extraction, amplification and detection of retroviral sequences, and oligonucleotides for use therein

LOCUS AX718623 18 bp DNA
DEFINITION Sequence 187 from Patent WO02103043.
ACCESSION AX718623
VERSION AX718623.1 GI:29891189
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 Beinforh,C. and Snaidr,U.
AUTHORS Method for the specific fast detection of bacteria which is harmful
TITLE to beer
JOURNAL Patent: WO 02103043-A 187 27-DEC-2002;
Vermicon AG (DE)
FEATURES
source Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 153 UCCAGACGGUACCGC 169
Db 1 TCCATACGGTACCACCG 17

RESULT 366
AR295199 19 bp DNA
DEFINITION Sequence 6934 from patent US 6537751.
ACCESSION AR295199
VERSION AR295199.1 GI:31682483
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
JOURNAL dis-equilibrium map of the human genome
Patent: US 6537751-A 6934 25-MAR-2003;
Genet S.A.;;
FRX;
FEATURES
source Location/Qualifiers
1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 2.3e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 38 TTCCAACCAUACGCTCC 54
Db 3 TTCCAACCAUACGCTCC 19

RESULT 367
AR295723 19 bp DNA
DEFINITION Sequence 7458 from patent US 6537751.
ACCESSION AR295723
VERSION AR295723.1 GI:31683007
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.

TITLE Biallelic markers for use in constructing a high density
JOURNAL dis-equilibrium map of the human genome
Patent: US 6537751-A 7458 25-MAR-2003;
Genet S.A.;;
FRX;
FEATURES
source Location/Qualifiers
1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 2.3e+02;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 684 GCCCACCACUACUUG 700
Db 1 GCCCACCCTTACTTTC 17

RESULT 368
AR105389 18 bp DNA
DEFINITION Sequence 27 from patent US 6096543.
ACCESSION AR105389
VERSION AR105389.1 GI:12818986
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Monia,B.P. and Cowser,L.M.
TITLE Antisense inhibition of human mek1 expression
JOURNAL Patent: US 6096543-A 27 01-AUG-2000;
Location/Qualifiers
1..18
source /organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 15; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 40 CCAACCAUACGCTCC 54
Db 4 CCAACCAUACGCTCC 18

RESULT 369
AR092811 18 bp DNA
DEFINITION Sequence 26 from patent US 5998206.
ACCESSION AR092811
VERSION AR092811.1 GI:10019563
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cowser,L.M.
TITLE Antisense inhibition of human G-alpha-12 expression
JOURNAL Patent: US 5998206-A 26 07-DEC-1999;
Location/Qualifiers
1..18
source /organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 66.7%; Pred. No. 2.4e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 246 CACCAUCCGCAUACUCC 263
Db 18 CACCTTCGACCAUACCTT 1

LOCUS CS185388 18 bp DNA linear PAT 04-NOV-2005
DEFINITION Sequence 81 from Patent EP1591534.
ACCESSION CS185388
VERSION CS185388.1 GI:80747461
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Beiboer,S.H.
TITLE A method of genotyping blood cell antigens and a kit suitable for genotyping blood cell antigens
JOURNAL Patent: EP 1591534-A 81 02-NOV-2005;
Stichting Sangquin Bloedvoorziening (NL)
FEATURES
source Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="probe HPA-3aa"

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1179 GGAGGAGCUGGGGAGG 1195
Db 17 GGAGGGGCTGGGAGTG 1

RESULT 362
LOCUS CS185395 18 bp DNA linear PAT 04-NOV-2005
DEFINITION Sequence 88 from Patent EP1591534.
ACCESSION CS185395
VERSION CS185395.1 GI:80747468
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Beiboer,S.H.
TITLE A method of genotyping blood cell antigens and a kit suitable for genotyping blood cell antigens
JOURNAL Patent: EP 1591534-A 88 02-NOV-2005;
Stichting Sangquin Bloedvoorziening (NL)
FEATURES
source Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="probe HPA-3aa CR"

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1179 GGAGGAGCUGGGGAGG 1195
Db 2 GGAGGGGCTGGGAGTG 18

RESULT 363
LOCUS DD184859/c 18 bp DNA linear PAT 19-JAN-2006
DEFINITION Probe sets and methods for identifying HLA-B allele.
ACCESSION DD184859
VERSION DD184859.1 GI:85637806
KEYWORDS JP 2005185172-A/285.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;

REFERENCE 1 (bases 1 to 18)
AUTHORS Tsukada,M.
TITLE Probe sets and methods for identifying HLA-B allele
JOURNAL Patent: JP 2005185172-A 285 14-JUL-2005;
CANON INC
COMMENT OS Homo sapiens
PN JP 2005185172-A/285
PD 14-JUL-2005
PF 25-DEC-2003 JP 2003430554
PI mamoru tsukada
CC
FH Key location/Qualifiers.
1..18
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 2e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1185 GCUGGGAGUGUGACU 1201
Db 18 GATGGGATGTGGACT 2

RESULT 364
LOCUS DD18481 18 bp DNA linear PAT 19-JAN-2006
DEFINITION Probe set and method for identification of allele of HLA.
ACCESSION DD18481
VERSION DD18481.1 GI:85646833
KEYWORDS WO 2005063985-A/922.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1 (bases 1 to 18)
AUTHORS Tsukada,M.
TITLE Probe set and method for identification of allele of HLA
JOURNAL Patent: WO 2005063985-A 922 14-JUL-2005;
CANON INC
COMMENT OS Homo sapiens
PN WO 2005063985-A/922
PD 14-JUL-2005
PF 24-DEC-2004 WO 2004JP019763
PR 25-DEC-2003 JP 03P 430556,25-DEC-2003 JP 03P 430555, PR
25-DEC-2003 JP 03P 430559,25-DEC-2003 JP 03P 430553, PR
25-DEC-2003 JP 03P 430558,25-DEC-2003 JP 03P 430557, PR
PI mamoru tsukada
CC
FH Key location/Qualifiers.
1..18
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 2e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1185 GCUGGGAGUGUGACU 1201
Db 18 GATGGGATGTGGACT 2

RESULT 365
AX718623

ACCESSION A97983
VERSION A97983.1 GI:6781221
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 18)
AUTHORS Pongers-Willense, M.J. and Van, D.J.
TITLE DETECTION OF MINIMAL RESIDUAL DISEASE IN LYMPHOID MALIGNANCIES
JOURNAL Patent: WO 9914366-A 13 25-MAR-1999;
DONGEN JACOBUS JOHANNES MARIA (NL); UNIV ERASMUS (NL)
FEATURES
source 1..18
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 2e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1173 GCCUGAGAGAGACTCG 1189
DB 1 GCATGAGAGAGACTCG 17
RESULT 357
LOCUS AR096229 18 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 13 from patent US 6005095.
ACCESSION AR096229
VERSION AR096229.1 GI:10024845
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Capaccioli, S., Morelli, S. and Nicolin, A.
TITLE Antisense transcript associated to tumor cells having a T(14;18) translocation and oligodeoxynucleotides useful in the diagnosis and treatment of said tumor cells
JOURNAL Patent: US 6005095-A 13 21-DEC-1999;
FEATURES
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 2e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 631 GUGGAAAGAGAACTGU 647
DB 2 GCTGAAAGAGAACTGT 18
RESULT 358
LOCUS AR096248/c 18 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 32 from patent US 6005095.
ACCESSION AR096248
VERSION AR096248.1 GI:10024882
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Capaccioli, S., Morelli, S. and Nicolin, A.
TITLE Antisense transcript associated to tumor cells having a T(14;18) translocation and oligodeoxynucleotides useful in the diagnosis and treatment of said tumor cells
JOURNAL Patent: US 6005095-A 32 21-DEC-1999;
FEATURES
Location/Qualifiers

source 1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 2e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 631 GUGGAAAGAGAACTGU 647
DB 17 GCTGAAAGAGAACTGT 1
RESULT 359
LOCUS AR118332 18 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 7 from patent US 6140492.
ACCESSION AR118332
VERSION AR118332.1 GI:14099238
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Morelli, S., Nicolin, A. and Quattrone, A.
TITLE Antisense transcript expressed in B lymphocytes and synthetic oligonucleotides useful to inhibit the activity thereof
JOURNAL Patent: US 6140492-A 7 31-OCT-2000;
FEATURES
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 2e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 631 GUGGAAAGAGAACTGU 647
DB 2 GCTGAAAGAGAACTGT 18
RESULT 360
LOCUS AR118342/c 18 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 17 from patent US 6140492.
ACCESSION AR118342
VERSION AR118342.1 GI:14099248
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Morelli, S., Nicolin, A. and Quattrone, A.
TITLE Antisense transcript expressed in B lymphocytes and synthetic oligonucleotides useful to inhibit the activity thereof
JOURNAL Patent: US 6140492-A 17 31-OCT-2000;
FEATURES
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 2e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 631 GUGGAAAGAGAACTGU 647
DB 17 GCTGAAAGAGAACTGT 1
RESULT 361
CS185388/c

/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.8e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1047 CGCCUCCGCGAGAGG 1063
Db 1 CGCTCTCCGAGAGG 17

RESULT 352
A56834 18 bp DNA linear PAT 03-MAR-1998
LOCUS Sequence 13 from Patent WO9627663.
DEFINITION A56834
ACCESSION A56834 GI:3712846
VERSION A56834.1
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Capaccioli, S., Morelli, S. and Nicolin, A.
TITLE AN ANTISENSE TRANSCRIPT ASSOCIATED TO TUMOR CELLS HAVING A T(14;18) TRANSLOCATION AND OLIGODEOXYNUCLEOTIDES USEFUL IN THE DIAGNOSIS AND TREATMENT OF SAID TUMOR CELLS
JOURNAL Patent: WO 9627663-A 13 12-SEP-1996;
COMMENT CONSIGLIO NAZIONALE RICERCA (IT)
FEATURES
source Other publication AU 4944296 960923.
1. .18
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 2e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 631 GUUGAAGAGAACUGU 647
Db 2 GCTGGAAGAGAACTGT 18

RESULT 353
A56852 18 bp DNA linear PAT 03-MAR-1998
LOCUS Sequence 31 from Patent WO9627663.
DEFINITION A56852
ACCESSION A56852 GI:3712864
VERSION A56852.1
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Capaccioli, S., Morelli, S. and Nicolin, A.
TITLE AN ANTISENSE TRANSCRIPT ASSOCIATED TO TUMOR CELLS HAVING A T(14;18) TRANSLOCATION AND OLIGODEOXYNUCLEOTIDES USEFUL IN THE DIAGNOSIS AND TREATMENT OF SAID TUMOR CELLS
JOURNAL Patent: WO 9627663-A 31 12-SEP-1996;
COMMENT CONSIGLIO NAZIONALE RICERCA (IT)
FEATURES
source Other publication AU 4944296 960923.
1. .18
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 2e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 631 GUUGAAGAGAACUGU 647
Db 17 GCTGGAAGAGAACTGT 1

RESULT 354
A56871 18 bp DNA linear PAT 03-MAR-1998
LOCUS Sequence 7 from Patent WO9627664.
DEFINITION A56871
ACCESSION A56871 GI:3712883
VERSION A56871.1
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Morelli, S., Nicolin, A. and Quattrone, A.
TITLE ANTISENSE TRANSCRIPT EXPRESSED IN B LYMPHOCYTES AND SYNTHETIC OLIGONUCLEOTIDES USEFUL TO INHIBIT THE ACTIVITY THEREOF
JOURNAL Patent: WO 9627664-A 7 12-SEP-1996;
COMMENT CONSIGLIO NAZIONALE RICERCA (IT)
FEATURES
source Other publication AU 4944396 960923.
1. .18
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 2e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 631 GUUGAAGAGAACUGU 647
Db 2 GCTGGAAGAGAACTGT 18

RESULT 355
A56881 18 bp DNA linear PAT 03-MAR-1998
LOCUS Sequence 17 from Patent WO9627664.
DEFINITION A56881
ACCESSION A56881 GI:3712893
VERSION A56881.1
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Morelli, S., Nicolin, A. and Quattrone, A.
TITLE ANTISENSE TRANSCRIPT EXPRESSED IN B LYMPHOCYTES AND SYNTHETIC OLIGONUCLEOTIDES USEFUL TO INHIBIT THE ACTIVITY THEREOF
JOURNAL Patent: WO 9627664-A 17 12-SEP-1996;
COMMENT CONSIGLIO NAZIONALE RICERCA (IT)
FEATURES
source Other publication AU 4944396 960923.
1. .18
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 2e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

RESULT 356
A97983 18 bp DNA linear PAT 26-JAN-2000
LOCUS Sequence 13 from Patent WO9914366.
DEFINITION

FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Synthetic Primer"

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 2e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1673 UGUGUGUGCCGAGUGUGA 1691
:::|||||:::|||||
Db 1 TGCTGCGGTGACAGTGTGA 19

RESULT 348
LOCUS CS191043 19 bp DNA linear PAT 14-NOV-2005
DEFINITION Sequence 133 from Patent WO2005103689.
ACCESSION CS191043
VERSION CS191043.1 GI:82397088
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 Spittaels,K.F.
AUTHORS Patent: WO 2005103689-A 133 03-NOV-2005;
JOURNAL Galapagos Genomics N.V. (BB)
FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide"

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 2e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 257 ACAUCCUGUAUUGUGUC 275
|||||:::|||||
Db 1 ACATGCTGTAGTGTGTC 19

RESULT 349
LOCUS CS193807 19 bp DNA linear PAT 14-NOV-2005
DEFINITION Sequence 133 from Patent WO2005103715.
ACCESSION CS193807
VERSION CS193807.1 GI:82399000
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 Spittaels,K.F.
AUTHORS Patent: WO 2005103715-A 133 03-NOV-2005;
JOURNAL Galapagos Genomics N.V. (BB)
FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide"

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 2e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 257 ACAUCCUGUAUUGUGUC 275
|||||:::|||||
Db 1 ACATGCTGTAGTGTGTC 19

Db
1 ACATGCTGTAGTGTGTC 19
|||||:::|||||
RESULT 350
LOCUS AX278625/c 19 bp DNA linear PAT 02-NOV-2001
DEFINITION Sequence 162 from Patent WO0177372.
ACCESSION AX278625
VERSION AX278625.1 GI:16606079
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 Remacle,J., Hamels,S., Zammateo,N., Lockman,L., Dufour,S.,
AUTHORS Alexandre,I. and de Longueville,F.
TITLE Identification of biological (micro) organisms by detection of the
JOURNAL their homologous nucleotide sequences on arrays
Patent: WO 0177372-A 162 18-OCT-2001;
Facultes Universitaires Notre-Dame de la Paix (BE)
FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="HTR7 Capture Probe"

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 2e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 510 CACGAGCCGCGACGAGUAC 528
|||||:::|||||
Db 19 CACGAGACCCCTCACGTAC 1

RESULT 351
LOCUS BD259402 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Regulation of repressor genes using nucleic acid molecules.
ACCESSION BD259402
VERSION BD259402.1 GI:33069172
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS Blatt,L., Zwick,M., Pavco,P. and Mcswigen,J.
TITLE Regulation of repressor genes using nucleic acid molecules
JOURNAL Patent: JP 2002541795-A 7195 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT
OS Eukaryote
PN JP 2002541795-A/7195
PD 10-DEC-2002
PF 11-APR-2000 JP 200611654
PR 12-APR-1999 US 60/129390
PI LAWRENCE BLATT, MICHAEL ZWICK PAMELA PAVCO JAMES MCSWIGEN PC
CI2N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
CI2P21/02,
PC
CI2P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1.91),(C12P21/02, PC
CI2R1.91),
PC (C12P21/02,C12R1.91),(C12P21/02,C12R1.91),C12N15/00,C12N5/00,
PC A61K37/02,
PC (C12N5/00,C12R1.91)
CC Regulation of repressor genes using nucleic acid molecules FH
Key Location/Qualifiers
FT source 1.17
FT Location/Qualifiers
1.17
/organism="Eukaryote".
FEATURES
source
1.17
/organism="unidentified"

FEATURES FT /organism='Canis familiaris (dog)'.
source 1. .20
/organism="Canis familiaris"
/mol_type="genomic DNA"
/db_xref="taxon:9615"

Query Match 0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 55.0%; Pred. No. 1.7e+02;
Matches 11; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 571 CUGGCGGCGGCAUCCUCU 590
Db 20 CTGGCATGGGTCACTCTTT 1

RESULT 339
BD230609/c 20 bp DNA linear PAT 17-JUL-2003
LOCUS BD230609
DEFINITION Total genome radiation hybrid map of canine genome and its use for identification of interesting genes.
ACCESSION BD230609
VERSION BD230609.1 GI:33040379
KEYWORDS JP 2002530091-A/478.
SOURCE Canis familiaris (dog)
ORGANISM Canis familiaris
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Laurasiatheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE 1 (bases 1 to 20)
AUTHORS Galibert, F. and Andre, C.
TITLE Total genome radiation hybrid map of canine genome and its use for identification of interesting genes
JOURNAL CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
COMMENT OS Canis familiaris (dog)
PN JP 2002530091-A/478
PD 17-SEP-2002
PF 15-NOV-1999 JP 2000582596
PR 13-NOV-1998 US 60/108193
PI FRANCIS GALIBERT, CATHERINE ANDRE
PC C12N15/09, C12Q1/68, C12N15/00
CC B04201R
FH Key
FT source 1. .20
Location/Qualifiers
FT Location/Qualifiers
1. .20
/organism="Canis familiaris"
/mol_type="genomic DNA"
/db_xref="taxon:9615"

FEATURES source
1. .20
/organism="Canis familiaris"
/mol_type="genomic DNA"
/db_xref="taxon:9615"

Query Match 0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 55.0%; Pred. No. 1.7e+02;
Matches 11; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 571 CUGGCGGCGGCAUCCUCU 590
Db 20 CTGGCATGGGTCACTCTTT 1

RESULT 340
AR337048 20 bp DNA linear PAT 17-AUG-2003
LOCUS AR337048
DEFINITION Sequence 21 from patent US 6566133.
ACCESSION AR337048
VERSION AR337048.1 GI:33722902
KEYWORDS
SOURCE unknown.
ORGANISM unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowser, L. M.

TITLE Antisense inhibition of dual specific phosphatase 9 expression
JOURNAL Patent: US 6566133-A 21 20-MAY-2003;
Isis Pharmaceuticals, Inc.; Carlsbad, CA
FEATURES source 1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 1.7e+02;
Matches 16; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1464 AGCGGCCGAGCCGACGUG 1483
Db 1 AGCGGCCGAGCCCTTCATG 20

RESULT 341
CQ897421/c 21 bp DNA linear PAT 08-NOV-2004
LOCUS CQ897421
DEFINITION Sequence 3 from Patent WO2004092378.
ACCESSION CQ897421
VERSION CQ897421.1 GI:55582202
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1
AUTHORS Jackson, J. K., Burt, H., Springate, C. and Gleave, M.
TITLE Method for treatment of cancerous angiogenic disorders
JOURNAL Patent: WO 2004092378-A 3 28-OCT-2004;
The University of British Columbia (CA)
FEATURES source 1. .21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 1.9e+02;
Matches 12; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1664 UCAGAGUCGCGGCGGCGC 1683
Db 20 TGAAGTCTGCTGCTGTC 1

RESULT 342
CQ897858/c 21 bp DNA linear PAT 08-NOV-2004
LOCUS CQ897858
DEFINITION Sequence 3 from Patent WO2004092379.
ACCESSION CQ897858
VERSION CQ897858.1 GI:55582465
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homiidae; Homo.
REFERENCE 1
AUTHORS Jackson, J. K., Burt, H., Springate, C. and Gleave, M.
TITLE Method for treatment of angiogenic disorders
JOURNAL Patent: WO 2004092379-A 3 28-OCT-2004;
The University of British Columbia (CA)
FEATURES source 1. .21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 16.8; DB 1; Length 21;

[illegible]

FEATURES	Location/Qualifiers
source	1. .17 /organism="Homo sapiens" /mol_type="genomic DNA" /db_xref="taxon:9606"
Qy	1567 AAAACCTTGGAACTC 1583
Db	17 AAAACCTTGGAACTC 1
Query Match	1.0%; Score 17; DB 1; Length 17;
Best Local Similarity	64.7%; Pred. No. 1.1e+02;
Matches	11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
RESULT 337	
AR482659/c	17 bp DNA linear PAT 14-MAY-2004
LOCUS	AR482659 105 from patent US 6703228.
DEFINITION	Sequence
ACCESSION	AR482659
VERSION	AR482659.1 GI:47245182
KEYWORDS	.
SOURCE	Unknown.
ORGANISM	Unclassified.
REFERENCE	1 (bases 1 to 17)
AUTHORS	Landers,J., Jordan,B., Housman,D.E. and Charrest,A.
TITLE	Methods and products related to genotyping and DNA analysis
JOURNAL	Patent: US 6703228-A 105 09-MAR-2004; MA
FEATURES	Massachusetts Institute of Technology; Cambridge, MA
source	Location/Qualifiers 1. .17 /organism="unknown" /mol_type="genomic DNA"
Qy	1567 AAAACCTTGGAACTC 1583
Db	17 AAAACCTTGGAACTC 1
Query Match	1.0%; Score 17; DB 1; Length 17;
Best Local Similarity	64.7%; Pred. No. 1.1e+02;
Matches	11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
RESULT 338	
BD230533/c	20 bp DNA linear PAT 17-JUL-2003
LOCUS	BD230533
DEFINITION	Total genome radiation hybrid map of canine genome and its use for
ACCESSION	BD230533
VERSION	BD230533.1 GI:33040303
KEYWORDS	JP 2002530091-A/402
SOURCE	Canis familiaris (dog)
ORGANISM	Canis familiaris Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Laurasiatheria; Carnivora; Fissipedia; Canidae; Canis
REFERENCE	1 (bases 1 to 20)
AUTHORS	Galibert,F. and Andre,C.
TITLE	Total genome radiation hybrid map of canine genome and its use for
JOURNAL	identification of interesting genes
COMMENT	Patent: JP 2002530091-A 402 17-SEP-2002; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE OS Canis familiaris (dog) PN JP 2002530091-A/402 PD 17-SEP-2002 PF 15-NOV-1999 JP 2000582596 PR 13-NOV-1998 US 60/108193 PI FRANCIS GALIBERT CATHERINE ANDRE PC C12N15/09,C12Q1/68,C12N15/00 CC B04201R FH Key FT source Location/Qualifiers 1. .20

misc_feature 18..19
/note="2#-deoxy-2#-Fluoro"
misc_feature 20..21
/note="n stands for thymidine"
misc_feature 21
/note="3#-3 attached terminal deoxybasic moiety, inverted
basic, inverted nucleotide or other terminal cap that is
optionally present"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAACACAAGAGCUGCU 1029
DB 1 GAACACAAGAGCTGCT 19

RESULT 332
CS096495/c CS096495 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 320 from Patent WO2005045040.
DEFINITION CS096495
ACCESSION CS096495
VERSION CS096495.1 GI:66952959
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macoswigen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 320 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source 1..21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: sirna antisense
region"

misc_feature 1..2
/note="2#-deoxy"
misc_feature 3
/note="2#-deoxy-2#-Fluoro"
misc_feature 4..5
/note="2#-deoxy"
misc_feature 6
/note="2#-deoxy-2#-Fluoro"
misc_feature 7
/note="2#-deoxy"
misc_feature 8..9
/note="2#-deoxy-2#-Fluoro"
misc_feature 10
/note="2#-deoxy"
misc_feature 11..12
/note="2#-deoxy-2#-Fluoro"
misc_feature 13
/note="2#-deoxy"
misc_feature 14..15
/note="2#-deoxy-2#-Fluoro"
misc_feature 16
/note="2#-deoxy"
misc_feature 17..19
/note="2#-deoxy-2#-Fluoro"
misc_feature 20..21
/note="n stands for thymidine"
misc_feature 20
/note="Phosphorothioate or Phosphordithioate
3#-Internucleotide linkage (optionally present)"
misc_feature 21
/note="3#-3 attached terminal glyceryl moiety or inverted

deoxybasic (optional y present)"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAACACAAGAGCUGCU 1029
DB 19 GAACACAAGAGCTGCT 1

RESULT 333
AX511437 20 bp DNA linear PAT 27-SEP-2002
LOCUS Sequence 1 from Patent WO0246421.
DEFINITION AX511437
ACCESSION AX511437
VERSION AX511437.1 GI:23392308
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Weiss, J. and Yamada, M.
TITLE Methods and compositions for analysis of m3 muscarinic
acetylcholine receptors
Patent: WO 0246421-A 1 13-JUN-2002;
JOURNAL THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US)
Location/Qualifiers

FEATURES
source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic"

Query Match 1.0%; Score 18.4; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 1.1e+02;
Matches 16; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 941 GGUCCACACCAAGAGCTGG 960
DB 1 GGTTCCACCAAGAGCTGG 20

RESULT 334
AX298730 20 bp DNA linear PAT 26-NOV-2001
LOCUS Sequence 364 from Patent WO0183749.
DEFINITION AX298730
ACCESSION AX298730
VERSION AX298730.1 GI:17128720
KEYWORDS
SOURCE Mus sp.
ORGANISM Mus sp.
MUS SP.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
Sciurognathi; Muroidae; Muridae; Murinae; Mus.

REFERENCE 1
AUTHORS Bachmanov, A.A., Beauchamp, G.K., Chatterjee, A., de Jong, P.J., Li, S.,
Li, X., Ohmen, J.D., Reed, D.R., Rose, D. and Tordoff, M.G.
TITLE Gene and sequence variation associated with sensing carbohydrate
compounds and other sweeteners
Patent: WO 0183749-A 364 08-NOV-2001;
JOURNAL WARNER-LAMBERT COMPANY (US); The Monell Chemical Senses Center
(US)
Location/Qualifiers

FEATURES
source 1..20
/organism="Mus sp."
/mol_type="unassigned DNA"
/db_xref="taxon:10095"

Query Match 1.0%; Score 18; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 1.3e+02;
Matches 15; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Acid (siNA)
JOURNAL Patent: WO 2005045040-A 317 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
3
misc_feature
/note="2#-deoxy-2#-Fluoro"
6
misc_feature
/note="2#-deoxy-2#-Fluoro"
8. .9
misc_feature
/note="2#-deoxy-2#-Fluoro"
11. .12
misc_feature
/note="2#-deoxy-2#-Fluoro"
14. .15
misc_feature
/note="2#-deoxy-2#-Fluoro"
17. .19
misc_feature
/note="2#-deoxy-2#-Fluoro"
20. .21
misc_feature
/note="n stands for thymidine"
20
/note="Phosphorothioate or Phosphorodithioate 3#-Internucleotide linkage (option a lly present)"
21
misc_feature
/note="3#-3 attached terminal glyceryl moiety or inverted deoxyabasic (optionall y present)"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1011 GAACACAAUGAGUCGUCU 1029
|||||||:|:|:|:|:
Db 19 GAACACAAUGAGTCGTCT 1
RESULT 330
LOCUS CS096493 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 318 from Patent WO2005045040.
ACCESSION CS096493
VERSION CS096493.1 GI:66952957
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards,I. and Macswigen,U.
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 318 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
1. .3
misc_feature
/note="2#-deoxy"
1
/note="5#-3 attached terminal deoxyabasic moiety, inverted abasic, inverted nucleotide or other terminal cap that is optionally present"
4
misc_feature
/note="2#-deoxy-2#-Fluoro"
5. .6
misc_feature

/note="2#-deoxy"
7
misc_feature
/note="2#-deoxy-2#-Fluoro"
8. .9
misc_feature
/note="2#-deoxy"
10
misc_feature
/note="2#-deoxy-2#-Fluoro"
11. .12
misc_feature
/note="2#-deoxy"
13
misc_feature
/note="2#-deoxy-2#-Fluoro"
14
misc_feature
/note="2#-deoxy"
15. .16
misc_feature
/note="2#-deoxy-2#-Fluoro"
17
misc_feature
/note="2#-deoxy"
18. .19
misc_feature
/note="2#-deoxy-2#-Fluoro"
20. .21
misc_feature
/note="n stands for thymidine"
21
/note="3#-3 attached terminal deoxyabasic moiety, inverted abasic, inverted nucleotide or other terminal cap that is optionally present"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1011 GAACACAAUGAGUCGUCU 1029
|||||||:|:|:|:|:
Db 1 GAACACAAUGAGTCGTCT 19
RESULT 331
LOCUS CS096494 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 319 from Patent WO2005045040.
ACCESSION CS096494
VERSION CS096494.1 GI:66952958
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards,I. and Macswigen,U.
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 319 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
1
/note="5#-3 attached terminal deoxyabasic moiety, inverted abasic, inverted nucleotide or other terminal cap that is optionally present"
4
misc_feature
/note="2#-deoxy-2#-Fluoro"
7
misc_feature
/note="2#-deoxy-2#-Fluoro"
10
misc_feature
/note="2#-deoxy-2#-Fluoro"
13
misc_feature
/note="2#-deoxy-2#-Fluoro"
15. .16
misc_feature
/note="2#-deoxy-2#-Fluoro"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAACAACAUGAUGCUGCU 1029
|||||:|:|:|:|:|:
1 GAACAACAATGATGCTGCT 19

Db 19 GAACAACAATGATGCTGCT 1

RESULT 327
CS096490 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 315 from Patent WO2005045040.
DEFINITION CS096490
ACCESSION CS096490.1 GI:66952954
VERSION
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswigen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 315 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

misc_feature
1. .2
/note="2#-O-Methyl"

misc_feature
3
/note="2#-deoxy-2#-Fluoro"

misc_feature
4. .5
/note="2#-O-Methyl"

misc_feature
6
/note="2#-deoxy-2#-Fluoro"

misc_feature
7
/note="2#-O-Methyl"

misc_feature
8. .9
/note="2#-deoxy-2#-Fluoro"

misc_feature
10
/note="2#-O-Methyl"

misc_feature
11. .12
/note="2#-deoxy-2#-Fluoro"

misc_feature
13
/note="2#-O-Methyl"

misc_feature
14. .15
/note="2#-deoxy-2#-Fluoro"

misc_feature
16
/note="2#-O-Methyl"

misc_feature
17. .19
/note="2#-deoxy-2#-Fluoro"

misc_feature
20. .21
/note="n stands for thymidine"

misc_feature
20
/note="Phosphorothioate or Phosphorodithioate
3#-Internucleotide Linkage (optionally present)"

misc_feature
21
/note="3#-3 attached terminal glyceryl moiety or inverted deoxyabasic (optionally present)"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAACAACAUGAUGCUGCU 1029
|||||:|:|:|:|:|:
1 GAACAACAATGATGCTGCT 19

Db 19 GAACAACAATGATGCTGCT 1

RESULT 328
CS096491 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 316 from Patent WO2005045040.
DEFINITION CS096491
ACCESSION CS096491
VERSION CS096491.1 GI:66952955
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswigen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 316 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"

misc_feature
1
/note="5#-3 attached terminal deoxyabasic moiety, inverted abasic, inverted nucleotide or other terminal cap that is optionally present"

misc_feature
4
/note="2#-O-Methyl or 2#-deoxy-2#-Fluoro"

misc_feature
7
/note="2#-O-Methyl or 2#-deoxy-2#-Fluoro"

misc_feature
10
/note="2#-O-Methyl or 2#-deoxy-2#-Fluoro"

misc_feature
13
/note="2#-O-Methyl or 2#-deoxy-2#-Fluoro"

misc_feature
15. .16
/note="2#-O-Methyl or 2#-deoxy-2#-Fluoro"

misc_feature
18. .19
/note="2#-O-Methyl or 2#-deoxy-2#-Fluoro"

misc_feature
20. .21
/note="2#-O-Methyl or 2#-deoxy-2#-Fluoro"

misc_feature
20
/note="n stands for thymidine"

misc_feature
21
/note="3#-3 attached terminal deoxyabasic moiety, inverted abasic, inverted nucleotide or other terminal cap that is optionally present"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAACAACAUGAUGCUGCU 1029
|||||:|:|:|:|:|:
1 GAACAACAATGATGCTGCT 19

Db 19 GAACAACAATGATGCTGCT 1

RESULT 329
CS096492 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 317 from Patent WO2005045040.
DEFINITION CS096492
ACCESSION CS096492
VERSION CS096492.1 GI:66952956
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswigen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic

```
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1715 AGUACGACGAGACAGUC 1733
Db 19 AGTACCAGCAGACAGAGTC 1

RESULT 324
CS096487 CS096487 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 312 from Patent WO2005045040.
ACCESSION CS096487
VERSION CS096487.1 GI:66952951
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 312 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
Location/Qualifiers
FEATURES
source 1..21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense
region"

misc_feature 1
/note="5'-3' attached terminal deoxyriabasic moiety, inverted
abasic, inverted nucleotide or other terminal cap that is
optionally present"
20..21
/note="n stands for thymidine"

misc_feature 21
/note="3'-3' attached terminal deoxyriabasic moiety, inverted
abasic, inverted nucleotide or other terminal cap that is
optionally present"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1011 GAACAACAUGAUGUCUCU 1029
Db 1 GAACAACAATGATGCTGCT 19

RESULT 325
CS096488 CS096488 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 313 from Patent WO2005045040.
ACCESSION CS096488
VERSION CS096488.1 GI:66952952
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 313 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
Location/Qualifiers
FEATURES
source 1..21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

misc_feature 1
/note="Description of Artificial Sequence: siNA antisense
region"
20..21
/note="n stands for thymidine"

misc_feature 20
/note="Phosphorothioate or Phosphorodithioate
3'-Internucleotide Linkage (optionally present)"
21
/note="3'-3' attached terminal glyceryl moiety or inverted
deoxyriabasic (optionally present)"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1011 GAACAACAUGAUGUCUCU 1029
Db 19 GAACAACAATGATGCTGCT 1

RESULT 326
CS096489 CS096489 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 314 from Patent WO2005045040.
ACCESSION CS096489
VERSION CS096489.1 GI:66952953
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 314 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
Location/Qualifiers
FEATURES
source 1..21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense
region"
1..3
/note="2'-O-Methyl"
4
/note="2'-O-Methyl"
5..6
/note="2'-deoxy-2'-Fluoro"
7
/note="2'-O-Methyl"
7
/note="2'-deoxy-2'-Fluoro"
8..9
/note="2'-O-Methyl"
10
/note="2'-deoxy-2'-Fluoro"
11..12
/note="2'-O-Methyl"
13
/note="2'-deoxy-2'-Fluoro"
14
/note="2'-O-Methyl"
15..16
/note="2'-deoxy-2'-Fluoro"
17
/note="2'-O-Methyl"
18..19
/note="2'-deoxy-2'-Fluoro"
20..21
/note="n stands for thymidine"
20
/note="Phosphorothioate or Phosphorodithioate
3'-Internucleotide Linkage (option a lly present)"
```

RESULT 320
LOCUS CS096474 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 299 from Patent WO2005045040.
ACCESSION CS096474
VERSION CS096474.1 GI:66952947
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
misc_feature
misc_feature
misc_feature
Query Match
Best Local Similarity
Matches

1.1%; Score 19; DB 1; Length 21;
94.7%; Pred. No. 1.1e+02;
18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

1712 AGCAGUACGACGAGACA 1730

RESULT 321
LOCUS CS096475 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 300 from Patent WO2005045040.
ACCESSION CS096475
VERSION CS096475.1 GI:66952948
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
misc_feature
misc_feature
misc_feature
Query Match
Best Local Similarity
Matches

1.1%; Score 19; DB 1; Length 21;
94.7%; Pred. No. 1.1e+02;
18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

1712 AGCAGUACGACGAGACA 1730

Db
19 AGCAGTACGACGAGACA 1
RESULT 322
LOCUS CS096476 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 301 from Patent WO2005045040.
ACCESSION CS096476
VERSION CS096476.1 GI:66952949
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
misc_feature
misc_feature
misc_feature
Query Match
Best Local Similarity
Matches

1.1%; Score 19; DB 1; Length 21;
89.5%; Pred. No. 1.1e+02;
17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

1714 CAGUACGACGAGACAGU 1732
19 CAGTACGACGAGACAGT 1

RESULT 323
LOCUS CS096477 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 302 from Patent WO2005045040.
ACCESSION CS096477
VERSION CS096477.1 GI:66952950
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
misc_feature
misc_feature
misc_feature
Query Match
Best Local Similarity
Matches

1.1%; Score 19; DB 1; Length 21;
89.5%; Pred. No. 1.1e+02;
17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

1714 CAGUACGACGAGACAGU 1732
19 CAGTACGACGAGACAGT 1

VERSION CS096470.1 GI:66952943
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 295 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1..21
misc_feature 20
misc_feature 21
misc_feature 21
/note="n stands for thymidine"
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.1e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 17 ACAGUACAACUCCUCCUU 35
19 ACAGTACACCTCGCCTT 1
RESULT 317
LOCUS CS096471 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 296 from Patent WO2005045040.
ACCESSION CS096471
VERSION CS096471.1 GI:66952944
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 296 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1..21
misc_feature 20
misc_feature 21
misc_feature 21
/note="n stands for thymidine"
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.1e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
QY 21 UACAACUCCUCCUCCUU 39
19 TACAACCTCGCCTTCTT 1
Db
RESULT 318
LOCUS CS096472 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 297 from Patent WO2005045040.
ACCESSION CS096472
VERSION CS096472.1 GI:66952945
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 297 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1..21
misc_feature 20
misc_feature 21
misc_feature 21
/note="n stands for thymidine"
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.1e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 315 CUUCUCUUAAGCCUGCC 333
19 CTTCCTTAAGCCTGACC 1
Db

LOCUS CS096473 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 298 from Patent WO2005045040.
ACCESSION CS096473
VERSION CS096473.1 GI:66952946
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 298 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1..21
misc_feature 20
misc_feature 21
misc_feature 21
/note="n stands for thymidine"
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.1e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 317 UCCUCUUAAGCCUGCCUG 335
19 TCCTCTTAAGCCTGACC 1
Db

```
misc_feature /note="2#-deoxy-2#-Fluoro"
14 /note="2#-O-methyl"
misc_feature 15.16
misc_feature /note="2#-deoxy-2#-Fluoro"
17 /note="2#-O-methyl"
misc_feature 18.19
misc_feature /note="2#-deoxy-2#-Fluoro"
20 /note="n stands for thymidine"
misc_feature 21
/note="3#-3 attached terminal deoxyabasic moiety"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1712 AGCAGUACGACGAGACA 1730
Db 19 AGCAGTACCGACGACAGACA 1

RESULT 314
CS096468/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 293 from Patent WO2005045040.
DEFINITION CS096468
ACCESSION CS096468
VERSION CS096468.1 GI:66952941
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
1 Richards, I. and Macswigen, J.
AUTHORS RNA interference mediated inhibition of cholinergic muscarinic
TITLE receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 293 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers
FEATURES
source
1.21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"
misc_feature 1
/note="2#-O-methyl"
2.3
misc_feature /note="2#-deoxy-2#-Fluoro"
4
misc_feature /note="2#-O-methyl"
5.9
misc_feature /note="2#-deoxy-2#-Fluoro"
10
misc_feature /note="2#-O-methyl"
11.12
misc_feature /note="2#-deoxy-2#-Fluoro"
13.14
misc_feature /note="2#-O-methyl"
15
misc_feature /note="2#-deoxy-2#-Fluoro"
16
misc_feature /note="2#-O-methyl"
17.18
misc_feature /note="2#-deoxy-2#-Fluoro"
19
misc_feature /note="2#-O-methyl"
20
misc_feature /note="n stands for thymidine"
21
/note="3#-3 attached terminal deoxyabasic moiety"
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1714 CAGUACGACGACGAGU 1732
Db 19 CAGTACCGACGACGACGT 1

RESULT 315
CS096469/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 294 from Patent WO2005045040.
DEFINITION CS096469
ACCESSION CS096469
VERSION CS096469.1 GI:66952942
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
1 Richards, I. and Macswigen, J.
AUTHORS RNA interference mediated inhibition of cholinergic muscarinic
TITLE receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 294 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers
FEATURES
source
1.21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"
misc_feature 1.2
/note="2#-O-methyl"
3.4
misc_feature /note="2#-deoxy-2#-Fluoro"
5
misc_feature /note="2#-O-methyl"
6.10
misc_feature /note="2#-deoxy-2#-Fluoro"
11
misc_feature /note="2#-O-methyl"
12.13
misc_feature /note="2#-deoxy-2#-Fluoro"
14.15
misc_feature /note="2#-O-methyl"
16
misc_feature /note="2#-deoxy-2#-Fluoro"
17
misc_feature /note="2#-O-methyl"
18.19
misc_feature /note="2#-deoxy-2#-Fluoro"
20
misc_feature /note="n stands for thymidine"
21
/note="3#-3 attached terminal deoxyabasic moiety"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1715 AGUACGACGACGAGUC 1733
Db 19 AGTACGACGACGACGATC 1

RESULT 316
CS096470/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 295 from Patent WO2005045040.
DEFINITION CS096470
ACCESSION CS096470
```

```
RESULT 311
CS096465/c          21 bp  RNA          linear  PAT 03-JUN-2005
LOCUS               CS096465
DEFINITION          Sequence 290 from Patent WO2005045040.
ACCESSION            CS096465
VERSION              CS096465.1  GI:66952938
KEYWORDS
SOURCE               synthetic construct
ORGANISM             synthetic construct
                    other sequences; artificial sequences.
REFERENCE
1  Richards,I. and Macswiggen,J.
   RNA interference mediated inhibition of cholinergic muscarinic
   receptor (CHRM3) gene expression using short interfering Nucleic
   Acid (siNA)
   Patent: WO 2005045040-A 290 19-MAY-2005;
   Location/Qualifiers
   1..21
   /organism="synthetic construct"
   /mol_type="unassigned RNA"
   /db_xref="taxon:32630"
   /note="Description of Artificial Sequence: siNA antisense
   region"
JOURNAL
Patent: WO 2005045040-A 290 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
Location/Qualifiers
1..21
source
misc_feature 1 /note="2#-deoxy-2#-Fluoro"
misc_feature 2..4 /note="2#-O-methyl"
misc_feature 5..6 /note="2#-deoxy-2#-Fluoro"
misc_feature 7..9 /note="2#-O-methyl"
misc_feature 10..12 /note="2#-deoxy-2#-Fluoro"
misc_feature 13..19 /note="2#-O-methyl"
misc_feature 20 /note="2#-O-methyl"
misc_feature 21 /note="n stands for thymidine"
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match
Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 317 UCCUCUUAAGCCUGCCUG 335
Db 19 TCCTCTTAAGCCTGCGCTG 1
RESULT 312
CS096466/c          21 bp  RNA          linear  PAT 03-JUN-2005
LOCUS               CS096466
DEFINITION          Sequence 291 from Patent WO2005045040.
ACCESSION            CS096466
VERSION              CS096466.1  GI:66952939
KEYWORDS
SOURCE               synthetic construct
ORGANISM             synthetic construct
                    other sequences; artificial sequences.
REFERENCE
1  Richards,I. and Macswiggen,J.
   RNA interference mediated inhibition of cholinergic muscarinic
   receptor (CHRM3) gene expression using short interfering Nucleic
   Acid (siNA)
   Patent: WO 2005045040-A 291 19-MAY-2005;
   SiRNA Therapeutics, Inc. (US)
   Location/Qualifiers
   1..21
   /organism="synthetic construct"
   /mol_type="unassigned RNA"
   /db_xref="taxon:32630"
JOURNAL
Patent: WO 2005045040-A 291 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
Location/Qualifiers
1..21
source
misc_feature 1 /note="2#-deoxy-2#-Fluoro"
misc_feature 2 /note="2#-O-methyl"
misc_feature 3..7 /note="2#-deoxy-2#-Fluoro"
misc_feature 8 /note="2#-O-methyl"
misc_feature 9..10 /note="2#-deoxy-2#-Fluoro"
misc_feature 11..12 /note="2#-O-methyl"
misc_feature 13 /note="2#-O-methyl"
```

```
/note="Description of Artificial Sequence: siNA antisense
region"
misc_feature 1 /note="2#-O-methyl"
misc_feature 2 /note="2#-deoxy-2#-Fluoro"
misc_feature 3..4 /note="2#-O-methyl"
misc_feature 5..8 /note="2#-deoxy-2#-Fluoro"
misc_feature 9..10 /note="2#-O-methyl"
misc_feature 11..13 /note="2#-deoxy-2#-Fluoro"
misc_feature 14 /note="2#-O-methyl"
misc_feature 15..17 /note="2#-deoxy-2#-Fluoro"
misc_feature 18 /note="2#-O-methyl"
misc_feature 19 /note="2#-deoxy-2#-Fluoro"
misc_feature 20 /note="2#-deoxy-2#-Fluoro"
misc_feature 21 /note="n stands for thymidine"
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match
Best Local Similarity 94.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 975 GCAGAGGACCAAGACCAC 993
Db 19 GCAGATGACCAAGACCAC 1
RESULT 313
CS096467/c          21 bp  RNA          linear  PAT 03-JUN-2005
LOCUS               CS096467
DEFINITION          Sequence 292 from Patent WO2005045040.
ACCESSION            CS096467
VERSION              CS096467.1  GI:66952940
KEYWORDS
SOURCE               synthetic construct
ORGANISM             synthetic construct
                    other sequences; artificial sequences.
REFERENCE
1  Richards,I. and Macswiggen,J.
   RNA interference mediated inhibition of cholinergic muscarinic
   receptor (CHRM3) gene expression using short interfering Nucleic
   Acid (siNA)
   Patent: WO 2005045040-A 292 19-MAY-2005;
   SiRNA Therapeutics, Inc. (US)
   Location/Qualifiers
   1..21
   /organism="synthetic construct"
   /mol_type="unassigned RNA"
   /db_xref="taxon:32630"
   /note="Description of Artificial Sequence: siNA antisense
   region"
JOURNAL
Patent: WO 2005045040-A 292 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
Location/Qualifiers
1..21
source
misc_feature 1 /note="2#-deoxy-2#-Fluoro"
misc_feature 2 /note="2#-O-methyl"
misc_feature 3..7 /note="2#-deoxy-2#-Fluoro"
misc_feature 8 /note="2#-O-methyl"
misc_feature 9..10 /note="2#-deoxy-2#-Fluoro"
misc_feature 11..12 /note="2#-O-methyl"
misc_feature 13 /note="2#-O-methyl"
```

JOURNAL Patent: WO 2005045040-A 287 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

misc_feature
1. .5
/note="2#-O-methyl"

misc_feature
6
/note="2#-deoxy-2#-Fluoro"

misc_feature
7. .10
/note="2#-O-methyl"

misc_feature
11. .12
/note="2#-deoxy-2#-Fluoro"

misc_feature
13
/note="2#-O-methyl"

misc_feature
14
/note="2#-deoxy-2#-Fluoro"

misc_feature
15
/note="2#-O-methyl"

misc_feature
16. .17
/note="2#-deoxy-2#-Fluoro"

misc_feature
18
/note="2#-O-methyl"

misc_feature
19
/note="2#-deoxy-2#-Fluoro"

misc_feature
20
/note="n stands for thymidine"

misc_feature
21
/note="3#-3 attached terminal deoxyabasic moiety"

Query Match
1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY
17 ACAGUACACCTGCGCTT 35
|||||:|||||:|||||:|
19 ACAGTACACCTGCGCTT 1

Db

RESULT 309
CS096463/C 21 bp RNA linear PAT 03-JUN-2005
LOCUS CS096463 Sequence 288 from Patent WO2005045040.
ACCESSION CS096463
VERSION CS096463.1 GI:66952936
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE
1
AUTHORS
TITLE
Richard, I. and Macswigen, J.
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 288 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

JOURNAL
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

misc_feature
1. .3
/note="2#-O-methyl"

misc_feature
4
/note="2#-deoxy-2#-Fluoro"

misc_feature
5. .9
/note="2#-O-methyl"

misc_feature
10
/note="2#-deoxy-2#-Fluoro"

misc_feature
11. .14
/note="2#-O-methyl"

misc_feature
15. .16
/note="2#-deoxy-2#-Fluoro"

misc_feature
17
/note="2#-O-methyl"

misc_feature
18
/note="2#-O-methyl"

misc_feature
19
/note="2#-deoxy-2#-Fluoro"

misc_feature
20
/note="2#-O-methyl"

misc_feature
21
/note="n stands for thymidine"

Query Match
1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY
21 UACACCTGCGCTTGGT 39
:|||||:|||||:|||||:|
Db 19 TACACCTGCGCTTGGT 1

RESULT 310
CS096464/C 21 bp RNA linear PAT 03-JUN-2005
LOCUS CS096464 Sequence 289 from Patent WO2005045040.
ACCESSION CS096464
VERSION CS096464.1 GI:66952937
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE
1
AUTHORS
TITLE
Richard, I. and Macswigen, J.
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 289 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

JOURNAL
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

misc_feature
1. .2
/note="2#-O-methyl"

misc_feature
3. .4
/note="2#-deoxy-2#-Fluoro"

misc_feature
5. .7
/note="2#-O-methyl"

misc_feature
8. .10
/note="2#-deoxy-2#-Fluoro"

misc_feature
11. .19
/note="2#-O-methyl"

misc_feature
20
/note="n stands for thymidine"

misc_feature
21
/note="3#-3 attached terminal deoxyabasic moiety"

Query Match
1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY
315 CUUCUCUUAAGCGGCC 333
|::|||:|::|||:|::|||
Db 19 CTCCTCTTAAGCTGGCC 1

/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
misc_feature 20..21
/note="n stands for thymidine"
misc_feature 20
/note="Phosphorothioate 3'-Internucleotide Linkage"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 975 GCAGUGACGACGACAC 993
|||||:|||||
19 GCAGATGACGACGACAC 1

Db 19 GCAGATGACGACGACAC 1

RESULT 305
LOCUS CS096459/c 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 284 from Patent WO2005045040.
ACCESSION CS096459
VERSION CS096459.1 GI:66952932
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswigen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 284 19-MAY-2005;
Sima Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
misc_feature 20..21
/note="n stands for thymidine"
misc_feature 20
/note="Phosphorothioate 3'-Internucleotide Linkage"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1712 AGCAGUACGACGACACA 1730
|||||:|||||
19 AGCAGTACGACGACAGACA 1

Db 19 AGCAGTACGACGACAGACA 1

RESULT 306
LOCUS CS096460/c 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 285 from Patent WO2005045040.
ACCESSION CS096460
VERSION CS096460.1 GI:66952933
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswigen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 285 19-MAY-2005;
Sima Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
misc_feature 20..21
/note="n stands for thymidine"
misc_feature 20
/note="Phosphorothioate 3'-Internucleotide Linkage"

source 1..21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
misc_feature 20..21
/note="n stands for thymidine"
misc_feature 20
/note="Phosphorothioate 3'-Internucleotide Linkage"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1714 CAGUACGACGACGACAGU 1732
|||||:|||||
19 CAGTACGACGACGACAGAGT 1

Db 19 CAGTACGACGACGACAGAGT 1

RESULT 307
LOCUS CS096461/c 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 286 from Patent WO2005045040.
ACCESSION CS096461
VERSION CS096461.1 GI:66952934
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswigen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 286 19-MAY-2005;
Sima Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
misc_feature 20..21
/note="n stands for thymidine"
misc_feature 20
/note="Phosphorothioate 3'-Internucleotide Linkage"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1715 AGUACGACGACGACAGUC 1733
|||||:|||||
19 AGTACGACGACGACAGAGTC 1

Db 19 AGTACGACGACGACAGAGTC 1

RESULT 308
LOCUS CS096462/c 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 287 from Patent WO2005045040.
ACCESSION CS096462
VERSION CS096462.1 GI:66952935
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswigen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

```
/note="Phosphorothioate 3'-Internucleotide Linkage"
Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY      17 ACAGUACAACGCGCCUUU 35
      19 ACAGTACACCTGCGCTT 1
Db

RESULT 301
CS096455/c      CS096455      21 bp      RNA      linear      PAT 03-JUN-2005
LOCUS      CS096455
DEFINITION      Sequence 280 from Patent WO2005045040.
ACCESSION      CS096455
VERSION      CS096455.1 GI:66952928
KEYWORDS
SOURCE      .
ORGANISM      synthetic construct
other sequences; artificial sequences.
REFERENCE      1
AUTHORS      Richards,I. and Macswiggen,J.
TITLE      RNA interference mediated inhibition of cholinergic muscarinic
      receptor (CHRM3) gene expression using short interfering Nucleic
      Acid (siNA)
JOURNAL      Patent: WO 2005045040-A 280 19-MAY-2005;
      Sirta Therapeutics, Inc. (US)
FEATURES
source      1. .21
      /organism="synthetic construct"
      /mol_type="unassigned RNA"
      /db_xref="taxon:32630"
      /note="Description of Artificial Sequence: siNA antisense
      region"
misc_feature      20. .21
      /note="n stands for thymidine"
misc_feature      20
      /note="Phosphorothioate 3'-Internucleotide Linkage"
Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
QY      21 UACAACGCGCCUUCUUU 39
      19 TACAACCTGCGCTTGT 1
Db

RESULT 302
CS096456/c      CS096456      21 bp      RNA      linear      PAT 03-JUN-2005
LOCUS      CS096456
DEFINITION      Sequence 281 from Patent WO2005045040.
ACCESSION      CS096456
VERSION      CS096456.1 GI:66952929
KEYWORDS
SOURCE      .
ORGANISM      synthetic construct
      synthetic construct
      other sequences; artificial sequences.
REFERENCE      1
AUTHORS      Richards,I. and Macswiggen,J.
TITLE      RNA interference mediated inhibition of cholinergic muscarinic
      receptor (CHRM3) gene expression using short interfering Nucleic
      Acid (siNA)
JOURNAL      Patent: WO 2005045040-A 281 19-MAY-2005;
      Sirta Therapeutics, Inc. (US)
FEATURES
source      1. .21
      /organism="synthetic construct"
      /mol_type="unassigned RNA"
      /db_xref="taxon:32630"
      /note="Description of Artificial Sequence: siNA antisense
      region"
```

```
misc_feature      20. .21
      /note="n stands for thymidine"
misc_feature      20
      /note="Phosphorothioate 3'-Internucleotide Linkage"
Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY      315 CUUCUCUUAAGCCUGGCC 333
      19 CTCCTCTTAAGCCTGCGCC 1
Db

RESULT 303
CS096457/c      CS096457      21 bp      RNA      linear      PAT 03-JUN-2005
LOCUS      CS096457
DEFINITION      Sequence 282 from Patent WO2005045040.
ACCESSION      CS096457
VERSION      CS096457.1 GI:66952930
KEYWORDS
SOURCE      .
ORGANISM      synthetic construct
other sequences; artificial sequences.
REFERENCE      1
AUTHORS      Richards,I. and Macswiggen,J.
TITLE      RNA interference mediated inhibition of cholinergic muscarinic
      receptor (CHRM3) gene expression using short interfering Nucleic
      Acid (siNA)
JOURNAL      Patent: WO 2005045040-A 282 19-MAY-2005;
      Sirta Therapeutics, Inc. (US)
FEATURES
source      1. .21
      /organism="synthetic construct"
      /mol_type="unassigned RNA"
      /db_xref="taxon:32630"
      /note="Description of Artificial Sequence: siNA antisense
      region"
misc_feature      20. .21
      /note="n stands for thymidine"
misc_feature      20
      /note="Phosphorothioate 3'-Internucleotide Linkage"
Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY      317 UCCUCUUAAGCCUGGCCUG 335
      19 TCCTCTTAAGCCTGCGCTG 1
Db

RESULT 304
CS096458/c      CS096458      21 bp      RNA      linear      PAT 03-JUN-2005
LOCUS      CS096458
DEFINITION      Sequence 283 from Patent WO2005045040.
ACCESSION      CS096458
VERSION      CS096458.1 GI:66952931
KEYWORDS
SOURCE      .
ORGANISM      synthetic construct
      synthetic construct
      other sequences; artificial sequences.
REFERENCE      1
AUTHORS      Richards,I. and Macswiggen,J.
TITLE      RNA interference mediated inhibition of cholinergic muscarinic
      receptor (CHRM3) gene expression using short interfering Nucleic
      Acid (siNA)
JOURNAL      Patent: WO 2005045040-A 283 19-MAY-2005;
      Sirta Therapeutics, Inc. (US)
FEATURES
source      1. .21
      /organism="synthetic construct"
      /mol_type="unassigned RNA"
```

CS096451
LOCUS CS096451 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 276 from Patent WO2005045040.
ACCESSION CS096451
VERSION CS096451.1 GI:66952924
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 276 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
1
/note="5#-3 attached terminal deoxyabasic moiety"
misc_feature
20. .21
/note="n stands for thymidine"
misc_feature
21
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match
Best Local Similarity 94.7%; Score 19; DB 1; Length 21;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1712 AGCAGUACGACGACAGACA 1730
Db 1 AGCAGTACCAGACGACAGACA 19
RESULT 298
LOCUS CS096452 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 277 from Patent WO2005045040.
ACCESSION CS096452
VERSION CS096452.1 GI:66952925
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 277 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
1
/note="5#-3 attached terminal deoxyabasic moiety"
misc_feature
20. .21
/note="n stands for thymidine"
misc_feature
21
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match
Best Local Similarity 89.5%; Score 19; DB 1; Length 21;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1714 CAGUACGACGACGACAGU 1732
Db 1 CAGTACCAGACGACAGACGT 19
RESULT 299
LOCUS CS096453 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 278 from Patent WO2005045040.
ACCESSION CS096453
VERSION CS096453.1 GI:66952926
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 278 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
1
/note="5#-3 attached terminal deoxyabasic moiety"
misc_feature
20. .21
/note="n stands for thymidine"
misc_feature
21
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match
Best Local Similarity 89.5%; Score 19; DB 1; Length 21;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 1715 AGUACGACGACGACAGUC 1733
Db 1 AGTACCAGACGACAGACGTC 19
RESULT 300
LOCUS CS096454 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 279 from Patent WO2005045040.
ACCESSION CS096454
VERSION CS096454.1 GI:66952927
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 279 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
misc_feature
20. .21
/note="n stands for thymidine"
misc_feature
20
/note="n stands for thymidine"

JOURNAL Patent: WO 2005045040-A 272 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
1
/note="5'-3 attached terminal deoxyabasic moiety"
misc_feature
20. .21
/note="n stands for thymidine"
misc_feature
21
/note="3'-3 attached terminal deoxyabasic moiety"
Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
Oy 21 UACAACUCCGCUUUGUU 39
:|||||:|||||:|||||:
1 TACAACCTGCGCTTGTT 19
Db
RESULT 294
CS096448 21 bp RNA linear PAT 03-JUN-2005
LOCUS CS096448
DEFINITION Sequence 273 from Patent WO2005045040.
ACCESSION CS096448
VERSION CS096448.1 GI:66952921
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
1 Richards,I. and Macswiggen,J.
AUTHORS
TITLE
-RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 273 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
1
/note="5'-3 attached terminal deoxyabasic moiety"
misc_feature
20. .21
/note="n stands for thymidine"
misc_feature
21
/note="3'-3 attached terminal deoxyabasic moiety"
Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
Oy 315 CUUCUCUUAAGCGCC 333
|::|||:|||||:|||||:
1 CTTCCTTAAGCTGACC 19
Db
RESULT 295
CS096449 21 bp RNA linear PAT 03-JUN-2005
LOCUS CS096449
DEFINITION Sequence 274 from Patent WO2005045040.
ACCESSION CS096449
VERSION CS096449.1 GI:66952922
KEYWORDS
SOURCE
synthetic construct

ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
1 Richards,I. and Macswiggen,J.
AUTHORS
TITLE
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 274 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
1
/note="5'-3 attached terminal deoxyabasic moiety"
misc_feature
20. .21
/note="n stands for thymidine"
misc_feature
21
/note="3'-3 attached terminal deoxyabasic moiety"
Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
Oy 317 UCCUCUUAAGCGCCUG 335
:|||||:|||||:|||||:
1 TCCTCTTAAGCTGCGCTG 19
Db
RESULT 296
CS096450 21 bp RNA linear PAT 03-JUN-2005
LOCUS CS096450
DEFINITION Sequence 275 from Patent WO2005045040.
ACCESSION CS096450
VERSION CS096450.1 GI:66952923
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
1 Richards,I. and Macswiggen,J.
AUTHORS
TITLE
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 275 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
1
/note="5'-3 attached terminal deoxyabasic moiety"
misc_feature
20. .21
/note="n stands for thymidine"
misc_feature
21
/note="3'-3 attached terminal deoxyabasic moiety"
Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Oy 975 GCAGUGACCAAGACCAC 993
|||||:|||||:|||||:
1 GCAGATGACCAAGACCAC 19
Db
RESULT 297

misc_feature 4 /note="2#-deoxy-2#-fluoro"
misc_feature 5..9 /note="2#-O-methyl"
misc_feature 10 /note="2#-deoxy-2#-fluoro"
misc_feature 11..12 /note="2#-O-methyl"
misc_feature 13..14 /note="2#-deoxy-2#-fluoro"
misc_feature 15 /note="2#-O-methyl"
misc_feature 16 /note="2#-deoxy-2#-fluoro"
misc_feature 17..18 /note="2#-O-methyl"
misc_feature 19 /note="2#-deoxy-2#-fluoro"
misc_feature 20..21 /note="2#-O-methyl"
misc_feature 20 /note="n stands for thymidine"
/note="Phosphorothioate 3#-Internucleotide linkage"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Oy 1714 CAGUACGACGACGACG 1732
Db 19 CAGTACGACGACGACGACT 1

RESULT 291
LOCUS CS096445/C 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 270 from Patent WO2005045040.
ACCESSION CS096445
VERSION CS096445.1 GI:66952918
KEYWORDS
SOURCE .
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 270 19-MAY-2005;
Sina Therapeutics, Inc. (US)
FEATURES
source Location/Qualifiers
1..21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

misc_feature 1..2 /note="2#-O-methyl"
misc_feature 3..4 /note="2#-deoxy-2#-fluoro"
misc_feature 5 /note="2#-O-methyl"
misc_feature 6..10 /note="2#-deoxy-2#-fluoro"
misc_feature 11 /note="2#-O-methyl"
misc_feature 12..13 /note="2#-deoxy-2#-fluoro"
misc_feature 14..15 /note="2#-O-methyl"
misc_feature 16 /note="2#-deoxy-2#-fluoro"

misc_feature 17 /note="2#-O-methyl"
misc_feature 18..19 /note="2#-deoxy-2#-fluoro"
misc_feature 20..21 /note="2#-O-methyl"
misc_feature 20 /note="n stands for thymidine"
/note="Phosphorothioate 3#-Internucleotide linkage"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Oy 1715 AGUACGACGACGACGACGUC 1733
Db 19 AGTACGACGACGACGACTC 1

RESULT 292
LOCUS CS096446 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 271 from Patent WO2005045040.
ACCESSION CS096446
VERSION CS096446.1 GI:66952919
KEYWORDS
SOURCE .
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 271 19-MAY-2005;
Sina Therapeutics, Inc. (US)
FEATURES
source Location/Qualifiers
1..21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"

misc_feature 1 /note="5#-3 attached terminal deoxybasic moiety"
misc_feature 20..21 /note="n stands for thymidine"
misc_feature 21 /note="3#-3 attached terminal deoxybasic moiety"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Oy 17 ACAGUACAACCCGACCCUU 35
Db 1 ACAGTACAACCTCGCCTT 19

RESULT 293
LOCUS CS096447 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 272 from Patent WO2005045040.
ACCESSION CS096447
VERSION CS096447.1 GI:66952920
KEYWORDS
SOURCE .
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

RESULT 288
 CS096442/c 21 bp RNA linear PAT 03-JUN-2005
 DEFINITION Sequence 267 from Patent WO2005045040.
 ACCESSION CS096442
 VERSION CS096442.1 GI:66952915
 KEYWORDS
 SOURCE
 ORGANISM
 synthetic construct
 other sequences; artificial sequences.

REFERENCE
 1 Richards, I. and Macswiggen, J.
 RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
 Patent: WO 2005045040-A 267 19-MAY-2005;
 SiRNA Therapeutics, Inc. (US)
 Location/Qualifiers

FEATURES
 source
 1..21
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Description of Artificial Sequence: siNA antisense region"

misc_feature
 1 /note="2#-O-methyl"
 2 /note="2#-deoxy-2#-fluoro"
 3..4 /note="2#-O-methyl"
 5..8 /note="2#-deoxy-2#-fluoro"
 9..10 /note="2#-O-methyl"
 11..13 /note="2#-deoxy-2#-fluoro"
 14 /note="2#-deoxy-2#-fluoro"
 misc_feature
 15..17 /note="2#-O-methyl"
 18 /note="2#-deoxy-2#-fluoro"
 misc_feature
 19 /note="2#-O-methyl"
 20..21 /note="2#-deoxy-2#-fluoro"
 misc_feature
 20 /note="n stands for thymidine"
 /note="Phosphorothioate 3'-Internucleotide linkage"

Query Match
 Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
 Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 975 GCAGUGACGACGACCAC 993
 Db 19 GCAGATGACGACGACCAC 1

RESULT 289
 CS096443/c 21 bp RNA linear PAT 03-JUN-2005
 DEFINITION Sequence 268 from Patent WO2005045040.
 ACCESSION CS096443
 VERSION CS096443.1 GI:66952916
 KEYWORDS
 SOURCE
 ORGANISM
 synthetic construct
 other sequences; artificial sequences.

REFERENCE
 1 Richards, I. and Macswiggen, J.
 RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic

Acid (siNA)
 Patent: WO 2005045040-A 268 19-MAY-2005;
 SiRNA Therapeutics, Inc. (US)
 Location/Qualifiers

FEATURES
 source
 1..21
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Description of Artificial Sequence: siNA antisense region"

misc_feature
 1 /note="2#-deoxy-2#-fluoro"
 2 /note="2#-O-methyl"
 3..7 /note="2#-deoxy-2#-fluoro"
 8 /note="2#-deoxy-2#-fluoro"
 9..10 /note="2#-O-methyl"
 11..12 /note="2#-deoxy-2#-fluoro"
 13 /note="2#-O-methyl"
 14 /note="2#-deoxy-2#-fluoro"
 15..16 /note="2#-O-methyl"
 17 /note="2#-deoxy-2#-fluoro"
 18..19 /note="2#-O-methyl"
 20..21 /note="2#-deoxy-2#-fluoro"
 misc_feature
 20 /note="n stands for thymidine"
 /note="Phosphorothioate 3'-Internucleotide linkage"

Query Match
 Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
 Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1712 AGCAGUACGACGACGACA 1730
 Db 19 AGCAGTACGACGACGACA 1

RESULT 290
 CS096444/c 21 bp RNA linear PAT 03-JUN-2005
 DEFINITION Sequence 269 from Patent WO2005045040.
 ACCESSION CS096444
 VERSION CS096444.1 GI:66952917
 KEYWORDS
 SOURCE
 ORGANISM
 synthetic construct
 other sequences; artificial sequences.

REFERENCE
 1 Richards, I. and Macswiggen, J.
 RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
 Patent: WO 2005045040-A 269 19-MAY-2005;
 SiRNA Therapeutics, Inc. (US)
 Location/Qualifiers

FEATURES
 source
 1..21
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Description of Artificial Sequence: siNA antisense region"

misc_feature
 1 /note="2#-O-methyl"
 2..3

SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 264 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
1. .3
misc_feature
/note="2#-O-methyl"
4
misc_feature
/note="2#-deoxy-2#-fluoro"
5. .9
misc_feature
/note="2#-O-methyl"
10
misc_feature
/note="2#-deoxy-2#-fluoro"
11. .14
misc_feature
/note="2#-O-methyl"
15. .16
misc_feature
/note="2#-deoxy-2#-fluoro"
17
misc_feature
/note="2#-O-methyl"
18
misc_feature
/note="2#-deoxy-2#-fluoro"
19
misc_feature
/note="2#-O-methyl"
20. .21
misc_feature
/note="n stands for thymidine"
20
misc_feature
/note="Phosphorothioate 3#-Internucleotide linkage"

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 21 UCAACCCUGCCUUGUUU 39
Db 19 TACACCTCGCCTTGTTT 1

RESULT 286
CS096440/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 265 from Patent WO2005045040.
DEFINITION CS096440
ACCESSION CS096440
VERSION CS096440.1 GI:66952913
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 265 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

misc_feature 1. .2
/note="2#-O-methyl"
3. .4
misc_feature
/note="2#-deoxy-2#-fluoro"
5. .7
misc_feature
/note="2#-O-methyl"
8. .10
misc_feature
/note="2#-deoxy-2#-fluoro"
11. .19
misc_feature
/note="2#-O-methyl"
20. .21
misc_feature
/note="n stands for thymidine"
20
/note="Phosphorothioate 3#-Internucleotide linkage"

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 315 CUUCUCUUAAGCCUGGCC 333
Db 19 CTCCTCTTAAGCCTGACC 1

RESULT 287
CS096441/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 266 from Patent WO2005045040.
DEFINITION CS096441
ACCESSION CS096441
VERSION CS096441.1 GI:66952914
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 266 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
1
misc_feature
/note="2#-deoxy-2#-fluoro"
2. .4
misc_feature
/note="2#-O-methyl"
5. .6
misc_feature
/note="2#-deoxy-2#-fluoro"
7. .9
misc_feature
/note="2#-O-methyl"
10. .12
misc_feature
/note="2#-deoxy-2#-fluoro"
13. .19
misc_feature
/note="2#-O-methyl"
20. .21
misc_feature
/note="n stands for thymidine"
20
/note="Phosphorothioate 3#-Internucleotide linkage"

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 317 UCCUCUUAAGCCUGGCCUG 335
Db 19 TCCTCTTAAGCCTGACCTG 1

misc_feature /note="2#-O-methyl"
16 /note="2#-deoxy-2#-fluoro"
misc_feature /note="2#-O-methyl"
17 .18 /note="2#-O-methyl"
misc_feature /note="2#-deoxy-2#-fluoro"
19 /note="2#-O-methyl"
misc_feature /note="2#-deoxy-2#-fluoro"
20 .21 /note="n stands for thymidine"
misc_feature /note="3#-3 attached terminal deoxyabasic moiety"
21 /note="3#-3 attached terminal deoxyabasic moiety"
1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1714 CAGUACGACGAGACAGU 1732
DB 1 CAGTACGACGAGACAGT 19
RESULT 283
CS096437 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 262 from Patent WO2005045040.
DEFINITION CS096437
ACCESSION CS096437.1 GI:66952910
VERSION
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
1
AUTHORS
TITLE
Richard, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 262 19-MAY-2005;
JOURNAL
SiRNA Therapeutics, Inc. (US)
LOCATION/Qualifiers
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense
region"
1. .2
/note="2#-O-methyl"
1 /note="5#-3 attached terminal deoxyabasic moiety"
3 /note="2#-deoxy-2#-fluoro"
4 /note="2#-O-methyl"
5. .6 /note="2#-deoxy-2#-fluoro"
7. .8 /note="2#-O-methyl"
9 /note="2#-deoxy-2#-fluoro"
10. .14 /note="2#-deoxy-2#-fluoro"
15 /note="2#-O-methyl"
16. .17 /note="2#-deoxy-2#-fluoro"
18. .19 /note="2#-O-methyl"
20. .21 /note="2#-deoxy-2#-fluoro"
21 /note="n stands for thymidine"
/note="3#-3 attached terminal deoxyabasic moiety"
1.1%; Score 19; DB 1; Length 21;
Query Match

Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1715 ACUACGACGACGACGUC 1733
DB 1 AGTACGACGACGACGATC 19
RESULT 284
CS096438 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 263 from Patent WO2005045040.
DEFINITION CS096438
ACCESSION CS096438.1 GI:66952911
VERSION
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
1
AUTHORS
TITLE
Richard, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 263 19-MAY-2005;
JOURNAL
SiRNA Therapeutics, Inc. (US)
LOCATION/Qualifiers
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"
1. .5
/note="2#-O-methyl"
6 /note="2#-deoxy-2#-fluoro"
7. .10 /note="2#-O-methyl"
11. .12 /note="2#-deoxy-2#-fluoro"
13 /note="2#-deoxy-2#-fluoro"
14 /note="2#-O-methyl"
15 /note="2#-deoxy-2#-fluoro"
16. .17 /note="2#-O-methyl"
18 /note="2#-deoxy-2#-fluoro"
19 /note="2#-O-methyl"
20 /note="2#-deoxy-2#-fluoro"
20. .21 /note="n stands for thymidine"
20 /note="Phosphorothioate 3'-internucleotide linkage"
/note="3#-3 attached terminal deoxyabasic moiety"
1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 17 ACAGUACACGCGCCUU 35
DB 19 ACAGTACAACTCGCCTT 1
RESULT 285
CS096439 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 264 from Patent WO2005045040.
DEFINITION CS096439
ACCESSION CS096439.1 GI:66952912
VERSION
KEYWORDS

JOURNAL Patent: WO 2005045040-A 259 19-MAY-2005;
Sima Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
1
/note="2#-O-methyl"
2
5#-3 attached terminal deoxyabasic moiety"
3. .5
/note="2#-deoxy-2#-fluoro"
6
/note="2#-O-methyl"
7. .9
/note="2#-deoxy-2#-fluoro"
10. .11
/note="2#-deoxy-2#-fluoro"
12. .15
/note="2#-O-methyl"
16. .17
/note="2#-deoxy-2#-fluoro"
18
/note="2#-O-methyl"
19
/note="2#-deoxy-2#-fluoro"
20. .21
/note="n stands for thymidine"
21
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1,1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 975 GCAGATGACCAAGACCAC 993
DB 1 GCAGATGACCAAGACCAC 19
RESULT 281
CS096435
LOCUS CS096435 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 260 from Patent WO2005045040.
ACCESSION CS096435
VERSION CS096435.1 GI:66952908
KEYWORDS
SOURCE .
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 260 19-MAY-2005;
Sima Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
1. .2
/note="2#-O-methyl"
1
/note="5#-3 attached terminal deoxyabasic moiety"
3
misc_feature

misc_feature
4. .5
/note="2#-O-methyl"
6
/note="2#-deoxy-2#-fluoro"
7
/note="2#-O-methyl"
8. .9
/note="2#-deoxy-2#-fluoro"
10. .11
/note="2#-O-methyl"
12
/note="2#-deoxy-2#-fluoro"
13. .17
/note="2#-O-methyl"
18
/note="2#-deoxy-2#-fluoro"
19
/note="2#-O-methyl"
20. .21
/note="n stands for thymidine"
21
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1,1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1712 AGCAGUACCAGACAGACA 1730
DB 1 AGCAGTACCAAGACAGACA 19
RESULT 282
CS096436
LOCUS CS096436 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 261 from Patent WO2005045040.
ACCESSION CS096436
VERSION CS096436.1 GI:66952909
KEYWORDS
SOURCE .
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 261 19-MAY-2005;
Sima Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
1
/note="2#-deoxy-2#-fluoro"
2. .3
5#-3 attached terminal deoxyabasic moiety"
4
/note="2#-O-methyl"
5
/note="2#-deoxy-2#-fluoro"
6. .7
/note="2#-O-methyl"
8. .9
/note="2#-deoxy-2#-fluoro"
10
/note="2#-O-methyl"
11. .15
/note="2#-deoxy-2#-fluoro"
misc_feature

```
misc_feature      3 /note="2#-O-methyl"
misc_feature      4.5 /note="2#-deoxy-2#-fluoro"
misc_feature      6.9 /note="2#-O-methyl"
misc_feature      10 /note="2#-deoxy-2#-fluoro"
misc_feature      11.15 /note="2#-O-methyl"
misc_feature      16 /note="2#-deoxy-2#-fluoro"
misc_feature      17.19 /note="2#-O-methyl"
misc_feature      20.21 /note="2#-deoxy-2#-fluoro"
misc_feature      21 /note="n stands for thymidine"
misc_feature      /note="3#-3 attached terminal deoxyabasic moiety"

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      21 UACACCGCGCCUUGUUU 39
Db      1 TACACCTCGCCTTGTGTT 19

RESULT 278
LOCUS      CS096432      21 bp      RNA
DEFINITION Sequence 257 from Patent WO2005045040.
ACCESSION  CS096432
VERSION     CS096432.1 GI:66952905
KEYWORDS
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Richards,I. and Macswiggen,J.
TITLE       RNA interference mediated inhibition of cholinergic muscarinic
            receptor (CHRM3) gene expression using short interfering Nucleic
            Acid (siNA)
JOURNAL     Patent: WO 2005045040-A 257 19-MAY-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES
            Location/Qualifiers
            1..21
            /organism="synthetic construct"
            /mol_type="unassigned RNA"
            /db_xref="taxon:32630"
            /note="Description of Artificial Sequence: siNA sense
            region"
            1..9
            /note="2#-deoxy-2#-fluoro"
            10..12
            /note="5#-3 attached terminal deoxyabasic moiety"
            13..15
            /note="2#-O-methyl"
            16..17
            /note="2#-deoxy-2#-fluoro"
            18..19
            /note="2#-O-methyl"
            20..21
            /note="2#-deoxy-2#-fluoro"
            21
            /note="n stands for thymidine"
            /note="3#-3 attached terminal deoxyabasic moiety"

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      315 CUUCUCUUAAGCCUGCC 333
Db      1 CTTCCTTAAGCCTGGCC 19

RESULT 279
LOCUS      CS096433      21 bp      RNA
DEFINITION Sequence 258 from Patent WO2005045040.
ACCESSION  CS096433
VERSION     CS096433.1 GI:66952906
KEYWORDS
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Richards,I. and Macswiggen,J.
TITLE       RNA interference mediated inhibition of cholinergic muscarinic
            receptor (CHRM3) gene expression using short interfering Nucleic
            Acid (siNA)
JOURNAL     Patent: WO 2005045040-A 258 19-MAY-2005;
            Sirna Therapeutics, Inc. (US)
FEATURES
            Location/Qualifiers
            1..21
            /organism="synthetic construct"
            /mol_type="unassigned RNA"
            /db_xref="taxon:32630"
            /note="Description of Artificial Sequence: siNA sense
            region"
            1..7
            /note="2#-deoxy-2#-fluoro"
            8..10
            /note="5#-3 attached terminal deoxyabasic moiety"
            11..13
            /note="2#-O-methyl"
            14..15
            /note="2#-deoxy-2#-fluoro"
            16..18
            /note="2#-deoxy-2#-fluoro"
            19
            /note="2#-O-methyl"
            20..21
            /note="2#-deoxy-2#-fluoro"
            21
            /note="n stands for thymidine"
            /note="3#-3 attached terminal deoxyabasic moiety"

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      317 UCCUCUUAAGCCUGCCUG 335
Db      1 TCCTCTTAAGCCTGCGCTG 19

RESULT 280
LOCUS      CS096434      21 bp      RNA
DEFINITION Sequence 259 from Patent WO2005045040.
ACCESSION  CS096434
VERSION     CS096434.1 GI:66952907
KEYWORDS
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Richards,I. and Macswiggen,J.
TITLE       RNA interference mediated inhibition of cholinergic muscarinic
            receptor (CHRM3) gene expression using short interfering Nucleic
            Acid (siNA)
```

RESULT 275
CS096429/c 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 254 from Patent WO2005045040.
ACCESSION CS096429
VERSION CS096429.1 GI:66952902
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 254 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
misc_feature 1. .2
/note="2#-deoxy"
misc_feature 3. .4
/note="2#-deoxy-2'-fluoro"
misc_feature 5
/note="2#-deoxy"
misc_feature 6. .10
/note="2#-deoxy-2'-fluoro"
misc_feature 11
/note="2#-deoxy"
misc_feature 12. .13
/note="2#-deoxy-2'-fluoro"
misc_feature 14. .15
/note="2#-deoxy"
misc_feature 16
/note="2#-deoxy-2'-fluoro"
misc_feature 17
/note="2#-deoxy"
misc_feature 18. .19
/note="2#-deoxy-2'-fluoro"
misc_feature 20. .21
/note="n stands for thymidine"
misc_feature 20
/note="Phosphorothioate 3'-Internucleotide Linkage"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY 1715 AGUACGACGACAGUC 1733
Db 19 AGTACGACGACAGACGTC 1
RESULT 276
CS096430 21 bp RNA linear PAT 03-JUN-2005
LOCUS CS096430
DEFINITION Sequence 255 from Patent WO2005045040.
ACCESSION CS096430
VERSION CS096430.1 GI:66952903
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic

Acid (siNA)
JOURNAL Patent: WO 2005045040-A 255 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature 1
/note="2#-O-methyl"
5#-3 attached terminal deoxyabasic moiety"
2
/note="2#-deoxy-2'-fluoro"
3. .4
/note="2#-O-methyl"
5
/note="2#-deoxy-2'-fluoro"
6
/note="2#-O-methyl"
7
/note="2#-deoxy-2'-fluoro"
8. .9
/note="2#-O-methyl"
10. .13
/note="2#-deoxy-2'-fluoro"
14
/note="2#-O-methyl"
15. .19
/note="2#-deoxy-2'-fluoro"
20. .21
/note="n stands for thymidine"
21
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
OY 17 ACAGUACAACCCUGCCUU 35
Db 1 ACAGTACAACCTCGCCCTT 19
RESULT 277
CS096431 21 bp RNA linear PAT 03-JUN-2005
LOCUS CS096431
DEFINITION Sequence 256 from Patent WO2005045040.
ACCESSION CS096431
VERSION CS096431.1 GI:66952904
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 256 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature 1
/note="2#-deoxy-2'-fluoro"
5#-3 attached terminal deoxyabasic moiety"
2
misc_feature 2

misc_feature /note="2#-deoxy-2#-fluoro"
9.10
misc_feature /note="2#-deoxy"
11.13
misc_feature /note="2#-deoxy-2#-fluoro"
14
misc_feature /note="2#-deoxy"
15.17
misc_feature /note="2#-deoxy-2#-fluoro"
18
misc_feature /note="2#-deoxy"
19
misc_feature /note="2#-deoxy-2#-fluoro"
20.21
misc_feature /note="n stands for thymidine"
20
misc_feature /note="Phosphorothioate 3#-Internucleotide Linkage"
20

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 975 GCAGAGGACCAAGACCAC 993
||||:|||||
Db 19 GCAGATGACCAAGACCAC 1

RESULT 273
CS096427/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 252 from Patent WO2005045040.
DEFINITION CS096427
ACCESSION CS096427
VERSION CS096427.1 GI:66952900
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 252 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1.21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"
1
misc_feature /note="2#-deoxy-2#-fluoro"
2
misc_feature /note="2#-deoxy"
3.7
misc_feature /note="2#-deoxy-2#-fluoro"
8
misc_feature /note="2#-deoxy"
9.10
misc_feature /note="2#-deoxy-2#-fluoro"
11.12
misc_feature /note="2#-deoxy"
13
misc_feature /note="2#-deoxy-2#-fluoro"
14
misc_feature /note="2#-deoxy"
15.16
misc_feature /note="2#-deoxy-2#-fluoro"
17
misc_feature /note="2#-deoxy"
18.19
misc_feature /note="2#-deoxy-2#-fluoro"

misc_feature 20.21
misc_feature /note="n stands for thymidine"
20
misc_feature /note="Phosphorothioate 3#-Internucleotide Linkage"
20

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 1712 AGCAGUACCAAGACAGACA 1730
||||:|||||
Db 19 AGCAGTACCAAGACAGACA 1

RESULT 274
CS096428/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 253 from Patent WO2005045040.
DEFINITION CS096428
ACCESSION CS096428
VERSION CS096428.1 GI:66952901
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 253 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1.21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"
1
misc_feature /note="2#-deoxy"
2.3
misc_feature /note="2#-deoxy-2#-fluoro"
4
misc_feature /note="2#-deoxy"
5.9
misc_feature /note="2#-deoxy-2#-fluoro"
10
misc_feature /note="2#-deoxy"
11.12
misc_feature /note="2#-deoxy-2#-fluoro"
13.14
misc_feature /note="2#-deoxy"
15
misc_feature /note="2#-deoxy-2#-fluoro"
16
misc_feature /note="2#-deoxy"
17.18
misc_feature /note="2#-deoxy-2#-fluoro"
19
misc_feature /note="2#-deoxy"
20.21
misc_feature /note="n stands for thymidine"
20
misc_feature /note="Phosphorothioate 3#-Internucleotide Linkage"
20

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 1714 CAGUACCAAGACAGAGU 1732
||||:|||||
Db 19 CAGTACCAAGACAGACAGT 1

```

misc_feature      /note="2#-deoxy-2#-fluoro"
19
misc_feature      /note="2#-deoxy"
20..21
misc_feature      /note="n stands for thymidine"
20
/note="Phosphorothioate 3#-Internucleotide Linkage"

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

OY      21 UCAACCCGCGCCUUGUUU 39
Db      19 TACAACCTCGCCCTTGT 1

RESULT 270
LOCUS      CS096424/c      21 bp      RNA
DEFINITION Sequence 249 from Patent WO2005045040.
ACCESSION  CS096424
VERSION     CS096424.1 GI:66952897
KEYWORDS
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Richards,I. and Macswiggen,J.
TITLE       RNA interference mediated inhibition of cholinergic muscarinic
            receptor (CHRM3) gene expression using short interfering Nucleic
            Acid (siNA)
JOURNAL     Patent: WO 2005045040-A 249 19-MAY-2005;
            Sitna Therapeutics, Inc. (US)
FEATURES
            Location/Qualifiers
            1..21
            /organism="synthetic construct"
            /mol_type="unassigned RNA"
            /db_xref="taxon:32630"
            /note="Description of Artificial Sequence: siNA antisense
            region"
            misc_feature      /note="2#-deoxy"
            1..2
            misc_feature      /note="2#-deoxy-2#-fluoro"
            3..4
            misc_feature      /note="2#-deoxy"
            5..7
            misc_feature      /note="2#-deoxy"
            8..10
            misc_feature      /note="2#-deoxy-2#-fluoro"
            11..19
            misc_feature      /note="2#-deoxy"
            20..21
            misc_feature      /note="n stands for thymidine"
            20
            /note="Phosphorothioate 3#-Internucleotide Linkage"

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

OY      315 CUUCUCUUAAGCCGCGCC 333
Db      19 CTTCCTTACGCTGACC 1

RESULT 271
LOCUS      CS096425/c      21 bp      RNA
DEFINITION Sequence 250 from Patent WO2005045040.
ACCESSION  CS096425
VERSION     CS096425.1 GI:66952898
KEYWORDS
SOURCE      synthetic construct

```

```

ORGANISM    synthetic construct
other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Richards,I. and Macswiggen,J.
TITLE       RNA interference mediated inhibition of cholinergic muscarinic
            receptor (CHRM3) gene expression using short interfering Nucleic
            Acid (siNA)
JOURNAL     Patent: WO 2005045040-A 250 19-MAY-2005;
            Sitna Therapeutics, Inc. (US)
FEATURES
            Location/Qualifiers
            1..21
            /organism="synthetic construct"
            /mol_type="unassigned RNA"
            /db_xref="taxon:32630"
            /note="Description of Artificial Sequence: siNA antisense
            region"
            misc_feature      /note="2#-deoxy-2#-fluoro"
            1
            misc_feature      /note="2#-deoxy"
            2..4
            misc_feature      /note="2#-deoxy"
            5..6
            misc_feature      /note="2#-deoxy-2#-fluoro"
            7..9
            misc_feature      /note="2#-deoxy"
            10..12
            misc_feature      /note="2#-deoxy-2#-fluoro"
            13..19
            misc_feature      /note="2#-deoxy"
            20..21
            misc_feature      /note="n stands for thymidine"
            20
            /note="Phosphorothioate 3#-Internucleotide Linkage"

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

OY      317 UCCUCUUAAGCCGCGCUG 335
Db      19 TCCTCTTACGCTGCGCTG 1

RESULT 272
LOCUS      CS096426/c      21 bp      RNA
DEFINITION Sequence 251 from Patent WO2005045040.
ACCESSION  CS096426
VERSION     CS096426.1 GI:66952899
KEYWORDS
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Richards,I. and Macswiggen,J.
TITLE       RNA interference mediated inhibition of cholinergic muscarinic
            receptor (CHRM3) gene expression using short interfering Nucleic
            Acid (siNA)
JOURNAL     Patent: WO 2005045040-A 251 19-MAY-2005;
            Sitna Therapeutics, Inc. (US)
FEATURES
            Location/Qualifiers
            1..21
            /organism="synthetic construct"
            /mol_type="unassigned RNA"
            /db_xref="taxon:32630"
            /note="Description of Artificial Sequence: siNA antisense
            region"
            misc_feature      /note="2#-deoxy"
            1
            misc_feature      /note="2#-deoxy-2#-fluoro"
            2
            misc_feature      /note="2#-deoxy"
            3..4
            misc_feature      /note="2#-deoxy"
            5..8

```

AUTHORS Richard, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 246 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
1. .2
/note="2#-deoxy"
misc_feature
1
/note="5#-3 attached terminal deoxyabasic moiety"
misc_feature
3
/note="2#-deoxy-2#-fluoro"
misc_feature
4
/note="2#-deoxy"
misc_feature
5. .6
/note="2#-deoxy-2#-fluoro"
misc_feature
7. .8
/note="2#-deoxy"
misc_feature
9
/note="2#-deoxy-2#-fluoro"
misc_feature
10. .14
/note="2#-deoxy"
misc_feature
15
/note="2#-deoxy-2#-fluoro"
misc_feature
16. .17
/note="2#-deoxy"
misc_feature
18. .19
/note="2#-deoxy-2#-fluoro"
misc_feature
20. .21
/note="n stands for thymidine"
misc_feature
21
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 1715 AGUACGACGACGAGCAGUC 1733
Db 1 AGTACCAGCAGACAGCAGTC 19
RESULT 268
CS096422/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 247 from Patent WO2005045040.
DEFINITION CS096422
ACCESSION CS096422
VERSION CS096422.1 GI:66952895
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE
1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 247 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

misc_feature
1. .5
/note="2#-deoxy"
misc_feature
6
/note="2#-deoxy-2#-fluoro"
misc_feature
7. .10
/note="2#-deoxy"
misc_feature
11. .12
/note="2#-deoxy-2#-fluoro"
misc_feature
13
/note="2#-deoxy"
misc_feature
14
/note="2#-deoxy-2#-fluoro"
misc_feature
15
/note="2#-deoxy"
misc_feature
16. .17
/note="2#-deoxy-2#-fluoro"
misc_feature
18
/note="2#-deoxy"
misc_feature
19
/note="2#-deoxy-2#-fluoro"
misc_feature
20. .21
/note="n stands for thymidine"
misc_feature
20
/note="Phosphorothioate 3'-Internucleotide Linkage"
Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
Qy 17 ACAGUACAACUCGCCCCUU 35
Db 19 ACAGTACAACCTGCCTT 1
RESULT 269
CS096423 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 248 from Patent WO2005045040.
DEFINITION CS096423
ACCESSION CS096423
VERSION CS096423.1 GI:66952896
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE
1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 248 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
misc_feature
1. .3
/note="2#-deoxy"
misc_feature
4
/note="2#-deoxy-2#-fluoro"
misc_feature
5. .9
/note="2#-deoxy"
misc_feature
10
/note="2#-deoxy-2#-fluoro"
misc_feature
11. .14
/note="2#-deoxy"
misc_feature
15. .16
/note="2#-deoxy-2#-fluoro"
misc_feature
17
/note="2#-deoxy"
misc_feature
18

```
misc_feature 21
/note="3#-3 attached terminal deoxyabasic moiety"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 975 GCAGAGGACGACGACAC 993
Db 1 GCAGATGACGACGACAC 19

RESULT 265
LOCUS CS096419 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 244 from Patent WO2005045040.
ACCESSION CS096419
VERSION CS096419.1 GI:66952892
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 244 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
LOCATION/Qualifiers
FEATURES
source 1..21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense
region"
misc_feature 1..2
/note="2#-deoxy"
misc_feature 1
/note="5#-3 attached terminal deoxyabasic moiety"
misc_feature 3
/note="2#-deoxy-2#-fluoro"
misc_feature 4..5
/note="2#-deoxy"
misc_feature 6
/note="2#-deoxy-2#-fluoro"
misc_feature 7
/note="2#-deoxy-2#-fluoro"
misc_feature 8..9
/note="2#-deoxy"
misc_feature 10..11
/note="2#-deoxy-2#-fluoro"
misc_feature 12
/note="2#-deoxy-2#-fluoro"
misc_feature 13..17
/note="2#-deoxy"
misc_feature 18
/note="2#-deoxy-2#-fluoro"
misc_feature 19
/note="2#-deoxy-2#-fluoro"
misc_feature 20..21
/note="n stands for thymidine"
misc_feature 21
/note="3#-3 attached terminal deoxyabasic moiety"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1712 AGCAGUACGACGACGACA 1730
Db 1 AGCAGTACGACGACGACA 19
```

```
RESULT 266
LOCUS CS096420 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 245 from Patent WO2005045040.
ACCESSION CS096420
VERSION CS096420.1 GI:66952893
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 245 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
LOCATION/Qualifiers
FEATURES
source 1..21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense
region"
misc_feature 1
/note="2#-deoxy-2#-fluoro"
misc_feature 5#-3 attached terminal deoxyabasic moiety"
misc_feature 2..3
/note="2#-deoxy"
misc_feature 4
/note="2#-deoxy-2#-fluoro"
misc_feature 5
/note="2#-deoxy"
misc_feature 6..7
/note="2#-deoxy"
misc_feature 8..9
/note="2#-deoxy-2#-fluoro"
misc_feature 10
/note="2#-deoxy"
misc_feature 11..15
/note="2#-deoxy"
misc_feature 16
/note="2#-deoxy-2#-fluoro"
misc_feature 17..18
/note="2#-deoxy"
misc_feature 19
/note="2#-deoxy-2#-fluoro"
misc_feature 20..21
/note="n stands for thymidine"
misc_feature 21
/note="3#-3 attached terminal deoxyabasic moiety"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1714 CAGUACGACGACGACGACU 1732
Db 1 CAGTACGACGACGACGACGT 19

RESULT 267
LOCUS CS096421 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 246 from Patent WO2005045040.
ACCESSION CS096421
VERSION CS096421.1 GI:66952894
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
```

DEFINITION Sequence 241 from Patent WO2005045040.
ACCESSION CS096416
VERSION CS096416.1 GI:66952889
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 241 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
1. .9
/note="2#-deoxy-2#-fluoro"
misc_feature
1
/note="5#-3 attached terminal deoxyabasic moiety"
misc_feature
10. .12
/note="2#-deoxy"
misc_feature
13. .15
/note="2#-deoxy-2#-fluoro"
misc_feature
16. .17
/note="2#-deoxy"
misc_feature
18. .19
/note="2#-deoxy-2#-fluoro"
misc_feature
20. .21
/note="n strands for thymidine"
misc_feature
21
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 315 CUCCUCUAGCCUGCC 333
DB 1 TCCTCTTAAGCCTGCGC 19
RESULT 263
LOCUS CS096417 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 242 from Patent WO2005045040.
ACCESSION CS096417
VERSION CS096417.1 GI:66952890
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 242 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
1. .7
/note="2#-deoxy-2#-fluoro"

misc_feature
1
/note="5#-3 attached terminal deoxyabasic moiety"
misc_feature
8. .10
/note="2#-deoxy"
misc_feature
11. .13
/note="2#-deoxy-2#-fluoro"
misc_feature
14. .15
/note="2#-deoxy"
misc_feature
16. .18
/note="2#-deoxy-2#-fluoro"
misc_feature
19
/note="2#-deoxy"
misc_feature
20. .21
/note="n strands for thymidine"
misc_feature
21
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 317 UCCUCUAGCCUGCCUG 335
DB 1 TCCTCTTAAGCCTGCGCTG 19
RESULT 264
LOCUS CS096418 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 243 from Patent WO2005045040.
ACCESSION CS096418
VERSION CS096418.1 GI:66952891
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 243 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
1
/note="2#-deoxy
5#-3 attached terminal deoxyabasic moiety"
2
/note="2#-deoxy-2#-fluoro"
3. .5
/note="2#-deoxy"
6
/note="2#-deoxy-2#-fluoro"
7. .9
/note="2#-deoxy"
10. .11
/note="2#-deoxy-2#-fluoro"
12. .15
/note="2#-deoxy"
16. .17
/note="2#-deoxy-2#-fluoro"
18
/note="2#-deoxy-2#-fluoro"
19
/note="2#-deoxy"
misc_feature
20. .21
/note="2#-deoxy-2#-fluoro"
misc_feature
21
/note="n strands for thymidine"

```
/db xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"
misc_feature
3..4
/note="2#-deoxy-2#-fluoro"
6..10
/note="2#-deoxy-2#-fluoro"
12..13
/note="2#-deoxy-2#-fluoro"
16
/note="2#-deoxy-2#-fluoro"
18..19
/note="2#-deoxy-2#-fluoro"
20..21
/note="n stands for thymidine"
misc_feature
20
/note="Phosphorothioate 3#-Internucleotide Linkage"

Query Match
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1715 AGUACGACGAGACAGC 1733
Db 19 AGTACGACGAGACAGC 1

RESULT 260
LOCUS CS096414 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 239 from Patent WO2005045040.
ACCESSION CS096414
VERSION CS096414.1 GI:66952887
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
1 Richards, I. and Macswiggen, J.
AUTHORS RNA interference mediated inhibition of cholinergic muscarinic
TITLE receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 239 19-MAY-2005;
Sina Therapeutics, Inc. (US)
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense
region"
1
/note="2#-deoxy
5#-3 attached terminal deoxyabasic moiety"
2
/note="2#-deoxy-2#-fluoro"
3..4
/note="2#-deoxy"
5
/note="2#-deoxy-2#-fluoro"
6
/note="2#-deoxy"
7
/note="2#-deoxy"
7
/note="2#-deoxy-2#-fluoro"
8..9
/note="2#-deoxy"
10..13
/note="2#-deoxy-2#-fluoro"
14
/note="2#-deoxy"
15..19
/note="2#-deoxy-2#-fluoro"
20..21
misc_feature
```

```
/note="n stands for thymidine"
misc_feature
21
/note="3#-3 attached terminal deoxyabasic moiety"

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 17 ACAGUACACCCUGCCUUU 35
Db 1 ACAGTACACCTCGCCCTT 19

RESULT 261
LOCUS CS096415 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 240 from Patent WO2005045040.
ACCESSION CS096415
VERSION CS096415.1 GI:66952888
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
1 Richards, I. and Macswiggen, J.
AUTHORS RNA interference mediated inhibition of cholinergic muscarinic
TITLE receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 240 19-MAY-2005;
Sina Therapeutics, Inc. (US)
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense
region"
1
/note="2#-deoxy-2#-fluoro
5#-3 attached terminal deoxyabasic moiety"
2
/note="2#-deoxy"
3
/note="2#-deoxy-2#-fluoro"
4..5
/note="2#-deoxy"
6..9
/note="2#-deoxy-2#-fluoro"
10
/note="2#-deoxy"
11..15
/note="2#-deoxy-2#-fluoro"
16
/note="2#-deoxy"
17..19
/note="2#-deoxy-2#-fluoro"
20..21
/note="n stands for thymidine"
21
/note="3#-3 attached terminal deoxyabasic moiety"

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 21 UACAACTCCGCCCTTTGTTT 39
Db 1 TACAACTCGCCCTTTGTTT 19

RESULT 262
LOCUS CS096416 21 bp RNA linear PAT 03-JUN-2005
```

```
/db xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"
2
misc_feature
/note="2#-deoxy-2#-fluoro"
5..8
misc_feature
/note="2#-deoxy-2#-fluoro"
11..13
misc_feature
/note="2#-deoxy-2#-fluoro"
15..17
misc_feature
/note="2#-deoxy-2#-fluoro"
19
misc_feature
/note="2#-deoxy-2#-fluoro"
20..21
/note="n stands for thymidine"
20
/note="Phosphorothioate 3'-Internucleotide Linkage"
20

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 975 GCAGAGGACCAAGACCAC 993
19 GCAGATGACGACAGACCAC 1

RESULT 257
CS096411/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 236 from Patent WO2005045040.
DEFINITION CS096411
ACCESSION CS096411
VERSION CS096411.1 GI:66952884
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
1 Richard, I. and Macswiggen, J.
AUTHORS RNA interference mediated inhibition of cholinergic muscarinic
TITLE receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 236 19-MAY-2005;
Sirma Therapeutics, Inc (US)
FEATURES
source
1..21
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"
1
misc_feature
/note="2#-deoxy-2#-fluoro"
3..7
misc_feature
/note="2#-deoxy-2#-fluoro"
9..10
misc_feature
/note="2#-deoxy-2#-fluoro"
13
misc_feature
/note="2#-deoxy-2#-fluoro"
15..16
misc_feature
/note="2#-deoxy-2#-fluoro"
18..19
misc_feature
/note="2#-deoxy-2#-fluoro"
20..21
/note="n stands for thymidine"
20
/note="Phosphorothioate 3'-Internucleotide Linkage"
20

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1712 AGCAGTACGACGAGACA 1730
```

```
19 AGCAGTACGACGAGACA 1

RESULT 258
CS096412/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 237 from Patent WO2005045040.
DEFINITION CS096412
ACCESSION CS096412
VERSION CS096412.1 GI:66952885
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
1 Richard, I. and Macswiggen, J.
AUTHORS RNA interference mediated inhibition of cholinergic muscarinic
TITLE receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 237 19-MAY-2005;
Sirma Therapeutics, Inc (US)
FEATURES
source
1..21
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"
1
misc_feature
/note="2#-deoxy-2#-fluoro"
2..3
misc_feature
/note="2#-deoxy-2#-fluoro"
5..9
misc_feature
/note="2#-deoxy-2#-fluoro"
11..12
misc_feature
/note="2#-deoxy-2#-fluoro"
15
misc_feature
/note="2#-deoxy-2#-fluoro"
17..18
misc_feature
/note="2#-deoxy-2#-fluoro"
20..21
/note="n stands for thymidine"
20
/note="Phosphorothioate 3'-Internucleotide Linkage"
20

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1714 CAGUACGACGACAGACAGU 1732
19 CAGTACGACGACGACAGACAGT 1

RESULT 259
CS096413/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 238 from Patent WO2005045040.
DEFINITION CS096413
ACCESSION CS096413
VERSION CS096413.1 GI:66952886
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
1 Richard, I. and Macswiggen, J.
AUTHORS RNA interference mediated inhibition of cholinergic muscarinic
TITLE receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 238 19-MAY-2005;
Sirma Therapeutics, Inc (US)
FEATURES
source
1..21
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
```

```

SOURCE      synthetic construct
ORGANISM    synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
AUTHORS    Richards,I. and Macswiggen,J.
TITLE      RNA interference mediated inhibition of cholinergic muscarinic
            receptor (CHRM3) gene expression using short interfering Nucleic
            Acid (siNA)
JOURNAL    Patent: WO 2005045040-A 232 19-MAY-2005;
            Sirta Therapeutics, Inc. (US)
FEATURES    Location/Qualifiers
            1..21
            /organism="synthetic construct"
            /mol_type="unassigned RNA"
            /db_xref="taxon:32630"
            /note="Description of Artificial Sequence: siNA antisense
            region"
            4
            misc_feature
            /note="2#-deoxy-2#-fluoro"
            10
            misc_feature
            /note="2#-deoxy-2#-fluoro"
            15..16
            misc_feature
            /note="2#-deoxy-2#-fluoro"
            18
            misc_feature
            /note="2#-deoxy-2#-fluoro"
            20..21
            misc_feature
            /note="n stands for thymidine"
            20
            /note="Phosphorothioate 3#-Internucleotide Linkage"

Query Match
Best Local Similarity 57.9%; Pred. No. 1.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy      21 UACAACCCGCGCCUUGUU 39
       :|||||:|||||:|||||:
Db      19 TACAACCTCGCCCTTGT 1

RESULT 254
CS096408/c  CS096408      21 bp      RNA      linear      PAT 03-JUN-2005
DEFINITION  Sequence 233 from Patent WO2005045040.
ACCESSION  CS096408
VERSION    CS096408.1 GI:66952881
KEYWORDS   .
SOURCE     synthetic construct
            synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
AUTHORS    Richards,I. and Macswiggen,J.
TITLE      RNA interference mediated inhibition of cholinergic muscarinic
            receptor (CHRM3) gene expression using short interfering Nucleic
            Acid (siNA)
JOURNAL    Patent: WO 2005045040-A 233 19-MAY-2005;
            Sirta Therapeutics, Inc. (US)
FEATURES    Location/Qualifiers
            1..21
            /organism="synthetic construct"
            /mol_type="unassigned RNA"
            /db_xref="taxon:32630"
            /note="Description of Artificial Sequence: siNA antisense
            region"
            3..4
            misc_feature
            /note="2#-deoxy-2#-fluoro"
            8..10
            misc_feature
            /note="2#-deoxy-2#-fluoro"
            20..21
            misc_feature
            /note="n stands for thymidine"
            20
            /note="Phosphorothioate 3#-Internucleotide Linkage"

Query Match
1.1%; Score 19; DB 1; Length 21;
1.1%; Score 19; DB 1; Length 21;
```

```

Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy      315 CUUCUCUUAAGCCUGGCC 333
       |||:|||||:|||||:
Db      19 TCCTCTTAAGCCCTGACC 1

RESULT 255
CS096409/c  CS096409      21 bp      RNA      linear      PAT 03-JUN-2005
DEFINITION  Sequence 234 from Patent WO2005045040.
ACCESSION  CS096409
VERSION    CS096409.1 GI:66952882
KEYWORDS   .
SOURCE     synthetic construct
            synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
AUTHORS    Richards,I. and Macswiggen,J.
TITLE      RNA interference mediated inhibition of cholinergic muscarinic
            receptor (CHRM3) gene expression using short interfering Nucleic
            Acid (siNA)
JOURNAL    Patent: WO 2005045040-A 234 19-MAY-2005;
            Sirta Therapeutics, Inc. (US)
FEATURES    Location/Qualifiers
            1..21
            /organism="synthetic construct"
            /mol_type="unassigned RNA"
            /db_xref="taxon:32630"
            /note="Description of Artificial Sequence: siNA antisense
            region"
            1
            misc_feature
            /note="2#-deoxy-2#-fluoro"
            5..6
            misc_feature
            /note="2#-deoxy-2#-fluoro"
            10..12
            misc_feature
            /note="2#-deoxy-2#-fluoro"
            20..21
            misc_feature
            /note="n stands for thymidine"
            20
            /note="Phosphorothioate 3#-Internucleotide Linkage"

Query Match
1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy      317 UCCUCUUAAGCCUGGCCUG 335
       |||:|||||:|||||:
Db      19 TCCTCTTAAGCCCTGACC 1

RESULT 256
CS096410/c  CS096410      21 bp      RNA      linear      PAT 03-JUN-2005
DEFINITION  Sequence 235 from Patent WO2005045040.
ACCESSION  CS096410
VERSION    CS096410.1 GI:66952883
KEYWORDS   .
SOURCE     synthetic construct
            synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
AUTHORS    Richards,I. and Macswiggen,J.
TITLE      RNA interference mediated inhibition of cholinergic muscarinic
            receptor (CHRM3) gene expression using short interfering Nucleic
            Acid (siNA)
JOURNAL    Patent: WO 2005045040-A 235 19-MAY-2005;
            Sirta Therapeutics, Inc. (US)
FEATURES    Location/Qualifiers
            1..21
            /organism="synthetic construct"
            /mol_type="unassigned RNA"
```

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 229 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
1 /note="2#-deoxy-2#-fluoro
5#-3 attached terminal deoxyabasic moiety"
4
misc_feature
6 /note="2#-deoxy-2#-fluoro"
7
misc_feature
10 /note="2#-deoxy-2#-fluoro"
10
misc_feature
16 /note="2#-deoxy-2#-fluoro"
16
misc_feature
19 /note="2#-deoxy-2#-fluoro"
19
misc_feature
20 /note="2#-deoxy-2#-fluoro"
20
misc_feature
21 /note="n stands for thymidine"
21
/note="3#-3 attached terminal deoxyabasic moiety"
21
Query Match
Best Local Similarity 89.5%; Score 19; DB 1; Length 21;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1714 CAGUACGACGAGACAGU 1732
Db 1 CAGTACGACGAGACAGT 19
RESULT 251
CS096405
LOCUS CS096405 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 230 from Patent WO2005045040.
ACCESSION CS096405
VERSION CS096405.1 GI:66952878
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 230 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
1
misc_feature
3 /note="5#-3 attached terminal deoxyabasic moiety"
3
misc_feature
5 /note="2#-deoxy-2#-fluoro"
5
misc_feature
9 /note="2#-deoxy-2#-fluoro"
9
misc_feature
9 /note="2#-deoxy-2#-fluoro"
9

misc_feature 15
/note="2#-deoxy-2#-fluoro"
18
misc_feature
20 /note="2#-deoxy-2#-fluoro"
20
misc_feature
21 /note="n stands for thymidine"
21
/note="3#-3 attached terminal deoxyabasic moiety"
21
Query Match
Best Local Similarity 89.5%; Score 19; DB 1; Length 21;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1715 AGUACGACGACGACGAC 1733
Db 1 AGTACGACGACGACGAC 19
RESULT 252
CS096406/c
LOCUS CS096406 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 231 from Patent WO2005045040.
ACCESSION CS096406
VERSION CS096406.1 GI:66952879
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 231 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
6
misc_feature
6 /note="2#-deoxy-2#-fluoro"
11
misc_feature
14 /note="2#-deoxy-2#-fluoro"
14
misc_feature
16 /note="2#-deoxy-2#-fluoro"
16
misc_feature
19 /note="2#-deoxy-2#-fluoro"
19
misc_feature
20 /note="2#-deoxy-2#-fluoro"
20
misc_feature
20 /note="n stands for thymidine"
20
/note="Phosphorothioate 3'-Internucleotide linkage"
20
Query Match
Best Local Similarity 73.7%; Score 19; DB 1; Length 21;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 17 ACAGUACACGCGCCUUU 35
Db 19 ACAGTACACGCGCCCTT 1
RESULT 253
CS096407/c
LOCUS CS096407 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 232 from Patent WO2005045040.
ACCESSION CS096407
VERSION CS096407.1 GI:66952880
KEYWORDS

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 226 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
1. .7
/note="2#-deoxy-2#-fluoro"
misc_feature
1
/note="5#-3 attached terminal deoxyabasic moiety"
misc_feature
11. .13
/note="2#-deoxy-2#-fluoro"
misc_feature
16. .18
/note="2#-deoxy-2#-fluoro"
misc_feature
20. .21
/note="n stands for thymidine"
misc_feature
21
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match
Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
Qy 317 UCCUCUAGCCGCGCCUG 335
Db 1 TCCCTTAAAGCTCGGCTTG 19
RESULT 248
LOCUS CS096402 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 227 from Patent WO2005045040.
ACCESSION CS096402
VERSION CS096402.1 GI:66952875
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 227 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
1
/note="5#-3 attached terminal deoxyabasic moiety"
misc_feature
2
/note="2#-deoxy-2#-fluoro"
misc_feature
6
/note="2#-deoxy-2#-fluoro"
misc_feature
10. .11
/note="2#-deoxy-2#-fluoro"
misc_feature
16. .17
/note="2#-deoxy-2#-fluoro"
misc_feature
19
/note="2#-deoxy-2#-fluoro"
misc_feature
20. .21
/note="2#-deoxy-2#-fluoro"

misc_feature
21
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match
Best Local Similarity 94.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1712 AGCAGUACCGACGAGACA 1730
Db 1 AGCAGTACCGACGAGACA 19
RESULT 249
LOCUS CS096403 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 228 from Patent WO2005045040.
ACCESSION CS096403
VERSION CS096403.1 GI:66952876
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 228 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
1
/note="5#-3 attached terminal deoxyabasic moiety"
misc_feature
3
/note="2#-deoxy-2#-fluoro"
misc_feature
6
/note="2#-deoxy-2#-fluoro"
misc_feature
8. .9
/note="2#-deoxy-2#-fluoro"
misc_feature
12
/note="2#-deoxy-2#-fluoro"
misc_feature
18
/note="2#-deoxy-2#-fluoro"
misc_feature
20. .21
/note="2#-deoxy-2#-fluoro"
misc_feature
21
/note="n stands for thymidine"
misc_feature
21
/note="3#-3 attached terminal deoxyabasic moiety"
Query Match
Best Local Similarity 94.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 1712 AGCAGUACCGACGAGACA 1730
Db 1 AGCAGTACCGACGAGACA 19
RESULT 250
LOCUS CS096404 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 229 from Patent WO2005045040.
ACCESSION CS096404
VERSION CS096404.1 GI:66952877
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

```

other sequences; artificial sequences.
REFERENCE
1
AUTHORS
  Richards, I. and Macswigen, J.
TITLE
  RNA interference mediated inhibition of cholinergic muscarinic
  receptor (CHRM3) gene expression using short interfering Nucleic
  Acid (siNA)
JOURNAL
  Patent: WO 2005045040-A 223 19-MAY-2005;
  Sirta Therapeutics, Inc. (US)
FEATURES
  source
    1. .21
    /organism="synthetic construct"
    /mol_type="unassigned RNA"
    /db_xref="taxon:32630"
    /note="Description of Artificial Sequence: siNA sense
    region"
  misc_feature
    1 /note="5#-3 attached terminal deoxyabasic moiety"
    2 /note="2#-deoxy-2'-fluoro"
  misc_feature
    5 /note="2#-deoxy-2'-fluoro"
  misc_feature
    7 /note="2#-deoxy-2'-fluoro"
  misc_feature
    10. .13 /note="2#-deoxy-2'-fluoro"
  misc_feature
    15. .19 /note="2#-deoxy-2'-fluoro"
  misc_feature
    20. .21 /note="2#-deoxy-2'-fluoro"
  misc_feature
    21 /note="n stands for thymidine"
    /note="3#-3 attached terminal deoxyabasic moiety"
Query Match
  1.1%; Score 19; DB 1; Length 21;
  Best Local Similarity 73.7%; Pred. No. 1.1e+02;
  Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY
  17 ACAGUACAACCCGCUUU 35
  |||||:|||||:|||||:
Db
  1 ACAGTACACCTCGCCTT 19

RESULT 245
LOCUS
  CS096399 21 bp RNA linear PAT 03-JUN-2005
DEFINITION
  Sequence 224 from Patent WO2005045040.
ACCESSION
  CS096399
VERSION
  CS096399.1 GI:66952872
KEYWORDS
  .
SOURCE
  synthetic construct
  synthetic construct
  other sequences; artificial sequences.
REFERENCE
  1
AUTHORS
  Richards, I. and Macswigen, J.
TITLE
  RNA interference mediated inhibition of cholinergic muscarinic
  receptor (CHRM3) gene expression using short interfering Nucleic
  Acid (siNA)
JOURNAL
  Patent: WO 2005045040-A 224 19-MAY-2005;
  Sirta Therapeutics, Inc. (US)
FEATURES
  source
    1. .21
    /organism="synthetic construct"
    /mol_type="unassigned RNA"
    /db_xref="taxon:32630"
    /note="Description of Artificial Sequence: siNA sense
    region"
  misc_feature
    1 /note="2#-deoxy-2'-fluoro
    5#-3 attached terminal deoxyabasic moiety"
  misc_feature
    3 /note="2#-deoxy-2'-fluoro"
  misc_feature
    6. .9 /note="2#-deoxy-2'-fluoro"
  misc_feature
    11. .15

```

```

/note="2#-deoxy-2'-fluoro"
17. .19 /note="2#-deoxy-2'-fluoro"
20. .21 /note="n stands for thymidine"
21 /note="3#-3 attached terminal deoxyabasic moiety"
Query Match
  1.1%; Score 19; DB 1; Length 21;
  Best Local Similarity 57.9%; Pred. No. 1.1e+02;
  Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
QY
  21 UACAACCCGCUUUGUU 39
  :|||||:|||||:|||||:
Db
  1 TACAACCTCGCCTTGT 19

RESULT 246
LOCUS
  CS096400 21 bp RNA linear PAT 03-JUN-2005
DEFINITION
  Sequence 225 from Patent WO2005045040.
ACCESSION
  CS096400
VERSION
  CS096400.1 GI:66952873
KEYWORDS
  .
SOURCE
  synthetic construct
  synthetic construct
  other sequences; artificial sequences.
REFERENCE
  1
AUTHORS
  Richards, I. and Macswigen, J.
TITLE
  RNA interference mediated inhibition of cholinergic muscarinic
  receptor (CHRM3) gene expression using short interfering Nucleic
  Acid (siNA)
JOURNAL
  Patent: WO 2005045040-A 225 19-MAY-2005;
  Sirta Therapeutics, Inc. (US)
FEATURES
  source
    1. .21
    /organism="synthetic construct"
    /mol_type="unassigned RNA"
    /db_xref="taxon:32630"
    /note="Description of Artificial Sequence: siNA sense
    region"
  misc_feature
    1. .9 /note="n stands for thymidine"
    /note="5#-3 attached terminal deoxyabasic moiety"
  misc_feature
    13. .15 /note="n stands for thymidine"
  misc_feature
    18. .19 /note="n stands for thymidine"
  misc_feature
    20. .21 /note="n stands for thymidine"
  misc_feature
    21 /note="3#-3 attached terminal deoxyabasic moiety"
Query Match
  1.1%; Score 19; DB 1; Length 21;
  Best Local Similarity 68.4%; Pred. No. 1.1e+02;
  Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY
  315 CUUCCUUAAGCCUGCC 333
  ||::||:|||||:|||||
Db
  1 CTTCCTTTAAGCCTG 19

RESULT 247
LOCUS
  CS096401 21 bp RNA linear PAT 03-JUN-2005
DEFINITION
  Sequence 226 from Patent WO2005045040.
ACCESSION
  CS096401
VERSION
  CS096401.1 GI:66952874
KEYWORDS
  .
SOURCE
  synthetic construct
  synthetic construct
  other sequences; artificial sequences.

```

SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 219 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source 1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature 20. .21
/note="n stands for thymidine"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 975 GCAGUGAGCCAGACCAC 993
|||||:|||||
Db 19 GCAGATGCACGACCAACCAC 1

RESULT 241
CS096395/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 220 from Patent WO2005045040.
DEFINITION CS096395
ACCESSION CS096395.1 GI:66952868
VERSION
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 220 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source 1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
misc_feature 20. .21
/note="n stands for thymidine"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1712 ACCAGUACGACGACAGACA 1730
|||||:|||||
Db 19 AGCAGTACGACGACAGACA 1

RESULT 242
CS096396/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 221 from Patent WO2005045040.
DEFINITION CS096396
ACCESSION CS096396.1 GI:66952869
VERSION
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct

ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 221 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source 1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
misc_feature 20. .21
/note="n stands for thymidine"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1714 CAGUACGACGACGACAGU 1732
|||||:|||||
Db 19 CAGTACGACGACGACAGT 1

RESULT 243
CS096397 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 222 from Patent WO2005045040.
DEFINITION CS096397
ACCESSION CS096397.1 GI:66952870
VERSION
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 222 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source 1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
misc_feature 20. .21
/note="n stands for thymidine"

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1715 AGUACGACGACGACAGUC 1733
|||||:|||||
Db 19 AGTACGACGACGACAGT 1

RESULT 244
CS096398 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 223 from Patent WO2005045040.
DEFINITION CS096398
ACCESSION CS096398.1 GI:66952871
VERSION
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct

VERSION CS096390.1 GI:66952863
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siRNA)
JOURNAL Patent: WO 2005045040-A 215 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1.21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
misc_feature 20..21
/note="n stands for thymidine"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 17 ACAGUACAACCTCGCCUUT 35
DB 19 ACAGTACAACCTCGCCTT 1
RESULT 237
CS096391/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 216 from Patent WO2005045040.
DEFINITION CS096391
ACCESSION CS096391
VERSION CS096391.1 GI:66952864
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siRNA)
JOURNAL Patent: WO 2005045040-A 216 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1.21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
misc_feature 20..21
/note="n stands for thymidine"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
QY 21 UACAACUCCGCUUUGUU 39
DB 19 TACAACCTCGCCTTGT 1
RESULT 238
CS096392/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 217 from Patent WO2005045040.
DEFINITION CS096392
ACCESSION CS096392
VERSION CS096392.1 GI:66952865

KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siRNA)
JOURNAL Patent: WO 2005045040-A 217 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1.21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
misc_feature 20..21
/note="n stands for thymidine"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 315 CUUCUCUUAAGCCUGGCC 333
DB 19 CTTCCTTTAAGCCTTGCC 1
RESULT 239
CS096393/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 218 from Patent WO2005045040.
DEFINITION CS096393
ACCESSION CS096393
VERSION CS096393.1 GI:66952866
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siRNA)
JOURNAL Patent: WO 2005045040-A 218 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1.21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"
misc_feature 20..21
/note="n stands for thymidine"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 317 UCCUCUUAAGCCUGGCC 335
DB 19 TCCTCTTAAGCCTTGCC 1
RESULT 240
CS096394/c 21 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 219 from Patent WO2005045040.
DEFINITION CS096394
ACCESSION CS096394
VERSION CS096394.1 GI:66952867
KEYWORDS

DEFINITION Sequence 211 from Patent WO2005045040.
ACCESSION CS096386
VERSION CS096386.1 GI:66952859
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
TITLE
JOURNAL
Patent: WO 2005045040-A 211 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
20. .21
/note="n stands for thymidine"
Query Match
Best Local Similarity 94.7%; Score 19; DB 1; Length 21;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 975 GCAGATGACCAAGACCAC 993
1 GCAGATGACCAAGACCAC 19
Db

RESULT 233
LOCUS CS096387 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 212 from Patent WO2005045040.
ACCESSION CS096387
VERSION CS096387.1 GI:66952860
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
TITLE
JOURNAL
Patent: WO 2005045040-A 212 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
20. .21
/note="n stands for thymidine"
Query Match
Best Local Similarity 94.7%; Score 19; DB 1; Length 21;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1712 AGCAGUACCGACAGACAGA 1730
1 AGCAGUACCGACAGACAGA 19
Db

RESULT 234
LOCUS CS096388 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 213 from Patent WO2005045040.

ACCESSION CS096388
VERSION CS096388.1 GI:66952861
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
TITLE
JOURNAL
Patent: WO 2005045040-A 213 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
20. .21
/note="n stands for thymidine"
Query Match
Best Local Similarity 89.5%; Score 19; DB 1; Length 21;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1714 CAGUACCGACGAGACAGU 1732
1 CAGTACCGACGAGACAGT 19
Db

RESULT 235
LOCUS CS096389 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 214 from Patent WO2005045040.
ACCESSION CS096389
VERSION CS096389.1 GI:66952862
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
TITLE
JOURNAL
Patent: WO 2005045040-A 214 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
20. .21
/note="n stands for thymidine"
Query Match
Best Local Similarity 89.5%; Score 19; DB 1; Length 21;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1715 AGUACCGACGAGACAGUC 1733
1 AGTACCGACGAGACAGTC 19
Db

RESULT 236
LOCUS CS096390 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 215 from Patent WO2005045040.
ACCESSION CS096390

CS096382 LOCUS CS096382 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 207 from Patent WO2005045040.
ACCESSION CS096382
VERSION CS096382.1 GI:66952855
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
20. .21
/note="n stands for thymidine"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
QY 21 UACACCTCGCCTTGTT 19
Db 1 TACACCTCGCCTTGTT 19
RESULT 230
CS096384

CS096382 LOCUS CS096382 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 207 from Patent WO2005045040.
ACCESSION CS096382
VERSION CS096382.1 GI:66952855
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
20. .21
/note="n stands for thymidine"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
QY 21 UACACCTCGCCTTGTT 19
Db 1 TACACCTCGCCTTGTT 19
RESULT 230
CS096384

LOCUS CS096384 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 209 from Patent WO2005045040.
ACCESSION CS096384
VERSION CS096384.1 GI:66952857
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
20. .21
/note="n stands for thymidine"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 315 CUUCUCUUAAGCCUGGCC 333
Db 1 CTTCCTTAAGCCTGCGCC 19
RESULT 231
CS096385

LOCUS CS096385 21 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 210 from Patent WO2005045040.
ACCESSION CS096385
VERSION CS096385.1 GI:66952858
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA sense region"
misc_feature
20. .21
/note="n stands for thymidine"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 317 UCCUCUUAAGCCUGGCC 335
Db 1 TCCTCTTAAGCCTGCGCCTG 19
RESULT 232
CS096386

other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 198 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source location/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 1753 GCACCCGAGCAGCCUUGU 1771
Db 19 GCACCCGAGCAGCCCTTGT 1

RESULT 224
LOCUS CS207422 19 bp DNA linear PAT 08-DEC-2005
DEFINITION Sequence 130 from Patent WO2005109000.
ACCESSION CS207422
VERSION CS207422.1 GI:83413729
KEYWORDS
SOURCE .
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Spittaels, K.F.
JOURNAL Patent: WO 2005109000-A 130 17-NOV-2005;
Galapagos Genomics N.V. (BE); Spittaels, Koenraad Frederick F. (BE)
FEATURES
source location/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="synthetic oligonucleotide"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 291 GCAGCTGAGAGCGTCAAC 309
Db 1 GCAGCTGAGAGCGTCAAC 19

RESULT 225
LOCUS CS207423 19 bp DNA linear PAT 08-DEC-2005
DEFINITION Sequence 131 from Patent WO2005109000.
ACCESSION CS207423
VERSION CS207423.1 GI:83413730
KEYWORDS
SOURCE .
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Spittaels, K.F.
JOURNAL Patent: WO 2005109000-A 131 17-NOV-2005;
Galapagos Genomics N.V. (BE); Spittaels, Koenraad Frederick F. (BE)
FEATURES
source location/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"

/db_xref="taxon:32630"
/note="synthetic oligonucleotide"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 549 GAGAGCCGCGTGTATGATC 567
Db 1 GAGAGCCGCGTGTATGATC 19

RESULT 226
LOCUS CS207424 19 bp DNA linear PAT 08-DEC-2005
DEFINITION Sequence 132 from Patent WO2005109000.
ACCESSION CS207424
VERSION CS207424.1 GI:83413731
KEYWORDS
SOURCE .
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Spittaels, K.F.
JOURNAL Patent: WO 2005109000-A 132 17-NOV-2005;
Galapagos Genomics N.V. (BE); Spittaels, Koenraad Frederick F. (BE)
FEATURES
source location/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="synthetic oligonucleotide"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 1014 CACCAUAGUAGCUGGCC 1032
Db 1 CACCAUAGUAGCUGTGC 19

RESULT 227
LOCUS CS207425 19 bp DNA linear PAT 08-DEC-2005
DEFINITION Sequence 133 from Patent WO2005109000.
ACCESSION CS207425
VERSION CS207425.1 GI:83413732
KEYWORDS
SOURCE .
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Spittaels, K.F.
JOURNAL Patent: WO 2005109000-A 133 17-NOV-2005;
Galapagos Genomics N.V. (BE); Spittaels, Koenraad Frederick F. (BE)
FEATURES
source location/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="synthetic oligonucleotide"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

OY 1581 UCUGGCGUACUGGUGGC 1599
Db 1 TCTGGGCTACTGGCTGTGC 19

RESULT 228

RESULT 219
 CS096369/c 19 bp RNA
 LOCUS CS096369
 DEFINITION Sequence 194 from Patent WO2005045040.
 ACCESSION CS096369
 VERSION CS096369.1 GI:66952842
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 FEATURES
 source
 1. .19
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 84;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1695 AAAAAGAGCGCAGACAG 1713
 Db 19 AAAAAGAGCGCAGACAG 1

RESULT 220
 CS096370/c 19 bp RNA
 LOCUS CS096370
 DEFINITION Sequence 195 from Patent WO2005045040.
 ACCESSION CS096370
 VERSION CS096370.1 GI:66952843
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 FEATURES
 source
 1. .19
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 84;
 Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1713 GCAGUACGACGACAGACAG 1731
 Db 19 GCAGUACGACGACAGACAG 1

RESULT 221
 CS096371/c 19 bp RNA
 LOCUS CS096371
 DEFINITION Sequence 196 from Patent WO2005045040.

ACCESSION CS096371
 VERSION CS096371.1 GI:66952844
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 FEATURES
 source
 1. .19
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 63.2%; Pred. No. 84;
 Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1731 GCGGCAUUUUCAACAG 1749
 Db 19 GCGGCAUUUUCAACAG 1

RESULT 222
 CS096372/c 19 bp RNA
 LOCUS CS096372
 DEFINITION Sequence 197 from Patent WO2005045040.
 ACCESSION CS096372
 VERSION CS096372.1 GI:66952845
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 FEATURES
 source
 1. .19
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 84;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 GCGGCAUCCGACAGGCC 1767
 Db 19 GCGGCAUCCGACAGGCC 1

RESULT 223
 CS096373/c 19 bp RNA
 LOCUS CS096373
 DEFINITION Sequence 198 from Patent WO2005045040.
 ACCESSION CS096373
 VERSION CS096373.1 GI:66952846
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 FEATURES
 source
 1. .19
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 84;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 84;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1605 CAACAGCACCGTGAACCCC 1623
DB 19 CAACAGCACCGTGAACCCC 1

RESULT 215
LOCUS CS096365/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 190 from Patent WO2005045040.
ACCESSION CS096365
VERSION CS096365.1 GI:66952838
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 190 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
location/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 84;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1623 CGUGGCUAUGCUCUGC 1641
DB 19 CGUGGCUAUGCUCUGC 1

RESULT 216
LOCUS CS096366/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 191 from Patent WO2005045040.
ACCESSION CS096366
VERSION CS096366.1 GI:66952839
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 191 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
location/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1641 CAACAAACAUCGAAACC 1659
DB 19 CAACAAACAUCGAAACC 1

RESULT 217
LOCUS CS096367/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 192 from Patent WO2005045040.
ACCESSION CS096367
VERSION CS096367.1 GI:66952840
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 192 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
location/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1659 CACUUCACAGUCGUCUG 1677
DB 19 CACUUCACAGUCGUCUG 1

RESULT 218
LOCUS CS096368/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 193 from Patent WO2005045040.
ACCESSION CS096368
VERSION CS096368.1 GI:66952841
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 193 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
location/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1677 GCUUGCCAGUGGACAAA 1695
DB 19 GCUUGCCAGUGGACAAA 1

receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 185 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers
1. 19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 84;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1533 UCUGUGAACACCUUUUGU 1551
DB 19 TCTGTGTAACACCTTTGT 1

RESULT 211
LOCUS CS096361 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 186 from Patent WO2005045040.
ACCESSION CS096361
VERSION CS096361.1 GI:66952834
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 186 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source Location/Qualifiers
1. 19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY -1551 UGACAGCUCGCAUACCCCAA 1569
DB 19 TGACAGCTGCAATACCCCAA 1

RESULT 212
LOCUS CS096362 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 187 from Patent WO2005045040.
ACCESSION CS096362
VERSION CS096362.1 GI:66952835
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 187 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source Location/Qualifiers

source 1. 19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1569 AACCUUUUGAAUCUGGCGC 1587
DB 19 AACCTTTGGAATCTGGCC 1

RESULT 213
LOCUS CS096363 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 188 from Patent WO2005045040.
ACCESSION CS096363
VERSION CS096363.1 GI:66952836
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 188 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source Location/Qualifiers
1. 19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1587 CUAUCGUCUGUCUACAU 1605
DB 19 CTACTGCTGTGCTACATC 1

RESULT 214
LOCUS CS096364 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 189 from Patent WO2005045040.
ACCESSION CS096364
VERSION CS096364.1 GI:66952837
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 189 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source Location/Qualifiers
1. 19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

DEFINITION Sequence 181 from Patent WO2005045040.
ACCESSION CS096356
VERSION CS096356.1 GI:66952829
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 181 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source Location/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 84;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1461 GAAGGGCCGACCCCTC 1479
DB 19 GAAGGGCCGACCCCTC 1

RESULT 207
LOCUS CS096357 19 bp RNA
DEFINITION Sequence 182 from Patent WO2005045040.
ACCESSION CS096357
VERSION CS096357.1 GI:66952830
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 182 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source Location/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1479 CAGUGCAUCUGCUGCC 1497
DB 19 CAGTGCATCTTCTTGCC 1

RESULT 208
LOCUS CS096358 19 bp RNA
DEFINITION Sequence 183 from Patent WO2005045040.
ACCESSION CS096358
VERSION CS096358.1 GI:66952831
KEYWORDS
SOURCE synthetic construct

ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 183 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source Location/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1497 CUCACAUCACTUGACC 1515
DB 19 CTTGATCATCATCTTGACC 1

RESULT 209
LOCUS CS096359 19 bp RNA
DEFINITION Sequence 184 from Patent WO2005045040.
ACCESSION CS096359
VERSION CS096359.1 GI:66952832
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 184 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source Location/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1515 CCCAUCACAUCAUGGU 1533
DB 19 CCCATACACATCATGCTT 1

RESULT 210
LOCUS CS096360 19 bp RNA
DEFINITION Sequence 185 from Patent WO2005045040.
ACCESSION CS096360
VERSION CS096360.1 GI:66952833
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic

Matches	15;	Conservative	4;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	1371	CUUGACGAGACCACTCUG	1389						
Db	19	CTTCAGGAGGCACTCTG	1						
RESULT 202									
LOCUS	CS096352/c	19 bp	RNA						
DEFINITION	Sequence 177 from Patent WO2005045040.								
ACCESSION	CS096352								
VERSION	CS096352.1	GI:66952825							
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
AUTHORS	1								
TITLE	Richards, I. and Macawiggen, J.								
	RNA interference mediated inhibition of cholinergic muscarinic								
	receptor (CHRM3) gene expression using short interfering Nucleic								
	Acid (siRNA)								
JOURNAL	Patent: WO 2005045040-A 177 19-MAY-2005;								
FEATURES									
source	1..19								
	Location/Qualifiers								
	/organism="synthetic construct"								
	/mol_type="unassigned RNA"								
	/db_xref="taxon:32630"								
	/note="Description of Artificial Sequence: siNA antisense								
	region"								
Query Match	1.1%;	Score 19;	DB 1;	Length 19;					
Best Local Similarity	73.7%;	Pred. No. 84;							
Matches	14;	Conservative	5;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	1389	GGCCAGAGGUCUCUCUG	1407						
Db	19	GGCCAGAGGTTGCTCTG	1						
RESULT 203									
LOCUS	CS096353/c	19 bp	RNA						
DEFINITION	Sequence 178 from Patent WO2005045040.								
ACCESSION	CS096353								
VERSION	CS096353.1	GI:66952826							
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
AUTHORS	1								
TITLE	Richards, I. and Macawiggen, J.								
	RNA interference mediated inhibition of cholinergic muscarinic								
	receptor (CHRM3) gene expression using short interfering Nucleic								
	Acid (siRNA)								
JOURNAL	Patent: WO 2005045040-A 178 19-MAY-2005;								
FEATURES									
source	1..19								
	Location/Qualifiers								
	/organism="synthetic construct"								
	/mol_type="unassigned RNA"								
	/db_xref="taxon:32630"								
	/note="Description of Artificial Sequence: siNA antisense								
	region"								
Query Match	1.1%;	Score 19;	DB 1;	Length 19;					
Best Local Similarity	89.5%;	Pred. No. 84;							
Matches	17;	Conservative	2;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	1407	GAGACCGAGAGUCAGATC	1425						
Db	19	GAGACCGAGAGTCAATC	1						

[illegible]

FEATURES Location/Qualifiers
source 1.19

/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1299 AGCCGUGACAGCAGCUAG 1317

Db 19 AGCCGTGACACGACTAAG 1

RESULT 198
LOCUS CS096348/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 173 from Patent WO2005045040.
ACCESSION CS096348
VERSION CS096348.1 GI:66952821
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 173 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES 1.19
source /organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 1317 GACUUCGACGUCACUCC 1335
Db 19 GACTCTGACGCTCACTCC 1

RESULT 199
LOCUS CS096349/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 174 from Patent WO2005045040.
ACCESSION CS096349
VERSION CS096349.1 GI:66952822
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 174 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES 1.19
source /organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1335 CUCAGGCGUAGAGCAGC 1353

Db 19 CTCAGTGGGTAGAGCAGC 1

RESULT 200
LOCUS CS096350/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 175 from Patent WO2005045040.
ACCESSION CS096350
VERSION CS096350.1 GI:66952823
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 175 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES 1.19
source /organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 1353 GGCACUCUACUCUCUCC 1371
Db 19 GGCACCTCACTCTGTCC 1

RESULT 201
LOCUS CS096351/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 176 from Patent WO2005045040.
ACCESSION CS096351
VERSION CS096351.1 GI:66952824
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 176 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES 1.19
source /organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;

SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 168 19-MAY-2005;
Sirma Therapeutics, Inc. (US)

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 84;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1227 GCGCCGAGAGCGCGAC 1245
Db 19 GCGCCGAGAGCGCGAC 1

RESULT 194
LOCUS CS096344/C 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 169 from Patent WO2005045040.
ACCESSION CS096344
VERSION CS096344.1 GI:66952817
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 169 19-MAY-2005;
Sirma Therapeutics, Inc. (US)

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1245 CGAGGAGCGAGUUUCCA 1263
Db 19 CGAGGAGCGAGTTTCCA 1

RESULT 195
LOCUS CS096345/C 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 170 from Patent WO2005045040.
ACCESSION CS096345
VERSION CS096345.1 GI:66952818
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.

TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 170 19-MAY-2005;
Sirma Therapeutics, Inc. (US)

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1263 AAAAGCUUCUCCAGCUU 1281
Db 19 AAAAGCTTCTCCAGCTT 1

RESULT 196
LOCUS CS096346/C 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 171 from Patent WO2005045040.
ACCESSION CS096346
VERSION CS096346.1 GI:66952819
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 171 19-MAY-2005;
Sirma Therapeutics, Inc. (US)

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1281 UCCGACUCCAGCUAGAGUCA 1299
Db 19 UCCGATCCAGCTAGACTCA 1

RESULT 197
LOCUS CS096347 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 172 from Patent WO2005045040.
ACCESSION CS096347
VERSION CS096347.1 GI:66952820
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 172 19-MAY-2005;
Sirma Therapeutics, Inc. (US)

Db 19 CTCACCAAGTACCTCA 1

RESULT 189
LOCUS CS096339/c 19 bp RNA
DEFINITION Sequence 164 from Patent WO2005045040.
ACCESSION CS096339
VERSION CS096339.1 GI:66952812

KEYWORDS
SOURCE .
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 164 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1155 ATCGGCAACCTCGAGGTG 1173
Db 19 ATCGGCAACCTCGAGGTG 1

RESULT 190
LOCUS CS096340/c 19 bp RNA
DEFINITION Sequence 165 from Patent WO2005045040.
ACCESSION CS096340
VERSION CS096340.1 GI:66952813

KEYWORDS
SOURCE .
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 165 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1173 GCTUGAGAGAGCUGGCG 1191
Db 19 GCTUGAGAGAGCUGGCG 1

RESULT 191
LOCUS CS096341/c

LOCUS CS096341 19 bp RNA
DEFINITION Sequence 166 from Patent WO2005045040.
ACCESSION CS096341
VERSION CS096341.1 GI:66952814

KEYWORDS
SOURCE .
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 166 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1191 GAUGGUGACUGAGAGC 1209
Db 19 GATGTGACCTTGAGAGG 1

RESULT 192
LOCUS CS096342/c 19 bp RNA
DEFINITION Sequence 167 from Patent WO2005045040.
ACCESSION CS096342
VERSION CS096342.1 GI:66952815

KEYWORDS
SOURCE .
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 167 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 84;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1209 GAAAGCGACAGCTGCAG 1227
Db 19 GAAAGCGACAGCTGCAG 1

RESULT 193
LOCUS CS096343/c 19 bp RNA
DEFINITION Sequence 168 from Patent WO2005045040.
ACCESSION CS096343
VERSION CS096343.1 GI:66952816

KEYWORDS

/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1065 GGACAUUGGCUCCGAGACG 1083

Db 19 GGACATTGGCTCCGAGACG 1

RESULT 195
LOCUS CS096335/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 160 from Patent WO2005045040.
ACCESSION CS096335
VERSION CS096335.1 GI:66952808
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 160 19-MAY-2005;
Sirma Therapeutics, Inc. (US)

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1083 GAGAGCCAUCCUCCAUCC 1101

Db 19 GAGAGCCATCTACTCCATC 1

RESULT 186
LOCUS CS096336/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 161 from Patent WO2005045040.
ACCESSION CS096336
VERSION CS096336.1 GI:66952809
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 161 19-MAY-2005;
Sirma Therapeutics, Inc. (US)

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"

Query Match 1.1%; Score 19; DB 1; Length 19;

Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1101 CGGCTCAGAGCTTCCGGGT 1119

Db 19 CGGCTCAGAGCTTCCGGGT 1

RESULT 187
LOCUS CS096337/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 162 from Patent WO2005045040.
ACCESSION CS096337
VERSION CS096337.1 GI:66952810
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 162 19-MAY-2005;
Sirma Therapeutics, Inc. (US)

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1119 UCACAGCACCACUCCUAC 1137

Db 19 TCACAGCACCACCTCTCAC 1

RESULT 188
LOCUS CS096338/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 163 from Patent WO2005045040.
ACCESSION CS096338
VERSION CS096338.1 GI:66952811
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 163 19-MAY-2005;
Sirma Therapeutics, Inc. (US)

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1137 CUCCAGCAGUUAUCCUCA 1155

1:|||||:|||||:|||||:|||||

AUTHORS	Richards, I. and Macwigggen, J.			
TITLE	RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)			
JOURNAL	Patent: WO 2005045040-A 155 19-MAY-2005;			
FEATURES	SiRNA Therapeutics, Inc (US)			
source	1. .19 /organism="synthetic construct" /mol_type="unassigned RNA" /db_xref="taxon:32630" /note="Description of Artificial Sequence: siNA antisense region"			
Query Match	1.1%;	Score 19;	DB 1;	Length 19;
Best Local Similarity	84.2%;	Pred. NO. 84;		
Matches	16;	Conservative 3;	Mismatches 0;	Indels 0;
Db	993	CAGCAGCAGUGACAGUCG3	1011	
	19	CAGCAGCAGTGCACGTTG3	1	
RESULT 181				
LOCUS	CS096331/c	19 bp	RNA	linear
DEFINITION	Sequence 156 from Patent WO2005045040.			
ACCESSION	CS096331			
VERSION	CS096331.1	GI:66952804		
KEYWORDS	. synthetic construct synthetic construct other sequences; artificial sequences.			
REFERENCE	1			
AUTHORS	Richards, I. and Macwigggen, J.			
TITLE	RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)			
JOURNAL	Patent: WO 2005045040-A 156 19-MAY-2005;			
FEATURES	SiRNA Therapeutics, Inc. (US)			
source	1. .19 Location/Qualifiers /organism="synthetic construct" /mol_type="unassigned RNA" /db_xref="taxon:32630" /note="Description of Artificial Sequence: siNA antisense region"			
Query Match	1.1%;	Score 19;	DB 1;	Length 19;
Best Local Similarity	78.9%;	Pred. NO. 84;		
Matches	15;	Conservative 4;	Mismatches 0;	Indels 0;
Db	1011	GAACACCAUAGAUGCUGCU	1029	
	19	GAACACCAATGATGCTGCT	1	
RESULT 182				
LOCUS	CS096332/c	19 bp	RNA	linear
DEFINITION	Sequence 157 from Patent WO2005045040.			
ACCESSION	CS096332			
VERSION	CS096332.1	GI:66952805		
KEYWORDS	. synthetic construct synthetic construct other sequences; artificial sequences.			
REFERENCE	1			
AUTHORS	Richards, I. and Macwigggen, J.			
TITLE	RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)			
JOURNAL	Patent: WO 2005045040-A 157 19-MAY-2005;			

FEATURES	Sirma Therapeutics, Inc. (US)
source	Location/Qualifiers
	1..19
	/organism="synthetic construct"
	/mol_type="unassigned RNA"
	/db_xref="taxon:32630"
	/note="Description of Artificial Sequence: siRNA antisense region"
Query Match	1.1%; Score 19; DB 1; Length 19;
Best Local Similarity	78.9%; Pred. No. 84;
Matches	15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY	1029 UGCCUCCCGAGAACUCC 1047
DB	19 TGCCCTCCCTCGAGAACTCC 1
RESULT 183	
LOCUS	CS096333/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION	Sequence 158 from Patent WO2005045040.
ACCESSION	CS096333
VERSION	CS096333.1 GI:66952806
KEYWORDS	.
SOURCE	synthetic construct
ORGANISM	synthetic construct
REFERENCE	other sequences; artificial sequences.
1	
AUTHORS	Richards, I. and Macswiggen, J.
TITLE	RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL	Patent: WO 2005045040-A 158 19-MAY-2005;
FEATURES	Sirma Therapeutics, Inc. (US)
source	Location/Qualifiers
	1..19
	/organism="synthetic construct"
	/mol_type="unassigned RNA"
	/db_xref="taxon:32630"
	/note="Description of Artificial Sequence: siNA antisense region"
Query Match	1.1%; Score 19; DB 1; Length 19;
Best Local Similarity	89.5%; Pred. No. 84;
Matches	17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY	1047 GCGCUCCCGACGAGAG 1065
DB	19 GCGCTCCTCGACGAGAG 1
RESULT 184	
LOCUS	CS096334 19 bp RNA linear PAT 03-JUN-2005
DEFINITION	Sequence 159 from Patent WO2005045040.
ACCESSION	CS096334
VERSION	CS096334.1 GI:66952807
KEYWORDS	.
SOURCE	synthetic construct
ORGANISM	synthetic construct
REFERENCE	other sequences; artificial sequences.
1	
AUTHORS	Richards, I. and Macswiggen, J.
TITLE	RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL	Patent: WO 2005045040-A 159 19-MAY-2005;
FEATURES	Sirma Therapeutics, Inc. (US)
source	Location/Qualifiers
	1..19
	/organism="synthetic construct"
	/mol_type="unassigned RNA"

CS096326/c
 LOCUS CS096326 19 bp RNA linear PAT 03-JUN-2005
 DEFINITION Sequence 151 from Patent WO2005045040.
 ACCESSION CS096326
 VERSION CS096326.1 GI:66952799
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 FEATURES
 source
 1. 19
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 73.7%; Pred. No. 84;
 Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 921 GUAGGCGCGCCGACUUC 939
 Db 19 GTATGCGCCCTGCCACTTC 1

RESULT 177
 LOCUS CS096327/c 19 bp RNA linear PAT 03-JUN-2005
 DEFINITION Sequence 152 from Patent WO2005045040.
 ACCESSION CS096327
 VERSION CS096327.1 GI:66952800
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 FEATURES
 source
 1. 19
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 84;
 Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 939 CUGGUCACCAACGAGC 957
 Db 19 CTGGTTCACCAACGAGC 1

RESULT 178
 LOCUS CS096328/c 19 bp RNA linear PAT 03-JUN-2005
 DEFINITION Sequence 153 from Patent WO2005045040.
 ACCESSION CS096328
 VERSION CS096328.1 GI:66952801

KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 FEATURES
 source
 1. 19
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 84;
 Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 957 CUGAAACCCAGCUCGAG 975
 Db 19 CTGAAACCCAGCTCCGAG 1

RESULT 179
 LOCUS CS096329/c 19 bp RNA linear PAT 03-JUN-2005
 DEFINITION Sequence 154 from Patent WO2005045040.
 ACCESSION CS096329
 VERSION CS096329.1 GI:66952802
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 AUTHORS
 TITLE
 JOURNAL
 FEATURES
 source
 1. 19
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 84;
 Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 975 GCAGATGACCAAGACCAC 993
 Db 19 GCAGATGACCAAGACCAC 1

RESULT 180
 LOCUS CS096330/c 19 bp RNA linear PAT 03-JUN-2005
 DEFINITION Sequence 155 from Patent WO2005045040.
 ACCESSION CS096330
 VERSION CS096330.1 GI:66952803
 KEYWORDS
 SOURCE
 ORGANISM
 REFERENCE
 1
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 831 AGAAAACTTGTTCACCCC 849
Db 19 AGAAAACTTGTTCACCCC 1

RESULT 172
LOCUS CS096322/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 147 from Patent WO2005045040.
ACCESSION CS096322
VERSION CS096322.1 GI:66952795
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswigen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 147 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 849 CACGGCGAGUUCGAGC 867
Db 19 CACGGCGAGUUCGAGC 1

RESULT 173
LOCUS CS096323/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 148 from Patent WO2005045040.
ACCESSION CS096323
VERSION CS096323.1 GI:66952796
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswigen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 148 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 867 CUGCAGAGUUGAGAACTU 885

Db 19 CTGCAGAGTTACGACTT 1

RESULT 174
LOCUS CS096324 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 149 from Patent WO2005045040.
ACCESSION CS096324
VERSION CS096324.1 GI:66952797
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswigen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 149 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 885 UCAACAGCAAGCAUGAAA 903
Db 19 TCAACAGCAAGCATGAAA 1

RESULT 175
LOCUS CS096325 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 150 from Patent WO2005045040.
ACCESSION CS096325
VERSION CS096325.1 GI:66952798
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswigen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 150 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 84;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 903 ACGCUCACAGAGAGAG 921
Db 19 ACGCTCAACAGAGAGAG 1

RESULT 176

JOURNAL Patent: WO 2005045040-A 142 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1.19

/mol_type="synthetic construct"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 759 GAUCUUAAGAAACUGAA 777
DB 19 GATCTATAAGAAACTGAA 1

RESULT 168
CS096318/c 19 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 143 from Patent WO2005045040.
DEFINITION CS096318
ACCESSION CS096318.1 GI:66952791
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 143 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1.19

/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 777 AAAGCGUACCAAGAGCUU 795
DB 19 AAAGCGTACCAAGAGCTT 1

RESULT 169
CS096319/c 19 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 144 from Patent WO2005045040.
DEFINITION CS096319
ACCESSION CS096319.1 GI:66952792
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 144 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1.19

/organism="synthetic construct"

/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 795 UGCGGCCUGCAAGCCUCU 813
DB 19 TGCTGCGCTGCAAGCCTCT 1

RESULT 170
CS096320/c 19 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 145 from Patent WO2005045040.
DEFINITION CS096320
ACCESSION CS096320.1 GI:66952793
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 145 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1.19

/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 84;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 813 UGGACAGAGCGCAGAGACA 831
DB 19 TGGAGACAGAGCGCAGAGACA 1

RESULT 171
CS096321/c 19 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 146 from Patent WO2005045040.
DEFINITION CS096321
ACCESSION CS096321.1 GI:66952794
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 146 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1.19

/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

VERSION CS096313.1 GI:66952786
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 138 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES 1. 19
source Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

OY 687 CACCAUACUUGGACCA 705
Db 19 CACCACTACTTTGGCACA 1

RESULT 164
LOCUS CS096314/c 19 bp RNA
DEFINITION Sequence 139 from Patent WO2005045040.
ACCESSION CS096314
VERSION CS096314.1 GI:66952787
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 139 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES 1. 19
source Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 84;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

OY 705 AGCCAUCCGCGCUUUUAU 723
Db 19 AGCCATCGCTCTTTTAT 1

RESULT 165
LOCUS CS096315/c 19 bp RNA
DEFINITION Sequence 140 from Patent WO2005045040.
ACCESSION CS096315
VERSION CS096315.1 GI:66952788
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 140 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES 1. 19
source Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 84;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

OY 723 UAUCCUGUACCAUUAUG 741
Db 19 TATGCTGTACCAATTATG 1

RESULT 166
LOCUS CS096316/c 19 bp RNA
DEFINITION Sequence 141 from Patent WO2005045040.
ACCESSION CS096316
VERSION CS096316.1 GI:66952789
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 141 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES 1. 19
source Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 84;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

OY 741 GACUUAUUUAACUGAGG 759
Db 19 GACTATTTTATCTGAGG 1

RESULT 167
LOCUS CS096317/c 19 bp RNA
DEFINITION Sequence 142 from Patent WO2005045040.
ACCESSION CS096317
VERSION CS096317.1 GI:66952790
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

QY 597 UUGGCGCUCGCGCAUCUG 615
DB 19 TTGGGCTCTGCGCATCTTG 1

RESULT 159

CS096309/c 19 bp RNA linear PAT 03-JUN-2005
Sequence 134 from Patent WO2005045040.

DEFINITION CS096309
ACCESSION CS096309.1 GI:66952782
KEYWORDS
SOURCE
ORGANISM

synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 134 19-MAY-2005;
Sirma Therapeutics, Inc. (US)

FEATURES 1.19
source Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 84;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 615 GUUCUGCAUAUCUUGUU 633
DB 19 GTTCTGCAATACCTTGT 1

RESULT 160

CS096310/c 19 bp RNA linear PAT 03-JUN-2005
Sequence 135 from Patent WO2005045040.

DEFINITION CS096310
ACCESSION CS096310.1 GI:66952783
KEYWORDS
SOURCE

ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 135 19-MAY-2005;
Sirma Therapeutics, Inc. (US)

FEATURES 1.19
source Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 633 UGGAAGAGAAUCUGCCU 651
DB 19 TGGAAAGAGAACTGTGCTT 1

RESULT 161
CS096311/c 19 bp RNA linear PAT 03-JUN-2005
Sequence 136 from Patent WO2005045040.

DEFINITION CS096311
ACCESSION CS096311.1 GI:66952784
KEYWORDS
SOURCE

ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 136 19-MAY-2005;
Sirma Therapeutics, Inc. (US)

FEATURES 1.19
source Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 651 UCCGGAGAGUGCUCUACUU 669
DB 19 TCCGGAGAGTGTCTCAT 1

RESULT 162

CS096312/c 19 bp RNA linear PAT 03-JUN-2005
Sequence 137 from Patent WO2005045040.

DEFINITION CS096312
ACCESSION CS096312.1 GI:66952785
KEYWORDS
SOURCE

ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 137 19-MAY-2005;
Sirma Therapeutics, Inc. (US)

FEATURES 1.19
source Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 669 UCAGUCUCUAGAGAGCC 687
DB 19 TCAGTCTCAGAGAGCCC 1

RESULT 163

CS096313/c 19 bp RNA linear PAT 03-JUN-2005
Sequence 138 from Patent WO2005045040.

DEFINITION CS096313
ACCESSION CS096313

/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 84;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 525 GAACGAGCCAAACGAACA 543
|:|||||
Db 19 GTACGAGCCAAACGAACA 1

RESULT 155
LOCUS CS096305 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 130 from Patent WO2005045040.
ACCESSION CS096305
VERSION CS096305.1 GI:66952778
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 130 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers 1. 19
FEATURES
source /organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 543 AACAAAGAGCCGGUG 561
|:|||||
Db 19 AACAAAGAGCCGGUGTG 1

RESULT 156
LOCUS CS096306 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 131 from Patent WO2005045040.
ACCESSION CS096306
VERSION CS096306.1 GI:66952779
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 131 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers 1. 19
FEATURES
source /organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 561 GAUGAUCGUGUCGUCUGG 579
|:|||||
Db 19 GATGATCGGTCGTGCTTGG 1

RESULT 157
LOCUS CS096307 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 132 from Patent WO2005045040.
ACCESSION CS096307
VERSION CS096307.1 GI:66952780
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 132 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers 1. 19
FEATURES
source /organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 84;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

Qy 579 GGUCAUCCUUGUCCU 597
|:|||||
Db 19 GGCATCTCTTGTGCTT 1

RESULT 158
LOCUS CS096308 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 133 from Patent WO2005045040.
ACCESSION CS096308
VERSION CS096308.1 GI:66952781
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 133 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers 1. 19
FEATURES
source /organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 84;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 125 19-MAY-2005;
Sirma Therapeutics, Inc (US)
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 453 CAGCAAGCCUCUUAUG 471
|||||:|||||:|||||
19 CAGCAATGCTCTGTATG 1

RESULT 151
LOCUS CS096301/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 126 from Patent WO2005045040.
ACCESSION CS096301
VERSION CS096301.1 GI:66952774
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 126 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 471 GAUCUCUGUCACG 489
|||||:|||||:|||||
19 GAATCTTCGTGTCATCAGC 1

RESULT 152
LOCUS CS096302/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 127 from Patent WO2005045040.
ACCESSION CS096302
VERSION CS096302.1 GI:66952775
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic

Acid (siNA)
JOURNAL Patent: WO 2005045040-A 127 19-MAY-2005;
Sirma Therapeutics, Inc (US)
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 84;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 489 CUUGACAGACUCUUCC 507
|||||:|||||:|||||
19 CTTTGACAGTACTTTCC 1

RESULT 153
LOCUS CS096303/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 128 from Patent WO2005045040.
ACCESSION CS096303
VERSION CS096303.1 GI:66952776
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 128 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 507 CAUCACGAGCGCGUCACG 525
|||||:|||||:|||||
19 CATCAGAGCGCGCTCAGC 1

RESULT 154
LOCUS CS096304 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 129 from Patent WO2005045040.
ACCESSION CS096304
VERSION CS096304.1 GI:66952777
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 129 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1. .19

RESULT 146
CS096296/c 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096296 Sequence 121 from Patent WO2005045040.
DEFINITION CS096296
ACCESSION CS096296
VERSION CS096296.1 GI:66952769
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 121 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 381 CUACAUCAUCAUGAUGA 399
Db 19 CTACATCATCATGATCGA 1

RESULT 147
CS096297/c 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096297 Sequence 122 from Patent WO2005045040.
DEFINITION CS096297
ACCESSION CS096297
VERSION CS096297.1 GI:66952770
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 122 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 399 AUGGCGCUUAGGGAACUG 417
Db 19 ATGGCGCTTAGGGAACCTTG 1

RESULT 148
CS096298 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096298 Sequence 123 from Patent WO2005045040.
DEFINITION

ACCESSION CS096298
VERSION CS096298.1 GI:66952771
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 123 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

OY 417 GGCCUGGACUCUGGCUU 435
Db 19 GGCCUGGACUCUGGCUU 1

RESULT 149
CS096299 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096299 Sequence 124 from Patent WO2005045040.
DEFINITION CS096299
ACCESSION CS096299
VERSION CS096299.1 GI:66952772
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 124 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 435 UGCCAUUGACUACGUAGCC 453
Db 19 TGCCATTGACTACGTAGCC 1

RESULT 150
CS096300/c 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096300 Sequence 125 from Patent WO2005045040.
DEFINITION CS096300
ACCESSION CS096300
VERSION CS096300.1 GI:66952773
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct

region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 291 GCAGCUGAAGCGUCAC 309
DB 19 GCAGCTGAAGACGCTCAC 1

RESULT 142
LOCUS CS096292/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 117 from Patent WO2005045040.
ACCESSION CS096292
VERSION CS096292.1 GI:66952765
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 117 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 309 CAACTACUCCUCCUUAAGC 327
DB 19 CAACTACTTCTCTTAAGC 1

RESULT 143
LOCUS CS096293/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 118 from Patent WO2005045040.
ACCESSION CS096293
VERSION CS096293.1 GI:66952766
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 118 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 327 CCUGGCCUGGCCGAUVC 345
DB 19 CCGGCTTGCGCGATCTG 1

RESULT 144
LOCUS CS096294/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 119 from Patent WO2005045040.
ACCESSION CS096294
VERSION CS096294.1 GI:66952767
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 119 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 84;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 345 GAUUAUCGGGUGAUUUA 363
DB 19 GATTATCGGGTCATTCA 1

RESULT 145
LOCUS CS096295/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 120 from Patent WO2005045040.
ACCESSION CS096295
VERSION CS096295.1 GI:66952768
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 120 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 363 AAUGAUCUGUUAAGACC 381
DB 19 AATGAATCTGTTCAGACC 1

receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 112 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 219 CUUACGGGCAUCCUGGCC 237
19 CTTAACGGGCATCTCGCC 1

RESULT 138
CS096288/c 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096288
DEFINITION Sequence 113 from Patent WO2005045040.
ACCESSION CS096288
VERSION CS096288.1 GI:66952761
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS 1
TITLE Richards, I. and Macswiggen, J.
JOURNAL RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 113 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 237 CUGGUGACCAUCCGCGC 255
19 CTTGGTACCATCATCGGC 1

RESULT 139
CS096289/c 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096289
DEFINITION Sequence 114 from Patent WO2005045040.
ACCESSION CS096289
VERSION CS096289.1 GI:66952762
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS 1
TITLE Richards, I. and Macswiggen, J.
JOURNAL RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 114 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

source
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 255 CAACAUCGUGAUAUUGUG 273
19 CAACATCTGTGTAATTGTG 1

RESULT 140
CS096290/c 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096290
DEFINITION Sequence 115 from Patent WO2005045040.
ACCESSION CS096290
VERSION CS096290.1 GI:66952763
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS 1
TITLE Richards, I. and Macswiggen, J.
JOURNAL RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 115 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 273 GUCAUUAAGUCACACAG 291
19 GTCAATTAAAGTCAACAG 1

RESULT 141
CS096291/c 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096291
DEFINITION Sequence 116 from Patent WO2005045040.
ACCESSION CS096291
VERSION CS096291.1 GI:66952764
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS 1
TITLE Richards, I. and Macswiggen, J.
JOURNAL RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 116 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

DEFINITION Sequence 108 from Patent WO2005045040.
ACCESSION CS096283
VERSION CS096283.1 GI:66952756
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 147 CUCCUCCAGACGGUACC 165
DB 19 CTCTCTCCAGACGGTACC 1

RESULT 134
LOCUS CS096284 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 109 from Patent WO2005045040.
ACCESSION CS096284
VERSION CS096284.1 GI:66952757
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 165 CACCGAUGACCCUCUGGA 183
DB 19 CACCGATGACCTTGGA 1

RESULT 135
LOCUS CS096285 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 110 from Patent WO2005045040.
ACCESSION CS096285
VERSION CS096285.1 GI:66952758
KEYWORDS
SOURCE
synthetic construct

ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 183 AGGUCANACCGUCUGCAA 201
DB 19 AGTCATACCGCTGCGAA 1

RESULT 136
LOCUS CS096286 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 111 from Patent WO2005045040.
ACCESSION CS096286
VERSION CS096286.1 GI:66952759
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 84;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 201 AGUGUCUACUCCGUCUC 219
DB 19 ACTGCTTCATCGCTTTC 1

RESULT 137
LOCUS CS096287 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 112 from Patent WO2005045040.
ACCESSION CS096287
VERSION CS096287.1 GI:66952760
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
synthetic construct
synthetic construct
other sequences; artificial sequences.
Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Oy 57 CUGAUAACAGCCCTCC 75
Db 19 CTGATACAGACCCCTCC 1

RESULT 129
CS096279/c
LOCUS CS096279 19 bp RNA
DEFINITION Sequence 104 from Patent WO2005045040.
ACCESSION CS096279
VERSION CS096279.1 GI:66952752
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 104 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"

JOURNAL
Patent: WO 2005045040-A 104 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers
1..19

FEATURES
source

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Oy 75 CGAUGCAGGCGCCCG 93
Db 19 CGATCGAGGCGCTCCCG 1

RESULT 130
CS096280/c
LOCUS CS096280 19 bp RNA
DEFINITION Sequence 105 from Patent WO2005045040.
ACCESSION CS096280
VERSION CS096280.1 GI:66952753
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 105 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"

JOURNAL
Patent: WO 2005045040-A 105 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers
1..19

FEATURES
source

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Oy 93 GGAACCGUCACUCAUUC 111
Db 19 GGGAAACCGTCACTTTC 1

RESULT 131
CS096281/c
LOCUS CS096281 19 bp RNA
DEFINITION Sequence 106 from Patent WO2005045040.
ACCESSION CS096281
VERSION CS096281.1 GI:66952754
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 106 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"

JOURNAL
Patent: WO 2005045040-A 106 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers
1..19

FEATURES
source

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Oy 111 CGGACGCUACAUGUUCU 129
Db 19 CGGACGCTACAAAGTTCT 1

RESULT 132
CS096282/c
LOCUS CS096282 19 bp RNA
DEFINITION Sequence 107 from Patent WO2005045040.
ACCESSION CS096282
VERSION CS096282.1 GI:66952755
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 107 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"

JOURNAL
Patent: WO 2005045040-A 107 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers
1..19

FEATURES
source

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Oy 129 UCGACGACGUGCAUUC 147
Db 19 TCGACGACGTGCAATTC 1

RESULT 133
CS096283/c
LOCUS CS096283 19 bp RNA
DEFINITION Sequence 108 from Patent WO2005045040.
ACCESSION CS096283
VERSION CS096283.1 GI:66952756
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 108 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense
region"

JOURNAL
Patent: WO 2005045040-A 108 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers
1..19

FEATURES
source

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Oy 147 UCGACGACGUGCAUUC 147
Db 19 TCGACGACGTGCAATTC 1

FEATURES
source
1.19
/note="Description of Artificial Sequence: s1NA antisense region"

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1753 GCACCCGAGCAGCCUUGU 1771
1 GCACCCGAGCAGCCCTTGT 19

RESULT 125
LOCUS CS096275/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 100 from Patent WO2005045040.
ACCESSION CS096275
VERSION CS096275.1 GI:66952748
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macawiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 100 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 3 GACCTUGCAUAUACAGU 21
19 GACCTTGACATATACAGT 1

RESULT 126
LOCUS CS096276/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 101 from Patent WO2005045040.
ACCESSION CS096276
VERSION CS096276.1 GI:66952749
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macawiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 101 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

/note="Description of Artificial Sequence: siNA antisense region"

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 21 UACAACCTGCGCTTGT 39
19 TACAACCTGCGCTTGT 1

RESULT 127
LOCUS CS096277/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 102 from Patent WO2005045040.
ACCESSION CS096277
VERSION CS096277.1 GI:66952750
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macawiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 102 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 39 UCAAAACAUACGCTCC 57
19 TCAAAACATCAGCTCTCC 1

RESULT 128
LOCUS CS096278/c 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 103 from Patent WO2005045040.
ACCESSION CS096278
VERSION CS096278.1 GI:66952751
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macawiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 103 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: siNA antisense region"

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 19;
Matches 84.2%; Pred. No. 84;

SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 95 19-MAY-2005;
FEATURES
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1695 AAAAAAGAGCGCGCAGCAG 1713
DB 1 AAAAAAGAGCGCGCAGCAG 19
RESULT 121
LOCUS CS096271 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 96 from Patent WO2005045040.
ACCESSION CS096271.1 GI:66952744
VERSION CS096271.1 GI:66952744
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 96 19-MAY-2005;
FEATURES
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 84;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 1713 GCAGUACGACGACGACG 1731
DB 1 GCAGTACGACGACGACG 19
RESULT 122
LOCUS CS096272 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 97 from Patent WO2005045040.
ACCESSION CS096272
VERSION CS096272.1 GI:66952745
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.

TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 97 19-MAY-2005;
FEATURES
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 84;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
OY 1731 GCGGUCANUUUUCACAG 1749
DB 1 GCGGTCATTTTCACAG 19
RESULT 123
LOCUS CS096273 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 98 from Patent WO2005045040.
ACCESSION CS096273
VERSION CS096273.1 GI:66952746
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 98 19-MAY-2005;
FEATURES
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1749 GCGGCAACCCGACGAGCC 1767
DB 1 GCGGCAACCCGACGAGCC 19
RESULT 124
LOCUS CS096274 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 99 from Patent WO2005045040.
ACCESSION CS096274
VERSION CS096274.1 GI:66952747
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 99 19-MAY-2005;
FEATURES
source 1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Db 1 CAACAGACCGTGAACCC 19

RESULT 116

LOCUS CS096266 19 bp RNA
DEFINITION Sequence 91 from Patent WO2005045040.
ACCESSION CS096266
VERSION CS096266.1 GI:66952739
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macawiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 91 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 84;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 1623 CGUGGCUAUGCUCUGC 1641

Db 1 GGTGCTAGCTCTGTGC 19

RESULT 117

LOCUS CS096267 19 bp RNA
DEFINITION Sequence 92 from Patent WO2005045040.
ACCESSION CS096267
VERSION CS096267.1 GI:66952740
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macawiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 92 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1641 CAACAAAACAUUCAGACC 1659

Db 1 CAACAAAACATTGAGACC 19

RESULT 118

CS096268

LOCUS CS096268 19 bp RNA
DEFINITION Sequence 93 from Patent WO2005045040.
ACCESSION CS096268
VERSION CS096268.1 GI:66952741
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macawiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 93 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1659 CACUUCAGAGUCGUCG 1677

Db 1 CACTTCAAGATGCTGCTG 19

RESULT 119

LOCUS CS096269 19 bp RNA
DEFINITION Sequence 94 from Patent WO2005045040.
ACCESSION CS096269
VERSION CS096269.1 GI:66952742
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macawiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 94 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1677 GCUUGCCAGUGUGACAA 1695

Db 1 GCTGCGCAGTGTGACAA 19

RESULT 120

LOCUS CS096270 19 bp RNA
DEFINITION Sequence 95 from Patent WO2005045040.
ACCESSION CS096270
VERSION CS096270.1 GI:66952743
KEYWORDS

/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 84;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1533 UUGUGAAGACCCUUUGU 1551
:|||||:|||||:|||||:
Db 1 TCTGGGAACACCTTTTGT 19

RESULT 112

LOCUS CS096262 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 87 from Patent WO2005045040.
ACCESSION CS096262
VERSION CS096262.1 GI:66952735
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, J. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 87 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1551 UGACAGCUGCAUACCCAAA 1569
:|||||:|||||:|||||:
Db 1 TGACAGCTGCAATACCCAAA 19

RESULT 113
LOCUS CS096263 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 88 from Patent WO2005045040.
ACCESSION CS096263
VERSION CS096263.1 GI:66952736
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, J. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 88 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;

Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1569 AACCUUUGAAUCCGGGC 1587
|||||:|||||:|||||:
Db 1 AACCTTTGGAACTGGGC 19

RESULT 114
LOCUS CS096264 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 89 from Patent WO2005045040.
ACCESSION CS096264
VERSION CS096264.1 GI:66952737
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, J. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 89 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1587 CUACUGCUGUCUACAU 1605
:|||||:|||||:|||||:
Db 1 CTACTGGCTGCTACATC 19

RESULT 115
LOCUS CS096265 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 90 from Patent WO2005045040.
ACCESSION CS096265
VERSION CS096265.1 GI:66952738
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, J. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 90 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 84;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1605 CAACAGACCCUGAACCC 1623
|||||:|||||:|||||:

AUTHORS Richards, I. and Macewiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 82 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 84;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1461 GAAAGCGGCCGAGCCCTC 1479
Db 1 GAAAGCGGCCGAGCCCTC 19

RESULT 108
LOCUS CS096258 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 83 from Patent WO2005045040.
ACCESSION CS096258
VERSION CS096258.1 GI:66952731
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macewiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 83 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1479 CAGTCCGATCTTGCTGCC 1497
Db 1 CAGTCCGATCTTGCTGCC 19

RESULT 109
LOCUS CS096259 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 84 from Patent WO2005045040.
ACCESSION CS096259
VERSION CS096259.1 GI:66952732
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macewiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 84 19-MAY-2005;

Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1497 CTTCAATCACTTGAGCC 1515
Db 1 CTTCAATCACTTGAGCC 19

RESULT 110
LOCUS CS096260 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 85 from Patent WO2005045040.
ACCESSION CS096260
VERSION CS096260.1 GI:66952733
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macewiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 85 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1515 CCCAUAACAUAUGGU 1533
Db 1 CCCAUAACAUAUGGU 19

RESULT 111
LOCUS CS096261 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 86 from Patent WO2005045040.
ACCESSION CS096261
VERSION CS096261.1 GI:66952734
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macewiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 86 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"

CS096253 LOCUS CS096253 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 78 from Patent WO2005045040.
ACCESSION CS096253
VERSION CS096253.1 GI:66952726
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 78 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 1389 GGCCAGAGGUGUCUG 1407
Db 1 GGCCAGAGGTTGCTCTG 19

RESULT 104
LOCUS CS096254 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 79 from Patent WO2005045040.
ACCESSION CS096254
VERSION CS096254.1 GI:66952727
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 79 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1407 GAAGCCGAGAGUCAGAGC 1425
Db 1 GAAGCCGAGAGTCAGATC 19

RESULT 105
LOCUS CS096255 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 80 from Patent WO2005045040.
ACCESSION CS096255
VERSION CS096255.1 GI:66952728

KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 80 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1425 CACUAGCGGAAAAGAGUG 1443
Db 1 CACTAGCGGAAAAGATG 19

RESULT 106
LOCUS CS096256 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 81 from Patent WO2005045040.
ACCESSION CS096256
VERSION CS096256.1 GI:66952729
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 81 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1443 GUCCUGGUCAGAGAGAG 1461
Db 1 GTCCCTGCTCAAGAGAG 19

RESULT 107
LOCUS CS096257 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 82 from Patent WO2005045040.
ACCESSION CS096257
VERSION CS096257.1 GI:66952730
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE
1

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 1299 AGCCGUGACACGCUAG 1317
|||||:|||||:|||||
DB 1 AGCCGTGACACGCTAAG 19

RESULT 99
LOCUS CS096249 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 74 from Patent WO2005045040.
ACCESSION CS096249
VERSION CS096249.1 GI:66952722
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 74 19-MAY-2005; Sirta Therapeutics, Inc. (US)
FEATURES
1.19
source Location/Qualifiers

1
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 1317 GACUUCGACGUCACUCC 1335
|||||:|||||:|||||
DB 1 GACTTCTACGTCACCTCC 19

RESULT 100
LOCUS CS096250 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 75 from Patent WO2005045040.
ACCESSION CS096250
VERSION CS096250.1 GI:66952723
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 75 19-MAY-2005; Sirta Therapeutics, Inc. (US)
FEATURES
1.19
source Location/Qualifiers

1
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 1335 CUCAGUGGUAAGACAG 1353

DB 1 CTAAGTGGTAAGACAG 19
|||||:|||||:|||||

RESULT 101
LOCUS CS096251 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 76 from Patent WO2005045040.
ACCESSION CS096251
VERSION CS096251.1 GI:66952724
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 76 19-MAY-2005; Sirta Therapeutics, Inc. (US)
FEATURES
1.19
source Location/Qualifiers

1
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 1353 GGCACUCUACUCUCC 1371
|||||:|||||:|||||
DB 1 GGCACCTCTACTCTGTC 19

RESULT 102
LOCUS CS096252 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 77 from Patent WO2005045040.
ACCESSION CS096252
VERSION CS096252.1 GI:66952725
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 77 19-MAY-2005; Sirta Therapeutics, Inc. (US)
FEATURES
1.19
source Location/Qualifiers

1
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 1371 CUCACAGAGCCACUCUG 1389
|||||:|||||:|||||
DB 1 CTTCAAGAGCCACCTCG 19

RESULT 103

JOURNAL Patent: WO 2005045040-A 69 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 84;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1227 GGGCCGAAGAGCGTGGAC 1245
|||||
Db 1 GGCCCGAAGAGCGTGGAC 19

RESULT 95
CS096245 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096245
DEFINITION Sequence 70 from Patent WO2005045040.
ACCESSION CS096245
VERSION CS096245.1 GI:66952718
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 70 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1245 CGAUGAGGCGAGUUNCCA 1263
|||||
Db 1 CGATGAGGCGAGTTCCTCA 19

RESULT 96
CS096246 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096246
DEFINITION Sequence 71 from Patent WO2005045040.
ACCESSION CS096246
VERSION CS096246.1 GI:66952719
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 71 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"

/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1263 AAAAGCTTCCCAAGCTT 1281
|||||
Db 1 AAAAGCTTCTCCAGCTT 19

RESULT 97
CS096247 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096247
DEFINITION Sequence 72 from Patent WO2005045040.
ACCESSION CS096247
VERSION CS096247.1 GI:66952720
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 72 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1281 UCCCAUCCAGCTUAGAGUCA 1299
:|||||
Db 1 TCCCAUCCAGCTAGAGTCA 19

RESULT 98
CS096248 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096248
DEFINITION Sequence 73 from Patent WO2005045040.
ACCESSION CS096248
VERSION CS096248.1 GI:66952721
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 73 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

VERSION	CS096240.1	GI:66952713
KEYWORDS	synthetic construct	
SOURCE	synthetic construct	
ORGANISM	other sequences; artificial sequences.	
REFERENCE	1 Richards,I. and Macawiggen,J. RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA) Patent: WO 2005045040-A 65 19-MAY-2005; Sirma Therapeutics, Inc. (US)	
AUTHORS	Location/Qualifiers	
TITLE	1..19 /organism="synthetic construct" /mol_type="unassigned RNA" /db_xref="taxon:32630" /note="Description of Artificial Sequence: Target Sequence/siNA sense region"	
JOURNAL		
FEATURES	source	
Query Match	1.1%; Score 19; DB 1; Length 19;	
Best Local Similarity	84.2%; Pred. NO. 84;	
Matches	16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;	
QY	1155 AUCGACAACTCCGAGGTG 1173 : :: : 1 ATCGACAACTCGAGGTG 19	
LOCUS	CS096241 19 bp RNA linear PAT 03-JUN-2005	
DEFINITION	Sequence 66 from Patent WO2005045040.	
ACCESSION	CS096241	
VERSION	CS096241.1 GI:66952714	
KEYWORDS	synthetic construct	
SOURCE	synthetic construct	
ORGANISM	other sequences; artificial sequences.	
REFERENCE	1 Richards,I. and Macawiggen,J. RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA) Patent: WO 2005045040-A 66 19-MAY-2005; Sirma Therapeutics, Inc. (US)	
AUTHORS	Location/Qualifiers	
TITLE	1..19 /organism="synthetic construct" /mol_type="unassigned RNA" /db_xref="taxon:32630" /note="Description of Artificial Sequence: Target Sequence/siNA sense region"	
JOURNAL		
FEATURES	source	
Query Match	1.1%; Score 19; DB 1; Length 19;	
Best Local Similarity	89.5%; Pred. NO. 84;	
Matches	17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;	
QY	1173 GCCUGAGAGAGCUGGG 1191 : 1 GCCTGAGGAGGAGCTGGGG 19	
LOCUS	CS096242 19 bp RNA linear PAT 03-JUN-2005	
DEFINITION	Sequence 67 from Patent WO2005045040.	
ACCESSION	CS096242	
VERSION	CS096242.1 GI:66952715	
KEYWORDS	synthetic construct	
SOURCE	synthetic construct	
ORGANISM	other sequences; artificial sequences.	

REFERENCE	1	Richards,I. and Macswiggen,J.
AUTHORS		RNA interference mediated inhibition of cholinergic muscarinic
TITLE		receptor (CHRM3) gene expression using short interfering Nucleic
JOURNAL		Acid (siNA)
FEATURES		Patent: WO 2005045040-A 67 19-MAY-2005;
source		Sirna Therapeutics, Inc. (US)
		location/Qualifiers
	1..19	/organism="synthetic construct"
		/mol_type="unassigned RNA"
		/db_xref="taxon:32630"
		/note="Description of Artificial Sequence: Target
		Sequence/siNA sense region"
Query Match	1.1%;	Score 19; DB 1; Length 19;
Best Local Similarity	76.9%;	Pred. No. 84;
Matches	15;	Conservative 4; Mismatches 0; Gaps 0;
Oy	1191	GAUGUGAGACUGGAGAG 1209
Db	1	GATGTCGACTTGAGAGG 19
: : : : : : : : :		
RESULT 93		
LOCUS	CS096243	19 bp, RNA
DEFINITION	Sequence 68 from Patent WO2005045040.	linear
ACCESSION	CS096243	
VERSION	CS096243.1	GI:66952716
KEYWORDS		
SOURCE		
ORGANISM		synthetic construct
REFERENCE		synthetic construct
AUTHORS	1	other sequences; artificial sequences.
TITLE		
JOURNAL		Richards,I. and Macswiggen,J.
FEATURES		RNA interference mediated inhibition of cholinergic muscarinic
source		receptor (CHRM3) gene expression using short interfering Nucleic
		Acid (siNA)
		Patent: WO 2005045040-A 68 19-MAY-2005;
		Sirna Therapeutics, Inc. (US)
		location/Qualifiers
	1..19	/organism="synthetic construct"
		/mol_type="unassigned RNA"
		/db_xref="taxon:32630"
		/note="Description of Artificial Sequence: Target
		Sequence/siNA sense region"
Query Match	1.1%;	Score 19; DB 1; Length 19;
Best Local Similarity	94.7%;	Pred. No. 84;
Matches	18;	Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Oy	1209	GAAGCCGACAGCUGCAG 1227
Db	1	GAAGCCGACAGCTGCAG 19
: : : : : : :		
RESULT 94		
LOCUS	CS096244	19 bp, RNA
DEFINITION	Sequence 69 from Patent WO2005045040.	linear
ACCESSION	CS096244	
VERSION	CS096244.1	GI:66952717
KEYWORDS		
SOURCE		synthetic construct
ORGANISM		synthetic construct
REFERENCE		other sequences; artificial sequences.
AUTHORS	1	
TITLE		Richards,I. and Macswiggen,J.
JOURNAL		RNA interference mediated inhibition of cholinergic muscarinic
FEATURES		receptor (CHRM3) gene expression using short interfering Nucleic
source		Acid (siNA)

OY 1065 GGACAUUGGCUCCGAGACG 1083
||||:||||:||||:||||:
DB 1 GGACATGGCTCCGAGACG 19

RESULT 86
CS096236

LOCUS CS096236 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 61 from Patent WO2005045040.
ACCESSION CS096236
VERSION CS096236.1 GI:66952709
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)

JOURNAL Patent: WO 2005045040-A 61 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 1083 GAGAGCAUCUACUCCAUVC 1101
|||||:||||:||||:||||:
DB 1 GAGAGCACTCTACTCCATC 19

RESULT 87
CS096237 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096237
DEFINITION Sequence 62 from Patent WO2005045040.
ACCESSION CS096237
VERSION CS096237.1 GI:66952710
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 62 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 1101 CGUGCUCAAGCUCGCGGU 1119
||:||||:||||:||||:||||:
DB 1 CGUGCUCAAGCTTCCGCGT 19

RESULT 88
CS096238 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096238
DEFINITION Sequence 63 from Patent WO2005045040.
ACCESSION CS096238
VERSION CS096238.1 GI:66952711
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 63 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 1119 UCACAGCACCAUCCUCCAC 1137
:|||||:||||:||||:||||:
DB 1 TCACAGCACCACTCTCCAC 19

RESULT 89
CS096239 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096239
DEFINITION Sequence 64 from Patent WO2005045040.
ACCESSION CS096239
VERSION CS096239.1 GI:66952712
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 64 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 1137 CUCCACCAAGUACCCUCA 1155
||:|||||:||||:||||:||||:
DB 1 CUCCACCAAGTTACCCUCA 19

RESULT 90
CS096240 19 bp RNA linear PAT 03-JUN-2005
LOCUS CS096240
DEFINITION Sequence 65 from Patent WO2005045040.
ACCESSION CS096240

/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 993 CAGCAGACAGUACAGUUG 1011
|||||:|||||:|||||:
Db 1 CAGCAGACAGTGCAGCTTG 19

RESULT 82
LOCUS CS096232 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 57 from Patent WO2005045040.
ACCESSION CS096232
VERSION CS096232.1 GI:66952705
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 57 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source Location/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1011 GAACAACAUGAUGUGCU 1029
|||||:|||||:|||||:
Db 1 GAACAACAATGATGCTGCT 19

RESULT 83
LOCUS CS096233 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 58 from Patent WO2005045040.
ACCESSION CS096233
VERSION CS096233.1 GI:66952706
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 58 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source Location/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1029 UGCGUCCCGAGACUCC 1047
:||||:||||:||||:||||:
Db 1 TGCCCTCCCGAGAACTCC 19

RESULT 84
LOCUS CS096234 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 59 from Patent WO2005045040.
ACCESSION CS096234
VERSION CS096234.1 GI:66952707
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 59 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source Location/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1047 CGCCUCCCGCAGCAGGAG 1065
|||||:|||||:|||||:
Db 1 CGCCTCCCTCCGACGAGAG 19

RESULT 85
LOCUS CS096235 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 60 from Patent WO2005045040.
ACCESSION CS096235
VERSION CS096235.1 GI:66952708
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 60 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source Location/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

other sequences; artificial sequences.

1
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

1
Richards,I. and Macawiggen,J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 52 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

1.
19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 921 GUAGGCCGCGCCACGCTTC 939
|:|||||:|||||:
1 GTATGCGCGCTGCCACTTC 19

RESULT 78
LOCUS CS096228 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 53 from Patent WO2005045040.
ACCESSION CS096228
VERSION CS096228.1 GI:66952701
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

1
Richards,I. and Macawiggen,J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 53 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

1.
19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 939 CUGGUTCAACCAAGAGC 957
|:|||||:|||||:
1 CTGTTCAACCAAGAGC 19

RESULT 79
LOCUS CS096229 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 54 from Patent WO2005045040.
ACCESSION CS096229
VERSION CS096229.1 GI:66952702
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

1
Richards,I. and Macawiggen,J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 54 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

1.
19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 957 CUGAACCACGCTCCGAG 975
|:|||||:|||||:
1 CTGAAACCCAGCTCCGAG 19

RESULT 80
LOCUS CS096230 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 55 from Patent WO2005045040.
ACCESSION CS096230
VERSION CS096230.1 GI:66952703
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

1
Richards,I. and Macawiggen,J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 55 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

1.
19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 84;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 975 GCAGATGACCAAGACAC 993
|:|||||:|||||:
1 GCAGATGACCAAGACAC 19

RESULT 81
LOCUS CS096231 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 56 from Patent WO2005045040.
ACCESSION CS096231
VERSION CS096231.1 GI:66952704
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

1
Richards,I. and Macawiggen,J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 56 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

1.
19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Acid (siNA)
Patent: WO 2005045040-A 54 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

1.
19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 957 CUGAACCACGCTCCGAG 975
|:|||||:|||||:
1 CTGAAACCCAGCTCCGAG 19

RESULT 80
LOCUS CS096230 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 55 from Patent WO2005045040.
ACCESSION CS096230
VERSION CS096230.1 GI:66952703
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

1
Richards,I. and Macawiggen,J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 55 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

1.
19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 84;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 975 GCAGATGACCAAGACAC 993
|:|||||:|||||:
1 GCAGATGACCAAGACAC 19

RESULT 81
LOCUS CS096231 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 56 from Patent WO2005045040.
ACCESSION CS096231
VERSION CS096231.1 GI:66952704
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

1
Richards,I. and Macawiggen,J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 56 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

1.
19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

RESULT 73
LOCUS CS096223 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 48 from Patent WO2005045040.
ACCESSION CS096223
VERSION CS096223.1 GI:66952696
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 48 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
LOCATION/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 849 CACGGGCGAGUUCUGAAGC 867
|||||||:|||||
1 CACGGGCGAGTCTCGAAGC 19

RESULT 74
LOCUS CS096224 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 49 from Patent WO2005045040.
ACCESSION CS096224
VERSION CS096224.1 GI:66952697
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 49 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
LOCATION/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 867 CUGCAGCAGUUCGGAACU 885
||:|||||:|||||:|
1 CTGCGCAGATTACGAACCT 19

RESULT 75
LOCUS CS096225 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 50 from Patent WO2005045040.

ACCESSION CS096225
VERSION CS096225.1 GI:66952698
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 50 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
LOCATION/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 885 UCACAGCAGAAAGCAUGAAA 903
:|||||||:|||||
1 TCACAGCAGAAAGCATGAAA 19

RESULT 76
LOCUS CS096226 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 51 from Patent WO2005045040.
ACCESSION CS096226
VERSION CS096226.1 GI:66952699
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macswiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 51 19-MAY-2005;
SiRNA Therapeutics, Inc. (US)
LOCATION/Qualifiers
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 84;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

OY 903 ACGCUCACAGAGAGAGAG 921
|||||||:|||||:|
1 ACGCTCCAAACAGAGAGAG 19

RESULT 77
LOCUS CS096227 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 52 from Patent WO2005045040.
ACCESSION CS096227
VERSION CS096227.1 GI:66952700
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct

Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 759 GAUCUAUAGGAACUGAA 777
Db 1 GATCTATAGGAAGACTGAA 19

RESULT 69
LOCUS CS096219 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 44 from Patent WO2005045040.
ACCESSION CS096219
VERSION CS096219.1 GI:66952692
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macewiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 44 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 777 AAAGCGUACCAAGAGCUU 795
Db 1 AAAGGCTACCAAGAGCTT 19

RESULT 70
LOCUS CS096220 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 45 from Patent WO2005045040.
ACCESSION CS096220
VERSION CS096220.1 GI:66952693
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macewiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 45 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 795 UGCGUCCUGCAAGCCUCU 813
Db 1 TCCTGACCTGCAAGCCTCT 19

RESULT 71
LOCUS CS096221 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 46 from Patent WO2005045040.
ACCESSION CS096221
VERSION CS096221.1 GI:66952694
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macewiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 46 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 84;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 813 UGCGACAGAGCGCAGACCA 831
Db 1 TCGACACAGAGCGCAGACCA 19

RESULT 72
LOCUS CS096222 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 47 from Patent WO2005045040.
ACCESSION CS096222
VERSION CS096222.1 GI:66952695
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macewiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 47 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
LOCATION/Qualifiers

FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 831 AGAAAACUUGUCCACCCC 849
Db 1 AGAAAACUUGUCCACCCC 19

receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 39 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 687 CACCAUACUUGGCACA 705
Db 1 CACCAUACUUGGCACA 19

RESULT 65
LOCUS CS096215 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 40 from Patent WO2005045040.
ACCESSION CS096215
VERSION CS096215.1 GI:66952688
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macawiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 40 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 84;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 705 AGCCAGCGCGCUUUUUAU 723
Db 1 AGCCAGCGCGCTTTTAT 19

RESULT 66
LOCUS CS096216 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 41 from Patent WO2005045040.
ACCESSION CS096216
VERSION CS096216.1 GI:66952689
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macawiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 41 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

JOURNAL
FEATURES
Location/Qualifiers

source

1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 84;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 723 UAUCCUGUACCAUUAUG 741
Db 1 TATGCCTGTACCAATTAT 19

RESULT 67
LOCUS CS096217 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 42 from Patent WO2005045040.
ACCESSION CS096217
VERSION CS096217.1 GI:66952690
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macawiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 42 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 84;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 741 GACUUAUUUUAUACUGAGC 759
Db 1 GACTATTTTATACUGAGC 19

RESULT 68
LOCUS CS096218 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 43 from Patent WO2005045040.
ACCESSION CS096218
VERSION CS096218.1 GI:66952691
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards, I. and Macawiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 43 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

JOURNAL
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target

DEFINITION Sequence 35 from Patent WO2005045040.
ACCESSION CS096210
VERSION CS096210.1 GI:66952683
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 35 19-MAY-2005;
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 84;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

OY 615 GUUCUGGCAUACUUGUU 633
DB 1 GTTCGGCAATACCTTGT 19

RESULT 61
LOCUS CS096211 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 36 from Patent WO2005045040.
ACCESSION CS096211
VERSION CS096211.1 GI:66952684
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 36 19-MAY-2005;
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 633 UGGAAGAAGACUGGCCU 651
DB 1 TCGAAGAGAACTGTGCT 19

RESULT 62
LOCUS CS096212 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 37 from Patent WO2005045040.
ACCESSION CS096212
VERSION CS096212.1 GI:66952685
KEYWORDS
SOURCE synthetic construct

ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 37 19-MAY-2005;
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

OY 651 UCCGGAGAGUGCCUUCAU 669
DB 1 TCCGGAGAGAGTCTTCATT 19

RESULT 63
LOCUS CS096213 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 38 from Patent WO2005045040.
ACCESSION CS096213
VERSION CS096213.1 GI:66952686
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 38 19-MAY-2005;
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 669 UCAGUUCUCAGUGAGCC 687
DB 1 TCAGTTCCTCAGTAGACC 19

RESULT 64
LOCUS CS096214 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 39 from Patent WO2005045040.
ACCESSION CS096214
VERSION CS096214.1 GI:66952687
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic

Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 525 GUACCGACCAACGAACA 543
Db 1 GTACCGAGCCAACGAACA 19

RESULT 56
LOCUS CS096206 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 31 from Patent WO2005045040.
ACCESSION CS096206
VERSION CS096206.1 GI:66952679
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macawiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 31 19-MAY-2005;
FEATURES
source 1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 543 AACAAAGAGAGCCGGUGUG 561
Db 1 AACAAAGAGAGCCGGTGTG 19

RESULT 57
LOCUS CS096207 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 32 from Patent WO2005045040.
ACCESSION CS096207
VERSION CS096207.1 GI:66952680
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macawiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 32 19-MAY-2005;
FEATURES
source 1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 561 GAUGAUGGUGUGGUGUGG 579
Db 1 GATGATCGTCTGCGCTTG 19

RESULT 58
LOCUS CS096208 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 33 from Patent WO2005045040.
ACCESSION CS096208
VERSION CS096208.1 GI:66952681
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macawiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 33 19-MAY-2005;
FEATURES
source 1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 84;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 579 GGUCAUCCUUCUUGUCUU 597
Db 1 GGTCACTCTCTTGTCTT 19

RESULT 59
LOCUS CS096209 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 34 from Patent WO2005045040.
ACCESSION CS096209
VERSION CS096209.1 GI:66952682
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macawiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 34 19-MAY-2005;
FEATURES
source 1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 84;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 597 UUGGCGUCUUGCGCAUCUG 615
Db 1 TTGGGCTCTCGCATCTTG 19

RESULT 60
LOCUS CS096210 19 bp RNA linear PAT 03-JUN-2005

FEATURES
source
1.19
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

OY 453 CAGCAUGCCUCGUUAUG 471
|||||:||||:||||:|
1 CAGCAATGCTCTGTATG 19

RESULT 52
LOCUS CS096202 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 27 from Patent WO2005045040.
ACCESSION CS096202
VERSION CS096202.1 GI:66952675
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
1
REFERENCE
AUTHORS
TITLE
Richards,I. and Macewiggen,J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 27 19-MAY-2005;
Stirna Therapeutics, Inc. (US)
Location/Qualifiers
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

FEATURES
source
1.19
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

OY 471 GAUCUCUGGUCUACAGC 489
|||||:||||:||||:|
1 GAATCTTCTGTCATCAGC 19

RESULT 53
LOCUS CS096203 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 28 from Patent WO2005045040.
ACCESSION CS096203
VERSION CS096203.1 GI:66952676
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
1
REFERENCE
AUTHORS
TITLE
Richards,I. and Macewiggen,J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 28 19-MAY-2005;
Stirna Therapeutics, Inc. (US)
Location/Qualifiers
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

FEATURES
source
1.19
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 84;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

OY 489 CUUACAGAUACUUUUC 507
|:::|||||:||||:|
1 CTTTACAGATACCTTTCC 19

RESULT 54
LOCUS CS096204 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 29 from Patent WO2005045040.
ACCESSION CS096204
VERSION CS096204.1 GI:66952677
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
1
REFERENCE
AUTHORS
TITLE
Richards,I. and Macewiggen,J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 29 19-MAY-2005;
Stirna Therapeutics, Inc. (US)
Location/Qualifiers
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

FEATURES
source
1.19
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 507 CAUACAGAGCCGCUACAG 525
|||||:|||||:||||:|
1 CATCAAGAGCCGCTCAGC 19

RESULT 55
LOCUS CS096205 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 30 from Patent WO2005045040.
ACCESSION CS096205
VERSION CS096205.1 GI:66952678
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
1
REFERENCE
AUTHORS
TITLE
Richards,I. and Macewiggen,J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 30 19-MAY-2005;
Stirna Therapeutics, Inc. (US)
Location/Qualifiers
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

FEATURES
source
1.19
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 84;

SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macawiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siRNA)
JOURNAL Patent: WO 2005045040-A 22 19-MAY-2005;
SIRna Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 381 CUACUACUACUACUACUACU 399
Db 1 CTACATCATCATCATCATCAT 19

RESULT 48
LOCUS CS096198 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 23 from Patent WO2005045040.
ACCESSION CS096198
VERSION CS096198.1 GI:66952671
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macawiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siRNA)
JOURNAL Patent: WO 2005045040-A 23 19-MAY-2005;
SIRna Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 399 AUGGACCCUAGGACUAGG 417
Db 1 ATGGGCTTAGGGAACCTTG 19

RESULT 49
LOCUS CS096199 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 24 from Patent WO2005045040.
ACCESSION CS096199
VERSION CS096199.1 GI:66952672
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macawiggen, J.

TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 24 19-MAY-2005;
SIRna Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 417 GAGCCUGAGCCUGAGCCUG 435
Db 1 GAGCCUGAGCCUGAGCCUG 19

RESULT 50
LOCUS CS096200 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 25 from Patent WO2005045040.
ACCESSION CS096200
VERSION CS096200.1 GI:66952673
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macawiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 25 19-MAY-2005;
SIRna Therapeutics, Inc. (US)
FEATURES Location/Qualifiers
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 435 UGCAUAGACUAGCUGAGCC 453
Db 1 TGCCATGACTAGCUGAGCC 19

RESULT 51
LOCUS CS096201 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 26 from Patent WO2005045040.
ACCESSION CS096201
VERSION CS096201.1 GI:66952674
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macawiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 26 19-MAY-2005;
SIRna Therapeutics, Inc. (US)

Db 1 GCAGCTGAAGACGTCAC 19

RESULT 43
LOCUS CS096193 19 bp RNA
DEFINITION Sequence 18 from Patent WO2005045040.
ACCESSION CS096193
VERSION CS096193.1 GI:66952666
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Richards,I. and Macawiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 18 19-MAY-2005;
FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 309 CACTUCCUCCUUAACG 327
Db 1 CAACTACTTCCTTAAGC 19

RESULT 44
LOCUS CS096194 19 bp RNA
DEFINITION Sequence 19 from Patent WO2005045040.
ACCESSION CS096194
VERSION CS096194.1 GI:66952667
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Richards,I. and Macawiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 19 19-MAY-2005;
FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 327 CCUGGCCUGGCCGAUCG 345
Db 1 CCTGACCTGTGCCATCTG 19

RESULT 45
LOCUS CS096195

LOCUS CS096195 19 bp RNA
DEFINITION Sequence 20 from Patent WO2005045040.
ACCESSION CS096195
VERSION CS096195.1 GI:66952668
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Richards,I. and Macawiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 20 19-MAY-2005;
FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 84;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 345 GAUUAUCCGCGUUAUUA 363
Db 1 GATTATCGGGGTCATTCA 19

RESULT 46
LOCUS CS096196 19 bp RNA
DEFINITION Sequence 21 from Patent WO2005045040.
ACCESSION CS096196
VERSION CS096196.1 GI:66952669
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Richards,I. and Macawiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 21 19-MAY-2005;
FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 363 AUAUAUCUGUUACGACC 381
Db 1 AATGAATCTGTACGACC 19

RESULT 47
LOCUS CS096197 19 bp RNA
DEFINITION Sequence 22 from Patent WO2005045040.
ACCESSION CS096197
VERSION CS096197.1 GI:66952670
KEYWORDS

/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 219 CTTAACGGGCAATCTG3CC 237
Db 1 CTTAACGGGCAATCTG3CC 19

RESULT 39
CS096189
LOCUS CS096189 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 14 from Patent WO2005045040.
ACCESSION CS096189
VERSION CS096189.1 GI:66952662
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards,I. and Macswiggen,J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 14 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

JOURNAL
source
1. 19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 237 CTUGUGAACCAUCAGCGC 255
Db 1 CTTGGTGACCATCATCGGC 19

RESULT 40
CS096190
LOCUS CS096190 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 15 from Patent WO2005045040.
ACCESSION CS096190
VERSION CS096190.1 GI:66952663
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards,I. and Macswiggen,J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 15 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

JOURNAL
source
1. 19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;

Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 255 CAACAUCUGUAAUUGUG 273
Db 1 CAACATCTGTAATGTG 19

RESULT 41
CS096191
LOCUS CS096191 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 16 from Patent WO2005045040.
ACCESSION CS096191
VERSION CS096191.1 GI:66952664
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards,I. and Macswiggen,J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 16 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

JOURNAL
source
1. 19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 273 GUCAUUUAAGGUCACAG 291
Db 1 GTCATTAAAGTCACAG 19

RESULT 42
CS096192
LOCUS CS096192 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 17 from Patent WO2005045040.
ACCESSION CS096192
VERSION CS096192.1 GI:66952665
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards,I. and Macswiggen,J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
Patent: WO 2005045040-A 17 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
Location/Qualifiers

JOURNAL
source
1. 19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 291 GCAGCUGAAGCGGCAAC 309
|||||:|||||:|||||

AUTHORS Richards, I. and Macswiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 9 19-MAY-2005;
FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 147 CUCUCUCCAGACGGUACC 165
Db 1 CTCCTCTCCAGACGGTACC 19

RESULT 35
LOCUS CS096185 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 10 from Patent WO2005045040.
ACCESSION CS096185
VERSION CS096185.1 GI:66952658
KEYWORDS
SOURCE .
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS 1
TITLE Richards, I. and Macswiggen, J.
JOURNAL RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 10 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 165 CACCGAUGACCCUCUGGA 183
Db 1 CACCGATGACCTCTGGGA 19

RESULT 36
LOCUS CS096186 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 11 from Patent WO2005045040.
ACCESSION CS096186
VERSION CS096186.1 GI:66952659
KEYWORDS
SOURCE .
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS 1
TITLE Richards, I. and Macswiggen, J.
JOURNAL RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 11 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"

Sirma Therapeutics, Inc. (US)
FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 183 AGGUCUACCCGUCUGCAA 201
Db 1 AGGTGATTCATCGCTTGC 19

RESULT 37
LOCUS CS096187 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 12 from Patent WO2005045040.
ACCESSION CS096187
VERSION CS096187.1 GI:66952660
KEYWORDS
SOURCE .
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS 1
TITLE Richards, I. and Macswiggen, J.
JOURNAL RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 12 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 84;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 201 AGUGGUCUUCAGCGCUC 219
Db 1 AGTGCTTCATCGCTTTC 19

RESULT 38
LOCUS CS096188 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 13 from Patent WO2005045040.
ACCESSION CS096188
VERSION CS096188.1 GI:66952661
KEYWORDS
SOURCE .
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS 1
TITLE Richards, I. and Macswiggen, J.
JOURNAL RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
Patent: WO 2005045040-A 13 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1.19
/organism="synthetic construct"
/mol_type="unassigned RNA"

CS096180 LOCUS CS096180 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 5 from Patent WO2005045040.
ACCESSION CS096180
VERSION CS096180.1 GI:66952653
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macawiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 5 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 84;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY 75 CGAUGCAGGCGUCCCCG 93
|||||:|||||:|||||
1 CGATGCAGGCGTCCCCCG 19

Db

RESULT 31
CS096181
LOCUS CS096181 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 6 from Patent WO2005045040.
ACCESSION CS096181
VERSION CS096181.1 GI:66952654
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macawiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 6 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 93 GGAACCGUCACUACUUC 111
|||||:|||||:|||||
1 GGAACCGTCACTCAATTC 19

Db

RESULT 32
CS096182
LOCUS CS096182 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 7 from Patent WO2005045040.
ACCESSION CS096182
VERSION CS096182.1 GI:66952655

KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macawiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 7 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 84;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

OY 111 CGGACGCUACAUGUUUCU 129
|||||:|||||:|||||
1 CGGACGCTACATGTTCT 19

Db

RESULT 33
CS096183
LOCUS CS096183 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 8 from Patent WO2005045040.
ACCESSION CS096183
VERSION CS096183.1 GI:66952656
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS
TITLE
1 Richards, I. and Macawiggen, J.
RNA interference mediated inhibition of cholinergic muscarinic
receptor (CHRM3) gene expression using short interfering Nucleic
Acid (siNA)
JOURNAL Patent: WO 2005045040-A 8 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target
Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 84;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY 129 UCGAGCAGTGGCAATTC 147
:|||||:|||||:|||||
1 TCGAGCAGCTGGCAATTC 19

Db

RESULT 34
CS096184
LOCUS CS096184 19 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 9 from Patent WO2005045040.
ACCESSION CS096184
VERSION CS096184.1 GI:66952657
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.
REFERENCE
1

Query Match 1.1%; Score 20.6; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 67;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

OY 228 CAUCCUGGCUUGUGGACCAU 248
||:||||:||||:||||:
1 CATCCTGGCCCTGGTACCAT 21

RESULT 26
CS096176 19 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 1 from Patent WO2005045040.
DEFINITION CS096176
ACCESSION CS096176.1 GI:66952649
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 1 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 3 GACCTUGCACAUAACAGU 21
||||:||||:||||:
1 GACCTTGCAATACACAGT 19

RESULT 27
CS096177 19 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 2 from Patent WO2005045040.
DEFINITION CS096177
ACCESSION CS096177
VERSION CS096177.1 GI:66952650
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 2 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 84;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

OY 21 UACAACUCGCGCCUUGUUU 39

Db :||||:||||:||||:
1 TACAACCTGCTTGT 19

RESULT 28
CS096178 19 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 3 from Patent WO2005045040.
DEFINITION CS096178
ACCESSION CS096178
VERSION CS096178.1 GI:66952651
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 3 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 84;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 39 UCCAACACUACGCUCCUCC 57
:||||:||||:||||:
1 TCCAACATCACTCTCTCC 19

RESULT 29
CS096179 19 bp RNA linear PAT 03-JUN-2005
LOCUS Sequence 4 from Patent WO2005045040.
DEFINITION CS096179
ACCESSION CS096179
VERSION CS096179.1 GI:66952652
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards,I. and Macswiggen,J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siNA)
JOURNAL Patent: WO 2005045040-A 4 19-MAY-2005;
Sirma Therapeutics, Inc. (US)
FEATURES
source 1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 84;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 57 CUGAUACAGAGCCCUCC 75
||:||||:||||:||||:
1 CTGATACAGAGCCCTCC 19

RESULT 30

receptor (CHRM3) gene expression using short interfering Nucleic Acid (siRNA)
Patent: WO 2005045040-A 203 19-MAY-2005;
Sirta Therapeutics, Inc. (US)
Location/Qualifiers
1. .23
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 95.7%; Pred. No. 41;
Matches 22; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 973 GAGCAGUAGACCAAGACCACAG 995
Db 1 GAGCAGATGACCAAGACCACAG 23

RESULT 22
CS096379 23 bp RNA linear PAT 03-JUN-2005
LOCUS CS096379 Sequence 204 from Patent WO2005045040.
DEFINITION CS096379
ACCESSION CS096379.1 GI:66952852
VERSION CS096379.1 GI:66952852
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macawiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siRNA)
JOURNAL Patent: WO 2005045040-A 204 19-MAY-2005;
Sirta Therapeutics, Inc. (US)
FEATURES
source
1. .23
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 91.3%; Pred. No. 41;
Matches 21; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1710 GCAGCAGUACGACGACAGACAGU 1732
Db 1 GCAGCAGTACGACGACAGACAGT 23

RESULT 23
CS096380 23 bp RNA linear PAT 03-JUN-2005
LOCUS CS096380 Sequence 205 from Patent WO2005045040.
DEFINITION CS096380
ACCESSION CS096380.1 GI:66952853
VERSION CS096380.1 GI:66952853
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macawiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siRNA)
JOURNAL Patent: WO 2005045040-A 205 19-MAY-2005;
Sirta Therapeutics, Inc. (US)
FEATURES
Location/Qualifiers

source

1. .23
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 91.3%; Pred. No. 41;
Matches 21; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1712 AGCAGUACGACGACGACAGUCG 1734
Db 1 AGCAGTACGACGACGACAGTCG 23

RESULT 24
CS096381 23 bp RNA linear PAT 03-JUN-2005
LOCUS CS096381 Sequence 206 from Patent WO2005045040.
DEFINITION CS096381
ACCESSION CS096381
VERSION CS096381.1 GI:66952854
KEYWORDS
SOURCE
ORGANISM
synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Richards, I. and Macawiggen, J.
TITLE RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering Nucleic Acid (siRNA)
JOURNAL Patent: WO 2005045040-A 206 19-MAY-2005;
Sirta Therapeutics, Inc. (US)
FEATURES
source
1. .23
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: Target Sequence/siNA sense region"

Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 91.3%; Pred. No. 41;
Matches 21; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1713 GCAGUACGACGACGACAGUCG 1735
Db 1 GCAGTACGACGACGACAGTCG 23

RESULT 25
AX154389 21 bp DNA linear PAT 22-JUN-2001
LOCUS AX154389 Sequence 487 from Patent WO0138576.
DEFINITION AX154389
ACCESSION AX154389
VERSION AX154389.1 GI:14536003
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Homnidae; Homo.

REFERENCE 1
AUTHORS Cargill, M., Ireland, J.S. and Lander, E.S.
TITLE Human single nucleotide polymorphisms
JOURNAL Patent: WO 0138576-A 487 31-MAY-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)
FEATURES
source
1. .21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

DEFINITION Sequence 199 from Patent WO2005045040.
ACCESSION CS096374
VERSION CS096374.1 GI:66952847
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
TITLE
JOURNAL
FEATURES
source

Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 69.6%; Pred. No. 41;
Matches 16; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

OY 15 UACGACUACACCTCGCCUUCU 37
Db 1 TAACGATCAACCTCGCCTTGT 23

RESULT 18
LOCUS CS096375 23 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 200 from Patent WO2005045040.
ACCESSION CS096375
VERSION CS096375.1 GI:66952848
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
TITLE
JOURNAL
FEATURES
source

Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 65.2%; Pred. No. 41;
Matches 15; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

OY 19 AGUACAACCGCCUUGUUC 41
Db 1 AGTACACCTCGCCTTTTTC 23

RESULT 19
LOCUS CS096376 23 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 201 from Patent WO2005045040.
ACCESSION CS096376
VERSION CS096376.1 GI:66952849
KEYWORDS
SOURCE

ORGANISM
REFERENCE
1
AUTHORS
TITLE
JOURNAL
FEATURES
source

Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 65.2%; Pred. No. 41;
Matches 15; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

OY 313 UACUUCUUAAGCTCGGCTG 335
Db 1 TACTTCTCTTAAAGCTGCGCTG 23

RESULT 20
LOCUS CS096377 23 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 202 from Patent WO2005045040.
ACCESSION CS096377
VERSION CS096377.1 GI:66952850
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
TITLE
JOURNAL
FEATURES
source

Query Match 1.3%; Score 23; DB 1; Length 23;
Best Local Similarity 65.2%; Pred. No. 41;
Matches 15; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

OY 315 CUUCUCUUAAGCTCGGCTG 337
Db 1 CTTCCTTAAAGCTGCGCTG 23

RESULT 21
LOCUS CS096378 23 bp RNA linear PAT 03-JUN-2005
DEFINITION Sequence 203 from Patent WO2005045040.
ACCESSION CS096378
VERSION CS096378.1 GI:66952851
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS
TITLE

ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 30)
AUTHORS Pausch,M.H. and Wess,J.
TITLE Method of modifying function of heterogenous G protein-coupled
JOURNAL Patent: JP 2002523091-A 4 30-JUL-2002;
BASF AG

COMMENT OS Artificial Sequence
PN JP 2002523091-A/4
PD 30-JUL-2002
PR 01-SEP-1999 JP 2000567692
PI 01-SEP-1998 US 60/098704
PI MARK HENRY PAUSCH,JURGEN WESS
PC C12N15/09,C07K14/72,C12N1/19,C12Q1/02,G01N33/15,G01N33/50, PC
G01N33/566,
PC G01N33/68/(C12N1/19,C12R1:865),C12N15/00
CC Description of Artificial Sequence:oligonucleotide FH Key
Location/Qualifiers
FT source 1..30
/organism='Artificial Sequence'.
Location/Qualifiers
1..30
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

FEATURES
source

Query Match 1..4%; Score 25.2; DB 1; Length 30;
Best Local Similarity 70.0%; Pred. No. 41;
Matches 21; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

OY 1495 GCCUUCAUCAUCUGACCCCAUACAAC 1524
DB 1 GCCTTATCATCATCGTGGACCCCTACACC 30

RESULT 14
BD235807 30 bp DNA linear PAT 17-JUL-2003
LOCUS BD235807
DEFINITION Method of modifying function of heterogenous G protein-coupled
receptor.
ACCESSION BD235807
VERSION BD235807.1 GI:33045577
KEYWORDS JP 2002523091-A/9.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 30)
AUTHORS Pausch,M.H. and Wess,J.
TITLE Method of modifying function of heterogenous G protein-coupled
JOURNAL Patent: JP 2002523091-A 9 30-JUL-2002;
BASF AG

COMMENT OS Artificial Sequence
PN JP 2002523091-A/9
PD 30-JUL-2002
PR 01-SEP-1999 JP 2000567692
PI 01-SEP-1998 US 60/098704
PI MARK HENRY PAUSCH,JURGEN WESS
PC C12N15/09,C07K14/72,C12N1/19,C12Q1/02,G01N33/15,G01N33/50, PC
G01N33/566,
PC G01N33/68/(C12N1/19,C12R1:865),C12N15/00
CC Description of Artificial Sequence:oligonucleotide FH Key
Location/Qualifiers
FT source 1..30
/organism='Artificial Sequence'.
Location/Qualifiers
1..30
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

FEATURES
source

Query Match 1..4%; Score 25.2; DB 1; Length 30;
Best Local Similarity 66.7%; Pred. No. 41;
Matches 20; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

OY 1498 UUCAUCAUCUUGACCCCAUACAACATC 1527
DB 1 TTATCATCATCATCGTGGACCTCGTCAACATC 30

RESULT 15
AX249066 31 bp DNA linear PAT 28-SEP-2001
LOCUS AX249066
DEFINITION Sequence 1145 from Patent WO0166800.
ACCESSION AX249066
VERSION AX249066.1 GI:15863689
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
Homnidae; Homo.

REFERENCE 1
AUTHORS Cargill,M., Ireland,J.S. and Lander,E.S.
TITLE Human single nucleotide polymorphisms
JOURNAL Patent: WO 0166800-A 1145 13-SEP-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)
Location/Qualifiers
source 1..31
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

FEATURES
source

Query Match 1..4%; Score 24.8; DB 1; Length 31;
Best Local Similarity 63.3%; Pred. No. 50;
Matches 19; Conservative 8; Mismatches 3; Indels 0; Gaps 0;

OY 1587 CUACUGGCUUGGCUACAUCACACGACCGU 1616
DB 1 CTACTGGCTCTGCTAYGTCAACAGCACCAT 30

RESULT 17
CS096374 23 bp RNA linear PAT 03-JUN-2005
LOCUS CS096374

[illegible]

source	1..30	/organism="synthetic construct"	/mol_type="genomic DNA"	/db_xref="taxon:32630"
Query Match	1.4%; Score 25.2; DB 1; Length 30;			
Best Local Similarity	70.0%; Pred. No. 41;			
Matches	21; Conservative 6; Mismatches 3; Indels 0; Gaps 0;			
Qy	1495 GCUCUACUACUGAGACCCCAUACAAC 1524			
DB	1 GCCTTCATCATCAGTGGACCCCTACACC 30			
RESULT 12				
BD235756				
LOCUS	30 bp DNA linear PAT 17-JUL-2003			
DEFINITION	Strengthened functional expression of heterogenous G			
ACCESSION	BD235756			
VERSION	BD235756.1 GI:33045526			
KEYWORDS	JP 2002523090-A/9.			
SOURCE	synthetic construct			
ORGANISM	synthetic construct			
REFERENCE	other sequences; artificial sequences.			
AUTHORS	1 (bases 1 to 30)			
TITLE	Pausch,M.H., Lai,M., Silverman,S., Birsan,C., Baumbauch,W., Tseng,E., Kajkowski,E.M. and Ozeberger,B.A., Strengthened functional expression of heterogenous G protein-coupled receptor			
JOURNAL	Patent: JP 2002523090-A 9 30-JUL-2002;			
COMMENT	BASE AG			
OS	Artificial Sequence			
PN	JP 2002523090-A/9			
PD	30-JUL-2002			
PF	01-SEP-1999 JP 2000567691			
PR	01-SEP-1998 US 60/098704			
PI	MARK HENRY PAUSCH,MARGARET LAI,SANFORD SILVERMAN,CAMELIA BIRSAN,			
PI	WILLIAM BAUMBAUCH,EUGENE TSENG,EILEEN MARIE KAJKOWSKI, PI BRADLEY ALTON OZEBERGER			
PC	C12N1/19,C07K14/72,C12N15/09,C12P21/02,C12Q1/02,G01N33/15, PC G01N33/50,			
PC	PC G01N33/566/(C12N1/19,C12R1:865), (C12P21/02,C12R1:865), C12N15/00			
CC	Description of Artificial Sequence:Oligonucleotide FH Key			
FT	Location/Qualifiers			
FT	1..30			
source	Location/Qualifiers			
	1..30			
	/organism="Artificial Sequence"			
	/organism="synthetic construct"			
	/mol_type="genomic DNA"			
	/db_xref="taxon:32630"			
Query Match	1.4%; Score 25.2; DB 1; Length 30;			
Best Local Similarity	66.7%; Pred. No. 41;			
Matches	20; Conservative 7; Mismatches 3; Indels 0; Gaps 0;			
Qy	1498 UUCAUCAUCACUGAGACCCCAUACAAC 1527			
DB	1 TTCATCATCAGTGGACCCCTACACATC 30			
RESULT 13				
BD235802				
LOCUS	30 bp DNA linear PAT 17-JUL-2003			
DEFINITION	Method of modifying function of heterogenous G protein-coupled receptor.			
ACCESSION	BD235802			
VERSION	BD235802.1 GI:33045572			
KEYWORDS	JP 2002523091-A/4.			
SOURCE	synthetic construct			

LOCUS	ARI09758	27 bp	DNA	linear	PAT 14-FEB-2001
DEFINITION	Sequence 182 from patent US 6114139.				
ACCESSION	ARI09758				
VERSION	ARI09758.1	GI:12826034			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 27)				
TITLE	Hinuma,S., Hosoya,M., Fujii,R., Ohtaki,T., Fukusumi,S. and Ohgi,K.				
JOURNAL	G-protein coupled receptor protein and a DNA encoding the receptor				
FEATURES	Patent: US 6114139-A 182 05-SEP-2000;				
source	location/Qualifiers				
	1..27				
	/organism="unknown"				
	/mol_type="unassigned DNA"				
Query Match	1.5%; Score 27; DB 1; Length 27;				
Best Local Similarity	74.1%; Pred. No. 19;				
Matches	20; Conservative 7; Mismatches 0; Indels 0; Gaps 0;				
Qy	1618 AACCCCGUGUCUAGUCUCUGGCAC 1644				
	: : : : : : : : :				
	: : : : : : : : :				
Db	1 AACCCCGTGTCTATGCTGTGGAC 27				
RESULT 7	BD235753	30 bp	DNA	linear	PAT 17-JUL-2003
LOCUS	BD235753/c				
DEFINITION	Strengthened functional expression of heterogenous G				
protein-coupled receptor.					
ACCESSION	BD235753				
VERSION	BD235753.1	GI:33045523			
KEYWORDS	JP 2002523090-A/6.				
SOURCE	synthetic construct				
ORGANISM	synthetic construct				
REFERENCE	other sequences; artificial sequences.				
AUTHORS	1 (bases 1 to 30)				
TITLE	Pausch,M.H., Lai,M., Silverman,S., Birsan,C., Baumbauch,W.,				
JOURNAL	Tseng,E., Kalkowski,E.M. and Ozenberger,B.A.				
	Strengthened functional expression of heterogenous G				
	protein-coupled receptor				
	Patent: JP 2002523090-A 6 30-JUL-2002;				
COMMENT	BASF AG				
OS	Artificial Sequence				
PN	JP 2002523090-A/6				
PD	30-JUL-2002				
PF	01-SEP-1999 JP 2000567691				
PR	01-SEP-1998 US 60/098704				
PI	MARK HENRY PAUSCH, MARGARET LAI, SANFORD SILVERMAN, CAMELIA PI				
	BIRSAN,				
	PI WILLIAM BAUMBAUCH, EUGENE TSENG, EILEEN MARIE KAJTOWSKI, PI				
	BRADLEY ALTON OZENBERGER				
	PC C12N1/19, C07K14/72, C12N15/09, C12P21/02, C12Q1/02, G01N33/15, PC				
	G01N33/50,				
	PC G01N33/566/(C12N1/19, C12R1:865), (C12P21/02, C12R1:865), C12N15/				
	PC 00				
CC	Description of Artificial Sequence:Oligonucleotide FH				
Location/Qualifiers					
FT	source	1..30			
	Location/Qualifiers				
	1..30				
	/organism="Artificial Sequence".				
FEATURES					
source	Location/Qualifiers				
	1..30				
	/organism="synthetic construct"				
	/mol_type="genomic DNA"				
	/db_xref="taxon:32630"				
Query Match	1.5%; Score 26.8; DB 1; Length 30;				
Best Local Similarity	73.3%; Pred. No. 26;				
Matches	22; Conservative 6; Mismatches 2; Indels 0; Gaps 0;				
Qy	GGCTUCATCATCUCUGACCCCAACAC 1524				
	: : : : : : : : :				
	: : : : : : : : :				

DB	LOCUS	DEFINITION	ACCESSION	VERSION	KEYWORDS	SOURCE	ORGANISM	REFERENCE	AUTHORS	TITLE	JOURNAL	COMMENT
DB	BD235804/c	Method of modifying function of heterogenous G protein-coupled receptor.	BD235804	BD235804.1	GI:33045574	JP 2002523091-A/6.	synthetic construct synthetic construct other sequences: artificial sequences.	1 (bases 1 to 30) Pausch,M.H. and Weese,J. Method of modifying function of heterogenous G protein-coupled Patent: JP 2002523091-A 6 30-JUL-2002;				
DB	GCCTTCATCATCAGTGGAGCCCTCAGAAC 1	30 bp DNA linear PAT 17-JUL-2003										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										
QY	1495	gcttucanvacacugagacccacacac 1524										
DB	30	gcttucanvacacugagacccacacac 1										

REFERENCE 1 (bases 1 to 37)
AUTHORS Lehmann-Bruinema, K., Liaw, C.W. and Lin, I.-L.
TITLE Non-endogenous, constitutively activated known G protein-coupled receptors
JOURNAL Patent: US 6806054-A 279 19-OCT-2004;
Arena Pharmaceuticals, Inc.; San Diego, CA
FEATURES
source 1..37
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.8%; Score 32.2; DB 1; Length 37;
Best Local Similarity 83.8%; Pred. No. 8.6;
Matches 31; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1449 GGUCAAGAGAGAAAGCGGCCAGACCCUCAGUGCG 1485
Db 1 GGTCAAGAGAGAAAGCGAAACAGACCTCAGTGGC 37

RESULT 2
LOCUS ARS91149/c 37 bp DNA linear PAT 15-DEC-2004
DEFINITION Sequence 280 from patent US 6806054.
ACCESSION ARS91149
VERSION ARS91149.1 GI:56638958
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 37)
AUTHORS Lehmann-Bruinema, K., Liaw, C.W. and Lin, I.-L.
TITLE Non-endogenous, constitutively activated known G protein-coupled receptors
JOURNAL Patent: US 6806054-A 280 19-OCT-2004;
Arena Pharmaceuticals, Inc.; San Diego, CA
FEATURES
source 1..37
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.8%; Score 32.2; DB 1; Length 37;
Best Local Similarity 83.8%; Pred. No. 8.6;
Matches 31; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1449 GGUCAAGAGAGAAAGCGGCCAGACCCUCAGUGCG 1485
Db 37 GGTCAAGAGAGAAAGCGAAACAGACCTCAGTGGC 1

RESULT 3
LOCUS AX280656 37 bp DNA linear PAT 02-NOV-2001
DEFINITION Sequence 279 from Patent WO0177172.
ACCESSION AX280656
VERSION AX280656.1 GI:16608031
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 37)
AUTHORS Lehmann-Bruinema, K., Liaw, C.W. and Lin, I.-L.
TITLE Non-endogenous, constitutively activated known G protein-coupled receptors
JOURNAL Patent: WO 0177172-A 279 18-OCT-2001;
Arena Pharmaceuticals, Inc. (US)
FEATURES
source 1..37
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 32.2; DB 1; Length 37;
Best Local Similarity 83.8%; Pred. No. 8.6;
Matches 31; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1449 GGUCAAGAGAGAAAGCGGCCAGACCCUCAGUGCG 1485
Db 1 GGTCAAGAGAGAAAGCGAAACAGACCTCAGTGGC 37

RESULT 4
LOCUS AX280657/c 37 bp DNA linear PAT 02-NOV-2001
DEFINITION Sequence 280 from Patent WO0177172.
ACCESSION AX280657
VERSION AX280657.1 GI:16608032
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 37)
AUTHORS Lehmann-Bruinema, K., Liaw, C.W. and Lin, I.-L.
TITLE Non-endogenous, constitutively activated known G protein-coupled receptors
JOURNAL Patent: WO 0177172-A 280 18-OCT-2001;
Arena Pharmaceuticals, Inc. (US)
FEATURES
source 1..37
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 32.2; DB 1; Length 37;
Best Local Similarity 83.8%; Pred. No. 8.6;
Matches 31; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1449 GGUCAAGAGAGAAAGCGGCCAGACCCUCAGUGCG 1485
Db 37 GGTCAAGAGAGAAAGCGAAACAGACCTCAGTGGC 1

RESULT 5
LOCUS AR109645 27 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 69 from patent US 6114139.
ACCESSION AR109645
VERSION AR109645.1 GI:12825921
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 27)
AUTHORS Hinuma, S., Hoshiyama, M., Fujii, R., Ohnaka, T., Fukusumi, S. and Ohgi, K.
TITLE G-protein coupled receptor protein and a DNA encoding the receptor
JOURNAL Patent: US 6114139-A 69 05-SEP-2000;
FEATURES
source 1..27
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.5%; Score 27; DB 1; Length 27;
Best Local Similarity 77.8%; Pred. No. 19;
Matches 21; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 240 GUGACCAUACGCGCAACUCCUGGU 266
Db 1 GGTGACATCATCGGCAATCTCTGT 27

RESULT 6
LOCUS AR109758

C 399	13.8	0.8	17	1	DD186275	ACCESSION:DD186275	C 472	12.8	0.7	16	1	AR087869	ACCESSION:AR087869
C 400	13.8	0.8	17	1	DD187816	ACCESSION:DD187816	C 473	12.8	0.7	16	1	AR091339	ACCESSION:AR091339
C 401	13.8	0.8	17	1	DD190912	ACCESSION:DD190912	C 474	12.8	0.7	16	1	AR118045	ACCESSION:AR118045
C 402	13.8	0.8	17	1	DD190916	ACCESSION:DD190916	C 475	12.8	0.7	16	1	AR119026	ACCESSION:AR119026
C 403	13.8	0.8	17	1	114562	ACCESSION:114562	C 476	12.8	0.7	16	1	AR127764	ACCESSION:AR127764
C 404	13.8	0.8	17	1	AR186612	ACCESSION:AR186612	C 477	12.8	0.7	16	1	AR144931	ACCESSION:AR144931
C 405	13.8	0.8	17	1	AR190186	ACCESSION:AR190186	C 478	12.8	0.7	16	1	AR145932	ACCESSION:AR145932
C 406	13.8	0.8	17	1	AR286275	ACCESSION:AR286275	C 479	12.8	0.7	16	1	AX927955	ACCESSION:AX927955
C 407	13.8	0.8	17	1	AR286512	ACCESSION:AR286512	C 480	12.8	0.7	16	1	BD009273	ACCESSION:BD009273
C 408	13.8	0.8	17	1	AR324465	ACCESSION:AR324465	C 481	12.8	0.7	16	1	BD233018	ACCESSION:BD233018
C 409	13.8	0.8	17	1	157076	ACCESSION:157076	C 482	12.8	0.7	16	1	C0858571	ACCESSION:C0858571
C 410	13.8	0.8	17	1	AR398265	ACCESSION:AR398265	C 483	12.8	0.7	16	1	CS020466	ACCESSION:CS020466
C 411	13.8	0.8	17	1	AR398502	ACCESSION:AR398502	C 484	12.8	0.7	16	1	CS113935	ACCESSION:CS113935
C 412	13.8	0.8	17	1	AR401922	ACCESSION:AR401922	C 485	12.8	0.7	16	1	CS228123	ACCESSION:CS228123
C 413	13.8	0.8	17	1	AR434213	ACCESSION:AR434213	C 486	12.8	0.7	16	1	CS251086	ACCESSION:CS251086
C 414	13.8	0.8	17	1	AR458624	ACCESSION:AR458624	C 487	12.8	0.7	16	1	126792	ACCESSION:126792
C 415	13.8	0.8	17	1	AR482658	ACCESSION:AR482658	C 488	12.8	0.7	16	1	141165	ACCESSION:141165
C 416	13.8	0.8	17	1	AR482660	ACCESSION:AR482660	C 489	12.8	0.7	16	1	191533	ACCESSION:191533
C 417	13.8	0.8	17	1	AR597925	ACCESSION:AR597925	C 490	12.8	0.7	16	1	AR574808	ACCESSION:AR574808
C 418	13.8	0.8	17	1	AX475754	ACCESSION:AX475754	C 491	12.8	0.7	16	1	AR575038	ACCESSION:AR575038
C 419	13.8	0.8	17	1	AX531289	ACCESSION:AX531289	C 492	12.8	0.7	16	1	AR580871	ACCESSION:AR580871
C 420	13.8	0.8	17	1	AX579508	ACCESSION:AX579508	C 493	12.8	0.7	16	1	AR589528	ACCESSION:AR589528
C 421	13.8	0.8	17	1	AX579990	ACCESSION:AX579990	C 494	12.8	0.7	16	1	AX007572	ACCESSION:AX007572
C 422	13.8	0.8	17	1	AX616050	ACCESSION:AX616050	C 495	12.8	0.7	16	1	AX132918	ACCESSION:AX132918
C 423	13.8	0.8	17	1	AX616051	ACCESSION:AX616051	C 496	12.8	0.7	16	1	AX133148	ACCESSION:AX133148
C 424	13.8	0.8	17	1	AX616052	ACCESSION:AX616052	C 497	12.4	0.7	15	1	AR041461	ACCESSION:AR041461
C 425	13.8	0.8	17	1	AX648760	ACCESSION:AX648760	C 498	12.4	0.7	15	1	AR056273	ACCESSION:AR056273
C 426	13.8	0.8	17	1	AX691839	ACCESSION:AX691839	C 499	12.4	0.7	15	1	AR056367	ACCESSION:AR056367
C 427	13.8	0.8	17	1	AX691840	ACCESSION:AX691840	C 500	12.4	0.7	15	1	AR071406	ACCESSION:AR071406
C 428	13.8	0.8	17	1	AX694246	ACCESSION:AX694246	C 501	12.4	0.7	15	1	AR092455	ACCESSION:AR092455
C 429	13.8	0.8	17	1	AX723814	ACCESSION:AX723814	C 502	12.4	0.7	15	1	AR092464	ACCESSION:AR092464
C 430	13.8	0.8	17	1	AX727076	ACCESSION:AX727076	C 503	12.4	0.7	15	1	AR114031	ACCESSION:AR114031
C 431	13.8	0.8	17	1	AX727544	ACCESSION:AX727544	C 504	12.4	0.7	15	1	AR114125	ACCESSION:AR114125
C 432	13.8	0.8	17	1	AX729874	ACCESSION:AX729874	C 505	12.4	0.7	15	1	AR133631	ACCESSION:AR133631
C 433	13.8	0.8	17	1	AX735559	ACCESSION:AX735559	C 506	12.4	0.7	15	1	AR133905	ACCESSION:AR133905
C 434	13.8	0.8	17	1	AX736610	ACCESSION:AX736610	C 507	12.4	0.7	15	1	AX937516	ACCESSION:AX937516
C 435	13.8	0.8	17	1	AX737723	ACCESSION:AX737723	C 508	12.4	0.7	15	1	BD074150	ACCESSION:BD074150
C 436	13.8	0.8	17	1	AX753822	ACCESSION:AX753822	C 509	12.4	0.7	15	1	BD208892	ACCESSION:BD208892
C 437	13.8	0.8	17	1	AX758163	ACCESSION:AX758163	C 510	12.4	0.7	15	1	BD208893	ACCESSION:BD208893
C 438	13.8	0.8	17	1	AX760563	ACCESSION:AX760563	C 511	12.4	0.7	15	1	BD208983	ACCESSION:BD208983
C 439	13.8	0.8	17	1	AX761179	ACCESSION:AX761179	C 512	12.4	0.7	15	1	CS002487	ACCESSION:CS002487
C 440	13.8	0.8	17	1	AX762401	ACCESSION:AX762401	C 513	12.4	0.7	15	1	CS002720	ACCESSION:CS002720
C 441	13.8	0.8	17	1	HS13BE11L	ACCESSION:HS13BE11L	C 514	12.4	0.7	15	1	CS005322	ACCESSION:CS005322
C 442	13.4	0.8	15	1	AR131712	ACCESSION:AR131712	C 515	12.4	0.7	15	1	CS005966	ACCESSION:CS005966
C 443	13.4	0.8	15	1	BD208668	ACCESSION:BD208668	C 516	12.4	0.7	15	1	CS104321	ACCESSION:CS104321
C 444	13.4	0.8	16	1	BD104552	ACCESSION:BD104552	C 517	12.4	0.7	15	1	AR179938	ACCESSION:AR179938
C 445	13.4	0.8	16	1	AR241772	ACCESSION:AR241772	C 518	12.4	0.7	15	1	AR179958	ACCESSION:AR179958
C 446	13.4	0.8	16	1	AX756484	ACCESSION:AX756484	C 519	12.4	0.7	15	1	AR180430	ACCESSION:AR180430
C 447	13.4	0.7	37	1	AR591148	ACCESSION:AR591148	C 520	12.4	0.7	15	1	AR180530	ACCESSION:AR180530
C 448	13.2	0.7	37	1	AR591149	ACCESSION:AR591149	C 521	12.4	0.7	15	1	AR226465	ACCESSION:AR226465
C 449	13.2	0.7	37	1	AX280656	ACCESSION:AX280656	C 522	12.4	0.7	15	1	AR226474	ACCESSION:AR226474
C 450	13.2	0.7	37	1	AX280657	ACCESSION:AX280657	C 523	12.4	0.7	15	1	161824	ACCESSION:161824
C 451	13	0.7	15	1	AR041251	ACCESSION:AR041251	C 524	12.4	0.7	15	1	AR708719	ACCESSION:AR708719
C 452	13	0.7	15	1	AR041763	ACCESSION:AR041763	C 525	12.4	0.7	15	1	AX633376	ACCESSION:AX633376
C 453	13	0.7	15	1	AR056190	ACCESSION:AR056190	C 526	12.4	0.7	15	1	AX633609	ACCESSION:AX633609
C 454	13	0.7	15	1	AR056412	ACCESSION:AR056412	C 527	12.4	0.7	15	1	AX636211	ACCESSION:AX636211
C 455	13	0.7	15	1	AR113948	ACCESSION:AR113948	C 528	12.4	0.7	15	1	AX636885	ACCESSION:AX636885
C 456	13	0.7	15	1	AR114170	ACCESSION:AR114170	C 529	12.4	0.7	19	1	CS096202	ACCESSION:CS096202
C 457	13	0.7	15	1	CS002360	ACCESSION:CS002360							ALIGNMENTS
C 458	13	0.7	15	1	CS002429	ACCESSION:CS002429							
C 459	13	0.7	15	1	CS005845	ACCESSION:CS005845							
C 460	13	0.7	15	1	CS006362	ACCESSION:CS006362							
C 461	13	0.7	15	1	AR285725	ACCESSION:AR285725							
C 462	13	0.7	15	1	AR397716	ACCESSION:AR397716							
C 463	13	0.7	15	1	AX633249	ACCESSION:AX633249							
C 464	13	0.7	15	1	AX633318	ACCESSION:AX633318							
C 465	13	0.7	15	1	AX636734	ACCESSION:AX636734							
C 466	13	0.7	15	1	AX637251	ACCESSION:AX637251							
C 467	13	0.7	16	1	AR435971	ACCESSION:AR435971							
C 468	12.8	0.7	16	1	AR001331	ACCESSION:AR001331							
C 469	12.8	0.7	16	1	AR037511	ACCESSION:AR037511							
C 470	12.8	0.7	16	1	AR054083	ACCESSION:AR054083							
C 471	12.8	0.7	16	1	AR062791	ACCESSION:AR062791							

ALIGNMENTS

RESULT 1
LOCUS AR591148 37 bp DNA
DEFINITION Sequence 279 from patent US 6806054.
ACCESSION AR591148
VERSION AR591148.1 GI:56638957
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

C 253	19	1.1	21	1	CS096407	ACCESSION:CS096407	326	19	1.1	21	1	CS096489	ACCESSION:CS096489
C 254	19	1.1	21	1	CS096408	ACCESSION:CS096408	C 327	19	1.1	21	1	CS096490	ACCESSION:CS096490
C 255	19	1.1	21	1	CS096409	ACCESSION:CS096409	C 328	19	1.1	21	1	CS096491	ACCESSION:CS096491
C 256	19	1.1	21	1	CS096410	ACCESSION:CS096410	C 329	19	1.1	21	1	CS096492	ACCESSION:CS096492
C 257	19	1.1	21	1	CS096411	ACCESSION:CS096411	C 330	19	1.1	21	1	CS096493	ACCESSION:CS096493
C 258	19	1.1	21	1	CS096412	ACCESSION:CS096412	C 331	19	1.1	21	1	CS096494	ACCESSION:CS096494
C 259	19	1.1	21	1	CS096413	ACCESSION:CS096413	C 332	19	1.1	21	1	CS096495	ACCESSION:CS096495
C 260	19	1.1	21	1	CS096414	ACCESSION:CS096414	C 333	18	1.0	20	1	AX511437	ACCESSION:AX511437
C 261	19	1.1	21	1	CS096415	ACCESSION:CS096415	C 334	18	1.0	20	1	AX298730	ACCESSION:AX298730
C 262	19	1.1	21	1	CS096416	ACCESSION:CS096416	C 335	17	1.0	22	1	AK675784	ACCESSION:AK675784
C 263	19	1.1	21	1	CS096417	ACCESSION:CS096417	C 336	17	1.0	17	1	BD241158	ACCESSION:BD241158
C 264	19	1.1	21	1	CS096418	ACCESSION:CS096418	C 337	17	1.0	17	1	AR482659	ACCESSION:AR482659
C 265	19	1.1	21	1	CS096419	ACCESSION:CS096419	C 338	16	0.9	20	1	BD230533	ACCESSION:BD230533
C 266	19	1.1	21	1	CS096420	ACCESSION:CS096420	C 339	16	0.9	20	1	BD230609	ACCESSION:BD230609
C 267	19	1.1	21	1	CS096421	ACCESSION:CS096421	C 340	16	0.9	20	1	AR337048	ACCESSION:AR337048
C 268	19	1.1	21	1	CS096422	ACCESSION:CS096422	C 341	16	0.9	21	1	CO897421	ACCESSION:CO897421
C 269	19	1.1	21	1	CS096423	ACCESSION:CS096423	C 342	16	0.9	21	1	CO897858	ACCESSION:CO897858
C 270	19	1.1	21	1	CS096424	ACCESSION:CS096424	C 343	16	0.9	21	1	AR670046	ACCESSION:AR670046
C 271	19	1.1	21	1	CS096425	ACCESSION:CS096425	C 344	16	0.9	21	1	AX663594	ACCESSION:AX663594
C 272	19	1.1	21	1	CS096426	ACCESSION:CS096426	C 345	16	0.9	20	1	AR428075	ACCESSION:AR428075
C 273	19	1.1	21	1	CS096427	ACCESSION:CS096427	C 346	16	0.9	20	1	AR337049	ACCESSION:AR337049
C 274	19	1.1	21	1	CS096428	ACCESSION:CS096428	C 347	15	0.9	19	1	CS174435	ACCESSION:CS174435
C 275	19	1.1	21	1	CS096429	ACCESSION:CS096429	C 348	15	0.9	19	1	CS191043	ACCESSION:CS191043
C 276	19	1.1	21	1	CS096430	ACCESSION:CS096430	C 349	15	0.9	19	1	CS193807	ACCESSION:CS193807
C 277	19	1.1	21	1	CS096431	ACCESSION:CS096431	C 350	15	0.9	19	1	AX278625	ACCESSION:AX278625
C 278	19	1.1	21	1	CS096432	ACCESSION:CS096432	C 351	15	0.9	17	1	BD259402	ACCESSION:BD259402
C 279	19	1.1	21	1	CS096433	ACCESSION:CS096433	C 352	15	0.9	18	1	AS6834	ACCESSION:AS6834
C 280	19	1.1	21	1	CS096434	ACCESSION:CS096434	C 353	15	0.9	18	1	AS6852	ACCESSION:AS6852
C 281	19	1.1	21	1	CS096435	ACCESSION:CS096435	C 354	15	0.9	18	1	AS6871	ACCESSION:AS6871
C 282	19	1.1	21	1	CS096436	ACCESSION:CS096436	C 355	15	0.9	18	1	AS6881	ACCESSION:AS6881
C 283	19	1.1	21	1	CS096437	ACCESSION:CS096437	C 356	15	0.9	18	1	A97983	ACCESSION:A97983
C 284	19	1.1	21	1	CS096438	ACCESSION:CS096438	C 357	15	0.9	18	1	AR096229	ACCESSION:AR096229
C 285	19	1.1	21	1	CS096439	ACCESSION:CS096439	C 358	15	0.9	18	1	AR096248	ACCESSION:AR096248
C 286	19	1.1	21	1	CS096440	ACCESSION:CS096440	C 359	15	0.9	18	1	AR118332	ACCESSION:AR118332
C 287	19	1.1	21	1	CS096441	ACCESSION:CS096441	C 360	15	0.9	18	1	AR118342	ACCESSION:AR118342
C 288	19	1.1	21	1	CS096442	ACCESSION:CS096442	C 361	15	0.9	18	1	CS185388	ACCESSION:CS185388
C 289	19	1.1	21	1	CS096443	ACCESSION:CS096443	C 362	15	0.9	18	1	CS185395	ACCESSION:CS185395
C 290	19	1.1	21	1	CS096444	ACCESSION:CS096444	C 363	15	0.9	18	1	DD184859	ACCESSION:DD184859
C 291	19	1.1	21	1	CS096445	ACCESSION:CS096445	C 364	15	0.9	18	1	DD184861	ACCESSION:DD184861
C 292	19	1.1	21	1	CS096446	ACCESSION:CS096446	C 365	15	0.9	18	1	AX718623	ACCESSION:AX718623
C 293	19	1.1	21	1	CS096447	ACCESSION:CS096447	C 366	15	0.9	19	1	AR295199	ACCESSION:AR295199
C 294	19	1.1	21	1	CS096448	ACCESSION:CS096448	C 367	15	0.9	19	1	AR295723	ACCESSION:AR295723
C 295	19	1.1	21	1	CS096449	ACCESSION:CS096449	C 368	15	0.8	18	1	AR105389	ACCESSION:AR105389
C 296	19	1.1	21	1	CS096450	ACCESSION:CS096450	C 369	14	0.8	18	1	AR092811	ACCESSION:AR092811
C 297	19	1.1	21	1	CS096451	ACCESSION:CS096451	C 370	14	0.8	18	1	DD174035	ACCESSION:DD174035
C 298	19	1.1	21	1	CS096452	ACCESSION:CS096452	C 371	14	0.8	18	1	AE61305	ACCESSION:AE61305
C 299	19	1.1	21	1	CS096453	ACCESSION:CS096453	C 372	14	0.8	18	1	AE61329	ACCESSION:AE61329
C 300	19	1.1	21	1	CS096454	ACCESSION:CS096454	C 373	14	0.8	18	1	AR100814	ACCESSION:AR100814
C 301	19	1.1	21	1	CS096455	ACCESSION:CS096455	C 374	14	0.8	18	1	AR100838	ACCESSION:AR100838
C 302	19	1.1	21	1	CS096456	ACCESSION:CS096456	C 375	14	0.8	17	1	AR157062	ACCESSION:AR157062
C 303	19	1.1	21	1	CS096457	ACCESSION:CS096457	C 376	14	0.8	17	1	AX722275	ACCESSION:AX722275
C 304	19	1.1	21	1	CS096458	ACCESSION:CS096458	C 377	14	0.8	17	1	AX723940	ACCESSION:AX723940
C 305	19	1.1	21	1	CS096459	ACCESSION:CS096459	C 378	14	0.8	18	1	CS173519	ACCESSION:CS173519
C 306	19	1.1	21	1	CS096460	ACCESSION:CS096460	C 379	14	0.8	18	1	CS185389	ACCESSION:CS185389
C 307	19	1.1	21	1	CS096461	ACCESSION:CS096461	C 380	14	0.8	18	1	CS185396	ACCESSION:CS185396
C 308	19	1.1	21	1	CS096462	ACCESSION:CS096462	C 381	14	0.8	18	1	AR216239	ACCESSION:AR216239
C 309	19	1.1	21	1	CS096463	ACCESSION:CS096463	C 382	14	0.8	18	1	AR241961	ACCESSION:AR241961
C 310	19	1.1	21	1	CS096464	ACCESSION:CS096464	C 383	14	0.8	16	1	A24597	ACCESSION:A24597
C 311	19	1.1	21	1	CS096465	ACCESSION:CS096465	C 384	14	0.8	17	1	BD128459	ACCESSION:BD128459
C 312	19	1.1	21	1	CS096466	ACCESSION:CS096466	C 385	14	0.8	17	1	AX673704	ACCESSION:AX673704
C 313	19	1.1	21	1	CS096467	ACCESSION:CS096467	C 386	14	0.8	17	1	AX729755	ACCESSION:AX729755
C 314	19	1.1	21	1	CS096468	ACCESSION:CS096468	C 387	14	0.8	17	1	AX733963	ACCESSION:AX733963
C 315	19	1.1	21	1	CS096469	ACCESSION:CS096469	C 388	14	0.8	31	1	AX249066	ACCESSION:AX249066
C 316	19	1.1	21	1	CS096470	ACCESSION:CS096470	C 389	13	0.8	17	1	BD067422	ACCESSION:BD067422
C 317	19	1.1	21	1	CS096471	ACCESSION:CS096471	C 390	13	0.8	17	1	BD241157	ACCESSION:BD241157
C 318	19	1.1	21	1	CS096472	ACCESSION:CS096472	C 391	13	0.8	17	1	BD241159	ACCESSION:BD241159
C 319	19	1.1	21	1	CS096473	ACCESSION:CS096473	C 392	13	0.8	17	1	CO617561	ACCESSION:CO617561
C 320	19	1.1	21	1	CS096474	ACCESSION:CS096474	C 393	13	0.8	17	1	CO875811	ACCESSION:CO875811
C 321	19	1.1	21	1	CS096475	ACCESSION:CS096475	C 394	13	0.8	17	1	CO889694	ACCESSION:CO889694
C 322	19	1.1	21	1	CS096476	ACCESSION:CS096476	C 395	13	0.8	17	1	CS185402	ACCESSION:CS185402
C 323	19	1.1	21	1	CS096477	ACCESSION:CS096477	C 396	13	0.8	17	1	CS185409	ACCESSION:CS185409
C 324	19	1.1	21	1	CS096487	ACCESSION:CS096487	C 397	13	0.8	17	1	DD185857	ACCESSION:DD185857
C 325	19	1.1	21	1	CS096488	ACCESSION:CS096488	C 398	13	0.8	17	1	DD186271	ACCESSION:DD186271

107	19	1.1	19	1	CS096257	ACCESSION: CS096257	C 180	19	1.1	19	1	CS096330	ACCESSION: CS096330
108	19	1.1	19	1	CS096258	ACCESSION: CS096258	C 181	19	1.1	19	1	CS096331	ACCESSION: CS096331
109	19	1.1	19	1	CS096259	ACCESSION: CS096259	C 182	19	1.1	19	1	CS096332	ACCESSION: CS096332
110	19	1.1	19	1	CS096260	ACCESSION: CS096260	C 183	19	1.1	19	1	CS096333	ACCESSION: CS096333
111	19	1.1	19	1	CS096261	ACCESSION: CS096261	C 184	19	1.1	19	1	CS096334	ACCESSION: CS096334
112	19	1.1	19	1	CS096262	ACCESSION: CS096262	C 185	19	1.1	19	1	CS096335	ACCESSION: CS096335
113	19	1.1	19	1	CS096263	ACCESSION: CS096263	C 186	19	1.1	19	1	CS096336	ACCESSION: CS096336
114	19	1.1	19	1	CS096264	ACCESSION: CS096264	C 187	19	1.1	19	1	CS096337	ACCESSION: CS096337
115	19	1.1	19	1	CS096265	ACCESSION: CS096265	C 188	19	1.1	19	1	CS096338	ACCESSION: CS096338
116	19	1.1	19	1	CS096266	ACCESSION: CS096266	C 189	19	1.1	19	1	CS096339	ACCESSION: CS096339
117	19	1.1	19	1	CS096267	ACCESSION: CS096267	C 190	19	1.1	19	1	CS096340	ACCESSION: CS096340
118	19	1.1	19	1	CS096268	ACCESSION: CS096268	C 191	19	1.1	19	1	CS096341	ACCESSION: CS096341
119	19	1.1	19	1	CS096269	ACCESSION: CS096269	C 192	19	1.1	19	1	CS096342	ACCESSION: CS096342
120	19	1.1	19	1	CS096270	ACCESSION: CS096270	C 193	19	1.1	19	1	CS096343	ACCESSION: CS096343
121	19	1.1	19	1	CS096271	ACCESSION: CS096271	C 194	19	1.1	19	1	CS096344	ACCESSION: CS096344
122	19	1.1	19	1	CS096272	ACCESSION: CS096272	C 195	19	1.1	19	1	CS096345	ACCESSION: CS096345
123	19	1.1	19	1	CS096273	ACCESSION: CS096273	C 196	19	1.1	19	1	CS096346	ACCESSION: CS096346
124	19	1.1	19	1	CS096274	ACCESSION: CS096274	C 197	19	1.1	19	1	CS096347	ACCESSION: CS096347
C 125	19	1.1	19	1	CS096275	ACCESSION: CS096275	C 198	19	1.1	19	1	CS096348	ACCESSION: CS096348
C 126	19	1.1	19	1	CS096276	ACCESSION: CS096276	C 199	19	1.1	19	1	CS096349	ACCESSION: CS096349
C 127	19	1.1	19	1	CS096277	ACCESSION: CS096277	C 200	19	1.1	19	1	CS096350	ACCESSION: CS096350
C 128	19	1.1	19	1	CS096278	ACCESSION: CS096278	C 201	19	1.1	19	1	CS096351	ACCESSION: CS096351
C 129	19	1.1	19	1	CS096279	ACCESSION: CS096279	C 202	19	1.1	19	1	CS096352	ACCESSION: CS096352
C 130	19	1.1	19	1	CS096280	ACCESSION: CS096280	C 203	19	1.1	19	1	CS096353	ACCESSION: CS096353
C 131	19	1.1	19	1	CS096281	ACCESSION: CS096281	C 204	19	1.1	19	1	CS096354	ACCESSION: CS096354
C 132	19	1.1	19	1	CS096282	ACCESSION: CS096282	C 205	19	1.1	19	1	CS096355	ACCESSION: CS096355
C 133	19	1.1	19	1	CS096283	ACCESSION: CS096283	C 206	19	1.1	19	1	CS096356	ACCESSION: CS096356
C 134	19	1.1	19	1	CS096284	ACCESSION: CS096284	C 207	19	1.1	19	1	CS096357	ACCESSION: CS096357
C 135	19	1.1	19	1	CS096285	ACCESSION: CS096285	C 208	19	1.1	19	1	CS096358	ACCESSION: CS096358
C 136	19	1.1	19	1	CS096286	ACCESSION: CS096286	C 209	19	1.1	19	1	CS096359	ACCESSION: CS096359
C 137	19	1.1	19	1	CS096287	ACCESSION: CS096287	C 210	19	1.1	19	1	CS096360	ACCESSION: CS096360
C 138	19	1.1	19	1	CS096288	ACCESSION: CS096288	C 211	19	1.1	19	1	CS096361	ACCESSION: CS096361
C 139	19	1.1	19	1	CS096289	ACCESSION: CS096289	C 212	19	1.1	19	1	CS096362	ACCESSION: CS096362
C 140	19	1.1	19	1	CS096290	ACCESSION: CS096290	C 213	19	1.1	19	1	CS096363	ACCESSION: CS096363
C 141	19	1.1	19	1	CS096291	ACCESSION: CS096291	C 214	19	1.1	19	1	CS096364	ACCESSION: CS096364
C 142	19	1.1	19	1	CS096292	ACCESSION: CS096292	C 215	19	1.1	19	1	CS096365	ACCESSION: CS096365
C 143	19	1.1	19	1	CS096293	ACCESSION: CS096293	C 216	19	1.1	19	1	CS096366	ACCESSION: CS096366
C 144	19	1.1	19	1	CS096294	ACCESSION: CS096294	C 217	19	1.1	19	1	CS096367	ACCESSION: CS096367
C 145	19	1.1	19	1	CS096295	ACCESSION: CS096295	C 218	19	1.1	19	1	CS096368	ACCESSION: CS096368
C 146	19	1.1	19	1	CS096296	ACCESSION: CS096296	C 219	19	1.1	19	1	CS096369	ACCESSION: CS096369
C 147	19	1.1	19	1	CS096297	ACCESSION: CS096297	C 220	19	1.1	19	1	CS096370	ACCESSION: CS096370
C 148	19	1.1	19	1	CS096298	ACCESSION: CS096298	C 221	19	1.1	19	1	CS096371	ACCESSION: CS096371
C 149	19	1.1	19	1	CS096299	ACCESSION: CS096299	C 222	19	1.1	19	1	CS096372	ACCESSION: CS096372
C 150	19	1.1	19	1	CS096300	ACCESSION: CS096300	C 223	19	1.1	19	1	CS096373	ACCESSION: CS096373
C 151	19	1.1	19	1	CS096301	ACCESSION: CS096301	C 224	19	1.1	19	1	CS207422	ACCESSION: CS207422
C 152	19	1.1	19	1	CS096302	ACCESSION: CS096302	C 225	19	1.1	19	1	CS207423	ACCESSION: CS207423
C 153	19	1.1	19	1	CS096303	ACCESSION: CS096303	C 226	19	1.1	19	1	CS207424	ACCESSION: CS207424
C 154	19	1.1	19	1	CS096304	ACCESSION: CS096304	C 227	19	1.1	19	1	CS207425	ACCESSION: CS207425
C 155	19	1.1	19	1	CS096305	ACCESSION: CS096305	C 228	19	1.1	19	1	CS096382	ACCESSION: CS096382
C 156	19	1.1	19	1	CS096306	ACCESSION: CS096306	C 229	19	1.1	19	1	CS096383	ACCESSION: CS096383
C 157	19	1.1	19	1	CS096307	ACCESSION: CS096307	C 230	19	1.1	19	1	CS096384	ACCESSION: CS096384
C 158	19	1.1	19	1	CS096308	ACCESSION: CS096308	C 231	19	1.1	19	1	CS096385	ACCESSION: CS096385
C 159	19	1.1	19	1	CS096309	ACCESSION: CS096309	C 232	19	1.1	19	1	CS096386	ACCESSION: CS096386
C 160	19	1.1	19	1	CS096310	ACCESSION: CS096310	C 233	19	1.1	19	1	CS096387	ACCESSION: CS096387
C 161	19	1.1	19	1	CS096311	ACCESSION: CS096311	C 234	19	1.1	19	1	CS096388	ACCESSION: CS096388
C 162	19	1.1	19	1	CS096312	ACCESSION: CS096312	C 235	19	1.1	19	1	CS096389	ACCESSION: CS096389
C 163	19	1.1	19	1	CS096313	ACCESSION: CS096313	C 236	19	1.1	19	1	CS096390	ACCESSION: CS096390
C 164	19	1.1	19	1	CS096314	ACCESSION: CS096314	C 237	19	1.1	19	1	CS096391	ACCESSION: CS096391
C 165	19	1.1	19	1	CS096315	ACCESSION: CS096315	C 238	19	1.1	19	1	CS096392	ACCESSION: CS096392
C 166	19	1.1	19	1	CS096316	ACCESSION: CS096316	C 239	19	1.1	19	1	CS096393	ACCESSION: CS096393
C 167	19	1.1	19	1	CS096317	ACCESSION: CS096317	C 240	19	1.1	19	1	CS096394	ACCESSION: CS096394
C 168	19	1.1	19	1	CS096318	ACCESSION: CS096318	C 241	19	1.1	19	1	CS096395	ACCESSION: CS096395
C 169	19	1.1	19	1	CS096319	ACCESSION: CS096319	C 242	19	1.1	19	1	CS096396	ACCESSION: CS096396
C 170	19	1.1	19	1	CS096320	ACCESSION: CS096320	C 243	19	1.1	19	1	CS096397	ACCESSION: CS096397
C 171	19	1.1	19	1	CS096321	ACCESSION: CS096321	C 244	19	1.1	19	1	CS096398	ACCESSION: CS096398
C 172	19	1.1	19	1	CS096322	ACCESSION: CS096322	C 245	19	1.1	19	1	CS096399	ACCESSION: CS096399
C 173	19	1.1	19	1	CS096323	ACCESSION: CS096323	C 246	19	1.1	19	1	CS096400	ACCESSION: CS096400
C 174	19	1.1	19	1	CS096324	ACCESSION: CS096324	C 247	19	1.1	19	1	CS096401	ACCESSION: CS096401
C 175	19	1.1	19	1	CS096325	ACCESSION: CS096325	C 248	19	1.1	19	1	CS096402	ACCESSION: CS096402
C 176	19	1.1	19	1	CS096326	ACCESSION: CS096326	C 249	19	1.1	19	1	CS096403	ACCESSION: CS096403
C 177	19	1.1	19	1	CS096327	ACCESSION: CS096327	C 250	19	1.1	19	1	CS096404	ACCESSION: CS096404
C 178	19	1.1	19	1	CS096328	ACCESSION: CS096328	C 251	19	1.1	19	1	CS096405	ACCESSION: CS096405
C 179	19	1.1	19	1	CS096329	ACCESSION: CS096329	C 252	19	1.1	19	1	CS096406	ACCESSION: CS096406

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 30, 2006, 13:47:12 ; Search time 10 Seconds
(without alignments)
3.528 Million cell updates/sec

Title: US-10-798-090A-305

Perfect score: 1773

Sequence: 1 augaccuagcacaauaacag.....caccgcagcagcguuag 1773

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 523 seqs, 9949 residues

Total number of hits satisfying chosen parameters: 1046

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 529 summaries

Database : rge.subdb:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	32.2	1.8	37	1	AR591148
2	32.2	1.8	37	1	AR591148
3	32.2	1.8	37	1	AR591149
4	32.2	1.8	37	1	AX280656
5	27	1.5	27	1	AR109645
6	27	1.5	27	1	AR109645
7	26.8	1.5	30	1	BD235807
8	26.8	1.5	30	1	BD235804
9	26	1.5	32	1	AR590948
10	26	1.5	32	1	AR590948
11	25.2	1.4	30	1	BD235751
12	25.2	1.4	30	1	BD235756
13	25.2	1.4	30	1	BD235802
14	25.2	1.4	30	1	BD235807
15	24.8	1.4	31	1	AX249066
16	24.8	1.4	31	1	AX249249
17	23	1.3	23	1	CS096374
18	23	1.3	23	1	CS096375
19	23	1.3	23	1	CS096376
20	23	1.3	23	1	CS096377
21	23	1.3	23	1	CS096378
22	23	1.3	23	1	CS096379
23	23	1.3	23	1	CS096380
24	23	1.3	23	1	CS096381
25	20.6	1.2	21	1	AX154389
26	19	1.1	19	1	CS096176
27	19	1.1	19	1	CS096177
28	19	1.1	19	1	CS096178
29	19	1.1	19	1	CS096179
30	19	1.1	19	1	CS096180
31	19	1.1	19	1	CS096181
32	19	1.1	19	1	CS096182
33	19	1.1	19	1	CS096183

34	19	1.1	19	1	CS096184	ACCESSION: CS096184
35	19	1.1	19	1	CS096185	ACCESSION: CS096185
36	19	1.1	19	1	CS096186	ACCESSION: CS096186
37	19	1.1	19	1	CS096187	ACCESSION: CS096187
38	19	1.1	19	1	CS096188	ACCESSION: CS096188
39	19	1.1	19	1	CS096189	ACCESSION: CS096189
40	19	1.1	19	1	CS096190	ACCESSION: CS096190
41	19	1.1	19	1	CS096191	ACCESSION: CS096191
42	19	1.1	19	1	CS096192	ACCESSION: CS096192
43	19	1.1	19	1	CS096193	ACCESSION: CS096193
44	19	1.1	19	1	CS096194	ACCESSION: CS096194
45	19	1.1	19	1	CS096195	ACCESSION: CS096195
46	19	1.1	19	1	CS096196	ACCESSION: CS096196
47	19	1.1	19	1	CS096197	ACCESSION: CS096197
48	19	1.1	19	1	CS096198	ACCESSION: CS096198
49	19	1.1	19	1	CS096199	ACCESSION: CS096199
50	19	1.1	19	1	CS096200	ACCESSION: CS096200
51	19	1.1	19	1	CS096201	ACCESSION: CS096201
52	19	1.1	19	1	CS096202	ACCESSION: CS096202
53	19	1.1	19	1	CS096203	ACCESSION: CS096203
54	19	1.1	19	1	CS096204	ACCESSION: CS096204
55	19	1.1	19	1	CS096205	ACCESSION: CS096205
56	19	1.1	19	1	CS096206	ACCESSION: CS096206
57	19	1.1	19	1	CS096207	ACCESSION: CS096207
58	19	1.1	19	1	CS096208	ACCESSION: CS096208
59	19	1.1	19	1	CS096209	ACCESSION: CS096209
60	19	1.1	19	1	CS096210	ACCESSION: CS096210
61	19	1.1	19	1	CS096211	ACCESSION: CS096211
62	19	1.1	19	1	CS096212	ACCESSION: CS096212
63	19	1.1	19	1	CS096213	ACCESSION: CS096213
64	19	1.1	19	1	CS096214	ACCESSION: CS096214
65	19	1.1	19	1	CS096215	ACCESSION: CS096215
66	19	1.1	19	1	CS096216	ACCESSION: CS096216
67	19	1.1	19	1	CS096217	ACCESSION: CS096217
68	19	1.1	19	1	CS096218	ACCESSION: CS096218
69	19	1.1	19	1	CS096219	ACCESSION: CS096219
70	19	1.1	19	1	CS096220	ACCESSION: CS096220
71	19	1.1	19	1	CS096221	ACCESSION: CS096221
72	19	1.1	19	1	CS096222	ACCESSION: CS096222
73	19	1.1	19	1	CS096223	ACCESSION: CS096223
74	19	1.1	19	1	CS096224	ACCESSION: CS096224
75	19	1.1	19	1	CS096225	ACCESSION: CS096225
76	19	1.1	19	1	CS096226	ACCESSION: CS096226
77	19	1.1	19	1	CS096227	ACCESSION: CS096227
78	19	1.1	19	1	CS096228	ACCESSION: CS096228
79	19	1.1	19	1	CS096229	ACCESSION: CS096229
80	19	1.1	19	1	CS096230	ACCESSION: CS096230
81	19	1.1	19	1	CS096231	ACCESSION: CS096231
82	19	1.1	19	1	CS096232	ACCESSION: CS096232
83	19	1.1	19	1	CS096233	ACCESSION: CS096233
84	19	1.1	19	1	CS096234	ACCESSION: CS096234
85	19	1.1	19	1	CS096235	ACCESSION: CS096235
86	19	1.1	19	1	CS096236	ACCESSION: CS096236
87	19	1.1	19	1	CS096237	ACCESSION: CS096237
88	19	1.1	19	1	CS096238	ACCESSION: CS096238
89	19	1.1	19	1	CS096239	ACCESSION: CS096239
90	19	1.1	19	1	CS096240	ACCESSION: CS096240
91	19	1.1	19	1	CS096241	ACCESSION: CS096241
92	19	1.1	19	1	CS096242	ACCESSION: CS096242
93	19	1.1	19	1	CS096243	ACCESSION: CS096243
94	19	1.1	19	1	CS096244	ACCESSION: CS096244
95	19	1.1	19	1	CS096245	ACCESSION: CS096245
96	19	1.1	19	1	CS096246	ACCESSION: CS096246
97	19	1.1	19	1	CS096247	ACCESSION: CS096247
98	19	1.1	19	1	CS096248	ACCESSION: CS096248
99	19	1.1	19	1	CS096249	ACCESSION: CS096249
100	19	1.1	19	1	CS096250	ACCESSION: CS096250
101	19	1.1	19	1	CS096251	ACCESSION: CS096251
102	19	1.1	19	1	CS096252	ACCESSION: CS096252
103	19	1.1	19	1	CS096253	ACCESSION: CS096253
104	19	1.1	19	1	CS096254	ACCESSION: CS096254
105	19	1.1	19	1	CS096255	ACCESSION: CS096255
106	19	1.1	19	1	CS096256	ACCESSION: CS096256

THIS PAGE BLANK (USPTO)

Qy	815	GGACGAGGCGCAGAG	828
Db	1	GGACGAGGCGCAGAG	14

Search completed: June 30, 2006, 13:52:28
Job time : 23 secs

RESULT 907
 AEA52090/c
 ID AEA52090 standard; DNA; 16 BP.
 XX
 AC AEA52090;
 XX
 DT 25-AUG-2005 (first entry)
 XX
 DE Prostate cancer gene PCR primer SEQ ID NO 693.
 XX
 KW gene expression; cell proliferation; hyperproliferation; cytostatic;
 KM neoplasm; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2005054517-A2.
 XX
 PD 16-JUN-2005.
 XX
 PP 01-DEC-2004; 2004WO-US040289.
 XX
 PR 01-DEC-2003; 2003EP-00090414.
 XX
 PR 10-FEB-2004; 2004EP-0009040.
 XX
 PR 10-MAY-2004; 2004EP-00090187.
 XX
 PR 21-JUL-2004; 2004EP-00090292.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Day KJ, Cottrell S, Distler J, Morotti A, Yamamura S, Dekker S;
 PI Ocamp Y, Devos T;
 XX
 DR WPI; 2005-425434/43.
 XX
 PT Detecting and/or differentiating prostate cell proliferative disorders in
 PT a subject by contacting genomic with reagent(s) that distinguishes
 PT between methylated and non-methylated CpG dinucleotides in target nucleic
 PT acids.
 XX
 PS Example 3; SEQ ID NO 693; 164pp; English.
 XX
 CC The invention describes a method of detecting and/or differentiating
 CC between prostate cell proliferative disorders in a subject comprising
 CC contacting genomic DNA isolated from a biological sample with at least
 CC one reagent, or series of reagents that distinguishes between methylated
 CC and non-methylated CpG dinucleotides within one or a combination of
 CC target nucleic acids e.g. HISTONE H4. Also described are: a treated
 CC nucleic acid derived from SEQ ID NO: 1-59, 1017-1028, 1116, 1171, where
 CC the treatment converts at least one unmethylated cytosine base of the
 CC genomic DNA sequence to uracil or another base that is detectable
 CC dissimilar to cytosine in terms of hybridization; a nucleic acid
 CC comprising at least 16 contiguous nucleotides of a treated genomic DNA
 CC sequence selected from SEQ ID NO: 60-295, 1029-1076, 1117-1120, 1172-1175
 CC and sequences complementary to them; an oligomer comprising a sequence of
 CC at least 9 contiguous nucleotides that is complementary to, or hybridizes
 CC under moderately stringent or stringent conditions to a treated genomic
 CC DNA sequence above; a set of oligomers comprising at least two
 CC oligonucleotides as above; and a kit useful for detecting and/or
 CC distinguishing between or among prostate cell proliferative disorder of a
 CC subject comprising at least one of a bisulfite reagent, or a methylation-
 CC sensitive restriction enzyme, and at least one nucleic acid molecule or
 CC peptide nucleic acid molecule comprising a contiguous sequence at least 9
 CC nucleotides that is complementary to, or hybridizes under moderately
 CC stringent or stringent conditions to a sequence selected from SEQ ID NO:
 CC 60-295, 1029-1076, 1117-1120, 1172-1175 and their complements. The
 CC method, nucleic acid, oligomer, set of oligonucleotide, and kit are
 CC useful for detecting and/or differentiating between or among cell
 CC proliferative disorders. This sequence represents a primer used in the
 CC isolation of gene encoding a prostate cell proliferation associated
 CC protein.
 XX
 SQ Sequence 16 BP; 3 A; 0 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 68.8%; Pred. No. 5.9e+02;
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
 Qy 1558 UGCANACCCAAACCU 1573
 Db 16 TCCATACCCAAACAT 1
 XX
 AC AEF09334/c
 ID AEF09334 standard; DNA; 16 BP.
 XX
 AC AEF09334;
 XX
 DT 09-MAR-2006 (first entry)
 XX
 DE Human PRSS8 Tpg probe SEQ ID NO:630.
 XX
 KW DNA methylation; epigenetic modification; cancer; cytostatic;
 KM tumor marker; Breast tumor; prognosis; ss; probe.
 XX
 OS Homo sapiens.
 XX
 OS Synthetic.
 XX
 PN WO2005123945-A2.
 XX
 PD 29-DEC-2005.
 XX
 PP 21-JUN-2005; 2005WO-BP006713.
 XX
 PR 21-JUN-2004; 2004EP-00090244.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Lesche R, Fassbender A, Juenemann K, Foekens J, Martens JWM;
 PI Maier S, Nimmrich I, Koenig T, Wang-Gohrke S;
 XX
 DR WPI; 2006-067522/07.
 XX
 PT Classifying breast cancers according to estrogen receptor status by
 PT obtaining a genomic DNA sample from a subject and determining the
 PT methylation status of CpG positions within a target nucleic acid.
 XX
 PS Example 1; SEQ ID NO 630; 412pp; English.
 XX
 CC The invention relates to classifying breast cancers according to estrogen
 CC receptor status comprising obtaining a genomic DNA sample from a subject,
 CC determining the methylation status of one or more CpG positions comprised
 CC within at least one target nucleic acid (comprising the gene IGFBP7
 CC and/or its regulatory regions) and determining the estrogen receptor
 CC status of the subject. The method also comprises obtaining a genomic DNA
 CC sample from a subject, determining the methylation status of one or more
 CC CpG positions comprised within at least one target nucleic acid
 CC consisting of one or a combination of the genes or genomic sequences
 CC consisting of IGFBP7, S100A2, ARHI, CSRG2, DAPK1, SFN, PTGS2, IGF1, SEQ
 CC ID NO: 12, ARL7, PLAU, MEF, S100A7, PABP3, SEQ ID NO: 19, SCGB3A1,
 CC SERPINE5, GSTP1, SEQ ID NO: 24, LIM DOMAIN KINASE 1, I16, SEQ ID NO: 27,
 CC ERA4, SEQ ID NO: 29, SFN, SEQ ID NO: 30, SLIT2, CCND2, HOXA5, APAF1, MGCI0561,
 CC PRDM2, PROSTAGLANDIN E2 RECEPTOR, SNGF, NR2E1, SFN, PRSS8 (appearing as
 CC AEF08705-AEF08745) and/or their regulatory regions by contacting the
 CC target nucleic acid with one or more agents (e.g. bisulfite) that convert
 CC cytosine bases that are unmethylated at the 5'-position to a base that is
 CC detectably dissimilar to cytosine in terms of hybridization properties,
 CC and determining the estrogen receptor status of the subject. The method
 CC is useful for classifying breast cancers according to estrogen receptor
 CC status, nodal status or progesterone receptor status. The present
 CC sequence is a probe that detects a region of a target DNA that containing
 CC an unmethylated CpG dinucleotide (i.e. the sequence has been converted to
 CC Tpg).
 XX
 SQ Sequence 16 BP; 3 A; 0 C; 7 G; 6 T; 0 U; 0 Other;

FT FT /tag= c
FT FT /mod_base= OTHER
FT FT /note= "Phosphorothioate linkages"
FT modified_base
FT 1..4
FT /tag= a
FT /mod_base= OTHER
FT /note= "Beta-D-oxy-LNA (locked nucleic acid). All beta-D
FT -oxy-LNA cytosines are 5-methylcytosine"
FT modified_base
FT 13..16
FT /tag= d
FT /mod_base= OTHER
FT /note= "Beta-D-oxy-LNA. All beta-D-oxy-LNA cytosines are
FT 5-methylcytosine"
XX US2005014712-A1.
XX
XX 20-JAN-2005.
XX
XX 10-FEB-2004; 2004US-00776934.
XX
XX 10-FEB-2003; 2003US-0446372P.
XX 19-NOV-2003; 2003US-0523591P.
XX
XX (HANS/) HANSEN B.
XX (THRU/) THRU C A.
XX (WEST/) WESTERGAARD M.
XX (PERE/) PETERSEN K D.
XX (WISS/) WISSENBACH M.
XX
XX Hansen B, Thru CA, Westergaard M, Petersen KD, Wissebach M;
XX WPI: 2005-100663/11.
XX
XX New oligomeric compound for the modulation of survivin, useful for
XX treating e.g. cancers, atherosclerosis, psoriasis, diabetic retinopathy,
XX rheumatoid arthritis, asthma, warts, or allergic dermatitis.
XX
XX Example 10; SEQ ID NO 272; 264pp; English.
XX
XX The invention relates to antisense oligonucleotides consisting of 8-50
XX nucleotides and/or nucleotide analogs which inhibit expression of human
XX survivin, an inhibitor of apoptosis which is also essential for cell
XX division and angiogenesis. The antisense oligonucleotides comprise a
XX subsequence of 8 or more nucleotides or nucleotide analogs, wherein the
XX subsequence is located within a sequence selected from ADM09444-ADM09586.
XX The oligonucleotides preferably contain one or more (preferably 6-10)
XX nucleotide analogs, especially a locked nucleic acid (LNA), and also
XX preferably contain a linkage group selected from a phosphate group, a
XX phosphorothioate group or a boranophosphate group. The invention also
XX relates to a conjugate comprising a survivin antisense oligonucleotide of
XX the invention and one or more non-nucleotide or non-polynucleotide
XX moieties covalently attached to the oligonucleotide, and a pharmaceutical
XX composition comprising a survivin antisense oligonucleotide or conjugate
XX of the invention, optionally further comprising a chemotherapeutic agent.
XX The survivin antisense oligonucleotides, and conjugates and compositions
XX containing them, are useful in the treatment of cancers such as
XX carcinomas (e.g., malignant melanoma, basal cell carcinoma, ovarian
XX carcinoma, breast carcinoma, non-small cell lung cancer, renal cell
XX carcinoma, bladder carcinoma, recurrent superficial bladder cancer,
XX stomach carcinoma, prostatic carcinoma, pancreatic carcinoma, lung
XX carcinoma, cervical carcinoma, cervical dysplasia, laryngeal
XX papillomatosis, colon carcinoma, colorectal carcinoma and carcinoma
XX tumors) (e.g., osteosarcoma, Ewing's sarcoma, chondrosarcoma,
XX malignant fibrous histiocytoma, fibrosarcoma, and Kaposi's sarcoma); or
XX gliomas. The survivin antisense oligonucleotides are also useful in the
XX treatment of conditions such as atherosclerosis, psoriasis, diabetic
XX retinopathy, rheumatoid arthritis, asthma, warts, and allergic
XX dermatitis. They may additionally be used for inhibiting cellular
XX proliferation, for modulating apoptosis and for treating a disease
XX related to abnormal angiogenesis. The survivin antisense oligonucleotides
XX of the invention are shorter than prior art survivin antisense
XX oligonucleotides (16-mers compared to 20-25-mers), therefore having
XX increased specificity and affinity for survivin mRNA, and also have

CC higher biostability and cell permeability. The present sequence
CC represents an antisense oligonucleotide targeted to the human survivin
CC cDNA target sequence shown in ADM09443 used in an example of the
CC invention.
XX
XX Sequence 16 BP; 1 A; 3 C; 2 G; 10 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 31.2%; Pred. No. 5.9e+02;
Matches 5; Conservative 9; Mismatches 2; Indels 0; Gaps 0;
QY 714 UGCUUUUUAUAGCCU 729
Db :||||:|:|:
1 TGCTTTTATGTTCCCT 16

RESULT 906
ADK85197
ID ADK85197 standard; DNA; 16 BP.
XX
XX
XX ADK85197;
AC
XX 05-MAY-2005 (first entry)
DT
XX
XX Mouse gadd45 DNA fragment, seqid:41.
DE
XX
XX Cell death; apoptosis; degeneration; cancer; cytostatic; neoplasm;
KW immunotherapy; chemotherapy; gene therapy; gadd45; ds.
KW
XX
XX Mus musculus.
OS
XX
XX EP1506784-A1.
PN
XX
XX 16-FEB-2005.
PD
XX
XX 26-JUL-2004; 2004EP-00017667.
PF
XX
XX 25-JUL-2003; 2003US-00626905.
PR
XX 02-DEC-2003; 2003US-0526231P.
XX
XX (UYCH-) UNIV CHICAGO.
XX
XX
XX Franzoso G, Desmaele B, Zazzeroni F, Papa S, Bubbici C;
PI
XX
XX WPI: 2005-154742/17.
XX
XX Method for modulating pathways leading to programmed cell death for
XX treating cancer, by obtaining peptide having specific amino acid sequence
XX and regulating JNK pathway using peptide or composition developed using
XX peptide sequence.
XX
XX Example 14; SEQ ID NO 41; 110pp; English.
XX
XX The invention relates to methods and compositions for modulating pathways
XX leading to programmed cell death or apoptosis. The method involves
XX selecting a target within the c-Jun-N-terminal kinase (JNK) pathway and
XX interfering the target by an agent that either upregulates or
XX downregulates the JNK pathway. The JNK modulator is effective in treating
XX degenerative disease and cancer. The method and compositions of the
XX invention are useful in immunotherapy, cancer chemotherapy and in gene
XX therapy. The present sequence is the mouse gadd45 DNA fragment. Gadd45 is
XX a modulator of JNK pathway.
XX
XX Sequence 16 BP; 3 A; 7 C; 5 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 5.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 956 GCUGAACCAGCUC 971
Db :|||||:|:|:
1 GCTGGAAACCCCGCGC 16

XX 07-APR-2005 (first entry)
DT Human survivin antisense oligonucleotide 33D, SEQ ID NO:275.
XX
XX Antisense therapy; apoptosis stimulation; neoplasm; carcinoma; melanoma;
XX basal cell carcinoma; ovary tumor; breast tumor;
XX non-small-cell lung cancer; renal cell carcinoma; bladder tumor;
XX stomach tumor; prostatic cancer; pancreas tumor; lung tumor;
XX uterine cervix tumor; cervical dysplasia; colon tumor; colorectal tumor;
XX sarcoma; osteosarcoma; Kaposi's sarcoma; anti-HIV; glioma; cytostatic;
XX endocrine disease; gynecology and obstetrics; genitourinary disease;
XX respiratory disease; musculoskeletal disease; dermatological disease;
XX proliferative disorder; atherosclerosis; antiarteriosclerotic;
XX cardiovascular disease; metabolic disorder; psoriasis; antipsoriatic;
XX immune disorder; diabetic retinopathy; antidiabetic; ophthalmological;
XX cardiovascular disease; ocular disease; rheumatoid arthritis;
XX anarthritic; antirheumatic; inflammation; asthma; antiasthmatic;
XX skin allergy; antiallergic; antiinflammatory; dermatological;
XX verruca vulgaris; virucide; cell proliferation; apoptosis modulation;
XX angiogenesis disorder; survivin; phosphorothioate; apoptosis modulation;
XX antisense oligonucleotide; ss.
XX Homo sapiens.
XX
XX Key location/Qualifiers
XX misc_binding 1..16
XX /tag= a
XX /bound_moiety= "Bases 288-273 of human survivin cDNA (SEQ
XX ID NO:1)"
XX modified_base 1..16
XX /tag= b
XX /mod_base= OTHER
XX /note= "Phosphorothioate linkages"
XX
XX US2005014712-A1.
XX
XX 20-JAN-2005.
XX
XX 10-FEB-2004; 2004US-00776934.
XX
XX 10-FEB-2003; 2003US-0446372P.
XX
XX 19-NOV-2003; 2003US-0523591P.
XX
XX (HANS/) HANSEN B.
XX (THRU/) THRU C A.
XX (WEST/) WESTERGAARD M.
XX (PETE/) PETERSEN K D.
XX (WISS/) WISSENBACH M.
XX
XX Hansen B, Thru CA, Westergaard M, Petersen KD, Wissenbach M;
XX
XX WPI, 2005-100663/11.
XX
XX New oligomeric compound for the modulation of survivin, useful for
XX treating e.g. cancers, atherosclerosis, psoriasis, diabetic retinopathy,
XX rheumatoid arthritis, asthma, warts, or allergic dermatitis.
XX
XX Example 10; SEQ ID NO 275; 264pp; English.
XX
XX The invention relates to antisense oligonucleotides consisting of 8-50
XX nucleotides and/or nucleotide analogs which inhibit expression of human
XX survivin, an inhibitor of apoptosis which is also essential for cell
XX division and angiogenesis. The antisense oligonucleotides comprise a
XX subsequence of 8 or more nucleotides or nucleotide analogs, wherein the
XX subsequence is located within a sequence selected from ADW09444-ADW09586.
XX The oligonucleotides preferably contain one or more (preferably 6-10)
XX nucleotide analogs, especially a locked nucleic acid (LNA), and also
XX preferably contain a linkage group selected from a phosphate group, a
XX phosphorothioate group or a boranophosphate group. The invention also
XX relates to a conjugate comprising a survivin antisense oligonucleotide of
XX the invention and one or more non-nucleotide or non-polynucleotide
XX moieties covalently attached to the oligonucleotide, and a pharmaceutical

CC composition comprising a survivin antisense oligonucleotide or conjugate
CC of the invention, optionally further comprising a chemotherapeutic agent.
CC The survivin antisense oligonucleotides, and conjugates and compositions
CC containing them, are useful in the treatment of cancers such as
CC carcinomas (e.g., malignant melanoma, basal cell carcinoma, ovarian
CC carcinoma, breast carcinoma, non-small cell lung cancer, renal cell
CC carcinoma, bladder carcinoma, recurrent superficial bladder cancer,
CC stomach carcinoma, prostatic carcinoma, pancreatic carcinoma, lung
CC carcinoma, cervical carcinoma, cervical dysplasia, laryngeal
CC papillomatosis, colon carcinoma, colorectal carcinoma and carcinoi
CC tumors); sarcomas (e.g., osteosarcoma, Ewing's sarcoma, chondrosarcoma,
CC malignant fibrous histiocytoma, fibrosarcoma, and Kaposi's sarcoma); or
CC gliomas. The survivin antisense oligonucleotides are also useful in the
CC treatment of conditions such as atherosclerosis, psoriasis, diabetic
CC retinopathy, rheumatoid arthritis, asthma, warts, and allergic
CC dermatitis. They may additionally be used for inhibiting cellular
CC proliferation, for modulating apoptosis and for treating a disease
CC related to abnormal angiogenesis. The survivin antisense oligonucleotides
CC of the invention are shorter than prior art survivin antisense
CC oligonucleotides (16-mers compared to 20-25-mers), therefore having
CC increased specificity and affinity for survivin mRNA, and also have
CC higher biostability and cell permeability. The present sequence
CC represents an antisense oligonucleotide targeted to the human survivin
CC cDNA target sequence shown in ADW09443 used in an example of the
CC invention.
XX
XX SEQ Sequence 16 BP; 1 A; 3 C; 2 G; 10 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 12.8; DB 1; Length 16;
XX Best Local Similarity 31.2%; Pred. No. 5; 9e+02;
XX Matches 5; Conservative 9; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 714 UGCUUUUUAUAGCCU 729
XX :||::||::||:|:
XX DB 1 TCGCTTTTATGTTCTT 16
XX
XX RESULT 905
XX ID ADW09714 standard; DNA; 16 BP.
XX AC ADW09714;
XX XX
XX DT 07-APR-2005 (first entry)
XX
XX Human survivin antisense oligonucleotide 33A, SEQ ID NO:272.
XX
XX Antisense therapy; apoptosis stimulation; neoplasm; carcinoma; melanoma;
XX basal cell carcinoma; ovary tumor; breast tumor;
XX non-small-cell lung cancer; renal cell carcinoma; bladder tumor;
XX stomach tumor; prostatic cancer; pancreas tumor; lung tumor;
XX uterine cervix tumor; cervical dysplasia; colon tumor; colorectal tumor;
XX sarcoma; osteosarcoma; Kaposi's sarcoma; anti-HIV; glioma; cytostatic;
XX endocrine disease; gynecology and obstetrics; genitourinary disease;
XX respiratory disease; musculoskeletal disease; dermatological disease;
XX proliferative disorder; atherosclerosis; antiarteriosclerotic;
XX cardiovascular disease; metabolic disorder; psoriasis; antipsoriatic;
XX immune disorder; diabetic retinopathy; antidiabetic; ophthalmological;
XX cardiovascular disease; ocular disease; rheumatoid arthritis;
XX antiarthritic; antirheumatic; inflammation; asthma; antiasthmatic;
XX skin allergy; antiallergic; antiinflammatory; dermatological;
XX verruca vulgaris; virucide; cell proliferation; apoptosis modulation;
XX angiogenesis disorder; survivin; phosphorothioate; cytosine methylation;
XX antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX
XX Key location/Qualifiers
XX misc_binding 1..16
XX /tag= b
XX /bound_moiety= "Bases 288-273 of human survivin cDNA (SEQ
XX ID NO:1)"
XX modified_base 1..16

CC increased specificity and affinity for survivin mRNA, and also have
 CC higher biostability and cell permeability. The present sequence
 CC represents a specifically claimed antisense oligonucleotide targeted to
 CC the human survivin cDNA target sequence shown in ADM09443.

XX Sequence 16 BP; 1 A; 3 C; 2 G; 10 T; 0 U; 0 Other;

Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 31.2%; Pred. No. 5.9e+02; Indels 0; Gaps 0;
 Matches 5; Conservative 9; Mismatches 2;

QY 714 UGCUUUUUAUAGCCU 729

DB 1 TGCCTTTTATGTTCC 16

RESULT 903

ADM09716

ID ADM09716 standard; DNA; 16 BP.

AC ADM09716;

DT 07-APR-2005 (first entry)

DE Human survivin antisense oligonucleotide 33C, SEQ ID NO:274.

XX Antisense therapy; apoptosis stimulation; neoplasm; carcinoma; melanoma;
 KM basal cell carcinoma; ovary tumor; breast tumor;
 KM non-small-cell lung cancer; renal cell carcinoma; bladder tumor;
 KM stomach tumor; prostatic cancer; pancreas tumor; lung tumor;
 KM uterine cervix tumor; cervical dysplasia; colon tumor; colorectal tumor;
 KM sarcoma; osteosarcoma; Kaposi's sarcoma; anti-HIV; glioma; cytostatic;
 KM endocrine disease; gynecology and obstetrics; genitourinary disease;
 KM respiratory disease; musculoskeletal disease; dermatological disease;
 KM proliferative disorder; atherosclerosis; antiarteriosclerotic;
 KM cardiovascular disease; metabolic disorder; psoriasis; antipsoriatic;
 KM immune disorder; diabetic retinopathy; antidiabetic; ophthalmological;
 KM cardiovascular disease; ocular disease; rheumatoid arthritis;
 KM antiarthritic; antirheumatic; inflammation; asthma; antiasthmatic;
 KM skin allergy; antiallergic; antiinflammatory; dermatological;
 KM verruca vulgaris; vitruide; cell proliferation; apoptosis modulation;
 KM angiogenesis disorder; survivin; phosphorothioate; cytosine methylation;
 KM antisense oligonucleotide; ss.

OS Homo sapiens.

Key Location/Qualifiers

misc_binding

1.16 /tag= b /bound molety= "Bases 288-273 of human survivin cDNA (SEQ

modified_base

1.16 /tag= a

modified_base

5.13 /tag= c

modified_base

13.16 /note= "Phosphorothioate linkages"

modified_base

13.16 /tag= d

modified_base

13.16 /note= "beta-D-oxy-LNAs (locked nucleic acid). All beta-D

10-FEB-2004; 2004US-00776934.

10-FEB-2003; 2003US-0446372P.

PR 19-NOV-2003; 2003US-0523591P.

XX (HANS/) HANSEN B.

PA (THRU/) THRU C A.

PA (WEST/) WESTERGAARD M.

PA (PETE/) PETERSEN K D.

PA (WISS/) WISENBACH M.

XX Hansen B, Thru CA, Westergaard M, Petersen KD, Wissenbach M,

PI WPI, 2005-100663/11.

DR WPI, 2005-100663/11.

XX New oligomeric compound for the modulation of survivin, useful for

PT treating e.g. cancers, atherosclerosis, psoriasis, diabetic retinopathy,

PT rheumatoid arthritis, asthma, warts, or allergic dermatitis.

XX Example 10; SEQ ID NO 274; 264pp; English.

PS The invention relates to antisense oligonucleotides consisting of 8-50

CC nucleotides and/or nucleotide analogs which inhibit expression of human

CC survivin, an inhibitor of apoptosis which is also essential for cell

CC division and angiogenesis. The antisense oligonucleotides comprise a

CC subsequence of 8 or more nucleotides or nucleotide analogs, wherein the

CC subsequence is located within a sequence selected from ADM09444-ADM09586.

CC The oligonucleotides preferably contain one or more (preferably 6-10)

CC nucleotide analogs, especially a locked nucleic acid (LNA), and also

CC preferably contain a linkage group selected from a phosphate group, a

CC phosphorothioate group or a boranophosphate group. The invention also

CC relates to a conjugate comprising a survivin antisense oligonucleotide

CC the invention and one or more non-nucleotide or non-polynucleotide

CC moieties covalently attached to the oligonucleotide; and a pharmaceutical

CC composition comprising a survivin antisense oligonucleotide or conjugate

CC of the invention, optionally further comprising a chemotherapeutic agent.

CC The survivin antisense oligonucleotides, and conjugates and compositions

CC containing them, are useful in the treatment of cancers such as

CC carcinomas (e.g., malignant melanoma, basal cell carcinoma, ovarian

CC carcinoma, breast carcinoma, non-small cell lung cancer, renal cell

CC carcinoma, bladder carcinoma, recurrent superficial bladder cancer,

CC stomach carcinoma, prostatic carcinoma, pancreatic carcinoma, lung

CC carcinoma, cervical carcinoma, cervical dysplasia, laryngeal

CC papillomatosis, colon carcinoma, colorectal carcinoma and carcinoma

CC tumors); sarcomas (e.g., osteosarcoma, Ewing's sarcoma, chondrosarcoma,

CC malignant fibrous histiocytoma, fibrosarcoma, and Kaposi's sarcoma); or

CC gliomas. The survivin antisense oligonucleotides are also useful in the

CC treatment of conditions such as atherosclerosis, psoriasis, diabetic

CC retinopathy, rheumatoid arthritis, asthma, warts, and allergic

CC dermatitis. They may additionally be used for inhibiting cellular

CC proliferation, for modulating apoptosis and for treating a disease

CC related to abnormal angiogenesis. The survivin antisense oligonucleotides

CC of the invention are shorter than prior art survivin antisense

CC oligonucleotides (16-mers compared to 20-25-mers), therefore having

CC increased specificity and affinity for survivin mRNA, and also have

CC higher biostability and cell permeability. The present sequence

CC represents an antisense oligonucleotide targeted to the human survivin

CC cDNA target sequence shown in ADM09443 used in an example of the

CC invention.

XX Sequence 16 BP; 1 A; 3 C; 2 G; 10 T; 0 U; 0 Other;

QY Query Match 0.7%; Score 12.8; DB 1; Length 16;

DB Best Local Similarity 31.2%; Pred. No. 5.9e+02;

Matches 5; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

QY 714 UGCUUUUUAUAGCCU 729

DB 1 TGCCTTTTATGTTCC 16

RESULT 904

ID ADM09717

ADM09717 standard; DNA; 16 BP.

AC ADM09717;

CC higher biostability and cell permeability. The present sequence
CC represents an antisense oligonucleotide targeted to the human survivin
CC cDNA target sequence shown in ADM09443 used in an example of the
CC invention.
XX
SQ Sequence 16 BP; 1 A; 3 C; 2 G; 10 T; 0 U; 0 Other;
Query Match 0.7%; Score 12.8; DB 1; Length 16;
Beet Local Similarity 31.2%; Pred. No. 5.9e+02;
Matches 5; Conservative 9; Mismatches 2; Indels 0; Gaps 0;
QY 714 UGCUUUUAUAGCCU 729
:|||||:|:|:
DB 1 TCGTTTATGTTCC 16
RESULT 902
ADM09475
ID ADM09475 strand; DNA; 16 BP.
XX
AC ADM09475;
XX
DT 07-APR-2005 (first entry)
XX
DE Human survivin antisense oligonucleotide, SEQ ID NO:33.
XX
KM Antisense therapy; apoptosis stimulation; neoplasm; carcinoma; melanoma;
KM basal cell carcinoma; ovary tumor; breast tumor;
KM non-small-cell lung cancer; renal cell carcinoma; bladder tumor;
KM stomach tumor; prostatic cancer; pancreas tumor; lung tumor;
KM uterine cervix tumor; cervical dysplasia; colon tumor; colorectal tumor;
KM sarcoma; osteosarcoma; Kaposi's sarcoma; anti-HIV; glioma; cytostatic;
KM endocrine disease; gynecology and obstetrics; genitourinary disease;
KM respiratory disease; musculoskeletal disease; dermatological disease;
KM proliferative disorder; atherosclerosis; antiarteriosclerotic;
KM cardiovascular disease; metabolic disorder; psoriasis; antipsoriatic;
KM immune disorder; diabetic retinopathy; antidiabetic; ophthalmological;
KM cardiovascular disease; ocular disease; rheumatoid arthritis;
KM antiarthritic; antirheumatic; inflammation; asthma; antiasthmatic;
KM skin allergy; antiallergic; antiinflammatory; dermatologic;
KM verruca vulgaris; virucide; cell proliferation; apoptosis modulation;
KM angiogenesis disorder; survivin; phosphorothioate; cytosine methylation;
KM antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
XX
Key Location/Qualifiers
FH 1..16
FT misc_binding
FT /tag= c
FT /bound moiety= "Bases 288-273 of human survivin cDNA (SEQ
FT ID NO:1)"
FT 1..5
FT modified_base
FT /tag= b
FT /mod_base= OTHER
FT /note= "Optionally phosphorothioate linkages when
FT nucleotides 1-4 are beta-D-oxy-1NAs. When nucleotides 1-4
FT are unmodified, the internucleotide linkages are
FT phosphorothioate"
FT 1..4
FT modified_base
FT /tag= a
FT /mod_base= OTHER
FT /note= "Optionally beta-D-oxy-1NAs (locked nucleic acid).
FT All beta-D-oxy-1NA cytosines are 5-methylcytosine"
FT 5..13
FT modified_base
FT /tag= d
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages"
FT 13..15
FT modified_base
FT /tag= e
FT /mod_base= OTHER
FT /note= "Optionally beta-D-oxy-1NAs. All beta-D-oxy-1NA
FT cytosines are 5-methylcytosine. Optionally
FT phosphorothioate linkages when bases 13-15 are beta-D-oxy

FT -1NAs. When nucleotides 13-15 are unmodified, the
FT internucleotide linkages are phosphorothioate"
FT 15..16
FT modified_base
FT /tag= f
FT /mod_base= OTHER
FT /note= "Optionally phosphorothioate linkage when
FT nucleotide 16 is beta-D-oxy-1NA. This linkage is
FT phosphorothioate when nucleotide 16 is unmodified"
FT 16
FT modified_base
FT /tag= g
FT /mod_base= OTHER
FT /note= "Optionally beta-D-oxy-1NA. When this nucleotide
FT is unmodified, the linkage between nucleotides 15 and 16
FT is phosphorothioate"
XX
XX US2005014712-A1.
XX
XX 20-JAN-2005.
XX
XX 10-FEB-2004; 2004US-0076934.
XX
XX 10-FEB-2003; 2003US-0446372P.
XX
XX 19-NOV-2003; 2003US-0523591P.
XX
XX (HANS/) HANSEN B.
XX (THRU/) THRU C. A.
XX (WEST/) WESTERGARD M.
XX (PETE/) PETERSEN K D.
XX (WISS/) WISENBACH M.
XX
XX Hansen B, Thru CA, Westergard M, Petersen KD, Wisenbach M;
XX WPI; 2005-100663/11.
XX
XX New oligomeric compound for the modulation of survivin, useful for
XX treating e.g. cancers, atherosclerosis, psoriasis, diabetic retinopathy,
XX rheumatoid arthritis, asthma, warts, or allergic dermatitis.
XX
XX Claim 1; SEQ ID NO 33; 264pp; English.
XX
XX The invention relates to antisense oligonucleotides consisting of 8-50
XX nucleotides and/or nucleotide analogs which inhibit expression of human
XX survivin, an inhibitor of apoptosis which is also essential for cell
XX division and angiogenesis. The antisense oligonucleotides comprise a
XX subsequence of 8 or more nucleotides or nucleotide analogs, wherein the
XX subsequence is located within a sequence selected from ADM09444-ADM09586.
XX The oligonucleotides preferably contain one or more (preferably 6-10)
XX nucleotide analogs, especially a locked nucleic acid (LNA), and also
XX preferably contain a linkage group selected from a phosphate group, a
XX phosphorothioate group or a boranophosphate group. The invention also
XX relates to a conjugate comprising a survivin antisense oligonucleotide of
XX the invention and one or more non-nucleotide or non-polynucleotide
XX moieties covalently attached to the oligonucleotide; and a pharmaceutical
XX composition comprising a survivin antisense oligonucleotide or conjugate
XX of the invention, optionally further comprising a chemotherapeutic agent.
XX The survivin antisense oligonucleotides, and conjugates and compositions
XX containing them, are useful in the treatment of cancers such as
XX carcinomas (e.g., malignant melanoma, basal cell carcinoma, ovarian
XX carcinoma, breast carcinoma, non-small cell lung cancer, renal cell
XX carcinoma, bladder carcinoma, recurrent superficial bladder cancer,
XX stomach carcinoma, prostatic carcinoma, pancreatic carcinoma, lung
XX carcinoma, cervical carcinoma, colorectal carcinoma and carcinoma
XX papillomatosis, colon carcinoma, colorectal carcinoma and carcinoma
XX tumors); sarcomas (e.g., osteosarcoma, Ewing's sarcoma, chondrosarcoma,
XX malignant fibrous histiocytoma, fibrosarcoma, and Kaposi's sarcoma); or
XX gliomas. The survivin antisense oligonucleotides are also useful in the
XX treatment of conditions such as atherosclerosis, psoriasis, diabetic
XX retinopathy, rheumatoid arthritis, asthma, warts, and allergic
XX dermatitis. They may additionally be used for inhibiting cellular
XX proliferation, for modulating apoptosis and for treating a disease
XX related to abnormal angiogenesis. The survivin antisense oligonucleotides
XX of the invention are shorter than prior art survivin antisense
XX oligonucleotides (16-mers compared to 20-25-mers), therefore having

CC more LNA units that are targeted to survivin. (I) is useful as a
 CC medicament and for the manufacture of a medicament for the treatment of
 CC cancer, in combination with chemotherapeutic agent such as busulfan
 CC (myleran), carboplatin (paraplatin), Taxol, doxorubicin (adriamycin),
 CC etc. (I) or a conjugate (II) containing (I) is useful in the preparation
 CC of a medicament for the treatment of atherosclerosis, psoriasis, diabetic
 CC retinopathy, rheumatoid arthritis, asthma, warts and allergic dermatitis.
 CC (II) or a pharmaceutical (III) containing (I) is useful for treating
 CC cancer in the form of a solid tumour, sarcoma, glioma or carcinoma chosen
 CC from malignant melanoma, basal cell carcinoma, ovarian carcinoma, breast
 CC carcinoma, non-small cell lung cancer, renal cell carcinoma, bladder
 CC carcinoma, recurrent superficial bladder cancer, stomach carcinoma,
 CC prostatic carcinoma, pancreatic carcinoma, lung carcinoma, cervical
 CC carcinoma, cervical dysplasia, laryngeal papillomatosis, colon carcinoma,
 CC colorectal carcinoma and carcinoïd tumours. The malignant melanoma is
 CC chosen from superficial spreading melanoma, nodular melanoma, lentigo
 CC maligna melanoma, acral melanoma, amelanotic melanoma, and desmoplastic
 CC melanoma. The sarcoma is chosen from osteosarcoma, Ewing's sarcoma,
 CC chondrosarcoma, malignant fibrous histiocytoma, fibrosarcoma and Kaposi's
 CC sarcoma. The treatment further involves administration of a
 CC chemotherapeutic agent such as taxanes, preferably Taxol, Paclitaxel or
 CC Docetaxel. (I), (II) or (III) is also useful for preventing or limiting
 CC apoptosis or for preventing cellular proliferation. This sequence
 CC corresponds to an antisense oligonucleotide targeted to the human
 CC survivin gene.
 CC
 CC Sequence 16 BP; 1 A; 3 C; 2 G; 10 T; 0 U; 0 Other;
 CC
 CC Query Match 0.7%; Score 12.8; DB 1; Length 16;
 CC Best Local Similarity 31.2%; Pred. No. 5.9e+02;
 CC Matches 5; Conservative 9; Mismatches 2; Indels 0; Gaps 0;
 CC
 CC 714 UGCUUUUNUANGCCU 729
 CC :|||||:|:|:
 CC Db 1 TGCCTTTTATGTTCC 16
 CC
 CC RESULT 901
 CC ADM09715
 CC ID ADM09715 standard; DNA; 16 BP.
 CC XX
 CC AC ADM09715;
 CC XX
 CC DT 07-APR-2005 (first entry)
 CC XX
 CC DE Human survivin antisense oligonucleotide 33B, SEQ ID NO:273.
 CC XX
 CC XX Antisense therapy; apoptosis stimulation; neoplasm; carcinoma; melanoma;
 CC KW basal cell carcinoma; ovary tumor; breast tumor;
 CC KW non-small-cell lung cancer; renal cell carcinoma; bladder tumor;
 CC KW stomach tumor; prostatic cancer; pancreas tumor; lung tumor;
 CC KW uterine cervix tumor; cervical dysplasia; colon tumor; colorectal tumor;
 CC KW sarcoma; osteosarcoma; Kaposi's sarcoma; anti-HIV; glioma; cytostatic;
 CC KW endocrine disease; gynecology and obstetrics; genitourinary disease;
 CC KW respiratory disease; musculoskeletal disease; dermatological disease;
 CC KW proliferative disorder; atherosclerosis; antiatherosclerotic;
 CC KW cardiovascular disease; metabolic disorder; psoriasis; antipsoriatic;
 CC KW immune disorder; diabetic retinopathy; antidiabetic; ophthalmological;
 CC KW cardiovascular disease; ocular disease; rheumatoid arthritis;
 CC KW antiarthritic; antirheumatic; inflammation; asthma; antiasthmatic;
 CC KW skin allergy; antiallergic; antiinflammatory; dermatological;
 CC KW verruca vulgaris; vincicide; cell proliferation; apoptosis modulation;
 CC KW angiogenesis disorder; survivin; phosphorothioate; cytosine methylation;
 CC KW antisense oligonucleotide; ss.
 CC KW
 CC XX Homo sapiens.
 CC OS
 CC XX
 CC FH Key Location/Qualifiers
 CC FT misc_binding 1..16
 CC FT /tag= b
 CC FT /bound_mietery= "Bases 288-273 of human survivin cDNA (SEQ
 CC FT ID NO:1)"
 CC FT modified_base 1..16

FT /tag= c
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages"
 FT modified_base 1..4
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Beta-D-oxy-LNAs (locked nucleic acid). All beta-D
 FT -oxy-LNA cytosines are 5-methylcytosine"
 FT modified_base 13..15
 FT /tag= d
 FT /mod_base= OTHER
 FT /note= "Beta-D-oxy-LNAs. All beta-D-oxy-LNA cytosines are
 FT 5-methylcytosine"
 PN US2005014712-A1.
 XX
 XX 20-JAN-2005.
 XX
 XX 10-FEB-2004; 2004US-00776934.
 XX
 XX 10-FEB-2003; 2003US-0446372P.
 PR 19-NOV-2003; 2003US-0523591P.
 XX
 XX (HANS/) HANSEN B.
 PA (THRU/) THRUE C A.
 PA (WEST/) WESTERGAARD M.
 PA (PETE/) PETERSEN K D.
 PA (WISS/) WISSENBACH M.
 XX
 XX Hansen B, Thrue CA, Westergaard M, Petersen KD, Wissenbach M;
 PI WPI; 2005-100663/11.
 DR
 XX
 PT New oligomeric compound for the modulation of survivin, useful for
 PT treating e.g. cancers, atherosclerosis, psoriasis, diabetic retinopathy,
 PT rheumatoid arthritis, asthma, warts, or allergic dermatitis.
 XX
 XX Example 10; SEQ ID NO 273; 264pp; English.
 XX
 CC The invention relates to antisense oligonucleotides consisting of 8-50
 CC nucleotides and/or nucleotide analogs which inhibit expression of human
 CC survivin, an inhibitor of apoptosis which is also essential for cell
 CC division and angiogenesis. The antisense oligonucleotides comprise a
 CC subsequence of 8 or more nucleotides or nucleotide analogs, wherein the
 CC subsequence is located within a sequence selected from ADM09444-ADM09586.
 CC The oligonucleotides preferably contain one or more (preferably 6-10)
 CC nucleotide analogs, especially a locked nucleic acid (LNA), and also
 CC preferably contain a linkage group selected from a phosphate group, a
 CC phosphorothioate group or a boranophosphate group. The invention also
 CC relates to a conjugate comprising a survivin antisense oligonucleotide of
 CC the invention and one or more non-nucleotide or non-poly-nucleotide
 CC moieties covalently attached to the oligonucleotide, and a pharmaceutical
 CC composition comprising a survivin antisense oligonucleotide or conjugate
 CC of the invention, optionally further comprising a chemotherapeutic agent.
 CC The survivin antisense oligonucleotides, and conjugates and compositions
 CC containing them, are useful in the treatment of cancers such as
 CC carcinomas (e.g., malignant melanoma, basal cell carcinoma, ovarian
 CC carcinoma, breast carcinoma, non-small cell lung cancer, renal cell
 CC carcinoma, bladder carcinoma, recurrent superficial bladder cancer,
 CC stomach carcinoma, prostatic carcinoma, pancreatic carcinoma, lung
 CC carcinoma, cervical carcinoma, cervical dysplasia, laryngeal
 CC papillomatosis, colon carcinoma, colorectal carcinoma and carcinoïd
 CC tumors); sarcomas (e.g., osteosarcoma, Ewing's sarcoma, chondrosarcoma,
 CC malignant fibrous histiocytoma, fibrosarcoma, and Kaposi's sarcoma); or
 CC gliomas. The survivin antisense oligonucleotides are also useful in the
 CC treatment of conditions such as atherosclerosis, psoriasis, diabetic
 CC retinopathy, rheumatoid arthritis, asthma, warts, and allergic
 CC dermatitis. They may additionally be used for inhibiting cellular
 CC proliferation, for modulating apoptosis and for treating a disease
 CC related to abnormal angiogenesis. The survivin antisense oligonucleotides
 CC of the invention are shorter than prior art survivin antisense
 CC oligonucleotides (16-mers compared to 20-25-mers), therefore having
 CC increased specificity and affinity for survivin mRNA, and also have

CC putative regulatory region.
 XX
 SQ Sequence 16 BP; 2 A; 2 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 50.0%; Pred. No. 5.9e+02;
 Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
 QY 1574 UUNUGAUCUGGCGUA 1589
 Db 1 TTTCGATCTCGGGCTA 16
 RESULT 899
 AAL56944
 ID AAL56944 standard; DNA; 16 BP.
 XX
 AC AAL56944;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human hypoxia-inducible factor-1 alpha antisense oligo #40.
 XX
 KW HIF-1alpha; hypoxia-inducible factor-1 alpha; human; antisense; cancer;
 KW pre-eclampsia; cytosstatic; gynaecological; antiinflammatory; nootropic;
 KW neuroprotective; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2003085110-A2.
 XX
 PD 16-OCT-2003.
 XX
 PF 04-APR-2003; 2003WO-IB001758.
 XX
 PR 05-APR-2002; 2002US-0370126P.
 XX
 PA (CURE-) CUREON AS.
 XX
 PI Thru CA, Hog AM, Kristjansen PBG;
 XX
 DR WPI; 2003-812728/76.
 XX
 PT New oligonucleotide that modulates hypoxia-inducible factor-1alpha,
 PT useful for treating e.g. cancer or Alzheimer's disease.
 XX
 PS Claim 1; Page 42; OPD; English.
 XX
 CC The present invention relates to compounds capable of modulating hypoxia-
 CC inducible factor-1alpha (HIF1a). The compounds are used to treat patients
 CC with, or at risk of developing, cancer (e.g. of breast, prostate,
 CC pancreas, lung), pre-eclampsia, inflammatory bowel disease or Alzheimer's
 CC disease, for modulating angiogenesis, proliferation of erythrocytes and
 CC other cells, iron, glucose and energy metabolism, pH regulation, tissue
 CC invasion, apoptosis, multiple drug resistance, cellular stress responses,
 CC and matrix metabolism, especially apoptosis where modulation is
 CC sensitivity to an apoptotic stimulus, particularly a chemotherapeutic
 CC agent and for inhibiting proliferation of cells (especially cancer cells)
 CC in vitro. The present sequence is an antisense oligonucleotide against
 CC HIF1alpha identified in the exemplification of the invention
 CC
 SQ Sequence 16 BP; 6 A; 3 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 62.5%; Pred. No. 5.9e+02;
 Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 1016 ACAATGAGUCGUCGUC 1031
 Db 1 AAAATGATCTACTGTC 16
 RESULT 900

ADR69964
 ID ADR69964 standard; DNA; 16 BP.
 XX
 AC ADR69964;
 XX
 DT 04-NOV-2004 (first entry)
 XX
 DE Human survivin gene modulatory oligonucleotide #32.
 XX
 KW ss; antiangiogenic; cytostatic; antiarteriosclerotic; antipsoriatic;
 KW antidiabetic; ophthalmological; antiarthritic; antirheumatic;
 KW antiasthmatic; anti-allergic; antiinflammatory; dermatological; anti-HIV;
 KW virocid; survivin antagonist; apoptosis inhibitor;
 KW cellular proliferation inhibitor; survivin; gene expression;
 KW abnormal angiogenesis; chemotherapeutic agent; busulfan; myleran;
 KW carboplatin; parapiatin; Taxol; doxorubicin; adriamycin; atherosclerosis;
 KW psoriasis; diabetic retinopathy; rheumatoid arthritis; asthma; warts;
 KW allergic dermatitis; cancer; tumour; sarcoma; glioma; carcinoma;
 KW melanoma; osteosarcoma; Ewing's sarcoma; chondrosarcoma;
 KW malignant fibrous histiocytoma; fibrosarcoma; Kaposi's sarcoma;
 KW Pacilitaxel; Docetaxel.
 XX
 OS Homo sapiens.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..16
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER = phosphorothioate internucleotide
 FT linkages, all locked nucleic acid (LNA) residues are 5'-
 FT methyl cytosine residues"
 FT 1..4
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER = beta-D-oxy-locked nucleic acid but
 FT optionally DNA nucleotides, optionally phosphate
 FT internucleotide linkages"
 FT 13..16
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER = beta-D-oxy-locked nucleic acid but
 FT optionally DNA nucleotides, optionally phosphate
 FT internucleotide linkages"
 XX
 PN WO2004069991-A2.
 XX
 PD 19-AUG-2004.
 XX
 PF 10-FEB-2004; 2004WO-DK000096.
 XX
 PR 10-FEB-2003; 2003DK-00000183.
 XX
 PR 18-NOV-2003; 2003DK-00001708.
 XX
 PA (SANT-) SANTARIS PHARMA AS.
 XX
 PI Hansen B, Thru CA, Peteren KD, Weeteregaard M, Wissenbach M;
 XX
 DR WPI; 2004-625494/60.
 XX
 PT New locked nucleic acid containing oligomeric compound capable of
 PT modulating survivin expression, useful for treating cancer such as breast
 PT carcinoma, lung carcinoma, etc.
 XX
 PS Claim 1; SEQ ID NO 33; 122bp; English.
 XX
 CC The invention relates to an oligomeric compound (I) capable of modulating
 CC survivin expression, having 8-50 nucleotides and/or nucleotide analogues,
 CC where the compound comprises a subsequence of at least 8 nucleotides or
 CC nucleotide analogues, where the subsequence is located within a sequence
 CC chosen from one of 143 sequences given in the specification. (I) is
 CC useful for treating a mammal suffering from or susceptible from a disease
 CC caused by abnormal angiogenesis, by administering (I) containing one or

CC against the proteins may be utilised for immunophenotyping of cell lines
CC and biological samples. The present sequence represents or contains the
CC region surrounding a single-nucleotide polymorphism in one of the genes
CC encoding one of the proteins listed above

SQ Sequence 16 BP; 9 A; 1 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 37.5%; Pred. No. 5.9e+02;
Matches 6; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

OY 583 AUCUCCUUUGCCUU 598
16 ATTCCCTTGTCTTT 1

RESULT 897
ACCS9079
ID ACCS9079 strand; DNA; 16 BP.

ACCS9079;

04-JUL-2003 (first entry)

Mouse gadd45beta core binding site kb-3 #2.

c-Jun-N-terminal kinase pathway; JNK pathway; cytostatic; mouse;
KW programmed cell death; TNFalpha; Fas; TRAIL; genotoxic agent; cancer;
KW apoptosis; Gadd45beta; JNK2; chronic inflammatory disease; Gadd45;
KW autoimmune condition; kb-3; ds.

OS Mus musculus.

PN WO2003028659-A2.

PD 10-APR-2003.

02-OCT-2002; 2002WO-US031548.

02-OCT-2001; 2001US-0326492P.

12-OCT-2001; 2001US-0328811P.

(UYGH-) UNIV CHICAGO.

Franzoso G, De Smaele E, Zazzeroni F, Papa S;

WPI; 2003-430155/40.

Modulating pathways leading to programmed cell death, by selecting a
PT target within Jun-N-terminal kinase pathway and interfering with the
PT target using agent that up or down regulates the JNK pathway.

Disclosure; Page 131; 131pp; English.

The invention relates to a novel method for modulating pathways leading
CC to programmed cell death, comprising selecting a target within the c-Jun-
CC N-terminal kinase (JNK) pathway, and interfering with the target using
CC an agent that either up regulates or down regulates the JNK pathway. The
CC method of the invention has cytostatic activity. A method of the
CC invention is useful for modulating pathways leading to programmed cell
CC death induced by TNFalpha, Fas, TRAIL, genotoxic agent such as
CC demorubicin or cisplatinum. Another method of the invention is useful
CC for screening and identifying an agent, preferably peptides, peptide
CC mimetics, peptide-like molecules, mutant proteins, cDNAs, antisense
CC oligonucleotides or constructs, lipids, carbohydrates or synthetic or
CC natural chemical compounds, that modulate JNK pathway in vitro. A method
CC of the invention may also be useful for treating cancer, and for
CC preventing apoptosis. Compounds that are capable of interfering with the
CC ability of Gadd45beta to associate with JNK2 are useful for treating
CC human diseases such as chronic inflammatory, and autoimmune conditions
CC and certain types of cancer. The present sequence is used in the
CC exemplification of the invention

SQ Sequence 16 BP; 3 A; 7 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 5.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 956 GCUGGAAACCCAGCUC 971
1 GCTGAAACCCCGCC 16

RESULT 898
ADE13992
ID ADE13992 strand; DNA; 16 BP.

ADE13992;

29-JAN-2004 (first entry)

Optineurin promoter motif, repeat element or regulatory region #101.

Human; optineurin; ds; ophthalmological; single nucleotide polymorphism;
KW SNP; glaucoma; progressive ocular hypertensive disorder;

KW glaucoma related disorder; motif; repeat element; regulatory region.

OS Homo sapiens.

PN US2003190617-A1.

09-OCT-2003.

06-MAR-2002; 2002US-00091281.

06-MAR-2002; 2002US-00091281.

(SIEB/) SI E.

(RAYM/) RAYMOND V.

(MORI/) MORISSETTE J.

Raymond V, Morissette J, Si E;

WPI; 2003-864168/80.

New nucleic acid sequences of the optineurin gene are useful to detect
PT polymorphisms particularly single nucleotide polymorphisms in the
PT optineurin promoter to diagnose, prognose and treat glaucoma and related
PT disorders.

Claim 11; SEQ ID NO 103; 159pp; English.

The invention relates to an isolated nucleic acid (N1) comprising at
CC least 20 but not more than 1500 consecutive nucleotides of the optineurin
CC promoter appearing as ADE13990. Also included are the optineurin promoter
CC operably linked to a heterologous nucleic acid, a nucleic acid capable of
CC detecting a single nucleotide polymorphism (SNP) in the optineurin
CC promoter, a host cell comprising the promoter operably linked to a
CC heterologous sequence, diagnosing or prognosing glaucoma in a sample
CC obtained from a cell or bodily fluid (comprising detecting a polymorphism
CC in a promoter region of the optineurin gene, associated with a glaucoma
CC phenotype), detecting a SNP sequence variation in a sample containing
CC DNA, detecting the presence of an optineurin promoter sequence variation
CC in a sample containing DNA, determining the presence or increased
CC susceptibility to glaucoma or to a progressive ocular hypertensive
CC disorder resulting in loss of visual field in a patient (or the severity
CC or progression of glaucoma in a patient, comprising providing
CC amplification reaction primers that direct amplification of a selected
CC nucleic acid region containing the variation within the optineurin
CC promoter and amplifying the DNA) and detecting a polymorphism (comprising
CC obtaining a sample containing human genomic DNA, providing a nucleic acid
CC capable of detecting a SNP located within an optineurin promoter, and
CC detecting the polymorphism). The invention is used to diagnose and
CC prognose glaucoma and also to treat glaucoma related disorders. The
CC present sequence is an optineurin promoter motif, repeat element or

KM blocker probe.
 OS Human papillomavirus.
 PN WO200196608-A1.
 XX
 PD 20-DEC-2001.
 XX
 PF 15-JUN-2001; 2001WO-US019353.
 XX
 PR 15-JUN-2000; 2000US-00594839.
 XX
 PA (DIGE-) DIGENE CORP.
 PI Anthony J, Lorincz A, Williams I, Troy J, Tang Y;
 XX
 DR WPI; 2002-130748/17.
 XX
 PT Detecting a target nucleic acid, for identifying microorganisms,
 PT diagnosing infections or detecting genetic abnormalities, comprises
 PT producing and detecting double-stranded hybrids between probes and the
 PT target nucleic acid.
 XX
 PS Claim 53; Page 24; 128pp; English.
 XX
 CC The invention relates to detecting a target nucleic acid comprising (a)
 CC hybridising a single-stranded or partially single-stranded target nucleic
 CC acid to a capture sequence probe and a signal sequence probe to form
 CC double-stranded hybrids between the probes and the target nucleic acid,
 CC where the capture sequence probe and the signal sequence probe are
 CC capable of hybridising to non-overlapping regions within the target
 CC nucleic acid and not hybridising to each other, (b) adding a blocker
 CC probe to the hybridisation reaction, where the blocker probe hybridises
 CC to excess non-hybridised capture sequence probes, (c) binding the hybrid
 CC to a solid phase to form a bound hybrid, and (d) detecting the bound
 CC hybrid. The method is used to detecting a target nucleic acid. The method
 CC is useful for identifying and classifying microorganisms, diagnosing
 CC infectious diseases, detecting and characterising genetic abnormalities,
 CC identifying genetic changes associated with cancer, studying genetic
 CC susceptibility to disease, and measuring response to various types of
 CC treatment. The method is also useful for detecting the presence of
 CC nucleic acid in test samples. The method is not only rapid and sensitive,
 CC but is also highly specific and capable of discriminating highly
 CC homologous nucleic acid target sequences. Blocker probes comprising
 CC oligonucleotides complementary to the capture sequence probes are used in
 CC the method to eliminate excess capture sequence probe, thus reducing the
 CC background signal in detection and increasing specificity of the assay.
 CC The present sequence is a blocker probe derived from HSV-1, HSV-2, HPV or
 CC HBV sequences
 XX
 SQ Sequence 16 BP; 4 A; 2 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 62.5%; Pred. No. 5.9e+02;
 Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 1254 CAGUUUUCGAAAAGC 1269
 DB ||:|||||
 16 CACTTTCGAAAAGC 1
 RESULT 896
 ABS59965/C
 ID ABS59965 standard; DNA; 16 BP.
 XX
 AC ABS59965;
 XX
 DT 05-NOV-2002 (first entry)
 XX
 DE Human DNA representing a single nucleotide polymorphism #115.
 XX
 KM Aminopeptidase P; XPNEP2; bradykinin receptor B1; ds; SNP; BDKRB1;
 KM tachykinin receptor B1; TACR1; C1 esterase inhibitor; C1NH; Kallikrein 1;

KM KLK1; bradykinin receptor B2; BDKRB2; gene therapy;
 KM angiotensin converting enzyme 2; ACE2; protease inhibitor 4; P14;
 KM polymorphism; haemangioma; tumour; sarcoma; Crohn's disease; trachoma;
 KM cardiovascular disease; angina pectoris; hypertension; heart failure;
 KM myocardial infarction; ventricular hypertrophy; vascular disease;
 KM aneurysm; embolism; thrombosis; coronary artery disease; angioedema;
 KM arteriosclerosis; atherosclerosis; hypersensitivity; sepsis;
 KM autoimmune disease; inflammatory arthritis; cancer; wound;
 KM viral infection; bacterial infection; fungal infection; COVID;
 KM Chronic obstructive pulmonary disease; enterocolitis;
 KM single-nucleotide polymorphism.
 XX
 OS Homo sapiens.
 XX
 PN WO200261131-A2.
 XX
 PD 08-AUG-2002.
 XX
 PF 03-DEC-2001; 2001WO-US047235.
 XX
 PR 04-DEC-2000; 2000US-0251015P.
 PR 02-JAN-2001; 2001US-0263678P.
 PR 02-MAR-2001; 2001US-0273037P.
 XX
 PA (BRIM) BRISTOL-MYERS SQUIBB CO.
 PA (TSUC/) TSUCHIHASHI Z.
 PA (HUII/) HUI L.
 XX
 PI Tsuchihashi Z, Hui L, Zerba KE, Ma-Edmonds M, Perrone MH;
 PI Swanson BN, Powell JR;
 XX
 DR WPI; 2002-619265/66.
 XX
 PT New isolated nucleic acid with at least one polymorphic position, useful
 PT for detecting, diagnosing and treating disorders such as angioedema,
 PT cancer, viral, bacterial or fungal infection, cardiovascular and
 PT autoimmune diseases.
 XX
 PS Disclosure; Page 664; 977pp; English.
 XX
 CC The invention relates to an isolated nucleic acid from a human gene
 CC encoding aminopeptidase P (XPNEP2), bradykinin receptor B1 (BDKRB1),
 CC tachykinin receptor B1 (TACR1), C1 esterase inhibitor (C1NH), kallikrein
 CC 1 (KLK1), bradykinin receptor B2 (BDKRB2), angiotensin converting enzyme
 CC 2 (ACE2) or protease inhibitor 4 (P14), comprising at least one
 CC polymorphic position. Also included are (1) a probe that hybridises to a
 CC polymorphic position as provided in the detailed summary of single
 CC nucleotide polymorphisms comprising additional 5' and 3' flanking genomic
 CC sequence; (2) analysing (M1) at least one nucleic acid sample comprising
 CC obtaining the sample from one or more individuals and determining the
 CC nucleic acid sequence at one or more polymorphic positions in a gene
 CC encoding a protein selected from the group above; (3) constructing (M2)
 CC haplotypes using the genes comprising grouping at least two nucleic acids
 CC ; (4) identifying (M3) an individual at risk of developing a disorder
 CC upon administration of an ACE inhibitor and/or vasopeptidase inhibitor
 CC using the polymorphic data; (5) a library of nucleic acids, each of which
 CC comprises one or more polymorphic positions within a gene encoding a
 CC human protein selected from the group above; and (6) genotyping (M4) an
 CC individual comprising obtaining a nucleic acid sample, determining the
 CC nucleotide present in at least one polymorphic position, and comparing at
 CC least one position with a known data set. The genes, (M1, M2, M3 and M4)
 CC and compositions are useful for detecting, diagnosing, treating,
 CC preventing various disorders such as angioedema and diseases which
 CC involve angiogenesis like haemangiomas, tumours, sarcomas, Crohn's
 CC disease, trachoma, and cardiovascular diseases, like angina pectoris,
 CC hypertension, heart failure, myocardial infarction, ventricular
 CC hypertrophy, vascular diseases, aneurysm, embolism, thrombosis, coronary
 CC artery disease, arteriosclerosis and/or atherosclerosis, and
 CC hypersensitivity reactions, sepsis, autoimmune diseases, inflammatory
 CC arthritis, cancer, wounds, viral, bacterial or fungal infection, Chronic
 CC obstructive pulmonary disease (COPD) and enterocolitis (many other
 CC diseases and disorders are listed in the specification). The
 CC polynucleotides are also useful for chromosome identification. Antibodies

PI Moribe T, Kaneshige T;
 XX
 DR WPI, 2000-400097/34.
 XX
 PR Simple, rapid and accurate method for distinguishing HLA class I allele
 PT type with possibility of mechanization and automation, applicable in
 PT judging donor-recipient compatibility during organ transplant and disease
 PT diagnosis.
 XX
 PS Claim 8; Page 53; 83pp; Japanese.
 XX
 CC The present invention describes a method for distinguishing a human
 CC leukocyte antigen (HLA) class I antigen or allele by a combination of
 CC polymerase chain reaction (PCR) using a primer pair whereby all HLA-A, -B
 CC or -C alleles can be amplified or using reverse hybridisation analysis
 CC comprising a DNA probe covalently bonded to microtitre plate wells which
 CC are hybridisable specifically with the base sequence of at least one
 CC specific HLA-A, -B or -C allele. The method is applicable in gene typing,
 CC judging donor-recipient compatibility during organ transplant and
 CC correlation analysis for diagnosis of various diseases. The method is
 CC simple, rapid and accurate, with possibility of mechanisation and
 CC automation, without the problems encountered by using the prior-art
 CC techniques. AAA65943 to AAA67072 represent oligonucleotide probes and PCR
 CC primers for use in the method of the present invention
 CC
 SQ Sequence 16 BP; 3 A; 2 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 75.0%; Pred. No. 5.9e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 QY 915 GAGGAAGUAGCGCGC 930
 Db 1 GAGGATGATGCTGC 16
 Db
 RESULT 889
 AAF58188/C
 ID AAF58188 standard; DNA; 16 BP.
 XX
 AC AAF58188;
 XX
 DT 23-APR-2001 (first entry)
 XX
 DE Primer #19.
 XX
 KW Human; multiple tumour suppressor; MTS; cancer; gene therapy; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6180776-B1.
 XX
 PD 30-JAN-2001.
 XX
 PF 22-JUL-1998; 98US-00120129.
 XX
 PR 18-MAR-1994; 94US-00214582.
 PR 18-MAR-1994; 94US-00215086.
 PR 18-MAR-1994; 94US-00215087.
 PR 01-JUN-1994; 94US-00251938.
 PR 17-MAR-1995; 95WO-US003316.
 PR 07-JUN-1995; 95US-00486047.
 XX
 PA (MYRI-) MYRIAD GENETICS INC.
 XX
 PI Kamb A;
 XX
 DR WPI, 2001-158668/16.
 XX
 PT Novel multiple tumor suppressor gene useful for diagnosing, prognosing
 PT and treating cancers, such as melanoma, leukemia, glioblastoma and
 PT Hodgkin's lymphoma.
 XX

PS Example 13; Col 51; 71pp; English.
 XX
 CC The present invention relates to human multiple tumor suppressor-2 (MTS2)
 CC gene. The invention is useful for diagnosing, prognosing and treating
 CC cancers. It is also useful for screening drugs for cancer therapy and
 CC gene therapy
 XX
 SQ Sequence 16 BP; 2 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 81.2%; Pred. No. 5.9e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 1465 GCGGCCGAGCCCTCA 1480
 Db 16 GCTGGCCGAGCCCTCA 1
 Db
 RESULT 890
 AAS02581/C
 ID AAS02581 standard; DNA; 16 BP.
 XX
 AC AAS02581;
 XX
 DT 29-AUG-2001 (first entry)
 XX
 DE PCR primer E1F used in analysis of multiple tumour suppressor MTS1/2.
 XX
 KW Human; multiple tumour suppressor; MTS1; MTS2; therapeutic; diagnostic;
 KW cancer; gene therapy; melanoma; leukemia; astrocytoma; glioblastoma;
 KW lymphoma; glioma; Hodgkin's lymphoma; chronic lymphatic leukemia;
 KW PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6210949-B1.
 XX
 PD 03-APR-2001.
 XX
 PF 30-NOV-1998; 98US-00201139.
 XX
 PR 17-MAR-1995; 95WO-US003316.
 PR 07-JUN-1995; 95US-00487033.
 PR 28-JUL-1995; 95US-00508735.
 XX
 PA (MYRI-) MYRIAD GENETICS INC.
 XX
 PI Stone S, Jiang P, Kamb A;
 XX
 DR WPI, 2001-280859/29.
 XX
 PT New mouse multiple tumor suppressor gene, useful for diagnosing or
 PT prognosing human cancer or as gene therapy for treating cancer,
 PT particularly melanoma, leukemia, astrocytoma, lymphoma or cancers of the
 PT pancreas or breast.
 XX
 PS Example 14; Col 54; 80pp; English.
 XX
 CC The sequence represents PCR primer E1F used in analysis of multiple
 CC tumour suppressor MTS1 and MTS2. The MTS genes, and expression products,
 CC are useful for treating, diagnosing or prognosing human cancer. In
 CC particular, the MTS gene is useful for diagnosing a predisposition to or
 CC as a gene therapy for melanoma, leukaemia, astrocytoma, glioblastoma,
 CC lymphoma, glioma, Hodgkin's lymphoma, chronic lymphatic leukaemia (CLL),
 CC or cancers of the pancreas, breast, thyroid, ovary, uterus, testis,
 CC kidney, stomach or rectum. The gene may be used in both cancerous and pre
 CC -cancerous cells
 XX
 SQ Sequence 16 BP; 2 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 81.2%; Pred. No. 5.9e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 1465 GCGGCCGAGCCCTCA 1480
 Db 16 GCTGGCCGAGCCCTCA 1
 Db

DT	14-JUL-2000	(first entry)	
XX			
XX	Antisense oligonucleotide #17	targeting the PTS operon.	
DE			
KM	Antisense oligonucleotide; treat; inhibit translation; diagnose;		
KW	cell wall biosynthesis; ribosomal RNA; ribosomal protein; pathogenicity;		
KM	nutrient uptake; bacterial infection; PTS operon; Haemophilus influenzae;		
XX	Phosphoenolpyruvate-sugar phosphotransferase system; ss.		
OS			
XX	Haemophilus influenzae.		
PN			
XX	WO200015265-A1.		
PD			
XX	23-MAR-2000.		
XX			
PF	15-SEP-1999;	99WO-US021950.	
XX			
PR	16-SEP-1998;	98US-0100591P.	
PR	16-SEP-1998;	98US-0100598P.	
PR	16-SEP-1998;	98US-0100599P.	
XX	16-SEP-1998;	98US-0100625P.	
PA	(VITA-) VITAGENIX INC.		
XX			
XX	Selfert W;		
DR	WPI; 2000-271267/23.		
XX			
PT	New antisense oligonucleotide, useful for treating and diagnosing		
PT	bacterial infections, interacts with and inhibits translation of a target		
PT	RNA sequence in bacteria.		
XX			
PS	Claim 10; Page 29; 50pp; English.		
XX			
CC	This sequence represents an antisense oligonucleotide that targets genes		
CC	of the phosphoenolpyruvate-sugar phosphotransferase system (PTS) operon.		
CC	The invention relates to antisense oligonucleotides (e.g. the present		
CC	sequence) which interact with and inhibit translation of a target RNA		
CC	sequence in a bacterium. The RNA sequences that the oligonucleotides		
CC	target encode proteins such as enzymes for biosynthesis of cell wall		
CC	proteins, ribosomal RNA, ribosomal proteins, proteins essential for		
CC	nutrient uptake, proteins associated with pathogenicity, subunits of DNA-		
CC	dependent RNA polymerase, and DNA polymerase. The antisense		
CC	oligonucleotides are used to treat or diagnose bacterial infections		
XX			
XX			
XX	Sequence 16 BP; 4 A; 3 C; 4 G; 5 T; 0 U; 0 Other;		
QY			
DB	383 ACAUCCAUCAUGAUGC 398		
	:		
	16 ACATCTGCATGATCG 1		
RESULT 887			
AAAI1192/c			
ID	AAAI1192 standard; DNA; 16 BP.		
XX			
XX	AAAI1192;		
XX			
DT	11-OCT-2000	(first entry)	
DE			
XX	Human multiple tumour suppressor 2 cDNA PCR primer E1P.		
KM	Variant; human; multiple tumour suppressor; MTS; mutation; melanoma;		
KM	cancer; diagnosis; PCR primer; ss.		
XX			
OS	Homo sapiens.		
XX			
XX	US6037462-A.		
XX			

```

PD      14-MAR-2000.
XX
PP      22-JUL-1998;    98US-00120130.
XX
PR      18-MAR-1994;    94US-00214582.
XX      18-MAR-1994;    94US-00215086.
PR      18-MAR-1994;    94US-00215087.
PR      14-APR-1994;    94US-00227369.
XX      01-JUN-1994;    94US-00251938.
PR      17-MAR-1995;    95MO-US003316.
XX      07-JUN-1995;    95US-00480810.
PA      (MYRI-) MYRIAD GENETICS INC.
XX
PI      Kamb A;
XX
DR      WPI; 2000-269915/23.
XX
PT      New mutants of the human multiple tumor suppressor gene, useful as
PT      diagnostic markers of cancer, contain specific base alterations or
XX      deletions.
PS      Example 13; Col 51; 72pp; English.
XX
CC      The invention relates to variants (AAA1196-A11206) of the human multiple
CC      tumour suppressor 1 (MTS1) gene (AAA11165). The variants have the
CC      following changes relative to this sequence: A at any of positions 265,
CC      447, 330 and 329; T at any of positions 172, 238, 341 and 148 and
CC      deletions of nucleotides 290-294, 172-179 or 128-129. The variants are
CC      somatic mutations of MTS1, indicative of predisposition to melanoma and
CC      many other cancers, so detecting them is useful for diagnosis, prognosis
CC      and monitoring of cancer (including prenatal analysis). Cells and animals
CC      that express the variant are useful as model systems for identifying
CC      potential anticancer agents. This sequence represents a primer used to
CC      screen for the human MTS2 sequence (AAA11182)
XX
SQ      Sequence 16 BP, 2 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match          0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 5.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY      1465 GCGGCCGACACCCTCA 1480
DB      16 GCTGGCCAGACCTCA 1

```

```

XX SQ Sequence 16 BP; 3 A; 4 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 5.9e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 725 UGCGUGACCAUUAU 740
Db 1 TGACTGTCTCATAT 16

RESULT 884
AAA86776
ID AAA86776 standard; DNA; 16 BP.
AC AAA86776;
XX
XX 04-DEC-2000 (first entry)
XX
XX PCNA hammerhead ribozyme recognition site #1.
XX
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotrophic; restenosis; ss.
XX
XX Mammalia.
XX
XX WO200032765-A2.
XX
XX 08-JUN-2000.
XX
XX 06-DEC-1999; 99WO-US028772.
XX
XX 04-DEC-1998; 98US-0110954P.
XX
XX (IMMU-) IMMUSOL INC.
XX
XX Trletz R, Welch PJ, Barber JR, Robbins JM;
XX
XX WPI; 2000-412314/35.
XX
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
XX PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
XX PCNA and Cyclin B1.
XX
XX Example 1; Page 24; 10pp; English.
XX
XX PS The present invention relates to a hairpin or hammerhead ribozyme,
XX CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
XX CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
XX CC Representative examples of ribozyme recognition sites are given in
XX CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
XX CC inhibiting restenosis by introduction of the ribozyme into cells. The
XX CC ribozyme is resistant to endonuclease activity and hence is efficient in
XX CC restenosis treatment
XX
XX SQ Sequence 16 BP; 3 A; 4 C; 2 G; 7 T; 0 U; 0 Other;
Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 5.9e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 725 UGCGUGACCAUUAU 740
Db 1 TGACTGTCTCATAT 16

RESULT 885
AAA39370/c
ID AAA39370 standard; DNA; 16 BP.
AC AAA39370;
XX
XX 12-SEP-2000 (first entry)

```

```

XX DE Human MTS2 PCR primer SEQ ID NO:21.
XX
XX KW Human; multiple tumour suppressor; MTS; somatic mutation; cancer;
XX KW diagnosis; germ line mutation; gene therapy; cytostatic; melanoma;
XX KW leukemia; astrocytoma; glioblastoma; lymphoma; glioma;
XX KW Hodgkin's lymphoma; PCR primer; ss.
XX
XX OS Homo sapiens.
XX
XX PN US6060301-A.
XX
XX PD 09-MAY-2000.
XX
XX PF 14-JUL-1998; 98US-00115252.
XX
XX PR 18-MAR-1994; 94US-00214582.
XX PR 18-MAR-1994; 94US-00215086.
XX PR 18-MAR-1994; 94US-00215087.
XX PR 14-APR-1994; 94US-00227369.
XX PR 01-JUN-1994; 94US-00251938.
XX PR 17-MAR-1995; 95WO-US003316.
XX PR 07-JUN-1995; 95US-00480810.
XX PR 08-DEC-1997; 97US-00986147.
XX
XX PA (MYRI-) MYRIAD GENETICS INC.
XX
XX PI Kamb A;
XX
XX DR WPI; 2000-349676/30.
XX
XX PT New vector useful for gene therapy of cancer associated with mutation in
XX PT tumor suppressor gene, comprises DNA sequence of multiple tumor
XX PT suppressor gene.
XX
XX PS Example 13; Col 52; 71pp; English.
XX
XX CC The present invention describes a vector (I) comprising an isolated DNA
XX CC sequence of a multiple tumour suppressor (MTS) gene having a
XX CC polynucleotide sequence of the human MTS1E1-beta. (I) is useful for
XX CC introducing wild-type MTS function to a cancerous or pre-cancerous cell
XX CC which carries diminished or mutant MTS alleles for suppressing neoplastic
XX CC growth of the recipient cells. (I) is also useful for increasing the
XX CC level of expression of MTS gene even in tumor cells in which the mutant
XX CC gene is expressed at a normal level but the gene product is not fully
XX CC functional. A host cell transformed with (I) is useful as a model system
XX CC to study cancer remission and drug treatment which promotes such
XX CC remission. The present invention relates to somatic mutations and germ
XX CC line mutations in the MTS gene and their use in the diagnosis and
XX CC prognosis of human cancer e.g. melanoma, leukaemia, astrocytoma,
XX CC glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, and cancers of the
XX CC pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and
XX CC rectum. The present sequence represents a PCR primer used in the
XX CC amplification of human MTS2, which is used in an example from the present
XX CC invention
XX
XX SQ Sequence 16 BP; 2 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 5.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1465 GCGGCCGAGACCCUCA 1480
Db 16 GCTGGCCAGACCTCA 1

RESULT 886
AAA13059/c
ID AAA13059 standard; DNA; 16 BP.
AC AAA13059;
XX
XX 12-SEP-2000 (first entry)

```

```
PR      18-MAR-1994;    94US-00215086.  
PR      18-MAR-1994;    94US-00215087.  
PR      14-APR-1994;    94US-00227369.  
PR      01-JUN-1994;    94US-00251938.  
PR      17-MAR-1995;    95WO-US003537.  
PR      07-JUN-1995;    95US-00474083.  
  
XX  
PA      (UTAH ) UNIV UTAH RES FOUND.  
PA      (MYRI-) MYRIAD GENETICS INC.  
XX  
PI      Skolnick ME, Cannon-Albright LA, Kamb A;  
XX  
DR      WPI, 2000-070785/06.  
XX  
PT      Diagnosing a polymorphism associated with a predisposition for cancer.  
XX  
PS      Example 13; Col 51; 74pp; English.  
XX  
CC      This sequence is a PCR primer for DNA encoding the human MTS2 protein.  
CC      The invention relates to a method for diagnosing a polymorphism  
CC      associated with a predisposition to cancer by detecting a germ-line  
CC      alteration of a wild-type Multiple Tumour Suppressor (MTS) gene or its  
CC      expression products in a human sample. The method comprises detecting a  
CC      germ-line alteration of a wild-type MTS gene or its expression products  
CC      in a human sample, the alteration indicating a predisposition to at least  
CC      one of the cancers. The cancer is selected from melanoma, leukaemia,  
CC      astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, chronic  
CC      lymphocytic leukemia (CLL), and cancers of the pancreas, breast,  
CC      thyroid, ovary, uterus, testis, kidney, stomach and rectum. The method  
CC      may be used as the basis for developing very important diagnostic tests  
CC      capable of predicting the predisposition to cancer. The MTS gene is  
CC      involved in the progression of multiple tumour types and may provide  
CC      means for a general anti-cancer therapy by virtue of its ability to  
CC      suppress tumour growth  
XX  
SQ      Sequence 16 BP; 2 A; 4 C; 7 G; 3 T; 0 U; 0 Other;  
  
Query Match          0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 81.2%; Pred. No. 5.9e+02;  
Matches   13; Conservative   1; Mismatches    2; Indels     0; Gaps     0;  
  
OY      1465 GCGGCCGACAGCCTCA 1480  
DB      16 GCTGGCCAGACCCTCA 1  
        ||| ||||| |||:  
RESULT 882  
AAZ39998/C  
ID      AAZ39998 standard; DNA; 16 BP.  
XX  
XX      AAZ39998;  
AC  
DT      11-FEB-2000 (first entry)  
XX  
DE      PCR primer for human multiple tumour suppressor 2 coding sequence.  
XX  
KW      Multiple tumour suppressor; MTS2; human; diagnosis; Hodgkin's lymphoma;  
KW      cancer predisposition; melanoma; leukaemia; lymphoma; glioma; PCR primer;  
KW      ss.  
XX  
OS      Synthetic.  
XX      Homo sapiens.  
PN      USS994095-A.  
XX  
PD      30-NOV-1999.  
PF      07-JUN-1995;    95US-00486047.  
PR      18-MAR-1994;    94US-00214582.  
PR      18-MAR-1994;    94US-00215086.  
PR      18-MAR-1994;    94US-00215087.  
PR      14-APR-1994;    94US-00227369.
```

PR		01-JUN-1994;	94US-00251938.
PR		17-MAR-1995;	95WO-US003316.
XX			
PA	(MYRI -)	MYRIAD GENETICS INC.	
XX			
PI	Kamb A;		
XX			
DR	WPI; 2000-038259/03.		
XX			
PT	Multiple tumor suppressor cDNA, useful for diagnosing or determining a predisposition to cancer.		
XX			
PS	Example 13; Col 51; 72pp; English.		
CC	This sequence represents a PCR primer for the human multiple tumour suppressor 2 (MTS2) coding sequence of the invention. The DNA sequences are useful for diagnosing or determining a predisposition to cancers e.g. melanoma, leukaemia, lymphoma, glioma, Hodgkin's lymphoma and cancers of the pancreas, breast, thyroid, ovary, kidney, uterus and stomach		
CC			
SQ	Sequence 16 BP; 2 A; 4 C; 7 G; 3 T; 0 U; 0 Other;		
Oy	Query March	0.7%; Score 12.8; DB 1; Length 16;	
DB	Best Local Similarity	81.2%; Pred. No. 5.9e+02;	
	Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;		
	1465 GCGGCCGACAGCCUCUA 1480 : 16 GCTGGCCAGACCCTCA 1		
RESULT 983			
ID	AAA86546		
XX	AAA86546 standard; DNA; 16 BP.		
AC	AAA86546;		
DT	04-DEC-2000 (first entry)		
DE	Cyclin B1 hairpin ribozyme recognition site #6.		
KM	Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.		
OS	Mammalia.		
PN	WO200032765-A2.		
PD	08-JUN-2000.		
PF	06-DEC-1999; 99WO-US028772.		
PR	04-DEC-1998; 98US-0110954P.		
PA	(IMMU-) IMMUSOL INC.		
PI	Tritz R, Welch PJ, Barber JR, Robbins JM;		
DR	WPI; 2000-412314/35.		
PT	New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1, PCNA and Cyclin B1.		
PS	Example 1; Page 16; 109pp; English.		
CC	The present invention relates to a hairpin or hammerhead ribozyme, designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.		
CC	Representative examples of ribozyme recognition sites are given in AA882415 to AAA6787. The ribozyme of the invention is useful for inhibiting restenosis by introduction of the ribozyme into cells. The ribozyme is resistant to endonuclease activity and hence is efficient in restenosis treatment		

DE Human MTS2 mRNA expression detection primer.
 XX Cytostatic; human; multiple tumour suppressor 2; MTS2; diagnostic;
 KM cancer; gene therapy; protein replacement therapy; PCR primer; ss.
 XX Homo sapiens.
 XX US6090578-A.
 XX 18-JUL-2000.
 PD 08-DEC-1997; 97US-00986515.
 XX 18-MAR-1994; 94US-00214582.
 PR 18-MAR-1994; 94US-00215086.
 PR 18-MAR-1994; 94US-00215087.
 PR 14-APR-1994; 94US-00227369.
 PR 01-JUN-1994; 94US-00251938.
 PR 17-MAR-1995; 95WO-US003316.
 PR 07-JUN-1995; 95US-00480810.
 XX (MRI-) MYRIAD GENETICS INC.
 XX Kamb A;
 PI MPI; 2000-514036/46.
 DR Novel protein composition useful in protein replacement therapy for
 PT diagnosing and treating cancer comprises a specific weight percent of
 PT human multiple tumor suppressor 1 polypeptide.
 XX Example 13; Col 52; 72pp; English.
 PS The invention relates to the isolation of the gene encoding the human
 CC multiple tumour suppressor 1 (MTS1) (AA95633). The MTS1 protein has a
 CC cytosolic activity and is used in protein replacement therapy. This
 CC sequence is a PCR primer used in the determination of the expression
 CC levels of human MTS2 gene from primary T cells. MTS1 is useful in
 CC diagnosing human cancers such as (ocular) melanoma, leukemia,
 CC astrocytoma, glioblastoma, lymphoma, glioma, Hodgkin's lymphoma, multiple
 CC myeloma, sarcoma, myosarcoma, cholangiocarcinoma, squamous cell
 CC carcinoma, CLL, and cancers of pancreas, breast, stomach, brain,
 CC prostate, bladder, thyroid, ovary, uterus, testis, kidney, colon and
 CC rectum. The MTS1 gene and protein is useful in gene therapy, protein
 CC replacement therapy and protein mimetic studies
 XX Sequence 16 BP; 2 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 81.2%; Pred. No. 5.9e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 1465 GCGGCCGACAGCCCTCA 1480
 DB 16 GCTGGCCAGACCTCA 1
 RESULT 880
 AA297624/C
 ID AA297624 standard; DNA; 16 BP.
 XX
 AC AA297624;
 XX
 DT 15-SEP-2003 (revised)
 DT 26-APR-2000 (first entry)
 XX
 DE HIV-1 protease gene probe SEQ ID NO:114.
 XX
 KM Human immunodeficiency virus; HIV; protease; probe; detection;
 KM drug selected mutation; hybridisation; genotyping; infection;
 KM drug resistance; ss.
 XX Human immunodeficiency virus 1.

XX
 PN WO967428-A2.
 XX
 PD 29-DEC-1999.
 XX
 PF 22-JUN-1999; 99WO-EP004317.
 XX
 PR 24-JUN-1998; 98EP-00870143.
 XX (INNO-) INNOGENETICS NV.
 PA Stuyver L;
 PI MPI; 2000-147219/13.
 DR Detection of drug-selected mutations in the HIV protease gene used to
 PT treat HIV infections.
 PT Claim 3; Page 34; 76pp; English.
 XX
 CC The present invention describes the detection of drug-selected mutations
 CC in the HIV protease gene. The method of detection allows the simultaneous
 CC characterisation of a range of codons involved in drug resistance using
 CC sets of probes optimised to function together in a reverse-hybridisation
 CC assay. AA297517 to AA297997 represent specifically claimed probes for use
 CC in the assay, and AA297479 to AA297501 represent specifically claimed HIV
 CC protease gene polymorphic nucleotide sequences. AA297502 to AA297515, and
 CC AA298004 to AA298007, represent PCR primers for the HIV protease gene,
 CC and AA297516 represents an HIV protease probe used in an example from the
 CC present invention. The method, probes and primers can be used for the
 CC detection of drug-selected mutations in the HIV protease gene. The method
 CC allows the simultaneous characterisation of a range of codons involved in
 CC drug resistance. The method may also be used for HIV protease genotyping
 CC assays. The probes are able to discriminate between wild type and mutated
 CC protease sequences. The method allows rapid and reliable detection of
 CC drug-selected mutation in HIV. (Updated on 15-SEP-2003 to standardise OS
 CC field)
 XX
 SQ Sequence 16 BP; 8 A; 1 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 50.0%; Pred. No. 5.9e+02;
 Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
 QY 685 CCCACCAUACUUNUG 700
 DB 16 CCCACTATTATTTTG 1
 RESULT 881
 AA248799/C
 ID AA248799 standard; cDNA; 16 BP.
 XX
 AC AA248799;
 XX
 DT 21-MAR-2000 (first entry)
 XX
 DE PCR primer for human MTS2 coding sequence.
 XX
 KM MTS; human; polymorphism detection; cancer predisposition; astrocytoma;
 KM Multiple Tumour Suppressor gene; melanoma; leukemia; glioblastoma;
 KM lymphoma; glioma; Hodgkin's lymphoma; chronic lymphocytic leukaemia;
 KM therapy; MTS2; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US5989815-A.
 XX
 PD 23-NOV-1999.
 XX
 PF 29-APR-1997; 97US-00848251.
 XX
 PR 18-MAR-1994; 94US-00214582.

CC suppressor (MTS) gene, to diagnose and treat cancer. The MTS gene is
 CC useful in the diagnosis and prognosis of human cancer, e.g. by standard
 CC nucleic acid hybridisation techniques, of patient samples. The mutated
 CC sequences are those that are present in somatic mutations of the gene in
 CC cancers. The vectors can be used for gene therapy strategies to replace
 CC function of the mutated protein in patients. These can also be used to
 CC construct protein mimetics, also for therapeutic strategies. In addition
 CC the expression constructs can also be used for recombinant production of
 CC MTS. Recombinant MTS can be used to screen for drugs to be used for
 CC cancer therapy, and the protein itself may also be used to restore MTS
 CC function in a cell

XX Sequence 16 BP; 2 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 81.2%; Pred. No. 5.9e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1465 GCGGCCGAGACCTCA 1480

Db 16 GCTGGCCAGACCTCA 1

RESULT 877

AAV1255/c

AAV1255 standard; DNA; 16 BP.

AAV1255;

15-JUL-1998 (first entry)

Human MTS2 PCR primer E1.F.

MTS1; MTS2; multiple tumour suppressor; diagnosis; cancer;
 germ-line mutation; familial melanoma locus; MLM; predisposition; ss.

Synthetic.

Homo sapiens.

US5739027-A.

14-APR-1998.

07-JUN-1995; 95US-00487033.

18-MAR-1994; 94US-00214582.

18-MAR-1994; 94US-00215086.

14-APR-1994; 94US-00227369.

01-JUN-1994; 94US-00251938.

17-MAR-1995; 95WO-US003316.

(MYRI-) MYRIAD GENETICS INC.

Kamb A;

WPI; 1998-250421/22.

DNA specific for Multiple Tumour Suppressor 1E1-beta gene - are useful
 for the diagnosis of cancers related to MTS1E1-beta mutation(s) and their
 treatment.

Example 13; Col 81-82; 72pp; English.

Primer AAV1255 is used in the isolation of the human multiple tumour
 suppressor protein, MTS2. The MTS gene locus is also referred to as the
 familial melanoma (MLM) gene locus, located on human chromosome 9p21.

Germ line mutations in MTS genes can be used in the diagnosis of
 predisposition to cancers, e.g. melanoma, leukaemia, astrocytoma,
 glioblastoma, lymphoma, Hodgkin's lymphoma, CLL, and cancers of
 the pancreas, breast, thyroid, ovary, uterus, testis, kidney, stomach and
 rectum

SQ Sequence 16 BP; 2 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 81.2%; Pred. No. 5.9e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1465 GCGGCCGAGACCTCA 1480

Db 16 GCTGGCCAGACCTCA 1

RESULT 878

AAV70600/c

AAV70600 standard; DNA; 16 BP.

AAV70600;

20-MAR-2003 (revised)

03-FEB-1999 (first entry)

PCR primer E1F for multiple tumour suppressor 2 gene.

Human; multiple tumour suppressor 2 gene; MTS2; cancer; PCR primer; ss.

Synthetic.

Homo sapiens.

US5843756-A.

01-DEC-1998.

28-JUL-1995; 95US-00508735.

17-MAR-1995; 95WO-US003316.

07-JUN-1995; 95US-00487033.

(MYRI-) MYRIAD GENETICS INC.

Jiang P, Kamb A, Stone S;

WPI; 1999-044585/04.

Mouse multiple tumour suppressor gene segment - useful for primer design.

Example 14; Col 54; 80pp; English.

PCR primers AAV70600-02 were used to amplify a human multiple tumour
 suppressor 2 (MTS2) gene. The MTS2 gene nucleotide sequence can be used
 to design primers to detect abnormalities i.e. polymorphisms which may
 predispose towards malignancies such as melanoma, leukaemia, astrocytoma,
 lymphoma, glioma, as well as tumours of e.g. the breast, thyroid, CLL,
 pancreas, uterus and kidneys. (Updated on 20-MAR-2003 to correct PR field.)

Sequence 16 BP; 2 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 81.2%; Pred. No. 5.9e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1465 GCGGCCGAGACCTCA 1480

Db 16 GCTGGCCAGACCTCA 1

RESULT 879

AAA95660/c

AAA95660 standard; DNA; 16 BP.

14-FEB-2001 (first entry)

XX	Human multiple tumour suppressor gene 2 cDNA primer E1F.
DE	
XX	primer; polymerase chain reaction; PCR; amplification; human; multiple;
KW	tumour; suppressor; MTS2; cancer; diagnosis; ss.
KM	
XX	Synthetic.
OS	
XX	US5624819-A.
PN	
XX	
PD	29-APR-1997.
XX	
PF	07-JUN-1995; 95US-00474177.
XX	
PR	18-MAR-1994; 94US-00214582.
PR	18-MAR-1994; 94US-00215086.
PR	14-APR-1994; 94US-00227369.
PR	01-JUN-1994; 94US-00251938.
PR	17-MAR-1995; 95WO-US003537.
XX	
PA	(MYRI-) MYRIAD GENETICS INC.
XX	(UTAH) UNIV UTAH RES FOUND.
P1	Cannon-Albright LA, Kamb A, Skolnick MH;
XX	
DR	WPI; 1997-258217/23.
XX	
PT	Human mutant multiple tumour suppressor gene sequences - for production
PT	of recombinant mutant polypeptide(s).
XX	
PS	Example 13; Col 79-80; 72pp; English.
CC	
CC	The present sequence is primer for the PCR amplification of the human
CC	multiple tumour suppressor gene 2 (MTS2) cDNA, useful in cancer
CC	diagnosis. (Updated on 25-MAR-2003 to correct PF field.)
XX	
SQ	Sequence 16 BP; 2 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
Query Match	0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity	81.2%; Pred. No. 5.9e+02;
Matches	13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
OY	1465 GCGGCCAGACCTCA 1480
DB	16 GCTGCCAGACCTCA 1
RESULT 875	
AAT60188	
ID	AAT60188 standard; DNA; 16 BP.
XX	
AC	AAT60188;
XX	
DT	03-FEB-1998 (first entry)
XX	
DE	Synthetic cyclin B1 ribozyme recognition site #6.
XX	
KW	Ribozyme; hairpin; hammerhead; recognition site; cyclin B1; restenosis;
KM	growth factor; oncogene; vascular disease;
KW	smooth muscle cell proliferation; ss.
XX	
OS	Synthetic.
XX	
PN	WO9710334-A2.
XX	
PD	20-MAR-1997.
XX	
PF	12-SEP-1996; 96WO-US014838.
XX	
PR	12-SEP-1995; 95US-00527060.
XX	
PA	(IMMU-) IMMUSOL INC.

```

XX Goldenberg T, Tricz R;
XX
XX WPI; 1997-202230/18.
XX
XX New hairpin and hammer:head ribozyme(s) - which inhibit abnormal smooth
XX muscle cell proliferation in vascular tissue, partic. for preventing or
XX treating restenosis.
XX
XX Example 1; Page 14; 50pp; English.
XX
XX This sequence represents a ribozyme recognition site for the Cyclin B1
XX gene which is cleaved by a hairpin ribozyme at position 678 and by a
XX hammerhead ribozyme at position 680. Novel ribozymes are being
XX investigated for their ability to inhibit the activity of a growth factor
XX (e.g. Cyclin B1) responsible for abnormal smooth muscle cell (SMC)
XX proliferation in vascular tissue leading to restenosis. The ribozymes can
XX also directly block the production of oncogenes and cell regulatory
XX factors involved with SMC growth following vascular injury
XX
XX Sequence 16 BP; 3 A; 4 C; 2 G; 7 T; 0 U; 0 Other;
XX
XX
XX Query Match 0.7%; Score 12.8; DB 1; Length 16;
XX Best Local Similarity 50.0%; Pred. No. 5.9e+02;
XX Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
XX
XX 725 UGCCUGUGACCAGUAAU 740
XX :||:|||||:
XX 1 TGACTGTCCTCATTTAT 16
XX
XX
XX RESULT 876
XX AAV53836/c
XX ID AAV53836 standard; DNA; 16 BP.
XX
XX AAV53836;
XX AC
XX DT 04-DEC-1998 (first entry)
XX
XX Nucleotide sequence of PCR primer 7.
XX
XX Multiple tumour suppressor; MTS; human; cancer; hybridisation;
XX somatic mutation; gene therapy; PCR; primer; amplification; ss-
XX Synthetic.
XX OS
XX US5801236-A.
XX PN
XX PD 01-SEP-1998.
XX
XX 07-JUN-1995; 95US-00480810.
XX
XX 18-MAR-1994; 94US-00214582.
XX PR 18-MAR-1994; 94US-00215086.
XX PR 18-MAR-1994; 94US-00215087.
XX PR 14-APR-1994; 94US-00227369.
XX PR 01-JUN-1994; 94US-00251938.
XX PR 17-MAR-1995; 95MO-US003316.
XX
XX (MYRI-) MYRIAD GENETICS INC.
XX PA
XX PI
XX PI Kamb A;
XX DR WPI; 1998-494842/42.
XX
XX Nucleic acids based on multiple tumour suppressor, MTS, sequences -
XX useful as hybridisation probes, primers and recombinant production of MTS
XX in the diagnosis and treatment of cancers related to MTS mutation(s).
XX
XX Example 13; Col 48; 73pp; English.
XX
XX This is the nucleotide sequence of a PCR primer used for amplification in
XX the method of the invention involving the used of the multiple tumour

```

CC lymphoma, CLL and cancers of the pancreas, thyroid, ovary, uterus,
 CC testis, kidney, stomach and rectum. The wild-type gene is useful for gene
 CC therapy and MTS polypeptides may also be used for protein replacement
 CC therapy. Also the polypeptides or cells contg. an altered MTS gene are
 CC useful for screening for potential cancer therapeutics

SQ Sequence 16 BP; 2 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 81.2%; Pred. No. 5.9e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 1465 GCGGCCAGACCCUCA 1480

Db 16 GCTGGCCAGACCTCA 1

RESULT 872

AA00733/C
 ID AA00733 standard; DNA; 16 BP.

AC AA00733;

DT 08-MAY-1996 (first entry)

DE Multiple tumour suppressor 2 (MTS2) gene PCR primer.

KW Multiple tumour suppressor; MTS2; cancer; diagnosis; assay;

KW predilection; melanoma; leukaemia; lymphoma; prognosis; pancreas;

KW breast; thyroid; PCR primer; ss.

OS Synthetic.

PN WO9525813-A1.

PD 28-SEP-1995.

PF 17-MAR-1995; 95WO-US003537.

PR 18-MAR-1994; 94US-00214582.

PR 18-MAR-1994; 94US-00215086.

PR 14-APR-1994; 94US-00227369.

PR 01-JUN-1994; 94US-00251938.

PA (UTAH) UNIV UTAH RES FOUND.

PA (MYRI-) MYRIAD GENETICS INC.

PI Skolnick MH, Cannon-Albright LA, Kamb A;

DR WPI, 1995-344626/44.

PT Detecting polymorphism associated with cancer pre:disposition - also DNA,

PT vectors and host cells e.g. for gene or protein replacement therapy and

PT drug screening.

PS Example 13; Page 72; 148pp; English.

CC An individual can be diagnosed as having a predisposition to cancer by

CC detecting an alteration in the wild type multiple tumour suppressor (MTS)

CC gene, using gene probes which hybridise to the MTS2 gene (amplified using

CC the PCR primers AA00733/26. The above assay can also be used in the

CC diagnosis and prognosis of melanoma, lymphoma, leukaemia and pancreas,

CC breast and thyroid cancers, etc

SQ Sequence 16 BP; 2 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

OY

1465 GCGGCCAGACCCUCA 1480

Db 16 GCTGGCCAGACCTCA 1

RESULT 873
 AA091218
 ID AA091218 standard; RNA; 16 BP.

AC AA091218;

DT 18-DEC-1997 (first entry)

DE Hairpin ribozyme recognition site in human hepatitis B virus 1164.

KW Hairpin ribozyme; inhibition; replication; infectivity; HBV;

KW hepatitis B virus; hepatitis; human; ss.

OS Hepatitis B virus.

FH Key Location/Qualifiers

FT misc_feature 5..6 /tag= a

FT /standard_name= "Cleavage_Site"

PN WO9708309-A2.

PD 06-MAR-1997.

PF 29-AUG-1996; 96WO-US013975.

PR 29-AUG-1995; 95US-00521255.

PA (IMMU-) IMMUSOL INC.

PI Goldenberg T, Yu M, Welch PJ, Barber JR;

DR WPI, 1997-179266/16.

PT New hairpin ribozyme - for inhibiting replication and infectivity of

PT hepatitis B virus.

PS Example 1; Page 17; 34pp; English.

CC A new hairpin ribozyme has been developed which is able to inhibit

CC replication and infectivity of hepatitis B virus (HBV). The present

CC sequence represents a hairpin ribozyme recognition site in human HBV. The

CC into a cell infected with HBV, or susceptible to infection, to inhibit

CC the replication/infectivity of HBV. Alternatively, cells transfected with

CC a vector ex vivo are administered to a patient. Hairpin ribozymes act on

CC (extra)hepatic RNA and so are potentially capable of eliminating

CC including chronic carriers. Also infection by hepatitis D (which requires

CC HBV surface antigen as its envelope) is prevented

SQ Sequence 16 BP; 2 A; 5 C; 5 G; 0 T; 4 U; 0 Other;

OY

326 GCGGCCAGACCCUCA 341

Db 1 GCGGCCAGACCCUCA 16

RESULT 874

AA09786/C

ID AA09786 standard; DNA; 16 BP.

AC AA09786;

DT 25-MAR-2003 (revised)

DT 10-SEP-1997 (first entry)

RESULT 867
AAD53513
ID AAD53513 standard; DNA; 15 BP.
XX
AC AAD53513;
XX
DT 28-MAY-2003 (first entry)
XX
DE Human GNRH2 gene polymorphism detecting ASO primer #5.
XX
KW Human; gonadotropin-releasing hormone 2; GNRH2; reproductive disorder;
KW gynecological; cytostatic; hormonal; target validation; gene therapy;
KW drug screening; lead compound; allele-specific oligonucleotide; ASO;
KW primer; ss.
XX
OS Homo sapiens.
XX
PN WO200294850-A2.
XX
PD 28-NOV-2002.
XX
PF 01-NOV-2001; 2001WO-US050630.
XX
PR 18-MAY-2001; 2001WO-US016353.
XX
PA (GENA-) GENA155ANCE PHARM INC.
XX
PI Duda A, Klem SE, Nandabalan K, Sausker EA;
XX
DR WPI; 2003-148454/14.
XX
PT New gonadotropin-releasing hormone 2 (GNRH2) polypeptide encoded by
PT genetic variants having polymorphisms in the GNRH2 gene, for studying the
PT function of, and treating disorders, such as, reproductive disorders.
XX
PS Claim 14; Col 13; 33pp; English.
XX
CC The invention relates to gonadotropin-releasing hormone 2 (GNRH2) and its
CC nucleic acid sequence. Polymorphic variants of the GNRH2 gene are useful
CC in studying the expression and function of GNRH2, and in expressing GNRH2
CC proteins for use in screening candidate drugs for treating diseases
CC associated with GNRH2 activity, such as reproductive disorders.
CC Polynucleotides comprising a polymorphic gene variant or fragment may be
CC used for therapeutic purposes, where a patient could benefit from
CC expression or increased expression of a particular GNRH2 protein isoform,
CC or an expression vector encoding the isoform may be administered to the
CC patient. Haplotype information is useful in improving the efficiency and
CC output of several steps in a drug discovery and development process,
CC including target validation, identifying lead compounds, and early phase
CC clinical trials. GNRH2 gene is used in gene therapy. The present sequence
CC is an allele-specific oligonucleotide (ASO) primer used for detecting
CC human GNRH2 gene polymorphisms
XX
SQ Sequence 15 BP; 2 A; 6 C; 3 G; 3 T; 0 U; 1 Other;
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 4.9e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
OY 1164 CCUGCAGGUGCCUGA 1178
DB 1 CCTGCAGCTGCTCTRA 15
RESULT 868
ACN37146
ID ACN37146 standard; DNA; 15 BP.
XX
AC ACN37146;
XX
DT 18-NOV-2004 (first entry)

XX
DE Human periodontal disease related gene PON1 PCR primer SEQ ID NO:56.
XX
KW Periodontal disease; polymorphism; ss; human; PCR; primer.
XX
OS Homo sapiens.
XX
PN WO2004042054-A1.
XX
PD 21-MAY-2004.
XX
PF 22-OCT-2003; 2003WO-IB004669.
XX
PR 23-OCT-2002; 2002JP-00308634.
XX
PA (HUB1-) HUBIT GENOMIX INC.
PA (KAMO/) KAMO1 K.
XX
PI Kamol K, Suzuki A, Numabe Y, Ji G, Muramatsu M, Baba M;
XX
DR WPI; 2004-400678/37.
XX
PT Single nucleotide polymorphisms associated with periodontal disease for
PT examination and assessment of susceptibility to periodontal disease.
XX
PS Example 1; SEQ ID NO 56; 0pp; Japanese.
XX
CC The invention relates to a novel method for examination of periodontal
CC disease in which genetic polymorphisms are detected in one or more of 51
CC genes. The method is useful for examination, diagnosis and assessment of
CC periodontal disease or risk of periodontal disease and the risk of its
CC progression to severe, aggressive and chronic periodontal disease. The
CC present sequence represents a PCR primer used in the exemplification of
CC the invention
XX
SQ Sequence 15 BP; 3 A; 8 C; 1 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 4.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
OY 62 UACACAGCCCCUC 74
DB 1 TACACAGCCCTC 13
RESULT 869
AAV43494/C
ID AAV43494 standard; RNA; 16 BP.
XX
AC AAV43494;
XX
DT 17-OCT-2003 (revised)
DT 14-SEP-1998 (first entry)
XX
DB HIV-1 co-receptor fusin target sequence 9.
XX
KW Endo-ribonuclease; ribozyme; cleave; co-receptor RNA; HIV infection;
KW chemokine receptor; CKR; fusin; ss.
XX
OS Human immunodeficiency virus 1.
XX
PN WO9817308-A1.
XX
PD 30-APR-1998.
XX
PF 24-OCT-1997; 97WO-US019923.
XX
PR 25-OCT-1996; 96US-0027875P.
PR 19-DEC-1996; 96US-00770235.
XX
PA (IMMU-) IMMUSOL INC.
XX

XX Sequence 15 BP; 3 A; 5 C; 3 G; 3 T; 0 U; 1 Other;
SQ Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 4.9e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 452 CCAGCAUCCUCUG 466
DB 1 CCAGCAAYGCTTCTG 15
RESULT 865
ABK81787
ID ABK81787 standard; DNA; 15 BP.
XX
AC ABK81787;
XX
DT 13-AUG-2002 (first entry)
XX
DE Human CHRM5 gene polymorphism detection ASO primer #13.
XX
KW Human; cholinergic receptor muscarinic 5; CHRM5; genotyping; haplotyping;
KM single nucleotide polymorphism; SNP; allele-specific oligonucleotide;
KW ASO; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200232924-A2.
XX
PD 25-APR-2002.
XX
PF 11-OCT-2001; 2001WO-US032022.
XX
PR 19-OCT-2000; 2000WO-US029071.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Bieglecki KM, Chew A, Choi JY, Denton RR, Nandabalan K;
PI Sausker EA, Stephens JC;
XX
DR WPI; 2002-435523/46.
XX
PT Novel cholinergic receptor, muscarinic 5 polynucleotide useful
PT therapeutically and in screening for candidate drug to treat diseases
PT related to the receptor activity.
XX
PS Claim 14; Page 13; 72pp; English.
XX
CC The present invention relates to a new cholinergic receptor, muscarinic 5
CC (CHRM5) polynucleotide comprising a sequence which is a polymorphic
CC variant for a reference sequence for the CHRM5 gene or its fragment, or a
CC polymorphic variant of a reference sequence for a CHRM5 cDNA or its
CC fragment. The invention is useful in drug screening assays. The molecules
CC of the invention are useful in studying the expression and function of
CC CHRM5, and in expressing CHRM5 protein for use in screening for candidate
CC drugs to treat diseases related to CHRM5 activity. The methods of the
CC invention are useful in developing diagnostic tests and therapeutic
CC treatments. The method is also useful in the design of clinical trials of
CC candidate drugs for treating specific condition or disease associated
CC with CHRM5 activity and is useful in determining whether an individual
CC has one of the haplotypes or one of the haplotype pairs. The invention is
CC useful in a variety of diagnostic and prognostic formats and therapeutic
CC methods. The invention is also useful in genotyping and/or haplotyping
CC the CHRM5 gene in an individual. The present nucleic acid sequence
CC represents one of a collection of allele-specific oligonucleotide (ASO)
CC primers (ABK81775-ABK81794) that were used in the invention to detect
CC polymorphisms in the human CHRM5 gene
XX
SQ Sequence 15 BP; 4 A; 4 C; 5 G; 1 T; 0 U; 1 Other;
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 4.9e+02;

Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 446 ACGUAGCCAGCAUG 460
DB 1 ACGTGCCAGCAAYG 15
RESULT 866
ABK81790/C
ID ABK81790 standard; DNA; 15 BP.
XX
AC ABK81790;
XX
DT 13-AUG-2002 (first entry)
XX
DE Human CHRM5 gene polymorphism detection ASO primer #16.
XX
KW Human; cholinergic receptor muscarinic 5; CHRM5; genotyping; haplotyping;
KM single nucleotide polymorphism; SNP; allele-specific oligonucleotide;
KW ASO; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200232924-A2.
XX
PD 25-APR-2002.
XX
PF 11-OCT-2001; 2001WO-US032022.
XX
PR 19-OCT-2000; 2000WO-US029071.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Bieglecki KM, Chew A, Choi JY, Denton RR, Nandabalan K;
PI Sausker EA, Stephens JC;
XX
DR WPI; 2002-435523/46.
XX
PT Novel cholinergic receptor, muscarinic 5 polynucleotide useful
PT therapeutically and in screening for candidate drug to treat diseases
PT related to the receptor activity.
XX
PS Claim 14; Page 13; 72pp; English.
XX
CC The present invention relates to a new cholinergic receptor, muscarinic 5
CC (CHRM5) polynucleotide comprising a sequence which is a polymorphic
CC variant for a reference sequence for the CHRM5 gene or its fragment, or a
CC polymorphic variant of a reference sequence for a CHRM5 cDNA or its
CC fragment. The invention is useful in drug screening assays. The molecules
CC of the invention are useful in studying the expression and function of
CC CHRM5, and in expressing CHRM5 protein for use in screening for candidate
CC drugs to treat diseases related to CHRM5 activity. The methods of the
CC invention are useful in developing diagnostic tests and therapeutic
CC treatments. The method is also useful in the design of clinical trials of
CC candidate drugs for treating specific condition or disease associated
CC with CHRM5 activity and is useful in determining whether an individual
CC has one of the haplotypes or one of the haplotype pairs. The invention is
CC useful in a variety of diagnostic and prognostic formats and therapeutic
CC methods. The invention is also useful in genotyping and/or haplotyping
CC the CHRM5 gene in an individual. The present nucleic acid sequence
CC represents one of a collection of allele-specific oligonucleotide (ASO)
CC primers (ABK81775-ABK81794) that were used in the invention to detect
CC polymorphisms in the human CHRM5 gene
XX
SQ Sequence 15 BP; 5 A; 1 C; 5 G; 3 T; 0 U; 1 Other;
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 4.9e+02;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
QY 686 CCAGCAUACUUCUG 700
DB 15 CVACCATCACTTTTG 1

CC	primer
SQ	Sequence 15 BP; 0 A; 6 C; 3 G; 5 T; 0 U; 1 Other;
OY	Query Match Best Local Similarity 0.7%; Score 13; DB 1; Length 15; Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0
DB	815 GGACAGGCGCAGAGA 829 : 15 GKCCAGGCGCAGAGA 1
RESULT 863	
ABSS59475/C	
ID	ABSS59475 standard; RNA; 15 BP.
XX	
AC	ABSS59475;
XX	
DT	05-NOV-2002 (first entry)
DE	RNA sequence #1, for sample identification.
XX	
KM	Genetic affinity; virus; genetic relative; node; bifurcating tree; ss;
KW	genetic relationship; signature probe; phylogenetic affinity;
KV	space flight; medicine; indoor air quality; bioweapon; mass destruction;
XX	epidemic; phylogenetic tree; air filtrate; government building;
KX	bioerrorism agent; molecular beacon; bacteria; Bacillus; Kohne approach.
OS	Borrelia sp.
OS	Brachyspieta sp.
OS	Spirochaeta sp.
OS	Treponema sp.
XX	
PN	WO200259348-A2.
XX	
PD	01-AUG-2002.
XX	
PF	26-JAN-2002; 2002WO-US002564.
XX	
PR	26-JAN-2001; 2001US-0264403P.
XX	
PA	(TECH-) TECHNOLOGY LICENSING CO LLC.
XX	
P1	Fox GE, Wilson RC, Zhang Z;
XX	
DR	WPI; 2002-619174/66.
XX	
PT	Determining the genetic affinity of organisms or viruses useful in
PT	bioerrorism, comprises determining which nodes in the bifurcating tree
PT	of genetic relationship that designs the signature probes produces the
PT	hybridization signal.
XX	
XX	Claim 15; Page 36; 62pp; English.
XX	
CC	The present invention relates to a new method for determining the genetic
CC	affinity of organisms or viruses in the test sample. The method involves
CC	identifying the closest known genetic relatives of the organisms or virus
CC	by determining which nodes in the bifurcating tree of genetic
CC	relationship was used to design the signature probe. The method is
CC	useful in identifying the phylogenetic affinity of an unknown organism
CC	useful for unanticipated problems involving microorganisms that concerns
CC	space flight, medicine, indoor air quality, bioweapons of mass
CC	destruction, or epidemics. The signature sequences are useful in the
CC	hybridisation to determine the phylogenetic tree positions of the
CC	organisms in the sample. The method can also be useful as an assay for
CC	bioerrorism. Air filtrate from a government building was collected and
CC	nucleic acids isolated. RNA was enriched using DNase and RNA fragmented
CC	by heating. Probes specific to several known bioerrorism agents give
CC	negative results. Molecular beacon based scoring of signature sequences
CC	reveals the presence of unexpectedly high concentrations of Bacteria with
CC	genetic affinity to genus Bacillus. The method provides a more rapid
CC	approach for determining the affinity of organisms in the test sample.

CC	The methodology is more general than the specifically targeted tests of
CC	the Kohne approach, and faster and more convenient than detailed
CC	sequencing of the rRNAs or their encoding DNA. The present nucleic acid
CC	sequence represents an RNA sequence that was used in the methods of the
CC	invention for sample identification
XX	
XX	Sequence 15 BP; 3 A; 4 C; 7 G; 0 T; 1 U; 0 Other;
XX	
QY	Query Match 0.7%; Score 13; DB 1; Length 15;
Db	Best Local Similarity 76.9%; Pred. No. 4.9e+02;
	Matches 10; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
	1024 GCUGCUGCCUCCC 1036
	:
	14 GCTGCTGCCTCCC 2
RESULT 864	
ID	ABK81771 standard; DNA; 15 BP.
AC	ABK81771;
XX	
DT	13-AUG-2002 (first entry)
XX	
DE	Human CHRM5 gene polymorphism detection ASO probe #7.
KW	Human: cholinergic receptor muscarinic 5; CHRM5; genotyping; haplotyping;
KW	single nucleotide polymorphism; SNP; allele-specific oligonucleotide;
XX	ASO; probe; ss.
XX	
OS	Homo sapiens.
PN	WO200232924-A2.
XX	
PD	25-APR-2002.
XX	
PF	11-OCT-2001; 2001WO-US032022.
XX	
PR	19-OCT-2000; 2000WO-US029071.
XX	
PA	(GENA-) GENAISSANCE PHARM INC.
XX	
PI	Bieglecki KM, Chew A, Choi JY, Denton RR, Nandabalan K;
PI	Sausker EA, Stephens JC;
XX	
DR	WPI; 2002-435523/46.
XX	
PS	Claim 14; Page 13; 72pp; English.
XX	
CC	The present invention relates to a new cholinergic receptor, muscarinic 5
CC	(CHRM5) polynucleotide comprising a sequence which is a polymorphic
CC	variant for a reference sequence for the CHRM5 gene or its fragment, or a
CC	polymorphic variant of a reference sequence for a CHRM5 cDNA or its
CC	fragment. The invention is useful in drug screening assays. The molecules
CC	of the invention are useful in studying the expression and function of
CC	CHRM5, and in expressing CHRM5 protein for use in screening for candidate
CC	drugs to treat diseases related to CHRM5 activity. The methods of the
CC	invention are useful in developing diagnostic tests and therapeutic
CC	treatments. The method is also useful in the design of clinical trials of
CC	candidate drugs for treating specific condition or disease associated
CC	with CHRM5 activity and is useful in determining whether an individual
CC	has one of the haplotypes or one of the haplotype pairs. The invention is
CC	useful in a variety of diagnostic and prognostic formats and therapeutic
CC	methods. The invention is also useful in genotyping and/or haplotyping
CC	the CHRM5 gene in an individual. The present nucleic acid sequence
CC	represents one of a collection of allele-specific oligonucleotide (ASO)
CC	probes (ABK81765-ABK81774) that were used in the invention to detect
CC	polymorphisms in the human CHRM5 gene

CC The invention comprises DNA, cDNA and protein sequences of the human
 CC electron-transfer flavoprotein, beta polypeptide (ETFB) gene (located on
 CC chromosome 19q13.3-13.4). The invention specifically relates to the
 CC identification of 27 novel polymorphic sites within the ETFB gene.
 CC Electron-transfer flavoprotein (ETP) is an obligatory electron acceptor
 CC for nine primary flavoprotein dehydrogenases and is located in the
 CC mitochondrial matrix. ETP is composed of an alpha (ETFA) and a beta
 CC (ETFB) subunit. Electrons accepted by ETP are transferred to the
 CC mitochondrial respiratory chain by ETP dehydrogenases (ETPDHs).
 CC Deficiency of ETP or ETPDH leads to glutaric acidemia type II (GATII).
 CC Therefore ETFB is a pharmacologically-important gene in the treatment of
 CC GATII. The novel ETFB polymorphisms identified in the invention are useful
 CC for genotyping and haplotyping the ETFB gene of an individual. The ETFB
 CC protein and nucleic acids of the invention are useful for studying the
 CC expression and function of ETFB in vivo. The ETFB protein and nucleic
 CC acids are also useful for testing the efficacy of therapeutic agents and
 CC compounds for glutaric acidemia type II. The nucleic acids of the
 CC invention are useful in the production of a transgenic animal expressing
 CC the ETFB gene. Nucleic acids ABU39414-ABU39440 represent claimed ETFB
 CC allele-specific probes. Nucleic acids ABU39441-ABU39494 represent claimed
 CC ETFB allele-specific PCR primers. Nucleic acids ABU39495-ABU39548
 CC represent claimed ETFB primer-extension oligonucleotides
 CC
 SQ Sequence 15 BP; 2 A; 4 C; 6 G; 2 T; 0 U; 1 Other;

Query Match 0.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 73.3%; Pred. No. 4.9e+02;
 Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1470 CCAGACCCCTCAGTGC 1484
 15 CTAGGCCCCCTCAGTGC 1

Db

RESULT 861

ABK34185
 ID ABK34185 standard; DNA; 15 BP.

AC ABK34185;

DT 08-MAY-2002 (first entry)

DE Human interleukin 12B (IL12B) gene, allele-specific oligonucleotide #9.

KM Human; interleukin 12B; IL12B; haplotype; SNP; primer; ss;

KW single nucleotide polymorphism; allele-specific oligonucleotide.

OS Homo sapiens.

PN WO200210190-A2.

PD 07-FEB-2002.

PF 30-JUL-2001; 2001WO-US023927.

PR 29-JUL-2000; 2000US-0221436P.

PA (GENA-) GENNAISSANCE PHARM INC.

PI Messer C, Sanchez A;

DR WPI; 2002-188721/24.

XX New genetic variants having polymorphisms in the human interleukin 12B
 PT (IL12B) gene, useful for studying the function of IL12B, and for creating
 PT disorders affected by expression or function of the IL12B isogene.

PS Claim 16; Page 13; 95pp; English.

XX The invention relates to an isolated polynucleotide, comprising genes and
 CC haplotypes of the interleukin 12B (IL12B) gene. The polynucleotide
 CC comprises polymorphic sites in the IL12B gene, referred to as PSI-11. The
 CC observed and identified haplotypes, isogenes and polymorphisms of the

CC IL12B gene, as well as the locations of these polymorphisms, are fully
 CC defined in a table in the specification. Also described is an isolated
 CC polypeptide comprising an amino acid sequence which is a polymorphic
 CC variant of a reference sequence for the IL12B protein or its fragment.
 CC Polynucleotides comprising a polymorphic gene variant or fragment may be
 CC used for therapeutic purposes, where a patient could benefit from
 CC expression or increased expression of a particular IL12B protein isoform,
 CC or an expression vector encoding the isoform may be administered to the
 CC patient. IL12B peptide variants may be used to as antigens to generate
 CC antibodies specific for the IL12B isoforms, and in drug screening assays.
 CC Compositions comprising the polynucleotide of the isogenes may be used to
 CC treat disorders affected by expression or function of the IL12B isogene.
 CC ABK34177-ABK34231 represent human interleukin 12B gene, allele-specific
 CC oligonucleotides of the invention

SQ Sequence 15 BP; 2 A; 4 C; 2 G; 6 T; 0 U; 1 Other;

Query Match 0.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 46.7%; Pred. No. 4.9e+02;
 Matches 7; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 205 GUCUUCACUCCUUC 219
 1 GTCCTCAYAGCTTTC 15

Db

RESULT 862

AAL42977/C
 ID AAL42977 standard; DNA; 15 BP.

AC AAL42977;

DT 08-AUG-2002 (first entry)

DE Human cerberus 1 (CER1) gene allele-specific oligonucleotide primer 8.

KM Human; PCR; allele-specific; SNP; single nucleotide polymorphism; ss;

KW cerberus 1 homologue; cysteine knot superfamily; CER1; drug screening;
 KW developmental disorder; polymorphic site; CER1 haplotyping; primer.

OS Homo sapiens.

PN WO200232929-A2.

PD 25-APR-2002.

PF 19-OCT-2001; 2001WO-US046100.

PR 19-OCT-2000; 2000US-0241634P.

PA (GENA-) GENNAISSANCE PHARM INC.

PI Kazemi A, Shah N;

DR WPI; 2002-43527/46.

XX Novel genetic variants of Cerberus 1 (Xenopus laevis) Homolog (Cysteine
 PT Knot Superfamily) (CER1) isogenes, useful for improving efficiency and
 PT reliability in drug development for treating developmental disorders.

PS Claim 14; Page 13; 75pp; English.

XX The invention relates to the identification of 13 novel polymorphic sites
 CC in the human cerberus 1 (Xenopus laevis) homologue (cysteine knot
 CC superfamily) (CER1) gene. The invention also comprises the amino acid and
 CC coding sequence of CER1. The CER1 protein is useful for screening drugs
 CC that target CER1 - for the treatment of developmental disorders. The CER1
 CC coding sequence is useful in studying the expression of CER1 isogenes,
 CC for screening and testing of drugs targeted against CER1 protein, and in
 CC testing the efficacy of therapeutic agents for treating developmental
 CC disorders. The 13 novel polymorphic sites identified in the invention are
 CC useful for haplotyping the CER1 gene of an individual. The present DNA
 CC sequence represents a human CER1 gene allele-specific oligonucleotide

XX Mcswigen J, Usman N, Blact L, Beigelman L, Burgin A,
PI Karpeisly A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B,
PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
XX WPI; 2001-244406/25.
XX
PT Enzymatic nucleic acid molecules able to cleave separate RNA molecules
PT are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
XX obesity and heart disease.
XX
PS Example 16; Page 619; 717pp; English.
XX
XX The present invention relates to the use of enzymatic nucleic acid
CC molecules (e.g. ribozymes) to modulate gene expression. The invention
CC also methods for their use to down regulate or inhibit the expression of
CC genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine
CC aminopeptidase (MeAP-2), human telomerase (hTERT), protein kinase C
CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
CC receptor-2 (HER2/C-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC nucleic acid molecules used to inhibit the expression of the said genes
CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
CC zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
CC for treating cancer, in particular breast cancer, Alzheimer's disease,
CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC diseases, hepatitis B infections, and hepatitis and hepatocellular
CC carcinoma. The enzymatic nucleic acid molecules can also be used as
CC diagnostic tools to examine genetic drift and mutations within diseased
CC cells and to detect the presence of specific RNA in a cell. The present
CC sequence represents a substrate/target sequence for a ribozyme used in
CC the examples of the present invention. Note: Some SEQ ID Nos are repeated
CC more than once in the specification, but these have different sequences
CC associated with them.
XX
SQ Sequence 15 BP; 4 A; 4 C; 4 G; 0 T; 3 U; 0 Other;
XX
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 4.9e+02;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
XX
QY 861 UCGAAGCTCGCAGC 873
DB 14 TCGAAGCTCGCAGC 2
XX
RESULT 859
AAD25418
ID AAD25418 standard; DNA; 15 BP.
XX
AC AAD25418;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human GNRH2 gene polymorphism detecting ASO primer #5.
XX
XX Human, gonadotropin-releasing hormone 2; GNRH2 gene; haplotyping;
KM genotyping; gene therapy; reproductive disorder; polymorphism;
KM allele specific oligonucleotide; ASO; primer; ss.
XX
OS Homo sapiens.
XX
XX WO200187910-A2.
XX
PN 22-NOV-2001.
XX
PD 18-MAY-2001; 2001WO-US016353.
XX
PP 18-MAY-2000; 2000US-0205187P.
XX
PR (GENA-) GENAISSANCE PHARM INC.
XX
PA Duda A, Klien SE, Nandabalan K, Sausker EA;
XX
PS

XX
DR WPI; 2002-055663/07.
XX
XX New genetic variants of gonadotropin-releasing hormone 2 isogene, useful
PT in studying expression and function of protein and for screening drugs to
PT treat diseases e.g. reproduction disorders.
XX
XX
PS Claim 16; Page 13; 64pp; English.
XX
XX The invention relates to genetic variants of human gonadotropin-
CC releasing hormone 2 (GNRH2) gene. The invention also relates to
CC compositions and methods for haplotyping and/or genotyping the GNRH2 gene
CC in an individual. Polynucleotides of the invention are useful for
CC studying the expression and function of GNRH2 and in expressing GNRH2
CC proteins for use in screening candidate drugs to treat diseases related
CC to GNRH2 activity. They are also used in gene therapy. The methods of the
CC invention are useful in determining whether an individual has a haplotype
CC or haplotype pairs. The haplotyping method is useful for improving the
CC efficiency and reliability of several steps in the discovery and
CC development of drugs for treating diseases associated with GNRH2
CC activity, e.g., reproductive disorders. The present sequence is an allele
CC specific oligonucleotide (ASO) primer used for detecting human GNRH2 gene
CC polymorphisms
XX
SQ Sequence 15 BP; 2 A; 6 C; 3 G; 3 T; 0 U; 1 Other;
XX
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 4.9e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1164 CCUGCAGUGCCUGA 1178
DB 1 CCRGCAGCTGCCCTRA 15
XX
RESULT 860
ABL39489/C
ID ABL39489 standard; DNA; 15 BP.
XX
AC ABL39489;
XX
DT 22-APR-2002 (first entry)
XX
DE Human ETRF8 allele-specific oligonucleotide primer 49.
XX
XX Human, electron-transfer flavoprotein beta polypeptide; ETRF8;
KM electron acceptor; mitochondrial matrix; glutaric acidemia type II;
KM novel polymorphic site; novel polymorphism; ETRF8 genotype; ss; GAI1;
KM ETRF8 haplotype; transgenic animal; primer; probe; chromosome 19q13;
KM primer-extension oligonucleotide; single nucleotide polymorphism; SNP.
XX
OS Homo sapiens.
XX
XX WO200202580-A2.
XX
PN 10-JAN-2002.
XX
PD 05-JUL-2001; 2001WO-US021306.
XX
PP 05-JUL-2000; 2000US-0215984P.
XX
PR (GENA-) GENAISSANCE PHARM INC.
XX
PA Bentivegna SC, Bieglecki KM, Kazemi A, Koshy B;
XX
PI WPI; 2002-154722/20.
XX
DR Novel isolated human electron-transfer-flavoprotein, beta polynucleotide,
XX useful for therapeutic purposes, for studying the expression and function
PT of the polynucleotide, and for expressing the flavoprotein.
XX
XX Claim 17; Page 15; 143pp; English.
XX
XX

Query Match 0.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 84.6%; Pred. No. 4.9e+02;
 Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

861 UCGAAGCUCGACG 873
 :|||||:
 15 TCGAGCTGCACG 3

RESULT 857
 ADV37407/C
 ID ADV37407 standard; RNA; 15 BP.
 XX
 AC ADV37407;
 XX
 DT 10-FEB-2005 (first entry)
 XX
 DE Human anti-HER2 NCH ribozyme substrate sequence #1098.
 KM Enzymatic nucleic acid molecule; gene expression; down regulation;
 KM protein-tyrosine-phosphatase-1b; PTB-1b; methionine aminopeptidase;
 KM MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
 KM beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
 KM c-erbB2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
 KM hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
 KM amberyne; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
 KM diabetes; obesity; cardiac disease; heart disease; age-related disease;
 KM hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
 KM ss.
 XX Homo sapiens.
 XX
 OS WO200116312-A2.
 XX
 PN 08-MAR-2001.
 PD
 XX
 PF 30-AUG-2000; 2000MO-US023998.
 XX
 XX 31-AUG-1999; 99US-0151713P.
 PR 27-SEP-1999; 99US-00406643.
 PR 27-SEP-1999; 99US-0156236P.
 PR 27-SEP-1999; 99US-0156467P.
 PR 08-NOV-1999; 99US-00436430.
 PR 06-DEC-1999; 99US-0169100P.
 PR 29-DEC-1999; 99US-00474432.
 PR 29-DEC-1999; 99US-0173612P.
 PR 30-DEC-1999; 99US-00476387.
 PR 04-FEB-2000; 2000US-00498824.
 PR 20-MAR-2000; 2000US-00531025.
 PR 14-APR-2000; 2000US-0197769P.
 PR 23-MAY-2000; 2000US-00578223.
 PR 09-AUG-2000; 2000US-00636385.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 PA
 XX
 PI McSwiggan J, Usman N, Blatt L, Belgelman L, Burgin A;
 PI Karpelisky A, Matulic-Adamic J, Svedler D, Draper K, Chowrira B;
 PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
 XX
 DR WPI; 2001-244406/25.
 XX
 PT Enzymatic nucleic acid molecules able to cleave separate RNA molecules
 PT are used for treating cancer; Alzheimer's disease, hepatitis, diabetes,
 PT obesity and heart disease.
 PT
 XX
 PS Example 7; Page 494; 717pp; English.
 XX
 CC The present invention relates to the use of enzymatic nucleic acid
 CC molecules (e.g. ribozymes) to modulate gene expression. The invention
 CC also methods for their use to down regulate or inhibit the expression of
 CC genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine
 CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C

CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
 CC receptor-2 (HER2/c-erbB2/neu), phospholamban (PLN), presenilin-1 (ps-1),
 CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
 CC nucleic acid molecules used to inhibit the expression of the said genes
 CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberyne,
 CC zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
 CC for treating cancer, in particular breast cancer, Alzheimer's disease,
 CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
 CC diseases, hepatitis B infections, and hepatitis and hepatocellular
 CC carcinoma. The enzymatic nucleic acid molecules can also be used as
 CC diagnostic tools to examine genetic drift and mutations within diseased
 CC cells and to detect the presence of specific RNA in a cell. The present
 CC sequence represents a substrate/target sequence for an anti-HER2 NCH
 CC ribozyme used in the examples of the present invention. Note: Some SEQ ID
 CC Nos are repeated more than once in the specification, but these have
 CC different sequences associated with them.

Sequence 15 BP; 5 A; 3 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 0.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 61.5%; Pred. No. 4.9e+02;
 Matches 8; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

936 CUUCUGGUCACG 948
 ||::||::|||
 13 CTTCTGTTGCACA 1

RESULT 858
 ADV63338/C
 ID ADV63338 standard; RNA; 15 BP.
 XX
 AC ADV63338;
 XX
 DT 10-FEB-2005 (first entry)
 XX
 DE Human Her2 class II ribozyme substrate sequence #11.
 XX
 XX Enzymatic nucleic acid molecule; gene expression; down regulation;
 KM protein-tyrosine-phosphatase-1b; PTB-1b; methionine aminopeptidase;
 KM MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
 KM beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
 KM c-erbB2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
 KM hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
 KM amberyne; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
 KM diabetes; obesity; cardiac disease; heart disease; age-related disease;
 KM hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
 KM ss.
 XX Homo sapiens.
 XX
 OS WO200116312-A2.
 XX
 PN 08-MAR-2001.
 PD
 XX
 PF 30-AUG-2000; 2000MO-US023998.
 XX
 XX 31-AUG-1999; 99US-0151713P.
 PR 27-SEP-1999; 99US-00406643.
 PR 27-SEP-1999; 99US-0156236P.
 PR 27-SEP-1999; 99US-0156467P.
 PR 08-NOV-1999; 99US-00436430.
 PR 06-DEC-1999; 99US-0169100P.
 PR 29-DEC-1999; 99US-00474432.
 PR 29-DEC-1999; 99US-0173612P.
 PR 30-DEC-1999; 99US-00476387.
 PR 04-FEB-2000; 2000US-00498824.
 PR 20-MAR-2000; 2000US-00531025.
 PR 14-APR-2000; 2000US-0197769P.
 PR 23-MAY-2000; 2000US-00578223.
 PR 09-AUG-2000; 2000US-00636385.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX

AC	AAP46812;
XX	
DT	30-MAR-2001 (first entry)
XX	
DE	IGFBP3 oligonucleotide #2232.
XX	
KW	Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KM	cytostatic; dermatological; cardiac; vinclide; ophthalmological; keloid;
KM	skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pteryiasis;
KM	IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW	growth factor mediated cell proliferation; ichthyosis; seborrhoea; rubra;
KV	kerctosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW	hyperneovascular condition; hyperplasia; kidney disease;
KW	neovascular condition of the retina; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO200078341-A1.
XX	
PD	28-DEC-2000.
XX	
PE	21-JUN-2000; 2000MO-AU000693.
XX	
PR	21-JUN-1999; 99US-0140345P.
XX	
PA	(MURD-) MURDOCH CHILDRENS RES INST.
XX	
PI	Wright CJ, Werther GA, Edmondson SR;
DR	WPI; 2001-041421/05.
XX	
PT	Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT	UV (ultra-violet) treatment (optional), and an antisense nucleic acid that
PT	inhibits or reduces growth factor mediated cell proliferation and/or
PT	inflammation.
XX	
PS	Example 7; Page 58; 201pp; English.
XX	
CC	The present invention relates to a method for ameliorating the effects of
CC	skin disorders. The method comprises contacting the skin with an
CC	antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC	receptor, IGF binding protein [IGBP]-2 or IGFBP3), which is capable of
CC	inhibiting or reducing growth factor mediated cell proliferation,
CC	inflammation and/or other disorders. The present sequence is an
CC	oligonucleotide which can be used to design the antisense
CC	oligonucleotides of the present invention (see AAP45151 and AAP45153-
CC	F45161). The method is useful for ameliorating the effects of psoriasis,
CC	ichthyosis, pteryiasis, ruba, pilaris, seborrhoea, keloids, keratosis,
CC	neoplasia, scleroderma, warts, benign growths, cancers of the skin, a
CC	hyperneovascular condition such as a neovascular condition of the retina,
CC	brain or skin, growth factor-mediated malignancies, other sclerotic
CC	disease, kidney disease, hyperproliferation of the inside of blood
CC	vessels or any other hyperplasia
XX	
SQ	Sequence 15 BP; 1 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
OY	
DG	Query Match 0.7%; Score 13; DB 1; Length 15; Best Local Similarity 92.3%; Pred. No. 4.9e+02; Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0, 648 GCCTCCGGAGAG 660 : 15 GCCTCCGGAGAG 3
RESULT 856	
ID ADV35610/c	ADV35610 standard; RNA; 15 BP.
AC ADV35610;	
XX	
PT 10-FEB-2005	(first entry)
XX	

DB 15 CTTCTCTYACAGAA 1

RESULT 853

AAFA8814/C

AAFA8814; standard; DNA; 15 BP.

AAFA8814;

30-MAR-2001 (first entry)

IGFBP3 oligonucleotide #2234.

Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic; cytostatic; dermatological; cardiac; vitreous; ophthalmological; keloid; skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis; IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris; growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba; keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease; hyperneovascular condition; hyperplasia; kidney disease; neovascular condition of the retina; ss.

Homo sapiens.

MO200078341-A1.

28-DEC-2000.

21-JUN-2000; 2000WO-AU000693.

21-JUN-1999; 99US-0140345P.

(MURD-) MURDOCH CHILDRENS RES INST.

Wright CJ, Werther GA, Edmondson SR;

WPI; 2001-041421/05.

Ameliorating the effects of a disorder, e.g. psoriasis, by administering UV (ultra-violet) treatment (optional) and an antisense nucleic acid that inhibits or reduces growth factor mediated cell proliferation and/or inflammation.

Example 7; Page 58; 201pp; English.

The present invention relates to a method for ameliorating the effects of skin disorders. The method comprises contacting the skin with an antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1 receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of inhibiting or reducing growth factor mediated cell proliferation, inflammation and/or other disorders. The present sequence is an oligonucleotide which can be used to design the antisense oligonucleotides of the present invention (see AAFA5151 and AAFA5153-F45161). The method is useful for ameliorating the effects of psoriasis, ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis, neoplasia, scleroderma, warts, benign growths, cancers of the skin, a hyperneovascular condition such as a neovascular condition of the retina, brain or skin, growth factor-mediated malignancies, other sclerotic disease, kidney disease, hyperproliferation of the inside of blood vessels or any other hyperplasia

Sequence 15 BP; 2 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 13; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 4.9e+02; Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

648 GCCTCCGGAGAG 660

13 GCCTCCGGAGAG 1

RESULT 854

AAFA8813/C

AAFA8813; standard; DNA; 15 BP.

AAFA8813;

30-MAR-2001 (first entry)

IGFBP3 oligonucleotide #2233.

Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic; cytostatic; dermatological; cardiac; vitreous; ophthalmological; keloid; skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis; IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris; growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba; keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease; hyperneovascular condition; hyperplasia; kidney disease; neovascular condition of the retina; ss.

Homo sapiens.

MO200078341-A1.

28-DEC-2000.

21-JUN-2000; 2000WO-AU000693.

21-JUN-1999; 99US-0140345P.

(MURD-) MURDOCH CHILDRENS RES INST.

Wright CJ, Werther GA, Edmondson SR;

WPI; 2001-041421/05.

Ameliorating the effects of a disorder, e.g. psoriasis, by administering UV (ultra-violet) treatment (optional) and an antisense nucleic acid that inhibits or reduces growth factor mediated cell proliferation and/or inflammation.

Example 7; Page 58; 201pp; English.

The present invention relates to a method for ameliorating the effects of skin disorders. The method comprises contacting the skin with an antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1 receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of inhibiting or reducing growth factor mediated cell proliferation, inflammation and/or other disorders. The present sequence is an oligonucleotide which can be used to design the antisense oligonucleotides of the present invention (see AAFA5151 and AAFA5153-F45161). The method is useful for ameliorating the effects of psoriasis, ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis, neoplasia, scleroderma, warts, benign growths, cancers of the skin, a hyperneovascular condition such as a neovascular condition of the retina, brain or skin, growth factor-mediated malignancies, other sclerotic disease, kidney disease, hyperproliferation of the inside of blood vessels or any other hyperplasia

Sequence 15 BP; 1 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 13; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 4.9e+02; Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

648 GCCTCCGGAGAG 660

14 GCCTCCGGAGAG 2

RESULT 855

AAFA8812/C

AAFA8812; standard; DNA; 15 BP.

XX AC AAT55673;
XX XX
DT 25-MAR-2003 (revised)
XX DT 21-MAR-1997 (first entry)
XX DE Human TNF-alpha hammerhead ribozyme target sequence (nt position 226).
XX
KM Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KM gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KM intercellular adhesion molecule; rei A; tumour necrosis factor;
KM TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KM translocation; chronic myelogenous leukaemia; CML; cancer;
KM Philadelphia chromosome; inflammation; autoimmune disease;
KM atherosclerosis; myocardial infarction; stroke; restenosis;
KM transplant rejection; rheumatoid arthritis; psoriasis;
KM myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KM human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KM ss.
XX
XX OS Homo sapiens.
XX PN W09523225-A2.
XX PD 31-AUG-1995.
XX PF 23-FEB-1995; 95WO-1B000156.
XX
XX 23-FEB-1994; 94US-00201109.
XX PR 29-MAR-1994; 94US-00218934.
XX PR 04-APR-1994; 94US-00222795.
XX PR 07-APR-1994; 94US-00224483.
XX PR 15-APR-1994; 94US-00227958.
XX PR 15-APR-1994; 94US-00228041.
XX PR 18-MAY-1994; 94US-00245736.
XX PR 06-JUL-1994; 94US-00271280.
XX PR 15-AUG-1994; 94US-00291932.
XX PR 16-AUG-1994; 94US-00291433.
XX PR 17-AUG-1994; 94US-00292620.
XX PR 19-AUG-1994; 94US-00293520.
XX PR 02-SEP-1994; 94US-00300000.
XX PR 08-SEP-1994; 94US-00303039.
XX PR 23-SEP-1994; 94US-00311486.
XX PR 23-SEP-1994; 94US-00311749.
XX PR 28-SEP-1994; 94US-00314397.
XX PR 03-OCT-1994; 94US-00316771.
XX PR 07-OCT-1994; 94US-00319492.
XX PR 11-OCT-1994; 94US-00321993.
XX PR 04-NOV-1994; 94US-00334847.
XX PR 10-NOV-1994; 94US-00337608.
XX PR 28-NOV-1994; 94US-00345516.
XX PR 16-DEC-1994; 94US-00357577.
XX PR 23-DEC-1994; 94US-00363233.
XX PR 30-JAN-1995; 95US-00380734.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpeisky A, Kislich K, Matulic-Adamic J, Mcswiggen JA;
PI Modak A, Pavco P, Beislerman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Usman N, Wincott FE, Woolf T;
XX
XX MPI, 1995-351090/45.
XX
XX Ribozymes having modified bases and methods for producing them - for use
XX PT in inhibiting disease related genes.
XX
XX PS Claim 2; Page 241; 407pp; English.
XX
XX The present sequence represents a preferred target sequence for an
XX enzymatic nucleic acid (i.e. a ribozyme) which cleaves TNF-alpha mRNA at
XX CC the nucleotide base position indicated in the DE line. Regions of the
XX CC mRNA that do not form secondary folding structures and that contain

CC potential hammerhead and hairpin ribozyme cleavage sites were identified
CC by computer analysis. Ribozymes directed against these mRNA sequences
CC were designed and synthesised with modifications that improve their
CC nuclease resistance. The ribozymes are designed to cleave the target
CC sequences and thereby inhibit TNF-alpha expression, making them
CC potentially useful for treating rheumatoid arthritis, septic shock and
CC other inflammatory disorders including psoriasis, as well as for
CC treatment of AIDS. (Updated on 25-MAR-2003 to correct PI field.)
XX
XX SQ Sequence 15 BP; 1 A; 8 C; 2 G; 0 T; 4 U; 0 Other;
XX
XX Query Match 0.7%; Score 13; DB 1; Length 15;
XX Best Local Similarity 92.3%; Pred. No. 4.9e+02;
XX Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1231 CAGAGAGCGUGG 1243
XX |||||
XX 13 CAGAGAGCGTGG 1
XX
XX RESULT 852
XX AA167297/C
XX ID AA167297 standard; DNA; 15 BP.
XX AC
XX AC AA167297;
XX
XX DT 11-FEB-2002 (first entry)
XX
XX DE Human FKBP8 allele-specific oligonucleotide (ASO) probe.
XX
XX FK506-binding protein 8; FKBP8; haplotyping; polymorphism; cancer; ss;
XX immunosuppression; human; allele-specific oligonucleotide; ASO; probe.
XX
XX OS Homo sapiens.
XX
XX PN W0200172965-A2.
XX PD 04-OCT-2001.
XX
XX 26-MAR-2001; 2001WO-US009718.
XX PR 24-MAR-2000; 2000US-0192125P.
XX
XX PA (GENA-) GENA1SSANCE PHARM INC.
XX PI Anastasio AB, Bentivegna SC, Choi JY, Klieem SE, Koshy B;
XX PI Stephens JC;
XX MPI; 2001-626261/72.
XX
XX PT New haplotypes of the FK506-binding protein 8 gene, useful for genotyping
XX PT that gene in individual and to design new therapy for associated disease
XX PT such as immunosuppression and cancer.
XX
XX PS Claim 15; Page 13; 98pp; English.
XX
XX The invention relates to haplotyping the FK506-binding protein 8 (38kD)
XX (FKBP8) gene in an individual. The method involves determining the
XX CC identity of the nucleotide pair at one or more polymorphic sites selected
XX CC from PI to p26 (described in the specification). The invention is useful
XX CC to improve the efficiency and reliability of several steps in the
XX CC discovery and development of drugs for treating diseases associated with
XX CC FKBP8 activity, for example immunosuppression and cancer. Sequences
XX CC AA167274-299 represent allele-specific oligonucleotide (ASO) probes for
XX CC detecting FKBP8 gene polymorphisms
XX
XX SQ Sequence 15 BP; 3 A; 2 C; 4 G; 5 T; 0 U; 1 Other;
XX
XX Query Match 0.7%; Score 13; DB 1; Length 15;
XX Best Local Similarity 66.7%; Pred. No. 4.9e+02;
XX Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1366 CUGUCCUUCAGGAA 1380

```

PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321993.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 18-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PI Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LM;
PI Grimm S, Karpeisky A, Kisch K, Matulic-Adamic J, McSwiggen JA;
PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Ueman N, Wincott FE, Woolf T;
XX WPI; 1995-351090/45.
XX
XX Ribozymes having modified bases and methods for producing them - for use
XX in inhibiting disease related genes.
XX
XX Claim 2; Page 250; 407pp; English.
XX
CC The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves TNF-alpha mRNA at
CC the nucleotide base position indicated in the DE line. Regions of the
CC mRNA that do not form secondary folding structures and that contain
CC potential hammerhead and hairpin ribozyme cleavage sites were identified
CC by computer analysis. Ribozymes directed against these mRNA sequences
CC were designed and synthesized with modifications that improve their
CC nuclease resistance. The ribozymes are designed to cleave the target
CC sequences and thereby inhibit TNF-alpha expression, making them
CC potentially useful for treating rheumatoid arthritis, septic shock and
CC other inflammatory disorders including psoriasis, as well as for
CC treatment of AIDS. (Updated on 25-MAR-2003 to correct PI field.)
XX
SQ Sequence 15 BP; 1 A; 7 C; 2 G; 0 T; 5 U; 0 Other;
XX
XX Query Match 0.7%; Score 13; DB 1; Length 15;
XX Best Local Similarity 92.3%; Pred. No. 4.9e+02;
XX Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1231 CAGAGAGCGGCG 1243
DB 13 CAGAGAGCGGTGG 1
XX
XX RESULT 850
XX AAT52188/C
XX ID AAT52188 standard; RNA; 15 BP.
XX
XX AC AAT52186;
XX
XX DT 25-MAR-2003 (revised)
XX DT 01-APR-1997 (first entry)
XX
XX DE Mouse ICAM hammerhead ribozyme target sequence (nt. position 54).
XX
XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
XX gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
XX intercellular adhesion molecule; rel A; tumour necrosis factor;
XX TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
XX translation; chronic myelogenous leukaemia; CML; cancer;
XX Philadelphia chromosome; inflammation; autoimmune disease;
XX atherosclerosis; myocardial infarction; stroke; restenosis;
XX transplant rejection; rheumatoid arthritis; psoriasis;
XX myocardial ischaemia; Kawasaki disease; septic shock; HIV;
XX human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
XX 58.
XX
XX Mus musculus.
XX OS
XX ID WO9523225-A2.
XX

```

```

XX
XX 31-AUG-1995.
XX
XX PD 23-FEB-1995; 95WO-1B000156.
XX
XX PF 23-FEB-1994; 94US-00201109.
XX
XX XX 23-FEB-1994; 94US-00218934.
XX
XX PR 29-MAR-1994; 94US-00222795.
XX
XX PR 04-APR-1994; 94US-00224483.
XX
XX PR 07-APR-1994; 94US-00227958.
XX
XX PR 15-APR-1994; 94US-00228041.
XX
XX PR 18-MAY-1994; 94US-00245736.
XX
XX PR 06-JUL-1994; 94US-00271280.
XX
XX PR 15-AUG-1994; 94US-00291932.
XX
XX PR 16-AUG-1994; 94US-00291433.
XX
XX PR 17-AUG-1994; 94US-00292620.
XX
XX PR 19-AUG-1994; 94US-00293520.
XX
XX PR 02-SEP-1994; 94US-00300000.
XX
XX PR 08-SEP-1994; 94US-00303039.
XX
XX PR 23-SEP-1994; 94US-00311486.
XX
XX PR 23-SEP-1994; 94US-00311749.
XX
XX PR 28-SEP-1994; 94US-00314397.
XX
XX PR 03-OCT-1994; 94US-00316771.
XX
XX PR 07-OCT-1994; 94US-00319492.
XX
XX PR 11-OCT-1994; 94US-00321993.
XX
XX PR 04-NOV-1994; 94US-00334847.
XX
XX PR 10-NOV-1994; 94US-00337608.
XX
XX PR 28-NOV-1994; 94US-00345516.
XX
XX PR 16-DEC-1994; 94US-00357577.
XX
XX PR 23-DEC-1994; 94US-00363233.
XX
XX PR 30-JAN-1995; 95US-00380734.
XX
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LM;
XX PI Grimm S, Karpeisky A, Kisch K, Matulic-Adamic J, McSwiggen JA;
XX PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
XX PI Tracz D, Ueman N, Wincott FE, Woolf T;
XX
XX DR WPI; 1995-351090/45.
XX
XX PT Ribozymes having modified bases and methods for producing them - for use
XX in inhibiting disease related genes.
XX
XX PS Claim 2; Page 177; 407pp; English.
XX
XX
CC The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
CC nucleotide base position indicated in the DE line. Regions of the mRNA
CC that do not form secondary folding structures and that contain potential
CC hammerhead and hairpin ribozyme cleavage sites were identified by
CC computer analysis. Ribozymes directed against these mRNA sequences were
CC designed and synthesised with modifications that improve their nuclease
CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
CC inhibit ICAM-1 expression, making them useful for reducing transplant
CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC correct PI field.)
XX
XX SQ Sequence 15 BP; 1 A; 3 C; 7 G; 0 T; 4 U; 0 Other;
XX
XX
XX Query Match 0.7%; Score 13; DB 1; Length 15;
XX Best Local Similarity 92.3%; Pred. No. 4.9e+02;
XX Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
QY 506 CCAUCAAGAGGCC 518
DB 15 CCATCAGAGGCC 3
XX
XX RESULT 851
XX AAT55673/C
XX ID AAT55673 standard; RNA; 15 BP.
XX

```

RESULT 848
AAT52257/c
ID AAT52257 standard; RNA; 15 BP.
XX
XX AAT52257;
AC
XX
DT 25-MAR-2003 (revised)
DT 01-APR-1997 (first entry)
XX
DE Mouse ICAM hammerhead ribozyme target sequence (nt. position 738).
XX
XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW intercellular adhesion molecule; rel A; tumour necrosis factor;
KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW Philadelphia chromosome; chronic myelogenous leukaemia; CML; cancer;
KW Philadelphia chromosome; inflammation; autoimmune disease;
KW atherosclerosis; myocardial infarction; stroke; restenosis;
KW transplant rejection; rheumatoid arthritis; psoriasis;
KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW ss.
XX
OS Mus musculus.
XX
XX WO9523225-A2.
XX
PD 31-AUG-1995.
XX
PF 23-FEB-1995; 95WO-IB000156.
XX
PR 23-FEB-1994; 94US-00201109.
PR 29-MAR-1994; 94US-00218934.
PR 04-APR-1994; 94US-00222795.
PR 07-APR-1994; 94US-00224483.
PR 15-APR-1994; 94US-00227958.
PR 15-APR-1994; 94US-00228041.
PR 18-MAY-1994; 94US-00245735.
PR 06-JUL-1994; 94US-00271280.
PR 15-AUG-1994; 94US-00291932.
PR 16-AUG-1994; 94US-00291433.
PR 17-AUG-1994; 94US-00292620.
PR 19-AUG-1994; 94US-00293520.
PR 02-SEP-1994; 94US-00300000.
PR 08-SEP-1994; 94US-00303039.
PR 23-SEP-1994; 94US-00311486.
PR 23-SEP-1994; 94US-00311749.
PR 28-SEP-1994; 94US-00314397.
PR 03-OCT-1994; 94US-00316771.
PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321932.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00362233.
PR 30-JAN-1995; 95US-00380734.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Chowrira B, Ditzenz A, Draper KG, Dudycz LM;
PI Grimm S, Karpeliesky A, Kisch K, Matulic-Adamic J, Mccarthygen JA;
PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Usman N, Wincott FB, Woolf T;
XX
XX WPI; 1995-351090/45.
XX
XX Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
XX
XX Claim 2; Page 177; 407pp; English.

CC The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
CC nucleotide base position indicated in the DE line. Regions of the mRNA
CC that do not form secondary folding structures and that contain potential
CC hammerhead and hairpin ribozyme cleavage sites were identified by
CC computer analysis. Ribozymes directed against these mRNA sequences were
CC designed and synthesised with modifications that improve their nuclease
CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
CC inhibit ICAM-1 expression, making them useful for reducing transplant
CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC correct PI field.)
XX
SQ Sequence 15 BP; 1 A; 3 C; 7 G; 0 T; 4 U; 0 Other;
XX
XX
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 4.9e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 506 CCAUCACGAGGCC 518
DB 15 CCAUCACGAGGCC 3
XX
XX
RESULT 849
AAT56190/c
ID AAT56190 standard; RNA; 15 BP.
XX
XX AAT56190;
AC
XX
DT 25-MAR-2003 (revised)
DT 14-MAY-1997 (first entry)
XX
DE Mouse TNF-a hammerhead ribozyme target sequence (nt position 297).
XX
XX Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW intercellular adhesion molecule; rel A; tumour necrosis factor;
KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW Philadelphia chromosome; chronic myelogenous leukaemia; CML; cancer;
KW Philadelphia chromosome; inflammation; autoimmune disease;
KW atherosclerosis; myocardial infarction; stroke; restenosis;
KW transplant rejection; rheumatoid arthritis; psoriasis;
KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW ss.
XX
XX Mus musculus.
XX
XX WO9523225-A2.
XX
XX 31-AUG-1995.
XX
XX 23-FEB-1995; 95WO-IB000156.
XX
XX 23-FEB-1994; 94US-00201109.
XX 29-MAR-1994; 94US-00218934.
XX 04-APR-1994; 94US-00222795.
XX 07-APR-1994; 94US-00224483.
XX 15-APR-1994; 94US-00227958.
XX 18-MAY-1994; 94US-00228041.
XX 06-JUL-1994; 94US-00245735.
XX 15-AUG-1994; 94US-00291932.
XX 16-AUG-1994; 94US-00291433.
XX 17-AUG-1994; 94US-00292620.
XX 19-AUG-1994; 94US-00293520.
XX 02-SEP-1994; 94US-00303039.
XX 08-SEP-1994; 94US-00311486.
XX 23-SEP-1994; 94US-00311749.
XX 28-SEP-1994; 94US-00314397.
XX 03-OCT-1994; 94US-00316771.

XX
PI Brewer GJ, Venta PJ, Yuzbasiyan-Gurkan V;
XX
DR WPI; 1997-435082/40.
XX
PT New oligonucleotide primers for diagnosis of genetic diseases and traits
PT in dogs - amplify specific regions of the genome containing
PT microsatellite repeats, especially for diagnosing copper toxicosis and
PT carriers.
XX
PS Claim 1; Page 18; 40pp; English.
XX
CC This invention relates to novel oligonucleotide PCR primers which may be
CC used to identify markers associated with genetic diseases and traits in
CC dogs, in particular to diagnose genetic diseases that are not
CC phenotypically visible and to identify carriers of recessive diseases. A
CC specific application is diagnosis of copper toxicosis (CT). The invention
CC can also be used to create a genetic map of the canine genome; to
CC generate breed-specific profiles; to establish paternity and to identify
CC dogs from DNA fingerprints. The method provides rapid analysis of the
CC target sequences from only a small sample of DNA. Diagnosis can be done
CC at any time in the dog's life. The present sequence is that of a PCR
CC primer of the invention.
XX
SQ Sequence 21 BP; 0 A; 8 C; 2 G; 11 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 13.4; DB 1; Length 21;
Best Local Similarity 53.3%; Pred. No. 7.9e+02;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
QY 1358 GUCUACUCUCUCUCU 1372
DB 7 CTCCTGCTCTGCTCT 21
XX
RESULT 846
ABI97828
ID ABI97828 standard; DNA; 37 BP.
XX
AC ABI97828;
XX
DT 18-FEB-2002 (first entry)
XX
DE Non-endogenous human GPCR 3' primer SEQ ID NO: 280.
XX
KW Human; G protein-coupled receptor; GPCR; non-endogenous; mutant;
KM constitutively activated GPCR; agonist; disease; PCR primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO200177172-A2.
XX
PD 18-OCT-2001.
XX
PF 05-APR-2001; 2001WO-US011098.
XX
PR 07-APR-2000; 2000US-0195747P.
XX
PA (AREN-) ARENA PHARM INC.
XX
PI Lehmann-Brinema K, Liaw CW, Lin I;
XX
DR WPI; 2001-648759/74.
XX
PT Identifying agonists of G protein-coupled receptors (GPCRs) for use in
PT disease treatment, comprises contacting candidate compounds with versions
PT of GPCRs.
XX
PS Example 2; Page 52; 394pp; English.
XX
CC The invention relates to G protein-coupled receptors (GPCRs) for which
CC the endogenous ligand has been identified. Non-endogenous constitutively
CC activated versions of known GPCRs are used in the invention for the
CC direct identification of candidate compounds as receptor agonists,
CC inverse agonists or partial agonists. Such agonists are useful as
CC therapeutic agents for diseases or disorders associated with GPCRs. The
CC present sequence is a primer used to prepare a non-endogenous version of
CC a known GPCR in an example illustrating the invention
XX
SQ Sequence 37 BP; 14 A; 8 C; 12 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 13.2; DB 1; Length 37;
Best Local Similarity 38.9%; Pred. No. 9.3e+02;
Matches 7; Conservative 8; Mismatches 3; Indels 0; Gaps 0;
QY 204 GGUCUACUCGUCUCUCU 221
DB 10 GGTCTGTTTCGCTTCTT 27
XX
RESULT 847
ABI97827/C
ID ABI97827 standard; DNA; 37 BP.
XX
AC ABI97827;
XX
DT 18-FEB-2002 (first entry)
XX
DE Non-endogenous human GPCR 5' primer SEQ ID NO: 279.
XX
KW Human; G protein-coupled receptor; GPCR; non-endogenous; mutant;
KM constitutively activated GPCR; agonist; disease; PCR primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO200177172-A2.
XX
PD 18-OCT-2001.
XX
PF 05-APR-2001; 2001WO-US011098.
XX
PR 07-APR-2000; 2000US-0195747P.
XX
PA (AREN-) ARENA PHARM INC.
XX
PI Lehmann-Brinema K, Liaw CW, Lin I;
XX
DR WPI; 2001-648759/74.
XX
PT Identifying agonists of G protein-coupled receptors (GPCRs) for use in
PT disease treatment, comprises contacting candidate compounds with versions
PT of GPCRs.
XX
PS Example 2; Page 52; 394pp; English.
XX
CC The invention relates to G protein-coupled receptors (GPCRs) for which
CC the endogenous ligand has been identified. Non-endogenous constitutively
CC activated versions of known GPCRs are used in the invention for the
CC direct identification of candidate compounds as receptor agonists,
CC inverse agonists or partial agonists. Such agonists are useful as
CC therapeutic agents for diseases or disorders associated with GPCRs. The
CC present sequence is a primer used to prepare a non-endogenous version of
CC a known GPCR in an example illustrating the invention
XX
SQ Sequence 37 BP; 14 A; 8 C; 12 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 13.2; DB 1; Length 37;
Best Local Similarity 38.9%; Pred. No. 9.3e+02;
Matches 7; Conservative 8; Mismatches 3; Indels 0; Gaps 0;
QY 204 GGUCUACUCGUCUCUCU 221
DB 28 GGTCTGTTTCGCTTCTT 11

CC activated versions of known GPCRs are used in the invention for the
CC direct identification of candidate compounds as receptor agonists,
CC inverse agonists or partial agonists. Such agonists are useful as
CC therapeutic agents for diseases or disorders associated with GPCRs. The
CC present sequence is a primer used to prepare a non-endogenous version of
CC a known GPCR in an example illustrating the invention
XX
SQ Sequence 37 BP; 14 A; 8 C; 12 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 13.2; DB 1; Length 37;
Best Local Similarity 38.9%; Pred. No. 9.3e+02;
Matches 7; Conservative 8; Mismatches 3; Indels 0; Gaps 0;
QY 204 GGUCUACUCGUCUCUCU 221
DB 28 GGTCTGTTTCGCTTCTT 11

Best Local Similarity 93.3%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 815 GGACGAGCGCAGAGA 829
DB 1 GGAGAGAGCGCAGAGA 15

RESULT 843

ACC78169/c
ID ACC78169 standard; DNA; 16 BP.

AC ACC78169;

DT 18-AUG-2003 (first entry)

DE Human GCP-2 SNPs amplifying antisense primer.

KW GCP-2; granulocyte chemotactic peptide-2; single nucleotide polymorphism;
KM antiinflammatory; cytostatic; antipsoriatic; antirheumatic; SNP; human;
KW antiarthritic; neuroprotective; gene therapy; genotyping; PCR; primer;
ss.

OS Homo sapiens.

PN EPI312614-A1.

PD 21-MAY-2003.

PF 16-NOV-2001; 2001EP-00402950.

PR 16-NOV-2001; 2001EP-00402950.

XX (GENO-) GENODYSSEY.

PA Bscary J;

PI Bscary J;

DR WPI; 2003-443129/42.

PT New polynucleotides and polypeptides of the Granulocyte Chemotactic
PT Peptide-2 gene, useful for preparing a medication for the prevention or
PT treatment of disorders involving the immune system, e.g. inflammation,
PT psoriasis or cancer.

PS Example 1; Page 23; 29pp; English.

XX The invention relates to polynucleotides derived from the Granulocyte
CC Chemotactic Peptide-2 (GCP-2) gene, and comprising new single nucleotide
CC polymorphisms (SNPs) where the SNPs are 1254-1255 Ins (C), 9563c, c574g,
CC c646g, g742t, a1026t or g1069c. The polynucleotide, polypeptide, vector,
CC host cell and/or antibody are useful for preparing a medication for the
CC prevention or treatment of diseases or disorders involving the immune
CC system, inflammation, tumor cell invasion, psoriasis, rheumatoid
CC arthritis, chronic polyarthritis, myelodysplastic syndrome, or carcinoma
CC (e.g. hepatocellular carcinoma or osteosarcoma). The GCP-2 protein is
CC also used for preparing a medication against a disease or disorder caused
CC by a GCP-2 variant. Sequences ACC78168-169 represent PCR primers for
CC amplifying the human GCP-2 SNPs g563t, c574g, c646g and g742t
XX
SQ Sequence 16 BP; 6 A; 4 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 60.0%; Pred. No. 5.1e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 592 GUCCUUGGCGCCU 606
DB 16 GTCCTTCGGGCTCCT 2

RESULT 844
AAC66362/c
ID AAC66362 standard; DNA; 18 BP.

XX AAC66362;

AC 22-FEB-2001 (first entry)

DE PCR primer used method to detect micro-organisms.

KW Detection; microorganism; environmental decontamination; decomposition;
KM organic halogen compound, PCR primer; ss.

OS Unidentified.

PN JP2000253880-A.

PD 19-SEP-2000.

PF 10-MAR-1999; 99JP-00062469.

PR 10-MAR-1999; 99JP-00062469.

XX (TOXE) TOSHIBA KK.

PA WPI; 2000-608063/58.

DR WPI; 2000-608063/58.

PT A method for detection of useful microorganisms and a method for
PT environmental decontamination with them.

PS Example 1; Page 7; 8pp; Japanese.

XX Oligonucleotides AAC66355 - AAC66360 are used in a method for the
CC detection of microorganisms. Micro-organisms are isolated by the presence
CC of the six nucleotide sequences. The micro-organisms isolated by this
CC method are used for environmental decontamination and the decomposition
CC of organic halogen compounds. The present sequence represents a PCR
CC primer used in an example illustrating the method of the invention
XX
SQ Sequence 18 BP; 4 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 18;
Best Local Similarity 66.7%; Pred. No. 6.3e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 189 UACCGUCGCGCAAGU 203
DB 15 TACCGTCGGAAGT 1

RESULT 845

ADG77919
ID ADG77919 standard; DNA; 21 BP.

XX ADG77919;

AC 11-MAR-2004 (first entry)

DE Canine disease marker-related PCR primer 763.

KW genetic disease; genetic trait; dog; carrier of recessive disease;
KM copper toxicosis; CT; canine genome map; breed-specific profile;
KW DNA fingerprint; dog identification; PCR; primer; ss.

OS Canis familiaris.

PN WO9731011-A1.

PD 28-AUG-1997.

PF 18-FEB-1997; 97WO-US002396.

PR 22-FEB-1996; 96US-0012060P.

XX (UNMI) UNIV MICHIGAN.
PA (UNMS) UNIV MICHIGAN STATE.

CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
 CC receptor-2 (HHR2/5-erb2/neu), phospholamban (PLN), preseinlin-1 (ps-1),
 CC preseinlin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
 CC nucleic acid molecules used to inhibit the expression of the said genes
 CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
 CC zincyme, and/or DNAzyme motifs. The methods of the invention are useful
 CC for treating cancer, in particular breast cancer, Alzheimer's disease,
 CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
 CC diseases, hepatitis B infections, and hepatitis and hepatocellular
 CC carcinoma. The enzymatic nucleic acid molecules can also be used as
 CC diagnostic tools to examine genetic drift and mutations within diseased
 CC cells and to detect the presence of specific RNA in a cell. The present
 CC sequence represents a ribozyme used in the examples of the present
 CC invention. Note: Some SEQ ID Nos are repeated more than once in the
 CC specification, but these have different sequences associated with them.

CC SQ Sequence 16 BP; 9 A; 0 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 40.0%; Pred. No. 5.1e+02;
 Matches 6; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

OY 206 UCUUCAUCCGCUUUCU 220
 :||:||||:||||:
 DB 15 TCTTCATCTCTTCT 1

RESULT 841
 ABL31167/C
 ID ABL31167 standard; DNA; 16 BP.

XX ABL31167;
 XX 21-MAR-2002 (first entry)
 XX
 XX Human HLA genotyping oligonucleotide SEQ ID NO 656.
 DE
 XX Human, human leukocyte antigen; HLA; genotype; polymorphism;
 KM immunogenetic; transplantation; genetic disease; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200192572-A1.
 XX
 XX 06-DEC-2001.
 PD
 XX 01-JUN-2001; 2001WO-JP004662.
 PF
 XX 01-JUN-2000; 2000JP-00164798.
 PR
 XX (NISN) NISSHINBO IND INC.
 PA (SYST-) SYSTEM RES INC.
 XX
 XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 PI WPI; 2002-122074/16.
 DR
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of
 PT individuals e.g. by determining immunogenetic differences when
 PT transplanting between them.
 XX
 XX Claim 10; Page 217; 345pp; Japanese.

XX The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridizing a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilized as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,

CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals

CC SQ Sequence 16 BP; 6 A; 3 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 66.7%; Pred. No. 5.1e+02;
 Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

OY 49 AGCUCCUCCUGAUA 63
 |||:||||:||||:
 DB 16 AGCTCCTCTGGTGA 2

RESULT 842
 ABX79735
 ID ABX79735 standard; cDNA; 16 BP.

XX ABX79735;
 XX 17-APR-2003 (first entry)
 XX
 XX EST polymorphic DNA repeat polynucleotide #60.
 DE
 XX EST; expressed sequence tag; ss; polymorphic repeat; tandem repeat;
 KM polymorphic marker prediction of ubiquitous simple sequences; POMPOUS;
 KM Rep-X; human; genetic disease; drug-treatment; Machado-Joseph;
 KM Haw River syndrome; Huntington's disease; fragile-X syndrome;
 KM Friedrich's ataxia; myotonic dystrophy; hyperandrogenemia;
 KM spinal atrophy; bulbar atrophy; spinocerebellar ataxia.
 XX
 XX Homo sapiens.
 OS
 XX US6472154-B1.
 XX
 XX 29-OCT-2002.
 PD
 XX 31-DEC-1999; 99US-00475947.
 PF
 XX 31-DEC-1999; 99US-00475947.
 PR
 XX (TEXA) UNIV TEXAS SYSTEM.
 XX
 XX Garner HR, Wren JD, Minna JD, Fondon JW;
 PI WPI; 2003-208818/20.
 DR
 XX Identifying a candidate polymorphic repeat within a coding sequence, for
 PT understanding or treating genetic disease, comprises detecting tandem
 PT repeats in a target coding sequence and scoring the repeats for
 PT polymorphic probability.
 XX
 XX Example; Col 267; 588pp; English.

XX The invention discloses a method for identifying a candidate polymorphic
 CC repeat within a coding sequence (expressed sequence tag, EST), which
 CC comprises detecting tandem repeats in a target coding sequence, scoring
 CC the repeats for polymorphic probability and generating a dataset
 CC correlating the repeats with polymorphic probability to identify a
 CC candidate polymorphic repeat. The computational methods (polymorphic
 CC marker prediction of ubiquitous simple sequences, POMPOUS, and Rep-X) are
 CC useful for identifying and detecting candidate polymorphic repeats in
 CC human genes, which can be used to understand, treat or eliminate genetic
 CC diseases, predispositions or adverse drug-treatment reactions. Examples
 CC of diseases linked to nucleotide repeats are Machado-Joseph, Haw River
 CC syndrome, Huntington's disease, fragile-X syndrome, Friedrich's ataxia,
 CC myotonic dystrophy, hyperandrogenemia, spinal and bulbar atrophy and
 CC spinocerebellar ataxia. The sequences presented in ABX79676-ABX80022 are
 CC the polymorphic repeats identified for a search of human ESTs

XX SQ Sequence 16 BP; 6 A; 1 C; 9 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 16;

PS Example 1; SEQ ID NO 121; 65pp; English.

XX The invention relates to a method of remodeling a dendrite comprising
CC transfecting a dendrite with an RNA comprising at least one intron, where
CC the dendrite comprises at least one component of a spliceosome and
CC further where the component of a spliceosome is capable of splicing an
CC RNA, allowing the RNA comprising at least one intron to be translated in
CC spliceosome components and allowing the spliced RNA to be translated in
CC the dendrite, where the dendrite is thus remodeled as a consequence of
CC the translation. The invention also relates to a method of remodeling a
CC dendrite interaction, a method of remodeling a synaptic network
CC comprising interaction with at least one dendrite, methods of splicing an
CC RNA and methods of translating an RNA. The splicing and translating
CC methods can alternatively be applied to an isolated synaptonemalosome
CC instead of the isolated dendrite. The methods are useful for remodeling a
CC dendrite, preferably for remodeling a synaptic network. This sequence
CC represents DNA encoding dendritically-spliced RNA used in the method of
CC the invention.

XX Sequence 15 BP; 0 A; 7 C; 1 G; 7 T; 0 U; 0 Other;

XX Query Match 0.8%; Score 13.4; DB 1; Length 15;
XX Best Local Similarity 93.3%; Pred. No. 4.5e+02;
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 819 AGAGCGAGACAGA 833
Db 15 AGAGCGAGACAGA 1

RESULT 839
AAK57943/C
ID AAK57943 standard; DNA; 16 BP.

AC AAK57943;
XX
XX 15-JUL-1999 (first entry)

DT PCR primer for G. oxydans D-sorbitol dehydrogenase coding sequence.
XX
XX D-sorbitol dehydrogenase; L-sorbose; 2-keto-L-gulononic acid; precursor;
KW L-aescorbic acid production; PCR primer; ss.

OS Synthetic.
OS Gluconobacter oxydans.

XX
XX WO9920763-A1.
PN 29-APR-1999.
PD
XX
XX 13-OCT-1998; 98WO-JP004612.
PF
XX
XX 17-OCT-1997; 97JP-00285280.
PR
XX
XX (FUJII) FUJISAWA PHARM CO LTD.
PA
XX
XX Saito Y, Ishii Y, Noguchi Y, Yoshikawa K, Soeda S;
PI WPI; 1999-302741/25.
DR

XX Gene group for D-sorbitol dehydrogenase, useful for simple large-scale
XX production of L-sorbose or 2-keto-L-gulononic acid as precursor for L-
XX ascorbic acid.
XX
XX Example 5; Page 26; 83pp; Japanese.

XX This sequence represents a PCR primer for DNA encoding the D-sorbitol
XX dehydrogenase of the invention. Cells transformed with a vector
XX containing DNA encoding the dehydrogenase can be used to produce L-
XX sorbose or 2-keto-L-gulononic acid as precursor for simple large-scale L-
XX ascorbic acid production
XX
XX Sequence 16 BP; 4 A; 5 C; 5 G; 2 T; 0 U; 0 Other;

XX Query Match 0.8%; Score 13.4; DB 1; Length 16;
XX Best Local Similarity 66.7%; Pred. No. 5.1e+02;
XX Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 227 GCATCCGCGCCUUG 241
Db 15 GCATCAGGCGCTTG 1

RESULT 840
ADU85273/C
ID ADU85273 standard; RNA; 16 BP.

AC ADU85273;
XX
XX 10-FEB-2005 (first entry)

DT Human MetAP-2 G-cleaver ribozyme sequence #10.
XX
XX

DE Enzymatic nucleic acid molecule; gene expression; down regulation;
KW Protein-cysteine-phosphatase-1b; PTB-1b; methionine aminopeptidase;
KW MetAP-2; human telomerase; hTER; protein kinase C alpha; PKC alpha;
KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
KW c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
KW hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
KW amberzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
KW hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
KW ss.

XX Homo sapiens.
XX
XX WO200116312-A2.
PN
XX
XX 08-MAR-2001.
PD
XX
XX 30-AUG-2000; 2000WO-US023998.
PF

XX 31-AUG-1999; 99US-0151713P.
PR 27-SEP-1999; 99US-00406643.
PR 27-SEP-1999; 99US-0156236P.
PR 27-SEP-1999; 99US-0156467P.
PR 08-NOV-1999; 99US-00436430.
PR 06-DEC-1999; 99US-0169100P.
PR 29-DEC-1999; 99US-00474432.
PR 29-DEC-1999; 99US-0173612P.
PR 30-DEC-1999; 99US-00476387.
PR 04-FEB-2000; 2000US-00498824.
PR 20-MAR-2000; 2000US-00531025.
PR 14-APR-2000; 2000US-0197769P.
PR 23-MAY-2000; 2000US-00578223.
PR 09-AUG-2000; 2000US-00636385.
XX
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Meswigen J, Usman N, Blatt L, Beigelman L, Burgin A;
PI Karpelsky A, Matulic-Adamic J, Svedler D, Draper K, Chowrira B;
PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
XX
XX WPI; 2001-24406/25.
DR

XX Enzymatic nucleic acid molecules able to cleave separate RNA molecules
XX are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
XX obesity and heart disease.
XX
XX Example 3; Page 260; 717pp; English.

XX The present invention relates to the use of enzymatic nucleic acid
XX molecules (e.g. ribozymes) to modulate gene expression. The invention
XX also methods for their use to down regulate or inhibit the expression of
XX genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine
XX aminopeptidase (MetAP-2), human telomerase (hTER), protein kinase C

CC vector of (3): (6) a method of treating a patient having a condition
CC associated with HCV infection, by contacting cells of the patient with
CC the nucleic acid molecule, and further employing one or more drug
CC therapies; (7) a method for inhibiting HCV replication in a mammalian
CC cell by administering the novel enzymatic nucleic acid; and (8) a method
CC of cleaving a separate RNA molecule by contacting the novel enzymatic
CC nucleic acid with the separate RNA molecule. The enzymatic nucleic acid
CC is useful for modulating the expression and/or replication of hepatitis C
CC virus (HCV), and for inhibiting the expression of HCV minus strand. The
CC nucleic acid may also be used to treat or prevent the occurrence of a
CC disease state in a patient. The present sequence represents an HCV
CC hammerhead ribozyme target substrate sequence which is used in the
CC exemplification of the present invention.

CC Sequence 15 BP; 3 A; 3 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 4.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 645 UGUGCCUCCGGAGAGA 659
Db 1 UGUGACUCCGGAGAGA 15

RESULT 837
AEB50501
ID AEB50501 standard; DNA; 15 BP.

AC AEB50501;

DT 06-OCT-2005 (first entry)

DE Human myosin heavy chain transcript, SEQ ID NO 269.

XX genetic marker; heart disease; cardiact; myocardial infarction; angina;
XX antianginal; myocarditis; congestive heart failure; cardiovascular-gen;
XX algorithm; ds; myosin heavy chain; SNP; single nucleotide polymorphism.

OS Homo sapiens.

PN WO2005069724-A2.

PD 04-AUG-2005.

PF 27-JAN-2005; 2005WO-IB001306.

PR 27-JAN-2004; 2004US-0539128P.

PR 27-JAN-2004; 2004US-0539129P.

PR 22-OCT-2004; 2004US-0620916P.

PR 25-OCT-2004; 2004US-0621131P.

PR 27-OCT-2004; 2004US-0622320P.

PR 17-NOV-2004; 2004US-0628123P.

PR 17-NOV-2004; 2004US-0628134P.

PR 17-NOV-2004; 2004US-0628190P.

PR 26-NOV-2004; 2004US-0630559P.

PR 27-JAN-2005; 2005US-00043788.

PA (COMP-) COMPUGEN LTD.

PI Cohen Y, Diber A, Toporik A, Pollock S, Levine Z,
PI Avallon-Soffer M, Cojocaru GS, Novik A, Kol G, Sella-Tavor O;
PI Walach S, Sameah-Greenwald S, Dahary D, Shemesh R;

XX WPI; 2005-542198/55.

PT Novel isolated chimeric polypeptide comprising first amino acid sequence
PT homologous to TRIC-HUMAN sequence, useful as biomarkers for diagnosing
PT heart disease such as myocardial infarct, angina pectoris, cardiomyopathy
PT and myocarditis.
PS Example 2; SEQ ID NO 269; 822pp; English.
XX

CC The present invention relates to a chimeric polypeptide (I) useful as a
CC biomarker for cardiac disease chosen from a chimeric polypeptide of SEQ
CC ID Nos. 301, 302, 303 or 304, comprising a first amino acid sequence
CC of at least 90% homologous to amino acids 1-124, 1-8, 1-36 or 1-8 of
CC TRIC-HUMAN, and a second amino acid sequence at least 95% homologous to a
CC polypeptide sequence corresponding to amino acids 125-137, 36-209, 37-66
CC or 9-13 of SEQ ID Nos. 301, 302, 303 or 304, where the first and second
CC amino acid sequences are contiguous and in a sequential order. (I) also
CC comprises an isolated polypeptide comprising a protein variant of SEQ ID
CC Nos. 301-304, or the sequence of tropoin I variant (SEQ ID Nos. 325, 354
CC -356 or 387). (I) can be an isolated polypeptide for a tail of SEQ ID No.
CC 301, 303 or 304, and an isolated chimeric polypeptide encoding for an
CC edge portion of SEQ ID No. 302, where at least two amino acids comprise
CC AK. Also claimed is an isolated polynucleotide (II) comprising a
CC transcript or the DNA sequence of Histropoin T7 PRSER, (SEQ ID Nos. 22-
CC 25, 353 or 386); or a segment chosen from a SEQ ID Nos. 110-149; an
CC isolated oligonucleotide, comprising an amplicon (III) chosen from a
CC sequence of humtropa seg1 amplicon, humtropa seg2 amplicon, amplicon
CC humtropa seg23-24-25 (SEQ ID No. 379, 382 or 385); a primer pair (IV),
CC capable of amplifying (III); an antibody (V); a kit (VI) for detecting
CC heart disorders, by detecting overexpression of a splice variant of (I)
CC or (II); detecting (MI) heart disorders, by detecting overexpression of a
CC splice variant of (I) or (II); and a biomarker (VII) capable of detecting
CC heart disorders. The heart disorder is a myocardial infarct, angina
CC pectoris, cardiomyopathy, myocarditis, congestive heart failure.
CC Identification of differentially expressed gene products and ESTs was
CC carried out by algorithm method and computer analysis. Splice variants
CC were identified by using the LEADS software package. The present sequence
CC is a human myosin heavy chain protein transcript.

CC Sequence 15 BP; 2 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 4.5e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 1030 GCCUCCUCCGAGAGAC 1044
Db 1 GCCTCCCTGAGAGAC 15

RESULT 838
AEB62264/C
ID AEB62264 standard; DNA; 15 BP.

AC AEB62264;

DT 29-DEC-2005 (first entry)

DE DNA encoding dendritically-spliced RNA #103.

XX Splicing; dendrite; translation; ss.

OS Unidentified.

PN WO2005100559-A1.

PD 27-OCT-2005.

PF 07-APR-2005; 2005WO-US011637.

PR 07-APR-2004; 2004US-0560039P.

XX (UTPE-) UNITV PENNSYLVANIA.

PI Eberwine J, Miyashiro K, Glanzer J;

XX WPI; 2005-725946/74.

PT Remodeling a dendrite, e.g. a synaptic network of the dendrite, comprises
PT transfecting a dendrite with an RNA comprising at least one intron, where
PT the dendrite comprises a spliceosome that is capable of splicing an RNA.
XX

CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
CC zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
CC for treating cancer, in particular breast cancer, Alzheimer's disease,
CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC diseases, hepatitis B infections, and hepatitis and hepatocellular
CC carcinoma. The enzymatic nucleic acid molecules can also be used as
CC diagnostic tools to examine genetic drift and mutations within diseased
CC cells and to detect the presence of specific RNA in a cell. The present
CC sequence represents a substrate/target sequence for an anti-HER2 NCH
CC ribozyme used in the examples of the present invention. Note: Some SEQ ID
CC Nos are repeated more than once in the specification, but these have
CC different sequences associated with them.
XX
SQ Sequence 15 BP; 6 A; 4 C; 4 G; 0 T; 1 U; 0 Other;
Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 4.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 945 CACACCAAGAGCGUG 959
DB 1 CACACCAAGAGCGUG 15
RESULT 835
ABX01143
ID ABX01143 standard; RNA; 15 BP.
XX
AC ABX01143;
XX
DT 23-DEC-2002 (first entry)
XX
DB Hepatitis C virus substrate #925 for HCV hammerhead ribozyme #925.
XX
KM Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
XX HCV ribozyme; HCV expression; HCV replication; cirrhosis; viremia;
XX liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
XX type I interferon; interferon alpha; interferon beta; cytostatic;
XX interferon gamma; consensus interferon; hepatotropic; antiinflammatory;
XX substrate; hammerhead ribozyme; HH ribozyme; ss.
XX
OS Hepatitis C virus.
XX
PN US2002082225-A1.
XX
PD 27-JUN-2002.
XX
PF 23-MAR-1999; 99US-00274553.
XX
PR 23-MAR-1999; 99US-00274553.
XX
PA (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX (ROBE/) ROBERTS B.
XX (PAVO/) PAVCO P A.
XX (MACE/) MACEJACK D.
XX
PI Blatt L, Mcswigen JA, Roberts B, Pavco PA, Macejack D;
XX
DR WPI; 2002-617759/66.
XX
PT New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
XX replication and are useful to treat hepatitis C virus infections and
XX cirrhosis, liver failure or hepatocellular carcinoma.
XX
PS Claim 1; Page 47; 80pp; English.
XX
CC The present invention relates to enzymatic nucleic acids which
XX specifically cleave RNA derived from Hepatitis C virus (HCV). The
XX enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
XX (HP) motif where the binding arms comprise sequences complementary to one
XX of the substrate sequences defined in the specification. The HCV
XX ribozymes are useful for modulating the expression and/or replication of

CC HCV. They can be used to treat cirrhosis, liver failure and/or
CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating
CC a condition associated with HCV infection in conjunction with one or more
CC other drug therapies, particularly type I interferon, especially
CC interferon alpha, beta or gamma or consensus interferon. The present
CC sequence represents a substrate for a HCV hammerhead (HH) ribozyme. Note:
CC Some of the sequence data for this patent did not form part of the
CC printed specification. The complete sequence data for this patent was
CC obtained in electronic format directly from the USPTO web site at
CC seqdata.uspto.gov/patids/entry.html
XX
SQ Sequence 15 BP; 3 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 4.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 645 UGUGCCUCGCGAGA 659
DB 1 UGUGCCUCGCGAGA 15
RESULT 836
AEB75851
ID AEB75851 standard; RNA; 15 BP.
XX
AC AEB75851;
XX
DT 22-SEP-2005 (first entry)
XX
DB Hepatitis C virus hammerhead ribozyme substrate sequence.
XX
KM ribozyme; enzymatic nucleic acid molecule; hepatitis C virus infection;
XX antiviral; gene therapy; substrate; ss.
XX
OS Hepatitis C virus.
XX
PN US2002013458-A1.
XX
PD 31-JAN-2002.
XX
PF 15-FEB-2000; 2000US-00504231.
XX
PR 23-MAR-1999; 99US-00274553.
XX
PA (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX (ROBE/) ROBERTS B.
XX (PAVO/) PAVO P A.
XX (MACE/) MACEJACK D.
XX
PI Blatt L, Mcswigen JA, Roberts B, Pavo PA, Macejack D;
XX
DR WPI; 2002-215899/27.
XX
PT New enzymatic nucleic acid molecule, which specifically cleaves minus
XX strand RNA derived from hepatitis C virus, useful for modulating the
XX expression and/or replication of hepatitis C virus.
XX
PS Example 1; Page 37; 65pp; English.
XX
CC The invention relates to an enzymatic nucleic acid molecule which
XX specifically cleaves minus strand RNA derived from hepatitis C virus
XX (HCV). The binding arms of the molecule comprise ribozyme sequences. The
XX molecule is selected from inozyme, G-cleaver, DNAzyme, amberzyme, and
XX zinzyme motifs. Also described: (1) a pharmaceutical composition
XX comprising the novel enzymatic nucleic acid; (2) a mammalian cell
XX including a nucleic acid sequence encoding at least one enzymatic
XX comprising a nucleic acid sequence encoding at least one enzymatic
XX nucleic acid molecule, in a manner, which allows expression of that
XX molecule; (4) a mammalian cell including an expression vector of (3); (5)
XX methods for treating cirrhosis, liver failure or hepatocellular carcinoma
XX by administering to a patient the novel enzymatic nucleic acid or the

KM MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
 KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
 KW c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
 KW hepatitis B virus; HBV; hammethead; HH; hairpin; NCH; inosyme; G-cleaver;
 KW amberyzyme; zinzyme; DNazyme; cancer; breast cancer; Alzheimer's disease;
 KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
 KW hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
 KW ss.
 OS Homo sapiens.
 XX WO200116312-A2.
 XX PD 08-MAR-2001.
 XX PF 30-AUG-2000; 2000MO-US023998.
 XX PR 31-AUG-1999; 99US-0151713P.
 XX PR 27-SEP-1999; 99US-00406643.
 XX PR 27-SEP-1999; 99US-0156236P.
 XX PR 27-SEP-1999; 99US-0156467P.
 XX PR 08-NOV-1999; 99US-00436430.
 XX PR 06-DEC-1999; 99US-0169100P.
 XX PR 29-DEC-1999; 99US-00474432.
 XX PR 30-DEC-1999; 99US-0173612P.
 XX PR 04-FEB-2000; 2000US-00498824.
 XX PR 20-MAR-2000; 2000US-00531025.
 XX PR 14-APR-2000; 2000US-019769P.
 XX PR 23-MAY-2000; 2000US-00578223.
 XX PR 09-AUG-2000; 2000US-00636385.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Mcswigen J, Usman N, Blatt L, Beigelman L, Burgin A,
 PI Karpetsky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B,
 PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
 XX WPI; 2001-244406/25.
 XX DR Enzymatic nucleic acid molecules able to cleave separate RNA molecules
 PT are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
 PT obesity and heart disease.
 XX PS Example 11; Page 467; 717pp; English.
 XX CC The present invention relates to the use of enzymatic nucleic acid
 CC molecules (e.g. ribozymes) to modulate gene expression. The invention
 CC also methods for their use to down regulate or inhibit the expression of
 CC genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine C
 CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
 CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
 CC receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
 CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
 CC nucleic acid molecules used to inhibit the expression of the said genes
 CC include hammethead (HH), hairpin, NCH (inosyme), G-cleaver, amberyzyme,
 CC zinzyme, and/or DNazyme motifs. The methods of the invention are useful
 CC for treating cancer, in particular breast cancer, Alzheimer's disease,
 CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
 CC diseases, hepatitis B infections, and hepatitis and hepatocellular
 CC carcinoma. The enzymatic nucleic acid molecules can also be used as
 CC diagnostic tools to examine genetic drift and mutations within diseased
 CC cells and to detect the presence of specific RNA in a cell. The present
 CC sequence represents a substrate sequence for an anti-Her2 hammethead
 CC ribozyme used in the examples of the present invention. Note: Some SEQ ID
 CC Nos are repeated more than once in the specification, but these have
 CC different sequences associated with them.
 XX SO Sequence 15 BP; 1 A; 2 C; 6 G; 0 T; 6 U; 0 Other;
 XX Query Match 0.84; Score 13.4; DB 1; Length 15;
 XX Best Local Similarity 93.34; Pred. No. 4.5e+02;
 XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1624 GUGUGCAUGGUCUG 1638
 DB 1 GUGUGCAUGGUCUG 15
 RESULT 834
 ADV35913
 ID ADV35913 standard; RNA; 15 BP.
 XX AC ADV35913;
 XX DT 10-FEB-2005 (first entry)
 XX DE Human anti-HER2 NCH ribozyme substrate sequence #356.
 XX KW Enzymatic nucleic acid molecule; gene expression; down regulation;
 KW protein-tyrosine-phosphatase-1b; PTB-1b; methionine aminopeptidase;
 KW MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
 KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
 KW c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
 KW hepatitis B virus; HBV; hammethead; HH; hairpin; NCH; inosyme; G-cleaver;
 KW amberyzyme; zinzyme; DNazyme; cancer; breast cancer; Alzheimer's disease;
 KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
 KW hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
 KW ss.
 OS Homo sapiens.
 XX WO200116312-A2.
 XX PD 08-MAR-2001.
 XX PF 30-AUG-2000; 2000MO-US023998.
 XX PR 31-AUG-1999; 99US-0151713P.
 XX PR 27-SEP-1999; 99US-00406643.
 XX PR 27-SEP-1999; 99US-0156236P.
 XX PR 27-SEP-1999; 99US-0156467P.
 XX PR 08-NOV-1999; 99US-00436430.
 XX PR 06-DEC-1999; 99US-0169100P.
 XX PR 29-DEC-1999; 99US-00474432.
 XX PR 30-DEC-1999; 99US-0173612P.
 XX PR 04-FEB-2000; 2000US-00498824.
 XX PR 20-MAR-2000; 2000US-00531025.
 XX PR 14-APR-2000; 2000US-019769P.
 XX PR 23-MAY-2000; 2000US-00578223.
 XX PR 09-AUG-2000; 2000US-00636385.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Mcswigen J, Usman N, Blatt L, Beigelman L, Burgin A,
 PI Karpetsky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B,
 PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
 XX WPI; 2001-244406/25.
 XX DR Enzymatic nucleic acid molecules able to cleave separate RNA molecules
 PT are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
 PT obesity and heart disease.
 XX PS Example 7; Page 478; 717pp; English.
 XX CC The present invention relates to the use of enzymatic nucleic acid
 CC molecules (e.g. ribozymes) to modulate gene expression. The invention
 CC also methods for their use to down regulate or inhibit the expression of
 CC genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine C
 CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
 CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
 CC receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
 CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
 CC nucleic acid molecules used to inhibit the expression of the said genes

```
RESULT 831
ID AAA91451 standard; DNA; 15 BP.
AC AAA91451;
XX
XX
DT 12-JUL-2001 (first entry)
XX
XX Human CHRM5 gene, allele specific oligonucleotide #21.
DE
XX CHRM5; human; cholinergic receptor muscarinic 5; polymorphic variant;
KM genotyping; haplotype; gene therapy; ss.
XX
OS Homo sapiens.
PN WO200128995-A2.
XX
XX 26-APR-2001.
PD
XX 19-OCT-2000; 2000MO-US029071.
XX
XX 21-OCT-1999; 99US-0160647P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX Chew A, Choi JY, Nandabalan K, Stephens JC;
PI WPI; 2001-300313/31.
XX
XX Isolated polynucleotide encoding the cholinergic receptor, muscarinic 5
PT (CHRM5), used to genotype/haplotype the CHRM5 gene, and to identify an
PT association between a trait and a polymorphism, comprises novel
PT polymorphisms.
XX
XX Claim 15; Page 46; 53pp; English.
XX
XX This sequence is a the human cholinergic receptor, muscarinic 5 (CHRM5)
CC gene, allele specific oligonucleotide. The invention relates to a
CC polymorphic variant of the CHRM5 gene sequence. The polymorphic sequence
CC is useful to genotype or haplotype the CHRM5 gene, to predict a haplotype
CC pair for the CHRM5 gene, and for identifying an association between a
CC trait (such as a clinical response to a drug targeting CHRM5). It is also
CC useful in gene therapy in patients who lack the CHRM5 isogene or have
CC only one copy of it, and in assays to measure the binding affinities of
CC one or more candidate drugs targeting CHRM5. The DNA sequence is used in
CC the treatment of disorders affected by expression or function of a novel
CC CHRM5 isogene of the invention. The protein encoded by the CHRM5 variant
CC is useful to identify drugs which target the CHRM5 polymorphic variant
CC protein. Antibodies against the protein can be used to neutralise the
CC CHRM5 isoform actively expressed in an individual, and is useful in
CC detection of CHRM5 in immunocytochemical, immunohistochemical and
CC immunofluorescence. A composition containing a genotyping oligonucleotide
CC for detecting a polymorphism in the CHRM5 gene is used to detect novel
CC CHRM5 polymorphisms of the invention
XX
XX Sequence 15 BP; 4 A; 4 C; 5 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 4.5e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
XX
XX 12-JUL-2001 (first entry)
DT
XX Human CHRM5 gene, allele specific oligonucleotide #24.
DE
XX CHRM5; human; cholinergic receptor muscarinic 5; polymorphic variant;
KM genotyping; haplotype; gene therapy; ss.
XX
XX Homo sapiens.
OS
XX WO200128995-A2.
PN
XX 26-APR-2001.
PD
XX 19-OCT-2000; 2000MO-US029071.
XX
XX 21-OCT-1999; 99US-0160647P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX Chew A, Choi JY, Nandabalan K, Stephens JC;
PI WPI; 2001-300313/31.
XX
XX Isolated polynucleotide encoding the cholinergic receptor, muscarinic 5
PT (CHRM5), used to genotype/haplotype the CHRM5 gene, and to identify an
PT association between a trait and a polymorphism, comprises novel
PT polymorphisms.
XX
XX Claim 15; Page 46; 53pp; English.
XX
XX This sequence is a the human cholinergic receptor, muscarinic 5 (CHRM5)
CC gene, allele specific oligonucleotide. The invention relates to a
CC polymorphic variant of the CHRM5 gene sequence. The polymorphic sequence
CC is useful to genotype or haplotype the CHRM5 gene, to predict a haplotype
CC pair for the CHRM5 gene, and for identifying an association between a
CC trait (such as a clinical response to a drug targeting CHRM5). It is also
CC useful in gene therapy in patients who lack the CHRM5 isogene or have
CC only one copy of it, and in assays to measure the binding affinities of
CC one or more candidate drugs targeting CHRM5. The DNA sequence is used in
CC the treatment of disorders affected by expression or function of a novel
CC CHRM5 isogene of the invention. The protein encoded by the CHRM5 variant
CC is useful to identify drugs which target the CHRM5 polymorphic variant
CC protein. Antibodies against the protein can be used to neutralise the
CC CHRM5 isoform activity expressed in an individual, and is useful in
CC detection of CHRM5 in immunocytochemical, immunohistochemical and
CC immunofluorescence. A composition containing a genotyping oligonucleotide
CC for detecting a polymorphism in the CHRM5 gene is used to detect novel
CC CHRM5 polymorphisms of the invention
XX
XX Sequence 15 BP; 5 A; 1 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 4.5e+02;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 686 CCACCAUACUUUG 700
DB 15 CCACCACTACTTTTG 1

RESULT 833
ID ADV20569 standard; RNA; 15 BP.
AC ADV20569;
XX
XX 10-FEB-2005 (first entry)
DT
XX Human anti-Her2 hammerhead ribozyme substrate sequence #9.
DE
XX Enzymatic nucleic acid molecule; gene expression; down regulation;
KM protein-tyrosine-phosphatase-1b; PTB-1b; methionine aminopeptidase;
```

CC vessels or any other hyperplasia
SQ Sequence 15 BP; 0 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 4.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1713 GCAGUACCGACGAG 1727
DB 15 GCAGCACCGACGAG 1

RESULT 829
AAFA6731/C
ID AAFA6731 standard; DNA; 15 BP.

AC AAFA6731;

DT 30-MAR-2001 (first entry)

DE IGFBP3 oligonucleotide #151.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytosolic; dermatological; cardiac; virucide; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; seborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.

OS Homo sapiens.

XX WO200078341-A1.

XX 28-DEC-2000.

XX 21-JUN-2000; 2000WO-AU000693.

XX 21-JUN-1999; 99US-0140345P.

XX (MURD-) MURDOCH CHILDRENS RES INST.

XX Wraight CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.

PS Example 7; Page 45; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAFA5151 and AAFA5153-
XX P4561). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, ptyriasis, ruba, pilaris, seborrhea, keloids, keratosis,
XX neoplasia, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia

SQ Sequence 15 BP; 0 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 4.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1712 ACAGUACCGACGAGA 1726
DB 15 ACAGCACCGACGAGA 1

RESULT 830
AAA91436
ID AAA91436 standard; DNA; 15 BP.

AC AAA91436;

DT 12-JUL-2001 (first entry)

DE Human CHRM5 gene, allele specific oligonucleotide #6.

XX CHRM5; human; cholinergic receptor muscarinic 5; polymorphic variant;
XX genotyping; haplotype; gene therapy; ss.

OS Homo sapiens.

XX WO200128995-A2.

XX 26-APR-2001.

XX 19-OCT-2000; 2000WO-US029071.

XX 21-OCT-1999; 99US-0160647P.

XX (GENA-) GENAISSANCE PHARM INC.

XX Chew A, Choi JY, Nandabalan K, Stephens JC;

XX WPI; 2001-300313/31.

XX Isolated polynucleotide encoding the cholinergic receptor, muscarinic 5
XX (CHRM5), used to genotype/haplotype the CHRM5 gene, and to identify an
XX association between a trait and a polymorphism, comprises novel
XX polymorphisms.

XX Claim 15; Page 44; 53pp; English.

XX This sequence is a the human cholinergic receptor, muscarinic 5 (CHRM5)
XX gene, allele specific oligonucleotide. The invention relates to a
XX polymorphic variant of the CHRM5 gene sequence. The polymorphic sequence
XX is useful to genotype or haplotype the CHRM5 gene, to predict a haplotype
XX pair for the CHRM5 gene, and for identifying an association between a
XX trait (such as a clinical response to a drug targeting CHRM5). It is also
XX useful in gene therapy in patients who lack the CHRM5 isogene or have
XX only one copy of it, and in assays to measure the binding affinities of
XX one or more candidate drugs targeting CHRM5. The DNA sequence is used in
XX the treatment of disorders affected by expression or function of a novel
XX CHRM5 isogene of the invention. The protein encoded by the CHRM5 variant
XX is useful to identify drugs which target the CHRM5 polymorphic variant
XX protein. Antibodies against the protein can be used to neutralise the
XX CHRM5 isoform activity expressed in an individual, and is useful in
XX detection of CHRM5 in immunocytochemical, immunohistochemical and
XX immunofluorescence. A composition containing a genotyping oligonucleotide
XX for detecting a polymorphism in the CHRM5 gene is used to detect novel
XX CHRM5 polymorphisms of the invention

SQ Sequence 15 BP; 3 A; 5 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 4.5e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 452 CCAGCAUCCUCUCUG 466

DB 1 CCAGCAUCCUCUCUG 15

CC single nucleotide polymorphism selected from cytosine at PS1, adenine at
CC PS2 or PS3, and cytosine at PS4. The invention also relates to a method
CC for genotyping and haplotyping the CHRM3 gene for identification of
CC variants. The polymorphic variant is useful for therapeutic purposes, for
CC studying the expression and biological function of CHRM3, as well as for
CC developing drugs targeting the CHRM3 protein. The variant is also useful
CC in diagnostics and forensic applications. The recombinant nonhuman
CC organism transfected with the polymorphic variant is useful for studying
CC expression of CHRM3 isogenes in vivo, for in vivo screening and testing
CC of drugs targeted against CHRM3 protein, and for testing the efficacy of
CC therapeutic agents and compounds for Alzheimer's disease, Sjogren's
CC syndrome, disorders associated with smooth muscle contractility and
CC sudden infant death syndrome. The CHRM3 protein variant is useful in drug
CC screening assays and its antibodies are useful in immunoassays to detect
CC CHRM3 protein variants in biological samples. The present sequence is an
CC allele-specific oligonucleotide (ASO) probe used for detecting human
CC CHRM3 gene polymorphism

SO Sequence 15 BP; 5 A; 5 C; 3 G; 2 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 4.5e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1285 AUCGAGCUAGAGUCA 1299
Db 1 ATCCAGCCAGAGTCA 15
|||||

RESULT 825
AAD05863

ID AAD05863 standard; DNA; 15 BP.

AC AAD05863;

DT 31-JUL-2001 (first entry)

DE Human cholinergic receptor, muscarinic 3 gene ASO primer #7.

KW Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;

KW single nucleotide polymorphism; forensic application; gene therapy;

KW Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;

KW sudden infant death syndrome; genotyping; haplotyping; ASO;

KW chromosome 1q41-q44; allele-specific oligonucleotide; PCR primer; ss.

OS Homo sapiens.

PN WO200129176-A2.

PD 26-APR-2001.

PF 12-OCT-2000; 2000MO-US028247.

PR 15-OCT-1999; 99US-0159860P.

PA (GENA-) GENA15SANCE PHARM INC.

PI Choi JY, Denton RR, Nandabalan K, Stephens JC;

DR WPI; 2001-300326/31.

PS Claim 15; Page 19; 54pp; English.

PT Novel polymorphic variant of reference sequence for human cholinergic

PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic

PT purposes.

XX The patent relates to polymorphic variants of human cholinergic receptor,

XX muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one

XX single nucleotide polymorphism selected from cytosine at PS1, adenine at

XX PS2 or PS3, and cytosine at PS4. The invention also relates to a method

XX for genotyping and haplotyping the CHRM3 gene for identification of

XX variants. The polymorphic variant is useful for therapeutic purposes, for

CC studying the expression and biological function of CHRM3, as well as for
CC developing drugs targeting the CHRM3 protein. The variant is also useful
CC in diagnostics and forensic applications. The recombinant nonhuman
CC organism transfected with the polymorphic variant is useful for studying
CC expression of CHRM3 isogenes in vivo, for in vivo screening and testing
CC of drugs targeted against CHRM3 protein, and for testing the efficacy of
CC therapeutic agents and compounds for Alzheimer's disease, Sjogren's
CC syndrome, disorders associated with smooth muscle contractility and
CC sudden infant death syndrome. The CHRM3 protein variant is useful in drug
CC screening assays and its antibodies are useful in immunoassays to detect
CC CHRM3 protein variants in biological samples. The present sequence is an
CC allele-specific oligonucleotide (ASO) primer used for detecting human
CC CHRM3 gene polymorphism

SO Sequence 15 BP; 4 A; 3 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 4.5e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 180 GCGAGGCUACCCGU 194
Db 1 GCGAGGCTATACCAT 15
|||||

RESULT 826
AAD05868/C

ID AAD05868 standard; DNA; 15 BP.

AC AAD05868;

DT 31-JUL-2001 (first entry)

DE Human cholinergic receptor, muscarinic 3 gene ASO primer #12.

KW Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;

KW single nucleotide polymorphism; forensic application; gene therapy;

KW Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;

KW sudden infant death syndrome; genotyping; haplotyping; ASO;

KW chromosome 1q41-q44; allele-specific oligonucleotide; PCR primer; ss.

OS Homo sapiens.

PN WO200129176-A2.

PD 26-APR-2001.

PF 12-OCT-2000; 2000MO-US028247.

PR 15-OCT-1999; 99US-0159860P.

PA (GENA-) GENA15SANCE PHARM INC.

PI Choi JY, Denton RR, Nandabalan K, Stephens JC;

DR WPI; 2001-300326/31.

PS Claim 15; Page 19; 54pp; English.

PT Novel polymorphic variant of reference sequence for human cholinergic

PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic

PT purposes.

XX The patent relates to polymorphic variants of human cholinergic receptor,

XX muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one

XX single nucleotide polymorphism selected from cytosine at PS1, adenine at

XX PS2 or PS3, and cytosine at PS4. The invention also relates to a method

XX for genotyping and haplotyping the CHRM3 gene for identification of

XX variants. The polymorphic variant is useful for therapeutic purposes, for

XX studying the expression and biological function of CHRM3, as well as for

XX developing drugs targeting the CHRM3 protein. The variant is also useful

XX in diagnostics and forensic applications. The recombinant nonhuman

XX organism transfected with the polymorphic variant is useful for studying

PT Novel polymorphic variant of reference sequence for human cholinergic
PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
PT purposes.
PS Claim 15; Page 19; 54pp; English.
XX
CC The patent relates to polymorphic variants of human cholinergic receptor,
CC muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
CC single nucleotide polymorphism selected from cytosine at P51, adenine at
CC P52 or P53, and cytosine at P54. The invention also relates to a method
CC for genotyping and haplotyping the CHRM3 gene for identification of
CC variants. The polymorphic variant is useful for therapeutic purposes, for
CC studying the expression and biological function of CHRM3, as well as for
CC developing drugs targeting the CHRM3 protein. The variant is also useful
CC in diagnostics and forensic applications. The recombinant nonhuman
CC organism transfected with the polymorphic variant is useful for studying
CC expression of CHRM3 isogenes in vivo, for in vivo screening and testing
CC of drugs targeted against CHRM3 protein, and for testing the efficacy of
CC therapeutic agents and compounds for Alzheimer's disease, Sjogren's
CC syndrome, disorders associated with smooth muscle contractility and
CC sudden infant death syndrome. The CHRM3 protein variant is useful in drug
CC screening assays and its antibodies are useful in immunoassays to detect
CC CHRM3 protein variants in biological samples. The present sequence is an
CC allele-specific oligonucleotide (ASO) primer used for detecting human
CC CHRM3 gene polymorphism
SQ Sequence 15 BP; 4 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
QY Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 4.5e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
Db 1173 GCGTAGAGAGGAGAT 15
1 GCGTAGAGAGGAGAT 15
RESULT 823
AAD05854
ID AAD05854 standard; DNA; 15 BP.
XX
AC AAD05854;
XX
DT 31-JUL-2001 (first entry)
XX
DE Human cholinergic receptor, muscarinic 3 gene ASO probe #6.
XX
KW Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
KW single nucleotide polymorphism; forensic application; gene therapy;
KW Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
KW sudden infant death syndrome; genotyping; haplotyping;
KW chromosome 1q41-q44; ASO; allele-specific oligonucleotide; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200129176-A2.
XX
PD 26-APR-2001.
XX
PF 12-OCT-2000; 2000WO-US028247.
XX
PR 15-OCT-1999; 99US-0159860P.
XX
PA (GENA-) GENA15SANCE PHARM INC.
XX
PI Choi JY, Denton RR, Nandabalan K, Stephens JC,
XX WPI, 2001-300326/31.
XX
PT Novel polymorphic variant of reference sequence for human cholinergic
PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
PT purposes.
XX

PS Claim 15; Page 19; 54pp; English.
XX
CC The patent relates to polymorphic variants of human cholinergic receptor,
CC muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
CC single nucleotide polymorphism selected from cytosine at P51, adenine at
CC P52 or P53, and cytosine at P54. The invention also relates to a method
CC for genotyping and haplotyping the CHRM3 gene for identification of
CC variants. The polymorphic variant is useful for therapeutic purposes, for
CC studying the expression and biological function of CHRM3, as well as for
CC developing drugs targeting the CHRM3 protein. The variant is also useful
CC in diagnostics and forensic applications. The recombinant nonhuman
CC organism transfected with the polymorphic variant is useful for studying
CC expression of CHRM3 isogenes in vivo, for in vivo screening and testing
CC of drugs targeted against CHRM3 protein, and for testing the efficacy of
CC therapeutic agents and compounds for Alzheimer's disease, Sjogren's
CC syndrome, disorders associated with smooth muscle contractility and
CC sudden infant death syndrome. The CHRM3 protein variant is useful in drug
CC screening assays and its antibodies are useful in immunoassays to detect
CC CHRM3 protein variants in biological samples. The present sequence is an
CC allele-specific oligonucleotide (ASO) probe used for detecting human
CC CHRM3 gene polymorphism
SQ Sequence 15 BP; 4 A; 0 C; 9 G; 2 T; 0 U; 0 Other;
QY Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 4.5e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
Db 1179 GGAGAGAGCGGAGAT 1193
1 GGAGAGAGCGGAGAT 15
RESULT 824
AAD05856
ID AAD05856 standard; DNA; 15 BP.
XX
AC AAD05856;
XX
DT 31-JUL-2001 (first entry)
XX
DE Human cholinergic receptor, muscarinic 3 gene ASO probe #8.
XX
KW Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
KW single nucleotide polymorphism; forensic application; gene therapy;
KW Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
KW sudden infant death syndrome; genotyping; haplotyping;
KW chromosome 1q41-q44; ASO; allele-specific oligonucleotide; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200129176-A2.
XX
PD 26-APR-2001.
XX
PF 12-OCT-2000; 2000WO-US028247.
XX
PR 15-OCT-1999; 99US-0159860P.
XX
PA (GENA-) GENA15SANCE PHARM INC.
XX
PI Choi JY, Denton RR, Nandabalan K, Stephens JC,
XX WPI, 2001-300326/31.
XX
PT Novel polymorphic variant of reference sequence for human cholinergic
PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
PT purposes.
PS Claim 15; Page 19; 54pp; English.
XX
CC The patent relates to polymorphic variants of human cholinergic receptor,
CC muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one

BR 15-OCT-1999; 99US-0159860P.
 XX (GENA-) GENAISSANCE PHARM INC.
 PA
 XX Choi JY, Denton RR, Nandabalan K, Stephens JC,
 PI
 XX MPI; 2001-300326/31.
 DR
 XX Novel polymorphic variant of reference sequence for human cholinergic
 PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
 PT purposes.
 XX
 XX Claim 15; Page 19; 54pp; English.
 XX
 CC The patent relates to polymorphic variants of human cholinergic receptor,
 CC muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
 CC single nucleotide polymorphism selected from cytosine at PS1, adenine at
 CC PS2 or PS3, and cytosine at PS4. The invention also relates to a method
 CC for genotyping and haplotyping the CHRM3 gene for identification of
 CC variants. The polymorphic variant is useful for therapeutic purposes, for
 CC studying the expression and biological function of CHRM3, as well as for
 CC developing drugs targeting the CHRM3 protein. The variant is also useful
 CC in diagnostics and forensic applications. The recombinant nonhuman
 CC organism transfected with the polymorphic variant is useful for studying
 CC expression of CHRM3 isogenes in vivo, for in vivo screening and testing
 CC of drugs targeted against CHRM3 protein, and for testing the efficacy of
 CC therapeutic agents and compounds for Alzheimer's disease, Sjogren's
 CC syndrome, disorders associated with smooth muscle contractility and
 CC sudden infant death syndrome. The CHRM3 protein variant is useful in drug
 CC screening assays and its antibodies are useful in immunoassays to detect
 CC CHRM3 protein variants in biological samples. The present sequence is an
 CC allele-specific oligonucleotide (ASO) primer used for detecting human
 CC CHRM3 gene polymorphism
 CC
 SQ Sequence 15 BP; 3 A; 8 C; 1 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 73.3%; Pred. No. 4.5e+02;
 Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
 QY 1279 CUUCCCAUCCAGCUA 1293
 DB 1 CTTCCCATCCAGCA 15
 AAD05864/C
 ID AAD05864 standard; DNA; 15 BP.
 AC AAD05864;
 XX
 XX 31-JUL-2001 (first entry)
 DT
 XX Human cholinergic receptor, muscarinic 3 gene ASO primer #8.
 DE
 XX Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
 KW single nucleotide polymorphism; forensic application; gene therapy;
 KW Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
 KW sudden infant death syndrome; genotyping; haplotyping; ASO;
 KW chromosome 1q41-q44; allele-specific oligonucleotide; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200129176-A2.
 PN
 XX 26-APR-2001.
 PD
 XX 12-OCT-2000; 2000WO-US028247.
 PF
 XX 15-OCT-1999; 99US-0159860P.
 PR
 XX (GENA-) GENAISSANCE PHARM INC.
 PA
 XX

PI Choi JY, Denton RR, Nandabalan K, Stephens JC;
 XX MPI; 2001-300326/31.
 DR
 XX Novel polymorphic variant of reference sequence for human cholinergic
 PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
 PT purposes.
 XX
 XX Claim 15; Page 19; 54pp; English.
 XX
 CC The patent relates to polymorphic variants of human cholinergic receptor,
 CC muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
 CC single nucleotide polymorphism selected from cytosine at PS1, adenine at
 CC PS2 or PS3, and cytosine at PS4. The invention also relates to a method
 CC for genotyping and haplotyping the CHRM3 gene for identification of
 CC variants. The polymorphic variant is useful for therapeutic purposes, for
 CC studying the expression and biological function of CHRM3, as well as for
 CC developing drugs targeting the CHRM3 protein. The variant is also useful
 CC in diagnostics and forensic applications. The recombinant nonhuman
 CC organism transfected with the polymorphic variant is useful for studying
 CC expression of CHRM3 isogenes in vivo, for in vivo screening and testing
 CC of drugs targeted against CHRM3 protein, and for testing the efficacy of
 CC therapeutic agents and compounds for Alzheimer's disease, Sjogren's
 CC syndrome, disorders associated with smooth muscle contractility and
 CC sudden infant death syndrome. The CHRM3 protein variant is useful in drug
 CC screening assays and its antibodies are useful in immunoassays to detect
 CC CHRM3 protein variants in biological samples. The present sequence is an
 CC allele-specific oligonucleotide (ASO) primer used for detecting human
 CC CHRM3 gene polymorphism
 CC
 SQ Sequence 15 BP; 4 A; 5 C; 3 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 66.7%; Pred. No. 4.5e+02;
 Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
 QY 192 CGUCUGCAUGUGU 206
 DB 15 CATCTGGCAAGTGT 1
 AAD05867
 ID AAD05867 standard; DNA; 15 BP.
 AC AAD05867;
 XX
 XX 31-JUL-2001 (first entry)
 DT
 XX Human cholinergic receptor, muscarinic 3 gene ASO primer #11.
 DE
 XX Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
 KW single nucleotide polymorphism; forensic application; gene therapy;
 KW Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
 KW sudden infant death syndrome; genotyping; haplotyping; ASO;
 KW chromosome 1q41-q44; allele-specific oligonucleotide; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200129176-A2.
 PN
 XX 26-APR-2001.
 PD
 XX 12-OCT-2000; 2000WO-US028247.
 PF
 XX 15-OCT-1999; 99US-0159860P.
 PR
 XX (GENA-) GENAISSANCE PHARM INC.
 PA
 XX Choi JY, Denton RR, Nandabalan K, Stephens JC;
 PI MPI; 2001-300326/31.
 DR
 XX

FT /tag= a
XX /note= "polymorphic site indicated by an ambiguity base"
XX
XX
XX WO200194365-A2.
XX
XX 13-DEC-2001.
XX
XX 11-JUN-2001; 2001WO-US018814.
XX
XX 09-JUN-2000; 2000US-0210568P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX PA
XX Choi JY, Koshy B, Sanchis A, Sausker EA;
XX WPI; 2002-404359/43.
XX
XX
XX New variants of phosphorylase kinase gamma 2 isoenzymes, useful for
XX improving efficiency and reliability in the development of drugs for
XX treating diseases e.g. liver cirrhosis.
XX
XX Claim 16; Page 13; 76pp; English.
XX
XX The present invention describes an isolated polynucleotide (I) comprising
XX a nucleotide sequence which is a polymorphic variant of a reference
XX sequence for human phosphorylase kinase gamma2 (testis) (PHKG2) gene or
XX its fragment, or a polymorphic variant of a reference sequence for a
XX PHKG2 cDNA or its fragment. Also described is an isolated polypeptide
XX (II) comprising an amino acid sequence which is a polymorphic variant of
XX a reference sequence for PHKG2 protein or its fragment, where the
XX reference sequence comprises a sequence (see ABB09290) of 406 amino
XX acids, and the polymorphic variant comprises one or more variant amino
XX acids selected from glutamic acid at a position corresponding to amino
XX acid position 153 and tryptophan at position corresponding to amino acid
XX position 339. (I) has hepatotropic activity and can be used in gene
XX therapy. (II) is useful in screening for drugs targeting (II), by
XX contacting a PHKG2 polymorphic variant with a candidate agent and
XX assaying for binding activity. The identified candidate agents targeting
XX PHKG2, are useful for treating liver cirrhosis and glycogen storage
XX diseases. The present sequence represents an allele specific
XX oligonucleotide (ASO) primer for the PHKG2 gene, which is used in the
XX exemplification of the present invention
XX
XX Sequence 15 BP; 3 A; 6 C; 4 G; 1 T; 0 U; 1 Other:
SQ
Query Match 0.8%; Score 13.6; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 4.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1467 GGCCGAGACCTCA 1480
DB 2 GGCCGAGACCTCA 15
RESULT 817
ID AA64643/c
XX AA64643 standard; RNA; 15 BP.
XX
XX AA64643;
XX
XX 20-JUL-1999 (first entry)
XX
XX Human B7-1 hammerhead ribozyme target SEQ ID NO:1275.
XX
XX Arthritic condition; graft tolerance; immune response; target; cleavage;
XX hammerhead ribozyme; halpin ribozyme; human; rabbit; mouse; collagenase;
XX stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
XX rheumatoid arthritis; autoimmune disease; allergy; inflammation;
XX diagnosis; ss.
XX
XX Homo sapiens.
XX
XX WO9618736-A2.
XX
XX

XX
XX 20-JUN-1996.
XX
XX 22-NOV-1995; 95WO-US015516.
XX
XX 13-DEC-1994; 94US-00354920.
XX
XX 23-DEC-1994; 94US-00363253.
XX
XX 23-DEC-1994; 94US-00363254.
XX
XX 17-FEB-1995; 95US-00390850.
XX
XX 20-APR-1995; 95US-00426124.
XX
XX 02-MAY-1995; 95US-00432874.
XX
XX 04-MAY-1995; 95US-00434509.
XX
XX 07-JUL-1995; 95US-0000951P.
XX
XX 07-JUL-1995; 95US-0000974P.
XX
XX 07-AUG-1995; 95US-00512861.
XX
XX 05-OCT-1995; 95US-00541365.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX PA
XX Belgelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
XX Mcswigen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
XX Karpetsky A, Thompson JD, Modak A, Burgin A;
XX WPI; 1996-300653/30.
XX
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
XX the treatment of arthritis, induction of graft tolerance or treatment of
XX auto-immune diseases.
XX
XX Claim 10; Page 167; 307pp; English.
XX
XX The present invention describes a novel enzymatic nucleic acid (ENA)
XX having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
XX; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
XX ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
XX can inhibit collagenase and stromelysin production in the synovial
XX membrane of joints for the treatment or prevention of arthritis,
XX particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
XX be used to treat antigen presenting cells of a donor to induce tolerance
XX in a recipient to an alloantigen of a donor. They can also be used for
XX enhancing graft tolerance or for treating autoimmune disease, and for
XX treating allergies and other inflammatory conditions. The ENA's can also
XX be used in diagnosis. Ribozyme therapy impacts on the expression of
XX stromelysin without introducing the non-specific effects upon gene
XX expression which accompany treatment with retinoids and dexamethasone.
XX The concentration of ribozyme required to affect a therapeutic treatment
XX is lower than that required of antisense molecules, and is highly
XX specific. The present sequence is used in the exemplification of the
XX present invention
XX
XX Sequence 15 BP; 5 A; 3 C; 3 G; 0 T; 4 U; 0 Other:
SQ
Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 4.5e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
QY 486 CAGCUGACAGCA 500
DB 15 CAGCUGACAGCA 1
RESULT 818
ID AA264090
XX AA264090 standard; RNA; 15 BP.
XX
XX AA264090;
XX
XX 28-MAR-2000 (first entry)
XX
XX Substrate for hammerhead ribozyme which cleaves HCV RNA at nt. 4851.
XX
XX Enzymatic nucleic acid; hammerhead ribozyme; virus replication; cleavage;
XX cirrhosis; liver failure; hepatocellular carcinoma; interferon; cancer;
XX
XX
XX

XX Probe: ss; blood; DNA typing; blood transfusion; blood group;
KW SNP detection; DNA microarray.
XX
XX Homo sapiens.
OS
XX WO2005095650-A1.
PN
XX 13-OCT-2005.
XX
PD 31-MAR-2005; 2005WO-NL000236.
XX
PF 01-APR-2004; 2004EP-00076046.
XX
PR (SANO-) STICHTING SANQUIN BLOEDVOORZIENING.
PA
XX Belboer SHW, Wieringa-Jelma H, Den Dunnen JT, De Haas M;
PI WPI; 2005-725532/74.
DR
XX Genotyping blood cell antigens, by amplifying and detectably labeling DNA
PT by multiplex PCR at region of locus of blood cell antigen containing
PT nucleotide polymorphism, determining genotype for blood cell antigens
PT using chimeric primers.
XX
XX Claim 13; SEQ ID NO 95; 80pp; English.
PS
XX The invention relates to genotyping (M1) blood cell antigens, comprising
CC subjecting DNA from the individual to a multiplex PCR to amplify (and
CC detectably label) a region of the locus of different blood cell antigens
CC containing the site of a nucleotide polymorphism (arranged in an array)
CC and using the amplified and labeled DNA fragments to determine the
CC genotype for each of the blood cell antigens, using a pair of blood cell
CC antigen-specific chimeric primers and a detectably labeled universal
CC primer. Also included are a kit (1) for genotyping blood cell antigens by
CC (M1) (comprising a pair of blood cell antigen-specific chimeric primers
CC for each blood cell antigen to be genotyped and a detectably labeled
CC universal primer, preferably a pair of detectably labeled universal
CC primer), a set of blood cell antigen-specific chimeric primer pairs
CC useful in a multiplex PCR (comprising at least two, preferably
CC substantially all of chimeric primers) and a set of blood cell antigen
CC allele-specific oligonucleotide probes useful for genotyping blood cell
CC antigens. (M1) enables genotyping of large number of blood cell antigens
CC and is a practical, rapid and reliable method for analyzing the
CC hybridization results to assign the clinically relevant blood cell
CC antigen genotypes. The present sequence is a blood group antigen specific
CC probe useful in the method of the invention.
CC
XX
SQ Sequence 17 BP; 2 A; 12 C; 2 G; 1 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 5.1e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
OY 1179 GGAGGAGCTGGGGAUGG 1195
Db 17 GGAGGGGCTGGGGCTGG 1
|||||:|||||:
|
RESULT 815
AED16029
ID AED16029 standard; DNA; 17 BP.
XX
AC AED16029;
XX
XX 15-DEC-2005 (first entry)
XX
DE Probe for blood cell antigen HPA3-allele a, HPA-3ba CR.
XX
XX Probe, ss; blood; DNA typing; blood transfusion; blood group;
KW SNP detection; DNA microarray.
XX
OS Homo sapiens.

XX
PN WO2005095650-A1.
XX
PD 13-OCT-2005.
XX
PF 31-MAR-2005; 2005WO-NL000236.
XX
PR 01-APR-2004; 2004EP-00076046.
XX
PR (SANO-) STICHTING SANQUIN BLOEDVOORZIENING.
PA
XX Belboer SHW, Wieringa-Jelma H, Den Dunnen JT, De Haas M;
PI WPI; 2005-725532/74.
DR
XX Genotyping blood cell antigens, by amplifying and detectably labeling DNA
PT by multiplex PCR at region of locus of blood cell antigen containing
PT nucleotide polymorphism, determining genotype for blood cell antigens
PT using chimeric primers.
XX
XX Claim 13; SEQ ID NO 102; 80pp; English.
PS
XX The invention relates to genotyping (M1) blood cell antigens, comprising
CC subjecting DNA from the individual to a multiplex PCR to amplify (and
CC detectably label) a region of the locus of different blood cell antigens
CC containing the site of a nucleotide polymorphism (arranged in an array)
CC and using the amplified and labeled DNA fragments to determine the
CC genotype for each of the blood cell antigens, using a pair of blood cell
CC antigen-specific chimeric primers and a detectably labeled universal
CC primer. Also included are a kit (1) for genotyping blood cell antigens by
CC (M1) (comprising a pair of blood cell antigen-specific chimeric primers
CC for each blood cell antigen to be genotyped and a detectably labeled
CC universal primer, preferably a pair of detectably labeled universal
CC primers), a set of blood cell antigen-specific chimeric primer pairs
CC useful in a multiplex PCR (comprising at least two, preferably
CC substantially all of chimeric primers) and a set of blood cell antigen
CC allele-specific oligonucleotide probes useful for genotyping blood cell
CC antigens. (M1) enables genotyping of large number of blood cell antigens
CC and is a practical, rapid and reliable method for analyzing the
CC hybridization results to assign the clinically relevant blood cell
CC antigen genotypes. The present sequence is a blood group antigen specific
CC probe useful in the method of the invention.
CC
XX
SQ Sequence 17 BP; 1 A; 2 C; 12 G; 2 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 5.1e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
OY 1179 GGAGGAGCTGGGGAUGG 1195
Db 1 GGAGGGGCTGGGGCTGG 17
|||||:|||||:
|
RESULT 816
ABL52248
ID ABL52248 standard; DNA; 15 BP.
XX
AC ABL52248;
XX
XX 15-JUL-2002 (first entry)
XX
DE Human PHKG2 allele specific oligonucleotide primer SEQ ID NO:35.
XX
XX Human; phosphorylase kinase gamma 2 (testis); PHKG2; enzyme; SNP;
KW phosphorylase kinase gamma 2; single nucleotide polymorphism;
KW polymorphic; hepatocytic; gene therapy; glycogen storage disease;
KW liver cirrhosis; allele specific oligonucleotide; ASO; primer; ss.
XX
XX Homo sapiens.
OS
XX Key Location/Qualifiers
FH misc_feature 14
FT

XX The invention relates to a novel probe set used for identifying human
 CC leukocyte antigen-contribution of MHC class I chain-related-A (HLA-MICA)
 CC alleles in a test substance. The probe set comprises several probes,
 CC where each probe has a partial sequence containing bases represented in
 CC capital letters in a fully defined HLA-MICA allele list, given in the
 CC specification. The probe set can identify a HLA-MICA allele in patients
 CC with an organ transplant, cancer, diabetes and other multiple-factor
 CC diseases, and enables the provision of tailored medical treatment to
 CC individual patients. This oligo sequence represents a probe used in the
 CC detection of a HLA-MICA allele of the invention.

XX Sequence 17 BP; 0 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1709 AGCAGCAGUACGACGAG 1725
 Db 17 AGCAGCAGCAGCAGCAG 1

RESULT 812
 AEB35374/C
 ID AEB35374 standard; DNA; 17 BP.

XX AEB35374;

XX 22-SEP-2005 (first entry)

DE Human leukocyte antigen - MICA allele detection probe, SEQ ID 34.

XX human leukocyte antigen; MICA; transplant rejection; cancer; cytostatic;
 KM diabetes; antidiabetic; multifactorial genetic disorder; probe; ss.

OS Homo sapiens.
 OS Synthetic.

PN JP2005185177-A.

XX 14-JUL-2005.

PF 25-DEC-2003; 2003JP-00430559.

PR 25-DEC-2003; 2003JP-00430559.

PA (CANO) CANON KK.

XX Tsukada M;

DR WPI; 2005-515776/53.

XX Probe set for identifying human leukocyte antigen (HLA)-MICA allele in
 PT test substance of patients with e.g. cancer and diabetes, enabling
 PT tailored medical treatment.

PS Claim 2; SEQ ID NO 34; 27bp; Japanese.

XX The invention relates to a novel probe set used for identifying human
 CC leukocyte antigen-contribution of MHC class I chain-related-A (HLA-MICA)
 CC alleles in a test substance. The probe set comprises several probes,
 CC where each probe has a partial sequence containing bases represented in
 CC capital letters in a fully defined HLA-MICA allele list, given in the
 CC specification. The probe set can identify a HLA-MICA allele in patients
 CC with an organ transplant, cancer, diabetes and other multiple-factor
 CC diseases, and enables the provision of tailored medical treatment to
 CC individual patients. This oligo sequence represents a probe used in the
 CC detection of a HLA-MICA allele of the invention.

XX Sequence 17 BP; 0 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 5.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1709 AGCAGCAGUACGACGAG 1725
 Db 17 AGCAGCAGCAGCAGCAG 1

RESULT 813
 AEB35374/C
 ID AEB35374 standard; DNA; 17 BP.

XX AEB35374;

XX 22-SEP-2005 (first entry)

DE Human leukocyte antigen-A DNA probe, SEQ ID 257.

XX human leukocyte antigen; HLA; probe; transplant rejection; cancer;
 KM cytostatic; diabetes; antidiabetic; multifactorial genetic disorder; ss.

OS Homo sapiens.

PN JP2005185176-A.

XX 14-JUL-2005.

PF 25-DEC-2003; 2003JP-00430558.

PR 25-DEC-2003; 2003JP-00430558.

PA (CANO) CANON KK.

XX Tsukada M;

DR WPI; 2005-515775/53.

XX Probe set for identifying human leukocyte antigen (HLA)-DP allele in
 PT patients with organ transplant, cancer or diabetes enabling tailored
 PT medical treatment.

PS Claim 2; SEQ ID NO 257; 90bp; Japanese.

XX The invention relates to a novel probe set for identifying a human
 CC leukocyte antigen-A (HLA-A) allele in a test substance. The probe set
 CC comprises several probes chosen from the fully defined nucleic acid
 CC sequences (SEQ ID No: 251-431 and SEQ ID No: 455-631) as given in the
 CC specification. The novel probe set can identify HLA-A alleles in patients
 CC with organ transplants, cancer, diabetes and other multiple-factor
 CC diseases, and enables tailored medical treatment to individual patients.
 CC This oligo sequence represents a human leukocyte antigen-A DNA probe of
 CC the invention.

XX Sequence 17 BP; 1 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.1e+02;
 Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 152 CUCGACGCGUACGACC 168
 Db 17 CTCGAGAGGACGACACC 1

RESULT 814
 AED16022/C
 ID AED16022 standard; DNA; 17 BP.
 XX AED16022;
 AC AED16022;

XX 15-DEC-2005 (first entry)

DE Probe for blood cell antigen HPA3-allele a, HPA-3ba.

CC modulating agents that exhibit a high degree of specificity for RNA of a
CC desired target. (I) is useful for modulating HER2 activity in a cell, and
CC for treating diseases or conditions related to levels of HER2 gene
CC expression. (I) is useful for treating cancer, such as pancreatic cancer,
CC bladder cancer, lung cancer, breast cancer or prostate cancer. The
CC present sequence represents a human HER2 substrate RNA sequence for a
CC DNAzyme (ribozyme), which is used in an example from the present
CC invention for the identification of potential target sites in human HER2
CC RNA.
XX
SQ Sequence 17 BP; 2 A; 3 C; 7 G; 0 T; 5 U; 0 Other;
XX
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1626 GUGCUAUGCUCUGGCA 1642
DB 1 GUGCUAUGCUCUGGCA 17
RESULT 810
AD234569
XX AD234569 standard; RNA; 17 BP.
XX AC AD234569;
XX DT 30-JUN-2005 (first entry)
XX DE Human HER2 substrate RNA sequence SEQ ID NO:5607.
XX KW short interfering RNA; siRNA; RNA interference; gene silencing;
XX cytosstatic; cancer; HER2; substrate; ss.
OS Homo sapiens.
XX
XX US2005080031-A1.
XX PN 14-APR-2005.
XX PD 26-NOV-2003; 2003US-00724270.
XX PF 18-MAY-2001; 2001US-0292217P.
XX PR 29-MAY-2001; 2001US-0294140P.
XX PR 06-JUN-2001; 2001US-0296249P.
XX PR 20-JUL-2001; 2001US-0306883P.
XX PR 13-AUG-2001; 2001US-0311865P.
XX PR 10-SEP-2001; 2001US-0318471P.
XX PR 20-FEB-2002; 2002US-0358580P.
XX PR 06-MAR-2002; 2002US-0362016P.
XX PR 11-MAR-2002; 2002US-0363124P.
XX PR 20-MAY-2002; 2002WO-US015876.
XX PR 29-MAY-2002; 2002US-00157580.
XX PR 29-MAY-2002; 2002WO-US016840.
XX PR 06-JUN-2002; 2002US-00163552.
XX PR 06-JUN-2002; 2002US-0386782P.
XX PR 29-AUG-2002; 2002US-0406784P.
XX PR 05-SEP-2002; 2002US-0408378P.
XX PR 09-SEP-2002; 2002US-0409293P.
XX PR 10-SEP-2002; 2002US-00238700.
XX PR 15-JAN-2003; 2003US-0440129P.
XX PR 20-FEB-2003; 2003WO-US005028.
XX PR 20-FEB-2003; 2003WO-US005346.
XX PR 16-APR-2003; 2003US-00417012.
XX PR 24-APR-2003; 2003US-00422704.
XX PR 30-APR-2003; 2003US-00427160.
XX PR 23-MAY-2003; 2003US-00444853.
XX PR 29-AUG-2003; 2003US-00652791.
XX PR 23-OCT-2003; 2003US-00693059.
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX PA Mcswigen J;
XX PI

XX DR WPI; 2005-331166/34.
XX XX Novel double-stranded short interfering RNA molecule having first
XX PT nucleotide sequence complementary to RNA encoding HER2 or its portion,
XX PT and second nucleotide sequence having complementarity to first sequence,
XX PT useful for treating cancer.
XX
PS Example 10; SEQ ID NO 5607; 143pp; English.
XX
XX The invention relates to a double-stranded short interfering RNA (siRNA)
XX molecule (I) comprising a first nucleotide sequence having 19-23
XX nucleotides complementary to an RNA sequence encoding HER2 or its
XX portion, and a second nucleotide sequence having 19-23 nucleotides
XX exhibiting complementarity to the first sequence, and including at least
XX one nucleotide that is not a 2'-OH containing ribonucleotide. Also
XX described is a method of producing a class of nucleic acid-based gene
XX modulating agents that exhibit a high degree of specificity for RNA of a
XX desired target. (I) is useful for modulating HER2 activity in a cell, and
XX for treating diseases or conditions related to levels of HER2 gene
XX expression. (I) is useful for treating cancer, such as pancreatic cancer,
XX bladder cancer, lung cancer, breast cancer or prostate cancer. The
XX present sequence represents a human HER2 substrate RNA sequence for a
XX DNAzyme (ribozyme), which is used in an example from the present
XX invention for the identification of potential target sites in human HER2
XX RNA.
XX
SQ Sequence 17 BP; 3 A; 3 C; 7 G; 0 T; 4 U; 0 Other;
XX
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 406 UUGAGGAGACUGGCTUG 422
DB 1 UUGAGGAGACUGGCTUG 17
RESULT 811
AEB35378/C
XX ID AEB35378 standard; DNA; 17 BP.
XX AC AEB35378;
XX DT 22-SEP-2005 (first entry)
XX DE Human leukocyte antigen - MICA allele detection probe, SEQ ID 38.
XX KW human leukocyte antigen; MICA; transplant rejection; cancer; cytostatic;
XX KW diabetes; antidiabetic; multifactorial genetic disorder; probe; ss.
OS Homo sapiens.
OS Synthetic.
XX JP2005185177-A.
XX PN 14-JUL-2005.
XX PD 25-DEC-2003; 2003JP-00430559.
XX PF 25-DEC-2003; 2003JP-00430559.
XX PR 25-DEC-2003; 2003JP-00430559.
XX (CANO) CANON KK.
XX PA Tsukada M;
XX PI WPI; 2005-515776/53.
XX DR Probe set for identifying human leukocyte antigen (HLA)-MICA allele in
XX PT test substance of patients with e.g. cancer and diabetes, enabling
XX PT tailored medical treatment.
XX PS Claim 2; SEQ ID NO 38; 27pp; Japanese.

CC amount of DLG5 and methods are useful for preparing a medicament for
CC treating IBD, ulcerative colitis and Crohn's disease. The human gene
CC encoding DLG5 is located on chromosome 10-q22.3. The present sequence is
CC a control PCR primer used in expression analysis of the dlgs gene.

SQ Sequence 17 BP; 2 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 5.1e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Oy 325 AGCCGCGCCGCGCGCA 341

Db 1 AGCCTCGCCTTGCCGA 17

RESULT 808

ADX99460
ID ADX99460 standard; DNA; 17 BP.

AC ADX99460;

DT 05-MAY-2005 (first entry)

DE Extend primer 33 used to genotype human MAPK10 SNP DNA.

XX SNP detection; breast tumor; endocrine disease;
XX gynecology and obstetrics; neoplasm; cytostatic; metastasis;
XX gene therapy; RNA interference; mitogen-activated protein kinase 10;
XX Jun N terminal kinase-3; MAPK10; ss; PCR; primer.

OS Homo sapiens.

PN WO2005014846-A2.

PD 17-FEB-2005.

PF 27-MAY-2004; 2004WO-US016939.

PR 24-JUL-2003; 2003US-0490234P.

PR 25-NOV-2003; 2003US-00723681.

PR 25-NOV-2003; 2003US-0525239P.

XX (SEQU-) SEQUENOM INC.

PI Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;

PI Hoyal-Wrightson CR;

DR WPI; 2005-163257/17.

PT Identifying risk of, preventing and/or treating breast cancer by
PT identifying and/or analyzing polymorphic variations in nucleotide
PT sequences within the human genome.

PS Example 5; Page 126; 617pp; English.

XX The invention relates to a novel method for identifying a subject at risk
XX of breast cancer comprising detecting the presence or absence of a
XX polymorphic variation associated with breast cancer. The method of the
XX invention demonstrates cytostatic activity and may be useful for
XX identifying a risk of, preventing and/or treating breast cancer and
XX cancer metastasis. The methods may be utilized for gene therapy or RNA
XX interference. The current sequence is that of an Extend primer of the
XX invention which was used to genotype a human mitogen-activated protein
XX kinase 10 (MAPK10) single nucleotide polymorphism (SNP).

SQ Sequence 17 BP; 7 A; 5 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1456 GAGAGAAAGCGGCCCA 1472

Db 1 GAGAGAAAGCGGCCCA 17

RESULT 809

ADZ33903
ID ADZ33903 standard; RNA; 17 BP.

AC ADZ33903;

DT 30-JUN-2005 (first entry)

DE Human HER2 substrate RNA sequence SEQ ID NO:4941.

XX short interfering RNA; siRNA; RNA interference; gene silencing;
XX cytostatic; cancer; HER2; substrate; ss.

OS Homo sapiens.

PN US2005080031-A1.

PD 14-APR-2005.

PF 26-NOV-2003; 2003US-00724270.

PR 18-MAY-2001; 2001US-0292217P.

PR 29-MAY-2001; 2001US-0294140P.

PR 06-JUN-2001; 2001US-0296249P.

PR 20-JUL-2001; 2001US-0306883P.

PR 13-AUG-2001; 2001US-0311865P.

PR 10-SEP-2001; 2001US-0318471P.

PR 20-FEB-2002; 2002US-0356580P.

PR 06-MAR-2002; 2002US-0362016P.

PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.

PR 29-MAY-2002; 2002US-00157580.

PR 06-JUN-2002; 2002US-00163552.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 10-SEP-2002; 2002US-00238700.

PR 15-JAN-2003; 2003US-0440129P.

PR 20-FEB-2003; 2003WO-US005028.

PR 20-FEB-2003; 2003WO-US005346.

PR 16-APR-2003; 2003US-00417012.

PR 24-APR-2003; 2003US-00422704.

PR 30-APR-2003; 2003US-00427160.

PR 23-MAY-2003; 2003US-00444851.

PR 29-AUG-2003; 2003US-00652791.

PR 23-OCT-2003; 2003US-00693059.

(SIRN-) SIRNA THERAPEUTICS INC.

PI Mcswigen J;

DR WPI; 2005-331166/34.

PT Novel double-stranded short interfering RNA molecule having first
PT nucleotide sequence complementary to RNA encoding HER2 or its portion,
PT and second nucleotide sequence having complementarity to first sequence,
PT useful for treating cancer.

PS Example 10; SEQ ID NO 4941; 143pp; English.

XX The invention relates to a double-stranded short interfering RNA (siRNA)
XX molecule (I) comprising a first nucleotide sequence having 19-23
XX nucleotides complementary to an RNA sequence encoding HER2 or its
XX portion, and a second nucleotide sequence having 19-23 nucleotides
XX exhibiting complementarity to the first sequence, and including at least
XX one nucleotide that is not a 2'-OH containing ribonucleotide. Also
XX described is a method of producing a class of nucleic acid-based gene

XX DR WPI: 2004-533378/51.
XX
XX PT Novel myosin-like protein-1, useful for treating or preventing disorder
XX PT associated with decreased expression or activity of human genome-derived
XX PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX PT function.
XX
XX PS Disclosure; SEQ ID NO 2301; Opp: English.
XX
XX CC The invention relates to a novel polypeptide (I) comprising a sequence
XX CC (S1) of myosin-like protein-1 (hGMDLP-1) having 2568 amino acids fully
XX CC defined in the specification, a fragment of at least 8 amino acids of
XX CC (S1), 95% deviation from (S1) which are conservative substitutions, and
XX CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or
XX CC antagonist of hGMDLP-1, or as an inhibitor of hGMDLP-1 activity. A
XX CC pharmaceutical composition of the invention is useful for treating or
XX CC preventing a disorder associated with decreased expression or activity of
XX CC hGMDLP-1, such as a disorder of heart and/or skeletal muscle function.
XX CC The present sequence represents a 17-mer nucleotide, used in the
XX CC invention for scanning the sequence represented in ACN63102
XX
XX SQ Sequence 17 BP; 4 A; 8 C; 4 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 82.4%; Pred. No. 5.1e+02;
XX Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 990 CCACGACGACGAGUGACA 1006
XX Db 1 CCACAGCCGCGAGTGCCA 17
XX
XX RESULT 806
XX ADS12595
XX ID ADS12595 standard; DNA; 17 BP.
XX
XX AC ADS12595;
XX
XX DT 16-DEC-2004 (first entry)
XX
XX DE Forward RT-PCR primer used to amplify human beta-actin DNA Seq.
XX
XX KW PCR; primer; ss; microarray; inflammatory bowel disease; Crohn's disease;
XX KW ulcerative colitis; screening method; antiinflammatory; anticulcer;
XX KW RT-PCR; real-time PCR; beta-actin.
XX
XX OS Homo sapiens.
XX
XX PN EP1462527-A1.
XX
XX PD 29-SEP-2004.
XX
XX PF 26-MAR-2003; 2003EP-00006943.
XX
XX PR 26-MAR-2003; 2003EP-00006943.
XX
XX PA (CONA-) CONARIS RES INST AG.
XX
XX PI Costello C, Ma N, Schreiber SD, Seegert D;
XX
XX DR WPI: 2004-663617/65.
XX
XX PT New diagnostic composition comprising specific nucleic acid molecules,
XX PT useful for diagnosing or developing a compound for treating inflammatory
XX PT bowel diseases or related disease e.g., Crohn's disease and ulcerative
XX PT colitis.
XX
XX PS Example 1; SEQ ID NO 5; 63pp; English.
XX
XX CC This invention relates to a novel diagnostic composition that comprises
XX CC nucleic acid molecules bound to a solid support (or microarray), wherein
XX CC each nucleic acid can hybridise to an mRNA of a gene that shows abnormal

CC expression in an gastrointestinal condition. Specifically, it refers to
CC DNA oligos useful for preparing a microarray chip for the diagnosis of
CC inflammatory bowel disease, Crohn's disease, ulcerative colitis or a
CC disposition thereof. The present invention describes nucleic acid
CC molecules useful for screening methods to identify compounds that can be
CC used for therapy or to prevent progression of the aforementioned
CC conditions. As such, the pharmaceutical compositions developed
CC accordingly exhibit antiinflammatory and anticulcer activities. This
CC oligonucleotide sequence is an RT-PCR primer used to amplify a human DNA
CC sequence differentially expressed in gastrointestinal disorders, given in
XX an exemplification of the invention.
XX
XX SQ Sequence 17 BP; 2 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 70.6%; Pred. No. 5.1e+02;
XX Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 325 AGCCUGACCGUGCCGA 341
XX Db 1 AGCCTCGCCTTTCCCA 17
XX
XX RESULT 807
XX ADV26279
XX ID ADV26279 standard; DNA; 17 BP.
XX
XX AC ADV26279;
XX
XX DT 10-MAR-2005 (first entry)
XX
XX DE Human beta-actin control forward primer.
XX
XX KW ss; primer; Inflammatory bowel disease; Crohn's disease;
XX KW ulcerative colitis; gastrointestinal-gen.; inflammation;
XX KW antiinflammatory; diagnosis; DNA polymorphism; PCR.
XX
XX OS Homo sapiens.
XX
XX PN WO2004109288-A1.
XX
XX PD 16-DEC-2004.
XX
XX PF 03-JUN-2004; 2004WO-SE000861.
XX
XX PR 06-JUN-2003; 2003GB-00013081.
XX
XX PR 26-NOV-2003; 2003GB-00027427.
XX
XX PA (ASTR) ASTRAZENECA AB.
XX
XX PI Corneliusen B, Schreiber S, Stoll M;
XX
XX DR WPI: 2005-057661/06.
XX
XX PT Identifying a compound capable of modulating the action of the DLG5
XX PT protein comprising subjecting one or more test compounds to a screen
XX PT comprising DLG5 polypeptide, its homologue or fragment.
XX
XX PS Example 3; SEQ ID NO 171; 79pp; English.
XX
XX CC The invention relates to identifying a compound capable of modulating the
XX CC action of the DLG5 protein comprising subjecting one or more test
XX CC compounds to a screen comprising a DLG5 polypeptide appearing as
XX CC ADV26112, its homologue or fragment. Also included are identifying a
XX CC potential anti-inflammatory bowel disease (anti-IBD) therapeutic
XX CC compounds, screening for a compound potentially useful for treating IBD,
XX CC a cell comprising a reporter gene under the control of the DLG5 promoter,
XX CC testing potential therapeutic agents for the ability to suppress IBD
XX CC phenotype, identifying inhibitors of transcription of DLG5, preparing a
XX CC pharmaceutical composition and diagnosing IBD or determining
XX CC susceptibility to develop IBD. The methods are useful for identifying a
XX CC compound capable of modulating the action of the DLG5 protein or
XX CC diagnosing IBD. The compound that is able to modulate that activity or

PI Blact L, Mcswigen J, Roberts E, Pavco PA, Macejack D;
XX WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
XX especially in combination with type I interferon therapy.
XX
PS Claim 1, SEQ ID NO 3957, 198pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferon. The present sequence represents a HCV DNAzyme substrate
CC sequence.
CC
CC Revised record issued on 22-SEP-2005 : No correction was made to this
CC record
XX
XX Sequence 17 BP; 2 A; 5 C; 5 G; 0 T; 5 U; 0 Other;
SQ
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.1e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1230 CCAGAGAGCGGAGCG 1246
DB 17 CCAGAGACATCGTGACG 1
RESULT 804
ADP46073
ID ADP46073 standard; DNA; 17 BP.
XX
XX ADP46073;
AC
XX
XX 26-AUG-2004 (first entry)
DT
XX
XX Extend primer 45 used to genotype human MAP kinase MAPK10 polymorphism.
DE
XX
XX breast cancer; cytosolic; gene therapy; human; ss; primer; PCR; SNP;
XX single nucleotide polymorphism; MAP kinase; MAPK10; JNK3; JNK3A; p493F12;
XX p54DSAPK MAP kinase; c-Jun kinase 3; JNK3 alpha protein kinase;
XX c-Jun N-terminal kinase 3; stress activated protein kinase beta;
XX chromosome 4q22.1-q23; probe.
XX
XX Homo sapiens.
OS
XX WO2004047623-A2.
PN
XX
XX 10-JUN-2004.
PD
XX
XX 25-NOV-2003; 2003WO-US037946.
PF
XX
XX 25-NOV-2002; 2002US-0429136P.
PR
XX
XX 24-JUL-2003; 2003US-0490234P.
PR
XX
XX (SEQV-) SEQUENOM INC.
PA
XX
XX Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
PI
XX
XX WPI; 2004-441051/41.
DR
XX
XX Identifying a subject at risk of breast cancer by detecting the presence
PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NPM1 or GALE
PT regions which are associated with breast cancer in a nucleic acid sample
PT from a subject.
XX
XX Example 5; Page 92; 289pp; English.
XX

CC The invention relates to a novel method for identifying a subject at risk
CC of breast cancer comprising detecting the presence or absence of one or
CC more polymorphic variations associated with breast cancer in a nucleic
CC acid sample from a subject. The method of the invention has cytostatic
CC applications and may be useful for identifying a subject at risk of
CC breast cancer, for early diagnosis, prevention and treatment of breast
CC cancer, possibly via gene therapy, as well as to analyse and predict a
CC response to a breast cancer treatment and in clinical drug trials. The
CC current sequence is that of an extend primer (also described as probe) of
CC the invention which was used to genotype human MAP kinase MAPK10 (JNK3;
CC JNK3A;p493F12;p54DSAPK MAP kinase;c-Jun kinase 3;JNK3 alpha protein
CC kinase;c-Jun N-terminal kinase 3;stress activated protein kinase beta)
CC gDNA which has been mapped to chromosomal position 4q22.1-q23.
XX
XX Sequence 17 BP; 7 A; 5 C; 4 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1456 GAGAGAGAGCGGCCA 1472
DB 1 GAGAGAGAACTGCGCA 17
RESULT 805
ACN65399
ID ACN65399 standard; DNA; 17 BP.
XX
XX ACN65399;
AC
XX
XX 02-DEC-2004 (first entry)
DT
XX
XX Human GDMPL-1 probe SEQ ID NO:2301.
DE
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPL-1;
XX hGDMPL-1 agonist hGDMPL antagonist; hGDMPL inhibitor; heart disorder;
XX skeletal muscle function.
XX
XX Homo sapiens.
OS
XX
XX US2004137589-A1.
PN
XX
XX 15-JUL-2004.
PD
XX
XX 26-NOV-2003; 2003US-00723361.
PF
XX
XX 26-MAY-2000; 2000US-0207456P.
PR
XX
XX 21-SEP-2000; 2000US-0234687P.
PR
XX
XX 27-SEP-2000; 2000US-0236359P.
PR
XX
XX 04-OCT-2000; 2000GB-00024263.
PR
XX
XX 30-JAN-2001; 2001WO-US000661.
PR
XX
XX 30-JAN-2001; 2001WO-US000662.
PR
XX
XX 30-JAN-2001; 2001WO-US000663.
PR
XX
XX 30-JAN-2001; 2001WO-US000664.
PR
XX
XX 30-JAN-2001; 2001WO-US000665.
PR
XX
XX 30-JAN-2001; 2001WO-US000666.
PR
XX
XX 30-JAN-2001; 2001WO-US000667.
PR
XX
XX 30-JAN-2001; 2001WO-US000668.
PR
XX
XX 30-JAN-2001; 2001WO-US000669.
PR
XX
XX 30-JAN-2001; 2001WO-US000670.
PR
XX
XX 05-FEB-2001; 2001US-0266860P.
PR
XX
XX 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
PA (GUY/) GU Y.
PA (GUY/) GU Y.
PA (PENN/) PENN S G.
PA (HANN/) HANZEL D K.
PA (HANN/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
PI
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX

```

XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KM HCV infection; type I interferon; DNAzyme.
XX Hepatitis C virus.
OS
XX US2003125270-A1.
PN
XX 03-JUL-2003.
PD
XX 18-DEC-2000; 2000US-00740332.
XX 18-DEC-2000; 2000US-00740332.
PR
XX 18-DEC-2000; 2000US-00740332.
XX
XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
XX WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 1906; 198bp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferon. The present sequence represents a HCV DNAzyme substrate
CC sequence.
CC
CC Revised record issued on 22-SEP-2005 : No correction was made to this
CC record
CC
XX
SQ Sequence 17 BP; 6 A; 2 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1451 UCAAGAGAGAAGCG 1467
DB 1 UCAAGAGAGUAGAGCG 17

RESULT 802
AD185893/C
ID AD185893 standard; RNA; 17 BP.
XX
XX AD185893;
AC
XX
XX 22-SEP-2005 (revised)
DT 03-JUN-2004 (first entry)
XX
XX HCV DNAzyme substrate sequence #3139.
DE
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KM HCV infection; type I interferon; DNAzyme.
XX Hepatitis C virus.
OS
XX US2003125270-A1.
PN
XX 03-JUL-2003.
PD
XX

```

```

PF 18-DEC-2000; 2000US-00740332.
XX 18-DEC-2000; 2000US-00740332.
PR
XX
XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
XX WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 3139; 198bp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferon. The present sequence represents a HCV DNAzyme substrate
CC sequence.
CC
CC Revised record issued on 22-SEP-2005 : No correction was made to this
CC record
CC
XX
SQ Sequence 17 BP; 2 A; 2 C; 9 G; 0 T; 4 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 5.1e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 508 AUCACGAGCGCCGUCAC 524
DB 17 ATCACGAGCCCGCTCAC 1

RESULT 803
AD186711/C
ID AD186711 standard; RNA; 17 BP.
XX
XX AD186711;
AC
XX
XX 22-SEP-2005 (revised)
DT 03-JUN-2004 (first entry)
XX
XX HCV DNAzyme substrate sequence #3957.
DE
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KM HCV infection; type I interferon; DNAzyme.
XX Hepatitis C virus.
OS
XX US2003125270-A1.
PN
XX 03-JUL-2003.
PD
XX 18-DEC-2000; 2000US-00740332.
XX 18-DEC-2000; 2000US-00740332.
PR
XX 18-DEC-2000; 2000US-00740332.
XX
XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX

```

RESULT 799
ADMS8521/C
ID ADMS8521 standard; RNA; 17 BP.
XX
AC ADMS8521;
XX
DT 03-JUN-2004 (first entry)
XX
DE Hepatitis B virus (HBV) RNA target sequence #655.
XX
KW Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW Hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW virucide; hepatocytic; antiinflammatory; cytosstatic.
XX
OS Hepatitis B virus.
XX
PN US2004054156-A1.
XX
PD 18-MAR-2004.
XX
PF 15-JAN-2003; 2003US-00342902.
XX
PR 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1993; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
XX
XX
PA (DRAP/) DRAPER K.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGEN J A.
PA (MORR/) MORRISSEY D.
XX
PI Draper K., Blatt L., Mcswigen JA, Morrissey D;
XX
DR WPI; 2004-247781/23.
XX
PT Novel enzymatic nucleic acid molecule, such as DNAszymes and inozymes
PT specifically cleaving RNA derived from hepatitis B virus and comprising
PT one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
PS Disclosure; SEQ ID NO 655; 122pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule that
CC specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC comprising one or more binding arms, without requiring the presence of a
CC 2'-OH group within the molecule for activity. The nucleic acids are
CC useful for treating hepatitis B virus infection, hepatitis,
CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC combination with other therapies such as lamivudine and interferons. The
CC nucleic acids are useful as diagnostic tools to examine genetic drift and
CC mutations within diseased cells, for detecting the presence of HBV RNA in
CC a cell, for the study of RNA and for down-regulating gene expression of
CC target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC sequence represents an HBV RNA target sequence, used in the scope of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 17 BP; 4 A; 4 C; 3 G; 0 T; 6 U; 0 Other;
XX
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 5.1e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
QY 828 GACAGAAAACUUGUCC 844
DB 17 GACAGAAAAGATTGTCC 1

RESULT 800
AD184170
ID AD184170 standard; RNA; 17 BP.
XX
AC AD184170;
XX
DT 22-SEP-2005 (revised)
DT 03-JUN-2004 (first entry)
XX
DE HCV DNAzyme substrate sequence #1416.
XX
KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNAzyme.
XX
OS Hepatitis C virus.
XX
PN US2003125270-A1.
XX
PD 03-JUL-2003.
XX
PF 18-DEC-2000; 2000US-00740332.
XX
PR 18-DEC-2000; 2000US-00740332.
XX
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
PI Blatt L., Mcswigen J, Roberts E, Pavco PA, Macejack D;
XX
DR WPI; 2004-031273/03.
XX
PT Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
PS Claim 1; SEQ ID NO 1416; 198pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNAzyme substrate
CC sequence.
CC
CC Revised record issued on 22-SEP-2005 : No correction was made to this
CC record
XX
SQ Sequence 17 BP; 4 A; 9 C; 2 G; 0 T; 2 U; 0 Other;
XX
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 507 CAUCACGAGCCGCUCA 523
DB 1 CAUCACGAGCCGCUCA 17
XX
RESULT 801
AD184660
ID AD184660 standard; RNA; 17 BP.
XX
AC AD184660;
XX
DT 22-SEP-2005 (revised)
DT 03-JUN-2004 (first entry)
XX
DE HCV DNAzyme substrate sequence #1906.
XX

XX DE Human VEGF receptor 1 (flt-1) DNAzyme target sequence SEQ ID 892.
 XX XX VEGF receptor; angiogenesis; cancer; tumor; ocular disease;
 XX KW diabetic retinopathy; age related macular degeneration;
 XX KW angiogenesis disorder; rheumatoid arthritis; psoriasis; wound healing;
 XX KW endometriosis; endometrial carcinoma; gynecological bleeding disorder;
 XX KW menstruation disorder; premenstrual syndrome; menopause; Gynecological;
 XX KW Cytostatic; Ophthalmological; Antidiabetic; antiangiogenic;
 XX KW Antipsoriatic; Antirheumatic; Antiarthritic; Vulnerrary; Hemostatic;
 XX KW Contraceptive; ss; enzymatic nucleic acid.
 XX OS Homo sapiens.
 XX PN WO200296927-A2.
 XX PD 05-DEC-2002.
 XX PF 29-MAY-2002; 2002WO-US017674.
 XX PR 29-MAY-2001; 2001US-00870161.
 XX PR 30-NOV-2001; 2001US-0334461P.
 XX PR 03-MAY-2002; 2002US-00138674.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PA (CHIR) CHIRON CORP.
 XX PI Escobedo J, Mewsigen J, Pavco P, Stinchcomb D, Sandberg J;
 XX PI Gordon G;
 XX DR WPI; 2003-140439/13.
 XX PT Novel enzymatic nucleic acids, ribozymes, which modulate expression of
 XX PT genes encoding vascular endothelial growth factor and/or VEGF receptor,
 XX PT useful for inhibiting tumor angiogenesis in cell, and for treating
 XX PT cancer.
 XX PS Disclosure; SEQ ID NO 892; 172pp; English.
 XX CC The invention relates to enzymatic nucleic acids (I) i.e.
 CC CC ribozymes/DNAzymes/Zinzymes that target and modulate expression of, genes
 CC CC encoding vascular endothelial growth factor (VEGF) and/or VEGF receptor
 CC CC (VEGFR1 and 2 encode by the Flt-1 and Kdr genes respectively). Also
 CC CC included are a composition comprising (I) and a carrier, administering
 CC CC (I) to a cell (by contacting the cell with the compound under conditions
 CC CC suitable for the administration), administering (I) to a cell (in
 CC CC conjunction with one or more other drug by contacting the cell with the
 CC CC compound and the other drug under conditions suitable for the
 CC CC administration), administering (I) to a mammal (by contacting the mammal
 CC CC with the compound under conditions suitable for the administration),
 CC CC treating (M1) a subject having endometriosis (by contacting a subject
 CC CC with, or administering to subject, a nucleic acid molecule (I1) that
 CC CC modulates expression of VEGF, VEGFR1, and/or VEGFR2), a mammalian cell
 CC CC (I11) comprising (I) and administering to a mammal (I) (in conjunction
 CC CC with a chemotherapeutic agent comprising contacting the mammal with the
 CC CC compound and the chemotherapeutic agent under conditions suitable for the
 CC CC administration). (I) is administered to a mammalian cell, preferably
 CC CC human cell in the presence of a delivery reagent which is a lipid such as
 CC CC cationic lipid or phospholipid, or a liposome. The enzymatic nucleic acid
 CC CC molecule has an endonuclease activity to cleave RNA encoded by an VEGFR1
 CC CC and/or VEGFR2 gene, and is in a hammerhead, inozyme, DNAzyme, G-cleaver,
 CC CC or Ambazyme configuration. The enzymatic nucleic acids are useful for
 CC CC inhibiting ocular angiogenesis associated with diabetic retinopathy or
 CC CC age-related diabetic retinopathy, in a subject. They are also useful for
 CC CC inhibiting angiogenesis, preferably tumor angiogenesis in cell, and for
 CC CC treating a subject having a condition associated with an increased level
 CC CC of VEGF receptor, where the condition is cancer, e.g. breast cancer, lung
 CC CC cancer (such as non-small cell lung carcinoma), colorectal cancer, renal
 CC CC cancer (such as renal cell carcinoma), pancreatic cancer. The enzymatic
 CC CC nucleic acids are useful for treating a subject (preferably human) having
 CC CC endometriosis, psoriasis, age-related macular degeneration, proliferative
 CC CC diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis,
 CC CC wound healing, endometrial carcinoma, gynecologic bleeding disorders,

CC irregular menstrual cycles, ovulation, premenstrual syndrome, and
 CC CC menopausal dysfunction. The enzymatic nucleic acids are useful for birth
 CC CC control by inhibiting ovulation or embryonic uterine implantation. The
 CC CC present sequence is a target sequence from the human VEGFR1/Flt-1 mRNA.
 XX SQ Sequence 17 BP; 5 A; 6 C; 6 G; 0 T; 0 U; 0 Other;
 XX
 XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
 XX Best Local Similarity 64.7%; Pred. No. 5.1e+02;
 XX Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 1023 UGCGUGGCGCCCGG 1039
 Db 17 TGCCTGTCGTCGCCCTGG 1

RESULT 798
 ADF92104
 ID ADF92104 standard; DNA; 17 BP.
 XX
 AC ADF92104;
 XX
 DT 26-FEB-2004 (first entry)
 XX
 DE Human cytokeratin 18-related R3 PCR primer - SEQ ID 192.
 XX
 KW human; cytokeratin; CK; LAMP; loop mediated isothermal amplification;
 KW tumour metastasis; prostate cancer; lymphoma; human; CK18; ss; primer;
 KW PCR; R3.
 XX
 OS Homo sapiens.
 XX
 PN WO2003097878-A1.
 XX
 PD 27-NOV-2003.
 XX
 PF 20-MAY-2003; 2003WO-JP006256.
 XX
 PR 21-MAY-2002; 2002JP-00145689.
 PR 17-JUN-2002; 2002JP-00175271.
 PR 09-JUL-2002; 2002JP-00197579.
 XX
 PA (SYSM-) SYSMEX CORP.
 XX
 PI Tada S, Akai Y, Imura Y, Abe S, Minekawa H;
 XX
 DR WPI; 2004-012543/01.
 XX
 PT LAMP nucleic acid amplification primers for detection of cytokeratin
 PT expression as indicator in diagnosis of tumour metastasis.
 XX
 PS Claim 3; SEQ ID NO 192; 266pp; Japanese.
 XX
 XX CC The invention relates to novel nucleic acid amplification primers for the
 CC CC detection of human cytokeratin (CK) 18, 19 or 20 expression by the LAMP
 CC CC (loop mediated isothermal amplification) method. The primers of the
 CC CC invention may be useful for the detecting cytokeratin 18-20 expression as
 CC CC an indicator for the diagnosis of tumour metastasis, particularly
 CC CC prostate cancer and lymphoma. The amplification using the primers is
 CC CC highly efficient and allows very sensitive detection of tumour
 CC CC metastasis. The current sequence is that of the human CK18-related PCR
 CC CC primer of the invention.
 XX
 XX SQ Sequence 17 BP; 2 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 64.7%; Pred. No. 5.1e+02;
 Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 853 GGCAGUUCUGAAGCUG 869
 Db 1 GGCCTGTCGTCGCCCTGG 17

XX DE Human PKR substrate sequence #1227.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX proglutinin D2 receptor; PTGDR; Ikappab kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
XX substrate; ds.
XX
XX OS Unidentified.
XX
XX PN WO200281628-A2.
XX
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-US010512.
XX
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Chowrira B, Haeblerli P, McSwiggen J, Fosnaugh K;
XX
XX DR WPI; 2003-058513/05.
XX
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 3646; 317bp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human PKR
XX substrate sequence.
XX
XX SQ Sequence 17 BP; 7 A; 3 C; 3 G; 0 T; 4 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 5.1e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 999 CAGUGACAGUGGAAACA 1015
XX DB 1 CAGUGACAGUGGAAACA 17
XX
XX RESULT 796
XX ADL49742
XX ID ADL49742 strand; RNA; 17 BP.
XX AC ADL49742;
XX DT 20-MAY-2004 (first entry)

XX DE Human PKR substrate sequence #856.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX proglutinin D2 receptor; PTGDR; Ikappab kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
XX substrate; ds.
XX
XX OS Unidentified.
XX
XX PN WO200281628-A2.
XX
XX PD 17-OCT-2002.
XX
XX PF 03-APR-2002; 2002WO-US010512.
XX
XX PR 05-APR-2001; 2001US-00827395.
XX PR 29-MAY-2001; 2001US-0294412P.
XX PR 28-AUG-2001; 2001US-0315315P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Blatt L, Chowrira B, Haeblerli P, McSwiggen J, Fosnaugh K;
XX
XX DR WPI; 2003-058513/05.
XX
XX PT Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX PS Claim 59; SEQ ID NO 3275; 317bp; English.
XX
XX CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human PKR
XX substrate sequence.
XX
XX SQ Sequence 17 BP; 4 A; 2 C; 6 G; 0 T; 5 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 5.1e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1385 CUCUGGCAAGAGGUGU 1401
XX DB 1 CUCUGGCAAGAGGUGU 17
XX
XX RESULT 797
XX AEB58314/c
XX ID AEB58314 strand; mRNA; 17 BP.
XX AC AEB58314;
XX DT 22-SEP-2005 (first entry)

Best Local Similarity 58.8%; Pred. No. 5.1e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1589 ACUGGCUUGCCUACAC 1605
DB 17 ACTGATGTCGATGATC 1

RESULT 793
AD149697/c

ID AD149697 standard; DNA; 17 BP.

AC AD149697;

DT 15-APR-2004 (first entry)

DE Human tumour suppression/reversion-related DNA sequence SegID2200.

XX tumour suppression; tumour reversion; apoptosis; virus resistance;
KM cytostatic; virucide; neuroprotective; nootropic; viral disease; probe;
KM primer; PCR; gene chip; antisense; viral disease; tumour;
KM cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX Homo sapiens.

XX MO2003025177-A2.

XX 27-MAR-2003.

PF 17-SRP-2002; 2002WO-1B004523.

PR 17-SRP-2001; 2001PR-00011980.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Teclerman A, Amson R, Tuijinder M;

DR WPI; 2003-313354/30.

PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.

PS Disclosure; SEQ ID NO 2200; 30pp; French.

XX This invention relates to novel isolated nucleic acid sequences involved
CC in the phenomena of tumour suppression, tumour reversion, apoptosis
CC and/or resistance to viruses. The invention may be useful for the
CC development of compounds with a cytostatic, virucide, neuroprotective,
CC nootropic or neuroleptic activity. The DNA sequences may be useful as
CC probes and primers for detecting, identifying, quantifying and/or
CC amplifying nucleic acid, for example as one component of a gene chip, in
CC vitro as antisense reagents and for production of recombinant
CC polypeptides. The invention may therefore be useful for preparation of
CC pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia. The
CC present sequence is that of a nucleic acid sequence of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedpct_sequences

XX Sequence 17 BP; 7 A; 3 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 47.1%; Pred. No. 5.1e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 32 CUUUGUUCGCAACAC 48

DB 17 CTTGTTCGAGATC 1

RESULT 794

ID ABX94795 standard; DNA; 17 BP.

XX ABX94795;

DT 08-JUL-2003 (first entry)

DE Beta-actin PCR primer #1.

XX Androgen receptor; human; acne; acneform skin disorder; acne rosacea;
KM antisense; steroid hormone receptor; steroid hormone metabolising enzyme;
KM Salpha-reductase; dermatological; antiestrogenic; sebaceous gland;
KM phosphorothioate; RT-PCR; primer; beta-actin; ss.

OS Unidentified.

XX WO2003017917-A2.

XX 06-MAR-2003.

PD 23-AUG-2002; 2002WO-EP009452.

XX 23-AUG-2001; 2001DE-01041443.

XX (RINA-) RINA TECHNOLOGIEN GMBH.

XX (ZOUB/) ZOUBOULIS C C.

XX Zouboulis CC;

XX WPI; 2003-278606/27.

PT Use of non-viral agents for treating acne or acneform skin conditions,
PT particularly antisense oligonucleotides directed against androgen
PT receptor or Salpha reductase.

PS Example 1; Page 18; 36pp; German.

XX This invention describes a novel method for treatment of acne and
CC acneform skin disorders, including rosacea, using a non-viral active
CC agent, prepared by molecular biological methods. The method comprises an
CC antisense oligonucleotide; (stabilised) ribozyme; (mirror) aptamer;
CC chimeric RNA/DNA oligonucleotide; naked plasmid DNA or DNA encapsulated
CC in a liposome, especially an antisense oligonucleotide specific for a
CC gene that encodes a steroid hormone receptor or steroid hormone
CC metabolising enzyme, particularly the androgen receptor and/or Salpha-
CC reductase. The products of the invention have dermatological and
CC antiestrogenic activity and can inhibit the androgen-induced stimulation
CC of sebaceous gland activity. The method of the invention provides
CC difficulties associated with reduced side effects and without the
CC represents a RT-PCR primer used to amplify the beta-actin gene, which is
CC used as a control during the amplification of the human androgen receptor
CC described in the disclosure of the invention

XX Sequence 17 BP; 2 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 70.6%; Pred. No. 5.1e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 325 AGCCUGGCUUGCCGA 341

DB 1 AGCCTCGCCTTTCGCA 17

RESULT 795

ID ADL50113 standard; RNA; 17 BP.

XX ADL50113;

DT 20-MAY-2004 (first entry)

CC suppression or reversion, apoptosis and/or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
SQ Sequence 17 BP; 8 A; 1 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.1e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1449 GGUCAAGGAGAGAAAG 1465
Db 1 GATCAAGGAGAGAAAG 17
RESULT 791
AD148646
ID AD148646 standard; DNA; 17 BP.
XX
XX AD148646;
AC
XX
XX
DT 15-APR-2004 (first entry)
XX
XX Human tumour suppression/reversion-related DNA sequence SeqID1149.
DB
XX
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
KM cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
XX cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX
XX WO2003025177-A2.
XX
XX
XX 27-MAR-2003.
PD
XX
XX 17-SEP-2002; 2002WO-IB004523.
PF
XX
XX 17-SEP-2001; 2001PR-00011980.
PR
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
PA
XX
XX Telerman A, Amson R, Tuijnder M;
PI
XX
XX WPI; 2003-313354/30.
DR
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumours and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
XX
XX Disclosure; SEQ ID NO 1149; 30pp; French.
PS
XX
XX This invention relates to novel isolated nucleic acid sequences involved
CC in the phenomena of tumour suppression, tumour reversion, apoptosis
CC and/or resistance to viruses. The invention may be useful for the
CC development of compounds with a cytostatic, virucide, neuroprotective,
CC neurotropic or neuroleptic activity. The DNA sequences may be useful as
CC probes and primers for detecting, identifying, quantifying and/or
CC amplifying nucleic acid, for example as one component of a gene chip, in
CC vitro as antisense reagents and for production of recombinant
CC polypeptides. The invention may therefore be useful for preparation of
CC pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia. The

CC present sequence is that of a nucleic acid sequence of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at [ftp://wipo.int/pub/publishedpct_sequences](http://wipo.int/pub/publishedpct_sequences)
XX
SQ Sequence 17 BP; 9 A; 1 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.1e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1449 GGUCAAGGAGAGAAAG 1465
Db 1 GATCAAGTGAAGAGAAAG 17
RESULT 792
AD150810/c
ID AD150810 standard; DNA; 17 BP.
XX
XX AD150810;
AC
XX
XX
DT 15-APR-2004 (first entry)
XX
XX Human tumour suppression/reversion-related DNA sequence SeqID3313.
DB
XX
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
KM cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
XX cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX
XX WO2003025177-A2.
XX
XX
XX 27-MAR-2003.
PD
XX
XX 17-SEP-2002; 2002WO-IB004523.
PF
XX
XX 17-SEP-2001; 2001PR-00011980.
PR
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
PA
XX
XX Telerman A, Amson R, Tuijnder M;
PI
XX
XX WPI; 2003-313354/30.
DR
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumours and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
XX
XX Disclosure; SEQ ID NO 3313; 30pp; French.
PS
XX
XX This invention relates to novel isolated nucleic acid sequences involved
CC in the phenomena of tumour suppression, tumour reversion, apoptosis
CC and/or resistance to viruses. The invention may be useful for the
CC development of compounds with a cytostatic, virucide, neuroprotective,
CC neurotropic or neuroleptic activity. The DNA sequences may be useful as
CC probes and primers for detecting, identifying, quantifying and/or
CC amplifying nucleic acid, for example as one component of a gene chip, in
CC vitro as antisense reagents and for production of recombinant
CC polypeptides. The invention may therefore be useful for preparation of
CC pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia. The
CC present sequence is that of a nucleic acid sequence of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at [ftp://wipo.int/pub/publishedpct_sequences](http://wipo.int/pub/publishedpct_sequences)
XX
SQ Sequence 17 BP; 5 A; 5 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;

```

XX 25-JAN-2002; 2002EP-00001160.
PF XX
PR 30-JAN-2001; 2001WO-US000666.
PR 23-MAY-2001; 2001US-00864761.
PR 21-DEC-2001; 2001US-0343331P.
XX XX
PA (ABOM-) ABOMICA INC.
XX XX
PI Gu Y;
XX XX
DR WPI; 2003-302724/30.
XX XX
PT New human sodium-hydrogen exchanger like protein 1 (NHEPL1), useful as a
PT passive replacement therapy or as a vaccine for treating or preventing
PT disorders associated with aberrant expression or activity of human
PT NHEPL1.
XX XX
PS Example 2; SEQ ID NO 600; 468bp; English.
XX XX
CC The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC exchanger like protein (NHEPL1). The NHEPL1 nucleic acid molecule, NHEPL1
CC polypeptide, an antibody against the protein or its antigen-binding
CC fragment is useful in therapy. The NHEPL1 nucleic acid molecule, NHEPL1
CC polypeptide and an agonist are particularly useful for manufacturing a
CC medicament for treating or preventing a disorder associated with
CC decreased expression or activity of human NHEPL1. The antibody or its
CC antigen-binding fragment, and an antagonist, are useful for manufacturing
CC a medicament for treating or preventing a disorder associated with
CC increased expression or activity of human NHEPL1. The NHEPL1 nucleic acid
CC or protein is useful as passive replacement therapy, as a vaccine, or in
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC spanning the sequence of the human NHEPL1 gene (ADC03514).
XX XX
SQ Sequence 17 BP; 2 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
XX XX
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 5.1e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
CY 1087 GCCAUCUACUCCAUCCG 1103
DB |||:|:|:|:|:|:
1 GCCATCTCTGCATCGT 17
XX XX
RESULT 789
ADCC37820
ID ADC37820 standard; DNA; 17 BP.
XX AC
XX ADC37820;
XX DT
XX 18-DEC-2003 (first entry)
XX DE
XX Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:169.
XX KW human; angiotensin-like protein 1; AMLP1; cytostatic; gene therapy;
XX AMLP1a; ss.
XX OS Synthetic.
XX Homo sapiens.
XX PN WO2003037931-A2.
XX PD
XX 08-MAY-2003.
XX PF
XX 01-NOV-2002; 2002WO-US035129.
XX PR
XX 01-NOV-2001; 2001US-0334773P.
XX PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX PI Shannon M, Phan T;
XX XX

```

DR WPI; 2003-430501/40.

PT New isolated nucleic acid molecule encoding a human angiomin-1-like protein, useful for treating or preventing a disorder associated with

PT decreased or increased expression or activity of AMLP1.

XX

PS Example 2; SEQ ID NO 169; 172pp; English.

XX

CC The present invention describes the human angiomin-1-like protein 1

CC (AMLPL). human AMLPL has cytosolic activity, and can be used in gene

CC therapy. The AMLPL protein, nucleic acid molecules, antibodies, and

CC compositions of the present invention can be used for treating or

CC preventing a disorder associated with decreased or increased expression

CC or activity of AMLPL. The present sequence represents a scanning

CC oligonucleotide for human AMLPL α , which is used in an example from the

CC present invention.

XX

SQ Sequence 17 BP; 7 A; 5 C; 5 G; 0 T; 0 U; 0 Other;

XX

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 5.1e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0

OY 1709 AGCAGCAGUACGACGAG 1725
||||| |||||
DB 1 AGCAGCAGCAACGACGAG 17

RESULT 790

AADB45399

ID ADB45399 standard; DNA; 17 BP.

XX

AC ADB45399;

XX

DT 18-DEC-2003 (first entry)

DE Tumour suppression/reversion associated nucleotide #5722.

XX

KW cytosolic; antiviral; neuroprotective; nocitropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.

XX

OS Homo sapiens.

OS

PN WO2003040369-A2.

PD 15-MAY-2003.

XX

PF 17-SEP-2002; 2002WO-IB004219.

PF

PR 17-SEP-2001; 2001FR-00011981.

PR

PA (MOLE-) MOLECULAR ENGINES LAB.

XX

PI Telerman A, Amson R, Tuijinder M;

PI WPI; 2003-441574/41.

DR

XX New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.

XX

PS Disclosure; Page 700; 771pp; French.

XX

CC The invention relates to the isolation of 6327 nucleotide sequences,

CC sequence of at least 15 consecutive nucleotides of these nucleotides, a

CC fragment having at least 80% identity, after optimal alignment, with the

CC nucleotides; a sequence that hybridizes under stringent conditions with

CC the nucleotides, or the complement, or corresponding RNA, of the

CC nucleotides. The nucleotides are used as probes or primers for detecting,

CC identifying, quantifying and/or amplifying nucleic acids, as in vitro

CC sense and antisense sequences, of nucleotides involved in tumour

KW primer; probe; tumour suppression; tumour reversion; apoptosis;
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
 KW diagnosis.
 OS Homo sapiens.
 XX MO2003040369-A2.
 XX
 XX
 PD 15-MAY-2003.
 XX
 PF 17-SEP-2002; 2002WO-1B004219.
 XX
 PR 17-SEP-2001; 2001PR-00011981.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijinder M;
 XX
 DR WPI; 2003-441574/41.
 XX
 PT New nucleic acid encoding human prostate membrane-specific antigen,
 PT useful e.g. for treatment of tumors and viral infection, also related
 PT polypeptide and antibodies.
 PS Disclosure; Page 558; 771pp; French.
 XX
 XX The invention relates to the isolation of 6327 nucleotide sequences,
 CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
 CC sequence having at least 80% identity, after optimal alignment, with the
 CC nucleotides, a sequence that hybridizes under stringent conditions with
 CC the nucleotides, or the complement, or corresponding RNA, of the
 CC nucleotides. The nucleotides are used as probes or primers for detecting,
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
 CC sense and antisense sequences, of nucleotides involved in tumour
 CC suppression or reversion, apoptosis and or viral resistance, to produce
 CC recombinant polypeptides, and to prepare transgenic animals, as
 CC experimental models. The nucleotides (also vectors containing them and
 CC cells containing the vectors), the encoded polypeptides and antibodies
 CC (Ab) against the polypeptide are useful for prevention and/or treatment
 CC of viral infections or diseases characterized by development of tumours
 CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
 CC Analysis of the expression of the nucleotides can be used for diagnosis
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can
 CC also be used to screen for their specific interactive molecules,
 CC potentially useful for treating diseases associated with abnormal
 CC expression of the nucleotides.
 CC
 SQ Sequence 17 BP; 6 A; 3 C; 4 G; 4 T; 0 U; 0 Other;
 XX
 XX
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 58.8%; Pred. No. 5.1e+02;
 Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 669 UCAGUUCUCCUAGUAGC 685
 Db 17 TCAGTACTCAGTGATC 1
 XX
 XX
 RESULT 787
 ID ADB43561
 XX ADB43561 standard; DNA; 17 BP.
 AC ADB43561;
 XX
 DT 18-DEC-2003 (revised)
 DT 04-DEC-2003 (first entry)
 XX
 DE Tumour suppression/reversion associated nucleotide #3884.
 XX
 XX cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
 KW primer; probe; tumour suppression; tumour reversion; apoptosis;
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
 KW diagnosis.

XX
 OS Homo sapiens.
 XX
 XX MO2003040369-A2.
 XX
 XX
 PD 15-MAY-2003.
 XX
 PF 17-SEP-2002; 2002WO-1B004219.
 XX
 PR 17-SEP-2001; 2001PR-00011981.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijinder M;
 XX
 DR WPI; 2003-441574/41.
 XX
 PT New nucleic acid encoding human prostate membrane-specific antigen,
 PT useful e.g. for treatment of tumors and viral infection, also related
 PT polypeptide and antibodies.
 PS Disclosure; Page 486; 771pp; French.
 XX
 XX The invention relates to the isolation of 6327 nucleotide sequences,
 CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
 CC sequence having at least 80% identity, after optimal alignment, with the
 CC nucleotides, a sequence that hybridizes under stringent conditions with
 CC the nucleotides, or the complement, or corresponding RNA, of the
 CC nucleotides. The nucleotides are used as probes or primers for detecting,
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
 CC sense and antisense sequences, of nucleotides involved in tumour
 CC suppression or reversion, apoptosis and or viral resistance, to produce
 CC recombinant polypeptides, and to prepare transgenic animals, as
 CC experimental models. The nucleotides (also vectors containing them and
 CC cells containing the vectors), the encoded polypeptides and antibodies
 CC (Ab) against the polypeptide are useful for prevention and/or treatment
 CC of viral infections or diseases characterized by development of tumours
 CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
 CC Analysis of the expression of the nucleotides can be used for diagnosis
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can
 CC also be used to screen for their specific interactive molecules,
 CC potentially useful for treating diseases associated with abnormal
 CC expression of the nucleotides.
 CC
 SQ Sequence 17 BP; 9 A; 1 C; 5 G; 2 T; 0 U; 0 Other;
 XX
 XX
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.1e+02;
 Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 1449 GGUCAAGGAGAGAAAG 1465
 Db 1 GATCAAGTGAAGAAAG 17
 XX
 XX
 RESULT 788
 ID ADC04113
 XX ADC04113 standard; DNA; 17 BP.
 AC ADC04113;
 XX
 DT 18-DEC-2003 (first entry)
 DT
 XX
 DE Human Na/H exchanger-like protein 1 gene oligonucleotide #560.
 XX
 XX ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
 KW NHE1P1; passive replacement therapy; vaccine; diagnosis.
 XX
 OS Homo sapiens.
 XX
 XX
 PN EP1273660-A2.
 XX
 PD 08-JAN-2003.

QY 1060 GAGGAGACAUGGACUC 1076
||||| :|||:
17 GAGGAGGCAATGGATC 1
Db

RESULT 784
ACC64254
ID ACC64254 standard; DNA; 17 BP.
XX
AC ACC64254;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour suppression, SEQ ID 1501.
XX
KM Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KM tumour suppression; tumour reversion; apoptosis; virus resistance;
KM viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KM schizophrenia; ss.
XX
XX OS Mus musculus.
XX
XX WO2003025176-A2.
XX
XX PD 27-MAR-2003.
XX
XX PF 17-SEP-2002; 2002WO-IB004210.
XX
XX PR 17-SEP-2001; 2001FR-00011979.
XX
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX
XX PI Telerman A, Amson R, Tuijnder M;
XX
XX DR WPI; 2003-333167/31.
XX
XX PT New isolated nucleic acid, useful for treating viral diseases associated
XX with tumours and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX PS Disclosure; Page 206; 738pp; French.
XX
XX CC The present invention relates to murine oligonucleotides (ACC62754-
XX ACC68806), which are associated with tumour suppression, tumour
XX reversion, apoptosis and virus resistance. The oligonucleotides are
XX useful as (1) as probes and primers for detecting, identifying,
XX quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX recombinant polypeptides. The oligonucleotides are useful for preparation
XX of pharmaceuticals for prevention and/or treatment of viral diseases
XX that are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia.
XX
XX SQ Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
XX

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 5.1e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 954 GAGCUGGAAACCCAGCU 970
|||:|||||:
1 GATCTGGAACCCAGAT 17
Db

RESULT 785
ADB41161
ID ADB41161 standard; DNA; 17 BP.
XX
XX AC ADB41161;
XX
XX DT 18-DEC-2003 (revised)
XX 04-DEC-2003 (first entry)
XX

DE Tumour suppression/reversion associated nucleotide #1484.
XX
XX KM Cytostatic; antiviral, neuroprotective; nootropic; neuroleptic; ss;
KM primer; probe; tumour suppression; tumour reversion; apoptosis;
KM virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KM diagnosis.
XX
XX OS Homo sapiens.
XX
XX WO2003040369-A2.
XX
XX PD 15-MAY-2003.
XX
XX PF 17-SEP-2002; 2002WO-IB004219.
XX
XX PR 17-SEP-2001; 2001FR-00011981.
XX
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX
XX PI Telerman A, Amson R, Tuijnder M;
XX
XX DR WPI; 2003-441574/41.
XX
XX PT New nucleic acid encoding human prostate membrane-specific antigen,
XX useful e.g. for treatment of tumours and viral infection, also related
XX polypeptide and antibodies.
XX
XX PS Disclosure; Page 205; 771pp; French.
XX
XX CC The invention relates to the isolation of 6327 nucleotide sequences,
XX CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
XX CC sequence having at least 80% identity, after optimal alignment, with the
XX CC nucleotides, a sequence that hybridizes under stringent conditions with
XX CC the nucleotides, or the complement, or corresponding RNA, of the
XX CC nucleotides. The nucleotides are used as probes or primers for detecting,
XX CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
XX CC sense and antisense sequences, of nucleotides involved in tumour
XX CC suppression or reversion, apoptosis and/or viral resistance, to produce
XX CC recombinant polypeptides, and to prepare transgenic animals, as
XX CC experimental models. The nucleotides (also vectors containing them and
XX CC cells containing the vectors), the encoded polypeptides and antibodies
XX CC (Ab) against the polypeptide are useful for prevention and/or treatment
XX CC of viral infections or diseases characterized by development of tumours
XX CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
XX CC Analysis of the expression of the nucleotides can be used for diagnosis
XX CC and/or prognosis of these diseases. The nucleotides and polypeptides can
XX CC potentially be useful for screening for their specific interactive molecules,
XX CC expression of the nucleotides.
XX
XX SQ Sequence 17 BP; 9 A; 2 C; 5 G; 1 T; 0 U; 0 Other;
XX

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.1e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1449 GGUCAAGGAGGAAG 1465
|:|||||:
1 GATCAAGCAGAGGAAG 17
Db

RESULT 786
ADB4177/c
ID ADB4177 standard; DNA; 17 BP.
XX
XX AC ADB4177;
XX
XX DT 18-DEC-2003 (revised)
XX 04-DEC-2003 (first entry)
XX
XX DE Tumour suppression/reversion associated nucleotide #4500.
XX
XX KM Cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;

XX Claim 1; Page 305; 387pp; English.
PS
XX The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAsymes,
CC inozymes, zincymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer 1 region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNzyme or minus strand DNzyme sequences disclosed in the present
CC invention
SQ
XX Sequence 17 BP; 2 A; 5 C; 5 G; 0 T; 5 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.1e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1230 CCAGAGAGCGGACG 1246
DB 17 CCAGAGACATGTCGACG 1
RESULT 782
ACC67984/C
ID ACC67984 standard; DNA; 17 BP.
XX
AC ACC67984;
DT 01-JUL-2003 (first entry)
DE Murine oligonucleotide associated with tumour suppression, SEQ ID 5231.
XX
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
XX viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX schizophrenia; ss.
XX
XX Mus musculus.
XX
XX WO2003025176-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004210.
XX
XX 17-SEP-2001; 2001FR-00011979.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-333167/31.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumours and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX
XX Disclosure; Page 642; 738pp; French.
XX
XX The present invention relates to murine oligonucleotides (ACC62754-
XX ACC68806), which are associated with tumour suppression, tumour
XX reversion, apoptosis and virus resistance. The oligonucleotides are
XX useful as (1) as probes and primers for detecting, identifying,
XX quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX recombinant polypeptides. The oligonucleotides are useful for preparation
XX of pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia
XX

CC - useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of a
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ
XX Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 5.1e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 1060 GAGAGGACATGTCGAC 1076
DB 17 GAGAGGACATGTCGAC 1
RESULT 783
ACC67516/C
ID ACC67516 standard; DNA; 17 BP.
XX
AC ACC67516;
DT 01-JUL-2003 (first entry)
DE Murine oligonucleotide associated with tumour suppression, SEQ ID 4763.
XX
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
XX viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX schizophrenia; ss.
XX
XX Mus musculus.
XX
XX WO2003025176-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004210.
XX
XX 17-SEP-2001; 2001FR-00011979.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-333167/31.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumours and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX
XX Disclosure; Page 587; 738pp; French.
XX
XX The present invention relates to murine oligonucleotides (ACC62754-
XX ACC68806), which are associated with tumour suppression, tumour
XX reversion, apoptosis and virus resistance. The oligonucleotides are
XX useful as (1) as probes and primers for detecting, identifying,
XX quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX recombinant polypeptides. The oligonucleotides are useful for preparation
XX of pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia
XX

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 5.1e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

SQL Sequence 17 BP; 6 A; 2 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1451 UCAGAGGAAGAAAGCG 1467
|||||||
DB 1 UCAGAGGAAGAAAGCG 17

RESULT 780
ACD51564/c
ID ACD51564 standard; RNA; 17 BP.
XX
AC ACD51564;
XX
DT 24-SEP-2003 (first entry)
XX
DE HBV hammerhead ribozyme substrate sequence #622.
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KM RNA stability; RNA expression; RNA synthesis; antisense;
KM enzymatic nucleic acid; hammerhead ribozyme; DNzyme; zinzyme;
KM amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
KM HBV reverse transcriptase; Enhancer I region; viral replication;
KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KM virucide; antiinflammatory; substrate; ss.
XX
XX Hepatitis B virus.
XX
XX WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEBP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
XX Example 1; Page 148; 387pp; English.

CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes,
CC inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV

CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNzyme or amberyne sequences
CC disclosed in the present invention
XX
SQL Sequence 17 BP; 4 A; 4 C; 3 G; 0 T; 6 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 5.1e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 828 GACGAGAAACUUGUCC 844
|||||||
DB 17 GACGAGAAAGATTGTCC 1

RESULT 781
ACD64713/c
ID ACD64713 standard; RNA; 17 BP.
XX
AC ACD64713;
XX
DT 30-SEP-2003 (first entry)
XX
XX HCV minus strand DNzyme substrate sequence #1680.
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KM RNA stability; RNA expression; RNA synthesis; antisense;
KM enzymatic nucleic acid; hammerhead ribozyme; DNzyme; zinzyme;
KM amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
KM HBV reverse transcriptase; Enhancer I region; viral replication;
KM degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KM liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KM virucide; antiinflammatory; substrate; ss.
XX
XX Hepatitis C virus.
XX
XX WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEBP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.

KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
 KW amberyze; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer 1 region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.

OS Hepatitis C virus.

PN WO200281494-A1.

PD 17-OCT-2002.

PF 26-MAR-2002; 2002WO-US009187.

PR 26-MAR-2001; 2001US-00817879.

PR 08-JUN-2001; 2001US-00877478.

PR 08-JUN-2001; 2001US-0296876P.

PR 24-OCT-2001; 2001US-0335059P.

PR 05-DEC-2001; 2001US-0337055P.

PA (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MACE/) MACEJAK D.

PA (MCSW/) MCSWIGEN J.

PA (MORR/) MORRISSEY D.

PA (PVC/) PAVCO P.

PA (LEBP/) LEE P.

PA (DRAP/) DRAPER K.

PA (ROBE/) ROBERTS E.

PI Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P;

PI Draper K, Roberts E;

DR WPI; 2003-229207/22.

PT Novel compound useful for treating cirrhosis, liver failure,

PT hepatocellular carcinoma, or condition associated with hepatitis C virus

PT infection.

PS Claim 1, Page 259; 387pp; English.

XX The present invention relates to nucleic acid molecules which modulate

XX the synthesis, expression and/or stability of Hepatitis C virus (HCV) or

XX Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense

XX and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,

XX inozymes, zinzymes, amberyzes, and G-cleaver ribozymes. Also disclosed

XX are nucleic acid decoy molecules and aptamers that bind to HBV reverse

XX transcriptase and/or HBV reverse transcriptase primer sequences, as well

XX as oligonucleotides that specifically bind the Enhancer 1 region of HBV

XX DNA. The nucleic acids may be used to modulate the expression of HBV

XX genes and HBV viral replication. Also disclosed is a method for screening

CC compounds and/or potential therapies directed against HBV, and compounds

CC that modulate the expression and/or replication of HCV. The compounds and

CC methods of the invention are useful for the treatment of degenerative and

CC disease states related to HBV and HCV infection, replication and gene

CC expression such as cirrhosis, liver failure, and hepatocellular

CC carcinoma. The present sequence represents a substrate for one of the HCV

CC DNAzyme or minus strand DNAzyme sequences disclosed in the present

CC invention

SO Sequence 17 BP; 4 A; 9 C; 2 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 5.1e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 507 CAUACGAGCGCGCUCA 523

DB 1 CAUACGAGCGCGCUCA 17

RESULT 779

ACD60608

ID ACD60608 standard; RNA; 17 BP.

AC ACD60608;

DT 24-SEP-2003 (first entry)

DE HCV DNAzyme substrate sequence #1906.

XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;

XX RNA stability; RNA expression; RNA synthesis; antisense;

XX enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;

XX amberyze; G-cleaver ribozyme; decoy molecule; aptamer;

XX HBV reverse transcriptase; Enhancer 1 region; viral replication;

XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;

XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;

XX virucide; antiinflammatory; substrate; ss.

OS Hepatitis C virus.

PN WO200281494-A1.

PD 17-OCT-2002.

PF 26-MAR-2002; 2002WO-US009187.

PR 26-MAR-2001; 2001US-00817879.

PR 08-JUN-2001; 2001US-00877478.

PR 08-JUN-2001; 2001US-0296876P.

PR 24-OCT-2001; 2001US-0335059P.

PR 05-DEC-2001; 2001US-0337055P.

PA (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MACE/) MACEJAK D.

PA (MCSW/) MCSWIGEN J.

PA (MORR/) MORRISSEY D.

PA (PVC/) PAVCO P.

PA (LEBP/) LEE P.

PA (DRAP/) DRAPER K.

PA (ROBE/) ROBERTS E.

PI Blatt L, Macejak D, Mcswigen J, Morrissey D, Pavco P, Lee P;

PI Draper K, Roberts E;

DR WPI; 2003-229207/22.

PT Novel compound useful for treating cirrhosis, liver failure,

PT hepatocellular carcinoma, or condition associated with hepatitis C virus

PT infection.

PS Claim 1, Page 268; 387pp; English.

XX The present invention relates to nucleic acid molecules which modulate

XX the synthesis, expression and/or stability of Hepatitis C virus (HCV) or

XX Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense

XX and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,

XX inozymes, zinzymes, amberyzes, and G-cleaver ribozymes. Also disclosed

XX are nucleic acid decoy molecules and aptamers that bind to HBV reverse

XX transcriptase and/or HBV reverse transcriptase primer sequences, as well

XX as oligonucleotides that specifically bind the Enhancer 1 region of HBV

KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 4; Page 151, 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ65520 - ABZ65524,
CC ABZ65530 - ABZ65585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 3 A; 3 C; 7 G; 0 T; 4 U; 0 Other;
XX
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 406 UUAGGGAACUUGGCCUG 422
Db 1 UUAGGGAACUUGGCCUG 17
XX
RESULT 777
ACD63055/C 0.8%; Score 13.8; DB 1; Length 17;
ID ACD63055 standard; RNA; 17 BP.
XX
AC ACD63055;
XX
DT 24-SEP-2003 (first entry)
XX
DB HCV minus strand DNAzyme substrate sequence #862.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense; inozyme; zinzyme;
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; zinzyme;
KW amberyzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis C virus.
XX
PN WO200281494-A1.

XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEBP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P,
PI Draper K, Roberts E;
XX
DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Claim 1; Page 290; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberyzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV. The compounds
CC that modulate the expression and/or replication of HCV, HBV, and compounds
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC invention
XX
SQ Sequence 17 BP; 2 A; 2 C; 9 G; 0 T; 4 U; 0 Other;
XX
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 5.1e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
Qy 508 AUCACGAGCCGCUAC 524
Db 17 ATCACACGAGCCGCTCAC 1
XX
RESULT 778
ACD59614 0.8%; Score 13.8; DB 1; Length 17;
ID ACD59614 standard; RNA; 17 BP.
XX
AC ACD59614;
XX
DT 24-SEP-2003 (first entry)
XX
DB HCV DNAzyme substrate sequence #1416.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;

Best Local Similarity 58.8%; Pred. No. 5.1e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1314 UAGAAGCUCUACGUGCA 1330

DB 1 TAAAGACTTCTCACCTCA 17

RESULT 774

ADB03585

ADB03585 standard; DNA; 17 BP.

AC ADB03585;

DT 20-NOV-2003 (first entry)

DE Human MD27 scanning oligonucleotide SEQ ID 4571.

XX Cytostatic; immunostimulant; gene therapy; vaccine; human;

XX zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;

XX chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;

XX developmental disorder; ss.

XX Homo sapiens.

XX EPI281758-A2.

XX 05-FEB-2003.

XX 30-JUL-2002; 2002EP-00016874.

XX 02-AUG-2001; 2001US-00922181.

XX (AECOM-) AECOMICA INC.

XX Shannon M, Gu Y, Nguyen C;

XX WPI; 2003-423107/40.

XX New zinc finger-containing proteins and nucleic acids, useful in

XX manufacturing a medicament for treating or preventing a disorder

XX associated with decreased or increased expression or activity of MD23,

XX MD24, MD27 or MD212, e.g. cancer.

XX Example 8; SEQ ID NO 4571; 103bp; English.

XX The present invention relates to novel human zinc finger-containing

XX proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is

XX encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,

XX MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome

XX 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,

XX or in manufacturing a medicament for treating or preventing a disorder

XX associated with decreased or increased expression or activity of MD23,

XX MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic

XX acids and proteins are also useful for diagnosing or monitoring a disease

XX caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic

XX acids can also be used as probes to detect and characterize gross

XX alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are

XX useful in constructing microarrays for measuring gene expression. The

XX proteins are useful as therapeutic agents for gene therapy or as

XX vaccines. The present sequence was used to illustrate the invention.

XX Sequence 17 BP; 4 A; 7 C; 1 G; 5 T; 0 U; 0 Other;

QY Query Match 0.8%; Score 13.8; DB 1; Length 17;

XX Best Local Similarity 58.8%; Pred. No. 5.1e+02;

XX Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1313 CUAAGCUCUACGUGC 1329

DB 1 CTAAGACTTCTCACCTC 17

RESULT 775

ABZ64829

ID ABZ64829 standard; RNA; 17 BP.

XX ABZ64829;

XX 21-MAR-2003 (first entry)

XX Human HER2 DNAzyme substrate #286.

XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;

XX enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytoskeletal; anti-HIV;

XX anti-rheumatic; cancer; AIDS; ss.

XX Homo sapiens.

XX WO200297114-A2.

XX 05-DEC-2002.

XX 29-MAY-2002; 2002WO-US016840.

XX 29-MAY-2001; 2001US-0294140P.

XX 06-JUN-2001; 2001US-0296249P.

XX 10-SEP-2001; 2001US-0318471P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Mcswigen J;

XX WPI; 2003-140484/13.

XX Novel short interfering RNA and enzymatic nucleic acid useful for

XX treating cancer, modulates the expression of a nucleic acid encoding

XX HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.

XX Claim 4; Page 138; 185bp; English.

XX The invention relates to a novel short interfering RNA (siRNA) nucleic

XX acid molecule or an enzymatic nucleic acid molecule, that modulates

XX expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,

XX human immunodeficiency virus (HIV) or a component of HIV. The nucleic

XX acid molecule of the invention has cytoskeletal, anti-HIV, and anti-

XX rheumatic activity. The nucleic acid molecules are useful for reducing

XX HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are

XX also useful for treating breast, ovarian, colorectal, lung, prostate,

XX bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences

XX shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,

XX ABZ66530 - ABZ66585 represent substrate/target sequences for the human

XX ribozymes of the invention

XX Sequence 17 BP; 2 A; 3 C; 7 G; 0 T; 5 U; 0 Other;

QY Query Match 0.8%; Score 13.8; DB 1; Length 17;

XX Best Local Similarity 88.2%; Pred. No. 5.1e+02;

XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1626 GUGCUAUGGUCUGUGCA 1642

DB 1 GUGCUAUGGUCUGUGCA 17

RESULT 776

ABZ65495

ID ABZ65495 standard; RNA; 17 BP.

XX ABZ65495;

XX 21-MAR-2003 (first entry)

XX Human HER2 DNAzyme substrate #952.

XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;

therapies such as monoclonal antibodies, RET-A-specific inhibitors or chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate, cyclophosphamide, doxorubin, fluorouracil carboplatin, edotreare, gemetabine or radiation therapy. The enzymatic and antisense nucleic acid molecules are also useful for treating inflammatory disease such as rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft rejection, gene therapy applications, ischaemia/reperfusion injury (central nervous system (CNS) and myocardial), glomerulonephritis, sepsis, allergic airway inflammation, inflammatory bowel disease or infection. This sequence represents the substrate of a novel enzymatic nucleic acid molecule

Sequence 17 BP; 2 A; 10 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 5.1e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

1175 CTGAGAGAGCGGCGG 1191
17 CTGAGAGAGCGCTCGGG 1

RESULT 772

ADB05992
ID ADB05992 standard; DNA; 17 BP.

AC ADB05992;

DT 20-NOV-2003 (first entry)

DE Human MD212 scanning oligonucleotide SEQ ID 6978.

XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
XX zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
XX chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
XX developmental disorder; ss.

OS Homo sapiens.

PN EP1281758-A2.

PD 05-FEB-2003.

PF 30-JUL-2002; 2002EP-00016874.

PR 02-AUG-2001; 2001US-00922181.

PA (AEOM-) AEOMICA INC.

PI Shannon M, Gu Y, Nguyen C;

XX WPI; 2003-423107/40.

DR New zinc finger-containing proteins and nucleic acids, useful in
XX manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
XX MD24, MD27 or MD212, e.g. cancer.

PS Example 8; SEQ ID NO 6978; 103pp; English.

XX The present invention relates to novel human zinc finger-containing
XX proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
XX encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
XX MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
XX 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
XX or in manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
XX MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
XX acids, and proteins are also useful for diagnosing or monitoring a disease
XX caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
XX acids can also be used as probes to detect and characterize gross

alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
XX useful in constructing microarrays for measuring gene expression. The
XX proteins are useful as therapeutic agents for gene therapy or as
XX vaccines. The present sequence was used to illustrate the invention.

Sequence 17 BP; 3 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 5.1e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

1313 CUAAGACUUCGACGUC 1329
1 CTGAGACTTCTGAGGTC 17

RESULT 773

ADB03586
ID ADB03586 standard; DNA; 17 BP.

AC ADB03586;

DT 20-NOV-2003 (first entry)

DE Human MD27 scanning oligonucleotide SEQ ID 4572.

XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
XX zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
XX chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
XX developmental disorder; ss.

OS Homo sapiens.

PN EP1281758-A2.

PD 05-FEB-2003.

PF 30-JUL-2002; 2002EP-00016874.

PR 02-AUG-2001; 2001US-00922181.

PA (AEOM-) AEOMICA INC.

PI Shannon M, Gu Y, Nguyen C;

XX WPI; 2003-423107/40.

DR New zinc finger-containing proteins and nucleic acids, useful in
XX manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
XX MD24, MD27 or MD212, e.g. cancer.

PS Example 8; SEQ ID NO 4572; 103pp; English.

XX The present invention relates to novel human zinc finger-containing
XX proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
XX encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
XX MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
XX 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
XX or in manufacturing a medicament for treating or preventing a disorder
XX associated with decreased or increased expression or activity of MD23,
XX MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
XX acids and proteins are also useful for diagnosing or monitoring a disease
XX caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
XX acids can also be used as probes to detect and characterize gross
XX alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
XX useful in constructing microarrays for measuring gene expression. The
XX proteins are useful as therapeutic agents for gene therapy or as
XX vaccines. The present sequence was used to illustrate the invention.

Sequence 17 BP; 5 A; 6 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

AC ACA06557;
 XX 03-JUN-2003. (first entry)
 XX NFKB sub-unit modulating inozyme substrate #376.
 DE
 XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KM G-cleaver; amberyze; cancer; RBL-A activity; breast cancer; human;
 KM lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KM oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KM cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KM lymphoma; glioma; multidrug resistant cancer; RBL-A-specific inhibitor;
 KM chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KM cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KM gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KM rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischemia;
 KM gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KM transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KM allergic airway inflammation; inflammatory bowel disease; infection; ss.
 XX
 XX Homo sapiens.
 OS
 XX US2002177568-A1.
 PN
 XX 28-NOV-2002.
 XX
 XX 23-MAY-2001; 2001US-00864785.
 PF
 XX 07-DEC-1992; 92US-00987132.
 PR 18-MAY-1994; 94US-00245466.
 PR 15-AUG-1994; 94US-00291932.
 PR 23-DEC-1996; 96US-00777916.
 XX
 XX (STIN/) STINCHOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 PI WPI; 2003-340953/32.
 DR
 XX Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 XX Claim 3; Page 32; 72pp; English.
 PS
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberyze
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating RBL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of RBL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of RBL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, RBL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule
 CC
 CC Sequence 17 BP; 2 A; 9 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 5.1e+02;
 Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 Oy 1174 CCUGAGGAGGAGCUGG 1190
 ||:|||||:|:|
 Db 17 CCGAGGAGGCGCTGG 1
 RESULT 771
 ACA06556/c
 ID ACA06556 standard; RNA; 17 BP.
 XX
 AC ACA06556;
 XX
 XX 03-JUN-2003 (first entry)
 DT
 XX NFKB sub-unit modulating inozyme substrate #375.
 DE
 XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KM G-cleaver; amberyze; cancer; RBL-A activity; breast cancer; human;
 KM lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KM oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KM cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KM lymphoma; glioma; multidrug resistant cancer; RBL-A-specific inhibitor;
 KM chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KM cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KM gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KM rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischemia;
 KM gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KM transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KM allergic airway inflammation; inflammatory bowel disease; infection; ss.
 XX
 XX Homo sapiens.
 OS
 XX US2002177568-A1.
 PN
 XX 28-NOV-2002.
 XX
 XX 23-MAY-2001; 2001US-00864785.
 PF
 XX 07-DEC-1992; 92US-00987132.
 PR 18-MAY-1994; 94US-00245466.
 PR 15-AUG-1994; 94US-00291932.
 PR 23-DEC-1996; 96US-00777916.
 XX
 XX (STIN/) STINCHOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 PI WPI; 2003-340953/32.
 DR
 XX Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 XX Claim 3; Page 32; 72pp; English.
 PS
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberyze
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating RBL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of RBL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of RBL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug

XX Sequence 17 BP; 4 A; 6 C; 5 G; 0 T; 2 U; 0 Other;
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 252 CGGCAACAUCCUGGUA 268
Db 1 CGGCAACAGCTCGGCA 17
RESULT 764
ID ACN12490
ACN12490 standard; RNA; 17 BP.
XX ACN12490;
XX 22-APR-2004 (first entry)
XX
XX MNV minus strand Zinzyme substrate SEQ ID NO 12493.
XX
XX MNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGEN J A.
XX
XX Blatt L, Mcswigen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (MNV), useful for treating a condition related to MNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 12493; 495bp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (MNV). The nucleic acid molecules are useful for
XX treating a condition related to MNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
XX Sequence 17 BP; 5 A; 5 C; 6 G; 0 T; 1 U; 0 Other;
QY Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 960 GAAACCGAGCCGAGC 976
Db 1 GAAAGCGAGCTCGGAGC 17
RESULT 765
ID ACN01779/c
ACN01779 standard; RNA; 17 BP.
XX ACN01779;
XX
XX 22-APR-2004 (first entry)
XX
XX MNV Inozyme substrate SEQ ID NO 1769.
XX
XX
XX MNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGEN J A.
XX
XX Blatt L, Mcswigen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (MNV), useful for treating a condition related to MNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 1769; 495bp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (MNV). The nucleic acid molecules are useful for
XX treating a condition related to MNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
XX Sequence 17 BP; 4 A; 3 C; 5 G; 0 T; 5 U; 0 Other;
QY Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 5.1e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 1369 UCCUUCAGGAGCCAC 1385
Db 17 TCGTTCATGAGCCAC 1
RESULT 766
ACN05337/c

CC The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention

CC Sequence 17 BP; 7 A; 0 C; 7 G; 0 T; 3 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 47.1%; Pred. No. 5.1e+02;
 Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

OY 32 CUUGUUUCCAAACAU 48
 DB 17 CTTCTTCCAAACCTC 1

RESULT 762
 ACN00273/C
 ID ACN00273 standard; RNA; 17 BP.
 ACN00273;
 ACN00273;
 22-APR-2004 (first entry)

WNV Hammerhead Ribozyme substrate SEQ ID NO 263.

WNV, West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 virucide; neuroprotective; antibacterial; replication; pancreatitis;
 encephalitis; myocarditis; meningitis; infection; hepatitis;
 liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 Amberzyme; Zinzyme; ss.

West Nile Virus.

MO200268637-A2.

06-SEP-2002.

19-OCT-2001; 2001WO-US048350.

20-OCT-2000; 2000US-0242411P.

(RIBO-) RIBOZYME PHARM INC.
 (BLAT/) BLATT L.
 (MCSW/) MCSWIGEN J A.

Blatt L, Mcswigen JA;

WPI; 2002-706994/76.

New nucleic acid molecule that modulates replication of West Nile Virus
 (WNV), useful for treating a condition related to WNV infection e.g.
 pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

Claim 23; SEQ ID NO 263; 495bp; English.

The invention relates to nucleic acid molecules that modulate replication
 of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 treating a condition related to WNV infection e.g. pancreatitis,
 encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 molecule is selected from the group of ribozymes consisting of
 Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The

CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention

CC Sequence 17 BP; 4 A; 3 C; 5 G; 0 T; 5 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 5.1e+02;
 Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

OY 1370 CCUUCAGGAGCCACU 1386
 DB 17 CGTTCATGAGCCACT 1

RESULT 763
 ACN04254
 ID ACN04254 standard; RNA; 17 BP.
 ACN04254;
 ACN04254;
 22-APR-2004 (first entry)

WNV Zinzyme substrate SEQ ID NO 4257.

WNV, West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 virucide; neuroprotective; antibacterial; replication; pancreatitis;
 encephalitis; myocarditis; meningitis; infection; hepatitis;
 liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 Amberzyme; Zinzyme; ss.

West Nile Virus.

MO200268637-A2.

06-SEP-2002.

19-OCT-2001; 2001WO-US048350.

20-OCT-2000; 2000US-0242411P.

(RIBO-) RIBOZYME PHARM INC.
 (BLAT/) BLATT L.
 (MCSW/) MCSWIGEN J A.

Blatt L, Mcswigen JA;

WPI; 2002-706994/76.

New nucleic acid molecule that modulates replication of West Nile Virus
 (WNV), useful for treating a condition related to WNV infection e.g.
 pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

Claim 23; SEQ ID NO 4257; 495bp; English.

The invention relates to nucleic acid molecules that modulate replication
 of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 treating a condition related to WNV infection e.g. pancreatitis,
 encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 molecule is selected from the group of ribozymes consisting of
 Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention

PA (RIBO-) RIBOZYME PHARM INC.
PT (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (MNV), useful for treating a condition related to MNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 8069; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 3 A; 7 C; 0 G; 0 T; 7 U; 0 Other;
XX
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 32 CUUUCUUUCCAAACAC 48
DB 1 CUUUCUUUCCAAACCC 17
XX
RESULT 760
ACN14064
ID ACN14064 standard; RNA; 17 BP.
XX
AC ACN14064;
XX
DT 22-APR-2004 (first entry)
XX
DE MNV minus strand DNazyme substrate SEQ ID NO 14067.
XX
XX MNV, West Nile Virus; antiinflammatory; cytosstatic; hepatotropic;
KM virucide; neuroprotective; antibacterial; replication; pancreatitis;
KM encephalitis; myocarditis; infection; hepatitis;
KM liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KM Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PP 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
PS WPI; 2002-706994/76.
XX

XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (MNV), useful for treating a condition related to MNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 14067; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
CC treating a condition related to MNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 5 A; 4 C; 4 G; 0 T; 4 U; 0 Other;
XX
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1368 GUCCUUCAGAGAGCCA 1384
DB 1 GUCCUUCAGAGAGCCA 17
XX
RESULT 761
ACN06766/C
ID ACN06766 standard; RNA; 17 BP.
XX
AC ACN06766;
XX
DT 22-APR-2004 (first entry)
XX
DE MNV Amberzyme substrate SEQ ID NO 6769.
XX
XX MNV, West Nile Virus; antiinflammatory; cytosstatic; hepatotropic;
KM virucide; neuroprotective; antibacterial; replication; pancreatitis;
KM encephalitis; myocarditis; infection; hepatitis;
KM liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KM Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PP 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
PS WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (MNV), useful for treating a condition related to MNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 6769; 495pp; English.
XX

PD 14-FEB-2002.
 XX
 PF 09-AUG-2001; 2001WO-US024970.
 XX
 PR 09-AUG-2000; 2000US-0224383P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX (SYNT) SYNTAX USA LLC.
 PA (THOM/) THOMPSON J.
 XX
 PI Thompson J, Mcswigen J, McKenzie T, Ayers D, Szymkowski DE;
 PI Grube A;
 XX
 DR MPI; 2002-217145/27.
 XX
 PT Enzymatic polynucleotide that down regulates expression of chloride
 PT channel calcium activated gene, useful for treating Chronic obstructive
 PT pulmonary disease (COPD), chronic bronchitis and asthma.
 XX
 PS Claim 4; Page 88; 152pp; English.
 XX
 CC The invention relates to enzymatic nucleic acid molecules that down
 CC regulate expression of chloride channel calcium activated 1 (ClCA1) genes
 CC by cleaving RNA derived from the genes. The nucleic acid sequences are
 CC useful as pharmaceutical agents for treating conditions such as chronic
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that are related to or will respond to the levels of ClCA1 in a cell or
 CC tissue. The sequences are useful for reducing ClCA1 activity in a cell,
 CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of ClCA1, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ClCA1 RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention
 CC
 SQ Sequence 17 BP; 5 A; 3 C; 2 G; 0 T; 7 U; 0 Other;
 QY
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 DB 358 AUUUCAGUAUCUGUU 374
 1 AGUUCAGUAUCUCUU 17
 RESULT 758
 ABE57457
 ID ABE57457 standard; RNA; 17 BP.
 XX
 AC ABE57457;
 XX
 DT 02-JUL-2002 (first entry)
 XX
 DE Human ClCA1 gene enzymatic nucleic acid #1828.
 XX
 KW Human; chloride channel calcium activated 1; ClCA1; ss; antisatmatic;
 KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
 KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
 KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
 KW acetylcysteine.
 XX
 OS Homo sapiens.
 XX
 PN WO20021674-A2.
 XX
 PD 14-FEB-2002.
 XX
 PF 09-AUG-2001; 2001WO-US024970.

XX
 PR 09-AUG-2000; 2000US-0224383P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX (SYNT) SYNTAX USA LLC.
 PA (THOM/) THOMPSON J.
 XX
 PI Thompson J, Mcswigen J, McKenzie T, Ayers D, Szymkowski DE;
 PI Grube A;
 XX
 DR MPI; 2002-217145/27.
 XX
 PT Enzymatic polynucleotide that down regulates expression of chloride
 PT channel calcium activated gene, useful for treating Chronic obstructive
 PT pulmonary disease (COPD), chronic bronchitis and asthma.
 XX
 PS Claim 4; Page 113; 152pp; English.
 XX
 CC The invention relates to enzymatic nucleic acid molecules that down
 CC regulate expression of chloride channel calcium activated 1 (ClCA1) genes
 CC by cleaving RNA derived from the genes. The nucleic acid sequences are
 CC useful as pharmaceutical agents for treating conditions such as chronic
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that are related to or will respond to the levels of ClCA1 in a cell or
 CC tissue. The sequences are useful for reducing ClCA1 activity in a cell,
 CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of ClCA1, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ClCA1 RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention
 CC
 SQ Sequence 17 BP; 5 A; 4 C; 1 G; 0 T; 7 U; 0 Other;
 QY
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 DB 360 UUCAUGAUAUCUGUUA 376
 1 UUCAUGAUAUCUCUUA 17
 RESULT 759
 ACN08066
 ID ACN08066 standard; RNA; 17 BP.
 XX
 AC ACN08066;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8069.
 XX
 KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; Dnazyme;
 KW Amberzyme; Zinzyme; ss.
 XX
 OS West Nile Virus.
 XX
 PN WO200268637-A2.
 XX
 PD 06-SEP-2002.
 XX
 PF 19-OCT-2001; 2001WO-US048350.
 XX
 PR 20-OCT-2000; 2000US-0242411P.

KM contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;
KM dysgenetic pregnancy; primer; ss.
XX
OS Homo sapiens.
XX
PN US2002102252-A1.
XX
PD 01-AUG-2002.
XX
PF 06-APR-2001; 2001US-00827998.
XX
PR 26-MAY-2000; 2000US-0207456P.
XX
PA (GUYX/) GU Y.
XX (SHAN/) SHANNON M E.
XX
PI Gu Y, Shannon ME;
XX
DR WPI; 2002-697817/75.
XX
PT New isolated nucleic acid encoding an isoform of human pregnancy
XX associated plasma protein E, for preventing or aborting pregnancy.
XX
PS Example 2; Page 158; 353pp; English.
XX
CC This invention describes a novel isolated nucleic acid that encodes one
XX of three new isoforms of human pregnancy associated plasma protein E,
XX hPAP-E. The products of the invention have abortive and contraceptive
XX activity and can be used for gene therapy or in a vaccine. The nucleic
XX acid, polypeptide encoded by it, or antibody to the polypeptide can be
XX used in pharmaceutical compositions or vaccines for preventing or
XX aborting pregnancy. PAP-E is used in the antenatal diagnosis of
XX dysgenetic pregnancies. The nucleic acids are used as probes to assess
XX the level of PAP-E isoform mRNA in chorionic villus samples, and the
XX antibodies can be used to assess the expression levels of PAP-E isoform
XX proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
XX antenatally. This sequence represents an oligomer used in scanning the
XX human PAP-E genes described in the disclosure of the invention
XX
SQ Sequence 17 BP; 4 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 5.1e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
QY 1674 GCUGCUGCCAGCUG 1690
DB 17 GCCGCTCTGCAGTGTG 1
XX
RESULT 756
ABV90085
ID ABV90085 standard; DNA; 17 BP.
XX
AC ABV90085;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 798.
XX
KM Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KM Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KM gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EP1239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
XX

PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Shannon M;
XX
DR WPI; 2002-684061/74.
XX
XX
PT Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 798; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
XX protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
XX acids (SI, ABB83999), a sequence having 65% sequence identity to (S1),
XX (S1) having 95% deviations, especially conservative substitutions or a
XX fragment of the sequences comprising at least 8 contiguous amino acids.
XX Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
XX adaptor protein that interacts with Rho family small GTPases as well as
XX downstream components of the signal transduction pathway. (I) is useful
XX for identifying a specific binding partner. (I) and nucleic acids (II)
XX encoding (I) are useful for diagnosing, monitoring disease and treating
XX caused by altered expression of human POSHL1 including diagnosing and
XX treating cancer, they useful in the development of vaccines and (II) is
XX useful in gene therapy. (II) is useful for constructing microarrays which
XX are useful for measuring and for surveying gene expression and creating
XX transgenic non-human animals capable of producing the proteins. The
XX present sequence is that of a scanning oligonucleotide useful in examples
XX of the invention. Note: The present sequence did not form part of the
XX printed specification, but is based on sequence information supplied to
XX Derwent by the European Patent Office
XX
SQ Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 5.1e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 281 AGGUCACAAGCAGCUG 297
DB 1 AAGTCATCAAGCAGCTG 17
XX
RESULT 757
ABK56975
ID ABK56975 standard; RNA; 17 BP.
XX
AC ABK56975;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #1346.
XX
KM Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KM antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KM chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KM oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KM acetylcysteine.
XX
OS Homo sapiens.
XX
PN WO200211674-A2.
XX

PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 PA Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI WPI; 2002-179446/23.
 DR
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption/ionization, comprises human myosin-like protein hGDMLP-1.
 XX
 PS Disclosure; SEQ ID NO 2301; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionization, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 4 A; 8 C; 4 G; 1 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 5.1e+02;
 Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 990 CCAAGCAGCAGGACA 1006
 Db 1 CCAAGCAGCAGGACA 17
 RESULT 754
 AB064199/c
 ID AB064199 standard; DNA; 17 BP.
 XX
 AC AB064199;
 XX
 DT 20-AUG-2002 (first entry)
 XX
 DE Human KTOM1a portion (AB063232) probe # 912.
 XX
 KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytoskeletal;
 KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;

KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
 XX
 OS Homo sapiens.
 PN WO200224750-A2.
 PD 28-MAR-2002.
 XX
 PF 21-SEP-2001; 2001WO-US029656.
 XX
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 28-AUG-2001; 2001US-0315676P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Zhang J;
 DR WPI; 2002-479509/51.
 XX
 PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
 PT acids encoding the protein, useful for treating subjects having defects
 PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
 PT e.g., liver or bone.
 XX
 PS Example 2; Page 277; 418pp; English.
 XX
 CC The invention relates to a novel isolated nucleic acid encoding human
 CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
 CC invention has cytoskeletal activity. The nucleotide may have a use in gene
 CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
 CC monitor a disease caused by altered expression of human KTOM1.
 CC Compositions comprising the nucleic acids, proteins or antibodies may be
 CC used to treat subjects having defects in KTOM1 which can manifest as
 CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
 CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
 CC function. The sequence represents a probe used in the invention to scan
 CC the nt 1-1001 portion of human KTOM1a (AB063232)
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 64.7%; Pred. No. 5.1e+02;
 Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 1280 UGCCAUCGAGGAG 1296
 Db 17 TTCCTCCAGGAGG 1
 RESULT 755
 AB075110/c
 ID AB075110 standard; DNA; 17 BP.
 XX
 AC AB075110;
 XX
 DT 24-DEC-2002 (first entry)
 XX
 DE Human PAPP-Ba associated 17-mer SEQ ID 636.
 XX
 KW PAPP-B; human; pregnancy associated plasma protein B; abortive;

CC molecules (e.g. ribozymes) to modulate gene expression. The invention
CC also methods for their use to down regulate or inhibit the expression of
CC gene encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine
CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
CC receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC nucleic acid molecules used to inhibit the expression of the said genes
CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
CC zincyme, and/or DNAzyme motifs. The methods of the invention are useful
CC for treating cancer, in particular breast cancer, Alzheimer's disease,
CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC diseases, hepatitis B infections, and hepatitis and hepatocellular
CC carcinoma. The enzymatic nucleic acid molecules can also be used as
CC diagnostic tools to examine genetic drift and mutations within diseased
CC cells and to detect the presence of specific RNA in a cell. The present
CC sequence represents a substrate/target sequence for a DNAzyme used in the
CC examples of the present invention. Note: Some SEQ ID Nos are repeated
CC more than once in the specification, but these have different sequences
CC associated with them.

CC
XX Sequence 17 BP; 7 A; 3 C; 6 G; 0 T; 1 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 58.8%; Pred. No. 5.1e+02;

Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 594 CCUUGGCGUCUGCCA 610

DB 17 CCTTGGGCTTCCCA 1

RESULT 752

ADN09199

ID ADN09199 standard; RNA; 17 BP.

AC ADN09199;

XX 10-FEB-2005 (first entry)

XX Human PTP-1B DNAzyme substrate sequence #185.

DE Enzymatic nucleic acid molecule; gene expression; down regulation;

KM protein-tyrosine-phosphatase-1b; PTB-1b; methionine aminopeptidase;

KM MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;

KM beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;

KM c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;

KM hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;

KM amberzyme; zincyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;

KM diabetes; obesity; cardiac disease; heart disease; age-related disease;

KM hepatitis B infection; hepatocellular carcinoma; genetic drift; human;

KM ss.

OS Homo sapiens.

XX WO200116312-A2.

XX 08-MAR-2001.

XX 30-AUG-2000; 2000WO-US02398.

XX 31-AUG-1999; 99US-0151713P.

XX 27-SEP-1999; 99US-0040664J.

XX 27-SEP-1999; 99US-0156236P.

XX 08-NOV-1999; 99US-0156467P.

XX 06-DEC-1999; 99US-0169100P.

XX 29-DEC-1999; 99US-0047443J.

XX 29-DEC-1999; 99US-0173612P.

XX 30-DEC-1999; 99US-0047638J.

XX 04-FEB-2000; 2000US-0049882J.

XX 20-MAR-2000; 2000US-0053102S.

XX 14-APR-2000; 2000US-0197769P.

PR 23-MAY-2000; 2000US-0057822J.

PR 09-AUG-2000; 2000US-0063638S.

XX (RIBO-) RIBOZYME PHARM INC.

PA Meswigen J, Usman N, Blatt L, Beigelman L, Burgin A;

PI Karpelsky A, Matulic-Adamic J, Swedler D, Draper K, Chowrira B;

PI Stinchcomb D, Beaudry A, Zimnen S, Ludwig J, Sprout BS;

PI WPI; 2001-244406/25.

DR Enzymatic nucleic acid molecules able to cleave separate RNA molecules

XX are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,

XX obesity and heart disease.

PT Example 2; Page 220; 717pp; English.

XX The present invention relates to the use of enzymatic nucleic acid

XX molecules (e.g. ribozymes) to modulate gene expression. The invention

XX also methods for their use to down regulate or inhibit the expression of

XX genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine

XX C aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase

XX alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor

XX receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),

XX presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic

XX nucleic acid molecules used to inhibit the expression of the said genes

XX include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,

XX zincyme, and/or DNAzyme motifs. The methods of the invention are useful

XX for treating cancer, in particular breast cancer, Alzheimer's disease,

XX diabetes, obesity, cardiac diseases e.g. heart disease, age-related

XX diseases, hepatitis B infections, and hepatitis and hepatocellular

XX carcinoma. The enzymatic nucleic acid molecules can also be used as

XX diagnostic tools to examine genetic drift and mutations within diseased

XX cells and to detect the presence of specific RNA in a cell. The present

XX sequence represents a substrate/target sequence for a DNAzyme used in the

XX examples of the present invention. Note: Some SEQ ID Nos are repeated

XX more than once in the specification, but these have different sequences

XX associated with them.

XX Sequence 17 BP; 4 A; 7 C; 5 G; 0 T; 1 U; 0 Other;

QY Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 5.1e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1209 GAAAGCGACCACTGCG 1225

DB 1 GACAGCGACGACGACGUCG 17

RESULT 753

ABN02309

ID ABN02309 standard; DNA; 17 BP.

AC ABN02309;

XX 29-MAY-2002 (first entry)

XX Human GDMUP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2301.

XX Human; genome-derived myosin-like protein 1; GDMUP-1; hGDMUP-1; heart;

XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

XX skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO2001192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.

AC ADV64685;
 XX
 DT 10-FEB-2005 (first entry)
 XX
 DE Human Her2 class II (zincyme) ribozyme substrate sequence #573.
 XX
 KW Enzymatic nucleic acid molecule; gene expression; down regulation;
 KW protein-tyrosine-phosphatase-1b; PTP-1B; methionine aminopeptidase;
 KW MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
 KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
 KW c-erbB2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
 KW hepatitis B virus; HBV; hammethead; HH; hairpin; NCH; zincyme; G-cleaver;
 KW amberyzyme; zincyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
 KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
 KW hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
 KW ss.
 XX Homo sapiens.
 OS
 XX WO200116312-A2.
 PN
 PD 08-MAR-2001.
 XX
 PF 30-AUG-2000; 2000WO-US023998.
 XX
 PR 31-AUG-1999; 99US-0151713P.
 PR 27-SEP-1999; 99US-00406643.
 PR 27-SEP-1999; 99US-0156236P.
 PR 27-SEP-1999; 99US-0156467P.
 PR 08-NOV-1999; 99US-00436430.
 PR 06-DEC-1999; 99US-0169100P.
 PR 29-DEC-1999; 99US-00474432.
 PR 29-DEC-1999; 99US-0173612P.
 PR 30-DEC-1999; 99US-00476387.
 PR 04-FEB-2000; 2000US-00498824.
 PR 20-MAR-2000; 2000US-00531025.
 PR 14-APR-2000; 2000US-0197769P.
 PR 23-MAY-2000; 2000US-00578223.
 PR 09-AUG-2000; 2000US-00636385.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswigen J, Usman N, Blatt L, Belgelman L, Burgin A;
 PI Karpelsky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B;
 PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
 XX
 DR WPI; 2001-244406/25.
 XX
 PT Enzymatic nucleic acid molecules able to cleave separate RNA molecules
 PT are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
 PT obesity and heart disease.
 XX
 PS Example 16; Page 635; 717pp; English.
 XX
 CC The present invention relates to the use of enzymatic nucleic acid
 CC molecules (e.g. ribozymes) to modulate gene expression. The invention
 CC also methods for their use to down regulate or inhibit the expression of
 CC genes encoding protein-tyrosine-phosphatase-1b (PTP-1B), methionine C
 CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
 CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
 CC receptor-2 (HER2/C-erbB2/neu), phospholamban (PLN), presenilin-1 (ps-1),
 CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
 CC nucleic acid molecules used to inhibit the expression of the said genes
 CC include hammethead (HH), hairpin, NCH (zincyme), G-cleaver, amberyzyme,
 CC zincyme, and/or DNAzyme motifs. The methods of the invention are useful
 CC for treating cancer, in particular breast cancer, Alzheimer's disease,
 CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
 CC diseases, hepatitis B infections, and hepatitis and hepatocellular
 CC carcinoma. The enzymatic nucleic acid molecules can also be used as
 CC diagnostic tools to examine genetic drift and mutations within diseased
 CC cells and to detect the presence of specific RNA in a cell. The present
 CC sequence represents a substrate/target sequence for a ribozyme used in
 CC the examples of the present invention. Note: Some SEQ ID Nos are repeated

CC more than once in the specification, but these have different sequences
 CC associated with them.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 7 G; 0 T; 4 U; 0 Other;
 XX
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 5.1e-02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 406 UUAGGGAACUUGCCUG 422
 DB 1 UUAGGGAACUUGCCUG 17
 RESULT 751
 ADN08955/c
 ID ADN08955 standard; RNA; 17 BP.
 XX
 AC ADN08955;
 XX
 DT 10-FEB-2005 (first entry)
 XX
 DE Human PTP-1B DNAzyme substrate sequence #65.
 XX
 KW Enzymatic nucleic acid molecule; gene expression; down regulation;
 KW protein-tyrosine-phosphatase-1b; PTP-1B; methionine aminopeptidase;
 KW MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
 KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
 KW c-erbB2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
 KW hepatitis B virus; HBV; hammethead; HH; hairpin; NCH; zincyme; G-cleaver;
 KW amberyzyme; zincyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
 KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
 KW hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
 KW ss.
 XX Homo sapiens.
 OS
 XX WO200116312-A2.
 PN
 PD 08-MAR-2001.
 XX
 PF 30-AUG-2000; 2000WO-US023998.
 XX
 PR 31-AUG-1999; 99US-0151713P.
 PR 27-SEP-1999; 99US-00406643.
 PR 27-SEP-1999; 99US-0156236P.
 PR 27-SEP-1999; 99US-0156467P.
 PR 08-NOV-1999; 99US-00436430.
 PR 06-DEC-1999; 99US-0169100P.
 PR 29-DEC-1999; 99US-00474432.
 PR 29-DEC-1999; 99US-0173612P.
 PR 30-DEC-1999; 99US-00476387.
 PR 04-FEB-2000; 2000US-00498824.
 PR 20-MAR-2000; 2000US-00531025.
 PR 14-APR-2000; 2000US-0197769P.
 PR 23-MAY-2000; 2000US-00578223.
 PR 09-AUG-2000; 2000US-00636385.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswigen J, Usman N, Blatt L, Belgelman L, Burgin A;
 PI Karpelsky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B;
 PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
 XX
 DR WPI; 2001-244406/25.
 XX
 PT Enzymatic nucleic acid molecules able to cleave separate RNA molecules
 PT are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
 PT obesity and heart disease.
 XX
 PS Example 2; Page 216; 717pp; English.
 XX
 CC The present invention relates to the use of enzymatic nucleic acid

PR	14-APR--2000;	2000US-0197769P.
PR	23-MAY--2000;	2000US-0057822Z.
PR	09-AUG--2000;	2000US-0063638S.
XX		
PA	(RIBO-) RIBOZYME PHARM INC.	
XX		
PI	Mcgwigen J, Usman N, Blatt L, Beigelman L, Burgin A,	
PI	Karpelsky A, Matulich-Adamic J, Sweedler D, Draper K, Chowrira B,	
PI	Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sprout BS;	
DR	WPI; 2001-244406/25.	
XX		
PT	Enzymatic nucleic acid molecules able to cleave separate RNA molecules	
PT	are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,	
PS	obesity and heart disease.	
XX		
PS	Example 16; Page 630; 717pp; English.	
XX		
CC	The present invention relates to the use of enzymatic nucleic acid	
CC	molecules (e.g. ribozymes) to modulate gene expression. The invention	
CC	also methods for their use to down regulate or inhibit the expression of	
CC	genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine	
CC	aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C	
CC	alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor	
CC	receptor-2 (HER2/c-erbB2/neu), phospholamban (PLN), presenilin-1 (ps-1),	
CC	presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic	
CC	nucleic acid molecules used to inhibit the expression of the said genes	
CC	include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,	
CC	zincyme, and/or DNAzyme motifs. The methods of the invention are useful	
CC	for treating cancer, in particular breast cancer, Alzheimer's disease,	
CC	diabetes, obesity, cardiac diseases e.g. heart disease, age-related	
CC	diseases, hepatitis B infections, and hepatitis and hepatocellular	
CC	carcinoma. The enzymatic nucleic acid molecules can also be used as	
CC	diagnostic tools to examine genetic drift and mutations within diseased	
CC	cells and to detect the presence of specific RNA in a cell. The present	
CC	sequence represents a substrate/target sequence for a ribozyme used in	
CC	the examples of the present invention. Note: Some SEQ ID Nos are repeated	
CC	more than once in the specification, but these have different sequences	
CC	associated with them.	
XX		
SQ	Sequence 17 BP; 2 A; 3 C; 7 G; 0 T; 5 U; 0 Other;	
	Query Match	0.8%; Score 13.8; DB 1; Length 17;
	Best Local Similarity	88.2%; Pred. No. 5.1e+02;
	Matches 15; Conservative	0; Mismatches 2; Indels 0; Gaps 0;
OY	1626 GUGCUAUGCUCUUGUCA 1642	
D8	1 GUGCUAUGCUCUGGCA 17	
RESULT 749		
ADM81480		
ID	ADM81480 standard; DNA; 17 BP.	
XX		
AC	ADM81480;	
XX		
DT	10-FEB-2005 (first entry)	
XX		
DB	Human PTP-1B hammerhead ribozyme substrate sequence #188.	
XX		
KM	Enzymatic nucleic acid molecule; gene expression; down regulation;	
KM	protein-tyrosine-phosphatase-1b; PTB-1B; methionine aminopeptidase;	
KM	MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;	
KM	beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;	
KM	c-erbB2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;	
KM	hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;	
KM	amberzyme; zincyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;	
KM	diabetes; obesity; cardiac disease; heart disease; age-related disease;	
KM	hepatitis B infection; hepatocellular carcinoma; genetic drift; human;	
KM	ds.	
XX		
OS	Homo sapiens	

```

XX XX WO200116312-A2.
XX PN
XX PD
XX PF 08-MAR-2001.
XX PP 30-AUG-2000; 2000WO-US023998.
XX PR 31-AUG-1999; 99US-0151713P.
XX PR 27-SEP-1999; 99US-00406643.
XX PR 27-SEP-1999; 99US-0156236P.
XX PR 27-SEP-1999; 99US-0156467P.
XX PR 08-NOV-1999; 99US-00436430.
XX PR 06-DEC-1999; 99US-0169100P.
XX PR 29-DEC-1999; 99US-0047443Z.
XX PR 29-DEC-1999; 99US-0173612P.
XX PR 30-DEC-1999; 99US-00476387.
XX PR 04-FEB-2000; 2000US-00498824.
XX PR 20-MAR-2000; 2000US-0053102S.
XX PR 14-APR-2000; 2000US-0197769P.
XX PR 23-MAY-2000; 2000US-00578223.
XX PR 09-AUG-2000; 2000US-00636385.
XX PA
XX PB (RIBO-) RIBOZYME PHARM INC.
XX PI Mcwigen J, Ueman N, Blatt L, Beigelman L, Burgin A,
XX PI Karpelsky A, Matulich-Adamic J, Swedler D, Draper K, Chowitra B,
XX PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sprout BS;
XX DR WPI; 2001-244406/25.
XX DX
XX PY Enzymatic nucleic acid molecules able to cleave separate RNA molecules
XX PT are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
XX PT obesity and heart disease.
XX PS Example 2; Page 184; 717pp; English.
XX CC The present invention relates to the use of enzymatic nucleic acid
XX CC molecules (e.g. ribozymes) to modulate gene expression. The invention of
XX CC also methods for their use to down regulate or inhibit the expression of
XX CC genes encoding protein-tyrosine-phosphatase-1b (PTN-1B), methionine
XX CC aminopeptidase (MecP-2), human telomerase (hTERT), protein kinase C
XX CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
XX CC receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
XX CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
XX CC nucleic acid molecules used to inhibit the expression of the said genes
XX CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
XX CC zincyme, and/or DNAzyme motifs. The methods of the invention are useful
XX CC for treating cancer. In particular breast cancer, Alzheimer's disease,
XX CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
XX CC diseases, hepatitis B infections, and hepatitis and hepatocellular
XX CC carcinoma. The enzymatic nucleic acid molecules can also be used as
XX CC diagnostic tools to examine genetic drift and mutations within diseased
XX CC cells and to detect the presence of specific RNA in a cell. The present
XX CC sequence represents a substrate/target sequence for a ribozyme used in
XX CC the examples of the present invention. Note: Some SEQ ID Nos are repeated
XX CC more than once in the specification, but these have different sequences
XX CC associated with them.
XX SQ Sequence 17 BP; 3 A; 11 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 70.6%; Pred. No. 5.1e+02;
XX Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1126 ACCGATCCCAACGCCAC 1142
XX Db 1 ACCCTCCGCACCTCCAC 117
XX
XX RESULT 750
XX ADV64685
XX ID ADV64685 standard; RNA; 17 BP.
XX

```

CC sequence represents a substrate/target sequence for a ribozyme used in
CC the examples of the present invention. Note: Some SEQ ID Nos are repeated
CC more than once in the specification, but these have different sequences
CC associated with them.
XX
SQ Sequence 17 BP; 2 A; 12 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 5.1e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 1127 CCATCCCAACACCCAC 1143
DB 1 CCTCTCCATCTCCAC 17
RESULT 747
ADV38943/C
ID ADV38943 standard; DNA; 17 BP.
AC ADV38943;
XX
XX 10-FEB-2005 (first entry)
XX
DE HBV hammerhead ribozyme substrate sequence #622.
XX
XX Enzymatic nucleic acid molecule; gene expression; down regulation;
XX protein-tyrosine-phosphatase-1b; PTB-1b; methionine aminopeptidase;
XX MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
XX beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
XX c-erbB2; neu; phospholamban; PLN; presenilin-1; ps-1; inosyme; G-cleaver;
XX hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inosyme; G-cleaver;
XX amberyzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
XX diabetes; obesity; cardiac disease; heart disease; age-related disease;
XX hepatitis B infection; hepatocellular carcinoma; genetic drift; ds.
XX
OS Hepatitis B virus.
XX
XX WO200116312-A2.
XX
XX 08-MAR-2001.
XX
XX 30-AUG-2000; 2000WO-US023998.
XX
XX 31-AUG-1999; 99US-0151713P.
XX 27-SEP-1999; 99US-00406643.
XX 27-SEP-1999; 99US-0156236P.
XX 27-SEP-1999; 99US-0156467P.
XX 08-NOV-1999; 99US-00436430.
XX 06-DEC-1999; 99US-0169100P.
XX 29-DEC-1999; 99US-00474432.
XX 29-DEC-1999; 99US-0173612P.
XX 30-DEC-1999; 99US-00476387.
XX 04-FEB-2000; 2000US-00498824.
XX 20-MAR-2000; 2000US-00531025.
XX 14-APR-2000; 2000US-0197769P.
XX 23-MAY-2000; 2000US-00578223.
XX 09-AUG-2000; 2000US-00636385.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX McSwiggan J, Ueman N, Blatt L, Beigelman L, Burgin A,
XX Karpelshy A, Matulic-Adamic J, Svedler D, Draper K, Chowrira B,
XX Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
XX
XX WPI; 2001-244406/25.
XX
XX Enzymatic nucleic acid molecules able to cleave separate RNA molecules
XX are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
XX obesity and heart disease.
XX
XX Example 6; Page 513; 717pp; English.

CC The present invention relates to the use of enzymatic nucleic acid
CC molecules (e.g. ribozymes) to modulate gene expression. The invention of
CC also methods for their use to down regulate or inhibit the expression of
CC genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine
CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
CC receptor-2 (HER2/c-erbB2/neu), phospholamban (PLN), presenilin-1 (ps-1),
CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC nucleic acid molecules used to inhibit the expression of the said genes
CC include hammerhead (HH), hairpin, NCH (inosyme), G-cleaver, amberyzyme,
CC zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
CC for treating cancer, in particular breast cancer, Alzheimer's disease,
CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC diseases, hepatitis B infections, and hepatitis and hepatocellular
CC carcinoma. The enzymatic nucleic acid molecules can also be used as
CC diagnostic tools to examine genetic drift and mutations within diseased
CC cells and to detect the presence of specific RNA in a cell. The present
CC sequence represents a substrate/target sequence for a ribozyme used in
CC the examples of the present invention. Note: Some SEQ ID Nos are repeated
CC more than once in the specification, but these have different sequences
CC associated with them.
XX
SQ Sequence 17 BP; 4 A; 4 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 5.1e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
QY 828 GACAGAAAACUUDGCC 844
DB 17 GACAGAAAAGATTGTCC 1
RESULT 748
ADV64213
ID ADV64213 standard; RNA; 17 BP.
AC ADV64213;
XX
XX 10-FEB-2005 (first entry)
XX
XX Human Her2 class II (zinzyme) ribozyme substrate sequence #336.
XX
XX Enzymatic nucleic acid molecule; gene expression; down regulation;
XX protein-tyrosine-phosphatase-1b; PTB-1b; methionine aminopeptidase;
XX MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
XX beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
XX c-erbB2; neu; phospholamban; PLN; presenilin-1; ps-1; inosyme; G-cleaver;
XX hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inosyme; G-cleaver;
XX amberyzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
XX diabetes; obesity; cardiac disease; heart disease; age-related disease;
XX hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
XX ss.
XX
XX Homo sapiens.
XX
XX WO200116312-A2.
XX
XX 08-MAR-2001.
XX
XX 30-AUG-2000; 2000WO-US023998.
XX
XX 31-AUG-1999; 99US-0151713P.
XX 27-SEP-1999; 99US-00406643.
XX 27-SEP-1999; 99US-0156236P.
XX 27-SEP-1999; 99US-0156467P.
XX 08-NOV-1999; 99US-00436430.
XX 06-DEC-1999; 99US-0169100P.
XX 29-DEC-1999; 99US-00474432.
XX 29-DEC-1999; 99US-0173612P.
XX 30-DEC-1999; 99US-00476387.
XX 04-FEB-2000; 2000US-00498824.
XX 20-MAR-2000; 2000US-00531025.

PA (CHIR) CHIRON CORP.
XX Pavco P, Mcswigen J, Stinchcomb D, Escobedo J;
XX WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 134; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 1 A; 5 C; 4 G; 0 T; 7 U; 0 Other;
XX
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 606 UGCCAUCUCUGUCG 622
DB 1 UGCCAUCUCUCUCG 17
XX
RESULT 743
AAV97482
ID AAV97482 standard; RNA; 17 BP.
XX
XX AAV97482;
XX
XX 17-MAR-1999 (first entry)
XX
DE Human EGF-R target sequence nucleotide position 2306.
XX
KW Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
KW hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
KW cancer; genetic drift; detection; mutation; ss.
XX
OS Homo sapiens.
XX
PN WO9833893-A2.
XX
XX 06-AUG-1998.
XX
PD 14-JAN-1998; 98WO-US000730.
XX
PF 31-JAN-1997; 97US-0036476P.
XX
PR 04-DEC-1997; 97US-00985162.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (UYAS-) UNIV ASTON.
XX
PI Akhtar S, Fell P, Mcswigen JA;
XX WPI; 1998-437449/37.
XX
DR Enzymatic nucleic acids - which cleave RNA derived from an epidermal
XX growth factor receptor, useful for inhibiting cell proliferation and for
XX treating cancers.
XX
PS Claim 5; Page 73; 109pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules (NAs)

CC which specifically cleave RNA derived from an epidermal growth factor
CC receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
CC represent specifically claimed target sequence from human EGF-R. AAV98044
CC to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
CC hairpin ribozymes respectively for human EGF-R. The NAs are useful for
CC cleaving EGF-R RNA in the treatment of a condition associated with EGFR
CC expression levels e.g. to inhibit cell proliferation in the prevention or
CC treatment of cancers. The NAs can also be used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of EGF-R RNA in a cell
XX
SQ Sequence 17 BP; 7 A; 1 C; 6 G; 0 T; 3 U; 0 Other;
XX
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 5.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 756 GAGCAUCUUAAGGAAA 772
DB 1 GAGCAUCUUGAAGGAAA 17
XX
RESULT 744
AAA36047C
ID AAA36047 standard; DNA; 17 BP.
XX
XX AAA36047;
XX
XX 26-JUL-2000 (first entry)
XX
DE Human genomic SNP allele specific oligonucleotide SEQ ID NO:104.
XX
KW Human; single nucleotide polymorphism; SNP; genotyping; DNA analysis;
KW allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
KW genomic classification; identification; DNA fingerprinting;
KW tumour characterisation; hybridisation; ss.
XX
OS Homo sapiens.
XX
PN WO200018960-A2.
XX
XX 06-APR-2000.
XX
PD 24-SEP-1999; 99WO-US022283.
XX
PF 25-SEP-1998; 98US-0101757P.
XX
PR (MASI) MASSACHUSETTS INST TECHNOLOGY.
XX
PA Landers JE, Jordan B, Housman DE, Charest A;
XX WPI; 2000-293181/25.
XX
DR Detection of single nucleotide polymorphisms in genomes by preparation
XX of reduced complexity genomes, useful for genotyping,
XX fingerprinting and determining allele frequency of SNPs.
XX
PT Disclosure; Page 56; 111pp; English.
XX
PS A method has been developed for detecting the presence or absence of a
XX single nucleotide polymorphism (SNP) allele in a genomic sample. The
XX method comprises preparing a reduced complexity genome (RCG) from the
XX genomic sample and analysing the RCG for the presence or absence of a SNP
XX allele. The method can be used to characterise a tumour, to generate a
XX genomic pattern for an individual genome or to generate a genomic
XX classification code for a genome. The method can be used to assess
XX whether a subject is at risk for developing a disease or to identify a
XX set of SNP alleles associated with a disease. The method can also be used
XX to perform linkage analysis. AAA35944 to AAA35947 represent sequences
XX used in the exemplification of the present invention. AAA35948 to
XX AAA36632 represent nucleotide sequences containing SNPs
XX
SQ Sequence 17 BP; 7 A; 1 C; 2 G; 7 T; 0 U; 0 Other;

XX		Human leukocyte antigen HLA-A exon 3 probe #14.
DE		
XX		Human; ss; Human leukocyte antigen; HLA-A; probe; genotyping;
KW		tissue typing; transplantation; graft-versus-host disease.
XX		
OS	Homo sapiens.	
XX		
PN	US5451512-A.	
PD	19-SEP-1995.	
XX		
PF	28-SEP-1993; 93US-00127954.	
PR	05-NOV-1991; 91US-00788113.	
PA	(HOF) HOFFMANN LA ROCHE INC.	
PI	Apple RJ, Bugawan TL, Erlich HA,	
DR	WPI, 1995-336258/43.	
XX		
PT	New oligo:nucleotide primers for HLA-A locus typing - used for typing	
PT	tissue for e.g. transplantation(s) and identifying individuals or disease	
PS	susceptibility.	
XX		
PS	Disclosure; SEQ ID NO 39; 80pp; English.	
XX		
CC	The invention relates to a pair of oligonucleotide (ON) primers for	
CC	amplifying the exon 1-2 region of the HLA-A locus (human leukocyte	
CC	antigen A), where the pair of primers consists of ONs, RAP1007 and DB337	
CC	(appearing as ADG76495 and ADG76496). Also included is a method for	
CC	amplifying a region of the HLA-A locus containing the first and second	
CC	exons, which consists of carrying out a PCR using the above primers. Also	
CC	disclosed are HLA-A genotyping probes for exon 2 and 3 and HLA-A allele	
CC	DNA/protein sequences. The method is used for typing HLA Class I A locus	
CC	nucleic acids for typing tissue for transplantation, determining	
CC	individual identity and identifying disease susceptible individuals e.g.	
CC	graft-versus-host disease. The method provides a rapid and precise system	
CC	for genotyping the alleles of the HLA-A locus, including those that	
CC	cannot be distinguished by serological methods. The present sequence is	
CC	an HLA-A genotyping probe of the invention. Note: The disclosure states	
CC	that the primers amplify exons 2 and 3, not 1 and 2 as stated in the	
CC	claims.	
XX		
SQ	Sequence 17 BP; 7 A; 6 C; 3 G; 1 T; 0 U; 0 Other;	
	Query Match 0.8%; Score 13.8; DB 1; Length 17;	
	Best Local Similarity 82.4%; Pred. No. 5, le+02;	
	Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0	
OY	1420 CAGAUCAUAACCGCAA 14356	
DB	1 CAGATCACCAAGCGCAA 17	
RESULT 741		
AAX71350		
ID	AAX71350 standard; RNA, 17 BP.	
XX		
AA	AAX71350;	
XX		
DT	28-JUL-1999 (first entry)	
XX		
DS	Human KDR VEGF receptor hammerhead ribozyme substrate #362.	
XX		
KW	Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;	
KW	KDR; hammethead ribozyme; hairpin ribozyme; cleavage;	
KW	tumour angiogenesis; proclastis; rheumatoid arthritis; ocular disease;	
KW	fms-like tyrosine kinase 1; kinase insert domain containing receptor;	
KW	focetal liver kinase 1; ss.	
XX		
SS	Homo sapiens.	

XX	WO9715662-A2.
PN	
XX	01-MAY-1997.
PD	
XX	
PF	25-OCT-1996; 96WO-US017480.
PR	26-OCT-1995; 95US-0005974P.
PR	11-JAN-1996; 96US-00584040.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
PA	(CHIR) CHIRON CORP.
XX	
Pt	Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
DR	WPI, 1997-259017/23.
XX	
PT	Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT	stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PS	rheumatoid arthritis, etc., in a human patient.
XX	
PS	Claim 4; Page 108; 218pp; English.
XX	
CC	The present invention describes nucleic acid molecules which modulate the
CC	synthesis, expression and/or stability of a mRNA encoding 1 or more
CC	receptors of vascular endothelial growth factor (VEGF). A patient
CC	(preferably human) having a condition associated with the level of the
CC	fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC	receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC	angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC	treated by administering the nucleic acid molecule or the expression
CC	vector to the patient. AA67275 to AA75752 represent specific examples
CC	of nucleic acid molecules from the present invention
XX	
SQ	Sequence 17 BP; 1 A; 5 C; 4 G; 0 T; 7 U; 0 Other;
OY	Query Match 0.8%; Score 13.8; DB 1; Length 17; Best Local Similarity 88.2%; Pred.No. 5.1e+02; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
DB	606 UGCCAUCUUGUUCGCGC 622 1 UGCCAUGUUCUCUGGC 17
RESULT 742	
AAx72924	
ID	AAx72924 standard; RNA; 17 BP.
AC	
XX	AAx72924;
DT	28-JUN-1999 (first entry)
DE	Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #357.
XX	
KM	Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KM	KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KM	tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KM	fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KM	foetal liver kinase 1; ss.
OS	
Mus sp.	
PN	WO9715662-A2.
PD	01-MAY-1997.
XX	
PF	25-OCT-1996; 96WO-US017480.
PR	26-OCT-1995; 95US-0005974P.
PR	11-JAN-1996; 96US-00584040.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.

CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX

Sequence 17 BP; 3 A; 3 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 4.9e+02;
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 888 ACAGCAAGCANGA 901
 DB 16 ACAGCAAGCANGA 3

RESULT 738

ACC53382/C
 ID ACC53382 standard; DNA; 17 BP.

AC ACC53382;

DT 27-JUN-2003 (first entry)

XX Human tumour suppressor sequence #2149.

XX 88; tumour suppressor; anticancer; cytostatic; tumour suppression;
 KW tumour regression; apoptosis; virus resistance; diagnosis;
 KW cellular degeneration.

OS Homo sapiens.

XX FR2826373-A1.

XX 27-DEC-2002.

XX 20-JUN-2001; 2001PR-00008139.

XX 20-JUN-2001; 2001PR-00008139.

XX (MOLE-) MOLECULAR ENGINES LAB SA.

XX Tuijinder M, Telerman A, Amson R;

XX WPI; 2003-250498/25.

XX New nucleic acid sequences associated with tumor suppression, regression,
 PT apoptosis or virus resistance are useful to diagnose and treat viral
 PT disease, development of tumor cells and cell degeneration.

XX Claim 1; Page 536; 798pp; French.

XX This sequence represents an isolated nucleic acid sequence associated
 CC with tumour suppression or regression, apoptosis or virus resistance. The
 CC invention relates to these sequences or sequences having at least 80%
 CC identity to them, and polypeptides encoded by the sequences or
 CC polypeptides having 80% identity to the polypeptide sequences. The
 CC invention is used to diagnose or treat viral disease or disease
 CC characterized by development of tumour cells or cellular degeneration
 XX

Sequence 17 BP; 5 A; 2 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 78.6%; Pred. No. 4.9e+02;
 Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1045 UCCGCCUCCUCCGA 1058
 DB 16 TCCGCTCTCTCCGA 3

RESULT 739

AA130657/C
 ID AA130657 standard; DNA; 31 BP.

AC AA130657;

DT 04-NOV-2004 (revised)

DT 18-OCT-2001 (first entry)

XX Human single nucleotide polymorphism (SNP) 166.

XX Human; resequence; genotype; disease; forensic; paternity testing;
 KW single nucleotide polymorphism; SNP; ss.

XX Homo sapiens.

XX Key Location/Qualifiers
 FH variation 16
 FT /*tag= a
 FT /standard_name= "single nucleotide polymorphism"

XX WO200166800-A2.

XX 13-SEP-2001.

XX 07-MAR-2001; 2001WO-US007268.

XX 07-MAR-2000; 2000US-0187510P.

XX 22-MAY-2000; 2000US-0206129P.

XX (WHED) WHITEHEAD INST BIOMEDICAL RES.

XX Cargill M, Ireland JS, Lander ES;

XX WPI; 2001-522952/57.

XX Nucleic acid molecules from the human genome which include polymorphic
 PT sites, useful in methods for predicting the presence, absence or severity
 PT of a particular phenotype or disorder (e.g. diabetes) associated with a
 PT particular genotype.

XX Claim 1; Page 98; 145pp; English.

XX The invention relates to the identification of nucleic acid molecules
 CC (AA129513-AA131314) from the human genome which include polymorphic sites
 CC which can predispose individuals to disease. Various genes from a number
 CC of individuals were resequenced and single nucleotide polymorphisms
 CC (SNPs) in these genes discovered. The method is useful for predicting the
 CC presence, absence or severity of a particular phenotype or disorder (e.g.
 CC diabetes) associated with a particular genotype. The nucleic acids
 CC containing the polymorphic sites may be useful in forensics and paternity
 CC testing
 CC

CC Revised record issued on 04-NOV-2004 : Correction to Feature Table Key

XX Sequence 31 BP; 5 A; 12 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 31;
 Best Local Similarity 53.3%; Pred. No. 9.7e+02;
 Matches 16; Conservative 4; Mismatches 10; Indels 0; Gaps 0;

QY 995 GCAGCAGUAGCAGUGGAAACAACAUAGUG 1024
 DB 30 GCAGCAGUAGCAGUGGAAACAACAUAGUG 1

RESULT 740

ADG76483
 ID ADG76483 standard; DNA; 17 BP.

XX ADG76483;

DT 11-MAR-2004 (first entry)

CC which involves exposing a sample (a cell lysate) comprising substrate
CC nucleic acid to the enzyme which produces at least one detectable
CC cleavage product. The enzyme is employed for detecting target DNAs and
CC RNAs comprising wild-type and mutant alleles of genes including genes
CC from humans, other animal or plants that are or may be associated with
CC disease or other conditions. In addition, the enzymes may be useful for
CC detecting and identifying strains of microorganisms including bacteria,
CC fungi, protozoa, ciliates and viruses, preferably detecting and
CC identifying viruses having RNA genomes, such as hepatitis C and human
CC immunodeficiency virus.

XX
SQ Sequence 17 BP; 7 A; 4 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 4.9e+02;
Matches 7; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 26 CCUCGCCUUGUNU 39
||:|||||:|:|:
Db 15 CCTGCCTTGTGTT 2

RESULT 736
ABT35752/c
ID ABT35752 standard; DNA; 17 BP.
XX
AC ABT35752;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 1389.
XX
KM Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KM antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KM schizophrenia; protein chip; gene therapy; tumour suppression;
KM human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-1B004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 195; 720pp; French.

XX
SQ The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell

CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention

XX
SQ Sequence 17 BP; 5 A; 2 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 4.9e+02;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1045 UCCGCCUCCUCCGA 1058
:|||||:|:|:
Db 16 TCGCCTCCTCCGA 3

RESULT 737
ABT39960/c
ID ABT39960 standard; DNA; 17 BP.
XX
AC ABT39960;
XX
DT 13-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 5597.
XX
KM Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KM antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KM schizophrenia; protein chip; gene therapy; tumour suppression;
KM human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-1B004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 688; 720pp; French.

XX
SQ The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in

SQL Sequence 18 BP; 2 A; 2 C; 12 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 4.9e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 1180 GAGGAGCTGGGGAUGG 1195

DB 1 GAGGGGCTGGGGAUGG 16

RESULT 732

AED16009/C ID AED16009 standard; DNA; 18 BP.

AC AED16009;

DT 15-DEC-2005 (first entry)

DE Probe for blood cell antigen HPA3-allele a, HPA-3ab.

KM Probe; ss; blood; DNA typing; blood transfusion; blood group;

XX SNP detection; DNA microarray.

OS Homo sapiens.

XX WO2005095650-A1.

PD 13-OCT-2005.

XX 31-MAR-2005; 2005WO-NL000236.

PR 01-APR-2004; 2004EP-00076046.

XX (SANO-) STRICHTING SANQUIN BLOEDVOORZIEENING.

PA Belboer SHW, Wieringa-Jelma H, Den Dunnen JT, De Haas M;

XX WPI; 2005-725532/74.

PT Genotyping blood cell antigens, by amplifying and detectably labeling DNA by multiplex PCR at region of locus of blood cell antigen containing PT nucleotide polymorphism, determining genotype for blood cell antigens using chimeric primers.

XX Claim 13; SEQ ID NO 82; 80bp; English.

CC The invention relates to genotyping (M1) blood cell antigens, comprising CC detecting DNA from the individual to a multiplex PCR to amplify (and CC detectably label) a region of the locus of different blood cell antigens CC containing the site of a nucleotide polymorphism) arranged in an array) CC and using the amplified and labeled DNA fragments to determine the CC genotype for each of the blood cell antigens, using a pair of blood cell CC antigen-specific chimeric primers and a detectably labeled universal CC primer. Also included are a kit (I) for genotyping blood cell antigens by CC (M1) (comprising a pair of blood cell antigen-specific chimeric primers CC for each blood cell antigen to be genotyped and a detectably labeled CC universal primer, preferably a pair of detectably labeled universal CC primers), a set of blood cell antigen-specific chimeric primer pairs CC useful in a multiplex PCR (comprising at least two, preferably CC substantially all of chimeric primers) and a set of blood cell antigen CC allele-specific oligonucleotide probes useful for genotyping blood cell CC antigens. (M1) enables genotyping of large number of blood cell antigens CC and is a practical, rapid and reliable method for analyzing the CC hybridization results to assign the clinically relevant blood cell CC antigen genotypes. The present sequence is a blood group antigen specific CC probe useful in the method of the invention.

XX Sequence 18 BP; 2 A; 12 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 4.9e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 1180 GAGGAGCTGGGGAUGG 1195

DB 18 GAGGGGCTGGGGAUGG 3

RESULT 733

AAZ44479 ID AAZ44479 standard; DNA; 16 BP.

AC AAZ44479;

DT 07-APR-2000 (first entry)

DE Tomato restriction fragment amplification primer 1 from set 1.

KM Detection; forensic; restriction fragment polymorphism; multiplex PCR;

XX primer; ss.

OS Lycopersicon esculentum.

XX EP969102-A2.

PD 05-JAN-2000.

PF 24-SEP-1992; 99EP-00115309.

XX 24-SEP-1991; 91EP-00402542.

PR 24-SEP-1992; 92EP-00402629.

XX (KEYG-) KEYGENE NV.

PI Zabeau M, Vos P;

XX WPI; 2000-099430/09.

PT New oligonucleotides, useful for tagging restriction fragments for genetic diagnosis.

XX Example 1G; Page 12; 42pp; English.

CC This invention describes a novel oligonucleotide (I) comprising an CC adapter sequence and part of the target sequence of a restriction CC endonuclease, and which has 1-10 selected nucleotides immediately CC adjacent to the 3' end of the target sequence. The products of the CC invention are used to tag restriction fragments which are to be amplified CC by the polymerase chain reaction (PCR). This technique may be used in the CC detection of restriction fragment polymorphisms (RFPs), including length CC polymorphisms. The products can also be used for genetic analysis, such CC as for the forensic typing of humans and the detection of the inheritance CC of determined traits in animals or plants and to monitor several diseases CC at once. The oligonucleotides and kits may also be used to identify CC species, races or varieties of animals or plants. The new adapters, CC oligonucleotides and methods for using them are more sensitive for CC detecting restriction fragment polymorphisms because not only differences CC in the target sites of the restriction endonuclease are detected as with CC prior art methods and oligonucleotides but also differences in the CC adjacent nucleotide sequences within the selective PCR primers. Multiplex CC PCR may only be used to monitor 5-8 different traits simultaneously and CC compromise conditions have to be established to allow all primer pairs to CC yield detectable products. In addition there are strong differences in CC the efficiency of amplification of different fragments and products of CC certain primer pairs are not detectable with multiplex PCR. In contrast, CC using the new techniques, all the primers have a substantial part of CC their nucleotide sequence in common and by selecting Amplified Fragment CC length Polymorphisms, the DNA markers are amplified with equal CC efficiency. AAZ44475-244526 represent primers used to illustrate the CC method of the invention

XX Sequence 16 BP; 4 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;

PI Garner HR, Wren JD, Minna JD, Fondon JW;
 XX WPI; 2003-208818/20.
 DR
 XX Identifying a candidate polymorphic repeat within a coding sequence, for
 PT understanding or treating genetic disease, comprises detecting tandem
 PT repeats in a target coding sequence and scoring the repeats for
 PT polymorphic probability.
 XX
 PS Example; Col 1089, 588pp; English.
 XX
 CC The invention discloses a method for identifying a candidate polymorphic
 CC repeat within a coding sequence (expressed sequence tag, EST), which
 CC comprises detecting tandem repeats in a target coding sequence, scoring
 CC the repeats for polymorphic probability and generating a dataset
 CC correlating the repeats with polymorphic probability to identify a
 CC candidate polymorphic repeat. The computational methods (polymorphic
 CC marker prediction of ubiquitous simple sequences, POMPOS, and Rep-X) are
 CC useful for identifying and detecting candidate polymorphic repeats in
 CC human genes, which can be used to understand, treat or eliminate genetic
 CC diseases, predispositions or adverse drug-treatment reactions. Examples
 CC of diseases linked to nucleotide repeats are Machado-Joseph, Haw River
 CC syndrome, Huntington's disease, fragile-X syndrome, Friedrich's ataxia,
 CC myotonic dystrophy, hyperandrogenaemia, spinal and bulbar atrophy and
 CC spinocerebellar ataxia. The sequences presented in ABX79676-ABX80022 are
 CC the polymorphic repeats identified for a search of human ESTs
 XX
 SQ Sequence 18 BP; 4 A; 5 C; 8 G; 1 T; 0 U; 0 Other;
 XX
 Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 4.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1701 GAGGCGCAACGACGAG 1716
 Db 1 GAGGCGCGAGCAGCAG 16
 XX
 RESULT 728
 ADD56523
 ID ADD56523 standard; DNA; 18 BP.
 XX
 AC ADD56523;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Human gene expression analysis multiplex Start-PCR primer #43.
 XX
 KW Gene expression; multiplex standardised reverse transcriptase-PCR;
 KW Start-PCR; high density oligonucleotide array; cDNA array;
 KW small biological sample; fine needle aspirate biopsy;
 KW laser captured microdissected material; human; primer; ss.
 XX
 OS Homo sapiens.
 XX
 OS US2003186246-A1.
 XX
 PD 02-OCT-2003.
 XX
 PF 28-MAR-2002; 2002US-00109349.
 XX
 PR 28-MAR-2002; 2002US-00109349.
 XX
 PA (WILL/) WILLEY J C.
 PA (CRAWF/) CRAWFORD B L.
 XX
 PI Willey JC, Crawford BL;
 XX
 DR WPI; 2003-811730/76.
 XX
 PT Direct comparison of numerical gene expression values between samples of
 PT genes comprises using multiplex standardized reverse transcription-
 PT polymerase chain reaction.

XX
 PS Example 1; SEQ ID NO 43; 59pp; English.
 XX
 CC The present invention relates to a method for the direct comparison of
 CC numerical gene expression values between samples of genes. The method
 CC comprises amplifying cDNA in the presence of a competitive template
 CC mixture and primer pairs for several genes and then amplifying aliquots
 CC of the PCR products using a primer pair specific for each gene. The
 CC method of amplification is by multiplex standardised reverse
 CC transcriptase-polymerase chain reaction (Start-PCR). High density
 CC oligonucleotide or cDNA arrays are used to measure PCR products following
 CC quantitative Start-PCR. The method is useful for the assessment of gene
 CC expression in small biological samples such as fine needle aspirate
 CC biopsies, and laser captured microdissected materials. The method allows
 CC for the standardised measurement of hundreds of genes from the same
 CC sample, which in prior art, could only be assessed for one gene. The
 CC present sequence represents a multiplex Start-PCR primer which can be
 CC used in the method of the present invention.
 XX
 SQ Sequence 18 BP; 4 A; 5 C; 7 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 4.9e+02;
 Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 OY 1221 GCTGCGAGCCCTGAG 1236
 Db 1 GCTGCGAGCCCTGAG 16
 XX
 RESULT 729
 ADX82758/C
 ID ADX82758 standard; DNA; 18 BP.
 XX
 AC ADX82758;
 XX
 DT 21-APR-2005 (first entry)
 XX
 DE Mediterranean anemia diagnosis chip-related oligonucleotide SeqID209.
 XX
 KW anemia; DNA chip; alpha-globulin; beta-globulin; ss.
 XX
 OS Unidentified.
 XX
 PN CN1453363-A.
 XX
 PD 05-NOV-2003.
 XX
 PF 23-APR-2002; 2002CN-00117287.
 XX
 PR 23-APR-2002; 2002CN-00117287.
 XX
 PA (YANE-) YANENG BIOTECHNOLOGY SHENZHEN CO LTD.
 XX
 PI Yang M;
 XX
 DR WPI; 2004-157428/16.
 XX
 PT DNA chip for diagnosing Mediterranean anemia, comprises substrate and
 PT probe fixed onto the substrate based on alpha- and beta-globulin mutant
 PT gene sequence.
 XX
 PS Claim 11; SEQ ID NO 209; 66pp; Chinese.
 XX
 CC This invention relates to a novel DNA chip for diagnosing Mediterranean
 CC anemia. The invention comprises substrate and a probe fixed onto the
 CC chip based on alpha- and beta-globulin mutant gene sequence. The DNA
 CC chip has high diagnosing efficiency and accuracy, low cost and short
 CC diagnosis time. The present sequence is that of an oligonucleotide which
 CC was used in the exemplification of the invention.
 XX
 SQ Sequence 18 BP; 3 A; 11 C; 2 G; 2 T; 0 U; 0 Other;
 XX

QY 1393 AAGAGGUGUGCUCUGA 1408
 |||||::|||::|
 DB 2 AAGAGGTTGCTCTCA 17

RESULT 725
 AAC66362
 ID AAC66362 standard; DNA; 18 BP.
 AC AAC66362;
 XX
 DT 22-FEB-2001 (first entry)
 XX
 DE PCR primer used method to detect micro-organisms.
 XX
 KW Detection; microorganism; environmental decontamination; decomposition;
 KW organic halogen compound; PCR primer; ss.
 XX
 OS Unidentified.
 XX
 PN JP2000253880-A.
 PD 19-SEP-2000.
 XX
 PF 10-MAR-1999; 99UP-00062469.
 XX
 PR 10-MAR-1999; 99UP-00062469.
 XX
 PA (TOKI) TOSHIBA KK.
 XX
 DR WPI; 2000-608063/58.
 XX
 PT A method for detection of useful microorganisms and a method for
 PT environmental decontamination with them.
 XX
 PS Example 1; Page 7; 8pp; Japanese.
 XX
 CC Oligonucleotides AAC66355 - AAC66360 are used in a method for the
 CC detection of microorganisms. Micro-organisms are isolated by the presence
 CC of the six nucleotide sequences. The micro-organisms isolated by this
 CC method are used for environmental decontamination and the decomposition
 CC of organic halogen compounds. The present sequence represents a PCR
 CC primer used in an example illustrating the method of the invention
 XX
 SQ Sequence 18 BP; 4 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 75.0%; Pred. No. 4.9e+02;
 Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 150 CUCUCCAGACGGUACC 165
 ||:|||||::|||
 DB 2 CTTTCCAGACGGTACC 17

RESULT 726
 AAH91930
 ID AAH91930 standard; DNA; 18 BP.
 XX
 AC AAH91930;
 XX
 DT 09-OCT-2001 (first entry)
 XX
 DE Human inflammatory bowel disease associated polymorphic site #1005.
 XX
 KW Human; inflammatory bowel disease; Crohn's disease; ulcerative colitis;
 KW single nucleotide polymorphism; SNP; chromosome 19p13; paternity test;
 KW chromosome 5q31-33; forensic test; gene therapy; ds.
 XX
 OS Homo sapiens.
 XX
 PN Key Location/Qualifiers
 FT misc_feature 11

FT /*tag= a
 FT /note="SNP, optionally A or G at this position"
 XX
 PN WO200142511-A2.
 XX
 PD 14-JUN-2001.
 XX
 PF 11-DEC-2000; 2000WO-US033632.
 XX
 PR 10-DEC-1999; 99US-0170257P.
 XX
 PR 10-APR-2000; 2000US-0196046P.
 XX
 PA (WHEE) WHITEHEAD INST BIOMEDICAL RES.
 PA (ELI-) ELLIPSIS BIOTHERAPEUTICS CORP.
 XX
 PI Daly M, Hudson TJ, Lander ES, Rioux J, Siminovitch K;
 XX
 DR WPI; 2001-367874/38.
 XX
 PT Testing for the presence of polymorphisms associated with inflammatory
 PT bowel disease, using a hybridization assay.
 XX
 PS Claim 1; Page 81; 463pp; English.
 XX
 CC The present invention describes a method for detecting the presence of
 CC polymorphisms associated with inflammatory bowel diseases such as
 CC ulcerative colitis and Crohn's disease. The methods can be used to detect
 CC the presence of genetic polymorphisms associated with inflammatory bowel
 CC disease and correlating their occurrence with disease states. They may be
 CC used in this way for phenotypic correlations, forensic, paternity
 CC testing, medicine and genetic analysis. The present sequence is a
 CC polymorphic site described in the exemplification of the invention
 XX
 SQ Sequence 18 BP; 3 A; 5 C; 4 G; 5 T; 0 U; 1 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 70.6%; Pred. No. 4.9e+02;
 Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1112 UGCCGGUACAGCACC 1128
 ::|||::|::|||
 DB 1 TTCCGGGTACAGGTACC 17

RESULT 727
 ABX79924
 ID ABX79924 standard; cDNA; 18 BP.
 XX
 AC ABX79924;
 XX
 DT 17-APR-2003 (first entry)
 XX
 DE BST polymorphic DNA repeat polynucleotide #249.
 XX
 KW Bst; expressed sequence tag; ss; polymorphic repeat; tandem repeat;
 KW polymorphic marker prediction of ubiquitous simple sequences; POMPOUS;
 KW Rep-X; human; genetic disease; drug-treatment; Machado-Joseph;
 KW Haw River syndrome; Huntington's disease; fragile-X syndrome;
 KW Friedrich's ataxia; myotonic dystrophy; hyperandrogenaemia;
 KW spinal atrophy; bulbar atrophy; spinocerebellar ataxia.
 XX
 OS Homo sapiens.
 XX
 PN US6472154-B1.
 XX
 PD 29-OCT-2002.
 XX
 PF 31-DEC-1999; 99US-00475947.
 XX
 PR 31-DEC-1999; 99US-00475947.
 XX
 PA (TEKA) UNIV TEXAS SYSTEM.
 XX

RESULT 723

ADM59618/C
ID ADM59618 standard; RNA; 17 BP.

XX AC ADM59618;

XX DT 03-JUN-2004 (first entry)

XX DE Hepatitis B virus (HBV) RNA target sequence #1752.

XX XX Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KM Hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KM cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KM virocidic; hepatotropic; antiinflammatory; cytostatic.

XX OS Hepatitis B virus.

XX PN US2004054156-A1.

XX PD 18-MAR-2004.

XX PF 15-JAN-2003; 2003US-00342902.

XX PR 14-MAY-1992; 92US-00882712.

XX PR 07-FEB-1994; 94US-00193627.

XX PR 08-NOV-1999; 99US-00436430.

XX PR 20-MAR-2000; 2000US-00531025.

XX PR 09-AUG-2000; 2000US-00636385.

XX PR 24-OCT-2000; 2000US-00696347.

XX PR 08-JUN-2001; 2001US-00877478.

XX PA (DRAP/) DRAPER K.

XX PA (BLAT/) BLATT L.

XX PA (MCSW/) MCSWIGGEN J A.

XX PA (MORR/) MORRISSEY D.

XX PI Draper K, Blatt L, Mcswiggen JA, Morrissey D;

XX DR WPI; 2004-247781/23.

XX PT Novel enzymatic nucleic acid molecule such as DNAzymes and inozymes
XX specifically cleaving RNA derived from hepatitis B virus and comprising
XX one or more binding arms, useful for treating hepatitis and cirrhosis.

XX BS Disclosure; SEQ ID NO 1752; 122pp; English.

XX The invention relates to an enzymatic nucleic acid molecule that
XX specifically cleaves RNA derived from hepatitis B virus (HBV) and
XX comprising one or more binding arms, without requiring the presence of a
XX 2'-OH group within the molecule for activity. The nucleic acids are
XX useful for treating hepatitis B virus infection, hepatitis,
XX hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
XX combination with other therapies such as lamivudine and interferons. The
XX nucleic acids are useful as diagnostic tools to examine genetic drift and
XX mutations within diseased cells, for detecting the presence of HBV RNA in
XX a cell, for the study of RNA and for down-regulating gene expression of
XX target genes in bacterial, fungal, viral, plant or mammalian cells. This
XX sequence represents an HBV RNA target sequence, used in the scope of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 17 BP; 4 A; 7 C; 3 G; 0 T; 3 U; 0 Other;

XX Query Match 0.8%; Score 14.4; DB 1; Length 17;

XX Best Local Similarity 68.8%; Pred. No. 4.4e+02;

XX Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

XX Db 1527 CAUGGUCUGGUGAAC 1542
XX 16 CAGGCTGCTGGTGAAC 1

RESULT 724

AAA95979
ID AAA95979 standard; DNA; 18 BP.

XX AC AAA95979;

XX DT 19-JAN-2001 (first entry)

XX DE TRAF-3 exon 2 5' splice donor site.

XX XX Human; TRAF-3; tumour necrosis factor receptor-associated factor 3;
KM delta130 TRAF-3; delta1221 TRAF-3; immunosuppressive; antiarthritic;
KM dermatologic; antihydrolytic; antitumor; anti-HIV; antibacterial;
KM uropathic; ophthalmologic; antiallergic; antihemorrhagic;
KM vasotropic; neuroprotective; haemostatic; CD40 signalling inhibitor;
KM gene therapy; necrosis factor kappaB activator; autoimmune disease;
KM infectious disease; allergy; 5' splice donor site; ds.

XX OS Homo sapiens.

XX PN WO200053629-A1.

XX PD 14-SEP-2000.

XX PF 10-MAR-2000; 2000MO-US006503.

XX PR 11-MAR-1999; 99US-00268544.

XX PA (UYCO) UNIV COLUMBIA NEW YORK.

XX PI Lederman S, Van Eynhoven W;

XX DR WPI; 2000-587425/55.

XX PT Novel tumor necrosis factor (TNF) receptor-associated factor deletion
XX isoforms for identifying an agent that inhibits CD-40 mediated cellular
XX signaling and for inhibiting e.g. rheumatoid arthritis and diabetes
XX mellitus.

XX PS Example 2; Fig 14; 170pp; English.

XX The present sequence is the 5' splice donor site of exon 2 of the gene
XX encoding tumour necrosis factor receptor (TNF)-associated factor 3 (TRAF-
XX 3). A number of TRAF-3 mRNA species have been identified and some of
XX these arise as a result of alternative mRNA splicing. TRAF-3 isoforms,
XX including delta130 and delta221 TRAF-3 deletion isoforms, are useful for
XX inhibiting activation of a CD40 ligand on a wide range of cells including
XX B cells, fibroblasts, endothelial cells, epithelial cells, T cells,
XX basophils, macrophages, Reed-Steinberg cells, dendritic cells, renal
XX cells or smooth muscle cells expressing CD40 on the cell surface. The
XX proteins are also useful for treating conditions associated with CD40-
XX mediated intracellular signaling, such as organ rejection as a result of
XX transplantation or an immune response after receiving gene therapy. It
XX may be useful for treating an CD40-dependent immune response in patients
XX suffering from an autoimmune disease such as rheumatoid arthritis,
XX myasthenia gravis, systemic lupus erythematosus, Grave's disease,
XX idiopathic thrombocytopenia purpura, haemolytic anaemia, diabetes
XX mellitus, a drug-induced autoimmune disease (drug-induced lupus),
XX psoriasis or hyper immunoglobulin (IgE) syndrome. The proteins may also
XX be used to treat an immune response associated with an infectious disease
XX such as Reiter's syndrome, spondylarthritis, Lyme disease, human
XX immunodeficiency virus (HIV) infection, syphilis or tuberculosis. They
XX may be used to treat an allergic response, atherosclerosis, reperfusion
XX injury and chronic inflammatory autoimmune diseases such as vasculitis,
XX scleroderma or multiple sclerosis

XX SQ Sequence 18 BP; 4 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

XX Query Match 0.8%; Score 14.4; DB 1; Length 18;

XX Best Local Similarity 62.5%; Pred. No. 4.9e+02;

XX Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

CC recombinant polypeptides. The oligonucleotides are useful for preparation
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterized by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia
 XX Sequence 17 BP; 3 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 62.5%; Pred. No. 4.4e+02;
 Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 473 AUCUUCUGUCAUCAG 488
 Db 2 ATCTCTGCTCATCAG 17

RESULT 721
 ACC64380/C
 ID ACC64380 standard; DNA; 17 BP.

AC ACC64380;
 DT 01-JUL-2003 (first entry)

DE Murine oligonucleotide associated with tumour suppression, SEQ ID 1627.
 XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
 XX tumour suppression; tumour reversion; apoptosis; virus resistance;
 XX viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
 XX schizophrenia; ss.

OS Mus musculus.

PN WO2003025176-A2.

PD 27-MAR-2003.

PF 17-SEP-2002; 2002WO-IB004210.

PR 17-SEP-2001; 2001PR-00011979.

PA (MOLE-) MOLECULAR ENGINES LAB.

PI Telerman A, Amson R, Tuijnder M;

DR WPI; 2003-333167/31.

XX New isolated nucleic acid, useful for treating viral diseases associated
 XX with tumour and cell degeneration, also related polypeptides, antibodies
 XX and transfected cells.

PS Disclosure; Page 221; 738pp; French.

XX The present invention relates to murine oligonucleotides (ACC62754-
 XX ACC68806), which are associated with tumour suppression, tumour
 XX reversion, apoptosis and virus resistance. The oligonucleotides are
 XX useful as (1) as probes and primers for detecting, identifying,
 XX quantifying and/or amplifying nucleic acid, e.g. as one component of a
 XX gene chip; in vitro as (anti)sense reagents; and (2) for production of
 XX recombinant polypeptides. The oligonucleotides are useful for preparation
 XX of pharmaceuticals for prevention and/or treatment of viral diseases that
 XX are characterized by development of tumours or cell degeneration,
 XX specifically cancer but also Alzheimer's disease and schizophrenia
 XX

XX Sequence 17 BP; 3 A; 8 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 81.2%; Pred. No. 4.4e+02;
 Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1178 AGGAGGAGCUGGCGAU 1193
 Db 17 AGTACGAGCTCGGCGAT 2

RESULT 722
 ADMS9672
 ID ADMS9672 standard; RNA; 17 BP.

AC ADMS9672;

DT 03-JUN-2004 (first entry)

DE Hepatitis B virus (HBV) RNA target sequence #1806.

XX Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
 XX hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
 XX cirrhosis; liver failure; lamivudine; interferon; genetic drift;
 XX virucide; hepatotropic; antiinflammatory; cyrostatic.

OS Hepatitis B virus.

PN US2004054156-A1.

PD 18-MAR-2004.

PF 15-JAN-2003; 2003US-00342902.

PR 14-MAY-1992; 92US-00882712.

PR 07-FEB-1994; 94US-00193627.

PR 08-NOV-1999; 99US-00436430.

PR 20-MAR-2000; 2000US-00531025.

PR 09-AUG-2000; 2000US-00636385.

PR 24-OCT-2000; 2000US-00696347.

PR 08-JUN-2001; 2001US-00877478.

XX (DRAP/) DRAPER K.

XX (BLAT/) BLATT L.

XX (MCSW/) MORRISSEY J A.

XX (MORR/) MORRISSEY D.

PI Draper K, Blatt L, Mcswiggen JA, Morrissey D;

DR WPI; 2004-247781/23.

XX Novel enzymatic nucleic acid molecule such as DNAszymes and inozymes
 XX specifically cleaving RNA derived from hepatitis B virus and comprising
 XX one or more binding arms, useful for treating hepatitis and cirrhosis.

PS Disclosure; SEQ ID NO 1806; 122pp; English.

XX The invention relates to an enzymatic nucleic acid molecule that
 XX specifically cleaves RNA derived from hepatitis B virus (HBV) and
 XX comprising one or more binding arms, without requiring the presence of a
 XX 2'-OH group within the molecule for activity. The nucleic acids are
 XX useful for treating hepatitis B virus infection, hepatitis,
 XX hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
 XX combination with other therapies such as lamivudine and interferons. The
 XX nucleic acids are useful as diagnostic tools to examine genetic drift and
 XX mutations within diseased cells, for detecting the presence of HBV RNA in
 XX a cell, for the study of RNA and for down-regulating gene expression of
 XX target genes in bacterial, fungal, viral, plant or mammalian cells. This
 XX sequence represents an HBV RNA target sequence, used in the scope of the
 XX invention. Note: The sequence data for this patent is also available in
 XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX

XX Sequence 17 BP; 4 A; 5 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 4.4e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1501 AUCAUCAUCUGGACCC 1516
 Db 2 AUCAUCAUCUGGACCC 17

CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberzyme sequences
CC disclosed in the present invention

XX SQ Sequence 17 BP; 4 A; 5 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 4.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1501 AUCAUCAUCUGAGCC 1516
Db 2 AUCAUCAUCUGAGCC 17

RESULT 719
ACD53927/C

XX ID ACD53927 standard; RNA; 17 BP.

XX AC ACD53927;

XX DT 24-SEP-2003 (first entry)

XX DE HBV zinzyme substrate sequence #97.

XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
XX RNA stability; RNA expression; RNA synthesis; antisense;
XX enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
XX amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
XX HBV reverse transcriptase; Enhancer I region; viral replication;
XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;
XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
XX virucide; antiinflammatory; substrate; ss.

XX OS Hepatitis B virus.

XX PN WO200281494-A1.

XX PD 17-OCT-2002.

XX PF 26-MAR-2002; 2002WO-US009187.

XX PR 26-MAR-2001; 2001US-00817879.

XX PR 08-JUN-2001; 2001US-00877478.

XX PR 08-JUN-2001; 2001US-0296876P.

XX PR 24-OCT-2001; 2001US-0330559P.

XX PR 05-DEC-2001; 2001US-0337055P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PA (BLAT/) BLATT L.

XX PA (MACE/) MACEJAK D.

XX PA (MCSW/) MCSWIGGEN J.

XX PA (MORR/) MORRISSEY D.

XX PA (PAYC/) PAYCO P.

XX PA (LEBP/) LEE P.

XX PA (DRAP/) DRAPER K.

XX PA (ROBE/) ROBERTS E.

XX PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Payco P, Lee P;

XX PI Draper K, Roberts E;

XX DR WPI; 2003-229207/22.

XX Novel compound useful for treating cirrhosis, liver failure,
XX hepatocellular carcinoma, or condition associated with hepatitis C virus
XX infection.

XX Example 1; Page 175; 387P; English.

CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC inozymes, zinzymes, amberzemes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberzyme sequences
CC disclosed in the present invention

XX SQ Sequence 17 BP; 4 A; 7 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 4.4e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1527 CAUGGUCUGAGAAC 1542
Db 16 CATGCTCTGTGTAC 1

RESULT 720
ACCG63215

XX ID ACCG63215 standard; DNA; 17 BP.

XX AC ACCG63215;

XX DT 01-JUL-2003 (first entry)

XX DE Murine oligonucleotide associated with tumour suppression, SEQ ID 462.

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
XX viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX schizophrenia; ss.

XX OS Mus musculus.

XX PN WO2003025176-A2.

XX PD 27-MAR-2003.

XX PF 17-SEP-2002; 2002WO-IB004210.

XX PR 17-SEP-2001; 2001FR-00011979.

XX PA (MOLE-) MOLECULAR ENGINES LAB.

XX PA Telerman A, Amson R, Thijnder M;

XX DR WPI; 2003-333167/31.

XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumours and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.

XX Disclosure; Page 85; 738P; French.

XX The present invention relates to murine oligonucleotides (ACCG2754-
XX ACCG6806), which are associated with tumour suppression, tumour
XX reversion, apoptosis and virus resistance. The oligonucleotides are
XX useful as (1) as probes and primers for detecting, identifying,
XX quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX gene chip; in vitro as (anti)sense reagents; and (2) for production of

CC them.
 XX Sequence 17 BP; 4 A; 5 C; 4 G; 0 T; 4 U; 0 Other;
 SQ Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 4.4e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1501 AUCAUCAUCUGAGACC 1516
 |||||
 2 AUCAUCAUCUGAGACC 17

Db

RESULT 714
 ADV48881
 ID ADV48881 standard; RNA; 17 BP.
 XX
 AC ADV48881;
 XX
 DT 10-FEB-2005 (first entry)

DE HBV zinzyme ribozyme substrate sequence #322.
 XX
 XX Enzymatic nucleic acid molecule; gene expression; down regulation;
 KW protein-tyrosine-phosphatase-1b; PTB-1b; methionine aminopeptidase;
 KW MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
 KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
 KW c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
 KW hepatitis B virus; HBV; hammetthead; HH; hairpin; NCH; inozyme; G-cleaver;
 KW amberyzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
 KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
 KW hepatitis B infection; hepatocellular carcinoma; genetic drift; ss.
 XX
 OS Hepatitis B virus.
 XX
 PN WO200116312-A2.
 XX
 PD 08-MAR-2001.
 XX
 PF 30-AUG-2000; 2000WO-US023998.
 XX
 PR 31-AUG-1999; 99US-0151713P.
 PR 27-SEP-1999; 99US-0040664J.
 PR 27-SEP-1999; 99US-0156236P.
 PR 27-SEP-1999; 99US-0156467P.
 PR 08-NOV-1999; 99US-00436430.
 PR 06-DEC-1999; 99US-0169100P.
 PR 29-DEC-1999; 99US-0047443Z.
 PR 29-DEC-1999; 99US-0173612P.
 PR 30-DEC-1999; 99US-00476387.
 PR 04-FEB-2000; 2000US-00498824.
 PR 20-MAR-2000; 2000US-0053102S.
 PR 14-APR-2000; 2000US-0197769P.
 PR 23-MAY-2000; 2000US-00578223.
 PR 09-AUG-2000; 2000US-0063638S.

PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Mcswigen J, Usman N, Blatt L, Beigelman L, Burgin A,
 PI Karpeisky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B,
 PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
 XX
 XX WPI; 2001-244406/25.
 DR
 XX Enzymatic nucleic acid molecules able to cleave separate RNA molecules
 PT are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
 PT obesity and heart disease.
 XX
 PS Example 6; Page 546; 717pp; English.
 CC The present invention relates to the use of enzymatic nucleic acid
 CC molecules (e.g. ribozymes) to modulate gene expression. The invention
 CC also methods for their use to down regulate or inhibit the expression of

CC genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine
 CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
 CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
 CC receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
 CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
 CC nucleic acid molecules used to inhibit the expression of the said genes
 CC include hammetthead (HH), hairpin, NCH (inozyme), G-cleaver, amberyzyme,
 CC zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
 CC for treating cancer, in particular breast cancer, Alzheimer's disease,
 CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
 CC diseases, hepatitis B infections, and hepatitis and hepatocellular
 CC carcinoma. The enzymatic nucleic acid molecules can also be used as
 CC diagnostic tools to examine genetic drift and mutations within diseased
 CC cells and to detect the presence of specific RNA in a cell. The present
 CC sequence represents a substrate for a ribozyme used in the examples of
 CC the present invention. Note: Some SEQ ID Nos are repeated more than once
 CC in the specification, but these have different sequences associated with
 CC them.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 4 G; 0 T; 4 U; 0 Other;

OY 1501 AUCAUCAUCUGAGACC 1516
 |||||
 2 AUCAUCAUCUGAGACC 17

Db

RESULT 715
 ADV48759/C
 ID ADV48759 standard; RNA; 17 BP.
 XX
 AC ADV48759;
 XX
 DT 10-FEB-2005 (first entry)

DE HBV zinzyme ribozyme substrate sequence #268.
 XX
 XX Enzymatic nucleic acid molecule; gene expression; down regulation;
 KW protein-tyrosine-phosphatase-1b; PTB-1b; methionine aminopeptidase;
 KW MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
 KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
 KW c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
 KW hepatitis B virus; HBV; hammetthead; HH; hairpin; NCH; inozyme; G-cleaver;
 KW amberyzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
 KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
 KW hepatitis B infection; hepatocellular carcinoma; genetic drift; ss.
 XX
 OS Hepatitis B virus.
 XX
 PN WO200116312-A2.
 XX
 PD 08-MAR-2001.
 XX
 PF 30-AUG-2000; 2000WO-US023998.
 XX
 PR 31-AUG-1999; 99US-0151713P.
 PR 27-SEP-1999; 99US-0040664J.
 PR 27-SEP-1999; 99US-0156236P.
 PR 27-SEP-1999; 99US-0156467P.
 PR 08-NOV-1999; 99US-00436430.
 PR 06-DEC-1999; 99US-0169100P.
 PR 29-DEC-1999; 99US-0047443Z.
 PR 29-DEC-1999; 99US-0173612P.
 PR 30-DEC-1999; 99US-00476387.
 PR 04-FEB-2000; 2000US-00498824.
 PR 20-MAR-2000; 2000US-0053102S.
 PR 14-APR-2000; 2000US-0197769P.
 PR 23-MAY-2000; 2000US-00578223.
 PR 09-AUG-2000; 2000US-0063638S.

XX XX WO200116312-A2.
 XX PN
 XX PD 08-MAR-2001.
 XX PF 30-AUG-2000; 2000WO-US023998.
 XX 31-AUG-1999; 99US-0151713P.
 XX 27-SEP-1999; 99US-00406643.
 XX 27-SEP-1999; 99US-0156236P.
 XX 27-SEP-1999; 99US-0156467P.
 XX 08-NOV-1999; 99US-00436430.
 XX 06-DEC-1999; 99US-0169100P.
 XX 29-DEC-1999; 99US-00474432.
 XX 29-DEC-1999; 99US-0173612P.
 XX 30-DEC-1999; 99US-00476387.
 XX 04-FEB-2000; 2000US-00498824.
 XX 20-MAR-2000; 2000US-00531025.
 XX 14-APR-2000; 2000US-0197769P.
 XX 23-MAY-2000; 2000US-00578223.
 XX 09-AUG-2000; 2000US-00636385.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Mcswiggen J, Usman N, Blatt L, Belgelman L, Burgin A;
 XX Karpelsky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B;
 XX Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
 XX WPI, 2001-244406/25.
 XX Enzymatic nucleic acid molecules able to cleave separate RNA molecules
 XX are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
 XX obesity and heart disease.
 XX Example 6; Page 554; 717pp; English.
 XX The present invention relates to the use of enzymatic nucleic acid
 XX molecules (e.g. ribozymes) to modulate gene expression. The invention of
 XX also methods for their use to down regulate or inhibit the expression of
 XX genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine
 XX alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
 XX receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
 XX presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
 XX nucleic acid molecules used to inhibit the expression of the said genes
 XX include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
 XX zincyme, and/or DNAzyme motifs. The methods of the invention are useful
 XX for treating cancer, in particular breast cancer, Alzheimer's disease,
 XX diabetes, obesity, cardiac diseases e.g. heart disease, age-related
 XX diseases, hepatitis B infections, and hepatitis and hepatocellular
 XX carcinoma. The enzymatic nucleic acid molecules can also be used as
 XX diagnostic tools to examine genetic drift and mutations within diseased
 XX cells and to detect the presence of specific RNA in a cell. The present
 XX sequence represents a substrate for a DNAzyme used in the examples of the
 XX present invention. Note: Some SEQ ID Nos are repeated more than once in
 XX the specification, but these have different sequences associated with
 XX them.
 XX SQ Sequence 17 BP; 4 A; 5 C; 4 G; 0 T; 4 U; 0 Other;
 XX Query Match 0.8%; Score 14.4; DB 1; Length 17;
 XX Best Local Similarity 93.8%; Pred. No. 4.4e+02;
 XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1501 AUCAUCAUCUGAGCC 1516
 Db 2 AUCAUCAUCUGAGCC 17
 RESULT 713
 ADV61822
 ID ADV61822 standard; RNA; 17 BP.
 XX

AC ADV61822;
 XX 10-FEB-2005 (first entry)
 XX DE HBV amberzyme ribozyme substrate sequence #359.
 XX 31-AUG-1999; 99US-0151713P.
 XX 27-SEP-1999; 99US-00406643.
 XX 27-SEP-1999; 99US-0156236P.
 XX 27-SEP-1999; 99US-0156467P.
 XX 08-NOV-1999; 99US-00436430.
 XX 06-DEC-1999; 99US-0169100P.
 XX 29-DEC-1999; 99US-00474432.
 XX 29-DEC-1999; 99US-0173612P.
 XX 30-DEC-1999; 99US-00476387.
 XX 04-FEB-2000; 2000US-00498824.
 XX 20-MAR-2000; 2000US-00531025.
 XX 14-APR-2000; 2000US-0197769P.
 XX 23-MAY-2000; 2000US-00578223.
 XX 09-AUG-2000; 2000US-00636385.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Mcswiggen J, Usman N, Blatt L, Belgelman L, Burgin A;
 XX Karpelsky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B;
 XX Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
 XX WPI, 2001-244406/25.
 XX Enzymatic nucleic acid molecules able to cleave separate RNA molecules
 XX are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
 XX obesity and heart disease.
 XX Example 6; Page 573; 717pp; English.
 XX The present invention relates to the use of enzymatic nucleic acid
 XX molecules (e.g. ribozymes) to modulate gene expression. The invention of
 XX also methods for their use to down regulate or inhibit the expression of
 XX genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine
 XX alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
 XX receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
 XX presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
 XX nucleic acid molecules used to inhibit the expression of the said genes
 XX include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
 XX zincyme, and/or DNAzyme motifs. The methods of the invention are useful
 XX for treating cancer, in particular breast cancer, Alzheimer's disease,
 XX diabetes, obesity, cardiac diseases e.g. heart disease, age-related
 XX diseases, hepatitis B infections, and hepatitis and hepatocellular
 XX carcinoma. The enzymatic nucleic acid molecules can also be used as
 XX diagnostic tools to examine genetic drift and mutations within diseased
 XX cells and to detect the presence of specific RNA in a cell. The present
 XX sequence represents a substrate for a ribozyme used in the examples of
 XX the present invention. Note: Some SEQ ID Nos are repeated more than once
 XX in the specification, but these have different sequences associated with

CC gene cluster ORFs are useful for chemically modifying a molecule in a
CC host cell. The host cell is a bacterium or eukaryotic cell, including a
CC mammalian, yeast, plant, fungal, or insect cell. The molecule is an
CC endogenous metabolite produced by the host cell or exogenously supplied
CC metabolite, or an amino acid, and the polypeptide is a peptide synthetase
CC or amino transferase. The polypeptides encoded by the lmm gene cluster
CC are useful for converting an auto-carrier protein to a holo-carrier
CC protein. lmm shows potent antitumour activity in tumour models in vivo.
CC The lmm gene cluster modules and/or catalytic domains are useful for
CC making various peptide and/or polypeptide, and/or hybrid
CC polypeptide/polypeptide metabolites. The proteins encoded by the ORFs are
CC useful alone, or in combination with other active domains to modify
CC various target substrates. The lmm gene cluster is useful to upregulate
CC endogenous lmm production to permit lmm production in cells and/or to
CC make various modified lmm. lmm, its analogue, or other polypeptide,
CC peptide or hybrid polypeptide/peptide metabolites are useful as
CC therapeutic agents, to treat a number of disorders, depending upon the
CC type of metabolites. ABX34290-ABX34431 represent PCR primers used to
CC amplify individual ORFs of the S. atroolivaceus leinamycin biosynthesis
CC gene cluster
XX
SQ Sequence 18 BP; 3 A; 8 C; 2 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 61.1%; Pred. No. 4.4e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
QY 1270 UUCUCCAGCUCUCCCAUC 1287
Db 1 TTGCCCAAGCTTCCCATC 18
:: |||||:: |||||:
RESULT 708
ADXS8092/C
ID ADXS8092 standard; DNA; 17 BP.
XX
AC ADXS8092;
XX
DT 21-APR-2005 (first entry)
XX
DE Primer Gamma 15 for single chain antibody heavy chain variable fragment.
XX
XX virucide; vaccine; single chain antibody; HSV; glycoprotein;
KM glycoprotein D; herpes simplex virus; HSV infection; RT-PCR; primer; ss;
KM heavy chain.
XX
OS Synthetic.
XX
XX WO2005011580-A2.
XX
PD 10-FEB-2005.
XX
PF 26-JUL-2004; 2004WO-US024013.
XX
PR 25-JUL-2003; 2003US-0489984P.
XX
PA (TEXA) UNIV TEXAS SYSTEM.
XX
PI Simmons A, Chen J;
XX
DR WPI; 2005-142827/15.
XX
PT New single chain antibody that specifically binds to a Herpes Simplex
PT virus (HSV) glycoprotein, useful in preparing a composition for
PT preventing or treating a HSV infection.
XX
XX Example 1; SEQ ID NO 30; 99pp; English.
XX
CC The specification describes a single chain antibody that specifically
CC binds to a herpes simplex virus (HSV) glycoprotein, e.g. glycoprotein D.
CC The single chain antibody of the invention is useful for preparing a
CC composition for preventing or treating a HSV infection. C region RT-PCR
CC primer ADXS8077 with gamma degenerate signal sequence RT-PCR primers

CC ADXS8078-ADXS8094 were used to amplify cDNA encoding single chain
CC antibody heavy chain variable fragments. The amplicons were used to
CC generate single chain antibodies of the invention.
XX
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 1 T; 0 U; 2 Other;
XX
Query Match 0.8%; Score 14.6; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 4.2e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
QY 595 CUUGGCGCUCUCCCAU 611
Db 17 CTTGRCGWCCTCCCAT 1
:: |||||:: |||||:
RESULT 709
AAT92041/C
ID AAT92041 standard; DNA; 18 BP.
XX
AC AAT92041;
XX
DT 15-JUN-1998 (first entry)
XX
DE Sense primer derived from tRNA-His for endogenous retroviruses.
XX
XX Human; genome; transfer RNA; pseudogene; primer; retrovirus;
KM reverse transcriptase; detection; endogenous; animal; evolution;
KM breeding programme; forensic science; primer; PCR; amplification;
KM polymerase chain reaction; ss.
XX
OS Synthetic.
XX
PN WO9709452-A1.
XX
PD 13-MAR-1997.
XX
PF 06-SEP-1996; 96WO-GB002196.
XX
PR 06-SEP-1995; 95GB-00018154.
XX
PA (UYCA-) UNIV CAMBRIDGE TECH SERVICES LTD.
XX
PI Petrik J;
XX
DR WPI; 1997-192926/17.
XX
PT Detecting retroviral DNA using labelled oligo:nucleotide(s) - which bind
PT to the primer binding site of a retroviral genome, useful as sequence
PT tag.
XX
PS Claim 2; Page 27; 39pp; English.
XX
XX The human genome is thought to contain around 1300 transfer RNA (tRNA)
CC genes and pseudogenes encoding 60-90 tRNAs. Of these, 20 have been
CC sequenced and 11 tRNA sequences have been shown to act as primers for
CC synthesising the (-)-strand of retroviruses by reverse transcriptase.
CC Sequences AAT92025-48 are sense primers identical to primer binding site
CC (PBS) sequences found in retroviral sequences, which are complementary to
CC the last 18 nucleotides of tRNA gene sequences. This sequence is derived
CC from known exogenous or endogenous retroviral sequences. They may also be
CC used to detect novel retroviruses or endogenous retroviral sequences
CC found in the human genomes. Endogenous retroviral sequences may serve as
CC useful tags in animal evolutionary studies and breeding programmes and,
CC potentially, in forensic sciences
XX
SQ Sequence 18 BP; 2 A; 3 C; 6 G; 5 T; 0 U; 2 Other;
XX
Query Match 0.8%; Score 14.6; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 4.6e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
QY 1113 UCCGGGUCACAGCACCA 1129

XX 02-JUN-2000.
 PD 05-OCT-1999; 99WO-US023196.
 PF 20-NOV-1998; 98US-00197380.
 PR (ISIS-) ISIS PHARM INC.
 PA Monia BP, Cowsett LM;
 PI WPI; 2000-400023/34.
 DR
 XX An antisense compound which inhibits expression of human MEK1, useful for
 PT treating cancer.
 PS Claim 3; Page 76; 101pp; English.
 CC MEK1 is part of the MAPK/ERK subgroup of the MAP kinases. It is thought
 CC that MEK1 is responsible for the proliferative or mitogenic response of
 CC tissues. Antisense oligonucleotides targeted to MEK1 may be used to
 CC inhibit expression of the gene. MEK1 inhibition may be useful for the
 CC treatment of conditions associated with the expression of MEK1, for
 CC example a hyperproliferative condition such as cancer. The present
 CC sequence is antisense oligonucleotide ISIS# 25011 that was targeted to
 CC the coding region of MEK1 mRNA
 XX
 SQ Sequence 18 BP; 6 A; 9 C; 1 G; 2 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15; DB 1; Length 18;
 Best Local Similarity 86.7%; Pred. No. 4.2e+02;
 Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 40 CCAACATCAGCTCC 54
 DB 4 CCAACATCAGCTCC 18
 RESULT 706
 AA257686/C
 ID AA257686 standard; DNA; 18 BP.
 XX
 AC AA257686;
 XX
 DT 05-APR-2000 (first entry)
 XX
 DE Human G-alpha-12 antisense inhibitor ISIS# 20675.
 XX
 KW G-alpha-12 inhibitor; antisense compound; cell differentiation; cancer;
 KW cell growth; metastatic growth; ss; ISIS# 20675.
 XX
 OS Homo sapiens.
 XX
 PN US5998206-A.
 XX
 PD 07-DEC-1999.
 XX
 PF 23-FEB-1999; 99US-00256496.
 XX
 PR 23-FEB-1999; 99US-00256496.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Cowsett LM;
 XX
 DR WPI; 2000-095920/08.
 XX
 PT Antisense inhibition of human G-alpha-12 expression.
 XX
 PS Example 15; Col 38; 36pp; English.
 CC This is a human G-alpha-12 antisense nucleotide sequence. G-alpha-12 is a
 CC member of the G12/13 subfamily of G-proteins. The primary function of G-

CC alpha-12 is in cell differentiation and growth. The invention relates to
 CC antisense compounds which are 8-30 nucleotides long (see AA257686-
 CC 257746). The antisense molecules are targeted to the human G-alpha-12
 CC nucleic acid molecule, and inhibit the expression of G-alpha-12. The
 CC molecules preferably have a modified internucleotide linkage, and at
 CC least one modified sugar moiety. The compounds target different regions
 CC of the human G-alpha-12 RNA. The expression of human G-alpha 12 is
 CC inhibited by contacting human cells or tissues in vitro with the
 CC antisense molecules. The oligonucleotides are used in modulating the
 CC function of nucleic acid molecules encoding G-alpha-12, ultimately
 CC modulating the amount of G-alpha-12 produced. The antisense compounds can
 CC be utilized for diagnostics, therapeutics, prophylaxis and as research
 CC agents and kits. They may be useful in the treatment of cancer, and
 CC metastatic growth
 XX
 SQ Sequence 18 BP; 5 A; 1 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 66.7%; Pred. No. 4.4e+02;
 Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 246 CAUCAUCCGCAACUCCU 263
 DB 18 CACTTCGACCACTCT 1
 RESULT 707
 ABX34294
 ID ABX34294 standard; DNA; 18 BP.
 XX
 AC ABX34294;
 XX
 DT 11-FEB-2003 (first entry)
 XX
 DE PCR primer #1 for S. atroolivaceus leinamycin gene cluster ORF-33.
 XX
 KW leinamycin biosynthesis gene cluster; lmm; open reading frame; ORF;
 KW anti-tumour antibiotic; broad spectrum antimicrobial activity;
 KW Gram-positive; Gram-negative bacteria; chemical modification; metabolite;
 KW apo-carrier protein; holo-carrier protein; tumour; polyketide;
 KW hybrid polypeptide/polyketide metabolite; lmm production; cytosstatic;
 KW PCR; primer; ss.
 XX
 OS Streptomyces atroolivaceus.
 XX
 PN WO20027179-A2.
 XX
 PD 03-OCT-2002.
 XX
 PF 22-MAR-2002; 2002WO-US008937.
 XX
 PR 26-MAR-2001; 2001US-0276935P.
 XX
 PA (BEGC) UNIV CALIFORNIA.
 XX
 PA (KYOW) KYOWA HAKKO KOGYO KK.
 XX
 PI Shen B, Cheng Y, Tang G;
 XX
 DR WPI; 2003-018907/01.
 XX
 PT Novel gene cluster responsible for synthesis of leinamycin in
 PT Streptomyces atroolivaceus useful for making various peptide and/or
 PT polyketide, and/or hybrid polypeptide/polyketide metabolites.
 XX
 PS Claim 1; Page 26; 185pp; English.
 XX
 CC The present invention relates to the isolation of the Streptomyces
 CC atroolivaceus leinamycin (lmm) biosynthesis gene cluster containing 71
 CC open reading frames (ORFs) (ORFs -35 through -1, ORFs lmmA through lmmZ,
 CC and ORFs +1 through +9). leinamycin is a novel anti-tumour antibiotic
 CC produced by several Streptomyces species. It exhibits broad spectrum
 CC antimicrobial activity against Gram-positive and Gram-negative bacteria,
 CC but not against fungi. The polypeptides encoded by the lmm biosynthesis

KW Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
 KW single nucleotide polymorphism; forensic application; gene therapy;
 KW Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
 KW sudden infant death syndrome; genotyping; haplotyping; ASO;
 KW chromosome 1q41-q44; allele-specific oligonucleotide; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200129176-A2.
 XX
 PD 26-APR-2001.
 XX
 PF 12-OCT-2000; 2000WO-US028247.
 XX
 PR 15-OCT-1999; 99US-0159860P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Choi JY, Denton RR, Nandabalan K, Stephens JC;
 XX WPI; 2001-300326/31.
 DR
 XX
 PT Novel polymorphic variant of reference sequence for human cholinergic
 PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
 PT purposes.
 XX
 PS Claim 15; Page 19; 54pp; English.
 XX
 CC The patent relates to polymorphic variants of human cholinergic receptor,
 CC muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
 CC single nucleotide polymorphism selected from cytosine at P51, adenine at
 CC P52 or P53, and cytosine at P54. The invention also relates to a method
 CC for genotyping and haplotyping the CHRM3 gene for identification of
 CC variants. The polymorphic variant is useful for therapeutic purposes, for
 CC studying the expression and biological function of CHRM3, as well as for
 CC developing drugs targeting the CHRM3 protein. The variant is also useful
 CC in diagnostics and forensic applications. The recombinant nonhuman
 CC organism transfected with the polymorphic variant is useful for studying
 CC expression of CHRM3 isogenes in vivo, for in vivo screening and testing
 CC of drugs targeted against CHRM3 protein, and for testing the efficacy of
 CC therapeutic agents and compounds for Alzheimer's disease, Sjogren's
 CC syndrome, disorders associated with smooth muscle contractility and
 CC sudden infant death syndrome. The CHRM3 protein variant is useful in drug
 CC screening assays and its antibodies are useful in immunoassays to detect
 CC CHRM3 protein variants in biological samples. The present sequence is an
 CC allele-specific oligonucleotide (ASO) primer used for detecting human
 CC CHRM3 gene polymorphism
 CC
 SQ Sequence 15 BP; 3 A; 3 C; 6 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.8%; Score 15; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 2.9e+02;
 Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 OY 180 GGGAGGUCUACCGU 194
 Db |||||:|||||:
 1 GGGAGCTCTACCGT 15
 ID AAA24961 standard; DNA; 17 BP.
 AC AAA24961;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1459.
 XX
 KW Oestrogen receptor; C-raf; k-ras; bcl-2; ribozyme; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
 KW gene expression modification; cancer; phosphorochiolate; endonuclease;
 KW anticancer; breast cancer; endometrium cancer; ss.

XX
 OS Homo sapiens.
 XX
 PN WO9954459-A2.
 XX
 PD 28-OCT-1999.
 XX
 PF 19-APR-1999; 99WO-US008547.
 XX
 PR 20-APR-1998; 98US-0082404P.
 XX
 PR 23-JUN-1998; 98US-00103636.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Thompson JD, Beigelman L, Mcswigen JA, Karpeisky A, Bellon L;
 PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerl P;
 PI Matulic-Adamic J;
 XX
 DR WPI; 2000-013248/01.
 XX
 PT New nucleic acids that interact, and optionally cleave, target sequences,
 PT used to treat cancer.
 XX
 PS Claim 77; Page 64; 148pp; English.
 XX
 CC The present invention describes nucleic acids (A) that interact stably
 CC with a target sequence and contain at least one phosphoro(di)thioate
 CC link, having endonuclease activity. (A), and more generally any catalytic
 CC nucleic acid (A') that modulates expression of the oestrogen receptor
 CC gene, are used to treat cancer (particularly of breast or endometrium),
 CC in vivo or by transforming cells ex vivo and implanting treated cells, or
 CC for other conditions associated with levels of oestrogen receptor.
 CC Because of the high selectivity for targeted RNA, (A) can also be used to
 CC correlate inhibition of gene expression with alterations in phenotype,
 CC particularly for identification of therapeutic targets, and as research
 CC reagents (for RNA, in the same way that restriction endonucleases are
 CC used with DNA). The combination of modifications in (A) improves
 CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
 CC AAA27747 represent oestrogen receptor hammerhead ribozyme sequences, and
 CC AAA24748 to AAA25592 represent their corresponding target sequences.
 CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
 CC sequences, and AAA26107 to AAA26218 represent their corresponding target
 CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
 CC antisense oligonucleotides used in the exemplification of the present
 CC invention
 CC
 SQ Sequence 17 BP; 2 A; 9 C; 2 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.8%; Score 15; DB 1; Length 17;
 Best Local Similarity 86.7%; Pred. No. 3.7e+02;
 Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 OY 1176 UGAGGAGGAGCUGGG 1190
 Db :|||||:|||||:
 16 TGAAGAGAGAGCTGGG 2
 ID AAA27262 standard; DNA; 18 BP.
 AC AAA27262;
 XX
 DT 20-SEP-2000 (first entry)
 XX
 DE Human MEK1 antisense oligonucleotide ISIS# 25011.
 XX
 KW Human; MEK1; MAPK/ERK; MEK1a; MAPKK; MEK1a; MAP kinase; cancer;
 KW proliferative; mitogenic; antisense; oligonucleotide; ss.
 OS Homo sapiens.
 XX
 PN WO200031106-A1.

ID AAD05865 standard; DNA; 15 BP.
 AC AAD05865;
 DT 31-JUL-2001 (first entry)
 DE Human cholinergic receptor, muscarinic 3 gene ASO primer #9.
 XX Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
 XX single nucleotide polymorphism; forensic application; gene therapy;
 XX Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
 XX sudden infant death syndrome; genotyping; haplotyping; ASO;
 XX chromosome 1q41-q44; allele-specific oligonucleotide; PCR primer; ss.
 KM
 KW
 OS Homo sapiens.
 XX WO200129176-A2.
 XX 26-APR-2001.
 XX 12-OCT-2000; 2000WO-US028247.
 XX 15-OCT-1999; 99US-0159860P.
 XX (GENA-) GENAISSANCE PHARM INC.
 XX Choi JY, Denton RR, Nandabalan K, Stephens JC;
 XX WPI; 2001-300326/31.
 XX
 XX Novel polymorphic variant of reference sequence for human cholinergic
 XX receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
 XX purposes.
 XX
 XX Claim 15; Page 19; 54pp; English.
 XX
 XX The patent relates to polymorphic variants of human cholinergic receptor,
 XX muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
 XX single nucleotide polymorphism selected from cytosine at PS1, adenine at
 XX PS2 or PS3, and cytosine at PS4. The invention also relates to a method
 XX for genotyping and haplotyping the CHRM3 gene for identification of
 XX variants. The polymorphic variant is useful for therapeutic purposes, for
 XX studying the expression and biological function of CHRM3, as well as for
 XX developing drugs targeting the CHRM3 protein. The variant is also useful
 XX in diagnostics and forensic applications. The recombinant nonhuman
 XX organism transfected with the polymorphic variant is useful for studying
 XX expression of CHRM3 isogenes in vivo, for in vivo screening and testing
 XX of drugs targeted against CHRM3 protein, and for testing the efficacy of
 XX therapeutic agents and compounds for Alzheimer's disease, Sjogren's
 XX syndrome, disorders associated with smooth muscle contractility and
 XX sudden infant death syndrome. The CHRM3 protein variant is useful in drug
 XX screening assays and its antibodies are useful in immunoassays to detect
 XX CHRM3 protein variants in biological samples. The present sequence is an
 XX allele-specific oligonucleotide (ASO) primer used for detecting human
 XX CHRM3 gene polymorphism
 XX
 XX Sequence 15 BP; 3 A; 3 C; 7 G; 2 T; 0 U; 0 Other;
 XX
 XX Query Match 0.8%; Score 15; DB 1; Length 15;
 XX Best Local Similarity 86.7%; Pred. No. 2.9e+02;
 XX Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 XX
 XX 1173 GCTUGGAGGAGGAGCU 1187
 XX ||:||:||:||:||:
 XX DB 1 GCTGAGGAGGAGGACT 15
 XX
 XX RESULT 702
 XX AAD05862/c
 XX ID AAD05862 standard; DNA; 15 BP.
 XX AC AAD05862;
 XX
 XX

DT 31-JUL-2001 (first entry)
 XX Human cholinergic receptor, muscarinic 3 gene ASO primer #6.
 DE Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
 XX single nucleotide polymorphism; forensic application; gene therapy;
 XX Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
 XX sudden infant death syndrome; genotyping; haplotyping; ASO;
 XX chromosome 1q41-q44; allele-specific oligonucleotide; PCR primer; ss.
 KM
 KW
 OS Homo sapiens.
 XX WO200129176-A2.
 XX 26-APR-2001.
 XX 12-OCT-2000; 2000WO-US028247.
 XX 15-OCT-1999; 99US-0159860P.
 XX (GENA-) GENAISSANCE PHARM INC.
 XX Choi JY, Denton RR, Nandabalan K, Stephens JC;
 XX WPI; 2001-300326/31.
 XX
 XX Novel polymorphic variant of reference sequence for human cholinergic
 XX receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
 XX purposes.
 XX
 XX Claim 15; Page 19; 54pp; English.
 XX
 XX The patent relates to polymorphic variants of human cholinergic receptor,
 XX muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
 XX single nucleotide polymorphism selected from cytosine at PS1, adenine at
 XX PS2 or PS3, and cytosine at PS4. The invention also relates to a method
 XX for genotyping and haplotyping the CHRM3 gene for identification of
 XX variants. The polymorphic variant is useful for therapeutic purposes, for
 XX studying the expression and biological function of CHRM3, as well as for
 XX developing drugs targeting the CHRM3 protein. The variant is also useful
 XX in diagnostics and forensic applications. The recombinant nonhuman
 XX organism transfected with the polymorphic variant is useful for studying
 XX expression of CHRM3 isogenes in vivo, for in vivo screening and testing
 XX of drugs targeted against CHRM3 protein, and for testing the efficacy of
 XX therapeutic agents and compounds for Alzheimer's disease, Sjogren's
 XX syndrome, disorders associated with smooth muscle contractility and
 XX sudden infant death syndrome. The CHRM3 protein variant is useful in drug
 XX screening assays and its antibodies are useful in immunoassays to detect
 XX CHRM3 protein variants in biological samples. The present sequence is an
 XX allele-specific oligonucleotide (ASO) primer used for detecting human
 XX CHRM3 gene polymorphism
 XX
 XX Sequence 15 BP; 4 A; 6 C; 3 G; 2 T; 0 U; 0 Other;
 XX
 XX Query Match 0.8%; Score 15; DB 1; Length 15;
 XX Best Local Similarity 73.3%; Pred. No. 2.9e+02;
 XX Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 XX
 XX 192 CGTCGCGCAAGGCGU 206
 XX ||:||:||:||:||:
 XX DB 15 CGTCGCGCAAGTGGT 1
 XX
 XX RESULT 703
 XX AAD05861
 XX ID AAD05861 standard; DNA; 15 BP.
 XX AC AAD05861;
 XX DT 31-JUL-2001 (first entry)
 XX DE Human cholinergic receptor, muscarinic 3 gene ASO primer #5.
 XX

OY 1179 GGAGGAGCGGGAGU 1193
|||:|||||:
Db 1 GGAGGAGCTGGGAT 15

RESULT 699
AAD05866/c
ID AAD05866 standard; DNA; 15 BP.
XX
AC AAD05866;
XX
DT 31-JUL-2001 (first entry)
XX
DE Human cholinergic receptor, muscarinic 3 gene ASO primer #10.
XX
KW Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
KW single nucleotide polymorphism; forensic application; gene therapy;
KW Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
KW sudden infant death syndrome; genotyping; haplotyping; ASO;
KW chromosome 1q41-q44; allele-specific oligonucleotide; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200129176-A2.
XX
PD 26-APR-2001.
XX
PF 12-OCT-2000; 2000WO-US028247.
XX
PR 15-OCT-1999; 99US-0159860P.
XX
PA (GENA-) GENA1SSANCE PHARM INC.
XX
PI Choi YJ, Denton RR, Nandabalan K, Stephens JC;
DR WPI; 2001-300326/31.
XX
PT Novel polymorphic variant of reference sequence for human cholinergic
PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
PT purposes.
XX
PS Claim 15; Page 19; 54pp; English.
XX
CC The patent relates to polymorphic variants of human cholinergic receptor,
CC muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
CC single nucleotide polymorphism selected from cytosine at PS1, adenine at
CC PS2 or PS3, and cytosine at PS4. The invention also relates to a method
CC for genotyping and haplotyping the CHRM3 gene for identification of
CC variants. The polymorphic variant is useful for therapeutic purposes, for
CC studying the expression and biological function of CHRM3, as well as for
CC developing drugs targeting the CHRM3 protein. The variant is also useful
CC in diagnostics and forensic applications. The recombinant nonhuman
CC organism transfected with the polymorphic variant is useful for studying
CC expression of CHRM3 isogenes in vivo, for in vivo screening and testing
CC of drugs targeted against CHRM3 protein, and for testing the efficacy of
CC therapeutic agents and compounds for Alzheimer's disease, Sjogren's
CC syndrome, disorders associated with smooth muscle contractility and
CC sudden infant death syndrome. The CHRM3 protein variant is useful in drug
CC screening assays and its antibodies are useful in immunoassays to detect
CC CHRM3 protein variants in biological samples. The present sequence is an
CC allele-specific oligonucleotide (ASO) primer used for detecting human
CC CHRM3 gene polymorphism
XX
SQ Sequence 15 BP; 3 A; 9 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.9e+02;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

OY 1185 GCUGGGGAUGGUGGA 1199
|||:|||||:
Db 15 GCTGGGGAUGGUGGA 1

RESULT 700
AAD05869
ID AAD05869 standard; DNA; 15 BP.
XX
AC AAD05869;
XX
DT 31-JUL-2001 (first entry)
XX
DE Human cholinergic receptor, muscarinic 3 gene ASO primer #13.
XX
KW Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
KW single nucleotide polymorphism; forensic application; gene therapy;
KW Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
KW sudden infant death syndrome; genotyping; haplotyping; ASO;
KW chromosome 1q41-q44; allele-specific oligonucleotide; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200129176-A2.
XX
PD 26-APR-2001.
XX
PF 12-OCT-2000; 2000WO-US028247.
XX
PR 15-OCT-1999; 99US-0159860P.
XX
PA (GENA-) GENA1SSANCE PHARM INC.
XX
PI Choi YJ, Denton RR, Nandabalan K, Stephens JC;
DR WPI; 2001-300326/31.
XX
PT Novel polymorphic variant of reference sequence for human cholinergic
PT receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
PT purposes.
XX
PS Claim 15; Page 19; 54pp; English.
XX
CC The patent relates to polymorphic variants of human cholinergic receptor,
CC muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
CC single nucleotide polymorphism selected from cytosine at PS1, adenine at
CC PS2 or PS3, and cytosine at PS4. The invention also relates to a method
CC for genotyping and haplotyping the CHRM3 gene for identification of
CC variants. The polymorphic variant is useful for therapeutic purposes, for
CC studying the expression and biological function of CHRM3, as well as for
CC developing drugs targeting the CHRM3 protein. The variant is also useful
CC in diagnostics and forensic applications. The recombinant nonhuman
CC organism transfected with the polymorphic variant is useful for studying
CC expression of CHRM3 isogenes in vivo, for in vivo screening and testing
CC of drugs targeted against CHRM3 protein, and for testing the efficacy of
CC therapeutic agents and compounds for Alzheimer's disease, Sjogren's
CC syndrome, disorders associated with smooth muscle contractility and
CC sudden infant death syndrome. The CHRM3 protein variant is useful in drug
CC screening assays and its antibodies are useful in immunoassays to detect
CC CHRM3 protein variants in biological samples. The present sequence is an
CC allele-specific oligonucleotide (ASO) primer used for detecting human
CC CHRM3 gene polymorphism
XX
SQ Sequence 15 BP; 3 A; 7 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 2.9e+02;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 1279 CUUCCAUCCAGCAGUA 1293
|||:|||||:
Db 1 CTTCCATCCACACTA 15

RESULT 701
AAD05865

CC allele-specific oligonucleotide (ASO) probe used for detecting human
CC CHRM3 gene polymorphism
XX
SQ Sequence 15 BP; 3 A; 5 C; 3 G; 4 T; 0 U; 0 Other;
0.8%; Score 15; DB 1; Length 15;
Query Match Best Local Similarity 73.3%; Pred. No. 2.9e+02;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
186 UCAUACCGUCUGGCA 200
:|||||:|||||
1 TCATACCGTCTGGCA 15
Db
RESULT 697
AAD05855
ID AAD05855 standard; DNA; 15 BP.
XX
XX AAD05855;
AC
XX 31-JUL-2001 (first entry)
DT
XX Human cholinergic receptor, muscarinic 3 gene ASO probe #7.
XX
XX Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
XX single nucleotide polymorphism; forensic application; gene therapy;
XX Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
XX sudden infant death syndrome; genotyping; haplotyping;
XX chromosome 1q41-q44; ASO; allele-specific oligonucleotide; probe; ss.
XX
XX Homo sapiens.
XX
XX WO200129176-A2.
XX
XX 26-APR-2001.
XX
XX 12-OCT-2000; 2000WO-US028247.
XX
XX 15-OCT-1999; 99US-0159860P.
XX
XX (GENA-) GENNAISSANCE PHARM INC.
XX
XX ChOI JY, Denton RR, Nandabalan K, Stephens JC;
XX WPI; 2001-300326/31.
XX
XX Novel polymorphic variant of reference sequence for human cholinergic
XX receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
XX purposes.
XX
XX Claim 15; Page 19; 54pp; English.
XX
XX The patent relates to polymorphic variants of human cholinergic receptor,
XX muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
XX single nucleotide polymorphism selected from cytosine at PS1, adenine at
XX PS2 or PS3, and cytosine at PS4. The invention also relates to a method
XX for genotyping and haplotyping the CHRM3 gene for identification of
XX variants. The polymorphic variant is useful for therapeutic purposes, for
XX studying the expression and biological function of CHRM3, as well as for
XX developing drugs targeting the CHRM3 protein. The variant is also useful
XX in diagnostics and forensic applications. The recombinant nonhuman
XX organism transfected with the polymorphic variant is useful for studying
XX expression of CHRM3 isogenes in vivo, for in vivo screening and testing
XX of drugs targeted against CHRM3 protein, and for testing the efficacy of
XX therapeutic agents and compounds for Alzheimer's disease, Sjogren's
XX syndrome, disorders associated with smooth muscle contractility and
XX sudden infant death syndrome. The CHRM3 protein variant is useful in drug
XX screening assays and its antibodies are useful in immunoassays to detect
XX CHRM3 protein variants in biological samples. The present sequence is an
XX allele-specific oligonucleotide (ASO) probe used for detecting human
XX CHRM3 gene polymorphism
XX
XX Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

.Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 2.9e+02;
Matches 12; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
1285 AUCACGCTAGAGUCA 1299
:|||||:|||||
1 ATCCAGCTAGAGTCA 15
Db
RESULT 698
AAD05853
ID AAD05853 standard; DNA; 15 BP.
XX
XX AAD05853;
AC
XX 31-JUL-2001 (first entry)
DT
XX Human cholinergic receptor, muscarinic 3 gene ASO probe #5.
XX
XX Human; cholinergic receptor muscarinic 3; CHRM3; drug screening;
XX single nucleotide polymorphism; forensic application; gene therapy;
XX Alzheimer's disease; Sjogren's syndrome; smooth muscle contractility;
XX sudden infant death syndrome; genotyping; haplotyping;
XX chromosome 1q41-q44; ASO; allele-specific oligonucleotide; probe; ss.
XX
XX Homo sapiens.
XX
XX WO200129176-A2.
XX
XX 26-APR-2001.
XX
XX 12-OCT-2000; 2000WO-US028247.
XX
XX 15-OCT-1999; 99US-0159860P.
XX
XX (GENA-) GENNAISSANCE PHARM INC.
XX
XX ChOI JY, Denton RR, Nandabalan K, Stephens JC;
XX WPI; 2001-300326/31.
XX
XX Novel polymorphic variant of reference sequence for human cholinergic
XX receptor, muscarinic 3 gene, useful for diagnostic and therapeutic
XX purposes.
XX
XX Claim 15; Page 19; 54pp; English.
XX
XX The patent relates to polymorphic variants of human cholinergic receptor,
XX muscarinic 3 (CHRM3) gene. The polymorphic variant comprises at least one
XX single nucleotide polymorphism selected from cytosine at PS1, adenine at
XX PS2 or PS3, and cytosine at PS4. The invention also relates to a method
XX for genotyping and haplotyping the CHRM3 gene for identification of
XX variants. The polymorphic variant is useful for therapeutic purposes, for
XX studying the expression and biological function of CHRM3, as well as for
XX developing drugs targeting the CHRM3 protein. The variant is also useful
XX in diagnostics and forensic applications. The recombinant nonhuman
XX organism transfected with the polymorphic variant is useful for studying
XX expression of CHRM3 isogenes in vivo, for in vivo screening and testing
XX of drugs targeted against CHRM3 protein, and for testing the efficacy of
XX therapeutic agents and compounds for Alzheimer's disease, Sjogren's
XX syndrome, disorders associated with smooth muscle contractility and
XX sudden infant death syndrome. The CHRM3 protein variant is useful in drug
XX screening assays and its antibodies are useful in immunoassays to detect
XX CHRM3 protein variants in biological samples. The present sequence is an
XX allele-specific oligonucleotide (ASO) probe used for detecting human
XX CHRM3 gene polymorphism
XX
XX Sequence 15 BP; 3 A; 1 C; 9 G; 2 T; 0 U; 0 Other;
Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.9e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

XX 21-APR-1999; 99WO-IB000822.
 XX 21-APR-1998; 98US-0082614P.
 XX 23-NOV-1998; 98US-0109732P.
 XX (GEST) GENSET.
 XX Cohen D, Blumenfeld M, Chumakov I;
 XX WPI; 2000-013267/01.
 XX Novel biallelic markers used to construct a high density disequilibrium
 XX map of the human genome.
 XX Claim 9; Page 1709; 2745pp; English.
 XX AAZ65654 to AAZ69578 represent human biallelic markers from the present
 XX invention, which contain a polymorphic base at position 24 of their
 XX nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
 XX primers for the biallelic markers. The biallelic markers of the invention
 XX have a variety of uses: they can be used for high density mapping of the
 XX human genome, and in complex association studies and haplotyping studies
 XX which are useful in determining the genetic basis for disease states.
 XX Compositions and methods of the invention can also be useful for the
 XX identification of the targets for the development of pharmaceutical
 XX agents and diagnostic methods, as well as the characterisation of the
 XX differential efficacious responses to and side effects from
 XX pharmaceutical agents acting on a disease as well as other treatment.
 XX N.B. The SEQ ID Nos 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
 XX 3367, are not actually given a sequence in the Sequence Listing from the
 XX present invention
 XX SQ Sequence 19 BP; 6 A; 8 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 70.6%; Pred. No. 4.2e+02;
 Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 38 UUCCAACAUACGCUCC 54
 Db 3 TTCCAACATCACTCC 19

RESULT 693

AAZ73102
 ID AAZ73102 standard; DNA; 19 BP.

AC AAZ73102;

DT 10-SEP-2001 (first entry)

DE Human biallelic marker upstream amplification primer SEQ ID NO:7458.

XX Human genome; biallelic marker; high density disequilibrium map;
 XX genomic map; haplotype; phenotype; polymorphic base; genotyping;
 XX haplotyping; hybridisation; identification; characterisation;
 XX amplification; single nucleotide polymorphism; SNP; PCR primer;
 XX diagnosis; ss.
 XX OS Homo sapiens.
 XX WO9954500-A2.
 XX 28-OCT-1999.
 XX 21-APR-1999; 99WO-IB000822.
 XX 21-APR-1998; 98US-0082614P.
 XX 23-NOV-1998; 98US-0109732P.
 XX (GEST) GENSET.

PI Cohen D, Blumenfeld M, Chumakov I;
 XX WPI; 2000-013267/01.
 XX Novel biallelic markers used to construct a high density disequilibrium
 XX map of the human genome.
 XX Claim 9; Page 1821; 2745pp; English.
 XX AAZ65654 to AAZ69578 represent human biallelic markers from the present
 XX invention, which contain a polymorphic base at position 24 of their
 XX nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
 XX primers for the biallelic markers. The biallelic markers of the invention
 XX have a variety of uses: they can be used for high density mapping of the
 XX human genome, and in complex association studies and haplotyping studies
 XX which are useful in determining the genetic basis for disease states.
 XX Compositions and methods of the invention can also be useful for the
 XX identification of the targets for the development of pharmaceutical
 XX agents and diagnostic methods, as well as the characterisation of the
 XX differential efficacious responses to and side effects from
 XX pharmaceutical agents acting on a disease as well as other treatment.
 XX N.B. The SEQ ID Nos 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
 XX 3367, are not actually given a sequence in the Sequence Listing from the
 XX present invention
 XX SQ Sequence 19 BP; 3 A; 7 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 58.8%; Pred. No. 4.2e+02;
 Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 684 GCCCACCACUACUUG 700
 Db 1 GCCCACCCTTACTTTG 17

RESULT 694

ADP79744/C
 ID ADP79744 standard; DNA; 19 BP.

AC ADP79744;

DT 04-NOV-2004 (first entry)

DE Hepatitis B virus core promoter region oligonucleotide SEQ ID NO:5.

XX drug resistance; hepatitis B virus; HBV; mutation; detection;
 XX core promoter region; HBV genotype; antiinflammatory; hepatotropic;
 XX virucide; gene; ds.
 XX OS Hepatitis B virus.
 XX WO2004053162-A1.
 XX 24-JUN-2004.
 XX 10-DEC-2003; 2003WO-JP015810.
 XX 11-DEC-2002; 2002JP-00359372.
 XX (ADL-) ADVANCED LIFE SCI INST INC.
 XX Rokuhara A, Matsumoto A, Tanaka E, Kiyosawa K;
 XX WPI; 2004-517253/49.
 XX Identifying drug resistance (especially to lamivudine) in hepatitis B
 XX virus, comprises detecting a mutation in the core promoter region of
 XX hepatitis B virus.
 XX Claim 5; SEQ ID NO 5; 40pp; Japanese.
 XX The present invention describes a method (M1) for identifying drug

AE016015
 ID AED16015 standard; DNA; 18 BP.
 AC AED16015;
 DE 15-DEC-2005 (first entry)
 DE Probe for blood cell antigen HPA3-allele a, HPA-3aa CR.
 KM Probe, ss; blood; DNA typing; blood transfusion; blood group;
 KM SNP detection; DNA microarray.
 OS Homo sapiens.
 PN WO2005095650-A1.
 PD 13-OCT-2005.
 PF 31-MAR-2005; 2005WO-NL000236.
 PR 01-APR-2004; 2004EP-00076046.
 PA (SANO-) STICHTING SANGUIN BLOEDVOORZIENING.
 PI Belboer SHW, Wieringa-Jelma H, Den Dunnen JT, De Haas M;
 DR WPI; 2005-725532/74.
 XX Genotyping blood cell antigens, by amplifying and detectably labeling DNA
 PT by multiplex PCR at region of locus of blood cell antigen containing
 PT nucleotide polymorphism, determining genotype for blood cell antigens
 PS using chimeric primers.
 PS Claim 13; SEQ ID NO 88; 80bp; English.
 XX The invention relates to genotyping (M1) blood cell antigens, comprising
 CC subjecting DNA from the individual to a multiplex PCR to amplify (and
 CC detectably label) a region of the locus of different blood cell antigens
 CC containing the site of a nucleotide polymorphism (arranged in an array)
 CC and using the amplified and labeled DNA fragments to determine the
 CC genotype for each of the blood cell antigens, using a pair of blood cell
 CC antigen-specific chimeric primers and a detectably labeled universal
 CC primer. Also included are a kit (I) for genotyping blood cell antigens by
 CC (M1) (comprising a pair of blood cell antigen-specific chimeric primers
 CC for each blood cell antigen to be genotyped and a detectably labeled
 CC universal primer, preferably a pair of detectably labeled universal
 CC primers), a set of blood cell antigen-specific chimeric primer pairs
 CC useful in a multiplex PCR (comprising at least two, preferably
 CC substantially all of chimeric primers) and a set of blood cell antigen
 CC allele-specific oligonucleotide probes useful for genotyping blood cell
 CC antigens. (M1) enables genotyping of large number of blood cell antigens
 CC and is a practical, rapid and reliable method for analyzing the
 CC hybridization results to assign the clinically relevant blood cell
 CC antigen genotypes. The present sequence is a blood group antigen specific
 CC probe useful in the method of the invention.
 SQ Sequence 18 BP; 2 A; 1 C; 13 G; 2 T; 0 U; 0 Other;
 QY Query Match 0.9%; Score 15.4; DB 1; Length 18;
 DB Best Local Similarity 82.4%; Pred. No. 3.8e+02;
 Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 1179 GGAGGAGCTGGGAGATGG 1195
 DB 2 GGAGGAGCTGGGAGATGG 18
 RESULT 691
 ID AED88402/C
 AC AED88402 standard; DNA; 18 BP.
 XX AED88402;
 XX

DT 26-JAN-2006 (first entry)
 XX Human Leukocyte Antigen B allele identification probe, SEQ ID 285.
 DE Human Leukocyte Antigen; transplant rejection; histocompatibility;
 KM HLA; leukocyte; antigen; cancer; cytostatic; diabetes mellitus; antidiabetic;
 KM preclinical testing; cancer; cytostatic; diabetes mellitus; antidiabetic;
 KM probe; ss.
 OS Homo sapiens.
 XX JP2005185172-A.
 PN JP2005185172-A.
 PD 14-JUL-2005.
 PF 25-DEC-2003; 2003JP-00430554.
 PR 25-DEC-2003; 2003JP-00430554.
 PA (CANO) CANON KK.
 PI Tsukada M;
 DR WPI; 2006-013379/02.
 XX Probe set for specific identification of an HLA-B allele in a sample,
 PT useful e.g. in matching transplant donors and recipients, and in
 PT determining suitable treatment for patients with conditions such as
 PT cancer and diabetes mellitus.
 PS Claim 2; SEQ ID NO 285; 152bp; Japanese.
 XX The invention relates to a novel probe set for the identification of a
 CC Human Leukocyte Antigen (HLA)-B allele in a sample. The invention further
 CC includes a method for identifying an HLA-B allele using the probe set.
 CC The probe set and method are useful for identifying an HLA-B allele in a
 CC sample. The information gained is useful, for example, in matching organ
 CC donors and recipients, and in guiding clinical decisions in the treatment
 CC of diseases such as cancer and diabetes mellitus. This oligo sequence
 CC represents a probe used in the identification of a Human Leukocyte
 CC Antigen B allele of the invention.
 SQ Sequence 18 BP; 4 A; 10 C; 1 G; 3 T; 0 U; 0 Other;
 QY Query Match 0.9%; Score 15.4; DB 1; Length 18;
 DB Best Local Similarity 70.6%; Pred. No. 3.8e+02;
 Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
 QY 1185 GCUGGAGUGGAGACU 1201
 DB 18 GATGGGATGGTGGACT 2
 RESULT 692
 ID AAZ72578
 AC AAZ72578 standard; DNA; 19 BP.
 XX AAZ72578;
 XX 10-SEP-2001 (first entry)
 DT Human biallelic marker upstream amplification primer SEQ ID NO:6934.
 DE Human genome; biallelic marker; high density disequilibrium map;
 KM genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KM haplotyping; hybridisation; identification; characterisation;
 KM amplification; single nucleotide polymorphism; SNP; PCR primer;
 KM diagnosis; ss.
 OS Homo sapiens.
 XX WO9954500-A2.
 PN WO9954500-A2.
 PD 28-OCT-1999.
 XX

XX 14-JUL-2005 (first entry)
 DT
 DE Indian hedgehog (1hh) gene, PCR primer Angl #1.
 XX
 XX Indian hedgehog; Hemostatic; Cell Therapy; cell proliferation;
 KW bone marrow transplantation; heart disease; cardiac;
 KW cardiovascular disease; liver disease; hepatotropic;
 KW gastrointestinal disease; cell culture; ss; primer; PCR.
 XX
 OS Homo sapiens.
 XX
 PN WO2005042740-A1.
 XX
 PD 12-MAY-2005.
 XX
 PF 18-MAR-2004; 2004WO-JP003695.
 XX
 PR 31-OCT-2003; 2003JP-00373173.
 XX
 PA (RENO-) RENOMEDIX INST INC.
 XX
 PI Kobune M, Hamada H, Nitsu Y;
 XX
 DR WPI; 2005-346876/35.
 XX
 PT Enhancing hematopoiesis-supporting ability of immortalized human bone-
 PT marrow stroma cells comprises transferring Indian hedgehog gene via
 XX retrovirus vector, for use in regeneration medicine.
 XX
 PS Disclosure; Page 10; 42pp; Japanese.
 XX
 CC The invention relates to a method for the proliferation of hematopoietic
 CC cells, which comprises expressing a polypeptide with use of a gene that
 CC encodes a polypeptide with the proliferative activity of hematopoietic
 CC cells selected from e.g. a polypeptide of sequence (I) with 202 amino
 CC acids ABA04765, a polypeptide containing at least 28-202 amino acid
 CC residues in the sequence (I) and a polypeptide derived from the sequence
 CC (I). Also included are: a similar method for the proliferation of
 CC hematopoietic cells by expressing a gene that contains a DNA chosen from
 CC (a) a DNA with a sequence of (II) of 609 base pairs ABA04766, (b) a DNA
 CC containing at least 81-606 base pairs in the sequence (II) and (c) a DNA
 CC hybridizable with any of the DNAs in (a) and (b) under stringent
 CC conditions and encoding a protein with Indian hedgehog activity; bone-
 CC marrow stroma cells transferred with the gene that encodes such
 CC polypeptide with proliferative activity on hematopoietic cells; a method
 CC for proliferating hematopoietic cells by co-culturing such bone-marrow
 CC stroma cells with hematopoietic cells; an expression vector for enhancing
 CC the hematopoiesis comprising a gene the encodes the already-specified
 CC polypeptide; and enhancement agents for hematopoietic cells containing
 CC the already-specified polypeptides as active ingredient. The bone-marrow
 CC stroma cells are particularly those previously with hTERT (human
 CC telomerase catalytic domain) gene transferred, and also with a gene that
 CC encodes a polypeptide with proliferative activity on hematopoietic cells
 CC transferred by using a retrovirus vector. The produced bone-marrow stroma
 CC cells are for use in regeneration medicine, e.g. bone-marrow transplant
 CC and tissue regeneration particularly of blood vessels, heart muscle and
 CC liver. With this method, the hematopoiesis-supporting ability of
 CC immortalized human bone-marrow stroma cells is greatly enhanced, and
 CC hematopoietic stroma cells are strongly amplified when the 1hh (Indian
 CC hedgehog) stroma cells are used. The hTERT stroma cell line (1hh stroma
 CC cell line) was established with use of a PRX-ZRS-hGFP vector for
 CC transferring an Indian hedgehog gene before overexpressing such gene. The
 CC present sequence represents a PCR primer used to amplify the Indian
 CC hedgehog (1hh) gene.
 CC
 SQ Sequence 18 BP; 5 A; 5 C; 6 G; 2 T; 0 U; 0 Other;
 XX
 XX
 Query Match 0.9%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 64.7%; Pred. No. 3.8e+02;
 Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
 OY 1676 UGUGUGGCGAGUGGAC 1692

DB :|||:||||:||||
 18 TGTGTCCAGTGTGAC 2
 RESULT 689
 AED16008/c
 ID AED16008 standard; DNA; 18 BP.
 XX
 AC AED16008;
 XX
 DT 15-DEC-2005 (first entry)
 XX
 DE Probe for blood cell antigen HPA3-allele a, HPA-3aa.
 XX
 KW Probe; ss; blood; DNA typing; blood transfusion; blood group;
 KW SNP detection; DNA microarray.
 XX
 OS Homo sapiens.
 XX
 PN WO2005095650-A1.
 XX
 PD 13-OCT-2005.
 XX
 PF 31-MAR-2005; 2005WO-NL000236.
 XX
 PR 01-APR-2004; 2004EP-00076046.
 XX
 PA (SANG-) STICHTING SANGUIN BLOEDVOORZIENING.
 XX
 PI Belboer SHW, Wieringa-Jelma H, Den Dunnen JT, De Haas M;
 XX
 DR WPI; 2005-725532/74.
 XX
 PT Genotyping blood cell antigens, by amplifying and detectably labeling DNA
 PT by multiplex PCR at region of locus of blood cell antigen containing
 PT nucleotide polymorphism, determining genotype for blood cell antigens
 XX using chimeric primers.
 XX
 PS Claim 13; SEQ ID NO 81; 80pp; English.
 XX
 CC The invention relates to genotyping (M1) blood cell antigens, comprising
 CC subjecting DNA from the individual to a multiplex PCR to amplify (and
 CC detectably label) a region of the locus of different blood cell antigens
 CC containing the site of a nucleotide polymorphism (arranged in an array)
 CC and using the amplified and labeled DNA fragments to determine the
 CC genotype for each of the blood cell antigens, using a pair of blood cell
 CC antigen-specific chimeric primers and a detectably labeled universal
 CC primer. Also included are a kit (I) for genotyping blood cell antigens by
 CC (M1) (comprising a pair of blood cell antigen-specific chimeric primers
 CC for each blood cell antigen to be genotyped and a detectably labeled
 CC universal primer, preferably a pair of detectably labeled universal
 CC primers), a set of blood cell antigen-specific chimeric primer pairs
 CC useful in a multiplex PCR (comprising at least two, preferably
 CC substantially all of chimeric primers) and a set of blood cell antigen
 CC allele-specific oligonucleotide probes useful for genotyping blood cell
 CC antigens. (M1) enables genotyping of large number of blood cell antigens
 CC and is a practical, rapid and reliable method for analyzing the
 CC hybridization results to assign the clinically relevant blood cell
 CC antigen genotypes. The present sequence is a blood group antigen specific
 CC probe useful in the method of the invention.
 CC
 SQ Sequence 18 BP; 2 A; 13 C; 1 G; 2 T; 0 U; 0 Other;
 XX
 XX
 Query Match 0.9%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 82.4%; Pred. No. 3.8e+02;
 Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 OY 1179 GGAGAGCUGGCGAUGG 1195
 DB 17 GGAAGGCGTGGGAGTGG 1
 RESULT 690

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 3.8e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1173 GCTUGAGAGAGAGCTUG 1189
||:|||||||:
Db 1 GCATGAGAGAGAGCTGG 17

RESULT 686
ADE14992
ID ADE14992 standard; DNA; 18 BP.
AC ADE14992;
XX
XX
XX 29-JUN-2004 (first entry)
DE Beer spoilage-associated primer SEQ ID 187.
XX
XX ss; primer; detection; beer-spoilage; lactic acid bacteria;
KM Gram-negative bacteria; spoilage bacteria.
XX
XX Lactobacillus buchneri.
OS
XX WO2002103043-A2.
XX
XX 27-DEC-2002.
XX
XX 19-JUN-2002; 2002WO-EP006808.
XX
XX 19-JUN-2001; 2001DE-01029410.
XX
XX (VERM-) VERMICON AG.
XX
XX Beinfuhr C, Snaidr J;
PI
XX
XX WPI; 2003-175243/17.
DR
XX
XX New oligonucleotides, useful for rapid detection of beer-spoilage
PT bacteria by in situ hybridization, are specific for type, genus or
PI species.
XX
XX
PS Claim 1; SEQ ID NO 187; 88pp; German.

CC This invention describes novel oligonucleotides used in a method for
CC detecting beer-spoilage bacteria in a sample. The bacteria detected
CC include lactic acid bacteria of the genera Lactobacillus or Pedococcus,
CC especially the species L. coryniformis, L. perolens, L. buchneri, L.
CC plantarum, L. fructivorans, L. lindneri, L. casei, L. brevis or P.
CC damnosus or Gram-negative bacteria of the genera Pectinatus and M.
CC Megaspilaeta, specifically P. trisingensis, P. cerevisiophilus and M.
CC cerevisiae. The oligonucleotides of the invention provide rapid detection
CC of spoilage bacteria (typically within 48 hours, compared with 7-12 days
CC for conventional culture methods), can detect all relevant bacteria in
CC parallel, can differentiate between species of the same genus, and are
CC easy to use. ADE14806-ADE15247 represent the oligonucleotides used in the
CC method of the invention.
XX
XX
SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 3.8e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 153 UCCAGACGGUACCCACCG 169
||:|||||||:
Db 1 TCCATACGGTACCAACCG 17

RESULT 687
ADM16801/C
ID ADM16801 standard; DNA; 18 BP.

XX
XX ADM16801;
AC
XX
XX 17-JUN-2004 (first entry)
DT
XX
XX Hepatitis B virus (HBV) genomic DNA, PCR primer HBV-CCC-F2.
DE
XX
XX Hepatitis B virus; HBV; covalently closed circular DNA; cccDNA;
KM liver cell; anti-HBV therapy; liver biopsy; antiviral therapy; PCR;
KM primer; ss.
XX
XX Hepatitis B virus.
OS
XX
XX US2004058314-A1.
XX
XX 25-MAR-2004.
XX
XX 29-MAY-2003; 2003US-00449801.
XX
XX 29-MAY-2002; 2002US-0383953P.
XX
XX (HEML/) HE M L.
XX (KUNG/) KUNG H.
XX (LINM/) LIN M C M.
XX
XX He ML, Kung H, Lin MCM;
PI
XX
XX WPI; 2004-338969/31.
XX
XX
XX Specific detection of Hepatitis B virus (HBV) covalently closed circular
PT (ccc) DNA from liver cell biopsies by real-time PCR, useful for guiding
PT long-term anti-HBV therapy.
XX
XX
XX Claim 9; SEQ ID NO 2; 17pp; English.

CC The present invention relates to a method for detecting Hepatitis B virus
CC (HBV) covalently closed circular (ccc) DNA. The method comprises
CC obtaining a sample of liver cells infected with HBV cccDNA virus from a
CC patient, preparing at least one primer for applying to at least one end
CC of the HBV cccDNA virus, amplifying the HBV cccDNA virus by PCR using at
CC least one primer, preparing at least one probe for applying to the HBV
CC cccDNA virus genome, where the probe comprises a dye and a dye quencher,
CC and conducting a second PCR to bind at least one primer to at least one
CC probe so that the dye and the dye quencher in the probe are separated
CC allowing the HBV cccDNA virus to be detected through the dye. Also
CC disclosed is a kit for the detection of HBV cccDNA in a patient. The
CC method of the invention is useful for detecting cccDNA of HBV in the form
CC of a HBV cccDNA genome from an infected liver cell and for providing
CC guidance to the patient undergoing long term anti-HBV therapy. The method
CC is efficient, rapid, economical and highly sensitive in monitoring HBV
CC cccDNA in infected human liver biopsies. The method is specific for HBV
CC cccDNA as viral genomic DNA is not amplified. The persistence of HBV
CC cccDNA is believed to be the major reason for relapse after HBV antiviral
CC therapy, but prior art methods are poor at quantifying cccDNA in infected
CC liver cells. The present sequence represents a PCR primer used in the
CC method of the invention.
XX
XX
SQ Sequence 18 BP; 4 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 3.8e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 1527 CAUGGUCUGUGAACA 1543
||:|||||||:
Db 17 CATGGTCTGTGTAACA 1

RESULT 688
AEA04773/C
ID AEA04773 standard; DNA; 18 BP.
XX
XX AEA04773;

PN US2004054156-A1.
XX
XX 18-MAR-2004.
XX
XX 15-JUN-2003; 2003US-00342902.
XX
XX 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
XX
XX (DRAP/) DRAPER K.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PA (MORR/) MORRISSEY D.
XX
XX Draper K, Blatt L, Mcswiggen JA, Morrissey D;
PI WPI; 2004-247781/23.
XX
XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
PT specifically cleaving RNA derived from hepatitis B virus and comprising
PT one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
XX Disclosure; SEQ ID NO 1123; 122pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule that
CC specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC comprising one or more binding arms, without requiring the presence of a
CC 2'-OH group within the molecule for activity. The nucleic acids are
CC useful for treating hepatitis B virus infection, hepatitis,
CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC combination with other therapies such as lamivudine and interferons. The
CC nucleic acids are useful as diagnostic tools to examine genetic drift and
CC mutations within diseased cells, for detecting the presence of HBV RNA in
CC a cell, for the study of RNA and for down-regulating gene expression of
CC target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC sequence represents an HBV RNA target sequence, used in the scope of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX
SQ Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;
Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.4e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
QY 1528 AUGGUCUGUGAACC 1544
DB 17 ATGGTCTGTGTGAAC 1

RESULT 682
ADM58990/C
ID ADM58990 standard; RNA; 17 BP.
XX
XX ADM58990;
AC
XX
XX 03-JUN-2004 (first entry)
DT
XX
XX Hepatitis B virus (HBV) RNA target sequence #1124.
DE
XX Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KM hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KM virucide; hepatotropic; antiinflammatory; cytostatic.
XX
XX Hepatitis B virus.
OS
XX
XX US2004054156-A1.
PN

XX
XX 18-MAR-2004.
PD
XX
XX 15-JUN-2003; 2003US-00342902.
PF
XX
XX 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
XX
XX (DRAP/) DRAPER K.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PA (MORR/) MORRISSEY D.
XX
XX Draper K, Blatt L, Mcswiggen JA, Morrissey D;
PI WPI; 2004-247781/23.
XX
XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
PT specifically cleaving RNA derived from hepatitis B virus and comprising
PT one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
XX Disclosure; SEQ ID NO 1124; 122pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule that
CC specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC comprising one or more binding arms, without requiring the presence of a
CC 2'-OH group within the molecule for activity. The nucleic acids are
CC useful for treating hepatitis B virus infection, hepatitis,
CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC combination with other therapies such as lamivudine and interferons. The
CC nucleic acids are useful as diagnostic tools to examine genetic drift and
CC mutations within diseased cells, for detecting the presence of HBV RNA in
CC a cell, for the study of RNA and for down-regulating gene expression of
CC target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC sequence represents an HBV RNA target sequence, used in the scope of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX
SQ Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;
Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.4e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
QY 1527 CAVGUCUGUGAACA 1543
DB 17 CATGGTCTGTGTGAAC 1

RESULT 683
AAT35438
ID AAT35438 standard; DNA; 18 BP.
XX
XX AAT35438;
AC
XX
XX 25-MAR-2003 (revised)
DT
XX 27-MAY-1997 (first entry)
DT
XX
XX Non-Hodgkin's B cell line bcl-2/Igh chimeric gene J6 or J6/E sequence.
DE
XX Non-Hodgkin's lymphoma; cell line DOHH2; DHL-4; leukaemia; chromosome;
KM t14; t18; q32; q21; N region; antisense; expression; inhibitor; bcl-2;
KW IGH; immunoglobulin heavy chain; hybrid; cell death; tumour; cancer;
KM neoplasia; diagnosis; translocation; chimera; ss.
XX
XX Synthetic.
OS
XX
XX WO9627663-A2.
PN

PA (LEBP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P,
 PI Draper K, Roberts E;
 DR WPI; 2003-229207/22.
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 PS Example 1; Page 158; 387pp; English.
 XX The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zincymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HCV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer 1 region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HBV
 CC ribozyme, inozyme, G-cleaver, zincyme, DNazyme or amberzyme sequences
 CC disclosed in the present invention
 CC
 SQ Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;
 XX
 Query Match 0.9%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 3.4e+02;
 Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
 QY 1528 AUGGUCUGUGAACAAC 1544
 Db 17 ATGGTGTGTGTGAACAC 1
 RESULT 680
 ACD52497/C
 ID ACD52497 standard; RNA; 17 BP.
 AC ACD52497;
 XX
 DT 24-SBP-2003 (first entry)
 XX
 DE HBV inozyme substrate sequence #423.
 XX
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zincyme;
 KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer 1 region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis B virus.
 XX
 PN WO200281494-A1.
 XX
 PD 17-OCT-2002.
 XX
 PF 26-MAR-2002; 2002WO-US009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.

PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PVC/) PAVCO P.
 PA (LEBP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P,
 PI Draper K, Roberts E;
 DR WPI; 2003-229207/22.
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 PS Example 1; Page 158; 387pp; English.
 XX The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zincymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer 1 region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HBV
 CC ribozyme, inozyme, G-cleaver, zincyme, DNazyme or amberzyme sequences
 CC disclosed in the present invention
 CC
 SQ Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;
 XX
 Query Match 0.9%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 3.4e+02;
 Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
 QY 1527 CAUGGUCUGUGAACA 1543
 Db 17 CATGGTGTGTGTGAACA 1
 RESULT 681
 ADM58989/C
 ID ADM58989 standard; RNA; 17 BP.
 AC ADM58989;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE Hepatitis B virus (HBV) RNA target sequence #1123.
 XX
 KW Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
 KW hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
 KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
 KW virucide; hepatotropic; antiinflammatory; cytostatic.
 XX
 OS Hepatitis B virus.
 XX

CC cells and to detect the presence of specific RNA in a cell. The present
CC sequence represents a substrate sequence for an inozyme used in the
CC examples of the present invention. Note: Some SEQ ID Nos are repeated
CC more than once in the specification, but these have different sequences
CC associated with them.

XX SQ Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

XX Query Match 0.9%; Score 15.4; DB 1; Length 17;

XX Best Local Similarity 70.6%; Pred. No. 3.4e+02;

XX Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

XX Db 1527 CAUGGUCUGUGAACA 1543

17 CATGCTCTGTGACAC 1

RESULT 678

ADV47175/C

ADV47175 standard; DNA; 17 BP.

XX AC ADV47175;

XX DT 10-FEB-2005 (first entry)

XX DE HBV inozyme substrate sequence #422.

KW Enzymatic nucleic acid molecule; gene expression; down regulation;
KW protein-tyrosine-phosphatase-1b; PTB-1b; methionine aminopeptidase;
KW MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
KW c-erbB2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
KW hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
KW amberyzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
KW hepatitis B infection; hepatocellular carcinoma; genetic drift; ds.

XX OS Hepatitis B virus.

XX FN WO200116312-A2.

XX PD 08-MAR-2001.

XX PF 30-AUG-2000; 2000WO-US023998.

XX PR 31-AUG-1999; 99US-0151713P.

XX PR 27-SEP-1999; 99US-0040664J.

XX PR 27-SEP-1999; 99US-0156236P.

XX PR 08-NOV-1999; 99US-00436430.

XX PR 06-DEC-1999; 99US-0169100P.

XX PR 29-DEC-1999; 99US-0047443Z.

XX PR 29-DEC-1999; 99US-0173612P.

XX PR 30-DEC-1999; 99US-0047638Z.

XX PR 04-FEB-2000; 2000US-00498824.

XX PR 20-MAR-2000; 2000US-00531025.

XX PR 14-APR-2000; 2000US-0197769P.

XX PR 23-MAY-2000; 2000US-0057822J.

XX PR 09-AUG-2000; 2000US-00636385.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Mcewiggen J, Usman N, Blatt L, Belgelman L, Burgin A;
XX PI Karpelsky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B;
XX PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
XX DR WPI, 2001-244406/25.
XX PT Enzymatic nucleic acid molecules able to cleave separate RNA molecules
XX PT are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
XX PT obesity and heart disease.
XX PS Example 6; Page 523; 717p; English.

XX The present invention relates to the use of enzymatic nucleic acid

CC molecules (e.g. ribozymes) to modulate gene expression. The invention

CC also methods for their use to down regulate or inhibit the expression of

CC genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine

CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C

CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor

CC receptor-2 (HER2/c-erbB2/neu), phospholamban (PLN), presenilin-1 (ps-1),

CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic

CC nucleic acid molecules used to inhibit the expression of the said genes

CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberyzyme,

CC zinzyme, and/or DNAzyme motifs. The methods of the invention are useful

CC for treating cancer, in particular breast cancer. Alzheimer's disease,

CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related

CC diseases, hepatitis B infections, and hepatitis and hepatocellular

CC carcinoma. The enzymatic nucleic acid molecules can also be used as

CC diagnostic tools to examine genetic drift and mutations within diseased

CC cells and to detect the presence of specific RNA in a cell. The present

CC sequence represents a substrate sequence for an inozyme used in the

CC examples of the present invention. Note: Some SEQ ID Nos are repeated

CC more than once in the specification, but these have different sequences

XX associated with them.

XX SQ Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

XX Query Match 0.9%; Score 15.4; DB 1; Length 17;

XX Best Local Similarity 70.6%; Pred. No. 3.4e+02;

XX Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

XX Db 1528 AUGGUCUGUGAACAAC 1544

17 ATGCTCTGTGACAC 1

RESULT 679

ACD52496/C

ACD52496 standard; RNA; 17 BP.

XX AC ACD52496;

XX DT 24-SEP-2003 (first entry)

XX DE HBV inozyme substrate sequence #422.

KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;

KW RNA stability; RNA expression; RNA synthesis; antisense;

KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; zinzyme;

KW amberyzyme; G-cleaver ribozyme; decoy molecule; aptamer;

KW HBV reverse transcriptase; Enhancer I region; viral replication;

KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;

KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;

KW virulence; antiinflammatory; substrate; ss.

XX OS Hepatitis B virus.

XX FN WO200281494-A1.

XX PD 17-OCT-2002.

XX PF 26-MAR-2002; 2002WO-US009187.

XX PR 26-MAR-2001; 2001US-0081787P.

XX PR 08-JUN-2001; 2001US-0087747P.

XX PR 08-JUN-2001; 2001US-0296876P.

XX PR 24-OCT-2001; 2001US-0335059P.

XX PR 05-DEC-2001; 2001US-0337055P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PA (BLAT/) BLATT L.

XX PA (MACE/) MACEJAK D.

XX PA (MCSW/) MCSWIGGEN J.

XX PA (MORR/) MORRISSEY D.

XX PA (PAVC/) PAVCO P.

CC inflammatory diseases, disorders, or conditions in a subject or organism,
CC such as psoriasis, eczema, dermatitis, Crohn's disease, and inflammatory
CC bowel disease, and for any other disease, trait, or condition that is
CC related to or will respond to the levels of STAT3 in a cell or tissue,
CC alone or in combination with other treatments or therapies. This oligo
CC sequence represents a STAT-3 siRNA strand of the invention.

XX Sequence 19 BP; 4 A; 5 C; 7 G; 0 T; 3 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 808 GCGTUCGACAGAGGAG 826
DB 1 GCGTUCGACAGAGGAG 19

RESULT 676

AAF07204
ID AAF07204 standard; DNA; 17 BP.

AC AAF07204;

DT 16-FEB-2001 (first entry)

DE Hammerhead ribozyme substrate #3461.

XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.

OS Homo sapiens.

PN WO200061729-A2.

PD 19-OCT-2000.

PF 11-APR-2000; 2000WO-US009721.

PR 12-APR-1999; '99US-0129390P.

PA (RIBO-) RIBOZYME PHARM INC.

PI Blatt L, Zwick M, Pavco P, Mcswigen J;

DR WPI; 2000-647423/62.

PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.

PS Claim 54; Page 135; 164pp; English.

CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TF2 Orphan receptor, ESR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha

XX Sequence 17 BP; 2 A; 7 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1047 GCGTUCGACAGAGG 1063

DB 1 GCGTUCGACAGAGG 17

RESULT 677

ADV47176/C
ID ADV47176 standard; DNA; 17 BP.

AC ADV47176;

DT 10-FEB-2005 (first entry)

DE HBV inozyme substrate sequence #423.

XX Enzymatic nucleic acid molecule; gene expression; down regulation;
KW protein-tyrosine-phosphatase-1b; PTB-1b; methionine aminopeptidase;
KW MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
KW c-erbB2; neu; phospholamban; PLN; presentin-1; ps-1; presentin-2; ps-2;
KW hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
KW amberyne; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
KW hepatitis B infection; hepatocellular carcinoma; genetic drift; ds.

OS Hepatitis B virus.

PN WO200116312-A2.

PD 08-MAR-2001.

PF 30-AUG-2000; 2000WO-US023998.

PR 31-AUG-1999; 99US-0151713P.

PR 27-SEP-1999; 99US-00406643.

PR 27-SEP-1999; 99US-0156236P.

PR 27-SEP-1999; 99US-0156467P.

PR 08-NOV-1999; 99US-00436430.

PR 06-DEC-1999; 99US-0169100P.

PR 29-DEC-1999; 99US-00474432.

PR 30-DEC-1999; 99US-0173612P.

PR 30-DEC-1999; 99US-00476387.

PR 04-FEB-2000; 2000US-00498824.

PR 20-MAR-2000; 2000US-00531025.

PR 14-APR-2000; 2000US-0197769P.

PR 23-MAY-2000; 2000US-00578223.

PR 09-AUG-2000; 2000US-00636385.

PA (RIBO-) RIBOZYME PHARM INC.

PI Mcswigen J, Usman N, Blatt L, Belgelman L, Burgin A;

PI Karpetsky A, Matulic-Adamic J, Svedler D, Draper K, Chowrira B;

PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;

DR WPI; 2001-244406/25.

PT Enzymatic nucleic acid molecules able to cleave separate RNA molecules
PT are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
PT obesity and heart disease.

PS Example 6; Page 523; 717pp; English.

CC The present invention relates to the use of enzymatic nucleic acid
CC molecules (e.g. ribozymes) to modulate gene expression. The invention
CC also methods for their use to down regulate or inhibit the expression of
CC genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine
CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
CC receptor-2 (HER2/c-erbB2/neu), phospholamban (PLN), presentin-1 (ps-1),
CC presentin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC nucleic acid molecules used to inhibit the expression of the said genes
CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberyne,
CC zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
CC for treating cancer, in particular breast cancer, Alzheimer's disease,
CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC diseases, hepatitis B infections, and hepatitis and hepatocellular
CC carcinoma. The enzymatic nucleic acid molecules can also be used as
CC diagnostic tools to examine genetic drift and mutations within diseased

PD 08-SEP-2005.
XX 15-DEC-2004; 2004US-00014373.
XX 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002US-00151116.
PR 17-MAY-2002; 2002US-05015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 22-JUL-2002; 2002US-00201394.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003US-05005028.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004US-05013456.
PR 24-MAY-2004; 2004US-05016390.
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Robin H, Mcswigen J;
XX WPI; 2005-604649/62.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of STAT3 RNA through RNA
PT interference, useful for treating cancer and inflammatory diseases e.g.
PT psoriasis in subject or organism.
XX
XX Example 3; SEQ ID NO 239; 266pp; English.
XX
XX The invention relates to a novel chemically synthesized double stranded
CC short interfering nucleic acid molecule that directs cleavage of a signal
CC transducer and activator of transcription 3 (STAT3) RNA by RNA
CC interference. The invention further includes a composition comprising the
CC short interfering nucleic acid in a carrier or diluent. The short
CC interfering nucleic acid has cytosaratic, antiposaratic, dermatological,
CC antiinflammatory, and gastrointestinal-Gen. activities. The short
CC interfering nucleic acid or its composition is useful for treating,
CC preventing, inhibiting, or reducing cancer, proliferative, and/or
CC inflammatory diseases, disorders, or conditions in a subject or organism,
CC such as psoriasis, eczema, dermatitis, Crohn's disease, and inflammatory
CC bowel disease, and for any other disease, trait, or condition that is
CC related to or will respond to the levels of STAT3 in a cell or tissue,
CC alone or in combination with other treatments or therapies. This oligo
CC sequence represents a STAT-3 siRNA strand of the invention.
XX
XX Sequence 19 BP; 3 A; 7 C; 5 G; 0 T; 4 U; 0 Other;
PS
Query Match 0.9%; Score 15.8; DB 1; Length 19;
Beet Local Similarity 78.9%; Pred. No. 3.8e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
Oy 808 GCCUCUGGACAGACAG 826
Db 19 GCCTCTGAGTCAGAGGAC 1
RESULT 675

AEC90918
ID AEC90918 standard; RNA; 19 BP.
XX
AC AEC90918;
XX
DT 17-NOV-2005 (first entry)
XX
XX STAT-3 siRNA antisense strand, SEQ ID 516.
DE
XX Signal-transducer and activator of transcription-3; RNA interference;
KW gene silencing; cytosaratic; antiposaratic; dermatological;
KW antiinflammatory; gastrointestinal-Gen.; cancer; inflammation; psoriasis;
KW eczema; dermatitis; Crohn's disease; inflammatory bowel disease; siRNA;
KW short interfering RNA; ss.
XX
OS Synthetic.
XX
XX US2005196781-A1.
XX
XX 08-SEP-2005.
XX
XX 15-DEC-2004; 2004US-00014373.
XX
XX 18-MAY-2001; 2001US-0292217P.
PR 20-JUL-2001; 2001US-0306883P.
PR 13-AUG-2001; 2001US-0311865P.
PR 20-FEB-2002; 2002US-0358580P.
PR 06-MAR-2002; 2002US-0362016P.
PR 11-MAR-2002; 2002US-0363124P.
PR 17-MAY-2002; 2002US-00151116.
PR 17-MAY-2002; 2002US-05015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 22-JUL-2002; 2002US-00201394.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003US-05005028.
PR 20-FEB-2003; 2003US-00427160.
PR 30-APR-2003; 2003US-00444853.
PR 23-MAY-2003; 2003US-00693059.
PR 23-OCT-2003; 2003US-00720448.
PR 24-NOV-2003; 2003US-00727780.
PR 03-DEC-2003; 2003US-00757803.
PR 14-JAN-2004; 2004US-0543480P.
PR 10-FEB-2004; 2004US-00780447.
PR 13-FEB-2004; 2004US-00826966.
PR 16-APR-2004; 2004US-05013456.
PR 30-APR-2004; 2004US-05016390.
PR 24-MAY-2004; 2004US-05016390.
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Robin H, Mcswigen J;
XX WPI; 2005-604649/62.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of STAT3 RNA through RNA
PT interference, useful for treating cancer and inflammatory diseases e.g.
PT psoriasis in subject or organism.
XX
XX Example 3; SEQ ID NO 516; 266pp; English.
PS
XX The invention relates to a novel chemically synthesized double stranded
CC short interfering nucleic acid molecule that directs cleavage of a signal
CC transducer and activator of transcription 3 (STAT3) RNA by RNA
CC interference. The invention further includes a composition comprising the
CC short interfering nucleic acid in a carrier or diluent. The short
CC interfering nucleic acid has cytosaratic, antiposaratic, dermatological,
CC antiinflammatory, and gastrointestinal-Gen. activities. The short
CC interfering nucleic acid or its composition is useful for treating,
CC preventing, inhibiting, or reducing cancer, proliferative, and/or

PT arthritis (RA), useful in identification of individuals at risk of
PT developing RA or other autoimmune disease, and in development of
PT therapeutic agents.

PS Claim 21; SEQ ID NO 49888; 141pp; English.

The invention relates to an isolated nucleic acid molecule comprising a least 8 contiguous nucleotides where one of the nucleotides is a single nucleotide polymorphism (SNP) selected from any one of the nucleotide sequences of SEQ ID Nos:1-669 and 1333-49582, or their complements. The SNPs are useful as targets for the design of diagnostic reagents and the development of therapeutic agents, as well as for disease association and linkage analysis. In particular, the SNPs are useful for identifying an individual who is at an increased or decreased risk for developing an autoimmune disease such as Rheumatoid arthritis, type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel diseases, psoriasis, thyroiditis, celiac disease, pernicious anaemia, asthma, vitiligo, glomerulonephritis, Graves' disease, myocarditis, Sjogren disease, or primary systemic vasculitis. Methods associated with the SNPs are useful for early detection of the disease, for providing clinically important information for the prevention and/or treatment of the autoimmune diseases particularly rheumatoid arthritis, and for screening and selecting therapeutic agents. The SNPs are useful for human identification applications. The genes containing the SNPs are useful for treating the diseases defined above. The nucleic acid molecules are useful as hybridization probes for genotyping SNPs in messenger RNA, cDNA, genomic DNA, and genomic clones. The nucleic acid molecules are useful for constructing host cells expressing a part or all of the nucleic acid molecules and variant peptides for constructing transgenic animals, for assaying or screening drugs that modulate nucleic acid expression, or for gene therapy in patients whose cells have aberrant gene expression. This sequence corresponds to a PCR primer which hybridises to the nucleic acids of the invention to amplify the SNP containing region. (Note: SEQ ID Nos 1-49582 are claimed and stated as being provided in the specification, however these sequences are not provided in the printed specification).

Sequence 19 BP; 1 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

```

Query Match      0.9%;  Score 15.8;  DB 1;  length 19;
Best Local Similarity 84.2%;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0.

```

QY 1713 GCAGUACCAGCAGAGACAG 1731

Db 19 GCAGTACCAGCAAGACCG 1

RESULT 673

ID AEC82252 standard; DNA; 19 BP.

AC AEC82252,

DT 17-NOV-2005 (first entry)

DE Human marker reverse primer SEQ ID NO:72.

KW DNA methylation; DNA preparation; marker; PCR; primer; ss.

OS Synthetic.

PN US2005202490-A1.

PD 15-SEP-2005.

PF 03-MAR-2005; 2005US-00071864.

PR 08-MAR-2004; 2004US-0551941P.

PA (MAKA/) MAKAROV V L.
PA (KAMB/) KAMBEROV E.
PA (SUNT/) SUN T.

PA	(PINT/	PINTER J H.
PA	(TAR/	TARRIER B J.
PA	(BRUE/	BRUENING E E
PA	(KURI/	KURIHARA T.
PA	(TESM/	TESMER T.
PA	(MMWI/	MMWIRICHIA J.

PI Makarov VL, Kamberov E, Sun T, Pinter JH, Tarrler BJ
PI Bruening EE, Kurihara T, Tesmer T, Mmwirichia J,

DR WPI: 2005-656755/67.

PT Preparing a DNA molecule by incorporating a nucleic acid molecule into at
PT least some of the DNA molecules digested with a methylation-sensitive
PT restriction enzyme and amplifying the first modified DNA molecules.

PS Disclosure; SEQ ID NO 72; 222pp; English

The invention relates to a method for preparing a DNA molecule. The method comprises: (a) providing a DNA molecule; (b) digesting the DNA molecule with a methylation-sensitive restriction enzyme and, optionally, an additional nuclease, to provide digested DNA molecules; (c) incorporating a nucleic acid molecule into at least some of the digested DNA molecules to provide first modified DNA molecules by (1) incorporating at least one primer from primers, the primers comprising a 5' constant sequence and a 3' variable sequence that is substantially non-self-complementary and substantially non-complementary to other primers; or (2) incorporating an oligonucleotide comprising an inverted repeat and a loop, under conditions where the oligonucleotide becomes blunt-end ligated to one strand of the molecule, thereby producing an oligonucleotide-linked molecule comprising a nick having a 3' hydroxyl group; (d) polymerization of the oligonucleotide-linked molecule from the 3' hydroxyl group of at least part of the oligonucleotide-linked molecule; and (e) amplifying one or more of the first modified DNA molecules to provide amplified first modified DNA molecules. The method is useful in preparing a DNA molecule for diagnosing or prognosing cancer. The method of the invention reduces the quantity of DNA required for methylation analysis from non-invasive clinical sources, e.g., serum, plasma or urine, since a majority of the DNA may remain in an unamplified form. The present sequence represents a human marker used for methylation analysis by quantitative real-time PCR, which is used in an example from the present invention.

SQ Sequence 19 BP; 3 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Query Match	0.9%	Score 15.8	DB 1	Length 19
Best Local Similarity	63.2%	Pred. No. 3.8e+02		
Matches 12; Conservative	5	Mismatches 2	Indels 0	Gaps 0

QY 1673 UGCUGUGGCCAGUGUGA 1691

Db 1 TGCTGCCGTGACAGTGTGA 19

RESULT 674

ID	AEC90641	standard; RNA; 19 BP.

AC AEC90641;

DT 17-NOV-2005 (first entry)

DE STAT-3 siRNA target/sense strand, SEQ ID 239.

KW Signal-transducer and activator of transcription-3; RNA interference;

KW antiinflammatory; gastrointestinal-Gen.; cancer; inflammation; psoriasis;

KW short interfering RNA; 88

OS Synthetic.

PN US2005196781-A1.

XX

PX		XX
PN	WO2003099227-A2.	
PD	04-DEC-2003.	
PF	23-MAY-2003; 2003WO-US016651.	
PI	23-MAY-2002; 2002US-0383249P.	
PR	14-APR-2003; 2003US-0462942P.	
PPA	(CEPT-) CEPTYR INC.	
PLI	Lewis SP, Klinghoffer R, Wilson LK;	
PMW	IWI; 2004-035036/03.	
PTD	New small interfering polynucleotide that modulates protein tyrosine phosphatase (PPP)IB polypeptide signal transduction, useful for treating disorders associated with altered PPPB signal transduction, e.g., diabetes or cancer.	
PS	Example 3; SEQ ID NO 126; 234pp; English.	
PXS	The invention relates to a novel isolated small interfering RNA (siRNA)	
CC	polynucleotide, comprising at least one nucleotide sequence from any of	
CC	the 20 fully defined sequences given in the specification. The invention	
CC	further relates to: a pharmaceutical composition comprising a new siRNA	
CC	polynucleotide and a physiological carrier; a recombinant nucleic acid	
CC	construct, comprising a polynucleotide that is capable of directing	
CC	transcription of an siRNA; a host cell transformed or transfected with	
CC	the above recombinant nucleic acid construct; a method for interfering	
CC	with expression of a protein tyrosine phosphatase (PPP)IB polypeptide,	
CC	its variant; a method for identifying a component of a PPPB signal	
CC	transduction pathway; a method for modulating an insulin receptor protein	
CC	phosphorylation state in a cell; a method for altering a Jak2 protein	
CC	phosphorylation state in a cell; and a method for creating a Jak2-	
CC	associated disorder. The siRNA has the following activities:	
CC	anti-diabetic, anorectic, anti-inflammatory, neuroprotective, cytosstatic,	
CC	immunosuppressive, and antimicrobial. The novel siRNA polynucleotides can	
CC	be used in gene therapy to treat disorders. The composition and methods	
CC	are useful in treating disorders associated with PTPB-mediated signal	
CC	transduction, such as diabetes, obesity, hyperglycemia-induced	
CC	apoptosis, inflammation, neurodegenerative disorders, cancer, autoimmune	
CC	diseases or infection. This polynucleotide sequence represents an siRNA	
CC	used for modulating the signal transduction of a protein tyrosine	
CC	phosphatase of the invention.	
SQ	Sequence 19 BP; 9 A; 3 C; 6 G; 0 T; 1 U; 0 Other;	
Query Match	0.9%; Score 15.8; DB 1; Length 19;	
Best Local Similarity	52.6%; Pred. No. 3.8e+02;	
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;		
OY	593 UCUCUGGACUCCGCCAV 611	
DZ	: :: :: :: :: :: :: :	
Db	19 TCCTTGGAGCCTTCAT 1	
RESULT 671		
ID	ADK98261	
XN	ADK98261 standard; DNA; 19 BP.	
AX	ADK98261;	
KX	06-MAY-2004 (first entry)	
DT	Primer of the invention #3981.	
DE	human; single nucleotide polymorphism; SNP; ss; primer.	
KV	Synthetic.	
DS	JIP2003259875-A.	
NN		

XX	16-SEP-2003.
PD	
XX	
PF	08-MAR-2002; 2002JP-00064373.
XX	
XX	
PR	08-MAR-2002; 2002JP-00064373.
XX	
XX	
PA	(KAGA-) KAGAKU GIUTSU SHINKO JIGYODAN.
XX	
DR	WPI; 2004-093977/10.
PT	Novel polynucleotide useful for PCR amplification along with two DNA
PT	fragment from another set of sequences, or for detecting single
XX	nucleotide polymorphism in human gene.
PS	Claim 2; SEQ ID NO 7290; 2627bp; Japanese.
CC	The present invention relates to a polynucleotide isolated from a human
CC	gene and is useful for detecting a single nucleotide polymorphism in a
CC	human gene or for diagnosing of disease. The invention enables the
CC	detection of a single nucleotide polymorphism in a human gene. The
CC	present sequence represents a primer of the invention.
XX	
XX	
SO	Sequence 19 BP; 2 A; 5 C; 7 G; 5 T; 0 U; 0 Other;
Query Match	0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity	63.2%; Pred. No. 3.8e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;	
Oy	1672 CUGCUGCUGUGCCAGUGUG 1690
	:: :: ::
Db	1 CCGCGCTGTCGACAGTGG 19
RESULT 672	
ADR27216/c	
ID	ADR27216 standard; DNA; 19 BP.
XX	
AC	ADR27216;
XX	
DT	04-NOV-2004 (first entry)
XX	
DE	Human single nucleotide polymorphism detection primer #306.
XX	
XX	ss; primer: single nucleotide polymorphism; SNP; diagnosis;
XX	disease association; linkage analysis; autoimmune disease;
KW	rheumatoid arthritis; diabetes; multiple sclerosis;
KW	systemic lupus erythematosus; inflammatory bowel disease; psoriasis;
KW	thyroiditis; celliac disease; pernicious anemia; asthma; vitiligo;
XX	glomerulonephritis; Graves' disease; myocarditis; Sjogren disease;
XX	primary systemic vasculitis; genotyping; gene therapy; PCR primer.
OS	Homo sapiens.
XX	
XX	WO2004067779-A2.
PD	
PD	12-AUG-2004.
XX	
PF	30-JAN-2004; 2004WO-US002652.
XX	
PR	30-JAN-2003; 2003US-0443566P.
PR	18-MAR-2003; 2003US-0455444P.
PR	25-APR-2003; 2003US-0465241P.
PR	15-AUG-2003; 2003US-0495115P.
XX	
XX	13-NOV-2003; 2003US-0519270P.
PA	(APPL-) APPLERA CORP.
XX	
EI	Cargill M, Begovich AB, Carlton VE, Schrodi SJ, Alexander HC;
XX	WPI; 2004-594223/57.
XX	
XX	New single nucleotide polymorphisms (SNPs) associated with rheumatoid

KM	sRNA; RNA interference; gene silencing; short interfering RNA.
XX	
OS	Synthetic.
XX	
PN	WO2005045040-A2.
XX	
PD	19-MAY-2005.
XX	
PF	20-AUG-2004; 2004WO-US027367.
XX	
PR	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00720448.
PR	03-DEC-2003; 2003US-00727780.
PR	14-JAN-2004; 2004US-00757803.
PR	10-FEB-2004; 2004US-0543480P.
PR	13-FEB-2004; 2004US-00780447.
PR	11-MAR-2004; 2004US-00798090.
PR	16-APR-2004; 2004US-00826966.
PR	30-APR-2004; 2004WO-US013456.
PR	24-MAY-2004; 2004WO-US016390.
PR	17-AUG-2004; 2004US-00919866.
XX	
PA	(SIRN-) SIRNA THERAPEUTICS INC.
XX	
PJ	Richards I, Macswigen J;
XX	
DR	WPI; 2005-356237/36.
XX	
PT	New short interfering nucleic acid molecule that directs cleavage of a
PT	cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT	respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT	disease.
XX	
PS	Claim 33; SEQ ID NO 245; 184bp; English.
CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (sin) molecule that directs cleavage of a
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC	(RNAi). The sinA molecule, compounds, compositions, and methods are
CC	useful for treating or preventing respiratory and pulmonary diseases,
CC	disorders, and/or conditions, including chronic obstructive pulmonary
CC	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC	present sequence represents a cholinergic receptor muscarinic 3 sRNA.
XX	
CX	Sequence 21 BP; 7 A; 5 C; 5 G; 2 T; 2 U; 0 Other;
QY	
Query Match	1.1%; Score 19; DB 1; Length 21;
Best Local Similarity	100.0%; Pred. No. 1.1e+02;
Matches	19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	1714 CAGUACCGCAGACGACGU 1732
DB	1 CAGUACCGCAGACGACGU 19
AAEA02391	
AAEA02391	standard; RNA; 21 BP.
AAEA02391	
28-JUL-2005	(first entry)
D5	Cholinergic receptor muscarinic 3 sRNA SEQ ID NO 275.
KM	Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM	Neuroprotective; Nootropic; Utopachic;
KM	chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM	sinusitis; inflammation; allergy; cystic fibrosis; alzheimer disease;
KM	mucritution disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM	sRNA; RNA interference; gene silencing; short interfering RNA.
XX	

OS	Synthetic.
XX	
PN	WO2005045040-A2.
XX	
PD	19-MAY-2005.
XX	
PF	20-AUG-2004; 2004WO-US027367.
XX	
PR	23-OCT-2003; 2003US-00693059.
PR	24-NOV-2003; 2003US-00720448.
PR	03-DEC-2003; 2003US-00727780.
PR	14-JAN-2004; 2004US-00757803.
PR	10-FEB-2004; 2004US-0543480P.
PR	13-FEB-2004; 2004US-00780447.
PR	11-MAR-2004; 2004US-00798090.
PR	16-APR-2004; 2004US-00826966.
PR	30-APR-2004; 2004MO-US013456.
PR	24-MAY-2004; 2004MO-US016390.
PR	17-AUG-2004; 2004US-00919866.
PA	(SIRN-) SIRNA THERAPEUTICS INC.
XX	
P1	Richards I, Macswigen J;
XX	
DR	WPI; 2005-356237/36.
XX	
PT	New short interfering nucleic acid molecule that directs cleavage of a
PT	cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT	respiratory and pulmonary diseases, e.g., chronic obstructive pulmonary
PT	disease.
XX	
PS	Claim 33; SEQ ID NO 275; 184pp; English.
XX	
CC	The invention relates to a chemically synthesized double stranded short
CC	interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC	cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC	(RNAi). The siRNA molecule, compounds, compositions, and methods are
CC	useful for treating or preventing respiratory and pulmonary diseases,
CC	disorders, and/or conditions, including chronic obstructive pulmonary
CC	disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC	cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC	present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX	
SO	Sequence 21 BP; 7 A; 6 C; 5 G; 2 T; 1 U; 0 Other;
Query Match	1.1%; Score 19; DB 1; Length 21;
Best Local Similarity	100.0%; Pred. No. 1.9e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0;	
OY	975 GCAGUAGACCAAGACCAC 993 DB 1 GCAGUAGACCAAGACCAC 19
RESULT 603	
ID	AEA02400/C
XX	
ID	AEA02400 standard; RNA; 21 BP.
XX	
AC	AEA02400;
DT	28-JUL-2005 (first entry)
DE	Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 284.
KW	Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW	Neuroprotective; Nootropic; Uropathic;
KW	chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW	sinusitis; inflammatory allergy; cystic fibrosis; alzheimer's disease;
KW	micturition disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX	siRNA; RNA interference; gene silencing; short interfering RNA.
XX	
OS	Synthetic.
XX	

KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; ashma: allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurction disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
OS Synthetic.
XX
XX WO2005045040-A2.
XX
XX PD 19-MAY-2005.
XX
XX PF 20-AUG-2004; 2004WO-US027367.
XX
XX PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004WO-US013456.
XX PR 24-MAY-2004; 2004WO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX
XX PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX PI Richards I, Macswigen J;
XX
XX DR WPI; 2005-356237/36.
XX
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX
XX PS Claim 33; SEQ ID NO 294; 184pp; English.
XX
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, and/or conditions, including chronic obstructive pulmonary
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1715 AGUACCAGACGAGACGAC 1733
DB 19 AGTACCAGACGAGACGATC 1
RESULT 600
AEA02350/C
ID AEA02350 standard; RNA; 21 BP.
XX
XX AC AEA02350;
XX
XX DT 28-JUL-2005 (first entry)
XX
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 234.
XX
XX KW Respiratory-Gen.; Antiaesthetic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW micrurction disorder; cholinergic receptor muscarinic 3; CHRM3; ss;

KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurction disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
OS Synthetic.
XX
XX PN WO2005045040-A2.
XX
XX PD 19-MAY-2005.
XX
XX PF 20-AUG-2004; 2004WO-US027367.
XX
XX PR 23-OCT-2003; 2003US-00693059.
XX PR 24-NOV-2003; 2003US-00720448.
XX PR 03-DEC-2003; 2003US-00727780.
XX PR 14-JAN-2004; 2004US-00757803.
XX PR 10-FEB-2004; 2004US-0543480P.
XX PR 13-FEB-2004; 2004US-00780447.
XX PR 11-MAR-2004; 2004US-00798090.
XX PR 16-APR-2004; 2004US-00826966.
XX PR 30-APR-2004; 2004WO-US013456.
XX PR 24-MAY-2004; 2004WO-US016390.
XX PR 17-AUG-2004; 2004US-00919866.
XX
XX PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX PI Richards I, Macswigen J;
XX
XX DR WPI; 2005-356237/36.
XX
XX PT New short interfering nucleic acid molecule that directs cleavage of a
XX PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
XX PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
XX PT disease.
XX
XX PS Claim 33; SEQ ID NO 234; 184pp; English.
XX
XX CC The invention relates to a chemically synthesized double stranded short
XX CC interfering nucleic acid (siNA) molecule that directs cleavage of a
XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
XX CC (RNAi). The siNA molecule, compounds, compositions, and methods are
XX CC useful for treating or preventing respiratory and pulmonary diseases,
XX CC disorders, and/or conditions, including chronic obstructive pulmonary
XX CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
XX CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
XX CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 6 A; 4 C; 7 G; 2 T; 2 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.9e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 317 UCCUCUAGCCUGCCUG 335
DB 19 TCCTCTTAGCCTGAGCTG 1
RESULT 601
AEA02361
ID AEA02361 standard; RNA; 21 BP.
XX
XX AC AEA02361;
XX
XX DT 28-JUL-2005 (first entry)
XX
XX DE Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 245.
XX
XX KW Respiratory-Gen.; Antiaesthetic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW micrurction disorder; cholinergic receptor muscarinic 3; CHRM3; ss;

```

; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 234
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (10)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-234
```

```
Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      317 UCCUCUAAGCCGCGCUG 335
         :||:|||||:|||||:
DB       19 TCCTCTAAGCCTGCGCTG 1
```

```

RESULT 920
US-10-919-866-235/C
; Sequence 235, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR FILING DATE: 2004-03-11
; PRIOR FILING DATE: 2004-05-24
; PRIOR FILING DATE: 2004-05-24
; PRIOR FILING DATE: 2004-04-16
; PRIOR FILING DATE: 2004-04-16
; PRIOR FILING DATE: 2004-01-14
; PRIOR FILING DATE: 2004-01-14
; PRIOR FILING DATE: 2003-11-24
; PRIOR FILING DATE: 2003-11-24
; PRIOR FILING DATE: 2003-11-23
; PRIOR FILING DATE: 2003-11-23
; PRIOR FILING DATE: 2003-05-23
; PRIOR FILING DATE: 2003-05-23
; PRIOR FILING DATE: 2003-02-20
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
```

```

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 235
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (2)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (11)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-235
```

```
Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      975 GCGAUGAGCAAGACAC 993
         |||||:|||||:|||||
DB       19 GCGATGAGCAAGACAC 1
```

```

RESULT 921
US-10-919-866-236/C
; Sequence 236, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR FILING DATE: 2004-03-11
; PRIOR FILING DATE: 2004-05-24
; PRIOR FILING DATE: 2004-05-24
; PRIOR FILING DATE: 2004-04-16
; PRIOR FILING DATE: 2004-04-16
; PRIOR FILING DATE: 2004-01-14
; PRIOR FILING DATE: 2004-01-14
```

```
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-11-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 324
;; SOFTWARE: Patentin version 3.3
;; SEQ ID NO 236
;; LENGTH: 21
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
;; NAME/KEY: misc feature
;; LOCATION: (1)..(1)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc feature
;; LOCATION: (3)..(7)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc feature
;; LOCATION: (9)..(10)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc feature
;; LOCATION: (13)..(13)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc feature
;; LOCATION: (15)..(16)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc feature
;; LOCATION: (18)..(19)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc feature
;; LOCATION: (20)..(21)
;; OTHER INFORMATION: n stands for thymidine
;; FEATURE:
;; NAME/KEY: misc feature
;; LOCATION: (20)..(20)
;; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-236

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1712 AGCAGUACGACGACAGACA 1730
DB 19 AGCAGTACGACGACGACAGA 1

RESULT 922
US-10-919-866-237/c
; Sequence 237, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
```

```
;; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
;; FILE REFERENCE: 400/205 (MEH804-183-A)
;; CURRENT FILING DATE: 2004-08-17
;; PRIOR APPLICATION NUMBER: US 10/798,090
;; PRIOR FILING DATE: 2004-03-11
;; PRIOR APPLICATION NUMBER: PCT/US04/16390
;; PRIOR FILING DATE: 2004-05-24
;; PRIOR APPLICATION NUMBER: US 10/826,966
;; PRIOR FILING DATE: 2004-04-16
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-11-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 324
;; SOFTWARE: Patentin version 3.3
;; SEQ ID NO 237
;; LENGTH: 21
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
;; NAME/KEY: misc feature
;; LOCATION: (2)..(3)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc feature
;; LOCATION: (5)..(9)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc feature
;; LOCATION: (11)..(12)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc feature
;; LOCATION: (15)..(15)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc feature
;; LOCATION: (17)..(18)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc feature
;; LOCATION: (20)..(21)
;; OTHER INFORMATION: n stands for thymidine
;; FEATURE:
;; NAME/KEY: misc feature
;; LOCATION: (20)..(20)
;; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-237

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1714 CAGUACGACGACGACAGU 1732
DB 19 CAGTACGACGACGACAGT 1
```

```

RESULT 923
US-10-919-866-238/C
; Sequence 238, Application US/10919866
; Publication No. US2005017664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sina)
; FILE REFERENCE: 400/205 (MBH04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919, 866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798, 090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757, 803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 238
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (3)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (12)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (16)..(16)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n strands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-238

```

```

Query Match      1.1%; Score 19; DB 1; Length 21;
Beet Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

OY      1715 AGUACGACGACGACAGCUC 1733
      ||:|||||
Db      19 AGTACGACGACGACAGTC 1

RESULT 924
US-10-919-866-239
; Sequence 239, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (SINA)
; FILE REFERENCE: 400/205 (MEHQ4-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 239
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (2)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (3)..(4)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:

```

```
NAME/KEY: misc_feature
LOCATION: (6)..(6)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (7)..(7)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8)..(9)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(14)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-239
```

```
Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      17  AAGAGACACCTCCGCTT 35
Db      1  AAGAGACACCTCCGCTT 19
```

```
RESULT 925
US-10-919-866-240
Sequence 240, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
PRIORITY FILING DATE: 2004-08-17
PRIORITY APPLICATION NUMBER: US 10/798,090
PRIORITY FILING DATE: 2004-03-11
PRIORITY APPLICATION NUMBER: PCT/US04/16390
PRIORITY FILING DATE: 2004-05-24
PRIORITY APPLICATION NUMBER: US 10/826,966
PRIORITY FILING DATE: 2004-04-16
PRIORITY APPLICATION NUMBER: US 10/757,803
PRIORITY FILING DATE: 2004-01-14
PRIORITY APPLICATION NUMBER: US 10/720,448
PRIORITY FILING DATE: 2003-11-24
PRIORITY APPLICATION NUMBER: US 10/693,059
PRIORITY FILING DATE: 2003-11-23
PRIORITY APPLICATION NUMBER: US 10/444,853
PRIORITY FILING DATE: 2003-05-23
PRIORITY APPLICATION NUMBER: PCT/US03/05346
PRIORITY FILING DATE: 2003-02-20
PRIORITY APPLICATION NUMBER: PCT/US03/05028
```

```
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 240
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc_feature
LOCATION: (2)..(2)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(3)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (4)..(5)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-240
```

```
Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      21  UACACCTCCGCTTCCGCTT 39
Db      1  UACACCTCCGCTTCCGCTT 19
```

```
RESULT 926
US-10-919-866-241
```

Sequence 241, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwigen, James
APPLICANT: Richards, Ivan
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
TITLE OF INVENTION: Acid (siNA)
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 241
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(12)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(17)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety

US-10-919-866-241
Query Match 1.1% Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 315 CUUCCUCCUUAAGCCUGGCC 333
DB 1 CUUCCUCCUUAAGCCUGGCC 19
RESULT 927
US-10-919-866-242
Sequence 242, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwigen, James
APPLICANT: Richards, Ivan
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
TITLE OF INVENTION: Acid (siNA)
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 242
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(7)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8)..(10)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(15)

```
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-242
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 317 UCCUCUAGCCUGGCCUG 335
Db 1 UCCUCUAGCCUGGCCUG 19
```

```
RESULT 928
US-10-919-866-243
Sequence 243, Application US/10919866
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MBHB04-183-A)
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/919,866
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See file wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 243
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sigma sense region
NAME/KEY: misc_feature
```

```
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc_feature
LOCATION: (2)..(2)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(5)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(6)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (7)..(9)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(11)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (12)..(15)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(17)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(18)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-243

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 975 GCAGATGACCAAGACCAC 993
Db 1 GCAGATGACCAAGACCAC 19

RESULT 929
US-10-919-866-244
Sequence 244, Application US/10919866
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MBHB04-183-A)
```

CURRENT APPLICATION NUMBER: US/10/919,866
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 244
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE: -
OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
FEATURE: -
NAME/KEY: misc feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-deoxy
FEATURE: -
NAME/KEY: misc feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE: -
NAME/KEY: misc feature
LOCATION: (3)..(3)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE: -
NAME/KEY: misc feature
LOCATION: (4)..(5)
OTHER INFORMATION: 2'-deoxy
FEATURE: -
NAME/KEY: misc feature
LOCATION: (6)..(6)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE: -
NAME/KEY: misc feature
LOCATION: (7)..(7)
OTHER INFORMATION: 2'-deoxy
FEATURE: -
NAME/KEY: misc feature
LOCATION: (8)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE: -
NAME/KEY: misc feature
LOCATION: (10)..(11)
OTHER INFORMATION: 2'-deoxy
FEATURE: -
NAME/KEY: misc feature
LOCATION: (12)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE: -
NAME/KEY: misc feature
LOCATION: (13)..(17)
OTHER INFORMATION: 2'-deoxy
FEATURE: -
NAME/KEY: misc feature

LOCATION: (18)..(18)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE: -
NAME/KEY: misc feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy
FEATURE: -
NAME/KEY: misc feature
LOCATION: (20)..(21)
OTHER INFORMATION: n strands for thymidine
FEATURE: -
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-244
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1712 AGCAGUACCGACGACAGA 1730
Db 1 AGCAGUACCGACGACAGA 19
RESULT 930
US-10-919-866-245
Sequence 245, Application US/10919866
GENERAL INFORMATION:
APPLICANT: Sirta Therapeutics, Inc.
APPLICANT: Richards, Ivan
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
PRIOR FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 245
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE: -
OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
FEATURE: -
NAME/KEY: misc feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE: -

```
NAME/KEY: misc feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyribasic moiety
FEATURE:
NAME/KEY: misc feature
LOCATION: (2)..(3)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (5)..(5)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (6)..(7)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (8)..(9)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (11)..(15)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (17)..(18)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyribasic moiety
US-10-919-866-245

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1714 CAGUACGACGAGACAGU 1732
Db      1 CAGUACGACGAGACAGU 19

RESULT 931
US-10-919-866-246
; Sequence 246, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richard, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
```

```
FILE REFERENCE: 400/205 (MHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
PRIOR FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See file wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: Patentln version 3.3
SEQ ID NO 246
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
NAME/KEY: misc feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyribasic moiety
FEATURE:
NAME/KEY: misc feature
LOCATION: (3)..(3)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (5)..(6)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (7)..(8)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (9)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (10)..(14)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (16)..(17)
OTHER INFORMATION: 2'-deoxy
FEATURE:
```

```

; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-246
```

```

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1715 AGUACGACGAGACGAGUC 1733
Db      1 AGUACGACGAGACGAGUC 19
```

```

RESULT 932
US-10-919-866-247/c
; Sequence 247, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See file Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: Patenclin version 3.3
; SEQ ID NO 247
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(5)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
```

```

; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(10)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(13)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-247

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      17 ACAGUAACACUCCUUCUU 35
Db      19 ACAGTACAACCTCGCCTT 1
```

```

RESULT 933
US-10-919-866-248/c
; Sequence 248, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
```

```
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-11-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 324
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 248
;; LENGTH: 21
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
;; NAME/KEY: misc_feature
;; LOCATION: (1)_(3)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (4)_(4)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (5)_(9)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (10)_(10)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (11)_(14)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (15)_(16)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (17)_(17)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (18)_(18)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (19)_(19)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (20)_(21)
;; OTHER INFORMATION: n stands for thymidine
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (20)_(20)
;; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-919-866-248

Query Match 1.1%; Score 19; DB 1; length 21;
Best Local Similarity 57.9%; Pred. No. 5.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
```

```
Db 19 TACAACTCGCCTTGTTT 1

RESULT 934
US-10-919-866-249/c
; Sequence 249; Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Silma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEH804-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 249
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (1)_(2)
; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (3)_(4)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (5)_(7)
;; OTHER INFORMATION: 2'-deoxy
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (8)_(10)
;; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (11)_(19)
;; OTHER INFORMATION: n stands for thymidine
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (20)_(21)
;; OTHER INFORMATION: n stands for thymidine
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (20)_(20)
```

```
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-249

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy      315 CUUCUCUUAAGCCUGGCC 333
Db      19 CTTCTTAAAGCTGGCC 1

RESULT 935
US-10-919-866-250/c
; Sequence 250, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 250
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (1)-(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; NAME/KEY: misc_feature
; LOCATION: (2)-(4)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)-(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)-(9)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
```

```
; LOCATION: (10)-(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)-(19)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)-(21)
; OTHER INFORMATION: n strands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)-(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-250

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy      317 UCCUCUUAAGCCUGGCCUG 335
Db      19 TCCTTTAAAGCTGGCTG 1

RESULT 936
US-10-919-866-251/c
; Sequence 251, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 251
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (1)-(11)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
```

```
/ NAME/KEY: misc_feature
/ LOCATION: (2)..(2)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (3)..(4)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (5)..(8)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (9)..(10)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (11)..(13)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (14)..(14)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (15)..(17)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (18)..(18)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (19)..(19)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: n_stands_for_thymidine
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n_stands_for_thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: Phosphorothioate 3'-internucleotide linkage
/ US-10-919-866-251

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 975 GCGAUGGACCAAGCCAC 993
DB 19 GCGATGACCAAGCCAC 1

RESULT 937
US-10-919-866-252/C
/ Sequence 252, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: McGivern, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/205 (MHB04-183-A)
/ CURRENT APPLICATION NUMBER: US/10/919,866
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966

/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 252
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(1)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (2)..(2)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (3)..(7)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (8)..(8)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (9)..(10)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (11)..(12)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (13)..(13)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (14)..(14)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (15)..(16)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (18)..(19)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n_stands_for_thymidine
/ FEATURE:
```

NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-252

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1712 AGACGACGACGACGACA 1730
||||:||||:||||:||||:
Db 19 AGACGACGACGACGACA 1

RESULT 938
US-10-919-866-253/c
Sequence 253, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See file wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 253
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (2)..(3)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro

FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(14)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(18)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n strands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-253

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1714 CAGUACGACGACGACAGU 1732
||||:||||:||||:||||:
Db 19 CAGTACCAGACGACGACGT 1

RESULT 939
US-10-919-866-254/c
Sequence 254, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23

PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 254
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(4)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(5)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(11)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (12)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(15)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(17)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-internucleotide linkage
US-10-919-866-254

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1715 AGUACGACGAGACAGUC 1733
||:|||||||||||||||:

DB 19 AGTACCAGCAGACAGTC 1
RESULT 940
US-10-919-866-255
Sequence 255, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sina Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
TITLE OF INVENTION: Acid (siNA)
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 255
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3' attached terminal deoxyribose moiety
FEATURE:
NAME/KEY: misc_feature
LOCATION: (2)..(2)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(4)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(5)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(6)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (7)..(7)

```
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (8)..(9)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (10)..(13)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (14)..(14)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (15)..(19)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-255
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 17 ACAGUACAACUCCUCCUU 35
DB 1 ACAGUACAACUCCUCCUU 19
```

```
RESULT 941
US-10-919-866-256
/ Sequence 256, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sigma Therapeutics, Inc.
/ APPLICANT: McSwigen, Ivan
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/205 (MEHB04-183-A)
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/919,866
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
```

```
/ SEQ ID NO 256
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(1)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(1)
/ OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (2)..(2)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (3)..(3)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (4)..(5)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (6)..(9)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (10)..(10)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (11)..(15)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (16)..(16)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (17)..(19)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-256
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 21 UACAACUCCUCCUCCUU 39
DB 1 UACAACUCCUCCUCCUU 19
```

```
RESULT 942
US-10-919-866-257
/ Sequence 257, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sigma Therapeutics, Inc.
/ APPLICANT: McSwigen, Ivan
```

TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE OF INVENTION: Acid (s1na)
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US 10/919,866
PRIORITY FILING DATE: 2004-08-17
PRIORITY APPLICATION NUMBER: US 10/798,090
PRIORITY FILING DATE: 2004-03-11
PRIORITY APPLICATION NUMBER: PCT/US04/16390
PRIORITY FILING DATE: 2004-05-24
PRIORITY APPLICATION NUMBER: US 10/826,966
PRIORITY FILING DATE: 2004-04-16
PRIORITY APPLICATION NUMBER: US 10/757,803
PRIORITY FILING DATE: 2004-01-14
PRIORITY APPLICATION NUMBER: US 10/720,448
PRIORITY FILING DATE: 2003-11-24
PRIORITY APPLICATION NUMBER: US 10/693,059
PRIORITY FILING DATE: 2003-11-23
PRIORITY APPLICATION NUMBER: US 10/444,853
PRIORITY FILING DATE: 2003-05-23
PRIORITY APPLICATION NUMBER: PCT/US03/05346
PRIORITY FILING DATE: 2003-02-20
PRIORITY APPLICATION NUMBER: PCT/US03/05028
PRIORITY FILING DATE: 2003-02-20
PRIORITY APPLICATION NUMBER: US 60/358,580
PRIORITY FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 257
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: s1na sense region
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc feature
LOCATION: (10)..(12)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc feature
LOCATION: (13)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (16)..(17)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-257

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 315 CUUCCUUAAGCCUGGCC 333
|||||
Db 1 CUUCCUUAAGCCUGGCC 19
RESULT 943
US-10-919-866-258
Sequence 258, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: S1na Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US 10/919,866
PRIORITY FILING DATE: 2004-08-17
PRIORITY APPLICATION NUMBER: US 10/798,090
PRIORITY FILING DATE: 2004-03-11
PRIORITY APPLICATION NUMBER: PCT/US04/16390
PRIORITY FILING DATE: 2004-05-24
PRIORITY APPLICATION NUMBER: US 10/826,966
PRIORITY FILING DATE: 2004-04-16
PRIORITY APPLICATION NUMBER: US 10/757,803
PRIORITY FILING DATE: 2004-01-14
PRIORITY APPLICATION NUMBER: US 10/720,448
PRIORITY FILING DATE: 2003-11-24
PRIORITY APPLICATION NUMBER: US 10/693,059
PRIORITY FILING DATE: 2003-11-23
PRIORITY APPLICATION NUMBER: US 10/444,853
PRIORITY FILING DATE: 2003-05-23
PRIORITY APPLICATION NUMBER: PCT/US03/05346
PRIORITY FILING DATE: 2003-02-20
PRIORITY APPLICATION NUMBER: PCT/US03/05028
PRIORITY FILING DATE: 2003-02-20
PRIORITY APPLICATION NUMBER: US 60/358,580
PRIORITY FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 258
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: s1na sense region
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)..(7)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (8)..(10)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc feature
LOCATION: (11)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (14)..(15)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc feature
LOCATION: (16)..(18)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:

```
/ NAME/KEY: misc_feature
/ LOCATION: (19)..(19)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-258

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 317 UCCUCUUAAGCCUGCCUG 335
Db 1 UCCUCUUAAGCCUGCCUG 19

RESULT 944
US-10-919-866-259
/ Sequence 259, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwiggen, Ivan
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/205 (MEHB04-183-A)
/ CURRENT APPLICATION NUMBER: US/10/919,866
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 259
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: sirna sense region
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(1)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(1)
/ OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
```

```
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (2)..(2)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (3)..(5)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (6)..(6)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (7)..(9)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (10)..(11)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (12)..(15)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (16)..(17)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (18)..(18)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: n stands for thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-259

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 975 GCAGUGACCAAGACCAC 993
Db 1 GCAGUGACCAAGACCAC 19

RESULT 945
US-10-919-866-260
/ Sequence 260, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwiggen, Ivan
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/205 (MEHB04-183-A)
/ CURRENT APPLICATION NUMBER: US/10/919,866
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
```

```

; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 260
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(11)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(3)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (4)..(5)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(7)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(11)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(17)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-O-methyl

```

```

; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
; US-10-919-866-260
;
; Query Match
; Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
; Matches 19; Conservative 0%; Pred.No. 5.1e+02;
; Mismatches 0; Indels 0; Gaps 0;
;
; QY 1712 AGCAGUACCGACGACGACCA 1730
; DB 1 AGCAGUACCGACGACGACCA 19
;
; RESULT 946
; US-10-919-866-261
; Sequence 261, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 261
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(3)

```

OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(5)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(7)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8)..(9)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(15)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(18)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-261

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1714 CAGUACGACGAGACAGU 1732
|||||
Db 1 CAGUACGACGAGACAGU 19

RESULT 947
US-10-919-866-262
Sequence 262, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirta Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MBHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390

PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 262
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
NAME/KEY: misc_feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(3)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(6)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (7)..(8)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (9)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(14)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(17)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)

```

; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxybasic moiety
US-10-919-866-262

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1715 AGUACGACGACGACGUC 1733
Db      1 AGUACGACGACGACGAGUC 19

RESULT 948
US-10-919-866-263/c
; Sequence 263, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
SEQ ID NO 263
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(5)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; NAME/KEY: misc_feature
; LOCATION: (7)..(10)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
```

```

; LOCATION: (11)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(13)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-919-866-263

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred.No.5.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

OY      17 ACAGUACACGCGCCUUY 35
Db      19 ACAGTACACCTCGCCTT 1

RESULT 949
US-10-919-866-264/c
; Sequence 264, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: McSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
```

PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 264
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(3)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(9)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(14)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(16)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(17)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(18)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-264

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 5.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 21 UACAACUCCGCCUUGUU 39
DB 19 TACAACCTCGCCTTCTTT 1

RESULT 950
US-10-919-866-265/c
Sequence 265, Application US/10919866

Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richard, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MBH04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 265
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(4)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(7)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(19)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-265

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;


```
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(8)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (9)..(10)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(14)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(17)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(18)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-919-866-267

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5,1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      975 GCAGATGACCAAGACCAC 993
DB      19 GCAGATGACCAAGACCAC 1

RESULT 953
US-10-919-866-268/c
; Sequence 268, Application US/10919866
; Publication No. US2005017664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MH804-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
```

```
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 268
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (2)..(2)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(7)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8)..(8)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (9)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(12)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(14)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(16)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(17)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-268

Query Match      1.1%; Score 19; DB 1; Length 21;
```

Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1712 AGCAGUACGACGACGACA 1730
DB 19 AGCAGTACCGACGACGACA 1

RESULT 954
US-10-919-866-269/c
Sequence 269, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: MCSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
TITLE OF INVENTION: Acid (siRNA)
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
PRIOR FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 269
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (2)..(3)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature

LOCATION: (11)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(14)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(18)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-269

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1714 CAGUACGACGACGACGACG 1732
DB 19 CAGTACCGACGACGACGACGT 1

RESULT 955
US-10-919-866-270/c
Sequence 270, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sigma Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: MCSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
PRIOR FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028

```

; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 270
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(11)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(15)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(16)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(17)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-919-866-270

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      1715 AGUACGACGAGACAGUC 1733
Db      19 AGTACGACGAGACAGATC 1

RESULT 956
US-10-919-866-271
; Sequence 271, Application US/10919866
```

```

; Publication No. US2005017664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 271
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3' attached terminal deoxyribose moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3' attached terminal deoxyribose moiety
US-10-919-866-271

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      17 ACAGUACAACCTCGCCUU 35
Db      1 ACAGUACAACCTCGCCUU 19

RESULT 957
US-10-919-866-272
; Sequence 272, Application US/10919866
; Publication No. US2005017664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
```

```

; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 272
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
; US-10-919-866-272

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      21 UACACCCUGCCCUUUGUU 39
Db      1 UACACCCUGCCCUUUGUU 19

RESULT 958
US-10-919-866-273
; Sequence 273, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; FILE REFERENCE: Acid (siNA)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
```

```

; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 273
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
; US-10-919-866-273

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      315 CUUCCUUAAGCCUGCC 333
Db      1 CUUCCUUAAGCCUGCC 19

RESULT 959
US-10-919-866-274
; Sequence 274, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; FILE REFERENCE: Acid (siNA)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
```

PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 274
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sRNA sense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(21)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-274

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 317 UCCUCUAGCCUGGCGG 335
Db 1 UCCUCUAGCCUGGCGG 19

RESULT 960
US-10-919-866-275
Sequence 275, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sina Therapeutics, Inc.
APPLICANT: Richards, Ivan
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
PRIOR FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3

PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 275
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: sRNA sense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-275

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 975 GCAGUGAGCAAGACCAC 993
Db 1 GCAGUGAGCAAGACCAC 19

RESULT 961
US-10-919-866-276
Sequence 276, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sina Therapeutics, Inc.
APPLICANT: Richards, Ivan
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
PRIOR FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 276

```

; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-276

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1712 AGCAGUACGACGACGACGA 1730
DB      1 AGCAGUACGACGACGACGA 19

RESULT 962
US-10-919-866-277
; Sequence 277, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 277
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc_feature
```

```

; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-277

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1714 CAGUACGACGACGACGACGU 1732
DB      1 CAGUACGACGACGACGACGU 19

RESULT 963
US-10-919-866-278
; Sequence 278, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 278
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
```

```
/ NAME/KEY: misc feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-278
```

```
Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1715 AGUACGACGACGACGACGUC 1733
      |||||
Db      1 AGUACGACGACGACGACGUC 19
```

```
RESULT 964
US-10-919-866-279/c
/ Sequence 279, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: McSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/205 (MEHB04-183-A)
/ CURRENT APPLICATION NUMBER: US/10/919,866
/ PRIOR FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 279
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: sirna antisense region
/ NAME/KEY: misc feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-279
```

```
Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      17 ACAGUACAACCCGCGCCU 35
      |||||
Db      19 ACAGUACAACCCGCGCCU 35
```

```
Db      19 ACAGUACAACCCGCGCCTT 1
```

```
RESULT 965
US-10-919-866-280/c
/ Sequence 280, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: McSwigen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/205 (MEHB04-183-A)
/ CURRENT APPLICATION NUMBER: US/10/919,866
/ PRIOR FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 280
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: sirna antisense region
/ NAME/KEY: misc feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-280
```

```
Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 5.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      21 UACAACCCGCGCCUUGUU 39
      |||||
Db      19 TACAACCTCGCCTTCTTT 1
```

```
RESULT 966
US-10-919-866-281/c
/ Sequence 281, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: McSwigen, James
```

```

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 281
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; US-10-919-866-281

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      315 CUUCCUUAAGCCUGGCC 333
DB      19 CTTCTTAAGCCTGCGCC 1

RESULT 967
; US-10-919-866-282/c
; Sequence 282, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
```

```

; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 282
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; US-10-919-866-282

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      317 UCCUUAAGCCUGGCCUG 335
DB      19 TCCTTAAGCCTGCGCTG 1

RESULT 968
; US-10-919-866-283/c
; Sequence 283, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
```

```

; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 283
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n strands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-919-866-283
```

```
Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

QY 975 GCAGAGGACGACGACAC 993

DB 19 GCAGATGACGACGACAC 1

RESULT 969

US-10-919-866-284/c

```

; Sequence 284, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 284
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
```

```

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n strands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-919-866-284
```

```
Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

QY 1712 AGCAGUACGACGACGACA 1730

DB 19 AGCAGTACGACGACGACA 1

RESULT 970

US-10-919-866-285/c

```

; Sequence 285, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 285
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n strands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide linkage
US-10-919-866-285
```

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1714 CAGUACGACGACGACG 1732
DB 19 CAGTACCAGACGACGACGT 1

RESULT 971
US-10-919-866-286/C

; Sequence 286, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCES: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 286
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-919-866-286

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1715 AGUACGACGACGACG 1733
DB 19 AGTACCAGACGACGACGT 1

RESULT 972

US-10-919-866-287/C
; Sequence 287, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCES: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 287
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(5)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(13)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(17)

```
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (18)..(18)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-287
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 17 ACAGAACACCTCGCCCTT 35
Db 19 ACAGTACACCTCGCCCTT 1
```

```
RESULT 973
US-10-919-866-288/c
; Sequence 288, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 288
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
; NAME/KEY: misc feature
```

```
LOCATION: (1)..(3)
FEATURE:
NAME/KEY: misc feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (5)..(9)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (11)..(14)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc feature
LOCATION: (15)..(16)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (17)..(17)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc feature
LOCATION: (18)..(18)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-288
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 5.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 21 UACACCTCGCCCTTGT 39
Db 19 TACACCTCGCCCTTGT 1

RESULT 974
US-10-919-866-289/c
; Sequence 289, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
```

```

; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 289
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (3)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)..(7)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (8)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (11)..(19)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
; US-10-919-866-289

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 315 CUCCUCUUAAGCCUGGCC 333
DB 19 CTTCTTAAGCCTGGCC 1

RESULT 975
US-10-919-866-290/c
; Sequence 290, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
```

```

; FILE REFERENCE: 400/205 (MEH804-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 290
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (2)..(4)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (7)..(9)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (10)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (13)..(19)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
; US-10-919-866-290

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 317 UCCUCUUAAGCCUGGCCUG 335
DB 19 TCTCTTAAGCCTGGCC 1
```

RESULT 976
US-10-919-866-291/c
; Sequence 291, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sinA)
; FILE REFERENCE: 400/205 (MBH04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 291
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sinA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(4)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)..(10)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-O-methyl

; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n strands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-291

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 975 GCAGTGCAGCCAGACCAC 993
Db 19 GCAGTGCAGCCAGACCAC 1

RESULT 977
US-10-919-866-292/c
; Sequence 292, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sinA)
; FILE REFERENCE: 400/205 (MBH04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 292
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:

```
OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
NAME/KEY: misc_feature
LOCATION: (2)..(2)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(7)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8)..(8)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (9)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(12)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(14)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(16)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(17)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-292

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1712 AGCAGUACGACGACGACA 1730
DB      19  AGCAGTACGACGACGACA 1

RESULT 978
US-10-919-866-293/c
; Sequence 293, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
```

```
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/205 (MEMB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-03-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 293
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
; FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (2)..(3)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(14)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(18)
```

```
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (19)..(19)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: n strands for thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-293

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1714 CAGUACGACGACGACGACG 1732
DB      19 CAGTACCAGCAGACGACGT 1

RESULT 979
US-10-919-866-294/c
/ Sequence 294, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: MCSwigen, James
/ APPLICANT: Richards, Ivan
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siRNA)
/ FILE REFERENCE: 400/205 (MEH04-183-A)
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/919,866
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/926,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 294
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(2)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
```

```
/ LOCATION: (3)..(4)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (5)..(5)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (6)..(10)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (11)..(11)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (12)..(13)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (14)..(15)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (16)..(16)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (17)..(17)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (18)..(19)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: n strands for thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-294

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1715 AGUACGACGACGACGACGUC 1733
DB      19 AGTACCAGCAGACGACGTC 1

RESULT 980
US-10-919-866-295/c
/ Sequence 295, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: MCSwigen, James
/ APPLICANT: Richards, Ivan
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siRNA)
/ FILE REFERENCE: 400/205 (MEH04-183-A)
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/919,866
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
```

```

; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 295
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-295
```

```

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      17 ACAAGAACACCTCGCCCTT 35
Db      19 ACAAGAACACCTCGCCCTT 1
```

```

RESULT 981
US-10-919-866-296/C
; Sequence 296, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
```

```

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 296
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-296
```

```

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 5.1e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      21 UACAACTCGCCCTTGTGTT 39
Db      19 TACAACTCGCCCTTGTGTT 1
```

```

RESULT 982
US-10-919-866-297/C
; Sequence 297, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MEHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; PRIOR FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 297
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-297

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 315 UCCUCUUAAGCCUGGCC 333
Db 19 TCCTCTTAAGCCTGGCC 1

RESULT 983

US-10-919-866-298/c
Sequence 298, Application US/10919866
Publication No. US20050176664A1

GENERAL INFORMATION:

APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James

TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic

FILE REFERENCE: 400/205 (MHB04-183-A)
CURRENT FILING DATE: 2004-08-17
PRIOR FILING DATE: 2004-08-17

PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24

PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16

PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14

PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24

PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23

PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23

PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20

Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3

SEQ ID NO 298
LENGTH: 21
TYPE: RNA

ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region

FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(20)

OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)

OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-298

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 317 UCCUCUUAAGCCUGGCC 335
Db 19 TCCTCTTAAGCCTGGCC 1

RESULT 984

US-10-919-866-299/c
Sequence 299, Application US/10919866
Publication No. US20050176664A1

GENERAL INFORMATION:

APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James

TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic

FILE REFERENCE: 400/205 (MHB04-183-A)
CURRENT FILING DATE: 2004-08-17
PRIOR FILING DATE: 2004-08-17

PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11

PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24

PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16

PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14

PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24

PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23

PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23

PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20

PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20

Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3

SEQ ID NO 299
LENGTH: 21
TYPE: RNA

ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region

FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(20)

OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)

OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-299

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 975 GCAGATGACCAAGACCAC 993
Db 19 GCAGATGACCAAGACCAC 1

RESULT 985
US-10-919-866-300/c

```
Sequence 300, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sitna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
Acid (siNA)
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT FILING DATE: 2004-08-17
PRIORITY FILING DATE: 2004-03-11
PRIORITY FILING DATE: 2004-03-11
PRIORITY FILING DATE: 2004-05-24
PRIORITY FILING DATE: 2004-05-24
PRIORITY FILING DATE: 2004-04-16
PRIORITY FILING DATE: 2004-04-16
PRIORITY FILING DATE: 2004-01-14
PRIORITY FILING DATE: 2003-11-24
PRIORITY FILING DATE: 2003-11-24
PRIORITY FILING DATE: 2003-11-23
PRIORITY FILING DATE: 2003-05-23
PRIORITY FILING DATE: 2003-05-23
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 300
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-300

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 5.1e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1712 AGCAGUACGACGACGACA 1730
DB      19 AGCAGTACGACGACGACACA 1

RESULT 986
US-10-919-866-301/C
Sequence 301, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sitna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
Acid (siNA)
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT FILING DATE: 2003-11-24
PRIORITY FILING DATE: 2003-05-23
PRIORITY FILING DATE: 2003-05-23
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 301
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-301
```

```
CURRENT FILING DATE: 2004-08-17
PRIORITY FILING DATE: 2004-03-11
PRIORITY FILING DATE: 2004-03-11
PRIORITY FILING DATE: 2004-05-24
PRIORITY FILING DATE: 2004-05-24
PRIORITY FILING DATE: 2004-04-16
PRIORITY FILING DATE: 2004-04-16
PRIORITY FILING DATE: 2004-01-14
PRIORITY FILING DATE: 2004-01-14
PRIORITY FILING DATE: 2003-11-24
PRIORITY FILING DATE: 2003-11-24
PRIORITY FILING DATE: 2003-11-23
PRIORITY FILING DATE: 2003-11-23
PRIORITY FILING DATE: 2003-05-23
PRIORITY FILING DATE: 2003-05-23
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 301
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-301

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1714 CAGUACGACGACGACGACU 1732
DB      19 CAGTACGACGACGACGACGT 1

RESULT 987
US-10-919-866-302/C
Sequence 302, Application US/10919866
Publication No. US20050176664A1
GENERAL INFORMATION:
APPLICANT: Sitna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
Acid (siNA)
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT FILING DATE: 2004-08-17
PRIORITY FILING DATE: 2004-03-11
PRIORITY FILING DATE: 2004-03-11
PRIORITY FILING DATE: 2004-05-24
PRIORITY FILING DATE: 2004-05-24
PRIORITY FILING DATE: 2004-04-16
PRIORITY FILING DATE: 2004-04-16
PRIORITY FILING DATE: 2004-01-14
PRIORITY FILING DATE: 2003-11-24
PRIORITY FILING DATE: 2003-11-24
```

```
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 302
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-919-866-302
```

```
Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

QY 1715 AGUACGACGAGACAGCUC 1733

Db 19 AGTACCAGCAGACAGCAGTC 1

```
RESULT 988
US-10-919-866-312
; Sequence 312, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 312
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety, inverted abasic,
; OTHER INFORMATION: inverted nucleotide or other terminal cap that is optionally pre
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety, inverted abasic, pre
; OTHER INFORMATION: inverted nucleotide or other terminal cap that is optionally pre
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-919-866-312
```

```
Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1011 GAACACACAUAGUCUGCU 1029

Db 1 GAACACACAUAGUCUGCU 19

```
RESULT 989
US-10-919-866-313/c
; Sequence 313, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/205 (MBHB04-183-A)
; CURRENT APPLICATION NUMBER: US/10/919,866
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 313
; LENGTH: 21
; TYPE: RNA
```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal glyceryl moiety or inverted deoxyabasic
; OTHER INFORMATION: (optionally present)
US-10-919-866-313

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 5.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      1011 GAACAACAUGAUGCUGCU 1029
Db      19  GAACAACAUGAUGCUGCTCT 1

RESULT 990
US-10-919-866-314
; Sequence 314, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/205 (MEH804-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: US 10/798,090
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 314
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA sense region
; FEATURE:
; NAME/KEY: misc_feature
```

```

; LOCATION: (1)..(3)
; OTHER INFORMATION: 2'-O-Methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(6)
; OTHER INFORMATION: 2'-O-Methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(9)
; OTHER INFORMATION: 2'-O-Methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(12)
; OTHER INFORMATION: 2'-O-Methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-O-Methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(17)
; OTHER INFORMATION: 2'-O-Methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(16)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide Linkage
; OTHER INFORMATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-919-866-314

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1011 GAACAACAUGAUGCUGCU 1029
Db      1  GAACAACAUGAUGCUGCU 19

RESULT 991
US-10-919-866-315/c
; Sequence 315, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
```

TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/919,866
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
Remaining Prior Application data removed - See File Wrapper or PALM.
SOFTWARE: PatentIn version 3.3
SEQ ID NO 315
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
NAME/KEY: misc_feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (4)..(5)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (7)..(7)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(13)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-O-Methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(3)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(6)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8)..(9)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature

LOCATION: (11)..(12)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(15)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(19)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide Linkage
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal glyceryl moiety or inverted deoxyabasic (d
US-10-919-866-315
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 5.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1011 GAACACATGATGATGCT 1029
DB 19 GAACACATGATGCT 1
RESULT 992
US-10-919-866-315
Sequence 316, Application US/10919866
Publication No. US2005017664A1
GENERAL INFORMATION:
APPLICANT: siRNA Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/205 (MEHB04-183-A)
CURRENT APPLICATION NUMBER: US 10/919,866
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
Remaining Prior Application data removed - See File Wrapper or PALM.
SOFTWARE: PatentIn version 3.3
SEQ ID NO 316
LENGTH: 21
TYPE: RNA

```
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
NAME/KEY: misc_feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
NAME/KEY: misc_feature
LOCATION: (7)..(7)
OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
NAME/KEY: misc_feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
NAME/KEY: misc_feature
LOCATION: (13)..(13)
OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
NAME/KEY: misc_feature
LOCATION: (18)..(18)
OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety, inverted abasic,
OTHER INFORMATION: inverted nucleotide or other terminal cap that is optionally pres
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety, inverted abasic,
OTHER INFORMATION: inverted nucleotide or other terminal cap that is optionally pres
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(21)
OTHER INFORMATION: n stands for thymidine
US-10-919-866-316

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAACACAUGAUGUGUCU 1029
DB 1 GAACACAUGAUGUGUCU 19

RESULT 993
US-10-919-866-317/c
; Sequence 317, Application US/10919866
; Publication No. US20050176664A1
; GENERAL INFORMATION:
; APPLICANT: Sina Therapeutics, Inc.
; APPLICANT: McSwigen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
; TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/205 (MEH04-183-A)
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: US 10/919,866
; PRIOR FILING DATE: 2004-03-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
```

```
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 317
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
NAME/KEY: misc_feature
LOCATION: (3)..(3)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
NAME/KEY: misc_feature
LOCATION: (6)..(6)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
NAME/KEY: misc_feature
LOCATION: (8)..(9)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(12)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
NAME/KEY: misc_feature
LOCATION: (14)..(15)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(19)
OTHER INFORMATION: 2'-deoxy-2'-Fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide linkage
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3' attached terminal glyceryl moiety or inverted deoxyabasic (C
US-10-919-866-317

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 5.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAACACAUGAUGUGUCU 1029
DB 19 GAACACAUGAUGUGUCU 1

RESULT 994
US-10-919-866-318
; Sequence 318, Application US/10919866
; Publication No. US20050176664A1
```

```

/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siRNA)
/ FILE REFERENCE: 400/205 (MEHB04-183-A)
/ CURRENT APPLICATION NUMBER: US/10/919,866
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 324
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 318
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siRNA sense region
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(3)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (5)..(6)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (8)..(9)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (11)..(12)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (14)..(14)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (14)..(14)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (17)..(17)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (4)..(4)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature

```

```

/ LOCATION: (7)..(7)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (10)..(10)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (13)..(13)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (15)..(16)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (18)..(19)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety, inverted abasic,
/ OTHER INFORMATION: inverted nucleotide or other terminal cap that is optionally pre
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety, inverted abasic,
/ OTHER INFORMATION: inverted nucleotide or other terminal cap that is optionally pre
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n strands for thymidine
/ US-10-919-866-318

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1011  GAAACAACAAUGAUGCGUCU 1029
Db       1  GAAACAACAAUGAUGCGUCU 19

RESULT 995
US-10-919-866-319
/ Sequence 319, Application US/10919866
/ Publication No. US20050176664A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Richards, Ivan
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Cholinergic Muscarinic
/ TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/205 (MEHB04-183-A)
/ CURRENT APPLICATION NUMBER: US/10/919,866
/ CURRENT FILING DATE: 2004-08-17
/ PRIOR APPLICATION NUMBER: US 10/798,090
/ PRIOR FILING DATE: 2004-03-11
/ PRIOR APPLICATION NUMBER: PCT/US04/16390
/ PRIOR FILING DATE: 2004-05-24
/ PRIOR APPLICATION NUMBER: US 10/826,966
/ PRIOR FILING DATE: 2004-04-16
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-14
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-11-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20

```

```

PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 319
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: 5' to 3' sense region
NAME/KEY: misc_feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (7)..(7)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(18)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety, inverted abasic,
OTHER INFORMATION: inverted nucleotide or other terminal cap that is optionally pres
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-5' attached terminal deoxyabasic moiety, inverted abasic,
OTHER INFORMATION: inverted nucleotide or other terminal cap that is optionally pres
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: n stands for thymidine
US-10-919-866-319

Query Match 1.1% Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5,1e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAACACACAUGAUGCGUCU 1029
DB 1 GAACACACAUGAUGCGUCU 19

RESULT 996
US-10-919-866-320/c
Sequence 320, Application US/10919866
Publication No. US2005017664A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Richards, Ivan
APPLICANT: MCSwigen, James
TITLE OF INVENTION: RNA interference Mediated Inhibition Of Cholinergic Muscarinic
TITLE OF INVENTION: Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic
TITLE OF INVENTION: Acid (sinA)

FILE REFERENCE: 400/205 (MEH04-183-A)
CURRENT APPLICATION NUMBER: US/10/919,866
CURRENT FILING DATE: 2004-08-17
PRIOR APPLICATION NUMBER: US 10/798,090
PRIOR FILING DATE: 2004-03-11
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-11-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 324
SOFTWARE: PatentIn version 3.3
SEQ ID NO 320
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: 5' to 3' antisense region
NAME/KEY: misc_feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (4)..(5)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (7)..(7)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(13)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(3)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(6)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (11)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
```

```
; NAME/KEY: misc_feature
; LOCATION: (14)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n strands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal glyceryl moiety or inverted deoxyabasic (c
US-10-919-866-320
```

```
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 5.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1011 GAACAACAUGAGUCGUCU 1029
DB 19 GAACAACATGATGCTGCT 1
```

```
RESULT 997
US-10-310-914A-446812/c
; Sequence 446812, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 446812
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-446812
```

```
Query Match 1.1%; Score 18.8; DB 1; Length 22;
Best Local Similarity 77.3%; Pred. No. 5.7e+02;
Matches 17; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1170 GGUGCCUGAGAGAGCTGGGG 1191
DB 22 GGTGTCTGCGGAGAGCTGGGG 1
```

```
RESULT 998
US-10-871-137-2/c
; Sequence 2, Application US/10871137
; Publication No. US20050042689A1
; GENERAL INFORMATION:
; APPLICANT: Peck, Amnon B
; TITLE OF INVENTION: DIAGNOSING SJORGENS SYNDROME
; FILE REFERENCE: 5853-169
; CURRENT APPLICATION NUMBER: US/10/871,137
; CURRENT FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 60/479,545
; PRIOR FILING DATE: 2003-06-18
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn version 3.3
```

```
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: reverse PCR primer
; LOCATION: (1)..(18)
US-10-871-137-2
```

```
Query Match 1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 4.8e+02;
Matches 16; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1753 GCACCCGAGCAGGCCUUG 1770
DB 18 GCACCCGAGCAGGCCCTTG 1
```

```
RESULT 999
US-11-083-784-97104
; Sequence 97104, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97104
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97104
```

```
Query Match 1.0%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 306 CACACACUACUUCUCUCU 323
DB 1 CACACACUACUUCUCUCU 18
```

```
RESULT 1000
US-11-101-244-97104
; Sequence 97104, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
```

```

; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97104
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97104

```

```

Query Match      1.0%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      306 CAACACUACUUCUCCUCU 323
Db      1 CAACACUACUUCUCCUCU 18

```

```

RESULT 1001
US-10-280-183A-364
; Sequence 364, Application US/10280183A
; Publication No. US20040081964A1
; GENERAL INFORMATION:
; APPLICANT: Pfizer Inc.
; APPLICANT: Bachmanov, Alexander A
; APPLICANT: Beauchamp, Gary K.
; APPLICANT: Chatterjee, Aubrobindo
; APPLICANT: De Jong, Pieter J.
; APPLICANT: Li, Shanru
; APPLICANT: Li, Xia
; APPLICANT: Ohmen, Jeffrey D
; APPLICANT: Reed, Danielle R.
; APPLICANT: Ross, David
; APPLICANT: Tordoff, Michael G.
; TITLE OF INVENTION: GENE AND SEQUENCE VARIATION ASSOCIATED WITH SENSING
; FILE REFERENCE: PC18306A
; CURRENT APPLICATION NUMBER: US/10/280,183A
; CURRENT FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: 60/200,794
; PRIOR FILING DATE: 2000-04-28
; NUMBER OF SEQ ID NOS: 652
; SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 364
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Mouse
US-10-280-183A-364

```

```

Query Match      1.0%; Score 18; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 5.7e+02;
Matches 15; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1335 CUCAGUGGUAAGACAC 1352
Db      2 CTCAGTGGTGAAGACAC 19

```

```

RESULT 1002
US-10-310-914A-1189557/C
; Sequence 1189557, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 138402
; SOFTWARE: PatentIn version 3.3

```

```

; SEQ ID NO 1189557
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1189557

```

```

Query Match      1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 6.4e+02;
Matches 15; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      53 CCUCUGAUACAGACCCCU 73
Db      21 CTCCTGGCTGCACAGCCCT 1

```

```

RESULT 1003
US-10-310-914A-1352943/C
; Sequence 1352943, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 138402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1352943
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1352943

```

```

Query Match      1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 6.4e+02;
Matches 15; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      53 CCUCUGAUACAGACCCCU 73
Db      21 CTCCTGGCTGCACAGCCCT 1

```

```

RESULT 1004
US-10-042-865-234
; Sequence 234, Application US/10042865
; Publication No. US20040029216A1
; GENERAL INFORMATION:
; APPLICANT: Padigaru, Muralidhara
; APPLICANT: Li, Li
; APPLICANT: Zerhusen, Bryan D
; APPLICANT: Casman, Stacie J
; APPLICANT: Shenoy, Suresh G
; APPLICANT: Spytek, Kimberly
; APPLICANT: Zhong, Mei
; APPLICANT: Gangolli, Beba A
; APPLICANT: Burgess, Catherine E
; APPLICANT: Patuturajan, Meera
; APPLICANT: Vernet, Corine A.M
; APPLICANT: Taylor, Sarah
; APPLICANT: Tchernev, Velizar T
; APPLICANT: Miller, Charles E
; APPLICANT: Guo, Xiaojia
; APPLICANT: Boldog, Ference L
; APPLICANT: Grosse, William M
; APPLICANT: Alsobrook II, John P
; APPLICANT: Edinger, Shlomit R
; APPLICANT: Rothenberg, Mark E
; APPLICANT: Elletman, Karen
; APPLICANT: MacDougall, John
; APPLICANT: Malyanakar, Uriel M

```

```

; APPLICANT: Millet, Isabelle
; APPLICANT: Peyman, John
; APPLICANT: Smithson, Glenda
; APPLICANT: Gunther, Erik
; APPLICANT: Stone, David
; TITLE OF INVENTION: Proteins, Polynucleotides Encoding Them and Methods of
; FILE REFERENCES: 21402-537
; CURRENT APPLICATION NUMBER: US/10/042,865
; CURRENT FILING DATE: 2002-05-17
; PRIOR APPLICATION NUMBER: 60/260,417
; PRIOR FILING DATE: 2001-01-09
; PRIOR APPLICATION NUMBER: 60/260,831
; PRIOR FILING DATE: 2001-01-10
; PRIOR APPLICATION NUMBER: 60/272,338
; PRIOR FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 60/274,876
; PRIOR FILING DATE: 2001-03-09
; PRIOR APPLICATION NUMBER: 60/284,704
; PRIOR FILING DATE: 2001-04-18
; NUMBER OF SEQ ID NOS: 264
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 234
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: PCR Primer
US-10-042-865-234
```

```

Query Match
Best Local Similarity 1.0%; Score 17.8; DB 1; Length 22;
Matches 13; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1558 UGCAUACCCGAAACCTUUGG 1578
      :||:|||||:|||||:
Db 2 TACATAGCCAAACCTTTGG 22
```

```

RESULT 1005
US-10-310-914A-1189555/c
; Sequence 1189555, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1189555
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1189555

Query Match
Best Local Similarity 1.0%; Score 17.8; DB 1; Length 22;
Matches 15; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 53 CCUCUGAUAACAGCCCCU 73
      ||:||||:|||||:
Db 22 CCTCTGCTGCACAGCCCT 2
```

```

RESULT 1006
US-10-310-914A-1352927/c
; Sequence 1352927, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
```

```

; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCES: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1352927
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1352927
```

```

Query Match
Best Local Similarity 1.0%; Score 17.8; DB 1; Length 22;
Matches 15; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 53 CCUCUGAUAACAGCCCCU 73
      ||:||||:|||||:
Db 22 CCTCTGCTGCACAGCCCT 2
```

```

RESULT 1007
US-11-083-784-14354
; Sequence 14354, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14354
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-14354
```

```

Query Match
Best Local Similarity 1.0%; Score 17.4; DB 1; Length 19;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1456 GAGAGAAAGCGGCCAGA 1474
      |||||||:|||||:
Db 1 GAGAGAAAGCGGCCAGA 19
```

```

RESULT 1008
US-11-083-784-96787
; Sequence 96787, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
```

```

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 1349US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 96787
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-96787

Query Match      1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 5.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1586 GCUACUGCGUCGUCACAU 1604
Db      1 GCUACUGCGUCGUCACGU 19

RESULT 1009
US-11-083-784-96842
; Sequence 96842, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 1349US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 96842
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-96842

Query Match      1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 5.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      453 CAGCAUGCGUCGUCUUAUG 471
Db      1 CAGCAUGCGUCGUCUUAUG 19

RESULT 1010
US-11-083-784-96860
; Sequence 96860, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
```

```

; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 1349US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 96860
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-96860

Query Match      1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 5.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      454 AGCAUAGCCUCGUCUUAUGA 472
Db      1 AGCAUAGCCUCGUCUUAUGA 19

RESULT 1011
US-11-083-784-96866
; Sequence 96866, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 1349US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 96866
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-96866

Query Match      1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 5.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      455 GCAUAGCCUCGUCUUAUGAA 473
Db      1 GCAUAGCCUCGUCUUAUGAA 19

RESULT 1012
US-11-083-784-96897
; Sequence 96897, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
```

```
/ APPLICANT: Dharmacom, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 96897
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-96897
```

```
Query Match          1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 5.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      482 UCAUCCGCTUUGCAGUA 500
          |||||
DB       1 UCAUCAGCTUUGCAGGUA 19
```

```
RESULT 1013
US-11-083-784-97147
/ Sequence 97147, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacom, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 97147
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-97147
```

```
Query Match          1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 5.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      300 GACGGUCAACAACUACUUC 318
          |||||
DB       1 GACAGUCAACAACUACUUC 19
```

```
RESULT 1014
US-11-083-784-574416
```

```
/ Sequence 574416, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacom, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 574416
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-574416
```

```
Query Match          1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 5.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1178 AGGAGAGCTUGGAGUGU 1196
          |||||
DB       1 AGGAGAGCTUGGAGUGU 19
```

```
RESULT 1015
US-11-083-784-738029
/ Sequence 738029, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacom, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 738029
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-738029
```

```
Query Match          1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 5.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      816 GACAGAGGAGAGAGAGAA 834
          |||||
DB       1 GACAGAGGAGAGAGAGAA 19
```

```
RESULT 1016
US-11-083-784-819276
; Sequence 819276, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 819276
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-819276
```

```
Query Match          1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 5.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      815 GGACAGAGCGCAGACAGA 833
DB      1 GGACAGAGCGCAGACAGA 19

RESULT 1017
US-11-101-244-14354
; Sequence 14354, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14354
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-14354
```

```
Query Match          1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 5.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
RESULT 1018
US-11-101-244-96787
; Sequence 96787, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 96787
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-96787
```

```
Query Match          1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 5.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1586 GCUACUGCGUGGCUACAU 1604
DB      1 GCUACUGCGUGGCUACGU 19

RESULT 1019
US-11-101-244-96842
; Sequence 96842, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 96842
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-96842
```

```
Query Match          1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 5.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

RESULT 1020

US-11-101-244-96860
; Sequence 96860, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 96860
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-96860

Query Match 1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 5.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 454 AGCAUGCCUCUGUUAUGA 472

Db 1 AGCAUGCCUCAGUUAUGA 19

RESULT 1021

US-11-101-244-96866
; Sequence 96866, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 96866
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-96866

Query Match 1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 5.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 455 GCAUGCCUCUGUUAUGA 473

Db 1 GCAUGCCUCAGUUAUGA 19

RESULT 1022

US-11-101-244-96897
; Sequence 96897, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 96897
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-96897

Query Match 1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 5.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 482 UCAUCAGCUCUUGACAGUA 500

Db 1 UCAUCAGCUCUUGACAGUA 19

RESULT 1023

US-11-101-244-97147
; Sequence 97147, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97147
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97147

Query Match 1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 5.9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 300 GACGUCACACACUACUUC 318

Db 1 GACGUCACACACUACUUC 19

RESULT 1024

```
US-11-101-244-574416
; Sequence 574416, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 574416
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-574416

Query Match
Best Local Similarity 94.7%; Score 17.4; DB 1; Length 19;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1178 AGGAGGAGCUGGGGAGUGU 1196
Db 1 AGGAGGAGCUGGGGAGUGU 19

RESULT 1025
US-11-101-244-738029
; Sequence 738029, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 738029
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-738029

Query Match
Best Local Similarity 1.0%; Score 17.4; DB 1; Length 19;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 816 GACAGAGCGACAGACAGAA 834
Db 1 GACAGAGCGACAGACAGAA 19

RESULT 1026
US-11-101-244-819276
; Sequence 819276, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 819276
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-819276

Query Match
Best Local Similarity 1.0%; Score 17.4; DB 1; Length 19;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 815 GGCAGAGCGCAGACAGACA 833
Db 1 GGCAGAGCGCAGACAGACA 19

RESULT 1027
US-10-310-914A-886273
; Sequence 886273, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; PRIOR FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 886273
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-886273

Query Match
Best Local Similarity 1.0%; Score 17.4; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1687 UGUGACAAAAGAGGC 1705
Db 1 UGUGACAAAAGAGGC 19

RESULT 1028
US-10-310-914A-1387018/c
; Sequence 1387018, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
```

;; CURRENT APPLICATION NUMBER: US/10/310,914A
;; CURRENT FILING DATE: 2002-12-06
;; NUMBER OF SEQ ID NOS: 138402
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO: 1387018
;; LENGTH: 20
;; TYPE: RNA
;; ORGANISM: Human
US-10-310-914A-1387018

Query Match 1.0%; Score 17.4; DB 1; Length 20;
Best Local Similarity 68.4%; Pred. No. 6.4e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1657 ACCACUUCAGAGCUGC 1675
DB 20 ACCACCTTCAGATGCTTC 2

RESULT 1029
US-11-041-456-14/C
; Sequence 14, Application US/11041456
; Publication No. US20050287549A1
; GENERAL INFORMATION:
; APPLICANT: HITACHI, LTD
; TITLE OF INVENTION: Method of genetic testing
; FILE REFERENCE: 310400293US01
; CURRENT APPLICATION NUMBER: US/11/041,456
; CURRENT FILING DATE: 2005-01-25
; PRIOR APPLICATION NUMBER: JP 2004-191781
; PRIOR FILING DATE: 2004-06-29
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO: 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA (primer)
US-11-041-456-14

Query Match 1.0%; Score 17.4; DB 1; Length 20;
Best Local Similarity 73.7%; Pred. No. 6.4e+02;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 239 AGACGGUACAACAUCU 317
DB 19 AGACGGTCCACCACTACTT 1

RESULT 1030
US-10-770-726-20980/C
; Sequence 20980, Application US/10770726
; Publication No. US2005026409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO: 20980
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-770-726-20980

Query Match 1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 7e+02;

Matches 17; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 902 AACGUCACAGAGGAA 920
DB 19 AACGGTCCACAGAGGAA 1

RESULT 1031
US-10-676-154-105/C
; Sequence 105, Application US/10676154
; Publication No. US20040081936A1
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; TITLE OF INVENTION: Genotyping and DNA Analysis
; FILE REFERENCE: M0656/7045 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/676,154
; CURRENT FILING DATE: 2003-09-29
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO: 105
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-10-676-154-105

Query Match 1.0%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 5.3e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1567 AAAACCUUGGAAUCU 1583
DB 17 AAAACCTTTCGAATCT 1

RESULT 1032
US-10-310-914A-1356690/C
; Sequence 1356690, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200 CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 138402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO: 1356690
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1356690

Query Match 1.0%; Score 17; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 6.9e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1175 CUGAGAGAGCUGGAG 1191
DB 20 CTGAGAGAGAGCTGGCG 4

RESULT 1033
US-09-922-146-21

```
; Sequence 21, Application US/09922146
; Publication No. US20030083285A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF DNL SPECIFIC PHOSPHATASE 9 EXPRESSION
; FILE REFERENCE: RTS-0252
; CURRENT APPLICATION NUMBER: US/09/922,146
; CURRENT FILING DATE: 2001-08-01
; NUMBER OF SEQ ID NOS: 48
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-922-146-21

Query Match
Best Local Similarity 0.9%; Score 16.8; DB 1; Length 20;
Matches 16; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1464 AGCGGCCAGACCCUACGUG 1483
Db 1 AGCGGCCAGACCCUACGUG 20

RESULT 1034
US-10-310-914A-34916
; Sequence 34916, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 34916
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-34916

Query Match
Best Local Similarity 0.9%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 864 AACGUGACAGGUAAGAAC 883
Db 1 AACGUGACAGGUAAGAAC 20

RESULT 1035
US-10-310-914A-44757
; Sequence 44757, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 44757
; LENGTH: 20
; TYPE: RNA

; ORGANISM: Human
US-10-310-914A-44757
Query Match
Best Local Similarity 0.9%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 813 UGGACAGAGCGACAGACG 832
Db 1 UGGACAGAGCGACAGACG 20

RESULT 1036
US-10-310-914A-85996/C
; Sequence 85996, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 85996
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-85996

Query Match
Best Local Similarity 0.9%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 814 GGGACAGGACGACAGACA 833
Db 20 GAGACAGGACGACAGACA 1

RESULT 1037
US-10-310-914A-205405
; Sequence 205405, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 205405
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-205405

Query Match
Best Local Similarity 0.9%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1681 UGCCAGUGGACAAAAAAA 1700
Db 1 UGCCAUGUGGCAAAAAAAA 20

RESULT 1038
US-10-310-914A-706110/C
; Sequence 706110, Application US/10310914A
```

```
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ APPLICANT: Shiller, Kiyazat
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 706110
/ LENGTH: 20
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-706110

Query Match
Best Local Similarity 75.0%; Score 16.8; DB 1; Length 20;
Matches 15; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 53 CCUCUGAUAACACAGCC 72
DB 20 CCTCTGATCCACAGCCAC 1

RESULT 1039
US-10-310-914A-740270
/ Sequence 740270, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ APPLICANT: Shiller, Kiyazat
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 740270
/ LENGTH: 20
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-740270

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 814 GGGACAGGCGACAGCA 833
DB 1 GGCACAGGCGACAGCA 20

RESULT 1040
US-10-310-914A-886771
/ Sequence 886771, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ APPLICANT: Shiller, Kiyazat
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 886771
/ LENGTH: 20
/ TYPE: RNA
/ ORGANISM: Human
```

```
US-10-310-914A-886771

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1622 CCGUGUCUAUUGCUCUGUC 1641
DB 1 CCCUGUCUAUUGCUCUGUC 20

RESULT 1041
US-10-310-914A-1225898
/ Sequence 1225898, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ APPLICANT: Shiller, Kiyazat
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 1225898
/ LENGTH: 20
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-1225898

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1567 AAAACCUUUGAUAUCUGG 1586
DB 1 AAAACAUAUUGAUAUCUGG 20

RESULT 1042
US-09-944-326-2/c
/ Sequence 2, Application US/09944326
/ Patent No. US20020128220A1
/ GENERAL INFORMATION:
/ APPLICANT: Gleave, Martin
/ APPLICANT: Rennie, Paul S.
/ APPLICANT: Miyake, Hideaki
/ APPLICANT: Nelson, Colleen
/ TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
/ FILE REFERENCE: UBC-P-020-2
/ CURRENT APPLICATION NUMBER: US/09/944,326
/ CURRENT FILING DATE: 2001-08-30
/ PRIOR APPLICATION NUMBER: 60/121,726
/ PRIOR FILING DATE: 1999-02-26
/ PRIOR APPLICATION NUMBER: 09/913,325
/ PRIOR FILING DATE: 2001-08-10
/ NUMBER OF SEQ ID NOS: 14
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 2
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Murine
/ FEATURE:
/ OTHER INFORMATION: mismatch control
US-09-944-326-2

Query Match
Best Local Similarity 60.0%; Score 16.8; DB 1; Length 21;
Matches 12; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1664 UCAAGUCGUCGUCGUCG 1683
```

Db 20 TGAAGATCTGCTGTGTGC 1

```
RESULT 1043
US-09-967-726A-2/c
; Sequence 2, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-2
```

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 7.8e+02;
Matches 12; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1664 UCAAGUCGUCGUCGUCG 1683
Db 20 TGAAGATCTGCTGTGTGC 1

```
RESULT 1044
US-10-080-794-2/c
; Sequence 2, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Womla, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Murine
; FEATURE:
; OTHER INFORMATION: mismatch control
US-10-080-794-2
```

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 7.8e+02;
Matches 12; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1664 UCAAGUCGUCGUCGUCG 1683
Db 20 TGAAGATCTGCTGTGTGC 1

```
RESULT 1045
US-10-786-720-8032/c
; Sequence 8032, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8032
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-8032
```

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 40.0%; Pred. No. 7.8e+02;
Matches 8; Conservative 10; Mismatches 2; Indels 0; Gaps 0;

Qy 614 UGUUCUGCAUACUUGUU 633
Db 21 TGTTCGTGCTACTTGTGTT 2

```
RESULT 1046
US-10-786-720-8034
; Sequence 8034, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8034
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-8034
```

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 7.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 614 UGUUCUGCAUACUUGUU 633
Db 1 UGUUCUGCAUACUUGUU 20

```
RESULT 1047
US-10-786-720-10264/c
; Sequence 10264, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
US-10-786-720-10264/c
```

; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10264
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-10264

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 40.0%; Pred. No. 7.8e+02;
Matches 8; Conservative 10; Mismatches 2; Indels 0; Gaps 0;

QY 614 UGUUCUGGCAUACUUGUU 633
:|::|||:|::|||:|::|||:
Db 21 TGTTCGTCTACTTCTTGT 2

RESULT 1048
US-10-786-720-10266
; Sequence 10266, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101311L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10266
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-10266

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 7.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 614 UGUUCUGGCAUACUUGUU 633
:|::|||:|::|||:|::|||:
Db 1 UGUUCUGGCAUACUUGUU 20

RESULT 1049
US-10-828-394-3/c
; Sequence 3, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC-P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-3

Query Match 0.9%; Score 16.8; DB 1; Length 21;

Best Local Similarity 60.0%; Pred. No. 7.8e+02;
Matches 12; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 1664 UCAAGAGCUGCUGCUGC 1683
:|::|||:|::|||:|::|||:
Db 20 TGAAGATCTGCTGCTGTC 1

RESULT 1050
US-10-828-395-3/c
; Sequence 3, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC-P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-3

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 7.8e+02;
Matches 12; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1664 UCAAGAGCUGCUGCUGC 1683
:|::|||:|::|||:|::|||:
Db 20 TGAAGATCTGCTGCTGTC 1

RESULT 1051
US-10-770-726-373
; Sequence 373, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 373
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-770-726-373

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 7.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 632 UUGAAAGAGACUGUGCCU 651
:|::|||:|::|||:|::|||:
Db 1 UUGAAAGAGACUGUGCCU 20

RESULT 1052

```

US-10-770-726-2392
; Sequence 2392, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2392
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-770-726-2392

Query Match
Best Local Similarity 90.0%; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 632 UUGGAAAGAGACUUGCCU 651
DB 2 UUGGAAAGAGACUUGCCU 21

RESULT 1053
US-10-770-726-23694/C
; Sequence 23694, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23694
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-770-726-23694

Query Match
Best Local Similarity 75.0%; DB 1; Length 21;
Matches 15; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1162 AACUCGAGUGGUCUGAGA 1181
DB 20 AACUCGAGUGGUCUGAGA 1

RESULT 1054
US-10-310-914A-70833
; Sequence 70833, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvuazac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 70833
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-70833

Query Match
Best Local Similarity 90.0%; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 534 CAACGACACACAAAGAGAG 553
DB 2 CAACGACACACAAAGAGAG 21

RESULT 1055
US-10-310-914A-146082
; Sequence 146082, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvuazac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 146082
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-146082

Query Match
Best Local Similarity 90.0%; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 GGACAGAGGCGAAGAGAA 834
DB 2 GGACAGAGGCGAAGAGAA 21

RESULT 1056
US-10-310-914A-146083
; Sequence 146083, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvuazac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 146083
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-146083

Query Match
Best Local Similarity 90.0%; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 GGACAGAGGCGAAGAGAA 834
DB 2 GGACAGAGGCGAAGAGAA 21

```

```
RESULT 1057
US-10-310-914A-526663
; Sequence 526663, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Bentwich, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 526663
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-526663

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 575 CUUGGUCACUCCUUGGC 594
Db 1 CUUGGCGCAUCCUUGGC 20

RESULT 1058
US-10-310-914A-886986
; Sequence 886986, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 886986
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-886986

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 144 UUUUCUCCUCCAGAGGUA 163
Db 2 UUUUCUCCUCCAGAGGUA 21

RESULT 1059
US-11-183-485-2/c
; Sequence 2, Application US/11183485
; Publication No. US20060029636A1
; GENERAL INFORMATION:
; APPLICANT: Hendriks, Marc
; TITLE OF INVENTION: MEDICAL DEVICES AND METHODS FOR REDUCING LOCALIZED FIBROSIS
; FILE REFERENCE: 134.02140101
; CURRENT APPLICATION NUMBER: US/11/183,485
; CURRENT FILING DATE: 2005-07-18
; PRIOR APPLICATION NUMBER: 60/589,700
; PRIOR FILING DATE: 2004-07-21
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
```

```
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Small interfering RNA in which bases 1-19 are ribonucleic acids,
; US-11-183-485-2

Query Match
Best Local Similarity 75.0%; Score 16.8; DB 1; Length 21;
Matches 15; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1441 AUGUCCUGGUCAGAGGAA 1460
Db 20 AGGTCCTTGCTCAAGGAGAA 1

RESULT 1060
US-11-183-486-2/c
; Sequence 2, Application US/11183486
; Publication No. US20060030538A1
; GENERAL INFORMATION:
; APPLICANT: Hendriks, Marc
; TITLE OF INVENTION: METHODS FOR REDUCING OR PREVENTING LOCALIZED FIBROSIS USING siRNA
; FILE REFERENCE: 134.02280101
; CURRENT APPLICATION NUMBER: US/11/183,486
; CURRENT FILING DATE: 2005-07-18
; PRIOR APPLICATION NUMBER: 60/589,724
; PRIOR FILING DATE: 2004-07-21
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Small interfering RNA in which bases 1-19 are ribonucleic acids,
; US-11-183-486-2

Query Match
Best Local Similarity 75.0%; Score 16.8; DB 1; Length 21;
Matches 15; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1441 AUGUCCUGGUCAGAGGAA 1460
Db 20 AGGTCCTTGCTCAAGGAGAA 1

RESULT 1061
US-10-310-914A-85413
; Sequence 85413, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 85413
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-85413

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 18;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```

OY      131  GAGCAGCUGGCAUUCU 148
          ||| ||||| ||||| |||||
DB      1  GAGAAAGCUGGCAUUCU 18

RESULT 1062
US-10-310-914A-598921/c
; Sequence 598921, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 598921
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-598921

Query Match      0.9%; Score 16.4; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 6.6e+02;
Matches 10; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

OY      1357 ACUCUACUCUCUGUCCTUC 1374
          |||: |||: |||: |||: |||: |||
DB      18  ACTCTTCTCTGTCTCTTC 1

RESULT 1063
US-10-310-914A-886257
; Sequence 886257, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 886257
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-886257

Query Match      0.9%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      1688 GUGACAAAATAAGAGGC 1705
          ||| ||||| ||||| ||||| |||||
DB      1  GUGACAAAATAAGAGGC 18

RESULT 1064
US-10-310-914A-1202840/c
; Sequence 1202840, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01

```

```

OY      171 UGACCCUCUGGAGAGUCA 188
      0.9%; Score 16.4; DB 1; Length 19;
      Best Local Similarity 72.2%; Pred. No. 7.2e+02;
      Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

      RESULT 1065
      US-10-310-914A-886252
      : Sequence 886252, Application US/10310914A
      : Publication No. US20060003322A1
      : GENERAL INFORMATION:
      : APPLICANT: Bentwich, Isaac
      : TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
      : FILE REFERENCE: 06087.0200.CPUS01
      : CURRENT APPLICATION NUMBER: US/10/310,914A
      : CURRENT FILING DATE: 2002-12-06
      : NUMBER OF SEQ ID NOS: 1388402
      : SOFTWARE: PatentIn version 3.3
      : SEQ ID NO 891339
      : LENGTH: 19
      : TYPE: RNA
      : ORGANISM: Human
      : US-10-310-914A-1202840

      Query Match      0.9%; Score 16.4; DB 1; Length 18;
      Best Local Similarity 94.4%; Pred. No. 6.6e+02;
      Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

      OY      814 GGCACAGAGCGACAGACA 831
      : 18 GGCACAGAGCGACAGACA 1
      :

      RESULT 1066
      US-10-310-914A-891339/C
      : Sequence 891339, Application US/10310914A
      : Publication No. US20060003322A1
      : GENERAL INFORMATION:
      : APPLICANT: Bentwich, Isaac
      : TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
      : FILE REFERENCE: 06087.0200.CPUS01
      : CURRENT APPLICATION NUMBER: US/10/310,914A
      : CURRENT FILING DATE: 2002-12-06
      : NUMBER OF SEQ ID NOS: 1388402
      : SOFTWARE: PatentIn version 3.3
      : SEQ ID NO 891339
      : LENGTH: 19
      : TYPE: RNA
      : ORGANISM: Human
      : US-10-310-914A-886252

      Query Match      0.9%; Score 16.4; DB 1; Length 19;
      Best Local Similarity 94.4%; Pred. No. 7.2e+02;
      Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

      OY      1687 UGUCACAAAAGAGAG 1704
      : 2 UGUCACAAAAGAGAG 19
      :

      RESULT 1067
      US-10-310-914A-891339/C
      : Sequence 891339, Application US/10310914A
      : Publication No. US20060003322A1
      : GENERAL INFORMATION:
      : APPLICANT: Bentwich, Isaac
      : TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
      : FILE REFERENCE: 06087.0200.CPUS01
      : CURRENT APPLICATION NUMBER: US/10/310,914A
      : CURRENT FILING DATE: 2002-12-06
      : NUMBER OF SEQ ID NOS: 1388402
      : SOFTWARE: PatentIn version 3.3
      : SEQ ID NO 891339
      : LENGTH: 19
      : TYPE: RNA
      : ORGANISM: Human
      : US-10-310-914A-886252

      Query Match      0.9%; Score 16.4; DB 1; Length 19;
      Best Local Similarity 94.4%; Pred. No. 7.2e+02;
      Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

      OY      1687 UGUCACAAAAGAGAG 1704
      : 2 UGUCACAAAAGAGAG 19
      :

```

Db 18 TGFCCCTCGGAGCTCA 1

RESULT 1067
US-10-310-914A-983423
; Sequence 983423, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kruzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 983423
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-983423

Query Match 0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 816 GACAGGCGACAGACAGA 833
Db 2 GGCAGAGCAGACAGACA 19

RESULT 1068
US-11-083-784-14345
; Sequence 14345, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14345
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-14345

Query Match 0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1458 GAAGAAAGCGGCCAGAC 1475
Db 1 GAAGAAAGCGGCCAGAC 18

RESULT 1069
US-11-083-784-14512

; Sequence 14512, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14512
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-14512

Query Match 0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1455 GGAGAAAGCGGCCCA 1472
Db 1 GGAGAAAGCGGCCCA 18

RESULT 1070
US-11-083-784-14599
; Sequence 14599, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14599
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-14599

Query Match 0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1455 GGAGAAAGCGGCCCA 1472
Db 1 GGAGAAAGCGGCCCA 18

```
RESULT 1071
US-11-083-784-14678
; Sequence 14678, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14678
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-14678
```

```
Query Match      0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      1455 GGAGAAAGAAAGCGGCCA 1472
Db      1 GGAGAAAGAAAGCGGCCA 18

RESULT 1072
US-11-083-784-14753
; Sequence 14753, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14753
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-14753
```

```
Query Match      0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

OY 1455 GGAGAAAGAAAGCGGCCA 1472

```
Db      1 GGAGAAAGAAAGCGGCCA 18

RESULT 1073
US-11-083-784-82206/C
; Sequence 82206, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 82206
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-82206
```

```
Query Match      0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 44.4%; Pred. No. 7.2e+02;
Matches 8; Conservative 9; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      616 UUCUGGCANUACUUCUGU 633
Db      19 TTCTGGCAATGCTTGT 2

RESULT 1074
US-11-083-784-82258/C
; Sequence 82258, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 82258
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-82258
```

```
Query Match      0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 44.4%; Pred. No. 7.2e+02;
```

Matches 8; Conservative 9; Mismatches 1; Indels 0; Gaps 0;
QY 616 UUCUGCAUACUUGUU 633
Db 18 TTCTGGCAATGCTTGT 1

RESULT 1075
US-11-083-784-246660
; Sequence 246660, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 246660
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-246660

Query Match 0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 285 CAACAAGCAGCTGAGAC 302
Db 2 CAACAAGCAGAGAGAC 19

RESULT 1076
US-11-083-784-498576
; Sequence 498576, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 498576
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-498576

Query Match 0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 774 UGAAAAGCGUACCAAGA 791
Db 2 UGAAAAGCGUACCAAGA 19

RESULT 1077
US-11-083-784-498676
; Sequence 498676, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 498676
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-498676

Query Match 0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 774 UGAAAAGCGUACCAAGA 791
Db 2 UGAAAAGCGUACCAAGA 19

RESULT 1078
US-11-083-784-498775
; Sequence 498775, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 498775
; LENGTH: 19

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-498775

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 774 UGAAAAAGCGUACCAAGA 791
Db 2 UGAAAAAGCGUACCAAGA 19

RESULT 1079
US-11-083-784-588102/c
; Sequence 588102, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 588102
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-588102

Query Match
Best Local Similarity 0.9%; Score 16.4; DB 1; Length 19;
Matches 12; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 106 CAUUCGCGAGCUACAUA 123
Db 19 CATTCGCGAGCTTCAAT 2

RESULT 1080
US-11-083-784-688861
; Sequence 688861, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
```

```
; SOFTWARE: Proprietary
; SEQ ID NO 688861
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-688861

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 483 CAUCAGCUUUGACAGAGA 500
Db 1 CAUCAGCUUUGACAGAGA 18

RESULT 1081
US-11-083-784-738023
; Sequence 738023, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 738023
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-738023

Query Match
Best Local Similarity 0.9%; Score 16.4; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 816 GACAGAGCGAGACAGAGA 833
Db 2 GACAGAGCGAGACAGAGA 19

RESULT 1082
US-11-083-784-829653/c
; Sequence 829653, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
```

;; PRIOR APPLICATION NUMBER: 60/426,137
;; PRIOR FILING DATE: 2002-11-14
;; NUMBER OF SEQ ID NOS: 1591911
;; SOFTWARE: Proprietary
;; SEQ ID NO: 829653
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-11-083-784-829653

Query Match 0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 7.2e+02;
Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1043 ACUCGCCUCUCCGACG 1060
DB 18 ACTCCTCTCTCTCCGACG 1

RESULT 1083

US-11-083-784-875701
;; Sequence 875701, Application US/11083784
;; Publication No. US20050245475A1
;; GENERAL INFORMATION:
;; APPLICANT: Dharmacon, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin
;; APPLICANT: Marshall, William
;; APPLICANT: Scaringe, Stephen
;; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;; FILE REFERENCE: 13499US
;; CURRENT APPLICATION NUMBER: US/11/083,784
;; PRIOR FILING DATE: 2005-03-18
;; PRIOR APPLICATION NUMBER: US/10/714,333
;; PRIOR FILING DATE: 2003-11-14
;; PRIOR APPLICATION NUMBER: 60/502,050
;; PRIOR FILING DATE: 2003-09-10
;; PRIOR APPLICATION NUMBER: 60/426,137
;; PRIOR FILING DATE: 2002-11-14
;; NUMBER OF SEQ ID NOS: 1591911
;; SOFTWARE: Proprietary
;; SEQ ID NO: 875701
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-11-083-784-875701

Query Match 0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 414 CUCGCCUCUGACUCUG 431
DB 1 CUCGACUCUGACUCUG 18

RESULT 1084

US-11-083-784-923326
;; Sequence 923326, Application US/11083784
;; Publication No. US20050245475A1
;; GENERAL INFORMATION:
;; APPLICANT: Dharmacon, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin
;; APPLICANT: Marshall, William
;; APPLICANT: Scaringe, Stephen
;; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;; FILE REFERENCE: 13499US
;; CURRENT APPLICATION NUMBER: US/11/083,784
;; PRIOR FILING DATE: 2005-03-18
;; PRIOR APPLICATION NUMBER: US/10/714,333

;; PRIOR FILING DATE: 2003-11-14
;; PRIOR APPLICATION NUMBER: 60/502,050
;; PRIOR FILING DATE: 2003-09-10
;; PRIOR APPLICATION NUMBER: 60/426,137
;; PRIOR FILING DATE: 2002-11-14
;; NUMBER OF SEQ ID NOS: 1591911
;; SOFTWARE: Proprietary
;; SEQ ID NO: 923326
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-11-083-784-923326

Query Match 0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1218 CAAGCUCGAGCCGAG 1235
DB 1 CAAGCUCGAGCCGAG 18

RESULT 1085

US-11-083-784-982420
;; Sequence 982420, Application US/11083784
;; Publication No. US20050245475A1
;; GENERAL INFORMATION:
;; APPLICANT: Dharmacon, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin
;; APPLICANT: Marshall, William
;; APPLICANT: Scaringe, Stephen
;; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;; FILE REFERENCE: 13499US
;; CURRENT APPLICATION NUMBER: US/11/083,784
;; PRIOR FILING DATE: 2005-03-18
;; PRIOR APPLICATION NUMBER: US/10/714,333
;; PRIOR FILING DATE: 2003-11-14
;; PRIOR APPLICATION NUMBER: 60/502,050
;; PRIOR FILING DATE: 2003-09-10
;; PRIOR APPLICATION NUMBER: 60/426,137
;; PRIOR FILING DATE: 2002-11-14
;; NUMBER OF SEQ ID NOS: 1591911
;; SOFTWARE: Proprietary
;; SEQ ID NO: 982420
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-11-083-784-982420

Query Match 0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 860 CUCGAGCUCGACGAGU 877
DB 2 CUCGAGCUCGAGCAGU 19

RESULT 1086

US-11-083-784-1083345
;; Sequence 1083345, Application US/11083784
;; Publication No. US20050245475A1
;; GENERAL INFORMATION:
;; APPLICANT: Dharmacon, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin
;; APPLICANT: Marshall, William
;; APPLICANT: Scaringe, Stephen
;; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;; FILE REFERENCE: 13499US

```

; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1083345
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1083345

Query Match
Best Local Similarity 0.9%; Score 16.4; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db
1 GAAGACCGGAGAGUCAGAU 18

RESULT 1087
US-11-083-784-1216237
; Sequence 1216237, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1216237
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1216237

Query Match
Best Local Similarity 0.9%; Score 16.4; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db
2 ACAACCCGCCUUGUUU 39
2 AUAACUCCGCCUUGUUU 19

RESULT 1088
US-11-083-784-1308145/c
; Sequence 1308145, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
```

```

; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1308145
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1308145

Query Match
Best Local Similarity 0.9%; Score 16.4; DB 1; Length 19;
Matches 10; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

Db
575 CUUGGCAUCCUUGU 592
18 CTTGGGCACTCTCTTG 1

RESULT 1089
US-11-083-784-1422064/c
; Sequence 1422064, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1422064
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1422064

Query Match
Best Local Similarity 0.9%; Score 16.4; DB 1; Length 19;
Matches 8; Conservative 9; Mismatches 1; Indels 0; Gaps 0;

Db
616 UUCUGCAUACUUGU 633
19 TTCTGGCACTCTTGT 2

RESULT 1090
US-11-083-784-1422087/c
; Sequence 1422087, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
```

```
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1422087
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1422087
```

```
Query Match          0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 44.4%; Pred. No. 7.2e+02;
Matches 8; Conservative 9; Mismatches 1; Indels 0; Gaps 0;
```

```
Oy      616 UUCUGCAUACUUGU 633
Db      18 TTCTGGATCTTCTT 1
```

```
RESULT 1091
US-11-101-244-14345
; Sequence 14345, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14345
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-14345
```

```
Query Match          0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Oy      1458 GAAGAAGCGCCGAC 1475
Db      1 GAAGAAGCGCCGAC 18
```

```
RESULT 1092
US-11-101-244-14512
; Sequence 14512, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
```

```
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14512
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-14512
```

```
Query Match          0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Oy      1455 GGAGAAGAAAGCGCCA 1472
Db      1 GGAGAAGAAAGCGCCA 18
```

```
RESULT 1093
US-11-101-244-14599
; Sequence 14599, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14599
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-14599
```

```
Query Match          0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Oy      1455 GGAGAAGAAAGCGCCA 1472
Db      1 GGAGAAGAAAGCGCCA 18
```

```
RESULT 1094
US-11-101-244-14678
; Sequence 14678, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
```

```
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/101,244
/ PRIOR FILING DATE: 2005-04-07
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 14678
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-101-244-14678

Query Match          0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1455 GGAGGAAGAAAGCGCCCA 1472
DB      1 GGAGGAAGAAAGCGCCCA 18
```

```
RESULT 1095
US-11-101-244-14753
/ Sequence 14753, Application US/11101244
/ Publication No. US20050246794A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/101,244
/ PRIOR FILING DATE: 2005-04-07
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 14753
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-101-244-14753

Query Match          0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1455 GGAGGAAGAAAGCGCCCA 1472
DB      1 GGAGGAAGAAAGCGCCCA 18
```

```
RESULT 1096
US-11-101-244-82206/C
/ Sequence 82206, Application US/11101244
/ Publication No. US20050246794A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
```

```
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/101,244
/ PRIOR FILING DATE: 2005-04-07
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 82206
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-101-244-82206

Query Match          0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 44.4%; Pred. No. 7.2e+02;
Matches 8; Conservative 9; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      616 UUCUGGCAUACUUGUU 633
DB      19 TTCTGGCAATGCTTGT 2
```

```
RESULT 1097
US-11-101-244-82258/C
/ Sequence 82258, Application US/11101244
/ Publication No. US20050246794A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/101,244
/ PRIOR FILING DATE: 2005-04-07
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 82258
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-101-244-82258

Query Match          0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 44.4%; Pred. No. 7.2e+02;
Matches 8; Conservative 9; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      616 UUCUGGCAUACUUGUU 633
DB      18 TTCTGGCAATGCTTGT 1
```

```
RESULT 1098
US-11-101-244-24660
/ Sequence 24660, Application US/11101244
/ Publication No. US20050246794A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
```

```

; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 246660
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-498660

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 285 CAACAAGCAGCTGAGAC 302
Db 2 CAACAAGCAGCTGAGAC 19

RESULT 1099
US-11-101-244-498576
; Sequence 498576, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 498576
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-498576

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 774 UGAAAAGCGUACCAAGA 791
Db 2 UGAAAAGCGUACCAAGA 19

RESULT 1100
US-11-101-244-498676
; Sequence 498676, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
```

```

; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 498676
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-498676

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 774 UGAAAAGCGUACCAAGA 791
Db 2 UGAAAAGCGUACCAAGA 19

RESULT 1101
US-11-101-244-498775
; Sequence 498775, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 498775
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-498775

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 774 UGAAAAGCGUACCAAGA 791
Db 2 UGAAAAGCGUACCAAGA 19

RESULT 1102
US-11-101-244-588102/c
; Sequence 588102, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
```

```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 588102
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-588102

Query Match          0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 7.2e+02;
Matches 12; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY      106 CAUUUCGCGACGCUACA 123
DB      19 CATTCCGCGACGCTTCAAT 2

RESULT 1103
US-11-101-244-688861
; Sequence 688861, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 688861
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-688861

Query Match          0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      483 CAUCAGCUTUUGACAGAU 500
DB      1 CAUCAGCUTUUGACAGGUA 18

RESULT 1104
US-11-101-244-738023
; Sequence 738023, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; FILE REFERENCE: Functional and Hyperfunctional siRNA
```

```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 738023
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-738023

Query Match          0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      816 GACAGAGCGACGACAGA 833
DB      2 GACAGAGCGACGACAGA 19

RESULT 1105
US-11-101-244-829653/C
; Sequence 829653, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 829653
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-829653

Query Match          0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 7.2e+02;
Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      1043 ACTCGCCUCUCGCCGAG 1060
DB      18 ACTCTCTCTCTCCGACG 1

RESULT 1106
US-11-101-244-875701
; Sequence 875701, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; FILE REFERENCE: Functional and Hyperfunctional siRNA
```

```

; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 875701
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-875701

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 414 CUUGGCCUGAGCCUCUG 431
DB 1 CUGAGCCUGAGCCUCUG 18

RESULT 1107
US-11-101-244-923326
; Sequence 923326, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 923326
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-923326

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1218 CAAGCUGAGCCGAGAA 1235
DB 1 CAAGCUGAGCCGAGAA 18

RESULT 1108
US-11-101-244-982420
; Sequence 982420, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
```

```

; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 982420
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-982420

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 860 CUGAAGCUGAGCAGU 877
DB 2 CUGAAGCUGAGCAGU 19

RESULT 1109
US-11-101-244-1083345
; Sequence 1083345, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1083345
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1083345

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1407 GAAGACCGAGAGUCAGAU 1424
DB 1 GAAGACCGAGAGUCAGAU 18

RESULT 1110
US-11-101-244-1216237
; Sequence 1216237, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
```

```

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1216237
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1216237

Query Match          0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      22 ACAACCCGCGCCUUGUUU 39
DB      2 AUAACCGCGCCUUGUUU 19

RESULT 1111
US-11-101-244-1308145/c
; Sequence 1308145, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1308145
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1308145

Query Match          0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 55.6%; Pred. No. 7.2e+02;
Matches 10; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY      575 CUGGCGCAUCCUCCUUUG 592
DB      18 CTTGGGCAATCTCCTTG 1

RESULT 1112
US-11-101-244-1422064/c
; Sequence 1422064, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
```

```

; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1422064
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1422064

Query Match          0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 44.4%; Pred. No. 7.2e+02;
Matches 8; Conservative 9; Mismatches 1; Indels 0; Gaps 0;

QY      616 UUCUGGCAUACUUGUUU 633
DB      19 TTCTGGAAATACCTTGTT 2

RESULT 1113
US-11-101-244-1422087/c
; Sequence 1422087, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1422087
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1422087

Query Match          0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 44.4%; Pred. No. 7.2e+02;
Matches 8; Conservative 9; Mismatches 1; Indels 0; Gaps 0;

QY      616 UUCUGGCAUACUUGUUU 633
DB      18 TTCTGGAAATACCTTGTT 1

RESULT 1114
US-11-110-274-540/c
; Sequence 540, Application US/1110274
; Publication No. US20050266502A1
; GENERAL INFORMATION:
; APPLICANT: Merck, Pascal G.
; APPLICANT: Hoffmann, Marcel
; APPLICANT: Spittaels, Koenraad F. F.
; TITLE OF INVENTION: Methods, Compositions and Compound Assays for Inhibiting
; FILE REFERENCE: P27,697-A USA
; CURRENT FILING DATE: 2005-04-20
; PRIOR APPLICATION NUMBER: 60/563,661
; PRIOR FILING DATE: 2004-04-20
; NUMBER OF SEQ ID NOS: 620
; SOFTWARE: PatentIn version 3.3
```

SEQ ID NO 540
LENGTH: 19
TYPE: DNA
ORGANISM: Homo sapiens
US-11-110-274-540

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 19;
Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 816 GACGAGCGCAGAGACAGA 833
DB 19 GACGAGCGCAGAGAGAGA 2

RESULT 1115
US-11-176-026A-33
Sequence 33, Application US/11176026A
Publication No. US20060069074A1
GENERAL INFORMATION:
APPLICANT: Lemanske, Robert
APPLICANT: Sorkness, Christine
APPLICANT: Chinchilli, Vernon
APPLICANT: Liu, Wenlei
APPLICANT: Phillips, Brenda
APPLICANT: Zeiger, Robert
APPLICANT: Heldt, Gregory
APPLICANT: Martinez, Fernando
APPLICANT: Klinecki, Walter
APPLICANT: Guilbert, Theresa
APPLICANT: Morgan, Wayne
APPLICANT: Szeffler, Stanley
APPLICANT: Larsen, Gary
APPLICANT: Tausieg, Lynn
APPLICANT: Spahn, Joseph
APPLICANT: Strunk, Robert
APPLICANT: Bacharier, Leonard
APPLICANT: Bloomberg, Gordon
TITLE OF INVENTION: GENETIC PREDICTOR OF EFFICACY OF ANTI-ASTHMATIC AGENT FOR
TITLE OF INVENTION: IMPROVING PULMONARY FUNCTION
FILE REFERENCE: 960296, 00195
CURRENT APPLICATION NUMBER: US/11/176, 026A
CURRENT FILING DATE: 2005-07-07
PRIOR APPLICATION NUMBER: US 60/585, 872
PRIOR FILING DATE: 2004-07-07
NUMBER OF SEQ ID NOS: 40
SOFTWARE: PatentIn version 3.3
SEQ ID NO 33
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Synthetic DNA forward primer for 252 SNP.
US-11-176-026A-33

Query Match
Best Local Similarity 66.7%; Score 16.4; DB 1; Length 19;
Pred. No. 7.2e+02;
Matches 12; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 328 CUGGCCUGGCCGAGUCCUG 345
DB 2 CTGGCCTGTGCTGATCTGTG 19

RESULT 1116
US-10-310-914A-417659
Sequence 417659, Application US/10310914A
Publication No. US20060003322A1
GENERAL INFORMATION:
APPLICANT: Bentwich, Isaac
APPLICANT: Shiler, Kiyazut
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
TITLE OF INVENTION: uses thereof

FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310, 914A
CURRENT FILING DATE: 2002-12-06
NUMBER OF SEQ ID NOS: 1388402
SOFTWARE: PatentIn version 3.3
SEQ ID NO 417659
LENGTH: 20
TYPE: RNA
ORGANISM: Human
US-10-310-914A-417659

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 20;
Pred. No. 7.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1685 AGUGUGACAAACAAACAGA 1702
DB 2 AGUGUGACAAACAAACAGA 19

RESULT 1117
US-10-310-914A-698822
Sequence 698822, Application US/10310914A
Publication No. US20060003322A1
GENERAL INFORMATION:
APPLICANT: Bentwich, Isaac
APPLICANT: Shiler, Kiyazut
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
TITLE OF INVENTION: uses thereof
FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310, 914A
CURRENT FILING DATE: 2002-12-06
NUMBER OF SEQ ID NOS: 1388402
SOFTWARE: PatentIn version 3.3
SEQ ID NO 698822
LENGTH: 20
TYPE: RNA
ORGANISM: Human
US-10-310-914A-698822

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 20;
Pred. No. 7.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 774 UGAAAGCGUACCAACAGA 791
DB 1 UGAAAGCGUACCAACAGA 18

RESULT 1118
US-10-310-914A-698823
Sequence 698823, Application US/10310914A
Publication No. US20060003322A1
GENERAL INFORMATION:
APPLICANT: Bentwich, Isaac
APPLICANT: Shiler, Kiyazut
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
TITLE OF INVENTION: uses thereof
FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310, 914A
CURRENT FILING DATE: 2002-12-06
NUMBER OF SEQ ID NOS: 1388402
SOFTWARE: PatentIn version 3.3
SEQ ID NO 698823
LENGTH: 20
TYPE: RNA
ORGANISM: Human
US-10-310-914A-698823

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 20;
Pred. No. 7.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 774 UGAAAGCGUACCAAGA 791
|||||
Db 1 UGAAAAAGCGUACAAAGA 18

RESULT 1119
US-10-310-914A-1371239
; Sequence 1371239, Application US/10310914A
; Publication No. US2006003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kivunat
; TITLE OF INVENTION: Bioinformaticlly detectable group of novel regulatory genes and
; TITLE OF INVENTION: Uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1371239
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1371239

Query Match 0.9%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1252 GGCAGUUVCCAAAA 1267
|||||
Db 3 GGCAGUUVCCAAAA 18

RESULT 1120
US-11-083-784-456075/c
; Sequence 456075, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 456075
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-456075

Query Match 0.9%; Score 16; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 7.8e+02;
Matches 14; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 907 UCCACAGAGAGAGU 922
:|||||
Db 19 TCACACAGAGAGAGT 4

RESULT 1121

US-11-083-784-1024020
; Sequence 1024020, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1024020
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1024020

Query Match 0.9%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1518 AUAACAUCUACUGU 1533
|||||
Db 3 AUAACAUCUACUGU 18

RESULT 1122
US-11-083-784-1258483
; Sequence 1258483, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1258483
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1258483

Query Match 0.9%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1665 CAAGUUCUGUCUG 1680
|||||
Db 2 CAAGUUCUGUCUG 17

```
RESULT 1123
US-11-083-784-1537374
; Sequence 1537374, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1537374
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1537374

Query Match          0.9%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 458 AUGCCUCUGUUAUGAA 473
DB 3 AUGCCUCUGUUAUGAA 18

RESULT 1124
US-11-101-244-456075/c
; Sequence 456075, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 456075
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-456075

Query Match          0.9%; Score 16; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 7.8e+02;
Matches 14; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 907 UCCAAAGAGAGAGAGU 922
DB 3 UCCAAAGAGAGAGAGU 922
```

```
DB 19 TCCACAGAGAGAGAGT 4

RESULT 1125
US-11-101-244-1024020
; Sequence 1024020, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1024020
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1024020

Query Match          0.9%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1518 AUAACAACAUCAUGGU 1533
DB 3 AUAACAACAUCAUGGU 18

RESULT 1126
US-11-101-244-1258483
; Sequence 1258483, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1258483
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1258483

Query Match          0.9%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1665 CAAGUUCUGUCUGUCUG 1680
DB 2 CAAGUUCUGUCUGUCUG 17
```

```
RESULT 1127
US-11-101-244-1537374
; Sequence 1537374, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1537374
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1537374

Query Match
Best Local Similarity 100.0%; Score 16; DB 1; Length 19;
Pred. No. 7.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 458 AUGCCUCUGUUAUGAA 473
DB 3 AUGCCUCUGUUAUGAA 18

RESULT 1128
US-09-922-146-22
; Sequence 22, Application US/09922146
; Publication No. US20030083285A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF DUAL SPECIFIC PHOSPHATASE 9 EXPRESSION
; FILE REFERENCE: RTS-0252
; CURRENT APPLICATION NUMBER: US/09/922,146
; CURRENT FILING DATE: 2001-08-01
; NUMBER OF SEQ ID NOS: 48
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-922-146-22

Query Match
Best Local Similarity 93.8%; Score 16; DB 1; Length 20;
Pred. No. 8.4e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1464 AGCGGCCGAGCCCTC 1479
DB 3 AGCGGCCGAGCCCTC 18

RESULT 1129
US-10-310-914A-593301
; Sequence 593301, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 593301
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-593301

Query Match
Best Local Similarity 100.0%; Score 16; DB 1; Length 20;
Pred. No. 8.4e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1177 GAGGAGAGCTUGGGGA 1192
DB 4 GAGGAGAGCTUGGGGA 19

RESULT 1130
US-10-310-914A-1148207/C
; Sequence 1148207, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1148207
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1148207

Query Match
Best Local Similarity 87.5%; Score 16; DB 1; Length 20;
Pred. No. 8.4e+02;
Matches 14; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 957 CUGGAACCCAGCUC 972
DB 17 CTGGAACCCAGCTCC 2

RESULT 1131
US-09-817-014-154/C
; Sequence 154, Application US/09817014
; Patent No. US20020106646A1
; GENERAL INFORMATION:
; APPLICANT: Remacie, Jose
; APPLICANT: Hamels, Sandrine
; APPLICANT: Zammateo, Nathalie
; APPLICANT: Lockman, Laurence
; APPLICANT: Dufour, Sophie
; APPLICANT: Alexandre, Isabelle
; APPLICANT: De longueville, Francoise
; TITLE OF INVENTION: IDENTIFICATION OF BIOLOGICAL
; TITLE OF INVENTION: (MICRO)ORGANISMS BY DETECTION OF THEIR HOMOLOGOUS NUCLEOTIDE
; FILE REFERENCE: VANM213.001AUS
; CURRENT APPLICATION NUMBER: US/09/817,014
; CURRENT FILING DATE: 2001-03-23
; PRIOR APPLICATION NUMBER: EP 00870055.1
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: EP 00870204.5
```

;; PRIOR FILING DATE: 2000-09-15
;; NUMBER OF SEQ ID NOS: 192
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 154
;; LENGTH: 19
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: capture probe HTR7
US-09-817-014-154

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.1e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 510 CACGAGCGCCGACGACGAC 528
DB 19 CACGAGACCCCTCAGCTAC 1

RESULT 1132

US-10-056-229-155/c
;; Sequence 155, Application US/10056229
;; Publication No. US20030198943A1
;; GENERAL INFORMATION:
;; APPLICANT: Remacle, Jose
;; APPLICANT: Hamels, Sandrine
;; APPLICANT: Zammateo, Nathalie
;; APPLICANT: Lockman, Laurence
;; APPLICANT: Dufour, Sophie
;; APPLICANT: Alexandre, Isabelle
;; APPLICANT: De Longueville, Francoise
;; TITLE OF INVENTION: IDENTIFICATION OF A LARGE NUMBER OF
;; TITLE OF INVENTION: BIOLOGICAL (MICRO)ORGANISMS GROUPS AT DIFFERENT
;; TITLE OF INVENTION: LEVELS BY THEIR DETECTION ON A SAME ARRAY
;; FILE REFERENCE: VANM213.001CPI
;; CURRENT APPLICATION NUMBER: US/10/056,229
;; CURRENT FILING DATE: 2002-01-23
;; PRIOR APPLICATION NUMBER: EP 00870055.1
;; PRIOR FILING DATE: 2000-03-24
;; PRIOR FILING DATE: 2000-03-24
;; PRIOR APPLICATION NUMBER: EP 00870204.5
;; PRIOR FILING DATE: 2000-03-24
;; PRIOR APPLICATION NUMBER: US 09/817,014
;; PRIOR FILING DATE: 2001-03-23
;; NUMBER OF SEQ ID NOS: 321
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 155
;; LENGTH: 19
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: capture probe HTR7
US-10-056-229-155

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.1e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 510 CACGAGCGCCGACGACGAC 528
DB 19 CACGAGACCCCTCAGCTAC 1

RESULT 1133

US-10-444-925-126/c
;; Sequence 126, Application US/10444925
;; Publication No. US20040009946A1
;; GENERAL INFORMATION:
;; APPLICANT: Lewis, Stephen Patrick
;; APPLICANT: Klinghoffer, Richard
;; APPLICANT: Wilson, Linda K.
;; TITLE OF INVENTION: MODULATION OF PTP1B SIGNAL TRANSDUCTION
;; FILE REFERENCE: BY RNA INTERFERENCE

;; FILE REFERENCE: 200125.441
;; CURRENT APPLICATION NUMBER: US/10/444,925
;; CURRENT FILING DATE: 2003-05-23
;; NUMBER OF SEQ ID NOS: 599
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 126
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Small interfering RNA
US-10-444-925-126

Query Match 0.3%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 8.1e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 593 UCCUUGGCGCCGCGCCAU 611
DB 19 TCCTTGCGCTCTCTCCAT 1

RESULT 1134

US-10-750-185-18826/c
;; Sequence 18826, Application US/10750185
;; Publication No. US200502603A1
;; GENERAL INFORMATION:
;; APPLICANT: MMT GENOMICS, INC.
;; APPLICANT: DENISE, Sue K.
;; APPLICANT: KERR, Richard
;; APPLICANT: ROSENFELD, David
;; APPLICANT: HOLM, Tom
;; APPLICANT: BATES, Stephen
;; APPLICANT: FANTIN, Dennis
;; TITLE OF INVENTION: COMPOSITIONS FOR INFERRING BOVINE TRAITS
;; FILE REFERENCE: MM1100-2
;; CURRENT APPLICATION NUMBER: US/10/750,185
;; CURRENT FILING DATE: 2003-12-31
;; PRIOR APPLICATION NUMBER: US 60/437,482
;; PRIOR FILING DATE: 2002-12-31
;; NUMBER OF SEQ ID NOS: 64922
;; SOFTWARE: PatentIn version 3.1
;; SEQ ID NO 18826
;; LENGTH: 19
;; TYPE: DNA
;; ORGANISM: Artificial sequence
;; FEATURE:
;; OTHER INFORMATION: Forward Primer
US-10-750-185-18826

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 49 AGCUCGCCGGAUACACA 67
DB 19 AGCTGTCTCGATACACA 1

RESULT 1135

US-10-750-623-18826/c
;; Sequence 18826, Application US/10750623
;; Publication No. US2005028751A1
;; GENERAL INFORMATION:
;; APPLICANT: MMT GENOMICS, INC.
;; APPLICANT: DENISE, Sue K.
;; APPLICANT: KERR, Richard
;; APPLICANT: ROSENFELD, David
;; APPLICANT: HOLM, Tom
;; APPLICANT: BATES, Stephen
;; APPLICANT: FANTIN, Dennis
;; TITLE OF INVENTION: METHODS AND SYSTEMS FOR INFERRING BOVINE TRAITS
;; FILE REFERENCE: MM1100-1

```

; CURRENT APPLICATION NUMBER: US/10/750,623
; CURRENT FILING DATE: 2003-12-31
; PRIOR APPLICATION NUMBER: US 60/437,482
; PRIOR FILING DATE: 2002-12-31
; NUMBER OF SEQ ID NOS: 64922
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 18826
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Forward Primer
US-10-750-623-18826
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      49 AGCUCCTCCUGAGUACACA 67
Db      19 AGCTGTCTCGATACACA 1
```

```
RESULT 1136
US-10-310-914A-151740/C
; Sequence 151740, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 151740
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-151740
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 42.1%; Pred. No. 8.1e+02;
Matches 8; Conservative 9; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      584 UCUCUCUUCUCCUUGGCG 602
Db      19 TCCTCTTGACTTGTC 1
```

```
RESULT 1137
US-10-310-914A-213659
; Sequence 213659, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 213659
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-213659
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
```

```
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      11 ACAUAAACAGUACAACCTUC 29
Db      1 ACAUACAGAGAACCACTUC 19
```

```
RESULT 1138
US-10-310-914A-302114
; Sequence 302114, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 302114
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-302114
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1168 CAGGUCCTGAGAGAGAGC 1186
Db      1 CAGCAGCUCGAGAGAGAGC 19
```

```
RESULT 1139
US-10-310-914A-302115
; Sequence 302115, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 302115
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-302115
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1168 CAGGUCCTGAGAGAGAGC 1186
Db      1 CAGCAGCUCGAGAGAGAGC 19
```

```
RESULT 1140
US-10-310-914A-396511
; Sequence 396511, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyazat
```

```
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ FILE OF INVENTION: uses thereof
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ CURRENT FILING DATE: 2002-12-06
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 396511
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-396511

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 810 CTCUGGACAGAGCCAGAG 828
DB 1 CTCUGGACAGAGCCAGAG 19

RESULT 1141
US-10-310-914A-520464/C
/ Sequence 520464, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ APPLICANT: Shlier, Kiyazat
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ FILE OF INVENTION: uses thereof
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ CURRENT FILING DATE: 2002-12-06
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 520464
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-520464

Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 415 UUGGCTUGAGCCTCCGCGC 433
DB 19 TTGACCTGTGACCTCTGAC 1

RESULT 1142
US-10-310-914A-605977/C
/ Sequence 605977, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ APPLICANT: Shlier, Kiyazat
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ FILE OF INVENTION: uses thereof
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ CURRENT FILING DATE: 2002-12-06
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 605977
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-605977

Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

```
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1179 GGAGAGCUGGAGGAGUGUG 1197
DB 19 GGTGAGCTGGGAGGAGG 1

RESULT 1143
US-10-310-914A-608678/C
/ Sequence 608678, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ APPLICANT: Shlier, Kiyazat
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ FILE OF INVENTION: uses thereof
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ CURRENT FILING DATE: 2002-12-06
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 608678
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-608678

Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1172 UGCCUGAGAGAGCUGGCG 1190
DB 19 TGCCTGTGCTGAGCTGGG 1

RESULT 1144
US-10-310-914A-629308/C
/ Sequence 629308, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ APPLICANT: Shlier, Kiyazat
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ FILE OF INVENTION: uses thereof
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ CURRENT FILING DATE: 2002-12-06
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 629308
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-629308

Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 787 AAAGACCTGCGGCGGCG 805
DB 19 AAAGACCTGCGGCGGCG 1

RESULT 1145
US-10-310-914A-647404/C
/ Sequence 647404, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ APPLICANT: Shlier, Kiyazat
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
```

```

; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 647404
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-647404

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1023 UGCGUGGCGCCUCCUGGAG 1041
Db 1 UGCGUGGCGCCUCCUGGAG 19

RESULT 1146
US-10-310-914A-647405
; Sequence 647405, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 647405
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-647405

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1023 UGCGUGGCGCCUCCUGGAG 1041
Db 1 UGCGUGGCGCCUCCUGGAG 19

RESULT 1147
US-10-310-914A-670737
; Sequence 670737, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 670737
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-670737

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

Qy 131 GAGCAGCTGGCGCAUUCUC 149
Db 1 GAGCAGCTGGCGCAUUCUC 19

RESULT 1148
US-10-310-914A-1016294/c
; Sequence 1016294, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1016294
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1016294

Query Match
Best Local Similarity 73.7%; Score 15.8; DB 1; Length 19;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1181 AGGAGGTGGGTGATGATGGA 1199
Db 19 AGGAGGTGGGTGATGATGGA 1

RESULT 1149
US-10-310-914A-1251060/c
; Sequence 1251060, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1251060
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1251060

Query Match
Best Local Similarity 73.7%; Score 15.8; DB 1; Length 19;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1178 AGGAGGAGCTGGGCGCTGCT 1
Db 19 AGGAGGAGCTGGGCGCTGCT 1

RESULT 1150
US-10-310-914A-1252140/c
; Sequence 1252140, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
```

```
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: Patentin version 3.3
; SEQ ID NO: 1252140
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1252140

Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1116 GGGUCACAGCACCACUCCUC 1134
DB 19 GGGGCACAGCACTATCTCTC 1

RESULT 1151
US-10-310-914A-1287594
; Sequence 1287594, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: Patentin version 3.3
; SEQ ID NO: 1287594
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1287594

Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1592 GGCUCUGUCACAUCAACAG 1610
DB 1 GACUCUGUCACAUCAACAG 19

RESULT 1152
US-11-014-373-239/C
; Sequence 239, Application US/11014373
; Publication No. US20050196781A1
; GENERAL INFORMATION:
; APPLICANT: Robin, Howard
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA INTERFERENCE MEDIATED INHIBITION OF STAT3 GENE EXPRESSION
; FILE REFERENCE: 400/241 MEBH04-1067
; CURRENT APPLICATION NUMBER: US/11/014,373
; CURRENT FILING DATE: 2004-12-15
; PRIOR APPLICATION NUMBER: PCT/US 04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
```

```
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 678
; SOFTWARE: Patentin version 3.3
; SEQ ID NO: 239
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Target Sequence/siNA sense region
US-11-014-373-239

Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 808 GGCUCUGACAGAGCAGCAG 826
DB 19 GCCTCTGAGTCAGAGGCAG 1

RESULT 1153
US-11-014-373-516
; Sequence 516, Application US/11014373
; Publication No. US20050196781A1
; GENERAL INFORMATION:
; APPLICANT: Robin, Howard
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA INTERFERENCE MEDIATED INHIBITION OF STAT3 GENE EXPRESSION
; FILE REFERENCE: 400/241 MEBH04-1067
; CURRENT APPLICATION NUMBER: US/11/014,373
; CURRENT FILING DATE: 2004-12-15
; PRIOR APPLICATION NUMBER: PCT/US 04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 678
; SOFTWARE: Patentin version 3.3
; SEQ ID NO: 516
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Target Sequence/siNA sense region
US-11-014-373-516

Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

Matches	17, Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
Qy	808	GCCTCTUGGGACAGAGGCAG	826					
Db	1	GCCTCTUGAGUCAGAGGCAG	19					

```

RESULT 1154
US-11-071-864-72
; Sequence 72. Application US/11071864
; Publication No. US20050202490A1
; GENERAL INFORMATION:
; APPLICANT: MAKAROV, VLADIMIR L.
; APPLICANT: KAMBEROV, EMMANUEL
; APPLICANT: SUN, TONG
; APPLICANT: PINTER, JONATHAN H.
; APPLICANT: TARRIER, BRENDAN J.
; APPLICANT: BRUENING, ERIC E.
; APPLICANT: KURIHARA, TAKAO
; APPLICANT: TESMER, TIM
; APPLICANT: M'WHIRICHA, JOSEPH
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR GENERATING AND AMPLIFYING
; TITLE OF INVENTION: DNA LIBRARIES FOR SENSITIVE DETECTION AND ANALYSIS OF
; TITLE OF INVENTION: DNA METHYLATION
; FILE REFERENCE: RUBC:023US
; CURRENT APPLICATION NUMBER: US/11/071,864
; PRIOR FILING DATE: 2005-03-03
; PRIOR APPLICATION NUMBER: 60/551,941
; PRIOR FILING DATE: 2004-03-08
; NUMBER OF SEQ ID NOS: 206
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 72
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Primer
US-11-071-864-72

```

```

RESULT 1155
US-11-083-784-14368
; Sequence 14368, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14368

```

```

; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-14368

```

Query Match	0.9%	Score 15.8;	DB 1;	Length 19;
Best Local Similarity	89.5%	Pred. No. 8.1e+02;		
Matches 17; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

```

RESULT 1156
US-11-083-784-14415
; Sequence 14415, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khavrova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional sRNA
; FILE REFERENCE: 1149905
; CURRENT APPLICATION NUMBER: US/11/083.784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 151911
; SOFTWARE: Proprietary
; SEQ ID NO 14415
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-14415

```

Query Match	0.94;	Score 15.8;	DB 1;	Length 19;
Best Local Similarity	89.5%;	Pred. No. 8.1e+02;		
Matches 17; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0

RESULT 1157
US-11-083-784-15086
Sequence: 15086, Application US/11083784
Publication NO. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaring, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 134990US
CURRENT APPLICATION NUMBER: US/11/083.784
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714.333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502, 050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426, 137
PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 15086
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-15086

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 236 UGAGACGGUCACACUA 314
Db 1 UGCACACGGUCACACUA 19

RESULT 1158

US-11-083-784-15128
; Sequence 15128, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:

; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 15128
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-15128

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 303 GGUCAACAUCUCCUCUC 321
Db 1 GGUCAACAUCUCCUCUC 19

RESULT 1159

US-11-083-784-22214/C
; Sequence 22214, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:

; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 22214
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-22214

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

OY 40 CCAACATCAGGCTTCTCT 58
Db 19 CCAACATCAGGCTTCTCT 1

RESULT 1160

US-11-083-784-25249
; Sequence 25249, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:

; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 25249
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-25249

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1011 GAACAAUAGUAGUCUCU 1029
Db 1 GAACAAUAGUAGUCUCU 19

RESULT 1161

US-11-083-784-25349
; Sequence 25349, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:

; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050

```

; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 25349
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-25349
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1011 GAACAACAUGAUGGCU 1029
DB      1 GAACUACAUGAUGCUACU 19
```

```
RESULT 1162
US-11-083-784-45869
; Sequence 45869, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 45869
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-45869
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1439 GGAUGUCCUUGGCAAGA 1457
DB      1 GAUGUCCUGGCAAGA 19
```

```
RESULT 1163
US-11-083-784-52416
; Sequence 52416, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```

; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 52416
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-52416
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      579 GGUCAUCCCUUUGUCUU 597
DB      1 GGUCAUCCCUUUGUCAU 19
```

```
RESULT 1164
US-11-083-784-52520
; Sequence 52520, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 52520
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-52520
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      579 GGUCAUCCCUUUGUCUU 597
DB      1 GGUCAUCCCUUUGUCAU 19
```

```
RESULT 1165
US-11-083-784-52639
; Sequence 52639, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
```

```
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 52639
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-52639
```

```
Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      579 GGUCAUCCUCCUUGUCCU 597
DB      1 GGUCAUCCUCCUUGUCCAU 19
```

```
RESULT 1166
US-11-083-784-52708
/ Sequence 52708, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 52708
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-52708
```

```
Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      579 GGUCAUCCUCCUUGUCCU 597
DB      1 GGUCAUCCUCCUUGUCCAU 19
```

```
RESULT 1167
US-11-083-784-52803
/ Sequence 52803, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
```

```
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 52803
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-52803
```

```
Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      579 GGUCAUCCUCCUUGUCCU 597
DB      1 GGUCAUCCUCCUUGUCCAU 19
```

```
RESULT 1168
US-11-083-784-52901
/ Sequence 52901, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 52901
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-52901
```

```
Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      579 GGUCAUCCUCCUUGUCCU 597
DB      1 GGUCAUCCUCCUUGUCCAU 19
```

```
RESULT 1169
US-11-083-784-86473
/ Sequence 86473, Application US/11083784
```

```
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 86473
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-86473
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 1664 UCAAGUCGUCGUCGUCG 1682

DB 1 UGAAGUCGUCGUGAUG 19

```
RESULT 1170
/ Sequence 96765, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 96765
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-96765
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 300 GACGUCACACUACUAC 318

DB 1 GACAGUCAUACUACUAC 19

```
RESULT 1171
US-11-083-784-96770
/ Sequence 96770, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 96770
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-96770
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 455 GCAUAGCCUCUGUAVGAA 473

DB 1 GCAUAGCCUCUGUAVGAA 19

```
RESULT 1172
US-11-083-784-96775
/ Sequence 96775, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ CURRENT FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 96775
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-96775
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 453 CAGCAUAGCCUCUGUAVG 471

DB 1 CAGCAUAGCCUCUGUAVG 19

Db 1 CAGCAUCCUCCGUCAU 19

RESULT 1173

US-11-083-784-96789

Sequence 96789, Application US/11083784
Publication No. US20050245475A1

GENERAL INFORMATION:

APPLICANT: Dharmaco, Inc.

APPLICANT: Khvorova, Anastasia

APPLICANT: Reynolds, Angela

APPLICANT: Leake, Devin

APPLICANT: Marshall, William

TITLE OF INVENTION: Functional and Hyperfunctional siRNA

FILE REFERENCE: 13499US

CURRENT APPLICATION NUMBER: US/11/083,784

PRIOR FILING DATE: 2005-03-18

PRIOR APPLICATION NUMBER: US/10/714,333

PRIOR FILING DATE: 2003-11-14

PRIOR APPLICATION NUMBER: 60/502,050

PRIOR FILING DATE: 2003-09-10

PRIOR APPLICATION NUMBER: 60/426,137

NUMBER OF SEQ ID NOS: 1591911

SOFTWARE: Proprietary

SEQ ID NO 96789

LENGTH: 19

TYPE: RNA

ORGANISM: Homo sapiens

US-11-083-784-96789

Query Match 0.9%; Score 15.8; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 8.1e+02; Mismatches 2; Indels 0; Gaps 0;

Qy 454 AGCAUCCUCCGUCAU 472

Db 1 AGCAUCCUCCGUCAU 19

RESULT 1174

US-11-083-784-96792

Sequence 96792, Application US/11083784
Publication No. US20050245475A1

GENERAL INFORMATION:

APPLICANT: Dharmaco, Inc.

APPLICANT: Khvorova, Anastasia

APPLICANT: Reynolds, Angela

APPLICANT: Leake, Devin

APPLICANT: Marshall, William

TITLE OF INVENTION: Functional and Hyperfunctional siRNA

FILE REFERENCE: 13499US

CURRENT APPLICATION NUMBER: US/11/083,784

PRIOR FILING DATE: 2005-03-18

PRIOR APPLICATION NUMBER: US/10/714,333

PRIOR FILING DATE: 2003-11-14

PRIOR APPLICATION NUMBER: 60/502,050

PRIOR FILING DATE: 2003-09-10

PRIOR APPLICATION NUMBER: 60/426,137

NUMBER OF SEQ ID NOS: 1591911

SOFTWARE: Proprietary

SEQ ID NO 96792

LENGTH: 19

TYPE: RNA

ORGANISM: Homo sapiens

US-11-083-784-96792

Query Match 0.9%; Score 15.8; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 8.1e+02; Mismatches 2; Indels 0; Gaps 0;

Qy 456 CAUCCUCCGUCAU 474

Db 1 CAUCCUCCGUCAU 19

RESULT 1175

US-11-083-784-96794

Sequence 96794, Application US/11083784
Publication No. US20050245475A1

GENERAL INFORMATION:

APPLICANT: Dharmaco, Inc.

APPLICANT: Khvorova, Anastasia

APPLICANT: Reynolds, Angela

APPLICANT: Leake, Devin

APPLICANT: Marshall, William

TITLE OF INVENTION: Functional and Hyperfunctional siRNA

FILE REFERENCE: 13499US

CURRENT APPLICATION NUMBER: US/11/083,784

PRIOR FILING DATE: 2005-03-18

PRIOR APPLICATION NUMBER: US/10/714,333

PRIOR FILING DATE: 2003-11-14

PRIOR APPLICATION NUMBER: 60/502,050

PRIOR FILING DATE: 2003-09-10

PRIOR APPLICATION NUMBER: 60/426,137

NUMBER OF SEQ ID NOS: 1591911

SOFTWARE: Proprietary

SEQ ID NO 96794

LENGTH: 19

TYPE: RNA

ORGANISM: Homo sapiens

US-11-083-784-96794

Query Match 0.9%; Score 15.8; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 8.1e+02; Mismatches 2; Indels 0; Gaps 0;

Qy 1511 GGACCCGUCAU 1529

Db 1 GGACCCGUCAU 19

RESULT 1176

US-11-083-784-96795

Sequence 96795, Application US/11083784
Publication No. US20050245475A1

GENERAL INFORMATION:

APPLICANT: Dharmaco, Inc.

APPLICANT: Khvorova, Anastasia

APPLICANT: Reynolds, Angela

APPLICANT: Leake, Devin

APPLICANT: Marshall, William

TITLE OF INVENTION: Functional and Hyperfunctional siRNA

FILE REFERENCE: 13499US

CURRENT APPLICATION NUMBER: US/11/083,784

PRIOR FILING DATE: 2005-03-18

PRIOR APPLICATION NUMBER: US/10/714,333

PRIOR FILING DATE: 2003-11-14

PRIOR APPLICATION NUMBER: 60/502,050

PRIOR FILING DATE: 2003-09-10

PRIOR APPLICATION NUMBER: 60/426,137

NUMBER OF SEQ ID NOS: 1591911

SOFTWARE: Proprietary

SEQ ID NO 96795

LENGTH: 19

TYPE: RNA

ORGANISM: Homo sapiens

US-11-083-784-96795

Query Match	0.9%	Score 15.8;	DB 1;	length 19;
Best Local Similarity	89.5%	Pred. No. 8.1e+02;		
Matches 17; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0

470 UGAUUCUUGGUCUACG 488

Db 1 UGAUCUCGCUCAUCAG 19

RESULT 1177
US-11-083-784-96884

Publication No. US20050245475A1

Query Match	0.9%;	Score 15.8;	DB 1;	Length 19;
Best Local Similarity	89.5%;	Pred. No. 8.1e+02;		
Matches 17; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0

1493 UUGCCUUCACUACUUG 1511

Db 1 UGGCUUCAUCACTUG 19

RESULT 1178
US-11-083-784-97127

Publication No. US20050245475A1

ORGANISM: Homo sapiens
US-11-083-784-97127

US-11-083-784-97127

Query Match	0.9%	Score 15.8;	DB 1;	Length 19;
Best Local Similarity	89.5%;	Pred. No. 8.1e+02;		
Matches 17; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

296 UGAGACCGUCACACUA 314

Db 1 UGCAGACAGUCAACACUA 19

RESULT 1179
US-11-083-784-97132

Publication No. US20050245475A1

Query Match	0.9%	Score 15.8;	DB 1;	Length 19;
Best Local Similarity	89.5%;	Pred. No. 8.1e+02;		
Matches 17; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

297 GAAGCGUCACCACTUAC 315

Db 1 GCAGACAGUCAACACUAC 19

RESULT 1180

; Sequence 97144, Application US/

TYPE: RNA

SEQ ID NO 97144
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-97144

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1586 GCUACUGGCUUGCUCAU 1604
DB 1 GCUACUGGCUUGCUCAU 19

RESULT 1181
US-11-083-784-97252
Sequence 97252, Application US/11083784
Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmoon, Inc.
APPLICANT: Reynolds, Angela
APPLICANT: Khvorova, Anastasia
APPLICANT: Marshall, William
APPLICANT: Leake, Devin
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/083,784
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO: 97252
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-97252

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 493 GACGAGUACUUUCCAUCA 511
DB 1 GACGAGUACUUUCCAUCA 19

RESULT 1182
US-11-083-784-155844/c
Sequence 155844, Application US/11083784
Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmoon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/083,784
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137

PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 155844
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-155844

Query Match
Best Local Similarity 63.2%; Score 15.8; DB 1; Length 19;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1020 UGAUGGUGGUGCCUG 1038
DB 19 TGAAGTCTGCTGCTCCCTG 1

RESULT 1183
US-11-083-784-193107/c
Sequence 193107, Application US/11083784
Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmoon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/083,784
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 193107
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-193107

Query Match
Best Local Similarity 68.4%; Score 15.8; DB 1; Length 19;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1400 UUGCUCUGAAGCAGAG 1418
DB 19 TTGCTATGAAGCAGATG 1

RESULT 1184
US-11-083-784-214402/c
Sequence 214402, Application US/11083784
Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmoon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/083,784
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14

```
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 214402
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-214402

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.1e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      1014 CACACAUGAUGCGUGCC 1032
DB      19  CACAAATGACGCTGCGGCC 1

RESULT 1185
US-11-083-784-222230
; Sequence 222230, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 222230
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-222230

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      300 GACGGUACAACUACUUC 318
DB      1  GACAGUCACCAACUACUUC 19

RESULT 1186
US-11-083-784-222321
; Sequence 222321, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
```

```
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 222321
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-222321

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      300 GACGGUACAACUACUUC 318
DB      1  GACGGUACAACUACUUC 19

RESULT 1187
US-11-083-784-342052
; Sequence 342052, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 342052
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-342052

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1653 CAGATCAGUUCAGAGUG 1671
DB      1  CAGAACCAUUGUAGUG 19

RESULT 1188
US-11-083-784-391588/C
; Sequence 391588, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
```

```
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 391588
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-391588

Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      42 AACATCAGCCTCCCTCTCG 60
DB      19 AACATCAGCCTCCCTCTCG 1

RESULT 1189
US-11-083-784-409997
; Sequence 409997, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Reynolds, Angela
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Marshall, William
; APPLICANT: Leake, Devin
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 409997
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-409997

Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 417946
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-417946

Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      815 GGACAGAGCGAGACAGCA 833
DB      1 GGACAGAGCGAGACAGCA 19

RESULT 1191
US-11-083-784-462391/c
; Sequence 462391, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 462391
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-462391

Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      1428 UAGCGGAAAGAGUCC 1446
DB      19 TAAAGCAAGAGAGATGCC 1

RESULT 1192
US-11-083-784-482025
; Sequence 482025, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
```

```

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 482025
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-482025
```

```

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY      1231 CAGAGAGCGUGAGCAGU 1249
DB      1 CAGAGAGCGUGAGAGAU 19
```

```

RESULT 1193
US-11-083-784-514801
; Sequence 514801, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 514801
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-514801
```

```

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY      859 UCUGAAGCUGAGCAGU 877
DB      1 UCUGAAGCUGAGAGAU 19
```

```

RESULT 1194
US-11-083-784-535685
```

```

; Sequence 535685, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 535685
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-535685
```

```

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY      655 GGAAGUGCGUCCAUUCAGU 673
DB      1 GGAAGUGAUUCAUUCAGU 19
```

```

RESULT 1195
US-11-083-784-576464/C
; Sequence 576464, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 576464
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-576464
```

```

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 8.1e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

```

QY      35 UGUUCCAAACUUCAGCUC 53
DB      19 TGTTCCAATATACAGATC 1
```

RESULT 1196

US-11-083-784-581851/c
; Sequence 581851, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 581851
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-581851

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 47.4%; Pred. No. 8.1e+02;
Matches 9; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 661 UGCUCAUUCAGUCCUCA 679

Db 19 TACTTCATTCAGTTCTCA 1

RESULT 1197

US-11-083-784-581953/c
; Sequence 581953, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 581953
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-581953

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 47.4%; Pred. No. 8.1e+02;
Matches 9; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 661 UGCUCAUUCAGUCCUCA 679

Db 19 TACTTCATTCAGTTCTCA 1

RESULT 1198
US-11-083-784-640147
; Sequence 640147, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 640147
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-640147

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 GGACAGAGCGCAGACAGA 833

Db 1 GGCACAGCGCAGACAGA 19

RESULT 1199
US-11-083-784-645531/c
; Sequence 645531, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 645531
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-645531

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 8.1e+02;

Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Oy 267 AAUUGUCUAUUAAGUC 285

Db 19 ACTGTGTCATGTAAGTC 1

RESULT 1200

US-11-083-784-653396/c

; Sequence 653396, Application US/11083784
; Publication No. US20050245475A1

; GENERAL INFORMATION:

; APPLICANT: Dharmoon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/083,784

; CURRENT FILING DATE: 2005-03-18

; PRIOR APPLICATION NUMBER: US/10/714,333

; PRIOR FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 653396

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-083-784-653396

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Oy 1038 GGAGAACUCCGCCUCC 1056

Db 19 GAAGAACTCTCTCTCC 1

RESULT 1201

US-11-083-784-653423/c

; Sequence 653423, Application US/11083784
; Publication No. US20050245475A1

; GENERAL INFORMATION:

; APPLICANT: Dharmoon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/083,784

; CURRENT FILING DATE: 2005-03-18

; PRIOR APPLICATION NUMBER: US/10/714,333

; PRIOR FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 653423

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-083-784-653423

Query Match 0.9%; Score 15.8; DB 1; Length 19;

Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Oy 1038 GGAGAACUCCGCCUCC 1056

Db 19 GAAGAACTCTCTCTCC 1

RESULT 1202

US-11-083-784-661229/c

; Sequence 661229, Application US/11083784
; Publication No. US20050245475A1

; GENERAL INFORMATION:

; APPLICANT: Dharmoon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/083,784

; CURRENT FILING DATE: 2005-03-18

; PRIOR APPLICATION NUMBER: US/10/714,333

; PRIOR FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 661229

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-083-784-661229

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 8.1e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Oy 316 UUCUUCUAAGCCUCC 334

Db 19 TTCCTTGAAGCTTGCC 1

RESULT 1203

US-11-083-784-691453/c

; Sequence 691453, Application US/11083784
; Publication No. US20050245475A1

; GENERAL INFORMATION:

; APPLICANT: Dharmoon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/083,784

; CURRENT FILING DATE: 2005-03-18

; PRIOR APPLICATION NUMBER: US/10/714,333

; PRIOR FILING DATE: 2003-11-14

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 691453

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-083-784-691453

TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-691453

Query Match
Best Local Similarity 63.2%; Score 15.8; DB 1; Length 19;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 411 GAACUGGCCUGGACCC 429
DB 19 GAACCTTGCCCTGTGACATC 1

RESULT 1204
US-11-083-784-691532/c
Sequence 691532, Application US/11083784
Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/083,784
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 691532
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-691532

Query Match
Best Local Similarity 63.2%; Score 15.8; DB 1; Length 19;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 411 GAACUGGCCUGGACCC 429
DB 19 GAACCTTGCCCTGTGACATC 1

RESULT 1205
US-11-083-784-770039
Sequence 770039, Application US/11083784
Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/083,784
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911

SOFTWARE: Proprietary
SEQ ID NO 770039
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-770039

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 466 GUUAUGAUCUCUGUCA 484
DB 1 GUUAUGAUCUCUCUGUCA 19

RESULT 1206
US-11-083-784-771283/c
Sequence 771283, Application US/11083784
Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/083,784
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 771283
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-771283

Query Match
Best Local Similarity 52.6%; Score 15.8; DB 1; Length 19;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 597 UUGGCGCCUGCCAUUCUG 615
DB 19 TTGCGCTCCTGCTCTTG 1

RESULT 1207
US-11-083-784-819337
Sequence 819337, Application US/11083784
Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/083,784
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10

```

; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 819337
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-819337

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      815 GGACGAGCGACGAGACAGA 833
Db      1  GGACGAGCGACGAGACAGA 19

RESULT 1208
US-11-083-784-845076
; Sequence 845076, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 845076
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-845076

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1524 CAUCAUGGUCUGUGAAC 1542
Db      1  CAUCAUGGUCUGUGAAC 19

RESULT 1209
US-11-083-784-860780
; Sequence 860780, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
```

```

; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 860780
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-860780

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      243 GACCAUCAUCGCAACAU 261
Db      1  GACCAUCAUCGCAACAU 19

RESULT 1210
US-11-083-784-878444/C
; Sequence 878444, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 878444
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-878444

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 8.1e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY      37 UUUCCAACAUCGUCU 55
Db      19  TTTCACAACGAGCTTCT 1

RESULT 1211
US-11-083-784-891418
; Sequence 891418, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
```

```
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 891418
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-891418

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      818 CAGAGCGAGACAGAAA 836
Db      1 CAGAGCGAGACAGAAUA 19

RESULT 1212
US-11-083-784-909909/c
; Sequence 909909, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 909909
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-909909

Query Match
Best Local Similarity 63.2%; Score 15.8; DB 1; Length 19;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY      274 UCAUUDUAGGUCACAGC 292
Db      19 TCATTTAAGATCATCAAGC 1

RESULT 1213
US-11-083-784-910002/c
; Sequence 910002, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
```

```
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 910002
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-910002

Query Match
Best Local Similarity 68.4%; Score 15.8; DB 1; Length 19;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      248 UCAUCCGCAACUCCUGU 266
Db      19 TAAACCGCAACATCCTGCT 1

RESULT 1214
US-11-083-784-910052/c
; Sequence 910052, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 910052
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-910052

Query Match
Best Local Similarity 68.4%; Score 15.8; DB 1; Length 19;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      248 UCAUCCGCAACUCCUGU 266
Db      19 TAAACCGCAACATCCTGCT 1

RESULT 1215
US-11-083-784-941780
; Sequence 941780, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
```

```

; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 941780
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-941780
```

```

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      306 CACCAACUACUUCUCCUUA 324
      ||||| ||||| ||||| |||||
DB      1 CACCAACUCCUUCUCCUUA 19
```

```

RESULT 1216
US-11-083-784-941970
; Sequence 941970, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 941970
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-941970
```

```

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      306 CACCAACUACUUCUCCUUA 324
      ||||| ||||| ||||| |||||
DB      1 CACCAACUCCUUCUCCUUA 19
```

```

RESULT 1217
US-11-083-784-1025790/c
; Sequence 1025790, Application US/11083784
; Publication No. US20050245475A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1025790
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1025790
```

```

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 8.1e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      267 AAUUGUGUCAUUUAAGGUC 285
      ||::||::||::||::||:
DB      19 AATTGTGTCATATAAGCTC 1
```

```

RESULT 1218
US-11-083-784-1038110/c
; Sequence 1038110, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1038110
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1038110
```

```

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 8.1e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      453 CAGCAUGCCUCCUGUUAUG 471
      ||||| ||||| ||||| |||||
DB      19 CATCACTGCCTCTGTATG 1
```

```

RESULT 1219
```

```
US-11-083-784-1052031/c
; Sequence 1052031, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1052031
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1052031
```

```
Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      41 CAACAGCAGCUCCTCTTGG 59
Db      19 CAACAGCAGCCTCTTGG 1
```

```
RESULT 1220
US-11-083-784-1052055/c
; Sequence 1052055, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1052055
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1052055
```

```
Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      42 AAACAGCAGCUCCTCTTGG 60
Db      19 AAACAGCAGCTCTCTTGG 1
```

```
RESULT 1221
US-11-083-784-1082966
; Sequence 1082966, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1082966
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1082966
```

```
Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      113 GCAGCTCAAGUCUUCUG 131
Db      1 GCAGCTCAAGUCUUCUG 19
```

```
RESULT 1222
US-11-083-784-1095950/c
; Sequence 1095950, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1095950
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1095950
```

```
Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```

Qy      634 GGAAGAGAACUGUGGCCUC 652
          |||||:|:|:|
Db      19 GTAGAGAGAACTGTGCTC 1

```

RESULT 1223
US-11-083-784-1143713

```

Sequence 11443713, Application US/11083784
Publication No. US20050245475v1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: leeke, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OR INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 134990US
CURRENT APPLICATION NUMBER: US/11/083,784
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 1143713
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-1143713

```

Query Match	0.9%	Score 15.8;	DB 1;	Length 19;
Best Local Similarity	89.5%;	Pred. No. 8.1e+02;		
Matches 17; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

QY	1193	UGGUGACUTUGGAGAGGAA	1211
Db	1	UGGAGGACCTUGGAGAGGAA	19

RESULT 1224

```

US-11-083-784-1202196/c
? Sequence 1202196, Application US/11083784
? Publication No. US20050245475A1
? GENERAL INFORMATION:
? APPLICANT: Dharmacon, Inc.
? APPLICANT: Khvorova, Anastasia
? APPLICANT: Reynolds, Angela
? APPLICANT: Leake, Devin
? APPLICANT: Marshall, William
? APPLICANT: Scaringe, Stephen
? TITLE OF INVENTION: Functional and Hyperfunctional siRNA
? FILE REFERENCE: 134990S
? CURRENT APPLICATION NUMBER: US/11/083,784
? CURRENT FILING DATE: 2005-03-18
? PRIOR APPLICATION NUMBER: US/10/714,333
? PRIOR FILING DATE: 2003-11-14
? PRIOR APPLICATION NUMBER: 60/502,050
? PRIOR FILING DATE: 2003-09-10
? PRIOR APPLICATION NUMBER: 60/426,137
? PRIOR FILING DATE: 2002-11-14
? NUMBER OF SEQ ID NOS: 1591911
? SOFTWARE: ProIdentary
? SEQ ID NO 1202196
? LENGTH: 19
? TYPE: RNA
? ORGANISM: Homo sapiens
US-11-083-784-1202196

```

Query Match 0.94; Score 15.8; DB 1; Length 19;

Best Local Similarity 57.9%; Pred. No. 8.1e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0.

```
Qy      141 CAUUUUCUCCUCCAGAC 159
      |||:::|:::|:::|:::|
Db      19 CAATTCTCCTCTTCAAC 1
```

RESULT 1225
US-11-083-784-1237713

```

Sequence 1237713, Application US/11083784
Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 134990US
CURRENT APPLICATION NUMBER: US/11/083,784
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 1237713
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-1237713

```

Query Match	0.9%	Score 15.8;	DB 1;	Length 19;
Best Local Similarity	89.5%;	Pred. No. 8.1e+02;		
Matches 17; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0

QY	1218	CAAGTCAGGCCCAAGAAG	1236
Db	1	CAAGTCAGGCCCAAGAAG	19

RESULT 1226

```

US-11-083-784-1267843/c
Sequence 1267843, Application US/11083784
Publication No. US20050245475a1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khavrova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leeke, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OR INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 134990US
CURRENT APPLICATION NUMBER: US/11/083.784
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 1267843
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens

```

US-11-083-784-1267843

Query Match
Best Local Similarity 63.2%; Score 15.8; DB 1; Length 19;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1648 ACAUUCAGACACACUUCU 1666
Db 19 ACATTAGACACACCTTCA 1

RESULT 1227

US-11-083-784-1267942/c
Sequence 1267942, Application US/11083784
Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmcon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 1267942
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-1267942

Query Match
Best Local Similarity 63.2%; Score 15.8; DB 1; Length 19;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1648 ACAUUCAGACACACUUCU 1666
Db 19 ACATTAGACACACCTTCA 1

RESULT 1228

US-11-083-784-1302272
Sequence 1302272, Application US/11083784
Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmcon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 1302272

LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-1302272

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 758 GGAUCUUAUGAGAAACUGA 776
Db 1 GGAUUAUGAGAAACUGA 19

RESULT 1229

US-11-083-784-1312578
Sequence 1312578, Application US/11083784
Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmcon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 1312578
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-1312578

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1720 CAGCAGAGACGUCGUCU 1738
Db 1 CAGCAGAGACGUCGUCU 19

RESULT 1230

US-11-083-784-1348446/c
Sequence 1348446, Application US/11083784
Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmcon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14

```
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1348446
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1348446
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      42 AAACATCAGCTCCCTCCG 60
Db      19 AAACATGAGCTCCACCTCG 1
```

```
RESULT 1231
US-11-083-784-1365309/C
; Sequence 1365309, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1365309
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1365309
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1392 CAAGAGGUTUGCUCUGAAG 1410
Db      19 CAACAGGTGCTGCTGAG 1
```

```
RESULT 1232
US-11-083-784-1372117
; Sequence 1372117, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
```

```
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1372117
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1372117
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1646 AAACATUCAGAACACACU 1664
Db      1 AAACATUCAGACUACU 19
```

```
RESULT 1233
US-11-083-784-1393220
; Sequence 1393220, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1393220
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1393220
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1119 UCACAGCACCAUCCUAC 1137
Db      1 UCACAGCACCAUCCACAC 19
```

```
RESULT 1234
US-11-083-784-1443908
; Sequence 1443908, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
```

```

1 PRIOR APPLICATION NUMBER: US10/714,333
2
3 PRIOR FILING DATE: 2003-11-14
4
5 PRIOR APPLICATION NUMBER: 60/502,050
6
7 PRIOR FILING DATE: 2003-09-10
8
9 PRIOR APPLICATION NUMBER: 60/426,137
10
11 PRIOR FILING DATE: 2002-11-14
12
13 NUMBER OF SEQ ID NOS: 1591911
14
15 SOFTWARE: Proprietary
16
17 SEQ ID NO 1443908
18
19 LENGTH: 19
20
21 TYPE: RNA
22
23 ORGANISM: Homo sapiens
24
25 US-11-083-784-1443908

```

Query Match	0.9%	Score 15.8;	DB 1;	Length 19;
Best Local Similarity	89.5%;	Pred. No. 8.1e+02;		
Matches 17; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

Qy 988 GACCACAGCAGCAGUGACA 1006
|||
Db 1 GACCACAGCUGCAUUGACA 19

RESULT 1235
US-11-083-784-1450263/c
; Sequence 1450263, Application US/11083784
; Publication No. US20050245475A1

```

GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 134991US
CURRENT APPLICATION NUMBER: US/11/083,784
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 1450263
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-1450263

```

Query Match	0.9%	Score 15.8;	DB 1;	length 19;
Best Local Similarity	57.9%	Pred. No. 8.1e+02;		
Matches 11; Conservative	6;	Mismatches 2;	Indels 0;	Gaps 0;

```

QY      1257 UUUUCCAAAAGCUCUCC 1275
          :::||||| ||:::||
Db      19  TTCTCCAATACTTCTCC 1

```

RESULT 1236
US-11-083-784-1462725/c
; Sequence 1462725, Application US/11083784
; Publication No. US20050245475A1

1 GENERAL INFORMATION:
 2 APPLICANT: Diarmacorn, Inc.
 3 APPLICANT: Khvorova, Anastasia
 4 APPLICANT: Reynolds, Angela
 5 APPLICANT: Leake, Devin
 6 APPLICANT: Marshall, William
 7 APPLICANT: Scaringe, Stephen
 8 TITLE OF INVENTION: Functional and Hyperfunctional siRNA

```

: FILE REFERENCE: 13499UN5
: CURRENT APPLICATION NUMBER: US/11/083,784A
: CURRENT FILING DATE: 2005-03-18
: PRIOR APPLICATION NUMBER: US/10/714,333
: PRIOR FILING DATE: 2003-11-14
: PRIOR APPLICATION NUMBER: 60/502,050
: PRIOR FILING DATE: 2003-09-10
: PRIOR APPLICATION NUMBER: 60/426,137
: PRIOR FILING DATE: 2002-11-14
: NUMBER OF SEQ ID NOS: 1591911
: SOFTWARE: Proprietary
: SEQ ID NO 1462725
: LENGTH: 19
: TYPE: RNA
: ORGANISM: Homo sapiens
US-11-083-784-1462725

```

Query Match	0.9%;	Score 15.8;	DB 1;	Length 19;
Best Local Similarity	73.7%;	Pred. No. 8.1e+02;		
Matches 14; Conservative	3;	Mismatches 2;	Indels 0;	Gaps 0;

QY 1428 UAGCGGAAAGGAGUCC 1446
:|||||:|:
Db 19 TAAGCAGAGGATGTC 1

RESULT 1237
US-11-083-784-1462771/c
; Sequence 1462771, Application US/11083784
; Publication No. US20050245475A1

```

1  GENERAL INFORMATION:
2  APPLICANT: Dharmacon, Inc.
3  APPLICANT: Khvorova, Anastasia
4  APPLICANT: Reynolds, Angela
5  APPLICANT: Leake, Devin
6  APPLICANT: Marshall, William
7  APPLICANT: Scaringe, Stephen
8  TITLE OF INVENTION: Functional and Hyperfunctional siRNA
9  FILE REFERENCE: 134991S
10 CURRENT APPLICATION NUMBER: US/11/083,784
11 CURRENT FILING DATE: 2005-03-18
12 PRIOR APPLICATION NUMBER: US/10/714,333
13 PRIOR FILING DATE: 2003-11-14
14 PRIOR APPLICATION NUMBER: 60/502,050
15 PRIOR FILING DATE: 2003-09-10
16 PRIOR APPLICATION NUMBER: 60/426,137
17 PRIOR FILING DATE: 2002-11-14
18 NUMBER OF SEQ ID NOS: 1591911
19 SOFTWARE: Proprietary
20 SEQ ID NO 1462771
21 LENGTH: 19
22 TYPE: RNA
23 ORGANISM: Homo sapiens
24 US-11-083-784-1462771

```

Query Match	0.9%	Score 15.8;	DB 1;	Length 19;
Best Local Similarity	73.7%	Pred. No. 8.1e+02;		
Matches	14;	Conservative	3;	Mismatches 2;
				Indels 0;
				Gaps 0;

```

QY      1427 CUAAGCGAALAGGAUUC 1445
          ||||| ||||| :|||
Db      19   CTAGCAGAAGAGATGTC 1

```

RESULT 1238
US-11-083-784-1466198/c
; Sequence 1466198, Application US/11083784
; Publication No. US20050245475A1

;; APPLICANT: Dharmacon, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin

```

; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/083,784
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1466198
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1466198

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      38 UUCGAAACGACGUCUCUC 56
Db      19 TTCGAAATACGAGCTCTC 1

RESULT 1239
US-11-083-784-1496063
; Sequence 1496063, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1496063
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1496063

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1628 GCUAUGCUCUGGCAACAA 1646
Db      1 GCUAUGCUCUGGCAACAA 19

RESULT 1240
US-11-083-784-1526168/c
; Sequence 1526168, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
```

```

; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1526168
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1526168

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 47.4%; Pred. No. 8.1e+02;
Matches 9; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY      616 UUCGCGCAUACUUCUGUG 634
Db      19 TTCGCGGAUACTTCTGCTG 1

RESULT 1241
US-11-083-784-1540139/c
; Sequence 1540139, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1540139
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1540139

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      43 AACAUACGUCUCUCUGGA 61
Db      19 AACATCAGACCACTTGTGA 1

RESULT 1242
US-11-083-784-1555890/c
; Sequence 1555890, Application US/11083784
```

Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/083,784
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 1555890
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-1555890

Db 19 CCAAGATGAGCTCTCTCT 1

```
RESULT 1246
US-11-083-784-1586107/c
; Sequence 1586107, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1586107
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1586107
```

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 42 AACACUACGCTCCTCTCTG 60
Db 19 AAGATGAGCTCTCTCTCTG 1

```
RESULT 1247
US-11-083-784-1586158/c
; Sequence 1586158, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1586158
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1586158
```

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 41 CCAACUACGCTCCTCTCTG 59
Db 19 CCAAGATGAGCTCTCTCTG 1

```
RESULT 1248
US-11-101-244-14368
; Sequence 14368, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14368
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-14368
```

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1460 AGAAGCGGCGCCAGACCCU 1478
Db 1 AGAAGCGGCGCAAGACUCU 19

```
RESULT 1249
US-11-101-244-14415
; Sequence 14415, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14415
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-14415
```

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1591 UGCUCUGGUCACUACA 1609
|||||
Db 1 UGCUCUGGUCACUACA 19

RESULT 1250
US-11-101-244-15086
; Sequence 15086, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 15086
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-15086

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 236 UGAGACGGUCACUACA 314
|||||
Db 1 UGAGACGGUCACUACA 19

RESULT 1251
US-11-101-244-15128
; Sequence 15128, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 15128
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-15128

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 303 GGUCAACAUCUACUCC 321

Db 1 GGUCAACAUCUACUCC 19

RESULT 1252
US-11-101-244-22214/C
; Sequence 22214, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 22214
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-22214

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 40 CCAACAUCAUCUCCUCC 58
|||||
Db 19 CCAACATCAGCTCTCT 1

RESULT 1253
US-11-101-244-25249
; Sequence 25249, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 25249
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-25249

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1011 GAACACAUAUGUCGU 1029
|||||

Db 1 GAACUACAUGAUGCUACU 19

```
RESULT 1254
US-11-101-244-25349
; Sequence 25349, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 25349
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-25349
```

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1011 GAACAACAUGAUGCU 1029
Db 1 GAACUACAUGAUGCUACU 19

```
RESULT 1255
US-11-101-244-45869
; Sequence 45869, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 45869
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-45869
```

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1439 GGAUGUCCUGGUGAAGA 1457
Db 1 GAUGUCCUGGCAAGA 19

```
RESULT 1256
US-11-101-244-52416
; Sequence 52416, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 52416
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-52416
```

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 579 GGUCAUCCUUGUCCU 597
Db 1 GGUCAUCCUUGUCCAU 19

```
RESULT 1257
US-11-101-244-52520
; Sequence 52520, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 52520
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-52520
```

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 579 GGUCAUCCUUGUCCU 597
Db 1 GGUCAUCCUUGUCCAU 19

RESULT 1258

US-11-101-244-52639
; Sequence 52639, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 52639
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-52639

Query Match

Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY

579 GGUCAUCCUCCUUGUCCU 597
|||||
Db 1 GGUCAUCCUCCUUGUCCAU 19

RESULT 1259

US-11-101-244-52708
; Sequence 52708, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 52708
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-52708

Query Match

Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY

579 GGUCAUCCUCCUUGUCCU 597
|||||
Db 1 GGUCAUCCUCCUUGUCCAU 19

RESULT 1260

US-11-101-244-52803
; Sequence 52803, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 52803
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-52803

Query Match

Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY

579 GGUCAUCCUCCUUGUCCU 597
|||||
Db 1 GGUCAUCCUCCUUGUCCAU 19

RESULT 1261

US-11-101-244-52901
; Sequence 52901, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 52901
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-52901

Query Match

Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY

579 GGUCAUCCUCCUUGUCCU 597
|||||
Db 1 GGUCAUCCUCCUUGUCCAU 19

RESULT 1262

```
US-11-101-244-86473
; Sequence 86473, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 86473
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-86473

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1664 UCAAGUGCUCGUCGUG 1682
DB      1 UGAAGUGCUCGUGAUG 19

RESULT 1263
US-11-101-244-96765
; Sequence 96765, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 96765
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-96765

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      300 GACGUCACACUACUUC 318
DB      1 GACAGUCAUAAUACUACUC 19

RESULT 1264
US-11-101-244-96770
```

```
; Sequence 96770, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 96770
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-96770

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      455 GCAUGCCUCUGUUGAA 473
DB      1 GCAUGCCUCUGUUGAA 19

RESULT 1265
US-11-101-244-96775
; Sequence 96775, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 96775
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-96775

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      453 CAGCAUGCCUCUGUUG 471
DB      1 CAGCAUGCCUCUGUUG 19

RESULT 1266
US-11-101-244-96789
; Sequence 96789, Application US/11101244
```

```
/ Publication No. US20050246794A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/101,244
/ PRIOR FILING DATE: 2005-04-07
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 96789
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-101-244-96789
```

```
Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 454 AGCAAGCCUCGUGUUAUGA 472
Db 1 AGCAAGCCUCGUGUUAUGA 19
```

```
RESULT 1267
US-11-101-244-96792
/ Sequence 96792, Application US/11101244
/ Publication No. US20050246794A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/101,244
/ PRIOR FILING DATE: 2005-04-07
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 96792
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-101-244-96792
```

```
Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 456 CAUAGCCUCGUGUUAUGAU 474
Db 1 CAUAGCCUCGUGUUAUGAU 19
```

```
RESULT 1268
US-11-101-244-96794
/ Sequence 96794, Application US/11101244
/ Publication No. US20050246794A1
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/101,244
/ PRIOR FILING DATE: 2005-04-07
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 96794
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-101-244-96794
```

```
Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1511 GGACCCGACACACAUCAU 1529
Db 1 GGACCCGACACACAUCAU 19
```

```
RESULT 1269
US-11-101-244-96795
/ Sequence 96795, Application US/11101244
/ Publication No. US20050246794A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/101,244
/ PRIOR FILING DATE: 2005-04-07
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 96795
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-101-244-96795
```

```
Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 470 UGAUUCUGUGUACAUCAU 488
Db 1 UGAUUCUGUGUACAUCAU 19
```

```
RESULT 1270
US-11-101-244-96884
/ Sequence 96884, Application US/11101244
/ Publication No. US20050246794A1
/ GENERAL INFORMATION:
```

```

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 96884
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-96884

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1493 UUGCCUUCACUACUACUUG 1511
      |||||
Db      1 UGCCTUUCACUACUACUUG 19
```

```

RESULT 1271
US-11-101-244-97127
; Sequence 97127, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97127
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97127
```

```

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY      296 UGAAGCGGUCACACACUA 314
      |||||
Db      1 UGCAGCAGUCACACACUA 19
```

```

; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97132
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97132
```

```

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      297 GAGACGGUCACACACUAC 315
      |||||
Db      1 GCAGCAGUCACACACUAC 19
```

```

RESULT 1273
US-11-101-244-97144
; Sequence 97144, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97144
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97144
```

```

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1586 GCUACUGGCUUCGCUACAU 1604
      |||||
Db      1 GCUACUGGCUUCGCUACGU 19
```

```

RESULT 1274
US-11-101-244-97252
; Sequence 97252, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
```

```
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97252
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97252
```

```
Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 493 GACGAGUACUUVUCCAUA 511
DB 1 GACCGUACUUVUCCAUA 19
```

```
RESULT 1275
US-11-101-244-155844/c
; Sequence 155844, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 155844
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-155844
```

```
Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1020 UGAGUCGUCGUCUCCUG 1038
DB 19 TGAGTCTGCTGCTCCCTG 1
```

```
RESULT 1276
US-11-101-244-193107/c
; Sequence 193107, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
```

```
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 193107
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-193107
```

```
Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1400 UUGCUCUGAAGACCAAG 1418
DB 19 TTGCTATGAAGACCAAGATG 1
```

```
RESULT 1277
US-11-101-244-214402/c
; Sequence 214402, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 214402
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-214402
```

```
Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1014 CACGAUGAGUCGUGGCC 1032
DB 19 CAACATGACGCTGCGGCC 1
```

```
RESULT 1278
US-11-101-244-222230
; Sequence 222230, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
```

```
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 222230
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-222230
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      300 GACGGUACAACAACUACUUC 318
      |||||
Db      1 GACAGUCACCAACUACUUC 19
```

```
RESULT 1279
US-11-101-244-222321
; Sequence 222321, Application US/11101244
; Publication No. US20050246794A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 222321
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-222321
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      300 GACGGUACAACAACUACUUC 318
      |||||
Db      1 GACGGUACAACAACUACUUC 19
```

```
RESULT 1280
US-11-101-244-342052
; Sequence 342052, Application US/11101244
; Publication No. US20050246794A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
```

```
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 342052
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-342052
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1653 CAGAACACUUCUACAAGU 1671
      |||||
Db      1 CAGAACACUUCUACAAGU 19
```

```
RESULT 1281
US-11-101-244-391588/c
; Sequence 391588, Application US/11101244
; Publication No. US20050246794A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 391588
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-391588
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      42 AAACATCAGCTCTCTCTGG 60
      |||||
Db      19 AAACATCAGCTCTCTCTGG 1
```

```
RESULT 1282
```

```
US-11-101-244-409997
; Sequence 409997, Application US/11101244
; Publication No. US20050246794A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
```

```

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 409997
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-409997
```

```

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      43 AACAUACGUCUCCUGA 61
Db      1 AACAUACGUCUCCUCAUGA 19
```

```

RESULT 1283
US-11-101-244-417946
; Sequence 417946, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 417946
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-417946
```

```

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      815 GGACAGAGCGACAGACAGA 833
Db      1 GGACAGAGCGACAGACAGA 19
```

```

RESULT 1284
US-11-101-244-462391/C
; Sequence 462391, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```

; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 462391
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-462391
```

```

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      1428 UAAGCGAAAGAGAUUCC 1446
Db      19 UAAGCGAAAGAGATGTC 1
```

```

RESULT 1285
US-11-101-244-482025
; Sequence 482025, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 482025
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-482025
```

```

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy      1231 CAGAGAGCGUGAGCAUG 1249
Db      1 CAGAGAGCGUGAGCAUG 19
```

```

RESULT 1286
US-11-101-244-514801
; Sequence 514801, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
```

```
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 514801
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-514801

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 859 UCUGAAGCUGCAGAGUU 877
Db 1 UCUGAAGCUGCAGAGUU 19

RESULT 1287
US-11-101-244-535685
; Sequence 535685, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Marshall, Devin
; APPLICANT: Leake, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 535685
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-535685

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 655 GGAGAGUGCUCUACUACGU 673
Db 1 GGAGAGUGCUCUACUACGU 19

RESULT 1288
US-11-101-244-576464/C
; Sequence 576464, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Marshall, Devin
; APPLICANT: Leake, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
```

```
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 576464
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-576464

Query Match
Best Local Similarity 57.9%; Score 15.8; DB 1; Length 19;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 35 UGUUCCAAACAUCAGCUC 53
Db 19 TGTTCGAAATATCAGATC 1

RESULT 1289
US-11-101-244-581851/C
; Sequence 581851, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Marshall, Devin
; APPLICANT: Leake, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 581851
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-581851

Query Match
Best Local Similarity 47.4%; Score 15.8; DB 1; Length 19;
Matches 9; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 661 UGUUCCAAACAUCAGCUC 679
Db 19 TACTTCATTCAGTTCTCA 1

RESULT 1290
US-11-101-244-581953/C
; Sequence 581953, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Marshall, Devin
; APPLICANT: Leake, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
```

;; PRIOR APPLICATION NUMBER: 60/502,050
;; PRIOR FILING DATE: 2003-09-10
;; PRIOR APPLICATION NUMBER: 60/426,137
;; PRIOR FILING DATE: 2002-11-14
;; NUMBER OF SEQ ID NOS: 1591911
;; SOFTWARE: Proprietary
;; SEQ ID NO 581953
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-11-101-244-581953

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 47.4%; Pred. No. 8.1e+02;
Matches 9; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 661 UGCUCUACUUCAGUCCUCA 679
DB 19 TACTTCATTTCAGTTCTCA 1

RESULT 1291
US-11-101-244-640147
;; Sequence 640147, Application US/11101244
;; Publication No. US20050246794A1
;; GENERAL INFORMATION:
;; APPLICANT: Dharmacon, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin
;; APPLICANT: Marshall, William
;; APPLICANT: Scaringe, Stephen
;; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;; FILE REFERENCE: 13499US
;; CURRENT APPLICATION NUMBER: US/11/101,244
;; PRIOR FILING DATE: 2005-04-07
;; PRIOR APPLICATION NUMBER: 60/502,050
;; PRIOR FILING DATE: 2003-09-10
;; PRIOR APPLICATION NUMBER: 60/426,137
;; PRIOR FILING DATE: 2002-11-14
;; NUMBER OF SEQ ID NOS: 1591911
;; SOFTWARE: Proprietary
;; SEQ ID NO 640147
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-11-101-244-640147

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 GGACAGAGCGACAGACAGA 833
DB 1 GGCGACAGCGACAGAGAGA 19

RESULT 1292
US-11-101-244-645531/C
;; Sequence 645531, Application US/11101244
;; Publication No. US20050246794A1
;; GENERAL INFORMATION:
;; APPLICANT: Dharmacon, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin
;; APPLICANT: Marshall, William
;; APPLICANT: Scaringe, Stephen
;; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;; FILE REFERENCE: 13499US
;; CURRENT APPLICATION NUMBER: US/11/101,244
;; PRIOR FILING DATE: 2005-04-07
;; PRIOR APPLICATION NUMBER: 60/502,050

;; PRIOR FILING DATE: 2003-09-10
;; PRIOR APPLICATION NUMBER: 60/426,137
;; PRIOR FILING DATE: 2002-11-14
;; NUMBER OF SEQ ID NOS: 1591911
;; SOFTWARE: Proprietary
;; SEQ ID NO 645531
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-11-101-244-645531

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 8.1e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 267 AAUUGUGUAAUUAAGUC 285
DB 19 ACTTGTCATTGAGAGTC 1

RESULT 1293
US-11-101-244-653396/C
;; Sequence 653396, Application US/11101244
;; Publication No. US20050246794A1
;; GENERAL INFORMATION:
;; APPLICANT: Dharmacon, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin
;; APPLICANT: Marshall, William
;; APPLICANT: Scaringe, Stephen
;; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;; FILE REFERENCE: 13499US
;; CURRENT APPLICATION NUMBER: US/11/101,244
;; PRIOR FILING DATE: 2005-04-07
;; PRIOR APPLICATION NUMBER: 60/502,050
;; PRIOR FILING DATE: 2003-09-10
;; PRIOR APPLICATION NUMBER: 60/426,137
;; PRIOR FILING DATE: 2002-11-14
;; NUMBER OF SEQ ID NOS: 1591911
;; SOFTWARE: Proprietary
;; SEQ ID NO 653396
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-11-101-244-653396

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1038 GGAGAACUCCGCGUCUCC 1056
DB 19 GAAGAACTCTCTCTCTCC 1

RESULT 1294
US-11-101-244-653423/C
;; Sequence 653423, Application US/11101244
;; Publication No. US20050246794A1
;; GENERAL INFORMATION:
;; APPLICANT: Dharmacon, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin
;; APPLICANT: Marshall, William
;; APPLICANT: Scaringe, Stephen
;; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;; FILE REFERENCE: 13499US
;; CURRENT APPLICATION NUMBER: US/11/101,244
;; PRIOR FILING DATE: 2005-04-07
;; PRIOR APPLICATION NUMBER: 60/502,050
;; PRIOR FILING DATE: 2003-09-10

```

; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 653423
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-653423
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      1038 GGAGAACUCCGCCUCCUCC 1056
DB      19  GAAGAACTCTCTCCTCC 1
```

```
RESULT 1295
US-11-101-244-661229/c
; Sequence 661229, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 661229
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-661229
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 8.1e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      316 UUCUCUUAAGCCUGCCU 334
DB      19  TTCCTTGAGCTTGCCCT 1
```

```
RESULT 1296
US-11-101-244-691453/c
; Sequence 691453, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
```

```

; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 691453
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-691453
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 8.1e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      411 GAACUUGCCUGGACUCC 429
DB      19  GAACCTGCCCTGTGACATC 1
```

```
RESULT 1297
US-11-101-244-691532/c
; Sequence 691532, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 691532
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-691532
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 8.1e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
```

```
OY      411 GAACUUGCCUGGACUCC 429
DB      19  GAACCTGCCCTGTGACATC 1
```

```
RESULT 1298
US-11-101-244-770039
; Sequence 770039, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
```

```
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 770039
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-770039

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 466 GUUAGUAGUCUUCUGUCA 484
DB 1 GUUAGUAGUCUUCUGUCA 19

RESULT 1299
US-11-101-244-771283/c
; Sequence 771283, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 771283
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-771283

Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 597 UUGGCGUCCUGCCAUUCUG 615
DB 19 TTGGCTCTGCTTCTTG 1

RESULT 1300
US-11-101-244-819337
; Sequence 819337, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
```

```
; SOFTWARE: Proprietary
; SEQ ID NO 819337
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-819337

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 GGCACAGGCGACGACACA 833
DB 1 GGCACAGGCGACGACACA 19

RESULT 1301
US-11-101-244-845076
; Sequence 845076, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 845076
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-845076

Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1524 CAUCAUGGUUCUGUGAAC 1542
DB 1 CAUCAUGGUUCUGUGAAC 19

RESULT 1302
US-11-101-244-860780
; Sequence 860780, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
```

```
; SEQ ID NO 860780
;
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-860780
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      243 GACCAUCAUCGCGCAACAU 261
Db      1 GACCAUCAUCUACAACAU 19
```

```
RESULT 1303
US-11-101-244-878444/c
; Sequence 878444, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 878444
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-878444
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 8.1e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      37 UUUCCAAACAUCAUCUCCU 55
Db      19 TTTCMAACAGCAGCTTCT 1
```

```
RESULT 1304
US-11-101-244-891418
; Sequence 891418, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 891418
```

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-891418
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      818 CAGAGCGAGAGACAGAAA 836
Db      1 CAGAGCAGAGACAGAAUA 19
```

```
RESULT 1305
US-11-101-244-909909/c
; Sequence 909909, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 909909
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-909909
```

```
Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 8.1e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      274 UCAUUAAGGUCACAGC 292
Db      19 TCATTAAAGATCATCAAGC 1
```

```
RESULT 1306
US-11-101-244-910002/c
; Sequence 910002, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 910002
; LENGTH: 19
```

TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-910002

Query Match
Best Local Similarity 68.4%; Score 15.8; DB 1; Length 19;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 248 UCAUGCGCAACUCCUGU 266
Db 19 TAACCGCAACATCTGTGT 1

RESULT 1307
US-11-101-244-910052/c
Sequence 910052, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 910052
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-910052

Query Match
Best Local Similarity 68.4%; Score 15.8; DB 1; Length 19;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 248 UCAUGCGCAACUCCUGU 266
Db 19 TAACCGCAACATCTGTGT 1

RESULT 1308
US-11-101-244-941780
Sequence 941780, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 941780
LENGTH: 19
TYPE: RNA

ORGANISM: Homo sapiens
US-11-101-244-941780

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 CAACAACUACUCCUCUUA 324
Db 1 CAACAACUCCUCCUCUUA 19

RESULT 1309
US-11-101-244-941970
Sequence 941970, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 941970
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-941970

Query Match
Best Local Similarity 89.5%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 306 CAACAACUACUCCUCUUA 324
Db 1 CAACAACUCCUCCUCUUA 19

RESULT 1310
US-11-101-244-1025790/c
Sequence 1025790, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 1025790
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens

US-11-101-244-1025790

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 8.1e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 267 AAUUGUCUAUUAAAGUC 265
||:|:|:|:|:|:|:|:|:
DB 19 AATGTGTCATATAAGCTC 1

RESULT 1311

US-11-101-244-1038110/C
; Sequence 1038110, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Marshall, William
; APPLICANT: Leake, Devin
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1038110
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1038110

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 8.1e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 453 CAGCAUGCCUCUGUUAUG 471
|||:|:|:|:|:|:|:|:|:
DB 19 CATGACTGCTCTGTATG 1

RESULT 1312

US-11-101-244-1052031/C
; Sequence 1052031, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Marshall, William
; APPLICANT: Leake, Devin
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1052031
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1052031

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 41 CAACAGCAGCUCCTCTTG 59
|||||:|:|:|:|:|:|:|:|:
DB 19 CAACAGCAGCCTCTCTTG 1

RESULT 1313

US-11-101-244-1052055/C
; Sequence 1052055, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Marshall, William
; APPLICANT: Leake, Devin
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1052055
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1052055

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 42 AAACAGCAGCUCCTCTTG 60
|||||:|:|:|:|:|:|:|:|:
DB 19 AAACAGCAGCTCTCTTG 1

RESULT 1314

US-11-101-244-1082966
; Sequence 1082966, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Marshall, William
; APPLICANT: Leake, Devin
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1082966
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1082966

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 113 GCAGCUCACAUUGUUCUG 131
DB 1 GCAGCUCACAUUGUUCUG 19

RESULT 1315

US-11-101-244-1095950/C
; Sequence 1095950, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2003-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1095950
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1095950

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 634 GGAAGAGACUCUGCCUC 652
DB 19 GTAAGAGAACTGTGCTC 1

RESULT 1316

US-11-101-244-1143713
; Sequence 1143713, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1143713
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1143713

Query Match 0.9%; Score 15.8; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1193 UGUGGACUCUGAGAGAA 1211
DB 1 UGAGAGACUCUGAGAGAA 19

RESULT 1317

US-11-101-244-1202196/C
; Sequence 1202196, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1202196
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1202196

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 8.1e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 141 CAUUCUCUCUCGAC 159
DB 19 CAATTCCTCTTCAAC 1

RESULT 1318

US-11-101-244-1237713
; Sequence 1237713, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1237713
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1237713

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1218 CAAGCUGAGGCCGAGAG 1236

DB 1 CAAGAVGACAGCCCAUG 19

RESULT 1319

US-11-101-244-1267843/c

; Sequence 1267843, Application US/11101244

; Publication No. US20050246794A1

; GENERAL INFORMATION:

; APPLICANT: Dharmaco, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 1267843

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-1267843

Query Match 0.9%; Score 15.8; DB 1; Length 19;

Best Local Similarity 63.2%; Pred. No. 8.1e+02;

Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1648 ACAUUCAGACCACTUUGA 1666

DB 19 ACATTAGCACCACTTCA 1

RESULT 1320

US-11-101-244-1267942/c

; Sequence 1267942, Application US/11101244

; Publication No. US20050246794A1

; GENERAL INFORMATION:

; APPLICANT: Dharmaco, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 1267942

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-1267942

Query Match 0.9%; Score 15.8; DB 1; Length 19;

Best Local Similarity 63.2%; Pred. No. 8.1e+02;

Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1648 ACAUUCAGACCACTUUGA 1666

DB 19 ACATTAGCACCACTTCA 1

RESULT 1321

US-11-101-244-1302272

; Sequence 1302272, Application US/11101244

; Publication No. US20050246794A1

; GENERAL INFORMATION:

; APPLICANT: Dharmaco, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 1302272

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-1302272

Query Match 0.9%; Score 15.8; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 8.1e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 758 GGAUUCUUAAGGAACUGA 776

DB 1 GGAUUAUGAGGAACTGA 19

RESULT 1322

US-11-101-244-1312578

; Sequence 1312578, Application US/11101244

; Publication No. US20050246794A1

; GENERAL INFORMATION:

; APPLICANT: Dharmaco, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 1312578

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-1312578

Query Match 0.9%; Score 15.8; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 8.1e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1720 CAGCAGAGACAGUCGCUCA 1738
|||||:|||||
Db 1 CAGCAGAGCAGCAGUCUCA 19

RESULT 1323
US-11-101-244-1348446/c
; Sequence 1348446, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1348446
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1348446

Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
Qy 42 AAACAUCAGCUCUCCUGG 60
|||||:|||||
Db 19 AAACATGAGCTCCACCTGG 1

RESULT 1324
US-11-101-244-1365309/c
; Sequence 1365309, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1365309
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1365309

Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
Qy 1392 CAAGAGGUTUUCUCUGAG 1410

Db 19 CACAGGTGTGCTCGAAG 1
|||||:|||||

RESULT 1325
US-11-101-244-1372117
; Sequence 1372117, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1372117
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1372117

Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1646 AAACAUCAGACCAUCUU 1664
|||||:|||||

RESULT 1326
US-11-101-244-1393220
; Sequence 1393220, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1393220
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1393220

Query Match
Best Local Similarity 0.9%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1119 UCACAGCACCAUCUCUAC 1137
|||||:|||||

Db 1 UCACGACGACCAUUCACAC 19

```
RESULT 1327
US-11-101-244-1443908
; Sequence 1443908, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1443908
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1443908
```

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 988 GACCAAGCAGCAGUGACA 1006
Db 1 GACCAAGCAGCAGUGACA 19

```
RESULT 1328
US-11-101-244-1450263/c
; Sequence 1450263, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1450263
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1450263
```

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 8.1e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1257 UUUUCCAAAAGCUCUCC 1275
Db 19 TTCTCCAAAATGCTCTCC 1

```
RESULT 1329
US-11-101-244-1462725/c
; Sequence 1462725, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1462725
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1462725
```

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1428 UAAAGCGAAAAGCAGUCC 1446
Db 19 TAAAGCAGAAAGAGATGTC 1

```
RESULT 1330
US-11-101-244-1462771/c
; Sequence 1462771, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1462771
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1462771
```

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1427 CUAAGCGAAAAGCAGUCC 1445
Db 19 CTAAGCAGAAAGAGATGTC 1

RESULT 1331

US-11-101-244-1466198/C
; Sequence 1466198, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1466198
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1466198

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 38 UUCGAACAGCAGCUCUC 56
Db 19 TTCGAATACGACTCTC 1

RESULT 1332

US-11-101-244-1496063
; Sequence 1496063, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1496063
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1496063

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1628 GCUAGCUCUGGCAACAA 1646
Db 1 GCUAGCUCUGCCTACAA 19

RESULT 1333

US-11-101-244-1526168/C
; Sequence 1526168, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1526168
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1526168

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 47.4%; Pred. No. 8.1e+02;
Matches 9; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

Qy 616 UUCUGCAUACUUGUG 634
Db 19 TTCGGAATCTTCTC 1

RESULT 1334

US-11-101-244-1540139/C
; Sequence 1540139, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1540139
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1540139

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 8.1e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 43 AACAVCAGCUCUCUGCA 61
Db 19 AACATCAGCAGCTTTGCA 1

RESULT 1335

```
US-11-101-244-1555890/c
; Sequence 1555890, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1555890
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1555890

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 8.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      1458 GAAGAAAGCGGCCGAGACC 1476
Db      19 GATGAAAGTGCCGAGACC 1

RESULT 1336
US-11-101-244-1567851/c
; Sequence 1567851, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1567851
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1567851

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 47.4%; Pred. No. 8.1e+02;
Matches 9; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

OY      206 UCUUACGCGUUCUUAAC 224
Db      19 TCTTATCGCTATCTTCAC 1

RESULT 1337
US-11-101-244-1571143/c

; Sequence 1571143, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1571143
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1571143

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 8.1e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

OY      38 UUCAACACUACGUCUCUC 56
Db      19 TTTCAACATCGTCTCTC 1

RESULT 1338
US-11-101-244-1586104/c
; Sequence 1586104, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1586104
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1586104

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

OY      40 CCAACACGAGCUCUCUCU 58
Db      19 CCAAGATGAGCTCTCTC 1

RESULT 1339
US-11-101-244-1586107/c
; Sequence 1586107, Application US/11101244
```

```
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 1586107
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-1586107
```

```
Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 42 AAACAUCAGCUCCTCTG 60
Db 19 AAAGATGAGCTCTCTG 1
```

```
RESULT 1340
US-11-101-244-1586158/C
Sequence 1586158, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 1586158
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-1586158
```

```
Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 8.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 41 CAACAUCAGCUCCTCTG 59
Db 19 CAAGATGAGCTCTCTG 1
```

```
RESULT 1341
US-09-877-478-1123/C
Sequence 1123, Application US/09877478
Publication No. US20030068301A1
```

```
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Draper, Kenneth
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
APPLICANT: Morrissey, Dave
TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
FILE REFERENCE: MBH00-845-H (400/029)
CURRENT APPLICATION NUMBER: US/09/877,478
CURRENT FILING DATE: 2001-12-31
PRIOR APPLICATION NUMBER: US 07/882,712
PRIOR FILING DATE: 1992-05-14
PRIOR APPLICATION NUMBER: US 09/531,025
PRIOR FILING DATE: 2000-03-20
PRIOR APPLICATION NUMBER: US 09/636,385
PRIOR FILING DATE: 2000-08-09
PRIOR APPLICATION NUMBER: US 09/696,347
PRIOR FILING DATE: 2000-10-24
PRIOR APPLICATION NUMBER: US 08/193,627
PRIOR FILING DATE: 1994-02-07
PRIOR APPLICATION NUMBER: US 08/433,993
PRIOR FILING DATE: 1995-05-04
PRIOR APPLICATION NUMBER: US 08/434,504
PRIOR FILING DATE: 1995-05-04
PRIOR APPLICATION NUMBER: US 09/436,430
PRIOR FILING DATE: 1999-11-08
NUMBER OF SEQ ID NOS: 6586
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1123
LENGTH: 17
TYPE: RNA
ORGANISM: Hepatitis B virus
US-09-877-478-1123
```

```
Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 7.3e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 1528 AUGGUCUGUGAAGAC 1544
Db 17 ATGGCTCTGTGACAC 1
```

```
RESULT 1342
US-09-877-478-1124/C
Sequence 1124, Application US/09877478
Publication No. US20030068301A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Draper, Kenneth
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
APPLICANT: Morrissey, Dave
TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
FILE REFERENCE: MBH00-845-H (400/029)
CURRENT APPLICATION NUMBER: US/09/877,478
CURRENT FILING DATE: 2001-12-31
PRIOR APPLICATION NUMBER: US 07/882,712
PRIOR FILING DATE: 1992-05-14
PRIOR APPLICATION NUMBER: US 09/531,025
PRIOR FILING DATE: 2000-03-20
PRIOR APPLICATION NUMBER: US 09/636,385
PRIOR FILING DATE: 2000-08-09
PRIOR APPLICATION NUMBER: US 09/696,347
PRIOR FILING DATE: 2000-10-24
PRIOR APPLICATION NUMBER: US 08/193,627
PRIOR FILING DATE: 1994-02-07
PRIOR APPLICATION NUMBER: US 08/433,993
PRIOR FILING DATE: 1995-05-04
PRIOR APPLICATION NUMBER: US 08/434,504
PRIOR FILING DATE: 1995-05-04
PRIOR APPLICATION NUMBER: US 09/436,430
PRIOR FILING DATE: 1999-11-08
```

; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: Patencin version 3.0
; SEQ ID NO 1124
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-1124

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 7.3e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1527 CAUGGUCUGUGACAC 1543
DB 17 CATGGTCTGTGACAC 1

RESULT 1343
US-10-342-902-1123/c
; Sequence 1123, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MEHB00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: Patencin version 3.2
; SEQ ID NO 1123
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1123

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 7.3e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1528 AUGGUCUGUGACAC 1544
DB 17 ATGGTCTGTGACAC 1

RESULT 1344
US-10-342-902-1124/c
; Sequence 1124, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication

; FILE REFERENCE: 400/075 (MEHB00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: Patencin version 3.2
; SEQ ID NO 1124
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-1124

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 7.3e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1527 CAUGGUCUGUGACAC 1543
DB 17 CATGGTCTGTGACAC 1

RESULT 1345
US-10-669-841-1123/c
; Sequence 1123, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwigen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP.
; FILE REFERENCE: 400/042US (MEHB02-249-B)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15


```
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 44756
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-44756

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      813 UGCGACAGAGCGACGAGA 829
Db      1 UCGGAGUAGAGCGACGAGA 17
      |||||
RESULT 1350
US-10-310-914A-101513
; Sequence 101513, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 101513
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-101513

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      152 CUCCAGAGCGUACGACC 168
Db      1 CUCCAGAGCGUACGACC 17
      |||||
RESULT 1351
US-10-310-914A-114172
; Sequence 114172, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 114172
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human

US-10-310-914A-114172
; Sequence 114173, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 114173
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-114173

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      797 CUGGCCUUCAGCCUCUCU 813
Db      1 CUGGCCUUCAGCCUCUCU 17
      |||||
RESULT 1352
US-10-310-914A-114173
; Sequence 114173, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 114173
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-114173

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      797 CUGGCCUUCAGCCUCUCU 813
Db      1 CUGGCCUUCAGCCUCUCU 17
      |||||
RESULT 1353
US-10-310-914A-159541
; Sequence 159541, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 159541
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-159541

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1748 AGCGCGCACCAGCAGCAG 1764
Db      2 AGCGCGCACCAGCAGCAG 18
      |||||
RESULT 1354
US-10-310-914A-172099/c
; Sequence 172099, Application US/10310914A
; Publication No. US20060003322A1
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ APPLICANT: Shiller, Kruzat
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ TITLE OF INVENTION: uses thereof
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ CURRENT FILING DATE: 2002-12-06
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 172099
/ LENGTH: 18
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-172099
```

```
Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 18;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1341 GGGUAGAGCAGCGCA 1357
DB 17 GGGTAGAGCAGCGCA 1
```

```
RESULT 1355
US-10-310-914A-254139
/ Sequence 254139, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ APPLICANT: Shiller, Kruzat
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ TITLE OF INVENTION: uses thereof
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ CURRENT FILING DATE: 2002-12-06
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 254139
/ LENGTH: 18
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-254139
```

```
Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 925 GGGCGGCGCAGCUCUG 941
DB 2 GGGCGGCGCAGCUCUG 18
```

```
RESULT 1356
US-10-310-914A-284580
/ Sequence 284580, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ APPLICANT: Shiller, Kruzat
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ TITLE OF INVENTION: uses thereof
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ CURRENT FILING DATE: 2002-12-06
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 284580
/ LENGTH: 18
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-284580
```

```
Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 994 AGCAGCAGGAGCAGCUG 1010
DB 2 AGCAGCAGGAGCAGCUG 18
```

```
RESULT 1357
US-10-310-914A-630021/C
/ Sequence 630021, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ APPLICANT: Shiller, Kruzat
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ TITLE OF INVENTION: uses thereof
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ CURRENT FILING DATE: 2002-12-06
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 630021
/ LENGTH: 18
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-630021
```

```
Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 18;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1165 CUCGAGGCGCUCAGCA 1181
DB 17 CTGCAAGTGCCTGAGCA 1
```

```
RESULT 1358
US-10-310-914A-738321/C
/ Sequence 738321, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ APPLICANT: Shiller, Kruzat
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ TITLE OF INVENTION: uses thereof
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ CURRENT FILING DATE: 2002-12-06
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 738321
/ LENGTH: 18
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-738321
```

```
Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 18;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1220 AGCTGAGGCGCAGAG 1236
DB 17 AGCTGAGGCGCAGAG 1
```

```
RESULT 1359
US-10-310-914A-793976
/ Sequence 793976, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
```

```

; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 793976
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-793976
```

```

Query Match          0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1155 AUGGACAACTGCGCAG 1171
Db      1  AUAAGACACCGCAG 17
```

```

RESULT 1360
US-10-310-914A-907246/C
; Sequence 907246, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 907246
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-907246
```

```

Query Match          0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 8e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1182 GGAGCUGGGGAGUGG 1198
Db      17  GGAGCTGTGATGTGG 1
```

```

RESULT 1361
US-10-310-914A-933182/C
; Sequence 933182, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 933182
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-933182
```

```

Query Match          0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 8e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      409 GGGACUUGGCCUGUA 425
Db      18  GGGAATCTGCGTGGGA 2
```

```

RESULT 1362
US-10-310-914A-958139/C
; Sequence 958139, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 958139
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-958139
```

```

Query Match          0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1709 AGCAGCAUACCAAGCAG 1725
Db      18  AGCAGCAGCACCAAGCAG 2
```

```

RESULT 1363
US-10-310-914A-1087769/C
; Sequence 1087769, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1087769
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1087769
```

```

Query Match          0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 8e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      225 GGGCAUUGGCCUGG 241
Db      18  GAGCATCTGCGCTTGG 2
```

```

RESULT 1364
US-10-310-914A-1267042/C
; Sequence 1267042, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
```

```

; APPLICANT: Shiler, Kyzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; PRIOR FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1267042
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1267042

Query Match
Best Local Similarity 41.2%; Score 15.4; DB 1; Length 18;
Matches 7; Conservative 9; Mismatches 1; Indels 0; Gaps 0;

QY 738 UAGACUUAUUUACU 754
DB 18 TATGATTATTACT 2

RESULT 1365
US-10-349-143-6934
; Sequence 6934, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumentfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Blallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/10/349,143
; PRIOR FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6934
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-21533 for SEQ 3000,
US-10-349-143-6934

Query Match
Best Local Similarity 70.6%; Score 15.4; DB 1; Length 19;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 38 UCCGAACUCCGCTCC 54
DB 3 TTCCAAACATCCTCC 19

RESULT 1366
US-10-349-143-7458
; Sequence 7458, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumentfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Blallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI

```

```

; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7458
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-4874 for SEQ 3524,
US-10-349-143-7458

Query Match
Best Local Similarity 58.8%; Score 15.4; DB 1; Length 19;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 684 GCCCACCACUACUUNG 700
DB 1 GCCCACCCTTACTTTG 17

RESULT 1367
US-10-310-914A-313799
; Sequence 313799, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kyzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; PRIOR FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 313799
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-313799

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1706 GCAAGCAGCAGUACG 1722
DB 2 GCAAGCAGCAGCAGCAG 18

RESULT 1368
US-10-310-914A-344052
; Sequence 344052, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kyzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; PRIOR FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3

```

SEQ ID NO 344052
LENGTH: 19
TYPE: RNA
ORGANISM: Human
US-10-310-914A-344052

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 535 AACGACACACAAAGG 551
DB 1 AACGACACACAAAGG 17

RESULT 1369
US-10-310-914A-446813/c
Sequence 446813, Application US/10310914A
Publication No. US20060003322A1
GENERAL INFORMATION:
APPLICANT: Bentwich, Isaac
APPLICANT: Shlier, Kiyazat
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310,914A
CURRENT FILING DATE: 2002-12-06
NUMBER OF SEQ ID NOS: 1388402
SOFTWARE: PatentIn version 3.3
SEQ ID NO 446813
LENGTH: 19
TYPE: RNA
ORGANISM: Human
US-10-310-914A-446813

Query Match
Best Local Similarity 82.4%; Score 15.4; DB 1; Length 19;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1175 CTGAGAGAGAGCTGGG 1191
DB 18 CTGAGAGAGAGCTGGG 2

RESULT 1370
US-10-310-914A-598899/c
Sequence 598899, Application US/10310914A
Publication No. US20060003322A1
GENERAL INFORMATION:
APPLICANT: Bentwich, Isaac
APPLICANT: Shlier, Kiyazat
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310,914A
CURRENT FILING DATE: 2002-12-06
NUMBER OF SEQ ID NOS: 1388402
SOFTWARE: PatentIn version 3.3
SEQ ID NO 598899
LENGTH: 19
TYPE: RNA
ORGANISM: Human
US-10-310-914A-598899

Query Match
Best Local Similarity 52.9%; Score 15.4; DB 1; Length 19;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 1358 CTCUACUCUCUCUCUC 1374
DB 19 CTCUACUCUCUCUCUC 3

RESULT 1371
US-10-310-914A-1061923
Sequence 1061923, Application US/10310914A
Publication No. US20060003322A1
GENERAL INFORMATION:
APPLICANT: Bentwich, Isaac
APPLICANT: Shlier, Kiyazat
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310,914A
CURRENT FILING DATE: 2002-12-06
NUMBER OF SEQ ID NOS: 1388402
SOFTWARE: PatentIn version 3.3
SEQ ID NO 1061923
LENGTH: 19
TYPE: RNA
ORGANISM: Human
US-10-310-914A-1061923

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 816 GACAGAGCAGACAG 832
DB 2 GACAGAGCAGACAG 18

RESULT 1372
US-10-310-914A-1157469/c
Sequence 1157469, Application US/10310914A
Publication No. US20060003322A1
GENERAL INFORMATION:
APPLICANT: Bentwich, Isaac
APPLICANT: Shlier, Kiyazat
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310,914A
CURRENT FILING DATE: 2002-12-06
NUMBER OF SEQ ID NOS: 1388402
SOFTWARE: PatentIn version 3.3
SEQ ID NO 1157469
LENGTH: 19
TYPE: RNA
ORGANISM: Human
US-10-310-914A-1157469

Query Match
Best Local Similarity 88.2%; Score 15.4; DB 1; Length 19;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1709 AGCAGCAGCAGCAG 1725
DB 18 AGCAGCAGCAGCAG 2

RESULT 1373
US-11-083-784-96831
Sequence 96831, Application US/11083784
Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmoon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 1349905
CURRENT APPLICATION NUMBER: US/11/083,784
CURRENT FILING DATE: 2005-03-18

```
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 96831
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-96831
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      658 GAGUCGUCGACUUCAGUU 674
Db      2 GAGUCGUCGACUUCAGUU 18
```

```
RESULT 1374
US-11-083-784-97156
; Sequence 97156, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 97156
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97156
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      609 CAUCUUGUUCGCGAAU 625
Db      1 CAUCUUGUUCGCGAGU 17
```

```
RESULT 1375
US-11-083-784-97216
; Sequence 97216, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 97216
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-97216
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      1522 AACCAUCGUCGUCGU 1538
Db      2 AACCAUCGUCGUCGU 18
```

```
RESULT 1376
US-11-083-784-103182/C
; Sequence 103182, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 103182
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-103182
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 47.1%; Pred. No. 8.7e+02;
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      581 UCAUCUCUUCGUCGU 597
Db      19 TCATCTCTGTGTCCTT 3
```

```
RESULT 1377
US-11-083-784-103190/C
; Sequence 103190, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
```

```

; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 103190
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-103190

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 47.1%; Pred. No. 8.7e+02;
Matches      8; Conservative      1; Indels      0; Gaps      0;

QY      581 UCAUCUCUUCUUCUUCU 597
      18 TCATCTCCTTGCTCCTT 2
      |||:||||:||||:
      |||:||||:||||:

RESULT 1378
US-11-083-784-131581
; Sequence 131581, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 131581
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-131581

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches      16; Conservative      0; Mismatches      1; Indels      0; Gaps      0;

QY      946 ACAACCAAGAGCUGGAA 962
      3 AGAACCAAGAGCUGGAA 19
      |||:|||||:|||||
      |||:|||||:|||||

RESULT 1379
US-11-083-784-164314/C
; Sequence 164314, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
```

```

; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 164314
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-164314

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 8.7e+02;
Matches     14; Conservative      2; Mismatches      1; Indels      0; Gaps      0;

QY      911 ACAGAGAGAGUAGGC 927
      17 ACAGAGAGAGATATGC 1
      |||:|||||:||||
      |||:|||||:||||

RESULT 1380
US-11-083-784-220921
; Sequence 220921, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 220921
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-220921

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches     16; Conservative      0; Mismatches      1; Indels      0; Gaps      0;

QY      1664 UCAAGAGUCGUCGUCG 1680
      1 UGAAGAGUCGUCGUCG 17
      |||:|||||:|||||
      |||:|||||:|||||

RESULT 1381
US-11-083-784-234743/C
; Sequence 234743, Application US/11083784
```

```
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 234743
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-234743
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 8.7e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      1646 AAACAUCGAAACACU 1662
      ||||:|||||:
DB      18 AAACATTCGAAACACT 2
```

```
RESULT 1382
US-11-083-784-234762/c
; Sequence 234762, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 234762
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-234762
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 8.7e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      1646 AAACAUCGAAACACU 1662
      ||||:|||||:
DB      19 AAACATTCGAAACACT 3
```

```
RESULT 1383
US-11-083-784-240931/c
; Sequence 240931, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 240931
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-240931
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 8.7e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      1198 GACTUGGAGGAAAGC 1214
      ||||:|||||:
DB      19 GACTTGAGAGAAAGC 3
```

```
RESULT 1384
US-11-083-784-259725/c
; Sequence 259725, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 259725
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-259725
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 47.1%; Pred. No. 8.7e+02;
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;
```

```
OY      616 UUCUGGCAUACUUCU 632
      ::||:|||||:
DB      616 UUCUGGCAUACUUCU 632
```

Db 19 TTCGGGAATCTTGT 3

```
RESULT 1385
; US-11-083-784-259762/c
; Sequence 259762, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 259762
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-259762
```

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 47.1%; Pred. No. 8.7e+02;
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 616 UUCUGCAUACUUGU 632
Db 18 TTCGGGAATCTTGT 2

```
RESULT 1386
; US-11-083-784-289369
; Sequence 289369, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 289369
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-289369
```

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1655 GAACCACTUCCAAGU 1671
Db 3 GAUUCACUUCACAAGU 19

```
RESULT 1387
; US-11-083-784-345636
; Sequence 345636, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 345636
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-345636
```

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 993 CAGCAGCAGUGACAGU 1009
Db 2 CAGCAGCAGUGAGAGU 18

```
RESULT 1388
; US-11-083-784-394748/c
; Sequence 394748, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 394748
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-394748
```

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 8.7e+02;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 479 UGCUUACGUCGUCUUCAG 495
:|||||:|:|:|
Db 18 TGCTCATCAGCTTCCTGAC 2

RESULT 1389

US-11-083-784-430047/C
; Sequence 430047, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 430047
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-430047

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 8.7e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 664 UUCAUUCAGUUCUCUACG 680
:|||||:|:|:|
Db 18 TTCATTCACTTCCTCTG 2

RESULT 1390

US-11-083-784-430081/C
; Sequence 430081, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 430081
; LENGTH: 19
; TYPE: RNA

; ORGANISM: Homo sapiens
US-11-083-784-430081

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 8.7e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 664 UUCAUUCAGUUCUCUACG 680
:|||||:|:|:|
Db 17 TTCATTCACTTCCTCTG 1

RESULT 1391

US-11-083-784-430146/C
; Sequence 430146, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 430146
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-430146

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 8.7e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 664 UUCAUUCAGUUCUCUACG 680
:|||||:|:~|:|:|
Db 18 TTCATTCACTTCCTCTG 2

RESULT 1392

US-11-083-784-430174/C
; Sequence 430174, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary

; SEQ ID NO 430174
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-430174

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 8.7e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 664 UUCAUUCAGUCCUGCAG 680
DB 17 TTCAITTCAGTCTCTCTG 1

RESULT 1393
US-11-083-784-440481/c
; Sequence 440481, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 440481
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-440481

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 8.7e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1200 CUUGAGAGGAAGCCG 1216
DB 17 CTTGGAAGGAAGCCG 1

RESULT 1394
US-11-083-784-496009
; Sequence 496009, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 496009
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-496009

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 635 GAAAGGAACUGUGCCU 651
DB 1 GAAAGGAACUGUGCCU 17

RESULT 1395
US-11-083-784-496109
; Sequence 496109, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 496109
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-496109

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 635 GAAAGGAACUGUGCCU 651
DB 1 GAAAGGAACUGUGCCU 17

RESULT 1396
US-11-083-784-496206
; Sequence 496206, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14

;; PRIOR APPLICATION NUMBER: 60/502,050
;; PRIOR FILING DATE: 2003-09-10
;; PRIOR APPLICATION NUMBER: 60/426,137
;; PRIOR FILING DATE: 2002-11-14
;; NUMBER OF SEQ ID NOS: 1591911
;; SOFTWARE: Proprietary
;; SEQ ID NO 496206
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-11-083-784-496206

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 635 GAAAGGAACTUGGCU 651
DB 1 GAAAGGAACTUGGCU 17

RESULT 1397
US-11-083-784-498533
;; Sequence 498533, Application US/11083784
;; Publication No. US20050245475A1
;; GENERAL INFORMATION:
;; APPLICANT: Dharmcon, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin
;; APPLICANT: Marshall, William
;; APPLICANT: Scaringe, Stephen
;; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;; FILE REFERENCE: 13499US
;; CURRENT APPLICATION NUMBER: US/11/083,784
;; CURRENT FILING DATE: 2005-03-18
;; PRIOR APPLICATION NUMBER: US/10/714,333
;; PRIOR FILING DATE: 2003-11-14
;; PRIOR APPLICATION NUMBER: 60/502,050
;; PRIOR FILING DATE: 2003-09-10
;; PRIOR APPLICATION NUMBER: 60/426,137
;; PRIOR FILING DATE: 2002-11-14
;; NUMBER OF SEQ ID NOS: 1591911
;; SOFTWARE: Proprietary
;; SEQ ID NO 498533
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-11-083-784-498533

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 775 GAAAGCGUACCAAGA 791
DB 1 GAAAGCGUACCAAGA 17

RESULT 1398
US-11-083-784-498633
;; Sequence 498633, Application US/11083784
;; Publication No. US20050245475A1
;; GENERAL INFORMATION:
;; APPLICANT: Dharmcon, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin
;; APPLICANT: Marshall, William
;; APPLICANT: Scaringe, Stephen
;; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;; FILE REFERENCE: 13499US
;; CURRENT APPLICATION NUMBER: US/11/083,784

;; CURRENT FILING DATE: 2005-03-18
;; PRIOR APPLICATION NUMBER: US/10/714,333
;; PRIOR FILING DATE: 2003-11-14
;; PRIOR APPLICATION NUMBER: 60/502,050
;; PRIOR FILING DATE: 2003-09-10
;; PRIOR APPLICATION NUMBER: 60/426,137
;; PRIOR FILING DATE: 2002-11-14
;; NUMBER OF SEQ ID NOS: 1591911
;; SOFTWARE: Proprietary
;; SEQ ID NO 498633
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-11-083-784-498633

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 775 GAAAGCGUACCAAGA 791
DB 1 GAAAGCGUACCAAGA 17

RESULT 1399
US-11-083-784-498733
;; Sequence 498733, Application US/11083784
;; Publication No. US20050245475A1
;; GENERAL INFORMATION:
;; APPLICANT: Dharmcon, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin
;; APPLICANT: Marshall, William
;; APPLICANT: Scaringe, Stephen
;; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
;; FILE REFERENCE: 13499US
;; CURRENT APPLICATION NUMBER: US/11/083,784
;; CURRENT FILING DATE: 2005-03-18
;; PRIOR APPLICATION NUMBER: US/10/714,333
;; PRIOR FILING DATE: 2003-11-14
;; PRIOR APPLICATION NUMBER: 60/502,050
;; PRIOR FILING DATE: 2003-09-10
;; PRIOR APPLICATION NUMBER: 60/426,137
;; PRIOR FILING DATE: 2002-11-14
;; NUMBER OF SEQ ID NOS: 1591911
;; SOFTWARE: Proprietary
;; SEQ ID NO 498733
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-11-083-784-498733

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 775 GAAAGCGUACCAAGA 791
DB 1 GAAAGCGUACCAAGA 17

RESULT 1400
US-11-083-784-522568/C
;; Sequence 522568, Application US/11083784
;; Publication No. US20050245475A1
;; GENERAL INFORMATION:
;; APPLICANT: Dharmcon, Inc.
;; APPLICANT: Khvorova, Anastasia
;; APPLICANT: Reynolds, Angela
;; APPLICANT: Leake, Devin
;; APPLICANT: Marshall, William
;; APPLICANT: Scaringe, Stephen

```

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 522568
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-522568

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 8.7e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      944 UCACACCAAGAGCUGG 960
      :|||||:|||||:|
Db      19 TCACATCCAGAGCTGG 3

RESULT 1401
US-11-083-784-535148
; Sequence 535148, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 535148
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-535148

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1120 CACGACCAUCCUCAA 1136
      :|||||:|||||:|
Db      2 CACAGGCCAUCUCCUA 18

RESULT 1402
US-11-083-784-552201
; Sequence 552201, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
```

```

; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 552201
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-552201

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1458 GAAGAAAGCGCCAGA 1474
      :|||||:|||||:|
Db      1 GAAGAAAGCGCCAGA 17

RESULT 1403
US-11-083-784-552292
; Sequence 552292, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 552292
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-552292

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1458 GAAGAAAGCGCCAGA 1474
      :|||||:|||||:|
Db      2 GAAGAAAGCGCCAGA 18

RESULT 1404
US-11-083-784-574443
; Sequence 574443, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
```

```
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 574443
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-574443
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 1178 AGGAGAGCGUGGGANG 1194
Db 3 AGGAGAGCGUGGUGANG 19
```

```
RESULT 1405
US-11-083-784-581822/c
/ Sequence 581822, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 581822
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-581822
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 8.7e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 663 CUUCAUUCAGUUCUCA 679
Db 19 CTTCAATTCAGTTTCTCA 3
```

```
RESULT 1406
US-11-083-784-581875/c
```

```
/ Sequence 581875, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 581875
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-581875
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 8.7e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 663 CUUCAUUCAGUUCUCA 679
Db 18 CTTCAATTCAGTTTCTCA 2
```

```
RESULT 1407
US-11-083-784-581922/c
/ Sequence 581922, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 581922
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-581922
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 8.7e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 663 CUUCAUUCAGUUCUCA 679
Db 19 CTTCAATTCAGTTTCTCA 3
```

RESULT 1408
US-11-083-784-581978/c
; Sequence 581978, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Marshall, William
; APPLICANT: Leake, Devin
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 581978
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-581978

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 8.7e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 663 CUUCAUUCGAGUUCUCA 679
Db 18 CTTCAATCAGTTCTCA 2

RESULT 1409
US-11-083-784-588110/c
; Sequence 588110, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Marshall, William
; APPLICANT: Leake, Devin
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 588110
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-588110

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 8.7e+02;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 107 AUUUCGCGAGUUCANAU 123

Db 19 ATTCCGCACTTCAT 3

RESULT 1410
US-11-083-784-596511/c
; Sequence 596511, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Marshall, William
; APPLICANT: Leake, Devin
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 596511
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-596511

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 8.7e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1516 CCUAACACAUCAUGU 1532
Db 19 CCATACACATCTGCT 3

RESULT 1411
US-11-083-784-621759
; Sequence 621759, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Marshall, William
; APPLICANT: Leake, Devin
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 621759
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-621759

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 973 GAGCAGUGGACCAAG 989
Db 3 GAGGAGUGGACCAAG 19

RESULT 1412
US-11-083-784-653624/c
; Sequence 653624, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 1349US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 653624
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-653624

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 8.7e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1647 AACAUUCAGAACCACTU 1663
Db 19 AACATTCAGAACCACTT 3

RESULT 1413
US-11-083-784-653627/c
; Sequence 653627, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 1349US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 653627
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-653627

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 8.7e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1647 AACAUUCAGAACCACTU 1663
Db 18 AACATTCAGAACCACTT 2

RESULT 1414
US-11-083-784-702236
; Sequence 702236, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 1349US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 702236
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-702236

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 764 AUAAGGAACUGAAAG 780
Db 1 AUAAGGAACUGAAG 17

RESULT 1415
US-11-083-784-812530
; Sequence 812530, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 1349US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 812530
; LENGTH: 19

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-812530

Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1383 CACUCUGGCCAAGAGU 1399
DB 2 CACACUGGCCAAGAGU 18

RESULT 1416
US-11-083-784-826194
; Sequence 826194, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 826194
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-826194

Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1177 GAGGAGAGCUGGAGU 1193
DB 2 GAGGAGAGCUGGAGU 18

RESULT 1417
US-11-083-784-913509/C
; Sequence 913509, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
```

```
; SOFTWARE: Proprietary
; SEQ ID NO 913509
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-913509

Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 19;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 355 GUCAUUUCAUGAUCU 371
DB 18 GTCATTCAATCAATCT 2

RESULT 1418
US-11-083-784-929681/C
; Sequence 929681, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 929681
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-929681

Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1458 GAAGAAAGGCCCGA 1474
DB 19 GAAGAAAGGCCCGA 3

RESULT 1419
US-11-083-784-946340/C
; Sequence 946340, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
```

; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 946340
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-946340

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 8.7e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 883 CUUACACGACCAAGCAU 899
DB 17 CTTCAACAGCAAGTAT 1

RESULT 1420

US-11-083-784-963463
; Sequence 963463, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 963463
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-963463

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 952 AAGAGCUGGAAACCCAG 968
DB 2 AAGAGCUGGAAACCCAG 18

RESULT 1421

US-11-083-784-968672/C
; Sequence 968672, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333

; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 968672
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-968672

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 8.7e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1308 CACAGCUAAGACUUCUG 1324
DB 18 CACAGCUAAGATTCTG 2

RESULT 1422

US-11-083-784-968744/C
; Sequence 968744, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 968744
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-968744

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 8.7e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1308 CACAGCUAAGACUUCUG 1324
DB 18 CACAGCUAAGATTCTG 2

RESULT 1423

US-11-083-784-1062866
; Sequence 1062866, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US

```
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1062866
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1062866

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 143 AUUUCUCCUCCAGAC 159
DB 2 AUUUCACUCCUCCAGAC 18

RESULT 1424
US-11-083-784-1085933
; Sequence 1085933, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1085933
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1085933

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1262 CAAAAGCUCUCCAG 1278
DB 2 CACAAAGCUCUCCAG 18

RESULT 1425
US-11-083-784-1092663
; Sequence 1092663, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
```

```
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1092663
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1092663

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 992 ACAGCAGAGUACAGU 1008
DB 3 ACAGCAGAGUACAGU 19

RESULT 1426
US-11-083-784-1092769
; Sequence 1092769, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1092769
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1092769

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 992 ACAGCAGAGUACAGU 1008
DB 3 ACAGCAGAGUACAGU 19

RESULT 1427
US-11-083-784-1136074
; Sequence 1136074, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
```

```

; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 1136074
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1136074
```

```

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1519 UACACAUCAUGGUCU 1535
Db      3 UACACAUCCUGGUCU 19
```

```

RESULT 1428
US-11-083-784-1153902
; Sequence 1153902, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 1153902
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1153902
```

```

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      993 CAGCAGCAGUACAGU 1009
Db      1 CAGCAGCAGUCCAGU 17
```

```

RESULT 1429
US-11-083-784-1232377
; Sequence 1232377, Application US/11083784
; Publication No. US20050245475A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 1232377
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1232377
```

```

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      886 CAACGCAAGCAUGAA 902
Db      1 CAACAGCUAAGCAUGAA 17
```

```

RESULT 1430
US-11-083-784-1237707
; Sequence 1237707, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 1237707
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1237707
```

```

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1218 CAAGCUGAGGCCGAGA 1234
Db      2 CAAGAUCCAGGCCGAGA 18
```

```

RESULT 1431
```

```
US-11-083-784-1287587
; Sequence 1287587, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1287587
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1287587
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      407 UAGGGAACUUGGCGCCUUG 423
      |||||
Db      2 UAGGGAACUUGGCGCCUUG 18
```

```
RESULT 1432
US-11-083-784-1287626
; Sequence 1287626, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1287626
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1287626
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      407 UAGGGAACUUGGCGCCUUG 423
      |||||
Db      1 UAGGGAACUUGGCGCCUUG 17
```

```
RESULT 1433
US-11-083-784-1297887/C
; Sequence 1297887, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1297887
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1297887
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 8.7e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      1358 CUCUACCCUUGGCGCCUUC 1374
      ||:|:|:|:|:|:|:|:|:|
Db      18 CTCCTACTCTGTCCTTC 2
```

```
RESULT 1434
US-11-083-784-1298560
; Sequence 1298560, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1298560
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1298560
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

QY 1271 UCUCCAAGCUCUCCAU 1287
|||
Db 1 UCACCAAGCUCUCCAU 17

RESULT 1435
US-11-083-784-1307050

/ Sequence 1307050, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:

/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 1307050
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-1307050

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1360 CUACUCUCUCCUCAA 1376
|||
Db 3 CCACUCUCUCCUCAA 19

RESULT 1436
US-11-083-784-1307134

/ Sequence 1307134, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:

/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 1307134
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-1307134

Query Match 0.9%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1360 CUACUCUCUCCUCAA 1376
|||
Db 3 CCACUCUCUCCUCAA 19

RESULT 1437
US-11-083-784-1324599

/ Sequence 1324599, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 1324599
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-083-784-1324599

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 577 UGGGUCACUCUCCUUGU 593
|||
Db 1 UGGGUCACUCUCCUUGU 17

RESULT 1438
US-11-083-784-1333743/C

/ Sequence 1333743, Application US/11083784
/ Publication No. US20050245475A1
/ GENERAL INFORMATION:

/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/083,784
/ PRIOR FILING DATE: 2005-03-18
/ PRIOR APPLICATION NUMBER: US/10/714,333
/ PRIOR FILING DATE: 2003-11-14
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 1333743
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens

US-11-083-784-1333743

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 8.7e+02;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 666 CAUUCAGUCCUCCAGUG 682
DB 18 CATTGAGTCTTAGTG 2

RESULT 1439

US-11-083-784-1384793
; Sequence 1384793, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1384793
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1384793

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1655 GAACCACTUUCAGAGUG 1671
DB 3 GCACCACTUUCAGAGUG 19

RESULT 1440

US-11-083-784-1412484/c
; Sequence 1412484, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1412484

; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1412484

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 8.7e+02;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 305 UCAACAACUACUCCUC 321
DB 19 TCAACAACUACUCCUC 3

RESULT 1441
US-11-083-784-1412498/c
; Sequence 1412498, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1412498
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1412498

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 8.7e+02;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 305 UCAACAACUACUCCUC 321
DB 18 TCAACAACUACUCCUC 2

RESULT 1442
US-11-083-784-1412508/c
; Sequence 1412508, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14

NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO: 1412508
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-1412508

Query Match
Best Local Similarity 64.7%; Score 15.4; DB 1; Length 19;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 305 UCAACACUACUCCUCC 321
DB 17 TCACACACTACTCTTC 1

RESULT 1443
US-11-083-784-1479942/c
Sequence 1479942, Application US/11083784
Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT FILING DATE: 2005-03-18
PRIOR FILING DATE: US/10/714,333
PRIOR APPLICATION NUMBER: 2003-11-14
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO: 1479942
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-1479942

Query Match
Best Local Similarity 76.5%; Score 15.4; DB 1; Length 19;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 41 CAACACUACUCCUCC 57
DB 18 CAACCTCAGCTCTCC 2

RESULT 1444
US-11-083-784-1563128/c
Sequence 1563128, Application US/11083784
Publication No. US20050245475A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT FILING DATE: US/11/083,784
CURRENT FILING DATE: 2005-03-18
PRIOR APPLICATION NUMBER: US/10/714,333
PRIOR FILING DATE: 2003-11-14
PRIOR APPLICATION NUMBER: 60/502,050

PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO: 1563128
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-083-784-1563128

Query Match
Best Local Similarity 47.1%; Score 15.4; DB 1; Length 19;
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 714 UGCUUUUANAUGCCUG 730
DB 18 TGCTATATATATGCTTG 2

RESULT 1445
US-11-101-244-96831
Sequence 96831, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT FILING DATE: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO: 96831
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-96831

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 658 GAGUGCUCAUUCAGUU 674
DB 2 GAGUGCUCAUUCAGUU 18

RESULT 1446
US-11-101-244-97156
Sequence 97156, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT FILING DATE: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10

```
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97156
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97156

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      609 CAUCUUGUUCUGGCAU 625
DB      1 CAUCUUGUUCUGGCAU 17

RESULT 1447
US-11-101-244-97216
; Sequence 97216, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 97216
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-97216

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1522 AACAUCAUGGUCUGCU 1538
DB      2 AACAUCAUGGUCUGCU 18

RESULT 1448
US-11-101-244-103182/C
; Sequence 103182, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
```

```
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 103182
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-103182

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 47.1%; Pred. No. 8.7e+02;
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY      581 UCAUCCUUCUUGUCCUU 597
DB      19 TCATCTCTTGTCCTT 3

RESULT 1449
US-11-101-244-103190/C
; Sequence 103190, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 103190
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-103190

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 47.1%; Pred. No. 8.7e+02;
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY      581 UCAUCCUUCUUGUCCUU 597
DB      18 TCATCTCTTGTCCTT 2

RESULT 1450
US-11-101-244-131581
; Sequence 131581, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
```

```
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 131581
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-101-244-131581
```

```
Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 946 ACAACCAAGAGCUGGAA 962
DB 3 AGAACCAAGAGCUGGAA 19
```

```
RESULT 1451
US-11-101-244-164314/c
/ Sequence 164314, Application US/11101244
/ Publication No. US20050246794A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/101,244
/ CURRENT FILING DATE: 2005-04-07
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 164314
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-101-244-164314
```

```
Query Match
Best Local Similarity 82.4%; Score 15.4; DB 1; Length 19;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 911 ACAGGAGAAGUAGGC 927
DB 17 ACAGGAGAAGUAGGC 1
```

```
RESULT 1452
US-11-101-244-220921
/ Sequence 220921, Application US/11101244
/ Publication No. US20050246794A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/101,244
/ CURRENT FILING DATE: 2005-04-07
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
```

```
/ SOFTWARE: Proprietary
/ SEQ ID NO 220921
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-101-244-220921
```

```
Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1664 UCAAGAVGCTGCTGCTG 1680
DB 1 UCAAGAVGCTGCTGCTG 17
```

```
RESULT 1453
US-11-101-244-234743/c
/ Sequence 234743, Application US/11101244
/ Publication No. US20050246794A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/101,244
/ CURRENT FILING DATE: 2005-04-07
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 234743
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-101-244-234743
```

```
Query Match
Best Local Similarity 76.5%; Score 15.4; DB 1; Length 19;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1646 AAACAUUCAGAACCAU 1662
DB 18 AAACAUUCAGAACCAU 2
```

```
RESULT 1454
US-11-101-244-234762/c
/ Sequence 234762, Application US/11101244
/ Publication No. US20050246794A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Dharmacon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/101,244
/ CURRENT FILING DATE: 2005-04-07
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
```

```

; SEQ ID NO 234762
;
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-234762

Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 19;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1646 AAACATTCAGAAACACT 1662
Db 19 AAACATTCAGAAACACT 3

RESULT 1455
US-11-101-244-240931/c
; Sequence 240931, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 240931
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-240931

Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 19;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1198 GACUCGAGAGAGAACG 1214
Db 19 GACCTGAGAGAGAACG 3

RESULT 1456
US-11-101-244-259725/c
; Sequence 259725, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 259725
```

```

; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-259725

Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 19;
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

Qy 616 UUCUGGCAUACUUCU 632
Db 19 TTCTGGAAATACTTGT 3

RESULT 1457
US-11-101-244-259762/c
; Sequence 259762, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 259762
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-259762

Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 19;
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

Qy 616 UUCUGGCAUACUUCU 632
Db 18 TTCTGGAAATACTTGT 2

RESULT 1458
US-11-101-244-289369
; Sequence 289369, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 289369
; LENGTH: 19
```

TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-289369

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1655 GAACGACUUCAGAGU 1671
DB 3 GAUUCACUUCAGAGU 19

RESULT 1459
US-11-101-244-345636
Sequence 345636, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 345636
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-345636

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 993 CAGCAGCAGUACAGU 1009
DB 2 CAGCAGCAGUACAGU 18

RESULT 1460
US-11-101-244-394748/C
Sequence 394748, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 394748
LENGTH: 19
TYPE: RNA

ORGANISM: Homo sapiens
US-11-101-244-394748

Query Match
Best Local Similarity 58.8%; Score 15.4; DB 1; Length 19;
Pred. No. 8.7e+02;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

OY 479 UGUCAUUCAGUCCUAC 495
DB 18 TGCTCATCAGCTTGCAC 2

RESULT 1461
US-11-101-244-430047/C
Sequence 430047, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 430047
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-430047

Query Match
Best Local Similarity 52.9%; Score 15.4; DB 1; Length 19;
Pred. No. 8.7e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

OY 664 UUCAUUCAGUCCUAC 680
DB 18 TTCATTCAGTCTCTCG 2

RESULT 1462
US-11-101-244-430081/C
Sequence 430081, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 13499US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 430081
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens

US-11-101-244-430081

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 8.7e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 664 UUCAUUCAGUUCUCAG 680
DB 17 TTCATTCAGTTCCTCTG 1

RESULT 1463

US-11-101-244-430146/C
; Sequence 430146, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 430146
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-430146

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 8.7e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 664 UUCAUUCAGUUCUCAG 680
DB 18 TTCATTCAGTTCCTCTG 2

RESULT 1464

US-11-101-244-430174/C
; Sequence 430174, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 430174
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-430174

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 8.7e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 664 UUCAUUCAGUUCUCAG 680
DB 17 TTCATTCAGTTCCTCTG 1

RESULT 1465

US-11-101-244-440481/C
; Sequence 440481, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 440481
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-440481

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 8.7e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1200 CUUGAGAGGAAAGCCG 1216
DB 17 CTGGAAGGAAAGCCG 1

RESULT 1466

US-11-101-244-496009
; Sequence 496009, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 496009
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-496009

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 635 GAAAGGAACTUGGCU 651
|||||
Db 1 GAAAGGAACTUGGCU 17

RESULT 1467

US-11-101-244-496109
; Sequence 496109, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 496109
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-496109

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 635 GAAAGGAACTUGGCU 651
|||||
Db 1 GAAAGGAACTUGGCU 17

RESULT 1468

US-11-101-244-496206
; Sequence 496206, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 496206
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-496206

Query Match 0.9%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 635 GAAAGGAACTUGGCU 651
|||||
Db 1 GAAAGGAACTUGGCU 17

RESULT 1469

US-11-101-244-498533
; Sequence 498533, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 498533
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-498533

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 775 GAAAGGAACTUGGCU 791
|||||
Db 1 GAAAGGAACTUGGCU 17

RESULT 1470

US-11-101-244-498633
; Sequence 498633, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 498633
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-498633

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 775 GAAAGCGUACCAAGA 791

Db 1 GAAAGCGUACCAAGA 17

RESULT 1471

US-11-101-244-498733

; Sequence 498733, Application US/11101244

; Publication No. US20050246794A1

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 498733

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-498733

Query Match 0.9%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 8.7e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 775 GAAAGCGUACCAAGA 791

Db 1 GAAAGCGUACCAAGA 17

RESULT 1472

US-11-101-244-522568/c

; Sequence 522568, Application US/11101244

; Publication No. US20050246794A1

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 522568

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-522568

Query Match 0.9%; Score 15.4; DB 1; Length 19;

Best Local Similarity 82.4%; Pred. No. 8.7e+02;

Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 944 UCAACACCAAGCTCG 960

Db 19 TCACATCCAAAGCTGG 3

RESULT 1473

US-11-101-244-535148

; Sequence 535148, Application US/11101244

; Publication No. US20050246794A1

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/101,244

; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 535148

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-535148

Query Match 0.9%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 8.7e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1120 CACAGCACCAUCCUCA 1136

Db 2 CACAGCCCAUCCUCA 18

RESULT 1474

US-11-101-244-552201

; Sequence 552201, Application US/11101244

; Publication No. US20050246794A1

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/101,244

; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 552201

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-552201

Query Match 0.9%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 8.7e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy	1458	GAAGAAAGCGGCCCA	1474
Db	1	GAAGAAAGCAGCCCA	17

```

RESULT 1475
US-11-101-244-552292
; Sequence 552292, Application US/11101244
; Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khvorova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 134990S
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 552292
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-552292

```

Oy	1458	GAAGAAAGCGCCAGA	1474
Db	2	GAAGAAAGCAGCCAGA	18

```

RESULT 1476
US-11-101-244-574443
? Sequence 574443, Application US/11101244
? Publication No. US20050246794A1
? GENERAL INFORMATION:
? APPLICANT: Dharmacon, Inc.
? APPLICANT: Khvorova, Anastasia
? APPLICANT: Reynolds, Angela
? APPLICANT: Leake, Devin
? APPLICANT: Marshall, William
? APPLICANT: Scaringe, Stephen
? TITLE OF INVENTION: Functional and Hyperfunctional siRNA
? FILE REFERENCE: 13499US
? CURRENT APPLICATION NUMBER: US/11/101,244
? CURRENT FILING DATE: 2005-04-07
? PRIOR APPLICATION NUMBER: 60/502,050
? PRIOR FILING DATE: 2003-09-10
? PRIOR APPLICATION NUMBER: 60/426,137
? PRIOR FILING DATE: 2002-11-14
? NUMBER OF SEQ ID NOS: 1591911
? SOFTWARE: Proprietary
? SEQ ID NO 574443
? LENGTH: 19
? TYPE: RNA
? ORGANISM: Homo sapiens
US-11-101-244-574443

```

QY 1178 AGGAGGAGCTGGGAUG 1194

Db 3 AGAGGAGCTGCGAUG 19

```

RESULT 1477
US-11-101-244-581822/c
Sequence 581822, Application US/11101244
Publication No. US20050246794A1
GENERAL INFORMATION:
APPLICANT: Dharmacon, Inc.
APPLICANT: Khavrova, Anastasia
APPLICANT: Reynolds, Angela
APPLICANT: Leake, Devin
APPLICANT: Marshall, William
APPLICANT: Scaringe, Stephen
TITLE OF INVENTION: Functional and Hyperfunctional siRNA
FILE REFERENCE: 134990US
CURRENT APPLICATION NUMBER: US/11/101,244
CURRENT FILING DATE: 2005-04-07
PRIOR APPLICATION NUMBER: 60/502,050
PRIOR FILING DATE: 2003-09-10
PRIOR APPLICATION NUMBER: 60/426,137
PRIOR FILING DATE: 2002-11-14
NUMBER OF SEQ ID NOS: 1591911
SOFTWARE: Proprietary
SEQ ID NO 581822
LENGTH: 19
TYPE: RNA
ORGANISM: Homo sapiens
US-11-101-244-581822

```

QY 663 CUUUAUUCAGUUCUUA 679
 ||::||::||::||: ||
 Db 19 CTTCAATTCAGTTTCTCA 3

```

RESULT 1478
US-11-101-244-581875/c
; Sequence 581875, Application US/11101244
; Publication NO. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIORITY FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIORITY FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIORITY FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 581875
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-11-101-244-581875

```

QY 663 CUUCAUUCAGUUCUCA 679
|::||::|||::|::|||

RESULT 1483

US-11-101-244-621759

; Sequence 621759, Application US/11101244

; Publication No. US20050246794A1

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/101,244

; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 621759

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-621759

Query Match

Best Local Similarity 0.9%; Score 15.4; DB 1; Length 19;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 973 GAGCAGUGGACCAAGA 989

Db 3 GAGCAGUGGACCAAGA 19

RESULT 1484

US-11-101-244-653624/c

; Sequence 653624, Application US/11101244

; Publication No. US20050246794A1

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/101,244

; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 653624

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-653624

Query Match

Best Local Similarity 0.9%; Score 15.4; DB 1; Length 19;

Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 1647 AACAUUCAGAACCAU 1663

Db 19 AACATTGAGACACTT 3

RESULT 1485

US-11-101-244-653627/c

; Sequence 653627, Application US/11101244

; Publication No. US20050246794A1

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/101,244

; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 653627

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-653627

Query Match

Best Local Similarity 0.9%; Score 15.4; DB 1; Length 19;

Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 1647 AACAUUCAGAACCAU 1663

Db 18 AACATTGAGACACTT 2

RESULT 1486

US-11-101-244-702236/c

; Sequence 702236, Application US/11101244

; Publication No. US20050246794A1

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/101,244

; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 702236

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-702236

Query Match

Best Local Similarity 0.9%; Score 15.4; DB 1; Length 19;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 764 AUAAGGAACUGAAAG 780

Db 1 AUAAGGAACUGAAAG 17

RESULT 1487

```
US-11-101-244-812530
; Sequence 812530, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 812530
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-812530

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1383 CACUCUGGCCAAGAGU 1399
Db      2 CACACUGGCCAAGAGU 18

RESULT 1488
US-11-101-244-826194
; Sequence 826194, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 826194
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-826194

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1177 GAGGAGAGCUGGAGU 1193
Db      2 GAGGAGAGCUGGAGU 18

RESULT 1489
US-11-101-244-913509/c

; Sequence 913509, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 913509
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-913509

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 8.7e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

Qy      355 GUCAUUUGCAUGAUCU 371
Db      18 GTCATTTCATCATCT 2

RESULT 1490
US-11-101-244-929681/c
; Sequence 929681, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 929681
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-929681

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1458 GAAGAAAGCGCCAGA 1474
Db      19 GAAGAAAGCGCCAGA 3

RESULT 1491
US-11-101-244-946340/c
; Sequence 946340, Application US/11101244
```

```
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 946340
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-946340
```

```
Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 8.7e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 883 CUCACACGACCAAGCAU 899
Db 17 CTTCAACACGACCAAGTAT 1
```

```
RESULT 1492
US-11-101-244-963463
; Sequence 963463, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 963463
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-963463
```

```
Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 952 AAGAGCTUGAAGCCAG 968
Db 2 AAGAGCTUGAAGCCAG 18
```

```
RESULT 1493
US-11-101-244-968672/c
; Sequence 968672, Application US/11101244
; Publication No. US20050246794A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 968672
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-968672
```

```
Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 8.7e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1308 CACAGCTAAGATTCG 1324
Db 18 CACAGCTAAGATTCG 2
```

```
RESULT 1494
US-11-101-244-968744/c
; Sequence 968744, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 968744
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-968744
```

```
Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 8.7e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1308 CACAGCTAAGATTCG 1324
Db 18 CACAGCTAAGATTCG 2
```

```
RESULT 1495
US-11-101-244-1062866
; Sequence 1062866, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
```

```

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1062866
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1062866
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      143 AUUUCUCCUCCUCCAGC 159
DB      2 AUUUCACUCCUCCAGAC 18
```

```
RESULT 1496
US-11-101-244-1085933
; Sequence 1085933, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1085933
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1085933
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1262 CAAAAGCTUCCUCCAG 1278
DB      2 CACAAAGCTUCCUCCAG 18
```

```
RESULT 1497
US-11-101-244-1092663
; Sequence 1092663, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
```

```

; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1092663
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1092663
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      992 ACAGCAGCAGUGACAGU 1008
DB      3 ACAGCAGAGUGACAGU 19
```

```
RESULT 1498
US-11-101-244-1092769
; Sequence 1092769, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1092769
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1092769
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      992 ACAGCAGCAGUGACAGU 1008
DB      3 ACAGCAGAGUGACAGU 19
```

```
RESULT 1499
US-11-101-244-1136074
; Sequence 1136074, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
```

```
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/101,244
/ CURRENT FILING DATE: 2005-04-07
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 1136074
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-101-244-1136074
```

```
Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1519 UACACACUACUGGUCU 1535
DB 3 UACACACUCCUGGUCU 19
```

```
RESULT 1500
US-11-101-244-1153902
/ Sequence 1153902, Application US/11101244
/ Publication No. US20050246794A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmcon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/101,244
/ CURRENT FILING DATE: 2005-04-07
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 1153902
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-101-244-1153902
```

```
Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 993 CAGCAGCAGUGGUCU 1009
DB 1 CAGCAGCAGUGGUCU 17
```

```
RESULT 1501
US-11-101-244-1232377
/ Sequence 1232377, Application US/11101244
/ Publication No. US20050246794A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmcon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
```

```
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/101,244
/ CURRENT FILING DATE: 2005-04-07
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 1232377
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-101-244-1232377
```

```
Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 886 CAACGCAAGCAGUCAA 902
DB 1 CAACGCUAAGCAGUCAA 17
```

```
RESULT 1502
US-11-101-244-1237707
/ Sequence 1237707, Application US/11101244
/ Publication No. US20050246794A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmcon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
/ APPLICANT: Leake, Devin
/ APPLICANT: Marshall, William
/ APPLICANT: Scaringe, Stephen
/ TITLE OF INVENTION: Functional and Hyperfunctional siRNA
/ FILE REFERENCE: 13499US
/ CURRENT APPLICATION NUMBER: US/11/101,244
/ CURRENT FILING DATE: 2005-04-07
/ PRIOR APPLICATION NUMBER: 60/502,050
/ PRIOR FILING DATE: 2003-09-10
/ PRIOR APPLICATION NUMBER: 60/426,137
/ PRIOR FILING DATE: 2002-11-14
/ NUMBER OF SEQ ID NOS: 1591911
/ SOFTWARE: Proprietary
/ SEQ ID NO 1237707
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-11-101-244-1237707
```

```
Query Match
Best Local Similarity 0.9%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1218 CAAGCUGCAGGCCAG 1234
DB 2 CAAGCUGCAGGCCAG 18
```

```
RESULT 1503
US-11-101-244-1287587
/ Sequence 1287587, Application US/11101244
/ Publication No. US20050246794A1
/ GENERAL INFORMATION:
/ APPLICANT: Dharmcon, Inc.
/ APPLICANT: Khvorova, Anastasia
/ APPLICANT: Reynolds, Angela
```

```

; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1287587
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1287587
```

```

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      407 UAGGGAACUUGGCCUUG 423
Db      2 UAGGGAACUUGGCCUUG 18
```

```

RESULT 1504
US-11-101-244-1287626
; Sequence 1287626, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1287626
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1287626
```

```

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      407 UAGGGAACUUGGCCUUG 423
Db      1 UAGGGAACUUGGCCUUG 17
```

```

RESULT 1505
US-11-101-244-1297887/c
; Sequence 1297887, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
```

```

; APPLICANT: Scaringe, Stephen
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1297887
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1297887
```

```

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 8.7e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      1358 CUCUACCUUGGCCUUC 1374
Db      18 CTCCTACTCTGTCCTTC 2
```

```

RESULT 1506
US-11-101-244-1298560
; Sequence 1298560, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1298560
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1298560
```

```

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      1271 UCUCGACGUCUCCGAC 1287
Db      1 UCACCAAGCUUCCGAC 17
```

```

RESULT 1507
US-11-101-244-1307050
; Sequence 1307050, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmcon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
```

```

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1307050
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1307050

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1360 CUACCUUGUCUCCUCAA 1376
Db      3 CCACCUCUGUCCUCCUCAA 19

RESULT 1508
US-11-101-244-1307134
; Sequence 1307134, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1307134
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1307134

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1360 CUACCUUGUCUCCUCAA 1376
Db      3 CCACCUCUGUCCUCCUCAA 19

RESULT 1509
US-11-101-244-1324599
; Sequence 1324599, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```

; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1324599
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1324599

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 8.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      577 UGGGUCACUCCUCCUUGU 593
Db      1 UGGGUCACUCCUCCUUGU 17

RESULT 1510
US-11-101-244-1333743/c
; Sequence 1333743, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1333743
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1333743

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 8.7e+02;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY      666 CAUUCAGUUCUCCUAGUG 682
Db      18 CATTGAGTCTCTTAGTG 2

RESULT 1511
US-11-101-244-1384793
; Sequence 1384793, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
```



```
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1479942
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1479942

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 8.7e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      41 CAAACUCCGCTCC 57
DB      18 CAAACTCAGCTCTCC 2

RESULT 1516
US-11-101-244-1563128/C
; Sequence 1563128, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmicon, Inc.
; APPLICANT: Reynolds, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1563128
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1563128

Query Match          0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 47.1%; Pred. No. 8.7e+02;
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY      714 UGCUUUUUAUAGCCUG 730
DB      18 TCGTTATATATGCGCTG 2

RESULT 1517
US-10-310-914A-190504
; Sequence 190504, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087,0200,CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: Patent version 3.3
; SEQ ID NO 190504
; LENGTH: 18

; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-190504

Query Match          0.8%; Score 15; DB 1; Length 18;
Best Local Similarity 73.3%; Pred. No. 8.6e+02;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      227 GCAUCCUGGCTTGG 241
DB      17 GCATCTGGGCTTGG 3

RESULT 1520
US-09-969-373-3175
```

```
; Sequence 3175, Application US/09969373
; Patent No. US2002013852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methode of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 3175
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-3175

Query Match
Best Local Similarity 66.7%; DB 1; Length 18;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 250 AUCGCAACUCCUGGUA 267
  |||||:||||:|
Db 1 ATCTGCACGCTCTGGTA 18

RESULT 1521
US-10-314-657-77
; Sequence 77, Application US/10314657
; Publication No. US2003017588A1
; GENERAL INFORMATION:
; APPLICANT: SHEN, Ben
; APPLICANT: CHENG, Yi-Qiang
; APPLICANT: TANG, Gong-Li
; TITLE OF INVENTION: Discrete Acyltransferases Associated with Type I Polyketide
; FILE REFERENCE: 054030-0021
; CURRENT APPLICATION NUMBER: US/10/314,657
; PRIOR FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: PCT/US02/08937
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: US 60/278,935
; PRIOR FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 214
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 77
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Streptomyces atroolivaceus
US-10-314-657-77

Query Match
Best Local Similarity 61.1%; DB 1; Length 18;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1270 UUCUCCAGCUUCCCAUC 1287
  ::|||||:||||:|
Db 1 TTGCCCAAGCTTCCCATC 18

RESULT 1522
US-10-473-193-77
; Sequence 77, Application US/10473193
; Publication No. US20050080247A1
; GENERAL INFORMATION:
; APPLICANT: SHEN, BEN
; APPLICANT: CHEN, YI-QIANG
; APPLICANT: TANG, GONG-LI
```

```
; TITLE OF INVENTION: LEINAMYCIN BIOSYNTHESIS GENE CLUSTER AND ITS COMPONENTS AND THEIR
; FILE REFERENCE: 309T-000110US
; CURRENT APPLICATION NUMBER: US/10/473,193
; PRIOR FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: US 60/278,935
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: PCT/US02/08937
; PRIOR FILING DATE: 2002-03-22
; NUMBER OF SEQ ID NOS: 222
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 77
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide PCR primer.
US-10-473-193-77

Query Match
Best Local Similarity 61.1%; DB 1; Length 18;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1270 UUCUCCAGCUUCCCAUC 1287
  ::|||||:||||:|
Db 1 TTGCCCAAGCTTCCCATC 18

RESULT 1523
US-10-310-914A-52517
; Sequence 52517, Application US/10310914A
; Publication No. US2006000332A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087,0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; PRIOR FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 52517
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-52517

Query Match
Best Local Similarity 88.9%; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 614 UGUUCUGGCAUUAUUG 631
  |||||:|||||:|
Db 1 UGUUUGGCAUUAUUG 18

RESULT 1524
US-10-310-914A-57984
; Sequence 57984, Application US/10310914A
; Publication No. US2006000332A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087,0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; PRIOR FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 57984
; LENGTH: 18
```



```
; ORGANISM: Human
US-10-310-914A-253464

Query Match
Best Local Similarity 72.2%; Pred. No. 9e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1064 AGGACAUUGGCUCCGAGA 1081
Db 18 AGGACATTGCTGGAGAGA 1

RESULT 1530
US-10-310-914A-257089
; Sequence 257089, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuvzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 257089
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-257089

Query Match
Best Local Similarity 88.9%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1022 AUGCUGCUCGCUCCUGG 1039
Db 1 AGGCGUGCUGCUCCUGG 18

RESULT 1531
US-10-310-914A-257374/C
; Sequence 257374, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuvzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 257374
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-257374

Query Match
Best Local Similarity 72.2%; Pred. No. 9e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1634 CUCUGGCAACAACAU 1651
Db 18 CTCGAGCAACAAGCAT 1

RESULT 1532
US-10-310-914A-273398/C
; Sequence 273398, Application US/10310914A

; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuvzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 273398
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-273398

Query Match
Best Local Similarity 72.2%; Pred. No. 9e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 800 GCCUGCAAGCUCUGGGA 817
Db 18 GCGTGAAGCTCTGGGA 1

RESULT 1533
US-10-310-914A-365721
; Sequence 365721, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuvzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 365721
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-365721

Query Match
Best Local Similarity 88.9%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1429 AAGCGAAGAGAUUGCC 1446
Db 1 AAGCAGAGAGAUUGCC 18

RESULT 1534
US-10-310-914A-365722
; Sequence 365722, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuvzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 365722
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
```

US-10-310-914A-365722

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1429 AACCGAAGAGAGUUGCC 1446

Db 1 AACGAGAGAGAGAGUUGCC 18

RESULT 1535

US-10-310-914A-408506/c
; Sequence 408506, Application US/10310914A
; Publication No. US20060003322A1

GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 408506
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-408506

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 9e+02;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1381 GCCACUCGCCCAAGAGG 1398

Db 18 GCCACTCTCCCAAGAGG 1

RESULT 1536

US-10-310-914A-491924/c
; Sequence 491924, Application US/10310914A
; Publication No. US20060003322A1

GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 491924
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-491924

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 9e+02;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 110 UCGGACGUCACAUUGUU 127

Db 18 TCGGACGCTCAATGTTT 1

RESULT 1537

US-10-310-914A-510774
; Sequence 510774, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 510774
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-510774

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1513 ACCCGAUAACAUAUG 1530

Db 1 ACUCGUAACCAUAUG 18

RESULT 1538

US-10-310-914A-527146
; Sequence 527146, Application US/10310914A
; Publication No. US20060003322A1

GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 527146
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-527146

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 79 GCAGGCGUCCCCCGGA 96

Db 1 GCAGGCGUCCCCCGGA 18

RESULT 1539

US-10-310-914A-536426/c
; Sequence 536426, Application US/10310914A
; Publication No. US20060003322A1

GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 536426
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-536426

```
Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 9e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy      1123 AGCACCAGCCTGCTCTCC 1140
Db      18 AGCACCATCTCTCTCTCC 1

RESULT 1540
US-10-310-914A-605966/c
; Sequence 605966, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 605966
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-605966

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 9e+02;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy      1179 GGAGAGCGCGGAGCGU 1196
Db      18 GGTGAGCTGCGGAGGCT 1

RESULT 1541
US-10-310-914A-749972
; Sequence 749972, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuvzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 749972
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-749972

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      285 CAACAAGCAGCGAGAGC 302
Db      1 CAACAAGCAGCGAGAGC 18

RESULT 1542
US-10-310-914A-802583/c
; Sequence 802583, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuvzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 802583
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-802583

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 61.1%; Pred. No. 9e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy      1676 UGCUUGCCAGUGUGACA 1693
Db      18 TTCTGTGACAGGTGACA 1

RESULT 1543
US-10-310-914A-814923/c
; Sequence 814923, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuvzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 814923
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-814923

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 9e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy      1164 CCUGAGUGCCUGAGCA 1181
Db      18 CCGCAGGTTCTGTGCA 1

RESULT 1544
US-10-310-914A-874488
; Sequence 874488, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuvzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 874488
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-874488
```

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 763 UUAAGGAACUCGAAAG 780
DB 1 UACAGGAAACUGAAAG 18

RESULT 1545

US-10-310-914A-922451/C
; Sequence 922451, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 922451
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-922451

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 9e+02;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 918 GAAGUAGGCCGCGGCCA 935
DB 18 GGAGCATGGCCGCTGCCA 1

RESULT 1546

US-10-310-914A-980703/C
; Sequence 980703, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 980703
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-980703

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 66.7%; Pred. No. 9e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 38 UUGCAAGACGAGCCUCU 55
DB 18 TTCATATCAGCAGCTCT 1

RESULT 1547

US-10-310-914A-992224
; Sequence 992224, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 992224
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-992224

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1708 AAGCAGCAGUACGACG 1725
DB 1 AAGCAGCAGUACGACG 18

RESULT 1548

US-10-310-914A-1016293/C
; Sequence 1016293, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1016293
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1016293

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 9e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1182 GAGCTGGGAGUGCGCA 1199
DB 18 GGAGGTGTGATGTGTGA 1

RESULT 1549

US-10-310-914A-1018095
; Sequence 1018095, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1018095
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1018095

Query Match 0.8%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 9e+02; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1181 AGGAGCUGGGAUGUGG 1198
|||
Db 1 AGCAGCUGGGGAGUGGGG 18

RESULT 1550

US-10-310-914A-1040396/c
; Sequence 1040396, Application US/10310914A
; Publication No. US20060003322A1

GENERAL INFORMATION:

APPLICANT: Bentwich, Isaac
APPLICANT: Shiler, Kivzatz
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310,914A
CURRENT FILING DATE: 2002-12-06
NUMBER OF SEQ ID NOS: 1388402
SOFTWARE: PatentIn version 3.3
SEQ ID NO 1040396
LENGTH: 18
TYPE: RNA
ORGANISM: Human

US-10-310-914A-1040396

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 9e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 816 GACAGAGCAGAGACAGA 833
|||
Db 18 GAGAGGAGACAGACAGA 1

RESULT 1551

US-10-310-914A-1057429/c
; Sequence 1057429, Application US/10310914A
; Publication No. US20060003322A1

GENERAL INFORMATION:

APPLICANT: Bentwich, Isaac
APPLICANT: Shiler, Kivzatz
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310,914A
CURRENT FILING DATE: 2002-12-06
NUMBER OF SEQ ID NOS: 1388402
SOFTWARE: PatentIn version 3.3
SEQ ID NO 1057429
LENGTH: 18
TYPE: RNA
ORGANISM: Human

US-10-310-914A-1057429

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 9e+02;

Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 50 GGUCCUCCUGAUAACCA 67
|||
Db 18 GCTCCTCTGGAAACCA 1

RESULT 1552

US-10-310-914A-1064707
; Sequence 1064707, Application US/10310914A
; Publication No. US20060003322A1

GENERAL INFORMATION:

APPLICANT: Bentwich, Isaac
APPLICANT: Shiler, Kivzatz

FILE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

FILE REFERENCE: 06087.0200.CPUS01

CURRENT APPLICATION NUMBER: US/10/310,914A

CURRENT FILING DATE: 2002-12-06

NUMBER OF SEQ ID NOS: 1388402

SOFTWARE: PatentIn version 3.3

SEQ ID NO 1064707

LENGTH: 18

TYPE: RNA

ORGANISM: Human

US-10-310-914A-1064707

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 9e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 572 UGGCUUGGGAUCCU 589
|||
Db 1 UGGCUUGGGAUCCU 18

RESULT 1553

US-10-310-914A-1069811
; Sequence 1069811, Application US/10310914A
; Publication No. US20060003322A1

GENERAL INFORMATION:

APPLICANT: Bentwich, Isaac
APPLICANT: Shiler, Kivzatz
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310,914A
CURRENT FILING DATE: 2002-12-06
NUMBER OF SEQ ID NOS: 1388402
SOFTWARE: PatentIn version 3.3
SEQ ID NO 1069811
LENGTH: 18
TYPE: RNA
ORGANISM: Human

US-10-310-914A-1069811

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 9e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1429 AAGCGGAAAGAUCC 1446
|||
Db 1 AAGCAGAGAGGAUCC 18

RESULT 1554

US-10-310-914A-1069812
; Sequence 1069812, Application US/10310914A
; Publication No. US20060003322A1

GENERAL INFORMATION:

APPLICANT: Bentwich, Isaac
APPLICANT: Shiler, Kivzatz
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310,914A
CURRENT FILING DATE: 2002-12-06
NUMBER OF SEQ ID NOS: 1388402
SOFTWARE: PatentIn version 3.3
SEQ ID NO 1069812
LENGTH: 18
TYPE: RNA
ORGANISM: Human

US-10-310-914A-1069812

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 9e+02;


```
QY      1041 GAACUCCGCCUCCUGCA 1058
      |||:|:|:|:|:|:|
Db      18 GAACCTCTCTCTCTCCA 1

RESULT 1560
US-10-310-914A-1330275
; Sequence 1330275, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kvuazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1330275
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1330275

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      899 UGAACGCCCAACAGCA 916
      |||:|:|:|:|:|:|
Db      1 UGAACGAUCCACAGCA 18

RESULT 1561
US-10-310-914A-1350954/C
; Sequence 1350954, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kvuazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1350954
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1350954

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 9e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      1170 GGUGCCUGAGAGAGCU 1187
      ||:|:|:|:|:|:|
Db      18 GGUGCGTGAAGAGAGCT 1

RESULT 1562
US-09-877-478-1752/C
; Sequence 1752, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
```

```
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MEH00-845-H (400/029)
; CURRENT FILING DATE: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1806
; LENGTH: 17
; TYPE: RNA

QY      1527 CAUGGUCUGUGAAC 1542
      ||:|:|:|:|:|
Db      16 CATGGCTGTGTGAAC 1

RESULT 1563
US-09-877-478-1806
; Sequence 1806, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwigen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MEH00-845-H (400/029)
; CURRENT FILING DATE: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1806
; LENGTH: 17
; TYPE: RNA

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 8.8e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```



```
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-1752

Query Match
Best Local Similarity 0.8%; Score 14.4; DB 1; Length 17;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1527 CAUGGUCUGUGAAC 1542
DB 16 CATGCTGCTGCTGAAC 1

RESULT 1567
US-10-669-841-1806
; Sequence 1806, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Lawrence, Blate
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
; FILE REFERENCE: 400/042US (MEH802-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1806
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-1806

Query Match
Best Local Similarity 0.8%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1501 AUCAUCAUCUGAGCC 1516
DB 2 AUCAUCAUCUGAGCC 17

RESULT 1568
US-10-310-914A-35633/C
; Sequence 35633, Application US/10310914A

; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 35633
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-35633

Query Match
Best Local Similarity 0.8%; Score 14.4; DB 1; Length 17;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 786 CAAAGAGCTUGCUGGC 801
DB 17 CAAAGAGCTTCTCGGC 2

RESULT 1569
US-10-109-349A-43
; Sequence 43, Application US/10109349A
; Publication No. US20030186246A1
; GENERAL INFORMATION:
; APPLICANT: Medical College of Ohio
; APPLICANT: Willey, James C.
; APPLICANT: Crawford, Erin L.
; TITLE OF INVENTION: MULTIPLEX STANDARDIZED REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REA
; FILE REFERENCE: 01154/2001-203
; CURRENT APPLICATION NUMBER: US/10/109,349A
; CURRENT FILING DATE: 2002-06-12
; NUMBER OF SEQ ID NOS: 282
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 43
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-109-349A-43

Query Match
Best Local Similarity 0.8%; Score 14.4; DB 1; Length 18;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1221 GCTGCAGGCCGAGAG 1236
DB 1 GCTGCAGGCCGCTGAAG 16

RESULT 1570
US-10-310-914A-87407/C
; Sequence 87407, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 87407
; LENGTH: 18
; TYPE: RNA
```

```
; ORGANISM: Human
US-10-310-914A-87407

Query Match
Best Local Similarity 93.8%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 817 ACAGAGCAGACAGACAG 832
   |||||
Db 16 ACAGAGCAGACAGACAG 1

RESULT 1571
US-10-310-914A-96132
; Sequence 96132, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kiyat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 96132
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-96132

Query Match
Best Local Similarity 93.8%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1413 CAGAAGUCAGAUCACT 1428
   |||||
Db 2 CAGAAGUCAGAUCACT 17

RESULT 1572
US-10-310-914A-157781/C
; Sequence 157781, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kiyat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 157781
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-157781

Query Match
Best Local Similarity 93.8%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 820 GAGGACGACGACGACAA 835
   |||||
Db 18 GAGGACGACGACGACAA 3

RESULT 1573
US-10-310-914A-178689
; Sequence 178689, Application US/10310914A

; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kiyat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 178689
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-178689

Query Match
Best Local Similarity 93.8%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1183 GAGCTGGGGAGUGG 1198
   |||||
Db 2 GAGCTGGGGAGUGG 17

RESULT 1574
US-10-310-914A-184112/C
; Sequence 184112, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kiyat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 184112
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-184112

Query Match
Best Local Similarity 75.0%; Score 14.4; DB 1; Length 18;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1017 CAUAGAUGGUGGCGC 1032
   |||||
Db 17 CAUAGAUGGUGGCGC 2

RESULT 1575
US-10-310-914A-193360/C
; Sequence 193360, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kiyat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 193360
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-193360
```

US-10-310-914A-193360

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 9.7e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 885 UCAACAGCAAGCAUG 900
DB 17 TCAACAGCAAGCTTG 2

RESULT 1576

US-10-310-914A-298526
; Sequence 298526, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 298526
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-298526

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 9.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1177 GAGGAGAGCTGGGGA 1192
DB 2 GAGGCGGAGCTGGGGA 17

RESULT 1577

US-10-310-914A-412825
; Sequence 412825, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 412825
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-412825

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 9.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1469 CCCAGAGCCGACGUC 1484
DB 3 CCCAGGCCGACGUC 18

RESULT 1578

US-10-310-914A-438320/c
; Sequence 438320, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 438320
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-438320

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 9.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 816 GACAGAGCAGAGACA 831
DB 16 GACAGAGCAGAGACA 1

RESULT 1579

US-10-310-914A-481091
; Sequence 481091, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 481091
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-481091

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 9.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1465 GGGGCCGAGCCGCA 1480
DB 1 GAGGCCGAGCCGCA 16

RESULT 1580

US-10-310-914A-504610
; Sequence 504610, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kiyazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 504610
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-504610

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 9.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1183 GAGCUCGGGAGUGUG 1198
|||||
DB 1 GAGCUCGGGAGUGUG 16

RESULT 1581

US-10-310-914A-517275
; Sequence 517275, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 517275
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-517275

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 9.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1034 CCCUGAGAACTCCGC 1049
|||||
DB 2 CCCUGAGAACTCCGC 17

RESULT 1582

US-10-310-914A-518000
; Sequence 518000, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 518000
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-518000

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 9.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1466 CCGCCGAGACCCUCAG 1481
|||||
DB 2 CUGCCGAGACCCUCAG 17

RESULT 1583

US-10-310-914A-537429/C
; Sequence 537429, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 537429
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-537429

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 68.8%; Pred. No. 9.7e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1188 GGGAGUGGAGCUCUG 1203
|||||
DB 16 GGGAGUGGAGCUCUG 1

RESULT 1584

US-10-310-914A-600496
; Sequence 600496, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 600496
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-600496

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 9.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1307 ACACAGCUNAAGACUUC 1322
|||||
DB 3 ACACAGCUNAAGACUUC 18

RESULT 1585

US-10-310-914A-689772
; Sequence 689772, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 689772
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-689772

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 9.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 818 CAGAGGACAGACAGA 833
|||
Db 3 CAGAGGACAGACAGA 18

RESULT 1586

US-10-310-914A-703052/C
; Sequence 703052, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kvuazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 703052
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-703052

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 68.8%; Pred. No. 9.7e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1674 GCUCGUCGACAGUGU 1689
|||
Db 18 GCTGCTGCCCACTGT 3

RESULT 1587

US-10-310-914A-724939
; Sequence 724939, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kvuazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 724939
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-724939

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 9.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 813 UGGAGACAGGACAGAG 828
|||
Db 1 UGGAGACAGGACAGAG 16

RESULT 1588

US-10-310-914A-743634/C
; Sequence 743634, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac

; APPLICANT: Shlier, Kvuazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 743634
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-743634

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 9.7e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1196 UGACUCUGAGAGGAA 1211
:|
Db 18 TGGACCTGGAGAGGAA 3

RESULT 1589

US-10-310-914A-750829/C
; Sequence 750829, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kvuazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 750829
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-750829

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 9.7e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1176 UGAGAGAGACUGCGG 1191
:|
Db 17 TGGGAGAGAGCTGGCG 2

RESULT 1590

US-10-310-914A-864924/C
; Sequence 864924, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shlier, Kvuazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 864924
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-864924

Query Match 0.8%; Score 14.4; DB 1; Length 18;

Best Local Similarity 81.2%; Pred. No. 9.7e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0.

RESULT 1591
US-10-310-914A-866395/c
; Sequence 866395, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

```

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
;
; TITLE OF INVENTION: uses thereof
;
; FILE REFERENCE: 06087.0200.CPUS01
;
; CURRENT APPLICATION NUMBER: US/10/310,914A
;
; CURRENT FILING DATE: 2002-12-06
;
; NUMBER OF SEQ ID NOS: 1388402
;
; SOFTWARE: PatentIn version 3.3
;
; SEQ ID NO 866395

```

```

; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-866395

```

Query Match	0.8%;	Score 14.4;	DB 1;	Length 18;
Best Local Similarity	87.5%;	Pred. No. 9.7e+02;		
Matches 14; Conservative	1;	Mismatches 1;	Indels 0;	Gaps 0;

```

QY      1450 GUC AAGGAG AAGAAG 1465
          ||:|||||
Db      16   GTC AAGGAG AAAAAAG 1

```

RESULT 1592
US-10-310-914A-923103/C
; Sequence 923103, Application US/10310914A
; Publication No. US20060003322A1

```

1  TITLE OF INVENTION: Biochemically detectable group of novel regulatory genes and
2
3  TITLE OF INVENTION: Uses thereof
4  FILE REFERENCE: 06087, 0200, CUS01
5  CURRENT APPLICATION NUMBER: US/10/310,914A
6  CURRENT FILING DATE: 2002-12-06
7  NUMBER OF SEQ ID NOS: 1388402
8
9  SOFTWARE: PatentIn version 3.3
10
11 SEQ ID NO 923103

```

ORGANISM: Human
US-10-310-914A-923103

Query Match	0.8%	Score 14.4;	DB 1;	Length 18;
Best Local Similarity	93.8%	Pred. No. 9.7e+02;		
Matches 15; Conservative	0;	Mismatches 1;	Indels 0;	Gaps 0;

```

Qy      816 GACAGAGGCAGAGACA 831
          | | | | | | | | | |
Db      16  GGCAGAGGCAGAGACA 1

```

RESULT 1593
US-10-310-914A-1115480/C
Sequence 1115480, Application US/10310914A
Publication No. US2006000332A1
GENERAL INFORMATION:
APPLICANT: Bentwich, Isaac
APPLICANT: Shlier, Kivlat

```

: TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
: TITLE OF INVENTION: uses thereof
: FILE REFERENCE: 06087.0200.CPUS01
: CURRENT APPLICATION NUMBER: US/10/310,914A
: CURRENT FILING DATE: 2002-12-06
: NUMBER OF SEQ ID NOS: 1388402
: SOFTWARE: PatentIn version 3.3
: SEQ ID NO 115480
: LENGTH: 18
: TYPE: RNA
: ORGANISM: Human
: US-10-310-914A-1115480

```

Query Match	0.8%	Score 14.4;	DB 1;	length 18;
Best Local Similarity	87.5%;	Pred. No. 9.7e+02;		
Matches 14; Conservative	1;	Mismatches 1;	Indels 0;	Gaps 0;

QY	954	GAGCTGGAAACCCAGC	965
		:	
Db	18	GAGCTGGAACCGAGC	3

RESULT 1594
US-10-310-914A-1192870/c
; Sequence 1192870, Application US/10310914A
; Publication No. US20060003322A1
Comment: INFORMATION

```

? TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
? TITLE OF INVENTION: uses thereof
? FILE REFERENCE: 06087.0200.CPUS01
? CURRENT APPLICATION NUMBER: US/10/310,914A
? CURRENT FILING DATE: 2002-12-06
? NUMBER OF SEQ ID NOS: 1388402
? SOFTWARE: PatentIn version 3.3
? SEQ ID NO 1192870
? LENGTH: 18
? TYPE: RNA
? ORGANISM: Human
? US-10-310-914A-1192870

```

Query Match	0.8%	Score 14.4;	DB 1;	Length 18;
Best Local Similarity	87.5%;	Pred. No. 9.7e+02;		
Matches 14; Conservative	1;	Mismatches 1;	Indels 0;	Gaps 0;

```

Qy      1114 CCGGUCACAGCACCA 1129
          |||||:||||| |||
Db      17   CCGGTCACAGAACCA 2

```

```

RESULT 1595
US-10-310-914A-1225415
; Sequence 1225415, Application US/10310914A
; Publication No. US2006000322A1
; GENERAL INFORMATION:

```

```

? TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
?
? TITLE OF INVENTION: use thereof
?
? FILE REFERENCE: 06087 0200.CPUS01
?
? CURRENT APPLICATION NUMBER: US/10/310,914A
?
? CURRENT FILING DATE: 2002-12-06
?
? NUMBER OF SEQ ID NOS: 1388402
?
? SOFTWARE: PatentIn version 3.3
?
? SEQ ID NO 1225415
?
? LENGTH: 18
?

```

ORGANISM: Human
US-10-310-914A-1225415

Query Match	0.88;	Score 14.4;	DB 1;	Length 18;
Best Local Similarity	93.88;	Pred. No. 9.7e+02;		

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1183 GAGCUGGGGAGUGUG 1198
 |||||:|||||
 DB 1 GAGCUGGGGAGUGUG 16

RESULT 1596
 US-10-310-914A-1258988/c
 ; Sequence 1258988, Application US/10310914A
 ; Publication No. US20060003322A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bentwich, Isaac
 ; APPLICANT: Shiller, Kivuzat
 ; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
 ; FILE REFERENCE: 06087.0200.CPUS01
 ; CURRENT APPLICATION NUMBER: US/10/310,914A
 ; CURRENT FILING DATE: 2002-12-06
 ; NUMBER OF SEQ ID NOS: 1388402
 ; SOFTWARE: PatentIn version 3.3
 ; SEQ ID NO 1258988
 ; LENGTH: 18
 ; TYPE: RNA
 ; ORGANISM: Human
 US-10-310-914A-1258988

Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 9.7e+02;
 Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1114 CCGGGUCACAGACCA 1129
 |||||:|||||
 DB 17 CCGGGTCACAGACCA 2

RESULT 1597
 US-10-310-914A-1364456
 ; Sequence 1364456, Application US/10310914A
 ; Publication No. US20060003322A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bentwich, Isaac
 ; APPLICANT: Shiller, Kivuzat
 ; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
 ; FILE REFERENCE: 06087.0200.CPUS01
 ; CURRENT APPLICATION NUMBER: US/10/310,914A
 ; CURRENT FILING DATE: 2002-12-06
 ; NUMBER OF SEQ ID NOS: 1388402
 ; SOFTWARE: PatentIn version 3.3
 ; SEQ ID NO 1364456
 ; LENGTH: 18
 ; TYPE: RNA
 ; ORGANISM: Human
 US-10-310-914A-1364456

Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 9.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1183 GAGCUGGGGAGUGUG 1198
 |||||:|||||
 DB 1 GAGCUGGGGAGUGUG 16

RESULT 1598
 US-10-310-914A-1385854/c
 ; Sequence 1385854, Application US/10310914A
 ; Publication No. US20060003322A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bentwich, Isaac
 ; APPLICANT: Shiller, Kivuzat
 ; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof
 ; FILE REFERENCE: 06087.0200.CPUS01
 ; CURRENT APPLICATION NUMBER: US/10/310,914A
 ; CURRENT FILING DATE: 2002-12-06
 ; NUMBER OF SEQ ID NOS: 1388402
 ; SOFTWARE: PatentIn version 3.3
 ; SEQ ID NO 1385854
 ; LENGTH: 18
 ; TYPE: RNA
 ; ORGANISM: Human
 US-10-310-914A-1385854

Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 9.7e+02;
 Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1114 CCGGGUCACAGACCA 1129
 |||||:|||||
 DB 17 CCGGGTCACAGACCA 2

RESULT 1599
 US-11-085-775-60/c
 ; Sequence 60, Application US/11085775
 ; Publication No. US20050260634A1
 ; GENERAL INFORMATION:
 ; APPLICANT: BALDWIN, DARYL
 ; APPLICANT: CLARK, HILARY
 ; APPLICANT: JUEB, ADRIAN
 ; APPLICANT: KOEPPEN, HARTMUT
 ; APPLICANT: QUAN, CLIFFORD
 ; APPLICANT: WU, THOMAS
 ; APPLICANT: ZHANG, ZEMIN
 ; TITLE OF INVENTION: ACHAETE-SCUTE LIKE-2 POLYPEPTIDES AND ENCODING NUCLEIC
 ; FILE REFERENCE: P5028R1P1-US
 ; CURRENT APPLICATION NUMBER: US/11/085,775
 ; CURRENT FILING DATE: 2005-03-21
 ; PRIOR APPLICATION NUMBER: PCT/US03/17682
 ; PRIOR FILING DATE: 2003-06-04
 ; PRIOR APPLICATION NUMBER: US 10/454,945
 ; PRIOR FILING DATE: 2003-06-04
 ; PRIOR APPLICATION NUMBER: US 60/407,087
 ; PRIOR FILING DATE: 2002-08-29
 ; NUMBER OF SEQ ID NOS: 78
 ; SEQ ID NO 60
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-11-085-775-60

Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 81.2%; Pred. No. 9.7e+02;
 Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1051 UCCUCCGAGAGAGG 1066
 :||:|||||
 DB 17 TCCTCCGACGAGTAGG 2

RESULT 1600
 US-10-310-914A-605977
 ; Sequence 605977, Application US/10310914A
 ; Publication No. US20060003322A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bentwich, Isaac
 ; APPLICANT: Shiller, Kivuzat
 ; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
 ; FILE REFERENCE: 06087.0200.CPUS01
 ; CURRENT APPLICATION NUMBER: US/10/310,914A
 ; CURRENT FILING DATE: 2002-12-06
 ; NUMBER OF SEQ ID NOS: 1388402

SOFTWARE: PatentIn version 3.3
 SEQ ID NO 605397
 LENGTH: 19
 TYPE: RNA
 ORGANISM: Human
 US-10-310-914A-605397

Query Match 0.8%; Score 14.2; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 1.1e+03;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1125 CACCAUCCUACACUCCACC 1143
 DB 1 CACCCUCCUCCAGCUCACC 19

RESULT 1601
 US-09-864-636A-1705/c
 Sequence 1705, Application US/09864636A
 Publication No. US20030104378A1
 GENERAL INFORMATION:
 APPLICANT: Third Wave Technologies
 APPLICANT: Allwai, Hatim
 APPLICANT: Bartholomay, Christian
 APPLICANT: Chenak, LuAnne
 TITLE OF INVENTION: Detection of RNA Sequences
 FILE REFERENCE: FORS-04944
 CURRENT APPLICATION NUMBER: US/09/864,636A
 CURRENT FILING DATE: 2002-10-15
 NUMBER OF SEQ ID NOS: 2640
 SOFTWARE: PatentIn version 3.0
 SEQ ID NO 1705
 LENGTH: 17
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthetic
 US-09-864-636A-1705

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 50.0%; Pred. No. 9.5e+02;
 Matches 7; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 26 CCUCGCCUUGUUU 39
 DB 15 CCTCGCCTTGT 2

RESULT 1602
 US-09-864-426A-1705/c
 Sequence 1705, Application US/09864426A
 Publication No. US20040018489A1
 GENERAL INFORMATION:
 APPLICANT: Third Wave Technologies
 APPLICANT: Ma, Wu Po
 APPLICANT: Lyamichev, Victor
 APPLICANT: Saiser, Michael
 TITLE OF INVENTION: Enzymes for the Detection of RNA Sequences
 FILE REFERENCE: FORS-04946
 CURRENT APPLICATION NUMBER: US/09/864,426A
 CURRENT FILING DATE: 2001-05-24
 NUMBER OF SEQ ID NOS: 2640
 SOFTWARE: PatentIn version 3.0
 SEQ ID NO 1705
 LENGTH: 17
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthetic
 US-09-864-426A-1705

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 50.0%; Pred. No. 9.5e+02;

Matches 7; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
 QY 26 CCUCGCCUUGUUU 39
 DB 15 CCTCGCCTTGT 2

RESULT 1603
 US-10-084-839-1705/c
 Sequence 1705, Application US/10084839
 Publication No. US20030186238A1
 GENERAL INFORMATION:
 APPLICANT: Third Wave Technologies
 APPLICANT: Allwai, Hatim
 APPLICANT: Argue, Brad T.
 APPLICANT: Bartholomay, Christian T.
 APPLICANT: Chenak, LuAnne
 APPLICANT: Curtis, Michelle L.
 APPLICANT: Eis, Peggy S.
 APPLICANT: Hall, Jeff G.
 APPLICANT: Ip, Hon S.
 APPLICANT: Kaiser, Michael
 APPLICANT: Kwiatkowski, Jr., Robert W.
 APPLICANT: Lukowiak, Andrew A.
 APPLICANT: Lyamichev, Victor
 APPLICANT: Ma, WuPo
 APPLICANT: Neri, Bruce P.
 APPLICANT: Olson, Sarah M.
 APPLICANT: Olson-Munoz, Marilyn C.
 APPLICANT: Schaefer, James J.
 APPLICANT: Skrzypczynski, Zbigniew
 APPLICANT: Takova, Tsetska Y.
 APPLICANT: Thompson, Lisa C.
 APPLICANT: Vedvik, Kevin L.
 TITLE OF INVENTION: RNA Detection Assays
 FILE REFERENCE: FORS-06666
 CURRENT APPLICATION NUMBER: US/10/084,839
 CURRENT FILING DATE: 2002-02-26
 NUMBER OF SEQ ID NOS: 4004
 SOFTWARE: PatentIn version 3.1
 SEQ ID NO 1705
 LENGTH: 17
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Synthetic
 US-10-084-839-1705

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 50.0%; Pred. No. 9.5e+02;
 Matches 7; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 26 CCUCGCCUUGUUU 39
 DB 15 CCTCGCCTTGT 2

RESULT 1604
 US-10-084-839-3966/c
 Sequence 3966, Application US/10084839
 Publication No. US20030186238A1
 GENERAL INFORMATION:
 APPLICANT: Third Wave Technologies
 APPLICANT: Allwai, Hatim
 APPLICANT: Argue, Brad T.
 APPLICANT: Bartholomay, Christian T.
 APPLICANT: Chenak, LuAnne
 APPLICANT: Curtis, Michelle L.
 APPLICANT: Eis, Peggy S.
 APPLICANT: Hall, Jeff G.
 APPLICANT: Ip, Hon S.

```

; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichiev, Victor
; APPLICANT: Lymaicheva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tsetska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 3966
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-3966

```

```

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 9.5e+02;
Matches 7; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      26 CCUGCCCUUGUUU 39
      ||:|||||:|:|:|
DB      15 CCTGCCCTTGT 2

```

```

RESULT 1605
US-10-084-839-3981/c
; Sequence 3981, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Alilawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: ID, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichiev, Victor
; APPLICANT: Lymaicheva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tsetska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: Patentin version 3.1

```

```

; SEQ ID NO 3981
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-3981

```

```

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 9.5e+02;
Matches 7; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      26 CCUGCCCUUGUUU 39
      ||:|||||:|:|:|
DB      15 CCTGCCCTTGT 2

```

```

RESULT 1606
US-10-374-466-84
; Sequence 84, Application US/10374466
; Publication No. US20040091865A1
; GENERAL INFORMATION:
; APPLICANT: Pangene Corporation
; TITLE OF INVENTION: The Use of Consensus Sequences for Targeted Homologous
; FILE REFERENCE: A-65678-1/RFT/NBC
; CURRENT APPLICATION NUMBER: US/10/374,466
; CURRENT FILING DATE: 2004-02-24
; PRIOR APPLICATION NUMBER: US/09/209,676
; PRIOR FILING DATE: 2002-06-18
; PRIOR APPLICATION NUMBER: US 60/070,734
; PRIOR FILING DATE: 1997-12-11
; NUMBER OF SEQ ID NOS: 95
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 84
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: MISC_FEATURE
; LOCATION: (3)
; OTHER INFORMATION: "n" at position 3 can be any base.
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-10-374-466-84

```

```

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 35.3%; Pred. No. 9.5e+02;
Matches 6; Conservative 10; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      304 GUCAACACUACUCCU 320
      |:|:|:|:|:|:|:|:|
DB      1 GTMAAAYATAYTYYT 17

```

```

RESULT 1607
US-09-801-274-1145/c
; Sequence 1145, Application US/09801274
; Patent No. US20020032319A1
; GENERAL INFORMATION:
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Iander, Eric S.
; TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
; FILE REFERENCE: 2825.2009-001
; CURRENT APPLICATION NUMBER: US/09/801,274
; CURRENT FILING DATE: 2001-03-07
; PRIOR APPLICATION NUMBER: US 60/187,510
; PRIOR FILING DATE: 2000-03-07
; PRIOR APPLICATION NUMBER: US 60/206,129
; PRIOR FILING DATE: 2000-05-22
; NUMBER OF SEQ ID NOS: 1802
; SOFTWARE: FastSeq for windows Version 4.0

```

Fri Jun 30 14:07:10 2006

US10798090A-305.rnpbm.s1

Page 511

```
; SEQ ID NO 1145
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-801-274-1145
```

Query Match	0.8%	Score 14;	DB 1;	Length 31;
Best Local Similarity	53.3%	Pred. No. 1.7e+03;		
Matches 16; Conservative	4;	Mismatches 10;	Indels 0;	Gaps 0;

```

OY      995 GCAGCAGUCACAGUTGGACACCAUAUG 1024
          ||||| : ||| | : : |
Db      30  GCAGCAATGGCAGTSCCAAAGTATGTTG 1

```

Search completed: June 30, 2006, 14:02:24
Job time : 40 secs

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 30, 2006, 14:05:15 ; Search time 0.001 Seconds
(without alignments)
244.674 Million cell updates/sec

Title: US-10-798-090A-305

Perfect score: 1773

Sequence: 1 augaccuugcacaauaacag.....cacccagcagcucugugag 1773

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 4 seqs, 69 residues

Total number of hits satisfying chosen parameters: 8

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 5 summaries

Database : rnpbn.subdb.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result	No.	Score	Query	Match	Length	DB	ID	Description
	C 1	16.8	0.9	20	1	US-10-511-937-788		Sequence 788, App
	2	13.8	0.8	17	1	US-10-514-776-192		Sequence 192, App
	3	13.8	0.8	17	1	US-10-559-415-171		Sequence 171, App
	C 4	12	0.7	15	1	US-10-567-072-31		Sequence 31, App1
	5	11.8	0.7	20	1	US-10-511-937-788		Sequence 788, App

ALIGNMENTS

RESULT 1
US-10-511-937-788/C
; Sequence 788, Application US/10511937
; Publication No. US20060088836A1
; GENERAL INFORMATION:
; APPLICANT: EXPRESSION DIAGNOSTICS, INC.
; APPLICANT: Wohlgemuth, Jay
; APPLICANT: Fry, Kirk
; APPLICANT: Woodward, Robert
; APPLICANT: Ly, Ngoc
; APPLICANT: Prentice, James
; APPLICANT: Morris, Macdonald
; APPLICANT: Rosenberg, Steven
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING
; TITLE OF INVENTION: AND MONITORING TRANSPLANT REJECTION
; FILE REFERENCE: 506612000104
; CURRENT APPLICATION NUMBER: US/10/511,937
; PRIOR FILING DATE: 2004-10-19
; PRIOR APPLICATION NUMBER: PCT/US2003/012946
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/131,831
; PRIOR FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: US 10/325,899

; PRIOR FILING DATE: 2002-12-20
; NUMBER OF SEQ ID NOS: 3117
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 788
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-511-937-788

Query Match 0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 75.0%; Pred. No. 0.34;
Matches 15; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 148 UCCUCUCGACGCGUACGAC 167
DB 20 TCCTCTCCAGAGGACGAC 1

RESULT 2

US-10-514-776-192

; Sequence 192, Application US/10514776

; Publication No. US20060094008A1

; GENERAL INFORMATION:

; APPLICANT: Symex Corporation

; TITLE OF INVENTION: CK primer

; FILE REFERENCE: GP03-1006PCT

; CURRENT APPLICATION NUMBER: US/10/514,776

; PRIOR FILING DATE: 2004-11-19

; PRIOR APPLICATION NUMBER: JP P2002-145689

; PRIOR FILING DATE: 2002-05-21

; PRIOR APPLICATION NUMBER: JP P2002-175271

; PRIOR FILING DATE: 2002-06-17

; PRIOR APPLICATION NUMBER: JP P2002-199759

; PRIOR FILING DATE: 2002-07-09

; NUMBER OF SEQ ID NOS: 474

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 192

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Artificial

; FEATURE: OTHER INFORMATION: Designed DNA based on CK18

US-10-514-776-192

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.4;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 853 GGCAGUCUCGAGCGUG 869
DB 1 GGCTGTTCTCCAAGCTG 17

RESULT 3

US-10-559-415-171

; Sequence 171, Application US/10559415

; Publication No. US2006010032A1

; GENERAL INFORMATION:

; APPLICANT: AstraZeneca AB et al

; TITLE OF INVENTION: Diagnostic Method

; FILE REFERENCE: 101073-1P WO

; CURRENT APPLICATION NUMBER: US/10/559,415

; PRIOR FILING DATE: 2005-12-06

; PRIOR APPLICATION NUMBER: 0313081.2

; PRIOR FILING DATE: 2003-06-06

; NUMBER OF SEQ ID NOS: 191

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 171

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-559-415-171

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.4;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 325 AGCCUGCCUGGCCGA 341
|||:||||:
DB 1 AGCCTGCCCTTGC CGA 17

RESULT 4

US-10-567-072-31/c
; Sequence 31, Application US/10567072
; Publication No. US20060134792A1
; GENERAL INFORMATION:
; APPLICANT: Kim, Cheol-Min
; APPLICANT: Park, Hee-Kyung
; APPLICANT: Cho, Mong
; APPLICANT: Jang, Hyun-Jung
; APPLICANT: Heo, Jeong
; TITLE OF INVENTION: Microarray Comprising Probes for Drug-Resistant Hepatitis B Virus
; TITLE OF INVENTION: Detection, Quality Control and Negative Control, and Method for
; TITLE OF INVENTION: Detecting Drug-Resistant Hepatitis B Virus Using the Same
; FILE REFERENCE: 50413/011001
; CURRENT APPLICATION NUMBER: US/10/567,072
; PRIOR FILING DATE: 2006-02-03
; PRIOR APPLICATION NUMBER: PCT/KR2004/001940
; PRIOR FILING DATE: 2004-08-02
; PRIOR APPLICATION NUMBER: 2003-0054204
; PRIOR FILING DATE: 2003-08-05
; NUMBER OF SEQ ID NOS: 83
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 31
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 548WV2 probe
US-10-567-072-31

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 3.2;
Matches 11; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1405 CUGAGACCGAGA 1416
|:|||||:
DB 14 CTGAAGACCGAGA 3

RESULT 5

US-10-511-937-788
; Sequence 788, Application US/10511937
; Publication No. US2006008836A1
; GENERAL INFORMATION:
; APPLICANT: EXPRESSION DIAGNOSTICS, INC.
; APPLICANT: Wohlgenuth, Jay
; APPLICANT: Fry, Kirk
; APPLICANT: Woodward, Robert
; APPLICANT: Ly, Ngoc
; APPLICANT: Prentice, James
; APPLICANT: Morris, MacDonald
; APPLICANT: Rosenberg, Steven
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING
; TITLE OF INVENTION: AND MONITORING TRANSPLANT REJECTION
; FILE REFERENCE: 506612000104
; CURRENT APPLICATION NUMBER: US/10/511,937
; CURRENT FILING DATE: 2004-10-19
; PRIOR APPLICATION NUMBER: PCT/US2003/012946
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/131,831
; PRIOR FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: US 10/325,899
; PRIOR FILING DATE: 2002-12-20
; NUMBER OF SEQ ID NOS: 3117

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 788

; LENGTH: 20

; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-511-937-788

Query Match 0.7%; Score 11.8; DB 1; Length 20;
Best Local Similarity 73.3%; Pred. No. 2.5;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 646 GUGCCUGCCGAGAG 660
|:|||||:
DB 4 GTGCCTTCGAGAG 18

Search completed: June 30, 2006, 14:05:15
Job time : 0.001 secs

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 30, 2006, 14:06:58 ; Search time 0.001 Seconds
(without alignments)
117.018 Million cell updates/sec

Title: US-10-798-090A-305

Perfect score: 1773
Sequence: 1 augaccuugcacaauaacag.....cacccgagcagcucuuag 1773

Scoring table: IDENTITY NUC
Gapop 10_0 , Gapext 0.5

Searched: 2 segs, 33 residues

Total number of hits satisfying chosen parameters: 4

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 3 summaries

Database : ret.subdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	14.4	0.8	18	1	AM249853
C 2	13.4	0.8	15	1	AM249689
3	9	0.5	15	1	AM249689

ALIGNMENTS

RESULT 1
AM249853 18 bp mRNA linear EST 07-JAN-2000
LOCUS 2821520.3prime NIH_MGC_7 Homo sapiens cDNA clone IMAGE:2821520 3',
DEFINITION mRNA sequence.
ACCESSION AM249853
VERSION AM249853.1 GI:6592846
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homiidae; Homo.
1 (bases 1 to 18)
NIH-MGC http://mgi.nci.nih.gov/.
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)
Other ESTs: 2821520.5prime
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: DCTD/DRP cDNA Library Preparation: Ling
Hong/Rubin Laboratory cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL) DNA Sequencing by: Berkeley MGC sequencing
Project Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNL at:

www.bio.lnl.gov/bdrp/image/image.html Base Calling / Quality
Scores: PHRED from University of Washington Genome Center. Vector
Trimming: cross match from University of Washington Genome Center
PHRAP suite. Poly-T identification: patmatch.pl from Berkeley
Protophila Genome Project. University of Washington Genome Center:
http://www.genome.washington.edu Low Quality Sequence: 0 contiguous
PHRED high quality bases following vector sequence. Very Low
Quality Sequence: Trace file contained 18 contiguous distinct peaks
following vector sequence. Polyadenylation: Based upon the presence
of a XhoI site followed by a run of 14 or more T residues at the
beginning of the sequence, this cDNA insert was polyadenylated.
Plate: LICM7 row: A column: 9.
Location/Qualifiers
1. 18
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:2821520"
/tissue_type="small cell carcinoma"
/cell_line="MGC3"
/lab_host="DH10B (phage-resistant)"
/note="Organ: lung; Vector: pOTB7; Site 1: XhoI; Site 2:
EcoRI; cDNA made by oligo-dT priming. Directionally
cloned into EcoRI/XhoI sites using the following 5'
adapter: GGCAAGAG(G). Size-selected >500bp for average
insert size 1.8kb. Library constructed by Ling Hong in
the laboratory of Gerald M. Rubin (University of
California, Berkeley) using ZAP-cDNA synthesis kit
(Stratagene) and Superscript II RT (Life technologies)."

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 0;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1685 AGTGTGACAAAAAAA 1700
DB 16 AGTGTGAAAAAAA 1

RESULT 2
AM249689 15 bp mRNA linear EST 07-JAN-2000
LOCUS 2819706.3prime NIH_MGC_7 Homo sapiens cDNA clone IMAGE:2819706 3',
DEFINITION mRNA sequence.
ACCESSION AM249689
VERSION AM249689.1 GI:6592682
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homiidae; Homo.
1 (bases 1 to 15)
NIH-MGC http://mgi.nci.nih.gov/.
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)
Other ESTs: 2819706.5prime
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: DCTD/DRP cDNA Library Preparation: Ling
Hong/Rubin Laboratory cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL) DNA Sequencing by: Berkeley MGC sequencing
Project Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNL at:
www.bio.lnl.gov/bdrp/image/image.html Base Calling / Quality
Scores: PHRED from University of Washington Genome Center. Vector
Trimming: cross match from University of Washington Genome Center
PHRAP suite. Poly-T identification: patmatch.pl from Berkeley
Protophila Genome Project. University of Washington Genome Center:
http://www.genome.washington.edu Low Quality Sequence: 13
contiguous PHRED high quality bases following vector sequence. Very
Low Quality Sequence: Trace file contained 15 contiguous distinct

peaks following vector sequence. Polyadenylation: Based upon the presence of a XhoI site followed by a run of 14 or more T residues at the beginning of the sequence, this cDNA insert was polyadenylated.

Plate: L1CM2 row: E column: 19
High quality sequence stop: 13.

FEATURES

source

1..15
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:2819706"
/issue_type="small cell carcinoma"
/cell_line="MGC3"
/lab_host="DH10B (phage-resistant)"
/note="Organ: lung; Vector: pOTB7; Site 1: XhoI; Site 2: EcoRI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGCAACGAG(G). Size-selected >500bp for average insert size 1.8kb. Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies)."

Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 0;

Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1686 GUGUCACAAAAAAA 1700

Db 15 GTGTGAAAAAAA 1

RESULT 3

AW249689

LOCUS 2819706.3prime NIH_MGC_7 Homo sapiens cDNA clone IMAGE:2819706 3',
DEFINITION mRNA sequence.

ACCESSION

AW249689

VERSION

KEYWORDS

SOURCE

ORGANISM

Homo sapiens (human)

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;

Hominiidae; Homo.

1 (bases 1 to 15)

NIH-MGC http://mgs.nci.nih.gov/

National Institutes of Health, Mammalian Gene Collection (MGC)

Unpublished (1999)

Other ESTs: 2819706.5prime

Contact: Robert Strausberg, Ph.D.

Email: cgaabs-r@mail.nih.gov

Tissue Procurement: DCTD/DTF cDNA Library Preparation: Ling

Hong/Rubin laboratory cDNA Library Arrayed by: The I.M.A.G.E.

Consortium (LIM) DNA Sequencing by: Berkeley MGC sequencing

Project Clone distribution: MGC clone distribution information can

be found through the I.M.A.G.E. Consortium/LIM at:

www.bio.11nl.gov/btrp/image/image.html Base Calling / Quality

Scores: PHRED from University of Washington Genome Center. Vector

Trimming: cross match from University of Washington Genome Center

PHRAP suite. Poly-T Identification: patmatch.pl from Berkeley

Drosophila Genome Project. University of Washington Genome Center:

http://www.genome.washington.edu Low Quality Sequence: 13

contiguous PHRED high quality bases following vector sequence. Very

low Quality Sequence: Trace file contained 15 contiguous distinct

peaks following vector sequence. Polyadenylation: Based upon the

presence of a XhoI site followed by a run of 14 or more T residues

at the beginning of the sequence, this cDNA insert was

polyadenylated.

Plate: L1CM2 row: E column: 19

High quality sequence stop: 13.

FEATURES

source

Location/Qualifiers
1..15
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:2819706"
/issue_type="small cell carcinoma"
/cell_line="MGC3"
/lab_host="DH10B (phage-resistant)"
/note="Organ: lung; Vector: pOTB7; Site 1: XhoI; Site 2: EcoRI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGCAACGAG(G). Size-selected >500bp for average insert size 1.8kb. Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies)."

Query Match 0.5%; Score 9; DB 1; Length 15;
Best Local Similarity 44.4%; Pred. No. 0;

Matches 4; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1739 UUUUUCACA 1747

Db 6 TTTTTCACA 14

Search completed: June 30, 2006, 14:06:58
Job time : 0.001 secs

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 30, 2006, 13:55:33 ; Search time 2 seconds
(without alignments)
3.732 Million cell updates/sec

Title: US-10-798-090A-305

Perfect score: 1773
Sequence: 1 augaccuugcacaauacag.....cacccgagcagcucuuag 1773

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 0.5

Searched: 124 segs, 2105 residues

Total number of hits satisfying chosen parameters: 248

Minimum DB seg length: 0
Maximum DB seg length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 128 summaries

Database : rni.subdb:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	32.2	1.8	37	1	US-09-826-509-279
2	32.2	1.8	37	1	US-09-826-509-280
3	27	1.5	27	1	US-08-513-974B-69
4	27	1.5	27	1	US-08-513-974B-182
5	26	1.5	32	1	US-09-826-509-79
6	21.4	1.2	25	1	US-09-396-196C-58455
7	20.2	1.1	25	1	US-09-396-196C-99629
8	20.2	1.1	25	1	US-09-396-196C-115275
9	17	1.0	17	1	US-09-404-912-105
10	16.8	0.9	20	1	US-09-922-146-21
11	16.8	0.9	21	1	US-10-080-794-2
12	16.4	0.9	20	1	US-09-723-368-5
13	16	0.9	20	1	US-09-922-146-22
14	15.4	0.9	18	1	US-08-894-784-13
15	15.4	0.9	18	1	US-08-894-784-32
16	15.4	0.9	18	1	US-08-894-736-7
17	15.4	0.9	18	1	US-08-894-736-17
18	15.4	0.9	19	1	US-09-422-978-6934
19	15.4	0.9	19	1	US-09-422-978-7458
20	15	0.8	18	1	US-09-197-380-27
21	14.8	0.8	18	1	US-09-256-496-26
22	14.6	0.8	18	1	US-09-043-085-17
23	14.6	0.8	18	1	US-09-043-085-41
24	14.4	0.8	17	1	US-08-720-625-7
25	14.4	0.8	18	1	US-09-268-544B-25
26	14.4	0.8	18	1	US-09-475-947A-249
27	14	0.8	17	1	US-09-209-676-84
28	13.8	0.8	17	1	US-08-127-954-39
29	13.8	0.8	17	1	US-08-366-783-15
30	13.8	0.8	17	1	US-08-985-162-262
31	13.8	0.8	17	1	US-08-584-040-4100
32	13.8	0.8	17	1	US-08-584-040-5674
33	13.8	0.8	17	1	US-09-474-432B-647

34	13.8	0.8	17	1	US-09-474-432B-884	Sequence 884, App
35	13.8	0.8	17	1	US-09-371-772B-1867	Sequence 1867, App
36	13.8	0.8	17	1	US-09-476-387-646	Sequence 646, App
37	13.8	0.8	17	1	US-09-476-387-883	Sequence 883, App
38	13.8	0.8	17	1	US-09-401-063-262	Sequence 262, App
39	13.8	0.8	17	1	US-09-827-998-636	Sequence 636, App
40	13.8	0.8	17	1	US-09-866-108A-2301	Sequence 2301, App
41	13.8	0.8	17	1	US-09-404-912-104	Sequence 104, App
42	13.8	0.8	17	1	US-09-404-912-106	Sequence 106, App
43	13.8	0.8	17	1	US-09-685-664B-1867	Sequence 1867, App
44	13.8	0.8	17	1	US-10-156-306B-2310	Sequence 1487, App
45	13.8	0.8	17	1	US-10-156-306B-2310	Sequence 2310, App
46	13.8	0.8	17	1	US-10-138-674B-1867	Sequence 1867, App
47	13.8	0.8	17	1	US-10-138-674B-1867	Sequence 1867, App
48	13.4	0.8	15	1	US-08-585-684B-137	Sequence 137, App
49	13.4	0.8	15	1	US-09-038-073-137	Sequence 137, App
50	13.4	0.8	16	1	US-09-475-947A-60	Sequence 60, App
51	13.2	0.7	37	1	US-09-826-509-279	Sequence 279, App
52	13.2	0.7	37	1	US-09-826-509-280	Sequence 280, App
53	13	0.7	15	1	US-08-311-486C-41	Sequence 41, App
54	13	0.7	15	1	US-08-292-620A-394	Sequence 553, App
55	13	0.7	15	1	US-08-292-620A-394	Sequence 394, App
56	13	0.7	15	1	US-08-292-620A-616	Sequence 616, App
57	13	0.7	15	1	US-09-071-845-394	Sequence 394, App
58	13	0.7	15	1	US-09-071-845-616	Sequence 616, App
59	13	0.7	15	1	US-09-474-432B-97	Sequence 97, App
60	13	0.7	15	1	US-09-476-387-97	Sequence 97, App
61	13	0.7	16	1	US-08-770-235A-54	Sequence 54, App
62	13	0.7	16	1	US-09-479-005A-230	Sequence 230, App
63	12.8	0.7	16	1	US-08-152-313-15	Sequence 15, App
64	12.8	0.7	16	1	US-08-474-177-11	Sequence 21, App
65	12.8	0.7	16	1	US-08-579-223-15	Sequence 15, App
66	12.8	0.7	16	1	US-08-487-033-21	Sequence 21, App
67	12.8	0.7	16	1	US-08-480-810-21	Sequence 21, App
68	12.8	0.7	16	1	US-08-527-060-10	Sequence 10, App
69	12.8	0.7	16	1	US-08-508-735-21	Sequence 21, App
70	12.8	0.7	16	1	US-08-848-251-21	Sequence 21, App
71	12.8	0.7	16	1	US-08-486-047-21	Sequence 21, App
72	12.8	0.7	16	1	US-09-120-130-21	Sequence 21, App
73	12.8	0.7	16	1	US-09-115-252-21	Sequence 21, App
74	12.8	0.7	16	1	US-08-986-515-21	Sequence 21, App
75	12.8	0.7	16	1	US-09-120-128-21	Sequence 21, App
76	12.8	0.7	16	1	US-08-765-340-152	Sequence 152, App
77	12.8	0.7	16	1	US-09-120-129-21	Sequence 21, App
78	12.8	0.7	16	1	US-09-201-139-21	Sequence 21, App
79	12.8	0.7	16	1	US-09-120-131-21	Sequence 21, App
80	12.8	0.7	16	1	US-09-686-791-4136	Sequence 4136, App
81	12.8	0.7	16	1	US-09-686-791-4366	Sequence 4366, App
82	12.8	0.7	16	1	US-09-856-662-17	Sequence 17, App
83	12.8	0.7	16	1	US-09-720-435A-114	Sequence 114, App
84	12.8	0.7	16	1	PCT-US94-12947A-15	Sequence 15, App
85	12.4	0.7	15	1	US-08-291-932A-378	Sequence 378, App
86	12.4	0.7	15	1	US-08-311-486C-251	Sequence 251, App
87	12.4	0.7	15	1	US-08-292-620A-477	Sequence 477, App
88	12.4	0.7	15	1	US-08-292-620A-571	Sequence 571, App
89	12.4	0.7	15	1	US-08-585-684B-2056	Sequence 2056, App
90	12.4	0.7	15	1	US-08-585-684B-2330	Sequence 2330, App
91	12.4	0.7	15	1	US-08-740-821-1	Sequence 11, App
92	12.4	0.7	15	1	US-08-667-939A-11	Sequence 11, App
93	12.4	0.7	15	1	US-08-667-939A-22	Sequence 22, App
94	12.4	0.7	15	1	US-08-577-081A-71	Sequence 71, App
95	12.4	0.7	15	1	US-08-908-643C-80	Sequence 80, App
96	12.4	0.7	15	1	US-09-071-845-477	Sequence 477, App
97	12.4	0.7	15	1	US-09-071-845-571	Sequence 571, App
98	12.4	0.7	15	1	US-09-038-073-2056	Sequence 2056, App
99	12.4	0.7	15	1	US-09-038-073-2330	Sequence 2330, App
100	12.4	0.7	15	1	US-09-081-646-6	Sequence 6, App
101	12.4	0.7	15	1	US-09-081-646-26	Sequence 26, App
102	12.4	0.7	15	1	US-09-081-646-498	Sequence 498, App
103	12.4	0.7	15	1	US-09-081-646-598	Sequence 598, App
104	12.4	0.7	15	1	US-08-433-123-11	Sequence 11, App
105	12.4	0.7	15	1	US-08-433-123-22	Sequence 22, App
106	12.4	0.7	15	1	US-10-134-021-19	Sequence 19, App

```
107 12.2 0.7 17 1 US-10-138-674B-7793 Sequence 7793, App
108 12 0.7 15 1 US-08-435-350-108 Sequence 108, App
109 12 0.7 15 1 US-08-266-414-5 Sequence 5, App1
110 12 0.7 15 1 US-08-291-932A-31 Sequence 31, App1
111 12 0.7 15 1 US-08-291-932A-220 Sequence 220, App
112 12 0.7 15 1 US-08-334-847-497 Sequence 497, App
113 12 0.7 15 1 US-08-334-847-657 Sequence 657, App
114 12 0.7 15 1 US-08-585-684B-1244 Sequence 1244, App
115 12 0.7 15 1 US-08-585-684B-1245 Sequence 1245, App
116 12 0.7 15 1 US-09-191-099-19 Sequence 19, App1
117 12 0.7 15 1 US-09-252-806-4 Sequence 4, App1
118 12 0.7 15 1 US-09-038-073-1244 Sequence 1244, App
119 12 0.7 15 1 US-09-038-073-1245 Sequence 1245, App
120 12 0.7 15 1 US-09-142-779-4 Sequence 4, App1
121 12 0.7 15 1 US-08-943-571-13 Sequence 13, App1
122 12 0.7 15 1 US-09-711-508-4 Sequence 4, App1
123 12 0.7 15 1 US-10-085-871C-10 Sequence 10, App1
124 12 0.7 15 1 US-10-085-871C-11 Sequence 11, App1
125 12 0.7 15 1 US-09-775-818-13 Sequence 13, App1
126 12 0.7 15 1 US-09-648-389A-1 Sequence 1, App1
127 12 0.7 15 1 US-09-341-700A-672 Sequence 672, App
128 11.8 0.7 20 1 US-09-723-368-5 Sequence 5, App1
```

ALIGNMENTS

```
RESULT 1
US-09-826-509-279
; Sequence 279, Application US/09826509
; Patent No. 6806054
; GENERAL INFORMATION:
; APPLICANT: Lehmann-Brunisma, Karin
; APPLICANT: Lin, I-Lin
; TITLE OF INVENTION: No. 6806054-Endogenous, Constitutively Activated Known G
; FILE REFERENCE: AREN-207
; CURRENT FILING DATE: 2001-04-05
; PRIOR FILING DATE: 2000-04-07
; PRIOR FILING DATE: 2000-04-07
; PRIOR APPLICATION NUMBER: 09/170,496
; PRIOR FILING DATE: 1998-10-13
; NUMBER OF SEQ ID NOS: 589
; SOFTWARE: PatentIn Version 2.1
; SEQ ID NO 279
; LENGTH: 37
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-826-509-279

Query Match 1.8%; Score 32.2; DB 1; Length 37;
Best Local Similarity 83.8%; Pred. No. 0.19; 3; Indels 0; Gaps 0;
Matches 31; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1449 GGUCAAGAGAGAAAGCGGCCGAGACCCUCAGUGCG 1485
Db 1 GGTCAAGAGAGAAAGCGAAACAGACCTCAGTGGC 37

RESULT 2
US-09-826-509-280/C
; Sequence 280, Application US/09826509
; Patent No. 6806054
; GENERAL INFORMATION:
; APPLICANT: Lehmann-Brunisma, Karin
; APPLICANT: Lin, Chen W.
; APPLICANT: Lin, I-Lin
; TITLE OF INVENTION: No. 6806054-Endogenous, Constitutively Activated Known G
; FILE REFERENCE: AREN-207
; CURRENT APPLICATION NUMBER: US/09/826,509
```

```
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 60/195,747
; PRIOR FILING DATE: 2000-04-07
; PRIOR APPLICATION NUMBER: 09/170,496
; PRIOR FILING DATE: 1998-10-13
; NUMBER OF SEQ ID NOS: 589
; SOFTWARE: PatentIn Version 2.1
; SEQ ID NO 280
; LENGTH: 37
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-826-509-280

Query Match 1.8%; Score 32.2; DB 1; Length 37;
Best Local Similarity 83.8%; Pred. No. 0.19; 3; Indels 0; Gaps 0;
Matches 31; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1449 GGUCAAGAGAGAAAGCGGCCGAGACCCUCAGUGCG 1485
Db 37 GGTCAAGAGAGAAAGCGAAACAGACCTCAGTGGC 1

RESULT 3
US-08-513-974B-69
; Sequence 69, Application US/08513974B
; Patent No. 6116139
; GENERAL INFORMATION:
; APPLICANT: Hinuma, Shuji
; APPLICANT: Hosoya, Masaki
; APPLICANT: Fujii, Ryo
; APPLICANT: Okaki, Tetsuya
; APPLICANT: Fukusumi, Shoji
; TITLE OF INVENTION: G PROTEIN COUPLED RECEPTOR PROTEIN,
; NUMBER OF SEQUENCES: 380
; CORRESPONDENCE ADDRESS:
; ADDRESSER: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
; STREET: 130 Water Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/513,974B
; FILING DATE: 14-SEP-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP95/01599
; FILING DATE: 10-AUG-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 7-093389
; FILING DATE: 19-AUG-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 7-057186
; FILING DATE: 16-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 7-007177
; FILING DATE: 20-JAN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 6-326611
; FILING DATE: 28-DEC-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 6-270017
; FILING DATE: 02-NOV-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 6-236357
; FILING DATE: 30-SEP-1994
```

PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-236356
FILING DATE: 30-SEP-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-189274
FILING DATE: 11-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-189273
FILING DATE: 11-AUG-1945
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-189272
FILING DATE: 11-AUG-1994
ATTORNEY/AGENT INFORMATION:
NAME: Resnick, David S.
REGISTRATION NUMBER: 34,235
REFERENCE/DOCKET NUMBER: 45753
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-523-3400
TELEFAX: 617-523-6440
INFORMATION FOR SEQ ID NO: 69:
SEQUENCE CHARACTERISTICS:
LENGTH: 27 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-513-974B-69

Query Match 1.5%; Score 27; DB 1; Length 27;
Best Local Similarity 77.8%; Pred. No. 0.7;
Matches 21; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 240 GGUGACCAUUGGCAUUCUGU 266
DB 1 GGUGACCAUUGGCAUUCUGU 27

US-08-513-974B-182
Sequence 182, Application US/08513974B
Patent No. 6114139
GENERAL INFORMATION:
APPLICANT: Hinuma, Shuji
APPLICANT: Hosoya, Masaki
APPLICANT: Fujii, Ryo
APPLICANT: Ohtaki, Tetsuya
APPLICANT: Fukusumi, Shoji
APPLICANT: Ohgi, Kazuhiko
TITLE OF INVENTION: G PROTEIN COUPLED RECEPTOR PROTEIN,
TITLE OF INVENTION: PRODUCTION, AND USE THEREOF
NUMBER OF SEQUENCES: 380
CORRESPONDENCE ADDRESS:
ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
STREET: 130 Water Street
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/513,974B
FILING DATE: 14-SEP-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/JP95/01599
FILING DATE: 10-AUG-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 7-093989
FILING DATE: 19-AUG-1995

PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 7-057186
FILING DATE: 16-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 7-007177
FILING DATE: 20-JAN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-326611
FILING DATE: 28-DEC-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-270017
FILING DATE: 02-NOV-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-236357
FILING DATE: 30-SEP-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-236356
FILING DATE: 30-SEP-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-189274
FILING DATE: 11-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-189273
FILING DATE: 11-AUG-1945
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6-189272
FILING DATE: 11-AUG-1994
ATTORNEY/AGENT INFORMATION:
NAME: Resnick, David S.
REGISTRATION NUMBER: 34,235
REFERENCE/DOCKET NUMBER: 45753
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-523-3400
TELEFAX: 617-523-6440
INFORMATION FOR SEQ ID NO: 182:
SEQUENCE CHARACTERISTICS:
LENGTH: 27 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-513-974B-182

Query Match 1.5%; Score 27; DB 1; Length 27;
Best Local Similarity 74.1%; Pred. No. 0.7;
Matches 20; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1618 AACCCGUGUCUAGCUCUGGCAAC 1644
DB 1 AACCCGUGUCUAGCUCUGGCAAC 27

US-09-826-509-79
Sequence 79, Application US/09826509
Patent No. 6806054
GENERAL INFORMATION:
APPLICANT: Lehmann-Brulinsma, Karin
APPLICANT: Liaw, Chen W.
APPLICANT: Lin, I-Lin
TITLE OF INVENTION: No. 6806054-Endogenous, Constitutively Activated Known G
TITLE OF INVENTION: Protein-Coupled Receptors
FILE REFERENCE: AREN-207
CURRENT APPLICATION NUMBER: US/09/826,509
FILING DATE: 2001-04-05
PRIOR APPLICATION NUMBER: 60/195,747
PRIOR FILING DATE: 2000-04-07
PRIOR APPLICATION NUMBER: 09/170,496
PRIOR FILING DATE: 1998-10-13
NUMBER OF SEQ ID NOS: 589
SOFTWARE: Patent Version 2.1
SEQ ID NO 79
LENGTH: 32

TYPE: DNA
ORGANISM: Homo sapiens
US-09-826-509-79

Query Match 1.5%; Score 26; DB 1; Length 32;
Best Local Similarity 80.8%; Pred. No. 1.7;
Matches 21; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1 AUGACCUUGCACAUAACAGUACAC 26
DB 7 ATGACCTTGACATATACGTACAC 32

RESULT 6
US-09-396-196G-58455
Sequence 58455, Application US/09396196G
Patent No. 6821724
GENERAL INFORMATION:
APPLICANT: Michael Miltmann
APPLICANT: David Mack
APPLICANT: David Lockhart
APPLICANT: Affymetrix, Inc.
TITLE OF INVENTION: Methods of Genetic Analysis
FILE REFERENCE: 3101.1
CURRENT APPLICATION NUMBER: US/09/396,196G
CURRENT FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: 60/100,678
PRIOR FILING DATE: 1998-09-17
NUMBER OF SEQ ID NOS: 127806
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 58455
LENGTH: 25
TYPE: DNA
ORGANISM: mus musculus
US-09-396-196G-58455

Query Match 1.2%; Score 21.4; DB 1; Length 25;
Best Local Similarity 60.9%; Pred. No. 5.7;
Matches 14; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 1526 UCAUGGUCUGUGACACCUU 1548
DB 3 TCATGCTCTGTGGACACTT 25

RESULT 7
US-09-396-196G-99629
Sequence 99629, Application US/09396196G
Patent No. 6821724
GENERAL INFORMATION:
APPLICANT: Michael Miltmann
APPLICANT: David Mack
APPLICANT: David Lockhart
APPLICANT: Affymetrix, Inc.
TITLE OF INVENTION: Methods of Genetic Analysis
FILE REFERENCE: 3101.1
CURRENT APPLICATION NUMBER: US/09/396,196G
CURRENT FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: 60/100,678
PRIOR FILING DATE: 1998-09-17
NUMBER OF SEQ ID NOS: 127806
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 99629
LENGTH: 25
TYPE: DNA
ORGANISM: mus musculus
US-09-396-196G-99629

Query Match 1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 72.0%; Pred. No. 9.3;
Matches 18; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1507 ACUUGACCCCAUACAUCAUUG 1531

DB 1 ACCTGGACCATATACATCATGG 25

RESULT 8
US-09-396-196G-115275
Sequence 115275, Application US/09396196G
Patent No. 6821724
GENERAL INFORMATION:
APPLICANT: Michael Miltmann
APPLICANT: David Mack
APPLICANT: David Lockhart
APPLICANT: Affymetrix, Inc.
TITLE OF INVENTION: Methods of Genetic Analysis
FILE REFERENCE: 3101.1
CURRENT APPLICATION NUMBER: US/09/396,196G
CURRENT FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: 60/100,678
PRIOR FILING DATE: 1998-09-17
NUMBER OF SEQ ID NOS: 127806
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 115275
LENGTH: 25
TYPE: DNA
ORGANISM: mus musculus
US-09-396-196G-115275

Query Match 1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 52.0%; Pred. No. 9.3;
Matches 13; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

QY 469 AUGAUCUUCUGUCUACGCUUG 493
DB 1 ATGAACCTTCTGTATTAGCTTGG 25

RESULT 9
US-09-404-912-105/C
Sequence 105, Application US/09404912
Patent No. 6703228
GENERAL INFORMATION:
APPLICANT: John Landers
APPLICANT: David Houseman
APPLICANT: Barbara Jordan
APPLICANT: Alain Charest
TITLE OF INVENTION: Methods and Products Related to
FILE REFERENCE: M0656/7045(HCL/MAT)
CURRENT APPLICATION NUMBER: US/09/404,912
CURRENT FILING DATE: 1999-09-24
PRIOR APPLICATION NUMBER: US 60/101,757
PRIOR FILING DATE: 1998-09-25
PRIOR APPLICATION NUMBER: PCT/US99/22283
PRIOR FILING DATE: 1999-09-24
NUMBER OF SEQ ID NOS: 691
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 105
LENGTH: 17
TYPE: DNA
ORGANISM: Homo Sapiens
US-09-404-912-105

Query Match 1.0%; Score 17; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 12;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1567 AAAACCUUGGAUUC 1583
DB 17 AAAACCTTTGGATCT 1

RESULT 10
US-09-922-146-21

```
/ Sequence 21, Application US/09922146
/ Patent No. 6566133
/ GENERAL INFORMATION:
/ APPLICANT: Lex M. Cowsett
/ APPLICANT: Brett P. Monia
/ TITLE OF INVENTION: ANTISENSE MODULATION OF DUAL SPECIFIC PHOSPHATASE 9 EXPRESSION
/ FILE REFERENCE: RTS-0252
/ CURRENT APPLICATION NUMBER: US/09/922,146
/ CURRENT FILING DATE: 2001-08-01
/ NUMBER OF SEQ ID NOS: 48
/ SEQ ID NO 21
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-09-922-146-21
```

```
Query Match 0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 20;
Matches 16; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1464 AGGGCCCGAGCCCTCAGG 1483
DB 1 AGGGCCCGAGCCCTCAGG 20
```

RESULT 11

```
US-10-080-794-2/c
/ Sequence 2, Application US/10080794
/ Patent No. 6900187
/ GENERAL INFORMATION:
/ APPLICANT: Gleave, Martin
/ APPLICANT: Miyake, Hideaki
/ APPLICANT: Nelson, Colleen
/ APPLICANT: Monia, Brett P.
/ TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
/ TITLE OF INVENTION: HAVING 2'-O-(2-METHOXY)ETHYL MODIFICATIONS
/ FILE REFERENCE: UBC-P-020-3
/ CURRENT APPLICATION NUMBER: US/10/080,794
/ CURRENT FILING DATE: 2002-02-22
/ PRIOR APPLICATION NUMBER: 60/121,726
/ PRIOR FILING DATE: 1999-02-26
/ PRIOR APPLICATION NUMBER: 09/913,325
/ PRIOR FILING DATE: 2001-08-10
/ PRIOR APPLICATION NUMBER: 09/944,326
/ PRIOR FILING DATE: 2001-08-30
/ NUMBER OF SEQ ID NOS: 19
/ SOFTWARE: Patentin Ver. 2.1
/ SEQ ID NO 2
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Murine
/ FEATURE:
/ OTHER INFORMATION: mismatch control
US-10-080-794-2
```

```
Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 23;
Matches 12; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1664 UCAGAGUCGUCGUCGUCG 1683
DB 20 TCAGAGTCCTGCTGCTGTC 1
```

```
RESULT 12
US-09-723-368-5
/ Sequence 5, Application US/09723368
/ Patent No. 6641818
/ GENERAL INFORMATION:
/ APPLICANT: NORTHWESTERN UNIVERSITY
```

```
/ APPLICANT: SPEAR, Patricia G.
/ APPLICANT: WARNER, Morgan S.
/ APPLICANT: GERAGHTY, Robert G.
/ APPLICANT: MARTINEZ, Wanda M.
/ APPLICANT: MONTGOMERY, Rebecca I.
/ APPLICANT: COHEN, Gary H.
/ APPLICANT: EISENBERG, Rosalyn J.
/ APPLICANT: WHITEBERG, Charles J.
/ APPLICANT: KRUMENACHER, Claude
/ APPLICANT: UNIVERSITY OF PENNSYLVANIA
/ TITLE OF INVENTION: CELLULAR PROTEINS WHICH MEDIATE HERPESVIRUS ENTRY
/ FILE REFERENCE: 200290.0050/201
/ CURRENT APPLICATION NUMBER: US/09/723,368
/ CURRENT FILING DATE: 2000-11-28
/ PRIOR APPLICATION NUMBER: U.S. 60/087,862
/ PRIOR FILING DATE: 1998-06-03
/ PRIOR APPLICATION NUMBER: PCT/US99/12235
/ PRIOR FILING DATE: 1999-06-02
/ NUMBER OF SEQ ID NOS: 26
/ SOFTWARE: Patentin Ver. 2.1
/ SEQ ID NO 5
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence:Primer PRR2A8
US-09-723-368-5
```

```
Query Match 0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 24;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1708 AAGCAGAGUACGACGAG 1725
DB 3 AAGCAGAGUACGACGAG 20
```

RESULT 13

```
US-09-922-146-22
/ Sequence 22, Application US/09922146
/ Patent No. 6566133
/ GENERAL INFORMATION:
/ APPLICANT: Lex M. Cowsett
/ APPLICANT: Brett P. Monia
/ TITLE OF INVENTION: ANTISENSE MODULATION OF DUAL SPECIFIC PHOSPHATASE 9 EXPRESSION
/ FILE REFERENCE: RTS-0252
/ CURRENT APPLICATION NUMBER: US/09/922,146
/ CURRENT FILING DATE: 2001-08-01
/ NUMBER OF SEQ ID NOS: 48
/ SEQ ID NO 22
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-09-922-146-22
```

```
Query Match 0.9%; Score 16; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 28;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1464 AGGGCCCGAGCCCTC 1479
DB 3 AGGGCCCGAGCCCTC 18
```

```
RESULT 14
US-08-894-784-13
/ Sequence 13, Application US/08894784
/ Patent No. 6005095
/ GENERAL INFORMATION:
/ APPLICANT: Capaccioli, Sergio
/ APPLICANT: Morelli, Susanna
```

APPLICANT: NICOLIN, Angelo
TITLE OF INVENTION: ANTISENSE TRANSCRIPT ASSOCIATED TO TUMOR
TITLE OF INVENTION: CELLS HAVING A T(14;18) TRANSLOCATION AND
TITLE OF INVENTION: OLIGODEOXYNUCLEOTIDES USEFUL IN THE DIAGNOSIS AND
NUMBER OF SEQUENCES: 49
CORRESPONDENCE ADDRESS:
ADDRESSEE: PINNEGAN, HENDERSON, FARABOW, GARRETT &
ADDRESSEE: DUNNER, LLP
STREET: 1300 I Street, NW
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/894,784
FILING DATE: 15-DEC-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/EP96/00852
FILING DATE: 02-MAR-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: IL M195 A 000420
FILING DATE: 03-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Paul, John C.
REGISTRATION NUMBER: 30,413
REFERENCE/DOCKET NUMBER: 05999.0005-00000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-408-4000
TELEFAX: 202-408-4400
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-894-784-13

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 26;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 631 GUUGAAGAAGACUGU 647
|:|||||:|:
DB 2 GCTGGAAGAAGACTGT 18

RESULT 15
US-08-894-784-32/c
Sequence 32, Application US/08894784
Patent No. 6005095
GENERAL INFORMATION:
APPLICANT: Capaccioli, Sergio
APPLICANT: Morelli, Susanna
APPLICANT: Nicolin, Angelo
TITLE OF INVENTION: ANTISENSE TRANSCRIPT ASSOCIATED TO TUMOR
TITLE OF INVENTION: CELLS HAVING A T(14;18) TRANSLOCATION AND
TITLE OF INVENTION: OLIGODEOXYNUCLEOTIDES USEFUL IN THE DIAGNOSIS AND
TITLE OF INVENTION: TREATMENT OF SAID TUMOR CELLS
NUMBER OF SEQUENCES: 49
CORRESPONDENCE ADDRESS:
ADDRESSEE: PINNEGAN, HENDERSON, FARABOW, GARRETT &
ADDRESSEE: DUNNER, LLP
STREET: 1300 I Street, NW
CITY: Washington
STATE: DC
COUNTRY: USA

ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/894,784
FILING DATE: 15-DEC-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/EP96/00852
FILING DATE: 02-MAR-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: IL M195 A 000420
FILING DATE: 03-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Paul, John C.
REGISTRATION NUMBER: 30,413
REFERENCE/DOCKET NUMBER: 05999.0005-00000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-408-4000
TELEFAX: 202-408-4400
INFORMATION FOR SEQ ID NO: 32:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-894-784-32

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 26;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 631 GUUGAAGAAGACUGU 647
|:|||||:|:
DB 17 GCTGGAAGAAGACTGT 1

RESULT 16
US-08-894-736-7
Sequence 7, Application US/08894736A
Patent No. 6140492
GENERAL INFORMATION:
APPLICANT: MORELLI, Susanna
APPLICANT: NICOLIN, Angelo
APPLICANT: QUATTROME, Alessandro
TITLE OF INVENTION: ANTISENSE TRANSCRIPT EXPRESSED IN B LYMPHOCYTES AND
TITLE OF INVENTION: SYNTHETIC OLIGONUCLEOTIDES USEFUL TO INHIBIT THE
TITLE OF INVENTION: ACTIVITY THEREOF
FILE REFERENCE: 10309-0002-0PCT
CURRENT APPLICATION NUMBER: US/08/894,736A
CURRENT FILING DATE: 1998-04-06
EARLIER APPLICATION NUMBER: PCT/EP96/00853
EARLIER FILING DATE: 1996-03-01
EARLIER APPLICATION NUMBER: IT M195A000419
EARLIER FILING DATE: 1997-03-03
NUMBER OF SEQ ID NOS: 23
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 7
LENGTH: 18
TYPE: DNA
ORGANISM: Homo sapiens
US-08-894-736-7

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 26;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 631 GUUGAAGAAGACUGU 647
|:|||||:|:
DB 2 GCTGGAAGAAGACTGT 18

RESULT 17
US-08-894-736-17/c
; Sequence 17, Application US/08894736A
; Patent No. 6140452
; GENERAL INFORMATION:
; APPLICANT: MORELLI, Susanna
; APPLICANT: NICOLIN, Angelo
; APPLICANT: QUATRONO, Alessandro
; TITLE OF INVENTION: ANTISENSE TRANSCRIPT EXPRESSED IN B LYMPHOCYTES AND
; TITLE OF INVENTION: SYNTHETIC OLIGONUCLEOTIDES USEFUL TO INHIBIT THE
; FILE REFERENCE: 10309-0002-0PCT
; CURRENT APPLICATION NUMBER: US/08/894, 736A
; EARLIER FILING DATE: 1998-04-06
; EARLIER APPLICATION NUMBER: PCT/EP96/00853
; EARLIER FILING DATE: 1996-03-01
; EARLIER APPLICATION NUMBER: IT M195A000419
; EARLIER FILING DATE: 1997-03-03
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-08-894-736-17

Query Match 0.9%; Score 15.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 26;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 631 GUGGAGAGAGACUGU 647
DB 17 GCTGAGAGAGACTGT 1

RESULT 18
US-09-422-978-6934
; Sequence 6934, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marica
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422, 978
; EARLIER FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298, 850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109, 732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082, 614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6934
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-21533 for SEQ 3000,
US-09-422-978-6934

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 30;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 38 UCCAAACUACGCTCC 54
DB 3 TTCCAACATCAGCTCC 19

RESULT 19
US-09-422-978-7458
; Sequence 7458, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marica
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422, 978
; EARLIER FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298, 850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109, 732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082, 614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7458
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-4874 for SEQ 3524,
US-09-422-978-7458

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 30;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 684 GCCGACCAUACUUG 700
DB 1 GCCCACCCTTACTTTG 17

RESULT 20
US-09-197-380-27
; Sequence 27, Application US/09197380
; Patent No. 6096543
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF MEX1 EXPRESSION
; FILE REFERENCE: RTS-0016
; CURRENT APPLICATION NUMBER: US/09/197, 380
; EARLIER FILING DATE: 1998-11-20
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 27
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-197-380-27

Query Match 0.8%; Score 15; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 31;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 40 CCAACAUACGCTCC 54
DB 4 CCAACATCAGCTCC 18

RESULT 21
US-09-256-496-26/c
; Sequence 26, Application US/09256496
; Patent No. 5998206

GENERAL INFORMATION:
APPLICANT: Lex M. Cowser
TITLE OF INVENTION: ANTISENSE MODULATION OF G-APLHA-12 EXPRESSION
FILE REFERENCE: RTS-0056
CURRENT APPLICATION NUMBER: US/09/256,496
CURRENT FILING DATE: 1999-02-23
NUMBER OF SEQ ID NOS: 86
SEQ ID NO: 26
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-256-496-26

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 66.7%; Pred. No. 33;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 246 CAUCCGCGCACATCCU 263
DB 18 CATCTCGACACATCTCT 1

RESULT 22
US-09-043-085-17
Sequence 17, Application US/09043085
Patent No. 6083685
GENERAL INFORMATION:
APPLICANT: Juraj Petrik
TITLE OF INVENTION: SYSTEMATIC EXTRACTION, AMPLIFICATION AND
TITLE OF INVENTION: DETECTION OF RETROVIRAL SEQUENCES, AND OLIGONUCLEOTIDES
TITLE OF INVENTION: FOR USE THEREIN
NUMBER OF SEQUENCES: 58
CORRESPONDENCE ADDRESSES:
ADDRESSEE: SALIMANCHIK, LLOYD & SALIMANCHIK
STREET: 2421 NW 41st STREET, SUITE A-1
CITY: GAINESVILLE
STATE: FLORIDA
COUNTRY: USA
ZIP: 32606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/043,085
FILING DATE: 6-MAR-1998
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB96/02196
FILING DATE: 6-SEP-1996
ATTORNEY/AGENT INFORMATION:
NAME: PACE, DORAN R.
REGISTRATION NUMBER: 38,261
REFERENCE/DOCKET NUMBER: GJE-20
TELECOMMUNICATION INFORMATION:
TELEPHONE: 352-375-8100
TELEFAX: 352-372-5800
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "Oligonucleotide"
US-09-043-085-17

Query Match 0.8%; Score 14.6; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 36;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1113 UCCGGUCACAGACCA 1129
DB 2 TCTGAGTCACGACCA 18

RESULT 23
US-09-043-085-41/C
Sequence 41, Application US/09043085
Patent No. 6083685
GENERAL INFORMATION:
APPLICANT: Juraj Petrik
TITLE OF INVENTION: SYSTEMATIC EXTRACTION, AMPLIFICATION AND
TITLE OF INVENTION: DETECTION OF RETROVIRAL SEQUENCES, AND OLIGONUCLEOTIDES
TITLE OF INVENTION: FOR USE THEREIN
NUMBER OF SEQUENCES: 58
CORRESPONDENCE ADDRESSES:
ADDRESSEE: SALIMANCHIK, LLOYD & SALIMANCHIK
STREET: 2421 NW 41st STREET, SUITE A-1
CITY: GAINESVILLE
STATE: FLORIDA
COUNTRY: USA
ZIP: 32606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/043,085
FILING DATE: 6-MAR-1998
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB96/02196
FILING DATE: 6-SEP-1996
ATTORNEY/AGENT INFORMATION:
NAME: PACE, DORAN R.
REGISTRATION NUMBER: 38,261
REFERENCE/DOCKET NUMBER: GJE-20
TELECOMMUNICATION INFORMATION:
TELEPHONE: 352-375-8100
TELEFAX: 352-372-5800
INFORMATION FOR SEQ ID NO: 41:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "Oligonucleotide"
US-09-043-085-41

Query Match 0.8%; Score 14.6; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 36;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1113 UCCGGUCACAGACCA 1129
DB 17 TCTGAGTCACGACCA 1

RESULT 24
US-08-720-625-7/C
Sequence 7, Application US/08720625
Patent No. 6242587
GENERAL INFORMATION:
APPLICANT: Naik, Unas P.
APPLICANT: Parise, Leslie V.
TITLE OF INVENTION: CALCIUM-INTRERIN BINDING PROTEIN
NUMBER OF SEQUENCES: 10
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Bell, Seltzer, Park & Gibson
STREET: P.O. Drawer 34009

```

CITY: Charlotte
STATE: No. 6242587th Carolina
COUNTRY: USA
ZIP: 28234

COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/720, 625
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Sibley, Kenneth D.
REGISTRATION NUMBER: 31,665
REFERENCE/DOCKET NUMBER: 5470-138
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-420-2200
TELEFAX: 919-881-3175
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "DNA primer"
US-08-720-625-7

```

Query Match	0.8%	Score 14.4	DB 1	Length 17
Best Local Similarity	68.8%	Pred. No. 34		
Matches 11; Conservative	4;	Mismatches 1;	Indels 0;	Gaps 0.
QY	248	UCAVGGCAACAUCCU	263	
	.. :	: :		
db	16	TCATCGACCAATCCT	1	

```

RESULT 25
US-09-268-544B-25
: Sequence 25, Application US/09268544B
: Patent No. 6410710
:
GENERAL INFORMATION:
: APPLICANT: Lederman, Seth
: APPLICANT: van Eyndhoven, Winfried
:
FILE OF INVENTION: TRAF-32
: FILE REFERENCE: 0575-58732
:
CURRENT APPLICATION NUMBER: US/09/268,544B
:
CURRENT FILING DATE: 1999-03-11
:
NUMBER OF SEQ ID NOS: 43
:
SOFTWARE: Patenting Ver. 2.1
:
SEQ ID NO 25
:
LENGTH: 18
:
TYPE: DNA
:
ORGANISM: Human
:
US-09-268-544B-25

```

	Query Match	Best Local Similarity	Score	DB	Length
Matches	10	Conservative	62.5%	Pred. No. 39	18
			5	Mismatches	1
				Indels	0
				Gaps	0
OY	1393	AAGAGGUTTCCTTCGA	1408		
		::: ::			
Db	2	AAGAGGTTGCTCTCA	17		

RESULT 26
US-09-475-947A-249
; Sequence 249, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.

```

; APPLICANT: Wren, Jonathan D.
; APPLICANT: Minna, John D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: URS00667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 249
; LENGTH: 18
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-249

Query Match      0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1701 GAGGCGCAGACGACG 1716
          |||||
DB      1 GAGGCGCAGACGACG 16

```

```

RESULT 27
US-09-209-676--84
; Sequence 84, Application US/09209676
; Patent No. 6524856
; GENERAL INFORMATION:
; APPLICANT: Pangene Corporation
; TITLE OF INVENTION: The Use of Consensus Sequences for Targeted Homologous
; TITLE OF INVENTION: Gene Isolation and Recombination in Gene Families
; FILE REFERENCE: A-65678-1/RFT/NBC
; CURRENT APPLICATION NUMBER: US/09/209,676
; CURRENT FILING DATE: 2002-06-18
; PRIOR APPLICATION NUMBER: US 60/070,734
; PRIOR FILING DATE: 1997-12-11
; NUMBER OF SEQ ID NOS: 95
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 84

```

```

? TYPE: DNA
? ORGANISM: Artificial Sequence
? FEATURE:
? NAME/KEY: MISC_FEATURE
? LOCATION: (3)_FEATURE
? OTHER INFORMATION: "n" at position 3 can be any base.
? FEATURE:
? OTHER INFORMATION: Description of Artificial Sequence: synthetic
? US-09-209-676-84

```

[illegible]

RESULT 28
US-08-127-954-39
Sequence 39, Application US/08127954
Patent No. 5451512
GENERAL INFORMATION:
APPLICANT: Apple, Raymond J.
APPLICANT: Bugawan, Teodorica L.
APPLICANT: Erlich, Henry A.
TITLE OF INVENTION: Methods and Reagents for HLA Class I A
TITLE OF INVENTION: Locus DNA Typing
NUMBER OF SEQUENCES: 173
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hoffmann-La Roche Inc.
STREET: 340 Kingsland Street

CITY: Nutley
STATE: New Jersey
COUNTRY: U.S.A.
ZIP: 07110-1199
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/127,954
FILING DATE:
CLASSIFICATION: 436
ATTORNEY/AGENT INFORMATION:
NAME: Petry, Douglas A.
REGISTRATION NUMBER: 35,321
REFERENCE/DOCKET NUMBER: 8873
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 814-2974
TELEFAX: (510) 814-2977
INFORMATION FOR SEQ ID NO: 39:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-127-954-39

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 42;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1420 CAGATCACCAGCGGCA 1436
DB 1 CAGATCACCAGCGGCA 17

RESULT 29
US-08-366-783-15
Sequence 15, Application US/08366783
Patent No. 5650554
GENERAL INFORMATION:
APPLICANT: Moloney, Maurice M
TITLE OF INVENTION: Oil-Body Proteins As Carriers Of
TITLE OF INVENTION: High-Value Peptides In Plants
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: DEHLINGER & ASSOCIATES
STREET: 350 CAMBRIDGE AVENUE, SUITE 250
CITY: PALO ALTO
STATE: California
COUNTRY: United States
ZIP: 94025-1536
TELEPHONE: (415) 324-0960
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-366-783-15

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 42;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1343 GUAGAGCAGCGGCACU 1359
DB 1 GTAAAGCAGCGGCAGT 17

RESULT 30
US-08-985-162-262
Sequence 262, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwigen, James
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
INFORMATION FOR SEQ ID NO: 262:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-262

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 42;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 756 GAGATCCTUUAAGGAA 772
DB 1 GAGATCCTUUAAGGAA 17

RESULT 31
US-08-584-040-4100
Sequence 4100, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ. ID NO.: 4100:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-4100

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 42;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 606 UGCCAUCUUCUCGCGC 622
DB 1 UGCCAUCUUCUCGCGC 17

RESULT 32
US-08-584-040-5674
Sequence 5674, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS

TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ. ID NO.: 5674:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-5674

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 42;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 606 UGCCAUCUUCUCGCGC 622
DB 1 UGCCAUCUUCUCGCGC 17

RESULT 33
US-09-474-432B-647
Sequence 647, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Belgelman, Leo
APPLICANT: Burgin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
FILE REFERENCE: MBH00-831-B (247/276)
CURRENT APPLICATION NUMBER: US/09/474,432B
CURRENT FILING DATE: 1999-12-19
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/084,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511

```

; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 647
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-647

Query Match
Best Local Similarity 8.2%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1626 GUGCUAUGGUCUGGCA 1642
DB 1 GUGCUAUGGUCUGGCA 17

RESULT 34
US-09-474-432B-884
; Sequence 884, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; PRIOR FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 884
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-884

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 406 UURGGGAACUUGGCTUG 422
DB 1 UURGGGAACUUGGCTUG 17

RESULT 35
US-09-371-772B-1867
; Sequence 1867, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
```

```

; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1867
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1867

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 606 UGCCAUCUGUUCUGGC 622
DB 1 UGCCAUCUGUUCUGGC 17

RESULT 36
US-09-476-387-646
; Sequence 646, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBH00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 646
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-646

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1626 GUGCUAUGGUCUGGCA 1642
DB 1 GUGCUAUGGUCUGGCA 17

RESULT 37
US-09-476-387-883
; Sequence 883, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
```

```

; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBH00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; PRIOR FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 883
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-883

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 42;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      406 UUAGGAGACUUGGCGG 422
DB      1 UUAGGAGAGCGGCGCG 17

RESULT 38
US-09-401-063-262
; Sequence 262, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Bell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: PASTSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
```

```

; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 262:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-401-063-262

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 42;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      756 GAGGAGUCUAGAGAAA 772
DB      1 GAGGAGUCUAGAGAAA 17

RESULT 39
US-09-827-998-636/C
; Sequence 636, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMRP-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 636
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-636

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 42;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      1674 GCUCUCUGCCAGGUG 1690
DB      17 GCCGCTGCGCAGTG 1

RESULT 40
US-09-866-108A-2301
; Sequence 2301, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
```

```

; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmca Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2301
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2301
```

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 42;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      990 CCACAGCAGCAGCAGCA 1006
Db      1 CCACAGCCGCGAGGCCA 17
```

```

RESULT 41
; Sequence 104, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/404,912
; PRIOR FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 104
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-404-912-104
```

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 42;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1567 AAAACCUUUUGAUCU 1583
Db      17 AAAACTTTTGAATCT 1
```

```

RESULT 42
US-09-404-912-106/c
; Sequence 106, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/404,912
; PRIOR FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 106
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-404-912-106
```

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 42;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1567 AAAACCUUUUGAUCU 1583
Db      17 AAAACTTTTGAATCT 1
```

```

RESULT 43
US-09-685-664B-1867
; Sequence 1867, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1867
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1867
```

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 42;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      606 UGCCAUCUUGUUGGC 622
Db      1 UGCCAUGUUCUUGGC 17
```

```
RESULT 44
US-10-156-306B-1487
; Sequence 1487, Application US/10156306B
; Patent No. 7022828
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306B
; NUMBER OF SEQ ID NOS: 8014
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1487
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306B-1487

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1385 CUCUGGCAAGAGUUU 1401
DB 1 CUGUGGACAAGAGUUU 17

RESULT 45
US-10-156-306B-2310
; Sequence 2310, Application US/10156306B
; Patent No. 7022828
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306B
; NUMBER OF SEQ ID NOS: 8014
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 2310
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306B-2310

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 999 CAGUGACAGUUGAACA 1015
DB 1 CAGUGACAGUUGAACA 17

RESULT 46
US-10-138-674B-1867
; Sequence 1867, Application US/10138674B
; Patent No. 7034009
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: MCSwigen, James
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674B
```

```
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20829
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1867
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674B-1867

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 606 UGCCAUCUUGUUCGCG 622
DB 1 UGCCAUGUUCUUCGCG 17

RESULT 47
US-10-138-674B-7793/C
; Sequence 7793, Application US/10138674B
; Patent No. 7034009
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: MCSwigen, James
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674B
; NUMBER OF SEQ ID NOS: 20829
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 7793
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674B-7793

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1023 UGUGUGUGCCUCCUGG 1039
DB 17 TGCTGCTGCGCCCTGG 1

RESULT 48
US-08-585-684B-137/C
; Sequence 137, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
```

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 137:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-137

Query Match
Best Local Similarity 66.7%; Pred. No. 36;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 486 GAGCUUGACAGAA 500
Db 15 GAGCTTGACTGATA 1

RESULT 49
US-09-038-073-137/c
Sequence 137, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAY TOLERANCE
AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440

TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 137:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-137

Query Match
Best Local Similarity 66.7%; Pred. No. 36;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 486 GAGCUUGACAGAA 500
Db 15 GAGCTTGACTGATA 1

RESULT 50
US-09-475-947A-60
Sequence 60, Application US/09475947A
Patent No. 6472154
GENERAL INFORMATION:
APPLICANT: Garner, Harold R.
APPLICANT: Wren, Jonathan D.
APPLICANT: Minna, John D.
TITLE OF INVENTION: Polymorphic Repeats in Human Genes
FILE REFERENCE: UTS00667
CURRENT APPLICATION NUMBER: US/09/475,947A
CURRENT FILING DATE: 1999-12-31
NUMBER OF SEQ ID NOS: 346
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 60
LENGTH: 16
TYPE: DNA
ORGANISM: human
US-09-475-947A-60

Query Match
Best Local Similarity 93.3%; Pred. No. 43;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 815 GGACAGAGCAGAGA 829
Db 1 GGAGAGAGCAGAGA 15

RESULT 51
US-09-826-509-279/c
Sequence 279, Application US/09826509
Patent No. 6806054
GENERAL INFORMATION:
APPLICANT: Lehmann-Brunisma, Karin
APPLICANT: Liaw, Chen W.
APPLICANT: Lin, I-Lin
TITLE OF INVENTION: Protein-coupled Receptors
TITLE OF INVENTION: Endogenous, Constitutively Activated Known G
FILE REFERENCE: ALEN-207
CURRENT APPLICATION NUMBER: US/09/826,509
CURRENT FILING DATE: 2001-04-05
PRIOR APPLICATION NUMBER: 60/195,747
PRIOR FILING DATE: 2000-04-07
PRIOR APPLICATION NUMBER: 09/170,496
PRIOR FILING DATE: 1998-10-13
NUMBER OF SEQ ID NOS: 589
SOFTWARE: PatentIn Version 2.1
SEQ ID NO 279
LENGTH: 37
TYPE: DNA
ORGANISM: Homo sapiens
US-09-826-509-279

Query Match
0.7%; Score 13.2; DB 1; Length 37;

Best Local Similarity 38.9%; Pred. No. 1.1e+02;
Matches 7; Conservative 8; Mismatches 3; Indels 0; Gaps 0;

QY 204 GGUUCUACGCGUUCU 221
Db 28 GGTCTGTTGCTTCTT 11

RESULT 52
US-09-826-509-280
; Sequence 280, Application US/09826509
; Patent No. 6806054
; GENERAL INFORMATION:
; APPLICANT: Lehmann-Brulnema, Karin
; APPLICANT: Liaw, Chen W.
; APPLICANT: Lin, I-Lin
; TITLE OF INVENTION: No. 6806054-Endogenous, Constitutively Activated Known G
; TITLE OF INVENTION: Protein-Coupled Receptors
; FILE REFERENCE: AREN-207
; CURRENT APPLICATION NUMBER: US/09/826,509
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 60/195,747
; PRIOR FILING DATE: 2000-04-07
; PRIOR APPLICATION NUMBER: 09/170,496
; PRIOR FILING DATE: 1998-10-13
; NUMBER OF SEQ ID NOS: 589
; SOFTWARE: Patentin Version 2.1
; SEQ ID NO 280
; LENGTH: 37
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-826-509-280

Query Match 0.7%; Score 13.2; DB 1; Length 37;
Best Local Similarity 38.9%; Pred. No. 1.1e+02;
Matches 7; Conservative 8; Mismatches 3; Indels 0; Gaps 0;

QY 204 GGUUCUACGCGUUCU 221
Db 10 GGTCTGTTGCTTCTT 27

RESULT 53
US-08-311-486C-41/c
; Sequence 41, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisch
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwigen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: TNF-
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,486C

; FILING DATE: September 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/166
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440

; TELEEX: 67-3510
; INFORMATION FOR SEQ ID NO: 41:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-311-486C-41

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 42;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1231 CAGAGAGCGUGG 1243
Db 13 CAGAGAGCGTGG 1

RESULT 54
US-08-311-486C-553/c
; Sequence 553, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisch
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwigen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: TNF-
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,486C
; FILING DATE: September 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849

FILED DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/166
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 553:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-311-486C-553

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 42;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1231 CAGAAGCGCTGG 1243
DB 13 CAGAAGCGCTGG 1

RESULT 55
US-08-292-620A-394/c
Sequence 394, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 394:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-394

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 42;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 506 CCAUACGAGGCC 518
DB 15 CCATCAGAGGCC 3

RESULT 56
US-08-292-620A-616/c
Sequence 616, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 616:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

TOPOLOGY: linear
US-08-292-620A-616

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 42;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 506 CCAUCCAGAGGCC 518
DB 15 CCATCCAGAGGCC 3

RESULT 57
US-09-071-845-394/c
Sequence 394, Application US/09071845
Patent No. 6132967

GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 394:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-394

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 42;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 506 CCAUCCAGAGGCC 518
DB 15 CCATCCAGAGGCC 3

RESULT 58
US-09-071-845-616/c
Sequence 616, Application US/09071845
Patent No. 6132967

GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 616:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-616

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 42;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 506 CCAUCCAGAGGCC 518
DB 15 CCATCCAGAGGCC 3

RESULT 59
US-09-474-432B-97/c

```
; Sequence 97, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; PRIOR FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 97
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-97
```

```
Query Match      0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 42;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      861 UCGAGCUCGACG 873
Db      14 TCGAAGCTGCAGC 2
```

```
RESULT 60
US-09-476-387-97/C
; Sequence 97, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MBH00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 97
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-97
```

```
Query Match      0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 84.6%; Pred. No. 42;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      861 UCGAGCUCGACG 873
Db      14 TCGAAGCTGCAGC 2
```

```
RESULT 61
US-08-770-235A-54/C
; Sequence 54, Application US/08770235A
; Patent No. 5939538
; GENERAL INFORMATION:
; APPLICANT: Leavitt, Markley C.
; APPLICANT: Tritz, Richard
; APPLICANT: Feng, Yu
; APPLICANT: Barber, Jack
; APPLICANT: Yu, Mang
; TITLE OF INVENTION: Methods and Compositions for Inhibiting
; TITLE OF INVENTION: HIV Infection of Cells By Cleaving HIV Co-Receptor RNA
; NUMBER OF SEQUENCES: 77
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/770,235A
; FILING DATE: 19-DEC-1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/027,875
; FILING DATE: 25-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: QUINE, Jonathan A.
; REGISTRATION NUMBER: P-41,261
; REFERENCE/DOCKET NUMBER: 016556-001610US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 54:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA
US-08-770-235A-54
```

```
Query Match      0.7%; Score 13; DB 1; Length 16;
Best Local Similarity 84.6%; Pred. No. 49;
Matches 11; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1238 GCGUGAGCAGUGG 1250
Db      13 GCGTGCAGCATGG 1
```

```
RESULT 62
US-09-479-005A-230/C
; Sequence 230, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

;; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;; FILE REFERENCE: MBH800-884-C
;; CURRENT APPLICATION NUMBER: US/09/479,005A
;; CURRENT FILING DATE: 2000-01-07
;; PRIOR APPLICATION NUMBER: US 09/444,209
;; PRIOR FILING DATE: 1999-11-19
;; PRIOR APPLICATION NUMBER: US 09/159,274
;; PRIOR FILING DATE: 1998-09-22
;; PRIOR APPLICATION NUMBER: US 60/059,473
;; PRIOR FILING DATE: 1997-09-22
;; NUMBER OF SEQ ID NOS: 1208
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 230
;; LENGTH: 16
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-09-479-005A-230

Query Match 0.7%; Score 13; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 49;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 990 CCACGACGACGACU 1002
DB 14 CCACGACGACGACT 2

RESULT 63
US-08-152-313-15
; Sequence 15, Application US/08152313
; Patent No. 5561041
; GENERAL INFORMATION:
; APPLICANT: Sidransky, David
; TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION BY
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Spensley Horn Judas & Lubitz
; STREET: 1880 Century Park East, Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90067
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/152,313
; FILING DATE: 12-NOV-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Wetherell, Jr., Ph.D., John R.,
; REGISTRATION NUMBER: 31,678
; REFERENCE/DOCKET NUMBER: PD-2912
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 455-5100
; TELEFAX: (619) 455-5110
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..16
US-08-152-313-15

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 53;

Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 45 CAUCAGUCUCUCUGG 60
DB 1 CACCAGCCCTCTGG 16

RESULT 64
US-08-474-177-21/C
; Sequence 21, Application US/08474177
; Patent No. 5624819
; GENERAL INFORMATION:
; APPLICANT: Skolnick, Mark H.
; APPLICANT: Cannon-Albright, Lisa A.
; APPLICANT: Kamb, Alexander
; TITLE OF INVENTION: GERMLINE MUTATIONS IN THE MTS GENE
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
; STREET: 1201 New York Avenue, Suite 1000
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/474,177
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/03537
; FILING DATE: 17-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/251,938
; FILING DATE: 01-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,087
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,086
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/227,369
; FILING DATE: 14-APR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/214,582
; FILING DATE: 18-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 24684-109348-E
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-962-4610
; TELEFAX: 202-962-8300
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
US-08-474-177-21

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 53;

Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1465 GCGGCCAGACCCUCA 1480
 |||||
 DB 16 GCTGGCCAGACCTCA 1

RESULT 65
 US-08-579-223-15
 ; Sequence 15, Application US/08579223
 ; Patent No. 5726019
 ; GENERAL INFORMATION:
 ; APPLICANT: Sidransky, David
 ; TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION BY
 ; TITLE OF INVENTION: ANALYSIS OF SPUTUM
 ; NUMBER OF SEQUENCES: 128
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Spensley Horn Judas & Lubitz
 ; STREET: 1880 Century Park East, Suite 500
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: USA
 ; ZIP: 90067
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patentin Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/579,223
 ; FILING DATE: 28-DEC-1995
 ; CLASSIFICATION: 435
 ; PRIORITY APPLICATION DATA:
 ; PRIORITY APPLICATION NUMBER: 08/152,313
 ; FILING DATE: 12-NOV-1993
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Wetherell, Jr., Ph.D., John R.,
 ; REGISTRATION NUMBER: 31,678
 ; REFERENCE/DOCKET NUMBER: PD-2912
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (619) 455-5100
 ; TELEFAX: (619) 455-5110
 ; INFORMATION FOR SEQ ID NO: 15:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 16 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: DNA (genomic)
 ; FEATURE:
 ; NAME/KEY: CDS
 ; LOCATION: 1..16
 ; US-08-579-223-15

Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 75.0%; Pred. No. 53;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 45 CAUCAGCUCUCCUGG 60
 |||||
 DB 1 CACCGACCCCTCTGG 16

RESULT 66
 US-08-487-033-21/C
 ; Sequence 21, Application US/08487033
 ; Patent No. 5739027
 ; GENERAL INFORMATION:
 ; APPLICANT: Kamb, Alexander
 ; TITLE OF INVENTION: MTS1-Beta GENE
 ; NUMBER OF SEQUENCES: 36
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP

STREET: 1201 New York Avenue, Suite 1000
 CITY: Washington
 STATE: DC
 COUNTRY: USA
 ZIP: 20005
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patentin Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/487,033
 ; FILING DATE: 07-JUN-1995
 ; CLASSIFICATION: 435
 ; PRIORITY APPLICATION DATA:
 ; PRIORITY APPLICATION NUMBER: PCT/US95/03316
 ; FILING DATE: 17-MAR-1995
 ; PRIORITY APPLICATION DATA:
 ; PRIORITY APPLICATION NUMBER: US 08/251,938
 ; FILING DATE: 01-JUN-1994
 ; PRIORITY APPLICATION DATA:
 ; PRIORITY APPLICATION NUMBER: US 08/215,087
 ; FILING DATE: 18-MAR-1994
 ; PRIORITY APPLICATION DATA:
 ; PRIORITY APPLICATION NUMBER: US 08/215,086
 ; FILING DATE: 18-MAR-1994
 ; PRIORITY APPLICATION DATA:
 ; PRIORITY APPLICATION NUMBER: US 08/227,369
 ; FILING DATE: 14-APR-1994
 ; PRIORITY APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/214,582
 ; FILING DATE: 18-MAR-1994
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Innen, Jeffrey L.
 ; REGISTRATION NUMBER: 28,957
 ; REFERENCE/DOCKET NUMBER: 24884-109348-C
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 202-962-4810
 ; TELEFAX: 202-962-8300
 ; INFORMATION FOR SEQ ID NO: 21:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 16 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: DNA (genomic)
 ; HYPOTHETICAL: NO
 ; ANTI-SENSE: NO
 ; ORIGINAL SOURCE:
 ; ORGANISM: Homo sapiens
 ; US-08-487-033-21

Query Match 0.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 81.2%; Pred. No. 53;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1465 GCGGCCAGACCCUCA 1480
 |||||
 DB 16 GCTGGCCAGACCTCA 1

RESULT 67
 US-08-480-810-21/C
 ; Sequence 21, Application US/08480810
 ; Patent No. 5801236
 ; GENERAL INFORMATION:
 ; APPLICANT: Kamb, Alexander
 ; TITLE OF INVENTION: MTS1 GENE
 ; NUMBER OF SEQUENCES: 36
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
 ; STREET: 1201 New York Avenue, Suite 1000
 ; CITY: Washington

STATE: DC
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/480,810
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/03316
FILING DATE: 17-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/251,938
FILING DATE: 01-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,087
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,086
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/227,369
FILING DATE: 14-APR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/214,582
FILING DATE: 18-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Ihnen, Jeffrey L.
REGISTRATION NUMBER: 28,957
REFERENCE/DOCKET NUMBER: 24884-109348
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-962-4810
TELEFAX: 202-962-8300
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-08-480-810-21

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 53;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1465 GCGGCCGACCCCTCA 1480
Db 16 GCTGCCAGACCTCA 1

RESULT 68
US-08-527-060-10
Sequence 10, Application US/08527060
Patent No. 584440
GENERAL INFORMATION:
APPLICANT: Goldenberg, Tsvi
APPLICANT: Tlitz, Richard
TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT
OF INFECTION: AND/OR PREVENTION OF RESTENOSIS
NUMBER OF SEQUENCES: 35
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle

STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/527,060
FILING DATE: 12-SEP-1995
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: McMaister, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 480124.402C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-527-060-10

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 53;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 725 UGCGUGCAGCAUUAU 740
Db 1 TGACTCTCCATTAT 16

RESULT 69
US-08-508-735-21/C
Sequence 21, Application US/08508735
Patent No. 5843756
GENERAL INFORMATION:
APPLICANT: Stone, Steven
APPLICANT: Jiang, Ping
APPLICANT: Kamb, Alexander
TITLE OF INVENTION: MTS GENE AND THERAPEUTIC USE THEREOF
NUMBER OF SEQUENCES: 47
CORRESPONDENCE ADDRESS:
ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
STREET: 1201 New York Avenue, Suite 1000
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/508,735
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US to be assigned
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/03316
FILING DATE: 17-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Ihnen, Jeffrey L.
REGISTRATION NUMBER: 28,957
REFERENCE/DOCKET NUMBER: 24884-109348
TELECOMMUNICATION INFORMATION:

TELEPHONE: 202-962-4848
TELEFAX: 202-962-8300
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-08-508-735-21

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 53;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1465 GCGGCCGAGACCCUCA 1480
Db 16 GCTGGCCAGACCTCA 1

RESULT 70
US-08-848-251-21/c
Sequence 21, Application US/08848251
Patent No. 5989815
GENERAL INFORMATION:
APPLICANT: Skolnick, Mark H.
APPLICANT: Cannon-Albright, Lisa A.
TITLE OF INVENTION: GERM-LINE MUTATIONS IN THE MTS GENE AND
TITLE OF INVENTION: METHOD FOR DETECTING PREDISPOSITION TO CANCER AT THE MTS
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESSES:
ADDRESSES: Venable, Baetjer, Howard & Civiletti, LLP
STREET: 1201 New York Avenue, Suite 1000
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/848,251
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/474,083
FILING DATE: 07-JUN-1995
APPLICATION NUMBER: PCT/US95/03537
FILING DATE: 17-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/251,938
FILING DATE: 01-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,087
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,086
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/227,369
FILING DATE: 14-APR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/214,582
FILING DATE: 18-MAR-1994
ATTORNEY/AGENT INFORMATION:

NAME: Ihnen, Jeffrey L.
REGISTRATION NUMBER: 28,957
REFERENCE/DOCKET NUMBER: 24884-109348-G
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-962-4810
TELEFAX: 202-962-8300
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-08-848-251-21

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 53;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1465 GCGGCCGAGACCCUCA 1480
Db 16 GCTGGCCAGACCTCA 1

RESULT 71
US-08-486-047-21/c
Sequence 21, Application US/08486047
Patent No. 5994095
GENERAL INFORMATION:
APPLICANT: Kamb, Alexander
TITLE OF INVENTION: MTS2 GENE
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESSES:
ADDRESSES: Venable, Baetjer, Howard & Civiletti, LLP
STREET: 1201 New York Avenue, Suite 1000
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/486,047
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/03316
FILING DATE: 17-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/251,938
FILING DATE: 01-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,087
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,086
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/227,369
FILING DATE: 14-APR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/214,582
FILING DATE: 18-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Ihnen, Jeffrey L.
REGISTRATION NUMBER: 28,957

REFERENCE/DOCKET NUMBER: 24884-109348-B
TELEPHONE: 202-962-4810
TELEFAX: 202-962-8300
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-09-120-130-21

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 53;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1465 GCGGCCGAGACCCUCA 1480
Db 16 GCTGGCCAGACCTCA 1

RESULT 72
US-09-120-130-21/c
Sequence 21, Application US/09120130
Patent No. 6037462
GENERAL INFORMATION:
APPLICANT: Kamb, Alexander
TITLE OF INVENTION: MTS1 GENE
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
STREET: 1201 New York Avenue, Suite 1000
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09120,130
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/480,810
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/251,938
FILING DATE: 01-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,087
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,086
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/227,369
FILING DATE: 14-APR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/214,582
FILING DATE: 18-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Ihnen, Jeffrey L.
REGISTRATION NUMBER: 28,957
REFERENCE/DOCKET NUMBER: 24884-109348
TELECOMMUNICATION INFORMATION:

TELEPHONE: 202-962-4810
TELEFAX: 202-962-8300
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-09-120-130-21

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 53;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1465 GCGGCCGAGACCCUCA 1480
Db 16 GCTGGCCAGACCTCA 1

RESULT 73
US-09-115-252-21/c
Sequence 21, Application US/09115252
Patent No. 6060301
GENERAL INFORMATION:
APPLICANT: Kamb, Alexander
TITLE OF INVENTION: MTS1 GENE
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
STREET: 1201 New York Avenue, Suite 1000
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09115,252
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/480,810
FILING DATE: 07-JUN-1995
APPLICATION NUMBER: PCT/US95/03316
FILING DATE: 17-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/251,938
FILING DATE: 01-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,087
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,086
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/227,369
FILING DATE: 14-APR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/214,582
FILING DATE: 18-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Ihnen, Jeffrey L.
REGISTRATION NUMBER: 28,957
REFERENCE/DOCKET NUMBER: 24884-109348
TELECOMMUNICATION INFORMATION:

TELEPHONE: 202-962-4810
TELEFAX: 202-962-8300
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-09-115-252-21

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 53;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1465 GCGGCCGAGACCCUCA 1480
Db 16 GCTGGCCAGACCTCA 1

RESULT 74
US-08-986-515-21/c
Sequence 21, Application US/08986515
Patent No. 6090578
GENERAL INFORMATION:
APPLICANT: Kamb, Alexander
TITLE OF INVENTION: MTS1 GENE
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
STREET: 1201 New York Avenue, Suite 1000
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/986,515
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/480,810
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/251,938
FILING DATE: 01-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,087
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,086
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/227,369
FILING DATE: 14-APR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/214,582
FILING DATE: 18-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Ihnen, Jeffrey L.
REGISTRATION NUMBER: 28,957
REFERENCE/DOCKET NUMBER: 24884-109348
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-962-4810
TELEFAX: 202-962-8300

INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-08-986-515-21

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 53;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1465 GCGGCCGAGACCCUCA 1480
Db 16 GCTGGCCAGACCTCA 1

RESULT 75
US-09-120-128-21/c
Sequence 21, Application US/09120128
Patent No. 6140473
GENERAL INFORMATION:
APPLICANT: Kamb, Alexander
TITLE OF INVENTION: MTS2 GENE
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
STREET: 1201 New York Avenue, Suite 1000
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/120,128
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/486,047
FILING DATE: 07-JUN-1995
APPLICATION NUMBER: PCT/US95/03316
FILING DATE: 17-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/251,938
FILING DATE: 01-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,087
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,086
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/227,369
FILING DATE: 14-APR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/214,582
FILING DATE: 18-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Ihnen, Jeffrey L.
REGISTRATION NUMBER: 28,957
REFERENCE/DOCKET NUMBER: 24884-109348-B
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-962-4810
TELEFAX: 202-962-8300

INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-09-120-128-21

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 53;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1465 GCGGCCGAGCCCTCA 1480
Db 16 GCTGGCCAGACCTCA 1

RESULT 76
US-08-765-340-152
Sequence 152, Application US/08765340
Patent No. 6150092
GENERAL INFORMATION:
APPLICANT: UCHIDA, K.,
APPLICANT: UCHIDA, T.,
APPLICANT: TANAKA, Y.,
APPLICANT: MATSUDA, Y.,
APPLICANT: KONDO, S.,
TITLE OF INVENTION: AN ANTISENSE NUCLEIC ACID
TITLE OF INVENTION: COMPOUND
NUMBER OF SEQUENCES: 185
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
STREET: 345 PARK AVENUE
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10154
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version
SOFTWARE: #1.30 (BPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/765,340
FILING DATE: 23-DEC-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 145146/94
FILING DATE: 27-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 311130/94
FILING DATE: 21-NOV-1994
ATTORNEY/AGENT INFORMATION:
NAME: SERUNIAN, LESLIE
REGISTRATION NUMBER: 35,353
REFERENCE/DOCKET NUMBER: 1452-4005
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 758-4800
TELEFAX: (212) 751-6849
INFORMATION FOR SEQ ID NO: 152:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
HYPOTHETICAL: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-08-765-340-152

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 53;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 674 UCCUCAGUGAGCCAC 689
Db 1 TCCTCAGTGGGACAC 16

RESULT 77
US-09-120-129-21/c
Sequence 21, Application US/09120129
Patent No. 6180776
GENERAL INFORMATION:
APPLICANT: Kamb, Alexander
TITLE OF INVENTION: MTS2 GENE
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
STREET: 1201 New York Avenue, Suite 1000
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/120,129
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/486,047
FILING DATE: 07-JUN-1995
APPLICATION NUMBER: PCT/US95/03316
FILING DATE: 17-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/251,938
FILING DATE: 01-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,087
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/215,086
FILING DATE: 18-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/227,369
FILING DATE: 14-APR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/214,582
FILING DATE: 18-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Ihnen, Jeffrey L.
REGISTRATION NUMBER: 28,957
REFERENCE/DOCKET NUMBER: 24884-109348-B
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-962-4810
TELEFAX: 202-962-8300
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-09-120-129-21

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 53;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1465 GCGGCCAGACCTCA 1480
DB 16 GCTGGCCAGACCTCA 1

RESULT 78

US-09-201-139-21/c
; Sequence 21, Application US/09201139
; Patent No. 6210949
; GENERAL INFORMATION:
; APPLICANT: Stone, Steven
; APPLICANT: Jiang, Ping
; APPLICANT: Kamb, Alexander
; TITLE OF INVENTION: MTS GENE AND THERAPEUTIC USE THEREOF
; NUMBER OF SEQUENCES: 47
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
; STREET: 1201 New York Avenue, Suite 1000
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/201,139
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/508,735
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/03316
; FILING DATE: 17-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 24884-109348
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-962-8300
; TELEFAX: 202-962-8300
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; US-09-201-139-21

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 53;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1465 GCGGCCAGACCTCA 1480
DB 16 GCTGGCCAGACCTCA 1

RESULT 79
US-09-120-131-21/c

; Sequence 21, Application US/09120131
; Patent No. 6218146

; GENERAL INFORMATION:
; APPLICANT: Kamb, Alexander
; TITLE OF INVENTION: MTS2 GENE
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Venable, Baetjer, Howard & Civiletti, LLP
; STREET: 1201 New York Avenue, Suite 1000
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/120,131
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/486,047
; FILING DATE: 07-JUN-1995
; APPLICATION NUMBER: PCT/US95/03316
; FILING DATE: 17-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/251,938
; FILING DATE: 01-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,087
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/215,086
; FILING DATE: 18-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/227,369
; FILING DATE: 14-APR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/214,582
; FILING DATE: 18-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 24884-109348-B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-962-4810
; TELEFAX: 202-962-8300
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; US-09-120-131-21

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 53;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1465 GCGGCCAGACCTCA 1480
DB 16 GCTGGCCAGACCTCA 1

RESULT 80
US-09-696-791-4136

```
; Sequence 4136, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: Patentln Ver. 2.0
; SEQ ID NO 4136
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Hairpin ribozyme recognition site for cyclin B1
US-09-696-791-4136

Query Match          0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 53;
Matches      8; Conservative      6; Mismatches      2; Indels      0; Gaps      0;

Qy      725 UGCCUGUACCAUUAU 740
      :|||:|||||:
Db      1 TGACTGTCTCCATTAT 16

RESULT 81
US-09-696-791-4366
; Sequence 4366, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Trletz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: Patentln Ver. 2.0
; SEQ ID NO 4366
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Hammerhead ribozyme recognition site for cyclin B1
US-09-696-791-4366

Query Match          0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 53;
Matches      8; Conservative      6; Mismatches      2; Indels      0; Gaps      0;

Qy      725 UGCCUGUACCAUUAU 740
      :|||:|||||:
Db      1 TGACTGTCTCCATTAT 16

RESULT 82
US-09-856-662-17
; Sequence 17, Application US/09856662
; Patent No. 6790616
; GENERAL INFORMATION:
; APPLICANT: MORIBE, Toyoki et al.
; TITLE OF INVENTION: Method for typing HLA class I genes
; FILE REFERENCE: 0032-0261P
; CURRENT APPLICATION NUMBER: US/09/856,662
; CURRENT FILING DATE: 2001-05-24
; PRIOR APPLICATION NUMBER: JP P1998-335151
; PRIOR FILING DATE: 1998-11-26
; NUMBER OF SEQ ID NOS: 130
```

```
; SOFTWARE: Patentln Ver. 2.0
; SEQ ID NO 17
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:DNA probe A368A
US-09-856-662-17

Query Match          0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 53;
Matches     12; Conservative      2; Mismatches      2; Indels      0; Gaps      0;

Qy      915 GAGGAAGUAGGCCGC 930
      |||||:|||||:
Db      1 GAGGATGTATGCTGC 16

RESULT 83
US-09-720-435A-114/C
; Sequence 114, Application US/09720435A
; Patent No. 6803187
; GENERAL INFORMATION:
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for detection of drug-selected mutations in the protease
; TITLE OF INVENTION: gene
; FILE REFERENCE: 11362.0030.PCUS00 INNS.030
; CURRENT APPLICATION NUMBER: US/09/720,435A
; CURRENT FILING DATE: 2001-06-25
; PRIOR APPLICATION NUMBER: PCT/EP99/04317
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 98870143.9
; PRIOR FILING DATE: 1998-06-24
; NUMBER OF SEQ ID NOS: 529
; SOFTWARE: Patentln version 3.2
; SEQ ID NO 114
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Aids-associated retrovirus
US-09-720-435A-114

Query Match          0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 50.0%; Pred. No. 53;
Matches      8; Conservative      6; Mismatches      2; Indels      0; Gaps      0;

Qy      685 CCCACCAUUAUUUG 700
      |||||:|||||:
Db      16 CCCACTATTATTATTG 1

RESULT 84
PCT-US94-12947A-15
; Sequence 15, Application PC/TUS9412947A
; GENERAL INFORMATION:
; APPLICANT: The Johns Hopkins University School of Medicine
; TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION BY
; TITLE OF INVENTION: ANALYSIS OF SPUTUM
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Spensley Horn Jubas & Lubitz
; STREET: 1880 Century Park East, Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90067
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentln Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/12947A
; FILING DATE: 10-NOV-1994
```

CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Haile, Ph.D., Lisa A.
REGISTRATION NUMBER: P-38,347
REFERENCE/DOCKET NUMBER: PD-2912
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 455-5100
TELEFAX: (619) 455-5110
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULAR TYPE: DNA (genomic)
FEATURE:
NAME/KEY: CDS
LOCATION: 1..16
PCT-US94-12947A-15

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 53;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 45 CAUCAGCUCUCUCG 60
DB 1 CACCGACCCCTCTGG 16

RESULT 85
US-08-291-932A-378/c
Sequence 378, Application US/08291932A
Patent No. 5658780
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth G.
APPLICANT: McSwigen, James
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: NP-KB
NUMBER OF SEQUENCES: 830
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/291,932A
FILING DATE: August 15, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600

Two

TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 378:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-291-932A-378

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 53;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1177 GAGCAGAGCTGGG 1190
DB 14 GAGCAGAGCTGGG 1

RESULT 86
US-08-311-486C-251
Sequence 251, Application US/08311486C
Patent No. 5811300
GENERAL INFORMATION:
APPLICANT: Sean Sullivan
APPLICANT: Kenneth Draper
APPLICANT: Kevin Kisch
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: TNF- α
NUMBER OF SEQUENCES: 1157
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/311,486C
FILING DATE: September 23, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/166
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 955-0440
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 251:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

Two

US-08-311-486C-251

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 53;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 96 AACGCGACUCACU 109
|||||
2 AACGCGACUCACU 15

RESULT 87

US-08-292-620A-477
; Sequence 477, Application US/08292620A
; Patent No. 5837542

GENERAL INFORMATION:

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/292,620A

FILING DATE: August 17, 1994

CLASSIFICATION: 435

PRIOR APPLICATION DATA: including application

PRIOR APPLICATION DATA: described below:

APPLICATION NUMBER: 08/008,895

FILING DATE: January 19, 1993

APPLICATION NUMBER: 07/989,849

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/149

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 477:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-292-620A-477

Query Match 0.7%; Score 12.4; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 53;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1355 CCACGCUACUCUG 1368

Db 1 CCACGCUACUCUG 14

RESULT 88

US-08-292-620A-571
; Sequence 571, Application US/08292620A
; Patent No. 5837542

GENERAL INFORMATION:

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/292,620A

FILING DATE: August 17, 1994

CLASSIFICATION: 435

PRIOR APPLICATION DATA: including application

PRIOR APPLICATION DATA: described below:

APPLICATION NUMBER: 08/008,895

FILING DATE: January 19, 1993

APPLICATION NUMBER: 07/989,849

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/149

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 571:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-292-620A-571

Query Match 0.7%; Score 12.4; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 53;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1355 CCACGCUACUCUG 1368
|||||
1 CCACGCUACUCUG 14

RESULT 89

US-08-585-684B-2056/C
; Sequence 2056, Application US/08585684B

Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2056:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-2056

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 53;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 282 GGUCAACAGCAGC 295
||:|||||
Db 15 GGTGACGACGAGC 2

RESULT 90
US-08-585-684B-2330/C
Sequence 2330, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.

ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2330:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-2330

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 53;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 282 GGUCAACAGCAGC 295
||:|||||
Db 15 GGTGACGACGAGC 2

RESULT 91
US-08-740-821-1
Sequence 1, Application US/08740821
Patent No. 5910583
GENERAL INFORMATION:
APPLICANT: Marks, Jeffrey R.
APPLICANT: Vaughn, James P.
APPLICANT: Iglehart, James D.
TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 8
CORRESPONDENCE ADDRESS:
ADDRESSEE: Bell, Seltzer, Park & Gibson, P.A.
STREET: Post Office Drawer 34009
CITY: Charlotte
STATE: No. 5910583th Carolina
COUNTRY: USA
ZIP: 28234
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/740,821
FILING DATE: 04-NOV-1996
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Sibley, Kenneth D.
REGISTRATION NUMBER: 31,665
REFERENCE/DOCKET NUMBER: 5405-134
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-420-2200
TELEFAX: 919-861-3175
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "OLIGONUCLEOTIDE"
US-08-740-821-1

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 64.3%; Pred. No. 53;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 1095 CUCCAGUGGUCUCA 1108
Db 1 CTCGATGGTGTCTCA 14

RESULT 92
US-08-667-939A-11
Sequence 11, Application US/08667939A
Patent No. 5998166
GENERAL INFORMATION:

APPLICANT: LEO, Shun
TITLE OF INVENTION: CD16-11 VARIANTS
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: BROWDY AND NEIMARK
STREET: 419 Seventh Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20004

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/667,939A
FILING DATE: 24-JUN-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/433,123
FILING DATE: 03-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: BROWDY, Roger L.
REGISTRATION NUMBER: 25,618
REFERENCE/DOCKET NUMBER: LEO-2A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-628-5197
TELEFAX: 202-737-3528

INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA

US-08-667-939A-11

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 53;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1712 AGCAGUACGACGAG 1725
Db 2 AGCAGTACGACGAG 15

RESULT 93
US-08-667-939A-22/C
Sequence 22, Application US/08667939A
Patent No. 5998166
GENERAL INFORMATION:

APPLICANT: LEO, Shun
TITLE OF INVENTION: CD16-11 VARIANTS
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: BROWDY AND NEIMARK
STREET: 419 Seventh Street, N.W., Suite 300
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/667,939A
FILING DATE: 24-JUN-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/433,123
FILING DATE: 03-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: BROWDY, Roger L.
REGISTRATION NUMBER: 25,618
REFERENCE/DOCKET NUMBER: LEO-2A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-628-5197
TELEFAX: 202-737-3528
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 53;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1712 AGCAGUACGACGAG 1725
Db 14 AGCAGTACGACGAG 1

RESULT 94
US-08-577-081A-71
Sequence 71, Application US/08577081A
Patent No. 6030775
GENERAL INFORMATION:

APPLICANT: Yang, Soo Young
TITLE OF INVENTION: Methods and Reagents for Typing HLA
NUMBER OF SEQUENCES: 84
CORRESPONDENCE ADDRESS:
ADDRESSEE: Oppedahl & Larson
STREET: 1992 Commerce Street Suite 309
CITY: Yorktown
STATE: NY
COUNTRY: US
ZIP: 10598

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/577,081A
FILING DATE: 435
CLASSIFICATION:
PRIOR APPLICATION DATA:

APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Larson, Marina T.
REGISTRATION NUMBER: 32,038
REFERENCE/DOCKET NUMBER: MSK-P-001-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (914) 245-3252
TELEFAX: (914) 962-4330
TELEX:
INFORMATION FOR SEQ ID NO: 71:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
HYPOTHETICAL: no
ANTI-SENSE: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: human
FEATURE:
OTHER INFORMATION: hybridization probe 1421K for typing of
US-08-577-081A-71
OTHER INFORMATION: HLA Class I genes
Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 53;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1420 CAGATCACCACGCG 1433
DB 1 CAGATCACCACGCG 14
RESULT 95
US-08-908-643C-80/C
Sequence 80, Application US/08908643C
Patent No. 6120995
GENERAL INFORMATION:
APPLICANT: Waldman, Scott A.
Pearlman, Joshua M.
Barber, Michael T.
Schultz, Stephanie
Parkinson, Scott J.
TITLE OF INVENTION: COMPOSITIONS THAT SPECIFICALLY BIND TO
COLORECTAL CANCER CELLS AND METHODS OF
USING THE SAME
NUMBER OF SEQUENCES: 85
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6120995rls LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 MB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/908,643C
FILING DATE: 07-Aug-1997
CLASSIFICATION: N/A
PRIOR APPLICATION DATA:
APPLICATION NUMBER: <Unknown>
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Mark Deluca
REGISTRATION NUMBER: 33,229
REFERENCE/DOCKET NUMBER: TJU-2209

TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 80:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
US-08-908-643C-80
SEQUENCE DESCRIPTION: SEQ ID NO: 80:
Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 57.1%; Pred. No. 53;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
QY 264 GGAUUGUGUCAU 277
DB 14 GGAATGTGTGTCAT 1
RESULT 96
US-09-071-845-477
Sequence 477, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwigen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 477:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-477

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 53;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1355 CCACUCUACCCUG 1368
DB 1 CCACGCUACCCUG 14

RESULT 97
US-09-071-845-571
Sequence 571, Application US/09071845
Patent No. 6132967
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Diaper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 571:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-571
Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 53;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1355 CCACUCUACCCUG 1368
DB 1 CCACGCUACCCUG 14

RESULT 98
US-09-038-073-2056/c
Sequence 2056, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2056:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-2056
Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 53;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 282 GGUCAACAAGCAGC 295
DB 15 GGTACGACAGCAGC 2
RESULT 99
US-09-038-073-2330/c
Sequence 2330, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE

TITLE OF INVENTION: INDUCTION OF GRaft TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION NUMBER: US/09/038,073
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2330:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-2330

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 53;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 282 GGUCAAGCAGCAGC 295
DB 15 GGTGACGACAGCAGC 2

RESULT 100
US-09-081-646-6
Sequence 6, Application US/09081646
Patent No. 6333152
GENERAL INFORMATION:
APPLICANT: Kinzler, Kenneth
APPLICANT: Vogelstein, Bert
APPLICANT: Zhou, Wei
TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
FILE REFERENCE: 01107,74664
CURRENT APPLICATION NUMBER: US/09/081,646
CURRENT FILING DATE: 1998-05-20
EARLIER APPLICATION NUMBER: 60/047,352
NUMBER OF SEQ ID NOS: 871
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 6
LENGTH: 15
TYPE: DNA
ORGANISM: Homo sapiens
US-09-081-646-6

Query Match 0.7%; Score 12.4; DB 1; Length 15;

Best Local Similarity 71.4%; Pred. No. 53;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 399 AUGGCGCUUAGGGA 412
DB 2 ATGGGCTTAGGGA 15

RESULT 101
US-09-081-646-26/C
Sequence 26, Application US/09081646
Patent No. 6333152
GENERAL INFORMATION:
APPLICANT: Kinzler, Kenneth
APPLICANT: Vogelstein, Bert
APPLICANT: Zhou, Wei
TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
FILE REFERENCE: 01107,74664
CURRENT APPLICATION NUMBER: US/09/081,646
CURRENT FILING DATE: 1998-05-20
EARLIER APPLICATION NUMBER: 60/047,352
NUMBER OF SEQ ID NOS: 871
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 26
LENGTH: 15
TYPE: DNA
ORGANISM: Homo sapiens
US-09-081-646-26

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 64.3%; Pred. No. 53;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 602 CUUCUGCAUUCUG 615
DB 14 CTCCTGCATCATG 1

RESULT 102
US-09-081-646-498
Sequence 498, Application US/09081646
Patent No. 6333152
GENERAL INFORMATION:
APPLICANT: Kinzler, Kenneth
APPLICANT: Vogelstein, Bert
APPLICANT: Zhou, Wei
TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
FILE REFERENCE: 01107,74664
CURRENT APPLICATION NUMBER: US/09/081,646
CURRENT FILING DATE: 1998-05-20
EARLIER APPLICATION NUMBER: 60/047,352
NUMBER OF SEQ ID NOS: 871
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 498
LENGTH: 15
TYPE: DNA
ORGANISM: Homo sapiens
US-09-081-646-498

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 53;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 399 AUGGCGCUUAGGGA 412
DB 2 ATGGGCTTAGGGA 15

RESULT 103
US-09-081-646-598/c
; Sequence 598, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzier, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152ml and
; TITLE OF INVENTION: Cancer Cells
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 598
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-598

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 53;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1158 GACAAACCCGACG 1171
DB 14 GACAAACCTGCATG 1

RESULT 104
US-08-433-123-11
; Sequence 11, Application US/08433123
; Patent No. 6444789
; GENERAL INFORMATION:
; APPLICANT: Luo, Shun
; TITLE OF INVENTION: CD16-II VARIANTS
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BROWDY AND NEIMARK
; STREET: 419 Seventh Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/433,123
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: BROWDY, Roger L.
; REGISTRATION NUMBER: 25,618
; REFERENCE/DOCKET NUMBER: LJO=2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; TELEX: 248633
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA

US-08-433-123-11

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 53;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1712 AGCAGUACGACG 1725
DB 2 AGCAGTAGCAGCAG 15

RESULT 105
US-08-433-123-22/c
; Sequence 22, Application US/08433123
; Patent No. 6444789
; GENERAL INFORMATION:
; APPLICANT: Luo, Shun
; TITLE OF INVENTION: CD16-II VARIANTS
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BROWDY AND NEIMARK
; STREET: 419 Seventh Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/433,123
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: BROWDY, Roger L.
; REGISTRATION NUMBER: 25,618
; REFERENCE/DOCKET NUMBER: LJO=2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; TELEX: 248633
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-433-123-22

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 53;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1712 AGCAGUACGACG 1725
DB 14 AGCAGTAGCAGCAG 1

RESULT 106
US-10-134-021-19/c
; Sequence 19, Application US/10134021
; Patent No. 6936259
; GENERAL INFORMATION:
; APPLICANT: POTTER, Andrew A.
; APPLICANT: PEREZ-CASAL, Jose
; APPLICANT: FONTAINE, Michael
; APPLICANT: SONG, Ximing
; TITLE OF INVENTION: CAMP FACTOR OF STREPTOCOCCUS UBERIS
; FILE REFERENCE: 9000-0030.20
; CURRENT APPLICATION NUMBER: US/10/134,021

;; CURRENT FILING DATE: 2002-04-26
;; NUMBER OF SEQ ID NOS: 19
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO 19
;; LENGTH: 15
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: 556-2
US-10-134-021-19

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 53;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 816 GACAGAGCAGAGA 829
DB 15 GACAGAGCAGAGA 2

RESULT 107
US-10-138-674B-7793
; Sequence 7793, Application US/10138674B
; Patent No. 7034009
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Rescbedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674B
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20829
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7793
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674B-7793

Query Match 0.7%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 76;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 984 CCAAGACCAGCAGCA 1000
DB 1 CCAAGCCAGCAGCAGCA 17

RESULT 108
US-08-435-350-108
; Sequence 108, Application US/08435350
; Patent No. 5599704
; GENERAL INFORMATION:
; APPLICANT: James D. Thompson
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: TREATMENT OF BREAST CANCER
; NUMBER OF SEQUENCES: 118
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)

;; SOFTWARE: WordPerfect (Version 5.1)
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/435,350
;; FILING DATE: 05-MAY-1995
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 07/936,531
;; FILING DATE: August 26, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 197/245
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 108:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-435-350-108

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1680 GUGCCAGUGUGA 1691
DB 3 GUGCCAGUGUGA 14

RESULT 109
US-08-266-414-5
; Sequence 5, Application US/08266414
; Patent No. 5610060
; GENERAL INFORMATION:
; APPLICANT: WARD, JERROLD M.
; APPLICANT: FOX, JAMES G.
; APPLICANT: COLLINS, JR., MICHAEL J.
; APPLICANT: GORELICK, PETER L.
; APPLICANT: BENVENISTE, RAOUL B.
; APPLICANT: TULLY, JOSEPH G.
; APPLICANT: GONDA, MATTHEW A.
; TITLE OF INVENTION: HELICOBLASTER HEPATITIS AND RELATED
; TITLE OF INVENTION: METHODS
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NEEDLE & ROSENBERG, P.C.
; STREET: Suite 1200, 127 Peachtree Street
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: USA
; ZIP: 30303
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/266,414
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Spratt, Gwendolyn D.
; REGISTRATION NUMBER: 36,016
; REFERENCE/DOCKET NUMBER: 1414.090
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 404/688-0880
; TELEFAX: 404/688-9880
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: oligonucleotide
US-08-266-414-5

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 75.0%; Pred. No. 61;
Matches 9; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1025 CUGUGCCUCCC 1036
DB 2 CUGUGCCUCCC 13

RESULT 110

US-08-291-932A-31/c
Sequence 31, Application US/08291932A
Patent No. 5658780
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: NF-KB
NUMBER OF SEQUENCES: 830
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/291,932A
FILING DATE: August 15, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ. ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-291-932A-31

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 75.0%; Pred. No. 61;
Matches 9; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 236 CCUGUGACCA 247
DB 15 CCTTGTGACCA 4

RESULT 111
US-08-291-932A-220/c
Sequence 220, Application US/08291932A
Patent No. 5658780
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: NF-KB
NUMBER OF SEQUENCES: 830
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/291,932A
FILING DATE: August 15, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ. ID NO: 220:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-291-932A-220

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 75.0%; Pred. No. 61;
Matches 9; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 236 CCUGUGACCA 247
DB 15 CCTTGTGACCA 4

RESULT 112
US-08-334-847-497/c
Sequence 497, Application US/08334847
Patent No. 5693532

GENERAL INFORMATION:
APPLICANT: McSwigen, James
APPLICANT: Draper, Kenneth
APPLICANT: Pavco, Pam
APPLICANT: Woolf, Tod
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING RESPIRATORY
TITLE OF INVENTION: SYNCTIAL VIRUS
NUMBER OF SEQUENCES: 909
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/334,847
FILING DATE: No. 5693532ember 4, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/032
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 497:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-334-847-497

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 61;
Matches 8; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1089 CAUCUACUCCAU 1100
DB 12 CATCTACTCAT 1

RESULT 113
US-08-334-847-657
Sequence 657, Application US/08334847
Patent No. 5693532
GENERAL INFORMATION:
APPLICANT: McSwigen, James
APPLICANT: Draper, Kenneth
APPLICANT: Pavco, Pam
APPLICANT: Woolf, Tod
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING RESPIRATORY
TITLE OF INVENTION: SYNCTIAL VIRUS
NUMBER OF SEQUENCES: 909
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California

COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/334,847
FILING DATE: No. 5693532ember 4, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/032
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 657:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-334-847-657

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 CAAACUACGCU 52
DB 1 CAAACUACGCU 12

RESULT 114
US-08-585-684B-1244/C
Sequence 1244, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1244:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-1244

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 83.3%; Pred. No. 61;
Matches 10; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1649 CAUUCAGAACCA 1660
Db 15 CATTGAGAACCA 4

RESULT 115
US-08-585-684B-1245/C
Sequence 1245, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1245:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-1245

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 83.3%; Pred. No. 61;

Matches 10; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 1649 CAUUCAGAACCA 1660
Db 14 CATTGAGAACCA 3

RESULT 116
US-09-191-099-19
Sequence 19, Application US/09191099
Patent No. 6096323
GENERAL INFORMATION:
APPLICANT: Walker, Richard L.
APPLICANT: Read, Deryck H.
APPLICANT: Hird, David W.
APPLICANT: Lefebvre, Rance B.
APPLICANT: Betty, Steven L.
APPLICANT: Cullor, James S.
APPLICANT: Lefler, Hank M.
TITLE OF INVENTION: The Regents of the University of California
TITLE OF INVENTION: Vaccine Against Papillomatous Digital Dermatitis (PDD)
FILE REFERENCE: 023070-081110US
CURRENT APPLICATION NUMBER: US/09/191,099
CURRENT FILING DATE: 1998-11-12
EARLIER APPLICATION NUMBER: US 08/943,571
EARLIER FILING DATE: 1997-10-03
NUMBER OF SEQ ID NOS: 20
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 19
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence:reverse primer
US-09-191-099-19

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 75.0%; Pred. No. 61;
Matches 9; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1025 CUCGUCGCUCCC 1036
Db 1 CTGCTGCTCTCCC 12

RESULT 117
US-09-252-806-4/C
Sequence 4, Application US/09252806
Patent No. 6171844
GENERAL INFORMATION:
APPLICANT: NUMATA, Kiochi
APPLICANT: ODA, Yasushi
APPLICANT: MIYATA, Masami
APPLICANT: OKAMURA, Yukio
APPLICANT: KIMURA, Toshiaki
APPLICANT: UCHIDA, Masatoshi
TITLE OF INVENTION: No. 6171844el Microorganisms and Method for Environmental
TITLE OF INVENTION: Purification using the Same
FILE REFERENCE: 77670/576
CURRENT APPLICATION NUMBER: US/09/252,806
CURRENT FILING DATE: 1999-02-19
NUMBER OF SEQ ID NOS: 10
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 4
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: synthetic DNA
US-09-252-806-4

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 75.0%; Pred. No. 61;

Matches 9; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1025 CUGUCGCUCCC 1036
|:|:|:|:|:|:|
Db 15 CTGCTGCTGCC 4

RESULT 118
US-09-038-073-1244/c
; Sequence 1244, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1244:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-1244

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 83.3%; Pred. No. 61;
Matches 10; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1649 CAUUCAGAACCA 1660
||:|:|:|:|:|:|
Db 15 CATTCAGAACCA 4

RESULT 119
US-09-038-073-1245/c
; Sequence 1245, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE

; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1245:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-1245

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 83.3%; Pred. No. 61;
Matches 10; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1649 CAUUCAGAACCA 1660
||:|:|:|:|:|:|
Db 14 CATTCAGAACCA 3

RESULT 120
US-09-142-779-4
; Sequence 4, Application US/09142779B
; Patent No. 620960
; GENERAL INFORMATION:
; APPLICANT: Khachigian, Levon M.
; TITLE OF INVENTION: Inhibition of Proliferation of Cells
; FILE REFERENCE: 273402002000
; CURRENT APPLICATION NUMBER: US/09/142,779B
; EARLIER FILING DATE: 1999-04-13
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 4
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; US-09-142-779-4

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 83.3%; Pred. No. 61;
Matches 10; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 924 UGCGCCGCUCCCA 935
:|||||:|||||
DB 3 TGCGCCGCTGCCA 14

RESULT 121

US-08-943-571-13
Sequence 13, Application US/08943571
Patent No. 6287575
GENERAL INFORMATION:
APPLICANT: Walker, Richard L.
APPLICANT: Read, Deryck H.
APPLICANT: Hird, David W.
APPLICANT: Lefebvre, Rance B.
APPLICANT: Berry, Steven L.
APPLICANT: Cullor, James S.
APPLICANT: Lefler, Hank M.
TITLE OF INVENTION: Vaccine Against Papillomatous Digital
TITLE OF INVENTION: Dermatitis (PDD)
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/943,571
FILING DATE: 03-OCT-1997
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Parent, Annette S.
REGISTRATION NUMBER: 42,058
REFERENCE/DOCKET NUMBER: 023070-081100US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
FEATURE:
NAME/KEY: -
LOCATION: 1..15
OTHER INFORMATION: /note="reverse primer"
US-08-943-571-13

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 75.0%; Pred. No. 61;
Matches 9; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1025 CUGCGCCUCCC 1036
:|||||:|||||
DB 1 CTGCTGCTGCC 12

RESULT 122
US-09-711-508-4/C
Sequence 4, Application US/09711508
Patent No. 6521444
GENERAL INFORMATION:
APPLICANT: NUMATA, Kiochi
APPLICANT: ODA, Yasushi

APPLICANT: MIYATA, Masami
APPLICANT: OKAMURA, Yukio
APPLICANT: KIMURA, Toshiaki
APPLICANT: UCHIDA, Masatoshi
TITLE OF INVENTION: No. 6521444el Microorganisms and Method for Environmental
FILE REFERENCE: 77670/576
CURRENT APPLICATION NUMBER: US/09/711,508
CURRENT FILING DATE: 2000-11-14
PRIOR APPLICATION NUMBER: US/09/252,806
PRIOR FILING DATE: 1999-02-19
NUMBER OF SEQ ID NOS: 10
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 4
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: synthetic DNA
US-09-711-508-4

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 75.0%; Pred. No. 61;
Matches 9; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1025 CUGCGCCUCCC 1036
:|||||:|||||
DB 15 CTGCTGCTGCC 4

RESULT 123
US-10-085-871C-10/C
Sequence 10, Application US/10085871C
Patent No. 6716615
GENERAL INFORMATION:
APPLICANT: Lee, Fang-Yu
APPLICANT: Lee, Ming-Liang
APPLICANT: Anderson, Hong C.
APPLICANT: Chiu, Chung-Ching
TITLE OF INVENTION: New Strains of Saccharothrix, Process for Producing Pravastatin U
FILE REFERENCE: 004135.P005
CURRENT APPLICATION NUMBER: US/10/085,871C
CURRENT FILING DATE: 2002-02-27
NUMBER OF SEQ ID NOS: 12
SOFTWARE: PatentIn version 3.1
SEQ ID NO 10
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer of 16S rDNA of Saccharothrix 44442 and Saccharothrix 45494
US-10-085-871C-10

Query Match 0.7%; Score 12; DB 1; Length 15;
Best Local Similarity 75.0%; Pred. No. 61;
Matches 9; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1025 CUGCGCCUCCC 1036
:|||||:|||||
DB 15 CTGCTGCTGCC 4

RESULT 124
US-10-085-871C-11
Sequence 11, Application US/10085871C
Patent No. 6716615
GENERAL INFORMATION:
APPLICANT: Lee, Fang-Yu
APPLICANT: Lee, Ming-Liang
APPLICANT: Anderson, Hong C.
APPLICANT: Chiu, Chung-Ching
TITLE OF INVENTION: New Strains of Saccharothrix, Process for Producing Pravastatin U

```

; TITLE OF INVENTION: Strains and Isolation Process of (HMG)-COA Reductase
; FILE REFERENCE: 004135.P005
; CURRENT APPLICATION NUMBER: US/10/085,871C
; CURRENT FILING DATE: 2002-02-27
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 11
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer of 16s rDNA of Saccharothrix 44442 and Saccharothrix 45494
US-10-085-871C-11

Query Match
Best Local Similarity 0.7%; Score 12; DB 1; Length 15;
Matches 9; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1025 CUGCGCCGCCCC 1036
DB 1 CTGCTGCTCTCC 12

RESULT 125
US-09-775-818-13/C
; Sequence 13, Application US/09775818
; Patent No. 6872525
; GENERAL INFORMATION:
; APPLICANT: Laboratory of Molecular Biophotonics
; TITLE OF INVENTION: Method for selectively separating live cells expressing
; FILE REFERENCE: PP00-0043-00
; CURRENT APPLICATION NUMBER: US/09/775,818
; CURRENT FILING DATE: 2000-04-28
; PRIOR APPLICATION NUMBER: JP 2000/028117
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: JP 2000/130793
; PRIOR FILING DATE: 2000-04-28
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 13
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Probe
US-09-775-818-13

Query Match
Best Local Similarity 0.7%; Score 12; DB 1; Length 15;
Matches 8; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 835 AACUUGUCCAC 846
DB 13 AACTTGTCAC 2

RESULT 126
US-09-648-389A-1
; Sequence 1, Application US/09648389A
; Patent No. 6969704
; GENERAL INFORMATION:
; APPLICANT: Pinsky, David
; APPLICANT: Stern, David
; APPLICANT: Yan, Shi-Fang
; TITLE OF INVENTION: Methods for Suppressing Early Growth Response-1 Protein (Egr-1)
; FILE REFERENCE: 0575/62683
; CURRENT APPLICATION NUMBER: US/09/648,389A
; CURRENT FILING DATE: 2000-08-25
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 1
```

```

; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-648-389A-1

Query Match
Best Local Similarity 0.7%; Score 12; DB 1; Length 15;
Matches 10; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 924 UGCGCGCCGCA 935
DB 3 TGGCGCTGCCA 14

RESULT 127
US-09-341-700A-672/C
; Sequence 672, Application US/09341700A
; Patent No. 6972171
; GENERAL INFORMATION:
; APPLICANT: Schlingensiefen, Karl-Hermann
; APPLICANT: Brysch, Wolfgang
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
; FILE REFERENCE: 10496/P63763USO
; CURRENT APPLICATION NUMBER: US/09/341,700A
; CURRENT FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: PCT/EP98/00497
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: EP 97 101 531.8
; PRIOR FILING DATE: 1997-01-31
; NUMBER OF SEQ ID NOS: 1764
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 672
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
US-09-341-700A-672

Query Match
Best Local Similarity 0.7%; Score 12; DB 1; Length 15;
Matches 5; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 740 UGACUUNUUAU 751
DB 14 TGACTATTAT 3

RESULT 128
US-09-723-368-5/C
; Sequence 5, Application US/09723368
; Patent No. 6641818
; GENERAL INFORMATION:
; APPLICANT: NORTHWESTERN UNIVERSITY
; APPLICANT: SPEAR, Patricia G.
; APPLICANT: WARNER, Morgyn S.
; APPLICANT: GERAGHTY, Robert G.
; APPLICANT: MARTINEZ, Wanda M.
; APPLICANT: MONTGOMERY, Rebecca I.
; APPLICANT: COHEN, Gary H.
; APPLICANT: EISENBERG, Roselyn J.
; APPLICANT: WHITEBECK, Charles J.
; APPLICANT: KRUMENACHER, Claude
; APPLICANT: UNIVERSITY OF PENNSYLVANIA
; TITLE OF INVENTION: CELLULAR PROTEINS WHICH MEDIATE HERPESVIRUS ENTRY
; FILE REFERENCE: 200290.0050/201
; CURRENT APPLICATION NUMBER: US/09/723,368
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: U.S. 60/087,862
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: PCT/US99/12235
; PRIOR FILING DATE: 1999-06-02
```

; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 5
; LENGTH: 20
; TYPR: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Primer PRR2A8
US-09-723-368-5

Query Match 0.7%; Score 11.8; DB 1; Length 20;
Best Local Similarity 53.3%; Pred. No. 1.2e+02;
Matches 8; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1020 UGAGCGCGCGCCUC 1034
:|:|:|:|:|:|:|:
Db 16 TGGTGTCTGTCTTC 2

Search completed: June 30, 2006, 13:55:36
Job time : 3 secs

THIS PAGE BLANK (uspto)

PN WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
PF
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX Richards I, Macswigen J;
PI
XX WPI; 2005-356237/36.
DR
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 284; 184pp; English.
PS
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 21 BP; 1 A; 5 C; 5 G; 2 T; 8 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.9e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1712 AGCAGUACCGAGAGACA 1730
Db 19 AGCAGTACCAGCAGAGACA 1
RESULT 604
AEA02419
ID AEA02419 standard; RNA; 21 BP.
XX
XX AEA02419;
AC
XX 28-JUL-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 312.
DE
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KM microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX WO2005045040-A2.
PN
XX

PD 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
PF
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PA
XX Richards I, Macswigen J;
PI
XX WPI; 2005-356237/36.
DR
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 312; 184pp; English.
PS
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 21 BP; 7 A; 4 C; 4 G; 2 T; 4 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1011 GAACAAACAUGAUGGUGU 1029
Db 1 GAACAAACAUGAUGGUGU 19
RESULT 605
AEA02330
ID AEA02330 standard; RNA; 21 BP.
XX
XX AEA02330;
AC
XX 28-JUL-2005 (first entry)
DT
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 214.
DE
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KM Neuroprotective; Nootropic; Uropathic;
KM Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KM sinusitis; inflammation; allergy; cystic fibrosis; alzheimer's disease;
KM microtubulin disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KM siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
OS
XX WO2005045040-A2.
PN
XX 19-MAY-2005.
PD
XX

PF 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX WPI; 2005-356237/36.
XX
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 214; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 21 BP; 7 A; 5 C; 5 G; 2 T; 2 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1715 AGUACCGACGACGACGUC 1733
DB 1 AGUACCGACGACGACGUC 19
RESULT 606
AEA02338/c
ID AEA02338 standard; RNA; 21 BP.
XX
XX AEA02338;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 222.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neutroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX

PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX WPI; 2005-356237/36.
XX
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 222; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
XX Sequence 21 BP; 2 A; 5 C; 5 G; 2 T; 7 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1715 AGUACCGACGACGACGUC 1733
DB 19 AGTACCGACGACGACGTC 1
RESULT 607
AEA02343
ID AEA02343 standard; RNA; 21 BP.
XX
XX AEA02343;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 227.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
XX Neutroprotective; Nootropic; Uropathic;
XX Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
XX sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
XX mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
XX siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX

PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 227; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 7 A; 6 C; 5 G; 2 T; 1 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 975 GCAGAGACGACGACAC 993
DB 1 GCAGAGACGACGACAC 19
RESULT 608
AEA02393
ID AEA02393 standard; RNA; 21 BP.
XX
XX AEA02393;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 277.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX
XX 24-NOV-2003; 2003US-00720448.
XX
XX 03-DEC-2003; 2003US-00727780.
XX
XX 14-JAN-2004; 2004US-00757803.

PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00826966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Richards I, Macswiggen J;
XX
XX WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
XX
XX Claim 33; SEQ ID NO 277; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
XX
SQ Sequence 21 BP; 7 A; 5 C; 5 G; 2 T; 2 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1714 CAGUACGACGACGACGU 1732
DB 1 CAGUACGACGACGACGU 19
RESULT 609
AEA02406/c
ID AEA02406 standard; RNA; 21 BP.
XX
XX AEA02406;
XX
XX 28-JUL-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 siRNA SEQ ID NO 290.
XX
XX Respiratory-Gen.; Antiasthmatic; Antiallergic; Antiinflammatory;
KW Neuroprotective; Nootropic; Uropathic;
KW Chronic obstructive pulmonary disease; asthma; allergic rhinitis;
KW sinusitis; inflammation; allergy; cystic fibrosis; alzheimers disease;
KW mutation disorder; cholinergic receptor muscarinic 3; CHRM3; ss;
KW siRNA; RNA interference; gene silencing; short interfering RNA.
XX
XX Synthetic.
XX
XX WO2005045040-A2.
XX
XX 19-MAY-2005.
XX
XX 20-AUG-2004; 2004WO-US027367.
XX
XX 23-OCT-2003; 2003US-00693059.
XX
XX 24-NOV-2003; 2003US-00720448.
XX
XX 03-DEC-2003; 2003US-00727780.
XX
XX 14-JAN-2004; 2004US-00757803.
XX
XX 10-FEB-2004; 2004US-0543480P.
XX
XX 13-FEB-2004; 2004US-00780447.

PR 11-MAR-2004; 2004US-00798090.
PR 16-APR-2004; 2004US-00825966.
PR 30-APR-2004; 2004WO-US013456.
PR 24-MAY-2004; 2004WO-US016390.
PR 17-AUG-2004; 2004US-00919866.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PI Richards I, Macswigen J,
DR WPI; 2005-356237/36.
XX
XX New short interfering nucleic acid molecule that directs cleavage of a
PT cholinergic receptor muscarinic 3 RNA, useful for treating or preventing
PT respiratory and pulmonary diseases, e.g. chronic obstructive pulmonary
PT disease.
PS Claim 33; SEQ ID NO 290; 184pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA via RNA interference
CC (RNAi). The siRNA molecule, compounds, compositions, and methods are
CC useful for treating or preventing respiratory and pulmonary diseases,
CC disorders, and/or conditions, including chronic obstructive pulmonary
CC disease, asthma, allergic rhinitis, sinusitis, inflammation, allergies,
CC cystic fibrosis, Alzheimer's disease, and/or urinary incontinence. The
CC present sequence represents a cholinergic receptor muscarinic 3 siRNA.
SQ Sequence 21 BP; 6 A; 4 C; 7 G; 2 T; 2 U; 0 Other;
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.9e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
OY 317 UCCUCUAGCCUGGCCUG 335
 :||||:||||:||||:
DB 19 TCCTCTTAGCCTGGCTG 1
RESULT 610
ADM27981
ID ADM27981 standard; RNA; 23 BP.
XX
XX ADM27981;
AC
XX 07-APR-2005 (first entry)
DT
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #278.
DB
XX gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH misc_difference 22..23
FT /tag= a
FT /note="deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-0042716P.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGEN J.
XX
XX Richards I, Mcswigen J;
PI
XX WPI; 2005-090672/10.
DR
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 278; 84pp; English.
PS
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 23 BP; 7 A; 5 C; 5 G; 2 T; 2 U; 2 Other;
Query Match 1.1%; Score 19; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1715 AGUACGACGACAGACGUC 1733
 |||||
DB 2 AGUACGACGACGACGUC 20
RESULT 611
ADM27930
ID ADM27930 standard; RNA; 23 BP.
XX
XX ADM27930;
AC
XX 07-APR-2005 (first entry)
DT
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #227.
DB
XX gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KM incontinence; ss.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH misc_difference 22..23

```

FT      /*tag= a
FT      /note= "deoxythymidine nucleotide"
XX
XX
XX      US2005014172-A1.
XX
XX      20-JAN-2005.
XX
XX      11-MAR-2004; 2004US-00798090.
XX
XX      20-FEB-2002; 2002US-0358580P.
XX      11-MAR-2002; 2002US-0363124P.
XX      20-MAY-2002; 2002WO-US015876.
XX      06-JUN-2002; 2002US-0386782P.
XX      29-AUG-2002; 2002US-0406784P.
XX      05-SEP-2002; 2002US-0408378P.
XX      09-SEP-2002; 2002US-0409293P.
XX      15-JAN-2003; 2003US-0440129P.
XX      20-FEB-2003; 2003WO-US005028.
XX      20-FEB-2003; 2003WO-US005346.
XX      30-APR-2003; 2003US-00427160.
XX      23-MAY-2003; 2003US-00444853.
XX      23-OCT-2003; 2003US-00693059.
XX      24-NOV-2003; 2003US-00720448.
XX      14-JAN-2004; 2004US-00757803.
XX
XX      (RICH/) RICHARDS I.
XX      (MCSW/) MCSWIGGEN J.
XX
XX      Richards I, Mcswiggen J;
XX
XX      WPI; 2005-090672/10.
XX
XX      Novel chemically synthesized double stranded short interfering nucleic
XX      acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX      RNA through RNA interference, useful for treating asthma.
XX
XX      Disclosure; SEQ ID NO 227; 84pp; English.
XX
XX      The invention relates to a chemically synthesized double stranded short
XX      interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX      cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX      where each strand of (I) has 19-23 nucleotides, and does not require the
XX      presence of nucleotides having a 2-hydroxy group for mediating RNA
XX      interference. (I) is useful for treating diseases e.g., asthma, allergic
XX      rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX      vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX      Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX      towards nuclease. Double stranded short interfering nucleic acid molecule
XX      was produced by solid phase oligonucleotide synthesis method. This
XX      sequence represents an example of a siRNA molecule of the invention.
XX
XX      Sequence 23 BP; 7 A; 6 C; 5 G; 2 T; 1 U; 2 Other:
XX
XX      Query Match      1.1%; Score 19; DB 1; Length 23;
XX      Best Local Similarity 100.0%; Pred. No. 2.4e+02;
XX      Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX      QY      975 GCGAGGCGACCAAGACCAC 993
XX      |||||||
XX      DB      2 GCGAGGCGACCAAGACCAC 20
XX
XX      RESULT 612
XX      ADW27990
XX      ID      ADW27990 standard; RNA; 23 BP.
XX
XX      AC      ADW27990;
XX
XX      DT      07-APR-2005 (first entry)
XX
XX      DE      Cholinergic receptor muscarinic 3 gene targeted siRNA #287.
XX
XX      KW      gene expression; antiasthmatic; antiinflammatory; CNS-Gen.;

```

```

KW      respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW      neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW      cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW      inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW      hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW      incontinence; ss.
XX
XX      Synthetic.
XX
XX      Key      Location/Qualifiers
XX      FT      misc_difference 22..23
XX      FT      /*tag= a
XX      FT      /note= "deoxythymidine nucleotide"
XX
XX      US2005014172-A1.
XX
XX      20-JAN-2005.
XX
XX      11-MAR-2004; 2004US-00798090.
XX
XX      20-FEB-2002; 2002US-0358580P.
XX      11-MAR-2002; 2002US-0363124P.
XX      20-MAY-2002; 2002WO-US015876.
XX      06-JUN-2002; 2002US-0386782P.
XX      29-AUG-2002; 2002US-0406784P.
XX      05-SEP-2002; 2002US-0408378P.
XX      09-SEP-2002; 2002US-0409293P.
XX      15-JAN-2003; 2003US-0440129P.
XX      20-FEB-2003; 2003WO-US005028.
XX      20-FEB-2003; 2003WO-US005346.
XX      30-APR-2003; 2003US-00427160.
XX      23-MAY-2003; 2003US-00444853.
XX      23-OCT-2003; 2003US-00693059.
XX      24-NOV-2003; 2003US-00720448.
XX      14-JAN-2004; 2004US-00757803.
XX
XX      (RICH/) RICHARDS I.
XX      (MCSW/) MCSWIGGEN J.
XX
XX      Richards I, Mcswiggen J;
XX
XX      WPI; 2005-090672/10.
XX
XX      Novel chemically synthesized double stranded short interfering nucleic
XX      acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX      RNA through RNA interference, useful for treating asthma.
XX
XX      Disclosure; SEQ ID NO 296; 84pp; English.
XX
XX      The invention relates to a chemically synthesized double stranded short
XX      interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX      cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX      where each strand of (I) has 19-23 nucleotides, and does not require the
XX      presence of nucleotides having a 2-hydroxy group for mediating RNA
XX      interference. (I) is useful for treating diseases e.g., asthma, allergic
XX      rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX      vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX      Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX      towards nuclease. Double stranded short interfering nucleic acid molecule
XX      was produced by solid phase oligonucleotide synthesis method. This
XX      sequence represents an example of a siRNA molecule of the invention.
XX
XX      Sequence 23 BP; 7 A; 4 C; 4 G; 2 T; 4 U; 2 Other:
XX
XX      Query Match      1.1%; Score 19; DB 1; Length 23;
XX      Best Local Similarity 100.0%; Pred. No. 2.4e+02;
XX      Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX      QY      1011 GACACAAUGAUGGUGCU 1029
XX      |||||||
XX      DB      2 GACACAAUGAUGGUGCU 20

```

RESULT 613
ADM27927
ID ADM27927 standard; RNA; 23 BP.
XX
AC ADM27927;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #224.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 22..23
FT /tag= a
FT /note= "deoxythymidine nucleotide"
XX
PM US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-APR-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 224; 84pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
CC

SEQ Sequence 23 BP; 3 A; 6 C; 2 G; 2 T; 8 U; 2 Other;
Query Match 1.1%; Score 19; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 21 UACAACTCCGCGCCUUGUUU 39
DB 2 UACAACTCCGCGCCUUGUUU 20
RESULT 614
ADM27933
ID ADM27933 standard; RNA; 23 BP.
XX
AC ADM27933;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #230.
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 22..23
FT /tag= a
FT /note= "deoxythymidine nucleotide"
XX
PM US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00798090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-APR-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
PI Richards I, Mcswiggen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 230; 84pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC

CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.

XX Sequence 23 BP, 7 A, 5 C, 5 G, 2 T, 2 U, 2 Other;

SO Query Match 1.1%; Score 19; DB 1; Length 23;

Best Local Similarity 100.0%; Pred. No. 2.4e+02; Mismatches 0; Indels 0; Gaps 0;

Qy 1715 AGUACCGACGACGACGUC 1733

Db 2 AGUACCGACGACGACGUC 20

RESULT 615

ADW27980 standard; RNA; 23 BP.

AC ADW27980;

DT 07-APR-2005 (first entry)

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #277.

KM gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KM neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KM incontinence; ss.

OS Synthetic.

FH Key Location/Qualifiers

FT misc_difference 22..23

FT /*tag= a /note= "deoxythymidine nucleotide"

FN US2005014172-A1.

PD 20-JAN-2005.

PE 11-MAR-2004; 2004US-00798090.

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

PR 20-FEB-2003; 2003WO-US005346.

PR 30-APR-2003; 2003US-00427160.

PR 23-MAY-2003; 2003US-00444853.

PR 23-OCT-2003; 2003US-00693059.

PR 24-NOV-2003; 2003US-00720448.

PR 14-JAN-2004; 2004US-00757803.

XX (RICH) RICHARDS I.

PA (MCSW) MCSWIGEN J.

XX Richards I, Mcswigen J;

PI

XX WPI; 2005-090672/10.

PT Novel chemically synthesized double stranded short interfering nucleic

PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3

PT RNA through RNA interference, useful for treating asthma.

XX Disclosure; SEQ ID NO 277; 84pp; English.

CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.

SO Sequence 23 BP, 7 A, 5 C, 5 G, 2 T, 2 U, 2 Other;

Query Match 1.1%; Score 19; DB 1; Length 23;

Best Local Similarity 100.0%; Pred. No. 2.4e+02; Mismatches 0; Indels 0; Gaps 0;

Qy 1714 CAGUACCGACGACGACG 1732

Db 2 CAGUACCGACGACGACG 20

RESULT 616

ADW27932 standard; RNA; 23 BP.

AC ADW27932;

DT 07-APR-2005 (first entry)

DE Cholinergic receptor muscarinic 3 gene targeted siRNA #229.

KM gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KM neurotropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KM hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KM incontinence; ss.

OS Synthetic.

FH Key Location/Qualifiers

FT misc_difference 22..23

FT /*tag= a /note= "deoxythymidine nucleotide"

FN US2005014172-A1.

PD 20-JAN-2005.

PE 11-MAR-2004; 2004US-00798090.

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 20-MAY-2002; 2002WO-US015876.

PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 15-JAN-2003; 2003US-0440129P.

PR 20-FEB-2003; 2003WO-US005028.

PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 223; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 23 BP; 7 A; 5 C; 5 G; 2 T; 2 U; 2 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1714 CAGUACGACGACGACGACG 1732
DB 2 CAGUACGACGACGACGACG 20
XX
RESULT 617
ADM27964
ID ADM27964 standard; RNA; 23 BP.
XX
AC ADM27964;
XX
DT 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #261.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW neurotropic; utropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH misc_difference 22..23
FT /tag= a
FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX

PF 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
XX (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswigen J;
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 261; 84pp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 23 BP; 7 A; 5 C; 5 G; 2 T; 2 U; 2 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1714 CAGUACGACGACGACGACG 1732
DB 2 CAGUACGACGACGACGACG 20
XX
RESULT 618
ADM27975
ID ADM27975 standard; RNA; 23 BP.
XX
AC ADM27975;
XX
DT 07-APR-2005 (first entry)
XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #272.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW neurotropic; utropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX

```

OS Synthetic.
XX Key Location/Qualifiers
FH misc_difference 22..23
FT /*tag= a
FT /note= "deoxythymidine nucleotide"
PN US2005014172-A1.
XX 20-JAN-2005.
PD
XX
XX 11-MAR-2004; 2004US-00798090.
PF
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 272; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 23 BP; 3 A; 6 C; 2 G; 2 T; 8 U; 2 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 23;
XX Best Local Similarity 100.0%; Pred.No.2.4e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 21 UACACCCUGCCCUUGUUU 39
DB 2 UACACCCUGCCCUUGUUU 20

```

```

XX
XX Cholinergic receptor muscarinic 3 gene targeted siRNA #256.
DE gene expression; antiasthmatic; anti-allergic; anti-inflammatory; CNS-Gen.;
XX respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
XX nootropic; uterapathic; short interfering RNA; RNA interference; siRNA;
XX cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
XX inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
XX hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
XX incontinence; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH misc_difference 22..23
FT /*tag= a
FT /note= "deoxythymidine nucleotide"
PN US2005014172-A1.
XX 20-JAN-2005.
PD
XX
XX 11-MAR-2004; 2004US-00798090.
PF
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 20-MAY-2002; 2002WO-US015876.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX 20-FEB-2003; 2003WO-US005028.
XX 20-FEB-2003; 2003WO-US005346.
XX 30-APR-2003; 2003US-00427160.
XX 23-MAY-2003; 2003US-00444853.
XX 23-OCT-2003; 2003US-00693059.
XX 24-NOV-2003; 2003US-00720448.
XX 14-JAN-2004; 2004US-00757803.
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
XX acid molecule that directs cleavage of cholinergic receptor muscarinic 3
XX RNA through RNA interference, useful for treating asthma.
XX
XX Disclosure; SEQ ID NO 256; 84bp; English.
XX
XX The invention relates to a chemically synthesized double stranded short
XX interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
XX cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
XX where each strand of (I) has 19-23 nucleotides, and does not require the
XX presence of nucleotides having a 2-hydroxy group for mediating RNA
XX interference. (I) is useful for treating diseases e.g., asthma, allergic
XX rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
XX vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
XX Alzheimer's disease or urinary incontinence. (I) has increased resistance
XX towards nuclease. Double stranded short interfering nucleic acid molecule
XX was produced by solid phase oligonucleotide synthesis method. This
XX sequence represents an example of a siRNA molecule of the invention.
XX
XX Sequence 23 BP; 3 A; 6 C; 2 G; 2 T; 8 U; 2 Other;
XX
XX Query Match 1.1%; Score 19; DB 1; Length 23;
XX Best Local Similarity 100.0%; Pred.No.2.4e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 21 UACACCCUGCCCUUGUUU 39

```

Db 2 UACAACCCGCGCCUUGUUU 20

RESULT 620
ADW27978
ID ADW27978 standard; RNA; 23 BP.
XX
XX ADW27978;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #275.
XX
XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
XX Synthetic.
OS
FH Key Location/Qualifiers
FT misc_difference 22..23
FT /tag= a
FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
XX disclosure; SEQ ID NO 275; 84pp; English.
PS
XX
XX The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance

CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 23 BP; 7 A; 6 C; 5 G; 2 T; 1 U; 2 Other;
Query Match 1.1%; Score 19; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 975 GCAGATGACCAAGCCAC 993
Db 2 GCAGATGACCAAGCCAC 20
RESULT 621
ADW27946
ID ADW27946 standard; RNA; 23 BP.
XX
XX ADW27946;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #243.
XX
XX
KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KW nootropic; utropathic; short interfering RNA; RNA interference; siRNA;
KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
KW incontinence; ss.
XX
XX Synthetic.
OS
FH Key Location/Qualifiers
FT misc_difference 22..23
FT /tag= a
FT /note= "deoxythymidine nucleotide"
XX
XX US2005014172-A1.
XX
XX 20-JAN-2005.
XX
XX 11-MAR-2004; 2004US-00798090.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
XX (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGGEN J.
XX
XX Richards I, Mcswiggen J;
XX
XX WPI; 2005-090672/10.
XX
XX Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX

PS Disclosure; SEQ ID NO 243; 84bp; English.
 XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 SQ Sequence 23 BP; 7 A; 6 C; 5 G; 2 T; 1 U; 2 Other;
 Query Match 1.1%; Score 19; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 GY 975 GCAGAGGACCAAGACCAC 993
 Db 2 GCAGAGGACCAAGACCAC 20
 RESULT 622
 ADM27962
 ID ADM27962 standard; RNA; 23 BP.
 AC ADM27962;
 XX
 DT 07-APR-2005 (first entry)
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #259.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer disease;
 KW incontinence; ss.
 KW
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT misc_difference 22..23
 FT /*tag= a
 FT /note= "deoxythymidine nucleotide"
 XX
 PN US2005014172-A1.
 PD 20-JAN-2005.
 PF 11-MAR-2004; 2004US-00798090.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-00427160.
 PR 23-MAY-2003; 2003US-00444853.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 14-JAN-2004; 2004US-00757803.
 XX

PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 XX
 PI Richards I, Mcswiggen J;
 XX
 DR WPI; 2005-090672/10.
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 PS Disclosure; SEQ ID NO 259; 84bp; English.
 XX
 CC The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 SQ Sequence 23 BP; 7 A; 6 C; 5 G; 2 T; 1 U; 2 Other;
 Query Match 1.1%; Score 19; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 GY 975 GCAGAGGACCAAGACCAC 993
 Db 2 GCAGAGGACCAAGACCAC 20
 RESULT 623
 ADM27948
 ID ADM27948 standard; RNA; 23 BP.
 AC ADM27948;
 XX
 DT 07-APR-2005 (first entry)
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #245.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimer disease;
 KW incontinence; ss.
 KW
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT misc_difference 22..23
 FT /*tag= a
 FT /note= "deoxythymidine nucleotide"
 XX
 PN US2005014172-A1.
 PD 20-JAN-2005.
 PF 11-MAR-2004; 2004US-00798090.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 XX

PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-0042716P.
 PR 23-MAY-2003; 2003US-0044853.
 PR 23-OCT-2003; 2003US-0069305P.
 PR 24-NOV-2003; 2003US-0072044P.
 PR 14-JAN-2004; 2004US-00757803.
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 PI Richards I, Mcswigen J;
 DR WPI; 2005-090672/10.
 XX
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.
 PS Disclosure; SEQ ID NO 245; 84pp; English.
 CC The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.
 CC Sequence 23 BP; 7 A; 5 C; 5 G; 2 T; 2 U; 2 Other;
 SQ
 XX
 XX
 PT Query Match 1.1%; Score 19; DB 1; Length 23;
 PT Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 PT Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1714 CAGUACGACGAGACAGU 1732
 DB 2 CAGUACGACGAGACAGU 20
 RESULT 624
 ADW27997
 ID ADW27997 standard; RNA; 23 BP.
 AC ADW27997;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #294.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.; respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective; nootropic; uteropathic; short interfering RNA; RNA interference; siRNA; cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis; inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction; hypertension; emphysema; irritable bowel syndrome; Alzheimers disease; incontinence; ss.
 KW
 XX
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FH misc_difference 22..23
 FT /*tag= a
 FT /note= "deoxythymidine nucleotide"
 XX

PN US2005014172-A1.
 XX
 XX 20-JAN-2005.
 PD
 XX
 PF 11-MAR-2004; 2004US-00798090.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 20-MAY-2002; 2002WO-US015876.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 PR 20-FEB-2003; 2003WO-US005028.
 PR 20-FEB-2003; 2003WO-US005346.
 PR 30-APR-2003; 2003US-0042716P.
 PR 23-MAY-2003; 2003US-0044853.
 PR 23-OCT-2003; 2003US-0069305P.
 PR 24-NOV-2003; 2003US-0072044P.
 PR 14-JAN-2004; 2004US-00757803.
 XX
 XX
 PA (RICH/) RICHARDS I.
 PA (MCSW/) MCSWIGGEN J.
 PI Richards I, Mcswigen J;
 DR WPI; 2005-090672/10.
 XX
 XX
 PT Novel chemically synthesized double stranded short interfering nucleic acid molecule that directs cleavage of cholinergic receptor muscarinic 3 RNA through RNA interference, useful for treating asthma.
 PS Disclosure; SEQ ID NO 303; 84pp; English.
 CC The invention relates to a chemically synthesized double stranded short interfering nucleic acid (siNA) molecule (I) that directs cleavage of a cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference, where each strand of (I) has 19-23 nucleotides, and does not require the presence of nucleotides having a 2-hydroxy group for mediating RNA interference. (I) is useful for treating diseases e.g., asthma, allergic rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary vasoconstriction or hypertension, emphysema, irritable bowel syndrome, Alzheimer's disease or urinary incontinence. (I) has increased resistance towards nuclease. Double stranded short interfering nucleic acid molecule was produced by solid phase oligonucleotide synthesis method. This sequence represents an example of a siRNA molecule of the invention.
 CC Sequence 23 BP; 7 A; 4 C; 4 G; 2 T; 4 U; 2 Other;
 SQ
 XX
 XX
 PT Query Match 1.1%; Score 19; DB 1; Length 23;
 PT Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 PT Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1011 GAACAAAGAGAGGCGGCU 1029
 DB 2 GAACAAAGAGAGGCGGCU 20
 RESULT 625
 ADW27943
 ID ADW27943 standard; RNA; 23 BP.
 AC ADW27943;
 XX
 DT 07-APR-2005 (first entry)
 XX
 DE Cholinergic receptor muscarinic 3 gene targeted siRNA #240.
 XX
 KW gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-Gen.; respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective; nootropic; uteropathic; short interfering RNA; RNA interference; siRNA; cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW

KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FH msc_difference 22..23
 FT /*tag= a
 FT /note= "deoxythymidine nucleotide"
 XX
 XX US2005014172-A1.
 XX
 XX 20-JAN-2005.
 XX
 XX 11-MAR-2004; 2004US-00798090.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 XX 11-MAR-2002; 2002US-0363124P.
 XX 20-MAY-2002; 2002WO-US015876.
 XX 06-JUN-2002; 2002US-0386782P.
 XX 29-AUG-2002; 2002US-0406784P.
 XX 05-SEP-2002; 2002US-0408378P.
 XX 09-SEP-2002; 2002US-0409293P.
 XX 15-JAN-2003; 2003US-0440129P.
 XX 20-FEB-2003; 2003WO-US005028.
 XX 20-FEB-2003; 2003US-00427160.
 XX 30-APR-2003; 2003US-00444853.
 XX 23-MAY-2003; 2003US-0044853.
 XX 23-OCT-2003; 2003US-00693059.
 XX 24-NOV-2003; 2003US-00720448.
 XX 14-JAN-2004; 2004US-00757803.
 XX
 XX (RICH/) RICHARDS I.
 XX (MCSW/) MCSWIGGEN J.
 XX
 XX Richards I, Mcswiggen J;
 XX
 XX WPI; 2005-090672/10.
 XX
 XX
 XX Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 XX
 XX Disclosure; SEQ ID NO 240; 84bp; English.
 XX
 XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 XX
 XX Sequence 23 BP; 3 A; 6 C; 2 G; 2 T; 8 U; 2 Other;
 XX
 XX Query Match 1.1%; Score 19; DB 1; Length 23;
 XX Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 XX 21 UACACCCUCCGCCUUGUUU 39
 XX |||||
 XX 2 UACAAACCCUCCGCCUUGUUU 20
 XX
 XX RESULT 626
 XX ADM27965
 XX ID ADM27965 standard; RNA; 23 BP.

XX
 XX AC ADM27965;
 XX
 XX 07-APR-2005 (first entry)
 XX
 XX Cholinergic receptor muscarinic 3 gene targeted siRNA #262.
 XX
 XX gene expression; antiasthmatic; antiallergic; antiinflammatory; CNS-gen.;
 KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
 KW motropic; uropathic, short interfering RNA; RNA interference; siRNA;
 KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
 KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
 KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;
 KW incontinence; ss.
 XX
 XX
 XX Synthetic.
 XX
 XX
 XX Key Location/Qualifiers
 FH msc_difference 22..23
 FT /*tag= a
 FT /note= "deoxythymidine nucleotide"
 XX
 XX US2005014172-A1.
 XX
 XX 20-JAN-2005.
 XX
 XX 11-MAR-2004; 2004US-00798090.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 XX 11-MAR-2002; 2002US-0363124P.
 XX 20-MAY-2002; 2002WO-US015876.
 XX 06-JUN-2002; 2002US-0386782P.
 XX 29-AUG-2002; 2002US-0406784P.
 XX 05-SEP-2002; 2002US-0408378P.
 XX 09-SEP-2002; 2002US-0409293P.
 XX 15-JAN-2003; 2003US-0440129P.
 XX 20-FEB-2003; 2003WO-US005028.
 XX 20-FEB-2003; 2003US-00427160.
 XX 30-APR-2003; 2003US-00444853.
 XX 23-MAY-2003; 2003US-0044853.
 XX 23-OCT-2003; 2003US-00693059.
 XX 24-NOV-2003; 2003US-00720448.
 XX 14-JAN-2004; 2004US-00757803.
 XX
 XX (RICH/) RICHARDS I.
 XX (MCSW/) MCSWIGGEN J.
 XX
 XX Richards I, Mcswiggen J;
 XX
 XX WPI; 2005-090672/10.
 XX
 XX
 XX Novel chemically synthesized double stranded short interfering nucleic
 PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
 PT RNA through RNA interference, useful for treating asthma.
 XX
 XX
 XX Disclosure; SEQ ID NO 262; 84bp; English.
 XX
 XX The invention relates to a chemically synthesized double stranded short
 CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a
 CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
 CC where each strand of (I) has 19-23 nucleotides, and does not require the
 CC presence of nucleotides having a 2-hydroxy group for mediating RNA
 CC interference. (I) is useful for treating diseases e.g., asthma, allergic
 CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
 CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
 CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
 CC towards nuclease. Double stranded short interfering nucleic acid molecule
 CC was produced by solid phase oligonucleotide synthesis method. This
 CC sequence represents an example of a siRNA molecule of the invention.
 XX
 XX
 XX Sequence 23 BP; 7 A; 5 C; 5 G; 2 T; 2 U; 2 Other;
 XX
 XX Query Match 1.1%; Score 19; DB 1; Length 23;
 XX

Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1715 AGUACGACGACAGACAGUC 1733

Db 2 AGUACGACGACAGACAGUC 20

RESULT 627

ADW27996

ID ADW27996 standard; RNA; 23 BP.

XX AC ADW27996;

XX DT 07-APR-2005 (first entry)

XX DB Cholinergic receptor muscarinic 3 gene targeted siRNA #293.

XX gene expression; antiallergic; antinflammatory; CNS-Gen.;

KW respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;

KW nootropic; uropathic; short interfering RNA; RNA interference; siRNA;

KW cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;

KW inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;

KW hypertension; emphysema; irritable bowel syndrome; Alzheimers disease;

KW incontinence; ss.

XX KM

XX OS Synthetic.

XX FH

XX FT misc_difference 22..23

XX FT /tag= a

XX FT /note= "deoxythymidine nucleotide"

XX FT

XX PN US2005014172-A1.

XX PD 20-JAN-2005.

XX XX

XX PF 11-MAR-2004; 2004US-00798090.

XX XX

XX PR 20-FEB-2002; 2002US-0358580P.

XX PR 11-MAR-2002; 2002US-0363124P.

XX PR 20-MAY-2002; 2002WO-US015876.

XX PR 06-JUN-2002; 2002US-0386782P.

XX PR 29-JUN-2002; 2002US-0406784P.

XX PR 05-SEP-2002; 2002US-0408378P.

XX PR 09-SEP-2002; 2002US-0409293P.

XX PR 15-JAN-2003; 2003US-0440129P.

XX PR 20-FEB-2003; 2003WO-US005346.

XX PR 30-APR-2003; 2003US-00427160.

XX PR 23-MAY-2003; 2003US-00444853.

XX PR 23-OCT-2003; 2003US-00693059.

XX PR 24-NOV-2003; 2003US-00720448.

XX PR 14-JAN-2004; 2004US-00757803.

XX XX

XX PA (RICH/) RICHARDS I.

XX PA (MCSW/) MCSWIGGEN J.

XX XX

XX PI Richards I, Mcswiggen J;

XX XX

XX DR WPI; 2005-090672/10.

XX XX

XX PT Novel chemically synthesized double stranded short interfering nucleic

XX PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3

XX PT RNA through RNA interference, useful for treating asthma.

XX XX

XX PS Disclosure; SEQ ID NO 302; 84pp; English.

XX XX

XX CC The invention relates to a chemically synthesized double stranded short

XX CC interfering nucleic acid (siNA) molecule (I) that directs cleavage of a

XX CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,

XX CC where each strand of (I) has 19-23 nucleotides, and does not require the

XX CC presence of nucleotides having a 2-hydroxy group for mediating RNA

XX CC

CC interference. (I) is useful for treating diseases e.g., asthma, allergic

CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary

CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,

CC Alzheimer's disease or urinary incontinence. (I) has increased resistance

CC towards nuclease. Double stranded short interfering nucleic acid molecule

CC was produced by solid phase oligonucleotide synthesis method. This

CC sequence represents an example of a siRNA molecule of the invention.

XX

XX SQ

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 246; 84pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 23 BP; 7 A; 5 C; 5 G; 2 T; 2 U; 2 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.4e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1715 AGUACGACGACGACGACGACGUC 1733
|||
Db 2 AGUACGACGACGACGACGACGUC 20
RESULT 629
ADW27994
ID ADW27994 standard; RNA; 23 BP.
XX
AC ADW27994;
XX
DT 07-APR-2005 (first entry)
XX
DE Cholinergic receptor muscarinic 3 gene targeted siRNA #291.
XX
KM gene expression; antiallergic; antiallergic; antiinflammatory; CNS-Gen.;
KM respiratory-gen.; hypotensive; gastrointestinal-gen.; neuroprotective;
KM nootropic; uteropathic; short interfering RNA; RNA interference; siRNA;
KM cholinergic receptor muscarinic 3; asthma; allergic rhinitis; sinusitis;
KM inflammation; allergy; cystic fibrosis; pulmonary vasoconstriction;
KM hypertension; emphysema; irritable bowel syndrome; Alzheimer's disease;
KM incontinence; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_difference 22..23
FT /tag= a
FT /note= "deoxythymidine nucleotide"
XX
PN US2005014172-A1.
XX
PD 20-JAN-2005.
XX
PF 11-MAR-2004; 2004US-00796090.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 20-MAY-2002; 2002WO-US015876.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-JUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PR 20-FEB-2003; 2003WO-US005028.
PR 20-FEB-2003; 2003WO-US005346.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.

PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 14-JAN-2004; 2004US-00757803.
XX
PA (RICH/) RICHARDS I.
PA (MCSW/) MCSWIGEN J.
XX
PI Richards I, Mcswigen J;
XX
DR WPI; 2005-090672/10.
XX
PT Novel chemically synthesized double stranded short interfering nucleic
PT acid molecule that directs cleavage of cholinergic receptor muscarinic 3
PT RNA through RNA interference, useful for treating asthma.
XX
PS Disclosure; SEQ ID NO 300; 84pp; English.
XX
CC The invention relates to a chemically synthesized double stranded short
CC interfering nucleic acid (siRNA) molecule (I) that directs cleavage of a
CC cholinergic receptor muscarinic 3 (CHRM3) RNA through RNA interference,
CC where each strand of (I) has 19-23 nucleotides, and does not require the
CC presence of nucleotides having a 2-hydroxy group for mediating RNA
CC interference. (I) is useful for treating diseases e.g., asthma, allergic
CC rhinitis, sinusitis, inflammation, allergy, cystic fibrosis, pulmonary
CC vasoconstriction or hypertension, emphysema, irritable bowel syndrome,
CC Alzheimer's disease or urinary incontinence. (I) has increased resistance
CC towards nuclease. Double stranded short interfering nucleic acid molecule
CC was produced by solid phase oligonucleotide synthesis method. This
CC sequence represents an example of a siRNA molecule of the invention.
XX
SQ Sequence 23 BP; 7 A; 4 C; 4 G; 2 T; 4 U; 2 Other;
XX
Query Match 1.1%; Score 19; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.4e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1011 GAACAAACAAUGAUGUGUCU 1029
|||
Db 2 GAACAAACAAUGAUGUGUCU 20
RESULT 630
AAI72996
ID AAI72996 standard; DNA; 20 BP.
XX
AC AAI72996;
XX
DT 09-SEP-2002 (first entry)
XX
DE M3 Muscarinic receptor sense primer.
XX
KM PCR; primer; mouse; M3 muscarinic receptor; intracellular loop; mutant;
KM appetite; weight control; obesity; ss.
XX
OS Mus musculus.
XX
PN WO200246421-A2.
XX
PD 13-JUN-2002.
XX
PF 26-OCT-2001; 2001WO-US051110.
XX
PR 30-OCT-2000; 2000US-024414P.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Wess J, Yamada M;
XX
DR WPI; 2002-471893/50.
XX
PT Non-human animal, e.g. mouse, with abnormal expression of the muscarinic
PT acid M3 receptor, useful for screening compounds having an effect on
PT appetite and weight control, in particularly compounds which can be used

PT to treat obesity.

XX Example 1; Page 28; 52pp; English.

XX The sequences given in AA172996-97 are primers which were used to amplify

CC a portion of the mouse M3 muscarinic receptor corresponding to the third

CC intracellular loop. The amplified sequence was used as a probe in the

CC isolation of the full length M3 muscarinic receptor genomic clone from a

CC 129SV/J mouse genomic library. This sequence was then used in the

CC generation of M3 receptor mutant mice with abnormal expression of the

CC muscarinic acid M3 receptor. Mice with abnormal expression of the

CC effect on appetite and weight control, in particularly compounds having an

CC can be used to treat obesity

XX Sequence 20 BP; 5 A; 6 C; 3 T; 0 U; 0 Other;

XX

XX Query Match 1.0%; Score 18.4; DB 1; Length 20;

XX Best Local Similarity 80.0%; Pred. No. 2.1e+02;

XX Matches 16; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 941 GGUUCACCAACCAAGACCTCG 960

DB 1 GGTTCACCAACCAAGACTCG 20

RESULT 631

AAE77801

ID AAE77801 standard; DNA; 20 BP.

XX AAE77801;

XX 09-FEB-2006 (first entry)

XX Human dopamine receptor D2 (DRD2) DNA oligonucleotide SEQ ID NO:1422.

XX

XX Diagnosis; therapeutic; neurological disease; psychiatric disorder;

XX neuropsychologic disorder; dopamine receptor D2; DRD2; ss.

XX Homo sapiens.

XX WO2005118843-A1.

XX 15-DEC-2005.

XX 01-JUN-2005; 2005WO-AU000775.

XX 01-JUN-2004; 2004AU-00902919.

XX (UNIV) UNIV QUEENSLAND TECHNOLOGY.

XX Morris CP, Van Daal A, Swagell CD, Lawford BR, Young RM;

XX WPI; 2006-047555/05.

XX Identifying genetic profile associated with a neurological, psychiatric,

XX or psychological condition, comprises screening individuals for a

XX polymorphism in a genetic locus comprising the dopamine receptor D2

XX (DRD2) gene.

XX Claim 31; SEQ ID NO 1422; 634pp; English.

XX The invention relates to a method of identifying a genetic profile

XX associated with a neurological, psychiatric or psychological condition,

XX phenotype or state including a sub-threshold neurological, psychiatric or

XX psychological condition, phenotype or state in an individual, comprising

XX screening individuals for a polymorphism in a genetic locus comprising

XX the dopamine receptor D2 (DRD2) gene. The invention also relates to a

XX genetic mutation providing a genetic marker for a neurological,

XX psychiatric, or psychological condition, state or phenotype in an

XX individual, where the presence of a 957C polymorphism is indicative of a

XX predisposition to developing a neurological, psychiatric or psychological

XX condition, phenotype or state. The compositions and methods are useful

CC for identifying a genetic profile associated with a neurological,

CC psychiatric or psychological condition. The method enables clinicians to

CC make a genetic-based diagnosis of a neurological, psychiatric or

CC psychological condition and can thereby implement treatment or

CC preventative or symptom-ameliorating protocols to reduce the adverse

CC consequences of the condition. This sequence represents a human dopamine

CC receptor D2 (DRD2) DNA oligonucleotide used in the scope of the

CC invention.

XX Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

XX

XX Query Match 1.0%; Score 18.4; DB 1; Length 20;

XX Best Local Similarity 85.0%; Pred. No. 2.1e+02;

XX Matches 17; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1604 UCACACGACCGGAAACCC 1623

DB 1 TCACACGCGCGGAAACCC 20

RESULT 632

ADG77919/C

ID ADG77919 standard; DNA; 21 BP.

XX ADG77919;

XX 11-MAR-2004 (first entry)

XX Canine disease marker-related PCR primer 763.

XX

XX genetic disease; genetic trait; dog; carrier of recessive disease;

XX copper toxicosis; CT; canine genome map; breed-specific profile;

XX DNA fingerprint; dog identification; PCR; primer; ss.

XX Canis familiaris.

XX WO9731011-A1.

XX 28-AUG-1997.

XX 18-FEB-1997; 97WO-US002396.

XX 22-FEB-1996; 96US-0012060P.

XX (UNMI) UNIV MICHIGAN

XX (UNMS) UNIV MICHIGAN STATE.

XX Brewer GJ, Venta PJ, Yuzbasiyan-Gurkan V;

XX WPI; 1997-435082/40.

XX New oligonucleotide primers for diagnosis of genetic diseases and traits

XX in dogs - amplify specific regions of the genome containing

XX microsatellite repeats, especially for diagnosing copper toxicosis and

XX carriers.

XX Claim 1; Page 18; 40pp; English.

XX This invention relates to novel oligonucleotide PCR primers which may be

XX used to identify markers associated with genetic diseases and traits in

XX dogs, in particular to diagnose genetic diseases that are not

XX phenotypically visible and to identify carriers of recessive diseases. A

XX specific application is diagnosis of copper toxicosis (CT). The invention

XX can also be used to create a genetic map of the canine genome; to

XX generate breed-specific profiles; to establish paternity and to identify

XX dogs from DNA fingerprints. The method provides rapid analysis of the

XX target sequences from only a small sample of DNA. Diagnosis can be done

XX at any time in the dog's life. The present sequence is that of a PCR

XX primer of the invention.

XX Sequence 21 BP; 0 A; 8 C; 2 G; 11 T; 0 U; 0 Other;

XX

XX Query Match 1.0%; Score 18.4; DB 1; Length 21;

Best Local Similarity 95.0%; Pred. No. 2.3e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 815 GGACAGAGCGACGACGAGA 834

Db 20 GGACAGAGCGACGAGAAAGAA 1

RESULT 633

ADM97793/C

ID ADM97793 standard; DNA; 18 BP.

AC ADM97793;

XX 05-MAY-2005 (first entry)

DE Reverse primer for RT-PCR of M3R cDNA, seq id 2.

XX Sjoegrens syndrome; diagnosis;

KM membrane-associated anti-type-3 muscarinic acetylcholine receptor; M3R;

XX RT-PCR; primer; ss.

OS Homo sapiens.

PN US2005042689-A1.

PD 24-FEB-2005.

PF 18-JUN-2004; 2004US-00871137.

PR 18-JUN-2003; 2003US-0479545P.

PA (PECK/) PECK A B.

PA (CHAS/) CHA S R.

PA (RAMI/) RAMIYA V K.

PA (HUMP/) HUMPHREYS-BAHER D E.

PA (HUMP/) HUMPHREYS-BEHER M G.

PI Peck AB, Cha SR, Ramiya VK, Gao J, Humphreys-Baher DE;

PI Humphreys-Baher MG;

DR WPI; 2005-180808/19.

XX Diagnosing Sjogren's syndrome in subject, involves obtaining biological

PT sample from subject and analyzing sample of presence of antibody that

PT specifically binds membrane-associated anti-type-3 muscarinic

PT acetylcholine receptor.

XX Example 1; SEQ ID NO 2; 23pp; English.

XX The invention relates to a method for diagnosing (M1) Sjogren's syndrome

CC in a subject. The method involves obtaining a biological sample from the

CC subject, analyzing the sample for the presence of an antibody that

CC specifically binds a membrane-associated anti-type-3 muscarinic

CC acetylcholine receptor (M3R), where the presence of the antibody in the

CC sample indicates that the subject has Sjogren's syndrome. The method is

CC useful for diagnosing Sjogren's syndrome in a subject by detecting anti-

CC M3R antibodies in a biological sample, where the biological sample is a

CC fluid chosen from blood, blood serum, saliva, tears, mucus and ascites

CC fluid. The current sequence represents a primer for the RT-PCR of M3R

CC cDNA.

XX Sequence 18 BP; 2 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

SEQ Query Match 1.0%; Score 18; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 1.8e+02;

-Matches 16; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1753 GCACCCGAGCAGCCCTTG 1770

Db 18 GCACCCGAGCAGCCCTTG 1

RESULT 634

AA597754

ID AA597754 standard; DNA; 20 BP.

XX AA597754;

XX 12-MAR-2002 (first entry)

DE Murine SACL gene-specific oligonucleotide PCR primer #321.

XX Human; mouse; SACL; carbohydrate; sweetener; ethanol; alcoholism; ss;

KM obesity; diabetes; transgenic embryo; body tissue; body fluid; pancreas;

KM blood; tongue; PCR primer; anorectic; antidiabetic; gene therapy;

XX protein replacement therapy.

OS Mus sp.

PN WO200183749-A2.

PD 08-NOV-2001.

PF 25-APR-2001; 2001WO-US013387.

PR 28-APR-2000; 2000US-0200794P.

PR 28-JUL-2000; 2000US-0221419P.

PR 10-NOV-2000; 2000US-0247443P.

PA (WARN) WARNER LAMBERT CO.

PA (MONE-) MONEILL CHEM SENSES CENT.

PI Bachmanov AA, Beauchamp GK, Chatterjee A, De Jong PJ, Li S, Li X;

PI Ohmen JD, Reed DR, Rose D, Tordoff MG;

DR WPI; 2002-075162/10.

XX Novel isolated polypeptide comprising variant form of mouse or human SACL

PT polypeptide, and is associated with altered preference for carbohydrates

PT or other sweeteners, useful for preventing obesity, diabetes, alcoholism.

XX Claim 14; Page 86; 23pp; English.

XX The invention relates to an isolated polypeptide, comprising a variant

CC form of mouse or human SACL polypeptide. The variant form is associated

CC with altered preference for carbohydrates, other sweeteners or ethanol.

CC The polypeptide and its associated DNA sequence can be produced by

CC recombinant techniques and is useful for preventing obesity, diabetes or

CC alcoholism associated with SACL expression. The sequences are useful in

CC screening for drugs and sweeteners. Recombinant cell lines and transgenic

CC embryos may be used in screening for and identifying agents that induce

CC or repress function of SACL. Predisposition to diabetes, obesity or

CC alcoholism can be ascertained by testing any fluid or tissue of a human

CC (such as blood, pancreas or tongue) for sequence variations of the SACL

CC gene. A sequence variation of the SACL locus may indicate a

CC predisposition to diabetes, obesity and/or alcoholism and may provide a

CC diagnostic mark. The polynucleotide can be detected in a biological

CC sample by contacting the DNA with a probe to form a hybridization complex

CC which is then detected. The sequences represent cDNA encoding human and

CC mouse SACL polypeptides and PCR primers specific for the SACL genes

XX Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

SEQ Query Match 1.0%; Score 18; DB 1; Length 20;

Best Local Similarity 83.3%; Pred. No. 2.3e+02;

Matches 15; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1335 CUCAGUGGUGAAGACAC 1352

Db 2 CTCAGTGGGTAAAGACAC 19

RESULT 635

ADM16094

1D	ADM16094 standard; DNA; 20 BP.
XX	
AC	ADM16094;
XX	
DT	15-JUL-2004 (first entry)
XX	
DE	Murine SACL DNA PCR primer #321.
XX	
KW	Mouse; SACL; PCR; ss; carbohydrate; sweetener; ethanol; obesity;
KW	diabetes; alcoholism; antidiabetic; alcohol; anorectic; antialcoholic;
XX	primer.
XX	
OS	Mus musculus.
XX	
PN	US2004081964-A1.
PD	
XX	29-APR-2004.
XX	
PE	25-OCT-2002; 2002US-00280183.
XX	
FR	25-OCT-2002; 2002US-00280183.
XX	
PA	(BACH/) BACHMANOV A. A.
PA	(BEAU/) BEAUCHAMP G. K.
PA	(LISS/) LI S.
PA	(LIXX/) LI X.
PA	(REED/) REED D. R.
PA	(TORD/) TORDOFF M. G.
PA	(ROSS/) ROSS D. A.
PA	(OHMA/) OHMAN J. D.
PA	(CHAT/) CHATTERJEE A.
PA	(DJON/) DE JONG P. J.
XX	
P1	Bachmanov AA, Beauchamp GK, Li S, Li X, Reed DR, Tordoff MG;
P1	Ross DA, Ohman JD, Chatterjee A, De Jong PJ;
XX	
DR	WPI; 2004-340133/31.
XX	
PT	New isolated polynucleotides for sensing carbohydrates, other sweeteners,
PT	or ethanol, useful for screening drugs for inhibition or restoration of
PT	gene function as antidiabetic, antioesity or antialcohol consumption
PT	therapies.
XX	
PS	Example 12; SEQ ID NO 364; 148bp; English.
XX	
CC	The invention relates to SACL polypeptides and the polynucleotides
CC	encoding them. The polynucleotides contain a variation associated with
CC	sensing carbohydrates, other sweeteners or ethanol. The invention also
CC	relates to a method for analysing a biomolecule in a biological sample,
CC	comprising altering SACL activity in the sample and measuring the
CC	activity, a method for analysing a polynucleotide in a biological sample,
CC	comprising contacting a polynucleotide in a biological sample with a
CC	probe where the probe hybridises to a SACL polynucleotide to form a
CC	hybridisation complex and detecting the hybridisation complex, a method
CC	of identifying susceptibility to obesity or diabetes comprising comparing
CC	the nucleotide sequence of the suspected SACL allele with a wild type
CC	nucleotide sequence, where the difference between the suspected allele
CC	and the wild-type sequence identifies a sequence variation of the SACL
CC	nucleotide sequence, and a method of treating or preventing obesity,
CC	diabetes or alcoholism associated with expression of SACL, comprising
CC	administering to a subject a pharmaceutical composition and a transgenic
CC	animal that carries an altered SACL allele. The methods and compositions
CC	of the invention are useful for screening drugs for inhibition or
CC	restoration of gene function as antidiabetic, antioesity or antialcohol
CC	consumption therapies and for identifying sweeteners and alcohols. This
CC	sequence represents a PCR primer used to amplify murine SACL DNA of the
CC	invention.
XX	
SC	Sequence 20 BP; 5 A; 5 G; 7 G; 3 T; 0 U; 0 Other;

Query Match	1.0%	Score 18	DB 1	Length 20
Best Local Similarity	83.3%	Pred. No. 2.3e+02		
Matches 15: Conservative	3	Mismatches 0	Indels 0	Gaps 0

QY	1335	CTCAGUGGGUAAGACAC	1352
		: : : : : :	
Db	2	CTCAGTGGGTAGAGCAC	19

RESULT 636
AAC88007/c
ID AAC88007 standard; DNA; 22 BP.

AC AAC88007;

DT 07-MAR-2001 (first entry)

Human CLASP probe/primer R4.

KM CLASP-1, CLASP-2; transmembrane protein; immunoreponse; inflammatory;
 KM cadherin-like asymmetry, proteol, autoimmune disease; immunosuppressive;
 KM immunomodulatory; antiinflammatory; arthritic; cytostatic;
 KM hypotensive; antitumoral; antiaheumic; haemostatic; neuroprotective;
 KM hypersensitivity; transplacental rejection response; immunodeficiency;
 KM proliferation; differentiation; inflammatory response; arthritis;
 KM inflammatory bowel disease; haematopoietic cell; blood protein disorder;
 KM anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;
 KM endometriosis; pregnancy induced hypertension; probe; primer; ss.

Homo sapiens.

PN WO200061747-A2.

PD 19-OCT-2000.

PF 13-APR-2000; 2000WO-US010158.

PR 14-APR-1999; 99US-0129171P.

PR 14-MAY-1999; 99US-0134117P.

PR 21-OCT-1999; 99US-0160860P.

PR 13-DEC-1999; 99US-0170453P.

PR 14-FEB-2000; 2000US-0182296P.

PA (ARBO-) ARBOR VITA CORP.

PI Lu PS;

PT Isolated cadherin-like asymmetry protein-2 polynucleotide and polypeptide used to diagnose, treat and prevent autoimmune diseases and inflammatory responses.

PS Disclosure; Page 40; 286pp; English.

The present invention describes cadherin-like asymmetry protein-2 (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory, anti-inflammatory, antiarthritic, cytostatic, hypotensive, antineumatic, antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be used to inhibit an immune response in a subject by interfering with the ability of a CLASP-2 protein to bind to another T cell or B cell. An immune response in a subject may also be inhibited by administering an antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides, proteins and antibodies can be used to prevent or treat a CLASP-2 mediated disease, such as an autoimmune disease caused or exacerbated by increased activity of Th1 cells. They can also be used to treat hypersensitivities, prevent transplantation rejection responses and augment immune responsiveness in immunodeficiency states, inhibit proliferation and differentiation of cells involved in an inflammatory response e.g. arthritis, inflammatory bowel disease and increase differentiation and proliferation of haematopoietic cells e.g. to treat anaemia, thrombocytopenia and other blood protein disorders. Disorders

CC created by disrupting CLASP-2 function include multiple sclerosis,
 CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.
 CC The present sequence represents a human CLASP probe/primer, given in the
 CC present invention

CC Sequence 22 BP; 1 A; 12 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 1.0%; Score 17.8; DB 1; Length 22;

Best Local Similarity 85.7%; Pred. No. 3e+02; Mismatches 2; Indels 0; Gaps 0;

Matches 18; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1174 CCGAGAGAGAGCGCGGAGG 1194

DB 22 CCGAGAGAGAGCGCGGAGG 2

RESULT 637

ABK84929/c

ID ABK84929 standard; DNA; 22 BP.

XX ABK84929;

DT 13-AUG-2002 (first entry)

DE Cadherin-like asymmetry protein (CLASP) primer #8.

XX Human; autoimmune disease; haematopoietic disorder; Disgeorge syndrome;

KW blood protein disorder; agammaglobulinaemia; dysgammaaglobulinaemia;

KW ataxia telangiectasia; common variable immunodeficiency; lymphopenia;

KW thrombocytopenia; haemoglobinuria; Addison's disease; Grave's disease;

KW haemolytic anaemia; multiple sclerosis; rheumatoid arthritis; lupus;

KW endometriosis; autoimmune thyroiditis; anaphylaxis; hypersensitivity;

KW autoimmune pulmonary inflammation; organ rejection; inflammation; CLASP;

KW PCR; primer; ss.

XX Homo sapiens.

XX WO20023117-A2.

XX 18-APR-2002.

XX 15-OCT-2001; 2001WO-US032202.

XX 13-OCT-2000; 2000US-00687837.

XX (ARBO-) ARBOR VITA CORP.

XX (GARM/) GARMAN J D.

XX (CAND/) CANDIA A F.

XX Lu PS;

XX MPI; 2002-416861/44.

XX The invention relates to an isolated polypeptide (I) comprising an amino

XX acid sequence that has 90 % sequence identity to one of the human

XX cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2a, 2B, 2C, 2B)

XX sequences (PS). (I) is useful for identifying a compound or agent that

XX binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for

XX detecting a nucleic acid encoding (I), or (II) is useful for preventing

XX inhibiting an immune response in a subject. A pharmaceutical composition

XX comprising a nucleic acid encoding (I), or (II) is useful for preventing

XX or treating a CLASP-2 mediated disease e.g. an autoimmune disease, where

XX the autoimmune disease is caused or exacerbated by increased activity of

XX TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for

XX detection or inhibition of CLASP-2 expression (e.g., antisense or

XX ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2

CC polynucleotides can express CLASP-2 polypeptides, produce anti- CLASP-

CC antibodies or are used as therapeutic polypeptides. The CLASP-2

CC polynucleotide or fragments can be used in diagnostics (e.g., as probes

CC for CLASP-2 expression), as a lymphocyte marker and for therapeutic

CC purposes. CLASP-2 polynucleotides can construct transgenic and knockout

CC animals, e.g., for screening of CLASP-2 agonists and antagonists. CLASP-2

CC polynucleotides can screen for CLASP-2 agonists and antagonists. CLASP-2

CC polypeptides or polynucleotides can treat deficiencies or disorders of

CC the immune system, by activating or inhibiting the activation.

CC differentiation of immune cells and can treat or detect deficiencies or

CC disorders of haematopoietic cells. CLASP-2 polypeptides or

CC polynucleotides can increase differentiation and proliferation of

CC haematopoietic cells, including the pluripotent stem cells to treat those

CC disorders associated with a decrease in certain (or many) types of

CC haematopoietic cells (e.g., immunologic deficiency syndromes including

CC blood protein disorders (e.g., agammaglobulinaemia,

CC dysgammaaglobulinaemia, ataxia telangiectasia, common variable

CC immunodeficiency, Disgeorge syndrome, lymphopenia, thrombocytopenia, or

CC haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or

CC detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia,

CC Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus,

CC endometriosis, autoimmune thyroiditis, and autoimmune pulmonary

CC inflammation. CLASP-2 can be used to treat anaphylaxis or

CC hypersensitivity to an antigenic molecule, organ rejection or graft-

CC versus-host disease (GVHD) and inflammation. ABK84922-ABK85018 represent

CC cadherin-like asymmetry protein (CLASP) coding sequences and PCR primers

CC of the invention

XX Sequence 22 BP; 1 A; 12 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 1.0%; Score 17.8; DB 1; Length 22;

Best Local Similarity 85.7%; Pred. No. 3e+02; Mismatches 2; Indels 0; Gaps 0;

Matches 18; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1174 CCGAGAGAGAGCGCGGAGG 1194

DB 22 CCGAGAGAGAGCGCGGAGG 2

RESULT 638

ABQ94025

ID ABQ94025 standard; DNA; 22 BP.

XX ABQ94025;

DT 21-OCT-2002 (first entry)

DE NOV11 reverse PCR primer.

XX Human; NOV; cytostatic; Cardiant; Antiinflammatory; Immunosuppressive;

KW Antiallergic; Haemostatic; Anti-HIV; Antidiabetic; Anorectic;

KW Antischismatic; Nephrotropic; Hepatotropic; Neuroprotective; Noctropic;

KW Antibacterial; Vitricide; Antiparasitic; Relaxant; Anticonvulsant;

KW Gene Therapy; NOV; cancer; heart disease; inflammation;

KW autoimmune disorder; allergy; blood disorder; AIDS; diabetes; obesity;

KW asthma; IGA nephropathy; cirrhosis; arthritis; Alzheimer's disease;

KW infection; stroke; muscular dystrophy; epilepsy; wasting disorder; PCR;

KW primer; ss.

XX Homo sapiens.

XX WO200255704-A2.

XX 18-JUL-2002.

XX 09-JAN-2002; 2002WO-US000554.

XX 09-JAN-2001; 2001US-0260417P.

XX 10-JAN-2001; 2001US-0260831P.

XX 28-FEB-2001; 2001US-0272338P.

XX 09-MAR-2001; 2001US-0274876P.

XX 18-APR-2001; 2001US-0284704P.

BA (CURA-) CURAGEN CORP.
 XX Padigaru M, Li L, Zehusen BD, Casman SJ, Shenoy S, Spytek KA;
 PI Zhong M, Gangoli EA, Burgess CE, Patturajan M, Vernet CM;
 PI Taylor S, Tchernov VT, Miller CE, Guo X, Boldog FL, Grosse WM;
 PI Alsbrook JP, Gerlach V, Edinger S, Rothenberg ME, Ellerman K;
 PI MacDougall J, Malyankar U, Millet I, Peyman J, Smithson G;
 PI Gunther E, Stone DJ;
 DR WPI; 2002-590674/63.
 XX NOVX polypeptides and encoding polymucleotides, useful for preventing or
 PT treating NOVX-associated disorders e.g. cancer, inflammation, or
 PT Alzheimer's disease, and in chromosome mapping, tissue typing or
 PT pharmacogenomics.
 XX Example 3; Page 300; 358pp; English.
 XX The present invention relates to coding sequences for NOV proteins
 CC (ABN85378-ABN85403 and ABB98401-ABB98424). The NOV proteins and coding
 CC sequences are useful for treating or preventing NOV-associated disorders
 CC or in the manufacture of a medication for treating the disorders, such as
 CC cancer, heart disease, inflammation, autoimmune disorders, allergies,
 CC blood disorders, AIDS, diabetes, obesity, asthma, IGA nephropathy,
 CC cirrhosis, arthritis, Alzheimer's disease, infections (e.g. bacterial,
 CC viral, parasitic), stroke, muscular dystrophy, epilepsy, and other
 CC wasting disorders associated with chronic diseases. The present sequence
 CC is a PCR primer for a NOV coding sequence, which was used in an example
 CC from the invention
 XX SQ Sequence 22 BP; 7 A; 5 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 1.0%; Score 17.8; DB 1; Length 22;
 Best Local Similarity 61.9%; Pred. No. 3e+02;
 Matches 13; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
 QY 1558 UGCNAUCCCAACCCUUNUG 1578
 :|||:|||||:|||||:
 Db 2 TACATGCGCCAAACCTTTGG 22
 RESULT 639
 ABE77800
 ID ABE77800 standard; DNA; 20 BP.
 XX ABE77800;
 AC
 XX
 DT 09-FEB-2006 (first entry)
 XX
 DE Human dopamine receptor D2 (DRD2) DNA oligonucleotide SEQ ID NO:1421.
 XX
 KW Diagnosis; therapeutic; neurological disease; psychiatric disorder;
 KW neuropsychologic disorder; dopamine receptor D2; DRD2; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2005118843-A1.
 XX
 PD 15-DEC-2005.
 XX
 PF 01-JUN-2005; 2005WO-AU000775.
 XX
 PR 01-JUN-2004; 2004AU-00902919.
 XX
 XX (UYOU-) UNIV QUEENSLAND TECHNOLOGY.
 PA
 XX Morris CP, Van Daal A, Swagell CD, Lawford BR, Young RM;
 PI
 XX WPI; 2006-047555/05.
 DR
 XX Identifying genetic profile associated with a neurological, psychiatric,
 PT or psychological condition, comprises screening individuals for a
 PT polymorphism in a genetic locus comprising the dopamine receptor D2

PT (DRD2) gene.
 XX
 XX Claim 31; SEQ ID NO 1421; 634pp; English.
 XX
 XX The invention relates to a method of identifying a genetic profile
 CC associated with a neurological, psychiatric or psychological condition,
 CC phenotype or state including a sub-threshold neurological, psychiatric or
 CC psychological condition, phenotype or state in an individual, comprising
 CC screening individuals for a polymorphism in a genetic locus comprising
 CC the dopamine receptor D2 (DRD2) gene. The invention also relates to a
 CC genetic mutation providing a genetic marker for a neurological,
 CC psychiatric, or psychological condition, state or phenotype in an
 CC individual, where the presence of a 957C polymorphism is indicative of a
 CC predisposition to developing a neurological, psychiatric or psychological
 CC condition, phenotype or state. The compositions and methods are useful
 CC for identifying a genetic profile associated with a neurological,
 CC psychiatric or psychological condition. The method enables clinicians to
 CC make a genetic-based diagnosis of a neurological, psychiatric or
 CC psychological condition and can thereby implement treatment or
 CC preventative or symptom-ameliorating protocols to reduce the adverse
 CC consequences of the condition. This sequence represents a human dopamine
 CC receptor D2 (DRD2) DNA oligonucleotide used in the scope of the
 CC invention.
 XX SQ Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 1.0%; Score 17.4; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;
 Matches 16; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 1604 UCAACGACCGUGAACCC 1622
 :|||||:|||||:
 Db 2 TCAACGCGCCGTGAACCC 20
 RESULT 640
 ABE77802
 ID ABE77802 standard; DNA; 20 BP.
 XX ABE77802;
 AC
 XX
 DT 09-FEB-2006 (first entry)
 XX
 DE Human dopamine receptor D2 (DRD2) DNA oligonucleotide SEQ ID NO:1423.
 XX
 KW Diagnosis; therapeutic; neurological disease; psychiatric disorder;
 KW neuropsychologic disorder; dopamine receptor D2; DRD2; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2005118843-A1.
 XX
 PD 15-DEC-2005.
 XX
 PF 01-JUN-2005; 2005WO-AU000775.
 XX
 PR 01-JUN-2004; 2004AU-00902919.
 XX
 XX (UYOU-) UNIV QUEENSLAND TECHNOLOGY.
 PA
 XX Morris CP, Van Daal A, Swagell CD, Lawford BR, Young RM;
 PI
 XX WPI; 2006-047555/05.
 DR
 XX Identifying genetic profile associated with a neurological, psychiatric,
 PT or psychological condition, comprises screening individuals for a
 PT polymorphism in a genetic locus comprising the dopamine receptor D2
 PT (DRD2) gene.
 XX
 XX Claim 31; SEQ ID NO 1423; 634pp; English.
 PS
 XX The invention relates to a method of identifying a genetic profile
 CC associated with a neurological, psychiatric or psychological condition,

CC phenotype or state including a sub-threshold neurological, psychiatric or
CC psychological condition, phenotype or state in an individual, comprising
CC screening individuals for a polymorphism in a genetic locus comprising
CC the dopamine receptor D2 (DRD2) gene. The invention also relates to a
CC genetic mutation providing a genetic marker for a neurological,
CC psychiatric, or psychological condition, state or phenotype in an
CC individual, where the presence of a 957C polymorphism is indicative of a
CC predisposition to developing a neurological, psychiatric or psychological
CC condition, phenotype or state. The compositions and methods are useful
CC for identifying a genetic profile associated with a neurological,
CC psychiatric or psychological condition. The method enables clinicians to
CC make a genetic-based diagnosis of a neurological, psychiatric or
CC psychological condition and can thereby implement treatment or
CC preventative or symptom-ameliorating protocols to reduce the adverse
CC consequences of the condition. This sequence represents a human dopamine
CC receptor D2 (DRD2) DNA oligonucleotide used in the scope of the
CC invention.
CC
SQ Sequence 20 BP; 6 A; 9 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 1.0%; Score 17.4; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.7e+02; Mismatches 1; Indels 0; Gaps 0;
Matches 17; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1605 CAACAGCACCGUGAACCC 1623
DB 1 CAACAGCGCGCTGAACCC 19
RESULT 641
ID AEE87549/C
ID AEE87549 standard; DNA; 20 BP.
XX
AC AEE87549;
XX
DT 23-FEB-2006 (first entry)
XX
DE Human gene 7 amplifying PCR primer 2.
XX
KM SNP detection; diagnosis; gene 7; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN US2005287549-A1.
XX
PD 29-DEC-2005.
XX
PF 25-JAN-2005; 2005US-00041456.
XX
PR 29-JUN-2004; 2004JP-00191781.
XX
PA (HITA) HITACHI LTD.
XX
PI Nagai K, Okano K, Noda H, Matsunaga H, Taniguchi K, Yazawa Y;
PI Kajiyama T;
XX
DR WPI; 2006-065742/07.
PT Genetic testing for detecting genetic polymorphisms, by allowing nucleic
PT acid sample having an anchor sequence at its 5' end to hybridize to a
PT support having a probe containing a sequence that is complementary to the
PT target sequence.
XX
PS Example 1; SEQ ID NO 14; 19pp; English.
XX
CC The present invention provides a method of genetic testing for detecting
CC genetic polymorphisms. The method involves allowing a nucleic acid sample
CC having an anchor sequence at its 5' end to hybridize to a support having,
CC immobilized on its surface, a probe containing a sequence that is
CC complementary to the target sequence; extending the complementary strand
CC from the probe utilizing the nucleic acid sample as a template;
CC dissociating and removing the nucleic acid sample from the extended probe
CC ; extending a complementary strand using the extended probe as a template

CC and a primer having a sequence identical to the anchor sequence and
CC detecting pyrophosphoric acid generated via the primer extension based on
CC bioluminescence. The present sequence is the human gene 7 amplifying PCR
CC primer. This sequence is used in the method of genetic testing for
CC detecting genetic polymorphisms.
CC
SQ Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 U; 0 Other;
Query Match 1.0%; Score 17.4; DB 1; Length 20;
Best Local Similarity 73.7%; Pred. No. 2.7e+02; Mismatches 1; Indels 0; Gaps 0;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
QY 299 AGACGUGUACAACUACU 317
DB 19 AGACGCTACCAACTACTT 1
RESULT 642
ID ADU29901
ID ADU29901 standard; DNA; 21 BP.
XX
AC ADU29901;
XX
DT 27-JAN-2005 (first entry)
XX
DE Knock-down target sequence #3239.
XX
KM Knock-down target sequence #3239.
XX
KM ds; RNA production; protein production; drug development;
XX knock-down target.
XX
OS Unidentified.
XX
PN MO2004094636-A1.
XX
PD 04-NOV-2004.
XX
PF 24-APR-2003; 2003WO-BE004362.
XX
PR 24-APR-2003; 2003WO-BE004362.
XX
PA (GALA-) GALAPAGOS GENOMICS NV.
PA (VSCR/) VAN DER SCHUREN J.
XX
PI Arts GJF, Lambrecht MJY, Djokic K, Clasen RJ, Masic B;
PI Griffioen S, Berge CTL;
XX
DR WPI; 2004-775940/76.
XX
PT New knockdown sequences, useful in lowering the amount of RNA and/or
PT protein production in cells used in drug development process.
XX
PS Claim 11; SEQ ID NO 3315; 402pp; English.
XX
CC The invention relates to a polynucleotide comprising an RNA sequence. The
CC polynucleotides, vector, libraries, and method are useful in lowering the
CC amount of RNA and/or protein production in cells used in drug development
CC process. The present sequence represents a knock-down target sequence.
XX
SQ Sequence 21 BP; 7 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3e+02; Mismatches 1; Indels 0; Gaps 0;
Matches 17; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1707 CAACGACGACGACGACG 1725
DB 2 CAACGACGACGACGACG 20
RESULT 643
ID AAA36048/C
ID AAA36048 standard; DNA; 17 BP.
XX

AC AAA36048;
 XX
 DT 26-JUL-2000 (first entry)
 XX
 DE Human genomic SNP allele specific oligonucleotide SEQ ID NO:105.
 XX
 XX Human, single nucleotide polymorphism; SNP; genotyping; DNA analysis;
 KW allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
 KW genomic classification; identification; DNA fingerprinting;
 KW tumour characterisation; hybridisation; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200018960-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 24-SEP-1999; 99WO-US022283.
 XX
 PR 25-SEP-1998; 98US-0101757P.
 XX
 PA (MASI) MASSACHUSETTS INST TECHNOLOGY.
 XX
 PI Landers JE, Jordan B, Houseman DE, Charest A;
 DR WPI; 2000-293181/25.
 XX
 PT Detection of single nucleotide polymorphisms in genomes by preparation
 PT and analysis of reduced complexity genomes, useful for genotyping,
 PT fingerprinting and determining allele frequency of SNPs.
 XX
 PS Disclosure; Page 56; 11pp; English.
 XX
 CC A method has been developed for detecting the presence or absence of a
 CC single nucleotide polymorphism (SNP) allele in a genomic sample. The
 CC method comprises preparing a reduced complexity genome (RCG) from the
 CC genomic sample and analysing the RCG for the presence or absence of a SNP
 CC allele. The method can be used to characterise a tumour, to generate a
 CC genomic pattern for an individual genome or to generate a genomic
 CC classification code for a genome. The method can be used to assess
 CC whether a subject is at risk for developing a disease or to identify a
 CC set of SNP alleles associated with a disease. The method can also be used
 CC to perform linkage analysis. AAA35944 to AAA35947 represent sequences
 CC used in the exemplification of the present invention. AAA35948 to
 CC AAA36632 represent nucleotide sequences containing SNPs
 CC
 SQ Sequence 17 BP; 6 A; 2 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 1.0%; Score 17; DB 1; Length 17;
 Best Local Similarity 64.7%; Pred. No. 2.2e+02;
 Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
 Oy 1567 AAAACUUUGAUAUCU 1583
 Db 17 AAAACCTTTGAAATCT 1
 RESULT 644
 ABS97720/C
 ID ABS97720 standard; DNA; 18 BP.
 XX
 AC ABS97720;
 XX
 DE 23-DEC-2002 (first entry)
 XX
 XX Human kelleikrin 2 (KLK2) gene PCR primer #5.
 DE
 XX
 KW Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1; PCR;
 KW cytochrome P450 A2; CYP4501A2; cytochrome P450 02B; CYP45002E1; LTP;
 KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MKP3; NR112;
 KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
 KW cyclooxgenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
 KW epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;

KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
 KW HNMT; Kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
 KW NADPH quinone oxidoreductase 2; NQO2; sulfoltransferase thermolabile; STM;
 KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
 KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
 KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
 KW multidrug resistance associated protein 3; cancer; prostate;
 KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
 KW altered drug metabolism; cardiovascular function; colorectal tumour;
 KW central nervous system; pulmonary; immunological.
 XX
 OS Homo sapiens.
 XX
 PN WO200257410-A2.
 XX
 PD 25-JUL-2002.
 XX
 PF 28-NOV-2001; 2001WO-US044838.
 XX
 PR 28-NOV-2000; 2000US-00724389.
 XX
 PA (DNAS-) DNA SCI LAB INC.
 XX
 PI Guida M, Hall J;
 DR WPI; 2002-698522/75.
 XX
 PT Isolated nucleic acid molecules having polymorphisms in known human genes
 PT e.g. cytochrome P450 and cathepsin S useful as genetic linkage markers
 PT for locating, identifying and characterizing the genes responsible for
 PT disorder-related traits.
 XX
 PS Example 14; Page 125; 714pp; English.
 XX
 CC This invention relates to the sequence of an isolated nucleic acid
 CC molecule comprising at least one base variation from that of a known
 CC human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),
 CC cytochrome P450 02B1 (CYP45002B1), adrenergic receptor beta1 (ADBR1),
 CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
 CC (ARNT), cathepsin S (CTSS), cyclooxgenase 2 (COX2), diazepam binding
 CC inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating
 CC protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
 CC transferase (HNMT), (Kallikrein 2) KLK2, nicotinamide -N-methyl
 CC transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
 CC sulfoltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
 CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
 CC transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
 CC (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
 CC (MRP3), orphan nuclear receptor (NR112), or acetylcholine muscarinic
 CC receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
 CC The polymorphisms in the human genes cited in the invention are useful as
 CC genetic linkage markers for locating and characterizing the genes that
 CC are responsible for specific traits within the genome and eventually
 CC identifying the genes responsible for a variety of disorder-related
 CC traits as a result of their e.g., overexpression, constitutive
 CC expression, mutation or underexpression, which may be used in diagnosing
 CC and/or treating the disorders. The nucleic acid molecules comprising the
 CC polymorphic sequences contained in CYP4501A1, CYP4501A2, CYP4502B1,
 CC ARNT, EPHX2, GST12, NNMT, NQO2, NR112, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
 CC MDR1 and/or MDR3 are useful for screening individuals for altered drug
 CC metabolism. The polymorphic sequences contained in CYP4501A1, CYP4501A2,
 CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for
 CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
 CC used to screen for altered cardiovascular function, in COX2 for altered
 CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
 CC nervous system function, in FLAP and HNMT for altered pulmonary,
 CC immunological or haematological function, in KLK2 for altered serine
 CC protease activity in the prostate, in LTF for altered immunological or
 CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
 CC peripheral nervous system function. The present sequence represents a PCR
 CC primer used to amplify the sequences of the invention
 XX
 SQ Sequence 18 BP; 0 A; 6 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 1.0%; Score 17; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 819 AGAGGACAGACAGAAA 835
 |||||
 DB 18 AGAGGACAGACAGAAA 2

RESULT 645
 AAA6616/C
 ID AAA6616 standard; DNA; 20 BP.

AC AAA6616;

DT 09-OCT-2000 (first entry)

DE Dog genomic marker oligonucleotide sequence SEQ ID NO:478.

KW Dog; genome; genomic marker; radiation hybrid map; identification;
 KM chromosome location; gene marker; polymorphic microsatellite marker;
 KM phenotype; behaviour; pedigree; ss.

XX Canis familiaris.

PN WO200029615-A2.

PD 25-MAY-2000.

PF 15-NOV-1999; 99WO-IB001907.

PR 13-NOV-1998; 98US-0108193P.

PS (CNRS) CNRS CENT NAT RECH SCI.

PI Galibert F, Andre C;

XX WPI; 2000-387821/33.

PT New radiation hybrid map of the dog, Canine familiaris, genome, useful
 for e.g. identifying genes implicated in phenotypic and behavioral traits
 or in genetic diseases and for studying dog pedigrees.

PS Claim 1; Page 73; 87pp; English.

CC The present invention describes a radiation hybrid map of the dog (Canine
 CC familiaris) genome comprising the genome location of a marker selected
 CC from AAA66139 to AAA66942. The radiation hybrid map is useful for
 CC identifying and localising dog genes, since it covers approximately 80 %
 CC of the dog genome and provides a dense map integrating different types
 CC (i.e. Type I and Type II) of markers. The map and the dog genome markers
 CC (or complementary sequences) are especially useful to identify genes
 CC responsible for phenotypic and behavioural traits in dogs, to identify
 CC morbid genes, to analyse diseases and identify implicated genes in such
 CC diseases and their alleles, and to study dog pedigrees. They may also be
 CC useful for isolating corresponding human gene sequences e.g. genes
 CC involved in genetic diseases

XX SQ Sequence 20 BP; 8 A; 5 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 55.0%; Pred. No. 3.2e+02;
 Matches 11; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 571 CUGGCUUGGUCACUCCUU 590
 |||||
 DB 20 CTGGCATGGGTCATCTCTT 1

RESULT 646
 AAA66540/C
 ID AAA66540 standard; DNA; 20 BP.

XX AAA66540;
 AC
 DT 09-OCT-2000 (first entry)

DE Dog genomic marker oligonucleotide sequence SEQ ID NO:402.

KW Dog; genome; genomic marker; radiation hybrid map; identification;
 KM chromosome location; gene marker; polymorphic microsatellite marker;
 KM phenotype; behaviour; pedigree; ss.

XX Canis familiaris.

PN WO200029615-A2.

PD 25-MAY-2000.

PF 15-NOV-1999; 99WO-IB001907.

PR 13-NOV-1998; 98US-0108193P.

PS (CNRS) CNRS CENT NAT RECH SCI.

PI Galibert F, Andre C;

XX WPI; 2000-387821/33.

PT New radiation hybrid map of the dog, Canine familiaris, genome, useful
 for e.g. identifying genes implicated in phenotypic and behavioral traits
 or in genetic diseases and for studying dog pedigrees.

PS Claim 1; Page 70; 87pp; English.

CC The present invention describes a radiation hybrid map of the dog (Canine
 CC familiaris) genome comprising the genome location of a marker selected
 CC from AAA66139 to AAA66942. The radiation hybrid map is useful for
 CC identifying and localising dog genes, since it covers approximately 80 %
 CC of the dog genome and provides a dense map integrating different types
 CC (i.e. Type I and Type II) of markers. The map and the dog genome markers
 CC (or complementary sequences) are especially useful to identify genes
 CC responsible for phenotypic and behavioural traits in dogs, to identify
 CC morbid genes, to analyse diseases and identify implicated genes in such
 CC diseases and their alleles, and to study dog pedigrees. They may also be
 CC useful for isolating corresponding human gene sequences e.g. genes
 CC involved in genetic diseases

XX SQ Sequence 20 BP; 8 A; 5 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 55.0%; Pred. No. 3.2e+02;
 Matches 11; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 571 CUGGCUUGGUCACUCCUU 590
 |||||
 DB 20 CTGGCATGGGTCATCTCTT 1

RESULT 647

ID ABZ81123 standard; DNA; 20 BP.

AC ABZ81123;

DT 10-MAY-2003 (first entry)

DE Dual specific phosphatase 9 phosphorothioate oligonucleotide SEQ:21.

KW Human; Dual specific phosphatase 9; antisense modulation; inhibitor;
 KM antiinflammatory; cytostatic; antibacterial; antisense therapy;
 KM hyperproliferative disorder; developmental disorder; infection;
 KM inflammatory disorder; inflammation; tumour formation; phosphorothioate;
 KM 2'-O-methoxyethyl; 2'-MOE; ss.

```
OS Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX FT /tag= a
XX FT /mod_base= OTHER
XX FT /note= "phosphorothioate linkages"
XX modified_base 1..5
XX FT /tag= b
XX FT /mod_base= OTHER
XX FT /note= "optional 2'-O-methoxyethyl (2'-MOE) gapmer"
XX modified_base 16..20
XX FT /tag= c
XX FT /mod_base= OTHER
XX FT /note= "optional 2'-O-methoxyethyl (2'-MOE) gapmer"
XX WO2003012123-A2.
XX
XX 13-FEB-2003.
XX
XX 31-JUL-2002; 2002WO-US024309.
XX
XX 01-AUG-2001; 2001US-00922146.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cowest LM, Monia BP;
XX
XX MPI; 2003-248184/24.
XX
XX New antisense oligonucleotides targeted to nucleic acids encoding Dual
XX specific phosphatase 9, useful for treating diseases associated with Dual
XX specific phosphatase 9, e.g. cancer, and for diagnostic and research
XX applications.
XX
XX Claim 3; Page 74; 94pp; English.
XX
XX The present invention describes a compound (1) that is 8-50 nucleobases
XX in length targeted to a nucleic acid molecule encoding Dual specific
XX phosphatase 9, and which specifically hybridizes with and inhibits the
XX expression of Dual specific phosphatase 9, or which specifically
XX hybridizes with at least an 8-nucleobase portion of an active site on a
XX nucleic acid molecule encoding Dual specific phosphatase 9. (1) has
XX antiinflammatory, cytosstatic and antibacterial activities, and can be
XX used in antisense therapy. The antisense compounds are useful for
XX modulating the expression of Dual specific phosphatase 9 and for treating
XX diseases or conditions associated with expression of Dual specific
XX phosphatase 9, e.g. hyperproliferative disorders, developmental disorders
XX or inflammatory disorders. The antisense compounds are also useful for
XX diagnostics, therapeutics, prophylaxis, e.g. to prevent or delay
XX infection, inflammation or tumor formation, as research reagents and
XX kits, and in distinguishing between functions of various members of a
XX biological pathway. The present sequence represents a human Dual specific
XX phosphatase 9 antisense phosphorothioate oligonucleotide, which is used
XX in an example from the present invention
XX
XX Sequence 20 BP; 4 A; 9 C; 5 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 16.8; DB 1; Length 20;
XX Best Local Similarity 80.0%; Pred. No. 3.2e+02;
XX Matches 16; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
XX
XX 1464 AGCGGCCGAGCCCTCAGG 1483
XX DB 1 AGCGGCCGAGCCCTCAGG 20
XX
XX RESULT 648
XX ADP10779/C
XX ID ADP10779 standard; DNA; 20 BP.
XX
XX AC ADP10779;
```

```
XX
XX 12-AUG-2004 (first entry)
XX
XX Set 1 left PCR primer for marker probe #124.
XX
XX transplant rejection; immune system; rheumatoid arthritis; lupus;
XX inflammatory bowel disease; multiple sclerosis; HIV; AIDS; ss; primer.
XX
XX Homo sapiens.
XX
XX WO2004042346-A2.
XX
XX 21-MAY-2004.
XX
XX 24-APR-2003; 2003WO-US012946.
XX
XX 24-APR-2002; 2002US-00131831.
XX
XX 20-DEC-2002; 2002US-00325899.
XX
XX (EXPR-) EXPRESSION DIAGNOSTICS INC.
XX
XX Wohlgenuth J, Fry K, Woodward R, Ly N, Prentice J, Morris M;
XX Rosenberg S;
XX MPI; 2004-400724/37.
XX
XX Diagnosing or monitoring transplant rejection, e.g. heart, kidney, liver,
XX pancreas, pancreatic islet, lung, bone marrow or stem cell transplant
XX rejection, in an individual, comprises detecting the expression level of
XX the genes.
XX
XX Claim 58; SEQ ID NO 788; 1762pp; English.
XX
XX The present invention relates to diagnosing or monitoring transplant
XX rejection, e.g. cardiac or kidney transplant rejection, in an individual
XX comprising detecting the expression level of one or more genes. The
XX methods, system and kits are useful in diagnosing or monitoring
XX transplant rejection, e.g. heart, kidney, liver, pancreas, pancreatic
XX islet, lung, bone marrow or stem cell transplant rejection, in an
XX xenotransplant rejection or mechanical organ replacement rejection, in an
XX individual. The method is also useful in assessing the immune status of
XX an individual. The methods are also useful in diagnosing and monitoring
XX diseases that involve the immune system, e.g. rheumatoid arthritis,
XX lupus, inflammatory bowel diseases, multiple sclerosis, HIV/AIDS or
XX viral, bacterial or fungal infection. The present sequence represents a
XX primer for a 50 mer oligonucleotide marker for diagnosis and monitoring
XX of allograft rejection and other disorders.
XX
XX Sequence 20 BP; 3 A; 3 C; 9 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 16.8; DB 1; Length 20;
XX Best Local Similarity 75.0%; Pred. No. 3.2e+02;
XX Matches 15; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
XX
XX 148 UCCUCUCGAGGAGUACAC 167
XX DB 20 TCCTCTCCAGAGGCAACAC 1
XX
XX RESULT 649
XX ABE77803
XX ID ABE77803 standard; DNA; 20 BP.
XX
XX ABE77803;
XX
XX 09-FEB-2006 (first entry)
XX
XX Human dopamine receptor D2 (DRD2) DNA oligonucleotide SEQ ID NO:1424.
XX
XX diagnosis; therapeutic; neurological disease; psychiatric disorder;
XX neuropsychologic disorder; dopamine receptor D2; DRD2; ss.
XX
XX OS Homo sapiens.
```

```

XX XX WO200511843-A1.
XX PN
XX XX 15-DEC-2005.
XX PD
XX PF 01-JUN-2005; 2005WO-AU000775.
XX PR 01-JUN-2004; 2004AU-00902919.
XX PA (UYOU-) UNIV QUEENSLAND TECHNOLOGY.
XX PI Morris CP, Van Daal A, Swagell CD, Lawford BR, Young RM,
XX PS WPI; 2006-047555/05.
XX DR
XX PT Identifying genetic profile associated with a neurological, psychiatric,
XX PT or psychological condition, comprises screening individuals for a
XX PT polymorphism in a genetic locus comprising the dopamine receptor D2
XX PT (DRD2) gene.
XX PS Claim 31; SEQ ID NO 1424; 634bp; English.
XX XX
XX CC The invention relates to a method of identifying a genetic profile
XX CC associated with a neurological, psychiatric or psychological condition,
XX CC phenotype or state including a sub-threshold neurological, psychiatric or
XX CC psychological condition, phenotype or state in an individual, comprising
XX CC screening individuals for a polymorphism in a genetic locus comprising
XX CC the dopamine receptor D2 (DRD2) gene. The invention also relates to a
XX CC genetic mutation providing a genetic marker for a neurological,
XX CC psychiatric, or psychological condition, state or phenotype in an
XX CC individual, where the presence of a 957C polymorphism is indicative of a
XX CC predisposition to developing a neurological, psychiatric or psychological
XX CC condition, phenotype or state. The compositions and methods are useful
XX CC for identifying a genetic profile associated with a neurological,
XX CC psychiatric or psychological condition. The method enables clinicians to
XX CC make a genetic-based diagnosis of a neurological, psychiatric or
XX CC psychological condition and can thereby implement treatment or
XX CC preventative or symptom-ameliorating protocols to reduce the adverse
XX CC consequences of the condition. This sequence represents a human dopamine
XX CC receptor D2 (DRD2) DNA oligonucleotide used in the scope of the
XX CC invention.
XX SQ Sequence 20 BP; 6 A; 8 C; 4 G; 2 T; 0 U; 0 Other;
XX XX
XX XX Query Match 0.9%; Score 16.8; DB 1; Length 20;
XX XX Best Local Similarity 80.0%; Pred. No. 3.2e+02;
XX XX Matches 16; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
OY 1606 AACAGCACCGUGAACCCGCU 1625
DB 1 AACAGCGCGCTGTAACCCCAT 20
XX XX
XX XX RESULT 650
XX XX ID AAA94224/C
XX XX AAA94224 standard; DNA; 21 BP.
XX AC AAA94224;
XX XX
XX DT 12-JAN-2001 (first entry)
XX XX
XX DE Murine testosterone-repressed prostate message-2 antisense control.
XX XX
XX KM Mouse; testosterone-repressed prostate message-2; TRPM-2; clusterin;
XX XX sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX OS Mus BP.
XX XX
XX PN WO200049937-A2.
XX PD 31-AUG-2000.
XX PF 25-FEB-2000; 2000WO-US004875.

```

```

XX XX 26-FEB-1999; 99US-0121726P.
XX PR (UYBR-) UNIV BRITISH COLUMBIA.
XX PA
XX PI Gleave M, Rennie PS, Miyake H, Nelson C;
XX PR WPI; 2000-533132/48.
XX DR
XX XX
XX PT Treating prostatic tumors and renal cancers by antisense inhibition of
XX PT the testosterone-repressed prostate messenger-2 gene.
XX PS Example 1; Page 35; 38pp; English.
XX XX
XX CC The present sequence is a mismatch control used with an antisense
XX CC oligonucleotide directed at the murine testosterone-repressed prostate
XX CC message-2 (TRPM-2, also known as clusterin, sulfated glycoprotein-2 or
XX CC SGP-2). The antisense sequence was shown to promote the regression of
XX CC tumours in mice, and similar oligonucleotides directed at human TRPM-2
XX CC can be used in the treatment of tumour cells expressing the TRPM-2 gene.
XX CC These include prostate cancer, renal cell cancer and some breast cancer
XX CC cells. In addition to this, they also increase the chemosensitivity of
XX CC the cells, meaning that conventional chemotherapy is more effective
XX XX
XX SQ Sequence 21 BP; 6 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
XX XX
XX XX Query Match 0.9%; Score 16.8; DB 1; Length 21;
XX XX Best Local Similarity 60.0%; Pred. No. 3.5e+02;
XX XX Matches 12; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
OY 1664 UCAAGAGUCGUCGUCGUCG 1683
DB 20 TGAAGATCCGCTGCTGTGC 1
XX XX
XX XX RESULT 651
XX XX ACF36396/C
XX XX ID ACF36396 standard; DNA; 21 BP.
XX AC ACF36396;
XX XX
XX DT 18-DEC-2003 (first entry)
XX XX
XX DE DNA sequence of a mismatch control oligonucleotide.
XX XX
XX KM TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
XX KM prostate cancer; anti-apoptotic protein; antisense; ss.
XX OS Synthetic.
XX OS
XX PN WO2003072591-A1.
XX PD 04-SEP-2003.
XX XX
XX PF 20-FEB-2003; 2003WO-US005305.
XX PR 22-FEB-2002; 2002US-00080794.
XX XX
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI
XX PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
XX DR WPI; 2003-689981/65.
XX XX
XX PT New modified antisense oligonucleotide, useful particularly for treating
XX PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.
XX PS Example 2; Page 39; 44pp; English.
XX XX
XX CC The invention relates to a compound consisting of an oligonucleotide with
XX CC a phosphorothioate backbone throughout, in which: (a) sugars on
XX CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
XX CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at

```

[illegible]

CC	This sequence is used in the exemplification of the invention
XX	
SQ	Sequence 21 BP; 4 A; 8 C; 7 G; 2 T; 0 U; 0 Other;
OY	Query Match 0.9%; Score 16.8; DB 1; Length 21; Best Local Similarity 70.0%; Pred. No. 3.5e+02; Matches 14; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
DB	1577 GGAAUUCGGCGUACUGGCUGC 1586 : :: :: : 21 GGACCCTGGGCTACTGAGCTG 2
RESULT 653	
ID	ADM83067/c
XX	ADM83067 standard; DNA; 21 BP.
XX	ADM83067;
DT	03-JUN-2004 (first entry)
DE	Human TRPM-2 antisense oligonucleotide #2.
XX	
KW	Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity; radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer; lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human; antisense; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
FH	Key Location/Qualifiers
FT	modified_base 1..21
FT	/tag= a
FT	/mod_base= OTHER
FT	/note= "phosphorothioate backbone"
XX	
PN	US2003158130-A1.
PD	21-AUG-2003.
PF	28-SEP-2001; 2001US-00967726.
PR	'25-FEB-2000; 2000WO-US004875. 28-SEP-2000; 2000US-0236301P. 10-AUG-2001; 2001US-00913325.
PA	(GLEA/) GLEAVE M.
PA	(RENN/) RENNE P S.
PA	(MIYA/) MIYAKE H.
PA	(NELS/) NELSON C.
PA	(ZELL/) ZELLMUEGER T.
PI	Gleaves M, Renne PS, Miyake H, Nelson C, Zellmewer T;
DR	WPI: 2003-778017/73.
PT	Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells
PT	that expresses testosterone-repressed prostate message-2 (TRPM-2)
XX	comprises administering a composition that inhibits expression of TRPM-2.
PS	Disclosure; SEQ ID NO 2; 14pp; English.
CC	The present invention provides a method for treating cancer in which
CC	cancer cells express testosterone-repressed prostate message-2 (TRPM-2).
CC	The invention is useful for enhancing the chemo-sensitivity or radiation-
CC	sensitivity of cancer cells for treating cancer such as prostate cancer,
CC	bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma
CC	(RCC). The invention is also useful in antisense gene therapy. The
CC	present sequence is human testosterone-repressed prostate message-2 (TRPM
CC	-2) antisense oligodeoxyribonucleotide (ODN).
XX	
SQ	Sequence 21 BP; 6 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

OS Synthetic.
XX
XX Key Location/Qualifiers
XX misc_feature 20..21
XX /tag= a
XX /label= misc_DNA
XX /note= "2 deoxynucleotide overhang"
XX
XX WO2004100990-A1.
XX
XX PD 25-NOV-2004.
XX
XX PF 19-MAY-2004; 2004WO-JP007145.
XX
XX PR 19-MAY-2003; 2003JP-00140685.
XX
XX PA (GENE-) GENECARE RES INST CO LTD.
XX
XX PI Takagi M, Shimamoto A, Furuchi Y, Sato A;
XX WPI; 2004-833899/82.
XX
XX DR Apoptosis inducing agent of cancer cell useful as anticancer agent,
XX PT comprises compound that suppresses expression of RecQ DNA helicase-family
XX PT gene/function of protein encoded by RecQ DNA helicase-family gene, as
XX PT active ingredient.
XX
XX Claim 10; SEQ ID NO 46; 262pp; Japanese.
XX
XX This invention describes a novel anticancer apoptosis inducing agent
XX which comprises (a) compound, which suppresses the expression of RecQ DNA
XX helicase-family gene, (b) DNA which expresses the double-stranded RNA
XX with RNA interfering (RNAi) effect with respect to RecQ DNA helicase-
XX family gene, or (c) a compound, which suppresses the function of protein
XX encoded by RecQ DNA helicase-family gene, as an active ingredient. The
XX invention also describes a method for screening for a candidate compound
XX with a protein encoded by RecQ DNA helicase-family gene. A compound,
XX which suppresses the expression of RecQ DNA helicase-family gene is a
XX transcription product or antisense nucleic acid of one part of RecQ DNA
XX helicase-family gene, or a nucleic acid which has ribozyme activity which
XX cleaves the transcription product of RecQ DNA helicase-family gene
XX specifically. It can also be a RecQ DNA helicase-family protein variant
XX which has dominant negative character with respect to the protein encoded
XX by RecQ DNA helicase-family gene, an antibody or a low molecular compound
XX coupled with the protein encoded by RecQ DNA helicase-family gene. The
XX RecQ DNA helicase-family gene is a WRN gene, BLM gene or RecQ1 gene. The
XX method of the invention is useful for manufacturing an anticancer agent
XX as a pharmaceutical composition. The novel agent is highly safe,
XX effective and does not cause any side effects when used as a
XX pharmaceutical. The products of the invention have cytostatic activity.
XX This sequence represents a double stranded siRNA (small interfering RNA)
XX molecule which is targeted to the RecQ1 gene.
XX
XX SQ Sequence 21 BP; 9 A; 3 C; 4 G; 2 T; 3 U; 0 Other;
XX
XX Query Match 0.9%; Score 16.8; DB 1; Length 21;
XX Best Local Similarity 55.0%; Pred. No. 3.5e+02;
XX Matches 11; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 657 AGAGUCGCAUUCAGUCC 676
XX ||||:||||:||||:||||:
XX Db 20 AGAGTTTTCATTCACTTC 1
XX
XX RESULT 657
XX AEA84953
XX ID AEA84953 standard; RNA; 21 BP.
XX
XX AC AEA84953;
XX
XX XX 11-AUG-2005 (first entry)
XX
XX DT Human lupus-related siRNA antisense strand #3403.
XX
XX DE

XX
XX KW Diagnosis; genetic marker; autoimmune disease;
XX KW systemic lupus erythematosus; lupus nephritis; nephritis;
XX KW immunosuppressive; nephrotropic; antiinflammatory; dermatological; ss;
XX KW gene silencing; RNA interference; short interfering RNA; siRNA.
XX
XX OS Homo sapiens.
XX
XX PN WO2004076639-A2.
XX
XX PD 10-SEP-2004.
XX
XX PF 26-FEB-2004; 2004WO-US005655.
XX
XX PR 26-FEB-2003; 2003US-044693P.
XX PR 26-FEB-2003; 2003US-0449753P.
XX PR 26-FEB-2003; 2003US-0449795P.
XX
XX PA (AMHP) WYETH.
XX PA (OTOO) O'TOOLE M M.
XX PA (WEIL/) WEI L.
XX
XX PI O'toole MM, Wei L;
XX
XX DR WPI; 2004-662008/64.
XX
XX PT New pharmaceutical composition comprising a polypeptide encoded by a gene
XX PT that is differentially expressed in a pre-symptomatic lupus-affected or -
XX PT predisposed tissues, and a carrier, useful for treating lupus.
XX
XX Claim 17; SEQ ID NO 10266; 86pp; English.
XX
XX The invention relates to a pharmaceutical composition comprising a
XX carrier and at least one active component selected from a polypeptide
XX encoded by a gene that is differentially expressed in pre-symptomatic
XX lupus-affected or lupus-predisposed tissues as compared to disease-free
XX tissues, a variant of the polypeptide and a polynucleotide encoding the
XX polypeptide or variant. The invention also relates to detecting an
XX expression profile of at least one gene in a biological sample of a
XX subject and comparing the expression profile to a reference expression
XX profile of the gene to detect or monitor an autoimmune disease in a
XX subject, where the gene is differentially expressed in pre-symptomatic
XX lupus-affected or lupus-predisposed tissues as compared to disease-free
XX tissues, administering a therapeutically or prophylactically effective
XX amount of the pharmaceutical composition in a subject, preferably a human
XX who has or is predisposed to systemic lupus erythematosus or lupus
XX nephritis, contacting an agent with lupus-affected or lupus-predisposed
XX cells and comparing expression profiles or protein activities of at least
XX one gene in the cells before and after the contacting to determine if the
XX agent modulates expression or protein activity of at least one gene,
XX administering an agent to a lupus-affected or lupus-predisposed subject
XX and comparing expression profiles or protein activities of at least one
XX gene in the biological sample before and after the administering to
XX determine if the agent modulates expression or protein activity of at
XX least one gene in the subject, where the gene is differentially expressed
XX in lupus-affected or lupus-predisposed kidney tissues as compared to
XX disease-free kidney tissues. The pharmaceutical composition is useful for
XX diagnosing, treating and preventing autoimmune diseases such as lupus
XX nephritis and systemic lupus erythematosus. This sequence represents a
XX human lupus-related siRNA antisense strand of the invention. Note: The
XX sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences.
XX
XX SQ Sequence 21 BP; 2 A; 3 C; 3 G; 0 T; 13 U; 0 Other;
XX
XX Query Match 0.9%; Score 16.8; DB 1; Length 21;
XX Best Local Similarity 90.0%; Pred. No. 3.5e+02;
XX Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 614 UGUUCUGCAUUCUUCU 633
XX |||||:|||||:|||||:|||||:
XX Db 1 UGUUCUGCAUUCUUCU 20
XX

RESULT 658
AEA82719/c
ID AEA82719 standard; cDNA; 21 BP.
XX
XX
AC AEA82719;
XX
DT 11-AUG-2005 (first entry)
XX
DE Human lupus-related siRNA target sequence #2659.
XX
RW Diagnosis; genetic marker; autoimmune disease;
XX systemic lupus erythematosus; lupus nephritis;
XX immunosuppressive; nephrotropic; antiinflammatory; dermatological, ss.
XX
OS Homo sapiens.
XX
PN WO2004076639-A2.
XX
PD 10-SEP-2004.
XX
PE 26-FEB-2004; 2004WO-US005655.
XX
PR 26-FEB-2003; 2003US-0449693P.
XX 26-FEB-2003; 2003US-0449753P.
XX 26-FEB-2003; 2003US-0449795P.
XX
PA (AMHP / WYETH-
XX (OTCOO / O'TOOLE M M.
PA (WEIL / WEI L.
XX
PI O'Coole MM, Wei L;
XX
DR WPI; 2004-662008/64.
XX
XX
PT New pharmaceutical composition comprising a polypeptide encoded by a gene
PT that is differentially expressed in a pre-symptomatic lupus-affected or -
PT predisposed tissues, and a carrier, useful for treating lupus.
XX
PS Claim 17; SEQ ID NO 8032; 86pp; English.
XX
XX
CC The invention relates to a pharmaceutical composition comprising a
CC carrier and at least one active component selected from a polypeptide
CC encoded by a gene that is differentially expressed in pre-symptomatic
CC lupus-affected or lupus-predisposed tissues as compared to disease-free
CC tissues, a variant of the polypeptide and a polynucleotide encoding the
CC polypeptide or variant. The invention also relates to detecting an
CC expression profile of at least one gene in a biological sample of a
CC subject and comparing the expression profile to a reference expression
CC profile of the gene to detect or monitor an autoimmune disease in a
CC subject, where the gene is differentially expressed in pre-symptomatic
CC lupus-affected or lupus-predisposed tissues as compared to disease-free
CC tissues, administering a therapeutically or prophylactically effective
CC amount of the pharmaceutical composition in a subject, preferably a human
CC who has or is predisposed to systemic lupus erythematosus or lupus
CC nephritis, contacting an agent with lupus-affected or lupus-predisposed
CC cells and comparing expression profiles or protein activities of at least
CC one gene in the cells before and after the contacting to determine if the
CC agent modulates expression or protein activity of at least one gene,
CC administering an agent to a lupus-affected or lupus-predisposed subject
CC and comparing expression profiles or protein activities of at least one
CC gene in the biological sample before and after the administering to
CC determine if the agent modulates expression or protein activity of at
CC least one gene in the subject, where the gene is differentially expressed
CC in lupus-affected or lupus-predisposed kidney tissues as compared to
CC disease-free kidney tissues. The pharmaceutical composition is useful for
CC diagnosing, treating and preventing autoimmune diseases such as lupus
CC nephritis and systemic lupus erythematosus. This sequence represents a
CC human lupus-related siRNA target sequence of the invention. Note: The
CC sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published pct sequences.

XX	SQ	Sequence	21 BP; 12 A; 3 C; 4 G; 2 T; 0 U; 0 Other;
XX		Query Match	0.9%; Score 16.8; DB 1; Length 21;
XX		Best Local Similarity	40.0%; Pred. No. 3.5e+02;
XX		Matches	8; Conservative 10; Mismatches 2; Indels 0; Gaps 0
OY		614 UGUNCUGGCAUACUUGUU 633	
DB		: :: :: :	
		21 TGTTCTGTGCATTACTTGT 2	
RESULT 659			
ID	AEA84951/C		
XX	AEA84951 standard; cDNA; 21 BP.		
XX	AC		
XX	AEA84951;		
XX			
DT	11-AUG-2005 (first entry)		
XX			
DE	Human lupus-related siRNA target sequence #3403.		
XX			
KW	Diagnosis; genetic marker; autoimmune disease;		
KM	systemic lupus erythematosus; lupus nephritis;		
XX	immunosuppressive; nephrotropic; antiinflammatory; dermatological; ss.		
OS	Homo sapiens.		
PN	WO2004076639-A2.		
PD	10-SEP-2004.		
PX			
PF	26-FEB-2004; 2004WO-US005655.		
PR	26-FEB-2003; 2003US-0449693P.		
PR	26-FEB-2003; 2003US-0449753P.		
XX	26-FEB-2003; 2003US-0449795P.		
PA	(AMHP) WYETH.		
PA	(OTOO//) O'TOOLE M M.		
RA	(WEIL/) WEI L.		
XX			
P1	O'toole MM, Wei L;		
XX			
DR	WPI; 2004-662008/64.		
XX			
PT	New pharmaceutical composition comprising a polypeptide encoded by a gene		
FT	that is differentially expressed in a pre-symptomatic lupus-affected or -		
PT	predisposed tissues, and a carrier, useful for treating lupus.		
XX			
PS	Claim 17; SEQ ID NO 10264; 86bp; English.		
XX			
CC	The invention relates to a pharmaceutical composition comprising a		
CC	carrier and at least one active component selected from a polypeptide		
CC	encoded by a gene that is differentially expressed in pre-symptomatic		
CC	lupus-affected or lupus-predisposed tissues as compared to disease-free		
CC	tissues, a variant of the polypeptide and a polynucleotide encoding the		
CC	polypeptide or variant. The invention also relates to detecting an		
CC	expression profile of at least one gene in a biological sample of a		
CC	subject and comparing the expression profile to a reference expression		
CC	profile of the gene to detect or monitor an autoimmune disease in a		
CC	subject, where the gene is differentially expressed in pre-symptomatic		
CC	lupus-affected or lupus-predisposed tissues as compared to disease-free		
CC	tissues, administering a therapeutically or prophylactically effective		
CC	amount of the pharmaceutical composition in a subject, preferably a human		
CC	who has or is predisposed to systemic lupus erythematosus or lupus		
CC	nephritis, contacting an agent with lupus-affected or lupus-predisposed		
CC	cells and comparing expression profiles or protein activities of at least		
CC	one gene in the cells before and after the contacting to determine if the		
CC	agent modulates expression or protein activity of at least one gene,		
CC	administering an agent to a lupus-affected or lupus-predisposed subject		
CC	and comparing expression profiles or protein activities of at least one		
CC	gene in the biological sample before and after the administering to		

CC for a cancer expressing clusterin. Also described are: an antisense
CC containing pharmaceutical composition (I) packaged in dosage unit form,
CC comprising an anti-clusterin antisense oligonucleotide, where the amount
CC of anti-clusterin antisense oligonucleotide in each dosage unit ranges
CC from 40-640 mg; and use of anti-clusterin antisense (II) in the
CC manufacture of a medicament for the treatment of cancer, where the
CC medicament is formulated to deliver a dosage of 40-640 mg of the
CC antisense to a patient. (M1) is useful for providing antisense therapy
CC for treatment of cancer chosen from prostate cancer, bladder cancer,
CC ovarian cancer, lung cancer (preferably non-small cell lung cancer),
CC renal cancer, melanoma, pancreatic cancer, metastases and cancer with
CC lymph node involvement, in a patient. (II) is useful in the manufacture
CC of a medicament for the treatment of cancer. This sequence represents an
CC anti-clusterin antisense oligonucleotide.

CC Sequence 21 BP; 6 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 3.5e+02;
Matches 12; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1664 UCAGAGUCGUCGUCGUCG 1683

Db 20 TGAAGATCCTGCTGCTGTGC 1

RESULT 662

AEF52902/C

ID AEF52902 standard; RNA; 21 BP.

AC AEF52902;

DT 23-MAR-2006 (first entry)

DE Human PLOD2 gene specific siRNA #1, antisense strand.

KW Translation; fibrosis; antiinflammatory; inflammation; DNA-RNA hybrid;

KW siRNA; short interfering RNA; RNA interference; gene silencing;

KW PLOD2 gene; ss.

OS Homo sapiens.

OS Synthetic.

Key misc_feature Location/Qualifiers

FT 20..21 /tag= a

FT /note= "Deoxythymidine"

PN US2006029636-A1.

PD 09-FEB-2006.

PF 18-JUL-2005; 2005US-00183485.

PR 21-JUL-2004; 2004US-0589700P.

PA (MEDT) MEDTRONIC INC.

PI Hendriks M;

DR WPI; 2006-144857/15.

PT Medical device useful for reducing fibrotic tissue formation comprises a

PT substrate, and active agent associated with the substrate.

PS Example 2; SEQ ID NO 2; 27pp; English.

CC The present invention relates to medical device useful for reducing
CC fibrotic tissue formation. The invention also provides a method for
CC delivering an active agent to a subject. The method involves providing a
CC medical device that includes a substrate and an active agent suppresses
CC the production and/or activity of telopeptide lysyl hydroxylase (TLH)
CC enzyme in collagen-producing cells associated with the substrate. The

CC substrate comprises a polynucleotide delivery matrix (DNA encoding
CC antisense, ribozyme, siRNA molecules) that interfere with a PLOD2 gene
CC and inhibit the translation of a TLH enzyme. The present sequence is a
CC human PLOD2 gene specific antisense siRNA.

CC Sequence 21 BP; 4 A; 7 C; 3 G; 2 T; 5 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 3.5e+02;
Matches 15; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1441 AUGUCCUGGUCAGAGGAA 1460

Db 20 AGGTCCTTGCTCAAGAGGAA 1

RESULT 663

AEF42813/C

ID AEF42813 standard; RNA; 21 BP.

AC AEF42813;

DT 23-MAR-2006 (first entry)

DE Human PLOD2 antisense siRNA #1 oligonucleotide SEQ ID NO:2.

KW siRNA; short interfering RNA; RNA interference; gene silencing; PLOD2;

KW telopeptide lysyl hydroxylase;

KW procollagen-lysine 2-oxoglutarate 5-dioxygenase 2; antiinflammatory;

KW fibrosis; DNA-RNA hybrid; ss.

OS Homo sapiens.

OS Synthetic.

Key misc_feature Location/Qualifiers

FT 20..21 /tag= a

FT /label= misc DNA

FT /note= "deoxythymidine"

PN US2006030538-A1.

PD 09-FEB-2006.

PF 18-JUL-2005; 2005US-00183486.

PR 21-JUL-2004; 2004US-0589724P.

PA (MEDT) MEDTRONIC INC.

PI Hendriks M;

DR WPI; 2006-154152/16.

PT Reducing or preventing fibrotic tissue formation in a subject, comprises

PT delivering a polynucleotide that suppresses production and/or activity of

PT telopeptide lysyl hydroxylase enzyme.

PS Example 1; SEQ ID NO 2; 26pp; English.

CC The invention relates to a method (M1) for reducing or preventing
CC fibrotic tissue formation in a subject. (M1) comprises delivering a
CC polynucleotide that suppresses telopeptide lysyl hydroxylase (TLH) enzyme
CC production/activity in collagen-producing cells, where the polynucleotide
CC has a small interfering RNA (siRNA) molecule or DNA encoding siRNA that
CC interferes with the PLOD2 (telopeptide lysyl hydroxylase) gene and
CC inhibits TLH enzyme translation, or interferes with a gene encoding a
CC protein in production/processing of the enzyme. Also described is a kit
CC comprising components for the formation of a polynucleotide delivery
CC matrix. (M1) is useful for reducing or preventing fibrotic tissue
CC formation in subject, where the fibrotic tissue formation is associated
CC with heart rhythm disorder, heart failure, valve disease, vascular
CC disease, diabetes, neurological diseases and disorders or surgery, and

Query Match 0.9%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 72.2%; Pred. No. 3.6e+02;
 Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
 QY 1015 AACGAGGATGCTGCTGCC 1032
 DB 1 AACGAGGATGCTGCTGCC 18

RESULT 666

AA235086
 ID AA235086 standard; DNA; 20 BP.

AC AA235086;
 XX

DT 13-MAR-2000 (first entry)
 XX

DE Herpesvirus entry protein B (HvEB) PCR primer PPR2A8.
 XX

KM Herpesvirus entry protein B; HvEB; tumour necrosis factor receptor;
 XX alphaherpesvirus; infection; therapy; human; PCR; primer; ss.

OS Synthetic.
 XX Homo sapiens.

PN WO9963063-A1.
 XX

PD 09-DEC-1999.
 XX

PF 02-JUN-1999; 99WO-US012235.
 XX

PR 03-JUN-1998; 98US-0087862P.
 XX

PA (NOUN) UNIV NORTHWESTERN.
 XX (UNPR-) UNIV PENNSYLVANIA.

PI Spear PG, Warner MS, Garghty RG, Martinez WM, Montgomery RI;
 XX Cohen GH, Eisenberg RJ, Whitbeck CJ, Krumenacher C;
 DR WPI; 2000-097325/08.

PT Novel proteins used to prevent viral infection and to identify other
 XX inhibitors.

PS Example 1; Page 57; 144pp; English.
 XX

CC Primer PPR2A8 was used in the PCR amplification of herpesvirus entry
 CC protein B (HvEB) cDNA (see also AA235084). HvEB is a novel member of the
 CC human tumour necrosis factor receptor family that mediates entry of an
 CC alphaherpesvirus (AHV) into cells. Cellular herpesvirus entry proteins
 CC (I) such as HvEB, their mutants, homologues, derivatives, variants and
 CC active fragments are claimed, as are recombinant cells (especially CHO,
 CC murine melanoma, swine testes), vectors, and anti-cellular herpesvirus
 CC protein compounds (II). Suitable (II) include antisense oligonucleotides,
 CC antibodies specific for (II), peptides and peptidomimetics. Methods of
 CC identifying (II), of inhibiting entry of an AHV into a cell using (II),
 CC and of treating an AHV infection in an animal, especially a human, using
 CC (II) are also claimed
 XX

SQ Sequence 20 BP; 8 A; 6 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 3.6e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1708 AAGCAGCAGUACCAGCAG 1725
 DB 3 AAGCAGCAGCAGCAGCAG 20

AC AAGCAGCAGCAGCAGCAGCAG
 XX

RESULT 667

AE77799
 ID AE77799 standard; DNA; 20 BP.

XX AE77799;
 AC

DT 09-FEB-2006 (first entry)
 XX

DE Human dopamine receptor D2 (DRD2) DNA oligonucleotide SEQ ID NO:1420.
 XX

KM Diagnose; therapeutic; neurological disease; psychiatric disorder;
 XX neuropsychologic disorder; dopamine receptor D2; DRD2; ss.

OS Homo sapiens.
 XX

PN WO2005118843-A1.
 XX

PD 15-DEC-2005.
 XX

PF 01-JUN-2005; 2005WO-AU000775.
 XX

PR 01-JUN-2004; 2004AU-00902919.
 XX

PA (UNPR-) UNIV QUEENSLAND TECHNOLOGY.
 XX

PI Morris CP, Van Daal A, Swagell CD, Lawford BR, Young RM;
 XX WPI; 2006-047555/05.

PT Identifying genetic profile associated with a neurological, psychiatric,
 PT or psychological condition, comprises screening individuals for a
 PT polymorphism in a genetic locus comprising the dopamine receptor D2
 PT (DRD2) gene.
 XX

PS Claim 31; SEQ ID NO 1420; 634pp; English.
 XX

CC The invention relates to a method of identifying a genetic profile
 CC associated with a neurological, psychiatric or psychological condition,
 CC phenotype or state including a sub-threshold neurological, psychiatric or
 CC psychological condition, phenotype or state in an individual, comprising
 CC screening individuals for a polymorphism in a genetic locus comprising
 CC the dopamine receptor D2 (DRD2) gene. The invention also relates to a
 CC genetic mutation providing a genetic marker for a neurological,
 CC psychiatric, or psychological condition, state or phenotype in an
 CC individual, where the presence of a 957C polymorphism is indicative of a
 CC predisposition to developing a neurological, psychiatric or psychological
 CC condition, phenotype or state. The compositions and methods are useful
 CC for identifying a genetic profile associated with a neurological,
 CC psychiatric or psychological condition. The method enables clinicians to
 CC make a genetic-based diagnosis of a neurological, psychiatric or
 CC psychological condition and can thereby implement treatment or
 CC preventative or symptom-ameliorating protocols to reduce the adverse
 CC consequences of the condition. This sequence represents a human dopamine
 CC receptor D2 (DRD2) DNA oligonucleotide used in the scope of the
 CC invention.
 XX

SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 83.3%; Pred. No. 3.6e+02;
 Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1604 UCAACGACCCGUAACC 1621
 DB 3 TCACACGCCCGGAACC 20

AC UCAACGACCCGUAACC
 XX

RESULT 668

AB281124
 ID AB281124 standard; DNA; 20 BP.

AC AB281124;
 XX

DT 10-MAY-2003 (first entry)
 XX

DE Dual specific phosphatase 9 phosphorothioate oligonucleotide SEQ:22.
 XX

XX Human; Dual specific phosphatase 9; antisense modulation; inhibitor;
 KM antiinflammatory; cytosolic; antibacterial; antisense therapy;
 KM hyperproliferative disorder; developmental disorder; infection;
 KM inflammatory disorder; inflammation; tumour formation; phosphorothioate;
 KM 2'-O-methoxyethyl; 2'-MOE; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages"
 FT modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "optional 2'-O-methoxyethyl (2'-MOE) gapmer"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "optional 2'-O-methoxyethyl (2'-MOE) gapmer"
 XX
 XX WO2003012123-A2.
 XX
 XX 13-FEB-2003.
 XX
 XX 31-JUL-2002; 2002WO-US024309.
 XX
 XX 01-AUG-2001; 2001US-00922146.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Cowert LM, Monia BP;
 XX
 XX WPI; 2003-248184/24.
 XX
 XX New antisense oligonucleotides targeted to nucleic acids encoding Dual
 PT specific phosphatase 9, useful for treating diseases associated with Dual
 PT specific phosphatase 9, e.g. cancer, and for diagnostic and research
 PT applications.
 XX
 XX Claim 3; Page 74; 94pp; English.
 XX
 XX The present invention describes a compound (I) that is 8-50 nucleobases
 CC in length targeted to a nucleic acid molecule encoding Dual specific
 CC phosphatase 9, and which specifically hybridises with and inhibits the
 CC expression of Dual specific phosphatase 9, or which specifically
 CC hybridises with at least an 8-nucleobase portion of an active site on a
 CC nucleic acid molecule encoding Dual specific phosphatase 9. (I) has
 CC antiinflammatory, cytostatic and antibacterial activities, and can be
 CC used in antisense therapy. The antisense compounds are useful for
 CC modulating the expression of Dual specific phosphatase 9 and for treating
 CC diseases or conditions associated with expression of Dual specific
 CC phosphatase 9, e.g. hyperproliferative disorders, developmental disorders
 CC or inflammatory disorders. The antisense compounds are also useful for
 CC diagnostics, therapeutics, prophylaxis, e.g. to prevent or delay
 CC infection, inflammation or tumour formation, as research reagents and
 CC kits, and in distinguishing between functions of various members of a
 CC biological pathway. The present sequence represents a human Dual specific
 CC phosphatase 9 antisense phosphorothioate oligonucleotide, which is used
 CC in an example from the present invention
 CC
 SO Sequence 20 BP; 4 A; 10 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.9%; Score 16; DB 1; Length 20;
 Best Local Similarity 93.8%; Pred. No. 4e+02;
 Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

1464 AGCGGCCGACCCUC 1479
 |||||
 3 AGCGGCCGACCTTC 18

RESULT 669
 ABA81947/C
 ID ABA81947 standard; DNA; 19 BP.
 XX
 XX ABA81947;
 AC
 XX
 XX 25-JAN-2002 (first entry)
 DT
 XX
 XX Rat G-protein serotonin receptor capture oligonucleotide HTR7.
 DE
 XX
 XX Microorganism detection; capture oligonucleotide; probe; cancer; biochip;
 KM polymorphism detection; genetic disease diagnosis; microarray; ss.
 XX
 XX Rattus sp.
 OS
 XX
 XX WO200177372-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 26-MAR-2001; 2001WO-BE000053.
 XX
 XX 24-MAR-2000; 2000EP-00870055.
 XX
 XX 15-SEP-2000; 2000EP-00870204.
 XX
 XX (UYNO-) UNIV NOTRE-DAME DE LA PAIX.
 XX
 XX Remacle J, Hamels S, Zammateo N, Lockman L, Dufour S;
 PI Alexandre J, De Longueville F;
 XX
 XX WPI; 2002-010921/01.
 XX
 XX Identifying or quantifying organisms or genes, useful e.g. for diagnosis,
 PT by detecting specific nucleotide sequences present among several
 PT homologous sequences.
 XX
 XX Example 12; Page 40; 56pp; English.
 XX
 XX The present invention provides a method of identifying or quantifying a
 CC microorganism in a sample by detecting its nucleotide sequence from
 CC amongst homologous sequences. The method can be used to detect
 CC microorganisms and polymorphisms, and to diagnosis genetic diseases
 CC including cancer. The present sequence is a capture oligonucleotide used
 CC in the exemplification of the invention
 CC
 XX Sequence 19 BP; 2 A; 3 C; 9 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 78.9%; Pred. No. 3.8e+02;
 Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 510 CACGAGCCGACGACGAC 528
 |||||
 19 CACGAGCCCTCAGCTAC 1
 Db

RESULT 670
 ADH01514/C
 ID ADH01514 standard; RNA; 19 BP.
 XX
 XX ADH01514;
 AC
 XX
 XX 11-MAR-2004 (first entry)
 DT
 XX
 XX Protein tyrosine phosphatase siRNA sequence, SEQ ID No 126.
 DE
 XX
 XX small interfering RNA; siRNA; protein tyrosine phosphatase; PTP; PTPB;
 KM insulin receptor protein phosphorylation; Jak2; antidiabetic; anorectic;
 KM antiinflammatory; neuroprotective; cytosolic; immunosuppressive;
 KM antimicrobial; gene therapy; ss; siRNA.
 XX
 XX Unidentified.